<SEC-DOCUMENT>0000950170-25-047201.txt : 20250331
<SEC-HEADER>0000950170-25-047201.hdr.sgml : 20250331
<ACCEPTANCE-DATETIME>20250331071602
ACCESSION NUMBER:		0000950170-25-047201
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		85
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250331
DATE AS OF CHANGE:		20250331

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cabaletta Bio, Inc.
		CENTRAL INDEX KEY:			0001759138
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39103
		FILM NUMBER:		25788880

	BUSINESS ADDRESS:	
		STREET 1:		2929 ARCH STREET
		STREET 2:		SUITE 600
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19104
		BUSINESS PHONE:		(267) 759-3100

	MAIL ADDRESS:	
		STREET 1:		2929 ARCH STREET
		STREET 2:		SUITE 600
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19104
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>caba-20241231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-03-31T06:40:25.9299+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:caba="http://www.cabalettabio.com/20241231" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_bda6a701-ab11-43cc-b428-f88207a26173" name="dei:DocumentFiscalPeriodFocus" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c">FY</ix:nonNumeric><ix:nonNumeric id="F_a4a91c46-2193-43b0-aa9d-8eb044cecb29" name="dei:EntityCentralIndexKey" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c">0001759138</ix:nonNumeric><ix:nonNumeric id="F_25eafd07-1076-4a8b-8d80-5c8a6d059661" name="dei:AmendmentFlag" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c">false</ix:nonNumeric><ix:nonNumeric id="F_193d1736-d030-4379-9165-2e37496bd364" name="dei:CurrentFiscalYearEndDate" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c">--12-31</ix:nonNumeric><ix:nonNumeric id="F_12ddf4b5-a62c-4ffa-84f2-711a71acbce0" name="ecd:TrdArrDuration" contextRef="C_d8920710-db59-443d-8539-f9ab7adae181" format="ixt-sec:durday">388</ix:nonNumeric><ix:nonNumeric id="F_f0564499-a995-4065-9bd0-26aa3bce6fbe" name="ecd:TrdArrDuration" contextRef="C_5d39951d-322e-4fbb-8300-8a74cf365c32" format="ixt-sec:durday">527</ix:nonNumeric><ix:nonNumeric id="F_823872a2-58d2-4796-aa66-411b0b1f08f7" name="ecd:TrdArrDuration" contextRef="C_249c212f-73ed-4f7d-aa7a-ae4c0064e772" format="ixt-sec:durday">368</ix:nonNumeric><ix:nonNumeric id="F_e881d3fc-fad6-4460-a675-9db9c9ce22a6" name="ecd:TrdArrDuration" contextRef="C_a7948e46-0c3f-4a80-bc84-1f696b1179b4" format="ixt-sec:durday">180</ix:nonNumeric><ix:nonFraction id="F_4ab01a83-cec0-465d-abc1-ee74933546db" name="us-gaap:CommitmentsAndContingencies" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_9b348112-6fc9-49be-b4f8-a3dfc1834bd8" name="us-gaap:CommitmentsAndContingencies" contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_11fb0b7e-26ca-48c1-8f03-76b57f37f299" name="us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" contextRef="C_b9ae082c-13ae-4e63-bf00-b9ef8a7a8fe2">http://www.cabalettabio.com/20241231#PropertyPlantAndEquipmentEstimatedUsefulLives1</ix:nonNumeric><ix:nonFraction id="F_d4311f9a-8cf2-4c85-b6fa-4408d3790ae7" name="us-gaap:NumberOfOperatingSegments" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" unitRef="U_Segment" decimals="0" format="ixt:num-dot-decimal">1</ix:nonFraction><ix:nonFraction id="F_aacb9393-82a1-4484-8aab-edf9ca81d63c" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_72b96170-7a04-4855-aa98-34638538347d" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_b8a328b1-c384-428d-aa72-eece52e52e47" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_7e18ccc8-731c-4531-8ac3-a3a38fdbfbb4" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_12ab2f03-70f4-4da9-bb26-c88cd3cb34ae" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_26624392-0d0a-48e8-85da-f2115c4b9abd" format="ixt-sec:durwordsen">three year</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="caba-20241231.xsd"/></ix:references><ix:resources><xbrli:context id="C_84c42e55-4cc8-4f96-915e-34a23c05bcb6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:December2022FinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_85326982-4e9e-4cd8-af12-fd49791a671c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_881cd698-8215-4730-9508-1b847dfa7222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">caba:StateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8820b6d6-f9b3-4f60-970e-aabd2aa79a08"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">caba:VotingCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8a7792c8-f29b-4a61-9156-afc843c668af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:DevelopmentAndManufacturingServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8c0ea3f5-c232-4ba9-935c-c4f9363bfb3d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8c193bbc-bddd-4caa-a616-ab7149fe99f2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8ca5d37c-2521-42fc-9e13-1ef37fce3df9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8cac32c4-7629-42a9-a8fa-069e7af9b310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8fc080aa-f389-40f6-aa75-a26757919ae1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_91bebac1-a194-4aa0-bdad-e2db91554491"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_91f04779-501e-4bce-bfef-a9538a16e993"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:WuxiAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_977637ab-94d3-4e63-b46a-770bc602ae50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9adfe3c2-df06-47b1-8164-ee5bca829cf8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9be04dd4-fea1-4302-8462-56ed42a391b0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9cdb36a0-6755-4f07-b415-12eeed80884e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9d30fac2-b87d-470d-bf79-785e498650f5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9d8c2f96-4509-44a0-991d-9d569f5f45f2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:AtTheMarketOfferingSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a03b5214-7513-436c-a38c-ffda0bc04870"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">caba:StevenNichtbergerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a19e5ed8-055f-4020-a172-1708aa7cf1d2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:MasterTranslationalResearchServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a1e38241-900a-43de-9175-5ee71906e75a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a2e82d17-72fd-4199-85b4-3a85429d0d81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a5bf8c63-11a0-4813-b9c1-88b3b3a7c7df"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">caba:GwendolynBinderOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a7948e46-0c3f-4a80-bc84-1f696b1179b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">caba:GwendolynBinderOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a7b119c2-8427-423c-9525-72e30103d06a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a801e2f0-ef59-43bc-a0d1-f52d9f8fad06"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:OxfordBiomedicaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a9395bbb-6b73-4262-b752-6b65e91be8cd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:AutolusHoldingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a9916f0c-e5a6-49b3-aa27-2f2599dab549"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b03d1e52-2a57-4c8e-a119-05d8db2d7eab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:NanjingIasoBiotherapeuticsCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b19a2baa-3b2d-484b-b93b-09bbee5dbbdd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b1d3cbe4-887e-45db-abd2-b02478b909a8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b2126428-bc71-49ae-8c88-165cc7805710"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b595787c-5321-4455-b3f0-010647595978"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b642840b-d1a1-4660-9f4a-5c26a6b65c07"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">caba:VotingCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b6d231da-185f-42c9-9b3d-442d6ca59665"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-21</xbrli:startDate><xbrli:endDate>2019-10-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b76590bb-7198-4431-94bb-7578a594bad1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">caba:VotingCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b8337e36-0fb0-43e5-b463-b4b3890b87c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b9ae082c-13ae-4e63-bf00-b9ef8a7a8fe2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b9c36061-77bc-4b94-8132-5e42f9fe5210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bb64bdf7-38f7-44f3-bf1c-98b0765c39e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-21</xbrli:startDate><xbrli:endDate>2019-10-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bb8841ed-9927-4eb0-bfb9-ea102a2a8da5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:AtTheMarketOfferingSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bc2a9f34-de0e-42e5-b295-2f8e567060bb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:OxfordBiomedicaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bec66754-fe9d-4822-a0f6-7256e0f5e854"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bee1c669-b105-4c4e-b815-f0043dad20ee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bf0b7bb5-9f31-48ec-a4d1-ec777a17246d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">caba:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:December2022FinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c1ca12da-bcbe-461c-97eb-dc0872b56a45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c31b10fb-e739-4340-b8e2-ac8464faec66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c46ec4f4-c805-417a-8a4d-faada740c019"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c4c22bdc-057a-44d3-8274-7b307be3dfea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c76069af-3284-4046-a825-2b5ff929db4a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c8879ca3-eb41-45e9-90ca-a45d8a858386"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c9d68995-263a-4813-8297-7b0cb06226df"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:NanjingIasoBiotherapeuticsCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cabc4cba-12e7-440b-9da0-7f7f6b8bb8ea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cb855622-a323-4d6a-9e19-5673661f83fe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ce2b1ce0-61ab-404b-aa60-52836ccb0f70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d4a74439-9471-4a4f-9351-6249071d95ae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">caba:GwendolynBinderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d6f1f45c-9b4a-4db4-bf99-cf7cd3f55c9a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d8712004-ce9c-421a-b7c6-3e8c260bf228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:OxfordBiomedicaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d8920710-db59-443d-8539-f9ab7adae181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">caba:StevenNichtbergerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_da3cad1c-31be-4130-aaba-7a1f51466edd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:NanjingIasoBiotherapeuticsCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e24a8a97-a5dc-4f15-92b4-2d95326ebc6a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">caba:VotingCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e4eaaa6c-1a38-4348-b779-9f2c88c6727b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e4f2dc83-5acc-4bcc-b167-66ba947b5532"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e627ab24-8781-4141-83d8-30137c5dce9f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e718fe30-2e2a-42ee-8ebb-122b140ad979"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eb964699-a57c-4d32-86ed-e6d61d366c5f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_edbf75ee-d36b-422e-9a54-1ab65dcfc82b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f01ad0a8-3dd5-4e30-b96a-3752be3dec4c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f1261fee-7643-4642-aa6e-b30416d960fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f4635c63-e1a0-4066-bb40-7f550db23dd1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandEighteenStockOptionAndGrantPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f4db9c45-8c5b-4699-a20a-4009f98cad84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f5851d98-3e59-44ab-89c0-e44329981682"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f59134f7-4690-4aaa-a4ad-dc44779c4c7a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:MasterTranslationalResearchServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f5bebf2f-73b3-440e-bc7e-082d8b539b8f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandEighteenStockOptionAndGrantPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fa08dd21-0e3b-409f-9df9-7d9051548e56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fbb28abe-5658-4753-b0b7-f0b655b95e73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:WuxiAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-24</xbrli:startDate><xbrli:endDate>2024-02-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fdc47b6b-c242-47bb-af45-4daed72aa461"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fdc8bd52-362d-49f3-9e45-6677140ad037"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_00142f0e-bf74-4dac-98f2-8c7944fde213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_009b7691-4723-4a29-a462-e1c82235024a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_02a92407-52fe-4b71-9603-dc350a954b27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0603accc-761b-4dd7-9cb1-3b0483ce98b5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:AutolusHoldingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_067790e2-b88b-48e5-8bbf-2c266ffc2b13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_071a7623-23cd-43a4-8077-7f5f839577fb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">caba:Rese-CelAndMuSK-CAARTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0c06bf87-692f-4caf-b799-574ffd3da54b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">caba:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:December2022FinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0c1b371f-ae73-4a6c-ba1b-1ded4756d505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:AutolusHoldingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0ca36e70-a499-407f-8dc9-ca889acf6ed1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0f0de8fd-770f-40d6-b430-5691463bc993"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1078f332-4fd3-4a24-94d7-ea03957d7227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:LonzaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_11dd7a1d-2e01-497c-a7de-cb3940339fe0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_11f1e157-c9cb-4fce-b81f-40d77ea635c9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_12b0a7be-84f3-45d4-9d6e-95533e750a7a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">caba:VotingCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_16370771-1761-414a-82f7-374ff37b95d5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:LonzaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1947669b-c145-49f5-aea0-60ae45e15e4f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:DevelopmentAndManufacturingServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_19532afe-5faa-47b1-a0ce-01e2a372f9f0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1a070b4c-533f-43fc-9a6b-b37ff298a84e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1b69037c-33e3-4056-95e8-3197e2253d28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:OxfordBiomedicaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1e1e3aab-a61d-436a-a436-d1b68af34f64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:December2022FinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1e81d161-d2c9-4466-ad56-b46b0e4daea1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1f0087e0-dac4-4dce-a0b5-2502f2165631"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2050f55b-9729-46ca-976a-a50c6da04429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:AtTheMarketOfferingSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_205ec67f-4f43-4431-93b3-98f31625b5c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_22da4d01-1dd8-4662-b3be-4451dc2b3435"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:AtTheMarketOfferingSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_239a468d-472b-4684-b508-dd3ca371e2de"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:OxfordBiomedicaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_249c212f-73ed-4f7d-aa7a-ae4c0064e772"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">caba:GwendolynBinderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2583f882-17d6-4155-a8a0-ab8287370f9a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_25d4f8d5-93ce-418d-8f55-f27f42cf8bf6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:LonzaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_26624392-0d0a-48e8-85da-f2115c4b9abd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandEighteenStockOptionAndGrantPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_269acac6-33ca-4743-9c91-3860f13c66c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_29f8f331-c6aa-4374-ab1d-8e739c14e615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:MayTwoThousandTwentyThreeFinancingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2aa93a55-952b-4b3f-94d7-89fe525c7f44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2b388bdd-20d2-49ab-a3f5-a0e370b1edf7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:MayTwoThousandTwentyThreeFinancingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">caba:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2c83b4bd-a25b-4fdd-8a75-b19f7b147a93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2dcaa877-5c12-4f55-882d-3d8601e906a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_32ecdf32-80a6-4f58-8b71-96d449c2f6c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandEighteenStockOptionAndGrantPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_343f9e90-d9f0-4ab3-ab0c-3a31e1b64b95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">caba:VotingCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_355bad0a-3e83-4a29-ad76-5f43d0ef52d7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3577cd65-82b8-42e6-844e-ca6167dba709"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_35f03d89-1210-4983-af91-5949af3be4e2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">caba:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:December2022FinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3819e40f-e461-41a7-97d5-7e402dc0c022"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:SponsoredResearchAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3c5b95c6-6f48-4cac-8c2f-d9294618a5d9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3cf6ca28-81b1-4647-b307-30db6e6d90f1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3e97ca82-cc21-4f56-9fdf-9c22c00b90af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_40d8b316-eb73-435b-b720-1f6b7d1ba479"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_41424f02-2797-4d2b-9ae9-195e1bbcc839"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:OxfordBiomedicaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_41757f68-a8c3-48bc-848b-2cb739ce9b63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:NanjingIasoBiotherapeuticsCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_42bda966-2bcc-4366-9ccc-53d8a69b796d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_438de52d-5f54-466c-a0d0-ff8e3b765da2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_43efc37e-6f8b-48fc-b2ca-860b7ba5abf4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_48b6f6be-97cc-4ef9-bae5-f20850435f20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4911bc2b-bbb5-4139-af54-75d9d982736e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4a78e058-f9de-403c-bcb2-4c5d292bf4a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_50b61005-316a-440c-b7d7-051b2270374c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">caba:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_50ec53a6-211e-4704-8e25-521e6deb405e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_540f0e6d-d008-4d25-b45d-014688c83725"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">caba:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_58107011-70e5-45db-96bf-b13e678c007f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_58f7eda9-d4b7-4543-b9f9-e26b3d10127c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_591ef989-ecdb-491c-873b-f35ee5894e2b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:MasterTranslationalResearchServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5ae7b143-7cde-44f4-9122-03f5df7ace32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">caba:StevenNichtbergerOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5c158f7e-d30a-4d7e-913b-54efddfa9032"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">caba:StateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5c849a35-78e8-4658-b224-1c019b513ae4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5d39951d-322e-4fbb-8300-8a74cf365c32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">caba:StevenNichtbergerOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5eb72df5-0321-4487-8ba8-cc5d3052b6cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:AutolusHoldingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_60702d76-a78f-433d-8046-7a817c666483"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">caba:FederalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_636f9b5e-113f-4fa8-938c-4b0bf99f0a58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_649a608e-fb57-4b77-b3df-53aea52c4927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6525b174-f1b8-46c9-95b2-6b44e02a8e4d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_68171875-88e5-4c5d-a904-b84ad5d56a17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:AtTheMarketOfferingSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_711abcf7-e6c1-4c74-8ec8-d2b808baace6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_71d3a4fa-64fd-456b-b2cd-92dccaa7ba87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_72321c97-c716-4fc6-b08a-a26615a95579"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_72b96170-7a04-4855-aa98-34638538347d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_72e98e9b-d795-49b3-92aa-8c76efc07029"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_734d3853-d0a8-4ac2-a327-a99b436ab861"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_751af1f3-2ee2-42ff-9b2c-27e58ba3e3be"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7552d055-8ba4-480a-a069-f83dd0658987"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_75b117c4-870a-43ee-97dd-4b546ab94807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:MayTwoThousandTwentyThreeFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_76f2bc1f-8bfe-42b0-8ef5-bd09ee4372d6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7bbbdb4f-492f-4e45-b1af-564db3e6c265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7bbcce38-fe4c-402a-abef-f39d1a8317bc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7e18ccc8-731c-4531-8ac3-a3a38fdbfbb4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7f97431a-51bc-48de-b369-469db20bdb17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">caba:FederalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_Segment"><xbrli:measure>caba:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_a817dc11-a357-48c9-937a-02cf05c1a9c1" fromRefs="F_c44390f8-728e-4a16-874c-98d61b07a67a F_79796396-a7d9-4c3c-85e3-fa935c557d67"/></ix:resources></ix:header></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;min-height:0.6in;position:relative;"></div><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1.5pt double;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Washington, D.C. 20549</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:38.462%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:38.462%;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2f2c6847-af50-4feb-949b-5013b2930df4" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10-K</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:38.462%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:38.462%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Mark One)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:5%;box-sizing:content-box;"/>
     <td style="width:95%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_c0e6552f-d6ec-474b-9d72-52e82ed76a50" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_935e48a0-2a61-4408-9a03-7f9e7d54af3f" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3a262f1a-3df1-41b4-b6f0-f28c5c127343" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024</span></ix:nonNumeric></span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:3pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:5%;box-sizing:content-box;"/>
     <td style="width:95%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_77140168-2e52-468b-8c3f-ab3d15ef1a79" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM                      TO</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">                     </span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commission File Number </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_583cbb4f-cbb3-4a0b-b18a-e2098dd521a5" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">001-39103</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:38.462%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:38.462%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:16pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e2eeb86b-6b1f-4fdd-abc9-14ca558bdc1d" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CABALETTA BIO, INC.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact name of Registrant as specified in its Charter)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:38.462%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:38.462%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:50%;box-sizing:content-box;"/>
     <td style="width:50%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_45107ea6-aa20-4963-a048-28e63c3eab1c" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_72d36a34-4d9d-4fc4-aa14-7491155e8faa" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">82-1685768</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">incorporation or organization)</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(I.R.S. Employer</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Identification No.)</span></p></td>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_2f11e6f3-7613-4531-ae5c-20e92b13f857" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2929 Arch Street</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:8pt;"><ix:nonNumeric id="F_abda6de5-9721-4901-889c-d962c4d96e9f" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Suite 600</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_e1835495-eff5-4aa4-915b-0122472572c7" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Philadelphia</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:8pt;"><ix:nonNumeric id="F_a96ac548-33fb-41f8-88f3-1ba12f528907" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="dei:EntityAddressStateOrProvince"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PA</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_b7c41b80-51f1-4afe-b1a5-c25d11050235" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">19104</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Zip Code)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registrant&#8217;s telephone number, including area code: (</span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fa78ccb9-7e15-41a3-b958-4430b21e14ca" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">267</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f64d440e-fd74-4faa-a270-6c3fe6b3c5f7" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">759-3100</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:38.462%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:38.462%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:39.988%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:18.004%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:40.008%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title of each class</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Symbol(s)</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_f78687fa-8eed-49c4-a3b1-28590a55f596" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common Stock, par value $0.00001 per share</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_09d92e55-a361-471a-b7fb-8ebe4f4045d3" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">CABA</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_0c391e0e-24d1-460a-a754-ed9bc442edb3" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The Nasdaq Global Select Market</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act: None</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4e071cd3-69b5-4d23-a8d7-86e54a80ca09" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="dei:EntityWellKnownSeasonedIssuer"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.  Yes </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c9f91611-0272-4fa1-bba8-dc015ad392fa" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="dei:EntityVoluntaryFilers"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_733903b5-93de-4081-9516-b9a89235919f" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="dei:EntityCurrentReportingStatus"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> No </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e599efad-ff4d-44ef-a8a4-a9e0c0f52982" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="dei:EntityInteractiveDataCurrent"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> No </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:18.9%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:55.84%;box-sizing:content-box;"/>
     <td style="width:1.06%;box-sizing:content-box;"/>
     <td style="width:20.08%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:2.12%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Large accelerated filer</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accelerated filer</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
    </tr>
    <tr style="height:3pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">.</span></p></td>
     <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_422274f0-102e-49e0-889e-15d0d20d7997" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Smaller reporting company</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_3106d169-5cc5-4178-9a6d-be66408fef4f" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Emerging growth company</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_282ebf46-ee93-4ed4-9ba4-a85e2b413f19" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_41d5aa01-831f-4f2f-ab90-55fbf008305e" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_4a661273-e600-4fe5-a30a-b5e13fb01a15" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).  Yes </span><span style="font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_b6b55afd-f3c6-4437-a666-ae0a25e12f0b" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of June 30, 2024 (the last business day of the registrant's most recently completed second fiscal quarter), the aggregate market value of the registrant's common stock held by non-affiliates was approximately $</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_19b938bd-21e2-4f4c-ac41-7085d28056c1" contextRef="C_355bad0a-3e83-4a29-ad76-5f43d0ef52d7" name="dei:EntityPublicFloat" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">350</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million based on the last reported sale price of the registrant's common stock on the Nasdaq Global Select Market on June 30, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The number of shares of registrant&#8217;s Common Stock outstanding as of March 27, 2025 was </span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_47934cca-5386-4464-966a-eb6be6e47c99" contextRef="C_b2126428-bc71-49ae-8c88-165cc7805710" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">50,743,101</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1.5pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:10.1%;box-sizing:content-box;"/>
     <td style="width:80.92%;box-sizing:content-box;"/>
     <td style="width:8.98%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Page</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_1"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART I</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1.</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_business"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Business</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1A.</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a_risk_factors"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Risk Factors</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1B.</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1C.</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1c_cybersecurity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Cybersecurity</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 2.</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_properties"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Properties</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 3.</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_legal_proceedings"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Legal Proceedings</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 4.</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_ii"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART II</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">95</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 5.</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5_market_for_registrants_common_equ"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">95</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 6.</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_6_reserved"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Reserved</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">95</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 7.</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7_managements_discussion_analysis_f"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">96</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 7A.</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7a_market_risk"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">110</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 8.</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_8_financial_statements_supplementar"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Financial Statements and Supplementary Data</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">110</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9.</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9_changes_in_disagreements_with_acc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">110</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9A.</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9a_controls_procedures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Controls and Procedures</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">111</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9B.</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9b_or_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Other Information</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">112</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9C.</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9c_disclosure_regarding_foreign"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">112</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_iii_1"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART III</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">113</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 10.</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_10_directors_executive_ficers_cor_1"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">113</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 11.</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_11_executive_compensation_1"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Executive Compensation</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">120</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 12.</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_12_security_ownership_certain_ben_1"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">128</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 13.</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_13_certain_relationships_related__1"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">131</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 14.</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_14"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Principal Accounting Fees and Services</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">133</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_iv"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART IV</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">134</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 15.</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_15_exhibits_financial_statement_sch"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Exhibits, Consolidated Financial Statement Schedules</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">134</span></p></td>
    </tr>
    <tr style="height:2.15pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 16</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_16_form_10_k_summary"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form 10-K Summary</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">134</span></p></td>
    </tr>
    <tr style="height:2.15pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#signatures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Signatures</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">139</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">i</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Summary of the Material and Other Risks Associated with Our Business</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a clinical-stage company with a limited operating history, have incurred significant losses since our inception, and anticipate that we will continue to incur significant losses for the foreseeable future.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are highly dependent on our relationships with University of Pennsylvania, or Penn, and/or WuXi Advanced Therapies, Inc., or WuXi, for our current manufacturing needs for our Phase 1/2 RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or Restoring Self-Tolerance, clinical trials for resecabtagene autoleucel (rese-cel, formerly referred to as CABA-201) and our Phase 1 clinical trial of MuSK-CAART, or the MusCAARTes</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">trial, and if Penn's or WuXi's manufacturing capacity is reduced or otherwise delayed or limited, including due to legislative action, or if we, Penn, WuXi or any third-party manufacturers encounter difficulties in manufacturing our product candidates, this could adversely impact the supply of product candidates for and enrollment in our trials.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are reliant on intellectual property licensed to us by Penn and Nanjing IASO Biotherapeutics Co., Ltd., or IASO, and termination of one of these license agreements would result in the loss of significant rights, which would have a material adverse effect on our business.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to obtain and maintain sufficient intellectual property protection for our current product candidates and technologies or any future product candidates, we may not be able to compete effectively in our markets.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will need to raise substantial additional funding before we can expect to complete development of any of our product candidates or generate any revenues from product sales.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to successfully develop our current programs into a portfolio of product candidates, or experience significant delays in doing so, we may not realize the full commercial potential of our current and future product candidates.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we encounter difficulties enrolling patients in our RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> clinical trials for rese-cel or future clinical trials, these clinical development activities could be delayed or otherwise adversely affected.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to advance our product candidates through clinical development, obtain regulatory approval and ultimately commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Results of earlier studies may not be predictive of future study or trial results, and we may fail to establish an adequate safety and efficacy profile to conduct clinical trials or obtain regulatory approval for our product candidates.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If serious adverse events, undesirable side effects or unexpected characteristics are identified during the development of any of our product candidates, we may need to delay, abandon or limit our further clinical development of those product candidates.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturing and administering our product candidates is complex and we may encounter difficulties in technology transfer to a contract manufacturing organization.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may establish our own manufacturing facility and infrastructure in addition to or in lieu of relying on third parties for the manufacture of our product candidates, which will be costly and time-consuming, and which may not be successful.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our future success depends in part upon our ability to retain our key employees, consultants and advisors and to attract, retain and motivate other qualified personnel. </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have identified conditions that raise substantial doubt about our ability to continue as a going concern. If we are unable to secure additional funding beyond our current cash position that enables our operations into the first half of 2026, we may be forced to delay, reduce or discontinue our product development programs efforts or other operations.</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Annual Report on Form 10-K, including the sections entitled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; contains express or implied forward-looking statements that are based on our management&#8217;s belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements in this Annual Report on Form 10-K include, but are not limited to, statements about:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the success, cost and timing and conduct of our clinical trial program, including our Phase 1/2 RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> clinical trials for rese-cel, our MusCAARTes</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">trial, and any other product candidates, including statements regarding the timing of initiation, enrollment and completion of the clinical trials and the period during which the results of the clinical trials will become available;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the expected timing and significance around the announcement of safety, biologic activity and/or any additional clinical data from our RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> clinical trials for rese-cel or MusCAARTes</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">trial;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing of and our ability to obtain and maintain regulatory approval of our product candidates, including rese-cel, MuSK-CAART, and our other product candidates, in any of the indications for which we plan to develop them, and any related restrictions, limitations, and/or warnings in the label of an approved product candidate;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectations for the tolerability and clinical activity of rese-cel and ability to advance this product candidate through our license agreement with IASO;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the potential benefits of our Orphan Drug, Rare Pediatric Disease and Fast Track designations;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expected use of proceeds from sales of our common stock in &#8220;at-the-market&#8221; offerings and other offerings, and the period over which such proceeds, together with existing cash, will be sufficient to extend our current cash runway beyond our current expectations into the first half of 2026 and meet our operating needs, including our ability to continue as a going concern;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our plans to pursue research and development of other product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the potential advantages of our proprietary Cabaletta Approach for B cell Ablation platform, called our CABA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> platform, and our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent to which our scientific approach and CABA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> platform may potentially address a broad range of diseases;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the potential benefits and success of our arrangements with Penn, the Children&#8217;s Hospital of Philadelphia, or CHOP, and WuXi;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to successfully leverage our research and translational insights;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectations regarding the results observed with the similarly-designed construct employed in recent academic publications, including the dosing regimen, and the implications on rese-cel;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to successfully commercialize our product candidates, including rese-cel, MuSK-CAART and any other product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the potential receipt of revenue from future sales of rese-cel, MuSK-CAART and any other product candidates, if approved;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the rate and degree of market acceptance and clinical utility of rese-cel, MuSK-CAART and any other product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our estimates regarding the potential market opportunity for rese-cel, MuSK-CAART and any other product candidates, and our ability to serve those markets;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our sales, marketing and distribution capabilities and strategy, whether alone or with potential future collaborators;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to establish and maintain arrangements or a facility for manufacture of rese-cel, MuSK-CAART and any other product candidates;</span></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain funding for our operations, including funding necessary to initiate and complete our RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> clinical trials of rese-cel, our MusCAARTes</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial and any ongoing preclinical studies of other product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectations for the efficiency of the trial design for our RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> clinical trials for rese-cel and the potential success and therapeutic benefits of rese-cel, including our belief that rese-cel may enable an &#8220;immune system reset&#8221; and provide deep and durable responses in patients across an increasing number of autoimmune diseases;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the potential achievement of milestones and receipt of payments under our collaborations;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to enter into additional collaborations with existing collaborators or other third parties;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates and our ability to operate our business without infringing on the intellectual property rights of others;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectations regarding international expansion and results of our efforts to do so; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the success of competing therapies that are or become available, and our competitive position;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for additional financing;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the impact of government laws and regulations in the United States and foreign countries; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to attract and retain key scientific or management personnel.</span></div></div><p style="text-indent:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this Annual Report on Form 10-K. The forward-looking statements contained in this Annual Report on Form 10-K are made as of the date of this Annual Report on Form 10-K, and we undertake no obligations to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise. Therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Annual Report on Form 10-K.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:center;" id="part_1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART I</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="item_1_business"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1. Business.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a clinical-stage biotechnology company focused on the discovery and development of innovative engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Our proprietary CABA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or Cabaletta Approach to B cell Ablation, platform encompasses two strategies. Our CARTA, or Chimeric Antigen Receptor T cells for Autoimmunity, approach is designed to potentially reset the immune system. Our legacy CAART, or Chimeric AutoAntibody Receptor T cells, approach is designed to engineer T cells to selectively engage and eliminate only disease-causing B cells. We believe our CABA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> platform has the potential to safely enable complete and durable responses for a broad range of autoimmune diseases and that it has potential applicability across dozens of autoimmune diseases that we have identified, evaluated and prioritized.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Resecabtagene autoleucel (rese-cel, formerly referred to as CABA-201) is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a broad range of autoimmune diseases and our lead product candidate within the CARTA strategy. Rese-cel is designed to achieve transient and deep depletion of all B cells following a single treatment by using T cells engineered to express an antibody fragment that recognizes a B cell receptor expressed on the surface of all B cells. The construct is designed to allow for the deep elimination of all B cells, including all B cells that contribute to disease, with subsequent repopulation by healthy na&#239;ve B cells. This approach has the potential to reset the immune system, providing meaningful durable and complete clinical responses to patients off immunosuppressive therapies.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2023, the United States Food and Drug Administration, or the FDA, granted clearance of our rese-cel Investigational New Drug, or IND, application for treatment of SLE in patients with active lupus nephritis, or LN, or active SLE without renal involvement. SLE is a chronic, potentially severe, autoimmune disease, most commonly impacting young women between the ages of 15 and 40 with higher frequency and more severity in people of color, where the immune system attacks healthy tissue throughout the body. SLE affects an estimated up to 320,000 patients in the U.S., and 150,000 patients in Europe, with LN as the most common end-organ manifestation, affecting approximately 40% of SLE patients. In May 2023, we announced the FDA granted Fast Track Designation for rese-cel, designed to deplete CD19-positive B cells and improve disease activity in patients with SLE and LN. The RESET-SLE</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Phase 1/2 clinical trial of rese-cel is designed to treat six SLE patients with active LN, and in a separate parallel cohort, six patients with active SLE without renal involvement, with a single weight-based dose of 1.0 x 10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> cells/kg. In March 2024, Health Canada issued a No Objection Letter in response to a Clinical Trial Application, or CTA, for the RESET-SLE</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial submitted by Cabaletta, enabling us to begin the process to activate clinical trial sites and pursue patient enrollment for the RESET-SLE</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial in Canada. In October 2024, the European Medicines Agency allowed a CTA submitted by Cabaletta for the RESET-SLE</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial to proceed, enabling us to begin the process of activating clinical trial sites and pursuing patient enrollment for the RESET-SLE</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial. The trial is open for enrollment across multiple sites in the United States and one site in the European Union.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2023, the FDA granted clearance of our rese-cel IND application for treatment of idiopathic inflammatory myopathies, or IIM, or myositis. Myositis refers to a group of autoimmune diseases characterized by inflammation and muscle weakness. The three myositis subtypes being evaluated in the RESET-Myositis</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Phase 1/2 clinical trial of rese-cel affect approximately 70,000 patients in the U.S. and approximately 85,000 patients in Europe and typically affect middle-aged individuals, particularly women. The RESET-Myositis</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> clinical trial, which is actively enrolling patients, is designed to treat six patients with dermatomyositis, six patients with anti-synthetase syndrome, and six patients with immune-mediated necrotizing myopathy, all in separate parallel cohorts. We announced the FDA granted Fast Track Designation for rese-cel for the treatment of patients with dermatomyositis to improve disease activity and Orphan Drug Designation for rese-cel for the treatment of myositis in January and February 2024, respectively. In March 2024, we announced the FDA granted Rare Pediatric Disease designation for rese-cel for juvenile dermatomyositis. The trial is open for enrollment across multiple sites in the United States and one site in the United Kingdom.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2023, we announced that the FDA granted clearance of our rese-cel IND application for treatment of systemic sclerosis, or SSc. SSc is a rare and potentially fatal chronic autoimmune disease characterized by progressive skin and internal organ fibrosis that can be life-threatening, including interstitial lung disease, pulmonary hypertension, and scleroderma renal crisis. SSc affects approximately 90,000 patients in the U.S. and approximately 60,000 patients in Europe, typically middle-aged individuals, particularly women. The RESET-SSc</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 1/2 clinical trial of rese-cel is designed to treat six patients with severe skin manifestations and six patients with severe organ involvement associated with SSc. We announced the FDA granted Fast Track Designation for rese-cel for the treatment of patients with SSc to improve associated organ dysfunction and Orphan Drug Designation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for rese-cel for the treatment of systemic sclerosis in January and March 2024, respectively. The trial is open for enrollment across multiple sites in the United States.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the FDA granted clearance of our rese-cel IND application for treatment of generalized myasthenia gravis, or gMG, a subset of patients with myasthenia gravis, or MG. MG is a rare autoimmune disease characterized by autoantibodies that interfere with signaling at the neuromuscular junction, or NMJ, leading to potentially life-threatening muscle weakness. The majority of patients with MG have autoantibodies known to be pathogenic based on their interference with proteins in the NMJ, of which the majority target AChR. gMG affects approximately 55,000 patients in the U.S. and approximately 100,000 patients in Europe. Symptoms of gMG include profound muscle weakness throughout the body, disabling fatigue, and potential shortness of breath due to respiratory muscle weakness, with risk for episodes of respiratory failure. Standard of care therapies include cholinesterase inhibitors, steroids, immunomodulators, and biologics, which typically require chronic administration, increasing the risk of serious long-term side effects. The RESET-MG</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Phase 1/2 clinical trial of rese-cel is designed to treat six patients with AChR-positive gMG and six patients with AChR-negative gMG, each in separate parallel cohorts. The trial is open for enrollment across multiple sites in the United States.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2024, we announced that we are working with active clinical sites to incorporate the RESET-PV</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial as a sub-study within the Phase 1 DesCAARTes</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial following the submission of a protocol amendment. The RESET-PV</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial will evaluate rese-cel as a monotherapy without preconditioning in patients with mucosal pemphigus vulgaris, or mPV, and mucocutaneous pemphigus vulgaris, or mcPV. Approximately 15,000 patients in the U.S. and approximately 20,000 patients in Europe are affected by PV. The trial is open for enrollment across multiple sites in the United States.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2024, we announced the initial clinical data from each of the first two patients dosed with rese-cel in the RESET-SLE</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and RESET-Myositis</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trials. In both of these patients, no cytokine release syndrome, or CRS, immune effector cell-associated neurotoxicity syndrome, or ICANS, infections or serious adverse events were observed through data cut-off of May 28, 2024. Rese-cel exhibited the anticipated profile of CAR T cell expansion and contraction with complete B cell depletion observed in both patients by day 15 post-infusion. Improvements in both patients&#8217; specific disease measures were observed, consistent with academic experience of a similar 4-1BB CD19-CAR T.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In late June 2024, a lupus nephritis patient with very active, refractory disease was dosed with rese-cel and experienced Grade 1 CRS and a protocol-defined dose-limiting toxicity of Grade 4 ICANS. The ICANS resolved rapidly following standard management. The study&#8217;s Independent Data Monitoring Committee reviewed data from the patient, and recommended that the study proceed as designed, without delay, at the current dose. We recommended protocol modifications designed to improve patient safety, including enhanced monitoring for fever and neurologic symptoms along with seizure prophylaxis for all patients, in line with the practice at many academic sites including at Erlangen University, the site of the CD19-CAR T studies led by Dr. Georg Schett. In July 2024, we provided standard notice to the FDA and communicated details of the event and proposed protocol changes to all active clinical sites within the RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> clinical trial program, including the requirement that the investigator promptly discuss the appropriateness and timing of infusion with the trial&#8217;s Medical Monitor.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, we announced updated clinical data at the American College of Rheumatology Convergence 2024 conference in the first 8 patients dosed across the lupus, myositis and systemic sclerosis clinical trials. Clinical data from these patients in the RESET-SLE</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, RESET-Myositis</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial and RESET-SSC</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial were presented in oral and poster presentations where compelling clinical responses were observed in lupus and myositis patients with up to six months of follow-up, and the first SSc patient demonstrated an emerging, drug-free clinical response.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2025, we announced the FDA granted clearance of our rese-cel IND application for treatment of multiple sclerosis, or MS. In addition, we announced the FDA granted Fast Track Designation for rese-cel for the treatment of relapsing and progressive forms of MS. The RESET-MS</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">trial is a Phase 1/2 open-label, dose escalation study of rese-cel in subjects with relapsing and progressive forms of MS, evaluated in separate cohorts. Approximately 750,000 patients in the U.S. and approximately 550,000 patients in Europe are affected by MS.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2025, we announced updated clinical and translational data from the first 10 patients in the RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> clinical trial program, with a data cut off of January 8, 2025. Overall, clinical responses continued to deepen over three SLE patients in DORIS remission, the first LN patient achieving complete renal response, and the first dermatomyositis patient maintaining a major total improvement score, or TIS improvement. Each of these patients discontinued all immunosuppressants and were off or tapering steroids as of January 8, 2025. The safety profile continued to suggest a favorable risk-benefit in the first 10 patients dosed with 90% of patients having experienced either no CRS or Grade 1 CRS and 90% of patients having experienced no ICANS.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2025, we learned of an important protocol deviation in the RESET-SSc</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial. In this case, the patient reported a fever three days prior to infusion. The Cabaletta Medical Monitor was not notified by the investigator prior to the site infusing the patient. Nine days following rese-cel infusion, the patient experienced a dose-limiting toxicity of grade 3 immune effector</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cell-associated neurotoxicity syndrome (ICANS) based on a transient period of confusion. There was no cerebral edema, seizures or motor dysfunction associated with the ICANS event, and the patient was arousable throughout. The ICANS resolved rapidly following treatment with dexamethasone, and the patient was discharged without further symptoms. After data review, the Independent Data Monitoring Committee recommended that the trial proceed at the current dose without delay and endorsed our proposal to require investigators to affirmatively confirm in writing to the company the absence of fevers or evidence of infection. As of March 14, 2025, 56 clinical sites across the U.S. and Europe were actively recruiting with 33 patients enrolled across the RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> clinical trial program.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our manufacturing strategy is comprised of two stages. The initial stage is designed to leverage the extensive early-stage manufacturing expertise of our academic partners and contract development and manufacturing organizations, or CDMOs, for rapid early development and clinical supply, and in parallel partner with commercially compliant CDMOs capable of supporting late-stage clinical studies and commercial production. Our aim is to achieve full manufacturing readiness through expanded CDMO relationships, establishment of our own manufacturing facilities, and/or through strategic partnership(s). We are leveraging the expertise in cell and vector manufacturing of our partners at the Children&#8217;s Hospital of Philadelphia, or CHOP, and the University of Pennsylvania, or Penn. For supply of lentiviral vector for the late-stage clinical and commercial manufacturing of rese-cel, we are working with Oxford Biomedica (UK) Limited, or Oxford. We have also collaborated with WuXi Advanced Therapies, Inc., or WuXi, to serve as an additional and commercially compliant cell manufacturing partner for our MusCAARTes</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> clinical trials to meet planned capacity and international supply requirements. In July 2024, we entered into a new technology transfer agreement with Lonza Houston Inc., or Lonza, another commercially compliant CDMO, to execute a technology transfer of our expected commercial manufacturing process for rese-cel. In December 2024, we entered into a Development and Manufacturing Services Agreement, or the Lonza Agreement, with Lonza to serve as one of our manufacturing partners for the global clinical development of rese-cel in multiple indications, including potential late-stage clinical trials and preparations for commercial readiness. This improved process is nearly fully closed, semi-automated, and more easily scaled than the current process. Transfer of this updated process will be performed from Cabaletta to Lonza in anticipation of being able to supply rese-cel drug product for any of Cabaletta&#8217;s ongoing and planned RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> clinical trials. We plan to secure commercial, scalable manufacturing capabilities through multiple potential strategies, including expanding existing or establishing new CDMO relationships, leasing, building, qualifying and operating our own manufacturing facility, and/or establishing a strategic partnership to rapidly and reliably scale manufacturing by leveraging the partner&#8217;s manufacturing expertise. We believe this later stage will enable control of product development and commercial supply for products arising from our CABA&#153; platform, enabling us to achieve continuous improvement of our product candidates. Multiple members of our team have previously built and led organizations that have constructed and commissioned cell therapy facilities, which we believe will enable us to build our own manufacturing organizations and facilities, if desirable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of our innovative manufacturing strategy where we intend to increase scale, reduce cost of goods and improve patient experience, in November 2023, we partnered with Cellares Corp., or Cellares, to evaluate their automated manufacturing platform, the Cell Shuttle</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, through the Cellares Technology Adoption Program, or TAP. As part of the collaboration, the companies have agreed on a proof-of-concept technology transfer process for the automated manufacture and release testing of rese-cel. In August 2024, we expanded our partnership with Cellares to facilitate the potential to incorporate the Cellares manufacturing platform to support the RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> clinical program. In March 2025, we and Cellares announced the successful conclusion of the Technology Adoption Program on Cellares&#8217; automated cell therapy manufacturing Cell Shuttle&#153;, facilitating the potential integration of the Cell Shuttle</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> into our clinical and commercial, if approved, manufacturing strategy for rese-cel. We are also evaluating pathways to improve patient experience and scalability of collection through the removal of the requirement for apheresis. Data were published at the American Society of Cell and Gene Therapy conference in May 2024 illustrating the feasibility of this approach.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our History and Team</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our scientific co-founders, Aimee Payne, M.D., Ph.D., and Michael Milone, M.D., Ph.D., began partnering at Penn in 2013 to combine Dr. Payne&#8217;s expertise in B cell-mediated autoimmune diseases with Dr. Milone&#8217;s deep and experienced insights into the design and implementation of CAR T products. Dr. Payne is a worldwide leader in characterizing B cell-mediated autoantibody repertoires in PV and other autoimmune diseases. Dr. Milone is a renowned scientist in CAR T therapy and was a co-inventor of and a key driver in the preclinical discovery and development efforts that yielded Kymriah&#174;, the first FDA-approved CAR T therapy for the treatment of B cell cancers. Their research attracted the attention of a colleague Steven Nichtberger, M.D., an adjunct professor at the Wharton School at the University of Pennsylvania, and in 2017, based on over a year of interaction and discussions regarding the optimal strategy to advance the scientific opportunity into a commercially developed product portfolio that could offer potentially curative treatment options to patients, Drs. Payne, Milone and Nichtberger decided to launch Cabaletta Bio. The longstanding and highly productive partnership between our co-founders has been complemented by additional management experience that brings a successful history of translating academic cellular therapy research from Penn and elsewhere into commercially sponsored clinical trials and the establishment of a GMP manufacturing facility and organization.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Gwendolyn Binder, Ph.D., our President, Science and Technology, was an early member of the Translational Research Program Operations team at Penn for over five years and participated in the submission and acceptance of multiple INDs for novel engineered T cell therapy products. As part of the cell therapy organization at Penn, Dr. Binder partnered with Dr. Milone and others to drive the IND-enabling translational studies that facilitated the initial CAR T clinical trial in B cell cancers at Penn. Dr. Binder also built and led a clinical stage biotechnology company&#8217;s manufacturing operations and quality teams, including creation of a fully functioning commercial grade GMP facility. Dr. Binder also built the translational research program and ultimately led the company&#8217;s research organization.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Chief Medical Officer, David Chang, M.D. was the late-stage clinical development leader of the only two drugs approved for SLE in the United States in over 60 years, belimumab, or Benlysta, and anifrolumab, or Saphnelo, through his roles at GlaxoSmithKline plc and AstraZeneca Pharmaceuticals LP prior to joining the team at Cabaletta Bio. Dr. Chang completed his fellowship in Rheumatology and was a faculty member in the Division of Rheumatology at the Perelman School of Medicine at the University of Pennsylvania prior to his transition to the biopharmaceutical industry.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our legacy CAART platform has yielded two clinical-stage cell therapy programs in mPV and MuSK MG, which have required collaborations between specialists &#8211; dermatologists and neurologists &#8211; and oncologists who are responsible for administering the cell therapy at each site. Given our track record of timely clinical trial implementation with CAART cell therapy in autoimmune diseases over the past five years at over a dozen sites across the United States, we believe that our team&#8217;s successful management of the complicated planning and logistics involved with implementation of these clinical trials has the potential to be an operating advantage. While advancing the CAART product candidates in our Phase 1 DesCAARTes</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and MusCAARTes</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trials and establishing our position in the field of autoimmunity, we were encouraged by results from an initial case report published in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">New England Journal of Medicine</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in August 2021 and a follow-up academic clinical study published in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Nature Medicine</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in September 2022, showing the potential for CD19-CAR T cell therapy to transform the course of SLE. In five patients with SLE, one-time treatment with a 4-1BB-containing CD19-CAR T cell therapy induced deep and durable clinical responses in all five patients within three months after treatment, with favorable tolerability. Healthy B cells repopulated in all patients within five months of treatment, and responses remained durable off SLE-associated medications for up to 2.5 years of follow-up, as of February 2024. These findings demonstrate the potential for CD19-CAR T cell therapy to &#8220;reset the immune system,&#8221; eliminating the cause of autoimmune disease with restoration of the healthy immune system.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Building on these results, we announced in October 2022 the development of rese-cel, a 4-1BB-containing CD19-CAR T investigational therapy, for the treatment of severe autoimmune diseases. Prompted by the initial case report in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">New England Journal of Medicine</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, we conducted a global search to identify the optimally designed product candidate for patients with autoimmune diseases to be highly similar to the construct used by Dr. Schett in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Nature Medicine</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> paper. We are employing a clinically-evaluated fully human CD19 binder that has high similarity, including identical epitopes and similar binding activity, to the construct employed in the academic reports. Our exclusive translational research partnership with Dr. Schett involves our robust translational research laboratory combined with confidential sharing of his unpublished clinical data to generate early and actionable insights from his trials that are informing our clinical development strategy and plans. As a result of the collaboration, in September 2023, Cabaletta scientists published &#8220;Cytokine and reactivity profiles in SLE patients following anti-CD19 CART therapy&#8221; in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Molecular Therapy: Methods and Clinical Development</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, highlighting studies performed on serum samples from the first six SLE patients treated with CD19-CAR T cell therapy by Dr. Georg Schett&#8217;s team. The publication reports that in the three months following infusion, cytokine markers of systemic inflammation resolved, autoantibody titers declined, and humoral immunity was maintained.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since announcing rese-cel in October 2022, Cabaletta has had five IND applications cleared within the routine 30-day period for the RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Phase 1/2 clinical trials in SLE, myositis, SSc, gMG and MS, in addition to the RESET-PV</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial that is evaluating rese-cel without preconditioning. Accelerated by the emerging clinical data with rese-cel, our team&#8217;s deep expertise in cell therapy in autoimmunity, demonstrated track record of strong clinical execution, positive regulatory interaction since 2018, and our successful cell therapy manufacturing, we are uniquely positioned to advance CD19-targeting cell therapy candidates to further our mission to develop therapies that deliver deep, durable and potentially curative responses for patients in a broad range of autoimmune diseases.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Strategy</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our goal is to build upon our deep expertise in engineered T cell therapies for autoimmune diseases to accelerate the discovery, development and commercialization of our product candidates. We believe achieving this goal could result in potentially curative therapies for patients with unmet medical needs who suffer from a broad range of autoimmune diseases with B cell involvement. To achieve this goal, key elements of our strategy include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.826300802485115%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Achieving compelling clinical responses and a favorable safety profile for our lead product candidate, rese-cel, across multiple autoimmune diseases driven by B cells. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Academic clinical data published in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Nature Medicine</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in September 2022 and in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">NEJM </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in February 2024, demonstrated that a CD19-CAR T cell therapy with a 4-1BB co-stimulatory domain following lymphodepletion with fludarabine and cyclophosphamide induced complete clinical responses in five out of five patients with moderate to severe, refractory SLE, with up to 2.5 years of follow up, as of February 2024. Our exclusive translational partnership with Dr. Schett, the lead investigator of the study, is focused on generation of additional translational data to gain a deeper understanding of the immunologic mechanisms of response and clinical insights from ongoing and continued clinical studies in multiple autoimmune disease indications. Due to the purposeful design of rese-cel to have a high level of functional and structural similarity to the construct used in these academic studies and engineered specifically for the use in autoimmune patients, we believe rese-cel may have the potential to transform the treatment of a broad range of autoimmune diseases. We have five IND applications cleared for the RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Phase 1/2 clinical trials in systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis and multiple sclerosis in addition to the RESET-PV</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial, which is evaluating rese-cel without preconditioning. All of these clinical trials are currently recruiting patients. As the academic data published to date showed robust clinical improvement with multiple years of follow-up in autoimmune patients, and given the similarity of rese-cel to the academic construct, we expect our initial clinical and translational data to provide insights that may predict longer-term outcomes.</span></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.826300802485115%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Utilizing our expertise in autoimmune cell therapy to enable a novel clinical strategy and efficient study design.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The first four RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Phase 1/2 clinical trials &#8211; RESET-SLE, RESET-Myositis, RESET-SSc and RESET-MG &#8211; are comprised of independent cohorts with well-defined disease sub-types, each comprised of 6 patients, which can enroll and dose patients in parallel. These trials are initiating at a weight-based cell dose that is equivalent to the weight-based dose of the 4-1BB-containing CD19-CAR T cell therapy used as was done in the academic publications (1.0 x 10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> cells/kg) with the same preconditioning regimen of fludarabine and cyclophosphamide. Each 6-patient cohort treated with an identical dose &#8211; without dose escalation requirement &#8211; is designed to inform discussions with the FDA on a registrational path for each indication, following the completion of any cohort. Our clinical strategy enables broad investigation of rese-cel across ten cohorts with well-defined patient populations in these four RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Phase 1/2 clinical trials with the same dose and similar design. In addition, the RESET-PV</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial is evaluating weight-based dosing of rese-cel without preconditioning. We have also received FDA Fast Track Designation for rese-cel in SLE, lupus nephritis, dermatomyositis, systemic sclerosis and multiple sclerosis. </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.826300802485115%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leveraging our cellular therapy knowledge and experience in addition to development efficiencies gained through our longstanding Penn collaboration to rapidly build fully integrated internal infrastructure.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We have differentiated expertise that we believe is uniquely suited to the continued buildout of our CABA&#153; platform, focused on autoimmune diseases. Our management team has expertise in conducting complex, interdisciplinary autoimmune-focused cell therapy clinical trials with a track record of positive regulatory interactions to support cell therapies in autoimmune diseases since 2018. We have had seven INDs for autoimmune cell therapies, each cleared within the routine 30-day period with six Fast Track Designations granted to date. In addition, we have a successful track record of manufacturing novel cell therapy product candidates with academic and industry partners. Not only does our team possess significant experience in the manufacturing of cell therapy product candidates, but our partnership with Penn allows us to utilize their existing infrastructure, which has accelerated our early development activities. In parallel, we continue to build out our internal capabilities while developing and continuing to implement a path to manufacturing independence, with established commercial CDMO partnerships to provide vector and cell processing capabilities at commercial grade and scale. </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.826300802485115%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Advancing the RESET</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> Phase 1/2 clinical trials to address significant unmet patient need while continuing to commit to optimize the patient experience.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We are focused on developing the first potentially curative targeted cellular therapies for patients with autoimmune diseases. We plan to expand development of rese-cel to a broad range of autoimmune diseases where the biologic opportunity for cure or treatment may be possible, addressing significant unmet patient need across multiple indications for rese-cel, with the goal of realizing the potential of rese-cel. While potentially serving a broad range of patients, we are committed to advancing to optimize the patient experience through minimizing the requirement for inpatient stay, optimizing the preconditioning regimen, reducing the burden of apheresis, and/or innovating to address scale in autoimmune disease.</span></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">B Cells in Autoimmune Diseases: Overview and Current Treatment Paradigm</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The body&#8217;s immune system, which is designed to protect the body from infection and cancer, includes B cells and T cells. In addition to producing antibodies against antigens that the body perceives as foreign, B cells are responsible for producing inflammatory cytokines, co-stimulating other immune cells, and presenting antigen to T cells to enable cell-mediated immunity. Autoimmune disease occurs when the immune response becomes mistakenly targeted to healthy tissues and cells, and B cells can contribute to the incitement and/or maintenance of these processes through their varied immune mechanisms. In the case of many autoimmune diseases, B cells are responsible for driving disease through production of autoantibodies, or antibodies against the &#8216;self,&#8217; that lead to disease, as well as through costimulation of T cells and through cytokine production.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><img src="img63895535_0.jpg" alt="img63895535_0.jpg" style="width:558px;height:267px;"/></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Thomas G. Forsthuber, et al. &#8220;B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets.&#8221; Therapeutic Advances in Neurological Disorders (2018): Vol 11: 1-13</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Key markers of B cell lineage.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> CD19 serves as a B cell marker from the pro B cell phase until differentiation to plasma cells, while CD20 is a surface marker expressed in a narrower range of the B cell maturation process. Rese-cel is directed to the CD19 B cell marker. CAAR T product candidates are designed to eliminate antigen specific B cells in each targeted disease, preventing their further development to antibody secreting plasma cells. IgM: immunoglobulin M; IgD: immunoglobulin D; IgA: immunoglobulin A; sIg: surface immunoglobulin, representing the autoantibody on the B cell surface.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is currently no cure for autoimmune diseases. Current treatment options for autoimmune diseases involve generalized immune suppression, achieved through corticosteroids, immunosuppressive medications and biologics. Most commonly, corticosteroids are used on both a chronic and acute basis to control disease and act via a variety of mechanisms to control or downregulate multiple inflammatory pathways. In many cases, systemic immunosuppressive medications often used in chemotherapy such as mycophenolate, azathioprine and methotrexate, are added in an effort to minimize symptoms and manage the expected recurrences in patients. Biologic therapies have emerged as a new class of therapies and have a variety of targets including cytokines, B cells, and co-stimulation molecules. All of these current treatment options impair or destroy healthy B cells and/or other immune cells as well as pathogenic ones, weakening the patient&#8217;s overall immune function, potentially putting them at risk for infection and impairing their response to vaccines. In general, these drugs require chronic administration and may have life-threatening side effects. We believe the ideal therapy in autoimmune diseases with B cell involvement would completely and specifically eliminate the pathogenic B cells with restoration of the normal immune system, enabling an &#8220;immune reset,&#8221; restoring the body&#8217;s immune system to its normal function of fighting foreign invaders, not healthy tissues.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Pipeline and Product Candidates</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide a deep and durable, perhaps curative, treatment for patients with autoimmune diseases. Our CABA&#153; platform encompasses two approaches &#8211; CARTA and CAART. Our current product candidate pipeline is illustrated below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.658%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img63895535_1.jpg" alt="img63895535_1.jpg" style="width:646px;height:284px;"/></p><p style="margin-left:4.658%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FTD &#8211; FDA Fast Track Designation received in dermatomyositis, SLE and lupus nephritis, systemic sclerosis, and multiple sclerosis.</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Additional pipeline candidate includes MuSK-CAART for MuSK-Ab positive MG, currently being evaluated in a Phase 1 trial.</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="margin-left:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Rese-cel for multiple autoimmune indications</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rese-cel is designed to achieve transient but deep depletion of all B cells following a single infusion, allowing for the elimination disease-causing B cells with subsequent repopulation by translational na&#239;ve healthy B cells. This strategy may be able to reset the immune system, providing potentially meaningful clinical responses to patients off immunosuppressive therapies. Cabaletta is advancing six RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Phase 1/2 clinical trials in SLE, myositis, SSc, gMG, PV and MS, with potential application in a broad range of other autoimmune diseases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rese-cel is comprised of a fully human anti-CD19 binder, which is the extracellular targeting domain. In addition, it contains a 4-1BB costimulatory domain and a CD3-zeta signaling domain, as shown in the figure below:</span></p><p style="text-indent:5.137%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><img src="img63895535_2.jpg" alt="img63895535_2.jpg" style="width:399px;height:330px;"/></p><p style="margin-left:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Image showing the design of rese-cel, with a fully human anti-CD19 binder, the 4-1BB costimulatory domain and the CD3-Zeta signaling domain. The costimulatory and signaling domain are identical to the construct used in the academic clinical studies published in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nature Medicine</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lancet Rheumatology </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">that were evaluated in SLE and myositis, respectively.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our exclusively licensed fully human CD19 binder has been clinically evaluated in a dual-CD19xCD22 CAR T candidate under development for B cell leukemia and lymphoma in an investigator-initiated trial in China in approximately 20 patients, where IASO has reported a tolerability profile that we believe is favorable for development in autoimmune diseases. Compared to FMC63-CART, rese-cel exhibits comparable biologic activity in vitro and in vivo (Peng, et al).</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Given its structural and functional similarity to the CD19-CAR T construct employed in the academic clinical study published in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Nature Medicine</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, including incorporation of a 4-1BB co-stimulatory domain, we believe rese-cel may have the potential to reset the immune system and transform treatment of a broad range of autoimmune diseases with high unmet need.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Disease Backgrounds</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Systemic lupus erythematosus is a chronic autoimmune disease, most common in young women between the ages of 15 and 40, with higher frequency and greater severity in people of color. In SLE, the immune system attacks healthy tissue throughout the body. It is results in a range of clinical manifestations, including end organ damage and an increased risk of death. SLE affects an estimated up to 320,000 patients in the U.S., and 150,000 patients in Europe. Lupus nephritis is the most common end-organ manifestation of SLE, affecting approximately 40% of SLE patients. Among these patients, the risk of end-stage renal disease is approximately 17% and the risk of death is approximately 12%, each within 10 years of diagnosis.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Myositis refers to a group of autoimmune diseases characterized by severe inflammation and muscle weakness. It commonly impacts women of middle age, and in some cases, myositis may also affect other organs and systems in the body, such as the lungs, heart, or skin. Myositis is classified into several subtypes based on the underlying immune mechanisms and clinical characteristics. Although the pathogenesis of myositis is not well understood, there are several subtypes thought to be driven by B cells, including</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">dermatomyositis, or DM, anti-synthetase syndrome, or ASyS, and immune-mediated necrotizing myopathy, or IMNM. All three subtypes can lead to severe functional impairment and may be life-threatening. Including juvenile myositis, or JIIM, patients, approximately 70,000 patients are affected by these subtypes in the U.S. and approximately 85,000 patients in Europe. Current standard of care typically involves medications to suppress the immune system and/or chronic intensive therapies such as intravenous immunoglobulin, or IVIg. Despite these therapies, many myositis patients have disease that remains refractory to existing medications.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Systemic sclerosis is a rare and potentially fatal chronic autoimmune disease characterized by progressive fibrosis and scarring of the skin and internal organs that can lead to life-threatening conditions, including interstitial lung disease, pulmonary hypertension, and scleroderma renal crisis. Although the etiology of SSc is not well understood, the pathogenic role of autoantibodies and B cells in SSc provides a rationale for studying CAR T therapy in this population. Approximately 90,000 patients in the U.S. and 60,000 patients in Europe are affected by SSc, commonly middle-aged women. Current treatments, which have modest effects, include generalized immunosuppression or drugs targeted to specific symptomatic manifestations. In some cases, autologous hematopoietic stem cell transplant may provide some benefits in organ involvement, but is associated with significant risks, including mortality, infertility, and secondary autoimmune disease, limiting its potential to be applied broadly. The risk of mortality in SSc remains high due to the lack of adequate treatments, with an average survival of approximately 12 years following initial diagnosis.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Myasthenia gravis is a rare autoimmune disease characterized by autoantibodies that interfere with signaling at the neuromuscular junction, or NMJ, leading to potentially life-threatening muscle weakness. The majority of patients with MG have autoantibodies known to be pathogenic based on their interference with proteins in the NMJ, of which the majority target AChR. Generalized MG affects approximately 55,000 patients in the U.S. and 100,000 patients in Europe. Symptoms of gMG include profound muscle weakness throughout the body, disabling fatigue, shortness of breath due to respiratory muscle weakness and risk for episodes of respiratory failure. Standard of care therapies include cholinesterase inhibitors, steroids, immunomodulators, and biologics, which often require chronic administration, increasing the risk of serious long-term side effects.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pemphigus vulgaris is an autoimmune disease that occurs when the immune system produces antibodies that attack a protein called desmoglein, or DSG. DSG normally enables skin cells and the cells lining the inside of your mouth, nose, throat, and eyelids to bind tightly together. Disruption by the antibodies directed to DSG can cause extensive, painful blistering and life-threatening wounds characteristic of PV. Approximately 15,000 patients in the U.S. and approximately 20,000 patients in Europe are affected by PV. Current therapies do not adequately control the underlying autoimmune process, and PV management often involves long-term immunosuppression, with high-dose steroids used in initial treatment and for relapses. The risk of mortality among patients with PV has been reported to be 2- to 3-fold higher than in the general population.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Multiple sclerosis is an autoimmune-mediated demyelinating disease of the central nervous system (CNS), affecting approximately 750,000 people in the U.S. and approximately 550,000 patients in Europe. The disease is more common in women than men, with onset of symptoms frequently between the ages of 20 and 40. The immune system attack on nerves within the brain and spinal cord impairs nerve electrical conduction, resulting in a wide range of symptoms including muscle weakness, sensory loss, visual impairment, incoordination, memory loss, fatigue, and walking difficulty. MS is classified into relapsing or progressive forms based on the pattern of clinical symptoms over time, with 85-90% experiencing a fluctuating (relapsing) course, and 10-15% steadily accumulating neurologic disability from disease onset (progressive). The pathogenesis of MS is multifactorial, with autoreactive B cells increasingly being recognized as a major driver of disease. Current standard of care therapies require chronic administration, which can be associated increased long-term risk of serious side effects.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Development Plan</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cabaletta is advancing RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Phase 1/2 clinical trials in SLE, myositis, SSc, gMG, PV and MS, with potential application in a broad range of other autoimmune diseases. Our rese-cel Phase 1/2 RESET-SLE</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, RESET-Myositis</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, RESET-SSc</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, RESET-MG</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and RESET-PV</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trials are currently enrolling patients. These five RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Phase 1/2 clinical trials are comprised of independent cohorts with specific objectively defined disease sub-types, which can enroll and dose patients in parallel, and each cohort is expected to be comprised of 6 patients. The trials are initiating at a weight-based dose, which is equivalent to the dose of the 4-1BB CD19-CAR T used in the academic publications (1.0 x 10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> cells/kg) with the same preconditioning regimen of fludarabine and cyclophosphamide, with the exception of the RESET-PV</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial, which is evaluating rese-cel without preconditioning. Our clinical strategy enables broad investigation of rese-cel across cohorts with well-defined patient populations in our Phase 1/2 clinical trials with the same dose and similar design. We have also received FDA Fast Track Designation for rese-cel in SLE, lupus nephritis, dermatomyositis, systemic sclerosis and multiple sclerosis.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">DSG3-CAART for Mucosal PV</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DSG3-CAART is a CAAR T cell therapy expressing DSG3 as the extracellular domain of a chimeric immunoreceptor and is designed to enable specific cytotoxicity toward B cells autoreactive to DSG3. We believe this strategy has the potential to directly eliminate the disease-causing cells in mucosal pemphigus vulgaris, or mPV, an autoimmune disease that causes blisters on the skin and mucous membranes, which may lead to lasting clinical remission without damage to the healthy immune system.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PV has two major subtypes: (1) mPV, which is caused by DSG3 autoantibodies and affects the mucous membranes; and (2) mcPV, which is caused by DSG3 and DSG1 autoantibodies, affecting both the mucous membranes and the skin. PV affects approximately 15,000 prevalent patients in the U.S., of which approximately 25% have mPV and 75% have mcPV.</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Like most autoimmune diseases, the current standard of care for PV relies on general immune suppression, which is often transiently effective but can lead to severe infection, potentially resulting in hospitalization and death.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Development Plan</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The DesCAARTes</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial is an open-label trial to assess the safety and tolerability of various dosing regimens of DSG3-CAART in the treatment of subjects with active mPV. The FDA granted DSG3-CAART Orphan Drug Designation for the treatment of PV in January 2020 and Fast Track Designation for improving healing of mucosal blisters in patients with mPV in May 2020. The DesCAARTes</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">trial is no longer dosing patients for treatment with DSG3-CAART after evaluation of clinical and translational data from the combination cohort, where patients were pre-treated with IVIg, cyclophosphamide and fludarabine prior to DSG3-CAART infusion. In October 2024, we presented data in an oral presentation at the European Society of Gene and Cell Therapy, or ESGCT, 31st Annual Congress showing that the use of preconditioning with DSG3-CAART did not provide serologic or clinical improvement and did not deeply deplete B-cell levels in patients with mPV.</span></p><p style="margin-left:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">MuSK-CAART for MuSK Myasthenia Gravis</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">MuSK-CAART is an investigational cell therapy aimed at treating patients with anti-MuSK antibody positive myasthenia gravis, or MuSK MG, who have active disease. We believe this strategy has the potential to directly eliminate the disease-causing cells in MuSK MG &#8211; induced by autoantibodies targeting the neuromuscular junction leading to potentially life-threatening muscle weakness to enable a complete and durable response for this disease. The current standard of care for patients with MuSK MG is typically corticosteroids in addition to one or more steroid-sparing immunosuppressive agents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Development Plan</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The MusCAARTes</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial is an open-label trial to assess the safety and tolerability of various dosing regimens of MuSK-CAART in the treatment of subjects with active MuSK MG. In February 2022, MuSK-CAART received Fast Track Designation from the FDA to improve activities of daily living and muscle strength in patients with MuSK antibody-positive myasthenia gravis. We are currently evaluating clinical and translational data from the A1 and A2 cohorts in the MusCAARTes</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial, where patients were treated with MuSK-CAART without preconditioning</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI',sans-serif;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturing</span></p><p style="margin-left:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Manufacturing Strategy</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are implementing a two-stage plan that we believe will ultimately enable us to achieve manufacturing independence. Part of our strategy relies on engaging non-profit and commercial suppliers early and in a staged manner. We believe partnering with proven and reputable manufacturing partners will allow us to efficiently deploy financial and personnel resources. The early phase of this plan is ongoing and utilizes the deep expertise in cell and vector manufacturing from our partners at Children&#8217;s Hospital of Philadelphia, or CHOP, and Penn, as well as commercial CDMO partnerships. We believe these facilities and partnerships will allow us to move efficiently into clinical trials with expanded commercial grade vector and cell product supply. We are aware that changes in any manufacturing process or facility introduces regulatory and scientific risk to a development program, if the changes result in a product that is not comparable. We plan to mitigate these risks across the two stages as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">By securing contract development and manufacturing organizations, or CDMOs, as partners during the early phase of our manufacturing strategy early on for both vector and cell manufacturing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We plan to prioritize potential partners who are qualified to, and have an established track record of, the commercial production of vector and cell products. We believe this allows us to make one change in our supply partners during an early period of clinical development to facilitate in vitro comparability testing and clinical validation, prior to controlled clinical studies.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.6798611111111111in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.139656180047857%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of this strategy, in January 2021 and as amended in August 2022, we entered into an agreement with WuXi to serve as an additional cell processing manufacturing partner for our MusCAARTes</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial and have since completed enabling engineering and patient production runs. In August 2023, as amended in August 2024, we entered into an agreement with WuXi to serve as one of our manufacturing partners for the global clinical development of rese-cel in multiple indications, including potential late-stage clinical trials and commercial readiness activities for rese-cel.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.6798611111111111in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.139656180047857%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to expand our clinical supply to address the increasing pace of enrollment in our clinical trials as well as to prepare for registrational trial(s) across the RESET clinical development program while expanding our manufacturing options for rese-cel, Cabaletta has expanded its CDMO agreements with Lonza to supply rese-cel clinical product under current Good Manufacturing Practices as soon as the second half of 2025.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.6798611111111111in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.139656180047857%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2021, we entered into the LSA with Oxford to supply lentiviral vector for the clinical and commercial development of our DSG3-CAART candidate. In May 2023, we amended the LSA with Oxford to expand the license to include our rese-cel program. In August 2023, we entered into a vector supply agreement with Oxford, and a related second amendment to the LSA, for rese-cel. In February 2024, we and Oxford entered into a third amendment to the LSA to update the patent schedule. In June 2024, we and Oxford entered into a fourth amendment to the LSA eliminating royalties on net sales of products that incorporate the Oxford technology if Oxford manufactures the vector. We believe these efforts will provide us with sufficient clinical-grade vector to move forward with our anticipated clinical trials.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In conjunction with our efforts to secure commercial supply for rese-cel, we plan to advance innovative manufacturing strategies in order to increase scale, reduce cost of goods and improve the patient experience. To this end, in November 2023, Cabaletta partnered with Cellares to evaluate Cellares&#8217; automated manufacturing platform, the Cell Shuttle&#153;, through Cellares&#8217; Technology Adoption Program. As part of the collaboration, the companies have agreed on a proof-of-concept technology transfer process for the manufacture of rese-cel. In August 2024, we expanded our partnership with Cellares to facilitate the potential to incorporate the Cellares manufacturing platform to support the RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> clinical program. In March 2025, we and Cellares announced the successful conclusion of the Technology Adoption Program on Cellares&#8217; automated cell therapy manufacturing Cell Shuttle&#153;, facilitating the potential integration of the Cell Shuttle</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> into our clinical and commercial, if approved, manufacturing strategy for rese-cel.</span></div></div><p style="margin-left:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cell Manufacturing</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have entered into a collaboration with the Clinical Cell and Vaccine Production Facility, or CVPF, at Penn, to provide focused scientific, technical and regulatory support for CAAR T and CAR T cell manufacture. CVPF is accredited by the Foundation for the Accreditation of Cellular Therapy and is capable of and experienced at supporting manufacture for early-phase clinical trials of novel cell therapy products in first-in-man clinical trials. We rely upon CVPF as one of our manufacturing partners to provide initial Phase 1 clinical trial drug supply for rese-cel. Penn&#8217;s manufacturing process for rese-cel is directly related to the process developed at Penn for early clinical trials of CD19-CAR T, which subsequently became known commercially as Kymriah. The process was later transferred to Novartis Pharmaceuticals Corporation and further modified for the Kymriah program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As we scale our manufacturing for our product candidates to meet our expected needs for further clinical trials, and while we continue to utilize Penn for Phase 1/2 studies in the US, we have brought on board commercial CDMOs capable of global and fully GMP compliant manufacturing, as well as other third parties for the manufacturing and processing of our clinical trial materials. Any CDMO that we select will be subject to cGMP requirements. We believe the use of contract manufacturing for our pipeline programs will be cost-effective and allow us to rapidly prepare for clinical trials in accordance with our development plans. In preparation for this transition, we have engaged multiple third-party contractors to manufacture clinical grade viral vector used to deliver the applicable CAAR or CAR gene into the T cells. We have also initiated development work with certain contractors for cGMP and commercial vector production. We expect third-party manufacturers will be capable of providing and processing sufficient quantities of our product candidates to meet anticipated clinical trial demands and commercial need. In January 2021 and as amended in August 2022, we entered into an agreement with WuXi to serve as an additional cell processing manufacturing partner for our MusCAARTes</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial and have since completed enabling engineering and patient production runs. In August 2023, as</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">amended in August 2024, we entered into an agreement with WuXi to serve as one of our manufacturing partners for the global clinical development of rese-cel in multiple indications, including potential late-stage clinical trials for rese-cel. In order to expand our clinical supply to address the increasing pace of enrollment in our clinical trials as well as to prepare for registrational trial(s) across the RESET clinical development program while expanding our manufacturing options for rese-cel, Cabaletta has expanded its CDMO agreements with Lonza, a leading CDMO, to supply rese-cel clinical product under current Good Manufacturing Practices as soon as the second half of 2025.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commercialization</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our aim is to become a fully integrated cellular therapy company focused on improving the lives of patients with autoimmune diseases. The product candidates from our CABA&#153; platform are designed to address autoimmune indications where there is a compelling opportunity to improve clinical outcomes in comparison with the current standard of care.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rese-cel is under development for autoimmune diseases with serious unmet medical need. Based on the differentiated expertise of Cabaletta&#8217;s team members and our years of experience in conducting cell therapy clinical trials in autoimmunity, we are focused on being the first company to launch a cell therapy product for patients with autoimmune diseases, while continuing to innovate on next-generation approaches and differentiation strategies to deliver an optimal product candidate profile.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We aim to achieve full manufacturing independence through expanding our CDMO relationships, establishment of our own manufacturing facilities, and/or through a strategic partnership. Our development and commercialization efforts will focus initially on the United States, with expansion to the European Union and Asia-Pacific geographies, potentially with the support of strategic partners.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competition</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong focus on intellectual property. We face competition from many different players, including large and specialty pharmaceutical and biotechnology companies, academic research organizations and governmental agencies. Any therapeutic candidates we successfully develop and commercialize will compete with the existing standard of care as well as any novel therapies that may gain regulatory approval in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are multiple companies with marketed CAR T therapies for the treatment of hematologic cancers, including Novartis Pharmaceuticals Corporation, Gilead Sciences, Inc., Bristol Myers Squibb, Johnson and Johnson, Inc., Legend Biotech Corporation and Autolus. A subset of these companies along with other biopharmaceutical companies have announced CD19-targeting therapies and other methods of engineering T cells in development for the treatment of autoimmune diseases with B cell involvement, including SLE, myositis, SSc and MG, among others. There are also a number of companies with leading autoimmune franchises but without disclosed cell therapy platforms who may become competitors.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Within the CAR T field, we recognize that a subset of companies with an investment and expertise in CAR T cell development for oncology indications have announced they intend to leverage their technology in autoimmune disease-affected populations. We are aware of other pharmaceutical and biotechnology companies that are exploring CART-19 as well as other methods of engineering T cells, natural killer, or NK, cells or bispecific antibodies for the treatment of autoimmune conditions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of the companies against which we are competing or against which we may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industry may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intellectual Property and Barriers to Entry</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We strive to protect the proprietary technologies that we believe are important to our business, including pursuing and maintaining patent protection intended to cover our product candidates and their use, as well as other inventions that are important to our business. In addition to patent protection, we also rely on know-how, confidentiality agreements, invention assignment agreements and trade secrets to protect aspects of our business that are not amenable to, or that we do not consider appropriate for,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">patent protection, to develop and maintain our proprietary position. The confidentiality agreements are designed to protect our proprietary information and the invention assignment agreements are designed to grant us ownership of technologies that are developed for us by our employees, consultants or certain other third parties. We seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in our agreements and security measures, either may be breached, and we may not have adequate remedies. In addition, our trade secrets may otherwise become known or independently discovered by competitors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our commercial success depends in part upon our ability to obtain and maintain patent and other proprietary protection for commercially important technologies, inventions and trade secrets related to our business, defend and enforce our intellectual property rights, particularly our patent rights, preserve the confidentiality of our trade secrets and operate without infringing valid and enforceable intellectual property rights of others.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The patent positions for biotechnology companies like us are generally uncertain and can involve complex legal, scientific and factual issues. In addition, the coverage claimed in a patent application can be significantly reduced before a patent is issued, and its scope can be reinterpreted and even challenged after issuance. As a result, we cannot guarantee that any of our product candidates will be protectable or remain protected by enforceable patents. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors. Any patents that we hold may be challenged, circumvented or invalidated by third parties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 1, 2025, our in-licensed patent estate included seven granted U.S. patents, seven granted foreign patents, seven pending U.S. patent applications, and 50 pending foreign patent applications. See &#8220;Our Material Agreements - IASO Agreement&#8221; and &#8220;Our Material Agreements - Amended and Restated License Agreement with the Trustees of the University of Pennsylvania and the Children&#8217;s Hospital of Philadelphia.&#8221; As of March 1, 2025, our Cabaletta-owned patent estate included three U.S. provisional patent applications and two pending international patent applications.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With regard to our rese-cel product candidate, under the IASO Agreement, we have in-licensed one patent family which is directed to a CD19-specific chimeric antigen receptor and a CD19-specific antibody and contains one pending U.S. patent application and counterpart patent applications pending in Australia, Canada, China, Europe, and Hong Kong. These patent applications, if issued, would be expected to expire in 2040. The family also contains granted patents in China and Japan, which are scheduled to expire in 2040. This patent family is owned by IASO and is exclusively licensed to us in the field of the license. We also own two international patent applications drawn to methods of treating autoimmune diseases with a chimeric antigen receptor, including a CD19-specific chimeric antigen receptor. Any granted patents claiming priority to these applications would be expected to expire in 2044. We also own one U.S. provisional patent application drawn to methods of treating autoimmune diseases with a chimeric antigen receptor, including a CD19-specific chimeric antigen receptor; one U.S. provisional patent application drawn to CD19-binding antibodies and CD19-specific chimeric antigen receptors; and one U.S. provisional patent application drawn to methods of manufacturing cell-therapy compositions. Any granted patents claiming priority to these applications would be expected to expire in 2045.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With regard to our MuSK-CAAR T cell product candidate, under the Amended and Restated License Agreement with Penn, we have in-licensed one patent family containing one issued U.S. patent with claims directed to a CAAR containing an extracellular domain containing a MuSK autoantigen and nucleic acids encoding the CAAR. This patent is scheduled to expire in 2039, without taking potential patent term extensions into account. This family also contains a counterpart patent granted in Japan which is scheduled to expire in 2039, and counterpart patent applications pending in the U.S., Australia, Canada, China, Europe, Hong Kong, Israel, Japan, Korea, Mexico and New Zealand, which if issued, would be expected to expire in 2039. This patent family is owned by Penn and exclusively licensed to us in the field of the license.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which we file, the patent term is 20 years from the earliest date of filing a non-provisional patent application. In the United States, the term of a patent covering an FDA-approved drug may be eligible for a patent term extension under the Hatch-Waxman Act as compensation for the loss of patent term during the FDA regulatory review process. The period of extension may be up to five years beyond the expiration of the patent but cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval. Only one patent among those eligible for an extension may be extended, and a given patent may only be extended once. Similar provisions are available in Europe and in certain other jurisdictions to extend the term of a patent that covers an approved drug. It is possible that issued U.S. patents covering each of our product candidates may be entitled to patent term extensions. If our product candidates receive FDA approval, we intend to apply for patent term extensions, if available, to extend the term of patents that cover the approved product candidates. We also intend to seek patent term extensions in any jurisdictions where they are available, however, there is no guarantee that the applicable authorities, including the FDA, will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to patent protection, we also rely on know-how and trade secret protection for our proprietary information that is not amenable to, or that we do not consider appropriate for, patent protection, to develop and maintain our proprietary position.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">However, trade secrets can be difficult to protect. Although we take steps to protect our proprietary information, including restricting access to our premises and our confidential information, as well as entering into agreements with our employees, consultants, advisors and potential collaborators, third parties may independently develop the same or similar proprietary information or may otherwise gain access to our proprietary information. As a result, we may be unable to meaningfully protect our know-how, trade secrets, and other proprietary information. In addition, we plan to rely on regulatory protection based on orphan drug exclusivities, data exclusivities, and market exclusivities. See &#8220;Government Regulation&#8221; for additional information.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Material Agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">IASO Agreement</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 7, 2022, we entered into an Exclusive License Agreement, or the IASO Agreement, with IASO. Pursuant to the IASO Agreement, we received an exclusive, worldwide license under certain IASO intellectual property to use a novel clinical-stage anti-CD19 binder to develop, manufacture, commercialize and otherwise exploit T cell products directed to CD19 for the purpose of diagnosis, prevention or treatment of any autoimmune or alloimmune indications in humans. IASO has the right of first negotiation if we desire to grant a third party an exclusive license to develop, manufacture, commercialize or otherwise exploit the licensed products in the Greater China region. Pursuant to the IASO Agreement, we and IASO have agreed, subject to certain exceptions, to refrain from engaging in certain competitive activities with respect to certain programs. As partial consideration for the exclusive license, IASO received an upfront payment of $2.5 million. IASO is also eligible to receive up to mid double digit millions in milestone payments based upon the achievement of specified pre-clinical, development and regulatory milestones, and up to an additional low triple digit millions in milestone payments based upon achievement of specified sales milestones, for a total consideration, inclusive of the upfront payment, of up to $162 million, along with tiered mid-single digit royalties on future net sales for licensed products that may result from the IASO Agreement. We also may sublicense through multiple tiers the rights granted to it by IASO under the IASO Agreement at any time, however, we must pay IASO a low double-digit percentage of any revenue obtained from sublicenses or options to third parties, subject to certain customary exclusions. The IASO Agreement will continue on a country-by-country, licensed product-by-licensed product basis until the expiration of the royalty term as identified in the IASO Agreement, unless earlier terminated. We and IASO may terminate the IASO Agreement for a material, uncured breach or insolvency of the other party. We may also terminate the IASO Agreement at will upon advance written notice and in the event IASO rejects the IASO Agreement due to bankruptcy-related matters. IASO may also terminate the IASO Agreement if we fail to achieve certain specified diligence milestones in a timely manner and/or if we commence any patent challenges with respect to the patents and patent applications relating to the licensed sequence, in each case upon advance written notice. A milestone payment of $1.5 million was paid to IASO in the first quarter of 2024 after the first patient in a rese-cel trial was dosed.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Oxford Biomedica</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2021, we entered into a Licence and Supply agreement, or LSA, with Oxford wherein the LSA grants us a non-exclusive license to Oxford&#8217;s LentiVector&#174; platform for its application in our DSG3-CAART program and puts in place a multi-year vector supply agreement. Under the terms of the agreement, we were required to pay Oxford an upfront fee, as well as costs associated with initial vector manufacturing activities. Oxford, is eligible to receive regulatory and sales milestones in the low tens of millions and royalties in the low single digits on net sales of products that incorporate the Oxford technology. We can terminate the agreement at will upon advance written notice and subject to certain manufacturing slot cancellation fees. In May 2023, we amended the LSA with Oxford to expand the license to include our rese-cel program for an upfront fee of $0.5 million and in August 2023, we entered into a vector supply agreement with Oxford, and a related second amendment to the LSA, for rese-cel with a total cost of up to approximately $5.0 million under the vector supply agreement. In February 2024, we and Oxford entered into a third amendment to the LSA to update the patent schedule. In June 2024, we and Oxford entered into a fourth amendment to the LSA eliminating royalties on net sales of products that incorporate the Oxford technology if Oxford manufactures the vector. In December 2024, the Company and Oxford entered into a work order for certain process characterization activities as part of commercial readiness activities. The Company can terminate the LSA or any work order under the LSA at will upon advance written notice and subject to certain cancellation fees.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">WuXi Manufacturing Agreement</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2021, we entered into a Development and Manufacturing Services Agreement, or the WuXi Agreement, with WuXi to serve as an additional cell processing manufacturing partner for the MuSK-CAART Phase 1 clinical trial, or MusCAARTes</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial. The WuXi Agreement is scheduled to expire upon completion of WuXi&#8217;s services related to MuSK-CAART and rese-cel. In August 2023, as amended in August 2024, we entered into an agreement with WuXi to serve as one of our manufacturing partners for the global clinical development of rese-cel in multiple indications, including potential late-stage clinical trials and commercial readiness activities for rese-cel. Under the August 2023 work orders, WuXi converted our non-dedicated suite to a dedicated suite for GMP manufacturing for our rese-cel and MuSK-CAART programs, or the Dedicated Suite, for an initial term of 18 months with two 18 month extensions at our sole option on six months' notice prior to the end of the term. In August 2024, we notified WuXi that we would extend the initial term by 18 months through August 2026. In addition, we agreed to certain monthly minimum runs. In August 2024, the 2023 work order related to GMP manufacturing was amended to reduce the minimum monthly runs through the end of 2024. In lieu of the original $1.5 million termination fee under the terms of the WuXi Agreement, we would</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">incur up to a $1.08 million termination fee if we terminate both the rese-cel and MuSK-CAART work orders for any reason. We may terminate for convenience the WuXi Agreement or any work order with six months' prior written notice, however, we may not terminate the Dedicated Suite without terminating both the MuSK-CAART and rese-cel GMP run work orders. WuXi may terminate the WuXi Agreement or any work order for convenience on 18 months' prior written notice, but such notice may not be effective prior to February 2028.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Amended and Restated License Agreement with the Trustees of the University of Pennsylvania and the Children&#8217;s Hospital of Philadelphia</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2018, we entered into a license agreement with Penn, which was amended and restated in July 2019 to include CHOP, collectively, the Institutions, and collectively with such amendment, as amended in May 2020 and October 2021, the License Agreement, pursuant to which we obtained (a) a non-exclusive, non-sublicensable, worldwide research license to make, have made and use products in two subfields of use, (b) effective as of October 2018, an exclusive, worldwide, royalty-bearing license, with the right to sublicense, under certain of the Institutions&#8217; intellectual property to make, use, sell, offer for sale and import products in the same two subfields of use, and (c) effective as of October 2018, a non-exclusive, worldwide, royalty-bearing license, with limited rights to sublicense, under certain of Penn&#8217;s know-how to make, have made, use, sell, offer for sale, import and have imported products in the same two subfields of use. Our rights are subject to the rights of the U.S. government and certain rights retained by the Institutions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless earlier terminated, the License Agreement expires on the expiration or abandonment or other termination of the last valid claim in Penn&#8217;s intellectual property licensed by us. We may terminate the License Agreement at any time for convenience upon 60 days' written notice. In the event of an uncured, material breach, Penn may terminate the License Agreement upon 60 days' written notice.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Master Translational Research Services Agreement</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2018, we entered into a Master Translational Research Services Agreement with Penn, or the Services Agreement, pursuant to which Penn agreed to perform certain services related to the research and development of the technology licensed to us under the License Agreement, as well as certain clinical, regulatory and manufacturing services. The Services Agreement will expire on the later of (i) October 19, 2021 or (ii) completion of the services for which we have engaged Penn under the Services Agreement. Either party may terminate this agreement with or without cause upon a certain number of days&#8217; prior written notice. The services encompassed by the Services Agreement are performed by different organizations at Penn pursuant to certain addenda to the Services Agreement, including the Center for Advanced Retinal and Ocular Therapeutics, or CAROT, Addendum, as amended in May 2020, and the CVPF Addendum.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2023, we entered into a second Master Translational Research Services Agreement with Penn, or the CARTA Services Agreement, pursuant to which Penn agreed to perform certain research, development and manufacturing activities. The CARTA Services Agreement will expire on the later of (i) February 9, 2026 or (ii) completion of the services for which we have engaged Penn under the CARTA Services Agreement. Either party may terminate this agreement with or without cause upon a certain number of days&#8217; prior written notice. The services encompassed by the CARTA Services Agreement are performed by different organizations at Penn pursuant to certain addenda to the CARTA Services Agreement.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Government Regulation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">U.S. Regulation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a biopharmaceutical company that operates in the United States, we are subject to extensive regulation. Our cell products will be regulated as biologics. With this classification, commercial production of our products will need to occur in registered facilities in compliance with cGMP for biologics. The FDA categorizes human cell- or tissue-based products as either minimally manipulated or more than minimally manipulated and has determined that more than minimally manipulated products require clinical trials to demonstrate product safety and efficacy and the submission of a BLA for marketing authorization. Our products are considered more than minimally manipulated and will require evaluation in clinical trials and the submission and approval of a BLA before we can market them.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Government authorities in the United States (at the federal, state and local level) and in other countries extensively regulate, among other things, the research, development, testing, manufacturing, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">biopharmaceutical products such as those we are developing. Our product candidates must be approved by the FDA before they may be legally marketed in the United States and by the appropriate foreign regulatory agency before they may be legally marketed in foreign countries. Generally, our activities in other countries will be subject to regulation that is similar in nature and scope as that imposed in the United States, although there can be important differences. Additionally, some significant aspects of regulation in Europe are addressed in a centralized way, but country-specific regulation remains essential in many respects. The process for obtaining regulatory marketing approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">U.S. Biological Product Development</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States, the FDA regulates biologics under the Federal Food, Drug, and Cosmetic Act, or FDCA, and the Public Health Service Act, or PHSA, and their implementing regulations. Biologics are also subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may result in delays to the conduct of a study, regulatory review and approval or subject an applicant to administrative or judicial sanctions. These sanctions could include, among other actions, the FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, license suspension or revocation, refusal to allow an applicant to proceed with clinical trials, imposition of a clinical hold, issuance of untitled or warning letters, product recalls or withdrawals from the market, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement of profits, or civil or criminal investigations or penalties. Any agency or judicial enforcement action could have a material adverse effect on us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our drug product candidates must be approved by the FDA through the Biologics License Application, or BLA, process before they may be legally marketed in the United States. The process required by the FDA before a biologic may be marketed in the United States generally involves the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">completion of extensive nonclinical, sometimes referred to as preclinical, laboratory tests, animal studies and formulation studies in accordance with applicable regulations, including the FDA&#8217;s Good Laboratory Practice, or GLP, regulations and standards; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">submission to the FDA of an IND which must become effective before human clinical trials may begin; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">approval by an independent institutional review board, or IRB, representing each clinical site before each clinical trial may be initiated; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">performance of adequate and well-controlled human clinical trials in accordance with applicable IND regulations, good clinical practices, or GCPs, and other clinical trial-related regulations to establish the safety and efficacy of the proposed drug product candidate for its proposed indication; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">submission to the FDA of a BLA, which includes not only the results of the clinical trials, but also, detailed information on the chemistry, manufacture and quality controls for the product candidate and proposed labeling; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities where the product is produced to assess compliance with the FDA&#8217;s current good manufacturing practice, or cGMP, requirements to assure that the facilities, methods and controls are adequate to preserve the product&#8217;s identity, strength, quality, purity and potency; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential FDA audit of the preclinical trial sites and/or clinical trial sites that generated the data in support of the BLA; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FDA review and approval of the BLA prior to any commercial marketing or sale of the product in the United States. </span></div></div><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The data required to support a BLA is generated in two distinct development stages: preclinical and clinical. The preclinical development stage generally involves laboratory evaluations of drug chemistry, formulation and stability, as well as studies to evaluate toxicity in animals, which support subsequent clinical testing. The conduct of the preclinical studies must comply with federal regulations, including GLPs. The sponsor must submit the results of the preclinical studies, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, as well as other information, to the FDA as part of the IND. An IND is a request for authorization from the FDA to administer an investigational drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for human trials. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA raises concerns or questions regarding the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">proposed clinical trials and places the IND on clinical hold within that 30-day time period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA may also impose clinical holds on a drug product candidate at any time before or during clinical trials due to safety concerns, non-compliance, or other issues affecting the integrity of the trial. Accordingly, we cannot be sure that submission of an IND will result in the FDA allowing clinical trials to begin, or that, once begun, issues will not arise that could cause the trial to be suspended or terminated.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the submission of an IND to the FDA before initiation of a clinical trial in the United States, certain human clinical trials involving recombinant or synthetic nucleic acid molecules are subject to oversight of institutional biosafety committees, or IBCs, as set forth in the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules, or NIH Guidelines. Under the NIH Guidelines, recombinant and synthetic nucleic acids are defined as: (i) molecules that are constructed by joining nucleic acid molecules and that can replicate in a living cell (i.e., recombinant nucleic acids); (ii) nucleic acid molecules that are chemically or by other means synthesized or amplified, including those that are chemically or otherwise modified but can base pair with naturally occurring nucleic acid molecules (i.e., synthetic nucleic acids); or (iii) molecules that result from the replication of those described in (i) or (ii). Specifically, under the NIH Guidelines, supervision of human gene transfer trials includes evaluation and assessment by an IBC, a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to public health or the environment, and such review may result in some delay before initiation of a clinical trial. While the NIH Guidelines are not mandatory unless the research in question is being conducted at or sponsored by institutions receiving NIH funding of recombinant or synthetic nucleic acid molecule research, many companies and other institutions not otherwise subject to the NIH Guidelines voluntarily follow them.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The clinical stage of development involves the administration of the drug product candidate to healthy volunteers and patients under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#8217;s control, in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria, and the parameters to be used to monitor subject safety and assess efficacy. Each protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND. Further, each clinical trial must be reviewed and approved by an IRB at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are also requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries. Sponsors of certain clinical trials of FDA-regulated products, including biologics, are required to register and disclose certain clinical trial information, which is publicly available at www.clinicaltrials.gov.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical trials are generally conducted in three sequential phases, known as Phase 1, Phase 2 and Phase 3, and may overlap. Phase 1 clinical trials generally involve a small number of healthy volunteers who are initially exposed to a single dose and then multiple doses of the drug product candidate. The primary purpose of these clinical trials is to assess the metabolism, pharmacologic action tolerability, adverse effects, and safety of the drug product candidate and, if possible, to gain early evidence on effectiveness. Phase 2 clinical trials typically involve studies in disease-affected patients to determine the dose required to produce the desired benefits. At the same time, safety and further pharmacokinetic and pharmacodynamic information is collected, as well as identification of possible adverse effects and safety risks and preliminary evaluation of efficacy. Phase 3 clinical trials generally involve large numbers of patients at multiple sites, in multiple countries, and are designed to provide the data necessary to demonstrate the efficacy of the product for its intended use, its safety in use, and to establish the overall benefit/risk relationship of the product and provide an adequate basis for product approval. Phase 3 clinical trials may include comparisons with placebo and/or other comparator treatments. The duration of treatment is often extended to mimic the actual use of a product during marketing. Generally, two adequate and well-controlled Phase 3 clinical trials are required by the FDA for approval of a BLA. In certain instances, FDA may condition approval of a BLA on the sponsor&#8217;s agreement to conduct additional clinical trials to further assess the biologic&#8217;s safety and effectiveness after BLA approval. Such post-approval trials are sometimes referred to as Phase 4 clinical trials. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication and further document clinical benefit in the case of drugs approved under Accelerated Approval regulations. Failure to exhibit due diligence with regard to conducting Phase 4 clinical trials could result in withdrawal of approval for products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Progress reports detailing the results of the clinical trials, among other information, must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and the investigators for serious and unexpected suspected adverse events, findings from other studies suggesting a significant risk to humans exposed to the biologic, findings from animal or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in vitro testing that suggest a significant risk for human subjects, and any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, if at all. The FDA, the IRB, or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether or not a trial may move forward at designated intervals based on access to certain data from the trial and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as interim data suggesting a lack of efficacy. We may also suspend or terminate a clinical trial based on evolving business objectives and/or competitive climate. Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug product candidate as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the drug product candidate and, among other things, must develop methods for testing the identity, strength, quality, potency and purity of the final product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the drug product candidate does not undergo unacceptable deterioration over its shelf life.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">BLA and FDA Review Process</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following trial completion, trial data are analyzed to assess safety and efficacy. The results of preclinical studies and clinical trials are then submitted to the FDA as part of a BLA, along with proposed labeling for the product and information about the manufacturing process and facilities that will be used to ensure product quality, results of analytical testing conducted on the chemistry of the drug product candidate, and other relevant information. The BLA is a request for approval to market the biologic for one or more specified indications and must contain proof of safety, purity, potency and efficacy, which is demonstrated by extensive preclinical and clinical testing. The application may include both negative or ambiguous results of preclinical and clinical trials as well as positive findings. Data may come from company-sponsored clinical trials intended to test the safety and efficacy of a use of a product, or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the investigational product to the satisfaction of the FDA. FDA approval of a BLA must be obtained before a biologic may be marketed in the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Prescription Drug User Fee Act, or PDUFA, as amended, each BLA must be accompanied by a significant user fee, which is adjusted on an annual basis. PDUFA also imposes an annual prescription drug product program fee. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Once a BLA has been accepted for filing, which occurs, if at all, sixty days after the BLA&#8217;s submission, the FDA&#8217;s goal is to review BLAs within 10 months of the filing date for standard review or six months of the filing date for priority review, if the application is for a product intended for a serious or life-threatening condition and the product, if approved, would provide a significant improvement in safety or effectiveness. The FDA has substantial discretion in the approval process and may refuse to accept any application or decide that the data is insufficient for approval, and may require additional preclinical, clinical or other studies before it accepts the filing. Additionally, the review process is often significantly extended by FDA requests for additional information or clarification.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After the BLA submission is accepted for filing, the FDA reviews the BLA to determine, among other things, whether the proposed drug product candidate is safe and effective for its intended use, and whether the drug product candidate is being manufactured in accordance with cGMP to assure and preserve the drug product candidate&#8217;s identity, strength, quality, purity and potency. The FDA may refer applications for novel drug product candidates or drug product candidates which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. The FDA will likely re-analyze the clinical trial data, which could result in extensive discussions between the FDA and us during the review process. The review and evaluation of a BLA by the FDA is extensive and time consuming and may take longer than originally planned to complete, and we may not receive a timely approval, if at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Before approving a BLA, the FDA will conduct a pre-approval inspection of the manufacturing facilities for the new product to determine whether the facilities comply with cGMPs. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the product within required specifications. In addition, before approving a BLA, the FDA may also audit data from clinical trials to ensure compliance with GCP requirements. After the FDA evaluates the application, manufacturing process and manufacturing facilities, it may issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete and the application will not be approved in its present form. A Complete Response Letter usually describes all of the specific deficiencies in the BLA identified by the FDA. The Complete Response Letter may require additional clinical data and/or an additional pivotal Phase 3 clinical trial(s), and/or other significant and time-consuming requirements related to clinical trials, preclinical studies or manufacturing. If a Complete Response Letter is issued, the applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, withdraw the application or request a hearing. Even if such data and information is submitted, the FDA may ultimately decide that the BLA does not satisfy the criteria for approval. Data obtained from clinical trials are not always conclusive, and the FDA may interpret data differently than we interpret the same data.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is no assurance that the FDA will ultimately approve a product for marketing in the United States, and we may encounter significant difficulties or costs during the review process. If a product receives marketing approval, the approval may be significantly limited to specific populations, severities of allergies, and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling or may condition the approval of the BLA on other changes to the proposed labeling, development of adequate controls and specifications, or a commitment to conduct post-market testing or clinical trials and surveillance to monitor the effects of approved products. For example, the FDA may require Phase 4 testing which involves clinical trials designed to further assess the product&#8217;s safety and effectiveness and may require testing and surveillance programs to monitor the safety of approved products that have been commercialized. The FDA may also place other conditions on approvals including the requirement for a Risk Evaluation and Mitigation Strategy, or REMS, to assure the safe use of the product. If the FDA concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS. The FDA will not approve the BLA without an approved REMS, if required. a REMS could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products. Product approvals may be withdrawn for non-compliance with regulatory standards or based on the results of post-market studies or surveillance programs. Additionally, post-approval, many types of changes to the approved product, such as adding new indications, changing manufacturing processes and adding labeling claims, are subject to further testing requirements and FDA review and approval. Such post-approval requirements can be costly and time-consuming and can affect the potential market and profitability of the product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Orphan Designation and Exclusivity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biological product intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making the product available in the United States for this type of disease or condition will be recovered from sales of the product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Orphan drug designation must be requested before submitting an NDA or BLA. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a product that has orphan drug designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same drug or biologic for the same indication for seven years from the date of such approval, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity on the basis of greater effectiveness or safety or providing a major contribution to patient care or in instances of drug supply issues. Competitors, however, may receive approval of either a different product for the same indication or the same product for a different indication but that could be used off-label in the orphan indication. Orphan drug exclusivity also could block the approval of one of our products for seven years if a competitor obtains approval before we do for the same product, as defined by the FDA, for the same indication we are seeking approval, or if our product is determined to be contained within the scope of the competitor&#8217;s product for the same indication or disease. If we pursue marketing approval for an indication broader than the orphan drug designation we have received, we may not be entitled to orphan drug exclusivity. Orphan drug status in the European Union has similar, but not identical, requirements and benefits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expedited Development and Review Programs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA has a Fast Track program that is intended to expedite or facilitate the process for reviewing new drugs and biological products that meet certain criteria. Specifically, new drugs and biological products are eligible for Fast Track Designation if they are</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">intended to treat a serious or life-threatening condition and nonclinical or clinical data demonstrate the potential to address unmet medical needs for the condition. Fast Track Designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a new drug or biologic may request the FDA to designate the drug or biologic as a Fast Track product concurrently with, or at any time after, submission of an IND, and the FDA must determine if the product qualifies for Fast Track Designation within 60 days of receipt of the sponsor&#8217;s request. Under the Fast Track Designation, the FDA may consider for review sections of the marketing application on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the application, the FDA agrees to accept sections of the application and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the application.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any product submitted to the FDA for marketing, including under a Fast Track program, may be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. Any product is eligible for priority review, or review within a six-month timeframe from the date a complete BLA is accepted for filing, if it has the potential to provide a significant improvement in safety and effectiveness compared to available therapies. The FDA will attempt to direct additional resources to the evaluation of an application for a new drug or biological product designated for priority review in an effort to facilitate the review.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, a product may be eligible for accelerated approval. An investigational drug may obtain accelerated approval if it treats a serious or life-threatening condition and generally provides a meaningful advantage over available therapies and demonstrates an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, or IMM, that is reasonably likely to predict an effect on IMM or other clinical benefit. As a condition of approval, the FDA may require that a sponsor of a drug or biological product receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials and, under the Food and Drug Omnibus Reform Act of 2022, or FDORA, the FDA is now permitted to require, as appropriate, that such trials be underway prior to approval or within a specific time period after the date of approval for a product granted accelerated approval. Under FDORA, the FDA has increased authority for expedited procedures to withdraw approval of a drug or indication approved under accelerated approval if, for example, the confirmatory trial fails to verify the predicted clinical benefit of the product. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product. Fast Track Designation, priority review and accelerated approval do not change the standards for approval but may expedite the development or approval process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Breakthrough Designation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A product can be designated as a breakthrough therapy if it is intended to treat a serious or life-threatening condition and preliminary clinical evidence indicates that it may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. A sponsor may request that a drug product candidate be designated as a breakthrough therapy concurrently with, or at any time after, the submission of an IND, and the FDA must determine if the drug product candidate qualifies for breakthrough therapy designation within 60 days of receipt of the sponsor&#8217;s request. If so designated, the FDA shall act to expedite the development and review of the product&#8217;s marketing application, including by meeting with the sponsor throughout the product&#8217;s development, providing timely advice to the sponsor to ensure that the development program to gather preclinical and clinical data is as efficient as practicable, involving senior managers and experienced review staff in a cross-disciplinary review, assigning a cross-disciplinary project lead for the FDA review team to facilitate an efficient review of the development program and to serve as a scientific liaison between the review team and the sponsor, and taking steps to ensure that the design of the clinical trials is as efficient as practicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accelerated Approval for Regenerative Medicine Advanced Therapies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FDA&#8217;s regenerative medicine advanced therapy, or RMAT, program is intended to facilitate efficient development and expedite review of regenerative medicine advanced therapies, which are intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition. A drug sponsor may request that FDA designate a drug as an RMAT concurrently with or at any time after submission of an IND. FDA has 60 calendar days to determine whether the drug meets the criteria, including whether there is preliminary clinical evidence indicating that the drug has the potential to address unmet medical needs for a serious or life-threatening disease or condition. A BLA for an RMAT may be eligible for priority review or accelerated approval through (1) surrogate or intermediate endpoints reasonably likely to predict long-term clinical benefit or (2) reliance upon data obtained from a meaningful number of sites. Benefits of such designation also include early interactions with FDA to discuss any potential surrogate or intermediate endpoint to be used to support accelerated approval. An RMAT that is granted accelerated approval and is subject to post approval requirements may fulfill such requirements through the submission of clinical evidence, clinical studies, patient registries, or other sources of real world evidence, such as electronic health records; the collection of larger confirmatory data sets; or post approval monitoring of all patients treated with such therapy prior to its approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="margin-left:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pediatric Trials</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Pediatric Research Equity Act, or PREA, a BLA or supplement to a BLA must contain data to assess the safety and efficacy of the product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDCA requires that a sponsor who is planning to submit a marketing application for a drug or biological product that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration submit an initial Pediatric Study Plan, or PSP, within sixty days of an end-of-Phase 2 meeting or as may be agreed between the sponsor and FDA. The initial PSP must include an outline of the pediatric study or studies that the sponsor plans to conduct, including study objectives and design, age groups, relevant endpoints and statistical approach, or a justification for not including such detailed information, and any request for a deferral of pediatric assessments or a full or partial waiver of the requirement to provide data from pediatric studies along with supporting information. The FDA and the sponsor must reach agreement on the PSP. A sponsor can submit amendments to an agreed-upon initial PSP at any time if changes to the pediatric plan need to be considered based on data collected from nonclinical studies, early phase clinical trials, and/or other clinical development programs. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of data or full or partial waivers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Post-Marketing Requirements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following approval of a new product, a manufacturer and the approved product are subject to continuing regulation by the FDA, including, among other things, monitoring and recordkeeping activities, reporting to the applicable regulatory authorities of adverse experiences with the product, providing the regulatory authorities with updated safety and efficacy information, product sampling, distribution, and tracking and tracing requirements, and complying with promotion and advertising requirements, which include, among others, standards for direct-to-consumer advertising, restrictions on promoting products for uses or in patient populations that are not described in the product&#8217;s approved labeling (known as &#8220;off-label use&#8221;), limitations on industry-sponsored scientific and educational activities, and requirements for promotional activities involving the internet. Although physicians may prescribe legally available drugs and biologics for off-label uses, manufacturers may not market or promote such off-label uses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Modifications or enhancements to the product or its labeling or changes of the site of manufacture are often subject to the approval of the FDA and other regulators, which may or may not be received or may result in a lengthy review process. Prescription drug promotional materials must be submitted to the FDA in conjunction with their first use.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States, once a product is approved, its manufacture is subject to comprehensive and continuing regulation by the FDA. The FDA regulations require that products be manufactured in specific approved facilities and in accordance with cGMPs. We rely, and expect to continue to rely, on third parties for the production of clinical and commercial quantities of our products in accordance with cGMP regulations. cGMP regulations require, among other things, quality control and quality assurance as well as the corresponding maintenance of records and documentation and the obligation to investigate and correct any deviations from cGMP. Manufacturers and other entities involved in the manufacture and distribution of approved products are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. These regulations also impose certain organizational, procedural and documentation requirements with respect to manufacturing and quality assurance activities. BLA holders using contract manufacturers, laboratories or packagers are responsible for the selection and monitoring of qualified firms, and, in certain circumstances, qualified suppliers to these firms. These firms and, where applicable, their suppliers are subject to inspections by the FDA at any time, and the discovery of violative conditions, including failure to conform to cGMP, could result in enforcement actions that interrupt the operation of any such facilities or the ability to distribute products manufactured, processed or tested by them. Discovery of problems with a product after approval may result in restrictions on a product, manufacturer, or holder of an approved BLA, including, among other things, recall or withdrawal of the product from the market.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA also may require post-approval testing, sometimes referred to as Phase 4 testing, REMS and post-marketing surveillance to monitor the effects of an approved product or place conditions on an approval that could restrict the distribution or use of the product. Discovery of previously unknown problems with a product or the failure to comply with applicable FDA requirements can have negative consequences, including adverse publicity, judicial or administrative enforcement, untitled or warning letters from the FDA, mandated corrective advertising or communications with doctors, and civil or criminal penalties, among others. Newly discovered or developed safety or effectiveness data may require changes to a product&#8217;s approved labeling, including the addition of new warnings and contraindications, and also may require the implementation of other risk management measures. Also, new government requirements, including those resulting from new legislation, may be established, or the FDA&#8217;s policies may change, which could delay or prevent regulatory approval of our products under development.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="margin-left:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Regulatory Matters</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturing, sales, promotion and other activities following product approval are also subject to regulation by numerous regulatory authorities in addition to the FDA, including, in the United States, the Centers for Medicare &amp; Medicaid Services, or CMS, other divisions of the Department of Health and Human Services, or HHS (e.g., the Office of Inspector General, or OIG, and Office for Civil Rights), the Drug Enforcement Administration, the Consumer Product Safety Commission, the Federal Trade Commission, the Occupational Safety &amp; Health Administration, the Environmental Protection Agency and state and local governments. In the United States, sales, marketing and scientific/educational programs must also comply with federal and state fraud and abuse laws, data privacy and security laws, transparency laws, and pricing and reimbursement requirements in connection with governmental payor programs, among others. The handling of any controlled substances must comply with the U.S. Controlled Substances Act and Controlled Substances Import and Export Act. Products must meet applicable child-resistant packaging requirements under the U.S. Poison Prevention Packaging Act. Manufacturing, sales, promotion and other activities are also potentially subject to federal and state consumer protection and unfair competition laws.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The distribution of pharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The failure to comply with regulatory requirements subjects firms to possible legal or regulatory action. Depending on the circumstances, failure to meet applicable regulatory requirements can result in criminal prosecution, fines or other penalties, injunctions, recall or seizure of products, total or partial suspension of production, denial or withdrawal of product approvals, or refusal to allow a firm to enter into supply contracts, including government contracts. In addition, even if a firm complies with FDA and other requirements, new information regarding the safety or efficacy of a product could lead the FDA to modify or withdraw product approval. Prohibitions or restrictions on sales or withdrawal of future products marketed by us could materially affect our business in an adverse way.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, legislation is drafted, introduced, passed in Congress and signed into law that could significantly change the statutory provisions governing the approval, manufacturing, and marketing of products regulated by the FDA. In addition to new legislation, FDA regulations, guidances, and policies are often revised or reinterpreted by the agency in ways that may significantly affect the manner in which pharmaceutical products are regulated and marketed. Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example: (i) changes to our manufacturing arrangements; (ii) additions or modifications to product labeling; (iii) the recall or discontinuation of our products; or (iv) additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">U.S. Patent Term Restoration and Marketing Exclusivity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depending upon the timing, duration and specifics of the FDA approval of our drug product candidates, some of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date. The patent term restoration period is generally one-half the time between the effective date of an IND and the submission date of a BLA plus the time between the submission date of a BLA and the approval of that application, except that the review period is reduced by any time during which the applicant failed to exercise due diligence. Only one patent applicable to an approved drug is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. The U.S. PTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we may apply for restoration of patent term for our currently owned or licensed patents to add patent life beyond its current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant BLA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An abbreviated approval pathway for biological products shown to be biosimilar to, or interchangeable with, an FDA-licensed reference biological product was created by the Biologics Price Competition and Innovation Act of 2009, or BPCI Act, which was part of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the ACA. This amendment to the PHSA attempts to minimize duplicative testing. Biosimilarity, which requires that the biological product be highly similar to the reference product notwithstanding minor differences in clinically inactive components and that there be no clinically meaningful differences between the product and the reference product in terms of safety, purity, and potency, can be shown through analytical studies, animal studies, and a clinical trial or trials. Interchangeability requires that a biological product be biosimilar to the reference product and that the product can be expected to produce the same clinical results as the reference product in any given patient and, for products administered multiple times, that the product and the reference product may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biological product. However, complexities associated with the larger, and often more complex,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">structure of biological products as compared to small molecule drugs, as well as the processes by which such products are manufactured, pose significant hurdles to implementation that are still being worked out by the FDA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reference biological product is granted twelve years of exclusivity from the time of first licensure of the product, and the FDA will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four years after first licensure. &#8220;First licensure&#8221; typically means the initial date the particular product at issue was licensed in the United States. This does not include a supplement for the biological product or a subsequent application by the same sponsor or manufacturer of the biological product (or licensor, predecessor in interest, or other related entity) for a change that results in a new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device, or strength, unless that change is a modification to the structure of the biological product and such modification changes its safety, purity, or potency. Whether a subsequent application, if approved, warrants exclusivity as the &#8220;first licensure&#8221; of a biological product is determined on a case-by-case basis with data submitted by the sponsor.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pediatric exclusivity is another type of regulatory market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods. This six-month exclusivity, which attaches to the twelve-year exclusivity period for reference biologics, may be granted based on the voluntary completion of a pediatric trial in accordance with an FDA-issued &#8220;Written Request&#8221; for such a trial, provided that at the time pediatric exclusivity is granted there is not less than nine months of term remaining.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pricing and Reimbursement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">United States</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sales of our products will depend, in part, on the extent to which our products, once approved, will be covered and reimbursed by third-party payors, such as government health programs, commercial insurance and managed healthcare organizations. These third-party payors are increasingly reducing reimbursements for medical products and services. The process for determining whether a third-party payor will provide coverage for a drug product, including a biologic, typically is separate from the process for setting the price of a drug product or for establishing the reimbursement rate that a payor will pay for the drug product once coverage is approved. Third-party payors may limit coverage to specific drug products on an approved list, also known as a formulary, which might not include all of the approved drugs for a particular indication.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to secure coverage and reimbursement for any drug product candidate that might be approved for sale, we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the drug product candidate, in addition to the costs required to obtain FDA or other comparable regulatory approvals. Whether or not we conduct such studies, our drug product candidates may not be considered medically necessary or cost-effective. A third-party payor&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Third party reimbursement may not be sufficient to enable us to maintain price levels high enough to realize an appropriate return on our investment in product development. In the United States, the principal decisions about reimbursement for new drug products are typically made by CMS, an agency within HHS. CMS decides whether and to what extent a new drug product will be covered and reimbursed under Medicare, and private payors tend to follow CMS to a substantial degree. However, no uniform policy of coverage and reimbursement for drug products exists among third-party payors and coverage and reimbursement levels for drug products can differ significantly from payor to payor. Additionally, one third-party payor&#8217;s decision to cover a particular product or service does not ensure that other payors will also provide coverage for the product or service, and the level of coverage and reimbursement can differ significantly from payor to payor. As a result, the coverage determination process will often require us to provide scientific and clinical support for the use of our products to each payor separately and can be a time-consuming process, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Factors payors consider in determining reimbursement are based on whether the product is:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a covered benefit under its health plan; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">safe, effective and medically necessary; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">appropriate for the specific patient; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cost-effective; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">neither experimental nor investigational. </span></div></div><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The containment of healthcare costs has become a priority of federal and state governments, and the prices of drugs, including biologics, have been a focus in this effort. The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">substitution of generic products. In many countries, the prices of drug products are subject to varying price control mechanisms as part of national health systems. In general, the prices of drug products under such systems are substantially lower than in the United States. Other countries allow companies to fix their own prices for drug products but monitor and control company profits. Accordingly, in markets outside the United States, the reimbursement for drug products may be reduced compared with the United States. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our net revenue and results. Decreases in third-party reimbursement for our drug product candidate or a decision by a third-party payor to not cover our drug product candidate could reduce physician usage of the drug product candidate and have a material adverse effect on our sales, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outside of the United States, the pricing of pharmaceutical products is subject to governmental control in many countries. For example, in the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been approved. Some countries may require the completion of additional studies that compare the cost effectiveness of a particular therapy to currently available therapies or so-called health technology assessments, in order to obtain reimbursement or pricing approval. Other countries may allow companies to fix their own prices for products but monitor and control product volumes and issue guidance to physicians to limit prescriptions. Efforts to control prices and utilization of pharmaceutical products will likely continue as countries attempt to manage healthcare expenditures. Historically, products launched in the European Union do not follow price structures of the United States and generally prices tend to be significantly lower.</span></p><p style="margin-left:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Healthcare Laws and Compliance Requirements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Healthcare providers, physicians, and third-party payors will play a primary role in the recommendation and prescription of any products for which we obtain marketing approval. Our business operations in the United States and our current and future arrangements with clinical investigators, healthcare providers, consultants, third-party payors and patients may expose us to broadly applicable federal and state fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute any drugs for which we obtain marketing approval. In the United States, these laws include: the federal Anti-Kickback Statute, the False Claims Act, and HIPAA.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Anti-Kickback Statute makes it illegal for any person, including a prescription drug manufacturer (or a party acting on its behalf), to knowingly and willfully solicit, receive, offer or pay any remuneration, directly or indirectly, in cash or in kind, that is intended to induce or reward referrals, including the purchase, recommendation, order or prescription of a particular drug, for which payment may be made under a federal healthcare program, such as Medicare or Medicaid. Violations of this law are punishable by imprisonment, criminal fines, administrative civil money penalties and exclusion from participation in federal healthcare programs. In addition, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it. Moreover, the ACA provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers, and formulary managers on the other. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we would not submit claims directly to payors, drug manufacturers can be held liable under the federal civil False Claims Act, which imposes civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities (including manufacturers) for, among other things, knowingly presenting, or causing to be presented to federal programs (including Medicare and Medicaid) claims for items or services, including drugs, that are false or fraudulent, claims for items or services not provided as claimed, or claims for medically unnecessary items or services. Penalties for a False Claims Act violation include three times the actual damages sustained by the government, plus mandatory civil penalties for each separate false claim, the potential for exclusion from participation in federal healthcare programs and, although the federal False Claims Act is a civil statute, conduct that results in a False Claims Act violation may also implicate various federal criminal statutes. The government may deem manufacturers to have &#8220;caused&#8221; the submission of false or fraudulent claims by, for example, providing inaccurate billing or coding information to customers or promoting a product off- label. Claims which include items or services resulting from a violation of the federal Anti-Kickback Statute are false or fraudulent claims for purposes of the False Claims Act. The federal False Claims Act also permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the federal False Claims Act and to share in any monetary recovery. Our future marketing and activities relating to the reporting of wholesaler or estimated retail prices for our products, if approved, the reporting of prices used to calculate Medicaid rebate information and other information affecting federal, state and third-party reimbursement for our products, and the sale and marketing of our product candidates, are subject to scrutiny under this law.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The civil monetary penalties statute imposes penalties against any person or entity that, among other things, is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, we may be subject to data privacy and security regulations by both the federal government and states in which we conduct our business. For example, HIPAA created new federal criminal statutes that prohibit among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the control or custody of, any healthcare benefit program, including private third party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up by trick, scheme or device, a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Like the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or the HITECH, and its implementing regulations, mandates, among other things, the adoption of uniform standards for the electronic exchange of information in common healthcare transactions, as well as standards relating to the privacy and security of individually identifiable health information, which require the adoption of administrative, physical and technical safeguards to protect such information. Among other things, HITECH makes HIPAA&#8217;s security standards directly applicable to business associates, defined as independent contractors or agents of covered entities, which include certain health care providers, health plans, and healthcare clearinghouses, that create, receive or obtain protected health information in connection with providing a service for or on behalf of a covered entity. HITECH also increased the civil and criminal penalties that may be imposed against covered entities and business associates and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions. In addition, certain state laws govern the privacy and security of health information and other personal data in certain circumstances, some of which are more stringent or otherwise different than HIPAA and many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and criminal penalties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, the federal Physician Payments Sunshine Act, or the Sunshine Act, within the ACA, and its implementing regulations, require that certain manufacturers of drugs, devices, biological and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) report annually to CMS information related to certain payments or other transfers of value made or distributed to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain other licensed health care practitioners and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members. In addition, many states also govern the reporting of payments or other transfers of value, many of which differ from each other in significant ways, are often not pre-empted, and may have a more prohibitive effect than the Sunshine Act, thus further complicating compliance efforts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may become subject to federal government price reporting laws, which would require us to calculate and report complex pricing metrics in an accurate and timely manner to government programs, as well as federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Similar federal, state and foreign fraud and abuse laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services. Such laws are generally broad and are enforced by various state agencies and private actions. Also, many states have similar fraud and abuse statutes or regulations that may be broader in scope and may apply regardless of payor, in addition to items and services reimbursed under Medicaid and other state programs. Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant federal government compliance guidance, and require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to distribute products commercially, we must comply with state laws that require the registration of manufacturers and wholesale distributors of drug and biological products in a state, including, in certain states, manufacturers and distributors who ship products into the state even if such manufacturers or distributors have no place of business within the state. Some states also impose requirements on manufacturers and distributors to establish the pedigree of product in the chain of distribution, including some states that require manufacturers and others to adopt new technology capable of tracking and tracing product as it moves through the distribution chain. Several states have enacted legislation requiring pharmaceutical and biotechnology companies to establish marketing compliance programs, file periodic reports with the state, make periodic public disclosures on sales, marketing, pricing, clinical trials and other activities, and/or register their sales representatives, as well as to prohibit pharmacies and other healthcare entities from providing certain physician prescribing data to pharmaceutical and biotechnology companies for use in sales</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and marketing, and to prohibit certain other sales and marketing practices. All of our activities are potentially subject to federal and state consumer protection and unfair competition laws.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, contractual damages, reputational harm, diminished profits and future earnings, individual imprisonment, exclusion of drugs from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our financial results. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. Ensuring business arrangements comply with applicable healthcare laws, as well as responding to possible investigations by government authorities, can be time- and resource- consuming and can divert a company&#8217;s attention from the business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Current and Future Legislation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States and some foreign jurisdictions, there have been, and likely will continue to be, a number of legislative and regulatory changes and proposed changes regarding the healthcare system directed at broadening the availability of healthcare, improving the quality of healthcare, and containing or lowering the cost of healthcare.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, in 2010, the ACA was enacted in the United States. The ACA includes measures that have significantly changed, and are expected to continue to significantly change, the way healthcare is financed by both governmental and private insurers. Among the provisions of the ACA of greatest importance to the pharmaceutical industry are that the ACA:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">made several changes to the Medicaid Drug Rebate Program, including increasing pharmaceutical manufacturers&#8217; rebate liability by raising the minimum basic Medicaid rebate on average manufacturer price, or AMP, on most branded prescription drugs and adding a new rebate calculation for &#8220;line extensions&#8221; (i.e., new formulations, such as extended release formulations) of solid oral dosage forms of branded products, as well as potentially impacting their rebate liability by modifying the statutory definition of AMP; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">imposed a requirement on manufacturers of branded drugs to provide a 70% point-of-sale discount as a condition for a manufacturer&#8217;s outpatient drugs being covered under Medicare Part D; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">extended a manufacturer&#8217;s Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expanded the entities eligible for discounts under the 340B Drug Discount Program; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">imposed an annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drugs, apportioned among these entities according to their market share in certain government healthcare programs, and </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">established a Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research. The research conducted by the Patient-Centered Outcomes Research Institute may affect the market for certain pharmaceutical products. The ACA established the Center for Medicare and Medicaid Innovation within CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. </span></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">31</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Budget Control Act of 2011 and subsequence legislation, among other things, created measures for spending reductions by Congress that include aggregate reductions of Medicare payments to providers of 2% per fiscal year, which remain in effect through 2031. Due to the Statutory Pay-As-You-Go Act of 2010, estimated budget deficit increases resulting from the American Rescue Plan Act of 2021, and subsequent legislation, Medicare payments to providers were further reduced starting on January 1, 2025; however, legislation has been introduced in the U.S. Congress that would, if enacted, reverse these payment reductions.&#8239;In addition to provider payment cuts under Medicare, the American Rescue Plan Act of 2021 also eliminated the statutory Medicaid drug rebate cap, previously set at 100% of a drug&#8217;s average manufacturer price, for single source and innovator multiple source drugs, effective January 1, 2024. These laws and regulations may result in additional reductions in Medicare and other healthcare funding available for healthcare providers and may otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The American Taxpayer Relief Act of 2012, which, among other things, further reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors, which may adversely affect our future profitability. </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 30, 2018, the Right to Try Act was signed into law. The law, among other things, provides a federal framework for certain patients to request access to certain IND products that have completed a Phase I clinical trial and that are undergoing investigation for FDA approval. There is no obligation for a pharmaceutical manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act. </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 13, 2017, CMS published a final rule that gives states greater flexibility in setting benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the ACA for plans sold through such marketplaces.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On&#8239;May 23, 2019, CMS published a final rule to allow Medicare Advantage Plans the option of using step therapy for Part B drugs beginning January 1, 2020.</span></div></div><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient assistance programs, and reform government program reimbursement methodologies for drugs. At a federal level, President Trump reversed some of President Biden&#8217;s executive orders including rescinding Executive Order 14087 entitled &#8220;Lowering Prescription Drug Costs for Americans." President Trump may issue new executive orders designed to impact drug pricing. A number of these and other proposed measures may require authorization through additional legislation to become effective. Congress and the Trump administration have indicated that they will continue to seek new legislative measures to control drug costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Inflation Reduction Act of 2022, or IRA includes several provisions that may impact our business to varying degrees, including provisions that reduce the out-of-pocket spending cap for Medicare Part D beneficiaries from $7,050 to $2,000 which became effective in 2025, thereby effectively eliminating the coverage gap; impose new manufacturer financial liability on certain drugs under Medicare Part D, allow the U.S. government to negotiate Medicare Part B and Part D price caps for certain high-cost drugs and biologics without generic or biosimilar competition; require companies to pay rebates to Medicare for certain drug prices that increase faster than inflation; and delay until January 1, 2032 the implementation of the HSS rebate rule that would have limited the fees that pharmacy benefit managers can charge. Further, under the IRA, orphan drugs are exempted from the Medicare drug price negotiation program, but only if they have one orphan designation and for which the only approved indication is for that disease or condition. If a product receives multiple orphan designations or has multiple approved indications, it may not qualify for the orphan drug exemption. The implementation of the IRA is currently subject to ongoing litigation challenging the constitutionality of the IRA&#8217;s Medicare drug price negotiation program. The effects of the IRA on our business and the healthcare industry in general is not yet known.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain drug access and marketing cost disclosure and transparency measures, and designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">32</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions could harm our business, financial condition, results of operations and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our drugs or put pressure on our drug pricing, which could negatively affect our business, financial condition, results of operations and prospects.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot predict what healthcare reform initiatives may be adopted in the future. Further federal, state and foreign legislative and regulatory developments are likely, and we expect ongoing initiatives to increase pressure on drug pricing. Such reforms could have an adverse effect on anticipated revenues from product candidates and may affect our overall financial condition and ability to develop product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The Foreign Corrupt Practices Act</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FCPA prohibits any U.S. individual or business from paying, offering, or authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Additional Regulation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the foregoing, state and federal laws regarding environmental protection and hazardous substances, including the Occupational Safety and Health Act, the Resource Conservancy and Recovery Act and the Toxic Substances Control Act, affect our business. These and other laws govern our use, handling and disposal of various biological, chemical and radioactive substances used in, and wastes generated by, our operations. If our operations result in contamination of the environment or expose individuals to hazardous substances, we could be liable for damages and governmental fines. We believe that we are in material compliance with applicable environmental laws and that continued compliance therewith will not have a material adverse effect on our business. We cannot predict, however, how changes in these laws may affect our future operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Europe / Rest of World Government Regulation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to regulations in the United States, we may be subject to a variety of regulations in other jurisdictions that we may in the future select governing, among other things, clinical trials and any commercial sales and distribution of our products. Whether or not we obtain FDA approval of a product, we would need to obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical trial application much like the IND prior to the commencement of human clinical trials. In the EU, for example, a clinical trial application must be submitted to each country&#8217;s national health authority and an independent ethics committee, much like the FDA and IRB, respectively. Once the clinical trial application is approved in accordance with a country&#8217;s requirements, clinical trial development may proceed. Because biologically sourced raw materials are subject to unique contamination risks, their use may be restricted in some countries.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The requirements and process governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, the clinical trials must be conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To obtain regulatory approval of an investigational drug or biological product under EU regulatory systems, we must submit an MAA. The application used to file the BLA in the United States is similar to that required in the EU, with the exception of, among other things, country-specific document requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For other countries outside of the EU, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, again, the clinical trials must be conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we or our potential collaborators fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">33</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="margin-left:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">European Union General Data Protection Regulation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to EU regulations related to the approval and commercialization of our products, we may be subject to the EU&#8217;s General Data Protection Regulation, or GDPR. The GDPR imposes stringent requirements for controllers and processors of personal data of persons in the EU, including, for example, ensuring an appropriate legal basis or condition applies to the processing of personal data, more robust disclosures to individuals and a strengthened individual data rights regime, shortened timelines for data breach notifications, limitations on retention of information, increased requirements pertaining to special categories of data, such as health data, and additional obligations when we contract with third-party processors in connection with the processing of the personal data. The GDPR also imposes strict rules on the transfer of personal data out of the European Union to the United States and other third countries. In addition, the GDPR provides that EU member states may make their own further laws and regulations limiting the processing of personal data, including genetic, biometric or health data.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, further to the UK&#8217;s exit from the EU, the GDPR ceased to apply in the UK at the end of the transition period on December 31, 2020. However, as of January 1, 2021, the UK&#8217;s European Union (Withdrawal) Act 2018 incorporated the GDPR (as it existed on December 31, 2020 but subject to certain UK specific amendments) into UK law, referred to as the UK GDPR. The UK GDPR and the UK Data Protection Act 2018 set out the UK&#8217;s data protection regime, which is independent from but aligned to the EU&#8217;s data protection regime.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The GDPR and UK GDPR apply extraterritorially, and we may be subject to the GDPR and UK GDPR because of our data processing activities that involve the personal data of individuals located in the European Union or United Kingdom, such as in connection with our EU and UK clinical trials. Failure to comply with the requirements of the GDPR or UK GDPR and the applicable national data protection laws of the EU member states and UK may result in fines of up to &#8364;20,000,000 (or &#163;17.5 million for the UK) or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, and other administrative penalties. GDPR and UK GDPR regulations may impose additional responsibility and liability in relation to the personal data that we process and we may be required to put in place additional mechanisms to ensure compliance with the new data protection rules.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">34</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Human Capital Resources</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we had 164 employees, 161 of whom were full-time and 3 whom were part-time. Of those, 135 were engaged in research and development activities. Two full-time employees are located in Switzerland. We do not have any employees that are represented by a labor union or covered under a collective bargaining agreement. We consider our relationship with our employees to be good.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our future success depends on our ability to attract, develop and retain key personnel, maintain our culture, and ensure diversity and inclusion in our board, management and broader workforce. Our human resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and additional employees. The principal purposes of our equity incentive plans are to attract, retain and motivate selected employees, consultants and directors through the granting of stock-based compensation awards. As these areas directly impact our ability to compete and innovate, they are key focus areas for our board of directors and senior executives. A testament to our strong culture is the strong results from our annual employee survey.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporate History and Trademarks</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We were incorporated under the laws of the State of Delaware in April 2017 under the name Tycho Therapeutics, Inc. In August 2018, our corporate name was changed to Cabaletta Bio, Inc. We have two subsidiaries, Cabaletta Bio GmbH, incorporated in Switzerland and Cabaletta Bio (Germany) GmbH, incorporated in Germany. Our principal executive offices are located at 2929 Arch Street, Suite 600, Philadelphia, PA 19104, and we have limited corporate and research operations in Germany and Switzerland. Our telephone number is (267) 759-3100, and our website address is www.cabalettabio.com. We do not incorporate the information on or accessible through our website into this Annual Report on Form 10-K, and you should not consider any information on, or that can be accessed through, our website to be part of this Annual Report on Form 10-K. We have included our website address in this Annual Report on Form 10-K solely as an inactive textual reference.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We view our operations and measure our business as one reportable segment. All of the Company's tangible assets are held in the United States. Refer to Note 8, Segment Information, to our consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K for additional information.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We own or have rights to various trademarks, service marks and trade names that we use in connection with the operation of our business. This Annual Report on Form 10-K may also contain trademarks, service marks and trade names of third parties, which are the property of their respective owners. Our use or display of third parties&#8217; trademarks, service marks, trade names or products in this Annual Report on Form 10-K is not intended to, and does not imply a relationship with, or endorsement or sponsorship by us. Solely for convenience, the trademarks, service marks and trade names referred to in this Annual Report on Form 10-K may appear without the &#174;, &#153; or SM symbols, but the omission of such references is not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable owner of these trademarks, service marks and trade names.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Available Information</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, including exhibits, and any amendments to these reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, are available free of charge on our website located at www.cabalettabio.com as soon as reasonably practicable after they are filed with or furnished to the SEC. These reports are also available at the SEC&#8217;s Internet website at www.sec.gov.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investors and others should note that we announce material information to our investors using our investor relations website (https:// https://www.cabalettabio.com/investors), SEC filings, press releases, public conference calls and webcasts. We use these channels as well as social media, including LinkedIn and X (formerly Twitter) (@CabalettaBio), to communicate with the public about our company, our business, our product candidates and other matters. It is possible that the information we post on social media could be deemed to be material information. Therefore, we encourage investors, the media, and others interested in our company to review the information we post on the social media channels listed on our investor relations website. Information that is contained in and can be accessed through our website or our social media posts are not incorporated into, and does not form a part of, this Annual Report on Form 10-K.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A copy of our Corporate Governance Guidelines, Code of Conduct and Business Ethics and the charters of the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee are posted on our website, www.cabalettabio.com, under the heading &#8220;Investors &amp; Media.&#8221;</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">35</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;" id="item_1a_risk_factors_1"><span id="item_1a_risk_factors"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1A. Risk Factors.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business involves material and other risks, some of which are summarized and described below. You should carefully consider the risks and uncertainties described below, together with all of the other information contained in this Annual Report on Form 10-K, including "Management's Discussion and Analysis of Financial Condition and Results of Operations" and the consolidated financial statements and the related notes. If any of the following risks actually occur, it could harm our business, prospects, operating results and financial condition and future prospects. In such event, the market price of our common stock could decline and you could lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations. This Annual Report on Form 10-K also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of factors that are described below and elsewhere in this Annual Report.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Business, Technology and Industry</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Clinical Development</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are early in our development efforts. If we are unable to advance our product candidates through clinical development, obtain regulatory approval and ultimately commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are early in our development efforts and we have not yet completed any clinical trials. Our ability to generate product revenues, which we do not expect will occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of one or more of our product candidates. Even if we are able to develop and commercialize a marketable product, we may face challenges generating revenue from product sales. The success of our product candidates will depend on several factors, including the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successful completion of preclinical studies resulting in data that is supportive of advancing to an investigational new drug, or IND, or clinical trial application, or CTA submission; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successful submission and acceptance of INDs, CTAs or comparable applications; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successful initiation of clinical trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">demonstration of adequate safety to progress to a therapeutic dose level; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successful patient enrollment in and completion of clinical trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">receipt and related terms of regulatory and marketing approvals and licensures from applicable regulatory authorities; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers for clinical supply and commercial manufacturing of our product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">making arrangements with various medical divisions across hospitals for administration of our product candidates, including with cancer treatment centers to conduct leukapheresis and with the relevant hospital divisions to perform infusion; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establishing sales, marketing and distribution and patient administration capabilities and launching commercial sales of our products, if and when licensed, whether alone or in collaboration with others; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acceptance of our products, if and when licensed, by patients, the medical community and third-party payors; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">effectively competing with established and emerging therapies targeting the same indications as our product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtaining and maintaining third-party coverage and adequate reimbursement; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintaining a continued acceptable safety profile of our products following licensure. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or be unable to successfully commercialize our product candidates, which would materially harm our business. If we do not receive regulatory approvals for our product candidates, we may not be able to continue our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cellular therapies, including our engineered chimeric antigen receptor T cell, or CAR T, chimeric autoantibody receptor T cell, or CAAR T, product candidates, represent a novel approach to the treatment of autoimmune diseases, which creates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">significant challenges for us. Negative perception or increased regulatory scrutiny of any product candidates that we develop could adversely affect our ability to conduct our business or obtain regulatory approvals for such product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cellular therapies are a novel approach to the treatment of autoimmune diseases, and negative perception or increased regulatory scrutiny of any product candidates that we develop could adversely affect our ability to conduct our business or obtain regulatory approvals for such product candidates. There are no cellular immunotherapies licensed to date in the United States or the European Union to treat autoimmune diseases or alloimmune responses. CAR T or CAAR T cell therapies for autoimmune or alloimmune diseases may not gain the acceptance of the public or the medical community. For example, CAR Ts and other cellular therapies have in some cases caused severe side effects, including death, and their broader use may therefore be limited. In the future, in the event such severe side effects are observed with other CAR T therapies (including those with a CD19 binder), it may increase negative perception of, and regulatory scrutiny on, our product candidates. For example, in November 2023, the FDA announced that it would be conducting an investigation into reports of T cell malignancies following treatment with BCMA-directed or CD19-directed autologous CAR T cell immunotherapies. The FDA also stated that patients and clinical trial participants receiving treatment with such approved products should be monitored life-long for new malignancies. In January 2024, the FDA determined that new safety information related to T cell malignancies should be included in the labeling with boxed warning language on these malignancies for all BCMA- and CD19-directed genetically modified autologous T cell immunotherapies. Public perception may be influenced by claims that gene therapy, including the insertion of a transgene, is unsafe, and products incorporating gene therapy may not gain the acceptance of the public or the medical community. The patient populations targeted by our product candidates are also typically not at risk of near-term death, even if they may suffer life-threatening symptoms, so patients will need to deem the benefits of cell therapy to be worth the risk of unknown potential adverse side effects. Our success will depend upon physicians who specialize in the treatment of autoimmune diseases targeted by our product candidates prescribing treatments that involve the use of our product candidates in lieu of, or in addition to, existing treatments with which they are more familiar and for which greater clinical data may be available. Adverse events in clinical trials of our product candidates, in clinical trials of others developing similar products or in the post-approval setting and the resulting publicity, as well as any other adverse events in the field of cellular therapies, could result in a decrease in demand for any product that we may develop.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are developing a pipeline of CAR T and CAAR T product candidates that are intended for use in treating individuals with autoimmune diseases. Advancing these novel product candidates creates significant challenges for us, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">manufacturing our product candidates to our specifications and in a timely manner to support our clinical trials, and, if licensed, commercialization; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sourcing clinical and, if licensed, commercial supplies for the materials used to manufacture our product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">understanding and addressing variability in the quality and quantity of a subject&#8217;s T cells, which could ultimately affect our ability to manufacture clinical supply and, if licensed, commercial supply of our product candidates in a reliable and consistent manner; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">educating medical personnel regarding the potential side effect profile of our product candidates, if licensed, such as the potential adverse side effects related to worsening of systemic lupus erythematosus, or SLE, idiopathic inflammatory myopathy (IIM), or myositis, systemic sclerosis, or SSc, muscle-specific kinase myasthenia gravis, or MuSK MG, generalized myasthenia gravis, or gMG, pemphigus vulgaris, or PV, multiple sclerosis, or MS, adverse effects related to infusion of activated T cells or medication taper, including cytokine release syndrome, or CRS, immune effector cell-associated neurotoxicity syndrome, or ICANS, or other unexpected adverse effects of therapy with our product candidates or potential class-wide side effects, such as those related to CD19-directed autologous CAR T cell immunotherapies; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">facilitating patient access to the limited number of facilities able to administer our product candidates, if licensed; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">using medicines to manage adverse side effects of our product candidates that may not adequately control the side effects and/or may have a detrimental impact on the efficacy of the treatment; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">utilizing preconditioning agents in patients to enhance engraftment in advance of administering our product candidates, which may increase the risk of adverse side effects and potentially reduce the population eligible for therapy; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtaining and maintaining regulatory approval for our product candidates, as the FDA and other regulatory authorities have limited or no experience with development of engineered T cell therapies for the treatment of autoimmune diseases where B cells may play a role in initiating or maintaining disease; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establishing sales and marketing capabilities upon obtaining any regulatory approval to gain market acceptance of a novel therapy; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">managing costs of inputs and other supplies while scaling production. </span></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">37</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, preclinical murine and other animal models may not exist or be adequate for some or all of the autoimmune diseases where B cells may play a role in initiating or maintaining disease we choose to pursue in our programs, and because we are early in the clinical development process, we are unable to predict whether there may be short-term or long-term effects from treatment with any product candidates that we develop. In developing our product candidates, we have not exhaustively explored different options in the method for manufacturing CAR T or CAAR T cells. We may find our existing manufacturing process may be substantially improved with future design or process changes, necessitating further clinical testing, delaying commercial launch of our first products, and causing us to incur additional expenses. For example, while we have used a lentiviral vector in our manufacturing process, we may in the future find that another viral vector or non-viral vector-based process offers advantages. Switching from one lentiviral vector to another or switching from lentiviral to another delivery system would necessitate additional process development and clinical testing, and this may delay the development of existing product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we do not know the doses to be evaluated in pivotal trials or, if licensed, commercially. Finding a suitable dose may delay our anticipated clinical development timelines, and we may elect to pause clinical trials to find a suitable dose or make assessments ahead of continuing a trial. Our expectations with regard to our scalability and costs of manufacturing may vary significantly as we develop our product candidates and understand these critical factors. We may experience delays in developing a sustainable, reproducible and scalable manufacturing process or transferring that process to commercial partners, which may prevent us from completing our clinical studies or commercializing our product candidates on a timely or profitable basis, if at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, our product candidates may not perform successfully in clinical trials or may be associated with adverse events that distinguish them from the CAR T therapies that have previously been licensed. For instance, subjects in our CAAR T clinical trials will be infused with our proposed therapies, and may possess strongly activating soluble antibodies, which are not present in oncology patients, and when they interact with our infused product candidates, could result in potential adverse side effects, such as CRS or ICANS. Additionally, adverse side effects caused by even one of our CAR T or CAAR T product candidates could negatively affect our ability to develop future product candidates based on our CABA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> platform. Unexpected side effects or clinical outcomes from any of our products candidates would significantly impact our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, the clinical study requirements of the FDA, the European Medicines Agency, or EMA, and other regulatory agencies and the criteria they use to determine the safety, potency and purity of a product candidate are determined according to the type, complexity, novelty and intended use and market of the potential products. The regulatory approval process for novel product candidates such as ours is less clear, and can be more complex and consequently have higher development risk, be more expensive and take longer than for other, better known or extensively studied pharmaceutical or other product candidates. Approvals by the FDA for existing cell therapies treating B cell-mediated diseases, such as Kymriah (Novartis Pharmaceuticals Corporation) and Yescarta</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Gilead Sciences, Inc.) in oncology indications, may not be indicative of what the FDA may require for approval of our therapies in autoimmune indications. Approvals by any regulatory agency may not be indicative of what any other regulatory agency may require for approval or what such regulatory agencies may require for approval in connection with new product candidates. As we advance our product candidates, we will be required to consult with these regulatory agencies and comply with applicable requirements and guidelines. If we fail to do so, we may be required to delay or discontinue development of such product candidates. These additional processes may result in a review and approval process that is longer than we otherwise would have expected. More restrictive statutory regimes, government regulations or negative public opinion would have an adverse effect on our business, financial condition, results of operations and prospects and may delay or impair the development and commercialization of our product candidates or demand for any products we may develop.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, responses by agencies at the federal and state level to negative public perception or ethical concerns may result in new legislation or regulations that could limit our ability to develop or commercialize any product candidates, obtain or maintain regulatory approval or otherwise achieve profitability. The FDA has expressed interest in further regulating biotechnology products, such as cellular therapies. Agencies at both the federal and state level in the United States, as well as the U.S. Congressional committees and other government entities or governing agencies have also expressed interest in further regulating the biotechnology industry. Such action may delay or prevent commercialization of some or all of our product candidates. Adverse developments in clinical trials of cellular therapy products conducted by others or in the post-approval setting may cause the FDA or other oversight bodies to change the requirements for approval of any of our product candidates. These regulatory review agencies and committees and the new requirements or guidelines they promulgate may lengthen the regulatory review process, require us to perform additional studies or trials, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patients receiving T cell-based immunotherapies, such as our product candidates, have in the past and may in the future experience serious adverse events, including ICANS, CRS and killing of cells other than the intended B cells that express the autoantibodies. If our product candidates are revealed to have high and unacceptable severity and/or prevalence of side effects or unexpected characteristics, their clinical development, regulatory approval, and commercial potential will be negatively impacted, which will significantly harm our business, financial condition and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product candidates are CAR T or CAAR T cell-based immunotherapies. In our clinical trials and other similarly designed cellular immunotherapies to treat cancer, there have been life threatening events related to ICANS and CRS requiring intense medical</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">38</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">intervention, such as intubation or medications to support blood pressure, and in several cases, resulted in death. We have observed events of CRS and ICANS in our ongoing rese-cel REstoring SElf-Tolerance, or RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, trial. ICANS is a condition that is currently defined clinically by cerebral edema, confusion, drowsiness, speech impairment, tremors, seizures or other central nervous system side effects, when such side effects are serious enough to lead to intensive care. CRS is a condition that is currently defined clinically by certain symptoms related to the release of cytokines, which can include fever, chills and low blood pressure, when such side effects are serious enough to lead to intensive care with mechanical ventilation or significant medications to support blood pressure. There is a possibility that our product candidates could have similarly life threatening serious adverse side effects, such as ICANS and CRS.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product candidates may have serious and potentially fatal consequences due to the targeting of cells within the body due to unexpected protein interactions with the CAR or CAAR. Although we have completed multiple preclinical studies designed to screen for toxicity caused by unintended off-target recognition by the cell binding domain of the DSG3 CAAR, MuSK CAAR and rese-cel and intend to screen future CAR and CAAR candidates not yet tested in patients through preclinical studies, our product candidates may still recognize and react with one or more proteins unrelated to the intended surface immunoglobin target protein to which it is designed to link. If unexpected binding occurs in normal tissue, our product candidates may target and kill the normal tissue in a patient, leading to serious and potentially fatal adverse events, undesirable side effects, toxicities or unexpected characteristics. Detection of any unexpected targeting may halt or delay any ongoing clinical trials for our product candidates and prevent or delay regulatory approval. While we have developed a preclinical screening process to identify cross-reactivity of our product candidates, we cannot be certain that this process will identify all potential tissue that our product candidates may target. For example, a membrane protein array with DSG3-CAART yielded one weak signal against a protein that is designed to bind to glycoproteins and which was detected in both the test and control conditions. Further analysis of this protein in confirmatory cell-based assays repeatedly demonstrated that DSG3-CAART does not recognize nor activate against this protein. We performed similar preclinical studies for the MuSK CAAR and rese-cel and did not observe any confirmed off target activity for MuSK-CAART or rese-cel. However, this further analysis may prove to be inaccurate. Any unexpected targeting that impacts patient safety could materially impact our ability to advance our product candidates into clinical trials or to proceed to marketing approval and commercialization. Furthermore, in the event subjects are re-treated, they may respond differently than other subjects given the same dose, and may not tolerate the dose or develop safety concerns.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Results of our studies could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. Undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other regulatory agencies. Our clinical trials of rese-cel represent the first evaluation of this product candidate in patients and rese-cel is directed against all B cells expressing CD19; therefore, there is a risk for prolonged B cell aplasia and/or hypogammaglobulinemia, which may predispose patients to infections. Given that the autoimmune and alloimmune diseases we are seeking to treat are, in some cases, less serious than the later stage cancers being treated with other immunotherapy products, we believe the FDA and other regulatory authorities likely will apply a different benefit-risk assessment thresholds such that even if our product candidate demonstrated a similar safety profile as current CAR T therapies, the FDA may ultimately determine that the harmful side effects outweigh the benefits and require us to cease clinical trials or deny approval of our product candidates. We believe tolerance for adverse events in the patient population being pursued with our CAAR T and CAR T cell therapies in autoimmune and alloimmune indications will be lower than it is in oncology, and the risks of negative impact from these toxicities may therefore be higher for us than for CAR T programs in oncology.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete the studies or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff, as toxicities resulting from T cell-based immunotherapies are not normally encountered in routine medical care. Medical personnel may need additional training regarding T cell-based immunotherapy product candidates to understand their side effects. Inadequate training in recognizing or failure to effectively manage the potential side effects of T cell-based immunotherapy product candidates could result in patient deaths. Any of these occurrences may harm our business, financial condition and prospects significantly. In addition to side effects caused by our product candidates, any preconditioning, administration process or related procedures, which we evaluate from time to time as part of our process improvement and optimization efforts, may also cause adverse side effects. For example, prolonged or persistent cytopenias and ICANS have been noted to be associated with the use of certain lymphodepleting regimens and CAR T therapies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Preconditioning regimens, as currently implemented in several of our clinical trials, may increase the risk of adverse side effects and impact our ability to accurately assess the efficacy of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In oncology patients receiving CAR T cell therapy, a lymphodepleting preconditioning regimen is typically used to condition the patient prior to CAR T cell infusion in order to improve tumor immunogenicity and to promote the expansion of the infused CAR T cells. Together, these effects have been shown to enhance the clinical activity of CAR T cells in oncology patients. These regimens often include cyclophosphamide and fludarabine and are usually administered within the week prior to infusion of CAR T cells. We implemented a preconditioning regimen in the DesCAARTes</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial where certain subjects were pre-treated with IVIg and cyclophosphamide, and other patients were pre-treated with IVIg, cyclophosphamide, and fludarabine prior to DSG3-CAART infusion, have included planned dosing cohorts in the MusCAARTes</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial where subjects are pre-treated with fludarabine and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">39</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cyclophosphamide prior to MuSK-CAART infusion, and we have incorporated a lymphodepleting preconditioning regimen of fludarabine and cyclophosphamide in our RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> clinical trials. We are evaluating rese-cel without preconditioning in our RESET-PV</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial in patients with mPV and mcPV. Serious adverse events have been observed in some patients following CAR T cell infusion, and these include infection, cytokine release syndrome and ICANS. The lymphodepleting and immunomodulatory preconditioning regimen may contribute to the occurrence and severity of these adverse events due to its role in inducing leukopenia, or low levels of white blood cells in the blood, including lymphopenia, or low levels of lymphocytes in the blood, and regulating the activation and effector functions of other immune cells and antibodies, and enhanced CAR T cell activity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, a lymphodepleting regimen may eliminate pathogenic B cells targeted by our CAAR T cell product candidates. As a result, any lymphodepleting regimen for preconditioning that we use may delay or otherwise adversely affect our ability to use DSG3 or MuSK autoantibody titers, a standard clinical assay, to assess the activity of DSG3-CAART and MuSK-CAART, respectively. An inability to use DSG3 or MuSK autoantibody levels to demonstrate the specific activity of our CAAR T cell product candidates may require us to rely on the subjective measurement of blister formation in patients in the DesCAARTes</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">trial or muscle weakness in the MusCAARTes</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial, which can be a less sensitive and accurate measurement of CAAR T cell activity. This therefore could delay a signal of potential biologic activity attributable to CAAR and therefore may slow clinical development. We will continue to evaluate emerging data from the MusCAARTes</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial on an ongoing basis, as well as other relevant clinical trials in autoimmune disease, and may make additional modifications, as appropriate.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to lymphodepleting preconditioning, other preconditioning regimens with immunomodulatory effects may be considered to prepare the body for CAR T or CAAR T infusion. For example, if autoantibody is found to reduce or inhibit function of CAAR T in the body, then pretreatment of patients with antibody reducing therapies, such as FcRN inhibitors, IVIg, plasmapheresis, or treatment of post rituximab patients may be considered. Some of these types of preconditioning are standard of care for this autoimmune population and therefore are already considered to have a beneficial risk profile in this patient population. These other preconditioning regimens may cause serious adverse events, including hypotension, thromboembolism, and opportunistic infections.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subjects in our RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trials, except for our RESET-PV</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial, will be treated with a standard preconditioning regimen consisting of fludarabine and cyclophosphamide prior to rese-cel infusion. In addition, the lymphodepleting regimen may eliminate some of the pathogenic B cells targeted by rese-cel. As a result, the lymphodepleting regimen may contribute to the initial clinical response that may be observed after rese-cel, which may make interpretation of early efficacy difficult to assess and may also delay our ability to characterize the activity of rese-cel independent of the effects of fludarabine and cyclophosphamide. We intend to evaluate this potential impact of preconditioning in our CAAR and rese-cel studies, through the comparison to non-lymphodepletion arms.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our clinical patients may experience increased or more severe adverse effects specifically related to the preconditioning regimens, such as severe allergic reactions, difficulty breathing, severe headaches, fevers and chills, serious infections, low blood counts, inflammation of the colon with bleeding, bladder irritation, blood clots, development of certain cancers, damage to the heart, lung or kidneys, and even death. These undesirable side effects, whether associated with the preconditioning regimen alone or in combination with our CAR T cell product candidates or CAAR T cell product candidates, could cause delays in patient enrollment in our clinical trials, could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a change to our clinical trial design, a more restrictive label or the delay or denial of regulatory approval by the FDA. Any of the foregoing may increase the duration and expense of the clinical development of our product candidates or limit market acceptance of such product candidates, if approved, any of which could have a material adverse effect on our business and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business is highly dependent on the success of our initial product candidates targeting autoimmune diseases where B cells may play a role in initiating or maintaining disease. All of our product candidates will require significant additional preclinical and/or clinical development before we can seek regulatory approval for and launch a product commercially.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business and future success depend on our ability to obtain regulatory approval of, and then successfully launch and commercialize our initial product candidates targeting autoimmune diseases where B cells may play a role in initiating or maintaining disease. There is no guarantee that we will be able to advance our product candidates through clinical development or obtain marketing approval for any of our product candidates. The process for obtaining marketing approval for any product candidate is very long and risky and there will be significant challenges for us to address in order to obtain marketing approval as planned, if at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The initial clinical results we have observed may not be predictive of results of subsequent cohorts in this clinical trial, or of any future clinical trials. Because rese-cel, DSG3-CAART and MuSK-CAART are the first three product candidates that we are testing in the clinic, we may experience preliminary complications surrounding trial design, protocol establishment and execution, establishing trial protocols, patient recruitment and enrollment, quality and supply of clinical doses, or safety issues.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, a failure of our clinical trials of DSG3-CAART, MuSK-CAART or rese-cel RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trials could influence physicians&#8217; and regulators&#8217; opinions with regard to the viability of our CABA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> platform more broadly, particularly if treatment-related side effects are observed. The occurrence of any of these risks could significantly harm our development plans and business prospects. If treatment-related side effects are observed with the administration of DSG3-CAART, MuSK-CAART or rese-cel, or if they are viewed</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">40</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">as less safe, potent or pure than other therapies, our ability to develop other CAAR T or CAR T cell therapies may be significantly harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have never successfully completed any clinical trials, and we may be unable to do so for any product candidates we develop.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have not yet demonstrated our ability to successfully complete any clinical trials, including large-scale, pivotal clinical trials, obtain regulatory approvals, manufacture a commercial scale product, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful commercialization. Although our key employees have significant experience in leading clinical development programs, our experience conducting clinical trials with our product candidates is limited. We may not be able to file INDs or CTAs for any of our other product candidates on the timelines we expect, if at all. For example, we cannot be certain that the IND-enabling or CTA-enabling studies for our future product candidates will be completed in a timely manner or be successful or that the manufacturing process will be validated in a timely manner. Even if we submit an IND or CTA for a future product candidate, the FDA, the EMA, or other foreign regulatory authorities may not clear the IND or CTA and allow us to begin clinical trials in a timely manner or at all. The timing of submissions on future product candidates will be dependent on further preclinical and manufacturing success. Moreover, we cannot be sure that submission of an IND or a CTA will result in the FDA or other foreign regulatory authorities allowing further clinical trials to begin, or that, once begun, issues will not arise that require us to suspend or terminate clinical trials. Commencing each of these clinical trials is subject to finalizing the trial design based on discussions with the FDA and other foreign regulatory authorities. Any guidance we receive from the FDA or other foreign regulatory authorities is subject to change. These regulatory authorities could change their position, including, on the acceptability of our trial designs or the clinical endpoints selected, which may require us to complete additional clinical trials or impose stricter approval conditions than we currently expect.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we may:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be delayed in obtaining marketing approval for our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not obtain marketing approval at all;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain approval for indications or patient populations that are not as broad as intended or desired;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be subject to post-marketing testing requirements; or</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">have the product removed from the market after obtaining marketing approval. </span></div></div><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk if we commercialize any products. For example, we may be sued if our product candidates cause or are perceived to cause injury or are found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inability to bring our product candidates to the market; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">decreased demand for our product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">injury to our reputation; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">withdrawal of clinical trial participants; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">initiation of investigations by regulators; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs to defend the related litigation; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a diversion of management&#8217;s time and our resources; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">substantial monetary awards to trial participants or patients; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product recalls, withdrawals or labeling, marketing or promotional restrictions; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">loss of revenue; </span></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">41</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">exhaustion of any available insurance and our capital resources; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the inability to commercialize any product candidate; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a decline in our share price. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since we have not yet commenced marketing of any products, we do not yet hold product liability insurance for commercialization of our product candidates. Our inability to obtain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products we develop, alone or with corporate collaborators. Our insurance policies may also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. Assuming we obtained clinical trial insurance for our clinical trials, we may have to pay amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with any future corporate collaborators entitle us to indemnification against losses, such indemnification may not be available or adequate should any claim arise.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to the Industry</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our product candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Undesirable or unacceptable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other foreign regulatory authorities. Further, clinical trials by their nature utilize a sample of the potential patient population. With a limited number of subjects and limited duration of exposure, rare and severe side effects of our product candidates may only be uncovered with a significantly larger number of patients exposed to the drug. Undesirable side effects could also result in an expansion in the size of our clinical trials, increasing the expected costs and timeline of our clinical trials. Additionally, results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licensed CAR T cell therapies and those under development have shown frequent rates of CRS and ICANS, and adverse events have resulted in the death of patients. Similar adverse events have occurred and could occur during treatment with our current or future CAR T or CAAR T cell product candidates. For example, activation of CAAR T cells by patient autoantibodies or alloantibodies could stimulate CRS. When CAAR T cells are infused and the CAAR binds to soluble antibodies in the blood or tissues of treated patients, these soluble antibodies may cause the CAAR T cells to proliferate, resulting in an activation of the immune system that is too high, leading to CRS. Further, it is possible that patients will exhibit acute rejection of the CAAR T cells because of preexisting immunity to the antigen within the CAAR. This could render our product candidates ineffective.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If unacceptable toxicities or health risks, including risks inferred from other unrelated immunotherapy trials, arise in the development of our product candidates, we could suspend or terminate our trials or the FDA, the Safety Monitoring Boards for our trials (e.g. Data Safety Monitoring Board, or DSMB, or Independent Data Safety Monitoring Committee, or IDMC), or local regulatory authorities such as institutional review boards, or IRBs, or independent ethics commits, or IECs, as applicable, could recommend or order us to cease clinical trials. Regulatory authorities, such as the FDA, could also deny approval of our product candidates for any or all targeted indications. Treatment-related side effects could also affect patient recruitment or the ability of enrolled subjects to complete the trial or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff, as toxicities resulting from T cell therapy are not normally encountered in the general patient population and by medical personnel. We expect to have to train medical personnel using CAR T or CAAR T cell product candidates to understand the side effect profile of our product candidates for both our preclinical studies and clinical trials and upon any commercialization of any of our product candidates, if licensed. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient deaths. Any of these occurrences may harm our business, financial condition and prospects significantly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our preclinical studies and clinical trials may fail to demonstrate the safety, potency and purity of any of our product candidates, which would prevent or delay regulatory approval and commercialization.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Before obtaining regulatory approvals for the commercial sale of any of our product candidates, we must demonstrate through lengthy, complex and expensive preclinical testing and clinical trials that our product candidates are safe, potent and pure for use in each target indication. Clinical trials are expensive and can take many years to complete, and their outcomes are inherently uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials, including in any post-approval studies of our product candidates. In addition, initial success in any clinical trials may not be indicative of results obtained when such trials are completed. There is typically an extremely high rate of attrition from the failure of product candidates proceeding through clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety, potency and purity profile despite having progressed through preclinical studies and initial clinical trials. Similarly, while we believe rese-cel has a similar overall design to the construct used for the patients in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">42</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Nature Medicine,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Lancet, Annals of Rheumatic Diseases, and Rheumatology</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> publications, those studies involved a small number of patients, and a different product candidate, and the initial clinical results observed in those studies may not be predictive of clinical trial results with rese-cel or any of our other product candidates, additionally, because those studies are not our own, we may not have access to accurate follow-up information or peer-reviewed results.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of potency or efficacy, insufficient durability of potency or efficacy or unacceptable safety issues, notwithstanding promising results in earlier trials, and we cannot be certain that we will not face similar setbacks. These setbacks have been caused by, among other things, preclinical and other nonclinical findings made while clinical trials were underway, or safety or efficacy observations made in preclinical studies and clinical trials, including previously unreported adverse events. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses and many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials nonetheless failed to obtain FDA or European Commission approval. Most product candidates that commence clinical trials are never approved as products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any preclinical studies or clinical trials that we may conduct may not demonstrate the safety, potency and purity necessary to obtain regulatory approval to market our product candidates. If the results of our ongoing or future preclinical studies and clinical trials are inconclusive with respect to evaluations of efficacy, the safety, potency and purity of our product candidates, if we do not meet the clinical endpoints with statistical and clinically meaningful significance, or if there are safety concerns associated with our product candidates, we may be prevented or delayed in obtaining marketing approval for such product candidates. In some instances, there can be significant variability in evaluations of efficacy, safety, potency or purity results between different preclinical studies and clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the clinical trial protocols and the rate of dropout among clinical trial participants. For example, because our CAAR T cell product candidates only target approximately 0.01% to 1% of the B cells in a patient, they may not engage enough of the target to achieve adequate engraftment necessary for elimination of all pathogenic B cells. Insufficient safety or potency in clinical trials may delay product development to enable time to modify the product candidate for next generation approaches or make manufacturing changes or may lead us to discontinue development of the product candidate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, our ongoing clinical trials utilize, and our planned trials may utilize, an &#8220;open-label&#8221; trial design. An &#8220;open-label&#8221; clinical trial is one where both the patient and investigator know whether the patient is receiving the investigational product candidate or either an active drug or placebo. Most typically, open-label clinical trials test only the investigational product candidate and sometimes may do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when they are receiving treatment. Open-label clinical trials may be subject to a &#8220;patient bias&#8221; where patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. In addition, open-label clinical trials may be subject to an &#8220;investigator bias&#8221; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. The results from an open-label trial may not be predictive of future clinical trial results with any of our product candidates for which we include an open-label clinical trial when studied in a controlled environment with a placebo or active control.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we cannot guarantee that the FDA or other foreign regulatory authorities will interpret the results of any of our ongoing or planned clinical trials as we do, and more trials could be required before we submit our product candidates for approval. To the extent that the results of the trials are not satisfactory to the FDA or other foreign regulatory authorities to support a marketing application, approval of our product candidates may be significantly delayed, or we may be required to expend significant additional resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to market any product outside of the United States, a company must also comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of products. Whether or not it obtains FDA approval for a product, an applicant will need to obtain the necessary approvals by the comparable foreign regulatory authorities before it can commence clinical trials or marketing of the product in those countries or jurisdictions. For example, the process governing approval of medicinal products in the European Union generally follows the same lines as in the United States but can differ in significant ways as well. It entails satisfactory completion of preclinical studies and adequate and well-controlled clinical trials to establish the safety and efficacy of the product for each proposed indication. It also requires the submission to the relevant competent authorities of a marketing authorization application and granting of a marketing authorization by these authorities before the product can be marketed and sold in the European Union.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interim, topline or preliminary data from any preclinical studies or clinical trials that we conduct may change as more data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our DesCAARTes</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial, MusCAARTes</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial, and RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trials in SLE, myositis, SSc, gMG, MS and PV are designed as open-label trials. From time to time, we may publicly disclose interim, preliminary or topline data from our preclinical studies and clinical trials, including safety data and evaluations of efficacy, which will be based on a preliminary analysis of then-available data,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">43</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and the results and related findings and conclusions are subject to change following our receipt of additional data or a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result, the topline results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available. From time to time, we may also disclose interim data from planned interim analyses in our clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects. Further, disclosure of interim data by us or our competitors, or by patients or caregivers who are aware that a patient is receiving investigational product, due to the open-label design of the trial, could result in volatility in the price of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulatory agencies, including the FDA or other foreign regulatory authorities, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the interim, topline or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The increasing use of social media platforms presents new risks and challenges.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Social media is increasingly being used to communicate about our clinical development programs and the diseases our product candidates are being developed to treat. We intend to utilize appropriate social media in connection with communicating about our development programs. Social media practices in the biopharmaceutical industry continue to evolve and regulations relating to such use are not always clear. This evolution creates uncertainty and risk of noncompliance with regulations applicable to our business. For example, patients may use social media channels to report an alleged adverse event during a clinical trial. When such disclosures occur, there is a risk that we fail to monitor and comply with applicable adverse event reporting obligations, or we may not be able to defend our business or the public&#8217;s legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our investigational products. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website, or a risk that a post on a social networking website by any of our employees may be construed as inappropriate promotion. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face regulatory actions, or incur other harm to our business.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may encounter substantial delays in our clinical trials or may not be able to conduct our trials on the timelines we expect or at all.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical testing is expensive, time consuming and subject to uncertainty. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. Even if these trials begin as planned, issues may arise that could suspend or terminate such clinical trials. A failure of one or more clinical trials can occur at any stage of testing, and our ongoing and future clinical trials may not be successful. Events that may prevent successful or timely completion of clinical development include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inability to generate sufficient preclinical, toxicology or other in vivo or in vitro data to support the initiation of clinical trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in sufficiently developing, characterizing or controlling a manufacturing process suitable for clinical trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in developing suitable assays for screening patients for eligibility for clinical trials with respect to certain product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in reaching a consensus with the FDA and other regulatory agencies on trial design; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in reaching agreement on acceptable terms with prospective CMOs, CROs and clinical study sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CMOs, CROs and clinical trial sites; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in obtaining required institutional review board, or IRB, approval at each clinical trial site; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">imposition of a temporary or permanent clinical hold by regulatory agencies for a number of reasons, including after review of an IND submission or amendment, or equivalent application or amendment; as a result of a new safety finding that presents unreasonable risk to clinical trial participants; a negative finding from an inspection of our clinical study operations </span></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">44</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or study sites; developments on trials conducted by competitors for related technology or by those that rely on a similar construct, design and/or third-party research that raise FDA or other foreign regulatory authorities concerns about risk to patients of the technology or construct broadly, and/or negative public perception of the same; or if FDA or other foreign regulatory authorities find that the investigational protocol or plan is clearly deficient to meet its stated objectives;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in recruiting eligible patients to participate in our clinical trials, including pediatric patients who need parental consent; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in treating one or more patients, once enrolled, due to a patient&#8217;s inability to accommodate parts of the complex study procedures schedule; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">difficulty collaborating with patient groups and investigators; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure by our CROs, other third parties or us to adhere to clinical trial requirements and the potential termination of ongoing agreements with our CROs; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">limitations on our recourse in our CRO relationship with Penn as compared to a CRO that is not an academic institution; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to perform in accordance with the FDA&#8217;s Good Clinical Practice, or GCP, requirements or applicable regulatory guidelines in other countries; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">transfer of manufacturing processes to any new CMO or our own manufacturing facilities or any other development or commercialization partner for the manufacture of product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in having patients complete participation in a trial or return for post-treatment follow-up; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">patients dropping out of a trial; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">occurrence of adverse events associated with the product candidate that are viewed to outweigh its potential benefits; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in the standard of care on which a clinical development plan was based, which may require new or additional trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of clinical trials of our product candidates being greater than we anticipate; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical trials of our product candidates producing negative or inconclusive results, which may result in our deciding, or regulators requiring us, to conduct additional clinical trials or abandon product development programs; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays or failure to secure supply agreements with suitable raw material suppliers, or any failures by suppliers to meet our quantity or quality requirements for necessary raw materials; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in manufacturing or inability to manufacture sufficient clinical supply (for example, due to capacity constraints, supply interruption, or the need to engineer the process to meet higher dose requirements), testing, releasing, validating or importing/exporting sufficient stable quantities of our product candidates for use in clinical trials or the inability to do any of the foregoing. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any inability to successfully complete preclinical and clinical development could result in additional costs to us or impair our ability to generate revenue. If we make manufacturing or formulation changes to our product candidates, we may be required to, or we may elect to, conduct additional trials to bridge our modified product candidates to earlier versions. Clinical trial delays could also shorten any periods during which our product candidates and products, if licensed, have patent protection and may allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We could also encounter delays if a clinical trial is suspended or terminated by us, the FDA or other regulatory authority, or if the IRBs of the institutions in which such trials are being conducted suspend or terminate the participation of their clinical investigators and sites subject to their review. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">45</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Delays in the initiation, conduct or completion of any clinical trial of our product candidates will increase our costs, slow down our product candidate development and approval process and delay or potentially jeopardize our ability to commence product sales and generate revenue. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. In the event we identify any additional product candidates to pursue, we cannot be sure that submission of an IND or comparable foreign regulatory submission will result in the FDA or other foreign regulatory authorities allowing clinical trials to begin in a timely manner, if at all.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, from time to time, we may publicly announce the expected timing of various scientific, clinical, regulatory, manufacturing and other product development milestones. These milestones may include the commencement, completion or development of data from our preclinical studies and clinical trials or the submission of regulatory filings, such as an IND or a CTA. All of these milestones are, and will be, based on a variety of assumptions. If any of the foregoing events impact our ability to meet the publicly announced timing of our milestones, we may experience adverse effects on our business, financial condition and prospects and the price of our common stock could decline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Monitoring safety of patients receiving our product candidates will be challenging, which could adversely affect our ability to obtain regulatory approval and commercialize our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For our RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, DSG3-CAART, MuSK-CAART and other planned clinical trials, we expect to continue to contract with academic medical centers and hospitals experienced in the assessment and management of toxicities arising during clinical trials. In the future, we may also contract with non-academic medical centers and hospitals with similar capabilities. Nonetheless, these centers and hospitals may have difficulty observing patients, including due to failure by patients to comply with post-clinical trial follow-up programs, and treating toxicities, which may be more challenging due to personnel changes, inexperience, inadequate institutional safety procedures, shift changes, house staff coverage or related issues. This could lead to more severe or prolonged toxicities or even patient deaths, which could result in us or the FDA delaying, suspending or terminating one or more of our clinical trials, and which could jeopardize regulatory approval. We also expect the centers using rese-cel, DSG3-CAART, MuSK-CAART and our other product candidates, if licensed, on a commercial basis could have similar difficulty in managing adverse events. Medicines used at centers to help manage adverse side effects of rese-cel, DSG3-CAART, MuSK-CAART and our other product candidates may not adequately control the side effects and/or may have a detrimental impact on the efficacy of the treatment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons. The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the trial until its conclusion. The enrollment of patients depends on many factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the size and nature of the patient population; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the patient eligibility criteria defined in the protocol; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the size of the patient population required for analysis of the trial&#8217;s primary endpoints; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">recruiting an adequate number of suitable patients to participate in a clinical trial; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtaining IRB and other required reviewing body approval at each clinical trial site; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the proximity of patients to trial sites; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the design of the trial and whether the FDA or other foreign regulatory authorities agree to the design and implementation of the trial; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to identify clinical trial sites and recruit clinical trial investigators with the appropriate capabilities, competencies and experience; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinicians&#8217;, patients&#8217; and parents' (for juvenile patients) perceptions as to the potential advantages and risks of the product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating, or with CAR T cell therapies broadly following the FDA&#8217;s investigation into reports of T cell malignancies for approved BCMA- and CD19-directed CAR T cell immunotherapies; </span></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">46</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the occurrence of dose-limiting toxicity in the clinical trial; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the efforts to facilitate timely enrollment in clinical trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the patient referral practices of physicians; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability to monitor patients adequately during and after treatment; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain and maintain patient consents; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the risk that patients enrolled in clinical trials will drop out of the trials before the infusion of our product candidates or trial completion; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability of patients to meet the complex follow-up requirements of the clinical trial. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Since the number of qualified clinical investigators is limited, some of our clinical trial sites may also be used by some of our competitors, which may reduce the number of patients who are available for our clinical trials in that clinical trial site.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, because our product candidates represent a departure from more commonly used methods for autoimmune diseases where B cells may play a role in initiating or maintaining disease treatment, potential patients and their doctors may be inclined to use conventional therapies, such as corticosteroids or systemic immunosuppressive medications, rather than enroll patients in our clinical trial. Delays in patient enrollment may result in increased costs or may affect the timing or outcome of our ongoing and planned clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our DesCAARTes</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial, our MusCAARTes</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial, our RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trials in SLE, myositis, SSc, gMG, PV and MS and any additional expected clinical trials for each of our product candidates will enroll a limited number of patients. The activity and toxicity data from these clinical trials of our product candidates may differ from future results of subsequent clinical trials that enroll a larger number of patients. Since the number of patients that we plan to dose in our MusCAARTes</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial, our RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trials in SLE, myositis, SSc, gMG, PV and MS is small, and the number of patients in clinical trials for any future product candidates may be small, the results from such clinical trials, once completed, may be less reliable than results achieved in larger clinical trials, which may hinder our efforts to obtain regulatory approval for our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In our RESET-PV</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">trial, RESET-MS</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and our MusCAARTes</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial, we plan to evaluate the toxicity profile of our product candidates and establish the recommended dose for the next clinical trial. The preliminary results of clinical trials with smaller sample sizes, such as our DesCAARTes</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial, our MusCAARTes</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial and our RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trials, as well as any clinical trials for future product candidates, can be disproportionately influenced by various biases associated with the conduct of small clinical trials, such as the potential failure of the smaller sample size to accurately depict the features of the broader patient population, which limits the ability to generalize the results across a broader community, thus making the clinical trial results less reliable than clinical trials with a larger number of patients. As a result, there may be less certainty that such product candidates would achieve a statistically significant effect in any future clinical trials. If we conduct any future clinical trials of DSG3-CAART, MuSK-CAART, or rese-cel, we may not achieve a statistically significant result or the same level of statistical significance, if any, that we might have anticipated based on the results observed in our DesCAARTes</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial, our MusCAARTes</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial, and RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trials, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Sales, Marketing and Competition</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The market opportunities for our product candidates may be limited to those patients who are ineligible for or have failed prior treatments and may be small.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our projections of both the number of people who have autoimmune diseases where B cells may play a role in initiating or maintaining disease we are targeting, as well as the subset of people with these diseases in a position to receive second or later lines of therapy and who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations, or market research and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these autoimmune diseases where B cells may play a role in initiating or maintaining disease. The number of patients may turn out to be lower than expected. Additionally, the potentially addressable patient population for our product candidates may be limited or may not be amenable to treatment with our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">47</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The biopharmaceutical and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong focus on intellectual property. We face competition from many different players, including large and specialty pharmaceutical and biotechnology companies, academic research organizations and governmental agencies. Any therapeutic candidates we successfully develop and commercialize will compete with the existing standard of care as well as novel therapies that may gain regulatory approval in the future. Many of our competitors have substantially greater financial, technical and other resources, such as larger research and development staff and experienced marketing and manufacturing organizations and well-established sales forces. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. Although we are the first and only company developing CAAR T drug candidates, we are one of several developing CAR T drug candidates for the treatment of autoimmune diseases where B cells may play a role in initiating or maintaining disease. Additionally, despite the significant differences in discovery, development and target populations between oncology and autoimmune targets, we recognize that companies with an investment and expertise in CAR T cell development for oncology indications could also attempt to leverage their expertise into autoimmune diseases where B cells may play a role in initiating or maintaining disease affected populations. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our competitors, either alone or with collaborative partners, may succeed in developing, acquiring or licensing on an exclusive basis drug or biologic products that are more effective, safer, more easily commercialized or less costly than our product candidates or may develop proprietary technologies or secure patent protection that we may need for the development of our technologies and products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Specifically, while rituximab is the first drug to have received regulatory approval in the United States in over 60 years for the treatment of PV, the target indication for DSG3-CAART, and the indication we are evaluating in the RESET-PV</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> study, we are aware that multiple biopharmaceutical companies have therapies in clinical development. We are also aware of other biopharmaceutical companies developing therapies for MuSK MG, SLE, myositis, SSc, gMG and MS. While we do not expect these product candidates to be directly competitive to our product candidates, even if we obtain regulatory approval of our product candidates, the availability and price of these other products could limit the demand and the price we are able to charge for our product candidates. We may not be able to implement our business plan if the acceptance of our product candidates is inhibited by price competition or the reluctance of physicians to switch from existing methods of treatment to our product candidates, or if physicians switch to other new drug or biologic products or choose to reserve our product candidates for use in limited circumstances.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if we obtain regulatory approval of our product candidates, the products may not gain the market acceptance among physicians, patients, hospitals, treatment centers and others in the medical community necessary for commercial success.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The use of engineered T cells as a potential treatment for B cell-mediated autoimmune diseases is a recent development and may not become broadly accepted by physicians, patients, hospitals, treatment centers and others in the medical community. We expect physicians to be particularly influential and we may not be able to convince them to use our product candidates for many reasons. Additional factors will influence whether our product candidates are accepted in the market, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the clinical indications for which our product candidates are licensed; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">physicians, hospitals, treatment centers and patients considering our product candidates as a safe and effective treatment; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the potential and perceived advantages of our product candidates over alternative treatments; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the prevalence and severity of any side effects; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product labeling or product insert requirements of the FDA or other regulatory authorities; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">limitations or warnings contained in the labeling approved by the FDA or other regulatory authorities; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing of market introduction of our product candidates as well as competitive products; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of treatment in relation to alternative treatments; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability of coverage and adequate reimbursement and pricing by third-party payors and government authorities; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the willingness of patients to pay out-of-pocket in the absence of coverage and adequate reimbursement by third-party payors and government authorities; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">relative convenience and ease of administration, including as compared to alternative treatments and competitive therapies; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the effectiveness of our sales and marketing efforts. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The product candidates we plan to develop and commercialize are premised on offering a potential cure for autoimmune diseases where B cells may play a role in initiating or maintaining disease, which may result in a high degree of uncertainty related to pricing</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">48</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and long-term demand for our product. Our target patient populations are relatively small. Because of this pricing and demand for our product candidates, if licensed, may not be adequate to support an extended period of commercial viability, which could adversely affect our continued ability to successfully produce and market our product or any follow-on products.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, if our product candidates are licensed but fail to achieve market acceptance among physicians, patients, hospitals, treatment centers or others in the medical community, we will not be able to generate significant revenue. Even if our products achieve market acceptance, we may not be able to maintain that market acceptance over time if new products or technologies are introduced that are more favorably received than our products, are more cost effective or render our products obsolete.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Business Development</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be successful in our efforts to identify additional product candidates. Due to our limited resources and access to capital, we must prioritize development of certain product candidates, which may prove to be wrong and may adversely affect our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we intend to explore other therapeutic opportunities, in addition to the product candidates that we are currently developing, we may fail to identify viable new product candidates for clinical development for a number of reasons. If we fail to identify additional potential product candidates, our business could be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research programs to pursue the development of our existing and planned product candidates for additional indications and to identify new product candidates and disease targets require substantial technical, financial and human resources whether or not they are ultimately successful. Our research programs may initially show promise in identifying potential indications and/or product candidates, yet fail to yield results for clinical development for a number of reasons, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the research methodology used may not be successful in identifying potential indications and/or product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential product candidates may be identified but may not be able to be expressed on T cells in a manner that enables product activity;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential product candidates may, after further study, be shown to have harmful adverse effects or other characteristics that indicate they are unlikely to be effective drugs; or </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">it may take greater human and financial resources than we will possess to identify additional therapeutic opportunities for our product candidates or to develop suitable potential product candidates through internal research programs, thereby limiting our ability to develop, diversify and expand our product portfolio. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because we have limited financial and human resources, we intend to initially focus on research programs and product candidates for a limited set of indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential or a greater likelihood of success. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accordingly, there can be no assurance that we will ever be able to identify additional therapeutic opportunities for our product candidates or to develop suitable potential product candidates through internal research programs, which could materially adversely affect our future growth and prospects. We may focus our efforts and resources on potential product candidates or other potential programs that ultimately prove to be unsuccessful.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to develop additional product candidates, our commercial opportunity will be limited.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">One of our core strategies is to pursue clinical development of additional product candidates beyond rese-cel, DSG3-CAART and MuSK-CAART. Developing, obtaining regulatory approval and commercializing additional product candidates will require substantial additional funding and is prone to the risks of failure inherent in medical product development. We cannot provide you any assurance that we will be able to successfully advance any of these additional product candidates through the development process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we receive FDA or other foreign regulatory authority approval to market additional product candidates for the treatment of autoimmune diseases where B cells may play a role in initiating or maintaining disease, we cannot assure you that any such product candidates will be successfully commercialized, widely accepted in the marketplace or more effective than other commercially available alternatives. If we are unable to successfully develop and commercialize additional product candidates, our commercial opportunity will be limited. Moreover, a failure in obtaining regulatory approval of additional product candidates may have a negative effect on the approval process of any other, or result in losing approval of any approved, product candidate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">49</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our management, scientific, and medical personnel, including our Chief Executive Officer and President, our Scientific Advisory Board members, our President, Science and Technology, our Chief Medical Officer, and our Chief Financial Officer. The loss of the services of any of our executive officers, other key employees, and other scientific and medical advisors, and our inability to find suitable replacements could result in delays in product development and harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competition for skilled personnel in our market is intense and may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all. To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided stock options that vest over time. The value to employees of stock options that vest over time may be significantly affected by movements in our stock price that are beyond our control and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of our management, scientific and development teams may terminate their employment with us on short notice. Although we have employment agreements with our key employees, these employment agreements provide for at-will employment, which means that any of our employees could leave our employment at any time, with or without notice. We do not maintain &#8220;key person&#8221; insurance policies on the lives of these individuals or the lives of any of our other employees. Our success also depends on our ability to continue to attract, retain and motivate highly skilled junior, mid-level and senior managers as well as junior, mid-level and senior scientific and medical personnel.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We expect to grow the size of our organization, and we may experience difficulties in managing this growth.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we had 160 full-time employees and two part-time employees. As our development and commercialization plans and strategies develop, and as we continue to broaden our operational capabilities, we expect to expand our employee base and continue to add managerial, operational, sales, research and development, marketing, financial and other personnel. Current and future growth imposes significant added responsibilities on members of management, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">identifying, recruiting, integrating, retaining and motivating additional employees in an increasingly competitive, inflationary market; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">managing our internal development efforts effectively, including the clinical and FDA or other regulatory authority review process for our product candidates, while complying with our contractual obligations to contractors and other third parties; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">improving our operational, financial and management controls, reporting systems and procedures. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our future financial performance and our ability to commercialize our product candidates will depend, in part, on our ability to effectively manage our growth, and our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants to provide certain services, including certain research and development as well as general and administrative support, pursuant to agreements which expire after a certain period of time. There can be no assurance that the services of independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval of our product candidates or otherwise advance our business. There can be no assurance that we will be able to manage our existing consultants or find other competent outside contractors and consultants on economically reasonable terms, or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, or if we are not able to raise sufficient funds in the future to support our hiring efforts beyond our research and development personnel, we may not be able to successfully implement the tasks necessary to further develop and commercialize our product candidates and, accordingly, may not achieve our research, development and commercialization goals.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Business disruptions, including due to natural disasters, global conflicts or political unrest, could seriously impact our operations, research and trials and harm our future revenue and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our operations, Penn&#8217;s operations, WuXi's operations and those of any CMOs, CROs and other contractors and consultants that we may engage could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or man-made disasters or business interruptions, for</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">50</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">which we are predominantly self-insured. Further, global conflicts or political unrest, such as the ongoing military conflict between Russia and Ukraine, the Israel-Hamas war, and the conflict in the Middle East may disrupt our global clinical trials and increase the likelihood of supply interruptions. Additionally, the effect of global financial and economic conditions and geopolitical events, including the presidential transition in the United States, events or changes related thereto or political unrest or otherwise, or similar events, may have an impact on our business. The occurrence of any of these business disruptions could seriously harm our research, clinical trials, operations and financial condition and increase our costs and expenses. Our ability to obtain clinical supplies of our product candidates could be disrupted if the operations of these suppliers are affected by a man-made or natural disaster or other business interruption.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are also current geopolitical tensions with China. Recently, the Biden administration signed multiple executive orders regarding China. One particular executive order titled Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy signed on September 12, 2022 will likely impact the pharmaceutical industry to encourage U.S. domestic manufacturing of pharmaceutical products. Moreover, there have been Congressional legislative proposals, such as the bill titled the BIOSECURE Act, which would, among other things, prohibit U.S. federal funding in connection with biotechnology equipment or services produced or provided by certain named Chinese &#8220;biotechnology companies of concern&#8221; (which, under the version of legislation passed by the U.S. House of Representatives on September 9, 2024, are WuXi AppTec, WuXi Biologics, MGI, BGI, and Complete Genomics) and loans and grants to, and federal contracts with any entity that uses biotechnology equipment or services from one of these entities in performance of the government contract, grant, or loan. The legislation also gives the federal government the authority to name additional &#8220;biotechnology companies of concern&#8221; that are engaged in research activities with the Chinese government and that pose a risk of U.S. national security. Previously, on May 15, 2024, the House Committee on Oversight and Accountability approved an updated version of the BIOSECURE Act which would delay the application of the BIOSECURE Act&#8217;s provisions (1) until January 1, 2032, with respect to biotechnology equipment and services provided or produced by a named biotechnology company of concern under a contract or agreement entered before the effective date of the legislation and (2) for a period of 5 years after the identification of new biotechnology companies of concern, with respect to biotechnology equipment and services provided or produced by an entity that the government identifies in the future as a biotechnology company of concern. On December 23, 2024, WuXi AppTec, parent company of WuXi, announced that it entered into a definitive agreement to sell the US and UK based operations of WuXi to Altaris, LLC, a healthcare investment firm headquartered in New York, and expected the transaction to close in the first half of 2025. On February 28, 2024, President Biden signed Executive Order 14117 (&#8220;Preventing Access to Americans' Bulk Sensitive Personal Data and United States Government-Related Data by Countries of Concern&#8221;) which implements a new framework to protect the privacy of personal data shared between the U.S. and Europe, which may, in effect, impact privacy laws with &#8220;countries of concern&#8221; such as China or Russia.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, due to our adoption of a more flexible work model following the COVID-19 pandemic, our increased prevalence of personnel working from home may negatively impact productivity, or disrupt, delay, or otherwise adversely impact our business operations. Further, this could increase our cyber security risk, create data accessibility concerns, and make us more susceptible to communication disruptions, any of which could adversely impact our business operations or delay necessary interactions with local and federal regulators, ethics committees, manufacturing sites, research or clinical trial sites and other important agencies and contractors.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Financial Condition and Capital Requirements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Past Financial Condition</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have incurred net losses in every period since our inception and anticipate that we will incur substantial net losses over the next several years, and may never achieve or maintain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate effect or an acceptable safety profile, gain regulatory approval and become commercially viable. We have no products licensed for commercial sale, and we will continue to incur significant research and development and other expenses related to our ongoing operations. Our net losses may fluctuate significantly from quarter to quarter and year to year. We have to date financed our operations primarily through private placements of our preferred stock, the sale of common stock in our initial and secondary public offerings and sales of our common stock from time to time in &#8220;at-the-market&#8221; offerings.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result, we are not profitable and have incurred net losses in each period since our inception. For the years ended December 31, 2024 and 2023, we recorded net losses of $115.9 million and $67.7 million, respectively. As of December 31, 2024, we had an accumulated deficit of $349.1 million. We expect to incur significant losses for the foreseeable future, and we expect these losses to increase substantially if, and as, we:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">continue our research and development efforts and submit additional INDs and/or CTAs for our product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">conduct preclinical studies and clinical trials for our current and future product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">further develop our product candidate platform; </span></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">51</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">continue to discover and develop additional product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintain, expand and protect our intellectual property portfolio; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">hire additional clinical, scientific manufacturing and commercial personnel; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establish a commercial manufacturing source and secure supply chain capacity sufficient to provide commercial quantities of any product candidates for which we may obtain regulatory approval, whether through a CMO or through a manufacturing facility that we establish; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acquire or in-license other product candidates and technologies, including advanced manufacturing and translational capabilities that we will need for the further development and possible commercialization of our product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seek marketing approvals for any product candidates that successfully complete clinical trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establish a sales, marketing and distribution infrastructure to support the sales and marketing of any product candidates for which we may obtain marketing approvals; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">add operational, financial and management information systems and personnel, including personnel to support our product development and planned future commercialization efforts, as well as to support our operations as a public company. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To become and remain profitable, we must succeed in developing, and eventually commercializing, a product or products that generate significant revenue. The ability to achieve this success will require us to be effective in a range of challenging activities, including completing preclinical testing and clinical trials of our product candidates, discovering additional product candidates, obtaining regulatory approval for these product candidates and manufacturing, marketing and selling any products for which we may obtain regulatory approval. We are only in the preliminary stages of most of these activities and have not yet demonstrated our ability to successfully develop any product candidate, obtain regulatory approvals, manufacture a commercial scale product or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. We may never be able to develop, manufacture or commercialize a marketable product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we are able to succeed in these activities, we may never generate revenues that are significant enough to achieve profitability. Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. Our expenses will increase if, among other things:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">there are any delays in completing our clinical trials or the development of any of our product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we are required by the FDA or other regulatory authorities to perform trials or studies in addition to, or different than, those expected; or </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">there are any third-party challenges to our intellectual property or we need to defend against any intellectual property-related claim. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses we will incur or when, if ever, we will be able to achieve profitability. Even if we succeed in commercializing one or more of our product candidates, we will continue to incur substantial research and development and other expenditures to develop, seek regulatory approval for and market additional product candidates. We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have a limited operating history, which may make it difficult to evaluate the success of our business to date and to assess our future viability, and we may face significant challenges and expense as we test our product candidates and build our capabilities.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We were incorporated in 2017 and initially acquired rights to license certain patent rights from Penn in August 2018, and acquired rights to license certain patent rights from Nanjing IASO Biotherapeutics Co., Ltd., or IASO, in October 2022. All of our product candidates are still in the preclinical development or clinical stage. We have not yet demonstrated our ability to successfully complete any clinical trials, including large-scale, pivotal clinical trials, obtain marketing approvals, manufacture clinical and commercial scale therapeutics, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful commercialization. Our ability to generate product revenue or profits, which we do not expect will occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of our product candidates, which may never occur. We may never be able to develop or commercialize a marketable product.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">52</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our limited operating history, particularly in light of the rapidly evolving cell therapy field, may make it difficult to evaluate our current business and predict our future performance. Our relatively short history as an operating company makes any assessment of our future success or viability subject to significant uncertainty. We will encounter risks and difficulties frequently experienced by clinical-stage companies in rapidly evolving fields. If we do not address these risks successfully, our business will suffer. Similarly, we expect that our financial condition and operating results will continue to fluctuate from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. As a result, our shareholders should not rely upon the results of any quarterly or annual period as an indicator of future operating performance.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently do not have in-house resources sufficient to enable the development of our product candidates, including our CAR T and CAAR T cell platforms. We are reliant on several manufacturing and support services from Penn through two Master Translational Research Service Agreements, or the CAART Services Agreement and CARTA Services Agreement, respectively, and collectively, the Services Agreements. We also rely on Penn for current manufacturing of rese-cel. Our ability to rely on services from Penn is limited to a specified period of time, to specific capabilities, and is subject to Penn&#8217;s right to terminate these services with or without cause. We are reliant on WuXi manufacturing services for MuSK-CAART and rese-cel in multiple indications through a Development, Manufacturing and Testing Services Agreement, or the WuXi Agreement. Our ability to rely on services from WuXi is limited to a specified period of time, to specific capabilities, and is subject to WuXi's right to terminate these services with or without cause. If we are unable to establish necessary relationships with third party partners and/or build our own capabilities, our operating and financial results could differ materially from our expectations, and our business could suffer. As we build our own capabilities, and enter into agreements with third parties, we expect to encounter risks and uncertainties frequently experienced by growing companies in new and rapidly evolving fields, including the risks and uncertainties described herein.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All of our programs require additional preclinical research and development, clinical development, regulatory approval in multiple jurisdictions, obtaining manufacturing supply, capacity and expertise, building of a commercial organization, substantial investment and significant marketing efforts before we generate any revenue from product sales. Other programs of ours require additional discovery research and then preclinical and clinical development. In addition, our product candidates must be licensed for marketing by the FDA or other foreign regulatory authorities before we may commercialize any product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have not generated any revenue from our product candidates and our ability to generate revenue from product sales and become profitable depends significantly on our success in a number of areas.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To become and remain profitable, we or any potential future collaborator must develop and eventually commercialize products with significant market potential at an adequate profit margin after cost of goods sold and other expenses. All of our product candidates are in the early stages of development and we will require additional preclinical studies, clinical development, regulatory review and approval, substantial investment, access to sufficient commercial manufacturing capacity and significant marketing efforts before we can generate any revenue from product sales. Our ability to generate revenue depends on a number of factors, including, but not limited to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">timely completion of our preclinical studies and clinical trials, which may be significantly slower or cost more than we currently anticipate and will depend substantially upon the performance of third-party academic and commercial contractors; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to complete IND-enabling studies and successfully submit INDs or comparable applications; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether we are required by the FDA or other foreign regulatory authorities to conduct additional clinical trials or other studies beyond those planned to support the licensure and commercialization of our product candidates or any future product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to demonstrate to the satisfaction of the FDA or other foreign regulatory authorities, the safety, potency, purity and acceptable risk to benefit profile of our product candidates or any future product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the prevalence, duration and severity of potential side effects or other safety issues experienced with our product candidates or future product candidates, if any; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of manufacturing and processing our product candidates being greater than we anticipate; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timely receipt of necessary marketing approvals from the FDA or other foreign regulatory authorities; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the willingness of physicians, operators of clinics and patients to utilize or adopt any of our product candidates or future product candidates to treat autoimmune diseases where B cells may play a role in initiating or maintaining disease; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability and the ability of third parties with whom we contract to manufacture adequate clinical and commercial supplies of our product candidates or any future product candidates, remain in good standing with regulatory authorities and develop, validate and maintain commercially viable manufacturing processes that are compliant with FDA&#8217;s current Good Manufacturing Practices, or cGMP; </span></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">53</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to successfully develop a commercial and competitive strategy and thereafter commercialize our product candidates or any future product candidates in the United States or other countries, if licensed for marketing, reimbursement, sale and distribution, whether alone or in collaboration with others; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">patient demand for our product candidates and any future product candidates, if licensed; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to establish and enforce intellectual property rights in and to our product candidates or any future product candidates. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of the factors listed above are beyond our control and could cause us to experience significant delays or prevent us from obtaining regulatory approvals or commercialize our product candidates. Even if we are able to commercialize our product candidates, we may not achieve profitability soon after generating product sales, if ever. If we are unable to generate sufficient revenue through the sale of our product candidates or any future product candidates, we may be unable to continue operations without continued funding.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Additionally, even if we succeed in commercializing one or more of our product candidates, we will continue to incur substantial research and development and other expenditures to research, develop and market additional product candidates. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our company also could cause you to lose all or part of your investment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Future Financial Condition</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We will require substantial additional financing to develop and commercialize our product candidates and implement our operating plans. We have also identified conditions that raise substantial doubt about our ability to continue as a going concern. If we fail to obtain additional financing or cannot obtain financing at the levels we require, we may be forced to delay, reduce or discontinue our plans and operations or unable to complete the development and commercialization of our product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our operations have consumed substantial amounts of cash since inception. We expect to continue to spend substantial amounts to continue the preclinical and clinical development of our product candidates, including our MusCAARTes</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial and our RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trials, and our research and development, preclinical studies and clinical trials for any future product candidates, to seek regulatory approvals for our product candidates, to enable commercial production of our products, if licensed, and to initiate and complete registration trials for multiple products. As of December 31, 2024, we had $164.0 million of cash and cash equivalents. Since our initial public offering, we have generated cash from public offerings of our common stock and pre-funded warrants to purchase our common stock resulting in aggregate net proceeds of approximately $280.0 million. While we currently expect our existing cash and cash equivalents to be sufficient to fund our operations into the first half of 2026 which includes initial clinical data on efficacy endpoints and tolerability from the initial rese-cel treated patients in the RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> clinical trials, we expect to require significant additional financing to complete these clinical trials and any future clinical trials of these and our other product candidates. Further, if marketing approval is received, we will require significant additional amounts of cash to launch and commercialize our product candidates. However, we have based this estimate on assumptions that may prove to be wrong. Additionally, changing circumstances may cause us to consume capital significantly faster than we currently anticipate, and we may need to spend more money than currently expected because of circumstances beyond our control. We may require substantial additional capital for the further development and commercialization of our product candidates, including funding our internal manufacturing capabilities, and may need to raise additional funds sooner if we choose to expand more rapidly than we presently anticipate. Because the length of time and activities associated with development of our product candidates is highly uncertain, we are unable to estimate the actual funds we will require for development and any approved marketing and commercialization activities. Our future funding requirements, both near- and long-term, will depend on many factors, including, but not limited to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the initiation, progress, timing, costs and results of preclinical studies and clinical trials for our product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the clinical development plans we establish for these product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number and characteristics of product candidates that we may develop or in-license; </span></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">54</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the terms of any collaboration agreements we may choose to conclude; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the outcome, timing and cost of meeting regulatory requirements established by the FDA or other foreign regulatory authorities; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of defending intellectual property disputes, including patent infringement actions brought by third parties against us or our product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the effect of competing technological and market developments; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of establishing and maintaining a supply chain for the development and manufacture of our product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost and timing of establishing, expanding and scaling manufacturing capabilities; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of maintaining the amount patient data for which we would be responsible following commercialization of one or more of our product candidates; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of establishing sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval in regions where we choose to commercialize our products on our own. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot be certain that additional funding will be available on acceptable terms, or at all. As widely reported, global credit and financial markets have experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, inflation, increases in unemployment rates and uncertainty about economic stability. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. Until we are able to generate sufficient revenue to finance our cash requirements, we will need to finance our future cash needs through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing or distribution arrangements. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue our research and development initiatives and clinical development plans. We could be required to seek collaborators for our product candidates at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available or relinquish or license on unfavorable terms our rights to our product candidates in markets where we otherwise would seek to pursue development or commercialization ourselves.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on our current operating plan, we believe there is substantial doubt about our ability to continue as a going concern for at least twelve months following the filing of this Annual Report on Form 10-K, and we will need to obtain additional funding. We may be forced to delay or reduce the scope of our product development programs, reduce our research and development costs and/or limit or cease our operations if we are unable to obtain additional funding to support our current operating plan. Our cash forecast contains estimates and assumptions based on success of our ongoing clinical trials, and management cannot predict the amount or timing of all expenditures with certainty. Nevertheless, our financial statements do not include any adjustments that might result from the outcome of this uncertainty. We will need to raise additional capital to fund our future operations and remain as a going concern. However, we cannot guarantee that we will be able to obtain any or sufficient additional funding or that such funding, if available, will be obtainable on terms satisfactory to us.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect that significant additional capital may be needed in the future to continue our planned operations, including conducting clinical trials, commercialization efforts, expanded research and development activities and costs associated with operating a public company. To raise capital, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities, investors may be materially diluted by subsequent sales. Such sales may also result in material dilution to our existing stockholders, and new investors could gain rights, preferences and privileges senior to the holders of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to our equity incentive plans, our management is authorized to grant stock options to our employees, directors and consultants. Additionally, the number of shares of our common stock reserved for issuance under the 2019 Stock Option and Incentive Plan, or the 2019 Plan, automatically increased on January 1, 2025 and will automatically increase each January 1 thereafter through and including January 1, 2029, by 4% of the total number of shares of our capital stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares determined by our board of directors. Unless our board of directors elects not to increase the number of shares available for future grant each year, our stockholders may experience additional dilution, which could cause our stock price to fall. In addition, on April 7, 2023, our board of directors adopted, and at our 2023 annual meeting our stockholders approved, an amendment to the 2019 Plan, or the Plan Amendment, to increase the aggregate number of shares authorized for issuance under the 2019 Plan by 3,000,000 shares, subject to adjustment. Our compensation committee determined the size of the increase to the reserved</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">55</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pool under the Plan Amendment based on projected equity awards to anticipated new hires, projected annual equity awards to existing employees and an assessment of the magnitude of increase that our institutional investors and the firms that advise them would likely find acceptable. We anticipate that the increased share reserve under our 2019 Plan, as amended by the Plan Amendment, will be sufficient to provide equity incentives to attract, retain, and motivate employees for a period of two years following the effective date of the Plan Amendment.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of the above events could significantly harm our business, prospects, financial condition and results of operations and cause the price of our common stock to decline.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We rely heavily on certain in-licensed patent and other intellectual property rights in connection with our development of our product candidates and, if we fail to comply with our obligations under our existing and any future intellectual property licenses with third parties, we could lose license rights that are important to our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to develop and commercialize our product candidates is heavily dependent on in-licenses to patent rights and other intellectual property granted to us by third parties. For example, we depend heavily on our License Agreement with Penn and CHOP, which was entered into in 2018, amended and restated in July 2019, and further amended in May 2020 and October 2021, pursuant to which we obtained (a) a non-exclusive, non-sublicensable, worldwide research license to intellectual property controlled by Penn and CHOP to make, have made and use products in two subfields of use, (b) effective as of October 2018, an exclusive, worldwide, royalty-bearing license, with the right to sublicense, under certain of such intellectual property to make, use, sell, offer for sale and import products in the same two subfields of use, and (c) effective as of October 2018, a non-exclusive, worldwide, royalty-bearing license, with limited rights to sublicense, under certain of Penn&#8217;s know-how, which know-how satisfies certain criteria and is listed on a mutually agreed to schedule, to make, have made, use, sell, offer for sale, import and have imported products in the same two subfields of use. We also depend on our Exclusive License Agreement with IASO, which was entered into in October 2022, pursuant to which we obtained a worldwide, exclusive license under certain intellectual property to develop, manufacture, commercialize and otherwise exploit T cell products directed to CD19 for the purpose of diagnosis, prevention or treatment of an autoimmune or alloimmune indication in humans, or the IASO Agreement. We may enter into additional license agreements in the future. Our license agreements with Penn, CHOP and IASO impose, and we expect that future license agreements will impose, various diligence, milestone payment, royalty, insurance and other obligations on us. If we fail to comply with our obligations under these licenses, our licensors, including Penn, CHOP and IASO may have the right to terminate these license agreements, in which event we might not be able to market our product candidates. Termination of any of our license agreements or reduction or elimination of our licensed rights may also result in our having to negotiate new or reinstated licenses with less favorable terms.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may need to obtain additional licenses from third parties to advance our research or allow commercialization of our product candidates, and we have done so from time to time. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we may be required to expend significant time and resources to develop or license replacement technology. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could harm our business significantly. We cannot provide any assurances that third-party patents do not exist which might be enforced against our current product candidates or future products, resulting in either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, in many cases, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we in-license from third parties. For example, pursuant to our IASO Agreement, IASO controls such activities for the patent rights licensed to us under such agreement. Pursuant to our License Agreement with Penn and CHOP, Penn controls such activities for the patent rights licensed to us under such agreement. Therefore, although we provide input to IASO, Penn and CHOP on these activities, we cannot be certain that these patents will be prosecuted, maintained and enforced in a manner consistent with the best interests of our business. If our current or future licensors or collaboration partners fail to obtain, maintain or protect any patents or patent applications licensed to us, our rights to such patents and patent applications may be reduced or eliminated and our right to develop and commercialize any of our product candidates that are the subject of such licensed rights could be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disputes may arise between us and our current and future licensors regarding intellectual property subject to a license agreement, including those related to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope of rights granted under the License Agreement or IASO Agreement and other interpretation-related issues; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether we have breached the License Agreement or IASO Agreement and whether any such breach is subject to a cure period; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; </span></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">56</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our right to sublicense patent and other rights to third parties under collaborative development relationships; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, disputes may arise between us and our current or future licensors regarding the ownership of intellectual property developed by us, such that we may be required to assign or otherwise transfer such intellectual property to such licensor. In the event that the assigned or transferred intellectual property is covered by an existing license agreement with such licensor we may be required to make additional royalty or milestone payments, or both, to such licensor. If the assigned or transferred intellectual property is not covered by an existing license agreement, then we may be required to enter into an additional license agreement to advance our research or allow commercialization of our product candidates, which may not be available on commercially reasonable terms or at all.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If disputes over intellectual property that we have licensed, or license in the future, prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If our efforts to protect the proprietary nature of the intellectual property related to our current and any future product candidates are not adequate, we may not be able to compete effectively in our market.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success depends in large part on our ability to obtain and maintain intellectual property protection in the United States and other countries with respect to our product candidates. If we do not adequately protect or enforce our intellectual property rights, competitors may be able to erode or negate any competitive advantage we may have, which could harm our business and ability to achieve profitability. To protect our proprietary position, we have filed and in-licensed patent rights in the United States and abroad relating to the product candidates that are important to our business. The patent application and approval process is expensive, complex and time-consuming. We or our licensors may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain. No consistent policy regarding the breadth of claims allowed in biotechnology and pharmaceutical patents has emerged to date in the United States or in many foreign jurisdictions. In addition, the determination of patent rights with respect to biological and pharmaceutical products commonly involves complex legal and factual questions, which has in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Pending patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications. Assuming the other requirements for patentability are met, currently, the first to file a patent application is generally entitled to the patent. However, prior to March 16, 2013, in the United States, the first to invent was entitled to the patent. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we or our licensors were the first to make the inventions claimed in the patents or pending patent applications, or that we and our licensors were the first to file for patent protection of such inventions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, because the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, the patents or pending patent applications that we own or in-license may be challenged in the courts or patent offices in the United States and abroad. For example, we may be subject to a third party preissuance submission of prior art to the U.S. Patent and Trademark Office, or USPTO, or become involved in post-grant review procedures, derivation proceedings, reexaminations, or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> inter partes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> review in the United States, or oppositions and other comparable proceedings in foreign jurisdictions, challenging our patent rights or the patent rights of others. An adverse determination in any such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and product candidates. In addition, given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of the patents we in-license or narrow the scope of our patent protection. In addition, the laws of foreign countries may not protect our rights to the same extent or in the same manner as the laws of the United States. For example, European patent law is more restrictive than U.S. patent law in connection with the patentability of methods of treatment of the human body and Chinese bankruptcy law may not provide a licensee the same protections as U.S. bankruptcy law. This could impact our in-license under the IASO Agreement with IASO, a China-based company, if IASO declared bankruptcy, and could have a material adverse effect on the development of rese-cel.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">57</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A European Unified Patent Court, or the UPC, came into force during 2023. The UPC is a common patent court to hear patent infringement and revocation proceedings effective for member states of the European Union. This could enable third parties to seek revocation of our European patents in a single proceeding at the UPC rather than through multiple proceedings in each of the jurisdictions in which the European patent is validated. Any such revocation and loss of patent protection could have a material adverse impact on our business and our ability to commercialize or license our technology and products. Moreover, the controlling laws and regulations of the UPC will develop over time, and may adversely affect our ability to enforce or defend the validity of our European patents. Although we have decided, and may continue to decide, to opt out certain of our European patents and patent applications from the UPC, if certain formalities and requirements are not met, then our European patents and patent applications could be challenged for non-compliance and brought under the jurisdiction of the UPC. Thus, we cannot be certain that our European patents and patent applications will avoid falling under the jurisdiction of the UPC.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot predict whether the patent applications that we own or in-license will issue as patents, whether the claims of any patent that has or may issue will provide us with a competitive advantage or prevent competitors from designing around the claims to develop competing technologies in a non-infringing manner, or whether we or our licensors will be able to successfully pursue patent applications in the future relating to our current product candidates or future products and product candidates. Moreover, the patent application and approval process is expensive and time-consuming. We or our licensors may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. Furthermore, we, or any future partners, collaborators, or licensees, may fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Therefore, we may miss potential opportunities to seek additional patent protection.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is possible that defects of form in the preparation or filing of patent applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, claim scope, or requests for patent term adjustments. If we fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If there are material defects in the form, preparation, prosecution or enforcement of the patents or patent applications we in-license, such patents may be invalid and/or unenforceable, and such applications may never result in valid, enforceable patents. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if the patent applications we own or in-license issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our patent rights by developing similar or alternative technologies or products in a non-infringing manner. Our competitors may also seek approval to market their own products similar to or otherwise competitive with our product candidates. Alternatively, our competitors may seek to market generic versions of any approved products by submitting abbreviated BLAs to the FDA during which process they may claim that our owned or in-licensed patents are invalid, unenforceable or not infringed. In these circumstances, we may need to defend or assert our intellectual property rights, or both, including by filing lawsuits alleging patent infringement. In any of these types of proceedings, a court or other agency with jurisdiction may find the patents we own or in-license invalid or unenforceable, or that our competitors are competing in a non-infringing manner. Thus, even if we own or in-license valid and enforceable patents, these patents still may not provide protection against competing products or processes sufficient to achieve our business objectives. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the future, we likely will need to expand our patent portfolio to pursue patent coverage for new product candidates that we wish to develop. The patent prosecution process is competitive, and other companies, some which may have greater resources than we do in this area, may also be pursuing intellectual property rights that we may consider necessary or attractive in order to develop and commercialize future product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be able to protect our intellectual property rights throughout the world.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Filing, prosecuting, maintaining, defending and enforcing patents on our product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States could be less extensive than those in the United States. Although our License Agreement and IASO Agreement grant us worldwide rights, there can be no assurance that we will obtain or maintain patent rights in or outside the United States under any future license agreements. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States even in jurisdictions where we and our licensors pursue patent protection. Consequently, we and our licensors may not be able to prevent third parties from practicing our inventions in all countries outside the United States, even in jurisdictions where we and our licensors pursue patent protection, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we and our licensors have not pursued and obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we and our licensors have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our product candidates and the patents we in-license or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">58</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of the patents we in-license or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights, even if obtained, in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put the patents we in-license at risk of being invalidated or interpreted narrowly and the patent applications we own or in-license at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We or our licensors may be subject to claims challenging the inventorship or ownership of the patents and other intellectual property that we own or license.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We or our licensors may be subject to claims that former employees, collaborators or other third parties have an ownership interest in the patents and intellectual property that we own or in-license or that we may own or in-license in the future. While it is our policy to require our employees and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own or such assignments may not be self-executing or may be breached. Our licensors may face similar obstacles. We or our licensors could be subject to ownership disputes arising, for example, from conflicting obligations of employees, consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against any claims challenging inventorship or ownership. If we or our licensors fail in defending any such claims, we may have to pay monetary damages and may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property, which could adversely impact our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Some intellectual property which we have in-licensed was discovered through government funded programs and thus is subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements, and a preference for U.S. industry. Compliance with such regulations may limit our exclusive rights and limit our ability to contract with non-U.S. manufacturers.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain of the intellectual property rights we have licensed, including rights licensed to us by Penn relating to our DSG3-CAART and DSG3/1-CAART product candidates, was generated through the use of U.S. government funding and may therefore be subject to certain federal laws and regulations. As a result, the U.S. government has certain rights to intellectual property embodied in our DSG3-CAART and DSG3/1-CAART product candidates and may have rights in future product candidates pursuant to the Bayh-Dole Act of 1980. These U.S. government rights in certain inventions developed under a government-funded program include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right to require us to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third party if it determines that: (i) adequate steps have not been taken to commercialize the invention; (ii) government action is necessary to meet public health or safety needs; or (iii) government action is necessary to meet requirements for public use under federal regulations, also referred to as &#8220;march-in rights&#8221;. The U.S. government also has the right to take title to these inventions if we, or the applicable licensor, such as Penn, fail to disclose the invention to the government and fail to file an application to register the intellectual property within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us or the applicable licensor to expend substantial resources. In addition, the U.S. government requires that products embodying the subject invention or produced through the use of the subject invention be manufactured substantially in the United States. The manufacturing preference requirement can be waived if the owner of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. manufacturers may limit our ability to contract with non-U.S. product manufacturers for product candidates covered by such intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may become involved in lawsuits to protect or enforce our patent rights or other intellectual property rights, which could be expensive, time consuming and unsuccessful.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competitors may infringe, misappropriate or otherwise violate patents, trademarks, copyrights or other intellectual property that we own or in-license. To counter infringement, misappropriation or other unauthorized use, we may be required to file claims, which can be expensive and time consuming and divert the time and attention of our management and scientific personnel. Any claims we assert against perceived violators could provoke these parties to assert counterclaims against us alleging that we infringe, misappropriate or otherwise violate their intellectual property, in addition to counterclaims asserting that the patents we in-license are invalid or unenforceable, or both. In any patent infringement proceeding, there is a risk that a court will decide that a patent we own or in-license is invalid or unenforceable, in whole or in part, and that we do not have the right to stop the other party from using the invention at issue.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">59</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the U.S., grounds for a validity challenge in a court proceeding could be an alleged failure to meet one or more statutory requirements for patentability, including, for example, lack of novelty, obviousness, lack of written description or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Additionally, third parties are able to challenge the validity of issued patents through administrative proceedings in the patent offices of certain countries, including the USPTO and the European Patent Office.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if the validity of a patent is upheld during a court proceeding, there is a risk that the court will construe the patent&#8217;s claims narrowly or decide that we do not have the right to stop the other party from using the invention at issue on the grounds that the patent claims do not cover the invention. An adverse outcome in a litigation or proceeding involving the patents we own or in-license could limit our ability to assert the patent against those parties or other competitors and may curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. Any of these occurrences could adversely affect our competitive business position, business prospects and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we establish infringement, misappropriation or another violation of our intellectual property rights, the court may decide not to grant an injunction against the offender and instead award only monetary damages, which may or may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our shares. Moreover, there can be no assurance that we will have sufficient financial or other resources to file and pursue such claims, which typically last for years before they are concluded. Even if we ultimately prevail in such claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we receive as a result of the proceedings. Any of the foregoing may have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in either the patent laws or the interpretation of the patent laws in the United States or other jurisdictions could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. On September 16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. When implemented, the Leahy-Smith Act included several significant changes to U.S. patent law that impacted how patent rights could be prosecuted, enforced and defended. In particular, the Leahy-Smith Act also included provisions that switched the United States from a &#8220;first-to-invent&#8221; system to a &#8220;first-to-file&#8221; system, allowed third-party submission of prior art to the USPTO during patent prosecution and set forth additional procedures to attack the validity of a patent by the USPTO administered post grant proceedings. Under a first-to-file system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to the patent on an invention regardless of whether another inventor had made the invention earlier. The USPTO developed new regulations and procedures governing the administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the first to file provisions, became effective on March 16, 2013. It remains unclear what impact, if any, the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of the patent applications we in-license and the enforcement or defense of the issued patents we in-license, all of which could have a material adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The patent positions of companies engaged in the development and commercialization of biologics are particularly uncertain. For example, the Supreme Court of the United States issued its decision in Association for Molecular Pathology v. Myriad Genetics, Inc., or Myriad, a case involving patent claims held by Myriad Genetics, Inc. relating to the breast cancer susceptibility genes BRCA1 and BRCA2. Myriad held that an isolated segment of naturally occurring DNA, such as the DNA constituting the BRCA1 and BRCA2 genes, is not patent-eligible subject matter, but that complementary DNA, which is an artificial construct that may be created from RNA transcripts of genes, may be patent-eligible. Thereafter, the USPTO issued a guidance memorandum instructing USPTO examiners on the ramifications of the Prometheus and Myriad rulings and apply the Myriad ruling to natural products and principles including all naturally occurring nucleic acids. Certain claims of our owned and in-licensed patent applications contain, and any future patents we may obtain may contain, claims that relate to specific recombinant DNA sequences that are naturally occurring at least in part and, therefore, could be the subject of future challenges made by third parties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">60</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot assure you that our efforts to seek patent protection for one or more of our product candidates will not be negatively impacted by this Supreme Court decision, rulings in other cases or changes in guidance or procedures issued by the USPTO. We cannot fully predict what impact the Supreme Court&#8217;s decisions in Myriad may have on the ability of life science companies to obtain or enforce patents relating to their products in the future. These decisions, the guidance issued by the USPTO and rulings in other cases or changes in USPTO guidance or procedures could have a material adverse effect on our existing patent rights and our ability to protect and enforce our intellectual property in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to protect the confidentiality of trade secrets, our business and competitive position would be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect certain proprietary know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce, and any other elements of our product candidate discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. However, trade secrets can be difficult to protect and some courts inside and outside the United States are less willing or unwilling to protect trade secrets. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors, and contractors. We cannot guarantee that we have entered into such agreements with each party that may have or has had access to our trade secrets or proprietary technology and processes. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, our trade secrets may otherwise become known or be independently discovered by competitors. Competitors and other third parties could infringe, misappropriate or otherwise violate our intellectual property rights, design around our protected technology or develop their own competitive technologies that fall outside of our intellectual property rights. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If our trade secrets are not adequately protected or sufficient to provide an advantage over our competitors, our competitive position could be adversely affected, as could our business. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating our trade secrets.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent term may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. In the United States, the Drug Price Competition and Patent Term Restoration Act of 1984 permits a patent term extension of up to five years beyond the normal expiration of the patent, which is limited to the approved indication (or any additional indications approved during the period of extension). However, a patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of the product&#8217;s approval by the FDA, only one patent applicable to an approved drug is eligible for the extension, and only those claims covering the approved drug, a method for using it or a method for manufacturing it may be extended. In the future, if and when our product candidates receive FDA approval, we plan to apply for patent term extensions on patents covering those product candidates in any jurisdiction where these are available. However, the applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to the patents we own or in-license, or may grant more limited extensions than we request. Moreover, we may not receive an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. If this occurs, our competitors may be able to take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be subject to claims asserting that our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain of our employees, consultants or advisors are currently, or were previously, employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these individuals or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">61</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management. Our licensors may face similar risks, which could have an adverse impact on intellectual property that is licensed to us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may become subject to claims that we are infringing certain third-party patents or other third-party intellectual property rights, any of which may prevent or delay our development and commercialization efforts and have a material adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our commercial success depends in part on avoiding infringing, misappropriating and otherwise violating the patents and other intellectual property and proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, and administrative proceedings such as interferences,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> inter partes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> review and post grant review proceedings before the USPTO and opposition proceedings before foreign patent offices. Numerous U.S. and foreign issued patents and pending patent applications, which are owned or controlled by third parties, including our competitors, exist in the fields in which we are pursuing product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third parties may assert that we or our licensors are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, methods of manufacture or methods for treatment relating to our product candidates and, because patent applications can take many years to issue, there may be currently pending third party patent applications which may later result in issued patents, in each case that our product candidates, their manufacture or use may infringe or be alleged to infringe. We may fail to identify potentially relevant patents or patent applications, incorrectly conclude that a patent is invalid or does not cover our activities, or incorrectly conclude that a patent application is unlikely to issue in a form of relevance to our activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Parties making patent infringement claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, including demonstrating non-infringement, invalidity or unenforceability of the respective patent rights in question, regardless of their merit, is time-consuming, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. For example, in order to successfully challenge the validity of any U.S. patent in federal court, we would need to overcome a presumption of validity. This is a high burden requiring us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, and we can provide no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. We may not have sufficient resources to bring these actions to a successful conclusion. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event that a holder of any such patents seeks to enforce its patent rights against us with respect to one or more of our product candidates, and our defenses against the infringement of such patent rights are unsuccessful, we may be precluded from commercializing our product candidates, even if approved, without first obtaining a license to some or all of these patents, which may not be available on commercially reasonable terms or at all. Moreover, we may be required to pay significant fees and royalties to secure a license to the applicable patents. Such a license may only be non-exclusive, in which case our ability to stop others from using or commercializing technology and products similar or identical to ours may be limited. Furthermore, we could be liable for damages to the holder of these patents, which may be significant and could include treble damages if we are found to have willfully infringed such patents. In the event that a challenge to these patents were to be unsuccessful or we were to become subject to litigation or unable to obtain a license on commercially reasonable terms with respect to these patents, it could harm our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are aware of third-party U.S. patents relating to the lentiviral vectors which may be used in the manufacture or use of our product candidates. We are also aware of a patent family that includes granted U.S. and European patent rights directed to methods using, and compositions containing, genetically engineered T cells that may be relevant to our rese-cel product candidate. If these patent rights were enforced against us, we believe that we have defenses against any such action, including that these patents would not be infringed by our product candidates and/or that these patents are not valid. However, if these patents were enforced against us and defenses to such enforcement were unsuccessful, unless we obtain a license to these patents, which may not be available on commercially reasonable terms, or at all, we could be liable for damages and precluded from commercializing any product candidates that were ultimately held to infringe these patents, which could have a material adverse effect on our business, financial condition, results of operations and prospects. Furthermore, even if our arguments are successful, we may incur substantial costs and the time and attention of our management and scientific personnel could be diverted in pursuing these proceedings, which could significantly harm our business and operating results.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even in the absence of a finding of infringement, we may need or may choose to obtain licenses from third parties to advance our research or allow commercialization of our product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, or at all. In that event, we would be unable to further develop and commercialize our product candidates. Claims that</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">62</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business. Any of the foregoing could materially adversely affect our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intellectual property rights do not necessarily address all potential threats.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">others may be able to make products that are similar to our product candidates or utilize similar cell therapy technology but that are not covered by the claims of our current or future patent portfolio; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we, or our current or future licensors or collaborators, might not have been the first to make the inventions covered by the issued patent or pending patent application that we license now or that we may license or own in the future; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we, or our current or future licensors or collaborators, might not have been the first to file patent applications covering certain of our or their inventions; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our licensed intellectual property rights; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">it is possible that our current or future licensed patent applications will not lead to issued patents; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors or other third parties; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our competitors or other third parties might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may not develop additional proprietary technologies that are patentable; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the patents of others may harm our business; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may choose not to file a patent application in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent application covering such intellectual property; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">third-party patents may issue with claims covering our activities; we may have infringement liability exposure arising from such patents. </span></div></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Reliance on Third Parties</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We currently, and will likely continue to, rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We depend and will continue to depend upon third parties, including independent investigators and collaborators, such as universities, medical institutions, CROs and strategic partners, to conduct our preclinical studies and clinical trials under agreements with us. Specifically, we depend on clinical trial sites to enroll patients and conduct the DesCAARTes</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial, MusCAARTes</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial and RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trials in a timely and appropriate manner. If our clinical trial sites do not conduct the trials on the timeline we expect or otherwise fail to support the trials, our clinical trial results could be significantly delayed, thereby adversely impacting our leadership position in the autoimmune cell therapy space and our ability to progress additional product candidates. As we open additional clinical trial sites, we expect to have to negotiate budgets and contracts with CROs and study sites, which may result in delays to our development timelines and increased costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will rely heavily on these third parties, including Penn and WuXi, to conduct our manufacturing, and as a result, will have limited control over pace at which these activities are carried out. Nevertheless, we are responsible for ensuring that each of our trials is conducted in accordance with applicable protocol, legal, regulatory and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities. We and these third parties are required to comply with FDA&#8217;s GCPs which are regulations and guidelines enforced by the FDA for product candidates in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of these third parties fail to comply with applicable GCP requirements, the clinical data generated in our clinical trials may be deemed unreliable and the FDA may require us to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">63</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">perform additional clinical trials before approving our marketing applications. We cannot provide assurance that, upon inspection, such regulatory authorities will not determine that some or all of our clinical trials do not fully comply with the GCP requirements. For any violations of laws and regulations during the conduct of our clinical trials, we could be subject to untitled and warning letters or enforcement action that may include civil penalties up to and including criminal prosecution. In addition, our clinical trials must be conducted with biologic product produced under cGMPs and will require a large number of test patients. We also are required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As widely reported, global credit and financial markets have experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. Regional or single-source dependencies may in some cases accentuate these risks. For example, the pharmaceutical industry in general, and in some instances we or our collaborators or other third parties on which we or they rely, depend on China-based suppliers or service providers for certain raw materials, products and services, or other activities, Our ability or the ability of our collaborators or such other third parties to continue to engage these China-based suppliers or service providers for certain preclinical research programs and clinical development programs could be restricted due to geopolitical developments between the United Sates and China, including as a result of the escalation of tariffs. In the event that one or more of our current or future service providers, manufacturers and other partners do not successfully carry out their contractual duties, meet expected deadlines, or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, due to the economic downturn, the enactment of legislative proposals or for any other reasons, then we may not be able to obtain, or may be delayed in obtaining, marketing approvals for any product candidates we may develop and will not be able to, or may be delayed in our efforts to, successfully commercialize our medicines. Our failure or the failure of these third parties to comply with applicable regulatory requirements or our stated protocols could also subject us to enforcement action. Moreover, our business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently rely on certain foreign or foreign-owned third-party vendors, including WuXi, to manufacture certain clinical materials or to provide services in connection with certain clinical trials. Such foreign and foreign-owned vendors may be subject to U.S. legislation or investigations, including legislation similar to the previously proposed BIOSECURE Act, sanctions, trade restrictions and other foreign regulatory requirements, which could increase the cost or reduce the supply of material available to us, delay the procurement or supply of such material, delay or impact clinical trials, have an adverse effect on our ability to secure significant commitments from governments to purchase our potential therapies and could adversely affect our financial condition and business prospects. In connection with WuXi, on December 23, 2024, WuXi AppTec, parent company of WuXi, announced that it entered into a definitive agreement to sell the US and UK based operations of WuXi to Altaris, LLC, a healthcare investment firm headquartered in New York, and expects that the transaction to close in the first half of 2025.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any third parties conducting our clinical trials will not be our employees and, except for remedies available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our ongoing preclinical and clinical programs. These third parties may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical studies or other drug development activities, which could affect their performance on our behalf. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to complete development of, obtain regulatory approval of or successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any of our relationships with trial sites, or any CRO that we may use in the future, terminates, we may not be able to enter into arrangements with alternative trial sites or CROs or do so on commercially reasonable terms. Switching or adding third parties to conduct our clinical trials involves substantial cost and requires extensive management time and focus. In addition, there is often a natural transition period when a new third party commences work. As a result, delays may occur, which can materially impact our ability to meet our desired clinical development timelines. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also expect to rely on other third parties to store and distribute drug supplies for our clinical trials. Any performance failure on the part of our distributors could delay clinical development or marketing approval of any product candidates we may develop or commercialization of our medicines, producing additional losses and depriving us of potential product revenue.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">64</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We intend to rely on third parties to manufacture our clinical product supplies, and we may have to rely on third parties to produce and process our product candidates, if licensed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we may eventually secure our own clinical manufacturing facility for any late phase clinical development that we undertake, we currently rely on third parties, including Penn and WuXi, to manufacture our product candidates, and we intend in the future to continue to rely on CMOs. In the case of any manufacturing performed for us by third parties, the services performed for us risk being delayed because of the competing priorities that such parties have for utilization of their manufacturing resources and any capacity issues that thereby arise.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not yet have sufficient information to reliably estimate the cost of the manufacturing and processing of our product candidates in clinical quantity or commercial quantity, and the actual cost to manufacture and process our product candidates could ultimately materially and adversely affect the commercial viability of our product candidates. As a result, we may never be able to develop a commercially viable product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, our anticipated reliance on a limited number of third-party manufacturers exposes us to the following risks:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may be unable to identify manufacturers on acceptable terms or at all because the number of potential manufacturers is limited and the FDA may have questions regarding any replacement contractor. This may require new testing and regulatory interactions. In addition, a new manufacturer would have to be educated in, or develop substantially equivalent processes for, production of our products after receipt of FDA questions, if any. </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our third-party manufacturers might be unable to timely formulate and manufacture our product or produce the quantity and quality required to meet our clinical and commercial needs, if any. </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contract manufacturers may not be able to execute our manufacturing procedures appropriately. </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any contract manufacturers that we engage may not perform as agreed or may not remain in the contract manufacturing business for the time required to supply our clinical trials or to successfully produce, store and distribute our product candidates. </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturers are subject to ongoing periodic unannounced inspection by the FDA and corresponding state agencies to ensure strict compliance with cGMP and other government regulations. We do not have control over third-party manufacturers&#8217; compliance with these regulations and standards. </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not own, or may have to share, the intellectual property rights to any improvements made by our third-party manufacturers in the manufacturing process for our product candidates. </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our third-party manufacturers could breach or terminate their agreement with us. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, all of our contract manufacturers are engaged with other companies to supply and/or manufacture materials or products for such companies, which exposes our manufacturers to regulatory risks related to the production of such materials and products. As a result, failure to meet the regulatory requirements for the production of those materials and products may affect the regulatory clearance of our contract manufacturers&#8217; facilities generally. If the FDA does not approve these facilities for the manufacture of our product candidates or if any agency withdraws its approval in the future, we may need to find alternative manufacturing facilities, which would negatively impact our ability to develop, obtain regulatory approval for or market our product candidates, if licensed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our contract manufacturers would also be subject to the same risks we face in developing our own manufacturing capabilities, as described above. Each of these risks could delay our clinical trials, the approval, if any of our product candidates by the FDA or the commercialization of our product candidates or result in higher costs or deprive us of potential product revenue. In addition, we will rely on third parties to perform release tests on our product candidates prior to delivery to patients. If these tests are not appropriately done and test data are not reliable, patients could be put at risk of serious harm.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For more information, see &#8220;Risk Factors&#8212;Risks Related to Manufacturing and Supply&#8221;.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may form or seek strategic alliances or enter into additional licensing arrangements in the future, and we may not realize the benefits of such alliances or licensing arrangements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may form or seek strategic alliances, create joint ventures or collaborations or enter into additional licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to our product candidates and any future product candidates that we may develop. Any of these relationships may require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business. In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our product candidates because they may be deemed to be at too early of a stage of development for</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">65</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborative effort and third parties may not view our product candidates as having the requisite potential to demonstrate safety, potency and purity. Any delays in entering into new strategic partnership agreements related to our product candidates could delay the development and commercialization of our product candidates in certain geographies for certain indications, which would harm our business prospects, financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we license products or businesses, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture. We cannot be certain that, following a strategic transaction or license, we will achieve the results, revenue or specific net income that justifies such transaction.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not realize the benefits of acquired assets or other strategic transactions, including any transactions whereby we acquire or license manufacturing and other advanced technologies.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2018, we entered into a License Agreement with Penn and CHOP which was amended and restated in July 2019, and further amended in May 2020 and October 2021, or the License Agreement, pursuant to which we were granted licenses to certain patent rights for the research and development of products, as well as an exclusive license under those same patent rights to make, use, sell and import such products, in the autoimmune disease and alloimmune response subfields, in each case, for the treatment of humans. In January 2021 and as amended in August 2022, we entered into an agreement with WuXi to serve as an additional cell processing manufacturing partner for our MusCAARTes</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial, and have since completed enabling engineering and patient production runs. In August 2023, as amended in August 2024, we entered into an agreement with WuXi to serve as one of our manufacturing partners for the global clinical development of rese-cel in multiple indications, including potential late-stage clinical trials and commercial readiness activities for rese-cel. In October 2022, we entered into the IASO Agreement, pursuant to which we were granted worldwide license under certain intellectual property to develop, manufacture, commercialize and otherwise exploit T cell products directed to CD19 for the purpose of diagnosis, prevention or treatment of an autoimmune or alloimmune indication in humans.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We actively evaluate various strategic transactions on an ongoing basis. We may acquire other businesses, products or technologies as well as pursue joint ventures or investments in complementary businesses. The success of our strategic transactions, including the License Agreement, and any future strategic transactions depends on the risks and uncertainties involved including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unanticipated liabilities related to acquired companies or joint ventures; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">difficulties integrating acquired personnel, technologies and operations into our existing business; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">retention of key employees; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">diversion of management time and focus from operating our business to management of strategic alliances or joint ventures or acquisition integration challenges; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">increases in our expenses and reductions in our cash available for operations and other uses; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disruption in our relationships with collaborators or suppliers as a result of such a transaction; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">possible write-offs or impairment charges relating to acquired businesses or joint ventures. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any of these risks or uncertainties occur, we may not realize the anticipated benefit of any acquisition or strategic transaction. Additionally, foreign acquisitions and joint ventures are subject to additional risks, including those related to integration of operations across different cultures and languages, currency risks, potentially adverse tax consequences of overseas operations and the particular economic, political, legal and regulatory risks associated with specific countries. For example, IASO is based in China and we may not receive the same protections under Chinese law, including with respect to applicable bankruptcy, insolvency, liquidation, arrangement, moratorium or similar laws relating to or affecting our rights.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future acquisitions or dispositions could result in potentially dilutive issuances of our equity securities, the incurrence of debt, contingent liabilities or amortization expenses or write-offs of goodwill, any of which could harm our financial condition.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">66</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Manufacturing and Supply</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are reliant on Penn and WuXi for our current manufacturing activities and Penn and/or WuXi's failure to perform or termination would disrupt normal business operations, and we intend to continue to rely on other third parties for our future manufacturing needs prior to establishing our own manufacturing facility.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are reliant on Penn and WuXi for our current manufacturing activities for our preclinical and clinical research. If Penn and its affiliated entities were to fail to perform their obligations in accordance with the terms of the Services Agreements or terminate the Services Agreements, or if WuXi were to fail to perform their obligations in accordance with the terms of the WuXi Agreement or terminate the WuXi Agreement, we may have difficulty continuing our normal business operations and our business prospects, financial condition and results of operations could be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are also current geopolitical tensions with China. These tensions and the related risks are described in the Risk Factor in this Report titled, &#8220;Risks Related to Business Development &#8211; Business disruptions, including due to natural disasters, global conflicts or political unrest, could seriously impact our operations, research and trials and harm our future revenue and financial condition.&#8221;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the CAART Services Agreement is scheduled to expire on the later of October 19, 2021 or completion of all research and development projects, and unless the CAART Services Agreement is amended, Penn will not be obligated to provide any further services under the CAART Services Agreement after that time. We currently anticipate that research and development projects under the CAART Services Agreement will continue through at least 2025. In addition, Penn has the right to terminate the CAART Services Agreement in whole at any time with 90 days&#8217; notice and to terminate any research and development project being performed under the CAART Services Agreement if the Penn service provider appointed to lead such project is unavailable and Penn is unavailable to find a replacement within 60 days for such service provider. Penn also has the right to terminate certain manufacturing services being performed under the CAART Services Agreement with 180 days&#8217; written notice. From time to time, we may enter into further addenda to the CAART Services Agreement that provide Penn with the right to terminate such addenda with limited notice periods. If we do not have adequate personnel and capabilities at the time that we assume responsibilities for such services, we may not be successful in effectively or efficiently transitioning these services from Penn, which could disrupt our business and have a material adverse effect on our financial condition and results of operations. Even if we are able to successfully transition these services, they may be more expensive or less efficient than the services we are receiving from Penn during the transition period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CARTA Services Agreement is scheduled to expire on the later of February 9, 2026 or completion of all research and development projects, and unless the CARTA Services Agreement is amended, Penn will not be obligated to provide any further services under the CARTA Services Agreement after that time. In addition, Penn has the right to terminate the CARTA Services Agreement in whole at any time with 180 days&#8217; notice. From time to time, we may enter into further addenda to the CARTA Services Agreement that provide Penn with the right to terminate such addenda with limited notice periods. If we do not have adequate personnel and capabilities at the time that we assume responsibilities for such services, we may not be successful in effectively or efficiently transitioning these services from Penn, which could disrupt our business and have a material adverse effect on our financial condition and results of operations. Even if we are able to successfully transition these services, they may be more expensive or less efficient than the services we are receiving from Penn during the transition period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The WuXi Agreement is scheduled to expire upon completion of WuXi's services related to MuSK-CAART and rese-cel. In August 2023, as amended in August 2024, we entered into new work orders under the WuXi Agreement for WuXi to serve as one of our cell processing manufacturing partners for the planned global clinical development of rese-cel in multiple indications, including potential late-stage clinical trials and commercial readiness activities for rese-cel. Under the August 2023 work orders, WuXi will convert our non-dedicated suite to a dedicated suite for GMP manufacturing for our rese-cel and MuSK-CAART programs, or the Dedicated Suite, for an initial term of 18 months with two 18 month extensions at our sole option on six months notice prior to the end of the term. In August 2024, we notified WuXi that we would extend the initial term by 18 months through August 2026. We may terminate for convenience with six months prior written notice, however, we may not terminate the Dedicated Suite without terminating both the MuSK-CAART and rese-cel GMP run work orders. In lieu of the existing 18 month termination right for convenience under the WuXi Agreement, WuXi may not terminate prior to February 2028. If WuXi were to fail to perform their obligations in accordance with the terms of the WuXi Agreement or terminate the WuXi Agreement, our clinical trials and commercial readiness may be adversely impacted which could in turn</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> materially and adversely affect our business, results of operations and prospects.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, we may not be able to achieve clinical manufacturing and cell processing through our CMOs or on our own on a timely basis. While our current manufacturing process is similar to the well-established process developed at Penn for CD19 CAR-T, or CART19, which was later commercialized, we have limited experience as an organization in managing the CAR-T or CAAR T engineering process at commercial scale. Finally, because clinical manufacturing and cell processing is highly complex and patient donor material is inherently variable, we cannot yet be sure that our manufacturing process, will consistently result in product that meets specifications for release. Success in manufacturing in smaller early phase clinical trials may not predict the frequency of success at larger late phase clinical trials, or success at the commercial phase production until process qualification and validation is completed and submitted for BLA filing.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">67</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our product candidates are uniquely manufactured. If we or any of our third-party manufacturers encounter difficulties in manufacturing our product candidates, our ability to provide supply of our product candidates for clinical trials or, if licensed, for commercial sale, could be delayed or stopped, or we may be unable to maintain a commercially viable cost structure.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The manufacturing process used to produce our product candidates is complex and novel, and it has not yet been validated for commercial production. The manufacture of our product candidates includes harvesting white blood cells from each patient, stimulating certain T cells from the white blood cells and thereby causing them to activate and proliferate, combining patient T cells with lentiviral delivery vector through a process known as transduction, expanding the transduced T cells to obtain the desired dose, formulating and freezing the cell product, and ultimately infusing the modified T cells back into the patient&#8217;s body. Because of the bespoke nature of this product for patients, the cost to manufacture our product candidates is higher than traditional small molecule chemical compounds and monoclonal antibodies. Furthermore, our manufacturing process development and scale-up is at an early stage, and evaluation of cost at large scale has not yet been finalized. The actual cost to manufacture and process our product candidates could be greater than we expect and could materially and adversely affect the commercial viability of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our manufacturing process may be susceptible to technical and logistics delays or failures due to the fact that each patient is an independent manufacturing lot, and also due to unique supply chain requirements. These include the collection of white blood cells from patients&#8217; blood, variability in the quality of white blood cells collected from patients&#8217; blood, cryopreservation of the white blood cells collected, packaging and shipment of frozen white blood cells to the manufacturing site in order to enable multi-site studies, procurement of lentiviral vectors that meet potency and purity requirements and shipment to the product candidate manufacturing site, shipment of the final product to clinical centers, manufacturing issues associated with interruptions in the manufacturing process, scheduling constraints for cell manufacturing slots, process contamination, equipment or reagent failure or supply shortage(s)/interruption(s), improper installation or operation of equipment, vendor or operator error, and inconsistency in cell growth. Even minor deviations from normal manufacturing processes could result in reduced production yields, lot failures, product defects, product recalls, product liability claims and other supply disruptions. If microbial, viral, or other contaminations are discovered in our product candidates or in the manufacturing facilities in which our product candidates are made, production at such manufacturing facilities may be interrupted for an extended period of time to investigate and remedy the contamination. Further, as product candidates are developed through preclinical studies to late-stage clinical trials toward approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods, are altered along the way in an effort to optimize processes and results. Such changes may result in the need to enroll additional patients or to conduct additional clinical studies to evaluate the impact of changes on product safety and efficacy. Penn has informed us that it will be unable provide clinical supply for any late-phase or non-U.S. clinical trials of our product candidates that we may conduct. Therefore, we will need maintain and/or add new agreements with additional CMOs to produce clinical supply of our product candidates for late-phase clinical trials and at the necessary scale. We cannot guarantee that we will be able to enter into such agreements on commercially acceptable terms, if at all. Such changes carry the risk that they will not achieve these intended objectives, and any of these changes could cause our product candidates to perform differently and affect the results of ongoing and planned clinical trials or other future clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we continue to optimize our manufacturing process for our product candidates, doing so is a difficult and uncertain task, and there are risks associated with scaling to the level required for advanced clinical trials or commercialization, including, among others, cost overruns, potential problems with process scale-up, process reproducibility, stability issues, lot consistency and timely availability of reagents and/or raw materials. If we are unable to adequately scale-up the manufacturing process for our product candidates with WuXi, we may need to transfer to another manufacturer and/or our own facility, which can be lengthy. If we are able to adequately establish and scale-up the manufacturing process for our product candidates with an alternative manufacturer, we will still need to negotiate with such manufacturer an agreement for commercial supply and it is not certain we will be able to come to agreement on terms acceptable to us. This may impact our cost of goods and thus commercial viability and/or competitiveness.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, many of the components which are required to support our cell manufacturing process, such as equipment, media, growth factors and disposables, are highly specialized and it is possible that the supply chain for these materials may be interrupted. If we are unable to promptly remedy such interruption, then there may be delays to our clinical development efforts.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">68</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The manufacturing process for any products that we may develop is subject to the FDA approval process, and we will need to contract with manufacturers who can meet all applicable FDA requirements on an ongoing basis.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The manufacturing process for any products that we may develop is subject to the FDA approval process, and we will need to contract with manufacturers who can meet all applicable FDA requirements on an ongoing basis. If we or our CMOs are unable to reliably produce products to specifications acceptable to the FDA, we may not obtain or maintain the approvals we need to commercialize such products. Even if we obtain regulatory approval for any of our product candidates, there is no assurance that either we or our CMOs will be able to manufacture the approved product in accordance with requirements from the FDA, to produce it in sufficient quantities to meet the requirements for the potential launch of the product, or to meet potential future demand. Any of these challenges could delay completion of clinical trials, require bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, suspension of production or recalls of the product candidates or marketed biologics, operating restriction and criminal prosecutions, delay approval of our product candidates, impair commercialization efforts, increase our cost of goods, and have an adverse effect on our business, financial condition, results of operations and growth prospects. Our future success depends on our ability to manufacture our products, if licensed, on a timely basis with acceptable manufacturing costs, while at the same time maintaining good quality control and complying with applicable regulatory requirements, and an inability to do so could have a material adverse effect on our business, financial condition, and results of operations. In addition, we could incur higher manufacturing costs if manufacturing processes or standards change, and we could need to replace, modify, design, or build and install equipment, all of which would require additional capital expenditures. Specifically, because our product candidates may have a higher cost of goods than conventional therapies, the risk that coverage and reimbursement rates may be inadequate for us to achieve profitability may be greater.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The manufacture of viral vectors is complex and variable, and there are a limited number of manufacturers able to supply us with viral vectors.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our MuSK-CAART and rese-cel product candidates utilize a lentiviral delivery vector and some or all of our other product candidates may require a lentiviral delivery vector, a key drug substance that delivers the CAR or CAAR to the target T cells. We do not have the capability to manufacture lentiviral vector and plan to obtain the vector we require from third parties. The manufacturing process for lentiviral vector is variable and still evolving. It is not uncommon for manufacturing runs to fail, whether due to contamination, supplier error, or equipment failure, or to be delayed. To the extent our product candidates use a lentiviral delivery vector, a lack of vector supply will cause us to be unable to manufacture our CAR T or CAAR T cells as well as a delay in patient enrollment, which may have a negative impact on our ability to successfully develop our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, there are a limited number of manufacturers capable of producing lentiviral vectors. It can be challenging to secure a relationship with any of these manufacturers, and the manufacturing and release process can take a significant amount of time. We have secured a supply of lentiviral vector from CAROT sufficient for a portion of the patients we plan to enroll in our MusCAARTes</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial and our RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> clinical trials. We have also reserved additional vector manufacturing capacity at Penn and CHOP and in December 2021, as amended in May 2023, February 2024 and May 2024, we secured a license and supply agreement with Oxford to establish a process and supply lentiviral vector for the clinical and commercial development of our rese-cel candidate. There is no assurance that we will be able to continue to secure adequate and timely supply of lentiviral vector. Moreover, we cannot be certain that our CAR T or CAAR T cell product candidates produced with lentiviral vector from different manufacturers will be comparable or that results of clinical trials will be consistent if conducted with lentiviral vector from different manufacturers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vector production also requires the production of high-quality DNA plasmids, for which there is also a limited number of suppliers. Although we have established relationships with suppliers for lentiviral vector and plasmids, we do not yet have our own clinical-scale manufacturing facility established, and are therefore highly dependent on the ability of these suppliers to manufacture necessary materials and to deliver these materials to us on a timely and reliable basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are to operate our own manufacturing facility, significant resources will be required and we may fail to successfully operate our facility, which could adversely affect our clinical trials and the commercial viability of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we establish our own manufacturing facility, our operations will be subject to review and oversight by the FDA and the FDA could object to our use of our manufacturing facility. We must first receive approval from the FDA prior to licensure to manufacture our product candidates, which we may never obtain. Even if licensed, we would be subject to ongoing periodic unannounced inspection by the FDA and corresponding state agencies to ensure strict compliance with cGMPs and other government regulations. Our license to manufacture product candidates will be subject to continued regulatory review. Our cost of goods development is at an early stage. The actual cost to manufacture and process our product candidates at a manufacturing facility of our own could be greater than we expect and could materially and adversely affect the commercial viability of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">69</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The manufacture of biopharmaceutical products is complex and requires significant expertise, and can be impacted by resource constraints, labor disputes and workforce limitations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The manufacture of biopharmaceutical products is complex and requires significant expertise, including the development of advanced manufacturing techniques and process controls. Manufacturers of cell therapy products often encounter difficulties in production, particularly in scaling out and validating initial production and ensuring the absence of contamination. These problems include difficulties with production costs and yields, quality control, including stability of the product, quality assurance testing, operator error, shortages of qualified personnel, as well as compliance with strictly enforced federal, state and foreign regulations. Furthermore, if contaminants are discovered in our supply of product candidates or in the manufacturing facilities upon which we currently or will rely, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. We cannot assure you that any stability or other issues relating to the manufacture of our product candidates, whether by Penn, WuXi, or other third-party CMOs, or at any manufacturing facility that we may establish, will not occur in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Penn, WuXi or other third-party CMOs that we engage, or we may fail to manage the logistics of storing and shipping our product candidates. Storage failures and shipment delays and problems caused by us, our vendors or other factors not in our control, such as weather, could result in loss of usable product or prevent or delay the delivery of product candidates to patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Penn, WuXi, or other third-party CMOs that we engage, or we may also experience manufacturing difficulties due to resource constraints, labor disputes or workforce limitations arising from the expanding need for manufacturing in the cell therapy field and the limited number of training programs for technical staff. If we were to encounter any of these difficulties, our ability to provide our product candidates to patients would be jeopardized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are dependent upon the availability of specialty raw materials and the production capabilities of small manufacturers to source the components of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product candidates require many specialty raw materials, some of which are manufactured by small companies with limited resources and experience to support a commercial product, and the suppliers may not be able to deliver raw materials to our specifications. In addition, those suppliers generally do not have the capacity to support commercial products manufactured under cGMP by biopharmaceutical firms. The suppliers may be ill-equipped to support our needs, especially in non-routine circumstances like an FDA inspection or medical crisis, such as widespread contamination. We also do not have contracts with many of these suppliers, and we may not be able to contract with them on acceptable terms or at all. Accordingly, we may experience delays in receiving key raw materials to support clinical or commercial manufacturing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, some raw materials are currently available from a single supplier, or a small number of suppliers. We cannot be sure that these suppliers will remain in business or that they will not be purchased by one of our competitors or another company that is not interested in continuing to produce these materials for our intended purpose. In addition, the lead time needed to establish a relationship with a new supplier can be lengthy, and we may experience delays in meeting demand in the event we must switch to a new supplier. The time and effort to qualify a new supplier could result in additional costs, diversion of resources or reduced manufacturing yields, any of which would negatively impact our operating results. Further, we may be unable to enter into agreements with a new supplier on commercially reasonable terms, which could have a material adverse impact on our business. We are also unable to predict how changing global economic conditions or global health concerns will affect our third-party suppliers and manufacturers. Regional or single-source dependencies may in some cases accentuate these risks. For example, the pharmaceutical industry generally, and in some instances our Company or our collaborators or other third parties on which we rely, depend on China-based suppliers or service providers for certain raw materials, products and services, or other activities. Our ability or the ability of our collaborators or such other third parties to continue to engage these China-based suppliers or service providers for certain preclinical research programs and clinical development programs could be restricted due to geopolitical developments between the United States and China, including as a result of the escalation of tariffs or other trade restrictions or if the previously proposed federal legislation known as the BIOSECURE Act or a similar law were to be enacted. Any negative impact of such matters on our third-party suppliers and manufacturers may also have an adverse impact on our results of operations or financial condition.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may encounter difficulties in production, particularly with respect to process development or scaling up of our manufacturing capabilities. If we encounter such difficulties, our ability to provide supply of our CAR T or CAAR T cells for clinical trials or for commercial purposes could be delayed or stopped.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">70</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Establishing clinical and commercial manufacturing and supply is a difficult and uncertain task, and there are risks associated with scaling to the level required for advanced clinical trials or commercialization, including, among others, increased costs, potential problems with process scale-out, process reproducibility, stability issues, lot consistency, and timely availability of reagents or raw materials. For example, we may find it difficult to establish a manufacturing process that is consistent. If this occurs, we may need to complete more than one manufacturing run for each treated patient, which would impact the availability of adequate coverage and reimbursement from third-party payors. Competitors that have developed CAR T cell therapies have had difficulty reliably producing engineered T cell therapies in the commercial setting. If we experience similar challenges manufacturing product candidates to approved specifications, this may limit our product candidates&#8217; utilization and our ability to receive payment for these product candidates once licensed. Alternatively, these challenges may require changes to our manufacturing processes, which could require us to perform additional clinical studies, incurring significant expense. We may ultimately be unable to reduce the expenses associated with our product candidates to levels that will allow us to achieve a profitable return on investment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we or our third-party suppliers use hazardous, non-hazardous, biological or other materials in a manner that causes injury or violates applicable law, we may be liable for damages.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our research and development activities involve the controlled use of potentially hazardous substances, including chemical and biological materials. We and our suppliers are subject to federal, state and local laws and regulations in the United States governing the use, manufacture, storage, handling and disposal of medical and hazardous materials. Although we believe that we and our suppliers&#8217; procedures for using, handling, storing and disposing of these materials comply with legally prescribed standards, we and our suppliers cannot completely eliminate the risk of contamination or injury resulting from medical or hazardous materials. As a result of any such contamination or injury, we may incur liability or local, city, state or federal authorities may curtail the use of these materials and interrupt our business operations. In the event of an accident, we could be held liable for damages or penalized with fines, and the liability could exceed our resources. We do not have any insurance for liabilities arising from medical or hazardous materials. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental regulations may impair our research, development and production efforts, which could harm our business, prospects, financial condition or results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in product candidate manufacturing or formulation may result in additional costs or delay, which could adversely affect our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As product candidates are developed through preclinical studies to later-stage clinical trials towards approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods or formulation, are altered along the way in an effort to optimize processes and results. Any of these changes could cause our product candidates to perform differently and affect the results of ongoing and planned clinical trials or other future clinical trials conducted with the altered materials or with materials made with the altered methods. Such changes may also require additional testing, or notification to, or approval by the FDA or other regulatory authorities. This could delay completion of clinical trials, require the conduct of bridging clinical trials or studies, require the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and/or jeopardize our ability to commence product sales and generate revenue.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Government Regulation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The regulatory approval process is lengthy and time-consuming, and we may experience significant delays in the clinical development and regulatory approval of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The research, testing, manufacturing, labeling, approval, selling, import, export, marketing and distribution of drug products, including biologics, are subject to extensive regulation by the FDA and other regulatory authorities in the United States and comparable authorities in other jurisdictions, such as the EMA in Europe. We are not permitted to market any biological drug product in the United States until we receive approval of a Biologics License Application, or BLA, from the FDA. We have not previously submitted a BLA to the FDA, or similar licensure filings to comparable foreign authorities. A BLA must include extensive preclinical and clinical data and supporting information to establish the product candidate&#8217;s safety, potency and purity for each desired indication. The BLA must also include significant information regarding the chemistry, manufacturing and controls for the product, including with respect to chain of identity and chain of custody of the product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">71</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect the novel nature of our product candidates to create further challenges in obtaining regulatory approval. For example, to our knowledge, the FDA has not previously reviewed regulatory applications for marketing authorization of CAR T cells for treatment of autoimmune disease or CAAR T cells for treatment of pemphigus, and there is no cell therapy currently approved by the FDA for the treatment of mPV, MuSK myasthenia gravis, SLE, myositis, SSc, gMG or MS. Because of this, we have little guidance as to which endpoints will be accepted, how many clinical trials we may expect to conduct, and whether open-label clinical trials will be deemed acceptable, among other things. We may also request regulatory approval of future CAR T or CAAR T cell-based product candidates by target, regardless of disease type or origin, which the FDA may have difficulty accepting if our clinical trials only involved diseases of certain origins. The FDA may also require a panel of experts, referred to as an Advisory Committee, to deliberate on the adequacy of the safety, potency and purity data to support licensure. The opinion of the Advisory Committee, although not binding, may have a significant impact on our ability to obtain licensure of the product candidates based on the completed clinical trials, as the FDA often adheres to the Advisory Committee&#8217;s recommendations. Further, given the rapidly evolving landscape of cell therapy, we could encounter a significant change in the regulatory environment for our product candidates once we have already begun one or more lengthy and expensive clinical trials for our product candidates. For example, the U.S. Supreme Court&#8217;s July 2024 decision to overturn prior established case law giving deference to regulatory agencies&#8217; interpretations of ambiguous statutory language has introduced uncertainty regarding the extent to which FDA&#8217;s regulations, policies, and decisions may become subject to increasing legal challenges, delays, and/or changes. Moreover, the incoming U.S. administration may propose policy changes that create additional uncertainty for our business and may result in increased regulatory uncertainty, judicial interpretations overturing precedent and other impacts to the agency rulemaking process. Accordingly, the regulatory approval pathway for our product candidates may be uncertain, complex, expensive and lengthy, and approval may not be obtained.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may also experience delays in completing ongoing and planned clinical trials for a variety of reasons, including delays related to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtaining regulatory authorization to begin a trial, if applicable; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability of financial resources to commence and complete the planned trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtaining approval at each clinical trial site by an independent IRB; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">recruiting suitable patients to participate in a trial; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">having patients complete a trial, including having patients enrolled in clinical trials dropping out of the trial before the product candidate is manufactured and returned to the site, or return for post-treatment follow-up; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical trial sites deviating from trial protocol or dropping out of a trial; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">addressing any patient safety concerns that arise during a trial; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adding new clinical trial sites; or </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">manufacturing sufficient quantities of qualified materials under cGMPs and applying them on a patient by patient basis for use in clinical trials. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We could also encounter delays if physicians encounter unresolved ethical issues associated with enrolling patients in clinical trials of our product candidates in lieu of prescribing existing treatments that have established safety and efficacy profiles. If we experience delays in the completion of, any future clinical trial of our product candidates, the commercial prospects for our product candidates will be harmed, and our ability to generate product revenue will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product development and approval process and jeopardize our ability to commence product sales and generate revenue. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may ultimately lead to the denial of regulatory approval of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">72</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We expect the product candidates we develop will be regulated as biological products, or biologics, and therefore they may be subject to competition.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Biologics Price Competition and Innovation Act of 2009, or BPCIA, was enacted as part of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively the ACA, to establish an abbreviated pathway for the approval of biosimilar and interchangeable biological products. The regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#8220;interchangeable&#8221; based on its similarity to a licensed biologic. Under the BPCIA, an application for a biosimilar product cannot be licensed by the FDA until 12 years after the reference product was licensed under a BLA. The law is complex and is still being interpreted and implemented by the FDA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that any of the product candidates we develop that is licensed in the United States as a biological product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider the subject product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Moreover, the extent to which a biosimilar, once licensed, will be substituted for any one of the reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.</span></p><p style="text-indent:5.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the European Union, there is a special regime for biosimilars, or biological medicinal products that are similar to a reference medicinal product but that do not meet the definition of a generic medicinal product. For such products, the results of appropriate preclinical or clinical trials must be provided in support of an application for market authorization. Guidelines from the EMA detail the type of quantity of supplementary data to be provided for different types of biological product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The regulatory landscape that will govern our product candidates is uncertain; regulations relating to more established cell therapies and other therapies for autoimmune diseases where B cells may play a role in initiating or maintaining disease are still developing, and changes in regulatory requirements could result in delays or discontinuation of development of our product candidates or unexpected costs in obtaining regulatory approval.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because we are developing novel CAR T and CAAR T cell product candidates that are unique biological entities, the regulatory requirements that we will be subject to are not entirely clear. Even with respect to more established products that fit into the categories of gene therapies or cell therapies, the regulatory landscape is still developing. For example, regulatory requirements governing gene therapy products and cell therapy products have changed frequently and may continue to change in the future. Moreover, there is substantial, and sometimes uncoordinated, overlap in those responsible for regulation of existing gene therapy products and cell therapy products. For example, in the United States, the FDA established the Office of Tissues and Advanced Therapies, or OTAT, in 2016, within its Center for Biologics Evaluation and Research, or CBER, to consolidate the review of gene therapy and related products, and the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER on its review. In September 2022, the FDA announced retitling of OTAT to the Office of Therapeutic Products, or OTP, and elevation of OTP to a &#8220;Super Office&#8221; to meet its growing cell and gene therapy workload. In addition, under guidelines issued by the National Institutes of Health, or NIH, gene therapy clinical trials are also subject to review and oversight by an institutional biosafety committee, or IBC, a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. Before a clinical trial can begin at any institution, that institution&#8217;s institutional review board, or IRB, and its IBC assesses the safety of the research and identifies any potential risk to public health or the environment. While the NIH guidelines are not mandatory unless the research in question is being conducted at or sponsored by institutions receiving NIH funding of recombinant or synthetic nucleic acid molecule research, many companies and other institutions not otherwise subject to the NIH Guidelines voluntarily follow them. Although the FDA decides whether individual gene therapy protocols may proceed, review process and determinations of other reviewing bodies can impede or delay the initiation of a clinical study, even if the FDA has reviewed the study and approved its initiation. Conversely, the FDA can place an IND application on clinical hold even if such other entities have provided a favorable review. Furthermore, each clinical trial must be reviewed and approved by an independent IRB at or servicing each institution at which a clinical trial will be conducted. In addition, adverse developments in clinical trials of gene therapy products conducted by others or in the post-approval context may cause the FDA or other regulatory bodies to change the requirements for approval of any of our product candidates. For example, after the FDA&#8217;s November 2023 announcement of its investigation into reports of T cell malignancies for BCMA- and CD19-directed CAR T cell immunotherapies, the FDA informed us that, based on those reports, patients receiving rese-cel in our clinical trials will require life-long monitoring for new malignancies.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Complex regulatory environments exist in other jurisdictions in which we might consider seeking regulatory approvals for our product candidates, further complicating the regulatory landscape. For example, in the European Union, a special committee called the Committee for Advanced Therapies was established within the EMA in accordance with Regulation (EC) No 1394/2007 on advanced-therapy medicinal products, or ATMPs, to assess the quality, safety and efficacy of ATMPs, and to follow scientific developments in the field. ATMPs include gene therapy products as well as somatic cell therapy products and tissue engineered products. These various regulatory review committees and advisory groups and new or revised guidelines that they promulgate from time to time may lengthen</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">73</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the regulatory review process, require us to perform additional studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions. Because the regulatory landscape for our CAR T and CAAR T cell product candidates is new, we may face even more cumbersome and complex regulations than those emerging for gene therapy products and cell therapy products. Furthermore, even if our product candidates obtain required regulatory approvals, such approvals may later be withdrawn because of changes in regulations or the interpretation of regulations by applicable regulatory agencies. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product to market could decrease our ability to generate sufficient product revenue to maintain our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for our product candidates, we will not be able to commercialize, or will be delayed in commercializing, our product candidates, and our ability to generate revenue will be materially impaired.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, distribution, import and export are subject to comprehensive regulation by the FDA and other regulatory agencies in the United States. Before we can commercialize any of our product candidates, we must obtain marketing approval. We have not received approval to market any of our product candidates from regulatory authorities in any jurisdiction and it is possible that none of our product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval. We, as a company, have no experience in filing and supporting the applications necessary to gain regulatory approvals and expect to rely on third-party CROs and/or regulatory consultants to assist us in this process. Securing regulatory approval requires the submission of extensive preclinical and clinical data and supporting information to the various regulatory authorities for each therapeutic indication to establish the drug candidate&#8217;s safety, potency and purity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securing regulatory approval also requires the submission of information about the drug manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The process of obtaining regulatory approvals is expensive, may take many years if additional clinical trials are required, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted IND, BLA or comparable application types in other countries, may cause delays in the approval or rejection of an application. The FDA and foreign regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other studies. Our product candidates could be delayed in receiving, or fail to receive, regulatory approval for many reasons, including the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA or other foreign regulatory authorities may disagree with the design or implementation of our clinical trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be unable to demonstrate to the satisfaction of the FDA that a drug candidate is safe, potent and pure for its proposed indication or a related companion diagnostic is suitable to identify appropriate patient populations; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the results of clinical trials may not meet the level of statistical significance required by the FDA or other foreign regulatory authorities for approval; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA or other foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of an BLA, or other submission or to obtain regulatory approval in the United States or elsewhere; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA or other foreign regulatory authorities may fail to approve the manufacturing processes, test procedures and specifications, or facilities that we may establish or of third-party manufacturers with which we may contract for clinical and commercial supplies; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the approval policies or regulations of the FDA or other foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Of the large number of drugs in development, only a small percentage successfully complete the FDA approval process and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">74</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain regulatory approval to market our product candidates, which would significantly harm our business, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect the novel nature of our product candidates to create further challenges in obtaining regulatory approval. As a result, our ability to develop product candidates and obtain regulatory approval may be significantly impacted. For example, the general approach for FDA approval of a new biologic or drug is for sponsors to seek licensure or approval based on dispositive data from well-controlled, Phase 3 clinical trials of the relevant product candidate in the relevant patient population. Phase 3 clinical trials typically involve hundreds of patients, have significant costs and take years to complete. We believe that we may be able to utilize the FDA&#8217;s Regenerative Medicine Advanced Therapy designation for our product candidates given the limited alternatives for treatments for certain rare diseases and autoimmune diseases where B cells may play a role in initiating or maintaining disease, but the FDA may not agree with our plans.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, approval of genetic or biomarker diagnostic tests may be necessary to advance some of our product candidates to clinical trials or potential commercialization. In the future, regulatory agencies may require the development and approval of such tests. Accordingly, the regulatory approval pathway for such product candidates may be uncertain, complex, expensive and lengthy, and approval may not be obtained.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, even if we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may not approve the price we intend to charge for our products, if licensed, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 28, 2023, the FDA issued a safety communication to provide information about reports of T-cell malignancy following BCMA-directed or CD19-directed autologous CAR T cell immunotherapies and subsequently initiated class safety labeling changes for the approved products in this class. B However, all currently approved CAR T-cell immunotherapies are in oncology indications, and the autoimmune diseases we are seeking to treat with rese-cel, a CD19-directed CAR T immunotherapy, are different indications from the approved oncology indications. Accordingly, the FDA and other regulatory authorities may apply a different benefit-risk assessment threshold such that even if our product candidate demonstrated a similar safety profile as current CAR T therapies, the FDA could ultimately determine that the harmful side effects outweigh the benefits and require us to cease clinical trials or deny approval of our product candidates. The FDA&#8217;s investigation may impact the FDA&#8217;s review of product candidates that we are developing, or that we may seek to develop in the future, which may, among other things, result in additional regulatory scrutiny of our product candidates, delay the timing for receiving any regulatory approvals or impose additional post-approval requirements on any of our product candidates that receive regulatory approval.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we experience delays in obtaining approval or if we fail to obtain approval of our product candidates, the commercial prospects for our product candidates may be harmed and our ability to generate revenues will be materially impaired.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even though we may apply for orphan drug designation for our product candidates, we may not be able to obtain orphan drug marketing exclusivity.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, defined as a disease or condition with a patient population of fewer than 200,000 in the United States, or a patient population of 200,000 or more in the United States when there is no reasonable expectation that the cost of developing and making available the drug or biologic in the United States will be recovered from sales in the United States for that drug or biologic. In order to obtain orphan drug designation, the request must be made before submitting a BLA. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages, and user-fee waivers. After the FDA grants orphan drug designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a product that has orphan drug designation subsequently receives the first FDA approval of that particular product for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a BLA, to market the same biologic (meaning, a product with the same principal molecular structural features) for the same indication for seven years, except in limited circumstances such as a showing of clinical superiority to the product with orphan drug exclusivity or if FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. As a result, even if one of our product candidates receives orphan exclusivity, the FDA can still approve other biologics that do not have the same principal molecular structural features for use in treating the same indication or disease or the same biologic for a different indication or disease during the exclusivity period. Furthermore, the FDA can waive orphan exclusivity if we are unable to manufacture sufficient supply of our product or if a subsequent applicant demonstrates clinical superiority over our product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">75</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have obtained from the FDA orphan drug designation for DSG3-CAART for the treatment of pemphigus vulgaris, for MuSK-CAART for the treatment of MuSK MG and for rese-cel for the treatment of idiopathic inflammatory myopathies (IIM, or myositis) and systemic sclerosis. We may seek orphan drug designation for certain other of our product candidates, but may be unable to obtain orphan drug designation for some or all of our product candidates in specific orphan indications in which we believe there is a medically plausible basis for the use of these products. Even if we obtain orphan drug designation, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan designated indication and may be lost if the FDA later determines that the request for designation was materially defective or if we are unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition, or if a subsequent applicant demonstrates clinical superiority over our products, if licensed. Although we may seek orphan drug designation for other product candidates, we may never receive such designations. In addition, the FDA may further reevaluate the Orphan Drug Act and its regulations and policies. We do not know if, when, or how the FDA may change the orphan drug regulations and policies in the future, and it is uncertain how any changes might affect our business. Depending on what changes the FDA may make to its orphan drug regulations and policies, our business could be adversely impacted.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The FDA has granted rare pediatric disease designation to rese-cel for the treatment of juvenile dermatomyositis. However, a marketing application for rese-cel or any other product candidate, if approved, may not meet the eligibility criteria for a priority review voucher.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA has granted rare pediatric disease designation to rese-cel for the treatment of juvenile dermatomyositis. Designation of a drug as a drug for a rare pediatric disease does not guarantee that an NDA or BLA for such drug will meet the eligibility criteria for a rare pediatric disease priority review voucher at the time the application is approved. Under the FDCA, we will need to request a rare pediatric disease priority review voucher in our original BLA for rese-cel. The FDA may determine that a BLA for rese-cel, if approved, does not meet the eligibility criteria for a priority review voucher, including for the following reasons:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">juvenile dermatomyositis no longer meets the definition of a rare pediatric disease; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the BLA contains an active ingredient that has been previously approved by the FDA; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the BLA does not rely on clinical data derived from studies examining a pediatric population and dosages of the drug intended for that population (that is, if the BLA does not contain sufficient clinical data to allow for adequate labeling for use by the full range of affected pediatric patients); or </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the BLA is approved for a different adult indication than the rare pediatric disease for which rese-cel is designated. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA&#8217;s rare pediatric disease priority voucher program began to sunset on December 20, 2024, on failure to pass a continuing resolution package that included its reauthorization. Under the amended statutory sunset provisions, after December 20, 2024, the FDA may award a priority review voucher for an approved rare pediatric disease product application only if the sponsor has rare pediatric disease designation for the drug and if that designation was granted by December 20, 2024. After September 30, 2026, the FDA may not award any rare pediatric disease priority review vouchers. Congress may vote to reauthorize this program, but its future remains unknown at this time. Absent any such reauthorization, if a BLA for rese-cel is not approved prior to September 30, 2026 for any reason, regardless of whether it meets the criteria for a rare pediatric disease priority review voucher, it will not be eligible for a priority review voucher.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">A fast track designation by the FDA, even if granted, may not lead to a faster development or regulatory review or approval process, and does not increase the likelihood that our current product candidate and any future product candidates will receive marketing approval.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a drug is intended for the treatment of a serious or life-threatening condition and the drug demonstrates the potential to address unmet medical needs for this condition, the drug sponsor may apply for FDA fast track designation for a particular indication. Fast track is a process designed to facilitate the development, and expedite the review of drugs to treat serious or life-threatening conditions and address an unmet medical need. We have received fast track designation for DSG3-CAART for improving healing of mucosal blisters in patients with mPV, for MuSK-CAART for improving activities of daily living and muscle strength in patients with MuSK antibody-positive myasthenia gravis and for rese-cel, designed to deplete CD19-positive B cells and improve disease activity in patients with SLE, LN and the myositis subtype of dermatomyositis, for the treatment of patients with systemic sclerosis to improve associated organ dysfunction and for the treatment of relapsing and progressive forms of MS. We may also apply for fast track designation for certain of our other product candidates, but there is no assurance that the FDA will grant this status to any of our other current or future product candidates. Marketing applications filed by sponsors of products in fast track development may qualify for priority review under the policies and procedures offered by the FDA, but the fast track designation does not assure any such qualification or ultimate marketing approval by the FDA. The FDA has broad discretion whether or not to grant fast track designation, so even if we believe a particular product candidate is eligible for this designation, there can be no assurance that the FDA would decide to grant it. Even though we have received fast track designation for certain of our product candidates, we may not experience a faster development process, regulatory</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">76</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">review or approval for these product candidates as compared to conventional FDA procedures, and receiving a fast track designation does not provide assurance of ultimate FDA approval. In addition, the FDA may withdraw fast track designation if it believes that the designation is no longer supported by data from our clinical development program. In addition, the FDA may withdraw any fast track designation at any time.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Although we may pursue expedited regulatory approval pathways for a product candidate, it may not qualify for expedited development or, if it does qualify for expedited development, it may not actually lead to a faster development or regulatory review or approval process.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we believe there may be an opportunity to accelerate the development of certain of our product candidates through one or more of the FDA&#8217;s expedited programs, such as fast track, breakthrough therapy, Regenerative Medicine Advanced Therapy, accelerated approval or priority review, we cannot be assured that any of our product candidates will qualify for such programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, we may seek a Regenerative Medicine Advanced Therapy, or RMAT, designation for some of our product candidates. An RMAT is defined as cell therapies, therapeutic tissue engineering products, human cell and tissue products, and combination products using any such therapies or products. Gene therapies, including genetically modified cells that lead to a durable modification of cells or tissues may meet the definition of a Regenerative Medicine Therapy. The RMAT program is intended to facilitate efficient development and expedite review of RMATs, which are intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition. A new drug application or a BLA for an RMAT may be eligible for priority review or accelerated approval through (1) surrogate or intermediate endpoints reasonably likely to predict long-term clinical benefit or (2) reliance upon data obtained from a meaningful number of sites. Benefits of such designation also include early interactions with FDA to discuss any potential surrogate or intermediate endpoint to be used to support accelerated approval. A Regenerative Medicine Therapy that is granted accelerated approval and is subject to post-approval requirements may fulfill such requirements through the submission of clinical evidence, clinical studies, patient registries, or other sources of real world evidence, such as electronic health records; the collection of larger confirmatory data sets; or post-approval monitoring of all patients treated with such therapy prior to its approval. Although RMAT designation or access to any other expedited program may expedite the development or approval process, it does not change the standards for approval. If we apply for RMAT designation or any other expedited program for our product candidates, the FDA may determine that our proposed target indication or other aspects of our clinical development plans do not qualify for such expedited program. Even if we are successful in obtaining a RMAT designation or access to any other expedited program, we may not experience faster development timelines or achieve faster review or approval compared to conventional FDA procedures. Access to an expedited program may also be withdrawn by the FDA if it believes that the designation is no longer supported by data from our clinical development program. Additionally, qualification for any expedited review procedure does not ensure that we will ultimately obtain regulatory approval for such product candidate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Disruptions at the FDA, the SEC and other government agencies, including from government shutdowns, or other disruptions to these agencies&#8217; operations, could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Currently, federal agencies in the U.S. are operating under a continuing resolution that is set to expire on September 30, 2025. The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs or biologics to be reviewed, which would adversely affect our business. For example, over the past decade, the U.S. government has shut down several times, and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue to fund our operations.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Significant political, trade, regulatory developments, and other circumstances beyond our control, could have a material adverse effect on our financial condition or results of operations.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We operate beyond the United States and, if approved, we may sell our products in countries throughout the world. Significant political, trade, or regulatory developments in the jurisdictions in which we may sell our products, such as those stemming from the change in U.S. federal administration, are difficult to predict and may have a material adverse effect on us. Similarly, changes in U.S.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">77</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">federal policy that affect the geopolitical landscape could give rise to circumstances outside our control that could have negative impacts on our business operations. For example, in 2025, the United States imposed tariffs on imports on its trading partners, including Canada, Mexico, the EU and China. Historically, tariffs have led to increased trade and political tensions. In response to tariffs, other countries have implemented retaliatory tariffs on U.S. goods. Political tensions as a result of trade policies could reduce trade volume, investment, technological exchange and other economic activities between major international economies, resulting in a material adverse effect on global economic conditions and the stability of global financial markets. Any changes in political, trade, regulatory, and economic conditions, including U.S. trade policies, could have a material adverse effect on our financial condition or results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Ongoing Regulatory Obligations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if we receive regulatory approval of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any regulatory approvals that we receive for our product candidates will require surveillance to monitor the safety, potency and purity of the product candidate. We believe it is likely that the FDA will require a Risk Evaluation and Mitigation Strategy, or REMS, in order to approve our product candidates, which could entail requirements for a medication guide, physician communication plans or additional elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA approves our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and GCPs for any clinical trials that we conduct post-approval. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any BLA, other marketing application and previous responses to inspectional observations. Additionally, manufacturers and manufacturers&#8217; facilities are required to comply with extensive FDA, and comparable foreign regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to cGMP regulations and applicable product tracking and tracing requirements. Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control. In addition, the FDA could require us to conduct another study to obtain additional safety or biomarker information. Additionally, under the Food and Drug Omnibus Reform Act of 2022, or FDORA, sponsors of approved drugs and biologics must provide six months&#8217; notice to the FDA of any changes in marketing status, such as the withdrawal of a drug, and failure to do so could result in the FDA placing the product on a list of discontinued products, which would revoke the product&#8217;s ability to be marketed.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, we will be required to comply with FDA promotion and advertising rules, which include, among others, standards for direct-to-consumer advertising, restrictions on promoting products for uses or in patient populations that are not described in the product&#8217;s approved uses (known as &#8220;off-label use&#8221;), limitations on industry-sponsored scientific and educational activities and requirements for promotional activities involving the internet and social media. Later discovery of previously unknown problems with our product candidates through follow-up programs with our clinical trial patients, including adverse events of unanticipated severity or frequency, or with our third-party suppliers or manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information, imposition of post-market studies or clinical studies to assess new safety risks, or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on the marketing or manufacturing of our product candidates, withdrawal of the product from the market or voluntary or mandatory product recalls; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fines, warning letters or holds on clinical trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of license approvals; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product seizure or detention, or refusal to permit the import or export of our product candidates; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA&#8217;s policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action. If these executive actions impose restrictions on FDA&#8217;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">78</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our research and development activities involve the use of biological and hazardous materials and produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials, which could cause an interruption of our commercialization efforts, research and development efforts and business operations, environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. Although we believe that the safety procedures utilized by our third-party manufacturers for handling and disposing of these materials generally comply with the standards prescribed by these laws and regulations, we cannot guarantee that this is the case or eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources and state or federal or other applicable authorities may curtail our use of certain materials and/or interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. Breach of certain environmental, health and safety laws and regulations could also in certain circumstances constitute a breach of our License Agreement with Penn. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses, we may incur due to injuries to our employees resulting from the use of hazardous materials or other work-related injuries, this insurance may not provide adequate coverage against potential liabilities. We do not carry specific biological waste or hazardous waste insurance coverage, workers compensation or property and casualty and general liability insurance policies that include coverage for damages and fines arising from biological or hazardous waste exposure or contamination.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are exposed to the risk of employee fraud or other illegal activity by our employees, independent contractors, consultants, commercial partners and vendors. Misconduct by these parties could include intentional, reckless and/or negligent conduct that fails to comply with the laws of the FDA, provide true, complete and accurate information to the FDA, comply with manufacturing standards we have established, comply with healthcare fraud and abuse laws in the United States and similar foreign fraudulent misconduct laws, or report financial information or data accurately or to disclose unauthorized activities to us. If we obtain FDA approval of any of our product candidates and begin commercializing those products in the United States, our potential exposure under such laws will increase significantly, and our costs associated with compliance with such laws are also likely to increase. These laws may impact, among other things, our current activities with principal investigators and research patients, as well as proposed and future sales, marketing and education programs. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">	</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Healthcare</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our product candidates, if licensed, profitably.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Successful commercialization of our product candidates, if licensed, will depend in part on the extent to which reimbursement for those drug products will be available from government health administration authorities, private health insurers, and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which drug products they will pay for and establish reimbursement levels. The availability and extent of reimbursement by governmental and private payors is essential for most patients to be able to afford a drug product. Sales of drug products depend substantially, both domestically and abroad, on the extent to which the costs of drugs products are paid for by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party payors. Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we obtain regulatory approval. Any product candidate for which we seek regulatory approval and reimbursement will need to meet or surpass our target product profile, or TPP, to be deemed a viable alternative to currently approved therapies. In addition, because our product candidates represent new approaches to the treatment of autoimmune diseases where B cells may play a role in initiating or maintaining disease, we cannot accurately estimate the potential revenue from our product candidates. For more information, see the section titled &#8220;Business&#8212;Government regulation&#8212;Pricing and Reimbursement&#8221; included in this annual report on Form 10-K.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">79</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Obtaining coverage and reimbursement of a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide the payor with supporting scientific, clinical and cost-effectiveness data for the use of our products, if licensed. In the United States, the principal decisions about reimbursement for new drug products are typically made by the Centers for Medicare and Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services, or HHS. CMS decides whether and to what extent a new drug product will be covered and reimbursed under Medicare, and private payors tend to follow CMS to a substantial degree. However, no uniform policy of coverage and reimbursement for drug products exists among third-party payors and coverage and reimbursement levels for drug products can differ significantly from payor to payor. Further, one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we obtain coverage for a given product, if the resulting reimbursement rates are insufficient, hospitals may not approve our product for use in their facility or third-party payors may require co-payments that patients find unacceptably high. Patients are unlikely to use our product candidates unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our product candidates. Separate reimbursement for the product itself may or may not be available. Instead, the hospital or administering physician may be reimbursed only for providing the treatment or procedure in which our product is used. Further, from time to time, CMS revises the reimbursement systems used to reimburse health care providers, including the Medicare Physician Fee Schedule and Outpatient Prospective Payment System, which may result in reduced Medicare payments. In some cases, private third-party payors rely on all or portions of Medicare payment systems to determine payment rates. Changes to government healthcare programs that reduce payments under these programs may negatively impact payments from private third-party payors, and reduce the willingness of physicians to use our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The marketability of any product candidates for which we receive regulatory approval for commercial sale may suffer if government and other third-party payors fail to provide coverage and adequate reimbursement. We expect downward pressure on pharmaceutical pricing to continue. Further, coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Healthcare legislative measures aimed at reducing healthcare costs may have a material adverse effect on our business and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay regulatory approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product candidates for which we obtain regulatory approval. We expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and in additional downward pressure on the price that we, or any collaborators, may receive for any approved products. For more information, see the section titled &#8220;Business&#8212;Government regulation&#8212;Current and Future Legislation&#8221; included in this annual report on Form 10-K.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot predict the initiatives that may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the demand for our product candidates, if we obtain regulatory approval; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to set a price that we believe is fair for our products, if licensed; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to generate revenue and achieve or maintain profitability; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the level of taxes that we are required to pay; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability of capital. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors, which may adversely affect our future profitability.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect that the healthcare reform measures that have been adopted and may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product and could seriously harm our future revenues. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">80</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our relationships with customers, healthcare providers, physicians, and third-party payors will be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, health information privacy and security laws, and other healthcare laws and regulations. If we or our employees, independent contractors, consultants, commercial partners and vendors violate these laws, we could face substantial penalties.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These laws may impact, among other things, our clinical research program, as well as our proposed and future sales, marketing and education programs. In particular, the promotion, sales and marketing of healthcare items and services is subject to extensive laws and regulations designed to prevent fraud, kickbacks, self-dealing and other abusive practices, including, without limitation, the federal Anti-Kickback Statute and the federal False Claims Act, which may constrain the business or financial arrangements and relationships through which such companies sell, market and distribute pharmaceutical products. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive and other business arrangements. We may also be subject to federal, state and foreign laws governing the privacy and security of individual identifiable health information and other personally identifiable information. For more information, see the section titled &#8220;Business&#8212;Government regulation&#8212;Other Healthcare Laws and Compliance Requirements&#8221; included in this annual report on Form 10-K.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Ensuring business arrangements comply with applicable healthcare laws, as well as responding to possible investigations by government authorities, can be time- and resource-consuming and can divert a company&#8217;s attention from the business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The failure to comply with any of these laws or regulatory requirements subjects entities to possible legal or regulatory action. Depending on the circumstances, failure to meet applicable regulatory requirements can result in civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, possible exclusion from participation in federal and state funded healthcare programs, contractual damages and the curtailment or restructuring of our operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws. Any action for violation of these laws, even if successfully defended, could cause a pharmaceutical manufacturer to incur significant legal expenses and divert management&#8217;s attention from the operation of the business. Prohibitions or restrictions on sales or withdrawal of future marketed products could materially affect business in an adverse way.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available, it is possible that some of our business activities, or our arrangements with physicians, some of whom receive stock options as compensation, could be subject to challenge under one or more of such laws. If we or our employees, independent contractors, consultants, commercial partners and vendors violate these laws, we may be subject to investigations, enforcement actions and/or significant penalties. We have adopted a code of business conduct and ethics, but it is not always possible to identify and deter employee misconduct or business noncompliance, and the precautions we take to detect and prevent inappropriate conduct may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs. It is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, disgorgement, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and/or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Data Privacy and Security</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Data collection is governed by restrictive regulations governing the use, processing, and cross-border transfer of personal information.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to stringent privacy and data protection requirements</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and these requirements may become more complex as we grow our business and begin to operate in other jurisdictions. For example, the collection, use, storage, disclosure, transfer, or other processing of personal data regarding individuals in the European Economic Area, or the EEA, including personal health data, is subject to the EU General Data Protection Regulation, or the EU GDPR, and similarly, processing of personal data regarding individuals in the UK is subject to the UK General Data Protection Regulation and the UK Data Protection Act 2018, or the UK GDPR, and together with the EU GDPR, or the GDPR. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">81</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">personal data, including requirements relating to having a legal basis or condition for processing personal data, stricter requirements relating to the processing of sensitive data (such as health data), where required by the GDPR obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches, requiring data protection impact assessments for high risk processing and taking certain measures when engaging third-party processors. The GDPR also imposes strict rules on the transfer of personal data to countries outside the EEA/UK, including the United States, and permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to &#8364;20 million (&#163;17.5 million under UK GDPR) or 4% of annual global revenues, whichever is greater. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. In addition, the GDPR includes restrictions on cross-border data transfers of personal data to countries outside the EEA/UK that are not considered by the European Commission and UK government as providing &#8220;adequate&#8221; protection to personal data, or third countries, including the United States. The GDPR may increase our responsibility and liability in relation to personal data that we process where such processing is subject to the GDPR, and we may be required to put in place additional mechanisms to ensure compliance with the GDPR, including as implemented by individual countries. Compliance with the GDPR is rigorous and time-intensive process that may increase our cost of doing business or require us to change our business practices, and despite those efforts, there is a risk that we may be subject to fines and penalties, litigation, and reputational harm in connection with our European activities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To enable the transfer of personal data outside of the EEA or the UK, adequate safeguards (for example, the European Commission approved Standard Contractual Clauses, or SCCs) must be implemented in compliance with European and UK data protection laws. In addition, transfers made pursuant to the SCCs (and other similar appropriate transfer safeguards) need to be assessed on a case-by-case basis taking into account the legal regime applicable in the destination country, in particular regarding applicable surveillance laws and relevant rights of individuals with respect to the transferred personal data, to ensure an &#8220;essentially equivalent&#8221; level of protection to that guaranteed in the EEA in the jurisdiction where the data importer is based, or the Transfer Impact Assessment. On June 4, 2021, the EC issued new forms of standard contractual clauses for data transfers from controllers or processors in the EU/EEA (or otherwise subject to the GDPR) to controllers or processors established outside the EU/EEA. The UK is not subject to the EC&#8217;s new standard contractual clauses but has published its own transfer mechanism, the International Data Transfer Agreement and International Data Transfer Addendum, or the IDTA, which enable transfers from the UK, and has also implemented a similar Transfer Impact Assessment requirement. Further, the EU and United States have adopted its adequacy decision for the EU-U.S. Data Privacy Framework, or the Framework, which entered into force on July 11, 2023. This Framework provides that the protection of personal data transferred between the EU and the United States is comparable to that offered in the EU. This provides a further avenue to ensuring transfers to the United States are carried out in line with GDPR. There has been an extension to the Framework to cover UK transfers to the United States. The Framework could be challenged like its predecessor frameworks. We will be required to implement these safeguards and carry out Transfer Impact Assessments when conducting restricted data transfers under the GDPR and doing so will require significant effort and cost, and may result in us needing to make strategic considerations around where EEA or UK personal data is stored and transferred, and which service providers we can utilize for the processing of EEA/UK personal data.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although the UK is regarded as a third country under the EU GDPR, the European Commission has issued a decision recognizing the UK as providing adequate protection under the EU GDPR, or the Adequacy Decision, and, therefore, transfers of personal data originating in the EEA to the UK remain unrestricted. The UK government has confirmed that personal data transfers from the UK to the EEA remain free flowing. The UK Government had introduced a Data Protection and Digital Information Bill which failed in the UK legislative process. The UK Government introduced the Data Protection and Digital Information Bill which failed in the UK legislative process. A new Data (Use and Access) Bill (&#8220;UK Bill&#8221;) has now been introduced into parliament. The aim of the UK Bill is to reform the UK&#8217;s data protection regime. If passed, the final version of the UK Bill may have the effect of further altering the similarities between the UK and EEA data protection regime. This may lead to additional compliance costs and could increase our overall risk. The respective provisions and enforcement of the EU GDPR and UK GDPR may further diverge in the future and create additional regulatory challenges and uncertainties.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EEA, the NIS 2 Directive (&#8220;NIS 2&#8221;) is replacing the cybersecurity legal framework under the current NIS framework, aiming to ensure a high level of cybersecurity in the region. NIS 2 brings new medium and large organisations providing services in the EEA within scope of the legal framework. It extends to additional sectors and expands the list of in-scope healthcare organisations, including to certain providers engaged in research and development of medicinal products. The new regime imposes direct obligations on management in respect of an in-scope organization's compliance with NIS 2, requires covered organisations to put in place certain cyber risk management measures, strengthens incident reporting requirements and provides supervisory authorities with a greater oversight. The majority of obligations will come into force when national legislation implementing NIS 2 becomes effective in the relevant EU Member State. EU Member States had until 17 October 2024 to transpose NIS 2 into national legislation, although many countries have still not completed the transposition. As such, the cybersecurity regulatory landscape in the EU is currently fragmented and uncertain. Although we are not currently subject to NIS 2, we have evaluated its requirements and have already implemented various cybersecurity measures that align with NIS 2 obligations. To the extent that we become subject to NIS 2 in the future, we will continue working closely with our Data Protection Officer to ensure that our compliance programs are fully aligned with NIS 2 and national</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">82</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">implementing legislation where applicable. Under NIS 2 companies may be subject to administrative fines of up to the higher amount of &#8364;10 million or 2% of worldwide turnover.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States, there has been a flurry of legislative activity related to privacy at the state level. In California, the California Consumer Privacy Act, or CCPA, went into effect on January 1, 2020, and became subject to enforcement by the California Attorney General&#8217;s office on July 1, 2020. The CCPA broadly defines personal information, and creates comprehensive individual privacy rights and protections for California consumers (as defined in the law), places increased privacy and security obligations on entities handling personal data of consumers or households, and provides for civil penalties for violations and a private right of action for data breaches. The CCPA requires covered companies to provide certain disclosures to consumers about their data collection, use and sharing practices, and to provide affected California residents with ways to opt-out of certain sales or transfers of personal information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, the California Privacy Rights Act, or CPRA, was passed in November 2020 and as of January 1, 2023 has imposed additional obligations on companies covered by the legislation. The CPRA significantly modified the CCPA, including by expanding consumers' rights with respect to certain sensitive personal information. The CPRA also created a new state agency that is vested with authority to implement and enforce the CCPA. While there is an exception for protected health information that is subject to HIPAA and clinical trial regulations, the effects of the CCPA, as amended by the CPRA are potentially significant and may require us to modify our data collection or processing practices and policies and to incur substantial costs and expenses in an effort to comply and decrease our potential exposure to regulatory enforcement and/or litigation.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Similar laws have been passed in numerous other states and proposed in others. Such proposed legislation, if enacted, may add additional complexity, variation in requirements, restrictions and potential legal risk, require additional investment of resources in compliance programs, impact strategies and the availability of previously useful data and could result in increased compliance costs and/or changes in business practices and policies. The existence of comprehensive privacy laws in different states in the country would make our compliance obligations more complex and costly and may increase the likelihood that we may be subject to enforcement actions or otherwise incur liability for noncompliance. There are also states that are specifically regulating health information. For example, Washington state recently passed a health privacy law that will regulate the collection and sharing of health information, and the law also has a private right of action, which further increases the relevant compliance risk. Connecticut and Nevada have also passed similar laws regulating consumer health data. In addition, other states have proposed and/or passed legislation that regulates the privacy and/or security of certain specific types of information. For example, a small number of states have passed laws that regulate biometric data specifically. These various privacy and security laws may impact our business activities, including our identification of research subjects, relationships with business partners and ultimately the marketing and distribution of our products. State laws are changing rapidly and there is discussion in the U.S. Congress of a new comprehensive federal data privacy law to which we may likely become subject, if enacted.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All of these evolving compliance and operational requirements impose significant costs, such as costs related to organizational changes, implementing additional protection technologies, training employees and engaging consultants and legal advisors, which are likely to increase over time. Further, various other jurisdictions around the world continue to propose new and/or amended laws that regulate the privacy and/or security of certain types of personal data. Complying with these laws, if enacted, would require significant resources and leave us vulnerable to possible fines and penalties if we are unable to comply. The regulatory framework governing the collection, processing, storage, use and sharing of certain information is rapidly evolving and is likely to continue to be subject to uncertainty and varying interpretations. It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our existing data management practices or the features of our services and platform capabilities. Compliance with the above and any other applicable privacy and data security laws and regulations is a rigorous and time-intensive process, and we may be required to put in place additional mechanisms ensuring compliance with the new data protection rules, modify our data processing practices and policies, utilize management&#8217;s time and/or divert resources from other initiatives and projects. Any failure or perceived failure by us, or any third parties with which we do business, to comply with our posted privacy policies, evolving laws, rules and regulations, industry standards, or contractual obligations to which we or such third parties are or may become subject, may result in actions or other claims against us by governmental entities or private actors, the expenditure of substantial costs, time and other resources or the incurrence of significant fines, penalties or other liabilities. In addition, any such action, particularly to the extent we were found to be guilty of violations or otherwise liable for damages, would damage our reputation and adversely affect our business, financial condition and results of operations.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If our security measures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">or those of our contractors, consultants or other service providers are breached or unauthorized access to confidential and/or proprietary information or other sensitive information, including individually identifiable health information or other personally identifiable information, is otherwise obtained, our reputation may be harmed, and we may incur significant liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We and the third parties upon which we rely face a variety of evolving threats, which could cause cybersecurity incidents or data breaches, which, could result in unauthorized access to systems and data, loss of data, and compromise, misuse, or corruption of such data and information. The systems of any CMOs that we may engage now or in the future, and present and future CROs, contractors, consultants and other service providers also could experience breaches or cybersecurity incidents leading to the exposure of confidential</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">83</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and sensitive information. Despite the implementation of security measures, our internal computer systems and information technology systems and infrastructure and those of our third party CROs, vendors, and other contractors and consultants upon which our business relies are vulnerable to breakdown or damage or interruption from, among other things, natural disasters, terrorism, war, telecommunication and electrical failures, and sophisticated cyber attacks, including the theft, fraud, and subsequent misuse of employee credentials, wrongful conduct by insider employees or vendors, denial-of-service attacks, ransomware attacks, business email compromises, computer malware, malicious codes, viruses, breakdown, wrongful intrusions, data breaches, and social engineering (including phishing attacks). Such threats are prevalent and continue to rise, are increasingly difficult to detect, and come from a variety of sources. Because the techniques used by computer programmers who may attempt to penetrate and sabotage our information technology systems and infrastructure, network security or our website change frequently and may not be recognized until launched against a target, we may be unable to anticipate these techniques or to adequately prevent or address them.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is also possible that unauthorized access to our confidential and/or proprietary information or other sensitive information, including customer or employee information, may be obtained through inadequate use of security controls by customers, suppliers or other vendors. We rely on such third parties to implement effective security measures and identify and correct for any failures, deficiencies, compromises or breaches.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event of a cybersecurity incident or data breach, our company could be required to provide legal notifications and disclosures, and could suffer loss of business, severe reputational damage adversely affecting investor confidence, regulatory inquiries, investigations and orders, litigation, indemnity obligations, damages for contract breach, penalties and fines for violation of applicable laws or regulations, significant costs for remediation and other liabilities. For example, the loss of preclinical study or clinical trial data from completed or future preclinical studies or clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security compromise or breach were to result in a loss or misappropriation of, or damage to, our data, systems, or applications, or inappropriate disclosure of confidential or proprietary information or other sensitive information, we could incur liability and the further development and commercialization of our product candidates could be delayed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have incurred and expect to incur significant expenses to prevent cybersecurity incidents and data breaches, including costs related to deploying additional personnel and protection technologies, training employees, and engaging third-party solution providers and consultants. Although we expend significant resources to create security protections that are designed to shield our confidential and/or proprietary information or other sensitive information, including customer data, against potential theft and security compromises or breaches, such measures cannot provide absolute security. Moreover, as we outsource more of our information systems to vendors and rely more on cloud-based information systems, the related security risks will increase, and we will need to expend additional resources to protect our technology and information systems.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Like other companies in our industry, we, and our third party vendors, have experienced and will continue to experience threats and cybersecurity incidents relating to our information technology systems and infrastructure. We remain at risk for future cybersecurity incidents and data breaches, including, without limitation, those that may occur as a result of third-party action, or wrongful conduct by insider employees or vendors or malfeasance and other causes. If, in the future, we experience a data breach or security incident, we could experience harm to our reputation, financial performance, and customer and vendor relationships. Further, we could experience possible legal notifications and disclosures, as well as litigation or regulatory investigations or actions by state and federal governmental authorities and non-U.S. authorities, including fines, penalties, and other legal and financial exposure and liabilities. Additionally, actual, potential or anticipated attacks or compromises may cause us to incur increasing costs, including costs to deploy additional personnel and protection technologies, train employees, conduct security incident investigation or remediation and engage third-party experts and consultants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our privacy and data security obligations. Further, although we maintain cyber liability insurance, this insurance may not provide adequate coverage against potential liabilities related to any experienced cybersecurity incident or breach.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interruptions in the availability of server systems or communications with internet or cloud-based services, or failure to maintain the security, confidentiality, accessibility or integrity of data stored on such systems, could harm our business.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely upon a variety of internet service providers, third-party web hosting facilities and cloud computing platform providers to support our business. Failure to maintain the security, confidentiality, accessibility or integrity of data stored on or processed by such systems could result in interruptions in our operations, damage our reputation in the market, increase our service costs, cause us to incur substantial costs, subject us to liability for damages and/or fines, and divert our resources from other tasks, any one of which could materially adversely affect our business, financial condition, results of operations and prospects. If our security measures or those of our third-party data center hosting facilities, cloud computing platform providers, or third-party service partners, are breached, and unauthorized access is obtained to or there is misuse of our data or our information technology systems, we may incur significant legal and financial exposure and liabilities.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">84</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also do not have control over the operations of the facilities of our cloud service providers and our third-party web hosting providers, and they also may be vulnerable to damage, security compromise or interruption from natural disasters, cybersecurity attacks, terrorist attacks, power outages and similar events or acts of misconduct. In addition, any changes in these providers&#8217; service levels may adversely affect our ability to meet our requirements and operate our business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Ownership of Our Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Ownership Generally</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our principal stockholders and management own a significant percentage of our stock and could be able to exert significant control over matters subject to stockholder approval.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, our executive officers, directors, and 5% stockholders beneficially owned, in the aggregate, approximately 28% of our common stock. Such calculations assume all shares of non-voting common stock, if any outstanding, are converted into voting common stock in accordance with the terms of our Third Amended and Restated Certificate of Incorporation, or the amended and restated certificate of incorporation. Accordingly, these stockholders could have the ability to influence us through this ownership position and significantly affect the outcome of all matters requiring stockholder approval. For example, these stockholders may be able to significantly affect the outcome of elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to establish and maintain proper and effective internal control over financial reporting, our operating results and our ability to operate our business could be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a public company, we are required to maintain internal control over financial reporting and to report any material weaknesses in such internal controls. The Sarbanes-Oxley Act requires that we evaluate and determine the effectiveness of our internal control over financial reporting and, beginning with our second annual report following our initial public offering, provide a management report on internal control over financial reporting. However, while we remain a smaller reporting company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ensuring that we have adequate internal financial and accounting controls and procedures in place so that we can produce accurate financial statements on a timely basis is a costly and time-consuming effort that needs to be re-evaluated frequently. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with generally accepted accounting principles. In compliance with Section 404 of the Sarbanes-Oxley Act, we have begun and will continue to dedicate internal resources, potentially engage outside consultants, and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting. Additionally, we will enhance control processes as needed, validate their effectiveness through testing, and implement a continuous monitoring and improvement process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Implementing any appropriate changes to our internal controls may distract our officers and employees, entail substantial costs to modify our existing processes, and take significant time to complete. These changes may not, however, be effective in maintaining the adequacy of our internal controls, and any failure to maintain that adequacy, or consequent inability to produce accurate financial statements on a timely basis, could increase our operating costs and harm our business. In addition, investors&#8217; perceptions that our internal controls are inadequate or that we are unable to produce accurate financial statements on a timely basis may harm our stock price and make it more difficult for us to effectively market and sell our service to new and existing customers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The dual class structure of our common stock may limit your ability to influence corporate matters and may limit your visibility with respect to certain transactions.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The dual class structure of our common stock may limit your ability to influence corporate matters. Holders of our common stock are entitled to one vote per share, while holders of our non-voting common stock are not entitled to any votes. Nonetheless, each share of our non-voting common stock may be converted at any time into one share of our common stock at the option of its holder by providing written notice to us, subject to the limitations provided for in our amended and restated certificate of incorporation. Additionally, stockholders who hold, in the aggregate, more than 10% of our common stock and non-voting common stock, but 10% or less of our common stock, and are not otherwise a company insider, may not be required to report changes in their ownership due to transactions in our non-voting common stock pursuant to Section 16(a) of the Exchange Act, and may not be subject to the short-swing profit provisions of Section 16(b) of the Exchange Act. In May 2024, 1,444,295 shares of non-voting common stock were converted to voting common stock and no shares of non-voting common stock remain outstanding.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">85</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. Certain holders of our common stock have rights, subject to conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act, except for shares held by affiliates, as defined in Rule 144 under the Securities Act. Any sales of securities by these stockholders could have a material adverse effect on the trading price of our common stock.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 21, 2024, we filed a registration statement on Form S-3 (File No. 333-278126) with the SEC, as amended on March 31, 2025, which amendment is not yet declared effective, or the Shelf Registration Statement, in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof for the purposes of selling, from time to time, our common stock, debt securities or other equity securities in one or more offerings. We also simultaneously entered into a Sales Agreement, or the 2024 Sales Agreement, with Cowen and Company, LLC, or the Sales Agent, to provide for the offering, issuance and sale of up to an aggregate amount of $200.0 million of our common stock from time to time in &#8220;at-the-market&#8221;, offerings under the Shelf Registration Statement and subject to the limitations thereof. The Shelf Registration Statement and 2024 Sales Agreement replaced our former registration statement and sales agreement, pursuant to which we had a $100 million at-the-market offering program, all of which we sold. We will pay to the Sales Agent cash commissions of up to 3.0 percent of the aggregate gross proceeds of sales of common stock under the 2024 Sales Agreement. Sales of common stock, debt securities or other equity securities by us may represent a significant percentage of our common stock currently outstanding. If we sell, or the market perceives that we intend to sell, substantial amounts of our common stock under the Shelf Registration Statement or otherwise, the market price of our common stock could decline significantly. In December 2024, we sold 1,225,000 shares pursuant to the 2024 ATM Program for net proceeds of $5.1 million, after deducting commissions of $0.1 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have also filed registration statements on Form S-8 to register shares issued or reserved for issuance under our equity compensation plans and will file additional registration statements on Form S-8 to register additional shares pursuant to the &#8220;evergreen&#8221; provisions under our equity compensation plans, the Plan Amendment and any subsequent amendments to our equity compensation plans. Shares registered under these registration statements on Form S-8 can be freely sold in the public market upon issuance and once vested, subject to volume limitations applicable to affiliates and the lock-up agreements described above. If any of these additional shares are sold, or if it is perceived that they will be sold, in the public market, the market price of our common stock could decline.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, certain of our employees, executive officers, and directors may enter into Rule 10b5-1 trading plans providing for sales of shares of our common stock from time to time. Under a Rule 10b5-1 trading plan, a broker executes trades pursuant to parameters established by the employee, director, or officer when entering into the plan, without further direction from the employee, officer, or director. A Rule 10b5-1 trading plan may be amended or terminated in some circumstances. Our employees, executive officers, and directors also may buy or sell additional shares outside of a Rule 10b5-1 trading plan when they are not in possession of material, nonpublic information.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to our Charter and Bylaws</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our amended and restated certificate of incorporation and amended and restated bylaws, as amended, or the amended and restated bylaws, contain provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a board of directors divided into three classes serving staggered three-year terms, such that not all members of the board will be elected at one time; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a prohibition on stockholder action through written consent, which requires that all stockholder actions be taken at a meeting of our stockholders; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a requirement that special meetings of stockholders be called only by the chairman of the board of directors, the chief executive officer, or by a majority of the total number of authorized directors; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">advance notice requirements for stockholder proposals and nominations for election to our board of directors; </span></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">86</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a requirement that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of the holders of not less than 75% of the votes that all our stockholders would be entitled to cast in an annual election of directors; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a requirement of approval of not less than 75% of all outstanding shares of our voting stock to amend any bylaws by stockholder action or to amend specific provisions of our amended and restated certificate of incorporation; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the authority of the board of directors to issue preferred stock on terms determined by the board of directors without stockholder approval and which preferred stock may include rights superior to the rights of the holders of common stock. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporate Law, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These anti-takeover provisions and other provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make it more difficult for stockholders or potential acquirors to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors and could also delay or impede a merger, tender offer or proxy contest involving our company. These provisions could also discourage proxy contests and make it more difficult for you and other stockholders to elect directors of your choosing or cause us to take other corporate actions you desire. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our amended and restated bylaws designate certain courts as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to our amended and restated bylaws, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware is the sole and exclusive forum for state law claims for: (i) any derivative action or proceeding brought on our behalf; (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, or other employees to us or our stockholders; (iii) any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law or our amended and restated certificate of incorporation or amended and restated bylaws (including the interpretation, application or validity thereof); or (iv) any action asserting a claim governed by the internal affairs doctrine (the Delaware Forum Provision). The Delaware Forum Provision will not apply to any causes of action arising under the Securities Act of 1933, as amended (the Securities Act) or the Securities Exchange Act of 1934. Our amended and restated bylaws further provide that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America are the sole and exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, or the rules and regulations promulgated thereunder, or the Federal Forum Provision. In addition, our amended and restated bylaws provide that any person or entity purchasing or otherwise acquiring any interest in shares of our common stock is deemed to have notice of and consented to the foregoing Delaware Forum Provision and Federal Forum Provision; provided, however, that stockholders cannot and will not be deemed to have waived our compliance with the U.S. federal securities laws and the rules and regulations thereunder.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Delaware Forum Provision and the Federal Forum Provision may impose additional litigation costs on stockholders in pursuing any such claims. Additionally, these forum selection clauses may limit our stockholders&#8217; ability to bring a claim in a judicial forum that they find favorable for disputes with us or our directors, officers or employees, which may discourage the filing of lawsuits against us and our directors, officers and employees even though an action, if successful, might benefit our stockholders. In addition, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. While the Delaware Supreme Court and other states have upheld the validity of federal forum selection provisions purporting to require claims under the Securities Act be brought in federal court, there is uncertainty as to whether other courts will enforce our Federal Forum Provision. If the Federal Forum Provision is found to be unenforceable, we may incur additional costs with resolving such matters. The Federal Forum Provision may also impose additional litigation costs on us and/or our stockholders who assert that the provision is invalid or unenforceable. The Court of Chancery of the State of Delaware or the federal district courts of the United States of America may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our stockholders.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Tax</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in tax laws could adversely affect our business and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The rules dealing with U.S. federal, state, and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our common stock. In recent years, many such changes have been made and changes are likely to continue to occur in the future. Future changes in tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations. Prospective investors in our common stock should consult with their</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">87</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">legal and tax advisors with respect to potential changes in tax laws and the tax consequences of investing in or holding our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2017, the U.S. Congress and the Trump administration made substantial changes to U.S. policies, which included comprehensive corporate and individual tax reform. In addition, the Trump administration called for significant changes to U.S. trade, healthcare, immigration and government regulatory policy. With the transition to the Biden administration in early 2021, changes to U.S. policy occurred and since the start of the Trump Administration in 2025, U.S. policy changes have been implemented at a rapid pace and additional changes are likely. Changes to U.S. policy implemented by the U.S. Congress, the Trump administration or any new administration have impacted and may in the future impact, among other things, the U.S. and global economy, international trade relations, unemployment, immigration, healthcare, taxation, the U.S. regulatory environment, inflation and other areas. Although we cannot predict the impact, if any, of these changes to our business, they could adversely affect our business. Until we know what policy changes are made, whether those policy changes are challenged and subsequently upheld by the court system and how those changes impact our business and the business of our competitors over the long term, we will not know if, overall, we will benefit from them or be negatively affected by them.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our ability to utilize our net operating losses and certain other tax attributes to offset future taxable income may be subject to certain limitations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we had U.S. federal, state and local net operating loss carryforwards of $157.4 million, $181.4 million and $88.7 million, respectively. $0.3 million of the federal amounts expire in 2037. The state net operating losses begin to expire in 2037 and the local net operating losses began to expire in 2024. Approximately $157.2 million of the federal net operating losses can be carried forward indefinitely. Certain net operating loss carryforwards could expire unused and be unavailable to offset future taxable income. In addition, in general, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, and corresponding provisions of state law, a corporation that undergoes an &#8220;ownership change&#8221; is subject to limitations on its ability to utilize its pre-change net operating loss carryforwards or tax credits, or NOLs or credits, to offset future taxable income or taxes. For these purposes, an ownership change generally occurs where the aggregate stock ownership of one or more stockholders or groups of stockholders who owns at least 5% of a corporation&#8217;s stock increases its ownership by more than 50 percentage points over its lowest ownership percentage within a specified testing period. Our existing NOLs or credits may be subject to limitations arising from previous ownership changes, and if we undergo an ownership change, our ability to utilize NOLs or credits could be further limited by Sections 382 and 383 of the Code. In addition, future changes in our stock ownership, many of which are outside of our control, could result in an ownership change under Sections 382 and 383 of the Code. Our NOLs or credits may also be impaired under state law. Accordingly, we may not be able to utilize a material portion of our NOLs or credits. Furthermore, our ability to utilize our NOLs or credits is conditioned upon our attaining profitability and generating U.S. federal and state taxable income. As described above under &#8220;&#8212;Risks Related to Our Financial Condition and Capital Requirements&#8221;, we have incurred significant net losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future; and therefore, we do not know whether or when we will generate the U.S. federal or state taxable income necessary to utilize our NOLs or credits. Under current law, U.S. federal net operating loss carryforwards generated in taxable years beginning after December 31, 2017 will not be subject to expiration. However, any such net operating loss carryforwards may only offset 80% of our annual taxable income in taxable years beginning after December 31, 2020.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">88</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General Risk Factors</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Adverse developments affecting the financial services industry could adversely affect our current and projected business operations and our financial condition and results of operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adverse developments that affect financial institutions, such as events involving liquidity that are rumored or actual, have in the past and may in the future lead to market-wide liquidity problems. For example, on March 10, 2023, Silicon Valley Bank was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation as receiver. Although we assess our banking relationships as we believe necessary or appropriate, our access to funding sources and other credit arrangements in amounts adequate to finance or capitalize our current and projected future business operations could be significantly impaired by factors that us, the financial institutions with which we have credit agreements or arrangements directly, or the financial services industry or economy in general. These factors could include, among others, events such as liquidity constraints or failures, the ability to perform obligations under various types of financial, credit or liquidity agreements or arrangements, disruptions or instability in the financial services industry or financial markets, or concerns or negative expectations about the prospects for companies in the financial services industry. While it is not possible at this time to predict the extent of the impact that high market volatility and instability of the financial services industry could have on economic activity and our business in particular, the failure of other banks and financial institutions and the measures taken by governments, businesses and other organizations in response to these events could adversely impact our business, financial condition and results of operations.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Public health crises, such as a pandemic, epidemic or outbreak of other highly infectious or contagious diseases, could seriously harm our research, development and potential future commercialization efforts, increase our costs and expenses and have a material adverse effect on our business, financial condition and results of operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Public health crises, such as a pandemic, epidemic or outbreak of other highly infectious or contagious diseases, could adversely impact our business, the business operations of third parties on whom we rely and our ongoing or planned research and development activities. Additionally, timely enrollment in our ongoing and planned clinical trials is dependent upon clinical trial sites which may be adversely affected by global health concerns. Public health crises could result in increased adverse events and deaths in our clinical trials. Some factors from public health crises that could delay or otherwise adversely affect enrollment in the clinical trials of our product candidates, as well as our business generally, include:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the potential diversion of healthcare resources away from the conduct of clinical trials to focus on public health crises, including the attention of physicians serving as our clinical trial investigators, hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our prospective clinical trials and the need for drugs, such as tocilizumab, and other supplies that clinical trial sites must have on hand to conduct our clinical trials to be used to address such public health crises;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">limitations on travel that could interrupt key trial and business activities, such as clinical trial site initiations and monitoring, domestic and international travel by employees, contractors or patients to clinical trial sites, including any government-imposed travel restrictions or quarantines that will impact the ability or willingness of patients, employees or contractors to travel to our clinical trial sites or secure visas or entry permissions, a loss of face-to-face meetings and other interactions with potential partners, any of which could delay or adversely impact the conduct or progress of our prospective clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">interruption in global shipping affecting the transport of clinical trial materials, such as patient samples, investigational drug product and conditioning drugs and other supplies used in our prospective clinical trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">interruptions in operations at our third-party manufacturers, which could result in delays or disruptions in the supply of our current product candidates and any future product candidates; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">business disruptions caused by potential workplace, laboratory and office closures and an increased reliance on employees working from home, disruptions to or delays in ongoing laboratory experiments and operations, product manufacturing and supply, staffing shortages, travel limitations or mass transit disruptions, any of which could adversely impact our business operations or delay necessary interactions with local regulators, ethics committees and other important agencies and contractors.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of these factors, and other factors related to any such disruptions that are unforeseen, could have a material adverse effect on our business and our results of operations and financial condition. Further, uncertainty around these and related issues could lead to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">89</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adverse effects on the economy of the United States and other economies, which could impact our ability to raise the necessary capital needed to develop and commercialize our product candidates.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The price of our stock may be volatile, and you could lose all or part of your investment.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The trading price of our common stock has been, and is likely to be in the future, highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control, including limited trading volume. In addition to the factors discussed in this &#8220;Risk Factors&#8221; section, these factors include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the commencement, enrollment or results of our planned preclinical studies or clinical trials of our product candidates or any preclinical studies or future clinical trials we may conduct, or changes in the development status of our product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our decision to initiate a preclinical study or clinical trial, not to initiate a preclinical study or clinical trial or to terminate an existing preclinical study or clinical trial; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adverse results or delays in preclinical studies or clinical trials of our product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any delay in our regulatory filings for our product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#8217;s review of such filings, including, without limitation, the FDA&#8217;s issuance of a &#8220;refusal to file&#8221; letter or a request for additional information; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our failure to commercialize our product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adverse regulatory decisions, including failure to receive regulatory approval of our product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in laws or regulations applicable to our product candidates, including, but not limited to, clinical trial requirements for approvals; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adverse developments concerning our manufacturers or suppliers; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our inability to obtain adequate product supply for any licensed product or inability to do so at acceptable prices; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our inability to establish collaborations, if needed; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">additions or departures of key scientific or management personnel; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unanticipated serious safety concerns related to the use of our product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">introduction of new products or services offered by us or our competitors; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to effectively manage our growth; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the size and growth of our initial target markets; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to successfully treat additional types of autoimmune diseases where B cells may play a role in initiating or maintaining disease; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">actual or anticipated variations in annual or quarterly operating results; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our cash position; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">publication of research reports about us or our industry or positive or negative recommendations or withdrawal of research coverage by securities analysts; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in the market valuations of similar companies; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">overall performance of the equity markets; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sales of our common stock by us or our stockholders in the future; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">trading volume of our common stock; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in accounting practices; </span></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">90</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ineffectiveness of our internal controls; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significant lawsuits, including patent or stockholder litigation; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">general political and economic conditions, including inflation and tariffs;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">global health concerns; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">other events or factors, many of which are beyond our control. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the stock market in general, and The Nasdaq Global Select Market and biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations in recent years that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. Securities class action litigation has often been instituted against companies, particularly in the biopharmaceutical and life sciences industries, following periods of volatility in the market price of a company&#8217;s securities. We have been subject to such a securities class action lawsuit filed in February 2022 and voluntarily dismissed by the plaintiff in October 2022, against certain of our officers and certain of our current and former directors, and may become subject to additional securities class action lawsuits in the future. This type of litigation could result in substantial costs and a diversion of management&#8217;s attention and resources, which would harm our business, operating results or financial condition.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business is affected by macroeconomic conditions, including rising inflation, interest rates and supply chain constraints.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Various macroeconomic factors could adversely affect our business and the results of our operations and financial condition, including changes in inflation, interest rates, the risk of economic slowdown or recession in the United States, instability in the banking system, and overall economic conditions and uncertainties such as those resulting from the current and future conditions in the global financial markets, including the presidential transition in the United States. Recent supply chain constraints have led to higher inflation, which if sustained could have a negative impact on our product development and operations. If inflation or other factors were to significantly increase our business costs, our ability to develop our current pipeline and new therapeutic products may be negatively affected. Interest rates, the liquidity of the credit markets and the volatility of the capital markets could also affect the operation of our business and our ability to raise capital on favorable terms, or at all, in order to fund our operations. Similarly, these macroeconomic factors could affect the ability of our third-party suppliers and manufacturers to manufacture clinical trial materials for our product candidates.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We do not intend to pay dividends on our common stock, so any returns will be limited to the value of our stock.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the appreciation of their stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are a &#8220;smaller reporting company,&#8221; and we cannot be certain if the reduced reporting requirements applicable to smaller reporting companies will make our common stock less attractive to investors.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are considered a &#8220;smaller reporting company&#8221; under Rule 12b-2 of the Exchange Act. We are therefore entitled to rely on certain reduced disclosure requirements, such as an exemption from providing selected financial data and executive compensation information. These exemptions and reduced disclosures in our SEC filings due to our status as a smaller reporting company also mean our auditors are not required to review our internal control over financial reporting and may make it harder for investors to analyze our results of operations and financial prospects. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our common stock prices may be more volatile. We will remain a smaller reporting company for as long as (i) the market value of our common stock held by non-affiliates is less than $250.0 million or (ii) our annual revenue is less than $100.0 million during the most recently completed fiscal year and the market value of our common stock held by non-affiliates is less than $700.0 million as of the prior June 30.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">91</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may seek additional capital through a combination of public and private equity offerings, debt financings, strategic partnerships and alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. The incurrence of indebtedness would result in increased fixed payment obligations and could involve certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. If we raise additional funds through strategic partnerships and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or product candidates or grant licenses on terms unfavorable to us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We could be subject to significant legal proceedings which may adversely affect our results of operations or financial condition.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to the risk of litigation, derivative claims, securities class actions, regulatory and governmental investigations and other proceedings, including proceedings arising from investor dissatisfaction with us or our performance or claims brought by employees, government agencies or supplies. In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because biotechnology and pharmaceutical companies have experienced significant stock price volatility in recent years. In addition, if any individuals acting on our behalf fails to satisfy his or her relevant legal or contractual duties, we could have liability to third parties, including the government or investors. If any claims were brought against us and resulted in a finding of substantial legal liability, the finding could materially adversely affect our business, financial condition or results of operations or cause significant reputational harm to us, which could seriously adversely impact our business. Allegations of improper conduct by private litigants or regulators, regardless of veracity, also may harm our reputation and adversely impact our ability to grow our business. Even if the allegations against us in future legal matters are unfounded or we ultimately are not held liable, the costs to defend ourselves may be significant and the litigation may subject us to substantial settlements, fines, penalties or judgments against us and may consume management&#8217;s bandwidth and attention, some or all of which may negatively impact our financial condition and results of operations. Litigation also may generate negative publicity, regardless of whether the allegations are valid, or we ultimately are liable, which could damage our reputation, and adversely impact our sales and our relationship with our employees, customers, and partners. If we face such litigation, it could result in substantial costs and a diversion of management&#8217;s attention and resources, which could harm our business.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The trading market for our common stock depends in part on the research and reports that securities or industry analysts publish about us or our business. In the event that one or more of the analysts who covers us downgrades our stock or publishes inaccurate or unfavorable research about our business, our stock price may decline. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">92</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="item_1b_unresolved_staff_comments"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1B. Unresolve</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">d Staff Comments.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">93</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ea3d7222-eb9e-4fa9-9b3d-f6e3c1191cd9" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_1c_cybersecurity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1C. Cybersecurity.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cyber Risk Management and Strategy</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div><ix:nonNumeric id="F_9fa0b9e6-e4e5-4954-93fa-bdd0e90ada18" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" escape="true"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We, under the oversight of the audit committee of our board of directors, have </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2f27f3f6-108d-42a8-ab94-3bd416adc067" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">implemented</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and maintain a cybersecurity risk management program that is designed to identify, assess, and mitigate risks from cybersecurity threats. Our risk management is supported by various tools and technologies, including third-party security solutions, monitoring, and alerting tools, designed to monitor, identify, and address risks from cybersecurity threats.</span></p></ix:nonNumeric></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_84f80487-f2de-4031-a33f-52df630b9384" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">engage </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">with other third-party providers and consultants to support our cyber risk management efforts, including through periodic security testing and assessments. We have a process to assess certain major </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2b926224-5f4a-43f7-b049-219ff820be72" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">third-party vendors and service providers</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, including through a review of responses to compliance questionnaires and contractual requirements, as appropriate.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We, like other companies in our industry, face a number of risks from cybersecurity threats in connection with our business. Although such risks have not </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bc35de04-ae39-4af9-aa34-ef71a2871863" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">materially affected</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and we do not believe they are reasonably likely to materially affect, us, including our business strategy, results of operations or financial condition, to date, we have, from time to time, experienced threats to and security incidents related to our data and systems. For more information about the risks from cybersecurity threats we face, please see Item 1A- Risk Factors.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governance Related to Cybersecurity Risks</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_62ad7bad-9773-4622-b2e8-b3d22e918237" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" escape="true"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors, as a whole and through its committees, has responsibility for the periodic review and oversight of information technology risks, including risks from cybersecurity threats.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b6f2d28b-a959-4a90-a2e0-33bc0ba157e2" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The audit committee is responsible for oversight of our cyber risk management program</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_165de482-4075-4927-b4c0-f6da1ba74e59" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The day-to-day management of the cyber program is directed by the Director of IT under the direction of the </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a45339e0-f061-4ebd-ab49-c4679691ed11" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Financial Officer</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Currently,</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_61a8dc57-7332-465e-9594-bf106907117e" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the Director of IT reports to the Chief Financial Officer and provides periodic updates to the Chief Financial Officer on cyber matters.</span></ix:nonNumeric></span></ix:nonNumeric></span></p><div><ix:nonNumeric id="F_10e4d4bb-ed62-4df3-b5c6-a3f316384ca1" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" escape="true"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Director of IT meets with the Chief Financial Officer periodically to discuss and review our cybersecurity risk management processes and to address matters related to potential cybersecurity and information technology risks, with input from the Company&#8217;s third-party technology providers, as appropriate. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_82b01fed-d41a-4757-b148-7ea212fb1b91" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Chief Financial Officer provides periodic reports on cybersecurity and information technology matters to the audit committee, which is responsible for reviewing and overseeing the Company&#8217;s risk management process, including risks from cybersecurity threats, as set forth in the audit committee charter.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1b0187d8-7149-4e97-91d3-712b2494fa3e" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The audit committee periodically reports</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> on cybersecurity risk management to the full board of directors.</span></p></ix:nonNumeric></div></ix:nonNumeric></div></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_2_properties"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 2. Pro</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">perties.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.288%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our corporate headquarters are located in Philadelphia, PA, where we lease 7,672 square feet of office space subject to a lease agreement that is in effect through June 30, 2026. We also have a lease consisting of approximately 13,179 square feet of laboratory space in Philadelphia, PA subject to a lease agreement that is in effect through August 31, 2026. We believe our facilities are currently adequate for us to conduct our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_3_legal_proceedings"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 3. Legal </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Proceedings.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may be involved in lawsuits, claims, investigations and proceedings, consisting of intellectual property, commercial, employment and other matters which arise in the ordinary course of business. While the outcome of any such proceedings cannot be predicted with certainty, as of December 31, 2024, we were not party to any legal proceedings that we would expect to have a material adverse impact on our financial position, results of operations or cash flow.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_4_mine_safety_disclosures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 4. Mine Saf</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ety Disclosures.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">94</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.658%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_ii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PAR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">T II</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="item_5_market_for_registrants_common_equ"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 5. Market for Registrant&#8217;s Common Equity, Related Stoc</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">kholder Matters and Issuer Purchases of Equity Securities.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our common stock trades on The Nasdaq Global Select Market under the symbol &#8220;CABA&#8221;. Trading of our common stock commenced on October 25, 2019, in connection with our initial public offering, or IPO. Prior to that time, there was no established public trading market for our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stockholders</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 27, 2025, we had approximately 68 holders of record of our common stock. The actual number of holders of our common stock is greater than this number of record holders and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers or held by other nominees. The number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dividend Policy</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have never declared or paid any cash dividends on our common stock. We currently intend to retain all available funds and any future earnings, if any, to fund the development and growth of our business. We do not expect to pay any cash dividends in the foreseeable future. Any future determination to pay dividends will be made at the discretion of our board of directors and will depend on various factors, including applicable laws, our results of operations, financial condition, future prospects, then applicable contractual restrictions and any other factors deemed relevant by our board of directors. Investors should not purchase our common stock with the expectation of receiving cash dividends.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity Compensation Plan</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by Item 5 of Form 10-K regarding equity compensation plans is incorporated herein by reference to Item 12 of Part III of this Annual Report on Form 10-K.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Issuer Purchases of Equity Securities</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We did not purchase any of our equity securities during the period covered by this Annual Report on Form 10-K.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Sales of Unregistered Securities</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="item_6_reserved"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 6. R</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">eserved.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:-4.885%;padding-left:4.658%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">95</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="item_7_managements_discussion_analysis_f"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 7. Management&#8217;s Discussion and Analysis of</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Financial Condition and Results of Operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and related notes appearing elsewhere in this Annual Report on Form 10-K, or this Annual Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the section entitled &#8220;Risk Factors,&#8221; our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. You should carefully read the section entitled &#8220;Risk Factors&#8221; to gain an understanding of the important factors that could cause actual results to differ materially from our forward-looking statements. Please also see the section entitled &#8220;Special Note Regarding Forward-Looking Statements.&#8221; We do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a clinical-stage biotechnology company focused on the discovery and development of innovative engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Our proprietary CABA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or Cabaletta Approach to B cell Ablation, platform encompasses two strategies. Our CARTA, or Chimeric Antigen Receptor T cells for Autoimmunity, approach is designed to potentially reset the immune system. Our legacy CAART, or Chimeric AutoAntibody Receptor T cells, approach is designed to engineer T cells to selectively engage and eliminate only disease-causing B cells. We believe our CABA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> platform has the potential to safely enable complete and durable responses for a broad range of autoimmune diseases and that it has potential applicability across dozens of autoimmune diseases that we have identified, evaluated and prioritized.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Resecabtagene autoleucel (rese-cel, formerly referred to as CABA-201) is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a broad range of autoimmune diseases and our lead product candidate within the CARTA strategy. Rese-cel is designed to achieve transient and deep depletion of all B cells following a single treatment by using T cells engineered to express an antibody fragment that recognizes a B cell receptor expressed on the surface of all B cells. The construct is designed to allow for the deep elimination of all B cells, including all B cells that contribute to disease, with subsequent repopulation by healthy na&#239;ve B cells. This approach has the potential to reset the immune system, providing meaningful durable and complete clinical responses to patients off immunosuppressive therapies.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2023, the United States Food and Drug Administration, or the FDA, granted clearance of our rese-cel Investigational New Drug, or IND, application for treatment of SLE in patients with active lupus nephritis, or LN, or active SLE without renal involvement. SLE is a chronic, potentially severe, autoimmune disease, most commonly impacting young women between the ages of 15 and 40 with higher frequency and more severity in people of color, where the immune system attacks healthy tissue throughout the body. SLE affects an estimated up to 320,000 patients in the U.S., and 150,000 patients in Europe, with LN as the most common end-organ manifestation, affecting approximately 40% of SLE patients. In May 2023, we announced the FDA granted Fast Track Designation for rese-cel, designed to deplete CD19-positive B cells and improve disease activity in patients with SLE and LN. The RESET-SLE</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Phase 1/2 clinical trial of rese-cel is designed to treat six SLE patients with active LN, and in a separate parallel cohort, six patients with active SLE without renal involvement, with a single weight-based dose of 1.0 x 10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> cells/kg. In March 2024, Health Canada issued a No Objection Letter in response to a Clinical Trial Application, or CTA, for the RESET-SLE</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial submitted by Cabaletta, enabling us to begin the process to activate clinical trial sites and pursue patient enrollment for the RESET-SLE</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial in Canada. In October 2024, the European Medicines Agency allowed a CTA submitted by Cabaletta for the RESET-SLE</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial to proceed, enabling us to begin the process of activating clinical trial sites and pursuing patient enrollment for the RESET-SLE</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial. The trial is open for enrollment across multiple sites in the United States and one site in the European Union.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2023, the FDA granted clearance of our rese-cel IND application for treatment of idiopathic inflammatory myopathies, or IIM, or myositis. Myositis refers to a group of autoimmune diseases characterized by inflammation and muscle weakness. The three myositis subtypes being evaluated in the RESET-Myositis</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Phase 1/2 clinical trial of rese-cel affect approximately 70,000 patients in the U.S. and approximately 85,000 patients in Europe and typically affect middle-aged individuals, particularly women. The RESET-Myositis</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> clinical trial, which is actively enrolling patients, is designed to treat six patients with dermatomyositis, six patients with anti-synthetase syndrome, and six patients with immune-mediated necrotizing myopathy, all in separate parallel cohorts. We announced the FDA granted Fast Track Designation for rese-cel for the treatment of patients with dermatomyositis to improve disease activity and Orphan Drug Designation for rese-cel for the treatment of myositis in January and February 2024,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">96</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">respectively. In March 2024, we announced the FDA granted Rare Pediatric Disease designation for rese-cel for juvenile dermatomyositis. The trial is open for enrollment across multiple sites in the United States and one site in the United Kingdom.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2023, we announced that the FDA granted clearance of our rese-cel IND application for treatment of systemic sclerosis, or SSc. SSc is a rare and potentially fatal chronic autoimmune disease characterized by progressive skin and internal organ fibrosis that can be life-threatening, including interstitial lung disease, pulmonary hypertension, and scleroderma renal crisis. SSc affects approximately 90,000 patients in the U.S. and approximately 60,000 patients in Europe, typically middle-aged individuals, particularly women. The RESET-SSc</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 1/2 clinical trial of rese-cel is designed to treat six patients with severe skin manifestations and six patients with severe organ involvement associated with SSc. We announced the FDA granted Fast Track Designation for rese-cel for the treatment of patients with SSc to improve associated organ dysfunction and Orphan Drug Designation for rese-cel for the treatment of systemic sclerosis in January and March 2024, respectively. The trial is open for enrollment across multiple sites in the United States.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the FDA granted clearance of our rese-cel IND application for treatment of generalized myasthenia gravis, or gMG, a subset of patients with myasthenia gravis, or MG. MG is a rare autoimmune disease characterized by autoantibodies that interfere with signaling at the neuromuscular junction, or NMJ, leading to potentially life-threatening muscle weakness. The majority of patients with MG have autoantibodies known to be pathogenic based on their interference with proteins in the NMJ, of which the majority target AChR. gMG affects approximately 55,000 patients in the U.S. and approximately 100,000 patients in Europe. Symptoms of gMG include profound muscle weakness throughout the body, disabling fatigue, and potential shortness of breath due to respiratory muscle weakness, with risk for episodes of respiratory failure. Standard of care therapies include cholinesterase inhibitors, steroids, immunomodulators, and biologics, which typically require chronic administration, increasing the risk of serious long-term side effects. The RESET-MG</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Phase 1/2 clinical trial of rese-cel is designed to treat six patients with AChR-positive gMG and six patients with AChR-negative gMG, each in separate parallel cohorts. The trial is open for enrollment across multiple sites in the United States.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2024, we announced that we are working with active clinical sites to incorporate the RESET-PV</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial as a sub-study within the Phase 1 DesCAARTes</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial following the submission of a protocol amendment. The RESET-PV</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial will evaluate rese-cel as a monotherapy without preconditioning in patients with mucosal pemphigus vulgaris, or mPV, and mucocutaneous pemphigus vulgaris, or mcPV. Approximately 15,000 patients in the U.S. and approximately 20,000 patients in Europe are affected by PV. The trial is open for enrollment across multiple sites in the United States.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2024, we announced the initial clinical data from each of the first two patients dosed with rese-cel in the RESET-SLE</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and RESET-Myositis</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trials. In both of these patients, no cytokine release syndrome, or CRS, immune effector cell-associated neurotoxicity syndrome, or ICANS, infections or serious adverse events were observed through data cut-off of May 28, 2024. Rese-cel exhibited the anticipated profile of CAR T cell expansion and contraction with complete B cell depletion observed in both patients by day 15 post-infusion. Improvements in both patients&#8217; specific disease measures were observed, consistent with academic experience of a similar 4-1BB CD19-CAR T.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In late June 2024, a lupus nephritis patient with very active, refractory disease was dosed with rese-cel and experienced Grade 1 CRS and a protocol-defined dose-limiting toxicity of Grade 4 ICANS. The ICANS resolved rapidly following standard management. The study&#8217;s Independent Data Monitoring Committee reviewed data from the patient, and recommended that the study proceed as designed, without delay, at the current dose. We recommended protocol modifications designed to improve patient safety, including enhanced monitoring for fever and neurologic symptoms along with seizure prophylaxis for all patients, in line with the practice at many academic sites including at Erlangen University, the site of the CD19-CAR T studies led by Dr. Georg Schett. In July 2024, we provided standard notice to the FDA and communicated details of the event and proposed protocol changes to all active clinical sites within the RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> clinical trial program, including the requirement that the investigator promptly discuss the appropriateness and timing of infusion with the trial&#8217;s Medical Monitor.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, we announced updated clinical data at the American College of Rheumatology Convergence 2024 conference in the first 8 patients dosed across the lupus, myositis and systemic sclerosis clinical trials. Clinical data from these patients in the RESET-SLE</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, RESET-Myositis</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial and RESET-SSC</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial were presented in oral and poster presentations where compelling clinical responses were observed in lupus and myositis patients with up to six months of follow-up, and the first SSc patient demonstrated an emerging, drug-free clinical response.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2025, we announced the FDA granted clearance of our rese-cel IND application for treatment of multiple sclerosis, or MS. In addition, we announced the FDA granted Fast Track Designation for rese-cel for the treatment of relapsing and progressive forms of MS. The RESET-MS</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">trial is a Phase 1/2 open-label, dose escalation study of rese-cel in subjects with relapsing and progressive forms of MS, evaluated in separate cohorts. Approximately 750,000 patients in the U.S. and approximately 550,000 patients in Europe are affected by MS.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">97</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2025, we announced updated clinical and translational data from the first 10 patients in the RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical trial program, with a data cut off of January 8, 2025. Overall, clinical responses continued to deepen over three SLE patients in DORIS remission, the first LN patient achieving complete renal response, and the first dermatomyositis patient maintaining a major total improvement score, or TIS improvement. Each of these patients discontinued all immunosuppressants and were off or tapering steroids as of January 8, 2025. The safety profile continued to suggest a favorable risk-benefit in the first 10 patients dosed with 90% of patients having experienced either no CRS or Grade 1 CRS and 90% of patients having experienced no ICANS.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2025, we learned of an important protocol deviation in the RESET-SSc</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial. In this case, the patient reported a fever three days prior to infusion. The Cabaletta Medical Monitor was not notified by the investigator prior to the site infusing the patient. Nine days following rese-cel infusion, the patient experienced a dose-limiting toxicity of grade 3 immune effector cell-associated neurotoxicity syndrome (ICANS) based on a transient period of confusion. There was no cerebral edema, seizures or motor dysfunction associated with the ICANS event, and the patient was arousable throughout. The ICANS resolved rapidly following treatment with dexamethasone, and the patient was discharged without further symptoms. After data review, the Independent Data Monitoring Committee recommended that the trial proceed at the current dose without delay and endorsed our proposal to require investigators to affirmatively confirm in writing to the company the absence of fevers or evidence of infection. As of March 14, 2025, 56 clinical sites across the U.S. and Europe were actively recruiting with 33 patients enrolled across the RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> clinical trial program.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our manufacturing strategy is comprised of two stages. The initial stage is designed to leverage the extensive early-stage manufacturing expertise of our academic partners and contract development and manufacturing organizations, or CDMOs, for rapid early development and clinical supply, and in parallel partner with commercially compliant CDMOs capable of supporting late-stage clinical studies and commercial production. Our aim is to achieve full manufacturing readiness through expanded CDMO relationships, establishment of our own manufacturing facilities, and/or through strategic partnership(s). We are leveraging the expertise in cell and vector manufacturing of our partners at the Children&#8217;s Hospital of Philadelphia, or CHOP, and the University of Pennsylvania, or Penn. For supply of lentiviral vector for the late-stage clinical and commercial manufacturing of rese-cel, we are working with Oxford Biomedica (UK) Limited, or Oxford. We have also collaborated with WuXi Advanced Therapies, Inc., or WuXi, to serve as an additional and commercially compliant cell manufacturing partner for our MusCAARTes</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> clinical trials to meet planned capacity and international supply requirements. In July 2024, we entered into a new technology transfer agreement with Lonza Houston Inc., or Lonza, another commercially compliant CDMO, to execute a technology transfer of our expected commercial manufacturing process for rese-cel. In December 2024, we entered into a Development and Manufacturing Services Agreement, or the Lonza Agreement, with Lonza to serve as one of our manufacturing partners for the global clinical development of rese-cel in multiple indications, including potential late-stage clinical trials and preparations for commercial readiness. This improved process is nearly fully closed, semi-automated, and more easily scaled than the current process. Transfer of this updated process will be performed from Cabaletta to Lonza in anticipation of being able to supply rese-cel drug product for any of Cabaletta&#8217;s ongoing and planned RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> clinical trials. We plan to secure commercial, scalable manufacturing capabilities through multiple potential strategies, including expanding existing or establishing new CDMO relationships, leasing, building, qualifying and operating our own manufacturing facility, and/or establishing a strategic partnership to rapidly and reliably scale manufacturing by leveraging the partner&#8217;s manufacturing expertise. We believe this later stage will enable control of product development and commercial supply for products arising from our CABA&#153; platform, enabling us to achieve continuous improvement of our product candidates. Multiple members of our team have previously built and led organizations that have constructed and commissioned cell therapy facilities, which we believe will enable us to build our own manufacturing organizations and facilities, if desirable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of our innovative manufacturing strategy where we intend to increase scale, reduce cost of goods and improve patient experience, in November 2023, we partnered with Cellares Corp., or Cellares, to evaluate their automated manufacturing platform, the Cell Shuttle</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, through the Cellares Technology Adoption Program, or TAP. As part of the collaboration, the companies have agreed on a proof-of-concept technology transfer process for the automated manufacture and release testing of rese-cel. In August 2024, we expanded our partnership with Cellares to facilitate the potential to incorporate the Cellares manufacturing platform to support the RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> clinical program. In March 2025, we and Cellares announced the successful conclusion of the Technology Adoption Program on Cellares&#8217; automated cell therapy manufacturing Cell Shuttle&#153;, facilitating the potential integration of the Cell Shuttle</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> into our clinical and commercial, if approved, manufacturing strategy for rese-cel. We are also evaluating pathways to improve patient experience and scalability of collection through the removal of the requirement for apheresis. Data were published at the American Society of Cell and Gene Therapy conference in May 2024 illustrating the feasibility of this approach.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We were incorporated in April 2017 and started principal operations in August 2018. Our operations to date have been financed primarily by proceeds from the sale of convertible notes and convertible preferred stock prior to our initial public offering, or IPO, and proceeds from the sale of our common stock in public equity offerings, including our IPO, &#8220;at-the-market&#8221; offerings and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">98</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">follow-on offerings of shares of our common stock and pre-funded warrants. As of December 31, 2024, we had $164.0 million in cash and cash equivalents.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">99</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="margin-left:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Material Agreements</span></p><p style="margin-left:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Refer to section titled &#8220;Business &#8211; Our Material Agreements&#8221; included in this annual report on Form 10-K for a discussion of our material agreements.</span></p><p style="margin-left:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Components of Operating Results</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, we have not generated any revenue from product sales and do not expect to generate any revenue from the sales of products for several years, if at all. If our development efforts for our current or future product candidates are successful and result in marketing approval, we may generate revenue in the future from product sales. We cannot predict if, when or to what extent we will generate revenue from the commercialization and sale of our product candidates. We may never succeed in obtaining regulatory approval for any of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may also in the future enter into license or collaboration agreements for our product candidates or intellectual property, and we may generate revenue in the future from payments as a result of such license or collaboration agreements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our research and development expenses include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888870241978623%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">personnel costs, which include salaries, benefits and stock-based compensation expense; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888870241978623%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expenses incurred under agreements with consultants and third-party contract organizations that conduct research and development activities on our behalf; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888870241978623%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs related to sponsored research service agreements; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888870241978623%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs related to production of preclinical and clinical materials, including fees paid to contract manufacturers; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888870241978623%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">licensing fees for intellectual property and know-how;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888870241978623%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">laboratory and vendor expenses related to the execution of preclinical studies and ongoing and planned clinical trials; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888870241978623%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">laboratory supplies and equipment used for internal research and development activities and related depreciation expense. </span></div></div><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have not reported program costs since inception because historically we have not tracked or recorded our research and development expenses on a pre-clinical program-by-program basis. We use our personnel and infrastructure resources across the breadth of our research and development activities, which are directed toward identifying and developing product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expense all research and development costs in the periods in which they are incurred. Costs for certain research and development activities are recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors and third-party service providers.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect our research and development expenses to increase substantially for the foreseeable future as we continue to invest in research and development activities related to developing our product candidates, including investments in manufacturing, as our programs advance and we conduct clinical trials. The process of conducting the necessary clinical research to obtain regulatory approval is costly and time-consuming, and the successful development of our product candidates is highly uncertain. As a result, we are unable to determine the duration and completion costs of our research and development projects or when and to what extent we will generate revenue from the commercialization and sale of any of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">100</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of the numerous risks and uncertainties associated with product development, we cannot determine with certainty the duration and completion costs of the current or future preclinical studies and clinical trials or if, when, or to what extent we will generate revenues from the commercialization and sale of our product candidates. We may never succeed in achieving regulatory approval for our product candidates. The duration, costs and timing of preclinical studies and clinical trials and development of our product candidates will depend on a variety of factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888870241978623%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successful completion of preclinical studies and IND and/or CTA-enabling studies; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888870241978623%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">development of chemistry, manufacturing and controls, or CMC, processes and procedures for purposes of IND and/or CTA applications; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888870241978623%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successful patient enrollment in, and the initiation and completion of, clinical trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888870241978623%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the impact of any business interruptions to our operations, including the timing and enrollment of patients in our ongoing and planned clinical trials, or to those of our clinical sites, manufacturers, suppliers, or other vendors resulting from public health crises; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888870241978623%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">receipt of regulatory approvals from applicable regulatory authorities; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888870241978623%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establishing commercial manufacturing capabilities or arrangements with third-party manufacturers; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888870241978623%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtaining and maintaining patent and trade secret protection and non-patent exclusivity; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888870241978623%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">launching commercial sales of our product candidates, if and when approved, whether alone or in collaboration with others; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888870241978623%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acceptance of our product candidates, if and when approved, by patients, the medical community and third-party payors; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888870241978623%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">effectively competing with other therapies and treatment options; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888870241978623%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a continued acceptable safety and efficacy profile following approval; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888870241978623%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">enforcing and defending intellectual property and proprietary rights and claims; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888870241978623%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">achieving desirable medicinal properties for the intended indications. </span></div></div><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may never succeed in achieving regulatory approval for any of our product candidates. We may obtain unexpected results from our preclinical studies and clinical trials. We may elect to discontinue, delay or modify clinical trials of some product candidates or focus on others. A change in the outcome of any of these factors could mean a significant change in the costs and timing associated with the development of our current and future preclinical and clinical product candidates. For example, if the FDA or another regulatory authority, were to require us to conduct clinical trials beyond those that we currently anticipate will be required for the completion of clinical development, or if we experience significant delays in execution of or enrollment in any of our preclinical studies or clinical trials, we could be required to expend significant additional financial resources and time on the completion of preclinical and clinical development. We expect our research and development expenses to increase for the foreseeable future as we continue the development of product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our general and administrative expenses consist primarily of personnel costs, costs related to maintenance and filing of intellectual property, depreciation expense and other expenses for outside professional services, including legal, human resources, information technology, audit and accounting services. Personnel costs consist of salaries, benefits and stock-based compensation expense. We expect our general and administrative expenses to increase over the next several years to support our continued research and development activities, manufacturing activities, increased costs of operating as a public company and the potential commercialization of our product candidates. We anticipate our general and administrative costs will increase with respect to the hiring of additional personnel, developing commercial infrastructure, fees to outside consultants, lawyers and accountants, and increased costs associated with being a public company such as expenses related to services associated with maintaining compliance with Nasdaq listing rules and SEC requirements, insurance and investor relations costs.</span></p><p style="margin-left:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Income</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other income consists of interest earned on our cash, cash equivalents and short-term investments and amortization of bond discount or premium.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">101</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="margin-left:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest Expense</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest expense consists primarily of interest expense associated with finance lease arrangements.</span></p><p style="margin-left:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Results of Operations for the years ended December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following sets forth our results of operations:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:57.477%;box-sizing:content-box;"/>
     <td style="width:1.399%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.776%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.399%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.776%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.399%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.776%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Statements of Operations Data:</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97,203</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55,424</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,779</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,938</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,236</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,702</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125,141</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74,660</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,481</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(125,141</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(74,660</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(50,481</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income:</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,025</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,985</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,040</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(748</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(748</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(115,864</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(67,675</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(48,189</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses were $97.2 million for the year ended December 31, 2024 as compared to $55.4 million for the year ended December 31, 2023. The table below summarizes our research and development expenses:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:41.548%;box-sizing:content-box;"/>
     <td style="width:1.92%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:15.563%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.92%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:15.563%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.92%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:15.563%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License of intellectual property</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,523</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,383</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(860</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Manufacturing of preclinical and clinical supplies</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,523</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,498</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,025</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Clinical trials</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,286</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,302</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,984</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,239</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,375</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,864</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Development services</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,417</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,486</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,931</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,215</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,380</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">835</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97,203</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55,424</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,779</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Specific changes in our research and development expenses year over year include a:</span></p><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888870241978623%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$16.9 million increase in personnel costs primarily driven by an increase in headcount to support overall growth related to our rese-cel program, including an increase of $4.6 million in stock-based compensation expense; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888870241978623%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$14.0 million increase in clinical trial costs primarily due to rese-cel clinical trial costs;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888870241978623%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$7.0 million increase in manufacturing costs primarily due to expanded cell processing capabilities and related activities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888870241978623%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$3.9 million increase in development services due to expanded lab space and related costs to support increased headcount performing research and translational activities; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888870241978623%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$0.8 million increase in other primarily due to increased travel, conference and training costs and other costs to support headcount growth; partially offset by a</span></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">102</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888870241978623%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$0.9 million decrease in license of intellectual property costs due to a $1.2 million upfront fee to Autolus pursuant to the Autolus Option and License Agreement and a $1.0 million milestone payment to IASO for IND clearance of rese-cel in the first quarter of 2023 compared to a $1.5 million milestone payment to IASO in the first quarter of 2024 for the first patient dosed in the rese-cel trial.</span></div></div><p style="margin-left:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses were $27.9 million for the year ended December 31, 2024 as compared to $19.2 million for the year ended December 31, 2023. The increase of $8.7 million in our general and administrative expenses year over year includes:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$6.5 million of additional personnel costs, primarily driven by an increase in headcount to support overall company growth, including an increase of $3.5 million in stock-based compensation expense; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$2.2 million higher administrative costs, including legal, information technology, and travel as well as other administrative costs.</span></div></div><p style="margin-left:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Income</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest income has increased $3.0 million for the year ended December 31, 2024 as compared to the year ended December 31, 2023, primarily as a result of increasing interest rates on a higher cash and cash equivalents balance due to a financing in May 2023 and proceeds from sales of common stock pursuant to the ATM Program in the fourth quarter of 2023, first quarter of 2024 and fourth quarter of 2024.</span></p><p style="margin-left:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest Expense</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest expense has increased $0.8 million for the year ended December 31, 2024 as compared to the year ended December 31, 2023, primarily as a result of finance lease arrangements from embedded leases within our WuXi manufacturing agreement.</span></p><p style="margin-left:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liquidity, Capital Resources and Going Concern</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From our inception in April 2017 to the time of our initial public offering, or IPO, our operations were financed by proceeds of $86.4 million from the sale of convertible notes and our convertible preferred stock and proceeds of $71.0 million from the sale of common stock in our IPO. Since our IPO, we have generated cash from public offerings of our common stock and pre-funded warrants to purchase our common stock resulting in aggregate net proceeds of approximately $280.0 million. As of December 31, 2024, we had $164.0 million in cash and cash equivalents which should enable us to fund our operations and capital expenditures into the first half of 2026. Cash in excess of immediate requirements is invested in accordance with our investment policy, primarily with a view to liquidity and capital preservation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have incurred losses since our inception and, as of December 31, 2024, we had an accumulated deficit of $349.1 million. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding prepaid expenses and other current assets, accounts payable and accrued expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any product candidates we may develop may never achieve commercialization and we anticipate that we will continue to incur losses for the foreseeable future. We expect that our research and development expenses, general and administrative expenses, and capital expenditures will continue to increase. As a result, until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings or other capital sources, including potentially collaborations, licenses and other similar arrangements. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research, manufacturing and development services, costs relating to the build-out of our headquarters, laboratories and manufacturing facility, license payments or milestone obligations that may arise, laboratory and related supplies, clinical costs, manufacturing costs, legal and other regulatory expenses and general overhead costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about our ability to continue as a going concern within one year after the date that the consolidated financial statements are issued. Based on our current operating plan, we believe there is substantial doubt about our ability to continue as a going concern for at least twelve months following the filing of this Annual Report on Form 10-K, and we will need to obtain additional funding. Our cash forecast</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">103</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">contains estimates and assumptions based on success of ongoing clinical trials, and we cannot predict the amount or timing of all expenditures with certainty. We will continue to seek funds through equity offerings, debt financings or other capital sources, including potentially collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. If we do raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders&#8217; rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Any failure to raise capital as and when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies. If we are unable to raise capital, we will need to delay, reduce or terminate certain planned activities to reduce costs.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">At-The-Market Offering Sales Agreement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 21, 2024, we filed an automatic shelf registration statement (File No. 333-278126), or 2024 S-3ASR, in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof for the purposes of selling, from time to time, our common stock, debt securities or other equity securities in one or more offerings. We also simultaneously entered into a Sales Agreement, or the 2024 Sales Agreement, with Cowen and Company, LLC, or the Sales Agent, to provide for the offering, issuance and sale of up to an aggregate amount of $200.0 million of our common stock from time to time in &#8220;at-the-market&#8221; offerings, or the 2024 ATM Program, under the 2024 S-3ASR and subject to the limitations thereof. We intend to convert the S-3ASR to S-3 by post-effective amendments in connection with the filing of this Annual Report. In December 2024, we sold 1,225,000 shares pursuant to the 2024 ATM Program for net proceeds of $5.1 million, after deducting commissions of $0.1 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We previously had a Sales Agreement with Cowen to provide for the offering, issuance and sale of up to an aggregate amount of $100.0 million of common stock from time to time in &#8220;at-the-market&#8221; offerings, or 2023 ATM Program, pursuant to our shelf registration statement on Form S-3 (File No. 333-270599), which was declared effective April 26, 2023. During the year ended December 31, 2023, we sold 4,760,899 shares pursuant to the 2023 ATM Program for net proceeds of $91.7 million, after deducting commissions of $2.4 million. In the first quarter of 2024, we sold 258,070 additional shares, completing the 2023 ATM Program for net proceeds of $5.7 million, after deducting commissions of $0.1 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">December 2022 Financing</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2022, we issued 126,815 shares of our common stock at a price of $5.52 per share and to certain investors in lieu of common stock, pre-funded warrants to purchase 6,213,776 shares of our common stock at a price of $5.51999 per pre-funded warrant. The purchase price per share of each pre-funded warrant represents the per share offering price for the common stock, minus the $0.00001 per share exercise price of such pre-funded warrant. Aggregate net proceeds were $32.6 million after deducting underwriting discounts and commissions and offering expenses of $2.4 million. As of December 31, 2024, 6,213,775 pre-funded warrants had been exercised and no warrants remain outstanding.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">May 2023 Financing</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2023, we issued 8,337,500 shares of our common stock in an underwritten public offering, including the exercise in full by the underwriters of their option to purchase an additional 1,087,500 shares, at a public offering price of $12.00 per share. Aggregate net proceeds were $93.8 million after deducting underwriting discounts and commissions and offering expenses of $6.3 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical products, we are unable to estimate the exact amount of our operating capital requirements. Our future funding requirements will depend on many factors, including, but not limited to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888870241978623%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope, progress, results and costs of researching, developing and manufacturing our lead product candidates or any future product candidates, and conducting preclinical studies and clinical trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888870241978623%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing of, and the costs involved in, obtaining regulatory approvals or clearances for our lead product candidates or any future product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888870241978623%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the impact of any business interruptions to our operations or to those of our clinical sites, manufacturers, suppliers, or other vendors resulting from public health crises; </span></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">104</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888870241978623%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number and characteristics of any additional product candidates we develop or acquire; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888870241978623%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing of any cash milestone payments if we successfully achieve certain predetermined milestones; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888870241978623%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of manufacturing our lead product candidate or any future product candidates and any products we successfully commercialize, including costs associated with building-out our manufacturing capabilities; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888870241978623%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of any such agreements that we may enter into; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888870241978623%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the expenses needed to attract and retain skilled personnel; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888870241978623%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs associated with being a public company; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888870241978623%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing, receipt and amount of sales of any future approved or cleared products, if any. </span></div></div><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, our operating plans may change, and we may need additional funds to meet operational needs and capital requirements for clinical trials and other research and development activities. We currently have no credit facility or committed sources of capital. Because of the numerous risks and uncertainties associated with the development and commercialization of our product candidates, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and anticipated product development programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash Flows</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our cash flows for the periods indicated:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:66.993%;box-sizing:content-box;"/>
     <td style="width:1.62%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.883000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.62%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.883000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by (used in):</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(88,222</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(53,549</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investing activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47,289</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(22,451</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financing activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,677</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">187,631</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effect of exchange rate changes on cash and cash equivalents</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(20</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net (decrease) increase in cash and cash equivalents</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(29,276</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">111,631</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="margin-left:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating Activities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024, cash used in operating activities of $88.2 million was attributable to our net loss of $115.9 million, partially offset by non-cash charges of $26.0 million for stock-based compensation charges, amortization of finance lease, non-cash operating lease expense, depreciation, amortization of premium on investments, accretion of operating lease liabilities and foreign currency exchange rates and a net change of $1.7 million in our net operating assets and liabilities.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2023, cash used in operating activities of $53.5 million was attributable to our net loss of $67.7 million, partially offset by non-cash charges of $14.1 million for stock-based compensation charges, amortization of premium on investments, non-cash lease expense, accretion of lease liabilities and depreciation and a net change of $0.1 million in our net operating assets and liabilities.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investing Activities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024, cash provided by investing activities of $47.3 million was attributable to $49.5 million from the maturity of short-term investments, partially offset by purchases of $2.2 million of property and equipment.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2023, cash used in investing activities of $22.5 million was attributable to $84.3 million of purchases of investments and $0.7 million of purchases of property and equipment, partially offset by $62.5 million of proceeds from maturities of investments.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">105</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="margin-left:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Financing Activities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024, cash provided by financing activities of $11.7 million was from $10.9 million in sales of common stock, net of issuance costs paid, $1.7 million from the exercise of employee stock and purchases of shares under our 2019 Employee Stock Purchase Plan, or 2019 ESPP, offset by $0.9 million in principal payments on finance leases.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2023, cash provided by financing activities of $187.6 million was from $185.2 million in sales of common stock, net of issuance costs paid and $2.4 million from the exercise of employee stock options and purchases of shares under our 2019 ESPP.</span></p><p style="margin-left:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contractual Obligations and Commitments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We lease our headquarters office space and lab space under non-cancelable operating lease agreements. The lease term of our office space commenced in May 2019 and was amended in October 2024 for an additional 12 months through June 30, 2026. The lease term of our lab space was amended in September 2024 for 23 months through August 2026. See Note 9 of the consolidated financial statements for additional detail on our leases. We also have an embedded lease with WuXi, our cell processing manufacturing partner through August 2026. Total undiscounted aggregate future finance and operating lease obligations under all of our leases as of December 31, 2024 are $17.1 million.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have no material contractual obligations not fully recorded on our balance sheets or fully disclosed in the notes to the consolidated financial statements. Our commitments include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">IASO Exclusive License Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> As partial consideration for the exclusive license, IASO received an upfront payment of $2.5 million. IASO is also eligible to receive up to mid double digit millions in milestone payments based upon the achievement of specified pre-clinical, development and regulatory milestones, and up to an additional low triple digit millions in milestone payments based upon achievement of specified sales milestones, for a total consideration, inclusive of the upfront payment, of up to $162 million, along with tiered mid-single digit royalties on future net sales for licensed products that may result from the IASO Agreement. We also may sublicense through multiple tiers the rights granted to it by IASO under the IASO Agreement at any time, however, we must pay IASO a low double-digit percentage of any revenue obtained from sublicenses or options to third parties, subject to certain customary exclusions. The IASO Agreement will continue on a country-by-country, licensed product-by-licensed product basis until the expiration of the royalty term as identified in the IASO Agreement, unless earlier terminated. A milestone payment of $1.5 million was paid to IASO in the first quarter of 2024 after the first patient in a rese-cel trial was dosed.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Oxford Licence and Supply Agreement. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the agreement, we were required to pay Oxford an upfront fee, as well as costs associated with initial vector manufacturing activities for our DSG3-CAART program. In May 2023, we amended the LSA with Oxford to expand the license to include our rese-cel program for an upfront fee of $0.5 million and in August 2023, we entered into a vector supply agreement with Oxford, and a related second amendment to the LSA, for rese-cel with a total cost of up to approximately $5.0 million under the vector supply agreement. In February 2024, the Company and Oxford entered into a third amendment to the LSA to update the patent schedule. We can terminate the agreement at will upon advance written notice and subject to certain manufacturing slot cancellation fees.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Autolus Option and License Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In January 2023, we entered into an Option and License Agreement, or the Autolus Agreement, with Autolus Holdings (UK) Limited (Autolus), wherein the Autolus Agreement grants us a non-exclusive license to access Autolus' RQR8 technology in our CD19-CAR T cell therapy program, and subject to additional nominal option exercise fees, up to four additional targets. In January 2025, the Company and Autolus agreed to novate the Autolus Agreement with both Autolus and Autolus Limited jointly assuming the rights, obligations and liabilities of Autolus under the Autolus Agreement. Under the terms of the Autolus Agreement, we were required to pay Autolus an upfront license fee of $1.2 million, of which $1.1 million was paid in 2023 and $0.1 million was paid in January 2024. Autolus is also eligible to receive regulatory milestones of up to $12 million for each licensed target, sales milestones of up to a total of $15 million and royalties in the low single digits on net sales of all products that incorporate the RQR8 technology. The Autolus Agreement will continue on a country-by-country, licensed product-by-licensed product basis until the expiration of the royalty term as identified in the Autolus Agreement, unless earlier terminated. We can terminate the Autolus Agreement at will upon advance written notice. Each of Autolus and us may terminate the Agreement for a material, uncured breach or insolvency of the other party.</span></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">106</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The Penn License Agreement. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the License Agreement, we are required to make milestone payments upon successful completion of certain development, regulatory and sales milestones on a product-by-product and geographical basis. The payment obligations under the License Agreement are contingent upon future events such as our achievement of specified development, regulatory and commercial milestones and we will be required to make development milestone payments and royalty payments in connection with the sale of products developed under the License Agreement. As of December 31, 2024, we are unable to estimate the timing or likelihood of achieving the milestones or making future product sales. </span></div></div><p style="margin-left:9.315%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the License Agreement, we must use commercially reasonable efforts to develop and commercialize a product in each subfield. During the term of the License Agreement until the first commercial sale of the first product, we are obligated to pay Penn a non-refundable, non-creditable annual license maintenance fee of $10,000. We are required to pay certain milestone payments upon the achievement of specified clinical and commercial milestones. Milestone payments are reduced by a certain percentage for the second product that achieves a milestone, by an additional percentage for the third product that achieves a milestone, and so on, for each subsequent product that achieves a milestone. In the event that we are able to successfully develop and launch multiple products under the License Agreement, total milestone payments could be approximately $21.0 million. Penn is also eligible to receive tiered royalties at percentage rates in the low single-digits, subject to an annual minimum royalty, on annual worldwide net sales of any products that are commercialized by us or our sublicensees that contain or incorporate, or are covered by, the intellectual property licensed by us. To the extent we sublicense our license rights under the License Agreement, Penn would be eligible to receive tiered sublicense income at percentage rates in the mid-single to low double-digits. We have also entered into a subscription and technology transfer agreement with Penn, pursuant to which we owed Penn an upfront subscription fee, which was paid in 2019, and a nominal non-refundable royalty on net sales of products, a portion of which will be credited toward milestone payments and royalties under this License Agreement. Technology transfer activities would be at our cost and subject to agreement as to the technology to be transferred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Master Translational Research Services Agreement with Penn.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Under the Services Agreement, we have contracted for additional research and development services from various laboratories within Penn. The Services Agreement will expire upon completion of the services for which we have engaged Penn under the Services Agreement. In May 2020, the Company amended its Addendum with CAROT to expand access to vector manufacturing. We may incur additional expenses up to $0.6 million through the remaining term of the CAROT Amended Addendum. In February 2023, we entered into a second Master Translational Research Services Agreement with Penn, or the CARTA Services Agreement, pursuant to which Penn agreed to perform certain research, development and manufacturing activities. The services encompassed by the CARTA Services Agreement are performed by different organizations at Penn pursuant to certain addenda to the CARTA Services Agreement. The CARTA Services Agreement will expire on the later of (i) February 9, 2026 or (ii) completion of the services for which we have engaged Penn under the CARTA Services Agreement. Either party may terminate this agreement with or without cause upon a certain number of days&#8217; prior written notice. We are committed to pay up to $3.0 million for cell processing manufacturing under the CARTA Services Agreement through December 31, 2025.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">WuXi Manufacturing agreement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In January 2021, we entered into the WuXi Agreement to serve as an additional cell processing manufacturing partner for the MusCAARTes</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">trial. In August 2023, we entered into new work orders under the WuXi Agreement for WuXi to serve as one of our cell processing manufacturing partners for the global clinical development of rese-cel in multiple indications, including potential late-stage clinical trials and commercial readiness activities for rese-cel. Under the August 2023 work orders, WuXi will convert our non-dedicated suite to a dedicated suite for GMP manufacturing for our rese-cel and MuSK-CAART programs for an initial term of 18 months with two 18 month extensions at our sole option on six months' notice prior to the end of the term. In addition, we agreed to certain monthly minimum runs. We would incur up to a $1.08 million termination fee if we terminate both the rese-cel and MuSK-CAART work orders for any reason. We may terminate for convenience the WuXi Agreement or any work order with six months' prior written notice, however, we may not terminate the Dedicated Suite without terminating both the MuSK-CAART and rese-cel GMP run work orders. </span></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">107</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div class="item-list-element-wrapper" style="margin-left:0.35in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.895751273567564%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Lonza Manufacturing agreement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In December 2024, we entered into the Lonza Agreement with Lonza to serve as one of our manufacturing partners for the global clinical development of rese-cel in multiple indications, including potential late-stage clinical trials and preparations for commercial readiness. Under the initial work order, Lonza will perform cell therapy manufacturing activities for our CAR-T cell therapy product rese-cel for a term of 12 months and total cost of approximately $16.0 million with the ability to extend the manufacturing period subject to the terms of the Lonza Agreement.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Purchase Commitments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In the normal course of business, we enter into various purchase commitments with third-party contract manufacturers for the manufacture and processing of our product candidates and related raw materials, contracts with contract research organizations for clinical trials and agreements with vendors for other services and products for operating purposes. These agreements generally provide for termination or cancellation other than for costs already incurred.</span></div></div><p style="margin-left:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Critical Accounting Policies and Significant Judgments and Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles, or GAAP. The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management&#8217;s judgments and estimates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While our significant accounting policies are described in more detail in Note 2 to our consolidated financial statements appearing elsewhere in this Annual Report, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our consolidated financial statements.</span></p><p style="margin-left:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We estimate costs of research and development activities conducted by service providers, which include the conduct of preclinical studies, contract manufacturing activities and clinical trial activities. We record the estimated costs of research and development activities based upon the estimated amount of services provided and include these costs in the accrued and other current liabilities on the balance sheets and within research and development expense on the statements of operations. Non-refundable advance payments made for goods or services that will be used or rendered for future research and development activities are deferred and capitalized and recognized as expense as the goods are received or the related services are rendered.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We estimate these costs based on factors such as estimates of the work completed and budget provided and in accordance with agreements established with our collaboration partners and third-party service providers. We make significant judgments and estimates in determining the accrued liabilities balance in each reporting period. As actual costs become known, we adjust our accrued liabilities. We have not experienced any material differences between accrued costs and actual costs incurred since our inception.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">108</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Smaller Reporting Company Status</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a &#8220;smaller reporting company,&#8221; as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended. We would cease to be a smaller reporting company if we have a public float in excess of $250 million, or have annual revenues in excess of $100 million and a public float in excess of $700 million, determined on an annual basis. This status allows us to take advantage of many of the same exemptions from disclosure requirements including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For a discussion of recently adopted accounting pronouncements please read Note 2, Summary of Significant Accounting Policies, to our consolidated financial statements included in this report.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For a discussion of recently issued accounting pronouncements please read Note 2, Summary of Significant Accounting Policies, to our consolidated financial statements included in this report.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">109</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="item_7a_market_risk"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 7A. Quantitative and Qualitative Disclosures About Market Risk.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are exposed to market risks in the ordinary course of our business. These risks primarily include interest rate sensitivities. We held cash and cash equivalents of $164.0 million as of December 31, 2024. We generally hold our cash in interest-bearing money market treasury fund accounts. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. Due to the short-term maturities of our cash equivalents, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our cash equivalents. Declines in interest rates, however, would reduce future investment income.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not have any foreign currency or derivative financial instruments. Inflation generally affects us by increasing our cost of labor and program costs. Although we do not believe that inflation has had a material impact on our financial position or results of operations to date, we may experience some effect in the near future (especially if inflation rates continue to rise) due to an impact on the costs to conduct clinical trials, labor costs we incur to attract and retain qualified personnel, and other operational costs. Inflationary costs could adversely affect our business, financial condition and results of operations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="item_8_financial_statements_supplementar"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 8. Consolidated Financial Statement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s and Supplementary Data.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The consolidated financial statements required to be filed pursuant to this Item 8 are appended to this Annual Report. An index of those consolidated financial statements is found in Item 15.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="item_9_changes_in_disagreements_with_acc"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9. Changes in and Disagreements with Accou</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ntants on Accounting and Financial Disclosure.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There has been no change of accountants nor any disagreements with accountants on any matter of accounting principles or practices of financial disclosure required to be reported under this Item.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">110</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="item_9a_controls_procedures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9A. Controls</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and Procedures.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has established disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) designed to ensure that information required to be disclosed in the reports that the Company files or submits under the Securities Exchange Act of 1934, as amended, or Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms and is accumulated and communicated to management, including the principal executive officer (our Chief Executive Officer) and principal financial officer (our Chief Financial Officer), to allow timely decisions regarding required disclosure. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated, as of December 31, 2024, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our disclosure controls and procedures have been designed to provide reasonable assurance of achieving their objectives. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) were effective at the reasonable assurance level as of December 31, 2024.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is a process designed to provide reasonable assurance of the reliability of financial reporting and of the preparation of consolidated financial statements for external reporting purposes, in accordance with U.S. generally accepted accounting principles.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Internal control over financial reporting includes policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect transactions and disposition of assets; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of consolidated financial statements in accordance with U.S. generally accepted accounting principles, and that receipts and expenditures are being made only in accordance with the authorization of its management and directors; and (3) provide reasonable assurance regarding the prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on its consolidated financial statements.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of the effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies and procedures included in such controls may deteriorate.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management has assessed the effectiveness of our internal control over financial reporting as of December 31, 2024. In making this assessment, management used the criteria established by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control - Integrated Framework (2013). These criteria are in the areas of control environment, risk assessment, control activities, information and communication, and monitoring. Management&#8217;s assessment included extensive documentation, evaluating and testing the design and operating effectiveness of its internal controls over financial reporting.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on management&#8217;s processes and assessment, as described above, management has concluded that, as of December 31, 2024, our internal control over financial reporting was effective.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Attestation Report of the Registered Public Accounting Firm</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a non-accelerated filer, we are not required to provide an attestation report of our independent registered public accounting firm on the effectiveness of our internal control over financial reporting.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">111</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in Internal Control over Financial Reporting</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There was no change in our internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) that occurred during the fiscal quarter ended December 31, 2024 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="item_9b_or_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9B. Other</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Information.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div><ix:nonNumeric id="F_ba49fc90-86d5-401f-8311-7dc12b279195" contextRef="C_438de52d-5f54-466c-a0d0-ff8e3b765da2" name="ecd:MtrlTermsOfTrdArrTextBlock" escape="true" continuedAt="F_ba49fc90-86d5-401f-8311-7dc12b279195_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rule 10b5-1 Trading Plans</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the fiscal quarter ended on December 31, 2024, none of our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ed32101e-27c6-46a4-b898-01d6bf0df2d5" contextRef="C_438de52d-5f54-466c-a0d0-ff8e3b765da2" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_78329bf4-af50-49d2-b228-d0088211f6c0" contextRef="C_438de52d-5f54-466c-a0d0-ff8e3b765da2" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0e433583-eea0-43fe-a846-0e9090d827c5" contextRef="C_438de52d-5f54-466c-a0d0-ff8e3b765da2" name="caba:Rule10B51ArrModifiedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_e521c342-f6f8-48c9-80de-4f93655cb3d5" contextRef="C_438de52d-5f54-466c-a0d0-ff8e3b765da2" name="caba:NonRule10B51ArrModifiedFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">modified</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6697ff6b-918e-48ba-83f9-4107e2dce2b9" contextRef="C_438de52d-5f54-466c-a0d0-ff8e3b765da2" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_a101396f-8878-4ba6-9747-78ff6852ee71" contextRef="C_438de52d-5f54-466c-a0d0-ff8e3b765da2" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">terminated</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> a &#8220;Rule 10b5-1 trading arrangement&#8221; or &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as those terms are defined in Item 408(a) of Regulation S-K, except as described in the table below:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
     <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
      <tr style="visibility:collapse;">
       <td style="width:21.5%;box-sizing:content-box;"/>
       <td style="width:12.42%;box-sizing:content-box;"/>
       <td style="width:15.34%;box-sizing:content-box;"/>
       <td style="width:16.64%;box-sizing:content-box;"/>
       <td style="width:14.7%;box-sizing:content-box;"/>
       <td style="width:19.4%;box-sizing:content-box;"/>
      </tr>
      <tr style="height:54.4pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
       <td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name and Title</span></p></td>
       <td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Action</span></p></td>
       <td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Action Date</span></p></td>
       <td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Duration of Trading Arrangements</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
       <td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Rule 10b5-1 Trading Arrangement?</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Y/N)*</span></p></td>
       <td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate Number of Securities Subject to Trading Arrangement</span></p></td>
      </tr>
      <tr style="height:35.95pt;word-break:break-word;white-space:pre-wrap;">
       <td style="padding-top:0in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_8c1b5cd2-9f1e-4c04-b5f9-cd8ffc78e4fc" contextRef="C_d8920710-db59-443d-8539-f9ab7adae181" name="ecd:TrdArrIndName"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Steven Nichtberger</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_40788efa-89db-4fb2-8a80-fa57f060d7d7" contextRef="C_d8920710-db59-443d-8539-f9ab7adae181" name="ecd:TrdArrIndTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></ix:nonNumeric></span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_537853c2-69ae-4eb0-a116-80e3343a1708" contextRef="C_d8920710-db59-443d-8539-f9ab7adae181" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Terminate</span></ix:nonNumeric></span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_d1ff8d6a-33d9-4f37-8ef5-c87250188d9b" contextRef="C_d8920710-db59-443d-8539-f9ab7adae181" name="ecd:TrdArrTerminationDate"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">October 18, 2024</span></ix:nonNumeric></span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_12ddf4b5-a62c-4ffa-84f2-711a71acbce0;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">July 8, 2024 - July</span></span></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31, 2025</span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Y</span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Up to </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f29b8f47-e3be-40de-8059-4c45fa576a9d" contextRef="C_a03b5214-7513-436c-a38c-ffda0bc04870" name="ecd:TrdArrSecuritiesAggAvailAmt" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">350,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares to be sold</span></p></td>
      </tr>
      <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
       <td style="padding-top:0in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_ad0c6520-413a-46c8-92e7-cee48123c6db" contextRef="C_5d39951d-322e-4fbb-8300-8a74cf365c32" name="ecd:TrdArrIndName"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Steven Nichtberger</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_79002335-d05e-4367-b1f8-ce5277322c9d" contextRef="C_5d39951d-322e-4fbb-8300-8a74cf365c32" name="ecd:TrdArrIndTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></ix:nonNumeric></span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_c2ec38c4-d236-4522-be8b-3253a1d0b866" contextRef="C_5d39951d-322e-4fbb-8300-8a74cf365c32" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adopt</span></ix:nonNumeric></span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_b6378822-f522-428b-b919-580ee211be3a" contextRef="C_5d39951d-322e-4fbb-8300-8a74cf365c32" name="ecd:TrdArrAdoptionDate"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">October 18, 2024</span></ix:nonNumeric></span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_f0564499-a995-4065-9bd0-26aa3bce6fbe;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 16, 2025 &#8211; July 27, 2026</span></span></span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Y</span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Up to </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7392ec15-f38a-477c-8bc2-c65d57199f8b" contextRef="C_5ae7b143-7cde-44f4-9122-03f5df7ace32" name="ecd:TrdArrSecuritiesAggAvailAmt" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">350,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares to be sold</span></p></td>
      </tr>
      <tr style="height:46.3pt;word-break:break-word;white-space:pre-wrap;">
       <td style="padding-top:0in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_27b2c07a-01a6-43f3-8aed-83045450ec50" contextRef="C_249c212f-73ed-4f7d-aa7a-ae4c0064e772" name="ecd:TrdArrIndName"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gwendolyn Binder</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_17c9fa72-29c4-4d47-bd31-11b6eff1d24b" contextRef="C_249c212f-73ed-4f7d-aa7a-ae4c0064e772" name="ecd:TrdArrIndTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">President of Science and Technology</span></ix:nonNumeric></span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_ace2887d-50d7-482c-a7d7-fef7cf638aac" contextRef="C_249c212f-73ed-4f7d-aa7a-ae4c0064e772" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Terminate</span></ix:nonNumeric></span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_9cf1b1cf-0bab-4989-918f-64c1cd192f77" contextRef="C_249c212f-73ed-4f7d-aa7a-ae4c0064e772" name="ecd:TrdArrTerminationDate"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 21, 2024</span></ix:nonNumeric></span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_823872a2-58d2-4796-aa66-411b0b1f08f7;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 20, 2024 &#8211; February 21, 2025</span></span></span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Y</span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Up to </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2829044d-0635-4dd3-a2b5-ac7b74e4c246" contextRef="C_d4a74439-9471-4a4f-9351-6249071d95ae" name="ecd:TrdArrSecuritiesAggAvailAmt" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">100,756</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares to be sold</span></p></td>
      </tr>
      <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
       <td style="padding-top:0in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_c73cecdb-3a8c-4fb8-b02a-a7b935a100b7" contextRef="C_a7948e46-0c3f-4a80-bc84-1f696b1179b4" name="ecd:TrdArrIndName"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gwendolyn Binder</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_a104b6c0-1694-4359-8eae-d11f787a1e0e" contextRef="C_a7948e46-0c3f-4a80-bc84-1f696b1179b4" name="ecd:TrdArrIndTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">President of Science and Technology</span></ix:nonNumeric></span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_5c99fc75-08af-4faf-8b94-35faba4a4e36" contextRef="C_a7948e46-0c3f-4a80-bc84-1f696b1179b4" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adopt</span></ix:nonNumeric></span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_caf42755-7b4d-4e5b-b048-a2944212492a" contextRef="C_a7948e46-0c3f-4a80-bc84-1f696b1179b4" name="ecd:TrdArrAdoptionDate"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 18, 2024</span></ix:nonNumeric></span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_e881d3fc-fad6-4460-a675-9db9c9ce22a6;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 27, 2025 to December 12, 2025</span></span></span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Y</span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Up to </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4689fcff-99d0-46d3-a6de-55cebd00c7f7" contextRef="C_a5bf8c63-11a0-4813-b9c1-88b3b3a7c7df" name="ecd:TrdArrSecuritiesAggAvailAmt" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">100,756</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares to be sold</span></p></td>
      </tr>
     </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* Denotes whether the trading plan is intended, when adopted, to satisfy the affirmative defense of Rule 10b5-1(c).</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) Except as indicated by footnote, each trading arrangement permitted or permits transactions through and including the earlier to occur of (a) the completion of all purchases or sales or (b) the date listed in the table.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:continuation id="F_ba49fc90-86d5-401f-8311-7dc12b279195_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2) Represents the modification, as described in Rule 10b5-1(c)(1)(iv) under the Exchange Act, of a written trading arrangement adopted on November 9, 2023 that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="item_9c_disclosure_regarding_foreign"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9C.</span><span id="notes_to_financial_statements"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">112</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iii_1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> III</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="item_10_directors_executive_ficers_cor_1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 10. Directors, Executive Off</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">icers and Corporate Governance.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth information about our directors and executive officers as of March 27, 2025.</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:28.98%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:34%;box-sizing:content-box;"/>
     <td style="width:1.72%;box-sizing:content-box;"/>
     <td style="width:11.2%;box-sizing:content-box;"/>
     <td style="width:1.72%;box-sizing:content-box;"/>
     <td style="width:16.5%;box-sizing:content-box;"/>
     <td style="width:1.72%;box-sizing:content-box;"/>
     <td style="width:3.16%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Positions and Offices Held with Cabaletta</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Officer/Director<br/>Since</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Class and Year in Which Term Will Expire</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Age</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Executive Officers</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Steven Nichtberger, M.D.</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer, President, Chairman of the Board of Directors and Director</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2017</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Class III&#8212;2025</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gwendolyn K. Binder, Ph.D.</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">President, Science and Technology</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2019</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Anup Marda, MBA</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2019</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">David J. Chang, M.D., M.P.H.</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Medical Officer</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2019</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Michael Gerard, J.D.</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General Counsel and Secretary</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2021</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Arun Das, M.D.</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Business Officer</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2022</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Non-Employee Directors</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Mark Simon, MBA (1)(2)(3)</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2018</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Class III&#8212;2025</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Scott Brun, M.D. (1)(3)</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2021</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Class I&#8212;2026</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shawn Tomasello, MBA (2)</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Class I&#8212;2026</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Catherine Bollard, MBChB, M.D. (3)</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2019</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Class II&#8212;2027</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Richard Henriques, MBA (1)(2)</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2019</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Class II&#8212;2027</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">69</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) Member of the Audit Committee.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2) Member of the Compensation Committee.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(3) Member of the Nominating and Corporate Governance Committee.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Executive Officers</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Steven Nichtberger, M.D.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Dr. Nichtberger has served as our Chief Executive Officer, President and Chairman of our board of directors since our founding in 2017. He is also a Professor of Professional Practice in the Vagelos LSM program and adjunct professor at The Wharton School of the University of Pennsylvania in addition to being a member of the board of directors of the BioAdvance Greenhouse Fund. Previously, Dr. Nichtberger served as president, chief executive officer, and a member of the board of directors of Tengion, Inc. from 2004 to 2011. In 2008, his leadership was recognized nationally with the National Ernst &amp; Young Entrepreneur of the Year Award for emerging companies. Earlier in his career, Dr. Nichtberger served as the head of global marketing for Merck and in various commercial operating roles at the company from 1995 to 2003. He has previously served as a member of the boards of directors of the Alliance for Regenerative Medicine (as a founding member), Pennsylvania Bio (including as chairman), and Biotechnology Industry Organization. From 2008 to 2019, he was a member of the board of overseers for the School of Arts &amp; Sciences at the University of Pennsylvania. Dr. Nichtberger received his M.D. from the State University of New York at Buffalo, his B.S. from The Wharton School at the University of Pennsylvania and his B.A. from the University of Pennsylvania. He completed internship, residency and fellowship in the Department of Medicine and the Division of Cardiology of the Mount Sinai Medical Center in New York. We believe Dr. Nichtberger is qualified to serve as a member and Chairman of our board of directors because of his scientific and medical background as well as his corporate leadership experience.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Gwendolyn K. Binder, Ph.D.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Dr. Binder joined our company in February 2019 as our Executive Vice President, Science and Technology and was appointed President, Science and Technology in January 2022. Dr. Binder is an R&amp;D executive with specialized expertise in the discovery and early clinical development and optimization of engineered T cell therapies. Prior to joining Cabaletta, Dr. Binder was the Chief Technology Officer of Adaptimmune Therapeutics Plc from March 2016 to January 2019, where she ultimately led the research team focusing on understanding mechanisms of tumor response and resistance and translating this understanding to next generation products and clinical study designs. In prior roles, from March 2011 to February 2016, she established and led the translational research group, in addition to the manufacturing and quality teams including oversight of the buildout of an in-house manufacturing facility. Earlier in her career, Dr. Binder served as Director of Operations for the Translational Research Program at the University of Pennsylvania, where she where she progressed multiple investigational new drug submissions for novel engineered T-cell therapies in HIV and oncology, including the CD19 CAR IND acquired by Novartis (now Kymriah), the first human gene editing IND, and three TCR engineered T cell therapy studies in oncology and HIV. Prior to that, she served as the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">113</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Director of Scientific Affairs at VIRxSYS Corporation in Gaithersburg Maryland where she supported the development of the first clinical lentiviral vector used in humans, for the application of engineered T cell therapy for HIV. In addition, Dr. Binder has served on the Board of Directors of Instil Bio (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies including a lead PD-L1xVEGF bispecific antibody for solid tumors, since July 2020, and as a member of the Scientific Advisory Board for Immatics, which is a publicly traded company developing engineered T cell immunotherapy for cancer, since July 2020. Dr. Binder studied viral immunology and translational research at the Johns Hopkins University in Baltimore, Maryland where she earned a Ph.D. in Cellular and Molecular Medicine in 2002. She has authored over 30 publications in the field, including top international journals such as &#8220;Science&#8221;, and &#8220;Nature Medicine&#8221;. She is a recognized leader in the biotechnology sector for the translational and clinical advancement of novel T cell therapies for patients with serious diseases.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Anup Marda, MBA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Mr. Marda joined our company in January 2019 as our Chief Financial Officer. From April 2001 to January 2019, Mr. Marda held positions at Bristol-Myers Squibb, including, most recently, as Vice President, Head of Global Corporate Financial Planning &amp; Analysis, and previously as Head of Finance, R&amp;D Operations and Head of Finance, R&amp;D Portfolio Management and Global Medical from 2014 to 2018. Prior to this, Mr. Marda held the role of Executive Director, U.S. Pharmaceuticals from 2012 to 2014 and Assistant Treasurer, Capital Markets from 2008 to 2012. Mr. Marda received his MBA from the Krannert School of Business of Purdue University and his B.Tech in Chemical Engineering from the Indian Institute of Technology Bombay.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">David J. Chang, M.D., M.P.H.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Dr. Chang joined our company in June 2019 as our Chief Medical Officer. From June 2015 to May 2019, he was Senior Vice President and Head, Inflammation, Autoimmunity &amp; Neuroscience, or IA&amp;NS, Global Medicines Development at AstraZeneca Pharmaceuticals LP, where he oversaw development projects of both biologics and small molecules in a variety of indications and led the late-stage clinical development organization for IA&amp;NS. From October 2007 to June 2015, Dr. Chang served in various positions at GlaxoSmithKline plc, including VP and Head, Immuno-Inflammation, Clinical Development. While at AstraZeneca and GlaxoSmithKline, he provided leadership in driving the clinical development and registration of the only two products approved for systemic lupus erythematosus in the US in over 60 years. He received his M.D. from New York University School of Medicine, his M.P.H. from Emory University and his B.S. from Yale University. Dr. Chang completed his internship and residency in internal medicine at the New York Hospital&#8212;Cornell University Medical Center and fellowship in rheumatology at the Hospital for Special Surgery&#8212;Cornell University Medical Center.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Michael Gerard, J.D. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mr. Gerard joined our company in September 2021 as our General Counsel and Secretary. Prior to joining Cabaletta, Mr. Gerard served as Associate General Counsel of Spark Therapeutics, Inc., or Spark, from September 2020 to August 2021. Prior to Spark, Mr. Gerard served in various legal roles at Sandoz, Inc., a division of the Novartis Group, beginning in 2013, with the most recent role being Executive Director, Associate General Counsel, Business Development and Licensing, Strategy and Portfolio. Earlier in his career, Mr. Gerard served as Assistant General Counsel at Aramark and as a litigator at the law firms of Morrison &amp; Foerster, LLP and K&amp;L Gates, LLP in New York. Mr. Gerard received a B.A. in Political Science from the University of Michigan, Ann Arbor and a J.D. from Cornell Law School.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Arun Das, M.D.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Dr. Das joined our company in July 2019 after serving as a consultant to the company since 2017, and served in several roles, most recently Executive Director of New Product Planning and Business Development, prior to being appointed Chief Business Officer in January 2022. He is also a Lecturer in the Health Care Management Department at the Wharton School of the University of Pennsylvania. Prior to joining Cabaletta, Dr. Das was a resident physician in General Pediatrics at the Children&#8217;s Hospital of Philadelphia from June 2018 to June 2019. Previously, he was an investment banking analyst in the healthcare group at Goldman Sachs from 2010 to 2012. In addition, Dr. Das has spent multiple years consulting in business development and operations for several start-ups in the biotechnology space. Dr. Das received his M.D. from Johns Hopkins University School of Medicine and a B.A. and B.S. dual degree from the University of Pennsylvania.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Non-Employee Directors</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Mark Simon, MBA</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Mr. Simon joined our board of directors in October 2018. He is a Strategic Advisor since 2020 to the Founder and CEO of Sun Pharmaceutical Industries Ltd., which is the largest pharmaceutical company in India, and a board observer of Sun Pharma Advanced Research Company Ltd., both public companies in India, where Mr. Simon is focused on accelerating their innovation initiatives. He is also a consultant to Stifel Nicolaus &amp; Company (NYSE: SF) and co-founder of Torreya Partners, LLC, a global investment banking firm serving companies in the life sciences industry that Stifel acquired in 2023. Prior to co-founding Torreya, Mr. Simon was a managing director and head of life sciences investment banking at Citigroup from 2002 to 2005 where he covered global pharmaceutical companies with a focus on large-capitalization players in the U.S., Europe and Japan. Prior to Citigroup, Mr. Simon served as a Managing Director at Robertson Stephens in San Francisco and New York where he was responsible for covering the biotechnology investment banking sector. During his tenure overseeing the group, he was involved in raising 45% of all biotechnology dollars raised in the U.S. from 1999-2001. Prior to joining the investment banking group, Mr.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">114</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Simon was a senior biotechnology research analyst at Robertson Stephens, and was named a Wall Street All-Star Analyst for three years in a row. He began his career at Kidder Peabody as a biotechnology research associate in 1984 and participated in the IPO of Genzyme and the early financings of companies such as Amgen. Mr. Simon currently serves on the boards of directors of several disease advocacy and philanthropic foundations in the oncology, CNS/neuroscience and metabolic areas. He previously served on the board of directors of Portage Biotech Inc. (Nasdaq: PRTG) until April 2024. Mr. Simon received his MBA from Harvard Business School and his B.A. from Columbia College. We believe that Mr. Simon is qualified to serve on our board of directors because of his extensive experience of over 35 years in the life sciences industry and biotechnology and specialty pharmaceutical transactions.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Scott Brun, M.D.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Dr. Brun joined our board of directors in June 2021. Dr. Brun is currently President at Gold Mast Consulting, LLC, an advisory firm he founded in 2019 to provide technical advice and strategic guidance related to biopharmaceutical research and development, pipeline portfolio management, commercialization of new therapeutics and strategic communications related to R&amp;D activities. Dr. Brun serves as a Venture Partner at Abingworth LLP and a Senior Medical Advisor to Launch Therapeutics. Prior to his current roles, Dr. Brun had two decades of experience in various leadership roles at AbbVie, Inc., including 15 years at the predecessor company, Abbott Laboratories. The majority of his career has been focused on leading teams and clinical development organizations across a broad variety of therapeutic areas including autoimmune, neurologic, and renal among others. He was most recently Corporate Vice President of Scientific Affairs and Head of AbbVie Ventures, a corporate venture fund responsible for investment opportunities within AbbVie&#8217;s R&amp;D therapeutic areas as well as technology platforms of interest from 2016 to 2019. Previously, Dr. Brun served as Corporate Vice President and Head of Pharmaceutical Development at AbbVie from 2013 to 2016. During his tenure at AbbVie, Dr. Brun oversaw a global organization with responsibilities for AbbVie&#8217;s entire portfolio of early and late-stage clinical pre-registration pipeline compounds as well as marketed compounds within oncology, neurology, immunology, renal, infectious disease, and women&#8217;s and men&#8217;s health therapeutic areas. Prior to joining AbbVie, Dr. Brun spent over 15 years at Abbott Laboratories, where he held positions of increasing leadership responsibility in drug development within the R&amp;D organization. Dr. Brun is a member of the boards of directors of Axial Biotherapeutics, Inc. and Trishula Therapeutics, Inc., both private, clinical-stage biopharmaceutical companies, Jasper Therapeutics, Inc. (Nasdaq: JSPR) a biotechnology company focused on targeting mast cells and stem cells to treat chronic diseases and Forte Biosciences, Inc. (Nasdaq: FBRX) a preclinical-stage company focused on autoimmune diseases. Previously, Dr. Brun served as a Senior Advisor to the business development team at Horizon Therapeutics plc (Nasdaq: HZNP) from 2020 to 2023. Dr. Brun received his B.S. in Biochemistry from the University of Illinois at Urbana-Champaign and earned his M.D. from the Johns Hopkins University School of Medicine. He completed his residency in ophthalmology at the Massachusetts Eye and Ear Infirmary, Harvard Medical School. We believe Dr. Brun is qualified to serve as a member of our board of directors because of his scientific background and significant experience in clinical and research efforts.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Shawn Tomasello, MBA</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ms. Tomasello joined our Board of Directors in July 2023. She is currently Chief Executive Officer at CoRegen, Inc., a private company. Prior to her current role, Ms. Tomasello served as the Chief Commercial Officer of Kite Pharma, where she oversaw the global commercialization of Yescarta, from 2015 to 2018 including through its acquisition by Gilead for $11.9 billion in October 2017. She was previously Chief Commercial Officer at Pharmacyclics, where she led commercial and medical affairs activities for Imbruvica&#174;, a first-in-class treatment for hematologic malignancies, from August 2014 until its acquisition by AbbVie for $21.0 billion in August 2015. Prior to Pharmacyclics, Ms. Tomasello served in leading commercial roles with multiple major pharmaceutical companies, including Celgene as President of the Americas Hematology and Oncology, where she led the company through five successful product launches encompassing 11 indications and played a critical role in acquisitions. At Genentech for 14 years prior, Ms. Tomasello was the National Director of Hematology for Rituxan. She currently serves on the board of directors of AlloVir, Inc. (Nasdaq: ALVR) since March 2022, 4D Molecular Therapeutics Inc. (Nasdaq: FDMT) since November 2020 and Centrexion Therapeutics Corp., a private, clinical-stage biopharmaceutical company, since 2017. She previously served as a board member of TCR2 Therapeutics Inc. (Nasdaq: TCRR) until June 2023, Urogen Pharma Ltd (Nasdaq: URGN) until 2022, Mesoblast, Ltd. (Nasdaq: MESO) until August 2022, Clementia Pharmaceuticals, Diplomat Pharmacy, Inc. until 2020, Abeona Therapeutics (Nasdaq: ABEO) until 2020, Principia Biopharma until 2020, and Gamida Cell Ltd. (Nasdaq: GMDA) until 2024, as well as several private boards. On such boards, she at various times has served and serves on the Compensation, Nominating and Corporate Governance, Compliance, and Transaction committees. Ms. Tomasello received her B.S. in Marketing from the University of Cincinnati and her M.B.A. from Murray State University in Kentucky. We believe Ms. Tomasello is qualified to serve as a member of our Board of Directors because of her experience serving in various commercial roles in the life sciences industry.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Catherine Bollard, MBChB, M.D.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Dr. Bollard joined our board of directors in April 2019. She currently serves as Senior Vice President and Chief Research Officer and Director of the Center for Cancer and Immunology Research at the Children&#8217;s National Research Institute (CNRI). She is also a faculty member of the Division of the Blood and Marrow Transplantation at CNH. Since 2013, Dr. Bollard has served as a tenured Professor of Pediatrics and Microbiology, Immunology and Tropical Medicine at the George Washington University and is the Associate Center Director (ACD) for Translational Research and Innovation within the George Washington Cancer Center. Prior to her move in 2013, Dr. Bollard was Professor of Pediatrics, Medicine and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">115</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Immunology at Baylor College of Medicine. She is a past president of the International Society for Cell Therapy (ISCT), and she served on the Cellular, Tissues and Gene Therapy Advisory Committee of the FDA until 2019. Dr. Bollard chaired the Non-Hodgkin&#8217;s Lymphoma Committee of the Children&#8217;s Oncology Group from 2012 to 2020 and in 2021 became the President of the Foundation for the Accreditation of Cellular Therapy (FACT). Dr. Bollard was the scientific co-founder of Catamaran Bio, a company developing novel, off-the-shelf chimeric antigen receptor (CAR)-NK cell therapies designed to treat a broad range of cancers and served on its Scientific Advisory Board until 2024. Dr. Bollard was previously on the board of directors and subsequently the Scientific Advisory Board of Mana Therapeutics. She currently serves on the SAB of Minovia Tx Ltd and serves as Chair of the DSMB for SOBI. Bollard also serves on the board of directors for Alliance for Regenerative Medicine and a nonprofit organization she co-founded called Access4Kids. Dr. Bollard received her medical degree (MBChB) and her doctor of medicine (MD) from the University of Otago Medical School in New Zealand. We believe Dr. Bollard is qualified to serve as a member of our board of directors because of her scientific background and significant experience in clinical and translational research efforts.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Richard Henriques, MBA. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mr. Henriques joined our board of directors in February 2019. Since 2015, he has been a senior fellow at the Center for High Impact Philanthropy at the University of Pennsylvania, with a focus on impact investing. From 2010 to 2014, Mr. Henriques was the Chief Financial Officer of the Bill &amp; Melinda Gates Foundation, where he was responsible for finance and accounting, financial planning and analysis, strategic planning, measurement and evaluation, program related investments and information technology. From 1981 to 2008, Mr. Henriques held positions at Merck &amp; Co., Inc., including as Senior Vice President of Finance for Global Human Health, Vice President and Corporate Controller, and Principal Accounting Officer. Mr. Henriques serves on the boards of directors or trustees of the Bucks County Playhouse, International Vaccine Institute, Heritage Conservancy, Delaware Canal 21, Fisherman&#8217;s Mark and The Franklin Institute. Mr. Henriques served on the board of directors of Arbutus Biopharma Corporation (Nasdaq: ABUS) from December 2014 to February 2025. Mr. Henriques received his MBA from the Wharton School of the University of Pennsylvania and a BA from the University of Pennsylvania. We believe that Mr. Henriques is qualified to serve as a member of our board of directors because of his extensive corporate leadership experience and expertise in finance and investment management.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Family Relationships and Legal Proceedings</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are no family relationships between or among any of our directors or executive officers. Our executive officers are appointed by, and serve at the discretion of, our board of directors. The principal occupation and employment during the past five years of each of our directors was carried on, in each case except as specifically identified above, with a corporation or organization that is not a parent, subsidiary or other affiliate of us. There is no arrangement or understanding between any of our directors and any other person or persons pursuant to which he or she is to be selected as a director.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are no material legal proceedings to which any of our directors, officers or affiliate, any owner of record or beneficially of more than five percent of any class of our voting securities, or any associate of any such director, officer, affiliate, or security holder is a party adverse to us or any of our subsidiaries or in which any such person has a material interest adverse to us or our subsidiary.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Board Committees</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors has established an audit committee, a compensation committee, and a nominating and corporate governance committee. Each of the audit committee, compensation committee, and nominating and corporate governance committee operates under a charter that satisfies the applicable standards of the SEC and Nasdaq. Our board of directors has also established a science and technology committee, an advisory committee of the board of directors which operates under a charter duly adopted by the board of directors. Each such committee reviews its respective charter at least annually. A current copy of the charter for each of the audit committee, compensation committee, nominating and corporate governance committee and science and technology committee is posted on the corporate governance section of our website, </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">www.cabalettabio.com/investors/corporate-governance/governance-documents</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. From time to time, our board of directors may establish certain committees for scientific, business or other matters.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Audit Committee</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Scott Brun, M.D., Richard Henriques, MBA and Mark Simon, MBA serve on the audit committee, which is chaired by Richard Henriques, MBA. Our board of directors has determined that each member of the audit committee is &#8220;independent&#8221; for audit committee purposes as that term is defined in the rules of the SEC and the applicable Nasdaq rules, and each has sufficient knowledge in financial and auditing matters to serve on the audit committee. Our board of directors has designated Mr. Henriques as an &#8220;audit</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">116</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">committee financial expert,&#8221; as defined under the applicable rules of the SEC. During the fiscal year ended December 31, 2024, the audit committee met seven times. The audit committee&#8217;s responsibilities include:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">appointing, approving the compensation of, and assessing the independence of our independent registered public accounting firm;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pre-approving auditing and permissible non-audit services, and the terms of such services, to be provided by our independent registered public accounting firm;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reviewing the overall audit plan with our independent registered public accounting firm and members of management responsible for preparing our financial statements;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reviewing and discussing with management and our independent registered public accounting firm our annual and quarterly financial statements and related disclosures as well as critical accounting policies and practices used by us;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">coordinating the oversight and reviewing the adequacy of our internal control over financial reporting;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establishing policies and procedures for the receipt and retention of accounting-related complaints and concerns;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">recommending based upon the audit committee&#8217;s review and discussions with management and our independent registered public accounting firm whether our audited financial statements and our related disclosures under the &#8220;Management&#8217;s Discussion and Analysis&#8221; section shall be included in our 2024 Annual Report;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">monitoring the integrity of our financial statements and our compliance with legal and regulatory requirements as they relate to our financial statements and accounting matters;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">preparing the audit committee report required by SEC rules to be included in our annual proxy statement;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reviewing all related person transactions for potential conflict of interest situations and approving all such transactions;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reviewing quarterly earnings releases; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">discussing the Company&#8217;s risk assessment and management guidelines, including the Company&#8217;s major financial risk exposures, cybersecurity risks and the steps that the Company&#8217;s management has taken to monitor and control such exposures and risks.</span></div></div><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All audit and non-audit services, other than </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">de minimis </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">non-audit services, to be provided to us by our independent registered public accounting firm must be approved in advance by our audit committee.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Compensation Committee</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Richard Henriques, MBA, Mark Simon, MBA and Shawn Tomasello, MBA serve on the compensation committee, which is chaired by Mark Simon, MBA. Our board of directors has determined that each member of the compensation committee is &#8220;independent&#8221; as defined in the applicable Nasdaq rules. During the fiscal year ended December 31, 2024, the compensation committee met four times. The compensation committee&#8217;s responsibilities include:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">annually reviewing and recommending to the board of directors corporate goals and objectives relevant to the compensation of our chief executive officer;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">evaluating the performance of our chief executive officer in light of such corporate goals and objectives and based on such evaluation (i) recommending to the board of directors the cash compensation of our chief executive officer and (ii) reviewing and approving grants and awards to our chief executive officer under equity-based plans;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reviewing and approving the compensation of our other executive officers;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reviewing and establishing our overall management compensation, philosophy, and policy;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">overseeing and administering our compensation and similar plans;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">evaluating and assessing potential and current compensation advisors in accordance with the independence standards identified in the applicable Nasdaq rules;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reviewing and making recommendations to our board of directors about our policies and procedures for the grant of equity-based awards;</span></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">117</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">preparing the compensation committee report required by SEC rules, if and when required, to be included in our annual proxy statement;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reviewing and discussing annually with management our &#8220;Compensation Discussion and Analysis,&#8221; if and when required, to be included in our annual proxy statement; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reviewing and approving the retention or termination of any consulting firm or outside advisor to assist in the evaluation of compensation matters.</span></div></div><p style="text-indent:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Nominating and Corporate Governance Committee</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Catherine Bollard, MBChB, M.D., Scott Brun, M.D., and Mark Simon, MBA, serve on the nominating and corporate governance committee, which is chaired by Scott Brun, M.D. Our board of directors has determined that each member of the nominating and corporate governance committee is &#8220;independent&#8221; as defined in the applicable Nasdaq rules. During the fiscal year ended December 31, 2024, the nominating and corporate governance committee met two times. The nominating and corporate governance committee&#8217;s responsibilities include:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">developing and recommending to the board of directors criteria for board and committee membership;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establishing procedures for identifying and evaluating board of director candidates, including nominees recommended by stockholders;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reviewing the composition of the board of directors to ensure that it is composed of members containing the appropriate skills and expertise to advise us;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">identifying individuals qualified to become members of the board of directors;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">recommending to the board of directors the persons to be nominated for election as directors and to each of the board&#8217;s committees;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reviewing and discussing with the board of directors corporate succession plans for our chief executive officer and other key officers;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">developing and recommending to the board of directors a code of business conduct and ethics and a set of corporate governance guidelines; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">overseeing the evaluation of our board of directors.</span></div></div><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The nominating and corporate governance committee considers candidates for board of directors membership suggested by its members and the chief executive officer. Additionally, in selecting nominees for directors, the nominating and corporate governance committee will review candidates recommended by stockholders in the same manner and using the same general criteria as candidates recruited by the committee and/or recommended by our board of directors. Any stockholder who wishes to recommend a candidate for consideration by the committee as a nominee for director should follow the procedures described in our proxy statement under the heading &#8220;Stockholder Proposals.&#8221; The nominating and corporate governance committee will also consider whether to nominate any person proposed by a stockholder in accordance with the provisions of our bylaws relating to stockholder nominations as described in our proxy statement under the heading &#8220;Stockholder Proposals.&#8221;</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Identifying and Evaluating Director Nominees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Our board of directors is responsible for filling vacancies on our board of directors and for nominating candidates for election by our stockholders each year in the class of directors whose term expires at the relevant annual meeting. The board of directors delegates the selection and nomination process to the nominating and corporate governance committee, with the expectation that other members of the board of directors, and of management, will be requested to take part in the process as appropriate.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Generally, the nominating and corporate governance committee identifies candidates for director nominees in consultation with management, through the recommendations submitted by stockholders or through such other methods as the nominating and corporate governance committee deems to be helpful to identify candidates. Once candidates have been identified, the nominating and corporate governance committee confirms that the candidates meet all of the minimum qualifications for director nominees established by the nominating and corporate governance committee. The nominating and corporate governance committee may gather information about the candidates through interviews, detailed questionnaires, comprehensive background checks or any other means that the nominating and corporate governance committee deems to be appropriate in the evaluation process. The nominating and corporate governance committee then meets as a group to discuss and evaluate the qualities and skills of each candidate, both</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">118</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">on an individual basis and taking into account the overall composition and needs of our board of directors. Based on the results of the evaluation process, the nominating and corporate governance committee recommends candidates for the board of directors&#8217; approval to fill a vacancy or as director nominees for election to the board of directors by our stockholders each year in the class of directors whose term expires at the relevant annual meeting.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Science and Technology Committee</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Catherine Bollard, MBChB, M.D., Scott Brun, M.D., and Shawn Tomasello, MBA, serve on the science and technology committee, which is chaired by Catherine Bollard, MBChB, M.D. The science and technology committee supports Board oversight of the Company&#8217;s research and development, manufacturing and supply activities, by providing a forum for review of strategic considerations and issues in such areas, as well as to evaluate relevant emerging technology and advances in the field. The science and technology committee was formed in July 2023 and held four meetings in during the fiscal year ended December 31, 2024.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Code of Business Conduct and Ethics</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have adopted a written code of business conduct and ethics that applies to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. A current copy of the code is posted on the corporate governance section of our website, which is located at </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">www.cabalettabio.com/investors/corporate-governance/governance-documents</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If we make any substantive amendments to, or grant any waivers from, the code of business conduct and ethics for any officer or director, we will disclose the nature of such amendment or waiver on our website or in a current report on Form 8-K.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Insider Trading Policies and Procedures</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a63e2146-4b8f-4855-aa3f-311dd2cd2642" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> an insider trading policy that governs the purchase, sale, and/or other transactions of our securities by our directors, officers, employees and designated consultants that we believe is reasonably designed to promote compliance with applicable insider trading laws, rules and regulations, and listing standards applicable to us. A copy of our insider trading policy is filed as Exhibit 19.1 to this Annual Report on Form 10-K for the fiscal year ended December 31, 2024. In addition, with regard to trading in our own securities, it is our policy to comply with the federal securities laws and the applicable exchange listing requirements.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our insider trading policy prohibits our directors, officers, employees and certain designated consultants, and their affiliated persons, from trading in company securities while in possession of material nonpublic information about our company. The policy also prohibits tipping (i.e., disclosing material nonpublic information about our company to others who may trade of the basis of that information). Under our insider trading policy, designated insiders may only trade in company securities at a time when they do not possess material nonpublic information about our company. We also require our directors, officers and certain other employees to receive approval before trading in company securities. Our insider trading policy also expressly prohibits short sales; purchases or sales of puts, calls, or other derivative securities or hedging transactions; using company securities as collateral in a margin account; or pledging company securities as collateral for a loan. Any waiver of the provisions of this policy requires the approval of our Audit Committee. To date, no such requests have been made or approved. We have also adopted an additional policy that governs adoption, modification and termination of written securities trading plans, known as Rule 10b5-1 plans, by our directors, executive officers and certain other persons. Our policy provides that all Rule 10b5-1 plans must comply with SEC rules applicable to the Rule 10b5-1 safe harbor and imposes additional requirements and limitations.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">119</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="item_11_executive_compensation_1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 11. Executiv</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">e Compensation.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our named executive officers for the year ended December 31, 2024 are:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Steven Nichtberger, M.D., our President and Chief Executive Officer;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Gwendolyn Binder, Ph.D., our President, Science and Technology; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">David J. Chang, M.D., M.P.H., our Chief Medical Officer.</span></div></div><p style="text-indent:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2024 Summary Compensation Table</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents the compensation awarded to, earned by or paid to each of our named executive officers for the years indicated. Dr. Nichtberger also serves as a member of our board of directors but does not receive any additional compensation for his service as a director.</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:24.85%;box-sizing:content-box;"/>
     <td style="width:1.579%;box-sizing:content-box;"/>
     <td style="width:4.058%;box-sizing:content-box;"/>
     <td style="width:1.579%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6.417%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.579%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.857%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.579%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.995%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.996%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:14.513%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Salary ($)</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Option Awards<br/>($)(1)</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Non-Equity<br/>Incentive Plan<br/>Compensation<br/>($)(2)</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">All Other<br/>Compensation<br/>($)(3)</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total ($)</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Steven Nichtberger, M.D.</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">646,328</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,008,417</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">428,157</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,045</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,096,947</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">President and Chief Executive Officer</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">597,417</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,784,529</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">412,288</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,045</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,808,279</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gwendolyn K. Binder, Ph.D.</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">529,687</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,581,003</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">246,869</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,357,559</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">President, Science and Technology</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">477,417</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,618,263</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">245,203</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,340,883</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">David J. Chang, M.D., M.P.H.</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">496,833</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,581,003</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">268,290</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,346,126</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Chief Medical Officer</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">476,910</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,379,202</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">244,940</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,101,052</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) Amounts reflect the grant date fair value of option awards granted in 2024 and 2023 in accordance with the Financial Accounting Standards Board&#8217;s Accounting Standards Codification Topic 718, or ASC 718. Such grant date fair value does not take into account any estimated forfeitures related to service-vesting conditions. For information regarding assumptions underlying the valuation of equity awards, see Note 10 to our financial statements for the year ended December 31, 2024. These amounts do not correspond to the actual value that may be recognized by the named executive officers upon vesting of applicable awards.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2) The amounts represent bonuses earned in 2024 and 2023 and paid in 2025 and 2024, respectively, pursuant to the Company&#8217;s cash incentive plan based on the factors described under &#8220;Non-Equity Incentive Plan Compensation&#8221; below.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(3) Amount includes reimbursements for life insurance premiums.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Narrative to 2024 Summary Compensation Table</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors and compensation committee review compensation annually for our chief executive officer and his direct reports. In setting executive base salaries and bonuses, and granting equity incentive awards, our board of directors considers compensation for comparable positions in the market, the historical compensation levels of our executives, individual performance as compared to our expectations and objectives, our desire to motivate our employees to achieve short-and long-term results that are in the best interests of our stockholders, and a long-term commitment to our company. We target a general competitive position, based on independent third-party benchmark analytics to inform the mix of compensation of base salary, bonus or long-term incentives.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors has historically determined our executives&#8217; compensation. Our compensation committee typically reviews and discusses management&#8217;s proposed compensation with the chief executive officer for all of his direct reports. Based on those discussions and its discretion, taking into account the factors noted above, the compensation committee determines the compensation for each executive officer other than the chief executive officer. Our board of directors discusses the compensation committee&#8217;s recommendations and ultimately approves the compensation of our chief executive officer without the chief executive officer and chief financial officer present. In 2024, the compensation committee continued to retain the services of Radford, an AON Hewitt company, as its external compensation consultant and the board of directors and the compensation committee considered Radford&#8217;s input on certain compensation matters as they deemed appropriate.</span></p><p style="margin-left:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Annual base salary</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each named executive officer&#8217;s base salary is a fixed component of annual compensation for performing specific duties and functions, and has been established by our board of directors taking into account each individual&#8217;s role, responsibilities, skills, and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">120</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">experience. Base salaries for our named executive officers are reviewed annually by our compensation committee, typically in connection with our annual performance review process, and adjusted from time to time, based on the recommendation of the compensation committee, to realign salaries with market levels after taking into account individual responsibilities, performance, and experience. The base salary of each named executive officer in 2024 is noted below:</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:46.96%;box-sizing:content-box;"/>
     <td style="width:2.18%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:24.36%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:2.18%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:20.32%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024 Base Salary through<br/>February 29, 2024</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Base Salary Effective<br/>March 1, 2024</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Steven Nichtberger, M.D.</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">602,200</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">638,300</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gwendolyn K. Binder, Ph.D.</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">480,500</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">500,200</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">David J. Chang, M.D., M.P.H.</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">480,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">500,200</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Non-Equity Incentive Plan Compensation</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Annual cash awards are determined based on company performance, which is assessed based on predetermined annual objectives, and on individual performance. When determining the individual component of our annual incentive awards, the compensation committee considers each executive&#8217;s contributions to the company&#8217;s strategic achievements and financial and operational performance. In addition, the compensation committee considers how each executive demonstrates Cabaletta behaviors.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each of our named executive officers was eligible to receive a bonus with respect to 2024 as a percentage of base salary listed below, modified by company and individual performance.</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:63.327%;box-sizing:content-box;"/>
     <td style="width:3.119%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:31.554000000000002%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024 Target Bonus Rate<br/>(% of base salary)</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Steven Nichtberger, M.D.</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gwendolyn K. Binder, Ph.D.</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">David J. Chang, M.D., M.P.H.</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
   </table><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company performance was assessed as achievement of 2024 company objectives, including certain clinical development, business development and financial and operational goals and development of a strong team culture. As a result, the compensation committee recommended and our board of directors approved 2024 company achievement at 108%.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The compensation committee recommended (and/or approved) and the board of directors approved (as applicable, in the instance of the chief executive officer), a further adjustment of bonuses based on the individual achievement of each of the named executive officers, as noted below:</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:60.4%;box-sizing:content-box;"/>
     <td style="width:2.94%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:34.660000000000004%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Individual<br/>Achievement (%)</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Steven Nichtberger, M.D.</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">114</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gwendolyn K. Binder, Ph.D.</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">115</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">David J. Chang, M.D., M.P.H.</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Long-term equity incentives</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our equity grant program is intended to align the interests of our named executive officers with those of our stockholders and to motivate them to make important contributions to our performance. In 2024, we granted stock options to each of our named executive officers, as reflected in the &#8220;Outstanding Equity Awards at 2024 Fiscal Year End Table&#8221; below.</span></p><p style="margin-left:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Employment arrangements with our named executive officers</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2019, we entered into amended and restated employment agreements with each of our named executive officers. Each of our named executive officers is employed at will.</span></p><p style="margin-left:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Steven Nichtberger, M.D.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under his amended and restated employment agreement, Dr. Nichtberger is entitled to an annual base salary, which is subject to review and redetermination by our board of directors or our compensation committee, and he is eligible to receive an annual bonus determined by our board of directors or the compensation committee (subject to the terms of any applicable incentive compensation plan that may be in effect from time to time), with a target amount calculated as a percentage of his annual base salary. Dr.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">121</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nichtberger is also eligible to participate in the employee benefit plans available to our employees, subject to the terms of those plans, and is reimbursed for his existing, personal life insurance policy premiums.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dr. Nichtberger&#8217;s employment agreement provides that, in the event that his employment is terminated by us without &#8220;cause&#8221; or by him for &#8220;good reason,&#8221; then subject to the execution and effectiveness of a separation agreement and release and compliance with his continuing obligations, he will be entitled to receive (i) an amount equal to (x) 12 months of base salary payable on our normal payroll cycle if such termination occurs outside of the period commencing 60 days before and ending 12 months after the occurrence of the first event constituting a &#8220;change in control&#8221;, or the Change in Control Period, or (y) 1.5 times the sum of his base salary plus his target bonus for the then-current year payable on our or our successor&#8217;s normal payroll cycle over 18 months if such termination occurs within Change in Control Period; (ii) payment of the monthly employer COBRA premium for the same level of group health coverage as in effect for Dr. Nichtberger on the date of termination for up to (x) 12 months if such termination occurs outside of the Change in Control Period, and (y) 18 months if such termination occurs within the Change in Control Period; and (iii) full acceleration of all stock options and other stock-based awards held by Dr. Nichtberger if such termination occurs within the Change in Control Period. In addition to standard good reason triggers, Dr. Nichtberger may elect to resign for good reason if within six months following the appointment of a chairperson of the board of directors, Dr. Nichtberger provides written notice of his reasonable dissatisfaction with such chairperson and the board fails to designate a new chairperson within 30 days of such notice. In the event of such a resignation for good reason outside of the Change in Control Period, subject to the execution and effectiveness of a separation agreement and release and compliance with his continuing obligations, in addition to the severance benefits described above, all stock options and other stock-based awards held by Dr. Nichtberger will accelerate and become fully exercisable or nonforfeitable.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The payments and benefits provided to Dr. Nichtberger under his employment agreement in connection with a sale event may not be eligible for a federal income tax deduction for the company pursuant to Section 280G of the Code. These payments and benefits also may be subject to an excise tax under Section 4999 of the Code. If the payments or benefits payable to Dr. Nichtberger in connection with a sale event would be subject to the excise tax on golden parachutes imposed under Section 4999 of the Code, then those payments or benefits will be reduced if such reduction would result in a higher net after tax benefit to Dr. Nichtberger.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, Dr. Nichtberger has entered into a non-competition, non-solicitation, confidentiality and assignment agreement with us that contains, among other things, non-competition and non-solicitation provisions that apply during the term of Dr. Nichtberger&#8217;s employment and for 12 months thereafter.</span></p><p style="margin-left:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Gwendolyn K. Binder, Ph.D.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under her amended and restated employment agreement, Dr. Binder is entitled to an annual base salary, which is subject to review and redetermination by our board of directors or our compensation committee, and she is eligible to earn an annual bonus with a target amount calculated as a percentage of her base salary. Dr. Binder is also eligible to participate in the employee benefit plans available to our employees, subject to the terms of those plans.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dr. Binder&#8217;s employment agreement provides that, in the event that her employment is terminated by us without &#8220;cause&#8221; or by her for &#8220;good reason,&#8221; then subject to the execution and effectiveness of a separation agreement and release and compliance with her continuing obligations, she will be entitled to receive (i) an amount equal to (x) nine months of base salary payable on our normal payroll cycle if such termination occurs outside of the Change in Control Period or (y) a lump sum in cash in the amount of 1.0 times the sum of her base salary plus her target bonus for the then-current year payable on our or our successor&#8217;s normal payroll cycle over 12 months if such termination is occurs within the Change in Control Period; (ii) payment of the monthly employer COBRA premium for the same level of group health coverage as in effect for Dr. Binder on the date of termination up to (x) nine months if such termination occurs outside of the Change in Control Period, and (y) 12 months if such termination occurs within the Change in Control Period; and (iii) full acceleration of all stock options and other stock-based awards subject to time-based vesting held by Dr. Binder if such termination occurs within the Change in Control Period.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The payments and benefits provided to Dr. Binder under her employment agreement in connection with a sale event may not be eligible for a federal income tax deduction for the company pursuant to Section 280G of the Code. These payments and benefits also may be subject to an excise tax under Section 4999 of the Code. If the payments or benefits payable to Dr. Binder in connection with a sale event would be subject to the excise tax on golden parachutes imposed under Section 4999 of the Code, then those payments or benefits will be reduced if such reduction would result in a higher net after-tax benefit to such officer.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, Dr. Binder has entered into a non-competition, non-solicitation, confidentiality and assignment agreement with us that contains, among other things, non-competition and non-solicitation provisions that apply during the term of Dr. Binder&#8217;s employment and for 12 months thereafter.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">122</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="margin-left:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">David J. Chang, M.D., M.P.H.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under his amended and restated employment agreement, Dr. Chang is entitled to an annual base salary, which is subject to review and redetermination by our board of directors or our compensation committee, and he is eligible to earn an annual bonus with a target amount calculated as a percentage of his base salary. Dr. Chang is also eligible to participate in the employee benefit plans available to our employees, subject to the terms of those plans.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dr. Chang&#8217;s employment agreement provides that, in the event that his employment is terminated by us without &#8220;cause&#8221; or by him for &#8220;good reason,&#8221; then subject to the execution and effectiveness of a separation agreement and release and compliance with his continuing obligations, he will be entitled to receive (i) an amount equal to (x) nine months of base salary payable on our normal payroll cycle if such termination occurs outside of the Change in Control Period or (y) a lump sum in cash in the amount of 1.0 times the sum of his base salary plus his target bonus for the then-current year payable on our or our successor&#8217;s normal payroll cycle over 12 months if such termination occurs within the Change in Control Period; (ii) payment of the monthly employer COBRA premium for the same level of group health coverage as in effect for Dr. Chang on the date of termination up to (x) nine months if such termination occurs outside of the Change in Control Period, and (y) 12 months if such termination occurs outside of the Change in Control Period; and (iii) full acceleration of all stock options and other stock-based awards subject to time-based vesting held by Dr. Chang if such termination occurs within the Change in Control Period.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The payments and benefits provided to Dr. Chang under his employment agreement in connection with a sale event may not be eligible for a federal income tax deduction for the company pursuant to Section 280G of the Code. These payments and benefits also may be subject to an excise tax under Section 4999 of the Code. If the payments or benefits payable to Dr. Chang in connection with a sale event would be subject to the excise tax on golden parachutes imposed under Section 4999 of the Code, then those payments or benefits will be reduced if such reduction would result in a higher net after-tax benefit to such officer.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, Dr. Chang has entered into a non-competition, non-solicitation, confidentiality and assignment agreement with us that contains, among other things, non-competition and non-solicitation provisions that apply during the term of Dr. Chang&#8217;s employment and for 12 months thereafter.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">123</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="margin-left:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Outstanding Equity Awards at 2024 Fiscal Year End Table</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents information regarding all outstanding stock awards and stock options held by each of our named executive officers as of December 31, 2024.</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:27.914%;box-sizing:content-box;"/>
     <td style="width:2.1%;box-sizing:content-box;"/>
     <td style="width:9.938%;box-sizing:content-box;"/>
     <td style="width:2.1%;box-sizing:content-box;"/>
     <td style="width:11.338%;box-sizing:content-box;"/>
     <td style="width:2.1%;box-sizing:content-box;"/>
     <td style="width:8.378%;box-sizing:content-box;"/>
     <td style="width:2.1%;box-sizing:content-box;"/>
     <td style="width:10.118%;box-sizing:content-box;"/>
     <td style="width:2.1%;box-sizing:content-box;"/>
     <td style="width:8.378%;box-sizing:content-box;"/>
     <td style="width:2.1%;box-sizing:content-box;"/>
     <td style="width:11.338%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="7" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Option awards</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="3" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Stock awards</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of Securities Underlying Unexercised Options (#) Exercisable</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of Securities Underlying Unexercised Options (#) Unexercisable</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Option Exercise Price ($)</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Option Expiration Date</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of Shares or Units of Stock that Have Not Vested (#)</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Market Value of Shares or Units of Stock that Have Not Vested ($)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Steven Nichtberger, M.D.</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">186,451<br/>229,677<br/>99,714<br/>300,000<br/>312,656<br/>261,250<br/>180,075<br/>&#8212;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;<br/>&#8212;(1)<br/>&#8212;(2)<br/>&#8212;(3)<br/>20,844(7)<br/>118,750(8)<br/>231,525(9)<br/>353,000(10)</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.01<br/>1.01<br/>11.00<br/>14.94<br/>11.47<br/>3.21<br/>11.09<br/>23.97</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10/28/2028<br/>10/28/2028<br/>10/23/2029<br/>2/28/2030<br/>2/28/2031<br/>1/17/2032<br/>1/17/2033<br/>2/28/2034</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;<br/>&#8212;<br/>&#8212;<br/>&#8212;<br/>&#8212;<br/>&#8212;<br/>&#8212;<br/>&#8212;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;<br/>&#8212;<br/>&#8212;<br/>&#8212;<br/>&#8212;<br/>&#8212;<br/>&#8212;<br/>&#8212;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gwendolyn K. Binder, Ph.D.</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100,756<br/>66,667<br/>29,908<br/>117,188<br/>110,000<br/>77,000<br/>&#8212;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;(4) <br/>&#160;&#8212;(5) <br/>&#160;&#8212;(2) <br/>&#160;7,812(7) <br/>&#160;50,000(8) <br/>&#160;99,000(9) <br/>&#160;130,000(10)</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.01 <br/>&#160;9.54 <br/>&#160;11.00 <br/>&#160;11.47 <br/>&#160;3.21 <br/>&#160;11.09 <br/>&#160;23.97</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10/28/2028<br/>8/21/2029<br/>10/23/2029<br/>2/28/2031<br/>1/17/2032<br/>1/17/2033<br/>2/28/2034</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;<br/>&#8212;<br/>&#8212;<br/>&#8212;<br/>&#8212;<br/>&#8212;<br/>&#8212;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;<br/>&#8212;<br/>&#8212;<br/>&#8212;<br/>&#8212;<br/>&#8212;<br/>&#8212;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">David J. Chang, M.D., M.P.H.</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">185,709<br/>48,836<br/>38,238<br/>106,406<br/>92,813<br/>65,625<br/>&#8212;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;(6)<br/>&#160;&#8212;(2)<br/>&#160;&#8212; (3)<br/>&#160;7,094(7)<br/>&#160;42,187(8) <br/>&#160;84,375(9)<br/>&#160;130,000(10)</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.30 <br/>&#160;11.00 <br/>&#160;14.94 <br/>&#160;11.47 <br/>&#160;3.21 <br/>&#160;11.09 <br/>&#160;23.97</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6/23/2029<br/>10/23/2029<br/>2/28/2030<br/>2/28/2031<br/>1/17/2032<br/>1/17/2033<br/>2/28/2034</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;<br/>&#8212;<br/>&#8212;<br/>&#8212;<br/>&#8212;<br/>&#8212;<br/>&#8212;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;<br/>&#8212;<br/>&#8212;<br/>&#8212;<br/>&#8212;<br/>&#8212;<br/>&#8212;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) These options vest over four years, with 25% vesting on October 11, 2019, and the remaining shares vesting in 36 equal monthly installments thereafter, subject to a continued service relationship with us.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2) These options vest over four years, with 25% vesting on October 24, 2020, and the remaining shares vesting in 12 equal quarterly installments thereafter, subject to a continued service relationship with us.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(3) These options vest over four years, with 25% vesting on March 1, 2021, and the remaining shares vesting in 12 equal quarterly installments thereafter, subject to a continued service relationship with us.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(4) These options vest over four years, with 25% vesting on October 11, 2019 and the remaining shares vesting in 12 equal quarterly installments thereafter, subject to a continued service relationship with us.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(5) These options vest over four years, with 25% vesting on August 22, 2020, and the remaining shares vesting in 12 equal quarterly installments thereafter, subject to a continued service relationship with us.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(6) These options vest over four years, with 25% vesting on June 17, 2020, and the remaining shares vesting in 12 equal quarterly installments thereafter, subject to a continued service relationship with us.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(7) These options vest over four years, with 25% vesting on March 1, 2022, and the remaining shares vesting in 12 equal quarterly installments thereafter, subject to a continued service relationship with us.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(8) These options vest over four years, with 25% vesting on January 18, 2023, and the remaining shares vesting in 12 equal quarterly installments thereafter, subject to a continued service relationship with us.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(9) These options vest over four years, with 25% vesting on January 18, 2024, and the remaining shares vesting in 12 equal quarterly installments thereafter, subject to a continued service relationship with us.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(10) These options vest over four years, with 25% vesting on March 1, 2025, and the remaining shares vesting in 12 equal quarterly installments thereafter, subject to a continued service relationship with us.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">124</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="margin-left:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Additional Narrative Disclosure</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">401(k) Savings Plan. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We participate in a retirement savings plan, or 401(k) plan, that is intended to qualify for favorable tax treatment under Section 401(a) of the Code, and contains a cash or deferred feature that is intended to meet the requirements of Section 401(k) of the Code. U.S. employees who are at least 21 years of age are generally eligible to participate in the 401(k) plan, subject to certain criteria. Participants may make pre-tax and certain after-tax (Roth) salary deferral contributions to the plan from their eligible earnings up to the statutorily prescribed annual limit under the Code. Participants who are 50 years of age or older may contribute additional amounts based on the statutory limits for catch-up contributions. Participant contributions are held in trust as required by law. An employee&#8217;s interest in his or her salary deferral contributions is 100% vested when contributed. We have the ability to make discretionary contributions under the plan and all eligible employees will receive a Safe Harbor matching contribution up to 4% of eligible pay for the 2024 plan year.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Health and Welfare Benefits</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. All of our full-time employees, including our executive officers are eligible to participate in certain medical, disability and life insurance benefit programs offered by us. We pay the premiums for term life insurance and long-term disability for all of our employees, including our executive officers. We also provide all employees, including executive officers, with a flexible spending account plan and paid time off benefits including, vacation, sick time and holidays. We do not sponsor any qualified or non-qualified defined benefit plans for any of our employees or executives.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compensation Risk Assessment</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that although a portion of the compensation provided to our executive officers and other employees is performance-based, our executive compensation program does not encourage excessive or unnecessary risk taking. Our compensation programs are designed to encourage our executive officers and other employees to remain focused on both short-term and long-term strategic goals, in particular in connection with our pay-for-performance compensation philosophy. As a result, we do not believe that our compensation programs are reasonably likely to have a material adverse effect on us.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Policy on Trading, Pledging and Hedging of Company Stock</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain transactions in our securities (such as purchases and sales of publicly traded put and call options, and short sales) create a heightened compliance risk or could create the appearance of misalignment between management and stockholders. In addition, securities held in a margin account or pledged as collateral may be sold without consent if the owner fails to meet a margin call or defaults on the loan, thus creating the risk that a sale may occur at a time when an officer or director is aware of material, non-public information or otherwise is not permitted to trade in Company securities. Our insider trading policy expressly prohibits short sales and derivative transactions of our stock by our executive officers, directors, employees and certain designated consultants and contractors, including short sales of our securities. Our insider trading policy expressly prohibits, without the advance approval of our audit committee, purchases or sales of puts, calls, or other derivative securities of the company or any derivative securities that provide the economic equivalent of ownership.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compensation Recovery Policy (Clawback Policy)</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On September 12, 2023, we adopted a Compensation Recovery Policy, or the Clawback Policy, in compliance with the requirements of the Dodd-Frank Act, final SEC rules and applicable Nasdaq listing standards (the &#8220;final clawback rules&#8221;), which covers our current and former executive officers, including all of our named executive officers. Under the Clawback Policy, in the event that we are required to prepare a restatement of our previously issued financial statements due to our material noncompliance with any financial reporting requirement under securities laws, we are required to recover (subject to certain limited exceptions described in the Clawback Policy and permitted under the final clawback rules) any cash or equity incentive-based compensation received by any current or former executive officer after the effective date of the Clawback Policy and in the three years prior to the date we are required to restate our financial statements that is in excess of the amount that would have been received based on the restated financial statements.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compensation Committee Interlocks and Insider Participation</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each of Richard Henriques, Mark Simon and Shawn Tomasello, served on the compensation committee during fiscal year 2024. No member of the compensation committee has ever been an officer or employee of the Company. None of our executive officers serve, or have served during the last fiscal year, as a member of the board of directors, compensation committee, or other</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">125</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">board committee performing equivalent functions of any other entity that has one or more executive officers serving as one of our directors or on our compensation committee.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Policy on the Timing of Awards of Options and Other Option-Like Instruments</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our compensation committee has generally granted annual equity awards, including stock option grants to our named executive officers, in the first quarter of each fiscal year, specifically early March. In addition, new hires receive stock option grants at the time of their hiring. Eligible employees, including our named executive officers, may voluntarily enroll in our Employee Stock Purchase Plan and receive an option to purchase shares at a discount using payroll deductions accumulated during the prior six months, with purchase dates occurring in May and November. During 2024, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_877bf23e-55dc-4a1e-89cd-9099745cca5f" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="ecd:AwardTmgMnpiCnsdrdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our compensation committee did not take into account any material nonpublic information when determining the timing and terms of equity incentive awards,</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_73f84098-89b8-4124-bb62-e35574bda805" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="ecd:MnpiDiscTimedForCompValFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we did not time the disclosure of material nonpublic information for the purpose of affecting the value of executive compensation.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> During 2024, we did not grant stock options to our named executive officers during any period beginning four business days before and ending one business day after the filing or furnishing of a Form 10-Q, 10-K or 8-K that discloses material nonpublic information.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Please see Item 10 for details regarding corporate governance, including the composition of our compensation committee, as required by Regulation S-K 407(e)(4) and (e)(5).</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Director Compensation</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents the total compensation for each person who served as a non-employee member of our board of directors and received compensation for such service during the fiscal year ended December 31, 2024. Other than as set forth in the table and described more fully below, we did not pay any compensation, make any equity awards or non-equity awards to, or pay any other compensation to any of the non-employee members of our board of directors in 2024. We reimburse members of our board of directors for reasonable travel expenses. Dr. Nichtberger, our Chief Executive Officer and President, did not receive any compensation for his service as a member and Chairman of our board of directors in 2024. Dr. Nichtberger&#8217;s compensation for service as an employee for fiscal years 2024 and 2023 is presented in &#8220;Executive Compensation&#8212;2024 Summary Compensation Table.&#8221;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:35.627%;box-sizing:content-box;"/>
     <td style="width:2.04%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:16.283%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.863%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:2.04%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.322%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:2.04%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.782%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fees Earned or<br/>Paid In Cash ($)</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Option Awards (1)(2)</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">All Other Compensation</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total ($)</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Catherine Bollard, MBChB, M.D.</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">181,810</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">241,810</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Scott Brun, M.D.</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">181,810</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">246,810</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Richard Henriques, MBA</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60,500</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">181,810</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">242,310</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Mark Simon, MBA</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,500</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">181,810</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">245,310</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shawn Tomasello, MBA</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">181,810</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">234,810</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) Amount shown reflects the grant date fair value of an option award granted during 2024. The grant date fair value was computed in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718, Compensation&#8212;Stock Compensation, or FASB ASC Topic 718, disregarding the effect of estimated forfeitures related to service-based vesting. See Note 10 to the financial statements in our 2024 Annual Report on Form 10-K regarding assumptions we made in determining the fair value of option awards.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2) As of December 31, 2024, the aggregate number of shares subject to option awards held by our non-employee directors were: Dr. Bollard: 134,428; Dr. Brun: 110,000; Mr. Henriques: 134,428; Mr. Simon: 134,428 and Ms. Tomasello 66,000. As of December 31, 2024, the aggregate number of unvested shares outstanding held by our non-employee directors were: Dr. Bollard: 22,000; Dr. Brun: 22,000; Mr. Henriques: 22,000; Mr. Simon: 22,000 and Ms. Tomasello 47,667.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Amended and Restated Non-Employee Director Compensation Policy</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under our director compensation policy, we pay our non-employee directors a cash retainer for service on the board of directors and for service on each committee on which the director is a member. The chairman of each committee receives a higher retainer for such service. These fees are payable in arrears in four equal quarterly installments on the last day of each quarter, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">that</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the amount of such payment is prorated for any portion of such quarter that the director is not serving on our board of directors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fees paid to non-employee directors for service on the board of directors and for service on each committee of the board of directors on which the director is a member for 2024 are as follows:</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">126</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:56.38%;box-sizing:content-box;"/>
     <td style="width:2.26%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:15.7%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:2.26%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:19.4%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Member Annual<br/>Retainer ($)</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Chairperson Annual<br/>Retainer ($)</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Board of Directors</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Audit Committee</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,500</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Compensation Committee</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,500</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nominating and Corporate Governance Committee</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Science and Technology Committee</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,500</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="text-indent:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2025, we amended our director compensation policy. Accordingly, the fees paid to non-employee directors for service on the board of directors and for service on each committee of the board of directors on which the director is a member for 2025 are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:56.38%;box-sizing:content-box;"/>
     <td style="width:2.26%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:15.7%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:2.26%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:19.4%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Member Annual<br/>Retainer ($)</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Chairperson Annual<br/>Retainer ($)</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Board of Directors</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Audit Committee</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Compensation Committee</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,250</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,500</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nominating and Corporate Governance Committee</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Science and Technology Committee</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,500</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="text-indent:4.658%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also reimburse our non-employee directors for reasonable out-of-pocket expenses incurred in connection with attending our board of director and committee meetings.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, each new non-employee director elected to our board of directors will be granted an initial, one-time award of a stock option to purchase 44,000 shares, which shall vest in equal quarterly installments over a three-year period from the date of vesting commencement, subject to continued service as a director through each such vesting date. In addition, on the date of each annual meeting of stockholders of our company, each non-employee director will receive an annual stock option award of 22,000 shares, which shall vest in full upon the earlier to occur of the first anniversary of the date of grant or the date of the next annual meeting </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">however</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board of directors determines that the circumstances warrant continuation of vesting.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This program is intended to provide a total compensation package that enables us to attract and retain qualified and experienced individuals to serve as directors and to align our directors&#8217; interests with those of our stockholders.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">127</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="item_12_security_ownership_certain_ben_1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 12. Security Ownership of Certain Beneficial Own</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ers and Management and Related Stockholder Matters.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity Compensation Plan Information</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table provides information as of December 31, 2024 regarding shares of common stock that may be issued under our equity compensation plans, consisting of the 2018 Plan, the 2019 Plan and the 2019 Employee Stock Purchase Plan, or the ESPP. We have no equity compensation plans that were not approved by security holders.</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:43.6%;box-sizing:content-box;"/>
     <td style="width:1.26%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:15.04%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.74%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:11%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.26%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:20.1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Plan Category</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of securities<br/>to be issued upon<br/>exercise of outstanding<br/>options, units and rights (#)</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-average<br/>exercise price of<br/>outstanding options,<br/>units and rights ($)</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of securities<br/>remaining available for<br/>future issuance under<br/>&#160;equity compensation plan<br/>(excluding securities<br/>referenced in first column)</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity compensation plans approved by security holders(1)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,231,148(2)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.63</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,693,564(3)(4)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity compensation plans not approved by security holders</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,231,148</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.63</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,693,564</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) Consists of our 2019 Stock Option and Incentive Plan, 2018 Stock Option and Grant Plan, and 2019 Employee Stock Purchase Plan. Following our initial public offering, we have not and will not grant any awards under our 2018 Stock Option and Grant Plan, but all outstanding awards under the 2018 Stock Option and Grant Plan will continue to be governed by their existing terms. The shares of common stock underlying any awards granted under the 2018 Stock Option and Grant Plan or 2019 Stock Option and Incentive Plan that are forfeited, canceled, reacquired by us prior to vesting, satisfied without the issuance of stock, or otherwise terminated (other than by exercise) and the shares of common stock that are withheld upon exercise of a stock option or settlement of such award to cover the exercise price or tax withholding will be added to the shares of common stock available for issuance under the 2019 Stock Option and Incentive Plan.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2) Includes 11,231,148 shares of common stock issuable upon the exercise of outstanding options, of which 1,235,458 are subject to our 2018 Stock Option and Grant Plan and 9,995,690 are subject to our 2019 Stock Option and Incentive Plan.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(3) As of December 31, 2024, there were 1,379,305 shares available for grant under the 2019 Stock Option and Incentive Plan and 314,259 shares available for grants under the 2019 Employee Stock Purchase Plan.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(4) The 2019 Stock Option and Incentive Plan provides that the number of shares reserved and available for issuance under the plan will automatically increase each January 1, beginning on January 1, 2020, by 4% of the outstanding number of shares of our common stock on the immediately preceding December 31. The 2019 Employee Stock Purchase Plan provides that the number of shares reserved and available for issuance will automatically increase each January 1, beginning on January 1, 2020, through January 1, 2029, by the least of 234,229 shares of our common stock, 1% of the outstanding number of shares of our common stock on the immediately preceding December 31, or such lesser number of shares as determined by our compensation committee.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth information, to the extent known by us or ascertainable from public filings, with respect to the beneficial ownership of our common stock as of March 7, 2025 by:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">each of our directors;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">each of our named executive officers;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">all of our directors and executive officers as a group; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">each person, or group of affiliated persons, who is known by us to beneficially own greater-than-5.0% of our common stock.</span></div></div><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The column entitled &#8220;Shares Beneficially Owned&#8221; is based on a total of 50,743,101 shares of our common stock outstanding as of March 7, 2025.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Beneficial ownership is determined in accordance with the rules and regulations of the SEC and includes voting or investment power with respect to our common stock. Shares of our common stock subject to options or warrants that are currently exercisable or exercisable within 60 days of March 7, 2025 are considered outstanding and beneficially owned by the person holding the options or warrants for the purpose of calculating the percentage ownership of that person but not for the purpose of calculating the percentage ownership of any other person. Except as otherwise noted, the persons and entities in this table have sole voting and investing power with respect to all of the shares of our common stock beneficially owned by them, subject to community property</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">128</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">laws, where applicable. Except as otherwise indicated in the table below, addresses of named beneficial owners are in care of Cabaletta Bio, Inc., 2929 Arch Street, Suite 600, Philadelphia, Pennsylvania 19104.</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:63.607%;box-sizing:content-box;"/>
     <td style="width:2.04%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:14.257%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:2.559%;box-sizing:content-box;"/>
     <td style="width:15.537%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="5" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares beneficially owned</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name and address of beneficial owner(1)</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Percentage</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">&gt; 5% Stockholders:</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">BlackRock, Inc.(2)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,397,260</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.7%</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Entities Affiliated with Adage Capital Partners, L.P.(3)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,634,475</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.2%</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">T. Rowe Price Investment Management, Inc.(4)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,673,724</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.2%</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Entities affiliated with Prudential Financial, Inc.(5)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,798,863</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.5%</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Bain Capital Life Sciences Opportunities III, LP(6)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,760,888</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.4%</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The Vanguard Group(7)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,553,710</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0%</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Named Executive Officers and Directors:</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Steven Nichtberger, M.D.(8)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,127,350</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.95%</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gwendolyn K. Binder, Ph.D.(9)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">603,831</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.18%</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">David Chang, M.D., M.P.H.(10)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">612,846</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.19%</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Catherine Bollard, MBChB, M.D.(11)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">113,428</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.22%</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Scott Brun, M.D.(12)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.17%</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Richard Henriques, MBA(13)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">112,428</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.22%</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Mark Simon, MBA(14)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">255,572</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.50%</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shawn Tomasello, MBA(15)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,667</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.05%</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">All executive officers and directors as a group (11 persons)(15)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,056,069</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.96%</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* Represents beneficial ownership of less than one percent.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) Unless otherwise indicated, the address for each beneficial owner is c/o Cabaletta Bio, Inc., 2929 Arch Street, Suite 600, Philadelphia, Pennsylvania 19104.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2) The information reported is based on information in a Schedule 13G/A, as filed by BlackRock, Inc. with the SEC on February 5, 2025. In that filing, BlackRock, Inc. reports sole voting power with respect to 3,329,097 shares of common stock and sole dispositive power with respect to 3,397,260 shares, and lists its address as 50 Hudson Yards, New York, New York 10001.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(3) The information is based on a Schedule 13G/A filed with the SEC on November 12, 2024. Consists of 3,036,645 shares of common stock and 597,830 shares of common stock issuable upon the exercise of pre-funded warrants held by Adage Capital Partners, L.P., or ACP. Adage Capital Partners GP, L.L.C., or ACPGP, is the general partner of ACP. Adage Capital Management, L.P., or ACM, is the investment manager of ACP. Adage Capital Advisors, L.L.C., or ACA, is managing member of ACPGP.</span><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adage Capital Partners LLC, or </span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ACPLLC</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, is the general partner of ACM, with respect to the shares of voting common stock directly held by ACP. Robert Atchinson and Phillip Gross are managing members of ACA and ACPGP and are general partners of ACP. Each of ACP, ACPGP, ACA, ACM, Robert Atchinson, and Phillip Gross have shared voting and dispositive power over all of the shares. The ability of the Adage entities to exercise their pre-funded warrants is subject to a beneficial ownership limitation, which prevents the Adage entities from exercising any portion of the warrants to the extent such exercise would result in the Adage entities exceeding a certain percentage of the total number of issued and outstanding shares of our common stock following such exercise. The address for Adage Capital Partners, L.P. is 200 Clarendon Street, 52nd Floor, Boston, Massachusetts 02116.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(4) The information reported is based on information in a Schedule 13G/A, as filed by T. Rowe Price Investment Management, Inc. (Price Investment Management) with the SEC on November 14, 2024. In that filing, T. Rowe Price Investment Management, Inc. (Price Investment Management) reports sole voting power with respect to 3,666,024 shares of common stock and sole dispositive power with respect to 3,673,724 shares, and lists its address as 101 E. Pratt Street, Baltimore, MD 21201.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(5) The information reported is based on information in a Schedule 13G/A, as filed by Prudential Financial, Inc. with the SEC on December 5, 2024. In that filing, Prudential Financial, Inc. reports shared voting and dispositive power over (i) 2,796,053 shares of our common stock, being 2,512,053 shares held through its subsidiary Jennison Associates LLC and 284,000 shares held through its subsidiary PGIM, Inc., and (ii) sole voting and dispositive power over 2,810 shares of our common stock held through its subsidiary PGIM Quantitative Solutions LLC. The address provided for Prudential Financial, Inc. is 751 Broad Street, New Jersey 07102.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(6) The information reported is based on information in a Schedule 13G, as filed by Bain Capital Life Sciences Opportunities III, LP with the SEC on August 22, 2024. In that filing, Bain Capital Life Sciences Opportunities III, LP reports shared voting power and shared dispositive power with respect to 2,760,888 shares of common stock. Bain Capital Life Sciences Investors, LLC, or BCLSI, is the manager of Bain Capital Life Sciences III General Partner, LLC, which is the general partner of Bain Capital Life Sciences Fund III, L.P., which is the sole member of Bain Capital Life Sciences Opportunities III GP, LLC, which is the general partner of Bain Capital Life Sciences Opportunities III, LP. As a result, BCLSI may be deemed to share voting and dispositive power with respect to the securities held by Bain Capital Life Sciences Opportunities III, LP. The address of BCLSI is 200 Clarendon Street, Boston, MA 02116.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">129</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(7) The information reported is based on information in a Schedule 13G/A, as filed by The Vanguard Group with the SEC on November 12, 2024. In that filing, The Vanguard Group reports shared voting power with respect to 31,135 shares of common stock, sole dispositive power with respect to 2,500,994 shares and shared dispositive power with respect to 52,716 shares, and lists its address as 100 Vanguard Blvd., Malvern, PA 19355.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(8) Consists of (i) 986,483 shares of common stock held by Dr. Nichtberger, (ii) 363,000 shares of common stock held by the 2017 Nichtberger Family Trust, or the Trust Shares, and (iii) 1,177,867 shares of common stock underlying options exercisable within 60 days of March 7, 2025. Dr. Nichtberger may be deemed to beneficially own the Trust Shares. Dr. Nichtberger disclaims beneficial ownership of the Trust Shares and this shall not be deemed an admission that he is the beneficial owner of the Trust Shares.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(9) Consists of (i) 20,000 shares of common stock held and (ii) 583,831shares of common stock underlying options exercisable within 60 days of March 7, 2025.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(10) Consists of 612,846 shares of common stock underlying options exercisable within 60 days of March 7, 2025.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(11) Consists of (i) 1,000 shares of common stock held and (ii) 112,428 shares of common stock underlying options exercisable within 60 days of March 7, 2025.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(12) Consists of 88,000 shares of common stock underlying options exercisable within 60 days of March 7, 2025.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(13) Consists of 112,428 shares of common stock underlying options exercisable within 60 days of March 7, 2025.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(14) Consists of (i) 143,144 shares of common stock held and (ii) 112,428 shares of common stock underlying options exercisable within 60 days of March 7, 2025.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(15) Consists of 25,667 shares of common stock underlying options exercisable within 60 days of March 7, 2025.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(16) See notes (7) through (14); also includes an aggregate of (i) 50,000 shares of common stock and (ii) 1,066,947 shares of common stock subject to options exercisable within 60 days of March 7, 2025 held by Anup Marda, our Chief Financial Officer, Michael Gerard, our General Counsel and Secretary, and Arun Das, M.D., our Chief Business Officer.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">130</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="item_13_certain_relationships_related__1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 13. Certain Relationships and Related</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Transactions, and Director Independence.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain Relationships and Transactions</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other than the compensation agreements and other arrangements described under &#8220;Executive compensation&#8221; and &#8220;Director compensation&#8221; in this Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and the transactions described below, since January 1, 2023, there has not been and there is not currently proposed, any transaction or series of similar transactions to which we were, or will be, a party in which the amount involved exceeded, or will exceed, $120,000 (or, if less, 1% of the average of our total assets amounts at December 31, 2023 and 2024) and in which any director, executive officer, holder of five percent or more of any class of our capital stock or any member of the immediate family of, or entities affiliated with, any of the foregoing persons, had, or will have, a direct or indirect material interest.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">May 2023 Offering</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2023, we issued 8,337,500 shares of our common stock at a price of $12.00 per share in connection with an underwritten public offering. Certain existing holders of five percent or more of a class of our capital stock participated in the transaction, as evidenced by the table below.</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:56.38%;box-sizing:content-box;"/>
     <td style="width:2.26%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:15.7%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:2.74%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:18.92%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Greater than Five Percent Holder</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate Common Stock Purchased</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Purchase Price</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adage Capital Partners LP</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">725,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,700,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fred Alger Management Inc</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">400,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,800,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cormorant Global Healthcare Master Fund LP</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">400,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,800,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commodore Capital LP</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">400,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,800,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Limitation of Liability and Indemnification of Officers and Directors</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our certificate of incorporation contains provisions that limit the liability of our directors for monetary damages to the fullest extent permitted by Delaware law. Consequently, our directors will not be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duties as directors, except liability for the following:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any breach of their duty of loyalty to our company or our stockholders;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section 174 of the Delaware General Corporation Law; or</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any transaction from which they derived an improper personal benefit.</span></div></div><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any amendment to, or repeal of, these provisions will not eliminate or reduce the effect of these provisions in respect of any act, omission or claim that occurred or arose prior to that amendment or repeal. If the Delaware General Corporation Law is amended to provide for further limitations on the personal liability of directors of corporations, then the personal liability of our directors will be further limited to the greatest extent permitted by the Delaware General Corporation Law.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we adopted bylaws which provide that we will indemnify, to the fullest extent permitted by law, any person who is or was a party or is threatened to be made a party to any action, suit or proceeding by reason of the fact that he or she is or was one of our directors or officers or is or was serving at our request as a director or officer of another corporation, partnership, joint venture, trust, or other enterprise. Our bylaws provide that we may indemnify to the fullest extent permitted by law any person who is or was a party or is threatened to be made a party to any action, suit, or proceeding by reason of the fact that he or she is or was one of our employees or agents or is or was serving at our request as an employee or agent of another corporation, partnership, joint venture, trust or other enterprise. Our bylaws also provide that we must advance expenses incurred by or on behalf of a director or officer in advance of the final disposition of any action or proceeding, subject to very limited exceptions.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have entered into and in the future plan to enter into agreements to indemnify our directors and executive officers. These agreements, among other things, require us to indemnify these individuals for certain expenses (including attorneys&#8217; fees), judgments, fines and settlement amounts reasonably incurred by such person in any action or proceeding, including any action by or in our right, on account of any services undertaken by such person on behalf of our company or that person&#8217;s status as a member of our board of directors to the maximum extent allowed under Delaware law.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">131</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Related person transaction policy</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors adopted a written related person transaction policy providing that transactions with our directors, officers and holders of five percent or more of our voting securities and their affiliates, each a related person, must be approved by our audit committee. This policy became effective on October 29, 2019, the date our registration statement for our initial public offering became effective. Pursuant to this policy, the audit committee has the primary responsibility for reviewing and approving or disapproving &#8220;related person transactions,&#8221; which are transactions between us and related persons in which the aggregate amount involved exceeds or may be expected to exceed $120,000 and in which a related person has or will have a direct or indirect material interest. For purposes of this policy, a related person is defined as a director, executive officer, nominee for director, or greater than 5% beneficial owner of our common stock, in each case since the beginning of the most recently completed year, and their immediate family members.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As appropriate for the circumstances, the audit committee will review and consider:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the related person&#8217;s interest in the related person transaction;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the approximate dollar amount involved in the related person transaction;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the approximate dollar amount of the related person&#8217;s interest in the transaction without regard to the amount of any profit or loss;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether the transaction was undertaken in the ordinary course of our business;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether the terms of the transaction are no less favorable to us than terms that could have been reached with an unrelated third party;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the purpose of, and the potential benefits to us of, the related-party transaction; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.888408776272181%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any other information regarding the related-party transaction or the related person in the context of the proposed transaction that would be material to investors in light of the circumstances of the particular transaction.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Director Independence</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Applicable Nasdaq rules require a majority of a listed company&#8217;s board of directors to be comprised of independent directors within one year of listing. In addition, the Nasdaq rules require that, subject to specified exceptions, each member of a listed company&#8217;s audit, compensation and nominating and corporate governance committees be independent and that audit committee members also satisfy independence criteria set forth in Rule 10A-3 under the Exchange Act and that compensation committee members satisfy independence criteria set forth in Rule 10C-1 under the Exchange Act. Under applicable Nasdaq rules, a director will only qualify as an &#8220;independent director&#8221; if, in the opinion of the listed company&#8217;s board of directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. In order to be considered independent for purposes of Rule 10A-3, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the board of directors, or any other board committee, accept, directly or indirectly, any consulting, advisory, or other compensatory fee from the listed company or any of its subsidiaries or otherwise be an affiliated person of the listed company or any of its subsidiaries. In addition, in affirmatively determining the independence of any director who will serve on a company&#8217;s compensation committee, Rule 10C-1 under the Exchange Act requires that a company&#8217;s board of directors must consider all factors specifically relevant to determining whether a director has a relationship to such company which is material to that director&#8217;s ability to be independent from management in connection with the duties of a compensation committee member, including: the source of compensation to the director, including any consulting, advisory or other compensatory fee paid by such company to the director, and whether the director is affiliated with the company or any of its subsidiaries or affiliates.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors has determined that all members of the board of directors, except Dr. Nichtberger are independent directors, including for purposes of the rules of Nasdaq and the SEC. In making such independence determination, our board of directors considered the relationships that each non-employee director has with us and all other facts and circumstances that our board of directors deemed relevant in determining their independence, including the beneficial ownership of our capital stock by each non-employee director. In considering the independence of the directors listed above, our board of directors considered the association of our directors with the holders of more than 5% of our common stock. There are no family relationships among any of our directors or executive officers. Dr. Nichtberger is not an independent director under these rules because he is an executive officer of the Company.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">132</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="item_14"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 14. Principal Accountant Fees and Services.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our independent public accounting firm is Ernst &amp; Young, Philadelphia, PA, PCAOB Auditor ID </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1a4349a2-6a23-4691-bc8c-c0c71c3a97bf" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="dei:AuditorFirmId"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">42</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cabaletta incurred the following fees from Ernst &amp; Young for the audit of the financial statements and for other services provided during the years ended December 31, 2024 and 2023.</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:55.6%;box-sizing:content-box;"/>
     <td style="width:2.7%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:16.36%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:2.7%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:18.64%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Audit fees(1)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">646,500</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">830,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Audit-Related fees(2)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax fees(3)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66,950</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">All other fees(4)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total fees</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">713,450</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">895,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) Audit fees consist of fees for the audit of our annual financial statements, the review of our interim financial statements included in our quarterly reports on Form 10-Q, comfort letters and consents.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2) Audit-related fees consist of services that are reasonably related to the performance of the audit or review of our financial statements. There were no such fees incurred in 2024 or 2023.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(3) Tax Fees consist of fees for tax compliance, advice and tax services.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(4) There were no other fees incurred in 2024 or 2023.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Audit Committee Pre-approval Policy and Procedures</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our audit committee has adopted policies and procedures relating to the approval of all audit and non-audit services that are to be performed by our independent registered public accounting firm. This policy provides that we will not engage our independent registered public accounting firm to render audit or non-audit services unless the service is specifically approved in advance by our audit committee or the engagement is entered into pursuant to the pre-approval procedure described below.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, our audit committee may pre-approve specified types of services that are expected to be provided to us by our independent registered public accounting firm during the next 12 months. Any such pre-approval details the particular service or type of services to be provided and is also generally subject to a maximum dollar amount.</span></p><p style="text-indent:4.658%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During our 2024 and 2023 fiscal years, no services were provided to us by Ernst &amp; Young other than in accordance with the pre-approval policies and procedures described above.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.6in;width:7.300000000000001in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.6in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">133</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:center;" id="part_iv"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IV</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="item_15_exhibits_financial_statement_sch"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 15. Exhibits, Consolidated Financ</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ial Statement Schedules.</span></p><p style="text-indent:5.231%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a) The following documents are filed as part of this Annual Report on Form 10-K:</span></p><p style="text-indent:5.231%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) Consolidated Financial Statements:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:92%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Page</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="#report_independent_registered_public_acc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></a></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="#balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Balance Sheets as of December 31, 2024 and 2023</span></a></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="#statements_operations"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Operations and Comprehensive Loss for the Years Ended December 31, 2024 and 2023</span></a></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="#statements_convertible_preferred_stock_s"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Stockholders&#8217; Equity for the Years Ended December 31, 2024 and 2023</span></a></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="#statements_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Cash Flows for the Years Ended December 31, 2024 and 2023</span></a></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="#notes_to_consolidated_statements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.231%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2) Consolidated Financial Statement Schedules:</span></p><p style="text-indent:5.231%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All consolidated financial statement schedules have been omitted because they are not applicable, not required or the information required is shown in the consolidated financial statements or the notes thereto.</span></p><p style="text-indent:5.231%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(3) Exhibits. The exhibits required by Item 601 of Regulation S-K and Item 15(b) of this Annual Report on Form 10-K are listed in the Exhibit Index immediately preceding the signature page of this Annual Report on Form 10-K. The exhibits listed in the Exhibit Index are incorporated by reference herein.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="item_16_form_10_k_summary"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 16. Form 10-K Summary</span></p><p style="text-indent:5.231%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">134</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INDEX TO FINANCIAL STATEMENTS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
     <td style="width:92%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Page</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#report_independent_registered_public_acc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></a></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Balance Sheets as of December 31, 2024 and 2023</span></a></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_operations"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Operations and Comprehensive Loss for the Years Ended December 31, 2024 and 2023</span></a></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_convertible_preferred_stock_s"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Stockholders&#8217; Equity for the Years Ended December 31, 2024 and 2023</span></a></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Cash Flows for the Years Ended December 31, 2024 and 2023</span></a></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_to_consolidated_statements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:center;" id="report_independent_registered_public_acc"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Report of Independent Regist</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ered Public Accounting Firm</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the Stockholders and the Board of Directors of Cabaletta Bio, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bb9d6b21-e8c3-4b04-bc40-2c73be4b6034" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="dei:AuditorOpinionTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Opinion on the Financial Statements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Cabaletta Bio, Inc. (the Company) as of December 31, 2024 and 2023, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity and cash flows for each of the two years in the period ended December 31, 2024, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company's Ability to Continue as a Going Concern</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company has suffered recurring losses from operations and has stated that substantial doubt exists about the Company&#8217;s ability to continue as a going concern. Management's evaluation of the events and conditions and management&#8217;s plans regarding these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis for Opinion</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Critical Audit Matter</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the account or disclosures to which it relates.</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:14.16%;box-sizing:content-box;"/>
     <td style="width:2.64%;box-sizing:content-box;"/>
     <td style="width:83.2%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;margin-right:0.04861111111111111in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Accounting for Accrued Clinical Trial Expenses</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Description of the Matter</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;margin-right:0.04861111111111111in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;margin-right:0.04861111111111111in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">As disclosed in Note 2 to the consolidated financial statements, the Company expenses research and development costs as incurred, which include costs relating to clinical trial activities. The Company&#8217;s accrued clinical trial expenses are based on factors such as estimates of the work completed in accordance with agreements established with a contract research organization. As disclosed in Note 5 to the consolidated financial statements, the Company&#8217;s total accrued expenses and other current liabilities related to research and development costs were $3.5 million at December 31, 2024, which included the estimated clinical trial expenses incurred as of December 31, 2024 but not paid as of that date.</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;margin-right:0.04861111111111111in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Auditing the Company&#8217;s accrued clinical trial expenses required subjective auditor judgement due to the estimation required by management in determining the services provided but not yet invoiced. Specifically, the amount of accrued clinical trial expenses recognized is sensitive to the availability of information to make the estimate, including the estimate of the period over which services will be performed, the associated cost of such services, and the level of services performed and progress in the period for which the Company has not yet received an invoice.</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">How We Addressed the Matter in Our Audit</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;margin-right:0.04861111111111111in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;margin-right:0.04861111111111111in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">To test the accrued clinical trial expenses our audit procedures included, among others, reviewing a sample of agreements with the service providers to corroborate key financial and contractual terms, and testing the accuracy and completeness of the underlying data used in the accrual expense computations. We also evaluated management&#8217;s estimates of the progress of a sample of clinical trial activities by making inquiries of the Company&#8217;s operations personnel that oversee the clinical trials and confirming information directly with the contract research organization. To evaluate the completeness of the accruals, we also examined subsequent invoices from the service providers and cash disbursements to the service providers, to the extent such invoices were received, or payments were made prior to the date that the consolidated financial statements were issued.</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> /s/ </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_208eb534-e79b-40b2-9936-2511afd95abf" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="dei:AuditorName"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ernst &amp; Young LLP</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We have served as the Company&#8217;s auditor since 2018.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fbe5128a-952a-4f88-ad26-ffa8e1c9e2b3" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="dei:AuditorLocation"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Philadelphia, Pennsylvania</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CABALETTA BIO, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="balance_sheets"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Balance </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sheets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands, except share and per share amounts)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:64.953%;box-sizing:content-box;"/>
     <td style="width:1.72%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:13.803%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.72%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:13.803%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current assets:</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d18dcd8-7992-4cb3-8e21-8eeee0d7e80d" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">163,962</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a60002a-fb91-4a1c-8e10-c42459d2f59f" contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">193,238</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term investments</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_823ff595-570b-42a1-9bec-43e81d093a56" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7646a108-d293-42d5-9d12-d992fd17d71b" contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">48,011</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_233f7aa9-0102-4ba8-9ec3-5c66dba02850" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,713</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b1feafb3-b46b-4756-8d34-3fcf710ea647" contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,241</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4bd3fbf9-9445-4755-aa15-2cc3e042ee75" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">166,675</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0455c4eb-fb23-4bd5-9723-a9eb218bfc07" contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">244,490</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1edd3ebb-b378-4439-99df-0f8edd240d5d" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,743</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_54b727fb-f68e-4b1e-bbdc-29a3e21f8f8c" contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,541</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Finance lease right-of-use assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e8cce044-ee24-416e-bb06-fefdb71dccc8" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="us-gaap:FinanceLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,020</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6bc608b-7425-44b2-a266-51b2412a08ca" contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc" name="us-gaap:FinanceLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e8dbf2b9-ca1f-48a8-a335-b3873f24131c" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,315</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1fdf4af6-5aa2-4937-b6a8-f685ea84b4eb" contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,910</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_02d7487a-aa75-4bae-93e9-2b50816273e2" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,293</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a7743452-fa8b-4836-94b3-79179f0daef4" contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,709</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total Assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eb928439-31ec-45a5-b85c-48ee6765e7ca" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">185,046</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_837b5261-1c85-41e4-ae87-0ecd82d9db24" contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">253,650</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Liabilities and stockholders&#8217; equity</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current liabilities:</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_867a5134-5a40-46cf-a5a9-ad44c024275b" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,923</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2edd427-5239-4139-806c-e452060da1f1" contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,547</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued and other current liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e687d651-3df5-4ad3-9a5d-9fd068618c56" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="caba:AccruedLiabilitiesAndOtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,188</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bb01d3ba-4c92-4f1b-95c6-07528f9754e3" contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc" name="caba:AccruedLiabilitiesAndOtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,887</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Finance lease liabilities, current portion</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e01e0c6-2e93-4538-b566-aa28a23e78c7" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="us-gaap:FinanceLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,989</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_614c7eee-4b21-4198-a7f1-4eca1eb688ce" contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc" name="us-gaap:FinanceLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities, current portion</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cbbf2ff3-e9a3-4559-8058-f6b06c6915be" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,986</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_662496ef-ae6f-4028-ab8f-aab5b6099e21" contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,560</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c6d2af0-0b54-4a2f-a980-402692d90be6" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,086</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4256d3cd-7c17-41d6-84ac-bdfebe4cedf1" contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,994</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Finance lease liabilities, net of current portion</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f2121fb6-7e8d-43d9-bbdf-effaa8cb5a32" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="us-gaap:FinanceLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,241</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c2b5de20-6322-4aa6-b074-dc881ac6b76b" contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc" name="us-gaap:FinanceLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities, net of current portion</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d9de347-7a5c-4798-a78c-df388f693632" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,384</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_688fbcd7-1eb9-4cba-9f8f-1dccad74a307" contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,458</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total Liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c438a3b9-3dcb-48f0-9fd3-109da98fd5a4" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,711</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d706ca5-cf37-4465-a189-65931d683bcd" contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,452</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_4ab01a83-cec0-465d-abc1-ee74933546db;"><span style="-sec-ix-hidden:F_9b348112-6fc9-49be-b4f8-a3dfc1834bd8;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commitments and contingencies (see Notes 6 and 7)</span></span></span></span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stockholders&#8217; equity:</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Preferred stock, $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eaf1ab88-c146-481e-a0db-cb364a0180d8" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_c7ede224-15e8-4168-b911-59c1205f8201" contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.00001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;par value: </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ec1225c-4716-4f3e-8242-a7bc73c9a489" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_33c6ed8f-aa62-4ae5-b66e-f11d554c0964" contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares authorized as of<br/>&#160;&#160;&#160;December 31, 2024 and December 31, 2023; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_834bea8d-1fbf-44b4-a503-540540e3d387" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_891774c2-6815-4d5a-9d25-bad03712d8b7" contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_e07c90a1-6043-44f1-b781-3c0684be9ba1" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_cc6ebf22-986e-43b9-9f15-9cbc1b05b05c" contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares issued or<br/>&#160;&#160;&#160;outstanding at December 31, 2024 and December 31, 2023</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de783f55-0cbc-48b9-a179-0ba2d0d266b7" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e0d51eea-1094-4443-b1ea-d34159fb8593" contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;Voting and non-voting common stock, $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba656154-bffb-49f9-af74-3a4a8fa27293" contextRef="C_12b0a7be-84f3-45d4-9d6e-95533e750a7a" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_fcd8f34a-d1dd-4bf1-8d26-c837c6af36c0" contextRef="C_343f9e90-d9f0-4ab3-ab0c-3a31e1b64b95" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_1ba98680-e884-44b3-a2cc-70e9d3318e8e" contextRef="C_8ca5d37c-2521-42fc-9e13-1ef37fce3df9" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_bb566eff-c175-4913-9d1d-928a43fcd663" contextRef="C_e718fe30-2e2a-42ee-8ebb-122b140ad979" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.00001</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;par value: </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f9940e3-d42e-4bf4-89f2-925e2397ab64" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_3012b919-41f6-4c4e-9b7e-c968e7fe8d8f" contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">150,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br/>&#160;&#160;(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce27ce6e-9146-4e47-803e-b120bd94c458" contextRef="C_12b0a7be-84f3-45d4-9d6e-95533e750a7a" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_93387c18-0325-4e99-95fe-9291ce54d5f2" contextRef="C_343f9e90-d9f0-4ab3-ab0c-3a31e1b64b95" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">143,590,481</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;voting and </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9eb1ac3c-82dc-4ce5-a49a-2695299c01d8" contextRef="C_8ca5d37c-2521-42fc-9e13-1ef37fce3df9" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_828c177e-4ac6-41aa-b1ce-5a1198c584d8" contextRef="C_e718fe30-2e2a-42ee-8ebb-122b140ad979" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,409,519</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;non-voting) shares authorized as of<br/>&#160;&#160;December 31, 2024 and December 31, 2023; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_14abca75-1b79-4591-a0aa-e38eac27e018" contextRef="C_12b0a7be-84f3-45d4-9d6e-95533e750a7a" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_83f08ddd-3a30-49fc-b5f2-d66d2bb5683e" contextRef="C_12b0a7be-84f3-45d4-9d6e-95533e750a7a" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">50,743,101</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;voting shares<br/>&#160;&#160;issued and outstanding as of December 31, 2024 and </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f5dbffe-8d46-4cb0-b519-d1f1753eaf24" contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_f195616c-fab6-4437-9076-3a07ab90fcaa" contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">47,823,232</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br/>&#160;&#160;(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c71affeb-7e1c-4d83-9f41-f0bce049a963" contextRef="C_343f9e90-d9f0-4ab3-ab0c-3a31e1b64b95" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_ae2b10f3-8405-4fcb-b8cf-402bd69f1679" contextRef="C_343f9e90-d9f0-4ab3-ab0c-3a31e1b64b95" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">46,378,937</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;voting and </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c3e4856c-e4fb-471e-961c-b770b8ff8f34" contextRef="C_e718fe30-2e2a-42ee-8ebb-122b140ad979" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_97ce7c3a-8b3e-4a71-a713-a434200e5639" contextRef="C_e718fe30-2e2a-42ee-8ebb-122b140ad979" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,444,295</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;non-voting) shares issued and<br/>&#160;&#160;outstanding as of December 31, 2023</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dda8b8cf-6666-43af-acae-ae877c785de4" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bed362f5-edf4-4485-9d6c-476f1cc1ebda" contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additional paid-in capital</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e761569-95fb-4dcb-bc08-259242249e71" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">501,435</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_817ef410-1391-4eaa-8169-302654c00eac" contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">469,396</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated other comprehensive income</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd017419-77fa-41ed-81fc-ec2501de9ac2" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_99f0066f-942f-4404-8c3d-921e9b900b17" contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated deficit</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e46f479-7df3-434c-b9d6-a6be526a182c" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">349,101</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_635f785a-78a4-4f74-b92f-ee57c30ba1c2" contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">233,237</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stockholders&#8217; equity</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c00cfae-bda5-4e52-97cf-b24b1a279e24" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">152,335</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd625fcf-2ae1-4dce-9b13-366c51b9a25e" contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">236,198</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities and stockholders&#8217; equity</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_931b0b4b-31ff-40c4-a892-c21c04cd9d68" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">185,046</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae2a3850-ca73-49b0-a573-0f1e527c1424" contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">253,650</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CABALETTA BIO, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_operations"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Statements of</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Operations and Comprehensive Loss</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands, except share and per share amounts)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:62.727%;box-sizing:content-box;"/>
     <td style="width:1.84%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:14.797%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.84%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:14.797%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2fc44488-5ead-424a-bde3-fd4349187e42" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">97,203</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1f3d2031-2716-46b3-8cd6-af41b3f14ba7" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">55,424</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_27d030b2-c23f-4854-aeb4-4e3c15c4469c" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,938</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9b7537b2-e4c3-406a-b0e4-4e84a66e4508" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,236</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f01b08f7-bd73-4898-b270-42143c65ebbf" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">125,141</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b728b479-e25d-48b7-b8e5-7de578d090d9" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">74,660</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df27dc50-4018-4e89-8c06-a257cd887d18" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">125,141</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5fa606ca-2a45-43b7-97cf-3a48548976dd" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">74,660</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income:</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6cf9ab91-3467-4ee5-8230-efdbaa632bc1" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,025</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bf10ba34-7e8c-42d8-be30-f859486d3f67" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,985</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ae90abe-ba1c-437a-8e72-16773144758c" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">748</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7059d7de-f1d4-4d6c-a9c0-aa8982131015" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_60245f9e-0eb8-4e52-8fa0-7ac1ddc46523" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">115,864</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_be350781-4599-4f69-9ad0-b061bae12e5d" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">67,675</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other comprehensive income:</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net unrealized (loss) gain on available-for-sale investments, net of tax</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_43ff0736-f4ea-4ea0-884a-cc141ef2e79c" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">39</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89e757bd-90ed-4189-987e-e6b438f3f912" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">86</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net comprehensive loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ef9874d-70da-4394-b7ec-ca3ecb7a6853" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">115,903</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d577544-a800-4fe3-be36-25a405d7a579" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">67,589</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share of voting and non-voting common stock, basic and diluted</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ec292cf2-8968-4efb-b9f1-e624e6b151ee" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_01224b6b-00fe-44b1-839f-21f812c79e50" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">2.34</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_08846307-4416-4596-8b37-311bf289f09c" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_1751971f-1a53-42b3-8644-c356f8505343" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.65</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CABALETTA BIO, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_convertible_preferred_stock_s"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Statements of </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stockholders&#8217; Equity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands, except share and per share amounts)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:30.006%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:11.002%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6.021000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.002%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.002%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.002%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8.962%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common Stock</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Additional<br/>Paid-in Capital</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated Other Comprehensive Income (Loss)</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated Deficit</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total<br/>Stockholders&#8217; Equity</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance&#8212;December 31, 2022</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_57b282fd-7581-490a-b1e5-b4d4ce96d7f1" contextRef="C_4a78e058-f9de-403c-bcb2-4c5d292bf4a9" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">29,445,134</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e0e9fc1-3c9e-40ed-ad39-54464d770a1e" contextRef="C_2dcaa877-5c12-4f55-882d-3d8601e906a2" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">270,129</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70057957-4c4a-4eb4-ba46-972f8a178865" contextRef="C_9adfe3c2-df06-47b1-8164-ee5bca829cf8" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">47</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3c3c87d-2fb8-4687-9121-362a4b58914a" contextRef="C_fdc47b6b-c242-47bb-af45-4daed72aa461" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">165,562</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5fcb77f6-7c62-4647-8889-fe1df28bbc91" contextRef="C_2c83b4bd-a25b-4fdd-8a75-b19f7b147a93" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">104,520</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b1ff1be-0dd3-42a1-bdd3-c12feb0e1628" contextRef="C_c8879ca3-eb41-45e9-90ca-a45d8a858386" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,343</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_29626de9-a0da-4eb5-8e51-61fa2eb4c09a" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,343</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock, net of issuance costs of $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c11c5a1-2575-4d43-8f9d-2e9082679e36" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,647</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d202342d-a91b-4ea0-bb1c-2d71d98f0543" contextRef="C_19532afe-5faa-47b1-a0ce-01e2a372f9f0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">13,098,399</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d9add11f-ddef-4d84-8247-428fa8d70c49" contextRef="C_c8879ca3-eb41-45e9-90ca-a45d8a858386" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">185,495</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_07220731-061c-47e2-8bf0-4bfe6511ea42" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">185,495</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock in connection with exercise of stock options</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_022a1743-56c9-47da-a79a-69cd80a48851" contextRef="C_19532afe-5faa-47b1-a0ce-01e2a372f9f0" name="caba:StockIssuedDuringPeriodShareStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">489,672</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_25c4928b-f0ff-4db6-8ac0-e22bc0de96a2" contextRef="C_c8879ca3-eb41-45e9-90ca-a45d8a858386" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,321</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fa2f6986-b177-4963-8c7c-23044cd54783" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,321</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock under employee stock purchase plan</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_63cdbc1a-56fa-4f73-8794-bf5fb63794dc" contextRef="C_19532afe-5faa-47b1-a0ce-01e2a372f9f0" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">16,053</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a3f6e846-5688-434d-a651-e9b3bbd8eb67" contextRef="C_c8879ca3-eb41-45e9-90ca-a45d8a858386" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">108</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4c528dd4-4d1b-4a1a-b840-f7dff6bf9836" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">108</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock upon exercise of pre-funded warrants</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6dce028-11c6-4d1e-be19-6c116618c370" contextRef="C_19532afe-5faa-47b1-a0ce-01e2a372f9f0" name="caba:IssuanceOfCommonStockAndPreFundedWarrantsForThePurchaseOfCommonStockNetOfIssuanceCosts" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">4,773,974</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net unrealized losses on available-for-sale securities</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b8821e9e-4861-409f-bf87-3a666026a064" contextRef="C_0ca36e70-a499-407f-8dc9-ca889acf6ed1" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">86</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c7a46567-9a46-4d2d-a00c-5cf04b4a98ed" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">86</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_896d6620-22b1-4825-8b2f-56eacb2efba5" contextRef="C_43efc37e-6f8b-48fc-b2ca-860b7ba5abf4" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">67,675</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6be83173-c271-4fc0-8ae5-8072be771275" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">67,675</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance&#8212;December 31, 2023</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_39b12353-f098-4148-bcc8-f64b3d776ded" contextRef="C_71d3a4fa-64fd-456b-b2cd-92dccaa7ba87" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">47,823,232</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7bbbf4fa-4606-4848-a2ce-c63eec566abf" contextRef="C_40d8b316-eb73-435b-b720-1f6b7d1ba479" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">469,396</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_297f1954-6fb6-499f-bbd9-724c84900415" contextRef="C_fa08dd21-0e3b-409f-9df9-7d9051548e56" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2e3fa353-f437-4d81-bb3e-991530d3c59a" contextRef="C_48b6f6be-97cc-4ef9-bae5-f20850435f20" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">233,237</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a42d57e-72e6-4d4f-a650-9a76ae5da692" contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">236,198</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_17072ef8-0299-4feb-aaf2-49d482981292" contextRef="C_eb964699-a57c-4d32-86ed-e6d61d366c5f" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,465</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f57d2b97-c73f-47cc-b066-aea5599f7308" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,465</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock, net of issuance costs of $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_04e842d5-a2ee-4ca1-bab7-bae318fb9f78" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">252</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ab978b3e-6a91-4077-9e01-91784092b766" contextRef="C_bec66754-fe9d-4822-a0f6-7256e0f5e854" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,483,070</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ee52af6-be50-4e86-bd56-bb863fc28933" contextRef="C_bec66754-fe9d-4822-a0f6-7256e0f5e854" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_76888019-1690-4547-bb8c-ca692cbc6eb2" contextRef="C_eb964699-a57c-4d32-86ed-e6d61d366c5f" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,875</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e9d52190-e6ff-44d8-a07a-666ac7c39e08" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,876</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock in connection with exercise of stock options</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b64e96b-fce5-4e95-8a06-85da53c17ec9" contextRef="C_bec66754-fe9d-4822-a0f6-7256e0f5e854" name="caba:StockIssuedDuringPeriodShareStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">210,695</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_36735e85-bfe4-41ec-ae29-6ddc0025414f" contextRef="C_eb964699-a57c-4d32-86ed-e6d61d366c5f" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,430</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_18d864d8-3d82-4c64-9a6a-6d6734bd6ef5" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,430</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock under employee stock purchase plan</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_75c4dc9d-a38e-4864-87dd-27e09b357580" contextRef="C_bec66754-fe9d-4822-a0f6-7256e0f5e854" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">58,056</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b418c71f-dfb2-443f-a743-d38e4115a33e" contextRef="C_eb964699-a57c-4d32-86ed-e6d61d366c5f" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">269</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f172ad2c-dbf7-4583-8efc-a093c96bffe2" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">269</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock upon exercise of pre-funded warrants</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f323fbd5-92c4-4b44-ad5f-6a194f83f1d8" contextRef="C_bec66754-fe9d-4822-a0f6-7256e0f5e854" name="caba:IssuanceOfCommonStockAndPreFundedWarrantsForThePurchaseOfCommonStockNetOfIssuanceCosts" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,168,048</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net unrealized losses on available-for-sale securities</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d331e40-e4d7-42c2-a739-4792906461ef" contextRef="C_2583f882-17d6-4155-a8a0-ab8287370f9a" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">39</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c9b8027-ee0d-4fa4-b6de-c19247c37898" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">39</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b98c8cd9-4741-411c-935d-50ba6d13ce9a" contextRef="C_3c5b95c6-6f48-4cac-8c2f-d9294618a5d9" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">115,864</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_504fca2a-ec76-4926-ad87-6cd58e0b64bd" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">115,864</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance&#8212;December 31, 2024</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e085c588-c533-48db-9c7b-5f7c406a8854" contextRef="C_e627ab24-8781-4141-83d8-30137c5dce9f" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">50,743,101</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bb342e51-7d75-4644-8be4-84f84a348fec" contextRef="C_e627ab24-8781-4141-83d8-30137c5dce9f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f4e8c2d-44f7-4d2f-8037-e54833ac0271" contextRef="C_a7b119c2-8427-423c-9525-72e30103d06a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">501,435</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_345dc4ac-6e23-4a6c-bf2a-624c13de0ebc" contextRef="C_ce2b1ce0-61ab-404b-aa60-52836ccb0f70" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">349,101</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_abcb9f9d-1b0b-4d25-b651-c1a83664dc02" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">152,335</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CABALETTA BIO, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_cash_flows"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Statements of</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Cash Flows</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:65.527%;box-sizing:content-box;"/>
     <td style="width:1.7%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:13.537%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.7%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:13.537%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from operating activities:</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_361b25c9-598d-4a0d-b630-914ab0193928" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">115,864</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d202c2d-0508-4d7a-b1b9-dbd2ecfce233" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">67,675</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8f0a782-5efe-4a2f-b233-f8ca86b06166" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,465</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aede5a9f-fd17-42ef-8c16-d766a07eefb3" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,343</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d9d86183-51e9-4e5f-bfe6-dc5c2112c291" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,711</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_58b9254c-336a-4f53-b7ae-2f0b3e8b1fa0" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,426</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization of finance lease</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_59e5ff8e-8083-4c9e-9747-38dd31fea978" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,102</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a887ded7-2d90-40af-8abc-6a97029f3aad" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-cash operating lease expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d55aa36b-069f-40c6-89a0-23dcf9e923ab" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="caba:NonCashLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,838</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_499806bd-31b0-44fe-9798-92b7889ffb57" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="caba:NonCashLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,070</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accretion of operating lease liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ddd97e4c-be29-484a-90da-85465d909394" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:AccretionExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">405</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_82eac9dd-5582-48f7-bcf9-2543df75f9b9" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:AccretionExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">408</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization of discount on investments</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e0b318cb-41fd-491b-9fcb-ad90cc91ba8e" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,528</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_52ee036c-5604-4232-af2d-ea08af31520c" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,222</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss on foreign currency exchange rates</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38d154c7-0b10-407a-bcf1-4f4f14539c3d" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:ForeignCurrencyTransactionLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4fb2586-daf3-472c-b1e5-6f56924bd29e" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:ForeignCurrencyTransactionLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:20pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eef85e26-106f-42e7-8f56-c4a8298287b9" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">528</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89bacb7e-056b-478a-a288-e6a7989b2119" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">954</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e3414d45-c308-4143-a66a-12e1393e8413" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">584</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_500f1684-2f8d-4ba5-8926-939db31dfc8e" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,144</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d4cb830-0f97-4cab-b338-9b89f9e27c03" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,011</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f92a667c-0f6f-4214-86f0-9a8bfe6989b4" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,675</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued and other current liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24084ff7-b32a-4e52-9643-bf0285ac9889" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,947</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b7a9df5e-fdc1-4309-a30f-fea0037039a9" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,980</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_011bca16-8395-49d2-bb2d-33b4c3adff19" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,291</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a2f78381-2cb8-45bf-b7fc-1040aae3bda1" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,456</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:40pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:40pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in operating activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_978c4c6b-1048-412c-8d7f-ceff7ec62c60" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">88,222</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c61127b-62bb-4060-b9ba-7bfd8232863a" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">53,549</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from investing activities:</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of property and equipment</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d316dd2e-f0da-4390-a0f9-4624e61d3c21" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,211</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_93862157-8cb8-4871-a172-19705859aaa8" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">687</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of investments</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d96b7854-1a11-440a-bd5b-52ce90b8fa28" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_27441a37-bb0b-4e46-9f0c-f86cd6272509" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,264</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from maturities of investments</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_73945376-fcab-43cf-bd77-cab7789cce7c" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49,500</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9cb84b95-0f3a-457b-8687-6bf377dafaa1" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62,500</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:40pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:40pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by (used in) investing activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4cfa6edd-bdab-49d0-86e0-aeb62dcc2cab" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">47,289</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1cd17e29-0c95-4033-becd-88d2adafbb1b" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">22,451</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from financing activities:</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from the issuance of common stock, net of issuance costs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1d14009-ab4c-40b1-9e4a-72f4be287d8b" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,875</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d9c56c3-9a08-40bc-b1d2-8de56b9a12e5" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">185,202</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from issuance of common stock in connection with the<br/>exercise of stock options</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c15b45d9-b50d-46f1-b2d8-fb538a6fbff2" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,430</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64e12873-e920-45a5-a717-a8e808d2b429" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,321</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from issuance of common stock under employee stock<br/>purchase plan</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_03e8a7f3-1c29-46c2-a896-24345e8d1300" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">269</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c14207ed-1880-4c94-86b5-7b0d8eea9b86" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">108</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Principal payments on finance leases</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2c16291d-b48c-4677-ab97-70f56a7885db" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:FinanceLeasePrincipalPayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">897</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_40ba2fd0-aaf4-4a87-8d75-499208f6baa4" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:FinanceLeasePrincipalPayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:40pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:40pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_661ec620-7d3a-4f70-84d3-bbc5cfef1a39" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,677</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e01ede2-7311-4670-950c-1aaee8b101e6" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">187,631</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effect of exchange rate changes on cash and cash equivalents</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_30dda0e7-3f0d-4040-9f32-46339baaf4c6" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">20</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9386e1f3-fc0d-4388-a2be-5574a86765c0" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net (decrease) increase in cash and cash equivalents</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e01d7229-5d1d-478e-aa0a-9f2f97ffe309" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">29,276</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b6c514af-790f-4130-896b-fad52a356e62" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">111,631</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents&#8212;beginning of period</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_44dbff7a-4c6b-41a4-b75b-3d27ac903665" contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">193,238</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b7d0e85b-d4d7-4bde-8fa2-d4719382b67a" contextRef="C_2c83b4bd-a25b-4fdd-8a75-b19f7b147a93" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">81,607</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents&#8212;end of period</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_516cce71-ad6c-46ce-bd48-68ec6ccbbfb1" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">163,962</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5404210e-c80d-48dc-8b4b-7a27e6ef970d" contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">193,238</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Supplemental disclosures</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for interest</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0844f7aa-ef3a-411b-b3bd-d9b876b1acd7" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">748</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_697e9064-0bd8-4941-8125-388bbcc99dfe" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment purchases included in accounts payable and accrued expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_93138d35-f359-4c9d-a50e-4c9f3358d20f" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">404</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b225cdc-8608-40ef-ba61-d75a1b5e95db" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">702</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right-of-use assets obtained in exchange for finance lease obligations</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98dc0a23-f769-4c23-a31a-fb7aca51662f" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,963</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e0b150a-5f15-4828-baeb-546245bcf345" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,048</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right-of-use assets obtained in exchange for operating lease obligations</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5233c344-e713-4ec0-9bc7-10ed88a7e70c" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,242</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a6990f8-63bc-4c34-a7eb-f535f0d35ab7" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CABALETTA BIO, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="notes_to_consolidated_statements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to the Consolidated Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands, except share and per share amounts)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_201342d3-e3d8-4393-b619-e8c35e0da91c" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. Basis of Presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cabaletta Bio, Inc. (the Company or Cabaletta) was incorporated in April 2017 in the State of Delaware as Tycho Therapeutics, Inc. and, in August 2018, changed its name to Cabaletta Bio, Inc. The consolidated financial statements include the accounts of Cabaletta Bio and its wholly owned subsidiaries: Cabaletta Bio GmbH and Cabaletta Bio (Germany) GmbH. All intercompany balances and transactions have been eliminated in consolidation.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is headquartered in Philadelphia, Pennsylvania. Cabaletta is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Principal operations commenced in April 2018.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risks and Uncertainties</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company does not expect to generate revenue from sales of engineered T cell therapies for autoimmune diseases or any other revenue unless and until the Company completes preclinical and clinical development and obtains regulatory approval for one or more product candidates. If the Company seeks to obtain regulatory approval for any of its product candidates, the Company expects to incur significant commercialization expenses.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing. As a result, the Company is unable to predict the timing or amount of increased expenses or when or if the Company will be able to achieve or maintain profitability. Further, the Company is dependent on third parties for certain research and development activities, including manufacturing services (Note 6 and Note 7). Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization. Even if the Company is able to generate revenues from the sale of its product candidates, if approved, it may not become profitable. If the Company fails to become profitable or is unable to sustain profitability on a continuing basis, then it may be unable to continue its operations at planned levels and be forced to reduce its operations.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Liquidity and Going Concern</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 205-40, Going Concern, ("ASC 205-40") the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern. The Company has sustained annual operating losses since inception and expects to continue to generate operating losses for the foreseeable future. As of December 31, 2024, the Company has incurred an accumulated deficit of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d9ccda5-7895-479d-8360-bb8b1732f52d" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">349,101</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and has a cash and cash equivalents balance of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_755523f6-7faa-42ca-9bc9-d04237de976b" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">163,962</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company&#8217;s ultimate success depends on the outcome of its research and development activities. Management expects to incur additional losses in the future as it continues its research and development and will need to raise additional capital to fully implement its business plan and to fund its operations. The Company intends to raise such additional capital through a combination of equity offerings, debt financings, government funding arrangements, strategic alliances or other sources. However, if such financing is not available at adequate levels and on a timely basis, or such agreements are not available on favorable terms, or at all, as and when needed, the Company will need to reevaluate its operating plan and may be required to delay or discontinue the development of one or more of its product candidates or operational initiatives. The Company expects that its current cash and cash equivalents may not be sufficient to fund operations for at least the next twelve months from the date of issuance of these consolidated financial statements. The Company's cash forecast contains estimates and assumptions based on success of ongoing clinical trials, and management cannot predict the amount or timing of all expenditures with certainty. Accordingly, the Company has concluded that substantial doubt exists about the Company&#8217;s ability to continue as a going concern. The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business.</span></p></ix:nonNumeric></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div><ix:nonNumeric id="F_23f0b9d9-b91b-4d67-b361-bafe56e64c99" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true" continuedAt="F_23f0b9d9-b91b-4d67-b361-bafe56e64c99_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. Summary of Significant Accounting Policies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5cb88f3a-b96c-4475-8b67-29835a00c97f" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:ConsolidationPolicyTextBlock" escape="true"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Principles of Consolidation</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying consolidated financial statements included herein have been prepared in conformity with accounting principles generally accepted in the United States ("GAAP") and under the rules and regulations of the U.S. Securities and Exchange Commission ("SEC"). All intercompany balances and transactions have been eliminated in consolidation.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8bd14386-07e5-41bc-9461-fbfd9446a5ea" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:UseOfEstimates" escape="true"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying consolidated financial statements include but are not limited to advance payments and accruals related to the Company&#8217;s research and development expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c4f99606-1b4b-478b-a7e3-4606e32bc334" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:OffBalanceSheetCreditExposurePolicyPolicyTextBlock" escape="true"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Off-Balance Sheet Risk and Concentrations of Credit Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist of cash and cash equivalents, which are invested in U.S. treasury-based money market funds. As of December 31, 2023, the Company held available-for-sale securities, which were invested in U.S. treasury securities. These investments matured in 2024. A portion of the Company&#8217;s cash is maintained at two federally insured financial institutions, and account balances may at times exceed federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk. The Company has no off&#8209;balance sheet risk, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_0af23376-06a7-42f4-be3d-0b8d50212bb9" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_73a397a5-9ddf-40aa-b061-f290ca49dcf7" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:InvestmentPolicyTextBlock" escape="true"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investments</span></p><p style="text-indent:27.8pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investments are available-for-sale and carried at estimated fair value. The Company&#8217;s valuations of available-for-sale debt securities are generally derived from independent pricing services based upon quoted prices in active markets for similar securities, with prices adjusted for yield and number of days to maturity, or based on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets. Management determines the appropriate classification of its investments in debt securities at the time of purchase and at the end of each reporting period. Investments with original maturities beyond three months at the date of purchase and which mature at, or less than, twelve months from the balance sheet date are classified as current.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unrealized gains and losses are excluded from earnings and are reported as a component of comprehensive income. The Company periodically evaluates whether declines in fair values of its available-for-sale securities below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors including the severity and duration of the unrealized loss as well as the Company&#8217;s ability and intent to hold the available-for-sale security until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the security or if more likely than not it will be required to sell any available-for-sale securities before recovery of its amortized cost basis. Realized gains and losses and declines in fair value judged to be other-than-temporary, if any, on available-for-sale securities are included in interest and other income, net. The cost of investments sold is based on the specific-identification method. Interest income on investments as well as amortization of discount or premium is included in interest income.</span></p></ix:nonNumeric></div></ix:nonNumeric></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div><ix:continuation id="F_23f0b9d9-b91b-4d67-b361-bafe56e64c99_1" continuedAt="F_23f0b9d9-b91b-4d67-b361-bafe56e64c99_2"><div><ix:nonNumeric id="F_d2473bcb-9625-43ec-ac80-a731dd7dfdad" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Property, Plant and Equipment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property, plant and equipment are recorded at cost less accumulated depreciation. Cost includes the acquisition costs and all costs necessary to bring the asset to the location and working condition necessary for its intended use. Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the accompanying statements of operations. Expenditures for normal, recurring or periodic repairs and maintenance related to property and equipment are charged to expense as incurred. The cost for planned major maintenance activities, including the related acquisition or construction of assets, is capitalized if it will result in future economic benefits.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_20f78872-f300-4cda-a6e6-ee169fcfb4b0" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="caba:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" escape="true" continuedAt="F_20f78872-f300-4cda-a6e6-ee169fcfb4b0_1"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Estimated useful lives for property and equipment are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
         <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
          <tr style="visibility:collapse;">
           <td style="width:24.825%;box-sizing:content-box;"/>
           <td style="width:16.023%;box-sizing:content-box;"/>
           <td style="width:59.152%;box-sizing:content-box;"/>
          </tr>
          <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Property and equipment</span></p></td>
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated useful life</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Laboratory equipment</span></p></td>
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_e8eed517-72d0-46c0-aafc-a08273968853" contextRef="C_540f0e6d-d008-4d25-b45d-014688c83725" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> Three years</span></ix:nonNumeric></span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_20bbe65b-3c16-4494-8732-9956e07b7e1c" contextRef="C_c76069af-3284-4046-a825-2b5ff929db4a" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> Three years</span></ix:nonNumeric></span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment</span></p></td>
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_fb64719f-8433-4cb5-a60b-77a7af364c6d" contextRef="C_cb855622-a323-4d6a-9e19-5673661f83fe" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> Three years</span></ix:nonNumeric></span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_11fb0b7e-26ca-48c1-8f03-76b57f37f299;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> Lesser of estimated useful life or remaining lease term</span></span></span></p></td>
          </tr>
         </table></ix:nonNumeric></div></ix:nonNumeric></div><div><ix:continuation id="F_20f78872-f300-4cda-a6e6-ee169fcfb4b0_1"></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5a99330b-0cb6-4385-ac55-816b529cc484" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" escape="true"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value Measurement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1&#8212;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2&#8212;Inputs (other than quoted prices included in Level 1) that are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_114b0ef4-c3e8-4e68-8596-699e4a21654b" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true" continuedAt="F_114b0ef4-c3e8-4e68-8596-699e4a21654b_1"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has leases related to its facilities used for offices and laboratory space, which are classified as operating leases as well as leases related to its manufacturing arrangements, which are classified as finance leases.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease and its classification based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets and current and non-current lease liabilities, as applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate to discount lease payments. Subsequent to the initial measurement, the Company will continue to account for:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the lease liability at the net present value using the incremental borrowing rate that was in effect as of the lease commencement, lease modification, or transition date, and;</span></div></div></ix:nonNumeric></div></ix:continuation></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div><ix:continuation id="F_23f0b9d9-b91b-4d67-b361-bafe56e64c99_2" continuedAt="F_23f0b9d9-b91b-4d67-b361-bafe56e64c99_3"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_114b0ef4-c3e8-4e68-8596-699e4a21654b_1"><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the finance lease and operating lease expense on a straight line basis.</span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leases with terms of 12 months or less are considered short-term leases and right-of-use assets and lease obligations are not recognized. Payments associated with short-term leases are expensed on a straight-line basis over the lease term.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In accordance with ASC 842, components of a lease should be split into three categories: lease components, non-lease components and non-components. The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components. Entities may elect not to separate lease and non-lease components. Rather, entities would account for each lease component and related non-lease component together as a single lease component. The Company has elected to aggregate all lease and non-lease components for each class of underlying assets into a single lease component for real-estate leases and embedded manufacturing arrangements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASC 842 allows for the use of judgment in determining whether the assumed lease term is for a major part of the remaining economic life of the underlying asset and whether the present value of lease payments represents substantially all of the fair value of the underlying asset. The Company applies the guidance in ASC 842-10-55-2 to assist in determining lease classification across its leases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d304c9a7-69f0-4f24-9b71-c66489b51235" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development costs include costs incurred for internal and external research and development activities and are expensed as incurred in the accompanying statements of operations. Research and development costs consist of salaries and benefits, including associated stock-based compensation, and laboratory supplies and facility costs, as well as fees paid to entities that conduct certain research and development and clinical trial activities on the Company&#8217;s behalf.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records accrued liabilities for estimated costs of research and development activities conducted by service providers, which include preclinical studies, contract manufacturing activities and clinical trial activities. The Company records the estimated costs of research and development activities based upon the estimated amount of services provided and in accordance with agreements established with service providers and includes these costs in accrued and other current liabilities in the accompanying balance sheets and within research and development expense in the accompanying statements of operations. Non-refundable advance payments made for goods or services that will be used or rendered for future research and development activities are deferred and capitalized and recognized as expense as the goods are received or the related services are rendered. The Company makes significant judgments and estimates in determining the accrued liabilities and prepaid expenses in each reporting period. As actual costs become known, the Company adjusts its accrued liabilities and prepaid expenses. The Company has not experienced any material differences between accrued costs and actual costs incurred since its inception.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_671d062d-054a-4a32-84ff-01c8b28cb523" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company measures its stock-based awards granted to employees and non-employees based on the estimated fair values of the awards on the respective grant dates. The Company uses the Black-Scholes option-pricing model (Black-Scholes) to estimate the fair value of its stock-based awards. The Company recognizes compensation expense for time-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award. The Company accounts for forfeitures of stock option awards as they occur.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_9ea6341f-8a05-463b-bc73-93da10f375b6" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true" continuedAt="F_9ea6341f-8a05-463b-bc73-93da10f375b6_1"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to temporary differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax base, as well as for net operating loss carryforwards and research and development credits, and are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.</span></p></ix:nonNumeric></div></ix:continuation></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div><ix:continuation id="F_23f0b9d9-b91b-4d67-b361-bafe56e64c99_3" continuedAt="F_23f0b9d9-b91b-4d67-b361-bafe56e64c99_4"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_9ea6341f-8a05-463b-bc73-93da10f375b6_1"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Valuation allowances are established when necessary to reduce deferred tax assets where, based upon the available evidence, the Company concludes that it is more-likely-than-not that the deferred tax assets will not be realized. In evaluating its ability to recover deferred tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. Because of the uncertainty of the realization of deferred tax assets, the Company has recorded a full valuation allowance against its deferred tax assets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reserves are provided for tax benefits for which realization is uncertain. Such benefits are only recognized when the underlying tax position is considered more-likely-than-not to be sustained on examination by a taxing authority, assuming they possess full knowledge of the position and facts. Interest and penalties related to uncertain tax positions are recognized in the provision of income taxes; however, the Company currently has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e616721a-cde5-479d-a4bf-c28cbd448c8c" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> interest or penalties related to uncertain income tax benefits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_617babe2-3688-4283-ab3f-e24514d7a125" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Loss Per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company calculates basic and diluted net loss per share in conformity with the two-class method required for participating securities because the Company had both voting and non-voting common stock outstanding in 2023 and for a portion of 2024. The rights, including the liquidation and dividend rights, of the holders of the voting and non-voting common stock are identical, except with respect to voting. Each share of non-voting common stock may be converted at any time into one share of voting common stock at the option of its holder by providing written notice to the Company, subject to the limitations provided for in the amended and restated certificate of incorporation. As of December 31, 2024, no shares of non-voting common stock remain outstanding.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted average number of shares of common stock, including any pre-funded warrants to purchase shares of common stock that may be outstanding. The undistributed loss for each year is allocated to common stockholders based on the contractual participation rights of the voting and non-voting common stock as if the losses for the year had been distributed. As the liquidation and dividend rights are identical, the undistributed losses are allocated on a proportionate basis. Diluted net loss per share attributable to common stockholders is computed under the if-converted method and assumes that all non-voting common stock has been converted to common stock. Since the Company was in a loss position for all periods presented, the effects of the other potentially dilutive securities are antidilutive.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_26535a93-4e4b-441a-9ddc-93d2ecebaeab" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segments</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (CODM) in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#8217;s CODM is its Chief Executive Officer (CEO). The Company has determined it operates in a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_d4311f9a-8cf2-4c85-b6fa-4408d3790ae7;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">single </span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">operating segment and has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef431787-d736-476a-a566-9e90177b37c7" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:NumberOfReportingUnits" unitRef="U_Segment" decimals="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reportable segment. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Refer to Note 8 &#8211; Segment Reporting for further information related to our segment.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_340945cb-61c1-4718-9f37-a93bbd65f4ca" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:DeferredChargesPolicyTextBlock" escape="true"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Deferred Offering Costs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After consummation of the equity financing, these costs are recorded as a reduction to the carrying value of stockholders&#8217; equity as a reduction of additional paid-in capital or equity generated as a result of such offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the statements of operations and comprehensive loss.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_740e5341-ca3b-4f32-a881-884c37b94c8f" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="caba:EmergingGrowthCompanyStatusPolicyTextBlock" escape="true"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Emerging Growth Company Status</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to December 31, 2024, the Company was an &#8220;emerging growth company&#8221; (EGC) as defined in the Jumpstart Our Business Startups Act, (JOBS Act), and elected to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies until the Company no longer qualifies as an EGC, including using the extended transition period for complying with new or revised accounting standards. As of December 31, 2024, the Company ceased to qualify as an EGC.</span></p></ix:nonNumeric></div></ix:continuation></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div><ix:continuation id="F_23f0b9d9-b91b-4d67-b361-bafe56e64c99_4"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fda64f71-7930-4401-8162-e392cec8407b" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the FASB issued Accounting Standards Update, or ASU, 2023-07, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Reporting (Topic 280) &#8211; Improvements to Reportable Segment Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This ASU requires that a public entity provide additional segment disclosures on an interim and annual basis. The amendments in this ASU should be applied retrospectively to all prior periods presented in the consolidated financial statements, unless impracticable. Upon transition, the segment expense categories and amounts disclosed in the prior periods should be based on the significant segment expense categories identified and disclosed in the period of adoption. The Company adopted this ASU for the annual period ended December 31, 2024 and the amendments have been applied retrospectively to all prior periods presented in the financial statements. Refer to Note 8 &#8211; Segment Reporting for further information related to our segment.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Improvements to Income Tax Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. ASU 2023-09 enhances the transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The guidance is effective for public business entities for annual periods beginning after December 15, 2024. Early adoption is permitted. This update is effective beginning with the Company&#8217;s 2025 fiscal year annual reporting period. The Company is currently planning to adopt this guidance when effective and is assessing the impact of the adoption on the Company&#8217;s consolidated financial statements and accompanying footnotes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03, Income Statement (Subtopic 220-40): Reporting Comprehensive Income-Expense Disaggregation Disclosures. ASU 2024-03 requires enhanced disclosures about components of expense captions on the face of the income statement. This standard will be effective for fiscal years beginning after December 15, 2026. Early adoption is permitted. ASU 2024-03 applies on a prospective basis for periods beginning after the effective date. However, retrospective application to any or all prior periods presented is permitted. The Company is currently planning to adopt this guidance when effective and is assessing the impact of the adoption on the Company&#8217;s consolidated financial statements and accompanying footnotes.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There have been no other new accounting pronouncements or changes to accounting pronouncements that, if adopted, would have or may have a material impact on the Company&#8217;s consolidated statements or disclosures.</span></p></ix:nonNumeric></div></ix:continuation></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div><ix:nonNumeric id="F_22fbaa35-b142-49ab-bd90-b3e739507d9a" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:FairValueDisclosuresTextBlock" escape="true" continuedAt="F_22fbaa35-b142-49ab-bd90-b3e739507d9a_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3. Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024 and 2023, the Company&#8217;s financial instruments included cash and cash equivalents, available-for-sale debt securities, accounts payable and accrued expenses. The carrying amounts for cash and cash equivalents, accounts payable and accrued expenses reported in the Company&#8217;s consolidated financial statements for these instruments approximate their respective fair values because of the short-term nature of these instruments.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e6be56cf-f22e-45ff-b50a-b8519c75415f" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" escape="true"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables present information about the Company&#8217;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values:</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.38%;box-sizing:content-box;"/>
         <td style="width:1.22%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.184000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.22%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.184000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.22%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.184000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.22%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.184000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Quoted<br/>Prices in<br/>Active Markets<br/>for Identical Assets <br/>(Level 1)</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial assets</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_26e4d58d-2301-4bf0-ba40-4c1d84cd5fb8" contextRef="C_1a070b4c-533f-43fc-9a6b-b37ff298a84e" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">162,634</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6f7869e-3643-46eb-8dac-49225a3fc2f6" contextRef="C_e4eaaa6c-1a38-4348-b779-9f2c88c6727b" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">162,634</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f47e5f25-783b-4b6e-bb36-d253a0dcdfd0" contextRef="C_11dd7a1d-2e01-497c-a7de-cb3940339fe0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c2facb6-0896-4225-8f85-a5d91528f42a" contextRef="C_f01ad0a8-3dd5-4e30-b96a-3752be3dec4c" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term investments:</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2f51a24a-0022-4735-8b1a-4920ae4c81b1" contextRef="C_b9c36061-77bc-4b94-8132-5e42f9fe5210" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c405ac06-a85c-42f0-b5a8-5ae5353629e0" contextRef="C_269acac6-33ca-4743-9c91-3860f13c66c8" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_369faa5a-bf39-4acc-84be-278b4cc8a43b" contextRef="C_f4db9c45-8c5b-4699-a20a-4009f98cad84" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4fd72c37-d457-49d6-aab4-5f86ae474048" contextRef="C_711abcf7-e6c1-4c74-8ec8-d2b808baace6" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d6651a79-a794-4c07-a4f6-904ffaab9f10" contextRef="C_3cf6ca28-81b1-4647-b307-30db6e6d90f1" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">162,634</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_75f07abf-07b9-4df3-bcc8-2698b222093b" contextRef="C_734d3853-d0a8-4ac2-a327-a99b436ab861" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">162,634</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc313c4d-e133-45ac-959d-70e66659f2a9" contextRef="C_9be04dd4-fea1-4302-8462-56ed42a391b0" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d8ae87d-a47e-4615-b509-8a3d60a9b1ea" contextRef="C_3e97ca82-cc21-4f56-9fdf-9c22c00b90af" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="text-indent:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.38%;box-sizing:content-box;"/>
         <td style="width:1.22%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.184000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.22%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.184000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.22%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.184000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.22%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.184000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Quoted<br/>Prices in<br/>Active Markets<br/>for Identical Assets<br/>(Level 1)</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial assets</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2bea2a0a-5117-4ac3-a237-7e4bc1ae6f15" contextRef="C_58107011-70e5-45db-96bf-b13e678c007f" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">180,124</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb6b50d2-8a22-4cd3-b5ce-e7be34a58592" contextRef="C_205ec67f-4f43-4431-93b3-98f31625b5c5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">180,124</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_00d5c32d-6c87-4911-b2d6-75fd93521492" contextRef="C_c4c22bdc-057a-44d3-8274-7b307be3dfea" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_065c7648-14ae-4843-81fa-d67fcd6f0b9e" contextRef="C_649a608e-fb57-4b77-b3df-53aea52c4927" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities - original maturity less than three months</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5ba8d7f0-9eb1-4001-827d-33ee1416e7d8" contextRef="C_b595787c-5321-4455-b3f0-010647595978" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,371</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_aacb9393-82a1-4484-8aab-edf9ca81d63c;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34350506-0a58-4ce6-ae26-b20985abf2f2" contextRef="C_76f2bc1f-8bfe-42b0-8ef5-bd09ee4372d6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,371</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_b8a328b1-c384-428d-aa72-eece52e52e47;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term investments:</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_29e88312-025a-49d1-b146-fdc738b5063e" contextRef="C_b595787c-5321-4455-b3f0-010647595978" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">48,011</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b499a156-deb5-4392-b7e6-cbacae98b08c" contextRef="C_72b96170-7a04-4855-aa98-34638538347d" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85c9c508-3743-4a4e-8bca-ccb6fe87482d" contextRef="C_76f2bc1f-8bfe-42b0-8ef5-bd09ee4372d6" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">48,011</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_30484aaf-ff53-4d07-a0ff-f9f1fbd5548e" contextRef="C_7e18ccc8-731c-4531-8ac3-a3a38fdbfbb4" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_57022b79-369d-431c-abc9-d88b1d9540a6" contextRef="C_d6f1f45c-9b4a-4db4-bf99-cf7cd3f55c9a" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">240,506</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_81bbd2e8-fee4-45e9-8279-ff0e04975be8" contextRef="C_7552d055-8ba4-480a-a069-f83dd0658987" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">180,124</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_96bece77-0e97-47d0-bc4c-5c5428ba026a" contextRef="C_636f9b5e-113f-4fa8-938c-4b0bf99f0a58" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">60,382</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a3d5ceb2-ebf7-43c2-a50c-cc446d49862a" contextRef="C_b19a2baa-3b2d-484b-b93b-09bbee5dbbdd" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div><ix:continuation id="F_22fbaa35-b142-49ab-bd90-b3e739507d9a_1"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Money market funds are measured at fair value on a recurring basis using quoted prices and are classified as Level 1. Investments are measured at fair value based on inputs other than quoted prices that are derived from observable market data and are classified as Level 2 inputs.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For debt securities classified as available-for-sale investments,</span><span><ix:nonNumeric id="F_303636ba-e989-457a-ac86-f925871a97c9" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" escape="true" continuedAt="F_303636ba-e989-457a-ac86-f925871a97c9_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the Company records unrealized gains or losses resulting from changes in fair value between measurement dates as a component of other comprehensive income. The Company did not hold any available-for-sale securities as of December 31, 2024:</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_303636ba-e989-457a-ac86-f925871a97c9_1" continuedAt="F_303636ba-e989-457a-ac86-f925871a97c9_2"><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:46.218%;box-sizing:content-box;"/>
         <td style="width:1.321%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:10.124%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.321%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:10.124%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.321%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:10.124%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.321%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:10.124%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized Cost</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross Unrealized Gains</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross Unrealized Losses</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair value</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial assets</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3caebc41-cb19-407f-9158-f57accfca6fd" contextRef="C_11f1e157-c9cb-4fce-b81f-40d77ea635c9" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">743</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dfb66b9c-750e-42a6-bb0d-a0631f9fbc5b" contextRef="C_11f1e157-c9cb-4fce-b81f-40d77ea635c9" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_780acd15-1a3e-45e5-9591-c49d9d85edc5" contextRef="C_11f1e157-c9cb-4fce-b81f-40d77ea635c9" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b7258617-7085-4893-b65e-e245bdc35adf" contextRef="C_11f1e157-c9cb-4fce-b81f-40d77ea635c9" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">743</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c86a90bd-99fc-4962-a052-222aabd8e854" contextRef="C_a9916f0c-e5a6-49b3-aa27-2f2599dab549" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">180,124</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a050f1eb-0e3d-4ed4-a1e5-f14e7527f0a0" contextRef="C_a9916f0c-e5a6-49b3-aa27-2f2599dab549" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cf729780-38e7-4ffb-a755-54122364dbad" contextRef="C_a9916f0c-e5a6-49b3-aa27-2f2599dab549" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d100c2f5-d7d4-4918-a486-25b4561ce648" contextRef="C_a9916f0c-e5a6-49b3-aa27-2f2599dab549" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">180,124</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities - original maturity less than three months</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c1695f8e-eee4-4ef5-9535-092154469955" contextRef="C_067790e2-b88b-48e5-8bbf-2c266ffc2b13" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,367</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f6f4dfd6-5033-44fe-b230-0d29b74ff7ec" contextRef="C_067790e2-b88b-48e5-8bbf-2c266ffc2b13" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_535e8679-accd-483b-9f94-72aa42a22e1c" contextRef="C_067790e2-b88b-48e5-8bbf-2c266ffc2b13" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4563610b-98d1-43e8-88df-39f68774f10b" contextRef="C_067790e2-b88b-48e5-8bbf-2c266ffc2b13" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,371</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Included in cash and cash equivalents</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f89587b-8a34-47ca-ad6e-4a58ae9daeea" contextRef="C_9d30fac2-b87d-470d-bf79-785e498650f5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">193,234</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98a16fdf-70e7-4116-a60e-a04bead7fe4c" contextRef="C_9d30fac2-b87d-470d-bf79-785e498650f5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb55978c-c02b-438d-bd0c-1fb9388c9957" contextRef="C_9d30fac2-b87d-470d-bf79-785e498650f5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_096548f5-6c84-465e-a43f-256ecf89fd01" contextRef="C_9d30fac2-b87d-470d-bf79-785e498650f5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">193,238</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities - due in one year or less</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Included in short-term investments</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5793ed36-96f7-4d1c-9f2a-0c85fd47872e" contextRef="C_751af1f3-2ee2-42ff-9b2c-27e58ba3e3be" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">47,976</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1cd58094-b711-4654-8eab-f1cca89ddab6" contextRef="C_751af1f3-2ee2-42ff-9b2c-27e58ba3e3be" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0dcfbd5e-98ff-4ce7-a14d-5e0e997a4b66" contextRef="C_751af1f3-2ee2-42ff-9b2c-27e58ba3e3be" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee1c4b49-3727-420d-a751-918ad836750e" contextRef="C_751af1f3-2ee2-42ff-9b2c-27e58ba3e3be" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">48,011</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de10d5c3-2a22-4a39-a23a-68740075a850" contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">241,210</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2055c061-357c-4f90-acc3-97bdb6b8a078" contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_841fd5bc-97b3-43e5-9a1b-a2ac18473ea2" contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e280718-7b41-4b4f-bfb0-7b7c0bbafbc2" contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">241,249</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:continuation></div></ix:continuation></div><div><ix:continuation id="F_303636ba-e989-457a-ac86-f925871a97c9_2"></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b495580f-4367-43a3-9fa5-5598a2489685" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4. Property, Plant and Equipment</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8c731623-f8ec-4c07-8b92-2feb6d58c9f8" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property, plant and equipment consists of the following:</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.883000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.883000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Laboratory equipment</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef3ae047-e668-4eff-9824-95a3b93efd83" contextRef="C_c31b10fb-e739-4340-b8e2-ac8464faec66" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,663</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e9a12173-bda6-4f56-aaa2-d16f38d57d15" contextRef="C_2aa93a55-952b-4b3f-94d7-89fe525c7f44" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,893</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_07cb8f32-635d-4b36-a757-3144ddfedc00" contextRef="C_c76069af-3284-4046-a825-2b5ff929db4a" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3">277</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c71a2878-1ac8-4223-bd03-26fe36ae51ea" contextRef="C_58f7eda9-d4b7-4543-b9f9-e26b3d10127c" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3">277</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9b96f3ce-2eee-474b-b64b-c570bb886dad" contextRef="C_cb855622-a323-4d6a-9e19-5673661f83fe" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3">196</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89846c29-f00a-41d7-835a-64860d86a60b" contextRef="C_e4f2dc83-5acc-4bcc-b167-66ba947b5532" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3">53</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c4f4e07-a251-48d6-adfa-7534917f8267" contextRef="C_b9ae082c-13ae-4e63-bf00-b9ef8a7a8fe2" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3">113</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_04bda1e9-6e95-4f68-bf58-ff9fda432cdc" contextRef="C_8cac32c4-7629-42a9-a8fa-069e7af9b310" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3">113</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property, plant and equipment</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_06003895-1861-4775-8cde-c57cfdfa2f05" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,249</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f4b846e4-5fdc-4170-89b3-8b552859994a" contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,336</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: accumulated depreciation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_501a0531-6b21-49d2-a343-3ba2e6e6b241" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,506</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1e823c9-2d34-43af-bb28-58d6338df5fb" contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,795</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property, plant and equipment, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd462f8e-6029-47af-849b-b1bd133166ff" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,743</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a082d7ac-2a50-4d57-b437-61d1c3bc4776" contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,541</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation expense was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b82c43ba-c169-4fe4-920d-52cf64228218" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,711</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da9ec90c-bf7a-4cc9-952e-bc5bd49c752e" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,426</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the years ended December 31, 2024 and 2023, respectively.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_5963bd17-0f8a-41e5-8569-b65c435843a1" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5. Accrued and Other Current Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e0b0153e-3a26-40a4-af6e-52e45228081b" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="caba:AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" escape="true" continuedAt="F_e0b0153e-3a26-40a4-af6e-52e45228081b_1"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued and other current liabilities consist of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.883000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.883000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development services</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_23dcf7e4-e6c6-46ca-bb85-c6637b08dd12" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="caba:AccruedResearchAndDevelopmentServicesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,491</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2f3c5845-7602-4867-9b0f-5822bd46594e" contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc" name="caba:AccruedResearchAndDevelopmentServicesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,459</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative services</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87f0cc2a-6499-47a9-a2dd-ece849308ee5" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="caba:AccruedGeneralAndAdministrativeServicesCurrent" unitRef="U_USD" scale="3" decimals="-3">342</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_42d8b524-a0cc-43d7-b61c-3b0666f25500" contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc" name="caba:AccruedGeneralAndAdministrativeServicesCurrent" unitRef="U_USD" scale="3" decimals="-3">188</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Compensation expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f4b613d7-9083-461f-b56a-ca5043e1a106" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,315</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba5dc9c4-38bd-468e-b0a2-133a18916687" contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,200</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_208cf7bd-826c-4c71-b2bc-01a705bdd92b" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="us-gaap:OtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3">40</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_67724abb-f4c2-4232-984c-0f2804df2229" contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc" name="us-gaap:OtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3">40</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_863bec2c-c291-42a3-bb8e-4c3b2fc6f076" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="caba:AccruedLiabilitiesAndOtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,188</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e6dd4cc-b793-47a9-a679-9535db465bf4" contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc" name="caba:AccruedLiabilitiesAndOtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,887</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div></ix:nonNumeric></div><div><ix:continuation id="F_e0b0153e-3a26-40a4-af6e-52e45228081b_1"></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_4d609147-aff6-490d-936d-d0497788a940" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="caba:CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock" escape="true" continuedAt="F_4d609147-aff6-490d-936d-d0497788a940_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6. Collaborations, Licensing Agreements and other Agreements</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Amended and Restated License Agreement with the Trustees of the University of Pennsylvania and Children&#8217;s Hospital of Philadelphia</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2018, the Company entered into a license agreement with Penn, as amended and restated in July 2019 to include the Children&#8217;s Hospital of Philadelphia (CHOP) as a party, and as amended in May 2020 and October 2021 (the License Agreement) pursuant to which the Company obtained (a) a non-exclusive, non-sublicensable worldwide license to certain of Penn&#8217;s intellectual property to conduct research, product development, clinical trials, cell manufacturing and other activities, and (b) an exclusive, worldwide, royalty-bearing right and license, with a right to sublicense, on a target-by-target basis, under certain of Penn&#8217;s intellectual property to make, use, sell, offer for sale, import, and otherwise commercialize products for the treatment of autoimmune and alloimmune diseases. Unless earlier terminated, the License Agreement expires on the expiration or abandonment or other termination of the last valid claim in Penn&#8217;s intellectual property licensed by the Company. The Company may terminate the License Agreement at any time for convenience upon 60 days' written notice. In the event of an uncured, material breach, Penn may terminate the License Agreement upon 60 days' written notice. Under the terms of the License Agreement, the Company was obligated to pay $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b1b8b91e-c890-4e36-8acf-e83bdc622d7b" contextRef="C_c1ca12da-bcbe-461c-97eb-dc0872b56a45" name="us-gaap:ContractualObligation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> annually for </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_97997435-0ed3-46a7-bc49-87ed40ec04ce" contextRef="C_9cdb36a0-6755-4f07-b415-12eeed80884e" name="caba:PaymentOfObligationTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> beginning August 2018 for funding to the laboratories of each of Drs. Milone and Payne. This was satisfied through completed sponsored research agreements with a total cost of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_42d470dc-ed99-455e-b9a7-124ea93e422d" contextRef="C_3819e40f-e461-41a7-97d5-7e402dc0c022" name="us-gaap:ContractualObligation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,560</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. During the term of the License Agreement until the first commercial sale of the first product, the Company is obligated to pay Penn a non-refundable, non-creditable annual license maintenance fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5ffdae03-55a0-46ae-88d0-69c57eff5b1e" contextRef="C_9cdb36a0-6755-4f07-b415-12eeed80884e" name="caba:LicenseMaintenanceFee" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In May 2020, the Company paid Penn an additional, non-refundable, non-creditable license fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed50ca85-1091-42fe-a76d-20df1a6da773" contextRef="C_bee1c669-b105-4c4e-b815-f0043dad20ee" name="caba:LicenseMaintenanceFee" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> under the amended License Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div><ix:continuation id="F_4d609147-aff6-490d-936d-d0497788a940_1" continuedAt="F_4d609147-aff6-490d-936d-d0497788a940_2"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is required to pay certain milestone payments upon the achievement of specified clinical and commercial milestones. Milestone payments are reduced by a certain percentage for the second product that achieves a milestone, by an additional percentage for the third product that achieves a milestone, and so on, for each subsequent product that achieves a milestone. In the event that the Company is able to successfully develop and launch multiple products under the License Agreement, total milestone payments could be approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fafd6349-2061-46fa-8d85-4780fa9e609b" contextRef="C_9cdb36a0-6755-4f07-b415-12eeed80884e" name="caba:MilestonePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Penn is also eligible to receive tiered royalties at percentage rates in the low single-digits, subject to an annual minimum royalty, on annual worldwide net sales of any products that are commercialized by the Company or its sublicensees that contain or incorporate, or are covered by, the intellectual property licensed by the Company. To the extent the Company sublicenses its license rights under the License Agreement, Penn would be eligible to receive tiered sublicense income at percentage rates in the mid-single to low double-digits. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d9f5ec2d-beb8-4dfe-8c0b-0cfc3721c264" contextRef="C_c1ca12da-bcbe-461c-97eb-dc0872b56a45" name="caba:CollaborativeAgreementPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> amounts due under the License Agreement as of December 31, 2024.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Master Translational Research Services Agreement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2018 and February 2023, the Company entered into services agreements (the CAART and CARTA Services Agreements) with Penn for research, development and manufacturing services from various laboratories within Penn. The activities are detailed in separately executed Penn organization-specific addenda. In May 2020, the Company amended its Addendum with the Center for Advanced Retinal and Ocular Therapeutics (CAROT) to expand access to vector manufacturing.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expense related to executed addenda under the master translational research service agreements with Penn recognized in the accompanying statements of operations was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4bf9c0a8-ba34-4673-899c-508a78f06c91" contextRef="C_f59134f7-4690-4aaa-a4ad-dc44779c4c7a" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,250</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1319bd26-add5-4712-beb6-67b34612de6c" contextRef="C_a19e5ed8-055f-4020-a172-1708aa7cf1d2" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,786</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for the years ended December 31, 2024 and 2023, respectively. The Company is </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">committed to pay up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7e14b10-c512-4825-aa9c-d26f2cc4373b" contextRef="C_591ef989-ecdb-491c-873b-f35ee5894e2b" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> under the CARTA Services Agreement for cell processing manufacturing through December 31, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company may incur additional expenses up to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_17c332ee-fbb5-4b93-826d-cbe06bd00f89" contextRef="C_f59134f7-4690-4aaa-a4ad-dc44779c4c7a" name="caba:RemainingResearchAndDevelopmentExpenseToBeIncurred" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">643</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> t</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">hrough the remaining term of the CAROT Amended Addendum.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Exclusive License Agreement with IASO Biotherapeutics</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 7, 2022, the Company entered into an Exclusive License Agreement (the IASO Agreement) with Nanjing IASO Biotherapeutics Co., Ltd. (IASO). Pursuant to the IASO Agreement, the Company received an exclusive, worldwide license under certain IASO intellectual property to use a novel clinical-stage anti-CD19 binder to develop, manufacture, commercialize and otherwise exploit T cell products directed to CD19 for the purpose of diagnosis, prevention or treatment of any autoimmune or alloimmune indications in humans. As partial consideration for the exclusive license, IASO received an upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_03bb0f87-f7f5-44a6-b0fd-a5e9e8464333" contextRef="C_c9d68995-263a-4813-8297-7b0cb06226df" name="caba:UpfrontPayment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,500</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. IASO is also eligible to receive up to mid double digit millions in milestone payments based upon the achievement of specified pre-clinical, development and regulatory milestones, and up to an additional low triple digit millions in milestone payments based upon achievement of specified sales milestones, for a total consideration, inclusive of the upfront payment, of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2bfcf2b2-aefb-4324-b2a5-5bbb24e4c0e9" contextRef="C_da3cad1c-31be-4130-aaba-7a1f51466edd" name="caba:UpfrontPayment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">162,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, along with tiered mid-single digit royalties on future net sales for licensed products that may result from the IASO Agreement. Upon the U.S. Food and Drug Association&#8217;s clearance of the rese-cel Investigational New Drug application for the treatment of systemic lupus erythematosus in March 2023, a milestone payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2a5103cb-a321-4d1d-acde-f1643a42f8e4" contextRef="C_b03d1e52-2a57-4c8e-a119-05d8db2d7eab" name="caba:MilestonePayment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was recognized in the accompanying statements of operations. A milestone payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7adb6826-76eb-49a3-a6f4-66064ce925c6" contextRef="C_41757f68-a8c3-48bc-848b-2cb739ce9b63" name="caba:MilestonePayment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,500</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was paid to IASO in the first quarter of 2024 after the first patient in a rese-cel trial was dosed.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IASO has the right of first negotiation if the Company desires to grant a third party an exclusive license to develop, manufacture, commercialize or otherwise exploit the licensed products in the Greater China region. Pursuant to the IASO Agreement, each of IASO and the Company have agreed, subject to certain exceptions, to refrain from engaging in certain competitive activities with respect to certain programs. The Company also may sublicense through multiple tiers the rights granted to it by IASO under the IASO Agreement at any time, however, it must pay IASO a low double-digit percentage of any revenue obtained from sublicenses or options to third parties, subject to certain customary exclusions. The IASO Agreement will continue on a country-by-country, licensed product-by-licensed product basis until the expiration of the royalty term as identified in the IASO Agreement, unless earlier terminated. Each of the Company and IASO may terminate the Agreement for a material, uncured breach or insolvency of the other party. The Company may also terminate the Agreement at will upon advance written notice and in the event IASO rejects the Agreement due to bankruptcy-related matters. IASO may also terminate the Agreement if the Company fails to achieve certain specified diligence milestones in a timely manner and/or if the Company commences any patent challenges with respect to the patents and patent applications relating to the licensed sequence, in each case upon advance written notice.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_4d609147-aff6-490d-936d-d0497788a940_2"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Licence and Supply Agreement with Oxford Biomedica</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2021, the Company entered into a Licence and Supply agreement (LSA) with Oxford Biomedica (UK) Limited (Oxford), wherein the LSA grants the Company a non-exclusive license to Oxford&#8217;s LentiVector&#174; platform for its application in the Company&#8217;s DSG3-CAART program and put in place a multi-year vector supply agreement. Under the terms of the agreement, the Company was required to pay Oxford an upfront fee, as well as costs associated with initial vector manufacturing activities for a total cost incurred of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9653ed06-2091-456e-b062-efb182022d5b" contextRef="C_d8712004-ce9c-421a-b7c6-3e8c260bf228" name="us-gaap:ContractualObligation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Oxford is eligible to receive regulatory and sales milestones in the low tens of millions and royalties in the low single digits on net sales of products that incorporate the Oxford technology. In May 2023, the Company amended the LSA with Oxford to expand the license to include the Company's rese-cel program for an upfront fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a4d378e6-0c69-46c2-9d09-e78fcddc2d67" contextRef="C_a801e2f0-ef59-43bc-a0d1-f52d9f8fad06" name="caba:UpfrontPayment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">500</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and in August 2023, the Company and Oxford entered into a vector supply agreement for rese-cel, and a related second amendment to the LSA, with a total cost under the vector supply agreement of up to approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_58fb0764-0510-4bd8-a267-2f0c068e37d9" contextRef="C_41424f02-2797-4d2b-9ae9-195e1bbcc839" name="us-gaap:ContractualObligation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, of which </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba169f1a-f7fd-4cc2-9cb1-c26db139fd34" contextRef="C_1b69037c-33e3-4056-95e8-3197e2253d28" name="us-gaap:OtherExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,500</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df4eea89-83b9-43b1-86fb-c0c16b2bc0cc" contextRef="C_239a468d-472b-4684-b508-dd3ca371e2de" name="us-gaap:OtherExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,500</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> were recognized as research and development expense for the years ended December 31, 2024 and 2023, respectively. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2024, the Company and Oxford entered into a third amendment to the LSA to update the patent schedule. In June 2024, the Company and Oxford entered into a fourth amendment to the LSA elimin</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ating royalties on net sales of products that incorporate the Oxford technology if Oxford manufactures the vector. In December 2024, the Company and Oxford entered into a work order with a cost of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b83477a-bcc0-49b6-a901-c02e505bb06f" contextRef="C_bc2a9f34-de0e-42e5-b295-2f8e567060bb" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for certain process characterization activities as part of commercial readiness activities. The Company can terminate the LSA or any work order under the LSA at will upon advance written notice and subject to certain cancellation fees.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Option and License Agreement with Autolus</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2023, the Company entered into an Option and License Agreement (Autolus Agreement) with Autolus Holdings (UK) Limited (Autolus), wherein the Autolus Agreement granted the Company a non-exclusive license to access Autolus' RQR8 technology in its CD19-CAR T cell therapy program, and subject to additional nominal option exercise fees, up to four additional t</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">argets. In January 2025, the Company and Autolus agreed to novate the Autolus Agreement with both Autolus and Autolus Limited jointly assuming the rights, obligations and liabilities of Autolus, under the Autolus Agreement. Under the terms of the Autolus Agreement, the Company was required to pay Autolus an upfront license fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_092af3de-8fd7-4792-811a-789fbcdcd47f" contextRef="C_5eb72df5-0321-4487-8ba8-cc5d3052b6cc" name="caba:UpfrontPayment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,200</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that was recognized as expense in the first quarter of 2023 in the accompanying statements of operations, of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_215611c4-63fd-4a21-aaa8-04934d22f42b" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="caba:UpfrontPayment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was paid in 2023 and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ab788524-0c99-4312-a5e4-959a0ce0e226" contextRef="C_0603accc-761b-4dd7-9cb1-3b0483ce98b5" name="caba:UpfrontPayment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was paid in January 2024. Autolus is also eligible to receive regulatory milestones of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_776555e9-5e5b-443e-b8ec-c1a8322ca670" contextRef="C_0c1b371f-ae73-4a6c-ba1b-1ded4756d505" name="caba:MilestonePayment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for each licensed target, sales milestones of up to a total of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a5d81c85-471b-4a64-aa97-21f774d43c3c" contextRef="C_a9395bbb-6b73-4262-b752-6b65e91be8cd" name="caba:MilestonePayment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and royalties in the low single digits on net sales of all products that incorporate the RQR8 technology. The Autolus Agreement will continue on a country-by-country, licensed product-by-licensed product basis until the expiration of the royalty term as identified in the Autolus Agreement, unless earlier terminated. The Company can terminate the Autolus Agreement at will upon advance written notice. Each of the Company and Autolus may terminate the Agreement for a material, uncured breach or insolvency of the other party.</span></p></ix:continuation></div><div><ix:nonNumeric id="F_8321823b-0f46-451e-ba31-4dcce04be62e" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true" continuedAt="F_8321823b-0f46-451e-ba31-4dcce04be62e_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7. Commitments and Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Manufacturing Agreements</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2021, the Company entered into a Development and Manufacturing Services Agreement (WuXi Agreement) with WuXi Advanced Therapies, Inc. (WuXi) to serve as an additional cell processing manufacturing partner for the MuSK-CAART Phase 1 clinical trial, or MusCAARTes</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial. The WuXi Agreement is scheduled to expire upon completion of WuXi's services related to MuSK-CAART and rese-cel. In August 2023, and as extended in August 2024, the Company entered into an agreement with WuXi to serve as one of the Company's manufacturing partners for the global clinical development of rese-cel in multiple indications, including potential late-stage clinical trials and commercial readiness activities for rese-cel. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_14593ec2-0454-41e4-bfd8-bff4f7637cd7" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="caba:InitialTermsOfAgreementDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the August 2023 work orders, WuXi converted the Company&#8217;s non-dedicated suite to a dedicated suite for GMP manufacturing for the Company&#8217;s rese-cel and MuSK-CAART programs, or the Dedicated Suite, for an initial term of 18 months with two 18-month extensions at the Company&#8217;s sole option on six months' notice prior to the end of the term. In August 2024, the Company sent a notice to WuXi to extend the initial term of the WuXi Agreement by 18 months through August 2026.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In addition, the Company agreed to certain monthly minimum runs. In August 2024, the 2023 work order related to GMP manufacturing was amended to reduce the minimum monthly runs through the end of 2024. In lieu of the original $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_32602e1e-aba4-43b0-b8e5-ecb3f2612132" contextRef="C_1947669b-c145-49f5-aea0-60ae45e15e4f" name="us-gaap:LiabilitiesSubjectToCompromiseEarlyContractTerminationFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,500</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> termination fee under the terms of the WuXi Agreement, the Company would incur up to a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0411d494-a873-4756-965f-e7eaa614416a" contextRef="C_071a7623-23cd-43a4-8077-7f5f839577fb" name="us-gaap:LiabilitiesSubjectToCompromiseEarlyContractTerminationFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,080</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> termination </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fee if it terminates both the rese-cel and MuSK-CAART work orders for any reason. The Company may terminate for</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_8321823b-0f46-451e-ba31-4dcce04be62e_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">convenience </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the WuXi Agreement or any work order with six months' prior written notice. However, the Company may not terminate the Dedicated Suite without terminating both the MuSK-CAART </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and rese-cel GMP run work orders. WuXi may terminate for convenience the WuXi Agreement or any work order on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_811dc02b-4bcf-45c6-bc13-059b4d8674b9" contextRef="C_8a7792c8-f29b-4a61-9156-afc843c668af" name="caba:LeaseExpirationMonth" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18 </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">months' prior written notice, but such notice may not be effective prior to February 2028.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, the Company entered into a Development and Manufacturing Services Agreement (the Lonza Agreement) with Lonza Houston Inc. (Lonza) to serve as one of the Company's manufacturing partners for the global clinical development of rese-cel in multiple indications, including potential late-stage clinical trials and preparations for commercial readiness. Under the initial work order, Lonza will perform cell therapy manufacturing activities for Cabaletta&#8217;s CAR-T cell therapy product rese-cel for a term of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_74bc3ebb-d384-4e9f-a048-3e643865c3df" contextRef="C_16370771-1761-414a-82f7-374ff37b95d5" name="caba:PaymentOfObligationTerm" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12 </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">months and total cost of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd936d1a-269b-4ea8-b235-798f6dcd5a4e" contextRef="C_25d4f8d5-93ce-418d-8f55-f27f42cf8bf6" name="us-gaap:ContractualObligation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> with the ability to extend the manufacturing period subject to the terms of the Lonza Agreement.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Purchase Commitments</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the normal course of business, the Company enters into various purchase commitments with third-party contract manufacturers for the manufacture and processing of its product candidates and related raw materials, contracts with contract research organizations for clinical trials and agreements with vendors for other services and products for operating purposes. These agreements generally provide for termination or cancellation, other than for costs already incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Indemnification</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company enters into certain types of contracts that contingently require the Company to indemnify various parties against claims from third parties. These contracts primarily relate to (i) the Company&#8217;s Amended and Restated Bylaws, as amended, (bylaws) under which the Company must indemnify directors and executive officers, and may indemnify other officers and employees, for liabilities arising out of their relationship, (ii) contracts under which the Company must indemnify directors and certain officers and consultants for liabilities arising out of their relationship, (iii) contracts under which the Company may be required to indemnify partners against certain claims, including claims from third parties asserting, among other things, infringement of their intellectual property rights, and (iv) procurement, consulting, or license agreements under which the Company may be required to indemnify vendors, consultants or licensors for certain claims, including claims that may be brought against them arising from the Company&#8217;s acts or omissions with respect to the supplied products, technology or services. From time to time, the Company may receive indemnification claims under these contracts in the normal course of business. In addition, under these contracts, the Company may have to modify the accused infringing intellectual property and/or refund amounts received.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event that one or more of these matters were to result in a claim against the Company, an adverse outcome, including a judgment or settlement, may have a material adverse effect on the Company&#8217;s future business, operating results or financial condition. It is not possible to determine the maximum potential amount under these contracts due to the limited history of prior indemnification claims and the unique facts and circumstances involved in each particular agreement.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Litigation</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, the Company may become involved in litigation or legal proceedings. While the outcome of any such proceedings cannot be predicted with certainty, as of December 31, 2024, the Company is not involved in any material litigation or legal proceedings that it would expect to have a material adverse impact on its financial position, results of operations, or cash flows.</span></p></ix:continuation></div><div><ix:nonNumeric id="F_786c2a45-f350-4bec-9f14-2f4cb26863b7" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:SegmentReportingDisclosureTextBlock" escape="true" continuedAt="F_786c2a45-f350-4bec-9f14-2f4cb26863b7_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8. Segment Information</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the CODM in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#8217;s CODM is the CEO. The Company has determined that it has one operating and reportable segment. The segment consists of the development of clinical and preclinical product candidates for the discovery and development of innovative engineered T cell therapies and related administrative activities. The</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div><ix:continuation id="F_786c2a45-f350-4bec-9f14-2f4cb26863b7_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CODM assesses performance and allocates resources based on the Company&#8217;s consolidated statement of operations, which is reported on the income statement as consolidated net loss and considers forecast-to-actuals variances on a quarterly basis for expenses that are deemed significant. Further, the CODM reviews the segment&#8217;s assets based on the consolidated balance sheet to assess liquidity and funding capacity. The majority of the Company's assets are located in the United States.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s CODM views specific categories within expenses as significant given the direct correlation between cash burn and profitability as a pre-revenue company. Significant segment expenses, as provided to the CODM, are presented below. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0886231f-b079-4af3-81ba-391a7a4f883f" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" escape="true" continuedAt="F_0886231f-b079-4af3-81ba-391a7a4f883f_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For additional information on the year over year change of segment expenses refer to Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_0886231f-b079-4af3-81ba-391a7a4f883f_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:57.12%;box-sizing:content-box;"/>
         <td style="width:2.1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:17.34%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:2.1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:17.34%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
         <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development expenses:</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_056b9d9a-26ab-4fb1-86b9-63e0e77f9beb" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="caba:PersonnelExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,239</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e240853-dcbf-4b0b-bd1a-f8c7e895a55b" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="caba:PersonnelExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,375</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Clinical trials</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b545a44-ccb1-4146-9973-4224b06ada51" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="caba:ClinicalTrials" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,286</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae080ada-2776-4bce-b8d4-a4120243e3ad" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="caba:ClinicalTrials" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,302</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Development services</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2e4faf97-7c41-4982-9418-97c3d1cd82be" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="caba:DevelopmentServices" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,417</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9583df05-d822-482d-b456-12d17e147b2b" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="caba:DevelopmentServices" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,486</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Manufacturing of preclinical and clinical supplies</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_229d9d11-5f3e-47ad-9db1-3df9c47d8bc2" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="caba:ManufacturingOfPreclinicalAndClinicalSupplies" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,523</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f65b428-7829-4614-91b7-fee455972b3f" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="caba:ManufacturingOfPreclinicalAndClinicalSupplies" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,498</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License of intellectual property</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9c1c408a-fe38-49ab-a848-efa80e517ea3" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="caba:LicenseOfIntellectualProperty" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,523</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98714bd3-4fcf-4047-aa93-0d910d8629e4" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="caba:LicenseOfIntellectualProperty" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,383</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other research and development costs </span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_79796396-a7d9-4c3c-85e3-fa935c557d67" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:OtherResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,215</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c44390f8-728e-4a16-874c-98d61b07a67a" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:OtherResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,380</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administration expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_23dd32c5-164f-4cd4-9f37-9bf962bb6329" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,938</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_96e7f203-9740-41b8-b52b-621df9297414" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,236</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_892cfdc1-5748-4c7b-a4ae-b6973abf9b03" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,025</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1a714770-b9ba-4d94-9bb9-ca3253a2f532" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,985</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dcdce305-8c92-4ee0-8e52-d780e0520eeb" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">748</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d098e5d7-7ad2-4aee-8703-714c97c02d7a" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_75f2952d-1139-4baf-a71e-1724dd72e730" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">115,864</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_19143ab4-827d-4bf8-a6cd-53180f3d0b64" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">67,675</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) </span><ix:footnote id="FNT_a817dc11-a357-48c9-937a-02cf05c1a9c1" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other research and development costs includes costs associated with information technology, travel, medical and scientific symposiums and conferences.</span></ix:footnote></p></ix:continuation></div></ix:continuation></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</span><span><ix:nonNumeric id="F_46311c08-170a-4dd0-8783-ca76ffb2e850" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:LesseeOperatingLeasesTextBlock" escape="true" continuedAt="F_46311c08-170a-4dd0-8783-ca76ffb2e850_1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Leases</span></ix:nonNumeric></span></p><div><ix:continuation id="F_46311c08-170a-4dd0-8783-ca76ffb2e850_1" continuedAt="F_46311c08-170a-4dd0-8783-ca76ffb2e850_2"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company leases office and laboratory space in addition to a manufacturing agreement which has been determined to contain an embedded lease.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating lease commitments</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company leases office and laboratory space which include rent escalations and are subject to additional variable charges, including common area maintenance, property taxes and property insurance. Given the variable nature of such costs, they are recognized as expense as incurred. Additionally, some of the Company&#8217;s leases are subject to certain fixed fees which the Company has determined to be non-lease components. The Company has elected the practical expedient to account for lease and non-lease components as a single-lease component and has included fixed payments related to non-lease components in calculating the operating lease liability. In 2024, the Company extended the terms of its lab and office operating leases and leased additional lab space </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">resulting in an increase in the right-of-use asset and lease liability of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0eccf7b4-3f80-4646-b539-b717c00a317e" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="caba:IncreaseInTheRouAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,242</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Finance lease commitments - Embedded leases</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As described further in Note 7, in August 2023, the Company entered into new work orders under the WuXi Agreement for WuXi to serve as one of the Company&#8217;s cell processing manufacturing partners for the global clinical development of rese-cel. WuXi converted the Company&#8217;s non-dedicated suite to a Dedicated Suite for GMP manufacturing for the Company&#8217;s rese-cel and MuSK-CAART programs, for an initial term of 18 months. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2de9201e-d712-4134-9e61-5e7a8aa950d5" contextRef="C_fbb28abe-5658-4753-b0b7-f0b655b95e73" name="caba:WorkOrdersTerm" continuedAt="F_2de9201e-d712-4134-9e61-5e7a8aa950d5_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">terms of the August 2023 work orders included both fixed costs and contingent variable costs. The lease commenced October 1, 2023. In 2024, the Company remeasured the lease due to resolution of the contingency related to variable costs and an amendment to the 2023 work order to extend the term of the agreement for an additional 18 months through August </span></ix:nonNumeric></span><span style=""></span></p></ix:continuation></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div><ix:continuation id="F_46311c08-170a-4dd0-8783-ca76ffb2e850_2" continuedAt="F_46311c08-170a-4dd0-8783-ca76ffb2e850_3"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_2de9201e-d712-4134-9e61-5e7a8aa950d5_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2026 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">resulting in an increase in the right-of-use asset and lease liability of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b27729ca-fce0-4f0f-ab93-423c885b988d" contextRef="C_91f04779-501e-4bce-bfef-a9538a16e993" name="caba:IncreaseInTheLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,963</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company may terminate the Dedicated Suite lease for convenience with six months&#8217; prior written notice and up to a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c0aa2f9c-66af-413b-a045-1981ab78511d" contextRef="C_fbb28abe-5658-4753-b0b7-f0b655b95e73" name="caba:TerminationFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,080</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> termination fee if both the rese-cel and MuSK-CAART work orders are terminated</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As described further in Note 7, in December 2024, the Company entered into the Lonza Agreement with Lonza to serve as one of our manufacturing partners. Under the initial work order, Lonza will perform cell therapy manufacturing activities for our CAR-T cell therapy product rese-cel for a term of 12 months and total cost of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d973522-131c-4f49-bc07-29cd9cb2687f" contextRef="C_1078f332-4fd3-4a24-94d7-ea03957d7227" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> with the ability to extend the manufacturing period subject to the terms of the Lonza Agreement. The Lonza Agreement is currently being evaluated for lease accounting under ASC 842. No right-of-use asset or liability was recognized as of December 31, 2024, as lease commencement begins in fiscal year 2025.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Summary of lease costs recognized under ASC 842</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9f65a08c-fc73-4488-8acb-a6c1aa2d03c4" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:LeaseCostTableTextBlock" escape="true"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company&#8217;s operating and finance leases for the years ended December 31, 2024 and 2023.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:59.224%;box-sizing:content-box;"/>
         <td style="width:2.001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:16.387%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:2.001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:16.387%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the year ended December 31,</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Finance leases</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_777ca4f4-bc6e-4b86-93bf-05745b1355f1" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:FinanceLeaseInterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">748</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5bc8998c-450d-45af-87b3-6b132dbd640c" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:FinanceLeaseInterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d273eb09-2f56-4898-9990-3a091f5cc331" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="caba:AmortizationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,102</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_23aaa067-ddd2-4edc-8040-777068ad8756" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="caba:AmortizationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total fixed finance lease cost</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_10c46884-7a30-46c0-9b53-91460e7f142b" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="caba:TotalFixedFinanceLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,850</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f7bdd30b-7ac8-4268-8176-4d1646dd6f36" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="caba:TotalFixedFinanceLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Variable lease cost</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_94d0d8e3-bb57-4bc1-bf31-59e81bb42215" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="caba:VariableLeaseCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">930</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_20622c75-a216-411c-82fa-5574828c1c7b" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="caba:VariableLeaseCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total finance lease cost</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_47ce3d2d-5e82-472e-b18d-b49665366ec5" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="caba:TotalFinanceLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,780</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3fdcd52a-fd14-42d5-bbf0-7cb8d8b5c75c" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="caba:TotalFinanceLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Operating leases</span></p></td>
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fixed lease cost</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_56e80b63-6b2d-4ed6-b020-2ad72176c74a" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="caba:FixedLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,247</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0acfd0bd-af28-4526-b12b-f4888e322ea2" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="caba:FixedLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,477</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total fixed operating lease cost</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d81eb27-2452-413b-9fff-614d4349cb69" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,247</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b9b000be-7b0d-4256-a075-070173556b11" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,477</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Variable lease cost</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_26b092df-41b9-4706-849d-33148099d425" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">296</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_46346d25-dda6-4588-9694-5ef1bb3ff2a3" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">65</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term lease cost</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe481d92-c2dd-414f-b6a5-e4deff5a6994" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:ShortTermLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">750</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6993b8d-124a-4c11-b03c-b8f47e5ced07" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:ShortTermLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">717</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease cost</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_94ef0e7d-3a87-4780-aaa2-3b1d8ed4330b" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,293</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1cf6e6d-aed8-4567-820e-9249c4363931" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,259</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash paid in the measurement of lease liabilities</span></p></td>
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating cash flows used for operating leases</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3706c602-955b-47a6-8eb9-419761e667b6" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="caba:OperatingCashFlowsUsedForOperatingLeases" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,291</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5fffaa27-2c2e-49ee-874a-a3259a535152" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="caba:OperatingCashFlowsUsedForOperatingLeases" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,456</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating cash flows used for finance leases</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_547ae942-e67a-4e22-a9ea-59704e8783d9" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="caba:OperatingCashFlowsUsedForFinanceLeases" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">748</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bf0fbb16-6ded-4a44-a247-03303fc1158d" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="caba:OperatingCashFlowsUsedForFinanceLeases" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financing cash flows for finance leases</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c1fb176-6df9-4f57-b290-d16b7227f7f2" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="caba:FinancingCashFlowsUsedForFinanceLeases" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">897</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9c635981-8efe-4a4c-a847-8952ff430927" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="caba:FinancingCashFlowsUsedForFinanceLeases" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Other information</span></p></td>
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average remaining lease term - finance leases (in years)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_b4f7d0cb-5510-416c-97ef-b5b948bbcb1e" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.7</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average discount rate - finance leases</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_14914ed7-3cd3-4197-b733-fccb463c6552" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">11.5</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2bb31d21-04b7-47a8-8c29-a9a5c2dea239" contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average remaining lease term - operating leases (in years)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_df212b8f-cac5-4d6c-88cc-3afebfcb8c3c" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.7</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_ad620c02-dddc-4e0f-a9f7-a97558f4b6ff" contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.5</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average discount rate - operating leases</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0255cbb1-8943-4c90-821f-312b213ecbe7" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">11.0</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9c39ef73-2a5c-4321-8b2b-5286c97b2095" contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">9.5</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:continuation></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_46311c08-170a-4dd0-8783-ca76ffb2e850_3"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For finance leases embedded in CDMO arrangements, interest expense is recognized using the effective interest method, applying the Company's incremental borrowing rate as required by ASC 842, and amortization expense is recognized on a straight-line basis over the shorter of the life of the asset or the term of the lease.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_65693f69-6a16-4a48-81f1-b51e7b7c8c99" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future lease payments under the non-cancelable operating and finance leases as of December 31, 2024 are as follows</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:
<br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.883000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.883000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Finance Leases</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Operating Leases</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6740247-f1c4-422b-886d-f54006c6f0b0" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="us-gaap:FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,328</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d4981f5-d99d-4cb8-baad-832438ea735c" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,227</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_00a128c0-07c2-49a0-8093-fe6b5a2748df" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="us-gaap:FinanceLeaseLiabilityPaymentsDueInRollingYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,792</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_022b0013-7e1a-44d7-bba7-2f4bc4fd8e8d" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,769</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Total undiscounted lease payments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_97157af5-454e-486b-94b1-9da314e192ac" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="caba:FinanceLesseeUndiscountedLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,120</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_60042ad8-9cd4-4a99-97e2-786d24347c54" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="caba:LesseeUndiscountedLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,996</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less imputed interest</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5fa7e614-469e-49b2-8402-a04a73390cff" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">890</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98bda9f5-1566-4ed8-85f6-bc7008df34f8" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">626</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Total lease liability</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba4385fe-960e-4a93-a42d-7a29c7e5d7b5" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,230</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce3700d7-54d6-40bc-9937-016b74718d16" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,370</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div></ix:continuation></div><p style="text-indent:5.231%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_71682c1b-3512-4b3a-a601-72b5a798b0dc" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" escape="true" continuedAt="F_71682c1b-3512-4b3a-a601-72b5a798b0dc_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10. Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the Company&#8217;s Third Amended and Restated Certificate of Incorporation filed in October 2019, the Company is authorized to issue </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca1db452-5c9f-4d3f-923c-a9d831824099" contextRef="C_e24a8a97-a5dc-4f15-92b4-2d95326ebc6a" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">143,590,481</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of voting common stock and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f6f51ec2-6d7e-434d-91ad-8af01b2dae4b" contextRef="C_edbf75ee-d36b-422e-9a54-1ab65dcfc82b" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">6,409,519</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of non-voting common stock. Holders of voting common stock shall have the exclusive right to vote for the election of directors of the Company and on all other matters requiring stockholder action. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f3125982-d823-4747-a599-7a4968188480" contextRef="C_42bda966-2bcc-4366-9ccc-53d8a69b796d" name="us-gaap:CommonStockConversionFeatures"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each share of the Company&#8217;s non-voting common stock may be converted at any time into one share of common stock at the option of its holder by providing 61 days written notice to the Company</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, subject to certain limitations, as described in the amended and restated certificate of incorporation. In May 2024, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_68070ef5-f909-40ce-9bb9-3979fcd5496a" contextRef="C_3577cd65-82b8-42e6-844e-ca6167dba709" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,444,295</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of non-voting common stock was converted to voting common stock and no shares of non-voting common stock remain outstanding.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">May 2023 Financing</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2023, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae540539-6bbc-41f4-a87b-ea9c64907ffa" contextRef="C_75b117c4-870a-43ee-97dd-4b546ab94807" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">8,337,500</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock in an underwritten public offering, including the exercise in full by the underwriters of their option to purchase an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a932df7-bdd7-4e93-ae03-cdfd278d8cb3" contextRef="C_29f8f331-c6aa-4374-ab1d-8e739c14e615" name="caba:AdditionalOptionsToBePurchasedByUnderwriters" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,087,500</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, at a public offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7cc6e6c5-2611-449a-bb85-4d815dce223f" contextRef="C_2b388bdd-20d2-49ab-a3f5-a0e370b1edf7" name="us-gaap:WarrantExercisePriceDecrease" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">12.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. Aggregate net proceeds were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_10100d70-5864-4be6-b0b8-5fc4987e911a" contextRef="C_2b388bdd-20d2-49ab-a3f5-a0e370b1edf7" name="us-gaap:ProceedsFromWarrantExercises" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">93,755</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> after deducting underwriting discounts and commissions and offering expenses of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9e73322-2396-4598-b013-4d9355c68545" contextRef="C_2b388bdd-20d2-49ab-a3f5-a0e370b1edf7" name="us-gaap:PaymentsForUnderwritingExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">6,295</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">December 2022 Financing</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2022, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b1c68ad0-d50e-4d64-b46e-070fad1d9eca" contextRef="C_1e1e3aab-a61d-436a-a436-d1b68af34f64" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">126,815</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce44d98d-f874-42d5-8f39-7b55d5430803" contextRef="C_84c42e55-4cc8-4f96-915e-34a23c05bcb6" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.52</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and to certain investors in lieu of common stock, pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ab3e876-b8f6-49de-8230-6651d623a006" contextRef="C_35f03d89-1210-4983-af91-5949af3be4e2" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">6,213,776</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b20e281-5ced-4f55-ae69-b0640a14ee7d" contextRef="C_bf0b7bb5-9f31-48ec-a4d1-ec777a17246d" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="5" format="ixt:num-dot-decimal">5.51999</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per pre-funded warrant. The purchase price per share of each pre-funded warrant represents the per share offering price for the common stock, minus the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fbadf753-0c62-49c5-9af6-8a61cd172e1b" contextRef="C_35f03d89-1210-4983-af91-5949af3be4e2" name="us-gaap:WarrantExercisePriceDecrease" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="5" format="ixt:num-dot-decimal">0.00001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share exercise price of such pre-funded warrant. Aggregate net proceeds were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e3aebb95-127d-45d7-bef3-0cfc989a5b2e" contextRef="C_35f03d89-1210-4983-af91-5949af3be4e2" name="us-gaap:ProceedsFromWarrantExercises" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">32,562</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> after deducting underwriting discounts and commissions and offering expens</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">es. As of December 31, 2024, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f6ce3c0d-bdf9-434f-9299-fe91ed7715a2" contextRef="C_0c06bf87-692f-4caf-b799-574ffd3da54b" name="caba:PreFundedWarrantsExercised" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">6,213,775</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> pre-funded warrants had been exercised and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_669babe3-4dba-4a41-9f50-d550486b9360" contextRef="C_bf0b7bb5-9f31-48ec-a4d1-ec777a17246d" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> warrants remain outstanding.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The pre-funded warrants were classified as a component of permanent stockholders&#8217; equity within additional paid-in capital and were recorded at the issuance date using a relative fair value allocation method. The pre-funded warrants are equity classified because they (i) are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, (ii) are immediately exercisable, (iii) do not embody an obligation for the Company to repurchase its shares, (iv) permit the holders to receive a fixed number of shares of common stock upon exercise, (v) are indexed to the Company&#8217;s common stock and (vi) meet the equity classification criteria. In addition, such pre-funded warrants do not provide any guarantee of value or return.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">At-the-Market Offering</span></p></ix:nonNumeric></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div><ix:continuation id="F_71682c1b-3512-4b3a-a601-72b5a798b0dc_1" continuedAt="F_71682c1b-3512-4b3a-a601-72b5a798b0dc_2"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 21, 2024, the Company filed an automatic shelf registration statement (S-3ASR) in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof for the purposes of selling, from time to time, the Company&#8217;s common stock, debt securities or other equity securities in one or more offerings. This S-3ASR became effective immediately. We intend to convert the S-3ASR to S-3 by post-effective amendments in connection with the filing of this Annual Report.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has a Sales Agreement with Cowen and Company, LLC (Cowen) to provide for the offering, issuance and sale of up to an aggregate amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_121419b7-5b8c-4439-9ad6-261a40c8c6f4" contextRef="C_22da4d01-1dd8-4662-b3be-4451dc2b3435" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">200.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of common stock from time to time in &#8220;at-the-market&#8221; offerings (2024 ATM Program) pursuant to its S-3ASR, and subject to the limitations thereof. In December 2024, the Company sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b682352e-0451-4bc2-a38a-fd05ac907cda" contextRef="C_2050f55b-9729-46ca-976a-a50c6da04429" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,225,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares pursuant to the 2024 ATM Program for net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0faa1e83-8cf5-47f4-9c4d-1bd9ae53cde3" contextRef="C_2050f55b-9729-46ca-976a-a50c6da04429" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">5,129</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, after deducting commissions of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_52c0ff3e-762b-4da8-9b0e-1275fba69fb6" contextRef="C_2050f55b-9729-46ca-976a-a50c6da04429" name="us-gaap:PaymentsForCommissions" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">105</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company previously had a Sales Agreement with Cowen to provide for the offering, issuance and sale of up to an aggregate amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd8a32e2-b1d9-4b3b-be8c-5637270ba6ef" contextRef="C_bb8841ed-9927-4eb0-bfb9-ea102a2a8da5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">100.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of common stock from time to time in &#8220;at-the-market&#8221; offerings (2023 ATM Program) pursuant to its shelf registration statement on Form S-3 (File No. 333-270599), which was declared effective April 26, 2023. During the year ended December 31, 2023, the Company sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af92227f-3399-4979-a807-2e7f13b93a67" contextRef="C_9d8c2f96-4509-44a0-991d-9d569f5f45f2" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">4,760,899</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares pursuant to the 2023 ATM Program for net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9c58f63a-4faf-45b0-9f5e-69dc153754a6" contextRef="C_9d8c2f96-4509-44a0-991d-9d569f5f45f2" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">91,740</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, after deducting commissions of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9058cb5-8664-4e10-a430-89b52a8ab426" contextRef="C_9d8c2f96-4509-44a0-991d-9d569f5f45f2" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">2,352</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In the first quarter of 2024, the Company sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_59d177a2-0451-4fd6-b126-e262c8afe502" contextRef="C_68171875-88e5-4c5d-a904-b84ad5d56a17" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">258,070</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> additional shares, completing the 2023 ATM Program for net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_420c4fac-84fe-494c-96a9-59ee53a5ddca" contextRef="C_68171875-88e5-4c5d-a904-b84ad5d56a17" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">5,746</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, after deducting commissions of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c8c8ac71-aec4-429b-9473-8278933162fc" contextRef="C_68171875-88e5-4c5d-a904-b84ad5d56a17" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">147</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2018 Stock Option and Grant Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2018, the Company adopted the 2018 stock option and grant plan (the 2018 Plan), which provided for the Company to sell or issue common stock, or other stock-based awards, to employees, members of the board of directors and consultants of the Company. The Company generally granted stock-based awards with service conditions only (service-based awards), although there was one grant with performance conditions. As of December 31, 2020, there are </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_496f86d5-1254-4a95-8e51-fa478bd6e765" contextRef="C_f5bebf2f-73b3-440e-bc7e-082d8b539b8f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> unvested options with performance conditions. Stock options granted under the 2018 Plan generally vest over </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_12ab2f03-70f4-4da9-bb26-c88cd3cb34ae;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_90059e2e-477d-46ac-a637-66d401eb9db4" contextRef="C_f4635c63-e1a0-4066-bb40-7f550db23dd1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_62f39829-1c88-44d8-9810-67e16f4ca88a" contextRef="C_32ecdf32-80a6-4f58-8b71-96d449c2f6c1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,959,411</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> options granted under the 2018 Plan prior to the Company&#8217;s IPO in October 2019. No further grants may be made under the 2018 Plan subsequent to the IPO.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2019 Stock Option and Incentive Plan</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 2019 Stock Option and Incentive Plan (2019 Plan) was approved by the Company&#8217;s board of directors on October 14, 2019, and became effective on October 23, 2019. The 2019 Plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock units, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights to the Company&#8217;s officers, employees, directors and consultants. The number of shares initially reserved for issuance under the 2019 Plan was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a5b65cb6-b9bd-4159-a55b-27604542daaa" contextRef="C_009b7691-4723-4a29-a462-e1c82235024a" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,342,288</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which will be increased each January 1 thereafter by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eeb24f45-da90-4643-afd3-b2532f3e7c44" contextRef="C_bb64bdf7-38f7-44f3-bf1c-98b0765c39e3" name="caba:IncreaseInShareReservedPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the number of shares of the Company&#8217;s common stock outstanding on the immediately preceding December 31 or such lesser number of shares determined by the Company&#8217;s board of directors or compensation committee of the board of directors. On June 1, 2023, at the 2023 Annual Meeting of Stockholders of the Company, the stockholders of the Company approved Amendment No. 1 to the 2019 Plan, increasing the number of shares of common stock reserved for issuance under the 2019 Plan by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9777cdb8-60ff-4202-bf8b-d76aefb15071" contextRef="C_b642840b-d1a1-4660-9f4a-5c26a6b65c07" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">3,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares. On January 1, 2025, the total number of shares under the 2019 Plan was increased by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_49fe6bb4-6056-4674-ae78-8308ff2a0222" contextRef="C_977637ab-94d3-4e63-b46a-770bc602ae50" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,029,724</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares pursuant to the 2019 Plan Evergreen Provision. As of December 31, 2024, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f2885f6-478b-4999-b88b-f34f5ba6410f" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="caba:SharesRemainingAvailableForIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,379,305</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares remaining available for issuance under the 2019 Plan.</span></p><div><ix:nonNumeric id="F_c182b43f-2f7c-4bac-b874-47f139152e4c" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true" continuedAt="F_c182b43f-2f7c-4bac-b874-47f139152e4c_1"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A summary of the stock option activity is presented below:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:continuation></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div><ix:continuation id="F_71682c1b-3512-4b3a-a601-72b5a798b0dc_2" continuedAt="F_71682c1b-3512-4b3a-a601-72b5a798b0dc_3"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_c182b43f-2f7c-4bac-b874-47f139152e4c_1">
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:33.84%;box-sizing:content-box;"/>
         <td style="width:1.18%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.6%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.66%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.120000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.18%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.64%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.66%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.120000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Shares</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Exercise Price</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (years)</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of January 1, 2024</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f5ef59b2-0130-4caa-9a12-d6f5a1ec8d72" contextRef="C_fdc8bd52-362d-49f3-9e45-6677140ad037" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">8,141,035</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c70c5f10-844d-49de-9159-6a73620c886f" contextRef="C_fdc8bd52-362d-49f3-9e45-6677140ad037" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">8.28</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_975d1126-59de-421e-bf97-53d1784843a8" contextRef="C_8c0ea3f5-c232-4ba9-935c-c4f9363bfb3d" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.6</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_920d1915-8a6a-4650-9724-819f16800510" contextRef="C_fdc8bd52-362d-49f3-9e45-6677140ad037" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">117,384</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b5afb2f6-60a6-4e15-9c98-aa3479d00733" contextRef="C_7bbcce38-fe4c-402a-abef-f39d1a8317bc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">3,476,700</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a6d52bd-2ec4-4341-8d5d-8379e82180e2" contextRef="C_7bbcce38-fe4c-402a-abef-f39d1a8317bc" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">16.13</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_144b931e-9405-4786-8a78-d9efec7007c7" contextRef="C_7bbcce38-fe4c-402a-abef-f39d1a8317bc" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">210,695</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dea74be3-79c3-476f-bc0a-ac7cccd45873" contextRef="C_7bbcce38-fe4c-402a-abef-f39d1a8317bc" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.79</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f67c9a4d-8844-430e-99e3-139f5b9362fd" contextRef="C_7bbcce38-fe4c-402a-abef-f39d1a8317bc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">2,889</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited/Cancelled</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bc9e7881-01a1-4177-8ef4-884641dec96f" contextRef="C_7bbcce38-fe4c-402a-abef-f39d1a8317bc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">175,892</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ac275a9-349d-4866-b100-366dd0e53ce3" contextRef="C_7bbcce38-fe4c-402a-abef-f39d1a8317bc" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">15.04</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2024</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_86c30a54-4baf-4c55-9e18-207ae04fe081" contextRef="C_72321c97-c716-4fc6-b08a-a26615a95579" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">11,231,148</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd98626c-d337-409f-b879-fc51956daef0" contextRef="C_72321c97-c716-4fc6-b08a-a26615a95579" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">10.63</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_694a7b79-0988-4b10-9dea-acac734c3f9f" contextRef="C_7bbcce38-fe4c-402a-abef-f39d1a8317bc" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.4</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af910429-4f55-4d17-b559-c8f67ac80068" contextRef="C_72321c97-c716-4fc6-b08a-a26615a95579" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">989</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options Exercisable at December 31, 2024</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_649901e0-5dd3-4bb5-a268-dc5d5296f35f" contextRef="C_72321c97-c716-4fc6-b08a-a26615a95579" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">5,642,705</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_735b10f9-65c3-4c8e-890e-6b82da79a8f1" contextRef="C_72321c97-c716-4fc6-b08a-a26615a95579" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.92</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_db1fb2b3-9533-4687-a951-5ea6998e0a97" contextRef="C_7bbcce38-fe4c-402a-abef-f39d1a8317bc" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.1</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f33da71f-fec8-4d63-b6aa-b088ce4a9499" contextRef="C_72321c97-c716-4fc6-b08a-a26615a95579" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">966</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:continuation></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate intrinsic value of options granted is calculated as the difference between the exercise price of the options and the estimated fair value of the Company&#8217;s common stock. The weighted average grant-date fair value of stock options granted during the year ended December 31, 2024 and 2023 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f7fc639e-9894-42a4-b72a-8d743d66f026" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">13.44</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_84616073-4435-44c7-a60e-d0dddaa90d97" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">9.51</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_aa5d490e-4146-4a77-91b6-5de0d3cc2f45" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of each award is estimated using Black-Scholes based on the following assumptions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:53.049%;box-sizing:content-box;"/>
         <td style="width:1.8%;box-sizing:content-box;"/>
         <td style="width:21.676%;box-sizing:content-box;"/>
         <td style="width:1.8%;box-sizing:content-box;"/>
         <td style="width:21.676%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d72a84af-0998-457e-9f1b-3f5469d86076" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.43</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_04322ca6-8740-418b-a415-7d8b5fe29e6c" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.60</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_95ed7dd0-a1b4-451c-9857-5c0bc0f1b947" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.38</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_304f8f79-9409-43e4-99b5-f7a4331916ba" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.68</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_44c994da-4072-44ea-a28e-d3d34696fe74" contextRef="C_02a92407-52fe-4b71-9603-dc350a954b27" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years&#8212;</span><span><ix:nonNumeric id="F_1b50e091-b286-4823-8ea5-17869cde7795" contextRef="C_cabc4cba-12e7-440b-9da0-7f7f6b8bb8ea" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.2</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_81919793-6469-4f1b-9b9c-ee28ff262d85" contextRef="C_0f0de8fd-770f-40d6-b430-5691463bc993" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years&#8212;</span><span><ix:nonNumeric id="F_655199ab-b79b-4e41-9683-810ec0a81820" contextRef="C_7bbbdb4f-492f-4e45-b1af-564db3e6c265" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.1</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e728c349-02f1-4ee4-9581-86ff95ec9a41" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">106</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_84afd0ff-30fa-4482-b328-b656789c50e9" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">111</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8268ae2-aaf0-4c7b-94f7-f5e1f76861bc" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">105</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed0def39-a080-4b87-ba83-1987d88df2af" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">107</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_35b620e9-0e0f-4503-abd9-ead582d959ba" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c5b817d1-dd47-40a8-8182-d5b4fc90e92b" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Black-Scholes requires the use of subjective assumptions which determine the fair value of stock-based awards. These assumptions include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected term</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The expected term represents the period that stock-based awards are expected to be outstanding. The expected term for option grants is determined using the simplified method, which is the midpoint between the vesting period and the contractual term of the option.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected volatility</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;As a privately held company prior to the Company&#8217;s IPO in October 2019, the Company has limited trading history for its common stock and, as such, the expected volatility is estimated based on a weighted average volatility for the Company's stock price and comparable publicly traded biotechnology companies over a period equal to the expected term of the stock-based awards. The comparable companies were chosen based on their similar size, stage in the life cycle or area of specialty. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of a stock-based award.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected dividend</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1cc64067-2cef-4d5d-b614-b0cdb98b2108" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has recorded stock-based compensation in the accompanying statements of operations as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.883000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.883000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_385e647d-2f82-4186-91ef-60a88296da02" contextRef="C_b1d3cbe4-887e-45db-abd2-b02478b909a8" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">10,163</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87342fa5-f2bc-49e5-8e80-b4174bbc04bd" contextRef="C_a2e82d17-72fd-4199-85b4-3a85429d0d81" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">5,520</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f69c34eb-273f-47f4-954e-d9568fc0df24" contextRef="C_5c849a35-78e8-4658-b224-1c019b513ae4" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">9,302</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fdb2761c-8576-4b14-9a82-79e9926cfebc" contextRef="C_8fc080aa-f389-40f6-aa75-a26757919ae1" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">5,823</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d944c956-0047-4516-9976-604a39aadd7f" contextRef="C_50ec53a6-211e-4704-8e25-521e6deb405e" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">19,465</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b8e0a92f-1ac7-4e42-b4fc-554c57f654eb" contextRef="C_85326982-4e9e-4cd8-af12-fd49791a671c" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">11,343</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:continuation></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_71682c1b-3512-4b3a-a601-72b5a798b0dc_3"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, there was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2c528e55-56cc-475b-868e-0fa2ac636da0" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">51,239</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of unrecognized compensation cost related to unvested option awards, which is expected to be recognized over a weighted-average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c566b247-9e2e-4c70-86a3-baad3d14a6fe" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.8</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2019 Employee Stock Purchase Plan</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 2019 Employee Stock Purchase Plan (2019 ESPP) was approved by the Company&#8217;s board of directors on October 14, 2019, and became effective on October 23, 2019. A total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7f5c376-3f39-4f99-9308-0de8bccf5ce9" contextRef="C_91bebac1-a194-4aa0-bdad-e2db91554491" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">234,229</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock were initially reserved for issuance under the 2019 ESPP, and such number of shares will be increased each January 1 thereafter through January 1, 2029 by the least of (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a3beba35-e8e0-410b-865e-52e5f04a48c0" contextRef="C_1f0087e0-dac4-4dce-a0b5-2502f2165631" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">234,229</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock, (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_44cb433b-828a-42e0-aa47-326eeed245fe" contextRef="C_b6d231da-185f-42c9-9b3d-442d6ca59665" name="caba:IncreaseInShareReservedPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the number of shares of the Company&#8217;s common stock outstanding on the immediately preceding December 31 or (iii) such lesser number of shares determined by the 2019 ESPP&#8217;s administrator. There was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c1ae1ea3-a906-4569-a17d-4def52ce1010" contextRef="C_6525b174-f1b8-46c9-95b2-6b44e02a8e4d" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_05067584-bf5a-4980-ae16-a8f2a11e9c5b" contextRef="C_8c193bbc-bddd-4caa-a616-ab7149fe99f2" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_5b7dbfa8-d8c2-4cb4-bc0f-bd90a5186d8d" contextRef="C_72e98e9b-d795-49b3-92aa-8c76efc07029" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> increase to the total number of shares </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">available under the 2019 ESPP on January 1, 2024, 2023 or 2022, respectively. As of December 31, 2024, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af795dfe-8976-4a48-b69f-1acffeee6259" contextRef="C_4911bc2b-bbb5-4139-af54-75d9d982736e" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">314,259</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares remaining available for issuance under the 2019 ESPP.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employee contributions are made through payroll deductions of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cca3a8f8-7582-47d9-a60f-c4ee32b61005" contextRef="C_b8337e36-0fb0-43e5-b463-b4b3890b87c5" name="caba:PercentageOfPayrollDeductionOnEligibleCompensation" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">15</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of eligible compensation over the offering period. A participant may not accrue rights to purchase more than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b2e5d884-68f1-4d7e-ac37-fae41f3a3dcd" contextRef="C_b8337e36-0fb0-43e5-b463-b4b3890b87c5" name="caba:EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> worth of the Company&#8217;s common stock for each calendar year in which such right is outstanding. At the end of each offering period, shares of the Company&#8217;s common stock may be purchased at </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f2331e8-ce21-43f1-86da-1f4aa78493cc" contextRef="C_b8337e36-0fb0-43e5-b463-b4b3890b87c5" name="caba:PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">85</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the lesser of the Company&#8217;s common stock on (i) the first trading day of the relevant offering period and (ii) the last trading day of the relevant offering period. Each offering period will be six months in duration and will commence on each December 1 and June 1.</span></p></ix:continuation></div><div><ix:nonNumeric id="F_23ff72bd-2af0-441d-8914-3f43b9246254" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true" continuedAt="F_23ff72bd-2af0-441d-8914-3f43b9246254_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11. Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f2952dda-33af-454d-8809-09b2b0fabcc0" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The reconciliation of federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:54.151%;box-sizing:content-box;"/>
         <td style="width:1.78%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:19.144000000000002%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.78%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:19.144000000000002%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected income tax benefit at the federal statutory rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c819d946-210b-4d0c-aec4-24d98e7191fa" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_36caf0b5-7afb-4e34-9967-46cc4259806f" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State and local taxes, net of federal benefit</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_75e4b7e6-dacc-4fbf-8a3b-eca6c0c21062" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">7.7</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4c656df4-2641-47b5-8ba8-60b139c9c223" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">7.6</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development credit, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_261722aa-ac8c-409e-aed9-930cc438fb83" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">5.3</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70620bd8-101d-4e17-b355-dfed7fe017a5" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">6.4</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-deductible items and other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ff21ac6-3456-4f34-b30d-f1e6817aeb7e" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="caba:EffectiveIncomeTaxRateReconciliationNondeductibleItemsAndOther" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">1.1</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4efa23ab-0435-4232-9cce-e2e08f6d5728" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="caba:EffectiveIncomeTaxRateReconciliationNondeductibleItemsAndOther" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in state and local tax rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c7a8c72-4845-4138-903d-a7a41810aa89" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="caba:ChangeInStateAndLocalTaxRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc3d095e-4b24-458e-8101-7d962e7492d5" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="caba:ChangeInStateAndLocalTaxRate" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34ffba2d-388a-4795-aed7-9cb13cfaf116" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">32.9</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a948cbe-e2d8-487a-8a4e-11d66d1ce558" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">33.8</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3bfbdd3f-8dd0-40d5-9c46-712ce080b811" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_221d714b-d545-4393-912d-eb97c7ba7c88" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. </span><span><ix:nonNumeric id="F_4d401ac0-419c-4555-943b-ca341f461808" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true" continuedAt="F_4d401ac0-419c-4555-943b-ca341f461808_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The principal components of the Company&#8217;s deferred tax assets and liabilities consisted of the following: </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:continuation id="F_4d401ac0-419c-4555-943b-ca341f461808_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.883000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.883000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal, state and local net operating loss carryforwards</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_94a35c4e-7919-4a54-998a-e6cc7d824b84" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,369</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6d870e5-e496-48e1-865c-a5d6bd9fbbac" contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,534</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized research and development costs</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_90bcd3de-70c2-480c-9b85-71cefddc540a" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="caba:CapitalizedRDCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,646</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ddd7476-3067-4530-a21b-38255cf3a5a9" contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc" name="caba:CapitalizedRDCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,830</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development tax credits</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_db0b98a4-6d4a-44d9-a71b-d49620386214" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,296</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2376181f-3309-4cca-912d-807a34c9bf52" contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,192</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation deductions</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_90dffe96-30d7-4b5b-b33f-164b45c53771" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,919</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ac1a16ec-ffb1-4668-99d7-b27a2915e6ee" contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,066</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License fee deductions</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e2e3d650-edee-4f4c-88a6-0122e1ded240" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="caba:DeferredTaxAssetsLicenseFeesDeductions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">221</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba31fcaf-f02c-4c75-b150-a73843c437f6" contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc" name="caba:DeferredTaxAssetsLicenseFeesDeductions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">240</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f50ac34-0a91-4058-aca1-597e40b4e5e6" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="caba:DeferredTaxAssetsOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,607</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5797f378-bf45-4f06-ac46-4b1efb90eb7e" contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc" name="caba:DeferredTaxAssetsOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,482</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4c11a143-571e-475c-9079-d6b859eb0e93" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,603</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_78e04ee0-46ca-449e-ae20-097eef0a4dcf" contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,665</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gross deferred tax assets</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c0c0f1b-5952-4a3c-8a58-716e5461cfec" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">114,661</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9fa993fb-d92a-4e1c-b10b-4c6a8f05e363" contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">74,009</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: valuation allowance</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc11702c-dde3-4434-82d4-b8b34a6e2e8d" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">110,723</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bf6b7e00-7e08-4cdd-9152-c9f4db34ead5" contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">72,560</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_296ccbb3-b463-44d3-a921-9a787463f812" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,938</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a200aeb-c334-4255-a34a-98ca4f7444b0" contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,449</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b89d67df-d02d-4490-87eb-8d573a3862c0" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="caba:OperatingLeaseAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,938</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2bdb42b0-e599-43d4-8792-de63a72f27cf" contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc" name="caba:OperatingLeaseAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,449</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred tax assets</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fdf8085d-3b7f-4d40-9cda-38e7e503e48d" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_03a8ef39-fdee-483a-b28d-5c1b61394bda" contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:continuation></div></ix:nonNumeric></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_23ff72bd-2af0-441d-8914-3f43b9246254_1"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company increased its valuation allowance by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a69cdc4f-039c-40ef-9e6e-9cb494619e05" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,163</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the year ended December 31, 2024 in order to maintain a full valuation allowance against its deferred tax assets. Based on the Company&#8217;s history of losses, the Company recorded a full valuation allowance against its deferred tax assets as of December 31, 2024. The Company intends to maintain a valuation allowance until sufficient positive evidence exists to support a reversal of the allowance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the Company had federal, state and local net operating loss carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_817bc51f-4291-4765-9b03-e4ff14ce8219" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="caba:DeferredTaxAssetsOperatingLossCarryforwardsFederal" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">157,448</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2133a288-d5b8-4310-bb37-06f327ac7cea" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="caba:DeferredTaxAssetsOperatingLossCarryforwardsState" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">181,362</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8704671b-7fc9-4089-938d-4222240f8963" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="caba:DeferredTaxAssetsOperatingLossCarryforwardsLocal" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">88,701</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively; $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_677e038e-24a2-4a36-8403-33f7abee461a" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">157,198</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the federal net operating losses do not expire, and the remaining $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_43db2cd1-d7ac-4030-9d52-1abb18a4a4eb" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" unitRef="U_USD" scale="3" decimals="-3">250</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2ff0b412-07fa-4b75-be19-1439621d5833" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="caba:OperatingLossCarryforwardsFederalCommencementOfExpirationDate"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2037</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The state net operating losses begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ca68e829-8a35-4d27-880f-859354d26cbb" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="caba:OperatingLossCarryforwardsStateCommencementOfExpirationDate"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2037</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The local net operating losses begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1a002b45-de79-46f5-b648-c61a3bcbcbfe" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="caba:OperatingLossCarryforwardsLocalCommencementOfExpirationDate"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2042</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As of December 31, 2024, the Company had federal and state research and development tax credit carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e6eeed2-e70f-4ebd-b5a6-e66354ea29a6" contextRef="C_60702d76-a78f-433d-8046-7a817c666483" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,684</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b6789ab-299b-484b-b734-3c5360af3624" contextRef="C_5c158f7e-d30a-4d7e-913b-54efddfa9032" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">612</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively, which begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_28374468-1b5e-4e80-869c-358001b1f6be" contextRef="C_7f97431a-51bc-48de-b369-469db20bdb17" name="caba:DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2038 </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c3168ba7-3b14-4e82-8b82-9e03747b4dfa" contextRef="C_881cd698-8215-4730-9508-1b847dfa7222" name="caba:DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2036</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively. Under the provisions of Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the IRC), these net operating losses, credit carryforwards and other tax attributes may be subject to limitation based on previous significant changes in ownership and upon future significant changes in ownership of the Company, as defined by the IRC.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company files income tax returns in the U.S. federal jurisdiction as well as in Pennsylvania and Philadelphia. The tax years 2023, 2022 and 2021 remain open to examination by the jurisdictions where the Company is subject to tax.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company evaluates tax positions for recognition using a more-likely-than-not recognition threshold, and those tax positions eligible for recognition are measured as the largest amount of tax benefit that is greater than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e35e36f-aa3f-45b4-a28c-3049ea9b29ff" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="caba:PercentageOfEligibleTaxPositionsForRecognition" unitRef="U_pure" scale="-2" decimals="2">50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% likely of being realized upon the effective settlement with a taxing authority that has full knowledge of all relevant information. As of December 31, 2024, the Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d0003b7f-abf0-4bb4-b665-c2a0df71c653" contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> unrecognized income tax benefits that would affect the Company&#8217;s effective tax rate if recognized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div><ix:nonNumeric id="F_2180a849-8752-4260-90f8-175d13828e0f" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:EarningsPerShareTextBlock" escape="true" continuedAt="F_2180a849-8752-4260-90f8-175d13828e0f_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12. Net Loss Per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company calculates basic and diluted net loss per share in conformity with the two-class method required for participating securities. For the year ended December 31, 2023, the Company had voting and non-voting common stock outstanding. In May 2024, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6aa0f6f3-d5f6-4dd6-ad8d-6f55777c9f57" contextRef="C_3577cd65-82b8-42e6-844e-ca6167dba709" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,444,295</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of non-voting common stock was converted to voting common stock and as of December 31, 2024, no shares of non-voting common stock remain outstanding. Since the rights of the voting and non-voting common stock are identical, except with respect to voting, the undistributed losses of the Company have been</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> allocated on a proportionate basis to the two classes. Basic net loss per share of common stock is computed by dividing the net loss per share of common stock by the weighted average number of shares of common stock outstanding for the period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted average shares of common stock outstanding as of December 31, 2023 included outstanding pre-funded warrants to purchase up to an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_63654c15-34f4-4ae6-95eb-96ca0af9e383" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,168,054</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4fe8ae2a-91c0-4558-b1e8-5993a169ffb0" contextRef="C_50b61005-316a-440c-b7d7-051b2270374c" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> pre-funded warrants remain outstanding as of December 31, 2024.</span></p><div><ix:nonNumeric id="F_83d1d007-63d2-4fa0-8096-e145dc530f27" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true" continuedAt="F_83d1d007-63d2-4fa0-8096-e145dc530f27_1"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Diluted net loss per share is calculated using the if-converted method, which assumes conversion of all non-voting common stock to voting common stock.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.4%;box-sizing:content-box;"/>
         <td style="width:1.92%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.88%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.92%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.88%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Voting common stock</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Non-voting common stock</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Basic net loss per share:</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;text-indent:5pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Allocation of undistributed losses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c0d48a13-3ec4-4c2e-8824-0717ced9c58b" contextRef="C_b76590bb-7198-4431-94bb-7578a594bad1" name="us-gaap:UndistributedEarningsLossAvailableToCommonShareholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">114,728</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_458ce38d-e2cb-48e3-b68e-0dd16ee855a6" contextRef="C_c46ec4f4-c805-417a-8a4d-faada740c019" name="us-gaap:UndistributedEarningsLossAvailableToCommonShareholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,136</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;text-indent:5pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average number of shares used in basic per share computation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd337ad4-40f7-4955-86ec-a3090c67b9c1" contextRef="C_b76590bb-7198-4431-94bb-7578a594bad1" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">49,038,726</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_46e3b592-24fb-4e40-a82b-af55ac9e97ed" contextRef="C_c46ec4f4-c805-417a-8a4d-faada740c019" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">485,378</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share, basic</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc29f862-785b-4871-a875-68f7399b6a4b" contextRef="C_b76590bb-7198-4431-94bb-7578a594bad1" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">2.34</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aeb7629b-22e1-4f2c-bfe9-3401baef0799" contextRef="C_c46ec4f4-c805-417a-8a4d-faada740c019" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">2.34</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Diluted net loss per share:</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;text-indent:5pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Allocation of undistributed losses for basic computation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1827bb1-4daa-484e-ba19-def976c2797e" contextRef="C_b76590bb-7198-4431-94bb-7578a594bad1" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">114,728</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a11c6414-9899-465f-8be9-269c6e99b383" contextRef="C_c46ec4f4-c805-417a-8a4d-faada740c019" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,136</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reallocation of undistributed losses as a result of conversion of<br/>&#160;&#160;&#160;&#160;&#160;non-voting to voting common shares</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa1b6e54-97bc-4de9-8bb9-5810c86b349e" contextRef="C_b76590bb-7198-4431-94bb-7578a594bad1" name="us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,136</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_767a8167-5392-43a1-8db7-2caa62a81d08" contextRef="C_c46ec4f4-c805-417a-8a4d-faada740c019" name="us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Allocation of undistributed losses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_be043cc6-c3e2-4879-9c21-b98ed5744986" contextRef="C_b76590bb-7198-4431-94bb-7578a594bad1" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">115,864</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_320b4b6a-f796-4052-8f5f-163af8e4fec8" contextRef="C_c46ec4f4-c805-417a-8a4d-faada740c019" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,136</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;text-indent:5pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average number of shares used in basic per share computation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_68ec595b-1fb9-42b8-947f-9a0f2379ff58" contextRef="C_b76590bb-7198-4431-94bb-7578a594bad1" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">49,038,726</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f9a92041-adda-4de6-9352-deb9a9b17d68" contextRef="C_c46ec4f4-c805-417a-8a4d-faada740c019" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">485,378</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Add: conversion of non-voting to voting common shares outstanding</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2fde431b-4303-4f4a-934b-e3e61dad1380" contextRef="C_b76590bb-7198-4431-94bb-7578a594bad1" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">485,378</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_51fea91e-30e5-45df-af20-aa9f5a215ea6" contextRef="C_c46ec4f4-c805-417a-8a4d-faada740c019" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average number of shares used in diluted per share computation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e293946-9fd4-4f6c-8b16-13c03bbbba3f" contextRef="C_b76590bb-7198-4431-94bb-7578a594bad1" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">49,524,104</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_108d2e0b-7250-488d-8fd0-891aa9034652" contextRef="C_c46ec4f4-c805-417a-8a4d-faada740c019" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">485,378</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share, diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7e81d2b-f218-4c00-b79c-bb701bdf3463" contextRef="C_b76590bb-7198-4431-94bb-7578a594bad1" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">2.34</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e3a30f4f-9880-4507-b34e-5a05d14f88f9" contextRef="C_c46ec4f4-c805-417a-8a4d-faada740c019" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">2.34</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div><ix:continuation id="F_2180a849-8752-4260-90f8-175d13828e0f_1"><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:continuation id="F_83d1d007-63d2-4fa0-8096-e145dc530f27_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.4%;box-sizing:content-box;"/>
         <td style="width:1.92%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.88%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.92%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.88%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31, 2023</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Voting common stock</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Non-voting common stock</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Basic net loss per share:</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;text-indent:5pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Allocation of undistributed losses</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d519e693-bae9-4bee-924a-78629ad30a6f" contextRef="C_8820b6d6-f9b3-4f60-970e-aabd2aa79a08" name="us-gaap:UndistributedEarningsLossAvailableToCommonShareholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">64,776</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d9742fc-b039-49e5-bd14-60347c1ed5e3" contextRef="C_00142f0e-bf74-4dac-98f2-8c7944fde213" name="us-gaap:UndistributedEarningsLossAvailableToCommonShareholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,899</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;text-indent:5pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average number of shares used in basic per share computation</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3b4e14e-da67-498d-92f7-7366d3e401c5" contextRef="C_8820b6d6-f9b3-4f60-970e-aabd2aa79a08" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">39,192,445</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5aa69b6d-de9e-496d-9b5e-e1ff9ed22bce" contextRef="C_00142f0e-bf74-4dac-98f2-8c7944fde213" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,753,505</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share, basic</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_67072577-1d0e-4061-bd90-fbf1f61f0010" contextRef="C_8820b6d6-f9b3-4f60-970e-aabd2aa79a08" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.65</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aeeab4b7-76ae-4fdb-a425-d8b431853330" contextRef="C_00142f0e-bf74-4dac-98f2-8c7944fde213" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.65</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Diluted net loss per share:</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;text-indent:5pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Allocation of undistributed losses for basic computation</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a87a869-686b-45ef-849e-95049b192210" contextRef="C_8820b6d6-f9b3-4f60-970e-aabd2aa79a08" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">64,776</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85c81fc7-e110-49e2-b095-e29c65abeef0" contextRef="C_00142f0e-bf74-4dac-98f2-8c7944fde213" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,899</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reallocation of undistributed losses as a result of conversion of<br/>&#160;&#160;&#160;&#160;&#160;non-voting to voting common shares</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_04c92786-2749-43ae-ab0f-a8ca0a4e6351" contextRef="C_8820b6d6-f9b3-4f60-970e-aabd2aa79a08" name="us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,899</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9b6cfe8-2d20-481a-85f4-9631d57fc1ad" contextRef="C_00142f0e-bf74-4dac-98f2-8c7944fde213" name="us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Allocation of undistributed losses</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_be395a05-bdcb-4569-a9e2-e3e450ab8c67" contextRef="C_8820b6d6-f9b3-4f60-970e-aabd2aa79a08" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">67,675</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3954f645-89c1-4376-b6ee-d723fe934ba6" contextRef="C_00142f0e-bf74-4dac-98f2-8c7944fde213" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,899</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;text-indent:5pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average number of shares used in basic per share computation</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f318593d-156f-41e5-a60a-a1a7f0ca8171" contextRef="C_8820b6d6-f9b3-4f60-970e-aabd2aa79a08" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">39,192,445</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_342e5967-b8ea-401d-b64e-d0a87f0377b3" contextRef="C_00142f0e-bf74-4dac-98f2-8c7944fde213" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,753,505</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Add: conversion of non-voting to voting common shares outstanding</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_db344903-b1f1-4cc7-b228-f6044c0cf1d1" contextRef="C_8820b6d6-f9b3-4f60-970e-aabd2aa79a08" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,753,505</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7552d1ad-13f0-460a-bc2b-776ba198debe" contextRef="C_00142f0e-bf74-4dac-98f2-8c7944fde213" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average number of shares used in diluted per share computation</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5033d2b3-c57e-41a2-9143-5d5e1ca7b93c" contextRef="C_8820b6d6-f9b3-4f60-970e-aabd2aa79a08" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">40,945,950</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0da210eb-2a78-46bd-9f0e-9ae56a18858b" contextRef="C_00142f0e-bf74-4dac-98f2-8c7944fde213" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,753,505</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share, diluted</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24bc6bb0-0cb4-4b20-8228-46701cac20cf" contextRef="C_8820b6d6-f9b3-4f60-970e-aabd2aa79a08" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.65</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_77110cc9-da59-44fe-89a1-10b2a72ca333" contextRef="C_00142f0e-bf74-4dac-98f2-8c7944fde213" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.65</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_143be6af-45a0-4bfc-aa8f-c2ea22753604" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true" continuedAt="F_143be6af-45a0-4bfc-aa8f-c2ea22753604_1"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share, as their effect is anti-dilutive:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.967%;box-sizing:content-box;"/>
         <td style="width:1.16%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.357%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.16%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.357%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options to purchase common stock</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7591595d-4290-4527-a7ef-0e3cc1bb3e86" contextRef="C_f5851d98-3e59-44ab-89c0-e44329981682" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">11,231,148</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24e9ca10-1824-4cce-8f89-a7dca2baf9e3" contextRef="C_1e81d161-d2c9-4466-ad56-b46b0e4daea1" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">8,141,035</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e72c530-3bc7-455b-9cd8-9f6b01ca1744" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">11,231,148</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cbf4f042-c25b-40d3-adc1-b015f147f7b6" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">8,141,035</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div></ix:continuation></div><div><ix:continuation id="F_143be6af-45a0-4bfc-aa8f-c2ea22753604_1"></ix:continuation></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d4eefa90-5123-402d-9a3b-4ee5c5338bb7" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13. 401(k) Savings Plan</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company maintains a defined-contribution savings plan under Section 401(k) of the IRC, or the 401(k) Plan. The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pretax basis. Effective January 1, 2020, the Plan provided for matching contributions on a portion of participant contributions pursuant to the 401(k) Savings Plan&#8217;s matching formula, up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_403830d0-6cbe-4046-8f03-ddaaff265f5d" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of eligible compensation. All matching contributions and participant contributions vest immediately. Contributions totaled $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0370faeb-d909-4fda-bbbf-44367199572d" contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c" name="us-gaap:DefinedContributionPlanCostRecognized" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">894</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a1c1ef00-b676-4716-a999-502cc53a9e1c" contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a" name="us-gaap:DefinedContributionPlanCostRecognized" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">521</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the years ended December 31, 2024 and 2023, respectively, and have been recorded in the statements of operations.</span></p></ix:nonNumeric></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXHIBIT INDEX</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:9.84%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:89.16%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
    </tr>
    <tr style="height:6pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/0001759138/000119312519278927/d759120dex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Third Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect (incorporated by reference to Exhibit 3.1 of the Registrant&#8217;s Current Report on Form 8-K (File No. 001-39103) filed on October 30, 2019)</span></a></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.2</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/0001759138/000119312519278927/d759120dex32.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Bylaws of the Registrant, as currently in effect (incorporated by reference to Exhibit 3.2 of the Registrant&#8217;s Current Report on Form 8-K (File No. 001-39103) filed on October 30, 2019)</span></a></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.3</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000156459022019677/caba-ex33_49.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 1 to the Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.3 to the Registrant's Quarterly Report on Form 10-Q (File No. 001-39103) filed with the SEC on May 12, 2022)</span></a></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/0001759138/000119312519268040/d686907dex41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Specimen Common Stock Certificate (incorporated by reference to Exhibit 4.1 of the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-234017) filed on October 16, 2019</span></a><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000095017024034422/caba-ex4_3.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Description of Securities (incorporated by reference to Exhibit 4.3 to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-39103) filed on March 21, 2024)</span></a></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000119312522302822/d397326dex41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 of the Registrant's Current Report on Form 8-K (File No. 001-39103) filed with the SEC on December 12, 2022</span></a></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1#</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/0001759138/000119312519258869/d686907dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">2018 Stock Option and Grant Plan, as amended, and form of award agreements thereunder (incorporated by reference to Exhibit 10.1 of the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-234017) filed on September 30, 2019)</span></a></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2#</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/0001759138/000119312519268040/d686907dex102.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">2019 Stock Option and Incentive Plan, and form of award agreements thereunder. (incorporated by reference to Exhibit 10.2 of the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-234017) filed on October 16, 2019)</span></a></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3#</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000119312523158936/d516711dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 1 to the Cabaletta Bio, Inc. 2019 Stock Option and Incentive Plan (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on June 1, 2023)</span></a></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4#</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/0001759138/000119312519268040/d686907dex103.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">2019 Employee Stock Purchase Plan. (incorporated by reference to Exhibit 10.3 of the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-234017) filed on October 16, 2019)</span></a></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.5#</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/0001759138/000156459019045375/caba-ex104_188.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Senior Executive Cash Incentive Bonus Plan (incorporated by reference to Exhibit 10.4 of the Registrant&#8217;s Quarterly Report on Form 10-Q filed on December 5, 2019)</span></a></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.6#</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/0001759138/000119312519258869/d686907dex105.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Indemnification Agreement between the Registrant and each of its directors (incorporated by reference to Exhibit 10.5 of the Registrant&#8217;s Registration Statement on Form S-1, filed with the SEC on September 30, 2019)</span></a></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.7#</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/0001759138/000119312519258869/d686907dex104.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Indemnification Agreement between the Registrant and each of its executive officers (incorporated by reference to Exhibit 10.4 of the Registrant&#8217;s Registration Statement on Form S-1, filed with the SEC on September 30, 2019)</span></a></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.8+</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/0001759138/000119312519258869/d686907dex106.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated License Agreement, dated as of July 23, 2019, among the Registrant, the Trustees of the University of Pennsylvania and the Children&#8217;s Hospital of Philadelphia (incorporated by reference to Exhibit 10.6 to the Registrant&#8217;s Registration Statement on Form S-1, filed with the SEC on September 30, 2019)</span></a></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">135</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:9.84%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:89.16%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.9+</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000119312519258869/d686907dex109.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Master Translational Research Services Agreement, dated as of October 2018, between the Registrant and the Trustees of the University of Pennsylvania (incorporated by reference to Exhibit 10.9 to the Registrant&#8217;s Registration Statement on Form S-1, filed with the SEC on September 30, 2019)</span></a></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.10+</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000119312519258869/d686907dex1010.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">CAROT Master Services Addendum to Master Translational Research Services Agreement, dated as of February 4, 2019, between the Registrant and the Trustees of the University of Pennsylvania (incorporated by reference to Exhibit 10.10 to the Registrant&#8217;s Registration Statement on Form S-1, filed with the SEC on September 30, 2019)</span></a></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.11+</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000119312519258869/d686907dex1011.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">CVPF Master Services Addendum to Master Translational Research Services Agreement, dated as of October 22, 2018, between the Registrant and the Trustees of the University of Pennsylvania (incorporated by reference to Exhibit 10.11 to the Registrant&#8217;s Registration Statement on Form S-1, filed with the SEC on September 30, 2019)</span></a></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.12</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000119312519258869/d686907dex1013.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Lease, dated as of February 11, 2019, between the Registrant and Brandywine Cira, L.P. (incorporated by reference to Exhibit 10.13 to the Registrant&#8217;s Registration Statement on Form S-1, filed with the SEC on September 30, 2019)</span></a></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.13#</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000119312519258869/d686907dex1016.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement between the Registrant and Steven Nichtberger (incorporated by reference to Exhibit 10.16 to the Registrant&#8217;s Registration Statement on Form S-1, filed with the SEC on September 30, 2019)</span></a></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.14#</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000119312519258869/d686907dex1017.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement between the Registrant and Anup Marda (incorporated by reference to Exhibit 10.17 to the Registrant&#8217;s Registration Statement on Form S-1, filed with the SEC on September 30, 2019)</span></a></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.15#</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000119312519258869/d686907dex1018.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement between the Registrant and Gwendolyn Binder (incorporated by reference to Exhibit 10.18 to the Registrant&#8217;s Registration Statement on Form S-1, filed with the SEC on September 30, 2019)</span></a></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.16#</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000119312519258869/d686907dex1019.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement between the Registrant and David Chang (incorporated by reference to Exhibit 10.19 to the Registrant&#8217;s Registration Statement on Form S-1, filed with the SEC on September 30, 2019)</span></a></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.17*</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="caba-ex10_17.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Fourth Amended and Restated Non-Employee Director Compensation Policy</span></a></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.18+</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000119312520153792/d933839dex102.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">First Amendment, dated May 27, 2020, to the Amended and Restated License Agreement, dated July 23, 2019, among the Registrant, the Trustees of the University of Pennsylvania and the Children&#8217;s Hospital of Philadelphia (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-39103) filed on May 28, 2020)</span></a></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.19+</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000156459020037278/caba-ex101_80.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment to CAROT Master Services Addendum to Master Translational Research Services Agreement, dated as of May 18, 2020 between the Registrant and the Trustees of the University of Pennsylvania (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-39103) filed on August 6, 2020)</span></a></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.20+</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000156459021053043/caba-ex102_47.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Second Amendment, dated October 19, 2021, to the First Amended and Restated License Agreement, dated May 27, 2020, among the Registrant, the Trustees of the University of Pennsylvania and the Children&#8217;s Hospital of Philadelphia (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-39103) filed on November 1, 2021)</span></a></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.21</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000156459022010726/caba-ex1026_216.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">First Amendment, dated February 15, 2022, to the Lease, dated as of February 11, 2019, between the Registrant and Brandywine Cira, L.P. (incorporated by reference to Exhibit 10.26 to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-39103) filed on March 17, 2022)</span></a></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.22#</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000156459022010726/caba-ex1028_217.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Employment Agreement (incorporated by reference to Exhibit 10.28 to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-39103) filed on March 17, 2022)</span></a></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">136</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:9.84%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:89.16%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.23+</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000156459022010726/caba-ex1030_56.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Option Agreement, dated December 23, 2021, by and between the Registrant and the Trustees of the University of Pennsylvania (incorporated by reference to Exhibit 10.30 to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-39103) filed on March 17, 2022)</span></a></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.24+</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000156459022010726/caba-ex1031_59.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Licence and Supply Agreement, dated December 30, 2021, by and between the Registrant and Oxford Biomedica (UK) Limited (incorporated by reference to Exhibit 10.31 to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-39103) filed on March 17, 2022)</span></a></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.25+</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000095017023040966/caba-ex10_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">First Amendment to the Licence and Supply Agreement, dated as of May 2, 2023, between the Registrant and Oxford Biomedica (UK) Limited (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-39103) filed on August 10, 2023)</span></a></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.26+</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000095017023061528/caba-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Second Amendment to the Licence and Supply Agreement, dated as of August 18, 2023, between the Registrant and Oxford Biomedica (UK) Limited (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-39103) filed on November 9, 2023)</span></a></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.27+</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000095017022024168/caba-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Exclusive License Agreement, dated October 7, 2022, by and between the Registrant and Nanjing IASO Biotherapeutics Co., LTD.(incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-39103) filed on November 10, 2022</span></a><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.28+</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000095017023008298/caba-ex10_34.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Development, Manufacturing, and Testing Services Agreement, dated January 11, 2021, between the Registrant and WuXi Advanced Therapies Inc. (incorporated by reference to Exhibit 10.34 to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-39103) filed on March 16, 2023)</span></a></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.29+</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000095017023020849/caba-ex10_1.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Master Translational Research Services Agreement, dated as of February 9, 2023, between the Registrant and the Trustees of the University of Pennsylvania (incorporated by reference to Exhibit 10.1 to the Registrant's Quarterly Report on Form 10-Q (File No. 001-39103) filed on May 11, 2023)</span></a></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.30+</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000095017024060045/caba-ex10_1.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Third Amendment to the Licence and Supply Agreement, dated as of February 21, 2024, between the Registrant and Oxford Biomedica (UK) Limited (incorporated by reference to Exhibit 10.1 to the Registrant's Quarterly Report on Form 10-Q (File No. 001-39103) filed on May 15, 2024)</span></a></p></td>
    </tr>
    <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.31+</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000095017024093325/caba-ex10_1.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Fourth Amendment to the Licence and Supply Agreement, dated as of June 24, 2024, between the Registrant and Oxford Biomedica (UK) Limited (incorporated by reference to Exhibit 10.1 to the Registrant's Quarterly Report on Form 10-Q (File No. 001-39103) filed on August 8, 2024)</span></a></p></td>
    </tr>
    <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.32+</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000095017024126733/caba-ex10_1.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Services Agreement, dated as of February 1, 2019, between the Registrant and CIC Innovation Communities, LLC (incorporated by reference to Exhibit 10.1 to the Registrant's Quarterly Report on Form 10-Q (File No. 001-39103) filed on November 14, 2024)</span></a></p></td>
    </tr>
    <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.33+</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000095017024126733/caba-ex10_2.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment to the Services Agreement, dated as of December 1, 2021, between the Registrant and CIC Innovation Communities, LLC (incorporated by reference to Exhibit 10.2 to the Registrant's Quarterly Report on Form 10-Q (File No. 001-39103) filed on November 14, 2024)</span></a></p></td>
    </tr>
    <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.34+</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000095017024126733/caba-ex10_3.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment to the Services Agreement, dated as of September 30, 2024, between the Registrant and CIC Innovation Communities, LLC (incorporated by reference to Exhibit 10.3 to the Registrant's Quarterly Report on Form 10-Q (File No. 001-39103) filed on November 14, 2024)</span></a></p></td>
    </tr>
    <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.35+</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000095017024126733/caba-ex10_4.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Second Amendment, dated September 24, 2024, to the Lease, dated as of February 11, 2019, between the Registrant and Brandywine Cira, L.P., as amended. (incorporated by reference to Exhibit 10.4 to the Registrant's Quarterly Report on Form 10-Q (File No. 001-39103) filed on November 14, 2024)</span></a></p></td>
    </tr>
    <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.1*</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="caba-ex19_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Insider Trading Policy</span></a></p></td>
    </tr>
    <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:12.95pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.1*</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="caba-ex21_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">List of Subsidiaries of the Registrant</span></a></p></td>
    </tr>
    <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">137</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:9.84%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:89.16%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.1*</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="caba-ex23_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consent of Ernst &amp; Young, independent registered public accounting firm</span></a></p></td>
    </tr>
    <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.1*</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="caba-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as amended</span></a></p></td>
    </tr>
    <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.2*</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="caba-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as amended</span></a></p></td>
    </tr>
    <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.1**</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="caba-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
    </tr>
    <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.2**</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="caba-ex32_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
    </tr>
    <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99.7</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000095017024034422/caba-ex99_7.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Cabaletta Bio, Inc.'s Compensation Recovery Policy (incorporated by reference to Exhibit 99.7 to the Registrant's Annual Report on Form 10-K (File No. 001-39103) filed on March 21, 2024)</span></a></p></td>
    </tr>
    <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.INS*</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.SCH*</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.CAL*</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.DEF*</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.LAB*</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Label Linkbase Document</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.PRE*</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:right;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104*</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101*)</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
   </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:84.615%;text-align:justify;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"># Management Contract or compensatory plan or arrangement.</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">+ Portions of this exhibit (indicated by asterisks) have been omitted pursuant to Item 601(b)(10) of Regulation S-K.</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* Filed herewith.</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">** The certifications furnished in Exhibit 32.1 and 32.2 hereto are deemed to accompany this Annual Report on Form 10-K and will not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Such certifications will not be deemed to be incorporated by reference into any filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates it by reference.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">138</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="signatures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNATURES</span></p><p style="text-indent:5.231%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:51.46%;box-sizing:content-box;"/>
     <td style="width:4%;box-sizing:content-box;"/>
     <td style="width:44.54%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cabaletta Bio, Inc.</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 31, 2025</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Steven Nichtberger</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Steven Nichtberger, M.D.</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Chief Executive Officer and President</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.231%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:34%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:44%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:20%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date</span></p></td>
    </tr>
    <tr style="height:6pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Steven Nichtberger</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Director, Chief Executive Officer and President</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 31, 2025</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Steven Nichtberger, M.D.</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</span><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:6pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Anup Marda</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Chief Financial Officer</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;March 31, 2025</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Anup Marda</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(Principal Financial and Accounting Officer)</span><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:6pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Catherine Bollard</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Director</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;March 31, 2025</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Catherine Bollard, M.D.</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:6pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Scott Brun</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Director</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;March 31, 2025</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Scott Brun, M.D.</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:6pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Richard Henriques</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Director</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;March 31, 2025</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Richard Henriques</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:6pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Mark Simon</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Director</span><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;March 31, 2025</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Mark Simon</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:6pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Shawn Tomasello</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:6pt;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Director</span><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 31, 2025</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shawn Tomasello</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">139</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.17
<SEQUENCE>2
<FILENAME>caba-ex10_17.htm
<DESCRIPTION>EX-10.17
<TEXT>
<html>
 <head>
  <title>EX-10.17</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;min-height:1in;position:relative;"></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.17</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CABALETTA BIO, INC.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:77.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.0805555555555555in;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FOURTH AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY</font></p><p style="font-size:10pt;margin-top:0.75pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.04027777777777777in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The purpose of this Third Amended and Restated Non-Employee Director Compensation Policy of Cabaletta Bio, Inc. (the &#x201c;Company&#x201d;), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company or its subsidiaries. In furtherance of the purpose stated above, all non-employee directors shall be paid compensation for services provided to the Company as set forth below:</font></p><p style="font-size:10pt;margin-top:0.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.3125in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid #000000;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash Retainers</font></p><p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.3125in;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:9pt;font-size:10pt;margin-top:1.45pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.042361111111111106in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Annual Retainer for Board Membership</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">: $40,000 for general availability and participation in meetings and conference calls of our Board of Directors, to be paid quarterly in arrears, pro-rated based on the number of actual days served by the director during such calendar quarter.</font></p><p style="margin-left:9pt;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:9pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additional Retainers for Committee Membership</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:</font></p><p style="margin-left:9pt;font-size:10pt;margin-top:0.8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:9pt;font-size:10pt;margin-top:1.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Audit Committee Chair:	$20,000</font></p><p style="margin-left:9pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:9pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Audit Committee member:	$10,000</font></p><p style="margin-left:9pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:9pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compensation Committee Chair:	$12,500</font></p><p style="margin-left:9pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:9pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compensation Committee member:	$6,250</font></p><p style="margin-left:9pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:9pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nominating and Corporate Governance Committee Chair:	$10,000</font></p><p style="margin-left:9pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:9pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nominating and Corporate Governance Committee member:	$5,000</font></p><p style="margin-left:9pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:9pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Science and Technology Committee Chair:	$15,000</font></p><p style="margin-left:9pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:9pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Science and Technology Committee member:	$7,500</font></p><p style="margin-left:9pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note: Chair and committee member retainers are in addition to retainers for members of the Board of Directors.</font></p><p style="font-size:10pt;margin-top:0.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid #000000;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity Retainers</font></p><p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:9pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Initial Award</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">: An initial, one-time stock option award (the &#x201c;Initial Award&#x201d;) of 44,000 shares will be granted to each new non-employee director upon his or her election to the Board of Directors, which shall vest in equal quarterly installments over three years from the date of vesting commencement, provided, however, that all vesting shall cease if the director resigns from the Board of Directors or otherwise ceases to serve as a director of the Company. The Initial Award shall expire ten years from the date of grant, and shall have a per share exercise</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;min-height:1in;position:relative;"></div><p style="margin-left:9pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">price equal to the Fair Market Value (as defined in the Company's 2019 Stock Option and Incentive Plan) of the Company's common stock on the date of grant. This Initial Award applies only to non-employee directors who are first elected to the Board of Directors subsequent to the Company's initial public offering.</font></p><p style="margin-left:9pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Annual Award</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">: Commencing in 2021, on each date of the Company's Annual Meeting of Stockholders following the completion of the Company's initial public offering (the &#x201c;Annual Meeting&#x201d;), each continuing non-employee member of the Board of Directors, other than a director receiving an Initial Award, will receive an annual stock option award (the &#x201c;Annual Award&#x201d;) of 22,000 shares, which shall vest in full upon the earlier to occur of the first anniversary of the date of grant or the date of the next Annual Meeting; provided, however, that all vesting shall cease if the director resigns from the Board of Directors or otherwise ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting. Such Annual Award shall expire ten years from the date of grant, and shall have a per share exercise price equal to the Fair Market Value (as defined in the Company's 2019 Stock Option and Incentive Plan) of the Company's common stock on the date of grant.</font></p><p style="margin-left:9pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each Initial Award and Annual Award will become immediately vested and exercisable upon a Sale Event (as defined in the Company's 2019 Stock Option and Incentive Plan).</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid #000000;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expenses</font></p><p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:9pt;font-size:10pt;margin-top:1.45pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.04097222222222222in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company will reimburse all reasonable out-of-pocket expenses incurred by non-employee directors in attending meetings of the Board or any Committee.</font></p><p style="margin-left:9pt;font-size:10pt;margin-top:0.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:9pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effective January 1, 2025</font></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19.1
<SEQUENCE>3
<FILENAME>caba-ex19_1.htm
<DESCRIPTION>EX-19.1
<TEXT>
<html>
 <head>
  <title>EX-19.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.85in;width:7.2700000000000005in;box-sizing:content-box;margin-right:auto;padding-right:0.38in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.94in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div><p style="margin-left:396pt;text-indent:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 19.1</font></p><p style="margin-left:106.45pt;font-size:10pt;margin-top:3.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.947222222222222in;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CABALETTA BIO, INC.</font></p><p style="margin-left:106.4pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.947222222222222in;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">STATEMENT OF COMPANY POLICY ON INSIDER TRADING AND DISCLOSURE</font></p><p style="margin-left:396pt;text-indent:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:11pt;text-indent:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.6375in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This memorandum sets forth the policy of Cabaletta Bio, Inc. and its subsidiaries (collectively, the &#x201c;Company&#x201d;) regarding trading in the Company&#x2019;s securities as described below and the disclosure of information concerning the Company. This Insider Trading Policy (the &#x201c;Insider Trading Policy&#x201d;) is designed to prevent insider trading or the appearance of impropriety, to satisfy the Company&#x2019;s obligation to reasonably supervise the activities of Company personnel, and to help Company personnel avoid the severe consequences associated with violations of insider trading laws. </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is your obligation to understand and comply with this Insider Trading Policy. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If you have a question regarding the Insider Trading Policy, you are encouraged to consult with the Company&#x2019;s General Counsel (the &#x201c;General Counsel&#x201d;).</font></p><p style="margin-left:11pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="part_i__overview"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART I. OVERVIEW</font></p><p style="font-size:10pt;margin-top:1.35pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.1499999999999999in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.5in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:7.022882056832454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">A.</font><div style="width:100%;display:inline;" id="a__to_whom_does_this_insider_trading_pol"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">To Whom does this Insider Trading Policy Apply?</font></div></div><p style="font-size:10pt;margin-top:4.95pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:11.55pt;text-indent:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.5861111111111111in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Insider Trading Policy is applicable to the Company&#x2019;s directors, officers</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">employees, and designated consultants (collectively, and solely for the purposes of this Insider Trading Policy, these persons are referred to as &#x201c;Insiders&#x201d;), and applies to any and all transactions (e.g. purchase, sale, exercise or other transfer) by such persons and their Affiliated Persons (as defined below) in the Company&#x2019;s securities, including its common stock, options to purchase common stock, any other type of securities that the Company may issue (such as preferred stock, convertible debentures, warrants, exchange-traded options or other derivative securities), and any derivative securities that provide the economic equivalent of ownership of any of the Company&#x2019;s securities or an opportunity, direct or indirect, to profit from any change in the value of the Company&#x2019;s securities.</font></p><p style="font-size:10pt;margin-top:3.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:11.55pt;text-indent:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.6375in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Part II of this Insider Trading Policy (the &#x201c;Trading Procedures&#x201d;) requires pre-clearance of all transactions in the Company's securities by Insiders and their Affiliated Persons and describes trading windows outside of which the persons covered by the Trading Procedures will be restricted from trading in the Company&#x2019;s securities.</font></p><p style="margin-left:47pt;font-size:10pt;margin-top:12.65pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Affiliated Persons&#x201d; means:</font></p><div class="item-list-element-wrapper" style="margin-left:0.42986111111111114in;display:flex;margin-top:3.75pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.7097222222222223in;min-width:0.25in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.6551277009576237%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">your spouse, child, parent, significant other or other family member, in each case, living in the same household;</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.42986111111111114in;display:flex;margin-top:5.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.7597222222222223in;min-width:0.25in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.6551277009576237%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">all trusts, family partnerships and other types of entities formed for your benefit of the Insider or for the benefit of a member of your family over which you have the ability to influence or direct investment decisions concerning securities;</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.42986111111111114in;display:flex;margin-top:5.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.6551277009576237%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">all persons who execute trades on your behalf; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.3999999999999999in;display:flex;margin-top:3.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.7902777777777777in;min-width:0.25in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.639230459903913%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">all investment funds, trusts, retirement plans, partnerships, corporations and other types of entities over which you have the ability to influence or direct investment decisions concerning securities.</font></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.85in;width:7.2700000000000005in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.38in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.85in;width:7.2700000000000005in;box-sizing:content-box;margin-right:auto;padding-right:0.38in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.94in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0.95pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:11pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.6375in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You are responsible for ensuring compliance with this Insider Trading Policy, including the Trading Procedures contained herein, by all of your Affiliated Persons.</font></p><p style="margin-left:11pt;text-indent:36pt;font-size:10pt;margin-top:11.5pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.6375in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event that you leave the Company for any reason, this Insider Trading Policy, including, if applicable, the Trading Procedures contained herein, will continue to apply to you and your Affiliated Persons until the later of: (1) the first trading day following the public release of earnings for the fiscal quarter in which you leave our Company or (2) the second trading day after any material nonpublic information known to you has become public or is no longer material.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.1499999999999999in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.5in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:7.022882056832454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">B.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">What is Prohibited by this Insider Trading Policy?</font></div></div><p style="margin-left:11pt;text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.6923611111111111in;text-align:left;" id="b__what_is_prohibited_by_this_insider_tr"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is generally illegal for you to trade in the securities of the Company, whether for your account or for the account of another, while in the possession of material, nonpublic information about the Company. It is also generally illegal for you to disclose material, nonpublic information about the Company to others who may trade on the basis of that information. These illegal activities are commonly referred to as &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">insider trading</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.&#x201d;</font></p><p style="margin-left:11pt;font-size:10pt;margin-top:11.9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prohibited Activities</font></p><p style="margin-left:11pt;text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.6375in;text-align:left;" id="prohibited_activities"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When you know or are in possession of material, nonpublic information about the Company, whether positive or negative, you are prohibited from the following activities:</font></p><div class="item-list-element-wrapper" style="margin-left:0.6499999999999999in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.7in;min-width:0.25in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7766722674310067%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">trading (whether for your account or for the account of another) in the Company&#x2019;s securities, which includes common stock, options to purchase common stock, any other type of securities that the Company may issue (such as preferred stock, convertible debentures, warrants, exchange-traded options or other derivative securities), and any derivative securities that provide the economic equivalent of ownership of any of the Company&#x2019;s securities or an opportunity, direct or indirect, to profit from any change in the value of the Company&#x2019;s securities, except for trades made in compliance with the affirmative defense of Rule 10b5-1 under the Exchange Act, such as when trades are made pursuant to a written plan that was adopted, or trading instructions that were given, before you knew or had possession of such material, nonpublic information and certain other conditions are satisfied;</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.6499999999999999in;display:flex;margin-top:5.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7766722674310067%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">giving trading advice of any kind about the Company; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.6499999999999999in;display:flex;margin-top:4pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.6499999999999999in;min-width:0.25in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7766722674310067%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disclosing such material, nonpublic information about the Company, whether positive or negative, to anyone else (commonly known as &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">tipping</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></div></div><p style="margin-left:10.95pt;text-indent:36pt;font-size:10pt;margin-top:3.4pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.7777777777777778in;text-align:left;" id="this_insider_trading_policy_does_not_app"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Insider Trading Policy does not apply to (1) an exercise of an employee stock option when payment of the exercise price is made in cash or (2) the withholding by the Company of shares of stock upon vesting of restricted stock or upon settlement of restricted stock units to satisfy applicable tax withholding requirements if (a) such withholding is required by the applicable plan or award agreement or (b) the election to exercise such tax withholding right was made by the Insider in compliance with the Trading Procedures. The policy does apply, however, to the use of outstanding Company securities to pay part or all of the exercise price of an option, any sale of stock as part of</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.85in;width:7.2700000000000005in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.38in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.85in;width:7.2700000000000005in;box-sizing:content-box;margin-right:auto;padding-right:0.38in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.94in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div><p style="margin-left:10.95pt;font-size:10pt;margin-top:3.4pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.7777777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a broker-assisted cashless exercise of an option, or any other market sale for the purpose of generating the cash needed to pay the exercise price of an option.</font></p><p style="margin-left:11pt;text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.7777777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These prohibitions continue whenever and for as long as you know or are in possession of material, nonpublic information. Remember, anyone scrutinizing your transactions will be doing so after the fact, with the benefit of hindsight. As a practical matter, before engaging in any transaction, you should carefully consider how enforcement authorities and others might view the transaction in hindsight.</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.6743055555555557in;text-align:center;" id="definition_of_material__nonpublic_inform"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Definition of Material, Nonpublic Information</font></p><p style="margin-left:11pt;text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.6375in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Insider Trading Policy prohibits you from trading in the Company&#x2019;s securities if you are in possession of information about the Company that is both &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">material</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; and &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">nonpublic</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.&#x201d; If you have a question whether certain information you are aware of is material or has been made public, you are encouraged to consult with the General Counsel.</font></p><p style="margin-left:0.55pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.6743055555555557in;text-align:center;" id="what_is__material__information_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">What is &#x201c;Material&#x201d; Information?</font></p><p style="margin-left:10.95pt;text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.6923611111111111in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information about the Company is &#x201c;material&#x201d; if it could reasonably be expected to affect the investment or voting decisions of a stockholder or investor, or if the disclosure of the information could reasonably be expected to significantly alter the total mix of information in the marketplace about the Company. In simple terms, material information is any type of information that could reasonably be expected to affect the market price of the Company&#x2019;s securities. Both positive and negative information may be material. While it is not possible to identify all information that would be deemed &#x201c;material,&#x201d; the following items are types of information that should be considered carefully to determine whether they are material:</font></p><div class="item-list-element-wrapper" style="margin-left:0.6499999999999999in;display:flex;margin-top:12.8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.7402777777777777in;min-width:0.5in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.553344534862013%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">developments regarding any programs in clinical development or subject to regulatory approval, including recent regulatory interaction and/or data that have been recently generated from ongoing or recently completed clinical trials;</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.6499999999999999in;display:flex;margin-top:5.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.8798611111111111in;min-width:0.5in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.553344534862013%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">developments regarding the intellectual property and/or freedom to operate for any of the current programs or product candidates under development;</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.6499999999999999in;display:flex;margin-top:5.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1in;min-width:0.5in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.553344534862013%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">developments regarding a change in the Company's publicly announced cash runway</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">;</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.6499999999999999in;display:flex;margin-top:5.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.1402777777777777in;min-width:0.5in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.553344534862013%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential restatements of the Company&#x2019;s financial statements, changes in auditors or auditor notification that the Company may no longer rely on an auditor&#x2019;s audit report;</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.6499999999999999in;display:flex;margin-top:3.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.7in;min-width:0.5in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.553344534862013%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pending or proposed corporate mergers, acquisitions, tender offers, joint ventures or dispositions of significant assets;</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.6499999999999999in;display:flex;margin-top:5.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.5in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.553344534862013%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in management or the Board of Directors;</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.6499999999999999in;display:flex;margin-top:5.8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.6798611111111111in;min-width:0.5in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.553344534862013%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significant actual or threatened litigation or governmental investigations or major developments in such matters;</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.6499999999999999in;display:flex;margin-top:5.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.5in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.553344534862013%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a cybersecurity incident;</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.6499999999999999in;display:flex;margin-top:5.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.1597222222222223in;min-width:0.5in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.553344534862013%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significant developments regarding products, customers, suppliers, orders, contracts or financing sources (e.g., the acquisition or loss of a contract);</font></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.85in;width:7.2700000000000005in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.38in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.85in;width:7.2700000000000005in;box-sizing:content-box;margin-right:auto;padding-right:0.38in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.94in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div><div class="item-list-element-wrapper" style="margin-left:0.6499999999999999in;display:flex;margin-top:5.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.75in;min-width:0.5in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.553344534862013%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in dividend policy, declarations of stock splits, or public or private sales of additional securities;</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.6499999999999999in;display:flex;margin-top:5.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.8902777777777777in;min-width:0.5in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.553344534862013%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential defaults under the Company&#x2019;s credit agreements or indentures, or the existence of material liquidity deficiencies; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.6499999999999999in;display:flex;margin-top:5.8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.5in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.553344534862013%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">bankruptcies or receiverships.</font></div></div><p style="margin-left:10.95pt;text-indent:36pt;font-size:10pt;margin-top:7.3pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.6826388888888889in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By including the list above, the Company does not mean to imply that each of these items above is </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">per se</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> material. The information and events on this list still require determinations as to their materiality (although some determinations will be reached more easily than others). For example, some new products or contracts may clearly be material to an issuer; yet that does not mean that all product developments or contracts will be material. This demonstrates, in our view, why no &#x201c;bright-line&#x201d; standard or list of items can adequately address the range of situations that may arise. Furthermore, the Company cannot create an exclusive list of events and information that have a higher probability of being considered material. The Securities and Exchange Commission (the &#x201c;SEC&#x201d;) has stated that there is no fixed quantitative threshold amount for determining materiality, and that even very small quantitative changes can be qualitatively material if they would result in a movement in the price of the Company&#x2019;s securities.</font></p><p style="margin-left:46.95pt;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">What is &#x201c;Nonpublic&#x201d; Information?</font></p><p style="margin-left:10.95pt;text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.6645833333333333in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Material information is &#x201c;nonpublic&#x201d; if it has not been disseminated in a manner making it available to investors generally. To show that information is public, it is necessary to point to some fact that establishes that the information has become publicly available, such as the filing of a report with the SEC, the distribution of a press release through a widely disseminated news or wire service, or by other means that are reasonably designed to provide broad public access.</font></p><p style="margin-left:11pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.6777777777777777in;text-align:left;" id="what_is__nonpublic__information_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Before a person who possesses material, nonpublic information can trade, there also must be </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adequate time for the market as a whole to absorb the information that has been disclosed. For the purposes of this Insider Trading Policy, information will be considered public after the close of trading on the second full trading day following the Company&#x2019;s public release of the information. As a general rule, you should consider information to be &#34;non-public&#34; until at least one full trading day has elapsed after the information has been broadly disseminated to the public in a press release, a public filing with the SEC, a pre-announced public webcast or another broad, non-exclusionary form of public communication. The term &#34;trading day&#34; means a day on which national stock exchanges are open for trading. A &#34;full&#34; trading day has elapsed when, after the public disclosure, trading in the relevant security has opened and then closed.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:11pt;text-indent:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.6923611111111111in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, if the Company announces material nonpublic information of which you are aware before trading begins on a Tuesday, the first time you can buy or sell Company securities is the opening of the market on Wednesday. However, if the Company announces this material information after trading begins on that Tuesday, the first time that you can buy or sell Company securities is the opening of the market on Thursday.</font></p><p style="margin-left:106.4pt;font-size:10pt;margin-top:7.4pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.9659722222222225in;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p><div class="item-list-element-wrapper" style="margin-left:0.1499999999999999in;display:flex;margin-top:3.4pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.1in;min-width:0.5in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:7.022882056832454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">C.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">What are the Penalties for Insider Trading and Noncompliance with this Insider Trading Policy?</font></div></div><p style="margin-left:11pt;text-indent:36pt;font-size:10pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.6375in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Both the SEC and the national securities exchanges, through the Financial Industry</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.85in;width:7.2700000000000005in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.38in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.85in;width:7.2700000000000005in;box-sizing:content-box;margin-right:auto;padding-right:0.38in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.94in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div><p style="margin-left:11pt;font-size:10pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.6375in;text-align:left;" id="c__what_are_the_penalties_for_insider_tr"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulatory Authority (&#x201c;FINRA&#x201d;), investigate and are very effective at detecting insider trading. The SEC, together with the U.S. Attorneys, pursue insider trading violations vigorously. For instance, cases have been successfully prosecuted against trading by employees in foreign accounts, trading by family members and friends, and trading involving only a small number of shares.</font></p><p style="font-size:10pt;margin-top:9.1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:47pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The penalties for violating insider trading or tipping rules can be severe and include:</font></p><div class="item-list-element-wrapper" style="margin-left:0.6499999999999999in;display:flex;margin-top:6.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7766722674310067%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disgorgement of the profit gained or loss avoided by the trading;</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.6499999999999999in;display:flex;margin-top:5.85pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.9402777777777778in;min-width:0.25in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7766722674310067%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">payment of the loss suffered by the persons who, contemporaneously with the purchase or sale of securities that are subject of such violation, have purchased or sold, as applicable, securities of the same class;</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.6499999999999999in;display:flex;margin-top:5.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7766722674310067%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">payment of criminal penalties of up to $5,000,000;</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.6499999999999999in;display:flex;margin-top:5.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7766722674310067%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">payment of civil penalties of up to three times the profit made or loss avoided; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.6499999999999999in;display:flex;margin-top:5.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7766722674310067%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">imprisonment for up to 20 years.</font></div></div><p style="font-size:10pt;margin-top:8.15pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:11pt;text-indent:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.6375in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company and/or the supervisors of the person engaged in insider trading may also be required to pay civil penalties of up to the greater of $1,525,000 or three times the profit made or loss avoided, as well as criminal penalties of up to $25,000,000, and could under certain circumstances be subject to private lawsuits.</font></p><p style="margin-left:11pt;text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.6375in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Violation of this Insider Trading Policy or any federal or state insider trading laws may subject the person violating such policy or laws to disciplinary action by the Company up to and including termination. The Company reserves the right to determine, in its own discretion and on the basis of the information available to it, whether this Insider Trading Policy has been violated. The Company may determine that specific conduct violates this Insider Trading Policy, whether or not the conduct also violates the law. It is not necessary for the Company to await the filing or conclusion of a civil or criminal action against the alleged violator before taking disciplinary action.</font></p><p style="font-size:10pt;margin-top:10.2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.1499999999999999in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.5in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:7.022882056832454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">D.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">How Do You Report a Violation of this Insider Trading Policy?</font></div></div><p style="font-size:10pt;margin-top:0.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:11pt;text-indent:35.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.6375in;text-align:left;" id="d__how_do_you_report_a_violation_of_this"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If you have a question about this Insider Trading Policy, including whether certain information you are aware of is material or has been made public, you are encouraged to consult with the General Counsel. In addition, if you violate this Insider Trading Policy or any federal or state laws governing insider trading, or know of any such violation by any director, officer or</font></p><p style="margin-left:11pt;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">employee of the Company, you must report the violation immediately to the General Counsel.</font></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.85in;width:7.2700000000000005in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.38in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.85in;width:7.2700000000000005in;box-sizing:content-box;margin-right:auto;padding-right:0.38in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.94in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div><p style="margin-left:11pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="part_ii__trading_procedures"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART II. TRADING PROCEDURES</font></p><div class="item-list-element-wrapper" style="margin-left:0.1499999999999999in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.5in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:7.022882056832454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">A.</font><div style="width:100%;display:inline;" id="a__special_trading_restrictions_applicab"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Special Trading Restrictions Applicable to Insiders</font></div></div><p style="margin-left:11pt;text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.6375in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the restrictions on trading in Company securities set forth above, Insiders and their Affiliated Persons are subject to the following special trading restrictions:</font></p><div class="item-list-element-wrapper" style="margin-left:0.6499999999999999in;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7766722674310067%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Special Closed Trading Periods</font></div></div><p style="margin-left:10.95pt;text-indent:36pt;font-size:10pt;margin-top:3.7pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.6375in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are times when the Company or certain members of its board of directors or senior management or support staff may be aware of a material, nonpublic development. Although an Insider may not know the specifics of such development, if an Insider engages in a trade before such development is disclosed to the public or resolved, such Insider and the Company might be exposed to a charge of insider trading that could be costly and difficult to refute. In addition, a trade by an Insider during such a period could result in adverse publicity for the Company.</font></p><p style="margin-left:10.95pt;font-size:10pt;margin-top:0.1pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.6645833333333333in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Therefore, Insiders may not trade in Company securities if they are notified by the General Counsel that the trading window is closed because of the existence of a material, nonpublic development or closed with respect to the securities of other companies, including specified peers or competitors of the Company. The General Counsel will subsequently notify the Insiders once the material, nonpublic development is disclosed to the public or resolved and that, as a result, the trading window is again open. While the General Counsel will undertake reasonable efforts to notify the Insiders that material, nonpublic events have developed, or are soon likely to develop, it is each Insider&#x2019;s individual duty to ensure that they do not make any trade in Company securities when material, nonpublic information exists, regardless of whether such Insider is aware of such development. The imposition of such a closed trading window announced to the Company generally should not be communicated to any other person, and may itself be considered under this Insider Trading Policy to be material nonpublic information</font><font style="color:#1f477b;white-space:pre-wrap;font-size:12pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf02e;</font></p><div class="item-list-element-wrapper" style="margin-left:0.6499999999999999in;display:flex;margin-top:10.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.5in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.553344534862013%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prohibited Transactions</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.6499999999999999in;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.8097222222222222in;min-width:0.25in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7766722674310067%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">No Short Sales</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. No Insider may at any time sell any securities of the Company that are not owned by such Insider at the time of the sale (a &#x201c;short sale&#x201d;).</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.6499999999999999in;display:flex;margin-top:8.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.6201388888888889in;min-width:0.25in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7766722674310067%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">No Purchases or Sales of Derivative Securities or Hedging Transactions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. No Insider may buy or sell puts, calls, other derivative securities of the Company or any derivative securities that provide the economic equivalent of ownership of any of the Company&#x2019;s securities or an opportunity, direct or indirect, to profit from any change in the value of the Company&#x2019;s securities or engage in any other hedging transaction with respect to the Company&#x2019;s securities, at any time.</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.6499999999999999in;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.6402777777777778in;min-width:0.25in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7766722674310067%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">No Company Securities Subject to Margin Calls</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. No Insider may use the Company&#x2019;s securities as collateral in a margin account.</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.6499999999999999in;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.8701388888888889in;min-width:0.25in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7766722674310067%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">No Pledges</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. No Insider may pledge Company securities as collateral for a loan (or modify an existing pledge).</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.6499999999999999in;margin-top:3.4pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.0798611111111111in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.588684259655829%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Distributions, Gifts and Other Transfers for No Consideration are Gifts Subject to Same Restrictions as All Other Securities Trades.</font></div></div><p style="margin-left:10.95pt;text-indent:36pt;font-size:10pt;margin-top:4.2pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.2381944444444446in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Insider may give or make any other transfer of Company securities without consideration (e.g., a partnership distribution gift) during a period when the Insider is</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.85in;width:7.2700000000000005in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.38in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.85in;width:7.2700000000000005in;box-sizing:content-box;margin-right:auto;padding-right:0.38in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.94in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div><p style="margin-left:10.95pt;font-size:10pt;margin-top:4.2pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.2381944444444446in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not permitted to trade.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:2.2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.1499999999999999in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.5in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:7.022882056832454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">B.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pre-Clearance Procedures</font></div></div><p style="margin-left:10.95pt;text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.6375in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Insider may trade (e.g. purchase, sale, exercise or other transfer) in Company securities unless the trade has been approved by the General Counsel in accordance with the procedures set forth below. The General Counsel will review and either approve or prohibit all proposed trades by Insiders in accordance with the procedures set forth below. The General Counsel may consult with the Company&#x2019;s other officers and/or outside legal counsel and will receive approval for their own trades from the Chief Financial Officer.</font></p><p style="margin-left:47pt;font-size:10pt;margin-top:11pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Procedures</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. No Insider may trade in Company securities until:</font></p><div class="item-list-element-wrapper" style="margin-left:0.8999999999999999in;display:flex;margin-top:13.65pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.55in;min-width:0.25in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.9249029901848895%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;" id="c__pre_clearance_procedures"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Insider has provided the General Counsel with either a pre-clearance request in the Morgan Stanley Shareworks system (&#34;Shareworks&#34;) for trades to be conducted through Shareworks and/or a Stock Transaction Request Form (form attached hereto) for trades to be conducted outside of Shareworks; which shall each provide the following information:</font></div></div><div class="item-list-element-wrapper" style="margin-left:1.520138888888889in;display:flex;margin-top:11.65pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.34821089897585%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the amount and nature of the proposed trade(s); and</font></div></div><div class="item-list-element-wrapper" style="margin-left:1.520138888888889in;display:flex;margin-top:3.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.5097222222222223in;min-width:0.25in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.34821089897585%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certifying to the General Counsel in writing prior to the proposed trade(s) that (i) the Insider is not in possession of material, nonpublic information concerning the Company; (ii) to the Insider&#x2019;s best knowledge, (a) the Insider has (or is deemed to have) engaged in any opposite way transactions within the previous six months that were not exempt from Section 16(b) of the Exchange Act and (b) if the transaction involves a sale by an &#x201c;affiliate&#x201d; of the Company or of &#x201c;restricted securities&#x201d; (as such terms are defined under Rule 144 under the Securities Act of 1933, as amended (&#x201c;Rule 144&#x201d;)), whether the transaction meets all of the applicable conditions of Rule 144.</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.8999999999999999in;display:flex;margin-top:3.65pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.9298611111111111in;min-width:0.25in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.9249029901848895%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The General Counsel or their designee has approved the trade(s) in writing on the Stock Transaction Request Form or in Shareworks.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:7.15pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:10.95pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.7777777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If practicable, an Insider should provide the General Counsel with the Stock Transaction Request Form and/or a pre-clearance request in Shareworks at least (2) business days prior to the intended trade date. The General Counsel does not assume the responsibility for, and approval from the General Counsel does not protect the Insider from, the consequences of prohibited insider trading.</font></p><p style="margin-left:10.95pt;text-indent:36pt;font-size:10pt;margin-top:6.25pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.6923611111111111in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Additional Information</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Insiders shall provide to the General Counsel any documentation reasonably requested by them in furtherance of the foregoing procedures. Any failure to provide such requested information will be grounds for denial of approval by the General Counsel.</font></p><p style="margin-left:10.95pt;text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.7243055555555555in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">No Obligation to Approve Trades</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The existence of the foregoing approval procedures does not in any way obligate the General Counsel to approve any trade requested by an Insider. The General Counsel may reject any trading request at their sole discretion. From time to time,</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.85in;width:7.2700000000000005in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.38in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.85in;width:7.2700000000000005in;box-sizing:content-box;margin-right:auto;padding-right:0.38in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.94in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div><p style="margin-left:10.95pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.7243055555555555in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an event may occur that is material to the Company and is known by only a few directors or executives. Insiders may not trade in Company securities if they are notified by the General Counsel that a proposed trade has not been cleared because of the existence of a material, nonpublic development in accordance with a restricted period or otherwise. Even if that particular Insider is not aware of the material, nonpublic development involving the Company, if any Insider engages in a trade before a material, nonpublic development is disclosed to the public or resolved, the Insider and the Company might be exposed to a charge of insider trading that could be costly and difficult to refute even if the Insider was unaware of the development. So long as the event remains material and nonpublic, the General Counsel may determine not to approve any transactions in the Company&#x2019;s securities. The General Counsel will subsequently notify the Insider once the material, nonpublic development is disclosed to the public or resolved. If an Insider requests clearance to trade in the Company&#x2019;s securities during the pendency of such an event, the General Counsel may reject the trading request without disclosing the reason.</font></p><p style="margin-left:10.95pt;text-indent:36pt;font-size:10pt;margin-top:11.9pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.6923611111111111in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Completion of Trades</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After receiving written clearance to engage in a trade signed by the General Counsel, an Insider must complete the proposed trade within two (2) business days or make a new trading request.</font></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:11pt;text-indent:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.6923611111111111in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Post-Trade Reporting</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any transactions in the Company&#x2019;s securities (including transactions under a Rule 10b5-1 Plan) by an Insider who is an executive officer or director required to make Section 16 filings must be reported to the General Counsel by completing the &#x201c;Confirmation of Transaction&#x201d; section of the Stock Transaction Request form attached to this Insider Trading Policy on the </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">same day</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in which such a transaction occurs. Each report an Insider makes to the General Counsel should include the date of the transaction, quantity of shares, price and broker-dealer through which the transaction was effected. This reporting requirement may be satisfied by sending (or having such Insider&#x2019;s broker send) duplicate confirmations of trades to the General Counsel if such information</font></p><p style="margin-left:10.95pt;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.9923611111111111in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is received by the General Counsel on or before the required date. Compliance by directors and executive officers with this provision is imperative given the requirement of Section 16 of the Exchange Act that these persons generally must report changes in ownership of Company securities within two (2) business days. The sanctions for noncompliance with this reporting deadline include mandatory disclosure in the Company&#x2019;s proxy statement for the next annual meeting of stockholders, as well as possible civil or criminal sanctions for chronic or egregious violators.</font></p><div class="item-list-element-wrapper" style="margin-left:0.1499999999999999in;display:flex;margin-top:11.6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.5in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:7.022882056832454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">C.</font><div style="width:100%;display:inline;" id="d__exemptions"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Exemptions</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.2798611111111111in;display:flex;margin-top:13.75pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.22013888888888888in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.149245969838794%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-Approved Rule 10b5-1 Plans</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Transactions effected pursuant to a Rule</font></div></div><p style="margin-left:10.95pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.6375in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10b5-1 Plan (as defined below) will not be subject to the Company&#x2019;s restricted period or pre- clearance procedures, and Insiders are not required to complete a Stock Transaction Request form for such transactions. Rule 10b5-1 of the Exchange Act provides an affirmative defense from insider trading liability under the federal securities laws for trading plans, arrangements or instructions that meet certain requirements. A trading plan, arrangement or instruction that meets the requirements of Rule 10b5-1 (a &#x201c;Rule 10b5-1 Plan&#x201d;) enables Insiders to establish arrangements to trade in Company securities outside of the Company&#x2019;s trading windows, even when in possession of material, nonpublic information. The Company has adopted a separate Rule 10b5-1 Plan with respect to Company securities. If an Insider intends to trade pursuant to a</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.85in;width:7.2700000000000005in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.38in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.85in;width:7.2700000000000005in;box-sizing:content-box;margin-right:auto;padding-right:0.38in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.94in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div><p style="margin-left:10.95pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.6375in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rule 10b5-1 Plan, such plan, arrangement or instruction must:</font></p><div class="item-list-element-wrapper" style="margin-left:0.8999999999999999in;display:flex;margin-top:9.7pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.9249029901848895%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">satisfy the requirements of Rule 10b5-1;</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.8999999999999999in;display:flex;margin-top:5.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.9249029901848895%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be documented in writing;</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.8999999999999999in;display:flex;margin-top:5.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.1in;min-width:0.25in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.9249029901848895%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be established during a trading window when such Insider does not possess material, nonpublic information; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.8999999999999999in;display:flex;margin-top:5.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.9249029901848895%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be pre-approved by the General Counsel.</font></div></div><p style="margin-left:10.95pt;text-indent:36pt;font-size:10pt;margin-top:5.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.5861111111111111in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any deviation from, or alteration to, the specifications of an approved Rule 10b5-1 Plan (including, without limitation, the amount, price or timing of a purchase or sale) must be reported immediately to the General Counsel. Any transaction pursuant to a Rule 10b5-1 Plan must be timely reported following the transaction in accordance with the procedures set forth above.</font></p><p style="margin-left:10.95pt;text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.6590277777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The General Counsel may refuse to approve a Rule 10b5-1 Plan as they deem appropriate including, without limitation, if they determine that such plan does not satisfy the requirements of Rule 10b5-1.</font></p><p style="margin-left:10.95pt;text-indent:36pt;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.9631944444444444in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any modification or termination of an Insider&#x2019;s prior Rule 10b5-1 Plan requires pre- approval by the General Counsel. A modification or termination must occur during a trading window and while such Insider is not aware of material, nonpublic information.</font></p><p style="font-size:10pt;margin-top:5.65pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.15000000000000002in;text-indent:36pt;font-size:0;margin-top:0.05pt;justify-content:flex-start;margin-bottom:0;margin-right:0.5902777777777778in;min-width:0.5in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.19619755557144%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;" id="employee_benefit_plans_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exercise of Stock Options</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The trading prohibitions and restrictions set forth in the Trading Procedures do not apply to the exercise of an option to purchase securities of the Company when payment of the exercise price is made in cash. However, the exercise of an option to purchase securities of the Company is subject to the current reporting requirements of Section 16 of the Exchange Act and, therefore, Insiders must comply with the post-trade</font></div></div><p style="margin-left:10.95pt;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.6777777777777777in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reporting requirement described in Section B above for any such transaction. In addition, the securities acquired upon the exercise of an option to purchase Company securities are subject to all of the requirements of this Insider Trading Policy, including the Trading Procedures contained herein. Moreover, the Trading Procedures apply to the use of outstanding Company securities to pay part or all of the exercise price of an option, any net option exercise, any exercise of a stock appreciation right, share withholding, any sale of stock as part of a broker- assisted cashless exercise of an option, or any other market sale for the purpose of generating the cash needed to pay the exercise price of an option.</font></p><div class="item-list-element-wrapper" style="margin-left:0.15000000000000002in;text-indent:36pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:0.6597222222222222in;min-width:0.5in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.19619755557144%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tax Withholding on Restricted Stock/Units</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The trading prohibitions and restrictions set forth in the Trading Procedures do not apply to the withholding by the Company of shares of stock upon vesting of restricted stock or upon settlement of restricted stock units to satisfy applicable tax withholding requirements if (a) such withholding is required by the applicable plan or award agreement or (b) the election to exercise such tax withholding right was made by the Insider in compliance with the Trading Procedures.</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.15000000000000002in;text-indent:36pt;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:0;margin-right:0.7in;min-width:0.5in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.19619755557144%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employee Stock Purchase Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The trading prohibitions and restrictions set forth in the Trading Procedures do not apply to periodic wage withholding contributions by the Company or employees of the Company which are used to purchase the Company&#x2019;s securities pursuant to the employees&#x2019; advance instructions under the Company&#x2019;s 2019 Employee Stock Purchase Plan. However, no Insider may: (a) elect to participate in the plan or alter their instructions regarding the level of withholding or purchase by the Insider of Company securities under such plan; or (b) make cash contributions to such plan (other than through periodic wage </font></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.85in;width:7.2700000000000005in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.38in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.85in;width:7.2700000000000005in;box-sizing:content-box;margin-right:auto;padding-right:0.38in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.94in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div><div class="item-list-element-wrapper" style="margin-left:0.15000000000000002in;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:0;margin-right:0.7in;min-width:0.5in;text-align:left;"><div style="width:100%;display:inline;" id="e__waivers"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">withholding) without complying with the Trading Procedures including Part II.B (Pre-Clearance Procedures). Any sale of securities acquired under such plan is subject to the prohibitions and </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions of the Trading Procedures including Part II.B (Pre-Clearance Procedures).</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.1499999999999999in;display:flex;margin-top:5.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.5097222222222223in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:7.158683643566784%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">D.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">WAIVERS</font></div></div><p style="margin-left:11pt;text-indent:36pt;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.6375in;text-align:left;" id="f__acknowledgment"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A waiver of any provision of this Insider Trading Policy, or the Trading Procedures contained herein, in a specific instance may be authorized in writing by the General Counsel, their designee or the Audit Committee of the Board of Directors, and any such waiver shall be </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reported to the Company&#x2019;s Board of Directors.</font></p><div class="item-list-element-wrapper" style="margin-left:0.1499999999999999in;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.5in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:7.022882056832454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">E.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ACKNOWLEDGMENT</font></div></div><p style="margin-left:11pt;text-indent:36pt;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.6375in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Insider Trading Policy will be delivered to all current Insiders and to all directors, officers, employees and designated consultants at the start of their employment or relationship with the Company. Upon first receiving a copy of this Insider Trading Policy, each individual must acknowledge that they have received a copy and agrees to comply with the terms of this Insider Trading Policy, and, if applicable, the Trading Procedures contained herein. The acknowledgment attached hereto must be returned within ten (10) days of receipt to the Company&#x2019;s General Counsel.</font></p><p style="margin-left:10.95pt;text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.6375in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This acknowledgment will constitute consent for the Company to impose sanctions for violation of the Insider Trading Policy, including the Trading Procedures, and to issue any necessary stop-transfer orders to the Company&#x2019;s transfer agent to ensure compliance.</font></p><p style="margin-left:11pt;text-indent:36pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.6375in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All directors, officers, employees and designated consultants will be required upon the Company&#x2019;s request to re-acknowledge and agree to comply with the Insider Trading Policy</font></p><p style="margin-left:11pt;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.7777777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(including any amendments or modifications). For such purpose, an individual will be deemed to have acknowledged and agreed to comply with the Insider Trading Policy, as amended from time to time, when copies of such items have been delivered by regular or electronic mail (or other delivery option used by the Company) by the General Counsel or their designee.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:10.95pt;text-indent:36pt;font-size:10pt;margin-top:5.2pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.6923611111111111in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Questions regarding this Insider Trading Policy are encouraged and may be directed to the General Counsel.</font></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:15.55pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amended &amp; restated effective February 13, 2024.</font></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.85in;width:7.2700000000000005in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.38in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.85in;width:7.2700000000000005in;box-sizing:content-box;margin-right:auto;padding-right:0.38in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.94in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div><p style="margin-left:155.35pt;font-size:10pt;margin-top:3.95pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="stock_transaction_request__revised_"><font style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:'Cambria',serif;font-kerning:none;min-width:fit-content;">S T O C K T R A N S A C T I O N R E Q U E S T</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:'Cambria',serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:10.35pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:'Cambria',serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:10.95pt;text-indent:-0.05pt;padding-left:0.05pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.6375in;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:7.5pt;font-family:'Cambria',serif;font-kerning:none;min-width:fit-content;">Pursuant to Cabaletta Bio, Inc.'s Special Trading Procedures for Insiders (the &#34;Trading Procedures&#34;), I hereby notify Cabaletta Bio, Inc. (the &#34;Company&#34;) of my intent to trade the securities of the Company as indicated below:</font></p><p style="font-size:10pt;margin-top:0.2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:5.15pt;font-size:10pt;margin-top:0.2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid #231f20;font-size:7.5pt;font-family:'Cambria',serif;font-kerning:none;min-width:fit-content;">REQUESTER INFORMATION</font></p><p style="margin-left:5.15pt;font-size:10pt;margin-top:3.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:7.5pt;font-family:'Cambria',serif;font-kerning:none;min-width:fit-content;">Insider's Name:	</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #221e1f;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p><p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid #231f20;font-size:7.5pt;font-family:'Cambria',serif;font-kerning:none;min-width:fit-content;">INTENT TO PURCHASE</font></p><p style="font-size:10pt;margin-top:3.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:7.5pt;font-family:'Cambria',serif;font-kerning:none;min-width:fit-content;">Number of shares: Intended trade date:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:7.5pt;font-family:'Cambria',serif;font-kerning:none;min-width:fit-content;">Means of acquiring shares:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #221e1f;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 	</font></p><p style="font-size:10pt;margin-top:3.95pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #221e1f;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 	</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:7.5pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x25a1;</font></p><p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:7.5pt;font-family:'Cambria',serif;font-kerning:none;min-width:fit-content;">Acquisition through employee benefit plan (please specify): </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #221e1f;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:7.5pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x25a1;</font></p><p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:7.5pt;font-family:'Cambria',serif;font-kerning:none;min-width:fit-content;">Purchase through a broker on the open market</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:7.5pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x25a1;</font></p><p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:7.5pt;font-family:'Cambria',serif;font-kerning:none;min-width:fit-content;">Other (please specify): </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #221e1f;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p><p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:7.5pt;font-family:'Cambria',serif;font-kerning:none;min-width:fit-content;">Date</font></p><p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:7.5pt;font-family:'Cambria',serif;font-kerning:none;min-width:fit-content;">Insider's Signature</font></p><p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid #231f20;font-size:7.5pt;font-family:'Cambria',serif;font-kerning:none;min-width:fit-content;">CERTIFICATION</font></p><p style="font-size:10pt;margin-top:3.1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:7.5pt;font-family:'Cambria',serif;font-kerning:none;min-width:fit-content;">I hereby certify that </font><font style="color:#231f20;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(</font><font style="color:#231f20;white-space:pre-wrap;font-size:7.5pt;font-family:'Cambria',serif;font-kerning:none;min-width:fit-content;">1</font><font style="color:#231f20;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) </font><font style="color:#231f20;white-space:pre-wrap;font-size:7.5pt;font-family:'Cambria',serif;font-kerning:none;min-width:fit-content;">I am not in possession of any material, nonpublic information concerning the Company, as defined in the Company's Statement of Company Policy on Insider Trading and Disclosure</font><font style="color:#231f20;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, (</font><font style="color:#231f20;white-space:pre-wrap;font-size:7.5pt;font-family:'Cambria',serif;font-kerning:none;min-width:fit-content;">2</font><font style="color:#231f20;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) to the best of my knowledge, the proposed trade(s) listed above does not violate the trading restrictions of Section 16 of the Securities Exchange Act of 1934, as amended, or Rule 144 under the Securities Act of 1933, as amended, and (3)</font></p><p style="font-size:10pt;margin-top:0.75pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:7.5pt;font-family:'Cambria',serif;font-kerning:none;min-width:fit-content;">I am not purchasing any securities of the Company on margin in contravention of the Company's Trading Procedures. I understand that, if I trade while possessing such information or in violation of such trading restrictions, I may be subject to severe civil and/or criminal penalties, and may b</font><font style="color:#231f20;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">e </font><font style="color:#231f20;white-space:pre-wrap;font-size:7.5pt;font-family:'Cambria',serif;font-kerning:none;min-width:fit-content;">subject to discipline by the Company including termination.</font></p><p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:7.5pt;font-family:'Cambria',serif;font-kerning:none;min-width:fit-content;">Other (please specify): </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #221e1f;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:7.5pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x25a1;</font></p><p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:7.5pt;font-family:'Cambria',serif;font-kerning:none;min-width:fit-content;">Sale through a broker on the open market</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:7.5pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x25a1;</font></p><p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:7.5pt;font-family:'Cambria',serif;font-kerning:none;min-width:fit-content;">Sale through employee benefit plan (please specify): </font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #221e1f;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:7.5pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x25a1;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #221e1f;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 	</font></p><p style="font-size:10pt;margin-top:3.95pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #221e1f;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 	</font></p><p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid #231f20;font-size:7.5pt;font-family:'Cambria',serif;font-kerning:none;min-width:fit-content;">INTENT TO SELL</font></p><p style="font-size:10pt;margin-top:3.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:7.5pt;font-family:'Cambria',serif;font-kerning:none;min-width:fit-content;">Number of shares:</font></p><p style="font-size:10pt;margin-top:1.1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:7.5pt;font-family:'Cambria',serif;font-kerning:none;min-width:fit-content;">Intended trade date: Means of selling shares:</font></p><p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid #231f20;font-size:7.5pt;font-family:'Cambria',serif;font-kerning:none;min-width:fit-content;">AUTHORIZED APPROVAL</font></p><p style="font-size:10pt;margin-top:6.35pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:'Cambria',serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:11.75pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:7.5pt;font-family:'Cambria',serif;font-kerning:none;min-width:fit-content;">Signature of </font><font style="color:#231f20;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General Counsel </font><font style="color:#231f20;white-space:pre-wrap;font-size:7.5pt;font-family:'Cambria',serif;font-kerning:none;min-width:fit-content;">(or designee)</font></p><p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:7.5pt;font-family:'Cambria',serif;font-kerning:none;min-width:fit-content;">Date</font></p><p style="font-size:10pt;margin-top:0.2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:'Cambria',serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:'Cambria',serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0.9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Cambria',serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:5.35pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid #231f20;font-size:7.5pt;font-family:'Cambria',serif;font-kerning:none;min-width:fit-content;">CONFIRMATION OF TRANSACTION</font></p><p style="font-size:10pt;margin-top:2.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:7.5pt;font-family:'Cambria',serif;font-kerning:none;min-width:fit-content;">I hereby confirm that the transaction(s) requested above was (were) executed as follows:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:7.5pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x25a1;</font></p><p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:7.5pt;font-family:'Cambria',serif;font-kerning:none;min-width:fit-content;">Purchase of shares:</font></p><p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:7.5pt;font-family:'Cambria',serif;font-kerning:none;min-width:fit-content;">*Number of shares:</font></p><p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #221e1f;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #221e1f;font-size:7.5pt;font-family:'Cambria',serif;font-kerning:none;min-width:fit-content;">Price per share:	Date and approximate time of purchase:	</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:7.5pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x25a1;</font></p><p style="margin-left:2pt;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:7.5pt;font-family:'Cambria',serif;font-kerning:none;min-width:fit-content;">Sale of shares:</font></p><p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:7.5pt;font-family:'Cambria',serif;font-kerning:none;min-width:fit-content;">*Number of shares:</font></p><p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:7.5pt;font-family:'Cambria',serif;font-kerning:none;min-width:fit-content;">Price per share:</font></p><p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:7.5pt;font-family:'Cambria',serif;font-kerning:none;min-width:fit-content;">Date and approximate time of sale:</font></p><p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:7.5pt;font-family:'Cambria',serif;font-kerning:none;min-width:fit-content;">Insider's Signature</font></p><p style="margin-left:0.4pt;font-size:10pt;margin-top:7.2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:7.5pt;font-family:'Cambria',serif;font-kerning:none;min-width:fit-content;">Insider's Name:</font></p><p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:7.5pt;font-family:'Cambria',serif;font-kerning:none;min-width:fit-content;">Date</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #221e1f;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 	</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:'Cambria',serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:'Cambria',serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:'Cambria',serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:6.65pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:7.5pt;font-family:'Cambria',serif;font-style:italic;font-kerning:none;min-width:fit-content;">*NOTE: Multiple lots must be listed on separate forms or broken out herein.</font></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.85in;width:7.2700000000000005in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.38in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>caba-ex21_1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html>
 <head>
  <title>EX-21.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;min-height:1in;position:relative;"></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 21.1</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cabaletta Bio, Inc.</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following is a list of subsidiaries of Cabaletta Bio, Inc. as of December 31, 2024.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:50%;box-sizing:content-box;"></td>
     <td style="width:50%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">SUBSIDIARY</font></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION</font></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cabaletta Bio, Inc.</font></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Delaware</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cabaletta Bio GmbH</font></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Switzerland</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cabaletta Bio (Germany) GmbH</font></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Germany</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>caba-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;min-height:1in;position:relative;"></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#333333;white-space:pre-wrap;font-weight:bold;font-size:10.5pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Exhibit 23.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">We consent to the incorporation by reference in the following Registration Statements:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:Calibri;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Registration Statement (Form S-8 No. 333-234367) pertaining to the Cabaletta Bio, Inc. 2018 Stock Option and Incentive Plan, the Cabaletta Bio, Inc. 2019 Stock Option and Incentive Plan, and the Cabaletta Bio, Inc. 2019 Employee Stock Purchase Plan, </font></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:Calibri;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Registration Statement (Form S-8 No. 333-237484) pertaining to the Cabaletta Bio, Inc. 2019 Stock Option and Incentive Plan and the Cabaletta Bio, Inc. 2019 Employee Stock Purchase Plan, </font></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:Calibri;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Registration Statement (Form S-8 No. 333-254342) pertaining to the Cabaletta Bio, Inc. 2019 Stock Option and Incentive Plan and the Cabaletta Bio, Inc. 2019 Employee Stock Purchase Plan,</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:Calibri;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(4)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Registration Statement (Form S-8 No. 333-263637) pertaining to the Cabaletta Bio, Inc. 2019 Stock Option and Incentive Plan,</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:Calibri;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(5)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Registration Statement (Form S-8 No. 333-270595) pertaining to the Cabaletta Bio, Inc. 2019 Stock Option and Incentive Plan,</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:Calibri;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(6)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Registration Statement (Form S-8 No. 333-273863) pertaining to the Cabaletta Bio, Inc. 2019 Stock Option and Incentive Plan;</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:Calibri;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(7)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Registration Statement (Form S-3 No. 333-278126) of Cabaletta Bio, Inc., and</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:Calibri;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(8)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Registration Statement (Form S-8 No. 333-278124) pertaining to the Cabaletta Bio, Inc. 2019 Stock Option and Incentive Plan;</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">of our report dated March 31, 2025, with respect to the consolidated financial statements of Cabaletta Bio, Inc. included in this Annual Report (Form 10-K) of Cabaletta Bio, Inc. for the year ended December 31, 2024.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">/s/ Ernst &amp; Young LLP</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Philadelphia, Pennsylvania</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">March 31, 2025</font></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>caba-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.27in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;min-height:1in;position:relative;"></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.1</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Steven Nichtberger, certify that:</font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.427%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K for the year ended December 31, 2024 of Cabaletta Bio, Inc. (the &#x201c;registrant&#x201d;);</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.427%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.427%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.427%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div><p style="margin-left:24.5pt;text-indent:-24.5pt;padding-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p><p style="margin-left:24.5pt;text-indent:-24.5pt;padding-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;  	</font></p><p style="margin-left:24.5pt;text-indent:-24.5pt;padding-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p><p style="margin-left:24.5pt;text-indent:-24.5pt;padding-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.427%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div><p style="margin-left:24.5pt;text-indent:-24.5pt;padding-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></p><p style="margin-left:24.5pt;text-indent:-24.5pt;padding-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></p><p style="text-indent:-24.5pt;padding-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:45.34%;box-sizing:content-box;"></td>
     <td style="width:4.94%;box-sizing:content-box;"></td>
     <td style="width:3.36%;box-sizing:content-box;"></td>
     <td style="width:46.36%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 31, 2025</font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Steven Nichtberger</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Steven Nichtberger, M.D.</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Chief Executive Officer and President</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.27in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.27in;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>caba-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.27in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;min-height:1in;position:relative;"></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.2</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Anup Marda, certify that:</font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.427%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K for the year ended December 31, 2024 of Cabaletta Bio, Inc. (the &#34;registrant&#34;);</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.427%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.427%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.427%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div><p style="margin-left:24.5pt;text-indent:-24.5pt;padding-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p><p style="margin-left:24.5pt;text-indent:-24.5pt;padding-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="margin-left:24.5pt;text-indent:-24.5pt;padding-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p><p style="margin-left:24.5pt;text-indent:-24.5pt;padding-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.427%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div><p style="margin-left:24.5pt;text-indent:-24.5pt;padding-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></p><p style="margin-left:24.5pt;text-indent:-24.5pt;padding-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></p><p style="text-indent:-24.5pt;padding-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:45.34%;box-sizing:content-box;"></td>
     <td style="width:4.94%;box-sizing:content-box;"></td>
     <td style="width:3.36%;box-sizing:content-box;"></td>
     <td style="width:46.36%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 31, 2025</font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Anup Marda</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Anup Marda</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Chief Financial Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Principal Financial and Accounting Officer)</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.27in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.27in;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>caba-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 32.1</font></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Annual Report of Cabaletta Bio, Inc. (the &#x201c;Company&#x201d;) on Form 10-K for the fiscal year ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</font></p><p style="margin-left:24.5pt;text-indent:-24.5pt;padding-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></p><p style="margin-left:24.5pt;text-indent:-24.5pt;padding-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></p><p style="text-indent:-24.5pt;padding-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:45.389%;box-sizing:content-box;"></td>
     <td style="width:4.961%;box-sizing:content-box;"></td>
     <td style="width:3.241%;box-sizing:content-box;"></td>
     <td style="width:46.409%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 31, 2025</font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Steven Nichtberger</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Steven Nichtberger, M.D.</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Chief Executive Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>caba-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
 <head>
  <title>EX-32.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 32.2</font></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Annual Report of Cabaletta Bio, Inc. (the &#x201c;Company&#x201d;) on Form 10-K for the fiscal year ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</font></p><p style="margin-left:24.5pt;text-indent:-24.5pt;padding-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></p><p style="margin-left:24.5pt;text-indent:-24.5pt;padding-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></p><p style="text-indent:-24.5pt;padding-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:45.389%;box-sizing:content-box;"></td>
     <td style="width:4.961%;box-sizing:content-box;"></td>
     <td style="width:3.241%;box-sizing:content-box;"></td>
     <td style="width:46.409%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 31, 2025</font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Anup Marda</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Anup Marda</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Chief Financial Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Principal Accounting and Financial Officer)</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img63895535_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img63895535_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &6 U(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBHYIH
MK>*2>>6.&"%&EFFE=8XHHD!9Y))'(2.-%!9W8A44%F( )H DHKB?"WQ*^'OC
MD:LW@OQQX3\6KH5[-INM-X;\0Z5K2Z3J-N[1SV&HG3KNX%E=Q2(T<D%R8I%D
M4H5W @=EYJ 9)P,J 3T+,,[1C/('4=C0!)140FC/\6/3(()^@(!_#&< G&.:
M#-& 26P  <[6QAN1SC!R.0!R?Q% $M%,\Q,D9Y&,C!SEN@V_>SWZ="*02QL,
MALCUP0!P#SD#L1QURPXYH DHK@-?^*?P]\+>,? ?P^\1>*])T?QI\3Y]?MOA
M_P"&[V9HM3\5W'A;21KOB&'2(-C?:)-)TC-_=KN4I;J[C<%;%_P+X_\ !OQ-
M\-V?C#P%X@T_Q1X9U"6^@LM:TN1IK&YFTS4+K2M0CBD94+-::A975K,-N!+"
MP!(P2 =A1110 444C':,X)]E&3_GZT +17G'COXP_"CX7G3!\2OB1X'\ ?VS
M]J_L@^,_%.B^&AJGV+ROMAL#K%[9_:Q:&>!;CR=_DM/"'V^8N>XL=4T[4[*S
MU+3+VUU'3M1MX+NPO[&>*ZLKRTNHUFMKNUNH6>"XMKB)TDAGBD>.6-T>-F5@
M2 7Z*C$R="2K 9*E2& SC)&.A.,'H<CUIX(894A@>A!!![=1QUXH 6BO,O#G
MQJ^$'C#Q/J/@GPG\4/ /B;QCI!O!JOA70/%NA:OXBTW^S[C[)?\ V_1K"^N-
M1M/L5V?LUUY]O&;>?]W*$->E>8@ZGVS@XSC.,XQG';KGC&>* 'T4SS4(!# @
MC((!((&<G@'I@Y],'->4>(_CM\(_".K^.=!\2^/-!T75_AI\/[;XJ>/+"^N'
MBG\,?#R\N=8M+3Q9J@\LB#2+BXT#68HI\LS'3[@[ J@D ]:HJK97MMJ-G:ZA
M93+<6=];07=I<)GRY[:YB2:":,D E)8G1U..0PJU0 4444 %%(2!C)QG/TX&
M3D]!P">?0TPRH!NR2..0"0=QVC!QC!/ .<'L: )**8LB. 5)()P/E89_ @'&
M.2>@!!/!% D0G&X CURO\P.?;K0 ^BF&11_>.02H"L2P !. ![\9QGG' )IO
MG1?WAC)7.#C<,?+T^]ST_/MD EHII95ZGMG@$\#N< X'N:0R(."W."<8.0 =
MI)&,@;N,D#GB@!]%0BXA)(\P9#M&1SG>H)*XQG<%!;;UV\D8J53N (!&?7@_
MY/4>U "T444 %%%% 'Q3^W3^UNO[&OPP\$_$B3P0WCN/Q?\ &;X=?"4Z9'K+
MZ*]C_P )[>WEFNLB9+#4'N3IS6I<V*Q1_:1+Q,KQJK_32?%'X:'5[/P[_P +
M"\$#Q#?7-]8V>@MXKT(:U=7VE(7U2RM]+-\+V>[TU58W]O% TMH%8SI'M./R
M1_X+JMG]E?X-JI3>O[9/[.IP^S:"=:UG87\SY-A(.[?^[(!W\ X_"O\ ;(_9
M.^&]E\#?VX/V[_#_ (B^)WA7]J3PC_P4UN_AS\/_ (BZ%XXUG3I?AQX8\7?'
M;PS\._%UIX&T&&1]&TF7Q7X9\6ZK'K6H7%A<W5W*+.]\V.2Q1B ?VB:)\4?A
MGXET_7-6\._$/P/K^E>&9YK7Q)J>B^*]"U33_#]U;@M/;:W>6-_/;Z5<0@$R
M0W\D$B!6+*-IQD'XX?!86.K:H?B]\,!IN@ZH-$US4#X^\*_8M'UEI%B72=4N
MO[5\C3]3:5TC%C=/%=&1E01%B!7\X_Q#_8Z^"O[%/@+_ (*A?!3]G/3O$/@?
MX??$/]@KP'\4_%5A<>+-;U^^O/B=JGB'XG>&-:^(W]J:W/J-[:^*M2T^PL&U
M"6V(BDN[1;I8?,5$KR";_@D#^Q@O[6/Q?^ ZZ'\2Y?A O[ WA7]IGQ#X*/Q8
M\;)IGC7]H+_A)_&?A5/BQXPVZF;C6O$;6MG::DKK=16/]M:;;7UQ9N(4@<_0
M--;MWZ:;_BM-=U<_JU\2_$?X>^#+6QOO&'COP=X4LM4N8;/3+SQ)XFT;0[74
M;NX+"WMK"XU.]M8KR><HXABMWD>4JPC5BIQ\[^,_VT/@+X+_ &E_ 7[+?B/Q
MWX=TKXB?$+X?:I\1-#CO=>T>SLY=(TV\>SB@:XN+F(?;-28&33K<3))>($:V
MCG$@S_(/\8/B%\)?VG_V+OV+?A_\5?A3\4?VQOVT;7]AKQW\;K30]5^,EW\,
M/AMX ^'/@_Q1XST6;X[ZYJUWKWAS0-4^(WA/5K6SM]#G9'U2\28IY$B+(B>^
M_L7?LM? 7]JGX^_\$>OC/^T+X*M_B1\3O$W_  3JT[QAJWBO7O$FM3:CJGB[
MX9ZA?6_@;5KR]L=7MX=6O-$M6DCAF9)XKU/]*N(;AAYU&OEMWOYVTZ]^E]$W
MJT[+2[W>RW25M>BUZ*_36R:O_87<^.?!6G:9'J]_XN\,6.DOJ;:&NIW>NZ7;
M:>VMI</:/I"WDUTENVII=QR6K6(E-T+F-X#%YJLHHVOQ/^&U]X@D\)V7Q \%
M7?BF*:]MI/#5MXIT2?7X[C33 NHP/H\=\VHK-8-<VRWL1MP]JUQ LZHTL8;^
M8#]LK7=*@_X)[^$M(758H-2N?^"OGC;0[&Q74IUU62XTW]HWXGW=QINGP)MN
MY_[/M(H))[>..*.VL4$CQQVR!&\G^#OP9\):)K7_  <!_MU>'[#5M8_:?_9W
M^-W[3'A[X#^);K5=3N;7X9P)\*/#GC*Y'AW1$NY-/6]U'7%T_6-4EGLY<QZ?
MI26]M$L4DEV=;6_SW73KI?336P->OEINM=7J[/3;7U[_ -;OA7XC_#SQU<ZO
M9^"?'?@WQA=^'[A;37K7POXFT77[G1+IGDC6VU:#2KV[ETZX:2&:,0WBPR%X
MI%"[D8#LZ_E(_P""&?[&'[7G[/'QAL_C%XW\!_LG?"GX2_'KX!>'-?U8?!#X
MN>._'/B_XXZK=W^E>)M%^)GC73/&M[JD;^);.UUR^&K:UHCV5M<7WB6\CN-X
M:SB3^K>C^OZ_I"[V_%6_K[WZA1110 4444 -<$HX&,[3C)P,XXR>.,]?;K7Y
M-?"G_@J-X3^(WQ]_;N_9RU7P+%X0^(/['>G:CKWABQN_$OVF3XV^%=#\ 6/B
M_P 2^(?#^=$L(].M/#VJ:EI_AO6%LIM:%E<7MM/.Z/*EO)^LS8P<G QR< \=
M^""#Q[&OX^?V@/#;_!SQ'^VK_P % O#5C-_:OP-_;$^)/P3^,&JPQ/);1?LP
M_';X!_"[P_X]O-2M[0&^E'A;Q7/X0\3V]['YSZ9!:W\A"0/)+$?U_7?Y:@?T
M2?LK_MM?#CX_?LL_"/\ :8\<:CX1^">F?%2SU66ST/QAXXT>T@L[G2O$NM>'
MGL8]:UMM%2_EFET6XN$$<"M\S*AE$*R-B>/_ -JCXN^#OC!<>";'X V6M?#A
M]6^'TVB?%6X^*/AC2-/UKP#K>CW^I?$7XB6FD7@-RV@_#"1-&M-3NHII(+YM
M8BN&FMH]GF?R5Z-8?LN_M#_LE?L._ 2?]F[QW^V=^T7IW[*7CWXTZ3\+Y_C)
M??!OX->!/@C<_&#XG"V^,5S?7OB/PUX6O/B!9W]Y;V5G,R2:F+*_9VD:W$CO
M^GGPU\(7W[15M_P2R^'OC0W5SJ/Q._X),?MC>";_ .U:K]OO89[_ $+X+>%K
M"*36K.007,^FF6SB36+>X?[3/;Q7$1<2),A;;73R>OXI][I^7J#T=O7\-._G
MW9_3ROB3P[&VG0-KVCK+JMG=:CI4;ZG8K+J>G6445S=ZA8)YJF\LK:WN+>>X
MN[=9((89X9)9 LBLV5X0^(OP^^(,%_=> O'7@[QM;:5>-I^IW'A+Q-HOB.'3
MK]02UC?RZ/>WB6EVH5BUM<-', K$IP<?R;-^U=X[^*/[*NI^+/ACJUKJ_P ;
M_P!A;_@F7XE^$OQ0NC=ND/PY^/GQ&N[3P7XK76YHF!&J:/X:^$D]]/=I(DFG
MQ:C<7\9*S6L[?0?_  0[_8A_:L_9(^-'Q0UGXF^!/V5_@S\%_BK\$O".MZ-\
M-_V</C!XU^)47C7QO9>(GFT[XQ:WI_CJ^UG4;?4K_P ,:I/HU[XATV^@L=6V
M6D*VT;1J$-?UWZ>7?\--=@>G7YO\-F[-[6OH]&?T\4444 %%%% !4<SF*&60
M#)CBD<#.,E%+8S@XSCK@_0U)5:Z*FUNAUQ;S @@X/[MQCMD<$'!H _.;]B/]
MOO3OVQ?B#^UW\/9? 3_#G6OV6_CSK7P>B6\U^/5)OB#X=TA[RW@^(NGVK:;I
MCV&F76L:7K6D/;H;Q([K3KB)[S>FT^>_LM?\%0- _:*_;1_;7_96O/AXOP_\
M,?L@V6E:I!\8M7\4P_\ ".?$72[W6+WP_K&LVT%WINGV.D:5I.MZ1JNGM=)J
M^HP>?IE\)I(3&K2?STZM\1OCA^QW\8/B#^U;\+@+#P1\6OB[_P %(?V9?%D*
M6K7-OJ'QZ;XD^,KO]EB!;%6%U)J&H^,?$UUHEG<S9MYX#;QR_8MH:G?"WPKH
M7P)^)'[:/@S]K'PQXO\ &NK^+/\ @FC^PSI'Q-^'WAC6[KPQKWQ,^.WQU^,'
MCG7=3\"#Q'IEW8VUE;>,_B+XS_X1O5KH:G##'HXN(;IX[.*#>;+^G_PWY_)A
MIYWTO^MN_3MU/ZR_CS^V/\ _@3\ ?%_[1VO_ !"\(Z_\-?!J8N]7\-^)-#UJ
MSOK\RB%=+T^]L;N\M;G4]WF,;*!I;D1Q3L8ML4A7UWX<_%_X:?$W0?#&N>"?
M&WA77[;Q;X=M_$^C6^E>(](U2\NM,EMK*YNIT@LKR>21-.&HV4-^T:LMG-<0
MQW!CDE13_"-;? S0-6^!7_!7K]E[XB_LUS?L_?";X-_"[]FOXY_"W]EO_A:<
MWQ&T'X7?$;6H/%6[QWHOB'1/$.H2V>L^+;2[>^UC11JL\<-S,K31L\B"+]_/
MV?\ X-? ;]E?]L[]@KX>?"/0= ^&_@-O^"<'Q]\4Q:?#JET;*XO[SQ-\!-1U
M_4WO=9U"YFE MXIKV:20R&&%9IS+"@D69I7O\OQ:79A_E_PZ7S]+[NVQ^Z-[
M\4_ACINGV^K:C\1? MAI5Y'?2VFI7OBW0+73[J/3 AU)[>\GU".VG73A(AOC
M%(WV0.AN/+W#,5_\6OA7IFKZ%X>U+XE_#_3]>\50Q3>&-$OO&'AZVU;Q'#<2
M-#;RZ'IL^HQWFKQ7$RM# UA#<+-*K1QEG5@/X\_"OP/^&_[7D?\ P2"^%/Q"
MNM8UKX._$3XW?MKWWB70_#/BS5-%T[XA>'['P3!X@TS1M>O]+:"XO_#M_=65
MI)?:9!<))(BS)'<-"LQ3-_;%_86_:K_:,_;W^.VK_L\_"G]E*/P=^R+XO^!'
M@7X7?%KXL_&#XC^"/BW^SQX;\.^"O ?Q-MK[X<:'IVN'PG)I=QJ&MZ_JT6J:
M]I=\^LZM<WMIJ#?9[%(J2V3>EU]SMMTZZ7L-JS:3NDVKM6T3M?1O=:_AYG]4
M/[</[2'B']DK]F?Q[\=?"'PQN_C+XL\+77A'3?"WPOT_6X?#%WXU\1>,_%^A
M>#]&TB#6KNVO+;39+G4-;A(EGM9(D"G>-IW5\E_\$_O^"D/Q6_:C^+_Q0_9W
M_::_9%\6_L:_'SX=>!M!^*-OX$\3^*8/&UMXH^'OB+5)M&L_$6B^)M-T+2M)
MNH;>_C,%Q:1337EL)HOM=M:R'8-G_@J38^/[_P#X)\Z[I^A>*-.TCXI7OC3]
MFNPTCQ=-I]GK&DZ9XQN?CO\ #6"SUR?27D6QU.SMM6D%V^GR.L5S&C6P;+Q@
M_&?[%W@+]JGX*_\ !5SQ=_PV/\5_ '[0'CKXY_LA+%X&\=>#M/TWP;?^#- ^
M%/C'P_=ZSX4N_AUHS+INF:-J\WB:QU*/Q),\]UK&IV+6J^3%;,E.VG_ T^_1
M7:OY[::B^7S]?\OU\C][?%/Q.^&W@:ZTFQ\;?$'P3X/O=>=H]$L_%/BK0O#]
MUK$B.D;QZ7;ZM?VDM^Z221QLEJDK*[HI 9@"S6/B1\.M&\3:/X,UOQYX-TCQ
M7XBC4Z'X7U+Q/H=CXCUP2R^5"-)T6ZO(]4U 22JZ1FSMIA)(K1KEQ@?@#XA_
M93_9R_X*)?\ !0S]M+2_VYM+N/$__#(Y^#>D?LU:+<^-M8\$VO@7P'XFL;WQ
MCJOQ+T4Z+J6F/<:QJGCJRGT>77;V6Z6)=!MM/"(&P?Q,^''P,_;W_;L_;D_:
M5_:$\.Z!^SAXK;]D[]O>Y^&?A;XW_%_XL>./#/QL_9\\%_#?Q_I>M>'= ^''
MAW2]5'@H:#J?ANYF%J^MV$C>(-1U2]C<"2-5F7];?C_7ROT/FNGEJ[::ZIZ[
M?F?T"S?\%4/BZMY\>;9/AUX*,?PG_P""B7PP_8VT]I;G55:^\%>.?&/@KPU=
M^*KMDFCQJ]LGB:YEL$B9;=W@A:8"-][_ +RH JA0" ,@ DDX!(R2V2<]<DDG
M/4U_&Y)N&H?MK,<2%/\ @NE^SXK,S%MCCXK_  ;39N64O');;HHX%(C9K>"+
MST&#9V_]D@.?S(_(D'^5&UO2/6^Z77J-[O2VKT[:[==A:***!!113'D2/&]@
MN>F>_(!QZXW GT&3T% #Z*C,J+R20.>2K <$ Y)&!R0.O7BD\Z+) <':=K$<
M@$'# M]T%2#N&<K@@@'B@"6BF&10,G(!)YP<8'?C^$Y&",YR/?#MPSCG_OEL
M?GC'Z\=Z %HIH=2,C)&,Y"L>^/3KGMUQSTYIDD\41"NX#$,P7JQ"[02 .>"Z
M_P#?0[4 2T5 MS"ZJZ.'C=0RR)EXV!8*"&7((+'&1QUYX-.$T1W8<-M.&(Y4
M'.#EON_*>&Y^4\'!XH EHIH=3TSU8=#SM."1QR/0C@Y&.>*;YJ=22!@D,00"
M!UP?;OG'/3- $E%(&!/'/&<CD'DC&>F1CD?_ %\+0 44UG5<DGH<'@DY(R.
M">1TP/;K3/.C&<D@#'S%6P?7!QV_BSC ()XYH EHJ%;B%@"KA@S;5V@G<?\
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M67V?5+Z>:5T:CXH_\$^?VQ_VW[7_ (*"_&3XB_#SX3_LO>-?VHOV:_A%\#_
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M@$'H0<'!QV/I]:*!!3'#%<(0#D<G/3.3C'<]*?37;:,XSR!CH.3CD] /<\4
M?SL_\%==<_8)T;]LO]C2#_@HWK?@O1_@#=_ ;]J:2U@\<ZCXKLM$O/'46L?!
MM=(:UC\+31W,VM0V$NJQZ<[*"C7<HAR[ KY5\-OVQ/VO/V>_V>?V!?@G\!OA
M4/BKJW[5&N_&7PM\ +KXFZ]+9S>"?@IX;G\.:A\$_&OCC4]65]7OM$LO"&MI
M+J-M<^9XBO;![!(Y&FC*O^JO[1_[)GAO]H3]M;]FOXA_%+X7?#3XH_!KX:?!
M3]H'PYK^F?$G1/#GB>RL/&WC'7OA9/X3N[+PWXBLM0628VGA[74.JV\0:U4F
M)9"MP^:/[2G[/7C/QI^UK_P3V^)'PSTGP[:?#3]GG5/BS_PG,,6I:9HZZ%HN
MOZ+X*TWP[::+HVY!);(-#NX!:6$*B"!(5 5!M9Z=/Q_KO^'>^@?-W[3O[:G[
M=_@SXD_%?4/V=_@S\-_'GP0_8P\+>#=5_:POM=\02:9XR\=>)=1\*Z;\0?''
MA/X)6K6;QQ7'A'P+J%MJTESK4J6^H7=[;:?9MYXFV?J3X#_:>^!'Q G\&:/X
M>^)7A$>*O'7A[3?$_A[P->:W86?C&ZTG5;,W]K<#P[-,FI[7M5DG5OLV)(T,
MBY4YK\C_ -JKX/\ [>^F_$W]L/X8?LX>"_A[XQ^$/[?6C^$HD^,6L_$O2O#<
M_P"S3XB_X0"P^%?Q%U77O"%_I%[JWCBSU?PMHUEJ&@Q^'[Q5AOCY$T5FZO<2
M?H3\.?V"_P!D?P#XU^''QAA^%?@J_P#CK\-_">B^$]$^+ES'>-XJ@L-$T630
M;98G?4GM (]/FGM8GDMI9!;R;=V=I5?U^>RM_2MVU>EMG>[_ $M\EK^CNC^8
M7]F/QM^R1#^U#^PS8? ZU\8?#3]LS5OVY_CI8_M&_%368?B)X9\'?$SP5%K_
M ,<8]5\"7'BG695\$_$2\UQ8?#-OX>\-Z2D\HN],$L+"+3VNW_H@_;=_:3_:
M:\/_ !)^%O[,?[$&@_##Q%^T=XZ\->,OBCX@O?C#J%[8_#_PC\*? <VA:9>W
M=^^F0S:A<Z[XC\1>*M#TO0X+2%[==M[=7LT440W?FGX;_9A_;(^).B_!O]E+
MQ;^S#\,/@Q\/O@U^U1K'QNU+]KB3XL>$O%/BCQ%X2T3XK^./'NGP^#O!VAZ/
M#XU\/>*?%6G^(M.T626YUZ"WT^P_M*WNI7M62W;] _VP/ G[0?PZ_:+^!W[8
MO[,?PM\.?'WQ)X2^&'Q%^!?Q)^%.H?$;2/AEJ.O^&O&EUX6\0^'_ !7IGB;Q
M#:ZEHT?_  C'B'PA&E]ILEO#J%[;:FC17;QQO"X[?EMHNGF_FWYMVU2'O_GY
M[6VT[+IHCX,_X*%?\%E?B/\ L@>(OA9\)_\ A*/V8/AG\9_#_P %="^+GQ^\
M)?&GQAK%BGB/6;^6]LKKX7_!V[T'P_K<$NNW-YH&LSVVNZRL&CQ)?Z/  7DN
MOLU_XJ_%S0OC_J7[>_QIT"PEM-$^)?\ P1=^$7C*RT[4%87=I;^(M2^/^K&P
MNO+5(I?):[DM))(9=KO:B147*;>U_:)_9D^.,?QTTK]I2;]A7]F?]LWQ#\;?
M@!X*\&_$?P#\0O%?PVL#\#OBSX7U'5M5EU_1O$'Q"\)ZU;^(_"M[;>)GT:]A
MT&'2;J\?P]%<O8R)+!Y/L_Q!_9,^,^O7_P"UM=V'A;X>:2/BS_P31^'G[.WA
M;1_".L:7I'ABW^+6@W?Q:N-6\.Z1IYM-/BTKPQ8_\)?I4.FZ@;.TM)8(Y"L$
M.TA6GOKZ:6ZKK>_3M;M>]R6M%:VZT]&O/I^)^P'P]##P'X*#$$_\(GX<QM!
M &C60 Z^V3@ 9)P!785S?@VVFL?"?AG3[EHFN=.T#1K"Z,,R7$8NK/3;6"Y5
M)D)20+,CKO4D-C/>NDI#"BBB@".0J,9 .01@YZ<$G(5B,8![>O88_E[_ &B?
M%O[64/Q._P""BG[47@[]LKXL^ ?#O[$'CSX-2^"_V?Y)=$N_A'XWL)? ?@SQ
M7KGA;6]);11?ZC/XXN-8N-(TX0WP^S:E>6CY<1R1C^H*;(\LXR V",@=0>"3
M_"1D$<CD$CC(_ _X$?L/_!#]HK]N#_@H'\2/C=X*\8>(+OP?\>?@1<^%M)U+
MQ=\0-!^&OB)- ^#'@S6],O=:\ 6&KZ=X*\:KI/B&$2)-K&EZL%FL+6&<B*-8
M*/TLUVNFK=;[[6];JP?UW_,^PI_^"F/PRB_:6O?V4[?X8?&C6?B/X0TGP5XH
M^*^MZ)X6@G\!_"CP1XQ\$+XWC\8^-?%5YJ=E#8Z'ID/FZ??+#%<:JMS#(T6F
MRVZ^:+GP=_X*2>!?C'\9=#^%]M\%?CWX)\&_$2[\5:;\#OC]X[\(66E_!SXW
M:GX/M-0U/4[?P+K$>L7&K*;G1M(UG6=';Q#HNCIJVG:3=SVC2*8ED\4\/_##
M5O'7[1?_  6,\-:'IC:7XF^(W@/X3>"/"'BB6P-F[SZS^R\^B6*6FMF$226=
MAK-\DCQ6[M%:7 FW(97<)^1O_!.6R_8L\5>-/A;^R?!X1_;<\!?\% _A?X?^
M*7@3Q5XTU?7/CUJ/PT^$'BOP[H7BCPOXD^*_A'4?$OB-OA9:V^N6%Y(?"+Z!
M90WD,7B:UMK>*W5)&C/\_P /\]_Z6K5K?/6_IHUY=U:^FFZ/U*_X+M?&OXK?
M!C]ECX.:A\)OC9K_ .S[J/CS]KOX ?#+Q9\4?#EY8:=>Z)X$\9:_=Z?XG9KW
M4[>YM;:W%INDENE0?9Y8896*H'(O_P#!*SQ[\7+SXD?M??"/Q#^T_J/[:?P9
M^%OBOP0_PQ_:!U7^Q]4U"W\0:_:^(&\:_"J_\1Z);6NF^(]1\(VFF^&M5N+Z
M"/RX&U\KYBB4QC\SO^"P/[*^L?LU_L->!8?CC\</CO\ MD_#^[_;A_9G\4^.
M;'XBP>)/B#JFD_#G0-6\2S^,-/L=(TJ?5=0N+34-)OI(KB&S:Q$T]M9JC)+Y
M*U]6?\$@/$7P!^(/[5?[2_CK]@+X6>/?@K^PHWPB^'NC:KX5\3^$/%WPX\-^
M*/VGY?&?B'4]?\8>&_!/C$M?VM_%X FTS3/$VK11P1:F\NE>;"[0B64_IKOM
M;R\^NW>US2WKUTT>ETTN9N^T7=+JW9-'Z.>)?^"B7@C3OVD/^&?O WP;^-_Q
MALM!UWPEX5^*_P 9OAEX8T_7?A1\&/$_C.XEBTG0?B!K4NLVNJP:C! MM?:M
M%I&CZFNEVEU ;J19/-C'">'O^"L/P&\6?&3PW\/_  _\/OC7J/PK\7?$N3X(
M>'_VJ1X'V?L_W_QGM]1DT:7X=1>)I]1BUDZG_P )$H\,KJ T(:'+K_F:?'J1
MDAF*?G5^S'^T=X6_X)V?M5?M0?L9?'KPM\6?$_Q>_:\_:\OOC1\#_%/@SX?:
M]XR\'^*/!OQN73]*T"+7/&D43Z9X3;X?WNEW\.I6.K7,45G:(ES8!?/E5/@K
M_@GKI'['_P &?C/\/OV2_P!J'X"_MA7?[;_A?]L;Q)XA\(65IJ?QQU3X"ZM'
MJ/Q.UGXC^ ?C0(X?$%O\)M,T?1=,U&/4=6AGL$OY[RRN&EM[M[I(B=?ZV^YZ
M]^VFF]RW2VOF][K1K5>JZ/3I:_ZTIX^^(">(?V=;>3QOXQ5-5_X+._'CP-J,
M)U[4XQJ/@G3]#^,9TWPA?H;B7[9X4LVL-/FM=)D_T +:VLJ0QA!7[X*"  <
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M#X UKQ[#\9D\0:UX"\1V6FZ?'JOA:[NDTV>&TMV18;@#;_5KYW!(7.-V1GD
M9() W=5!(YR2& '%+',).0-JD9!<[6]2#&P#+@<Y/H<@8H_K]?SU!-K9M>CM
MTM^6GHVNK/YHOAQXL\ _">Z_9TN/ G_!'/\ X*7Z&G[*FH^.]1^"ELNF>![C
M3O#;?$;1(/#7B2VFMI_BC(=7L?[#A2VTV'4=[:?#"/(;><'EOCJ_@']H7XYV
M?[0GC7_@E'_P5ST'QR\?A&#Q7IGPY\2:-\//!/Q'A\$W,DGAY?B;X1\+_%ZR
MTKQ@;"U0:5)+?(UQ<Z((M,EDEMX%CB_J%\\#JI/.!M*G/O\ ,4P.F/7\#09L
M%59=C'L64@8R2,@E02H^4$C)/H.0/O?JV_S/P._:)_:PUK]J#X*>*O@%\3/^
M"3G_  4\M/ /B]=&2_E\&Z/X!\&^*--ET'6+#7]'U/0?$VB_%!=4T;4=,U;2
MK&[M[VSF2ZADC5X6+@L/G[]E'7?"O[('C?Q!\3/AY_P2H_X*W^,OB)XC\-IX
M-N/&_P <=?T/XP>)]+\+1WUOJ,NAZ#J?B_XM7TFCZ7?7MO;WFH6MAY/VEK.-
M7)CCAB;^G)I@ 6PI7'RX?+%N/EV $C'.2"2-K$KBOD_QY^W;^R-\+_B;)\&_
MB%\?_A=X0^)T$NG6]QX-U_QAHNF:O:SZK;)>6$5U#=7<9MGN;:6"6-9Q&S)*
MC %64D#^O\C\+OVFKGP'^U;\3/#WQ?\ B-_P27_X*P^&O'NB:;9:#?:O\)-:
MT;X3-XS\.V.MQ>(++1/B'%X,^+]C#XQTNPU."::"VU2.<K;7D]HKF&21(\#Q
M3X>^$/B;XZ0?M VG_!(#_@JYX%\8S^(])\8>+M!^&.N:;\/?AS\2_%&AZHNK
MZ?KOQ1^'WAGXT67AWQMJZW,,"-<:K;RB>TCCM+AS;R7"'^IV*Z6:*.6)HG66
M-)8W217BDC<$B2-U.UXVQE&5BKJ0ZEEY,GFGGA2,@#YU!QW."0#CG/(S_#N'
M) /YG$UWP#>ZAXS,W_!(;_@IW;-\4/VE?"?[4GBRZEM_ EI9?\+?\+:UX?UO
M2M<5H_B>/L>BV6I^'],NK_18U-A<+!.9?,$SLW]*FAZA+JND:=J4^FWVC37U
MK%<RZ5J<<<.H6#RC>UM>1133QQSQD[9$2:15/&[C \@^.'Q_^&_[/VD>%O$'
MQ,U*]TS3?&'CWP=\.-"DL["?4FG\4>.?$>D^%/#MK-';9\JWNM8UNPBFG9BL
M$<CR%'V''3^ _BMX2^(>K_$;0O#-U<W5_P#"KQW+\./&*W%N\"V?BF'P]H'B
MB6UMY6^6\A&D^)=+F%Q&JQ[Y)(L!HSE_U?[OR_7T#^OZ^9Z;1112 *IW>"K+
MM)?RF96X^4*03MRKD.YPN0CD<':0"*N53NSA9#\H(@=ER ?F0,<?W@2"3\H+
M,H8 ,1B@#^3/]F?QS^V=HO@;]EC]M[Q/^WC\4O&NF?&?]L>/X$^)OV9?B#%X
M?U/PCXI\+>+/B7KWP]6S\$K;:=IU[INLZ!INGIXFM+J!F\I;._F#"-8K:OU#
M^"7[5/BCX+? ;XM^++[X9_'?]ICQ;J/[;/[0WP^\'_#WX7:=_P )GXYFTW2/
M%%]<Q6RS^(-7TO2]+T'P]HVGW#'^T-4LD4+%;6,4\\Z0GYI_X(\?L"_L^ZC^
MS_\ #']IGQWX \7ZG\:O"_Q)^,^LZ GCKQIX_OO#?A+7[+X@>)],T_Q)X7^&
M&LZTW@OP_K4.G;QINKV6@0WD1OKV\AE6XU&XD/S?^TC\5/'7P/\ V61?7OQ-
M^.?[//PJ\2_\%,/VC=.^+GQ3^!/@?7/$_P 5-!\-7-WXMU/PM#HVFZ5;0Z_#
MH'B+Q59:+;:AKND7-JQTZ=E\V:RFF5CYI=MWV^>FM_3=W#^GHE=^B27^2T6A
M^M=Y_P %5/A;?? KX4_%7X>_![X[_%'Q_P#%[QKX]^'7AW]G#P?X,TZ?XUZ=
MXU^$,^JP?&31=>TC4]=T[P_I\_PSET34H_$-P?$4EK-*(%TN>_:YA!M?'?\
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MW@MWN)KBXF\(:JL4,,"*[3O)(T48C5&+%R-K8VG\O_\ @CU^P]\#?AQ^RO\
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MXYAU"]D^(/BK43J5HVDZ1X8T_2M1OM:M);8ZT;>RN6TW3;TVY(E^!7_!8O\
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MOB;X>?"VZNMEG]FTN]T^6P6"QLM/TJZTNQL+K3HVD\Y4^M_BK\?- _X)<_\
M!6W]L3]I;]I?P;\4?$_PB_;2^#OP=\-_ [7OA=\.]>^)EU%XP^$>E6-AXG\
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M7_X)LC<!\-OB: PP0/VD_P!HH97(8!O^+J?, RHV.!E0< X(_9; ]!^0]O\
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MZ8LL&I>.?$?B34;2$65K;Q?9+:ZAMLQ!_*+\CZGP/0=,=!TP!CZ8 'T ]*
M,X &>N!C/U]:+_U9   &<#&22?J>II:** "D90P*L,@]1ZTM% 'YY?M,?\$P
M/V/_ -KCX@0_$WXV^$?&.N>+K?3(=)AOM!^,7Q=\$6B6<$K2Q)_9'@KQSX?T
MHRHS,1<?9!,3MW,P!W?.H_X(+_\ !-E2&7X;?$U64@JP_:3_ &B@0PP001\5
M 0002"#D9&#QS^RV!C&!CTP,<YSQ[Y/YFC ]!^0]_P#$_F?4T[VVM]R]>JZ@
M?C2/^"#'_!-L;<_#CXF_*I08_:3_ &C!A6+[U7_BZIVJP=@5Y!+.3G<13?\
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MP=XR^$&G:UIFFW>E1:_X3N9$CTJX\11I=3//IMI!H=U<6=S'IKS16[-70?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MN;62XU 26D?F^5^#/^%__$GQI^QQ^QK^U'<?$'0/AYXL\:?&#5]>T+5KC3M
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M)J3BI'Z?T445^,G["%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MHI ,?YS^II:2::NG?S^?R&%%%%, HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "D.<<=>/U(%+37.!^(_P ?Z4K7<;6O=6OM;FC?\-/F-;KU
M7YGYZ_M7^-O$GA?]H[]C[2M*\0ZAI.BZYXI\6OXAT^WO[BTL=5M],LM->(:F
M(IPDRVRWTCVRWD+V1E=K69XI+VTECPM(_P""@</C/QUX7\!Z!\'O&<=GX^\1
M^(/#WA;Q=?:EI5GIUY:Z!$MS?:Y%"(KB66TALI[:X!L)+P>7.9FNH!$GG/\
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M@LUH+%Y?55?#2E.$:L8U8QDX.*T]HE?>^BTV=FFD^BBBO./0(I7* -DX&<@
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MP3X^\+7-IX@0::J;M>TV.80W6DRN\4S!#&LMT!'$\DDD*V[?NIG!_(SX*?\
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MM^5[:LGNX8KN"YM)T$EO<0&"93T=)5(DC/)^5XBR.K=1P1M:OCOP9^PI\"_
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MXS,OEE)BLB.Z.^Z1YG+1/+!;QQ!9(/Z:D)VJ, ,%!(RS $ # ) )&.^!G.<
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M<^ZQM=0>-;B:R8QI(A?(8[G('FA5^Q%C(QN<L0>I !P ,9QU.<DGWQQBO9X
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M+6M:T'[.%L_#GQ,T&TTK4]+UVQA9C;P7 ?4-:U*VNXGM?*E6[@N46&XA>?\
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M\8QBFW*4J-112MU;DMVEYH_GC_8RVG]I?_@G^P P?V?O'"1MY3*P\KQ+XZB
M,C/*"ODP.D;^=(DD B6(3*J7D/\ 36OWO^ C^2U^.'[/G[!GQC^%WQ?_ &7/
M'WB+5/"$VE_!CX7>(_!GC"+3=4O;V6[U/5=5\1:E%)I'VFSBFFLXUU>UR9Q
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M[S4=4U"YE:2XUC7M3N7N]7U>[=(X5DN+VZD=R1!$H5541H,!?PU_8F7&J?\
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MMTU"%TUONWY?B=%13(V5U!#!O7G/<CU/I3Z]DO\ 'S6S] HHHH **** "D.
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M.&C!+GH.6R.>QQ_WU\M<DWQ5TH$JJ!L;AN,ZA6(^ZP(^8*00#\I.0YQ@+O\
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MWVM_[(TEHP;=50S7-QO;?O#G#0(P*HH(4!@SQG:<'E7\%V,PR=0U0,Q+8^U
MA6(.>44!C]P,=X) 7<<[ /2(-.B!#9)#$]6'SDG+%MN,,6.21M_@7;M48O\
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M$8F"-]ED\U9@J)Y0BRZ($"G[Q\$^,;?6;&W)N(I,KDF,<CY1M!4X=0QY&[H
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M 9/)550MQO=V0# )49P'<A5[&\F,%K)*@)*J<#!))(*@8"NQPQ!PJDG& "2
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M>',@4%F;(VGSO3OVW?CY9X>\?PEJT1E5FAN?#J6J6\2E"Z0RV4D+2, 0@:=
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M.Y^?:L[=OZ?_  #V&K?<FO1KKY]]_5CJ***0CSSXC7LECX5U62-BK-93B-@
M=C%=JLPVME022>#@<D< CY?TF#;!:QC"D1^<Y'SER^YQ\P#!O,;YLAQC"* 0
M0*^A_BZ&_P"$5O&#$!50]<<?:K3/)(P"-PR"1\Q#JR%P?"[%0+@-D*H4H2 %
M")M!!;/!,?S,HRH"EL GD^[ECMAZEK7Y[7NDTN5*U^BUVO;335GD9BW>BKW7
M(VELN:*6OJG;71W2UNT?"G[='CJ:+3/"GPQTX21'59CXBULP392ZM+2)8[*U
MG0;I&07<C70 ?:?)7Y6VJ5^+_#^@*BQ.B1EY5C9W5 "!MP45U W@*-J-N"HA
M;9C,Q/L?[2-Q-K7[07BV9WB,.CV&@Z#"T:@[UM=-L[@B8X9"[S7+2EE)( "X
M$T;,E7PWI06*"1@"Q"\J 0026+ E0&5-Y((W,9!C<$B11^O972C@<IP=.*C&
M52E&O/SE749MRT6T6DM7=6N?1X&DJ6%I)67-",GMJYI2O?:[;=K::K32PFG>
M&T 7S44G #H(P=RG:'+E2?E<J,H%((!RF< =,V@(54BT0J0 OR,IP0-HR!C+
M$*!M=@7<G<=[L?5O#/A1Y=C$LS,P9%V@D,%!')^ZKMN#$$;0I9D(5U'HTO@T
M"W;Y4=B55&4,"S95"!OC*CAR9&#*JHVXK\HSR5LRIPJ<CDFV^K?DK[?+39+9
MZ'3S).UO^!MN];_?I9+LSXRU?PZJ*SJYR$Z"%ER=V0P:1'<;F^4G"%BFT$AB
M#Y-KN@J[RAHP&VKN&QF,IPS K&$8@[G5C@@N2'<Q%-S_ &GXK\,&U=V8*-L6
MYPT87*LJ%05W$D%6 =<;@Q,9888KX%XHTWRLSH ?+8A8]G!QG(QL9F#AB47<
MJJ&+CRT1F;T\'BU-1:=XR25M_P"72Z2T_%7NM4K-;7Z/IOV5EMYZ6N_70_0;
M]DWQI)XS^#6AV-_\VJ^$);KPO=RO<&2>YM+&7.DW,P$>Z/%M(8HAN9B(R^]R
M?,/O&I0[D)(&%;J 002=R $-D;1M/#*<@': 58_!O[#MW/;>)_BAH^]GMKK2
M=&UB)6F,A2X@OKF"7RHL(L4(%]E7C697<REIU?=$OZ"7@!1P0"-H(!YZD9/.
M?7U/UK\YSB@L/F^+C%**G5]K%+9>WM4=NEU=II:)[)61\GFD8QKRNM7)/2V\
MK:WMH[7VND]$[)6^5/B@QT?QKX0UF)BKZ@LEA<+C"2FTD6XA1Y/,4 1YD"!$
MD=-[M@*\DB_HQ\+;LWW@G1KI@0628*"V2%%Q(!D_Q':%W$C[V<= :_/7XZ6G
MG:9X6O5.V33O$.00%&5NX1"59L[@, -M!(D)&Y  0?NKX&7!N/AGX=F VAFN
M$&.ZK=3*.>^X $@DXZ9( KY/-%:JW'W;P3=EN];MVV>EKZ-]V[M].7W^KQN[
MVE)*]]D[+Y6Z*]MK]%[)7SW\9[J26+3=-4D"XNX'DV[6W(L4LQ!1MH8!XV<@
MLR@[?W3$*#]"5\R_%;<?$6F==N7/7Y=XM' .-Q&_8I&=I; /*X)3+*VOK-*4
MK2<8J23>\E:S?FG=KNTC7%7^K5K.S]G.VMOLN_57TOH</I2LTNY1C9(NQ$('
M#$[@ ,;=VZ3GC"H&#GYA'^/?[0OCG4OB=\7M?MG$Z:+X,U+4O!^D6LCDVZ+I
MU],E]=Q(J; ;AV9)&999&6%=[;(PL?[$QWBZ387VI$QC[!8WM\IE(V,UM:W,
MF9,L,L64;6P I #.B$D?B%H\1U.[NM2E*/+JNH3WTS\O'Y]Y=-=N4+HL@4RS
M(P695F(3S6P755_4.$J,77QN+G&[HQITX2>K@ZO,Y./9N$6FTG=-JZ;;(R6B
MG.K7:BVN51=E=73YM;W3;:;NMU;16.AT71#*47RMHP@\PE_F5%91ERSR95L*
MBO(SH&4 H &/I=EX:5=J21JS?-PH<J3N!<JL9VY!WY# %P0RD%78Z'A[16>2
M.!2-[.@.%8C))!9F4EFR<,2V<,5 ')8^]>'_  BKQQ,/*,A5FD$JHW.^4AR"
M QVDJHVJ2"P9RAPA]W&8U4]9MV;5EV3V;OKKMM*S:V5VOH&[6DU>^R[:+]=W
M9O;97/ ;KPY (I%D@1248 JLF=RD ;=N P P=XZG[QP3)7GFK:"(B[("0K+@
M,,[MK+\V".63A@,E@Q4#Y0K5]L:IX(58B'C$;_*Q,<3!=N7.65H]NQ5CP I(
MC(!8 .FWQ'Q)H;V<DG&49]IS&N%9\;5QM()4Y< J-FT%]H8E<\+F$*C7)/JK
MINR;=K:>>R>_;42DGMIW[+:S[-=+_BNOR;8:EJ7@7Q;X?\8:894N/#FKP:J+
M:V86YO;:QE6\NK)V41)LN+:/:Q7$&X*A8Q^8J_O-I][:ZUI.EZS9!1:ZKIEE
MJ%KL<2HL5[;QS&)7!8%(9',>_(RJ;VS]ZOQ'\2Z0I%U%(!M83.6;A4&U51BS
M;UR%=VR%W1JK.IWQ>8/U0_9EU:[U[X(^#[N\+*]B=5T2(^;YA:TTO4[B&U!;
MS'\O;;%(5C#(4C2,[(6?8GF<64H5</@\:DM*OU>=M&W4BIP;[\OLY]-Y:6O<
M\K-Z2G04XOWG)+K>]NCNGLK-;6U2NVSTK4H(W6>&5/W<R.K'YMC(T;K(K#"J
M593\X<XSU8,PQXK\!I9?#_Q4/ADJ4CLO$$D,<:%ECC2XMTNT&QR0A*,7"AM@
M60-$74>:?>M2*O&H(RA()')!RK9X(!YP #M!( ([5X-X89K']IC28B6']HSZ
M-?':!&,FT^S2,3G9))($)D)&YDQN8 )(WY_CU?#2;2;5M6KM-[Z[ZVU_RO?Q
M,ODU7<+NSBFTGH[<L;IN]W=VOKI?KJOT]!R >F0#CZTV0@(Q)P ,YYXQSGC/
M3KT//09IP.0".X!J.?\ U,G^XW\J^=LMK:=CW'L_^&_'H?'_ (JO6U/Q3J4F
M[=]DACLT&<+&YDE>4@(WWB"@\P%3(48!\EV'(^-_$0\#>!/%_C(0>:_AWP[J
M.K10[@GG7UM:NUE"Q?<J>;<O%EC&X8?+M;[M:CJQUC7268L=7NC@D-N#$$@'
M@GEDZ#Y=JH&89)^>?VOM<N-+^$+Z-;O$L/B;6=/LKT2)^\>RL[FTN&CA"R*"
M27W%6W(_#,I0-N^VRO#O$U\OP\7[LZE-2BF[."<'+1=US/LGK>R;/$C2]OF,
M:;2=JR=FF[0BHSG'2VKC%[6OUTO;\N-/BU#Q%J=UK.L7$NIZAJ,\\EY<7CF:
MX>=UC?:TY 7"%T"*'"L$D(5%VJ?7M(T)FVY53A!N?#9;)(=5&>5VL,_(I;!8
MGYUV8_AK3,R01G*I& NQUW, HW;#_K2H4LH4;G 1<R-@)(WOWA?P^UR408;8
MC8(4NH*X*Y"%E*NI!7YN H0#8"#^GXFLJ:23Y8TXVLM$EI[J[:6V26R?1'V%
MEIT25GY?"[?/JUOU[')6^@HV EL PPP/[QG!^7YOFW,,,O;A0W3<2*JWWAQ3
M&RB)%=0Q).\!0=Q!V@#! 8L#MX4!04&U:^I=*\&@VZ&.+>"$4>:N\L5WA@OE
M>8<@H2N_C:I!1U,BUA:[X/1,A8]I5<HZ)A6(57/S;$.U"6VY+JK$>820"?&C
MF-)UN1:-;M/LUHGNWM>^EF[-M-$KDO\ "EU4M/+RO?O>_77:_P 4ZUHC#S(C
M""A5QM,;'(W.A9 49 OEX!!8MU8H<@'U3]D?QU>>!?BM;>#Y8;B31/B.5T:\
M9[KRH+#5H+>^GTV^$,A\AIB,18!C:X7&P2[%C2SXCT4H9(V))5'/RJ,#YFZ
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MD5KY0_+KKKYO<T:***X3I/*OBO>/:>%=1",PDG2*W5EV[P\]P(QM&"<NBF+
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M+LC^64JNYV:,%=IVD8VR,  )FW>=_#.:'R@F_!$MJ^6W_P#+,['^9V"A8Y2
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M23:M;F6SLX[=>M_*R3:OK^H2_=7Z#^7X_P Z9* 8V![J1^8(_K^=2 8&!T'
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M[+J[DDIA%=857]ZD;-Q?C;PPXBED6 H51_-5%)9 5E+S%4VJ(H_FD+.Y\N9
M(]C ,OT/X)O+2TMYC<&,AD(;<0""KS @L.5)1HP&/.#&B@LT9K@?B%<6;_;G
MC\EOW$^1L+C<5D()#(PWN@DD"[4R9#_I*+*I@_.Z&,JO&N'+I=6E[R;E[K=[
M^[;6RLM%;75HXHRM*]];N_GJE\F[:ZZ_RK1O\X_'&E+$SX23[@!!7!(9V!3
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M Y[]AS7UCXL02^'M67O]DN''7@(F]CPK\[00HVG+$#(.#7R3X?YLHE/!\N4
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MCC)./O;XH2Q>2V"N3;1X8%@I_P!8^\.H"L^TI@'S0H2*1")%6&7X>\7\O=H
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M'W1R,KEFV/"B@O&YW1@-YD@^6/AD\2_9<$C]R4888D&21\%@HVD[0 CL%5B
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MS(B)NCCD4(-P9T!)4*,YWCV\M)I)Y;<QF-;>7YP9 "Q1P 2R;N56-$+A)74
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MQ1S6]U$(YXI$5EEB(99(9>26CE#2K,,_,'*GH!6U\8XOL7B7P]>,6$=W!/:
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M;,IW.3&(V &Y@&^E_P!F;X?3Z%H^J>.M:T_[/JOB(K;:0DZ@W=KHT"SH[^6
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M (SD@  *"S%2J*>%]%^-%KFRM-1P +&]L)';&<Q[KA'#,JETXF !)9>-F/G
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MGJ>_6O!KU/:3<K;N][WO?7[M=&VY=]SVX1Y(I=DELE;1*VFG3IH/I&.!^/\
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M+<@%0PR5(&5(*ON&Y?+(.\$KQG(^(Y;*71]8U73Y&*0I=_:K=,*%>UD>6,;
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MD@E=W(.,9P,\XQR!V'M7/7_B/0].9UN]<TFTEB.PPS:C:PNL@(Q&\!W2 D(
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M5JF^5V6FOEKH[=2Q49))SETO:ZZKLKV;7STOIOJR3R$Y<[6R!\K;BH^7: V
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M#OA2VTJ",%65@J8!P>% QR#C/+8XXR<"NP6)%"J%&U<X]3G(YX]#DG<#N (
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M]C46E[:WK*2I^SSQ.VY6*E1&9!-N&U@592WR9'RG(]H\1?"'3-061DBG(90
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MTI8(!CJP8@8;DD)O@\3_  "LY LR6-P\L/S0N+H QL""62:,;R265W)X1HP
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M4M+BU*ZBT:XTV:-KFZB,DL/YV?LF_L]:OJ/[$NE^"_!/[ WQ _9-@\=?MN_
M2_\ $W@GXDZC!XN^,.J?#GP+\1_!GBG7/B;\3]0GL(EETZR70+[2M&L1=:E;
M6F@-'>))%))+&OT!_P %D?!GC;XF:K^Q5\&/A/'"WC#X^_%?XD?L\>)[NT%P
M^K>#/@=\6?A%K^G?&'XC6%O8N98E\(>&M-+H\ZC2QJ5[8I>,4CC0G;S2W5K7
MMKZ6U^;W=F'FTMFM^NFO_#JSUMUM^GW[(G[1$/[5OP%\'?'JQ\-R^%-%\>WG
MC"?PWI-S>B_NI_#6A>-?$/A?0M<EG6WMT \1Z=HD&N11(KI%#?PHDTJX=OI>
MO+O@Q\,O#WP7^%OPZ^$?A.)8?#7PR\"^%_ VAJD<<*R:?X:TBTTJ*Y,4*1QB
M>[-JUU=,%^:>9G4X<Y]1H$%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% %>2>"")I99DAA4@-+*\<48+$* 7D*@$DA1D\D@#DBJ?\ :^E9"'4]/R02
M%^W6FXA< D#S,D#<H8]B5Y'&?%?VB]$N/$/PQ\1:+:O=P7%_8&-+BU3S6B,4
M\5P#Y2%78EXHRI5@8RI8!FPT?Y'GX)>)]S*=6\;R+&%5F%O$K/R<L-DT:!S'
M(5.(T!<"X4[4CA'R.?9QQ-E^)I4,FX7_ +=HSI>TJ8B6:4,"Z<XMKE2K1:E9
M)---/F:23;3,JE2K"2Y*'M-KOVNSTZ]=$W>RLVEI<_=O^U-)Q_R$K#_P,M,_
M^C/_ ->>IZ!?[4TG_H)Z?_X&6G_Q=?A ?@GXH(8?VMXW+8(R+10"Q>0EU7[8
M"$$;E0FY6#^6ZL%C6-''X)^)R6QJOCG!WD?Z*N<.I\M01=CYHS(S.0%5U51'
MY9CB8>#_ *S>('_1OGO_ -%'@_[O_3OKK:^MTKV2,O;8G_H'?_@[_#Y>3_"_
M4_=W^U-)_P"@GI__ (&6G_Q=)_:FD_\ 02L/_ RT_P#CF>?R^F./PB_X4GXF
M)YU7QQ@[2V+9 0,2>8@(NSM:1F)B(!6$;%;>8U:-/^%)^)R.=6\;AF!!/V50
M%8NQWX%YD)Y<C*$5BP=5<,%CBC N)_$!:?\ $/GTU_UBPG97VI=->G:UT"KX
MG_H'ET_Y>_X?[OK^O4_=_P#M32?^@EIX_P"WRT_^.$\>_P"M']J:3_T$]/\
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M;V;347KK&S?1AVZU2"KQCAX.<8U)VY_9Q;BI32C:4N5-R4='I:^YT#:QI;$
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MK\+_ /A3OB?C_B;^,,<\_P!GKP00,$;]W.200"N 22!C)_PIWQ/D@ZOXP'.
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MNP)&"#@GG !.Y<O_ %R\5/\ HT_:_P#QE&6]>7_J%]=5Y=T'^IGA?_T==?\
MB+9GY?\ 3_T_'S/W1_M?2?\ H*Z?_P"!MI_\<KR#Q%\)?A'XG^,OP^^/>KPV
MEW\3OA?X2\<>#/!6N?VZ\<&E:#\0GT63Q5:MIBW(TZYFU$Z#I:I=7$#W%O'!
M(D,B)+(&_([_ (4[XGSC^V/&'I_R#ACMWW8_B'/3K_=;!_PIWQ/D@ZOXP'.
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MIP3C@E7*\;AD@D<-R0I(4?!WQ.<?\3CQASC'_$N'?)&?FX/'(."#@'!(R_\
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M['L/R'H*#X3\.'_F#V.?7[/%GZ_=_P Y/MCH:* N^_\ 7])'/?\ "*>'NO\
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M%C]?L\7MC^'L!@?_ *J/^$4\.'G^Q['U_P"/>/GG/]W_ #]>:W/-'M_WT/\
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MWT/\* OY2_\  9?Y>:^\P_\ A%/#W_0)LN?^G>+W_P!GW/YGUH_X13P]_P!
MFR[_ /+O%WS_ +/N?S/K6YYH]O\ OH?X4>:/;_OH?X4!?RE_X#+_ "\U]YA_
M\(IX>_Z!-E_X#Q^^?X>^3GZGUH_X13P[_P! FR_\!XO?_8]S^9]36YYH]O\
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M/YGU-'_"*>'O^@39?^ \7O\ [/N?S/J:W/-'M_WT/\*/-'M_WT/\* OY2_\
M 9?Y>:^\P_\ A%/#O7^R++/4'[/%D<D_W?4Y^O-'_"*>'O\ H$V7_@/%[?[/
ML/R'H*W/-'M_WT/\*/-'M_WT/\* OY2_\!E_EYK[S#_X13P]_P! FR_\!XO;
M_9]A^0]!1_PBGA[_ *!-E_X#Q>W^S[#\AZ"MSS1[?]]#_"CS1[?]]#_"@+^4
MO_ 9?Y>:^\P_^$4\/?\ 0)LO_ >+V_V?8?D/04?\(IX>_P"@39?^ \7M_L^P
M_(>@K<\T>W_?0_PH\T>W_?0_PH"_E+_P&7^7FOO,/_A%/#W_ $";+_P'B]O]
MGV'Y#T%'_"*>'O\ H$V7_@/%[?[/L/R'H*W/-'M_WT/\*/-'M_WT/\* OY2_
M\!E_EYK[S#_X13P]_P! FR_\!XO;_9]A^0]!1_PBGA[_ *!-E_X#Q>W^S[#\
MAZ"MSS1[?]]#_"CS1[?]]#_"@+^4O_ 9?Y>:^\P_^$4\/?\ 0)LO_ >+V_V?
M8?D/04?\(IX>_P"@39?^ \7M_L^P_(>@K<\T>W_?0_PH\T>W_?0_PH"_E+_P
M&7^7FOO,/_A%/#W_ $";+_P'B]O]GV'Y#T%'_"*>'?\ H$V7_@/%[?['L/R'
MH*W/-'M_WT/\*/-!Z8_[Z_\ K4#OY2_\!EY>7FOO1@CPKH:2*\6FV:'<"^(4
M&0"#@%5!!..N>#R.2370; H4( H0;0!QA0I"J.#P#C P0,9QQBF^<GO^5!E!
M&%//'4<=><]>WMUJ5)-V2>OH^W1-M_)-_<-II7DG%*UY2322T6K:LEJM]ODS
M/O-%TS4662^LK>YD5=NZ6)'.#C=RRDX)'3I[=:I#PGX<'']D6..O_'O%UY_V
M>V3CTZ=.*W59N,X.5W8!!'3L0!GG R/4''(J0'(S5:/5--6O=:[]^P/1VOTO
MH_-?K;\#G_\ A%/#O_0(L>1C_CWCZ#H/N]!QCZ"C_A%/#O\ T"+'H1_Q[Q\
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M]Y<G_";ZI_S^WAR"1AI3D#.2,2\CCJ,YRN/O+D7 O"NG_"?A.G_,ORSKR_\
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M=.7_ *>>7Y^5_P!Y_P#A<WB+_HX3XK?^%0__ ,G4?\+F\1?]'"?%;_PJ'_\
MDZOP8_X3?5/^?V\.02,-*<@9R1B7D<=1G.5Q]Y<G_";ZI_S^WAR"1AI3D#.2
M,2\CCJ,YRN/O+D7 O"NG_"?A.G_,ORSKR_\ 4+_>8+..(M/^%K-^G_,RQG3E
M_P"GGE^?E?\ >?\ X7-XB_Z.$^*W_A4/_P#)U'_"YO$7_1PGQ6_\*A__ ).K
M\&/^$WU3_G]O#D$C#2G(&<D8EY''49SE<?>7)_PF^J?\_MX<@D8:4Y SDC$O
M(XZC.<KC[RY%P+PKI_PGX3I_S+\LZ\O_ %"_WF"SCB+3_A:S?I_S,L9TY?\
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M/RO^\_\ PN7Q%_T<)\5O_"ID_P#D[C\*/^%S>(O^CA/BM_X5#_\ R=7X,?\
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ML9TY?^GGE^?E?]Y_^%R^(O\ HX3XK]<_\C3)Z8_Y_P#I[=,\]>:/^%S>(O\
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M %"_WF"SCB+3_A:S?I_S,L9TY?\ IYY?GY7_ 'G_ .%S>(O^CA/BM_X5#_\
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M+H3SC-7%XW"J2GF6+E%WK4ERRC[2-T]+J]G;7W7K_HL>'M134M*L[U0Q$MO
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M<C(S$,#(QAL-STX;'A/_  FEI_T,&E#IUO(>,XZX/;=SC^XV,Y3<?\)I:?\
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ML=_T#U?_  5+R_N]-?N/=CJI&?NG! ^^.0<\C,0P !DAL, 0<=<!U4\\*<'
M^;KP3D9B&!@=&PW(XZX\*/C:UY/_  D&E9(Y N[?_8) &0 <DC@@?*P!P5WG
M_":VO/\ Q4&E#^'/VN#H"H##'(R.<X#$*^1E@&?^M.7?]!N&_P#"BEY?W_7[
MO,/]7L=_T#U=O^?,M]/+IU_!]_=?[5/.-IY&,..0<_,,Q# X'#88Y&!P<']J
MGG&TX.!AQR.1N&8AQP,9P3D8!YQX5_PFMJ?^9@TH=!_Q]P\<*.<>F>2,DE'/
M)*[C_A-K4@G_ (2#2AGG'VNWR#\_ P<#H. 0OS+GH=A_K5EW_0;AO_"BC_\
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M)#&\)\A);95L?)E;ZJ_:)\9^(T_:X_X)QZ0NLWZ:6G@GX>W%OI\#-]FAGO\
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MY'[!P]GF#RW(\IP&(QV%^L8/+L%AZW+B*?(ZE+#PA)P3E%I7CJFHV=]+WO\
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M[X_XLCX1_B#8O-4_VMI7_2NH^3>AP!A]LAPN?<?^'E_QB_Z(OX'_ /"[G_\
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MK-@^4?E59Q\X]Q_X>7_&+_HB_@?_ ,+N?_YGJ/\ AY?\8O\ HB_@?_PNY_\
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MU#PI1PH4Y)9-V&5E]R_X>7_&(C!^"_@?'_8]S]_^Y>H_X>7_ !B_Z(OX'_\
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M)2H8BI5F^:2O&%.32C*3M&+FOD3_ (<O_LZ\8^"_@\\<_P"EZJ.<G!'^E'
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M1B:* R327EO^. U/>0@/EJ2.IW#L6!W&-,,50$EEQM)R3M*_MO\ L8W,\/\
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MLJ<U3DO;UY4^1TW_ #1Z%\;_ (@^*+LV'AKP[XD\0W^ XL=!L]5UJ[:$D@7
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M<XQ_IS<YVX_A[[UQZ[E]1GY _M1/^>1Q_OGUQ_<Z8Y/0XQ@$Y /[53_GD?\
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M,XC/(PV'."!@X_U8S\P&,@#(R<8&3V4_Y9?>_P#,/[5I]J'_ (*AY?\ 3O\
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M, GN>< ' 3_A)KG;CRX]V,;L';NQUV[<[<_P[L]MW>OVL_X<:^)?^BH_$?\
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M'>8=J?\ X4>GEZ?TW<7TP.#-/WV-VU_V7$:[:NU/=:[67EJK?BI_PD]SQB-
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M:_6#^" HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&V_[Y8^F?XN0>21T8@%LD\'_  C>D_\ /E;_ /?+Y[<YW9SC(SUP ,X) **
M#_A&])_Y\;;_ +Y;VZ?-T7DJ. I (P2<'_"-Z3_SXVW_ 'RQ],_Q<@\DCHQ
M+9)X** #_A&])_Y\K?\ [Y?/;G.[.<9&>N !G!(!_P (WI/_ #XVW_?+>W3Y
MNB\E1P%(!&"3@HH /^$;TG_GQMO^^6/IG^+D'DD=&(!;)/!_PC>D_P#/E;_]
M\OGMSG=G.,C/7  S@D HH /^$;TG_GQMO^^6]NGS=%Y*C@*0",$G!_PC>D_\
M^-M_WRQ],_Q<@\DCHQ +9)X** #_ (1O2?\ GRM_^^7SVYSNSG&1GK@ 9P2
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61110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img63895535_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img63895535_1.jpg
M_]C_X  02D9)1@ ! @$ E@"6  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &[ _(# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#Z8_X*;?\
M!1_]MGX+?MY?M'?"WX7?M!>,_!_@'PAXE\+6GAOPUIR:/+9:5;ZA\-_!>M7L
M5N][IEU=;+C5=3O[PI).ZQ/<M%"(X$CB3X2_X>W_ /!1?_HZ;Q__ -^/#O\
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MR7-K,89I)*U7$ZM)*6*<9)MRBN:$JJE%-TYI.22?+*S>IX#_ ,/;_P#@HO\
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M_'_0_P#+#PY_\I*_.6D;H?H?Y4?4,#_T!8/_ ,)J'_R'E^?=A];Q7_05B?\
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M +\>'?\ Y24?\/;_ /@HO_T=-X__ ._'AW_Y25^<E%'U# _] 6#_ /":A_\
M(>7Y]V'UO%?]!6)_\'U?_D_+\^[/T;_X>W_\%%_^CIO'_P#WX\.__*2C_A[?
M_P %%_\ HZ;Q_P#]^/#O_P I*_.2BCZA@?\ H"P?_A-0_P#D/+\^[#ZWBO\
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M '[TW_Y"KXHHH ^U_P#AXI^V9_T7/Q3_ -^]-_\ D*C_ (>*?MF?]%S\4_\
M?O3?_D*OBBB@#[7_ .'BG[9G_1<_%/\ W[TW_P"0J/\ AXI^V9_T7/Q3_P!^
M]-_^0J^N_P!G#X)>%=2_8\^&/Q*T#]A[1/VM/B)XE^*'C_PWXIDG\477A:_T
M3PYI&I7JZ5?SW;7!LI88VB@TN)?(A6)66:>1@KL:/QQ_8%^&6N_M!?%_P_\
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M ![7'_7";_T6U 'ZJ_M(_MU_M5^#/BBFA^&/C!XCTC23\-_@YK)LH/LDL?\
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M:-:_;<\0_#'1M+^-'A33_#7PNT#5-2^'_P $OA?I'BN;7-5M/"GAV;PSX?\
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MUB#1VG_LZ+59[.&.SEU-+5+Z6SCCM9)V@18U_JI_XAHD_P"CF+G_ ,)NV_\
MD&C_ (AHD_Z.8N?_  F[;_Y!K;#YWD&%5J5>JO<HT_>H8B7NT(<E/>GHU&33
M>[UOLS.ME>;U[>TA2?O5)Z5J,;NK)2G>TM4VDTMET/Y3**_JS_XAHD_Z.8N?
M_";MO_D&C_B&B3_HYBY_\)NV_P#D&NK_ %GR;_H(J?\ A/B/_E?G^?9F']A9
MC_SZI_\ @^E_\D?RF4C=#]#_ "K^K3_B&C7_ *.8N?\ PG+;_P"0*IW7_!M=
M%;1L[_M*WA4 YV^%U;VP"FE./IDC/;-+_6?)O^@BI_X38C_Y6']A9C_SZI_^
M#Z7_ ,D?@Y^V+U_9"_[,)_9O_P#2CX@U\=U_6)\9_P#@B):?$>3X6KJOQVFT
M8_"GX)^ /@A8FQT&6Y_MG2_A_)KLEGXAO?M&D#[-J.IG795NK.#-M!]FC\DY
M=Z\//_! ?PV"1_PT=JO!QG_A&8__ )4UEA^),HA2A"6(FI+FNOJ]=[R;6JI]
MFOQ[,UK9)F$ZDI1IT[-1M>M26T8I_:[H_FKHK^E+_AP3X:_Z..U3_P )F/\
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MO^CCM4_\)F/_ .5-'^L^3?\ 014_\)\1_P#*_/\ /LP_L+,?^?5/_P 'TO\
MY(_FMHK^E+_AP3X:_P"CCM4_\)F/_P"5-'_#@GPU_P!'':I_X3,?_P J:/\
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MHK][/^'(>L_]%HT__P %L_\ \K:/^'(>L_\ 1:-/_P#!;/\ _*VB_D_N]/\
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M>GWK^NOY]F?@G17[V?\ #D/6?^BT:?\ ^"V?_P"5M'_#D/6?^BT:?_X+9_\
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M]_\ G@5])44>UJ_\_*G_ ('+_/R7W![*G_)#_P !7]=/S[L^;?\ AE/X8_\
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M  "/^7E^?=GP#_P[0_9=_N?&[_Q)7X_?_/$H_P"':'[+O]SXW?\ B2OQ^_\
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M4E%J2L[_ *61?\%+/^"1:+@_$7]OT?[GQ,_:7 _+_A=P ],#C\ZD_P"'E_\
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M4664WC)2JN%"-/V<'65:I2I3_>__ (>7_P#!(K_HHW_!0#_PYG[2W_S[Z/\
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M\P-3I;_J*_NK\0_XE;\-/^@OB[_P\X+_ .='DON/ZYO^'E__  2*_P"BC?\
M!0#_ ,.9^TM_\^^C_AY?_P $BO\ HHW_  4 _P##F?M+?_/OK^1FBC_B)&?_
M /0/D_3_ )@:G2W_ %%?W5^(?\2M^&G_ $%\7?\ AYP7_P Z/)?<?US?\/+_
M /@D5_T4;_@H!_X<S]I;_P"??1_P\O\ ^"17_11O^"@'_AS/VEO_ )]]?R,T
M4?\ $2,__P"@?)^G_,#4Z6_ZBO[J_$/^)6_#3_H+XN_\/."_^='DON/ZYO\
MAY?_ ,$BO^BC?\% /_#F?M+?_/OH_P"'E_\ P2*_Z*-_P4 _\.9^TM_\^^OY
M&:*/^(D9_P#] ^3]/^8&ITM_U%?W5^(?\2M^&G_07Q=_X><%_P#.CR7W']<W
M_#R__@D5_P!%&_X* ?\ AS/VEO\ Y]]'_#R__@D5_P!%&_X* ?\ AS/VEO\
MY]]?R,T4?\1(S_\ Z!\GZ?\ ,#4Z6_ZBO[J_$/\ B5OPT_Z"^+O_  \X+_YT
M>2^X_L/\$?\ !0/_ ()(^._%_ASP;:_&3]M7PQ=>)]7M-%M-?\<_&;]ICPYX
M0TRZOI!#;3^(=?'QCOTT;36G:.&;4KBV:TLS(LUY);VJ37$7Z[C]CCX/LJ.G
MBK]HR2.1(Y8I8OVM/VBY8IH9462*:&6/XEM'-#-&RRPS1,\<L;K)&S(RL?\
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M/_P)_P"?DON/E;_AC?X0_P#0S_M'_P#B6/[1W_SR:/\ AC?X0_\ 0S_M'_\
MB6/[1W_SR:^J:*/84?\ GU3_ / (^7EY(/:3_GG_ .!/_/R7W'RPO[&_PA+*
M#XG_ &CR"P!_XRQ_:.]?;XE _D1]:Q]"_8^^$USI%I-/XJ_:0DF=KL/(?VL/
MVC@6V7DZ)D?\+*Q\J*J\ <#GFOL%/OK_ +R_S%87AO\ Y =E_OWW_I?<U#HT
M>>*]E3MRS=N2.Z=-+IT*4Y\K]^7Q1^T^TO/R7W+L?./_  QO\(?^AG_:/_\
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M>?\ X$_\_)?<?*W_  QO\(?^AG_:/_\ $L?VCO\ YY-'_#&_PA_Z&?\ :/\
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M2?\ //\ \"?^?DON/E;_ (8W^$/_ $,_[1__ (EC^T=_\\FC_AC?X0_]#/\
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MN_JS\KG_ !,MX2?]#O,?_#!G/E_U!^?X/L?Q]T5_8)_Q#<_LV_\ 1RWQX_\
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M8)_Q#<_LV_\ 1RWQX_\ "8^'/_R+1_Q#<_LV_P#1RWQX_P#"8^'/_P BT?\
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M%*2:C*%KPNFY1=VKQT<D_>4GIWNEJFEW']HW_P#T+NK?^!.A_P#RUH_M&_\
M^A=U;_P)T/\ ^6M<==?&'X4V.D6VOWOQ"\+6FAWEMX[O+75KC4/+L)[/X7FZ
M7XC7<=PT6W[-X*:QNUU^=ML5JT#JC3$H'XOP]^U1^S7XLUK0/#?ACXY_#C7?
M$'BG7IO"_AS1M.UY9M1U?Q##;I=_V5:V[0HR375M(DVESW/D66N*V-$NM1<,
MH2HUFFTJS2NVU3=DE:[;Y+*UG>^UG?:0_:TTTFZ:;M9.;N[\MK+GUO=6MOS*
MVZ/9?[1O_P#H7=6_\"=#_P#EK1_:-_\ ]"[JW_@3H?\ \M:^=O&'[97[-OA'
MP7\3_&J?%3PQXFM?A)IT=_XNTGPS>/J&K(]UJD>@Z;::<A@2VU0:EX@EAT.#
M4M-GO=(@U&58+J^AD*H_=Z7^T1\"M:\67O@'2_BSX'O_ !UIGA^[\3:EX1LM
M92?6;32M.T>+7M4;8T45O->Z5I,T5_JFDQ3G6-,LW6YU+3K.+<R-X>NE=JLD
MKW?)M90;O[NB2G%MO2TTWH]4J]%NW-2;TTYWJVVDOBW;C)66NC[:>G?VC?\
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M /Z%W5O_  )T/_Y:UK44<LOYY?='R\O+\?6Y=?RQ_P#)O_DOZN_*V3_:-_\
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MZ=[ZO4:\*I_$J?XY?^E,[Z?\.G_@C_Z2@HHHJ"PHHHH **** "BBB@ HHHH
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M"G%U),/_  7B_P""D(QGXE?#49.!GX*_#X9/H/\ B6<G@\>U+_P_A_X*1?\
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M?_+/+\^[#_B%7AG_ -$!P?\ ^([E7_S*?L3_ ,/X?^"D7_12?AM_X93X??\
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M_P#=;_OD_P"%&Q_[K?\ ?)_PKSO_ (5EX=_Z"7CC_P +[Q5_\LJ/^%9>'?\
MH)>./_"^\5?_ "RHYJG\D?\ P/\ ^U]?Z>A[O>7_ ("O_DO7^GIZ)L?^ZW_?
M)_PK(@!&N:P""#]AT/@C';4ZY+_A67AW_H)>./\ POO%7_RRK4\.:'9Z!J&L
MV-C/JEQ"T&CW!?5]6O\ 6;K?(NH*RB[U&>><1 1KLA#B.,EBJ@NQ,MR;AS12
M7.M5+F^S+I9==/Q\AJWO6;;Y-FDM.>&M[OKIMYG75_"Y_P %7OV</VBO&O\
MP42_:D\5>#/@!\;O&'A;6?&/AJXT?Q+X6^%/CKQ!X?U>WB^&_@JTEGTS6=)T
M*[TZ_ABNK>XM99;6YE2.Y@F@9A+$ZK_='4ZW-RBA$N)T1<[566157)R<*& &
M3R<#K7@\3<.4N)L%0P5;%5,)&ABH8I5*5.%64G&E5I<CC.44DU6<KIWO%+9L
M_1_"_P 2,9X89[C<\P65X;-JF-RFKE,L/BL15PT*=.KC<#C'6C.E3J2<XRP,
M8*#BHM5)-M.*3_D+_P""!/P,^-_PR_;%^(NO?$KX,_%CX=:%=?LZ^*]*M=;\
M=_#KQ?X1TBYU2?QU\/;F#3+?4M?TC3[.?4)K:UNKB*RCF:YD@MKB5(S'#(R_
MTO\ Q!_9J\ _&+XGZGXL^,?A?P/\2? [_!P_"OP_X,\4>&+/7+G0;S6O$VH:
MWXU\465UJUM<VNF:EJ^G_P!@:5I>HZ2+;6-/&F7#FZ1)(17TF\\\J[9)I9%!
MR%>1W4'IG#,1G!(SUJ*NGAO)H\-Y='+J&*J8A1JUJJKSA&E4O6<7**4)-)+E
MLFG=IN^YY_B3QQB/$GB6IQ)CLNP^6U:F#P6#>#P]>IB:/+@H2C&;G5ITY2<^
M9MQ<;)I6/AK2_P!E/QS!X*U70M4\=^"KOQ3:_LJ/^RWX&\4:?X6NM,A\/Z1J
MGB3Q#<^*_%$^G6D,$=IJ'B;PE/X3TO48=$6W%UK6B:A=W#M97D2CF]._87BL
M/CM>>/SX@\.S?#V3XEZ'\6;.QDO/BR?':Z[X4T#1M)\&>$KO0H/B#:_!2?PQ
MX.O] TC4]"\12^!KKQ<ECI]MH#-$B?VJ/T)HKZ)8JNN:T^7F33Y4EI*UTK)6
M7NIV6BDV[7;9^?/#47RWBWRM-7;>L;VNVW=V=F]VDE?0_.#3OV,?BSJG@RQ\
M#?$'XG_#34M!\/\ PAO?@QX=L?"_A+Q59+<:+XM^*_A;QI\5/%OBB]UK5;^Y
MU'Q7\1O!OAR3PQ<VEA%9Z+HNHZC<26HNK"2>23VSQ#^S?KFN:WXFUFT\8:'X
M;N_$OQ]7XOMJ.D: TNH:7H?@KX2W'PZ^!WANSAN52RN+OX;ZY_9GC'RKDKHA
MN+"2UT^%?M4C'ZSHI/$UI.[DMY.RA!*\W%R=DK:RA&6WQ+FW&L/2723TBKN4
MK^[HM;WT3<=_A?+M9'YB^"OV(/C!X=U*X\2ZU\2?AKKGB Z/\'/#JVEY=?'7
MQ+HNKZ5\._B_I/Q0\:W&N7?CCQQX@U+3;SXDMH6CF;3/!MKX>\.Z/JE@ML=-
MO],D-PG:W_[(_P 6]5\*S_#J^^*?P\A\$^#Y_C7K?PIO]+\&>(+3QYJ_C7XT
MV'C+1;OQ?\9M9EU:>QO-1\-:)\0/$\6?!5M:S^+]7DTW5M>NK:/3UTZ3]!:*
MIXNNW=RC>]U[D-+1Y5;32T;Q]&^MFI6%HK92VM;GEK>2EK9Z^\E+M=+IH?$4
MO[+7C2#5_$WA*P\8^"[?X >)_B9X)^+^M:/9>%M2C^.6H:G\.-)\(6_A;X;V
M?B^XU1/!UGX/L=1\!^'Y-'\02Z;_ ,))HVE"X\/6?V2WG?54^5?A]X+^--WX
M:U"R^(GP?^(%_P##GX*?LY?$_P"!?PI\-Z/\&I?!GQ3\8^.?CG>6GAW4M:O+
M'4_&^OVFK75CX>L8KCQ[X]T6^TWX=17VHWOB6RO-8:?4)+']AZ*<<54BFFHR
MNXM-I)IQBX.2<4GS2IMTW+?ETZ*Q+"P;34I1M?2[::;4HJSVC&:4TEUO=ZGA
M7[.GPJUOX3?#'1=+\;ZU!XJ^*VO66C:U\6O&$"%(->\96WA_2]#%GI@9Y&@\
M,^%-(TO3_"_A>S60Q1:9IOVT#[5J5[)+[K117/.3G*4I;R=W962\DEHDEHDM
M$DDDDC>,5"*BMHI)7=WZMO5M[MO5N[>K"BBBI*"BBB@ HHHH **** "BBB@
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M7_!^[S/55[+32RU^[_@_=YE+Q)_R,6N_]A:__P#2AZQ:VO$G_(Q:[_V%K_\
M]*'K%KZ2G_#I_P""/_I*/)"BBBK **** "BBB@ HHHH **** "BBB@ HHHH
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M^ GC*#QCXA^/SZ/H&EZAIXBOO#/B70/"\,T4&FI)J<GCC4;C3%U R:E/;\6
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M_P VGSHO^>L?_?:_XT>=%_SUC_[[7_&O]);_ (9Z_8C_ .B(?LA_^&]^"?\
M\K*/^&>OV(_^B(?LA_\ AO?@G_\ *RC_ (A5B_\ H=X+_P )JO\ \M]?Z6I_
MQ-KE/_1"9WT_YFF%\O\ J"\_^'TO_FT^=%_SUC_[[7_&CSHO^>L?_?:_XU_I
M+?\ #/7[$?\ T1#]D/\ \-[\$_\ Y64?\,]?L1_]$0_9#_\ #>_!/_Y64?\
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M,>(/"NC7'B?P]J7AO5;J?5O"]GXCN[[09;+5;+3XM7M-.OKW3KTP7$=UYO\
M\.N_AAI'P^^ ?@?X<?M ?M:?!J__ &=_AA_PI[PAXX^%7QCB\,^(M=\!O??V
MC-IWC31I?#&H_#[6K^:]"SG7+;P5INLQF*WCBODAM;:.'],J*FGQ)GE.%"G#
M,J_L\-3H4J4)>SG!4L-0K86A3G"<)1JTZ6&Q%;#PA54XJC)4K<D(*-SX=R6I
M*O.67T>?$5*U6K.+J0FZN(KT<36J0E"<94IU<10I5YRI.$G5BZE^:<W+PO\
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MRTW]D_5OCQ\'_A)KWQ?NO@]^V/\ '3X7_"WX1?#?X0^ KGX@1Z'XG\)_#WX
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M;XE^$/[/GQP^(W_!2GP-K\7PW^&/@C]G3XK_ +,?Q<^(7Q$\$>&?"WA^ZL_
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MUV;6I_EQ)*,I14XS2DTIQYU&:3LI152,*BC+1I3A":37-",KI-HIVQ_[K?\
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M)R><\]:5O^"._P#P4H<,'_9*\9,&968-XF^&A!9<!6.?&W5<#:>HQQ7]:O\
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M ,.YH?\ \@4O^(Y_1>?_ #6_B+K;_FT/BW_=_P"K7>?]6U%QW])K_HU_"_\
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MQ"_N_P#59^?Y>5_Y*C_P1V_X*3E_,/[)/C$R9#;SXE^&>[<H 5L_\)KDLH
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MS*S!O$GPS;>1@?,!XV!8E0$)!#E?E##C']:__#V3]C__ *++\&/_  [FA_\
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MDY(&/&W ) X]AZ"O8(O^"='_  5AM/@G<_ #2/V1)O#_ (!U?Q58^,/&-[H
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M !"_\+_Q%_\ )-'_  K;1O\ H/\ Q"_\+_Q%_P#)->@44>SA_*@YY_S2_P#
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M@\\XX]>>.._'6D(()!&"."#U!]#0 4444 %%%% !1110 44=>E.*." 58$]
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MM>%5_B5-OCE_Z5Z>O]/3T*:7LZ>OV(=/[L?\W]WF>O45Y#_PIZR_Z*#\7O\
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M:/\ A3UE_P!%!^+W_AR-?_\ CM&OE]__  /7^GH67?\ #T_S?W>9Z]17D/\
MPIZR_P"B@_%[_P .1K__ ,=H_P"%/67_ $4'XO?^'(U__P".T:^7W_\  ]?Z
M>A9=_P /3_-_=YGKU%>0_P#"GK+_ **#\7O_  Y&O_\ QVC_ (4]9?\ 10?B
M]_X<C7__ ([1KY??_P #U_IZ%EW_  ]/\W]WF>O45Y#_ ,*>LO\ HH/Q>_\
M#D:__P#':/\ A3UE_P!%!^+W_AR-?_\ CM&OE]__  /7^GH67?\ #T_S?W>9
MZ]17D/\ PIZR_P"B@_%[_P .1K__ ,=H_P"%/67_ $4'XO?^'(U__P".T:^7
MW_\  ]?Z>A9=_P /3_-_=YGKU%>0_P#"GK+_ **#\7O_  Y&O_\ QVC_ (4]
M9?\ 10?B]_X<C7__ ([1KY??_P #U_IZ%EW_  ]/\W]WF>O45Y#_ ,*>LO\
MHH/Q>_\ #D:__P#':/\ A3UE_P!%!^+W_AR-?_\ CM&OE]__  /7^GH67?\
M#T_S?W>9Z]7X/?M<_L(?"[]KSQ_K7_"W-"L?$FG>&?'OC#4O#=N_B'Q7H$NG
MWFIRQ:?J$KOX;GLFN?M$%E @2YEGCBV%XUC=F)_8/_A3UE_T4'XO?^'(U_\
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M8'CTZVO^'C?_  30_P"C[+?_ ,*KXH?_ #$U^6?\2N^#W_1RO&#_ ,:*X_\
M+_JI_/\ %=U;]:_XBE]([_H3<2]/^:#S#^[_ -2[UO\ /MKX-_PXE_9#_P"B
M>:5_X<;XL?\ RTH_X<2_LA_]$\TK_P .-\6/_EI7O/\ P\;_ .":'_1]EO\
M^%5\4/\ YB:/^'C?_!-#_H^RW_\ "J^*'_S$T?\ $KO@]_T<KQ@Z?\Y%<?\
ME_U4_P#5_-6%XI?2/T_X1N)>G_-!YA_=_P"I?ZW^?;7P;_AQ+^R'_P!$\TK_
M ,.-\6/_ ):4?\.)?V0_^B>:5_X<;XL?_+2O>?\ AXW_ ,$T/^C[+?\ \*KX
MH?\ S$T?\/&_^":'_1]EO_X57Q0_^8FC_B5WP>_Z.5XP=/\ G(KC_P O^JG_
M *OYJPO%+Z1^G_"-Q+T_YH/,/[O_ %+_ %O\^VO@W_#B7]D/_HGFE?\ AQOB
MQ_\ +2C_ (<2_LA_]$\TK_PXWQ8_^6E>\_\ #QO_ ()H?]'V6_\ X57Q0_\
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MI7_AQOBQ_P#+2O>?^'C?_!-#_H^RW_\ "J^*'_S$T?\ #QO_ ()H?]'V6_\
MX57Q0_\ F)H_XE=\'O\ HY7C!T_YR*X_\O\ JI_ZOYJPO%+Z1^G_  C<2]/^
M:#S#^[_U+_6_S[:^#?\ #B7]D/\ Z)YI7_AQOBQ_\M*/^'$O[(?_ $3S2O\
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ML+C]N6TMY3?:DPCC\3_$Z-#&U_<-%)M3P8Z[YHRLLC9W,[%G 8XK6_X>-_\
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M /"J^*'_ ,Q-'_$KO@]_T<KQ@Z?\Y%<?^7_53_U?S5A>*7TC]/\ A&XEZ?\
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M[(VV=\=/VO=&T7P'^T#;?!G]HR\U+XK>/=$_87_9'TCXH:)XF\5+X[UCX*?
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M_$\UC_KQT/J0.VI^M:M4+K2M+OI!->Z=97<P18Q+<6\<L@1<E4#.I(4$G '
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ME2$55!!&%55Z  8'_"/:!_T!=+_\ H/_ (BC_A'M _Z NE_^ 4'_ ,13O/\
MEC_X%Z?W?ZMZ76G=_<O\S=,LQB$)E<PABXA,I\H.>"XCW; Q'!8#)]:#)*5"
MF1RH" *9"5 CW>6 -V (]S;,?=W-MQDYPO\ A'M _P"@+I?_ (!0?_$4?\(]
MH'_0%TO_ , H/_B*=Y_RQ_\  _\ [7^K/RN:=W]R_P SH%N+E0X6XF42L7E"
MSL!(YR"[@. [$,V6;).3SR:19[A"Q2>5"\8B<K,REX@ HC8A@6C"@*$.5
M&!6!_P (]H'_ $!=+_\  *#_ .(H_P"$>T#_ * NE_\ @%!_\12O/^2/_@7I
M_=Z?IZ7-.[^Y?YF^)[@1^2)Y1#\W[H3,(_G^_P#NPVWYOXN/F[YI3<7)D64W
M$QE0EDD,[&1&( )5R^Y20 "002 ,]!7/_P#"/:!_T!=+_P# *#_XBC_A'M _
MZ NE_P#@%!_\11>?\D?_  +T_N_U;T#3N_N7^9NF69B6,KEC()BQE))E'24D
MMDR#LY^8>M,.222<DDDDL"22<DDDY))Y)/)/-8O_  CV@?\ 0%TO_P  H/\
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M#^QJ1E"5.K[5P]G-3BXRLU)-7/P%_9Y_;,^/.L?M.?LQ^%?V7/\ @HG\;O\
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M_%VG6IMA^QWX.ES=7USO/QDUY#F]NY;HI@> FXC,NP'/(&<+G O?\1+'B_\
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M\VO?_,#1_P 1+'B__HS?P;_X>;7O_F!H]AX5_P#0;C/_  5G7_R@/KWTM_\
MH39)_P"#^#/_ )Y>O]/3Y7_X<-_&_P#Z.C_93_\ !K\5O_G:4?\ #AOXW_\
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MEF,:#E&E'%U%7AAI5)8:$85,3*6?_P +4^&__0ZZ'_W]N/\ Y&H_X6I\-_\
MH==#_P"_MQ_\C5WW']U?^^5_PHX_NK_WRO\ A7W5I_S0_P# '_\ +/7^EK^"
MZ=I=/M+RO]CU^_[N!_X6I\-_^AUT/_O[<?\ R-1_PM3X;_\ 0ZZ'_P!_;C_Y
M&KON/[J_]\K_ (4<?W5_[Y7_  HM/^:'_@#_ /EGK_2U-.TNGVEY7^QZ_?\
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MG:73[2\K_8]?O^[@?^%J?#?_ *'70_\ O[<?_(U'_"U/AO\ ]#KH?_?VX_\
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M ?\ \L]?Z6LZ=I=/M+RO]CU^_P"[@?\ A:GPW_Z'70_^_MQ_\C4?\+4^&_\
MT.NA_P#?VX_^1J[[C^ZO_?*_X4<?W5_[Y7_"BT_YH?\ @#_^6>O]+4T[2Z?:
M7E?['K]_W<#_ ,+4^&__ $.NA_\ ?VX_^1J/^%J?#?\ Z'70_P#O[<?_ "-7
M?<?W5_[Y7_"CC^ZO_?*_X46G_-#_ , ?_P L]?Z6IIVET^TO*_V/7[_NX'_A
M:GPW_P"AUT/_ +^W'_R-1_PM3X;_ /0ZZ'_W]N/_ )&KON/[J_\ ?*_X4<?W
M5_[Y7_"BT_YH?^ /_P"6>O\ 2U-.TNGVEY7^QZ_?]W _\+4^&_\ T.NA_P#?
MVX_^1J/^%J?#?_H==#_[^W'_ ,C5WW']U?\ OE?\*./[J_\ ?*_X46G_ #0_
M\ ?_ ,L]?Z6IIVET^TO*_P!CU^_[N!_X6I\-_P#H==#_ ._MQ_\ (U'_  M3
MX;_]#KH?_?VX_P#D:N^X_NK_ -\K_A1Q_=7_ +Y7_"BT_P":'_@#_P#EGK_2
MU-.TNGVEY7^QZ_?]W _\+4^&_P#T.NA_]_;C_P"1J/\ A:GPW_Z'70_^_MQ_
M\C5WW']U?^^5_P *./[J_P#?*_X46G_-#_P!_P#RSU_I:FG:73[2\K_8]?O^
M[@?^%J?#?_H==#_[^W'_ ,C4?\+4^&__ $.NA_\ ?VX_^1J[[C^ZO_?*_P"%
M'']U?^^5_P *+3_FA_X _P#Y9Z_TM33M+I]I>5_L>OW_ '<#_P +4^&__0ZZ
M'_W]N/\ Y&H_X6I\-_\ H==#_P"_MQ_\C5WW']U?^^5_PHX_NK_WRO\ A1:?
M\T/_  !__+/7^EJ:=I=/M+RO]CU^_P"[@?\ A:GPW_Z'70_^_MQ_\C4?\+4^
M&_\ T.NA_P#?VX_^1J[[C^ZO_?*_X4<?W5_[Y7_"BT_YH?\ @#_^6>O]+4T[
M2Z?:7E?['K]_W<#_ ,+4^&__ $.NA_\ ?VX_^1J/^%J?#?\ Z'70_P#O[<?_
M "-7?<?W5_[Y7_"CC^ZO_?*_X46G_-#_ , ?_P L]?Z6IIVET^TO*_V/7[_N
MX'_A:GPW_P"AUT/_ +^W'_R-1_PM3X;_ /0ZZ'_W]N/_ )&KON/[J_\ ?*_X
M4<?W5_[Y7_"BT_YH?^ /_P"6>O\ 2U-.TNGVEY7^QZ_?]W _\+4^&_\ T.NA
M_P#?VX_^1J#\5?AL ?\ BM-#^ZPXEN2>01T^S5WW']U?^^5_PHXPWRK]UOX5
M_NGVHM/^:'_@#_\ EGK_ $M33M+I]M>5_P#EWZ_>CJ/"TL9\,>'"&&#H.D$=
M1UT^W[$9'XT4_P +<>&?#N/^@%I'_IOMZ*^:T[/[_P#@>O\ 2U]=7LO1=/3S
M]?Z6N=XD_P"1BUW_ +"U_P#^E#UBUM>)/^1BUW_L+7__ *4/6+7TE/\ AT_\
M$?\ TE'D!1115@%%6+2);B[MH')"S7$,3%<;@LDBHQ7((R QQD$9Z@U^#GP1
M_;"_X*I?M3:E^T!JW[/WP[_8RNO!'P/^.7CWX/R0_$2]\>^'/$FJS^$[VYFL
MBLEKK%UIA-WHPLUGU*>XTZV74))F:*VMT+KYF89K0RZIA:-2CB\16QCKJA1P
M>'EB:LOJ\(5*K<(M-*,)IW5V]=#Z7(.%L=Q#A\TQF'QF49?@\F6!>/QF<YE1
MRS#4GF5:KA\'"-6LG&4ZM6C.-M%'1MI,_=NBOSG_ &)/^"@?AK]I/]E#Q+^T
MC\9K/PG\!E^%_C3Q1X ^+-Y?>(U_X5[I>K>%TTFX;6=#U_4I7EETO4[?6["*
M#3WGO[U=5\VQLI]366REG^G/A%^U1^S;\>_"_B?QK\&_C?\ #OX@>%O!$<L_
MC76-'UV.VA\'VL-M/>O?>)X-8CTV\T3339VUS=1ZGJ%M!ITL$$[Q73^3*$O"
MYKEV,I86K0Q=!K&T%B<-3G4C2KU:%FY5(X>HXUK0M)5'R>XXR4K<K,LUX5XB
MR;$YKAL?E&.B\ES!Y7F>)H8>IB\OPN.<HQIX>>8X6-7 \]?GIRPR5>]>%2G*
MDI*<;^^45\K?"/\ ;C_8^^/?C63X<?!K]HOX9_$+QVD-Y<0^%M#U:YCU34[;
M3T>2^N-"CU.RL(O$$5I%')/.=%EOG2U1[O8;5'F6]K'[:7[(_A[XO1_ +7/V
MC/A1I7QDDU*VT3_A ;SQ-#%JD.O7A06OA^\O?*.B6&OW#2QQQ:+>ZI;ZD9G6
MW:V6X>.)[CF672IQK1S# RHU*JP\*T<7AW2G7:35"%15'"=9IJU*,G-_RF,^
M&N(Z>*K8*IP_GE/&X?"/,,1@ZF49A#%4,!'XL=6P\L.JU+!Q^UBJD(T%UJ(^
MFZ*<4<.4*L'#;"A4[P^<;2N,[L\;<9SQC-?*>H_MS?L<:1\6E^!.I_M+?"2R
M^+C:RGAM_!4_B5%N[?Q))*L$?AR\U40'P_9:\]PRVHTJ[U>&\6\(LGC2\_<5
MM7Q.&PR@\3B*&'56:ITW7K4Z*J5)?#3INI*//4?2$;R?1'%@<LS+,W7CEN78
M_,98:A/%8E8#!XG&/#8:G;VF)Q"PU*JZ.'A=<]:IRTXW7-)'U517S7\7?VR/
MV4O@#XRTGX>?&K]H'X9?#/QQK<%M=6/A?Q1KOV;58[.]<QV5[JL-M;W2:!97
MD@*VMYKTFFV\X_>QR- &E7Q[XL_M5>-?!/[>7['O[,'AS3_!^J?#;]HGX9_$
MSQQXC\231WE[X@MYO"%KJUWH,GA75++4TT@Z5J,5E;2S2S66H+=V\QEM;A$:
M-JYJ^:8##\REB:4YPQ>#P56E1G"K5HXC'8BGA</"O3A)SH\]6I&[J*-H\TK-
M)GI8'A?/<>H2IY=B:%&ME.<9WA<3C:%;"87'9=D67U\RS&M@<36IQHXSV.&P
MU2RP\JBE5=.FY1<T?0W[07QR\/?L_?#RZ\;ZY;/JE[<72Z1X9T&*86[ZUKDL
M,MPD,UR5?[)IMG;PRWFIW821XX$6&"-[FX@4_D-)_P %)/C\VM'4HI_ ,6F"
M4RKX>_X1R"33Q:[\+$]Z]Z=9;Y"$-P-21FD^<!<[*^W_ /@H+HNK0>'?A#\3
M+?2IM>\/_#'QZVH^*-(C19(GL]1.E265Q=JZO&EG+<Z4VERSRJ8XY=1MT<@3
M U^5NE?'&\VS0ZY!J$45UXB\2:VTWA^#1KBYTI-9\'OX>TM-(/B*.[N9I]"U
M=SK]NNIZG+!YS/Y;).$=?["\'>">&,PX.CG&+X;R_B;,,;7QU+&3Q]>G)9?]
M6KU:-++\-AIT,1[&M/#0H8V6(C"G7DL=32JNG"G&/\6^,7&W$^7<8RR?"\1Y
MAPUE^"H8"I@J>7T:D'CUB:-&K6S#$XF%>A[:C'$SKX*-!SG1A]1JN5)3G4D_
MW;_9T^/V@_M#_#__ (2S3+/^QM:TN[32?%?AXSFY32]4>%;F":QN6"R76DZE
M;EI[">11*K17-I,7FM9'?U'7/]2?H?Y"O@G_ ()ZZ-J=]!\:?BI_94NA>%O'
MWB/1['PUISQ101W#:"-3EU74(H[6&"R8^=J,$-Y+8PQ6/]IO?V]JB):F./[V
MUS_4GZ'^0K\ \0LGRW(>,L]RG*+QP&$Q%#V5!UOK$L%4KX+#8G%9?*O>3JO+
M\56K8+GE*53]Q:K*553D_P!^\/LXS+/N#LDS7-K2Q^*H5%5KJC]76-IT,;B<
M-ALP5!**I+,,+1HXWDC&,/W]Z<8TW"*^GO@U_P D[T3_ *ZZM_Z=[ZO4:\N^
M#7_).]$_ZZZM_P"G>^KU&OR^I_$J?XY?^E,_0J?\.G_@C_Z2@HHHJ"PHHHH
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MH7A?7],TBYL-)_LAO$=VT*6T$&\3$PK_ $+Q?:7 2$2R")O/545G\J0#;YR
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MBCYO\/\ +^KORL?)?C_G_5WY6\@_X23XT_\ 1+?"7_ASI?\ YB:/^$D^-/\
MT2WPE_X<Z7_YB:]?HH^;_#_+^KORL?)?C_G_ %=^5O(/^$D^-/\ T2WPE_X<
MZ7_YB:/^$D^-/_1+?"7_ (<Z7_YB:]?HH^;_  _R_J[\K'R7X_Y_U=^5O(/^
M$D^-/_1+?"7_ (<Z7_YB:/\ A)/C3_T2WPE_X<Z7_P"8FO7Z*/F_P_R_J[\K
M'R7X_P"?]7?E;R#_ (23XT_]$M\)?^'.E_\ F)H_X23XT_\ 1+?"7_ASI?\
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MXW[17_AT?$O_ ,F4U_\ @H[^WO&K._[9'[1"(HRS-\4O$JJH]23>@ ?4TO\
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M_3GR_#S97_$!_&G_ */!BO\ Q(N-/+_I_P";^[S/["_^'4'[$_\ T89\(/\
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M'C?[?7 _X;&_:*))  'Q0\3$DDX  %YDDDX ')/ J>Z_X*(?\%!;"YGLK_\
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M2_\ H1/#?_A>C_YG:/[6^)?_ $(GAO\ \+T?_,[7?457LW_S\J??#_Y F_\
M=A_Y/_\ )^O]+7@?[6^)?_0B>&__  O1_P#,[1_:WQ+_ .A$\-_^%Z/_ )G:
M[ZBCV;_Y^5/OA_\ (!?^[#_R?_Y/U_I:\#_:WQ+_ .A$\-_^%Z/_ )G:/[6^
M)?\ T(GAO_PO1_\ ,[7?44>S?_/RI]\/_D O_=A_Y/\ _)^O]+7@?[6^)?\
MT(GAO_PO1_\ ,[1_:WQ+_P"A$\-_^%Z/_F=KOJ*/9O\ Y^5/OA_\@%_[L/\
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M2V=XD_Y&+7?^PM?_ /I0]8M;7B3_ )&+7?\ L+7_ /Z4/6+7TE/^'3_P1_\
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M 7$&;U\/A\-&CGTJ-%U,154\WQ%+%9I@(2Q.904JV&RNCR_5Z5\!+Q6BNO\
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M#_T('CG_ ,(_Q'_\K:/9U/\ GW/_ ,!E_D'UK#?]!%#_ ,'4_P#Y(Y"BNO\
M^%>_$'_H0/'/_A'^(_\ Y6T?\*]^(/\ T('CG_PC_$?_ ,K:/9U/^?<__ 9?
MY!]:PW_010_\'4__ )(Y"BNO_P"%>_$'_H0/'/\ X1_B/_Y6T?\ "O?B#_T(
M'CG_ ,(_Q'_\K:/9U/\ GW/_ ,!E_D'UK#?]!%#_ ,'4_P#Y(Y"BNO\ ^%>_
M$'_H0/'/_A'^(_\ Y6T?\*]^(/\ T('CG_PC_$?_ ,K:/9U/^?<__ 9?Y!]:
MPW_010_\'4__ )(Y"O?_ -EKX@?'SX9_'WX:>)_V8I_$0^-W_"16>E>"M)\-
M6<NJ7?BJZU.5()_">HZ(G[G7=!UV#=:ZUIE\/L+V)EN)Y+;[,MW!Q7AKX,_%
M_P 8^(=$\)^%_A9\0M;\2>)-4LM$T+2+/P=X@-UJ6JZC.EM96D)ET^.)&FFD
M56EFDB@A3=+/+'"CNO\ ;=_P2W_X);^$_P!ASPG#\1/B+#I/BW]J3Q;I/D>(
M?$$(BOM(^%VD7T2M<^!/ MRRE9+R13Y'BWQ9"$FUB9'TS37CT*,G4?I^%>&\
MRSW,:?U:57!X?"5*=;$9@E*$L-RR4H+#R]URQ;:O1C%^XU[6;C&*O^5^+7B;
MPQP'PYB%F=/!YYC\WP^(PF7<.3E2K0S.-2'LJ\LPIM5(T\IIQJ)8RI4@_;*7
MU:C&=6I:/ZE?#^]\<ZEX$\&ZC\3O#^A^$_B1?>&=&NO'GACPSJ\FO>'O#_BR
M:RB?7-)T;69HH9-2T^SOC+%;W#(PVCRUN+M(UNY^NHHK^G(1<(0@Y2FXQC%S
MGR\\W%).4^6,8\TK7ERQC&[=HI:'^6M6:J5:E2-*G1C4J3G&C14U1HJ<G)4J
M2JSJU%2II\E-5*M2IR)<]2<KR91115$!1110 4444 %%%% !1110 Y/OK_O+
M_,5A>&_^0'9?[]]_Z7W-;J??7_>7^8K"\-_\@.R_W[[_ -+[FH?\2/\ @J?^
ME4RE\$O\4?RF;=%%%62%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4=F_W6_P#0311V;_=;_P!!- '5^%_^19\._P#8"TC_
M --]O11X7_Y%GP[_ -@+2/\ TWV]%?+GKQV7HOR,[Q)_R,6N_P#86O\ _P!*
M'K%K:\2?\C%KO_86O_\ TH>L9068*,98@#) &2<#). !ZDG ZFOI:?\ #I_X
M(_\ I*/(%5'<D(K,0"Q"J6(51EF( . !R3T Y-8^O:!H/BK1M1\.>*="T7Q-
MX=UBV-GK'A_Q%I5AKFAZM:&1)3::GI&J6]UI^H6QEBBE\B[MYHO,CCDV[T1A
M^./[1_[1/_"Z/VBO@U\%;O4/B[\.?AWX;_:V\ ^&CX0L_A+\8M/O_CA-\.KR
M[\7^,?'FO^*;3P.=$NO@]H>I:)I'AWPCX:T37+K_ (2*;4]1^(_CB73?"6D:
M1#7Z0R_%S1_C)X$^)L_PC^('B;X<:EX0%Q%KOQ \5_!7QCIDOA6"S2ZU/6]2
M\.:!\6O#WA'1O%5Y#HVG:D-.U:)=<\-Z9>/:7^H6^H1"*SN?+H9OA,74QE&F
MZ514)2I0A[>A[3%U(4I5,13IT:DX6C3CRKFJRC&:DYOEH\M2?UF/X3S;*,/D
MV,Q$<1AIX^G3QE6J\%CUA\HH5L53P^ Q&)QN'HUG.I7J^UE[/"4JM2C.DJ$/
M;8UU,-1^A(K8QK%;0P&-(HHXH((HMBQP11JD,<42J D,<2JL:HH1(U4* H J
M1H)D*J\,JL_W%:-@7[?*",MSP<9P>.M?B'K.A>-M3_8R_8"^"[^&_%/Q_P#&
MO[27QETOXP_$;PEXH\=Z=H/BCXI>"=,A\9?M$^-+/Q9XTU2YT_2;.VOK.X\&
M:9K#,L&DO"T.DV=G!#<VT"^=>.H=8\!>#OVZ_A)X ^#5W^SAXU^(>G?LE?!#
MP?\ LL>&_B+!XKTR\UGX]>+]8T*+XMZ/X\L-7E\&Z#XD\?>'3XC\*ZCIVBMI
M]SHVG>!H=?\ $WVQ+BRN(N"IQ$Z?*W@9\GU6-:=YUE*.(EED\S6#C)8.6&G5
MC25*#BL4J\G5YJ>&G&%Y>[A_#Z&)G4I1SW#NM_:E7"4;4<#[.IE]+B?"<+/.
M:M.IG5+-*&$EBZV+KJJ\JG@*=/!.GB,SH5JW+2_H!>&:,!I(I$4G +HR@GGC
M) &< G'7 STI(XI9<^5'))M +;$9MH/3.T'&3P,]3P*_*/X!>!M/^&?[:_AK
MPII_[-D7[&*WW[.'Q%UY? 6A_$NP^)^F_'VWL/&G@K1I-;\13>%-2NO#'AR\
M^$5Q<V\^E7&J6@U_79?&EW!IMZNG6.I6LGL5O\,_"_[5O[1_[1NB_&NRF\>^
M /V>]6^&?P[^'WP6O-6UBS\&V^I>*_AYIGQ"\2_%CQ=X=T;4--'BC7?$5WKL
M/AWP?J&OM>:;X?T;PO?G1+>WU*\U*ZKOH9G4KTH<N%BL35QL\%3HSK5J5/GI
MX:6+G.K.O@J6*HQ5&$[0G@?:3G[-PA*A5AB'X6+X;PN#Q%5U,TG++:&2T,[K
M8RCA,!BZ_L<1F5+*:-'#4L!GF,RG&5)8RO1<ZM#/WAJ-%UX5JT,PPM;+E]]B
M&8NT8BD+I]Y C%UQ_>7&1^('/%->.2)MLB/&V =KJ5.#T(# $@]CT/:OREO_
M (9?!KXO_$[]DG]FGPOXAU/X[_L\^&[3]I?]HS6[#Q%XLU;QOI,FB>&=03X1
M> / +>(HYK/5=>\%>#/B%XR\3Z=X2AUK4=9G@B\)K:C5]372;>8=]\#?#-]X
M3\=_MT?"?X%^-I/A=\'/A[KOPGM?!&L7%C)\1O#GP8^(UW\/W\0_'OP_X!T3
MQ9JTFGBVT?3/^$:U:;PS=W]SX;\*^--;O)+G2Y!]MTF14\TJ3JQC]5@Z4ZSP
MT9T<7"M.=>.6_P!I3]E%TJ5">'45*A'$/$PYJO+S4J<&Y1NOPOAJ6%JU5FE>
MGB:.#69U*&-RBKA*-' 5.)O]6J3Q-2GC,7CJ.8NI*&85,NAE=?DP;J*EBL16
MA"G5_1P1R%@@C<NP!5 K%B"-P(4#)!7Y@0,8YZ4CHZ,5=61AC*NI5AGD9! /
M(Z5^-VC:)XF@_8?_ &1O^$\U'XN_$CX?_%CXPGXJ?M4W>D/XB\7?%WQK\*/B
M+=^/_&VG-KFD> 8!XT\1^$I]:O\ X7V?Q+TOX=Z2TEMX,6>UBTR'P[]LMQZM
M^Q%\=/A[X>\):UX8-A\5?#_PX\=_M2_&'PQ^RYX9O_AS\6?&$FA_"W1?$>@^
M$XM(O=9TOP_XIM/ 'A:U^("^+SX;TOQSKVE1^'M$=K,/;6&E31V>=#.Z=2OA
MJ-:E##+$82EB+U<1%3IRK4J%6,7!TXP=%.O##_6/;+FQ=Z$*4DG4-\;P5B</
M@<RQ>$Q-;-)9=FN,R[EP>7U)T*\,'BL9AISA6CB)UX8V4<#B,Q_L^6"<:>3J
M./JXR#DL._T^2":1=T<,KKDC<D;LN1C(R 1D9&1U&0::L;NVU$=V )*JI9@!
MU. "<#N<<=Z_+SX;_"?X.?M$_!_XA?M6_M4ZA-K.I:KXG^-;Q>+=4\=^)O"^
MC?LN_#[X;>./%?@O1= ^'\VB:WIFF_#OQ!X.TOPU%X@\4>*HX&\3ZKXQNKB\
MU*[NK>'3K%/G/]OWXM:%XV\/:O\ LQZ7\0?BWK'ASX'_   G^*WBCXA^&_!7
MQ/\ &FN?$OX]6G@B/5_V=O 7B[Q9\*_!=YI6A75O;BW^,_Q';Q OAFRO+J]\
M%?:+:WLI-3C@C$9XL-@WC:M&@J=6G3J8&F\;"%;$*MS2I1KPJ48QPKE2C.LW
M&>)2A3JQUJP5.>V7\$/,LZCD>&QN-G7PF*Q&%S[$PR2K6P>6RP<J-'%RP52A
MC:M3-%2Q=:G@DJM+*Y3KU\)4M'"UIXFC^V^N^&-"\8Z-?^&_%'AS1O%OA[4D
MA35?#_B'1K'Q!H>HQ07$5W!'J.D:G;7>GWL<-W!!<Q)<V\JQW$$4Z!98D==A
MXGAV(\31 (JQHR&,"-!L144@ (@4(H4!5"A0 !@?D+\?]<N/VF?C+^RCINF_
ML^R_M4>"M%_93U_]ICQC\+(?B+X:^'^E76L_%U?!_A3X>ZK=WWB74;'2->O+
M%=/\:'P_HRSFY>_NUOHFCCM'<>W?\$]/#EHW@_XB_&'P?X8TGX2?"7XS>(=
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M]SXX\,KX,C\6ZSIWQ#N=*2&X\2ZI&-,NWTZUO4T.[N(---Q\MZQXB^//C?\
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M*<J4(:4^9J.B16LK6.QL[2QA+F&SMH+6(R$-(8[>)(8R[*JAG*H"Q"J"V2%
MXJS117C-W;;W>K/72222T25DNR04444#"BBB@ K\6?C=^TW^S-\%?C%XY\'?
M%[]K72_@[XLGU_5O$(\(ZWX\CT&[BTC5M6OUT[4;>Q.DW)CL;UK2X6VD,K&3
M[-)DX2OVFK_/%_X."_\ E)!XO_[)GX,_]2#QU7A\0YY7X?RYYAAZ%&O4]M2H
M<E=U5#EJ<TG*]*=.?,G!6]ZW=-V:_3?"7@++_$?BS_5S,\;C<!AEE6-S'V^
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M4P]%0PM3'.E4Q='))X2&*>"HU,53P+K_ %VIATJU/#SA*$I?VA_\-^?L%_\
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M7E^7;7L_XE'X/_Z*CB;_ ,%Y-Y?]2WR?W^1_H1?\-^?L%_\ 21KPK_X=Q/\
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MR,^F0?H:_P ]RBC_ (BGFW_0LRW_ ,"QWE_U%>7Y=M3_ (E'X/\ ^BHXF_\
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M?Y>2^XX'_A Y_P#HH7Q*_P#"BMO_ )5T'P'/@_\ %POB5T8_\C%:]@3WTO\
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M?^";7_1]G[*?_A\?A]_\O: /O:BO@G_AZ;_P3:_Z/L_93_\ #X_#[_Y>T?\
M#TW_ ()M?]'V?LI_^'Q^'W_R]H ^]J*^"?\ AZ;_ ,$VO^C[/V4__#X_#[_Y
M>T?\/3?^";7_ $?9^RG_ .'Q^'W_ ,O: /O:BO@G_AZ;_P $VO\ H^S]E/\
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M/C3^ROX@T#XCZQ\)/A':_M&_M._MV_'KP1X:NO%FCVMC\5O%7Q$\2^)O@_\
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M^$7_ $/\=_XCV?>7_4O\T?SST5_0Q_P[<_X([_\ 28OX?_\ A3?!'_YI*/\
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M_B/9]Y?]2_S1_//17]#'_#MS_@CO_P!)B_A__P"%-\$?_FDH_P"';G_!'?\
MZ3%_#_\ \*;X(_\ S24?\0_XI_Z J'_APP'E_P!1'G_5U<_XF3\(O^A_CO\
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MEG_P\W@W_P"6-'_#RK_@G?\ ]'Q_LL_^'F\&_P#RQH]I3_GC]Z\O\T%GV?\
M7_#K[S[8HKXG_P"'E7_!._\ Z/C_ &6?_#S>#?\ Y8T?\/*O^"=__1\?[+/_
M (>;P;_\L:/:4_YX_>O+_-!9]G_7_#K[S[:3[Z_[R_S%87AO_D!V7^_??^E]
MS7R(O_!2K_@G?N7_ (SC_99^\/\ FLW@WU_["-8N@?\ !27_ ()Z0Z/:13?M
MO?LN0RH]YNCD^,G@Y'7=>W#*2K:B#AE(8'NI!'!J'4A[2+YXVY)K==72M^92
M^%_XH_E+_-?>?>%%?$__  \J_P""=_\ T?'^RS_X>;P;_P#+&C_AY5_P3O\
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MU]Y]L45\3_\ #RK_ ()W_P#1\?[+/_AYO!O_ ,L:/^'E7_!._P#Z/C_99_\
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M!P\<D;*Z,.&5@1UHKYNS[/[OZ[K[SUTU9:]%^G^:^\A\2?\ (Q:[_P!A:_\
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M"O\ GWFO_A>O_F?R_/NQ?\1BXT_Y^97_ .&]>7_3[R_JRM_89_P_1_X)V?\
M1(OBQ_X9'X6?_-I1_P /T?\ @G9_T2+XL?\ AD?A9_\ -I7\>=%'_$&>"O\
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MC.$XQG"<&I1G"23C*,HW4HR5G&2;35FG:Q@?\(EX/_Z$SP9_X2/AS_Y64?\
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M -B67_%&>#3\][R?"7ATG_C_ +GN=,)]OH .@%=XGWU_WE_F*PO#?_(#LO\
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M9?<@LNR_K_AE]Q@?\(EX/_Z$SP9_X2/AS_Y64?\ ")>#_P#H3/!G_A(^'/\
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M,6N_]A:__P#2AZQ:VO$G_(Q:[_V%K_\ ]*'K%KZ6G_#I_P""/_I*/("BBBK
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M+#J&58GZU7?LJD'3]AB\PH*4)<LL=@8TE[M6HZ'],U%%%?%GV(4444 %%%%
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M#^W_ (@_]$U@_P#"\T/_ .0J/[?^(/\ T36#_P +S0__ )"HYUVG_P""Y_\
MR/G^?9AR^</_  .'_P EYK[SOZ*X#^W_ (@_]$U@_P#"\T/_ .0J/[?^(/\
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M ,+S0_\ Y"H_M_X@_P#1-8/_  O-#_\ D*CG7:?_ (+G_P#(^?Y]F'+YP_\
M X?_ "7FOO._HK@/[?\ B#_T36#_ ,+S0_\ Y"H_M_X@_P#1-8/_  O-#_\
MD*CG7:?_ (+G_P#(^?Y]F'+YP_\  X?_ "7FOO._HK@/[?\ B#_T36#_ ,+S
M0_\ Y"H_M_X@_P#1-8/_  O-#_\ D*CG7:?_ (+G_P#(^?Y]F'+YP_\  X?_
M "7FOO._HK@/[?\ B#_T36#_ ,+S0_\ Y"H_M_X@_P#1-8/_  O-#_\ D*CG
M7:?_ (+G_P#(^?Y]F'+YP_\  X?_ "7FOO._HK@/[?\ B#_T36#_ ,+S0_\
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M^:L_+[U_F>JFK+?9='_D4O$G_(Q:[_V%K_\ ]*'K%K:\2?\ (Q:[_P!A:_\
M_2AZQ:^DI_PZ?^"/_I*/)"BBBK **** "BBB@ HHHH **** "BBB@ HHHH :
M_P!T_A_,5R6N?ZD_0_R%=:_W3^'\Q7):Y_J3]#_(4$O=_P#;G_I3/I[X-?\
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MHPVISO*%G*5_S3\$?\$G?V1?"7P:^+/P$UVP^*?Q;^&_QCU/PUK?B;3?C/\
M%GQC\0M3T?6_!\5ZGAW6?!&NZE>Q:MX-U739KZ6\BOM#N[:XDNHXC,\D*O#)
M=_9S_P""57[(W[,GBCQ%X\\%:/\ $7Q;\0M?\(ZOX"A\>_%GXG^+/B5XI\,>
M#M?MGM=9T'P=>^(KR>V\.6NHQOBZGL;,7TB@P&[%K)-;R_H_155.*.(ZM+%T
M*F=YG*CCYJ>,I?7*RIXF:ITJ7-5@IJ,N:E0HTYZ6J0I4XU%*,(I*'#>04ZF%
MK0R?+E6P,>3"57A:,JF'C[2I52ISE%RBH5:U:I3U_=SJU)4^5SDW^*6B?\$%
M/V*/#=C8:5X?\;_M<Z)I.F%/L&D:/^T_\0]*TJT59C<&.VTW3YK:SMXI)V>6
M6."&-7DDD<C>[,?TD^.O[+WPN_:*T_X0:9\2$\236WP0^+7@;XU>!SHNOW&D
MS#QO\/5NU\/2ZU+''*VK:6!>SF_TZ;9'>L5,DBE>?HFBEB^)N(,?7P^*QN<8
M_$XC"2K2PU>KB)RJT)8B,85Y4YMWBZT8QC4:=Y)).X87AS(<#0KX7"93@</A
ML5&C#$4*5",:56.'DY4(S@O=<:4FW35K1;T,_5M-M=:TO4M'O1(;+5M/O--N
MQ$YBE-K?V\EK<".0 F.0Q2N$< E&PP&17Y[^&O\ @EG^R3X6T/\ 8]T#3] \
M8W%I^PYXK\2^,O@5<:CXPO+R_M]8\5>(/^$JU-?%]TUNK>*;&/Q EOJ=A9W2
MPQV5Q9VQB.%D$OZ,45PX/-,QR^$Z>!QN)PD*L_:5(T*TZ:G/ZMBL%S246KOZ
MICL9A[O_ )=8FM#:;1VXO+,OQTX5,9@\/BITX<E.5>E&HX0^LX7&<L>9.T?K
M6!PF(M_S]PU*>\$?%/AC_@GQ^RWX?^&?[0'P<U+P)-XZ^&G[3/Q5\7_&3XK>
M%/'VK7?B&QU#QKXVN;"]U6XT68_9+WP]:VEYIEG>:&NEW4%YHEY"EUI][#<(
MDB^#?![_ ((V?L,_!OQ_X=^(UAX0^(7Q!UCP/JEMK/PYTCXP?%CQU\2_!_PX
MU2QF2;3KWP=X2\1:M/H=G<Z6T-N-,GU"TU.;3VMK:>TDBNK>*=/U/HKMAQ-Q
M#2ABZ=/.\TIT\<[XN%/&XB$<1+V4:#E4C&:3E*A"-"<M'4HQ5*;E!*)QSX;R
M"K/"SJ9-EE2>"26$E4P="<J$55E7C&#E!M1C7E*O"+O&%:3JQ2F^8****\,]
MH**** "BBB@ HHHH *_A2_X+;_M _'CX8_M\^,/#7PV^-7Q6^'WAT^!_#.IG
M0?!7Q \4^&-&.I7NO>,5O-0.FZ-JEG9F]NUMX%N;KR?.G$$0D=A&F/[K:_S]
M?^"]_P#RD3\7_P#9.?"'_I_\;U^O>"5"AB.-94\11I5Z?]BX^7LZU.%6',JV
M"L^2I&4;J[L[75V?E'C-7KX?@Q5,/6JT*G]LY?'VE&I.E/E=+&-QYJ<HRY6T
MFU>S:5UHC\]HOVR/VPI)(H(/VH_VC9)II8X(((/C#\1))IYYI%BA@@ABUYI)
M9II72*&&-6DED98XU9V4'0UG]K7]MGPYJE[H?B/]I#]J+P[KNFW"VFI:%K_Q
M1^*6BZYIUVZQNEI?Z/J>KVNI65TZS0LEM<VL4[K+$RQD2(6]X_8 ^%^@:?=^
M./VMOB3XK^&?P^\)? M6T+X):O\ &K4M5T7X;^-?VM_$&B:A?_"[1-0N]'T#
MQ/J=_I_PQM+2Z^+7B*SL=!U*)[G1?"FDZG]DM->:X3[L\>Z!K$W[9GCW]HSP
MS<^&_C7\:]8_X)A^%?VG?@9KOAFUF\;:%\0OV@/#_@+PE\)O&WQ4\!66M:+8
M7GC76_ LOAKX@_$G0(9_#L6HQZUH<&JG1DN-+$:?TACLRR;!YEB,!#(\NJT\
M-@JDY8B6&H4:4\R4L(Z>7^U>$G1A"&&Q,<1B\3SS^K4^=NC/V-=1_G7!9?G&
M*R[#XZ>=9A2GB,;2IQP\<36JU8Y<XXA3Q_LEBHU9SGB,,\/A</R0^LU.6U6*
MK4G/\N?%'[17_!0/P.='7QQ\9OVR?!+>(HA-X='C+QA\:O"I\0PMY>V701K]
MUIYUF-O.BVOIOVI6\V/:3O7//W/[6_[:UEJLV@WO[2?[3]GKUOJ!TFXT&[^*
MGQ/MM<M]6$XM3I,^CSZS'J4.J"Z(MCITELMZ+DBW\CSB$KZZ_9.M/VMOC+XL
M^"EO\;/&?Q!\2_LQ_$?]K'P!XB\5W?QGUR?Q-K'B#Q'\%[/6_BUXV\4?#.V^
M(+W_ (KCBT#P5H>NV?Q%\2^!Q:>&U&JZ/X<\87,LEUI]DGT)\&],^"'[1'Q[
M_9*_:DM_@XWPNU3QQ^VA^TI\;?%UW_PGGC3QY?>/O@5^S=X7TCXZ^*O&_CI/
M%EW/I$/BW_A-Y[G2$N/!^F^&/"LEN9]';28C9+='/$YCEN GB*>*R/*<3]5P
MV(K5:^74\'6HPJ4\/C<31P]:-:G1K4ZM2.5YC"<*,,4Z;H0J5?9JM*%.L-@,
MRQT,/4PV=YKAOK.)PU"E0S"KC*56=.I7P&'JXBC.C4K4:E*G+,LNG"=:>%55
M5ITZ?M'34ZOY_>)_C#_P4L\$:-)XC\;?$#]NSP5X<ADMXIO$7C#4OC_X6T"&
M6[=8K2*;6M>&GZ9#)=2LL=LDETK3R,J1!V(!\T7]LO\ ;"=D1/VI_P!HQY)'
M2*../XR?$-Y))9'$<<4<::^7DDDD94CC16>1V5$4LP!_1^3XI>"M5_9Z_:)_
M:)^%_P :_P!J;XUW'Q\\1:[^R_\ %;P]^U-XET?PW\+/V;3^T3J"^+-&^,'B
M_P (>%?$WQ*B\5:#J=MH^NV'P]U/1XK&W\"^)=!O)+^RFU&'0[&]\@_9'_9O
M\&?#7QYXO_:*^('QR_9F\0_#?]GW2]/D^%_C^Z\6^,IO@1XW_:S\4:7K=W\'
M/ASK.O7_ ,.;7Q'?OX";1Y_BUXWTW3?!>K6B6&B^&=+OKF.W\1R2V]T<?EL,
M'CZ^-R+ 0KX2K]7HT*66\E3%8ODPZ6$]C5PKK4*DL3B*-*C*LH_6*52.,I0>
M%:JS*V!S&>,P%# YYCYT<535>M7JYCS4\+A5.JWBW5I8KV5>G'#8:I6JQHN7
MU>K3G@ZTUBE*FOF"?]IS]O&U\1S>#;KX\_M;VOC*WDDBN?!USX_^+UOXMMI8
MK,ZE-%<>&)M0378)8=-5M1ECEL$>+3U:^<+:J91S@_;._:_8!E_:J_:)*D @
MCXS_ !!(((R""/$&"".01P17[$>-]-OM+_:M\6_MH:Y$O[0EK8?\$J]"^-WB
M'Q-\+]8\0/HOQ-^)/B+P19_L@^)O$6A>,8]#TSQ'!I=UXF?Q%JFM:[!H%AK.
MEZ99ZK=P6=A-9I<6_P"8G[5?P3\+Z1XW_9=T+X8_#-O@UX\^/WP0^%WBKQC\
M!X-;\3^);3X9_$'XA>,M>\,>%++3)/&U]JWC73;'QMX2MO"7CZW\,>*M4U/6
M=(C\1JC7)M+JUC2LKS')\?5P]&KDF7T76P=&I5JPPV"G2P^/CAZF)Q^#JPG"
MGBX0PM*-!K$3PL:4I5HTJTJ-:=.E4SS/ 9Q@*6(JT\ZQ]54<96ITJ4\3C85<
M1@77HX? 8RE.$ZF$G+%5'54J$<5*HHT75I*M1C5JP\S_ .&S?VP/^CJ?VBO_
M  \WQ"_^:"C_ (;-_; _Z.I_:*_\/-\0O_F@K])Y_P!FC]D/XQ>/_CO\#OAE
M\+S\*-*\$?M9?LU_LL_#3]H.X^(GC;Q+XK\2^/O'/CS4O"/Q5.H>&]<UF?P$
MWA5_"W@CQWXH\*:/9:,=>M-6.A/=^)+NTU#^SX.NOOV-/V)?BWX@\$_#KX=Q
M>(O UY??M.VWPF\.>)/!7@G]JFW\1^.?!?A/PSXQ\1?%3P-\0=8_:+\(Z#\.
M;K]H :7X9TB?PHOPML=*TZ'Q!KESI=YX4NM/.G3RX//^&:?\;AZO2Y*<*^(O
MDN"JK"8>IA,/C:5?%2PTZ\:<)T:S]Q.5:G/#XF-:E35-N6\<CXEJ6]CG]"KS
MU)4:%LYQM)XK$4\75P=2AAHXFG0E4G3JT(OG:C1J0KX9T:M1U;1_*K_ALW]L
M#_HZG]HK_P /-\0O_F@H_P"&S?VP/^CJ?VBO_#S?$+_YH*]]^.GA?X-ZC^R-
MX1^,GA?]DG4OV<?'/Q$_:,\0> /AK'_PG?Q4\5KXI^#GPT\$OJ_BO7;C1?B!
M=W=Q=>*+?Q3XG\.>&O%?BG2X+/P[?WVDRIH&AZ UGJ\4WC'['_PD\&_%GXB>
M.;GX@Z3XB\6>#/@W\#?BI\?=;^'?@^]GTSQ1\4D^&>DVMW8^ -+U:TMKW4-'
MLM8U+4;.Z\4:SI=E=:MIGA#3M>N],2*]CANK?VJ<\DE@,5F%3)</0IX.KB*-
M2C/!Y74K2JX::I3A3EAJM?"S;KJ6'3>)48UH3C5E349M>/4CG4,=A<!3SJO7
MJ8JGAZM.K3QF9PHQIXB$:M.=2.)I8?$Q2H<E>26'E*5*494HU'.*E!I?[7'[
M:NNZE8Z+H7[2G[3VNZUJES'9:7HNB?%7XGZQK&J7LQ(AL]-TK3M9N;_4+N4@
MB*UM+>:>0@[(VP:N:=^U/^W/K&M2>&M&_:#_ &KM8\2PG45G\-Z1\1_BSJ?B
M& Z-'--K(GT.QU.XU6$Z/#;7,VK>;:)_9D5M<27WD)!*R?IU\$]!^%OP=\4_
MLZ_M:Z1^SE'^SSX]^&W[*W[6W[:OC?P<OBKX@^)M .E^&73X,?LUW^@Z3\3-
M2U;Q!X?TGQ9XOU&Y\26-IJVI7VHZE>7+ZA9ZA)I,VDV%MZA!X:TG]E3QM_P4
MK^/=HQB^*7C/X;?M,_%3P5-&?)F\"?!+Q=K.F^$/ MXLBQ>=;ZG\=?C=\3K&
MUTB2**WDD\$?"75723[/XD#'YVOGN51JU*.'X;P4IRHNG@X5Z& 4ZV:4\TGE
MU?!SEA8XO#QI4Z?U?&1KTZ]3VU*O"$(^TJ0C/Z"ADF:RI4JU?B+&1IQK*IBY
MT:^/<:.6SRVEF%#%PAB986O*K4FJ^$E0J4*;HUJ$YU)>RA4E'\B/"_[1?_!0
M+QQ9ZOJ7@?XS_MD>-]-\/1>?X@U'P9XQ^-/BO3]!A\I[CSM;OO#]WJ-KI$0@
MCDG,FH2VR""-YB1&K,.07]L_]KYP&7]JK]HEE/((^,_Q!(/_ )<'^37ZFZSX
M+^)EU^TY^RW^R)\&?C7\>?V<OA!H_P %OV:=9_9AU_X"_#[QKXU\-_%#Q_\
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MS[L/[5S3_H99A_X6XGR_Z>^2/I3_ (;-_; _Z.I_:*_\/-\0O_F@H_X;-_;
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MG9;']BTY^TA"?+.'/",^2I'EG#F2?+..O+.-[2C=VDF@HHHJ2PHHHH ****
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M]1D\W4+8>'[ 0:=%:WTI:2\M88([>YD>1YHG:20MXX/V$?VV  !^R1^T6 .
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MT:3^T7_X:'QM_P#*>C_AA']MC_HTG]HO_P -#XV_^4]?W\?\(SJ/_18/&?\
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MX81_;8_Z-)_:+_\ #0^-O_E/1_PPC^VQ_P!&D_M%_P#AH?&W_P IZ_O_ /\
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MAG_YFZ/^(ZYW_P!$_EG3_F(Q7E_?]?QV^R?\0+R;_H?9E_X3X;R_N^O];?P
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M>3"U<9"G&.#NFJE2A3IP4?;U$W#VTFY0IN4::ASS<N_HK@/^$*UK_HIWC_\
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M7B,PK3PV#I5>%LMS:%.K5AC9UL)BJV-Q%90>99=B<%F4YQR[!5\%7H5IP\;
M\3\4T\1D5',L=&K5J8_$X''X7#8"C#$8JK2XGS#*IU*5*I@H4L5A:6#H47-9
M?F&&QF7PA+'XRAC:->C&7[+_ !:_;[^*'P@^*'QY\!:]^RRM_HGP)^!VL_M$
MW_BW3?CGX::7Q)\,DOO'6B>$9[#PW-X02ZL/$7BC7_ >H6%WHEY?LGAVUO+/
M49]0OT<0-!^SO_P4[\%_M&_&[X,_!;PO\+O$NF7/Q0_9]N_C+XD\1WOB#2[B
MS^&7C+2[Q;;6O@IKUA!9K<:AXPT6)DO-0OK::VM(;>>U)M<W "?3GQ4_9#^%
M/Q@\2?&#Q3XKN?&$.J?&[]GVR_9J\9#1M=@L+:'X=V&N^+_$,$^APR:;='3O
M$W]H>-M9#ZO))=PM;K91?80;=GEXOX1?L _L]? [XJ2?&#X>:?XHTOQ9/XU^
M,'CRXCGUV*YT>XUOXVZ1\/\ 1O%\4MC_ &=')_9EI!\.-'N?#MA'=1QZ3?:E
MXAN=UR=5*P?"QQ7!L\MK1JY;7I9HL"XX>IAZF-]@\;_9\8JI7C7Q]9-?VC*<
MX^SC&FJ<(*5)PE*+^WEA>,(9E1E2S&A5RSZZIXBG7IX-5_J7U]R=.BZ.!I6:
MP$8P?/)U'.<W&KSQC)?;%%%%?%GV(4444 %%%% !7\EG_!3+_@E=\</VS?VN
M_&/Q?^'?C_X4>&/#ZZ/8>#3IWC2\\6P:Q_:'AS6O$DMY<^7HGA?6++[%,NJ0
M"V;[9YY,<HE@C 0O_6G7Y ?%?XL_ [X>_%CQUH/Q'_:@\._"OQ#-XEUK5U\+
M^(_BEX"\)7\&F7^JWJV5[;Z5XAMA?KIUT8+A;2X?S(Y_(E6.5S&V/JN#LYSK
M(<W>.R&FZN/^IUJ'(L*L9^XJ5*+JOV+C*UG""Y[>[?S/FN*\FR;/<I^H9[45
M/ ?6J%?F>*^J7KTHU8TE[;FCO&I4?)?WK7MH?S@1_P#!O5^U?+AU^,?[.H.T
MC+:E\1\XSTR/A^>.AQGWIY_X-X_VL#NS\8_V<CNQNSJ7Q'.['3=_Q;[G';.<
M5_0];?M)_LF@9/[>O@!>.G_"_?A$!_#SG[)D^G/ICM5K_AI3]DO_ */W\ ?^
M'_\ A%_\AU^I_P#$3?$Y6_V2?G_PA176/_3I?\#7JC\T_P"(9^&G_05'_P /
MW_W7^ODS^=<?\&\G[6 VX^,?[.0V\+C4OB.-H/4+_P 6_P",^U=7X$_X(.?M
MO?##QCX?^(/P_P#V@?V??"GC7PI?/J?ASQ'IM]X\>_T?49+2XL6O;,7WPUN[
M47(M;NXCCEDMY&A,GFPE)DCD3]_?^&E/V2_^C]_ '_A__A%_\AT?\-*?LE_]
M'[^ /_#_ /PB_P#D.HGXE>)=6$Z=3 .I3J0=.I3J</TYPJ0G%1G"<)4G&4)Q
ME*,XR3BXN2::5G4/#7PVISA4IXU4ZE.49TYPX@E"=.<6I0G"<:JE"49*,HRB
MTXR2:::T_G77_@WC_:P7=CXR?LYY8EG8ZI\22SL226=C\/RSLQ)+,Q+,2222
M32#_ (-XOVKU&!\8OV<0-V[ U'XC@;AT; ^'WWAZ]:_HI_X:4_9+_P"C]_ '
M_A__ (1?_(='_#2G[)?_ $?OX _\/_\ "+_Y#JO^(F^)W_0'/I_S(H_W?^G?
MKZ:]B?\ B&?AI_T%0_\ #]Z?]/?3^DS^=<_\&\?[6!&T_&/]G/ .1C4_B0-K
M<G<I'P_!5@22&4A@>00>:^@_BC_P22_X*@?&SPM8>"?BO^V)\'/''A>PU#3-
M7;3-4OO%=K)K.LZ+IK:-HNM^,-5T?X3Z;K7CS7-'TJ26PTK6?'&I>(M3T^">
MX%I=PO<3/)^TO_#2G[)?_1^_@#_P_P#\(O\ Y#H_X:4_9+_Z/W\ ?^'_ /A%
M_P#(=8U/$3Q&K5*%:ME=.K6PTG+#U:O#E&I5P\I^SYY4*DZ+G1E/ECSNFXM\
MJNWR1-Z7AYX>4:=:E1S*I2I8B,8UZ5+B2I3IUXQORQK4X5U"K&//+E5124>:
M5DKL_G7/_!O'^U@<Y^,?[.1R03G4OB.<D="?^+?<D8&">1CBE_XAY/VL1G'Q
MD_9S&XY;_B9_$CDD $G_ (M_R2 !D]@!7]$__#2G[)?_ $?OX _\/_\ "+_Y
M#H_X:4_9+_Z/W\ ?^'_^$7_R'6W_ !$WQ._Z Y]/^9#'^[_T[]?Q[&'_ !#/
MPT_Z"H?^'[_[KY_GV9_.NO\ P;Q_M8(,)\8_V<E'7"ZE\1U&?7 ^'PIW_$/-
M^UE_T67]G3_P:?$C_P"=_7]$W_#2G[)?_1^_@#_P_P#\(O\ Y#H_X:4_9+_Z
M/W\ ?^'_ /A%_P#(='_$3?$[_H#GT_YD,?[O_3OU_'L'_$,_#3_H*A_X?O3_
M *>^?]69_.S_ ,0\W[67_19?V=/_  :?$C_YW]'_ !#S?M9?]%E_9T_\&GQ(
M_P#G?U_1-_PTI^R7_P!'[^ /_#__  B_^0Z/^&E/V2_^C]_ '_A__A%_\AT?
M\1-\3O\ H#GT_P"9#'^[_P!._7\>P?\ $,_#3_H*A_X?O_NOG^?9G\[/_$/-
M^UE_T67]G3_P:?$C_P"=_1_Q#S?M9?\ 19?V=/\ P:?$C_YW]?T3?\-*?LE_
M]'[^ /\ P_\ \(O_ )#H_P"&E/V2_P#H_?P!_P"'_P#A%_\ (='_ !$WQ._Z
M Y]/^9#'^[_T[]?Q[!_Q#/PT_P"@J'_A^_\ NOG^?9G\[/\ Q#S?M9?]%E_9
MT_\ !I\2/_G?T?\ $/-^UE_T67]G3_P:?$C_ .=_7]$W_#2G[)?_ $?OX _\
M/_\ "+_Y#H_X:4_9+_Z/W\ ?^'_^$7_R'1_Q$WQ._P"@.?3_ )D,?[O_ $[]
M?Q[!_P 0S\-/^@J'_A^_^Z^?Y]F?SL_\0\W[67_19?V=/_!I\2/_ )W]'_$/
M-^UE_P!%E_9T_P#!I\2/_G?U_1-_PTI^R7_T?OX _P##_P#PB_\ D.C_ (:4
M_9+_ .C]_ '_ (?_ .$7_P AT?\ $3?$[_H#GT_YD,?[O_3OU_'L'_$,_#3_
M *"H?^'[_P"Z^?Y]F?SL_P#$/-^UE_T67]G3_P &GQ(_^=_1_P 0\W[67_19
M?V=/_!I\2/\ YW]?T3?\-*?LE_\ 1^_@#_P__P (O_D.C_AI3]DO_H_?P!_X
M?_X1?_(='_$3?$[_ * Y]/\ F0Q_N_\ 3OU_'L'_ !#/PT_Z"H?^'[_[KY_G
MV9_.S_Q#S?M9?]%E_9T_\&GQ(_\ G?T?\0\W[67_ $67]G3_ ,&GQ(_^=_7]
M$W_#2G[)?_1^_@#_ ,/_ /"+_P"0Z/\ AI3]DO\ Z/W\ ?\ A_\ X1?_ "'1
M_P 1-\3O^@.?3_F0Q_N_]._7\>P?\0S\-/\ H*A_X?O_ +KY_GV9_.S_ ,0\
MW[67_19?V=/_  :?$C_YW]*/^#>7]K(D#_A<O[.G) _Y"GQ([G_LG]?T2_\
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M3J2K2J).6(JUGS2KU:NCE5E*3<5&,;0C",>_HK@/^$%OO^BE?$W_ ,'6@?\
MS+T?\(+??]%*^)O_ (.M _\ F7KS.:?_ #[E_P"!0_\ DOZL_*_J67=?C_D=
M_17 ?\(+??\ 12OB;_X.M _^9>C_ (06^_Z*5\3?_!UH'_S+T<T_^?<O_ H?
M_)?U9^5RR[K\?\COZ*X#_A!;[_HI7Q-_\'6@?_,O1_P@M]_T4KXF_P#@ZT#_
M .9>CFG_ ,^Y?^!0_P#DOZL_*Y9=U^/^1W]%<!_P@M]_T4KXF_\ @ZT#_P"9
M>C_A!;[_ **5\3?_  =:!_\ ,O1S3_Y]R_\  H?_ "7]6?E<LNZ_'_([^BN
M_P"$%OO^BE?$W_P=:!_\R]'_  @M]_T4KXF_^#K0/_F7HYI_\^Y?^!0_^2_J
MS\KEEW7X_P"1W]%<!_P@M]_T4KXF_P#@ZT#_ .9>C_A!;[_HI7Q-_P#!UH'_
M ,R]'-/_ )]R_P# H?\ R7]6?E<LNZ_'_([^BN _X06^_P"BE?$W_P '6@?_
M #+T?\(+??\ 12OB;_X.M _^9>CFG_S[E_X%#_Y+^K/RN67=?C_D=_17 ?\
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MNOQ_R._HK@/^$%OO^BE?$W_P=:!_\R]'_""WW_12OB;_ .#K0/\ YEZ.:?\
MS[E_X%#_ .2_JS\KEEW7X_Y'?T5P'_""WW_12OB;_P"#K0/_ )EZ/^$%OO\
MHI7Q-_\ !UH'_P R]'-/_GW+_P "A_\ )?U9^5RR[K\?\COZ*X#_ (06^_Z*
M5\3?_!UH'_S+T?\ ""WW_12OB;_X.M _^9>CFG_S[E_X%#_Y+^K/RN67=?C_
M )'?T5P'_""WW_12OB;_ .#K0/\ YEZ/^$%OO^BE?$W_ ,'6@?\ S+T<T_\
MGW+_ ,"A_P#)?U9^5RR[K\?\COZ*X#_A!;[_ **5\3?_  =:!_\ ,O1_P@M]
M_P!%*^)O_@ZT#_YEZ.:?_/N7_@4/_DOZL_*Y9=U^/^1W]'9O]UO_ $$UP'_"
M"WW_ $4KXF_^#K0/_F7H_P"$%O\ !_XN5\3APQXUK0!T!./^17Z'H?;-'-/_
M )]R_P# H?\ R7]6?E<LNZ_'_(]J\+_\BSX=_P"P%I'_ *;[>BD\+J#X:\/'
M<XSH6DG 90!_H%OP!L.!Z<FBOF[>:_'_ "_JWI?UELM]EV\O/^K/ROG^)/\
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MG1?"OAB[O/%6IA?%VN^ M5UBQ\&^(+."V2$\]X5^-.B>(_VAOCY\1?AGXI^
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M7]?\,ON&>7'_ ,\T_P"^5_PH\N/_ )YI_P!\K_A3Z*+ON_Z_X9?<%EV7]?\
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M_$C_ (*G_I5,I?!+_%'\IFW1115DA1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %'9O]UO\ T$T4=F_W6_\ 030!U?A?_D6?
M#O\ V M(_P#3?;T4>%_^19\._P#8"TC_ --]O17RYZ\=EZ+\C.\2?\C%KO\
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M'_\ G9T?\.WKK_I(%_P4J_\ $E]'_P#G9T ?I517YJ_\.WKK_I(%_P %*O\
MQ)?1_P#YV='_  [>NO\ I(%_P4J_\27T?_YV= 'Z545^:O\ P[>NO^D@7_!2
MK_Q)?1__ )V='_#MZZ_Z2!?\%*O_ !)?1_\ YV= 'Z545^:O_#MZZ_Z2!?\
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M( )/B=^S8X!R _B;X@, ?4!OAN1GWI3_ ,&]?[8C##?$_P#9M8 @@'Q/\0"
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M #N*/^(>[]L;_HJ'[-__ (5'Q!_^=Q7[)?\ "NOV8?\ I,7^U%_XG_\ "?\
M^9*C_A77[,/_ $F+_:B_\3_^$_\ \R5"\8^.=/WF7=/^8"C_ '?[WK_3U/\
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M_P#YDJ/^%=?LP_\ 28O]J+_Q/_X3_P#S)5P7G_S[?3[2\O+S_JZ/0_M[)/\
MH<95_P"''!^7_3[^K>E_UXHK\A_^%=?LP_\ 28O]J+_Q/_X3_P#S)4?\*Z_9
MA_Z3%_M1?^)__"?_ .9*B\_^?;Z?:7EY>?\ 5T']O9)_T.,J_P##C@_+_I]Y
M_P!:7_7BBOR'_P"%=?LP_P#28O\ :B_\3_\ A/\ _,E1_P *Z_9A_P"DQ?[4
M7_B?_P )_P#YDJ+S_P"?;Z?:7EY>?]70?V]DG_0XRK_PXX/_ .7?U9^5_P!>
M**_(?_A77[,/_28O]J+_ ,3_ /A/_P#,E1_PKK]F'_I,7^U%_P")_P#PG_\
MF2HO/_GV^GVEY>7G_5T']O9)_P!#C*O_  XX/R_Z?>?X>E_UXHK\A_\ A77[
M,/\ TF+_ &HO_$__ (3_ /S)4?\ "NOV8?\ I,7^U%_XG_\ "?\ ^9*B\_\
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MG^?X/L??5%? O_#!5W_T?C_P4D_\2;TG_P"=C1_PP5=_]'X_\%)/_$F])_\
MG8T<T_Y/_)EY?YO[O,+^3^[T_P _P?8^_$^^O^\O\Q6%X;_Y =E_OWW_ *7W
M-?$2?L%7>Y?^,\O^"D@^8<C]IO2<]1_U3&L;0/V#KN71[.3_ (;N_P""D$66
MO!Y</[3.EK$I6]N%)53\,V(W8W-SRQ8\ @"'*?M(^Y]B?VEWI7^[7UL4G[DM
M'\4.G=2_+KV/T1HKX%_X8*N_^C\?^"DG_B3>D_\ SL:/^&"KO_H_'_@I)_XD
MWI/_ ,[&KYI_R?\ DR\O\W]WF3?R?W>G^?X/L??5%? O_#!5W_T?C_P4D_\
M$F])_P#G8T?\,%7?_1^/_!23_P 2;TG_ .=C1S3_ )/_ "9>7^;^[S"_D_N]
M/\_P?8^^J*^!?^&"KO\ Z/Q_X*2?^)-Z3_\ .QH_X8*N_P#H_'_@I)_XDWI/
M_P [&CFG_)_Y,O+_ #?W>87\G]WI_G^#['WU17P+_P ,%7?_ $?C_P %)/\
MQ)O2?_G8T?\ #!5W_P!'X_\ !23_ ,2;TG_YV-'-/^3_ ,F7E_F_N\POY/[O
M3_/\'V/OJBO@7_A@J[_Z/Q_X*2?^)-Z3_P#.QH_X8*N_^C\?^"DG_B3>D_\
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M\?\ ]JSQ=-J?@6ZURV^&'@;4+'PUI'PXU75M;M3<^$?#_C/P?X#\1"^\ RW
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MK"XO?A\DVO&S^&<7B[Q7I/@K5CK-L !UW=6A=;7;2TO;FUC=+3WFE:ST-:?
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M_P"0J/\ AB6#_HNW[8G_ (DQXS_^0J/9X?\ Z")?^"9?_)^O]/0YZW_/E?\
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M ';_ &O)_IT!?1D\,U_RZSG>G+_D:/>G'EC_ ,PVUG+F6TWK-2<8L_D<T_\
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MTR2^-]:VK17\-LLUM,R\_P"""7[8=W::5:_\)%^S':R:9;W4$E_:^,O'(O\
M5C<WDUVEQJSW'@.XMWGLHI5T^S-C;V,2V$$"3Q3W*R7,O]=?_#&'A#_HLW[4
M/_A_/&?_ ,>H_P"&,/"'_19OVH?_  _GC/\ ^/4_[176$NC^S_=_O?XOGKO8
M7_$LGAFU9TLZLX*F_P#A5E?E4HSW^K7O=:ROS.-XN3CH_P"4_P %_P#!%O\
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M7QCXZ_MG38[&&_AGT[3I8_ T5A'I^KB]BDU5+K3[NYDDTW3OLEU91I=1W?\
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MG&U\"V@35;5(&@MI+M;RT$-Q<++9RL8GB_KI_P"&,/"'_19OVH?_  _GC/\
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M+Z]#_GW/[X^7GYO[O,_1/8/^>/W/_+^K/RN^BF?\,8>$/^BS?M0_^'\\9_\
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M#PA_T6;]J'_P_GC/_P"/4?7H?\^Y_?'R\_-_=YA[!_SQ^Y_Y?U9^5Y4^^O\
MO+_,5A>&_P#D!V7^_??^E]S6Q_PQAX0'(^,_[40(Z$?'SQGD'U'[[J*;'^Q9
MX,B18H?C%^T[#$N=D4/QX\8Q1)N)9BL:2JH+N6=R!EG9F8EB34_78.2E[.=E
M%JUXW]YP=]^G*_4KV#Y6N9:N+V?1._\ Z5^#\KRT4S_AC#PA_P!%F_:A_P##
M^>,__CU'_#&'A#_HLW[4/_A_/&?_ ,>JOKT/^?<_OCY>?F_N\R?8/^>/W/\
MR_JS\KOHIG_#&'A#_HLW[4/_ (?SQG_\>H_X8P\(?]%F_:A_\/YXS_\ CU'U
MZ'_/N?WQ\O/S?W>8>P?\\?N?^7]6?E=]%,_X8P\(?]%F_:A_\/YXS_\ CU'_
M  QAX0_Z+-^U#_X?SQG_ /'J/KT/^?<_OCY>?F_N\P]@_P">/W/_ "_JS\KO
MHIG_  QAX0_Z+-^U#_X?SQG_ /'J/^&,/"'_ $6;]J'_ ,/YXS_^/4?7H?\
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M[G_E_5GY7?1V;_=;_P!!-,_X8P\(?]%F_:A_\/YXS_\ CU'_  QAX0_Z+/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
>HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img63895535_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img63895535_2.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" I&#&(# 2(  A$! Q$!_\0
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M?L6FV5GI]I]IN9/L]C:6UI#L@@BC2'471/YZ?YFJH/[4DO37_+]3^ROXM?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"X_XF^G?;[#1O!^[1O$=CXCL/^$[UWPM_P )!HD5[/X8_MNZM_L;_@C^U/\
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M]%/ECV_,3JS?VG]R7Y(_%C_AQ/\ LC_]%%_:-_\ "N^&?_SH:/\ AQ/^R/\
M]%%_:-_\*[X9_P#SH:_:>BCECV7]?\-^?=B]I/\ F9^+'_#B?]D?_HHO[1O_
M (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\
MF9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M
M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_
M^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_
M (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\
MF9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M
M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_
M^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_
M (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\
MF9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M
M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_
M^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_
M (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\
MF9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M
M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_
M^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_
M (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\
MF9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M
M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_
M^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_
M (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\
MF9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M
M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_
M^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_
M (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\
MF9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M
M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_
M^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_
M (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\
MF9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M
M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_
M^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_
M (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\
MF9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M
M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_
M^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_
M (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\
MF9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M
M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_
M^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_
M (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\
MF9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M
M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_
M^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_
M (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\
MF9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M
M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_
M^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_
M (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\
MF9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M
M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_
M^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_
M (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\
MF9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M
M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_
M^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_
M (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\
MF9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M
M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_
M^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_
M (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\
MF9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M
M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_
M^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_
M (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\
MF9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M
M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_
M^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_
M (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\
MF9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M
M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_
M^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_
M (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\2OJUK#:6^H3S6/AZ\T-K/5+%+;6;B_CU.QT[\T/B1^S3^T;\&]#M/$_Q?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MC:W_ *>_A7\(?AA\$/"-GX$^$O@;PYX \*67V>3^RO#FG0V7]H7UOIFG:/\
MVUKM]A]2\2>([O3=)TVVU3Q-X@O-3\0ZQ]B@FU74[V=/-/HU%;**7KW.6<Y3
M>NW1+;_@_,****9 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/_>^U_5I7\I?_!L9_P WN?\ =MG_ +WVOZM*\/B3_D=8W_N6_P#42@>IDO\
MR+,-_P!QO_4BJ%%%%>&>H%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?^19AO\ N-_ZD50HHHKPSU HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%%;['&VV[O5L****!!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MS/.\DKN"N[]%MZBK2LE%;O5^G_!?Y,Z.BBBM3E"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MDV4%OIMK[W6\59)??ZG#.7-)OIT]%HO\PHHHIDA1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ML_:YBKM>6OW&U1VA)]=OOT_(_<JBBBMCB"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%% !1110 4444 %%%% 'YR_\%7/BU_PJ;]B'XL?8O$']@>(_B7_8OPE\-_\
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M +D__=H^7XD_Y@O^YG_W ?U:?\&QG_-[G_=MG_O?:_JTK^4O_@V,_P";W/\
MNVS_ -[[7]6E>'Q)_P CK&_]RW_J)0/4R7_D68;_ +C?^I%4****\,]0****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** /Y&_P#@M[XM\/>)/VR]+T?1=0^V
MZEX ^"O@?PEXMMOLE];_ -D^(;W7O&OCNVT_SKNV@@O_ #/"GC7PSJOVO3);
MVQ3^T_L,ERFI66H6=I^/=?>__!4#Q;X>\:_MY?M$ZQX9U#^T]-L_$?AOPE<W
M/V2^LO+\0^ / /A/P)XMT_R=0MK2=_[)\5^&]:TK[7'$]C?_ &+[=IES>Z;<
M6EY/\$5A)W;]3N@K0BO[J_(_3W_@CUX2\0^)/V\OACK&BZ?]MTWP!X<^)?BW
MQ;<_:[&W_LGP]>^ =?\  EMJ'DW=S!/?^9XK\:^&=*^R:9%>WR?VG]NDMDTV
MRU"\M/[*Z_EA_P""#OA+Q#>?M%?&'QW;:?YGA3PW\%9/"6M:K]KL4^Q>(?&O
MCGPEK'AG3_L,ERFI7']IZ;X \6W/VNTLY[&R_LGR=0N;2>_TR*]_J>K2&WS_
M ,CFK.\_1)?F_P!0HHHJS(**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@#_.Z\8^$O$/@#Q=XJ\">+=/_ +)\5^"O
M$>N>$O$VE?:[&_\ [,\0^&]3NM'UK3_MVF7-[IM[]BU*RN;;[7I]Y=V-QY?G
M6ES/ \<K\Y7UA^W;X2\0^"OVR_VG-'\3:?\ V9J5Y\:O'WBVVMOM=C>^9X>\
M?Z]=^._"6H>=I]S=P)_:WA3Q)HNJ_9))4OK#[;]AU.VLM2M[NS@^3ZYSO3ND
M^Z3^\_J>_P""#OBWP]>?LZ_&'P);:AYGBOPW\:I/%NM:5]DOD^Q>'O&O@;PE
MH_AG4/MTELFFW']IZEX \6VWV2TO)[ZR_LGSM0MK2"_TR6]_<JOYJ/\ @@5X
MM\/6?B[]ICP)<ZAY?BOQ)X<^&'BW1=*^R7S_ &WP]X*U/QKH_B;4/MT=L^FV
M_P#9FI>/_"5M]DN[R"^O?[6\[3[:[@L-3ELOZ5ZVB[Q7W?<<E56J2^3^](**
M**HS"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ K_ "EZ_P!6BO\ *7K[C@S_ )F7_<G_ .[1\OQ)_P P7_<S
M_P"X#^K3_@V,_P";W/\ NVS_ -[[7]6E?RE_\&QG_-[G_=MG_O?:_JTKP^)/
M^1UC?^Y;_P!1*!ZF2_\ (LPW_<;_ -2*H4445X9Z@4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 ?P2?MB?\G<?M3?]G&_&_\ ]69XGKYRKM?B3X[U?XI?
M$7Q]\3?$%MIMGKWQ%\:^*O'>MVFCPW5OI%KJ_B[7;_Q!J5MI5O>WFH7L&FP7
MNH316,-W?WUU%:K$EQ>7,JO,_%5SG>M$O1']&G_! #_F[3_N@_\ [V:OZ-*_
M%C_@A/\ \FC_ !%_[.-\7?\ JL_A#7[3UM%6BO2_WZG)5=ZDO5+[DD%%%%49
MA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 ?Q8_\%:O^4@OQ_P#^Z5?^J3^&]?G+7[3_ /!=C_D[CX=?]FY>$?\
MU9GQ>K\6*PDK2?K?[]3N@[PC_A2^[0_:?_@A/_R=Q\1?^S<O%W_JS/A#7]8-
M?QS?\$;/'>K^$?VZ/!/A_3;;39[+XI>"OB-X$\02WT-U+=6>D:?X8NOB;#<Z
M,]O>6T5OJ3:]\.=$M)9KV'4+5M(NM5MTLTO9[2_L?[&:TAL_7]$<U;X_5+]0
MHHHJS(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "O\I>O]6BO\I>ON.#/^9E_P!R?_NT?+\2?\P7_<S_ .X#
M^K3_ (-C/^;W/^[;/_>^U_5I7\I?_!L9_P WN?\ =MG_ +WVOZM*\/B3_D=8
MW_N6_P#42@>IDO\ R+,-_P!QO_4BJ%%%%>&>H%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M***\,]0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1%UK369F8X5547)+,Q(  !))P!F@5GV_K^FOO.AHHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MKP^)/^1UC?\ N6_]1*!ZF2_\BS#?]QO_ %(JA1117AGJ!1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_G+T445SGH']8/_!"?
M_DT?XB_]G&^+O_59_"&OVGK\6/\ @A/_ ,FC_$7_ +.-\7?^JS^$-?M/6\=E
MZ+\CBJ?'+U"BBBF0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !17
MS%\?/VU?V1?V6O[2@_:'_:3^"WPBUK3/!5Y\0_\ A#?&GQ#\-:9\1=8\'6?]
MLI_;'A/X:?VA)X_\:_VA=^'M;TK0M/\ "'AO7-4\1Z[IEUH'A^RU/6H_L!_'
M7XL?\'0/_!,+X=>(K+1/!\_[0?QZTRZT6VU6?QA\)_A+::/X=TV^GOM2M)?#
M=[:_'/Q?\&/%LFM6=O8VNJ7,^G>%[_PZUCK&FQVFOW6IQ:OIVE<.)S++\([8
MG&8:C).W).K#VG_@M-SLNKY;+K8^@ROA/B;.HJ>59%FF-I-<RKT<'6^K6M=?
M[3*$</=K6,?:<TM>5.S/Z)Z*_A.^+_\ P=N?M$ZU_P (]_PH/]D;X+?#3[-_
M:W_"6?\ "W_&_CGXX?VUYW]F?V%_PCW_  A</[/?_",?V;Y6L_VM_:7_  EW
M]M?;],^Q_P!@?V3=?VU^;WQH_P"#B7_@JS\8+[QNNG?'S1?@QX2\;Z++H$G@
M7X+_  T\"^'['PM8WGAV'P]JD_@CQ[XHT;QG\;/#>M:@ZW?B"+Q):_%23Q%X
M>\1:C-?>#]5\.6]CHEEI7AU^,,GI7]G+$XEII+V5!P3O&][UY46HI^Z_=YKZ
MQC*.I^AY?X&<<XSE>*IY7E2:<IK&9A&M.'+44.51RZGCH2J2A>K!*HJ;BN6=
M6G4?(?Z:5?/GQ8_:V_93^ OB*R\'_'/]IK]GSX,>+=2T6V\2:=X7^+'QG^''
MPZ\17_AV\OM2TNTU^RT3QAXDT?4[K1;K4]'U?3K;58+62QGOM*U*TBG:XL;J
M.+_)U^+'[6W[5GQZ\.V7@_XY_M-?M!_&?PEINM6WB33O"_Q8^,_Q'^(OAVP\
M16=CJ6EVFOV6B>,/$FL:9:ZU:Z9K&KZ=;:K!:QWT%CJNI6D4ZV]]=1R^8?#S
MX;?$7XN^,='^'GPG\ ^-?B?X_P#$/]H?V!X&^'GA;7/&OC'7/[)TN]US5?['
M\,^&[#4]:U/^S-%TS4M8U#[%93_8]+T^]U"Y\NTM)YH_*J\;N34,+EKE*3BH
MNK7;;;=N54J=*[;=E&U2[?V>A]GA/H^0I0E6S?BJ-.G3C4G5CA,O4(0A!<WM
M98O$XM1C&,5*512PJ44K^T239_J#_%C_ (+??\$IO@QXBLO"_C#]M/X8:QJ=
M_HMMK\%U\)].\=?'KP['8W5]J6G107OC#X&>$OB+X2TW6EN-*NI+GPWJ.MVO
MB*SL9=-U2[TJ#3-8TB[OOD?XO_\ !S;_ ,$M/AI_PCW_  A?BOXT_M"?VU_:
MW]I?\*@^#VL:+_PB/]F_V9]C_P"$A_X7YJ'P/^T_V_\ ;[K^R?\ A$_^$G\G
M^Q=3_MW^Q?-T;^UOX@OAY_P2>_X*7_$_QCH_@;PW^PM^T]IFM:Y_:'V*]^(?
MPC\6_"+P=!_9FEWNL7/]L?$/XL:=X*\ >'O,M-/GAT_^W_$VF?VMJDEEH>E?
M;-:U/3=/N_KCPW_P;H?\%=M=\1:!HFJ?LS:+X,TS6-:TK2M1\8>)/CO\ +KP
M[X4L=0OH+2[\2:_:^#_B9XK\6W.BZ%;S2:IJL'A?POXD\136-K/'HF@:QJ;6
MNG7.;XBXEQ"E]6RJT7)1C.&!QE64'H[.;FZ5[-7<J:M&5[+1G2O"_P )LLE3
M_M7C/GK1I.I4H8CB#(\)3KQ:G!5(8>%".+4%*+<%3Q$G*I3Y7*:YH/\ I<_X
MBO\ _@G;_P!$9_;2_P##=_ W_P"B,KY'\2?\'>7AVU\1:_:^#_V"-:UWPE;:
MUJL'A?6_$G[2ECX4\1:QX=AOIX]$U77_  OI?P,\9Z9X;UK4-,6UN]5T#3O&
M'BNQT>^FGTZT\2:[;VT>J77PG_Q"@?\ !1+_ *+-^Q;_ .'$^.7_ -#G7:_#
MS_@TQ_;.U/QCH]E\6/VD/V8?!7@"?^T/[?\ $WP\G^*OQ/\ &.F>7I=[-I7]
MC^!O$GP\^$6BZY]LUJ/3=/U#[;\0_#W]F:7=WNL6W]K7>GP:'J9+&<:U'&,,
M/.DW)*\<-A4G?1<TJW/",4]7+W4MV["I9'X X6-6K6S2CC(1IN7)5S3-I2BH
M)R;I4\!["M4J-*RII593=HP@YM7^G?\ B+Y_ZQZ?^;9__DT4?\1?/_6/3_S;
M/_\ )HH_XA!O^LA?_FIG_P"4O1_Q"#?]9"__ #4S_P#*7J_^,[_K^QC'_CG/
M^O\ 7H/^(OG_ *QZ?^;9_P#Y-%=K\//^#NOX=:GXQT>R^+'[#OC7P5X G_M#
M^W_$WP\^.NA_$_QCIGEZ7>S:5_8_@;Q)\,/A%HNN?;-:CTW3]0^V_$/P]_9F
MEW=[K%M_:UWI\&AZGQ7_ !"#?]9"_P#S4S_\I>OBW_B% _X*)?\ 19OV+?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%(2%!9B%502S$@
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ME8@(P((?.TCH: /0:*^2+S]O7]C"QE,,W[37P<=QG+6?C72=0BX.#BXL)KF
M\],2'(Y&00:[+PO^UM^RWXTN(K+PM^T3\%-9OYVVPZ;:_$SP>-4F;_IEI<VK
MQ:A(,\92V(SQG-*Z[K^O^'7WCY9?RO[F?0M%1Q2Q3Q1SP21S0S1I+#-$ZR12
MQ2*'CDCD0E'C="&1U)5E(9200:DIB"BBB@ HHI&954LQ"JH+,S$!54#)))X
M Y)/ ')H _G[_P""Z_QZ_LGP=\+OV<='O=E[XMOY/B7XUABDVR+X>T*2YTCP
ME97" GS+35]??6=1*L%*77A2S<$@D5_,Y7UQ^W3\>6_:._:E^+'Q+M;PW?AJ
M37Y/#/@<JY: >"O"8_L/0;FV7)$2:S#:2>(KB(,RK?:Q=D,0V:^1ZPD[MO[O
MZ_$[:<>6"77=^K_JWR"OTE_X)X_L R?MN:I\2+C6_&&J> O!OP_L-%A;7-,T
M:VU>XU/Q-KUQ<O9Z5!%>W=E!Y-KI6FZA>:C)'))-;O/I*LBI>!C^;5?VR?\
M!,3X"_\ "@OV0/AOINH67V/Q9\0X'^*OC /'Y=PNH^,;>TGT6QN$8>;#/I/A
M&V\.Z9=VTAS#J%M?-LC:5T#BDWKVN*K-QCIHV[+\WO\ =\SX$_X<'?#K_HXK
MQK_X0NA?_+RC_AP=\.O^CBO&O_A"Z%_\O*_?^BM.2/;\7_F<_M:G\WX1_P C
M\ /^'!WPZ_Z.*\:_^$+H7_R\H_X<'?#K_HXKQK_X0NA?_+ROW_HHY(]OQ?\
MF'M:G\WX1_R/P _X<'?#K_HXKQK_ .$+H7_R\H_X<'?#K_HXKQK_ .$+H7_R
M\K]_Z*.2/;\7_F'M:G\WX1_R/P _X<'?#K_HXKQK_P"$+H7_ ,O*_<[X>>!M
M!^&/@/P9\.O"UO\ 9?#G@;PQH?A/182%\P:;H.FV^FVKSL@427,T5LLUU,1O
MGN9)9I"SR,Q[&BFHI;(F4Y2MS.]MM$OR2"BBBF2%%%% !1110 4444 %%%%
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M6KKXCZQK6L>';JX\-P0:#\;/!_AW2IK'0-<30+RXM->M/$_X3_M-_P#!K?\
MM\?">^N[[]G?Q%\,/VK_  E)K6CZ5H]KI6N:;\&/BF;&[\.R:CK/B3Q)X/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[WVOZM*\/B3_ )'6-_[EO_42@>IDO_(LPW_<;_U(JA1117AGJ!1110 4444
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MO;RX<1P6MI!+<W,[D$A(8(5>65R 2%1&. 3CBOI#P3^QE^UA\1/)?PC^SO\
M%W4;6XV^3J=UX(UO0]%EW\@IKFO6NF:.PP0S$7V%4JS85@3_ '0^%/A_X#\"
M6WV/P/X)\(^#;3:$^R^%/#>C>';;8,83R-(LK.+:-JX7;@8'' KKJA4^[^XV
M==](KYN_Y6/YUO\ @EU^P1^UM^SG^T-:_%;XH^#-)\$^#;[P/XH\+:U9S^,O
M#6L:[<PZLMAJ&F1IIWAG4=;A"#6-'TR:=+J\MI($3<T?F(8J_HIHHJTDE9&,
MI.;N[7\OZ9E:YKFC^&=%U?Q'XAU*ST;0= TR^UG6M7U"=+:PTO2M,M9;W4-0
MO;B0B."UL[2&6XN)7(6.*-F)P*_B_P#^"A_[=?B/]L/XFS6>B75]I7P.\$ZA
M=6_P[\,.9;8ZO(F^UF\=^([4E?-UW6(M_P#9UM.F/#FC3+IENBWEQK5[J?ZB
M?\%L?VO9]#TK2?V2O NJ-#?^(;2Q\5?&"[LIRLUOH)E%QX6\%2O&Q*'6IX1X
MCUNW;RI?[,M?#\9,UAK-W$W\U%9SET73?S_X;\_0WHPLN=[N]O)=_5_EZA11
M7[!?\$G?V%+3]I'Q_=_&'XH:.+WX+_##5;>&WTF]AWV'Q!\>1)#?6V@7,;J8
M[OP]X?MY;75?$L#DQ7[W>CZ-+%=65_JJ6\I-NR-I244V]E_5C7_8._X)+>+_
M -H;3M'^+'QRO-7^'/P@OUAO_#^B644=OXZ^(-@V'BOK3[;#-#X7\,7BX>UU
MF\M+O4=8MOWVDZ=%87=EKI_I2^#W[+7[/7P#TVUT[X3_  D\%^$Y+6-(SK<.
MCV^H>*[PQ@ 2:EXNU47WB749 <LIO-4F6)F80I$IVU[U'&D2)%$B1Q1HL<<<
M:A$C1 %1$10%5%4!550 H    I];**7KW..<Y3W>G9;?\'YG)^,O ?@CXB:-
M<^'?'W@_PSXUT&[C>*YT?Q5H>F:]ITJ2#:X:TU2VNH Q&"'5 ZL%965E4C^2
M/_@JK^P[X;_9/^(OACQC\+;:YL_A)\51JQT[0IKBXO1X*\5:,;6;5/#]O>W3
MS74NBW]E?VVI:!]MN)[R/RM7L7ED@TZWEE_L(K\Q/^"K/[,_Q4_:B^ O@3P9
M\&_"UKXH\9:'\8M%\1W,5UKF@>'X[#PPG@SQUIFJ7CWWB#4M-MY8SJFHZ!$]
MI9R7-_*[QS1VKV]O<RPJ2NMKOH.E+EDM;)Z.[LO7Y?\  /XTJ*_8+P]_P1%_
M;+UDQG5-0^#?A-6P9/[<\;ZQ=R1CJPV^&/"7B%'DQD*HE$9; :5%)<>Z^'?^
M""/Q0N=G_"6?M!^ M%SM\S_A'?!_B'Q1MS][9_:6H^$-^/X=WE[N^VLN63Z/
M\OS.EU(+[2^6OY7/IG_@@YXPO-2^!GQH\#SRO+;>%/B?INOV*NVX6\?C'PS;
M6L\$6>4A-QX3>X\L8037$\@&^60M^[%? G[!O[">F_L/:!\0=(M/B3>?$F\^
M(6H^'=0O]0N/"L/A.&P_X1RVU:VMX+6QCU_Q$\BS_P!KSR2/+?90HJJ""37W
MW6T;I*^_]?H<M1IS;CJG;OV5]_,Y;QQXQT+X>>"_%GCWQ/="R\.>"O#>M^*M
M=NSMS!I.@:;<ZI?R(K,H>06MK+Y4>X&23;&OS,*_@$^+GQ)UWXQ?%#Q_\4_$
MKEM<\?\ BS7/%-_'YC2QVC:O?S74&G6S, 19:7;/#IUC'A5BL[6")554 ']2
M?_!:OX]?\*V_9GTSX2Z3>^1XD^.GB%-+NHXY-EQ'X%\(RV6N>)9E9#YB"\U:
M3POHLB,%CN]/U+5(2[*DD;_R45G-ZV[;_P!?UN;4(VBY=W9>B_X/Y!1114&Y
MT^F^-O&>C6<>GZ1XM\3Z580F1H;'3=>U6QLXFED:64QVUK=Q0QF25WDD*H"\
MC,[99B3>_P"%E?$7_H?O&O\ X56N_P#R?7%44 =K_P +*^(O_0_>-?\ PJM=
M_P#D^C_A97Q%_P"A^\:_^%5KO_R?7%44 =K_ ,+*^(O_ $/WC7_PJM=_^3Z/
M^%E?$7_H?O&O_A5:[_\ )]<510!VO_"ROB+_ -#]XU_\*K7?_D^OZW?^"0'P
MK\1^"_V5+/XA^--3UO5/$_QKURY\7PMKFHWU_<V/@W3?,T3PC:1_;9Y_+AOH
MX-4\3021,//M?$5MO&8E5?Y0_@9\*=9^.7QA^&WPCT'S%U'X@>+]&\._:8X_
M-.FV%Y=(=8UF1.=UOHFD1WVKW7!(MK*4A6(P?[]O"_AO1O!OAKP]X0\.V<>G
M>'_"NAZ3X<T+3XO]58Z/HEA;Z9IEG'T^2VLK6"%?]E!5P6M_E\_Z_,PKRLE'
MOJ_1;?C^1N5_%1_P5?M?LG[?_P"T!'C DN?AQ=+QP?M?PA\ 7+$>OSRL"?[P
M-?VKU_&7_P %?K7[/^WO\6Y<8^W:+\,;K/KL^&OA:RS_ .2>/PJI[+U_1D4/
MC?\ A?YH_,NBBBLCJ/\ 1-\,IL\-^'TZ;-$TE,>FVPMQ_2MNLW15V:/I*?W-
M,L%_[YM8A_2M*N@\\*_G?_X+$_MZ?V?;ZG^R+\)-:_TZ\AC7XX>(],N,&TL9
MT6:W^&EI=0MG[1?Q-'=^-#$RB*Q:U\-RR2F]\0V%O^@/_!2+]N'3?V0?A,UA
MX8N[.Z^-_P 0[2]T[X>Z4_E7)\/V@4V^H^/M6M'#I]@T0R>5HUO=(T6LZ^8+
M;R+G3['6FM?XQ-4U/4=;U+4=9UB_N]4U?5[Z[U/5-3U"XEN[_4=1OYY+J]OK
MV[G9Y[F[N[F66XN;B9WEFFD>21F=B3G.71?/_+^NGJ;T87?.]EMYOO\ +\_0
MHT45]Q_L%_L9>)?VR/C#;>' +W2?AAX3>RUCXI>+;=-IT_1I)G^S>']*GD1X
M#XF\3M;SV>E(XD%E;1:AK<UO=0:5):W&:5]$=#:BFWLC[/\ ^"2W[ ?_  NW
MQ3:?M%_%K1?-^$?@C5L^"M"U*WS:_$;QGI<X)N9X)5VWOA'PI=QAKX,IL]:U
MZ./1G-U::=X@L3_5M7-^#_"'AGP!X6\/^"?!NC67A[PKX6TFRT/0-$TZ+RK/
M3=+T^!+>UMH5)9VVQH#+-*\D]Q,TEQ<2RSRR2-TE;Q5EY]3CG-SE?IT7;_A^
MH4444R HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M88@0HSLS@9JX1O=O;]3.K-PLEN]?DO\ ,_FW_P"'!WQ$_P"CB_!?_A":Y_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% '^<O1117.>@?U@_P#!"?\ Y-'^(O\ V<;XN_\ 59_"&OVGK\6/^"$__)H_
MQ%_[.-\7?^JS^$-?M/6\=EZ+\CBJ?'+U"BBBF0%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%>+?M&?'SX=?LM?
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M._<J1DY3JX;FC0Q7-/F4*\H5X?QU_P#!"'_@N]_PI;_A#?V)/VW/&7_%EO\
M0/#'P#^/GB>__P"2+?ZNST;X7?%'6;R3_DBW^IL/!/C:_F_XLM_H_AWQ%<?\
M*6_LW4O@M_=C7^6)_P %,_\ @D1^TO\ \$QO$6AW?Q'ET7XD_!/QWK6M:1\.
M_CGX$M=7C\.WE]97VKRZ5X0^(&D:E:K<?#KXGZKX2TV'Q@OA-]1\1^'=0L9-
M:M? _CSQV_@KQK/H/Z0_\$@/^#A+XB_LG_\ "K/V7?VNIO\ A/\ ]DS1?/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2/4D\.ZY?:.M_&BLZHEXMF+A5#,%60 ,P&3QE9G3N%?WF?L7?$'5/BE^RA\
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M_9*<J=*FPHHHKUSXH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /,
M/C1\%_A9^T1\+/&_P3^-G@C1?B+\+?B+HLN@>,/!^OQ3-8ZG8M-#=VL\%S:3
M6NIZ/K6CZG:V.N>&_$FAWVF^(O"WB+3=*\2>&]5TK7M*T[4;;_-(_P""N_\
MP2(^*?\ P3(^*<6HZ=+K7Q%_93^(NM75M\'/C'<VL+7VFWS0W6I#X3_%@Z;:
MVNF:/\3]'TRUN[K3=2M;33?#OQ3\.Z;>^,/!]EI5]I7CSP'\.O\ 4&KS#XT?
M!?X6?M$?"SQO\$_C9X(T7XB_"WXBZ++H'C#P?K\4S6.IV+30W=K/!<VDUKJ>
MCZUH^IVMCKGAOQ)H=]IOB+PMXBTW2O$GAO5=*U[2M.U&V\/.\DH9Q0L^6EBZ
M47]7Q%MNOLJMM949/UE3D^>%[RC/]!\/_$#,>!\QYH^TQ>2XNI'^TLMYOBVC
M]<P?,U"EC:4$DFW&GB:<50KM)4:U#_/E_P""(O\ P6Z\1?L#>(M,_9T_:+U/
M6O%?[%WBO6IGM+M(;[7?$7[-7B+7;Z2ZU'QEX-TZUCNM3UCX8:QJ=U/JGQ+^
M&FEP7-];WUS?_$CX;V$WC.;QAX/^+?\ HG^&_$GAWQGX=T#QAX/U_1?%?A+Q
M7HNE>)/"_BCPWJMCKOAWQ)X=UVQ@U31-?T#6]+GNM,UC1=8TRZM=1TK5=.NK
MFQU"QN8+NTGFMYHY&_S$_P#@KO\ \$B/BG_P3(^*<6HZ=+K7Q%_93^(NM75M
M\'/C'<VL+7VFWS0W6I#X3_%@Z;:VNF:/\3]'TRUN[K3=2M;33?#OQ3\.Z;>^
M,/!]EI5]I7CSP'\.OT[_ ." 7_!;KP[^S78^%/V$/VL]3T7PW\ [K6M63X&?
M&RYAL='L?@]XB\9^(M1\2:OX-^+%]%';6\WPP\5^+==U76=-^)>ILU]\,_$6
ML7MOXVO[KX4:A!KGP<^:R'-\1E>)>2YNW2A!\E"I5?\  DVN2G*=^5X:I%WI
M5;N-/W5?V4DZ7ZSXC<#Y;Q?E4./>"(QQE;$1^L9EA<''_?Z*C+VV*IX=+GAF
MN&G'DQN$Y8U<1:I)P^NTI1Q?]Y=%%%?H)_,H4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MGQ'K.E:!H]DADO-5UO4;32M-M(P"3)<WU]-!:P( "2\LJ* "2< U^,/[;?\
MP5\^%'PV\,Z_X!_9JUZR^)OQ4U*SNM+C\;Z/B[\ >!'N(WADU>UU=U^R>,-<
MM4<3Z/;:*+[PZER4N=3U646<FBW_ /+/KGBGQ/XGF2X\2^(]>\0SQ#$<VN:O
MJ&K31C&,))?W%PZ#'&%8<<5A4G-O96'&BDTV[VZ6T^>]U]UR6XN)[N>>ZNII
M;FYN9I+BXN)Y'FGGGF=I)III9"TDLLLC,\DCLSN[,S$L2:BHKZ/_ &8OV6/B
MS^UC\1+3P!\+]%>:**2VG\5>+KZ*:/POX*T::5D?5M?U!$*HS)'/_9VE0&35
M-8GAD@T^VE\N>2"#9M)7>B1]#_\ !,G]E&__ &G?VD/#L^K:8\_PL^%=[IGC
MGXBWDT#/I]XMA=_:/#G@YV(\J6X\6:K:""YM"Z2-X=LO$%U&WF6L:2?VI5\Z
M_LN?LR_#O]D_X3:+\*_A[;-+';G^TO$_B:[ABBUCQEXHN888]1\0ZL8RX1YA
M#%;:?8)++!I.EV]GIT$DJV[3S?15;15EYO?_ "..I/GEY+1?J_G^5@K^5O\
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M@YOE4$,ZBKM?>_0=27+!OKLO5_U?Y'[ZT445N<04444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 ?YR]%%%<YZ!_6#_P0G_Y-'^(O_9QOB[_ -5G\(:_:>OQ8_X(3_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _D^_X+L?\G<?
M#K_LW+PC_P"K,^+U?BQ7[3_\%V/^3N/AU_V;EX1_]69\7J_%BL9_$_E^2.VG
M\$?0_1K_ ()*_P#*07X ?]U5_P#5)_$BO[3J_BQ_X)*_\I!?@!_W57_U2?Q(
MK^TZKAL_7]$85_C7^%?FPHHHJS$**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "O\ *7K_ %:*_P I>ON.#/\
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M/7]5G+,$40Z?I5M=W<F78*-D+98@#D@5^I_[._\ P1N_:A^+=S8ZI\3K>Q^
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MHH **** "BBB@ HHHH _/G_@H_\ \$X/@5_P4J^!5Q\)_BQ;_P#".^-?#O\
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M6UC<6-M?_$CX;V$/@R'QAX/^$G]$]?X['Q#^'GQU_9$^.NL> _'FC^-?@?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#^3[_@NQ_R=Q\.O^S<O"/_ *LSXO5^+%?M/_P78_Y.X^'7_9N7
MA'_U9GQ>K\6*QG\3^7Y([:?P1]#]&O\ @DK_ ,I!?@!_W57_ -4G\2*_M.K^
M+'_@DK_RD%^ '_=5?_5)_$BO[3JN&S]?T1A7^-?X5^;"BBBK,0HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M_P I>O\ 5HK_ "EZ^XX,_P"9E_W)_P#NT?+\2?\ ,%_W,_\ N _JT_X-C/\
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M\?/AU^U+\"OA5^T/\)]2_M/P!\7?!6B^-- \Z\T.\U31_P"T[<?VKX3\3?\
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M?X5^;"BBBK,0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6SMWLPHHHK(L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBO9E%%%??'\V!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\2U&6MOM4TY2W;THJRWTNU_)!75^"/'GCGX9>*-+\<?#?QGXK^'WC31/MO\
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MK345-6\I(WAC<73MR8K$12=[*K/EOYQ<N5^=T[G] _\ Q$A_MQ?]$K_92_\
M"'^+W_S\Z^K?^(G/_JR/_P V3_\ Q!5_*717)/A_)ZEN; TU:]N2I6I[VW]G
M4AS;:<U[:VM=WZ(YOF,+VQ4W>WQ0ISVOMSPE;?6UK]=D?UE:#_P<VZ'<:YHU
MOXG_ &--6T?PU/JVG0^(=6T'X]6?B/7-+T.6\A35M1T;P]J'P@\*V&O:M96#
M7%SIVC7WB?PY9ZI>10V-SKVCPSOJ%O\ 2_\ Q$A_L._]$K_:M_\ "'^$/_S\
MZ_B>HKGGPQD\FN6A4IVW4*]9I^;]I.H_N:7D;1SS,8IWJPGYRI4TUY+DC!?>
MF_,_MA_XB0_V'?\ HE?[5O\ X0_PA_\ GYT?\1(?[#O_ $2O]JW_ ,(?X0__
M #\Z_B>HJ/\ 5;*?Y*__ (/E_D5_;V8?S4O_  4O\S^V'_B)#_8=_P"B5_M6
M_P#A#_"'_P"?G1_Q$A_L._\ 1*_VK?\ PA_A#_\ /SK^)ZBC_5;*?Y*__@^7
M^0?V]F'\U+_P4O\ ,_OC\$?\%W?^":_BSPOI>OZ]\8/%?PRU:_\ MOVOP1XX
M^$?Q,O\ Q1HGV74;NR@_M2[^&_AKX@^"Y?[2MK:'5[+^Q?%^K^7IU_:1:C]@
MU9+[2[+J_P#A]W_P2_\ ^CG/_,+_ +0G_P Z>O\ /QHK%\(Y8VVJV-BFVU%5
M:-DF]ES8=RLME=MVW;>IHN(<:DDZ>&;22NX5;OS=JR5WN[)+LDC_ $#O^'W?
M_!+_ /Z.<_\ ,+_M"?\ SIZ/^'W?_!+_ /Z.<_\ ,+_M"?\ SIZ_S\:*7^J&
M6_\ /_'?^#</_P#,P_\ 6+&_\^L+_P" 5?\ Y>?Z!W_#[O\ X)?_ /1SG_F%
M_P!H3_YT]'_#[O\ X)?_ /1SG_F%_P!H3_YT]?Y^-%'^J&6_\_\ '?\ @W#_
M /S,'^L6-_Y]87_P"K_\O/\ 42^"'QO^%_[1WPO\,?&?X,^)_P#A,OAKXR_M
MK_A&_$G]B^(?#W]I?\(]XAU;PIK'_$G\5Z3H>OV?V/7]#U2P_P!/TNU^T?9?
MM5KY]E/;7,WJU?E+_P $0_\ E%_^S'_W6C_UH7XL5^K5?!8RC'#XO%8>#DX4
M,37HP<VG)QI590BY-**<FHIMJ*3=[)+0^LPU25;#T*TDE*K1I5)*-U%2G",F
MHIMM)-NUVW;=O<****YC8**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M***P-?\ %7AOPK;BZ\1:YIFCQM#=3PK?7<4-Q=I9(DETMA:%C=ZA-$LD0^S6
M,-Q<.\T,4<3231(\RE&$7*<HPBMY2:C%:VU;:2UTU>YI2HU<14A1H4JE:K4=
MH4J4)5*DW9NT(04I2=DW9)NR;Z&_17Q[XS_:F2"X-IX$T6&\CAF*R:QXA2X6
MWNDC>ZB<66E6ES:W:PSJ+.ZMKV]O;:X"-/;7.C0R!95^:?$OQ*\=^+T>#Q!X
MGU.]M)(88)M/BDCT[2[A+>X-W"USI>F1V>G7,T=P5E6YGM9+C,4 ,I6W@$?A
MXKB#!4&XT5/$S5U[EHTKKO4EJTWLX0FM'KM?]"RGPRS_ #",*N-E1RFA+E=L
M1>KB^63U:PM)I1E%*[IUZ]":;C%I>\X_HUKWQ3^'GAKS%U?Q=HT<T%Z^GW%G
M9W!U;4+6\C\X2PW6FZ0E]?VODO!+%/)<6T<4$X6"5TFDBC?R'6?VIO!=HEZF
MBZ+K^LW<$QBM&G2STK2[]$N%C:Y6[>YO-1MH9+</<6RSZ*+ASY4%S!:,\CP?
M!=%>+6XCQL[JE"C05G9J+J35^MYOD=MU^[WWNM#[[ ^%F08?EEC*^.S":<7*
M,JL<-0E9IM*%"*K14K.,O]I;Y7[KC)<Q]>:A^UEJ$EG,FE>";*ROV\OR+G4-
M<GU.SCQ*AE\ZQMM,TF:??")(X]FH6_ERNDS>:D;02?*W[5=YIO[9/[/GQ._9
MH^-/AS1[KX<?%71;32M;D\-W'B'0?$6DWVCZUI?BCPOXDT#5(]=N;>'6O"GB
MW0M"\3:5!JVGZQX=O[[28-/\3Z!X@\.W6J:)?YE%>?6S7,*\9PJXF4X3A*G.
M')2C"<))J491C",9*2;3NG=.STT/IL#P=PUEM:CB,%E=*CB,-B*>*P^(=;%5
M:]'$490G2JTJU:O4J4Y4YTX3ARR2C-<R2DVW_G9_MJ_L@>/_ -B/XYZM\&/'
MFHZ7XAADTNV\7>!/&&CM%!:>-/ &K:CJVF:+XBFT8W=Y?>&-4:^T/5](USPW
MJ4T\NF:UI.H+IFI>(?#LFB>)];_K:_X(??\ !=7XH_&>SL/V1?VG_L7Q ^*'
M@KP5>7GPR^+>M>(H-+\9?%GP_P"'9;))_#7C>]U.[N[OQ=\4/"^A2S:E%KVE
M:+?ZWX]\&Z+KGBGQW<P>*?"'B+Q;\1/JK]MO]B3X3?MQ_":;X>?$.'^Q?%&B
M_;M2^&'Q/TVQAN_$OPX\2W<,,<MU:Q236G]M>%]:^R65KXS\&75[:6'B:PM+
M.>"\T7Q1HOA7Q5X=_@__ .%*?M'?#CX_?\*>TKX??%#1OVD? ?BCS--\'>!]
M,US4?B5I7B7PO;?\);9Z[X0'@P7VJ7WV'2[&/QIH'BSPG/>6%UH$5IXPT+5;
MC1GM=4?P*.(QF3XGVV#JSA"JU%QC:49I.ZISC)2C*46VZ;E%NS=F[S1^E8[*
M\CXZRKZEGF#P]?$8-.I"I4YJ=2A.4>66(H5J,Z56G3JJ,5B84ZD(74.9>[0D
MO]6/2OVL-&FN'76_!VIZ=:"%FCFTK5;76;AK@/&$B>UN[70HXX6C,KM.MW(Z
MND<8MG65I8?4?#_Q[^&'B#[)%_;_ /8E[=_:/]"\06TVF_9O(\YO]+U/$V@P
M^=%#YMO_ ,3=O,\V&W^6]D^S#\;_ -GB;XR3_ SX3/\ M"Z?I>F?&]? ?AR'
MXH6VCZQI>N6DGC"WTZ&#5M0FO=!T/P]X=@U35IH_[5US1_#%A<>%?#VM7FH:
M!X8USQ/H&F:=XDU;V2OJZ'$681Y74=.LFDVJM)0E9M.W[KV:C)*Z5XM*[NI-
M*WXSC_"_AFLZD,/'%8&<7*,9X3%RKTG**E%.V+6)=2G*34WRU(2DHI0G!-W_
M &$T_4=/U:SAU#2K^RU.PN/,\B^T^Z@O;.?RI7@E\FYMI)(9/+FCDADV.VR6
M-XVPZ,!<K\@M*UK6="N'N]$U;4]&NY(6MI+K2K^ZTZXDMW>.5X'FM)89&A:2
M&*1HF8HSQ1N5+(I'OOAK]ISQWI3HGB"WTSQ5:&::69I8(]&U38]N(X;:VN],
MA73H88;A5N&:?1;NXE#SP&=%>![;V,/Q)AIVCB:52A+1.</WM/LV[)5(KJDH
M3=KJ[:5_ALT\*LUP_/4RK&8?,*:YG&C6_P!CQ36\(1<I3PU25KQ<YUL/%M*7
M+%2:A^@%%>7>$/C)\/\ QFD2V&MPZ;J,LT%LNBZ\\&EZH]Q=7$UM:06J23R6
MFI3731*Z1:3=W[Q"XMH[E8+B=(*]1KWZ5:C7@IT:D*L']J$E):]'9Z/HT[--
M--)IGYKC,#C<OK2P^.PM?"5HMIT\12G2D[6UCS)*<6FG&<'*$HM2C)Q:;***
M*U.0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH _D^_X+L?\G<?#K_LW+PC_P"K,^+U?BQ7[3_\%V/^3N/A
MU_V;EX1_]69\7J_%BL9_$_E^2.VG\$?0_1K_ ()*_P#*07X ?]U5_P#5)_$B
MO[3J_BQ_X)*_\I!?@!_W57_U2?Q(K^TZKAL_7]$85_C7^%?FPHHHJS$****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_.7HHHKG/0/ZP?\
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MXL?^"2O_ "D%^ '_ '57_P!4G\2*_M.JX;/U_1&%?XU_A7YL****LQ"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ K_*7K_5HK_*7K[C@S_F9?]R?_NT?+\2?\P7_ ',_^X#^K3_@V,_YO<_[
MML_][[7]6E?RE_\ !L9_S>Y_W;9_[WVOZM*\/B3_ )'6-_[EO_42@>IDO_(L
MPW_<;_U(JA1117AGJ!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4UW2-6=V5$16=W=@JHB@EF9B0%50"68D  $DXIU?F;_P5?_:*
MF^ ?[)WB73M"OS9>-_C%<GX8^&Y()"EY9:9JMI//XTUF'85EC%IX9AN]+AO(
M726QU;7=)N4;<@!3=DWV'%<S275V/Y_O^"FO[;FJ?M5_&&^\+^%-7F_X49\,
M]4O-*\$6%K.ZV'BO5[4R66J?$*^C4A;N34W$]MX9,X/]G>&S$T$-I>ZOK0N/
ML/\ X)Y?\$DM#^*_@S0/CI^TU_;,7A7Q+!%JW@;X6Z;=W.AW6OZ#, ]EXB\8
M:Q:M#JUEI6L0G[5HVD:)/IVH75@]GJT^L16]TFGR_A%X9U#2=)\2:!JNO:(/
M$NAZ9K6EZAK'ATWSZ6NOZ79WT%Q?Z*VI1V]W)IZZI:QRV+7L=K<26JSF=(96
M0(?ZI_V'?^"H7CG]K;XUZ+\&=(_9Z\.^#/#=AX:UC7_$/B#3O&]]J,?A?PWH
M%G%9V/V31QX3TVVD6ZUN]T'0K>W^UVL5O'J'GH'6V\B3.-F[RW;T6N_^72QT
MS4H02AHDG=W2>EO35^7;3H?K-\,OA7\.O@UX2L_ OPM\'Z)X'\)6$UQ<V^B:
M#:BVM?M=V5:ZO;AV:2XO+ZY*)]HO;R:>[G\M!+,P10/SW_X*F?MK7/[*OP>M
MO"O@+4DM?C1\6(M0TOPM=0NK7/@[PW;*D/B#QML&XQW\/VB'2O#!E"*VL7,N
MIQ?:4T"\M)?U&9E16=V5$12SNQ"JJJ"69F) 55 )))  !).*_A;_ &\?VB+C
M]IO]I[XD_$:"]>[\)VFIOX/^'<?F,]O!X%\+S3V&C7%JC$F%=>F-[XINH=S"
M/4-=NU5M@0"I.RLM+Z+R1E2CSRN]4M7?J^B^?Z,R/V3?V6?B/^V;\8X?A_X6
MNWLX2LOB+X@>/=6CN-1L_#&A-=(M]K%_F6.;5=9U&ZG%OI.EF[AN=8U*8F:Z
MM+&#4=3LOZUOV:/^"=?[,'[+LVB>(/!G@MO$7Q'T:*79\3O&=W)K/B@75U93
MV%[<Z7!^YT+PX)[2[O+0#0M)L;@V5S);W5W>%GF?^;G]B+_@H[#^Q/X#\3^%
M/#WP'T3QMK_C'Q$FN>(O&>H>-KK1-0O;6RLX[+0]"6RMO"^HK'INBJ^I75LK
MWDSO?:SJ<Y*),D,7];?P1\:>*?B/\(OAU\0/&GA:W\$^)?&WA/2/%.H^$[;4
M)]430%UVV74K#39KVYL]/GEO8--N;,:@DEG ;>_-S;;2(0[*"7J_1Z?I<NLY
M^D=EKOWO;IV1ZE1116ASA1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 <1\0_B5X ^$WA;4/&WQ+\8>'_  1X4TQ1]LUSQ'J5OIMDLK*[16D#3NLE
M[J%SY;I9Z;91W%_>RCR;2VFE(0_S_?M7_P#!;UW_ +3\'?LD^'O+7]]:O\7_
M !QIH,A&"HNO!W@B\4JG.V6VU/QBCDC?%<^$4.R>O(O^"Y?QY_X2OXR> _@%
MI%[OTGX5:"?$_BF&*3Y'\:^-H()[&TNX@2&ET;PC!IEY9R?*RKXKOHRO<_A9
M6<I.[2^_^MCHITE92EK?5)[6Z7[]S[E_9=\&^/OVY/VR?AMHOQ1\1^(OB#<:
M]XDB\1_$37/$FH76JW)\#>%-^OZ]8/<7#R)IUA?6=J?#NE6MLD5A8W6K65M:
MVL<12*O[@55454151$4*B* JJJ@!550 %50       !BOY]/^"$_P%_LSPM\
M4_VC]8LMMWXFO(_AAX)GECVR+H6C26NM>,;VW8@^;::IK;:#IR2(5V77AC4(
MCNR=O]!M."TN^KOY_P!?YD5I7E9;15OGU_1?(*_ER_X+F_'K_A*/BYX _9^T
M>]WZ7\+]#/B[Q9!%)\C^,_&<$3Z7:7<>3F;1?"4%G?6DF%(B\772$-P1_4;7
MS)XR_8R_96^(?B?6?&GCGX$?#KQ5XL\0W0O=;\0:UH<=]JFIW2PQ6ZS7=S*Y
M>1DMX88(QPL<,4<4:K&BJ*DKJQ,)*,N9INVUN_\ PU_G8_@RK^E7_@A+\!O[
M/\.?%7]H_6++;<^(+N+X6^"9Y8]L@T?2GL]=\9WL#,#YMKJ6KMX<TZ.:/:$N
M?#NI0$N2P3]4O^'?W[%?_1L_PF_\)BW_ /BJ^D? 7P_\$_"WPII?@;X=^%]&
M\&^$-$^V?V3X=T"SCL-+L#J%]<ZG?-;VT0"JUWJ%Y=7EPYRTMQ<2R,2S&IC"
MSN[/_/3_ (/Y^FDZJE'E2:OO>VW_  _X?<=A1115F 4444 %%%9NLZQI7AW2
M-5U_7=1L](T30].O=7UC5=0GCM;#3-+TVVEO+_4+VYE98K>TL[6&6XN)Y&5(
MHHW=R%4F@#G/B)\1?!'PF\%Z_P#$+XB^)--\)^#?#%B^H:UKFJRF.VM80RQQ
M11QQK)<7E]>3O%::?IUE#<7^HWLT%E8VUQ=3Q0O_ "<_MS?\%5OBC^TA>:Q\
M/_A+=:Q\+?@>7FLGM[.X-EXU\?VN7C:X\5ZI92F33-'O(B0/".E7/V1X9)(]
M=O=;S#%9>;?\%%_V]/$/[7_Q&FT/PS>7^E? ;P1J5S#X%\/$S6I\2WD/F6LG
MC[Q):L4:74]2B:5=$LKJ,?\ ".Z+/]DCBBU*^UNXOOS;K*4KZ+;\SJITE&TI
M:RW2Z+_@_ET[A17V;^Q]^PW\9?VR?$\]AX&M(?#_ (&T6ZA@\7_$S7H+C_A'
M-!,BI*VGV,46R;Q%XD>V836V@Z?(A19+:;5K[1["YCOJ_I__ &>?^"67[)/P
M$L;&XO/ EE\7O&L*1M>>,?BG9V?B.-KM0&:32/"5Q%)X4T6"*;=)8NNF7FLV
MR^6L^MWDD2STE%OR7<J=2,-'J^RZ>O8_BU5'<.41F$:[Y"JEA&F]4WN0"%7>
MZ)N; WNJYRP!;7^BQIFDZ7HEG%IVC:;I^D:? ,06.F6=M86<(P!B*VM8XH(Q
M@ 81 , #M7RG^T?^PY^SG^TYX:U32O'/P^T'3/%%U;3KI/Q(\,:5I^C>.="O
MV1OL]XFL6=O#)K%M!*1)+HVN_P!H:3<@OOM4G,=Q%7L_/\"%75]8V7>]_P!$
M?PIU[3^SY\>O'_[-?Q6\,?%KX<:E)9:WX?NT%]I[RR+I?B?09I8CJ_A?7H$.
M+K2-8MX_)F4@S6EPMMJ=@]OJ=C974&=\=/@_XG^ /Q>\?_!WQAY;Z_X"\07.
MC7%W CQVVJ612*]T;7+..0F6.QU[1;O3]9LDFQ,EI?0K,%E5U'D]9[>1MHUW
M37WIG^@Y\&OBKX8^./PK\!_%OP=*TGAWQ[X<L-?L(Y65KBQDN4,>H:1>E/D&
MH:)J<5YI&HK'F-+ZQN$1F10Q],K\5O\ @AI\0+SQ'^R_XV\"WT[S?\*X^*>I
M1Z2K,2MIH/BW1]+UR*U0$D*/^$@7Q+>-MVJ6O3\N[<S?M36Z=TGW1Q27+)KL
M_P .GX'.^+_%6B>!?"?B?QMXENUT_P .^#_#^L^)]>OGQML]'T'3KC5-2N2"
MR@^39VLT@7<-Q4+D$U_ -\:/BAK?QJ^+/Q$^+'B(L-6^('B[6O$T\#2&5=/@
MU*]EET_28'(!-IHVG?9-*L@1\MI9PI_#7]37_!:'X]?\*O\ V7K?X8:3>_9_
M$_QVU]/#K)')Y=S'X'\-/::WXONHR"6\NYNF\.>';F,KMGL-?O5W#85;^1BL
MYO6W;?\ K^MS>A&R<NKT7HO\W^045]M_\$[_ ("#]HG]K3X6>"[^Q%]X4T'4
MS\0?'4<D8EM6\*^"WAU.:QOD(.;/Q!J_]C^%YNA']N*=RXW+_:S_ ,*W^'?_
M $(7@O\ \);0_P#Y!I1CS*][%SJJ#2M=VN]=OZU_#N?YY=%?Z&$OPQ^&T\;1
M3_#WP/-$X >*7PGH,D;@$, R/IY5@" 1D'! /45\K?'K_@G9^R=\>_#6I:3J
MOPF\)>!_$=S;S?V7X]^'&@:3X.\4:5J!1EM[Z>31;2SLO$,4+$"33O$5KJ=G
M+$66-+><0W,->S?1_P!?B0JZZQ:^=_\ +^ON/X>*]G^ /Q[^(_[-GQ.T#XJ?
M##6I=+U[19U2]LG>5M'\2Z))+&^I>&O$5E')&NH:+JD<:I/"Q6:VG2WU'3YK
M34[*RO+>7]HKX$^,/V:_C'XU^#?C<1RZQX1U(16VJ6T4D5AXAT.]ACOM"\1:
M<LA9A9ZQI=Q;78@:226QN'N-.N6%W9W"+XG6>WD;:-=&FODT?Z /[/?QO\)_
MM&_!SP)\9/!A:/1_&FCI>2Z=+*DUWH6LVLLMAK_AZ_=%17O-#UBUO=.EF6-(
MKM;=+VW4VMS [>SU_/7_ ,$%_BK>7OAGXZ_!:_NGDM- U7PW\1O#=N[ES$/$
M,%WX?\4K&&YB@2;0_#$RQH?+-Q>W4NU))7:7^A2MT[I,XIQY9./9Z>CU7YA1
M56^OK'2[&\U/4[RUT[3=.M;B^U#4+ZXAM+&QL;2%[B[O+R[N'C@M;6U@CDGN
M+B>1(884>21U168?D_\ M&_\%B?V8/@VFH:-\-[JZ^/?C:W$D,=KX-N4LO U
MM=+G;_:/CZZM[BRO+<\,DWA/3_%$4A_=236S;G0;2W8E%R=DF_ZZO9?,_6>2
M2.&-Y972**)&DDDD94CCC12SN[L0J(B@LS,0JJ"20!7X_P#[7_\ P5^^"GP,
MCU/P?\%6TSXW?%&'SK1[G3KQV^&GAB\0%"^L>([%P?$MS;R%6.C^%9Y()2D]
MK?>(M&NXA&_X#?M/_P#!1;]IK]J=KW2/%?BW_A#_ (>7+.B_#3P"UWH7AFXM
MB3MC\03_ &F;6?%;LHC::/7M1N]+6YC^T:?I6G%O+'PG6;F^FGF]_P"OO.B%
M&VLG?R6WS?7^M3V;XY_M!?%S]I#QM=>/OC!XQU'Q7K<OFQ:?;S,+?1/#VGR2
M>8ND>&M$@V:?HNF1D*3!9PK)=2J;S4)KR_EGNI?&:*^K_P!B'X$/^T?^U!\)
MOA?<6C77AV\\11:_XV^4F%/!/A96UWQ)#/( 1!_:MC9'0K69P5&HZK9)M<N$
M:-WZO\S;2*[)+IIHC^KG_@F1\!?^%!?L@?#;2=0LOL?BSX@6S?%3QBKQ^5<+
MJGC*WM+G2;&YC8"6&XTCPG;^'=)N[>0DQ7]G>,%0R,@_0"FHB1HL<:JB(JHB
M(H5$10%5550 JJ  J@    # IU="T278X6[MONVPK\9/^"G'_!2M/V<;6[^!
M_P $[^SO?CCJU@K>(_$06&]M/A5I6H6ZRVKB"19+:Z\;:E:S)=Z7872R6^C6
M,D&KZE;S?:M-M;G[5_;K_:GT[]D;]GSQ-\2%^R77C34W3PG\--&N@)(M2\:Z
MM;W+V5S=6X*M-I>@6=M>^(-50M$ES;:;_9JSPW6H6I;^'?Q'XCUWQ?X@UKQ5
MXHU6]UWQ'XCU2^UO7=9U*=[F_P!4U;4[F2[O[^\G<EI;BZN99)9&.!N8A0%
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M;V\$:10000HL<,,,485(HHHU5(XT541%"J  !4M%%;G"%%%% !1110!\4?\
M!0WX\_\ #._[)?Q5\:V-[]B\5:WI)\ >!G23R[D>*_&B3:5;7MBV0/M>@:6V
MK>*(U.0RZ%("K_<;^&ZO]!CXI_!7X4?&[2=-T'XM^ O#OQ!T;2-1.KZ9I?B:
MR&H65GJ9MIK/[?#;NPC%TMI<7%NDQ4ND,\R(5660-X=_P[^_8K_Z-G^$W_A,
M6_\ \542BY6U_K^OR\S:G4C!6:;;=W:WE;KZ_P!;?Q]_L7? J3]H[]IOX2_"
MF6V>XT+5_$L&K>,BH;9%X)\-(^O^*5DE'RV[WVDZ?/I-G,YV_P!I:A91!7>5
M(W_O"BBC@CCAAC2&&%$BBBB18XXHXU"1QQQH J(B@*B* JJ    !7@_PP_9;
M_9V^"_B&X\6?"GX.>!/ 7B6ZTJXT2XUOPYHEO8ZC)I-W<V=W=6!N5W.MM/<Z
M?932HI7>UM'N) P?>Z<8\J)J3YVK*R2Z]WO_ %Y?)%%%%49A1110 4444 %%
M%% !1110 4444 %%%% 'YX?\%1OCU_PH?]C[XAW.G7OV3Q9\3(T^%'A,QR>7
M<+<>+K:[C\0WT#(?.ADTWP?:^(;JVNX@#;ZF-.'F1R2Q-7\4U?M;_P %NOCU
M_P )[^T)X9^"FD7OFZ#\%/#HFUF**3,4GCOQQ!8ZOJ*R;"8Y_P"S/#,'AFVA
M+EI+.\N]9ML1NTZM^*58S=WZ:?YG92C:"[RU_P OPU^9]L?\$\O@+_PT1^UI
M\*_!5]9?;?"NAZL/B!XY1X_-M3X4\%R0ZK<V5ZN"?LGB#5%TGPO(1@AM<0AD
M^^O]R%?@U_P0O^ O_"-_"SXB?M"ZQ9;-2^).LKX)\(3S1XD3P?X/G9];O;.4
M#FVUOQ9,^GW2$G%QX-B8!1R_[RUI!67KK_E_7F85I7G;I'3Y]?\ +Y!1115&
M04444 %%%% !1110 4444 %%%% !1110!^!W_!=/X]_V!\.?AO\ LZZ/>[-1
M\?ZJWC_QE!%)B5/"?A:=[3PY97<>?FM-;\4R7&HPL%)6Z\&?>49#_P Q%?VR
M?M2?L)_LC?&#7O%'Q^_:%@\1"70/"D;ZYKS^.]=T30] \*>%+">Y?R;*RG2V
MM+2WC^VZA.D*-)<7MU=3!7FN-I_C,^(%WX0U3QWXMO/AUHE[X?\  MWXDU9_
M!>A7]Y<:GJ>G>&FOYET*TU&^N)9Y[S4QIPMOM\WF,DEZTQA5(?+C7*:=[OKM
M\CKHM<MDGINWU;^?R]%J?KM_P1(^ O\ PG_[1/B+XSZO9>=H'P1\.M_94LL>
MZ&3QYXVAOM'TG8)!Y4W]F^'(?%%[)LW2V5])HUS^[=X'/]1_Q%\=:#\,/ /C
M3XC^*)_LWAWP+X7USQ9K,H*B3^SM!TVXU*YC@#$"2ZGCMS!:PC+SW,D4,:L\
MBJ?CS_@FY^S7-^S'^RSX+\,:Y8?8?'WC1I/B+\0XI8]EU9^(/$=M:?8]"N P
MWQR^&O#UIH^BWEN'>!=6M-4N8"%NVS]2_&;X0>#?CS\-_$?PH^(,>K3^#?%B
M6$.NVFBZO>:'>WEMIVIV>KPVO]I6#QW<5M+>6%M]KBBD1;NW62TGWVTTT3W%
M67GO\_ZT,)R4IW^S=*_DMVOQ:/X(/B;\0->^*WQ%\<?$SQ/+YWB#Q[XJUWQ9
MJQ#,T<5YKNHW&H26MONY2SL_/%I90@*D%I###&J1QJHYK1-%U3Q)K6D>'=#L
MIM1UK7M4T_1=(T^W7=<7^J:I=PV.GV4"D@--=7<\,$2Y&7D49&:_6+_@J;^S
M_P#LC?LO:MX$^%?P*T+6(/B??K+XJ\<W>H>,=9\0Q>'O"\D$MIH&CRV5[=36
MT&I>(;M[C5F$B+>V>FZ58S!1:ZW"\D__  1N_9GN/B_^T?'\7-<T]I? GP%2
MW\0K-/%FUU'XB:@L\/@S3HBR@22Z,T=[XMDD@=GLKO1M&2X41ZE#ORMK;SMI
MK_5NIT\ZY.=:*VE_PT]=/^ ?U!_LZ_!_2_@#\#OA?\'=)\EX/ ?A'2]'O;J!
M=D6I:\T9OO$VLA-J[6UKQ%=ZIJSJ5!#WK CBO:***WV.)N[;>[U84444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% '^<O1117.>@?U@_P#!"?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?^19AO\ N-_ZD50HHHKPSU HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ML[ -&NK^+I]<@NXU!29/#NF3;VPH3A_^'!WPZ_Z.*\:_^$+H7_R\K]OOA/\
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MO;'5-/DF@M[@VEY"+FVMK@2P1^6U&J[K\#6T9):)IK33IY']\G[+?[1/A/\
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M.V4FH^(/%6N:3X<T+3XO];?:QK=_;Z9IEG'_ +=S>W4$*?[3BL.OUQ_X(T?
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MGQJLU>TU>6ZN9;CP1\/+I05:W\17%C<0W>O>)(2-LOAK3KRT^P.7.MZK97<
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M %_3"I4YK)*T5LO\^FG1= HHHJC,**** "BBB@ HHHH **** "BBB@ HHHH
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M[/W=;I+]#J***^//>"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ35G%NO22@I*=*G&I]]4445]J?@84444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!_)]_P78_Y.X^'7_9N7A'_P!69\7J_%BOVG_X
M+L?\G<?#K_LW+PC_ .K,^+U?BQ6,_B?R_)';3^"/H?HU_P $E?\ E(+\ /\
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M$\6:MJEO9:"+\V6F:7-X?\;>%X+2P>?4KFZO(WMKB6[N%MFEG*6EM'%]I?\
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M "BBB@ HHHH **** "BBB@#_ #EZ***YST#^L'_@A/\ \FC_ !%_[.-\7?\
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MQX&\4:M?7^7QCS%TWQIHB%,_<16 Y8U^%]93^)_+\D=5-WA'T2^[1G]%/_!
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M^"A,K&YEEN?$T,4<=MX<U"Y_H]JX)VN[^2\OZ_K4QK.+=HI:;M):^5UVZ_\
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M$/\ :$UBRWZ9\-=&7P5X0GECS&_C#QA [ZW>6<N#BXT7PG#)I]TA*_N/&,+
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M'@_1/A[X,\)> O#5N;3P[X*\-:'X3T*U)#-!I'A[3+72=.B=@%#R):6D0D?
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M(P0#6KX&\0IX1\;>#O%<L!NH_#'BGP_XADMEQNN$T75K34G@7<0N95MC&-Q
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M7PA82(W"36GAK3M+AN0JHKW:W$VQ6E85\^JK.RHBEF8A55069F8X"J!DDDD
M  DDX%92=VV=4(\L4NO7U>K_ ,C]\/\ @AG^SLGB3X@>/?VE-?L1+IOP\M7\
M!^!)9HPT;>,?$=BL_B;4K5ROR76A>%+BVTQANP\'C.0@%X@R_P!.]?)7[#/P
M&7]G#]ESX3_#.YM!:>)(?#\7B3QP"@6=O&WBL_VYX@M[A\ RMH]Q=IX>MI2J
MLUAH]FI4%<5]:UK%62^]^IR5)<TF^FR]%M]^_P PHHHJB HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _
MSEZ***YST#^L'_@A/_R:/\1?^SC?%W_JL_A#7[3U^+'_  0G_P"31_B+_P!G
M&^+O_59_"&OVGK>.R]%^1Q5/CEZA1113("BBB@ HHHH **** "BBB@ HHHH
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MWVINW._.S7*O1OJ%%%%>X>:%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %?IE^Q#\8H+G3I?@UK3^7>Z=_:FM^#KN6
M;3H(+G3IIX[S5O#D4&RVO;G4K:]N=1\0V[AM4GN=.GU?S6TZRT*V2Y_,VND\
M'^*]8\#>*-"\7:#-Y.K>']2MM2M-TEU'!<>2_P"_L+W[%<VES+INI6S3:?JE
MK'<P_;-.NKJT>01S/7%F&#CC<+4H-+FMSTI/[-6*?)+T=W&7]V4CHPM=X:M"
MHOA^&:_F@VN9?@FO-(_H<HKF_!_BO1_'/A?0O%V@S>=I/B#3;;4K3=):R3V_
MG)^_L+W[%<W=M%J6FW*S:?JEK'<S?8]1M;JT>0R0O725^:RC*$I1DG&46XR3
MW4D[-/S35F?7IJ24D[II--;--737J@HHHI#"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH ***YKQCXGL_!OAC6O$U\OF0Z39-.D&Z5/M=Y(Z6VGV
M/FPV]T\'VZ_FMK/[2;>2*V\_[1.!#'(PF<XTX2G.2C"$93G)[1C%.4I/R23;
M-:%&KB:U'#T(2JU\15IT:-./Q5*M6:ITX1O9<TYR45JM6CY[_:0^)J:3I;>
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#^3[_@NQ_R=Q\.O^S<O"/\
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M'X__ /#K_P#;R_Z-V\1_^%)X!_\ FLH<7?9OSLQQG&2O=+6R3:3Z=/F?5/\
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M2?"^D7NCZ7IGA#4+IU\)J(+_ %/5[J>74]'AM]?%S)>N6M]8MX2 8"S?Q_\
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MXU*>& ,0)+JY2W^SVD(R\]U+%#&K22*I[2OS7_X*E^$/V@?BA^S@OPA_9]\
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M\1_^%)X!_P#FLK.=W9)/OM_7F=%&RO)M)O1)M+M?[VT?!%?W(?\ !/+X"_\
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MSX6TZSU/QQXCN39RP&UU?7]/NYAX>T+2[-;6Z-NJ";7]6@C+!69OQR_X=?\
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MQ5J=K;:IXBL+Q8H;2U\.Z$?M%G&PNM%O9(7D@GC8_E1_PZ__ &\O^C=O$?\
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M,+C0?#MEK-]K&KZ-<)'X:TG^W;VVTK2=/M/#EH/%8>SMQJ!U&61VDUK?3O\
MY?KZD*5.+Y8\J;W:M;YO\DKZ]MS^>VOOC_@FA\!?^&@/VOOAGH=_9?;/"G@:
M[;XH^,U>/S+<Z-X+N+6[TZRND(V2VNL^*I_#VB7<3,N^SU&Y8;MA4I_PZ_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'*\']=QE.DU^[C^]K?\ 7N#5U_V_)QAY<U^AR8VO]7P\YKXW[E/_ !R3L_\
MMU)R^5CXGO;V\U&\N]0U"[N;^_O[F>]OKZ]GENKR]O+J5Y[F[N[F=Y)KBYN)
MG>:>>9WEFE=Y)'9V)-:BBOT=))62LEHDMDNQ\EON%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^D'["
M_P 5?^0Q\(]9O/\ GOXC\&?:;C_=_P"$BT&T^U:C_P!<O$&GZ7I6F_\ 0W:M
M?3_=K](*_GC\'^*]8\#>*-"\7:#-Y.K>']2MM2M-TEU'!<>2_P"_L+W[%<VE
MS+INI6S3:?JEK'<P_;-.NKJT>01S/7[\>#_%>C^.?"^A>+M!F\[2?$&FVVI6
MFZ2UDGM_.3]_87OV*YN[:+4M-N5FT_5+6.YF^QZC:W5H\ADA>OB.(<%['$QQ
M4%:GB?CMM&M%>]_X'&TO.2FSZ/*L1[2BZ,G[]'X?.F]O_ 7[ODG$Z2BBBOGC
MU0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OA+]I7XB1:[J\/@
M;3&WV'AJ]:YU>Y26SG@O=<:U$44$#1++-#_8D-S>V=T&N8F?4+J\M;FQ1],M
MYY?K7XC>,[?P%X/U?Q%*86NX(?LVD6LQ0B]UFZ!BT^#R6NK.2YACD)O+^*UG
M%TFEVM]<0JS08K\K;FYN+RXGN[N>:ZN[J:6YNKJYE>>XN;B=VEFGGFE9I)II
MI&:2661F>1V9W8L23\SQ%C73I0P5.5I5DIUK;JDG[L>ZYYJ[M9\L&G[LFG^L
M^%W#\<5BZV?8FGS4<#)T,"I7M+&3@O:UK;2^KT9J,>9-*I64XVJ44U#1117Q
MI^[A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% '3>#O$]YX-\4:+XFL5\R;2;U9W@W1)]KLY$>V
MU"Q\V:WND@^W6$US9_:1;R2VWG_:( )HXV'ZH^'M>T_Q/H>E^(-*D\VPU:RA
MO(,O \L/F+^]M;G[--<0QWME,)+2^@2:3[/>03V[.7C:OR(K[(_9>\=_\A'X
M?ZC<_P#/76?#?G3?3^V-*M_/O/\ <U>TL;"R_P"A@O[J7I7T7#V.='$/"3E^
MZQ#;A?:-=))?^#(QY/.2@C\O\3>'XX[+8YU0IWQ>614:[BFY5<OE-N2:6_U:
MK-UD]%&G/$-MZ6^R****^V/Y_"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#^3[_@NQ_R=Q\.O^S<O"/_ *LSXO5^+%?M/_P78_Y.X^'7_9N7
MA'_U9GQ>K\6*QG\3^7Y([:?P1]#]&O\ @DK_ ,I!?@!_W57_ -4G\2*_M.K^
M+'_@DK_RD%^ '_=5?_5)_$BO[3JN&S]?T1A7^-?X5^;"BBBK,0HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M_P I>O\ 5HK_ "EZ^XX,_P"9E_W)_P#NT?+\2?\ ,%_W,_\ N _JT_X-C/\
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M29OCLLFY26%KRC2J25G5P\TJF'JM62YIT9PE-1O&,W**;2NRBBBNH\@****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% '^<O1117.>@?U@_P#!"?\ Y-'^(O\ V<;XN_\
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M=H-N%WJ^6_F?6X*M[?#4IMWDER3[\T-&W_B5I:::V"BBBO/.L**** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?YR]%%%<YZ!_
M6#_P0G_Y-'^(O_9QOB[_ -5G\(:_:>OQ8_X(3_\ )H_Q%_[.-\7?^JS^$-?M
M/6\=EZ+\CBJ?'+U"BBBF0%%%% !1110 4444 %?G1^WSXUB6S\#_  YMY+:2
M::YN/&NK1/;W@O+6*WBN]"\/2079*6#6U^]UXG6[MU6XO$ETZRE8V4,B"_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5]A?LI>)7%QXG\'RO,T<D,/B73T6&W%O
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M****LQ"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ K_*7K_5HK_*7K[C@S_F9?]R?_NT?+\2?\P7_ ',_^X#^
MK3_@V,_YO<_[ML_][[7]6E?RE_\ !L9_S>Y_W;9_[WVOZM*\/B3_ )'6-_[E
MO_42@>IDO_(LPW_<;_U(JA1117AGJ!1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P"19AO^XW_J15"BBBO#/4"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** /Y/O\ @NQ_R=Q\.O\ LW+PC_ZLSXO5
M^+%?M/\ \%V/^3N/AU_V;EX1_P#5F?%ZOQ8K&?Q/Y?DCMI_!'T/T:_X)*_\
M*07X ?\ =5?_ %2?Q(K^TZOXL?\ @DK_ ,I!?@!_W57_ -4G\2*_M.JX;/U_
M1&%?XU_A7YL****LQ"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ K_*7K_5HK_*7K[C@S_F9?]R?_ +M'R_$G
M_,%_W,_^X#^K3_@V,_YO<_[ML_\ >^U_5I7\I?\ P;&?\WN?]VV?^]]K^K2O
M#XD_Y'6-_P"Y;_U$H'J9+_R+,-_W&_\ 4BJ%%%%>&>H%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% '^<O1117.>@?U@_\$)_^31_B+_V<;XN_]5G\(:_:
M>OQ8_P""$_\ R:/\1?\ LXWQ=_ZK/X0U^T];QV7HOR.*I\<O4****9 4444
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MH^OZ!J%SI>KZ9=:;XB\^ROK20Q3P2-%H\D3[74E)89)(94*RPR21.KM](5^
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /Y/O\ @NQ_R=Q\.O\
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M]VV?^]]K^K2O#XD_Y'6-_P"Y;_U$H'J9+_R+,-_W&_\ 4BJ%%%%>&>H%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1%3I*:UY;27^&5K_ */T1PX>7+5Y7IS7B_5:K\5;YG[15_/_ /\ !3OXF?\
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M2Q_%G_LIGCS_ -2G5:_7'_@DY_R)/Q@_[&GPS_Z:=0KHK?[NO2'Z'-0_C?\
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MI']*>#7_ "067?\ 87F?_J;6"BBBOAC]3"BBB@ HHHH **** "BBB@ HHHH
M*^]/V5KFW;P-KMHL\+7<'BRYN9K594-Q#;W6CZ-%:SRPAC)'#<R6=W'!*ZA)
MGM;E(V9H)0OP77V%^R7<VZW'CNT:>%;N>'PY<PVK2H+B:WM7UN*ZGBA+"22&
MVDO+2.>5%*0O=6R2,K3Q!O8R&?)F=%:6J1JP;;M;]U*:MYMP4;>?<^&\1J'M
MN$LPG>5\/5P5=**OS?[91HR3ZJ,85I3;6W+KI<^SJ***_0#^: HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MXL?^"2O_ "D%^ '_ '57_P!4G\2*_M.JX;/U_1&%?XU_A7YL****LQ"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ K_*7K_5HK_*7K[C@S_F9?]R?_NT?+\2?\P7_ ',_^X#^K3_@V,_YO<_[
MML_][[7]6E?RE_\ !L9_S>Y_W;9_[WVOZM*\/B3_ )'6-_[EO_42@>IDO_(L
MPW_<;_U(JA1117AGJ!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MWJMWJ?V/[7_PL*U^U?9?M7D?:/LUOYVSS/(BW>6O,_\ #I'_ *N!_P#,4_\
MXR:[U5HN$8RDGI&Z<9;JWEW//]C7C)RC%IW=FI1Z_,\5_P"'IW[0_P#T*OP?
M_P#"=\8?_-[1_P /3OVA_P#H5?@__P"$[XP_^;VO:O\ ATC_ -7 _P#F*?\
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M%C_P25_Y2"_ #_NJO_JD_B17]IU7#9^OZ(PK_&O\*_-A1115F(4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M?Y2]?ZM%?Y2]?<<&?\S+_N3_ /=H^7XD_P"8+_N9_P#<!_5I_P &QG_-[G_=
MMG_O?:_JTK^4O_@V,_YO<_[ML_\ >^U_5I7A\2?\CK&_]RW_ *B4#U,E_P"1
M9AO^XW_J15"BBBO#/4"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M K^;^OZ0*^3XH_Y@?^YG_P!USW,F_P"8G_N#_P"Y0HHHKY,]P**** "BBB@
MHHHH **** /C?]K7_FG_ /W-?_NMU\;U]D?M:_\ -/\ _N:__=;KXWK\]SS_
M )&F*_[@?^HU$_ISP\_Y(_)_^ZA_ZM,:%%%%>2?:!1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MA[_D8Q_Z\U?RB>=FG^Z2_P =/_TH^)Z***^\/F HHHH **** "BBB@ HHHH
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M +JK_P"J3^)%?VG5<-GZ_HC"O\:_PK\V%%%%68A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5_E+U_JT5_E+
MU]QP9_S,O^Y/_P!VCY?B3_F"_P"YG_W ?U:?\&QG_-[G_=MG_O?:_JTK^4O_
M (-C/^;W/^[;/_>^U_5I7A\2?\CK&_\ <M_ZB4#U,E_Y%F&_[C?^I%4****\
M,]0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_)]_P78_Y.X^
M'7_9N7A'_P!69\7J_%BOVG_X+L?\G<?#K_LW+PC_ .K,^+U?BQ6,_B?R_)';
M3^"/H?HU_P $E?\ E(+\ /\ NJO_ *I/XD5_:=7\6/\ P25_Y2"_ #_NJO\
MZI/XD5_:=5PV?K^B,*_QK_"OS844459B%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7^4O7^K17^4O7W'!G_
M #,O^Y/_ -VCY?B3_F"_[F?_ ' ?U:?\&QG_ #>Y_P!VV?\ O?:_JTK^4O\
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M?:VUC8V6@^ K2RLK."*VM+2UM_!6APV]M:VT"I#;V\$2)%##$B1Q1JJ(JJH
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M_?\ PGK1ED6/H7DYTLUJ5&G>T:=;"81047MK.E5;2V>OV@HHHKYT_40HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?J)\6%%%% !1110 4444 %%%% !1110 4444 %%%% '\V_\ P44_Y.O\>_\
M8)\$?^H=HM>__P#!)_\ Y*+\5_\ L2M'_P#3Z*\ _P""BG_)U_CW_L$^"/\
MU#M%KW__ ()/_P#)1?BO_P!B5H__ *?17?4_W5?X*?YQ//C_ +R_^OD_SD?N
M3117PU_P4"U7XI>%_@:GC7X6>*_$'A:\\+^)M,E\43>'[R2RN)_#&JQ7.E22
M/+"IN!]DUNYT5]T3Q^5!+=32.$C)'%&/-)1NE=VN]M3NE+EBY6;LKV6]EO\
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M+;\6_P#LED'_ *ENB5_1_7B^(W_)58S_ +!\%_ZC0/I?!G_D@\O_ .PS,O\
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MB,*_QK_"OS844459B%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7^4O7^K17^4O7W'!G_,R_[D__ ':/E^)/
M^8+_ +F?_<!_5I_P;&?\WN?]VV?^]]K^K2OY2_\ @V,_YO<_[ML_][[7]6E>
M'Q)_R.L;_P!RW_J)0/4R7_D68;_N-_ZD50HHHKPSU HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M06TL-N681 U\Q_L7_P#!/_P#^RG ?%6J7L/CSXOZA9/:7OBZ6S-OIGAVTN4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110![O^SAI5QJ'Q2TR[A>%8M"TS6=5NUE9U>2WFL9-
M$5+8)&ZO,+O6;61EE:%!;QSN)#(L<4OZ,U\B?LHZ#LT_Q9XGECLG^U7MEH-E
M-LW:A;_88#J&IQ^8T(\FRO/[1TAMD5PWVB>QW7$*?9;9W^NZ^^R"BZ674Y/1
MUZE2M;LFU3C]\:<9*W1][G\V>)..6,XIQ%.+3C@,-AL#&2M9N,98JHO6%7%5
M*;OK>#6R04445[1\$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJ=1\S4N6)1117OGYL%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?R?
M?\%V/^3N/AU_V;EX1_\ 5F?%ZOQ8K]I_^"['_)W'PZ_[-R\(_P#JS/B]7XL5
MC/XG\OR1VT_@CZ'Z-?\ !)7_ )2"_ #_ +JK_P"J3^)%?VG5_%C_ ,$E?^4@
MOP _[JK_ .J3^)%?VG5<-GZ_HC"O\:_PK\V%%%%68A1110 4444 %%%% !11
M10 4444 %%%% !1110 5_-%\>/\ @W:_X7;\<?C-\9O^&P?^$9_X6Y\5_B)\
M3O\ A&_^&?O[:_X1_P#X3[Q?K'BK^P_[8_X7;I/]K?V3_:WV#^TO[+TW[?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3333335TTUHTUJFM&@HHHH&%%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '\GW_!=C_D[C
MX=?]FY>$?_5F?%ZOQ8K]I_\ @NQ_R=Q\.O\ LW+PC_ZLSXO5^+%8S^)_+\D=
MM/X(^A^C7_!)7_E(+\ /^ZJ_^J3^)%?VG5_%C_P25_Y2"_ #_NJO_JD_B17]
MIU7#9^OZ(PK_ !K_  K\V%%%%68A1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 ?YR]%%%<YZ!_6#_P $)_\ DT?XB_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 ?R??\%V/^3N/AU_V;EX1_\ 5F?%ZOQ8K]I_^"['
M_)W'PZ_[-R\(_P#JS/B]7XL5C/XG\OR1VT_@CZ'Z-?\ !)7_ )2"_ #_ +JK
M_P"J3^)%?VG5_%C_ ,$E?^4@OP _[JK_ .J3^)%?VG5<-GZ_HC"O\:_PK\V%
M%%%68A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 ?YR]%%%<YZ!_6#_P0G_Y-'^(O_9QOB[_ -5G\(:_:>OQ8_X(3_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5]E&Q1117D'<%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MTXSA*=.<)R****P/1"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI2K46[*M2;>B2J0NWVW/I>BBBL#4**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU,/-PJ1MORR5^6:[Q?7=76Z>C284445U& 4444 %%%% !1110 4444 %%%%
M!1110 445[9\'?@-XY^,VHI_8=I]@\+VNI0V&O>+KT1C3M)WP/=S1VML\]O<
MZWJ4=LL>W3=.W^3/>Z7_ &O=:18W\>H+G5K4J%.56M.-.G%7E*;LEV2ZMMZ1
MBKRD[))MI%PISJ24*<7.4MHQ5WZ^26[;LDM6TCB?A[\/?%'Q/\46/A+PE8_;
M-2O,RSSREXM.TG3HGC2[U?5[M(Y?L>FV?FQB641RSSSRV]A86]YJ5Y965Q^V
M'P=^#OA?X,^%TT'04^V:E>>3<>)/$EQ"D6H^(-1B1U6655>7['IMGYLT>D:1
M'-+!IT$LSO+>:E>:GJ=_M_#OX8^"_A;H<&A>#]&MK!%MK:#4-5>&W?7->EM6
MN9$O=>U2.&&;4;D37MY+"CA+/3UNI+32[2PL%AM(N_KX7-<WGCY>RI<U/"Q=
MU%Z2JR6TZEM$E]F%VD_>;<K<OTN"P$<,N>=IUFM9=()[QA?J^LM&UHDE>Y11
M17BGH!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 0W-M;WEO/:7<$-U:74,MM=6MS$D]O<V\Z-%-!/#*
MK1S0S1LT<L4BLDB,R.I4D'X8^,7P!_X1:SF\4>"EO;W0X//GUG2)W^U7FC0&
M625;RQE"+-=Z-:0LL%REP;C4-/BA%_=75]:R7MQIOW;17%CL!0Q])PJQM-)^
MSJI>_3;L[KO%M+F@])+L[27T'#W$F8\.8N.(P=1RH3G!XO!3DU0Q5.-URS5G
MR5(QE+V5:*YZ<GJIP<Z<_P ;Z*^[OBI^SMI^O?:->\"QV6B:K%9'S/#D%M!:
M:1K$\'E+#]C9)(+;1+V2V66-\0MI]]=+:O<?V;))J&I3_#VH:=J&DWDVGZK8
M7NF7]OY?GV.H6L]E>0>;$D\7G6US''-'YD,D<T>]%WQ2)(N4=2?@L=E^(P%3
MDK1O"3?LZL=:=1+L]XR76$K26Z3BU)_TAP_Q-E?$>&]M@:O+7IQ3Q."JVCB<
M-)V7O1VJ4FVN2O3YJ<K\K<:JG3A2HHHKA/H HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH ***]]^%OP&USQUC5=<:]\->&T^R2P3RV3+J&NQ3^1<D:1%<
M^4D=E)82%XM<ECNK/SY;=;2TU,)?+9[X?#5\545*A3=2;[:**ZN4G:,4K;MK
M717;2//S/-<OR?"SQF8XF&&H0LKRO*<Y-I*%*E!2J59MM>[3C)I7E*T(RDN!
M^'?P[USXCZXNE:4OV>RM_+FUG69HF>STFS=F"NZAD^T7MQLD33]/21);R5)&
M:2WLK>]O;3]&? ?P\\-_#K2Y=,\/P3%KJ8SW^I7SQ3ZIJ#J9/LZW=Q#!;1&&
MSCD:&TMH((+>$--,(C=W5Y<7&_H/A[0_#&GQZ5X?TNRTFPCV'R+.%8O.E2"&
MV^TW4O,U[>R0V\*3WUW)/>7'EJUQ/(XW5LU]UEF4TL!'GERU<2[\U6SM!/3E
MI)_"K:2E92E=WM&T5_.W%O&N-XDJNA1]I@\I@XNG@^9<]>46I>VQDH.U27.E
M*G23=*ERQ<5*HG5D4445ZY\0%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&J6\.HP6.IZC9PWB31VU]=PJEQ)_I^5_/Q_Q#>?L._\ 15/VK?\ PN/A#_\
M.,KZ3AW,L'EL\74Q3J*56-&%+D@YJR=1U.9*UG?V=OF>+G."Q.-CAXX=0:A*
MI*?-)1U:@H6OOISW^1_$]17]L/\ Q#>?L._]%4_:M_\ "X^$/_SC*/\ B&\_
M8=_Z*I^U;_X7'PA_^<97U/\ K3E/\]?_ ,$2_P SPO[!S#^6E_X-7^1_$]17
M]D'Q(_X-JOV<M4T.TM_A!^T/\;/ WB5-6@FOM6^)&E^!/BKH=QH:V=\ESIUI
MX>\,:-\&[^SU::_DTRY@UF;Q/?V=O9VE]8R:#=3:C;ZAI?B?_$,9_P!7N?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MXL?^"2O_ "D%^ '_ '57_P!4G\2*_M.JX;/U_1&%?XU_A7YL****LQ"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ K_*7K_5HK_*7K[C@S_F9?]R?_NT?+\2?\P7_ ',_^X#^K3_@V,_YO<_[
MML_][[7]6E?RE_\ !L9_S>Y_W;9_[WVOZM*\/B3_ )'6-_[EO_42@>IDO_(L
MPW_<;_U(JA1117AGJ!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_G+T4
M45SGH']8/_!"?_DT?XB_]G&^+O\ U6?PAK]IZ_%C_@A/_P FC_$7_LXWQ=_Z
MK/X0U^T];QV7HOR.*I\<O4****9 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '^<
MO1117.>@?U@_\$)_^31_B+_V<;XN_P#59_"&OVGK\6/^"$__ ":/\1?^SC?%
MW_JL_A#7[3UO'9>B_(XJGQR]0HHHID!1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_.7HHH
MKG/0/ZP?^"$__)H_Q%_[.-\7?^JS^$-?M/7XL?\ !"?_ )-'^(O_ &<;XN_]
M5G\(:_:>MX[+T7Y'%4^.7J%%%%,@**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@#\S_\ @I;^PGI'[7?PFO?$'@OPWILG[1W@'38W
M^&^N-J=KX>D\2Z1#J2WNL?#CQ%J5S:3V6HZ;J-E/J]WX,CUB?2[70/'-Q:W
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M(,]Q$J?!&.Q>(3639]7FG'A]2KS2AEN?5)3674:4FZ.?3IX>AAJKSJM6PO\
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M8;_N-_ZD50HHHKPSU HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _SEZ*
M**YST#^L'_@A/_R:/\1?^SC?%W_JL_A#7[3U^+'_  0G_P"31_B+_P!G&^+O
M_59_"&OVGK>.R]%^1Q5/CEZA1113("BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;P]G-<09/RX7'5IQ3E37]H4UA\VIJG*450S"E&4:52-2A2****]D_;@HHHH
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M 4444 %%%% !1110 4444 %%%% !1110 4444 ?YR]%%%<YZ!_6#_P $)_\
MDT?XB_\ 9QOB[_U6?PAK]IZ_%C_@A/\ \FC_ !%_[.-\7?\ JL_A#7[3UO'9
M>B_(XJGQR]0HHHID!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MXURC^QY.K2ISQ%7'8+,\/C<#&-1.5>%3!1J8Z=&ARUD\NIXAS]A0KPG\=_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT,/2>74*E.I7ISP^48'"X/+?:4:T\/B\5A\7F-"-*..=.)1117NG] !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *S=9UG2/#ND:KX@\0:KINA:!H6FWVLZYKFLWUKI>D:-I&EVLM[J6JZKJ5
M[+!9:=ING64$]W?7UW/#:VEK#+<7$L<4;N/ OVE?VL/@=^R7X0M?%WQH\6_V
M-_;/]L0>$?#&EV5QK/B_QMJ>C:9)J=SI?AS1;0?]>6GSZ]K=SHWA#1]3UG0;
M3Q%XCT;^V=/DG_DT_;3_ ."F7QQ_;"^W^$<?\*M^!]U_PCT__"I-#U&WU?\
MM74]"\Z[_M3QEXT_L30]9\4^=K-Q_:%KH/V;2O"%A_9'A6[_ .$<NO%&@?\
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M:GBG2D\+@*6"P\\9+,"BBBOK3^Q@HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!_G+T445SGH']8/_!"?_DT?XB_]G&^+O_59_"&OVGK\6/\
M@A/_ ,FC_$7_ +.-\7?^JS^$-?M/6\=EZ+\CBJ?'+U"BBBF0%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.<9DJ=.MCJM)XBM'#PDHX;!TJDJ&"H8;#VI(HHHKT#]&"BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#^3[_@NQ_R=Q\.O^S<O"/\ ZLSXO5^+%?M/_P %V/\ D[CX=?\
M9N7A'_U9GQ>K\6*QG\3^7Y([:?P1]#]&O^"2O_*07X ?]U5_]4G\2*_M.K^+
M'_@DK_RD%^ '_=5?_5)_$BO[3JN&S]?T1A7^-?X5^;"BBBK,0HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_
MREZ_U:*_S+OVO/V6_B)^QS\??'GP+^(NG:M%-X<U:^G\&^)]1TF+1[/XD_#N
M?4[^V\'_ !(T&WM=5UZP72?%5A9-/-8V>O:Q+X:UR#6O!VM7<7B7PYK=C:?:
M\&U(*ICZ3DE4G'#3A!O64:;KJ;7=1=2%_P#$O,^9XDA-PPE11;A"5:,I=(RF
MJ3BGVYN25O1G] __  ;):]H=OKG[9?ABXUG28/$NL:3\!=>TGP]-J-G%KFJ:
M'X<O/B_I_B'6=.TEYEO[W2=!O_%7ABQUK4;:WEL]+O/$>@VU]-!-K&GI<?UE
M5_EA>"/'GCGX9>*-+\<?#?QGXK^'WC31/MO]C>+_  1XBU?PGXHTC^TM.N](
MU'^R]?T&\L-6L/M^DW]]I=[]DNXOM6G7MW93^9;7,T3_ +#?LZ_\%[/VZ?@M
M_9&C?$'6?"G[1O@NP_X0O2Y;'XG:,EAXYM/"_ACS+35[30_B1X0.B:M>^*_%
MFDR1PZEXW^*>G?%C45U>PT_7I[*_N9M?@U_HSOAW%XW%UL;A:E*;JJGS4:C=
M.:=.G"E:$K2A)-04O?=.UVM;*^.5YQ0PV'IX6O"<5!SM5BE.-ISE4]Z-U)6<
MFO=4MD[:NW]V]%?S;_#?_@Y5_9RU30[NX^+_ .SQ\;/ WB5-6GAL=)^&^J>!
M/BKH=QH:V=B]MJ-WXA\3ZS\&[^SU::_DU.VGT:'PQ?V=O9VEC?1Z]=3:C<:?
MI?Z,^"/^"Q/_  37^(/BC2_"&@_M4>%+#5M7^V_9+OQQX3^)GPR\+Q?8-.N]
M4G_M3QO\2/!/A/P7HGF6UE-%9?VUK]A_:6HO::1IWVK5K^QLKGY2MD^:8>_M
M,#B+)2;E3INM!**3;<Z/M()).]VTG9V>CM[]/,<#5MR8JC=VLIS5.3<M$E&I
MR2;OT2NM+K5'Z7T5XG\-_P!I;]G+XR:Y=^&/A!\?_@G\5?$MAI,^O7WA[X;_
M !5\">.=<L]#M;RQT^YUF[TGPQKVJ7]OI-O?ZIIEC/J,UNEG#>:C8VTDRS7=
MNDGME>?.$Z;Y9PE"6_+.+B[/9V:3U.N,HS5X2C);7BU)7[73:"BBBI*"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH _SEZ***YST#^L'_@A/_P FC_$7_LXWQ=_ZK/X0
MU^T]?BQ_P0G_ .31_B+_ -G&^+O_ %6?PAK]IZWCLO1?D<53XY>H4444R HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** /QD_X+HZSJ^E_L=^$K+3=5U+
M3K+Q%\??!FC>(+2QOKJTM==TB#P3\2O$$&E:S;V\L<6J:;#K^A:'KD5C>I/:
MQZOHVE:DD0O=.M)X?Y(J_M:_X*P_"/\ X6U^P[\6?L7A_P#X2#Q)\,_[$^+G
MAK_B;?V5_8G_  AFH)_PF_B#][J6FV&I?V;\*=2^(/\ Q*;_ .W_ &SSO^)1
MIMUXDCT3R_XI:_(>.:52&<PJ2NX5L'1E3?O62A.K"4+M)<RE'F<8MV4XR=G*
MQ_B[]/S*\PP?C=@\PQ2G/ YQP5DM;+*J]O*E"&#Q>:8'%83GJ4X48XBEB:,\
M55P^'G55.CC\+7J.-3%."_M(_P""06C:1I?[ 'P7O=-TK3=.O?$6I?%'6?$%
MW8V-K:76NZO!\5O&GA^#5=9N+>*.75-2AT#0M#T.*^O7GNH](T;2M-2466G6
MD$/Z85_//_P1%_;#L=2\/7/[&WC.;[/K/A[_ (2CQM\'M5N;WP]8V.I>'KR^
M@UGQ7\.K2Q$6FZSJ7B33=9U+Q%\0M/F63Q/?:EX>OO%PNG\/:-X%TV+4OZ&*
M_0^'<30Q62Y?*A)-4<+1PU56LX5Z%*%.K%KNY+G3^U&49_:/]+/HT<3Y#Q3X
M&^&U?(*\*M/)>%,DX8S6DJ:HU,)GW#^5X/+LWH5J2^&<\52EC*51ZXK"XK#X
MS;$(****]L_=@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@#^3[_@NQ_P G<?#K_LW+PC_ZLSXO5^+%?M/_
M ,%V/^3N/AU_V;EX1_\ 5F?%ZOQ8K&?Q/Y?DCMI_!'T/T:_X)*_\I!?@!_W5
M7_U2?Q(K^TZOXL?^"2O_ "D%^ '_ '57_P!4G\2*_M.JX;/U_1&%?XU_A7YL
M****LQ"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGA&\M;'Q#-X*\3O WAKQSI.G37^G.=>\'ZMKFAW-GJFDZA9ZC<6&JZ?<W/\
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MVBY*,*:^:IJ*?J[LVCF./@FEBZ[OK[U24W\G-R:]%H?T#_\ $2'^W%_T2O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M '57_P!4G\2*_M.JX;/U_1&%?XU_A7YL****LQ"BBB@ HHHH **** "BBB@
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MJ%S<^_FG$>'RZM/"QH5*^(IJ#FN94Z47.,9Q3FU.4GR24FHT^751Y[\W+Y.
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M\3^&/V3?V:/#GB7PYJVG:]X>\0Z#\"/A;H^N:#KFCWD.H:3K.C:MI_A6WO\
M2]6TN_M[>^T[4;&X@O+*\@AN;::*:)'7Z7HHKGG4J5&G4J3J-:)SG*32[+F;
MM\C:,(034(1@GJU&*BF^[LD%%%%04%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ML?\ )W'PZ_[-R\(_^K,^+U?BQ6,_B?R_)';3^"/H?HU_P25_Y2"_ #_NJO\
MZI/XD5_:=7\6/_!)7_E(+\ /^ZJ_^J3^)%?VG5<-GZ_HC"O\:_PK\V%%%%68
MA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5_E+U_JT5_E+U]QP9_S,O^Y/\ ]VCY?B3_ )@O^YG_ -P']6G_
M  ;&?\WN?]VV?^]]K^K2OY2_^#8S_F]S_NVS_P![[7]6E>'Q)_R.L;_W+?\
MJ)0/4R7_ )%F&_[C?^I%4****\,]0**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MCGKRU4>VK]7M]VOWA1116A@%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_G+T445SGH
M']8/_!"?_DT?XB_]G&^+O_59_"&OVGK\6/\ @A/_ ,FC_$7_ +.-\7?^JS^$
M-?M/6\=EZ+\CBJ?'+U"BBBF0%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&EZ'I-I\.-=U^34O$&H_"_[8?_!*;X__ +*]C-XST&7_ (7C\*8?MLE]XO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH _SEZ***YST#^L'_@A/_R:/\1?^SC?%W_JL_A#7[3U^+'_  0G
M_P"31_B+_P!G&^+O_59_"&OVGK>.R]%^1Q5/CEZA1113("BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OS/_:^_P""6G[.
M_P"U):ZIX@T/2]-^"OQCU'4K?4I_B?X.T!9[76Y)=7U35?$!\;^!+35O#V@>
M+=2\1RZYJ5W?^+'GTOQQ+J\&AW%[XHU'0]+N/#FI_IA17+B\%A<?1E0QE"G7
MI237+-:QNK<T)JTZ<^TZ<HS6ZDF?*<8\#\(^(.2XCA_C/A_+>(<IQ$)QEAL?
M1YIT)U(.F\1@<72E3QN6XV,6_98[+\1A<;0=I4:].24E_"9^U7^PG^T1^QY=
M6$WQ9\-Z;=^#]:U(:-X?^)/@S4VU[P/K6KC2+76)]*6YN+32]?T+4HXIKZWM
M;'Q=X?\ #MUKLF@^(KOPU%K6D:-=ZFGQU7^C-K.C:1XBTC5?#_B#2M-UW0-=
MTV^T;7-#UFQM=4TC6=(U2UELM2TK5=-O8I[+4=-U&RGGM+ZQNX)K6[M9I;>X
MBDBD=#^('[8?_!%7X>_%&^F\;_LMZEX;^"WBN?[;/K/P^UJ'6Y?A?XEU/4_$
M,5_+JFF7MB^LZE\,O[/TV^UF*/0?#GAK6_"%U#8>&-$T/PYX)@M]5U>__.,W
MX(KT>>OE,WB*2][ZI5:6(BM+JE4?+"LEJU&7LZBBE%.M4UE_F%XT?0*S[)?K
MV?\ @]C:O$F5P_?O@_-:U"EQ%A:;Y76AE6926&P&<TJ-ZE6EAL2L!F2PT(8:
MC/.<>XRQ'X7_ +,?_!07]J#]D_[-I?PY\<_VYX"M_._XM5\08KOQ3\/4\[^W
M[C_B4:=_:&GZSX.W:SXCOO$=_P#\('KWA;_A(=;ALI_%']N6EO\ 8W_JG_8\
M_P""C'P _;"L8=*T'4O^%>?%:'[%;7WPE\;:KHUOXAU6^;P]+KNJW?PZN(KQ
M?^%A^&]+_L[Q!%-J&GV.G>(;"QT-]9\4^$?"UAJFC-?_ ,;7QJ^!?Q9_9V\<
M3_#CXS^"M2\"^,(--T[64TV^N--U&UO](U6-WLM5T;7-#O=4T#7=-DEAN["6
M^T75+^UM=7T[5=$NY8-7TG4K*T\FKQLKXCS3(ZCP]55*U"G+DJ8'%.<)47&Z
M<*4IQE/#23WAR.G>[E2<M5^'>$OTFO%KP$S.?#>:T\RSOA_*\0\#F/ /%E7'
M8+%9/+"\].I@LIKXVC7QW"^(HU&U4P:P=; JISRKY7.N_:1_T>**_E&_9!_X
M+2_%GX7W6E^#OVG8]2^,OPUM--N+.'Q=I6GZ:?C/HLEEI&EV7A^&6_N]6\/Z
M!X]TWS=*G76;GQ7);^.+^_\ $5]XFU'QYK+:5;^&]3_IR^%7Q?\ A?\ '#PA
M9^//A'XZ\-_$#PI>_9X_[5\.:C#>_P!GWUQIFG:S_8NO6.4U+PWXDM--U;3;
MG5/#'B"STSQ#H_VV"'5M,LIW\H?J64Y[E^<0;PM1QK12=3#5;0KPTU:BFU."
M>G/3<HIZ2Y6['^MOA!X_^'/C5@9UN%,TGALXPT(RS#AC.%1P>?8).*E*K'"Q
MK5J>/P2=U]>R^MB</!VAB)4*S]BO1Z***]@_; HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@#^3[_@NQ_R=Q\.O^S<O"/\ ZLSXO5^+%?M/_P %V/\
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M!ZF2_P#(LPW_ '&_]2*H4445X9Z@4444 %%%% !1110 4444 %%%% !1110
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MLXJDN:;:VV7HO\W=_,****H@**** "BBB@ I&945G=@JJ"S,Q"JJJ,EF)P
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M,6@>*=/9ES\FH^'-4U2R8E6"^?OV,5 K^]NMH.ZUW7]:G)5@HRTT36W9K?\
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M:?:XT8?8?"F@:MJFH6?AS1K=I)-GEF?5M09O-U74;E([*UL?H^BO/_BE\4O
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M$!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110!_G+T445SGH']8/_!"?_DT?XB_]G&^+O\ U6?PAK]I
MZ_%C_@A/_P FC_$7_LXWQ=_ZK/X0U^T];QV7HOR.*I\<O4****9 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M98B<L/0IY7B'@L%C?WCHHHK[L_T'"BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-G9P06L$,*4I<JLMWU[?\'R\_5&4H<\[R^&.R[O=_+H_33N>H_M%_M+?%O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH^)-7UG_ (23^V6\ V%YHUWHW@7P[XD_H8K_ #AZ_M:_X)F_MI_\-A? X_\
M"77_ -J^.'PM_L[0_BWY'A[^PM,U7^U[C6_^$+\9:7]DFN-&F_X2G1M#N?[>
MM=/_ +(^P>+]*\1_9/"N@>%[KPK]O]K@[B">*BLJQD^:O2@Y82M*5Y5J4$W.
MC-R=Y5:4?>@U=SHQGS6=+FJ?NWT)_I'8OBZA#PAXWQWUCB#*L!.MP9G&*KN>
M+SW*\%"I5QF2XR=>JZF)S3)\)%8G 5*2J3Q>2X?%O$QI3RB6(Q_Z/4445]\?
MZ)A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!_)]_P78_Y.X^'7_9N7A'_P!69\7J
M_%BOVG_X+L?\G<?#K_LW+PC_ .K,^+U?BQ6,_B?R_)';3^"/H?HU_P $E?\
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MU\#>#YY8\QOXN\70&;7KRTDP=MSHGA2$:?<J2H-MXR0@.<E/P6K^Y7_@GO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _P Y>BBBN<]
M_K!_X(3_ /)H_P 1?^SC?%W_ *K/X0U^T]?BQ_P0G_Y-'^(O_9QOB[_U6?PA
MK]IZWCLO1?D<53XY>H4444R HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P!QO_4BJ%%%%>&>H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5_%#_P %0?CU_P +Z_;!^(U]
MI][]K\)_#>5/A3X1*2>9;M9^#[B[AUZ^@93Y4T6J>,+KQ%?6MU&,3Z;+IZ[Y
M4BC<_P!7/[:GQUC_ &<?V8_BS\5(KE+?7M+\-SZ1X,#%=\OC;Q*Z:#X7:.(_
M-<+8:I?PZO>0IAO[.TZ]D+(D;2+_  ?R22322332/++*[R2RR.SR22.Q9Y)'
M8EG=V)9W8EF8DDDDFLYO9?-_U_6QT4(ZN7;1?F_T^\9117LG[//PAU7X^?&[
MX8?![1_.2Y\>^+M+T6[NH%#R:9HGFF\\2:R$*L&31/#UKJ>KR@JV8[)QM/0Y
M[G0W9-O9:L_JH_X([_ 7_A4/[)>E>-=4LOL_BKXYZK)\0+UY8]EU%X4A1M*\
M"V+-@"2TFTJ&Z\461^8A?%<H+?P)^KE96A:)I7AG0]&\-Z%90Z;HGA_2M.T3
M1M.MUVV]AI6DVD-AI]E I)*PVMI;PP1+DX2-1DUJUNE9)=C@D^:3;ZO_ (;[
MD%%%%,04444 %%%% !7SI^UK\;[7]G/]G3XL?%^66%-0\+>%;M?#,,^UDO/&
M.LO'H?A"T:)LF6&7Q%J.G->*BNR6*74Y4QPN1]%U_.C_ ,%V_CULA^$_[-NC
M7OS2M+\5_'$$,F"(XS?^'? ]C.8SRKR?\)5J5S9S'AH=$O/+.8) I.R;+A'F
MDEYW?HM7_D?SFW=W=7]W<WU]<37=[>W$UW=W5Q(\UQ<W5S(TUQ<3RR%GEFFE
M=Y)9'8N[LS,2235>BBL#M/MC_@GE\!?^&B?VM/A7X*OK+[;X5T/51\0/'*/'
MYMJ?"G@MX=5N+&]7!/V3Q!JJZ3X7D(P5;7$(9,;U_N0K\&O^"%_P%_X1OX6?
M$3]H76++9J?Q)UD>"O"$\T>)$\'^#YV?6[RSDP,VVM>+)I-/ND);_2/!L) 4
M9+_O+6T%9>NO^7]>9R5I7G;I'3Y]?\OD%?F1_P %:OCU_P *4_9 \7:/IE[]
MF\6?&6YC^%FAK')MN(])UFWGNO&M[L4B0VR^$[34M'>=646]]KNG,22ZH_Z;
MU_(Y_P %I/CU_P +._:?M/A;I-[]H\,_ G0$T&1(Y-]O)XX\4)9ZYXMN8V4[
M2]K9)X;T"XC*E[>_T._0M\Q523LG]R%2CS379:OY?\&Q^/5%%%8G8?L9_P $
M5_@(/B9^TWJ'Q6U:R^T>&O@5X?;6;=Y8]]O)XZ\5I>:)X6@=6&QFL].C\3:[
M#(K&2UU#2=-E"@NKK_6Y7YG_ /!)OX"_\*2_8_\ !FI:E9?9?%GQBGD^*NOF
M2/;<1Z=KMO;V_@RR+L!*((_"-II.I_9G51;:AK&IJ%W2.\GZ85M%62\]?O..
MK+FF^RT7R_X-PHHHJC,_'K_@M)\>O^%8_LP6GPMTJ]^S^)OCMX@309(XI/+N
M(_ _A=[/7/%MRC*=P2ZO7\-:!<1E0EQ8:Y?H7PK(W\CE?IO_ ,%:OCU_PNO]
MK_Q=H^F7OVKPG\&K:/X6:&L4FZWDU;1[B>Z\;7OEJ3&+EO%EWJ.CO.A8W%CH
M6G,6 143\R*QD[M_<CLI1Y8+N]7\_P#@6"OW?_X(8_ 7_A)_BS\0?V@M8L]^
ME_#'1%\'^$II8_D?QEXS@D&KWEI+@_O]$\)07-A=H2O[GQA;,-V#M_""O[B?
M^"=?P%_X9X_9)^%G@^^LOL7BKQ%IG_"Q/'*/'Y=R/%'C2.#4WLKU,#%WH&BC
M1?#$V,@G1 0S9W$@KOTU_P OZ\A5I6A;K+1>G7\-/F?;]%%<;\1?'6@_##P#
MXT^(WBBX^S>'? OA?7/%FLR@J'_L[0=-N-2N8X Q DN9X[<P6L(R\]S)%#&K
M/(JG8Y#^7S_@M[\>O^$Z_: \+?!'2+WS="^"WAT76MQ129BD\>>.(++5;V.4
M(3'/_9?A>#PU% S%I+.[U#6;;$3-,'_$RNY^)WQ U[XK_$7QQ\3/$\OG>(/'
MOBK7?%FK$,S1Q7FN:C<:A):V^[E+.S$ZVEE" J06D$,,:HD:J.&K!N[;[G=&
M/+%1[+\>OXA6KH6A:WXGUG3/#OAO2-2U[7]:O;?3='T71[*YU+5=4U"[D6*V
MLM/L+..:ZN[JXE98X8((GDD8@*I-=M\'/A-XQ^.OQ/\ !GPD\ VMM=^+?'.L
M1Z/I*WLTEO86Q$,UY?:CJ5Q%#<RV^F:3IMK>:IJ4\-M<316-G<216\\BK$_]
MBW[$O_!.[X1?L=Z/!K,,<'COXRZA9>3X@^)FJV,:2V*SQ[;K1O!.GRM/_P (
MWHA!:*XF2636=9!9M4OFM/LFF6#47+T[BG44%KJ^B_K9?TCX0_8(_P""/VD>
M"_[%^+G[5^FZ?XB\6K]GU+P[\'':#4?#?AJ4;9H+OQW+&TMGXEUJ-MI7P[ \
M_ANP*M_:4NO33"WTS\9_^"CWA*/P5^V_^T9HL4"6T4_CL>)8H8XQ%&J>-=#T
M?QDIC10JJC_V]O4* N&XK^XZOY!/^"U7A;_A'_VU[W5Q%L'CCX7> O$Y?&!,
MUF-8\%E\_P 15?"*1$]0$4=,54HI+1;=?\_G8RI3<JC;>\79=-U_P3\DJ[WX
M5>,9/AY\4/AOX_B9TE\#>/?!_C"-X\^8K^&?$.G:TK)CG<&L@5QR3C%<%169
MT;G^C+%+'-''-"Z2Q2HDL4L;!TDCD4.CHRDJR.I#*P)# @@X-/KY^_90\:_\
M+%_9D^ /C5Y?/NO$'PA\ 7>I2;MW_$YC\-:=:ZVA;^(Q:O;WL18X)*98 Y ^
M@:Z%JD^YY[T;78*_G-_X+Z^*9@O[-'@F&1A;NWQ-\4ZA#N.V2:(>#-)T>3:#
MC="DVN+N()Q/A2/G#?T95_,S_P %\;*XC^(/[.>I,K?9;OP;X^LH6(^4W&GZ
MWX>GN5!Z%ECU.U+#L&4GJ*F?POY?FC2DOWB^;_!_\/\ (_G]HHHK$[#]Q?V,
M_P#@D5X<_:=_9Y\%?&_Q+\7_ !'X+NO&EUXG-EH.E^%M,U2WAT[0/$^K>&8;
ME[N\U2UF:6\GT:YN0GDJ@ADA*%@VX_4G_#@[X=?]'%>-?_"%T+_Y>5]W?\$I
M?$&G:_\ L&_ O[!)&TNB6WC3P_J<"$%[34=.^('BDM',!PLEQ:3V>HJ#R8+V
M%SRQK]$:U48M+3HNK_S.652:E)7LDVEHMKZ=#\ /^'!WPZ_Z.*\:_P#A"Z%_
M\O*/^'!WPZ_Z.*\:_P#A"Z%_\O*_?^BGR1[?B_\ ,GVM3^;\(_Y'X ?\.#OA
MU_T<5XU_\(70O_EY1_PX.^'7_1Q7C7_PA="_^7E?H-^T5_P4F_9C_9A^)ME\
M)_B/J_BB[\4R:3!J^LMX1T*V\0Z?X2AO=KZ;9^)G35;6^M-3U*T8:C:Z?8Z?
MJ-Q'IKV][>I:0W^G->:7@C_@I7^PYX^\E=)_:'\&:1/+@-!XWBUOX?>0Y )C
MFNO&VE:%I_RDX,L5Y+;D@[)G )I6AMI?;=_YE<]:R>MGUY5_E]W<_.?_ (<'
M?#K_ *.*\:_^$+H7_P O*^@_V7/^"0OPU_9I^-7A3XT?\+2\1_$'4/!J:M-H
MF@ZQX9TK2M/BU?4M*N](@U:::VU&]DEETR"^N;BRB\I1'?BUNUD22U3/ZG^%
M/'_@3QW;?;? _C7PEXRL]@D^U^%/$FC>(K;8<8?S](O;R+8=RX;?@[A@\BNM
MIJ,=&EYK5_YDNI-IIO>Z:LOGT"OYP/\ @NW\>O-N_A/^S;H]YE+6.7XK^.(8
MI,@W$XO_  [X(L9C&1M>& >*M2N;28DLEYHMX(U AD?^C:]O+33K.[U"_N8;
M.QL+:>\O;NYD6*WM;2UB>>YN9Y7(2*&"%'EED<A4169B ":_@G_:P^-UW^T5
M^T3\5_C!/),UCXL\5WC>&X9]ZR67@_25CT3PA9/&V!%-;^&].TQ;M56-9+TW
M,Y17E>E-V5N_Z%48WE?^57^;T7ZOY'SQ1170^$?"VM^./%?AGP7X:LWU#Q%X
MNU_1_#.@V"9WWFL:[J%OI>FVJD D&>\NH8]V#MW9(P*R.H_I8_X(9?L\KX=^
M'7C[]I+7+$+JOQ"OY/ 7@>>:/$D7@WPU>)/XEO[23'S6^O>+(H=-F4G*3^"\
M@!9,O^]]>7_!/X6Z)\$OA'\.OA+X>"'2OA_X1T;PU%<+&(FU&ZL+2-=3UB=!
MP+O6M3:\U:\(P&N[V9@!G ]0K>*LDOO]3AG+FDWYZ>G3\ HHHIDA1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110!_G+T445SGH']8/_  0G_P"31_B+_P!G&^+O
M_59_"&OVGK\6/^"$_P#R:/\ $7_LXWQ=_P"JS^$-?M/6\=EZ+\CBJ?'+U"BB
MBF0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !117BG[1OQO\/?LW_ [XE?&[Q/!]MTWX?^&Y
M]3MM*\V^MO[?\0WMQ;Z-X1\,?;M/TG79]*_X2CQ7J6B^'O[:DTF]L=$_M/\
MM;4XTTVRNY8XJU:=&G4K59*%*E"=6I.7PPITXN4Y/RC%-OR1P9KFF7Y)E>99
MUFV*I8'*LHP&,S3,\=7;5#!Y?E^'J8O&8JLXJ4E2P^&I5*U1J+:A!M)O0_DB
M_P""M_QJM?C+^VQ\0+?2I]-O- ^#^FZ3\%=(O;'3M7TZZN+KPA/J6I>-(-93
M6'#7>I:-\2O$7C;P_%J.G6ECI%[I&D:5/IZ:A$QUS5?E[]CSP;_PL#]JW]G'
MPC+X5_X3;3=6^-?PV_X2+PQ)H?\ PDECJ?A"P\6Z5J?C/^VM%:UO8+WPW9>%
M++6=0\3_ &ZVETRV\/6FIW>J[--@NI$\4\9>+O$/Q \7^*O'GB[4/[6\5^-O
M$FN>+O$^J_9+&P_M/Q#XDU.ZUG6M0^PZ9;66FV7VW4KVYN?LFGV=I8V_F^3:
M6T$"1Q)^S?\ P0M^"MKXU_:(\??&?5(--NK+X(>"8+'1$EU'5[75]/\ ''Q3
M;5=#TW6;&RLDCTO5--A\#Z%\1]%U6+6[MX[6ZU_1KNPTJ\O8DU+1/P_"JIG?
M$-*77&9@Z\DU\-",W6FN6\U^[H0DHQ;DO=2E)J\C_!#A*GF'CM])/+*[5ZG&
MWB-5SW%0K4DOJN18?'UL]QU%8=SQL/\ A/X>P->E0P]2MB*;^KTZ-;%3IN>(
M/ZN:***_<S_?X**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /Y/O\ @NQ_R=Q\.O\
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M]VV?^]]K^K2O#XD_Y'6-_P"Y;_U$H'J9+_R+,-_W&_\ 4BJ%%%%>&>H%%%%
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M6[\6_L[^ /BMIUJ]S-\(O'DEKK#HA/V+PO\ $.UM=)N[UW .$'B?1_!]CM.
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M99_P21^ O_"EOV0O"FNZG9?9O%GQHNY/BCK321XN(]%U6"&T\#V7F$*YM?\
MA%K6QUR.)E'D7GB#4%&=Q9B*NUY:A5ERP?=Z??O^!^GE%%%;'&%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!_G+T445SGH']8/_  0G_P"31_B+_P!G
M&^+O_59_"&OVGK\6/^"$_P#R:/\ $7_LXWQ=_P"JS^$-?M/6\=EZ+\CBJ?'+
MU"BBBF0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !7\FG_!9#]M/_A=/Q0/[-O@._P#-^&'P
M4\27/_"8R7/A[^S[[6_CCH$WB3PQKGV34[^:34I_#?@G3;^\\-Z?]FL- M]3
M\0WGBZ_F_P"$IT.+P1K5O^CW_!6G_@H+_P *'\(2? #X(>.?[-^/7BO[+_PF
MVJ:#%Y^I_"[X>ZEIEU._D:]#J$'_  BGQ(\5^?I+^'/(M-2UO1?"%QJGBF/_
M (135=2^'7B.\_DTK\WXSS^+4\GPDKNZ^O58R5E:S6&BXRU=]:Z:5K1IZMU(
MK_+_ .G#](BA4I8KP3X.QGM)^UI2X]S;"8B$J4?8R52EPI1J8>M)RJQK1C6X
M@IU(P]C*EA\LESSGF-"D5_=%_P $^OV8_P#AD_\ 9@\#?#G5+;[/X]USS?B#
M\5?WWG;/B%XIM+#^T=(_T?7_ !'HS?\ "':-I^@^ _M_AR^AT3Q#_P (M_PE
M$%E;W>N7F_\ $#_@C'^Q'=>/O'$/[6/Q)T34K;P/\.=2 ^#UEJNB:1<:%\0O
M'"QZQINI^*(GU?[5>OIOPLO8K:XT;4M,TFWCF^(S6-UH_BRVU3X<^(M#NOZE
M:Z.",FE0I3S;$0<:F(@Z6$C)6<<.VG.O9NZ=:45&F[1?LH2DG*G73/I?H&^"
M.(R'*<;XQ<1X.=#,.),%/*^#,+B:2A5P_#TJT*F/SWDJ2E.$\[Q&'HX?+*CI
M8>LLJPF(Q5&IB<OSZC)%%%%?H!_HV%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MW\O^":1K<J2459+O][VZZ_?Y:_YW?_"&^+_^A5\2?^"/5/\ Y%K^O[_@D7\
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M_:9^+/Q6C\.^*+C0]8\2SZ7X.5]$U8)#X)\-HF@^%=D+6N+=[W2-/M]4O84
M7^TK^]E)>25W;^Z.BIE'FZV^1<)\C;M>ZMO;KKT/\[O_ (0WQ?\ ]"KXD_\
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M>62T^)/P^L;S7-&%BI9DG\1:7;1S:UX1FCB\L7?]LVB:2ERYM]/UK5$43O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M"M/B_P"/'_"<_!#X 2?\(I\!=2\K0=4\;?9=3TWXA?%'3(/[0AUZ#?/=0?\
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MXO5^+%8S^)_+\D=M/X(^A^C7_!)7_E(+\ /^ZJ_^J3^)%?VG5_%C_P $E?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _SEZ***YST#^L
M'_@A/_R:/\1?^SC?%W_JL_A#7[3U^+'_  0G_P"31_B+_P!G&^+O_59_"&OV
MGK>.R]%^1Q5/CEZA1113("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M480A"*48PC%*,8Q244DDDD%%%%,L**** "BBB@ HHHH **** "BBB@ HHHH
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O\
M*7K_ $#OVGO^"R_["W[.WA?Q%-H/QA\*?'CXE6OA1-?\&_#GX.ZN_C+3O%FH
MWVHW.CZ9I&H_%/PSI_B'X:^#?(O;6;4?$L6LZ])XHT7PO ^LZ=X0\0WNH>&M
M$\0_Y^-??\(X7$4(8ZI6HU*4*SPRI.I!P<_9JNYN*DE)Q7M(>];E;;2;<9)?
M)<0UZ-66%A3JPJ2IJLYJ$E+EY_9<JDU=)ODEI>Z2NTDU?^K3_@V,_P";W/\
MNVS_ -[[7]6E?RE_\&QG_-[G_=MG_O?:_JTKYSB3_D=8W_N6_P#42@>SDO\
MR+,-_P!QO_4BJ%%%%>&>H%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^R_VY_PN:^^+GV?^Q?L=S_9O_"-_\(_YO]K:A_;']K>7I?\ 9OYH?&;]J_\
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MP0G_ .31_B+_ -G&^+O_ %6?PAK]IZWCLO1?D<53XY>H4444R HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HK-UG6=(\.Z1JOB#Q!JNFZ%H&A
M:;?:SKFN:S?6NEZ1HVD:7:RWNI:KJNI7LL%EIVFZ=903W=]?7<\-K:6L,MQ<
M2QQ1NX_GG_:^_P""W]KIUUJG@;]CS2--UV*33;>-_CGXQTS5X;6"ZU32-46]
M3P1\.-<T[1KTZEX=O;O0KJP\2^.EFTB?5]+US2;OX<:[H$FF^(-1\W,LVP&4
MTE5QM90YK^SI1]^M5:W]G33NTKI2F^6G%N*E.+E&_P"7^*/C'X?>#V4T\UXX
MSVE@)XKVBRS*,-'ZYGN<5*4;U(Y;E=*2K5*5-N$*^.KO#Y;A*E;#T\7C<//$
M4%4_7?\ :F_;7^ '[(7AX:K\5O%/VKQ)=?V3)HWPO\(S:-J_Q0UZQU>^O[*+
M6M/\*WVLZ1]E\-VO]D:W+=^)]<OM(\/";2+G1K74[KQ)=:5HNH_RL?MI_P#!
M3+XX_MA?;_"./^%6_ ^Z_P"$>G_X5)H>HV^K_P!JZGH7G7?]J>,O&G]B:'K/
MBGSM9N/[0M=!^S:5X0L/[(\*W?\ PCEUXHT#_A*K_P"!?%WC+Q?\0/$.H>+O
M'GBKQ)XV\5ZM]D_M7Q/XNUS4_$GB'4_L%C;:98_VAK6LW5[J5[]BTVRL]/M/
MM-S+]FL;2VM(=D$$4:'A'P;XO^('B'3_  CX#\*^)/&WBO5OM?\ 97ACPCH>
MI^)/$.I_8+&YU.^_L_1=&M;W4KW[%IME>:A=_9K:7[-8VES=S;(()9$_*\XX
MIS#-Y2PU#FPN#J/D6'HMNK74FXI5JD5SSYT[.C"U)W2E&HTI'^1'C9]+3Q(\
M9J]?AG(5BN%.#,?5>!I<-9-4G5S;B"%>=3#T:.>9A0IQQ>-^N4Z_L:F1X+V6
M5UI3A2Q&'S&M2HXE<W7W1^R5_P $]?VB/VM]7T"]\,^%-2\(?".^U*WBUSXS
M^*-/:S\*6.D+=:U::E?>$[2]N=,O?B3J5E>^'=4T,Z5X/>\M=/\ $K:;IOB_
M6?"&GWSZU:_L5^Q'_P $6M(\(76B?$[]KR33?%'B;3M2T37O#_P8T+4+75_
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M3>.6X"+NL)0;V]Z"FONGS+YVN?GY\,?^"5/_  3N^$?]N?\ "*_LE_"C5O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH _SEZ***YST#^L'_@A/_R:/\1?
M^SC?%W_JL_A#7[3U^+'_  0G_P"31_B+_P!G&^+O_59_"&OVGK>.R]%^1Q5/
MCEZA1113("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO;?VE*IM;3EMN[WTMX$>(,=&]UAYWM\5.2MOMR5(;];WVTMK?_0._P"'W?\
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MV:^9VIJ23BTT]4TTTUW36C"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** /\ .7HHHKG/0/ZP?^"$_P#R:/\ $7_LXWQ=_P"JS^$-?M/7XL?\$)_^
M31_B+_V<;XN_]5G\(:_:>MX[+T7Y'%4^.7J%%%%,@**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#^3[_ (+L?\G<?#K_ +-R\(_^K,^+U?BQ7[3_ /!=C_D[CX=?]FY>$?\
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MTN9U*-&LDJU*G547=*I3C-)O1M*2:3MU1^4O_#D3_@E__P!&Q_\ F:/VA/\
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M 4444 ?YR]%%%<YZ!_6#_P $)_\ DT?XB_\ 9QOB[_U6?PAK]IZ_%C_@A/\
M\FC_ !%_[.-\7?\ JL_A#7[3UO'9>B_(XJGQR]0HHHID!1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M** "BBB@#_.7HHHKG/0/ZP?^"$__ ":/\1?^SC?%W_JL_A#7[3U^+'_!"?\
MY-'^(O\ V<;XN_\ 59_"&OVGK>.R]%^1Q5/CEZA1113("BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** /\Y>BBBN<] _K!_X(3_\FC_$7_LXWQ=_ZK/X0U^T]?BQ_P $
M)_\ DT?XB_\ 9QOB[_U6?PAK]IZWCLO1?D<53XY>H4444R HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@?N+1117Y^?2!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/X&)_P"OL/\ T@****^./HPHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_ #EZ
M***YST#^L'_@A/\ \FC_ !%_[.-\7?\ JL_A#7[3U^+'_!"?_DT?XB_]G&^+
MO_59_"&OVGK>.R]%^1Q5/CEZA1113("BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ*_,_P#B+7B%_P!%%4_\-V4?_.\^L_U+X9_Z%<?_  JQW_S2?Q6?\0;OP_\
M^C^/&/\ XCSHG_SWJ/\ B#=^'_\ T?QXQ_\ $>=$_P#GO5_:G11_Q%KQ"_Z*
M*I_X;LH_^=X?ZE\,_P#0KC_X58[_ .:3^*S_ (@W?A__ -'\>,?_ !'G1/\
MY[U'_$&[\/\ _H_CQC_XCSHG_P ]ZO[4Z*/^(M>(7_115/\ PW91_P#.\/\
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M.U#^S]-\3?;?".I?Z)]K^V_VS;M_8FG_ "6US/;?:?%=MX?_ -+M_L_D[/\
M2[F+36O=W[55_.SHVKZAX?U?2M>TBX^R:KHFI6.KZ9=>5!/]FU#3;J*\LKCR
M+F*:VF\FYABD\JXAE@DV[)8I(V9#_0[9WEGJ-G:ZAI]U;7]A?VT%Y8WUG/%=
M6=Y9W42SVUU:W,#O#<6UQ"Z303PN\4T3K)&[(P)_SS/Z8+-%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110!_)]_P %V/\ D[CX=?\ 9N7A
M'_U9GQ>K\6*_:?\ X+L?\G<?#K_LW+PC_P"K,^+U?BQ6,_B?R_)';3^"/H?H
MU_P25_Y2"_ #_NJO_JD_B17]IU?Q8_\ !)7_ )2"_ #_ +JK_P"J3^)%?VG5
M<-GZ_HC"O\:_PK\V%%%%68A1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %?Q/?\ !R'_ ,GQ?"O_ +-2
M\#_^K>^.=?VPU_$]_P '(?\ R?%\*_\ LU+P/_ZM[XYU]'PK_P C:'_7BO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_.7HHHKG/0/ZP?^"$__)H_
MQ%_[.-\7?^JS^$-?M/7XL?\ !"?_ )-'^(O_ &<;XN_]5G\(:_:>MX[+T7Y'
M%4^.7J%%%%,@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MSR*C3Q>%Q4FK*-'$RH8I+>UJ=2CBH*^R]W7S3/Y*OV@O^"4/_!R1\-OMVH?
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MXL?^"2O_ "D%^ '_ '57_P!4G\2*_M.JX;/U_1&%?XU_A7YL****LQ"BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% '^<O1117.>@?U@_\$)_^31_B+_V<;XN_P#59_"&OVGK\6/^"$__
M ":/\1?^SC?%W_JL_A#7[3UO'9>B_(XJGQR]0HHHID!1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?D5^W!J^GZ
ME\9K6SLKCSKGP_X*T/2-7C\J>/[)J$U_K6O16^^6*..?=I6MZ9=>;;/- OVG
MR&E%S#<0Q?KK7XJ_M;?\G!_$#_N5/_4)\-T ?PW_ /!P)_R>3\-/^S9?!O\
MZM/XSU^&-?L#_P %Q_B-_P )O^WGX@\,_P!C?V9_PI[X9?#CX<_;?[0^V_\
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M)_+\D=M/X(^A^C7_  25_P"4@OP _P"ZJ_\ JD_B17]IU?Q8_P#!)7_E(+\
M/^ZJ_P#JD_B17]IU7#9^OZ(PK_&O\*_-A1115F(4444 %%%% !1110 4444
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MJ5[/78^[Q->O1C_L^"JXN=O=C3JX:C!/HI2KUJ<HKSA3GZ'Z;?&3]I']GO\
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M.X^'7_9N7A'_ -69\7J_%BL9_$_E^2.VG\$?0_1K_@DK_P I!?@!_P!U5_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 ?YR]%%%<YZ!_6#_P0G_Y-'^(O_9QOB[_U6?PA
MK]IZ_%C_ ((3_P#)H_Q%_P"SC?%W_JL_A#7[3UO'9>B_(XJGQR]0HHHID!11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P#AY#_P40_Z/U_;0_\ $I/CC_\ -S1_P\A_X*(?]'Z_MH?^)2?''_YN:/\
MB7[-O^BBR[_PCQ/_ ,F'_$2<%_T+,5_X.I?Y'^QQ7\KG_!WE_P HV?@C_P!G
MP_#;_P!4+^TM7\-7_#R'_@HA_P!'Z_MH?^)2?''_ .;FO,?BO^UI^U5\>?#M
MEX0^.7[3/[07QF\)Z;K5MXDT[PO\5_C-\1OB)X=L/$5G8ZCI=IK]EHGB_P 2
M:QIMKK5KINL:OIUMJD%M'?06.J:C:13K;WUS'+[_  OX+9EP_P 093G-7.\#
MB*>78N.(G0IX;$0G4C&,H\L92FXQ?O;M6T/-SCCO"9EEF,P$,!B*4\51=.-2
M=6G*,6Y1=VDKM:=#Y]HHHK^AC\S"BBB@ HHHH _L"_X-^_\ DS;XE_\ 9S7C
M+_U5GP8K^OS]@/2-0ATCXF:]+;[=*U+4O"^D65UYL#>=J&B6NMWFIV_D+*;F
M/[-;>(-(D\V6&.";[7LMY99(+E(?Y/?^"%/P^UGP9^PM%XCU2YTR>Q^+/Q@^
M(7Q!\.16$UU+=66C:;;^'/A7/;:VEQ96L-MJ;^(?AGKUY%#83ZE:MHUWI%P]
M['?3WFG6']>_["/_ "2+Q'_V4?5__48\(5_!?B-5IUN.>)YTIJ<5FV(I-K95
M*'+1JP]85:<X2_O1=KH_HOAB$H</Y0I)Q;P5*:3_ )9IS@_24)1DO)H^U:**
M*^+/="BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#^3[_@NQ_R
M=Q\.O^S<O"/_ *LSXO5^+%?M/_P78_Y.X^'7_9N7A'_U9GQ>K\6*QG\3^7Y(
M[:?P1]#]&O\ @DK_ ,I!?@!_W57_ -4G\2*_M.K^+'_@DK_RD%^ '_=5?_5)
M_$BO[3JN&S]?T1A7^-?X5^;"BBBK,0HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OXGO^#D/_D^+X5_
M]FI>!_\ U;WQSK^V&OXGO^#D/_D^+X5_]FI>!_\ U;WQSKZ/A7_D;0_Z\5__
M $E'C9]_R+Y?]?:7YL_*7]@__D^+]C/_ +.M_9W_ /5O>#Z_TNZ_S1/V#_\
MD^+]C/\ [.M_9W_]6]X/K_2[KNXQ_P!YP?\ UXJ?^G$<O#G\#$_]?8?^D!11
M17QQ]&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 ?YR]%%%<YZ!_6#_P $)_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!_G+T445SGH']8/\ P0G_ .31_B+_ -G&^+O_
M %6?PAK]IZ_%C_@A/_R:/\1?^SC?%W_JL_A#7[3UO'9>B_(XJGQR]0HHHID!
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %><?%_PC_PG7PP\=>%8]/_ +5O=5\-ZC_8]A]K^P^?XAL83J/AO_2C
M<V<47E:]9Z=-_I5Q'8OY?EW^^R>>-O1Z* /Y>OC7\.?^%P_!KXM_"3^V?^$=
M_P"%I?#+Q[\.?^$@_L_^U_["_P"$W\*ZKX9_MG^ROMVF?VG_ &9_:?VW^S_[
M2T_[;Y'V;[=:>;]HC_S?*_U%_B_X1_X07XG^.O"L>G_V59:5XDU'^Q[#[7]N
M\CP]?3'4?#?^E&YO)9?-T&\TZ;_2KB2^3S/+O]EZD\:_Y\7_  4_^#VL_!C]
MNG]H72-4;4[NQ\<>.M4^,/AS6K_P_=:!:ZSHWQ9N)?'$ZZ(+BYO(=:TSPOXA
MUC7O ,OB"PNI+74]9\(ZNSVVE7T5YHVG?T5]'_-E3QN?Y'4FKXG#X;,\-%V3
M4L+4EAL7RM4[S<XXK"OEE53A&BY4Z<E*M.'YCXDX-RH9;CXQ=J56MA:K6NE:
M,:M&_O>ZHNC65U!W<TI234%+X%HHHK^GC\E"BBB@#^D3_@U8_P"4K.D_]F^_
M&3_T'PS7^F)7^9W_ ,&K'_*5G2?^S??C)_Z#X9K_ $Q*_COQS_Y+:'_8EP'_
M *>QA^W^'O\ R()?]A^)_P#3= _RZO\ @LK^Q3^V5\0_^"H/[9_C7P!^R3^T
MUXY\&^(OB]<W_A_Q;X/^ WQ4\3>&==L&T#0HA>Z-KVB^%+W2M3M#+%+&+FRN
MYX3)'(@?<C ?F7_P[V_;Z_Z,>_:__P#$:?C/_P#,57^R317J9=X[9EEV7X#+
MX</X&K# 8+"X.-26,Q$95(X6A3H*<HJDU&4U3YFDVDW9-I:\F*\/,)BL3B,3
M+,L1"6(KUJ[BJ%-J+K5)5'%-RNU%RLF]6D?XVW_#O;]OK_HQ[]K_ /\ $:?C
M/_\ ,51_P[V_;Z_Z,>_:_P#_ !&GXS__ #%5_LDT5V_\3!9I_P!$YE__ (6X
MC_Y5Z_TM</\ B&N#_P"AIB?_  12_P#DS_&V_P"'>W[?7_1CW[7_ /XC3\9_
M_F*H_P"'>W[?7_1CW[7_ /XC3\9__F*K_9)HH_XF"S3_ *)S+_\ PMQ'_P J
M]?Z6I_Q#7!_]#3$_^"*7_P F?XVW_#O;]OK_ *,>_:__ /$:?C/_ /,57F_Q
M0_99_:<^"&@6?BOXT_LY_'?X0^%M0UBW\/6'B7XH?"'X@^ - OM?N[+4-2M=
M#L]9\5^'M)TZYUBYT[2=5O[?3(;E[V:RTS4+J.!H+*YDC_VD:_E<_P"#O+_E
M&S\$?^SX?AM_ZH7]I:O>X7\:LQX@X@RK):N1X+#4\QQ4</.O3Q=><Z2E&4N:
M,)4U&37+LVEKOIKYN;\!X7+<LQF/AF%>K+"T74C3E1IQC-J459M2;2UW2/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH _D^_X+L?\G<?#K_LW+PC_P"K
M,^+U?BQ7[3_\%V/^3N/AU_V;EX1_]69\7J_%BL9_$_E^2.VG\$?0_1K_ ()*
M_P#*07X ?]U5_P#5)_$BO[3J_BQ_X)*_\I!?@!_W57_U2?Q(K^TZKAL_7]$8
M5_C7^%?FPHHHJS$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ K^)[_@Y#_Y/B^%?_9J7@?_ -6]\<Z_
MMAK^)[_@Y#_Y/B^%?_9J7@?_ -6]\<Z^CX5_Y&T/^O%?_P!)1XV??\B^7_7V
ME^;/RE_8/_Y/B_8S_P"SK?V=_P#U;W@^O]+NO\T3]@__ )/B_8S_ .SK?V=_
M_5O>#Z_TNZ[N,?\ ><'_ ->*G_IQ'+PY_ Q/_7V'_I 4445\<?1A1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% '^<O1117.>@?U@_\ !"?_ )-'^(O_ &<;XN_]
M5G\(:_:>OQ8_X(3_ /)H_P 1?^SC?%W_ *K/X0U^T];QV7HOR.*I\<O4****
M9 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ18P:?;27<D$-O"]R\-NC3O#;P1-*7:.&)"$7;K^8S]9"BBB@ HHHH ****
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M^;/RE_8/_P"3XOV,_P#LZW]G?_U;W@^O]+NO\T3]@_\ Y/B_8S_[.M_9W_\
M5O>#Z_TNZ[N,?]YP?_7BI_Z<1R\.?P,3_P!?8?\ I 4445\<?1A1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% '^<O1117.>@?U@_P#!"?\ Y-'^(O\ V<;XN_\
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M '57_P!4G\2*_M.JX;/U_1&%?XU_A7YL****LQ"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_B>_X.
M0_\ D^+X5_\ 9J7@?_U;WQSK^V&OXGO^#D/_ )/B^%?_ &:EX'_]6]\<Z^CX
M5_Y&T/\ KQ7_ /24>-GW_(OE_P!?:7YL_*7]@_\ Y/B_8S_[.M_9W_\ 5O>#
MZ_TNZ_S1/V#_ /D^+]C/_LZW]G?_ -6]X/K_ $NZ[N,?]YP?_7BI_P"G$<O#
MG\#$_P#7V'_I 4445\<?1A1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH _D^_P""['_)W'PZ_P"S<O"/_JS/B]7XL5^T_P#P78_Y.X^'7_9N
M7A'_ -69\7J_%BL9_$_E^2.VG\$?0_1K_@DK_P I!?@!_P!U5_\ 5)_$BO[3
MJ_BQ_P""2O\ RD%^ '_=5?\ U2?Q(K^TZKAL_7]$85_C7^%?FPHHHJS$****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 ?YR]%%%<YZ!_6#_P0G_Y-'^(O_9QOB[_U6?PAK]IZ_%C_
M ((3_P#)H_Q%_P"SC?%W_JL_A#7[3UO'9>B_(XJGQR]0HHHID!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 5^=G[9GP*O+^5_C!X1TVYO)DMMOQ#MX;J6XE2STZSL[32_$=GIS1.
MZVUA86KV?B%K6Y$5K9V^FZH--2&'Q#JJ_HG10!_(/^VE^Q;\*?VV_A3-\/OB
M##_8WB?1OMVH_#/XF:=8PW7B3X=^)+N&&.6ZM8I)K7^V?#&L_9;*V\8^#KF]
MM;#Q)86MG-#>:-XGT;POXH\/?P4_$SX9^/?@WX]\4?##XG^%]3\&>//!FIR:
M1XC\.:O'&MU8W2QQ7$$L4]O+/8ZEIFI6,]KJFB:WI=U>Z-KVC7MAK6BW]_I-
M_9WD_P#K'_M1?LN_\(W_ &C\2OAKIW_%-_O;WQ5X5LHO^1;ZR7&MZ);QC_D6
M_O2ZEIL2_P#%-_/>6:?\(WYT/AO\,OVS?V$O@A^VGX"U70?'6A:9H'Q'CTRV
MMO _QJTC0M.F\>^#;K2I-5N]&LI;\_8[[Q+X%6^UO5GUOX?:EJD.C:E'JM_?
MZ9-H'BR/1?%>B_K_ (9>)D^$*D\JS;V^)R#%582AR-U*F45IS?ML10IZNIAJ
MJFZF*PT/?<X*OAX^UE6IXGXGBSA2.=Q6,P7LZ694H24KI1CC81C[E*I/11JP
M<5&C5EIRR=.J^14Y4OX Z*^A_P!I+]ECXW_LG^/=0\ _&?P5J>@31ZGJEAX<
M\6PV>HS> OB#:Z5'IMS/K?P_\57%C9V/B73%L=;T6ZO8H5AUGP])JMMI'BS2
M- \0QWFCVOSQ7]@X3%X7'8:CC,%B*.*PN(IJK0Q&'J1JT:M.6TZ=2#<9+=:/
M1IIV::/Q*M1K8>K4H5Z4Z-:E)PJ4JD7"<)+=2C))I]=5JFFM&%%%%=!D%%%%
M !1110 4444 %?<__!/O]BWQ)^VU\>M(\!^3XGTGX5>'MNN?&/X@>'[&PF_X
M1'PV+:_FTO2[>]U>:+3+?Q/XZU/3_P#A&O#,?V?7+^R\[5?&'_"*^(= \'>(
M[:+TW_@GW_P31^*W[9_C+2-;\0:9XG^'?[.ECMU3Q-\5;G2)K'_A++"VU6_T
MFX\*_"2YU6R?3/$_B>\U/1]5TC4M<MXM4\-_#[[#>W_B:.^UA/#_ (,\6?VB
M_ ']G7X5?L^^#M-^$7P ^'=KX/\ #4^N7=]:>'M$.L:YJVN>)?$%S%'+>:AJ
MNKWFL>)_%&N7A2PTFSN-6U+4[^'2[#1O#^GO%I.DZ5I]I^-^)/BE@N&J&*R7
M)ZJQ7$56C.FZM)TYX?)G43@ZN(E>2ECX)\^'P?)*,)*-;%\M-4Z&)^YX5X0K
MYK4HX_'0='+(3C-0FI1JX[E:DH4U9-8:7PU:_,G)-PH7ES5*73?"?X3^#OA9
MX.\&_"#X0>#;7PWX2\-VMIX<\'>#O#EI<W!4W%RS+%$K-=ZIK6N:UJEW/?ZI
MJE_/J&O>)->U"]U;5KW4=8U&[N[C]V_V9_@M_P *?\#G^UX/*\;^*?LU]XM\
MO4?M]K:_8Y+[^Q=&M?)2.R3^RK*^E^WRV_VSS]7N]1\K5;_2XM*\CD_V:OV:
MK/X5V<'B_P 7P6U_\1[ZV81QAHKJS\&V=U$4FT[3ID+PW&MW$+M!K.LP,\21
M/+H^CRMIS:AJ&O\ UU7\?U:M6O5J5JU2I6K5JDZM6K5G*I5JU:DG.I4J5)MS
MG4G-N4YR;E*3<I-MMG[;"$*<(TZ<8PA",80A"*C"$(I1C&,8I*,8I)1BDDDD
MDK(****S*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** /Y/O^"['_)W'PZ_[-R\(_\ JS/B]7XL5^T__!=C_D[CX=?]FY>$?_5F
M?%ZOQ8K&?Q/Y?DCMI_!'T/T:_P""2O\ RD%^ '_=5?\ U2?Q(K^TZOXL?^"2
MO_*07X ?]U5_]4G\2*_M.JX;/U_1&%?XU_A7YL****LQ"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M_B>_X.0_^3XOA7_V:EX'_P#5O?'.O[8:_B>_X.0_^3XOA7_V:EX'_P#5O?'.
MOH^%?^1M#_KQ7_\ 24>-GW_(OE_U]I?FS\I?V#_^3XOV,_\ LZW]G?\ ]6]X
M/K_2[K_-$_8/_P"3XOV,_P#LZW]G?_U;W@^O]+NN[C'_ 'G!_P#7BI_Z<1R\
M.?P,3_U]A_Z0%%%%?''T84444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_G+T445
MSGH']8/_  0G_P"31_B+_P!G&^+O_59_"&OVGK\6/^"$_P#R:/\ $7_LXWQ=
M_P"JS^$-?M/6\=EZ+\CBJ?'+U"BBBF0%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!_G+T445SGH']8/_!"?_DT?
MXB_]G&^+O_59_"&OVGK\6/\ @A/_ ,FC_$7_ +.-\7?^JS^$-?M/6\=EZ+\C
MBJ?'+U"BBBF0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(^"VL?VCJ5OBTMY-GA_2K6\WW%VOV'RXK*7^&G_A#/$O_0-_\G+#_P"2J/\
MA#/$O_0-_P#)RP_^2J/]?<=_+E7W5O\ YL#_ (ENX>_GXS_\"P/_ ,XC^RS5
M_P#@JM_P3UTW4+BRL_VEM-\06T/E>7J^D?";]H*'3[OS((I7^SQ:]\(]$U5?
M(DD>VE^UZ9;;IX96@\ZV,-Q+F_\ #V3_ ()_?]%]_P#,5_&K_P"=Q7\<O_"&
M>)?^@;_Y.6'_ ,E4?\(9XE_Z!O\ Y.6'_P E4?Z^X[^7*ONK?_-@?\2W</?S
M\9_^!8'_ .<1_9]X?_X*D?\ !.O6?M?]H_M7>&_"7V;[/Y/_  D'PB_:9N?[
M0\[SO,^R?\(K\#O$VS[)Y4?VC[?]BW?:8?LOVG;<?9_?/"O_  4C_P"",D7D
MS>-_V_-2OO,TV/[1IOA7]F[]I?2OL>KO]G>7R=;U?X+:Q_:.FV^+NWCW^']*
MNKS?;W;?8?+ELI?X1?\ A#/$O_0-_P#)RP_^2J/^$,\2_P#0-_\ )RP_^2J/
M]?<=_+E7W5O_ )L#_B6[A[^?C/\ \"P/_P XC_1K^'W_  6J_P""%GPS@L?^
M$8_:2TU=5L<R)XGU/]GG]IO5/%$EU+I\>F7ETNM77P0>YL/M]LDGVJPT?^S=
M(5[J]^RZ=;1W<\;^L_\ $0U_P1[_ .CO?_, _M0__.4K_,[_ .$,\2_] W_R
M<L/_ )*H_P"$,\2_] W_ ,G+#_Y*H_U]QW\N5?=6_P#FP/\ B6[A[^?C/_P+
M _\ SB/],3_B(:_X(]_]'>_^8!_:A_\ G*4?\1#7_!'O_H[W_P P#^U#_P#.
M4K_,[_X0SQ+_ - W_P G+#_Y*H_X0SQ+_P! W_R<L/\ Y*H_U]QW\N5?=6_^
M; _XENX>_GXS_P# L#_\XC_3$_XB&O\ @CW_ -'>_P#F ?VH?_G*4?\ $0U_
MP1[_ .CO?_, _M0__.4K_,[_ .$,\2_] W_R<L/_ )*H_P"$,\2_] W_ ,G+
M#_Y*H_U]QW\N5?=6_P#FP/\ B6[A[^?C/_P+ _\ SB/]/GX>?\%W?^"2_P 3
M_&.C^!O#?[9G@K3-:US^T/L5[\0_!7Q<^$7@Z#^S-+O=8N?[8^(?Q8^'O@KP
M!X>\RTT^>'3_ .W_ !-IG]K:I)9:'I7VS6M3TW3[O]._AY\2?AU\7?!VC_$/
MX3^/O!7Q/\ >(?[0_L#QS\//%.A^-?!VN?V3JE[H>J_V/XF\-W^IZ+J?]F:U
MIFI:/J'V*]G^QZII][I]SY=W:3PQ_P"-S=:#K5F91<:9>JL"&265('FMT0()
M&<W, DMRB(<R,)2(R&5RK*P'J?P#_:,^.O[+7Q%TWXL?L\?%7QK\(O'^F?8X
M?[?\%ZU<:9_;&EV>NZ-XE_X1GQ9I69-%\:^"M0UKP]HE[KO@;Q?INN>#O$?]
MF6MMX@T/4[2/R#W83CFLY+ZUA*%6FWK/"3G3E&+Y6FHU)UHS=N9VYZ:E>.L;
M/F^>SKZ.^!A3DLGSG,L'B8Q]VCG5"CB*=2<>=2C*KA:&!J4(MNFN98?$.GR3
MO"?M(JE_L3T5_'9_P3#_ .#G'_A8?C'P'\ _^"A6B>"O!5WK_P!G\-:5^UEX
M;N/^$5\'-KD>E^&]+T!OC?X'GBN-%\)?\);K5OXGU+Q7\6_"6L^'OAUX8U36
M_#MG=_"SP)X T_Q)XZT'^OGPWXD\.^,_#N@>,/!^OZ+XK\)>*]%TKQ)X7\4>
M&]5L==\.^)/#NNV,&J:)K^@:WI<]UIFL:+K&F75KJ.E:KIUU<V.H6-S!=VD\
MUO-'(WV^7YG@\SI>UPE53Y7:=.2Y*M-V3M.#U2UTE'FA)W49.SM_/7$W"6>\
M(XQ8/.L&Z#J)RP^)I25;!XJ";7-A\1%<LFN5N5&:IXBFG%U:4%.+EM4445Z!
M\T%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '\GW_  78_P"3
MN/AU_P!FY>$?_5F?%ZOQ8K]I_P#@NQ_R=Q\.O^S<O"/_ *LSXO5^+%8S^)_+
M\D=M/X(^A^C7_!)7_E(+\ /^ZJ_^J3^)%?VG5_%C_P $E?\ E(+\ /\ NJO_
M *I/XD5_:=5PV?K^B,*_QK_"OS844459B%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5_$]_P '(?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /\Y>BBBN<] _
MK!_X(3_\FC_$7_LXWQ=_ZK/X0U^T]?BQ_P $)_\ DT?XB_\ 9QOB[_U6?PAK
M]IZWCLO1?D<53XY>H4444R HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MWV@NAGV3VLSNL%W"&V$@MMBF5AF"X:-1+Y>YT8;Q%--Y4I3^E;_@WM_X*_\
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M_P"K>\'U_I=U_FB?L'_\GQ?L9_\ 9UO[._\ ZM[P?7^EW7=QC_O.#_Z\5/\
MTXCEX<_@8G_K[#_T@****^./HPHHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-XO_ +&\2_M)?&G2O[=\)_\ "/\ ]H_\)G\'O@[ITOC3Q9_Q/;K1+ZP\._\
M"._%J^^ >I?Z'K.A>*-7\W['IO\ :?AI/&EJG].U?Q;_ /!WS_SCT_[NS_\
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M1M/,,BP&+Q+M!<U:&(QV C*\8Q<K8?!4(WJ.<_=LI*"A"!1117UA^+!1110
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MJ%%%%,@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^)_+\D=M/X(^A^C7_!)7_E(+\ /^ZJ_^J3^)%?VG5_%C_P $E?\ E(+\ /\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /\Y>BBBN
M<] _K!_X(3_\FC_$7_LXWQ=_ZK/X0U^T]?BQ_P $)_\ DT?XB_\ 9QOB[_U6
M?PAK]IZWCLO1?D<53XY>H4444R HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *_BW_P"#OG_G'I_W=G_[[/7]I%?Q;_\
M!WS_ ,X]/^[L_P#WV>OG^*?^1#C_ /N5_P#4S#GZ9X._\G&X=_[J_P#ZHLS/
MY!_AM_S&O^X=_P"W]>H5Y?\ #;_F-?\ <._]OZ]0K\!QO^\U?^W/_3<#_3+A
M[_D3X/\ [F/_ %*KA1117*>T%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !7+^,_^1:U+_MS_ /2^UKJ*Y?QG_P BUJ7_ &Y_^E]K
M6M#^/1_Z^T__ $N)Q9E_R+L?_P!@6*_],5#]+/\ @WE_Y3"?LA?]U^_]9>^-
M=?Z=E?YB?_!O+_RF$_9"_P"Z_?\ K+WQKK_3LK]SX)_Y%6(_[&%7_P!1L(?Y
MS>/_ /R666?]DS@__5KG(4445]@?AH4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!_)]_P78_Y.X^'7_9N7A'_U9GQ>K\6*_:?_ (+L?\G<?#K_ +-R
M\(_^K,^+U?BQ6,_B?R_)';3^"/H?HU_P25_Y2"_ #_NJO_JD_B17]IU?Q8_\
M$E?^4@OP _[JK_ZI/XD5_:=5PV?K^B,*_P :_P *_-A1115F(4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !7\3W_!R'_P GQ?"O_LU+P/\ ^K>^.=?VPU_$]_P<A_\ )\7PK_[-2\#_
M /JWOCG7T?"O_(VA_P!>*_\ Z2CQL^_Y%\O^OM+\V?E+^P?_ ,GQ?L9_]G6_
ML[_^K>\'U_I=U_FB?L'_ /)\7[&?_9UO[.__ *M[P?7^EW7=QC_O.#_Z\5/_
M $XCEX<_@8G_ *^P_P#2 HHHKXX^C"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7_=?O_67OC77^G97^8G_ ,&\O_*83]D+_NOW_K+WQKK_ $[*_<^"?^15B/\
ML85?_4;"'^<WC_\ \EEEG_9,X/\ ]6N<A1117V!^&A1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&?\ V=;^SO\ ^K>\'U_I=U_FB?L'_P#)\7[&?_9UO[.__JWO!]?Z7==W&/\
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MLNG<_J<LH)+6SM+6:[GOYK:V@@EOKH0+=7LD,21O=W*VT-O;">X93-,+>""
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% '^<O1117.>@?U@_\$)_^31_B+_V<;XN_P#59_"&OVGK\6/^"$__ ":/
M\1?^SC?%W_JL_A#7[3UO'9>B_(XJGQR]0HHHID!1110 4444 %%%% !1110
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MPJ_^HV$/\YO'_P#Y+++/^R9P?_JUSD****^P/PT**** "BBB@ HHHH ****
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MPC_Z*E\.?_"W\,__ "SHNN_]?TU]X[/L_P"O^'7WGHU%<GH7CWP+XHO)-/\
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M-T-.NKDVXG,$PA,VP2F&4)N\M\%UW_K^F@L^W]?TU]YTE%(2%!9B%502S$@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '\GW_!=C_D[C
MX=?]FY>$?_5F?%ZOQ8K]I_\ @NQ_R=Q\.O\ LW+PC_ZLSXO5^+%8S^)_+\D=
MM/X(^A^C7_!)7_E(+\ /^ZJ_^J3^)%?VG5_%C_P25_Y2"_ #_NJO_JD_B17]
MIU7#9^OZ(PK_ !K_  K\V%%%%68A1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?Q/?\'(?_ "?%\*_^
MS4O _P#ZM[XYU_;#7\3W_!R'_P GQ?"O_LU+P/\ ^K>^.=?1\*_\C:'_ %XK
M_P#I*/&S[_D7R_Z^TOS9^4O[!_\ R?%^QG_V=;^SO_ZM[P?7^EW7^:)^P?\
M\GQ?L9_]G6_L[_\ JWO!]?Z7==W&/^\X/_KQ4_\ 3B.7AS^!B?\ K[#_ -("
MBBBOCCZ,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "OCO]O?X\C]G+]E3XK_ !#L[P6?BBXT1_!_@5E?9<_\)EXOW:+I-W: D"2;
M0H[B[\3O'D;K70[G&2 I^Q*_F0_X+J_'K^W/'WPS_9TT>]WZ?X'TQ_B)XS@B
MDW1MXH\2Q2Z?X8LKJ/.4N]%\-1W^HQ_+AK3QC$=S$;44G9-_=_7XETX\TTNF
M[]%_5OF?@,2222<D\DGJ3ZFBBBL#M/W6_P""&GP%_P"$J^,/CSX_ZQ9;]*^%
M>A?\(MX4GEC^1_&OC6WGAU"[M)""#+HWA&'4+.[C&UE3Q99N"1D5_4E7PS_P
M3B^ O_#/7[(WPN\*WUE]B\5^*M//Q)\<(\?E7(\2>-8;;4%LKQ, K>:#H":%
MX:N!EAYFBLP8AJ^YJVBK)?>SBJ2YIM]-EZ+^K_,****H@*YOQEXLT/P%X1\4
M^.?$UVMAX<\'>'M9\4:]>M@BTT?0=.N=4U*XPS*&,5I:S.J;AO8!002*Z2OQ
MX_X+2_'K_A67[,-G\+-)O?L_B7XZ^($T*6.*3R[B/P-X7>SUSQ9<(RG>$NKY
M_#6@7$94)<6&M:A&7PK(R;LF^Q45S22[O\.K^2/Y:/C'\3=<^,_Q5^(7Q7\1
MLW]L>/\ Q;K?B>ZA,AE2QCU2^EGL]*MW(!^QZ18FVTNR7 $=I9P1@ **\UHH
MK [DK*RV6B/Z'_\ @BM\-_"OPU\#?'3]L?XGZEIGA;PQI5H?A[HGB77IH[*P
MTS1=--AXA\=:F9I_]8EY?/X3TC3WM5:>XOK+4]*MEN+F<V]>#?MP_P#!7CXD
M?&2^U?X>?LYZAK/PO^$Z//87/BVTDETSXB>/( 6CDN/MT++=>#= NAS;:9ID
ML.NW5M\VL:E#%>7&@VGPO\=?VF=2\6_"_P"%_P"S3\/KJYT;X%?!_1[:);&W
M,EHWQ(^(=U)<:GXO^(WB"'Y)9+:_\1ZEJ\GA#2+W>VB:)+;O<1QZI<W20?(-
M5S65EIW?5OK_ )?+<S4$Y.<M6WHGT6RNN_Y>NH^662:22::1Y9I7>6665VDD
MEDD8L\DCL2SN[$L[L2S,222236EH6AZQXGUO1_#?A[3;O6->\0:I8:+HFDV$
M+7%]J>K:I=166G:?9P("\UU>7<\-O!$HR\LBJ.M95?T+_P#!%C]C+^UM2G_:
M[^(6E9TW1YM0T+X+V%[#F.^UA/.T[Q)X\6.10KP:.#<^'- E_>HVK/KMV$@N
M]&TZX9)7=OZ14Y*,6W\EW?1?UT/V"_80_9.T?]D+X":!X"\NTNO'NN^5XG^*
M.O6X63^T_%][;1K+IUK=8#RZ)X9MA'HFC >7%/';W.K?9X+S5[T/ZO\ M#_M
M*?"+]EWP#<_$+XN^)8]&TS=+;:+H]HB7OB7Q9JJ1>:FB^&-&$L4NHW[@J9I7
MDM]-TZ)Q=ZM?Z?8J]RFC^T%\=O W[-OPE\6_%_XA7;0Z%X8LM]O86[QC4_$.
MMW1,&C>&]&BD($VJ:Q>F.VAW8@M(3/J-Z\&GV=W<0_Q"?M-_M,?$O]JSXI:O
M\3OB3J3/+.\MIX:\-6TTK:#X+\.+,\ECX>T*W? 2"!6#WMZZ"\U>^:;4;]WN
M)CMTD^5))?\  .:$'4DY/:^K[OLOZT1]M_M3_P#!7;]H[XZWFI:#\,]2N_@3
M\-9'FM[;3O"-^\?CK5[,DJD_B#QQ"L&HV<TJ9+:?X5.B6<4<K6=Y-K'E+>2?
ME1>WU[J=Y<ZAJ-Y=:A?WLTES>7U[<2W=Y=W$S%Y;BYN9WDFGFE<EY)97>1V)
M9F))-5:]Y^ O[,OQP_:9\1S>&?@QX!U7Q=<V(A?6=45K?3?#?A^&=F$4VN^(
M]4FM-'TTRK',]K:2W9U"_6"==.L[N2)XQFVWOJ=*48+1**Z_\%O]3P:BOV]T
M'_@A+^TM>V"7.O\ Q1^"^@WLD7F#3K:^\9ZT\+D K#=72>$["W2122LK6C7L
M*D9CEF!S7R3^U#_P3-_:;_95\.7'CKQ9IGAOQK\/;.:"'4_&?P\U.^U:PT$W
M<R06;^(=,U;2M$UW2X+BXDCMO[1&FW.C0W<D%I+JBSW5FEP<K71@IP;LI*[/
MSXK[4_9)_;O^.O[(WB33Y?"/B*^\1?#EKQ'\1_"CQ!?W%SX4U6RDD+7KZ1%-
M]H/A3775FE@US1(X9'NH[<:O;:OIZ2Z=-\5T4D[:H;2:LTFO,_T#_@;\:? _
M[0GPK\'_ !=^'=\][X8\8::+R"*X$<>HZ3?P2/::MH.KP1R2I;ZMHFI07.G7
M\4<DL#36YGM)[FSFM[F;UFOYZ/\ @@E\0M6O/#G[0GPLN[B671=!U?P3XZT.
M!F9H[2^\2VNNZ'XCV@Y$8N8O#/AQU12%+Q3N5W,S-_0O6Z=TF<4X\LG'>WY-
M77YA7D?Q[^+6D? GX,?$OXOZYY3V/@#PAJ^OQVLS^6NIZI!;F'0M%5\KMFUS
M7)M.T>W.Y1]HOH@64?,/7*_!#_@NG\>O^$?^&WPV_9WT>]V:C\0=6;Q[XQ@B
MDQ(GA+PI,UKX>LKN//S6NM^*99M1@8*2+KP8<LHX<;LFPA'FDEYZ^G7\#^9_
MQ'X@U?Q;XAU[Q5X@O9=2U[Q-K.J>(-;U&<YFO]7UF^GU'4KV8C@RW5Y<S3R$
M<;W-8U%%8'<?T#?\$KM>^#7[('[/WQ,_:[^/'B.S\-/\2-9D\ _#?3O+%[XK
M\3:!X+876OP^#M%@(O=5_MOQ7=PZ;?R?N].TV?PG!<ZK>Z;9%KIOGW]JO_@L
M7\??C-<:EX:^"TEU\"?AU(TMO%=:-=I+\3=;M3E!-J?BR$#_ (1LS*$G2Q\(
MBRO+)VDMIO$>KP8<_DAJ6NZUK,.DVVJZKJ&HVV@Z:FCZ';7EW-/;:/I27-S>
MC3M+MY':&PLVOKR\OY;>U2*.:_O;R^E5[J[N)I/L;]G;_@GE^U5^TU:6NN>
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M/5-2OIGN+R^OKRX>2>YN;B9WDEED=F9F))J)2MHM_P O^";4J?-[TOA[=_\
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MTX/=)O?JW?OU_0_$.BOJG]IK]C#]H#]DO5+*T^+WA%+;1-7GDM=!\;^'KO\
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M?5^OS/QZHISH\3O'(C1R1LR21NI1T="5='5@&5E8%65@"I!! (IM26?T0_\
M!'O]O7Q=?^+]/_9/^+WB"\\1:7K&GWC_  <\1:S=276JZ-J.C64NH77@*[U"
MY=I;O1+O2+2\NO#/VJ8S:3>6']@6AN+/4]+M-*_I'K^!3]E36-1T#]IW]G?5
M]*DDCO[+XW?"V2#RR090_C;1(9K5]I!:&\@DEM9X\XEAFDC;Y7-?WUUK!Z>C
MM^1RUHI236EU=KS_ ."%%%?G;_P4%_;X\*_L9^!8;'2H[#Q-\;?&5C<-X$\'
MSR,]IIEH&DMI/&GBQ()$GA\/V-RKQ6-DDD%WXDU*"73K&6"VM-7U/2[;MJS)
M)R:25V_Z^X]C_:H_;-^!_P"R'X7CUKXH:^T_B'4[>:7PM\/= \B^\9^*'C+1
M^;9Z=)/#%I^DQS(T=UKVKSV6E0.C6\=Q<:@T%C/_ #%_M,_\%:/VH?CU<ZAI
M'A#79?@;\/9VEBM_#GP^U"XMO$MW9L2%&O\ CY$M->NIV1GCGAT(>&])N(7\
MJYTNX*^:WYY_$GXE^._B_P"--=^(?Q)\3:GXN\8^([MKS5=:U6;S)I6/RPVU
MM"BI;6&G6406VT[2["&VT_3K2.*TLK:"WBCB7AJR<V]M%^/]>AU0I1CJ[2E^
M"]%^KU]"Q=W=U?W-Q>WUS<7EY=S27%U=W<TEQ<W-Q*Q>6>XGF9Y9II78O)+(
M[.[$LS$DFJ]?47[/'[&?[1G[4=S)_P *@^'6HZMH5K<_9=1\::M+!X?\%:;,
MN#+#-XBU1X+6]O+=61Y]+T8:IJ\<<D<IT_RW5C^CUK_P0A_:5ETP3W?Q7^"%
MKJS1JXTY+[QU<V:.RDF*74QX+BD4H=JLT6FSIDN4+JJF24F]DRW.*=G))]KZ
MGX?U?TO5-3T34;+5]%U&_P!(U;3;B*\T[5-+O+BPU&PNX&#PW5E>VDD5S:W$
M+@/%/!+'+&P#(P(S7U!^TU^Q5^T'^R5?V47Q<\(QPZ!J]R]GH?CGPW>C7?!>
ML7<<;RFS@U:.&WN-/U!HHIIH=*UZPTC5;BW@GNK>REMH9)E^4*0TTU=-->1_
M1[_P36_X*L>(O$/B3P]^S[^U!KHU>ZUV>VT7X=_%S4GCBU*75YF6WT[PMX]N
M,)'J#ZI*8[/1_%4@6_;4GAM?$#WYOSJ]C_177^<RCO&ZR1LR.C*Z.C%71U(9
M65E(*LI *L""" 0<BO[C?^">/Q]O_P!H[]DSX8>/->O&OO&.EV=UX&\<74C^
M9<7?B;P?-_9<FJ7<F?FO?$&DC2/$=YA45;G6)41%15K6$F]']_D<]:"C:459
M/1KHGT^_^MS[9HHHJS **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@#_.7HHHKG/0/ZP?^"$__)H_Q%_[
M.-\7?^JS^$-?M/7XL?\ !"?_ )-'^(O_ &<;XN_]5G\(:_:>MX[+T7Y'%4^.
M7J%%%%,@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "OXM_\ @[Y_YQZ?]W9_^^SU_:17\6__  =\_P#./3_N[/\ ]]GK
MY_BG_D0X_P#[E?\ U,PY^F>#O_)QN'?^ZO\ ^J+,S^0?X;?\QK_N'?\ M_7J
M%>7_  V_YC7_ '#O_;^O4*_ <;_O-7_MS_TW _TRX>_Y$^#_ .YC_P!2JX44
M45RGM!1110 4444 %%%* 20 "22  !DDG@  <DD]!0 E%?U8?\$U_P#@W:NO
MB?X6\._&W]N?4/$_@OP_K]K:ZSX6^ /AN8Z%XRO])ND2XLK[XG:_-#+>^$DO
M[=A*/!VBP0>*(+>>%]6U[PWJ<%UHB_T4^'/^"1W_  37\+:-'H6F_L<_!J[L
MHHEA6X\1Z+>^,-995"C=)XA\6:CK6ORRG:"T\FI-,26)?+-G[7+>!,YQ]".(
MJ.A@85(J5.&)=3V\HM7C)TJ<).FFNE24:G7DL?S[Q7])#@/AO,:V5X6GF7$6
M(PU25+$U\IAA?[/I58/EJ4H8S$XBBL3.#NG+"TJV';32Q#DFE_F345_?!^UW
M_P &ZG[&WQG\/:KJ?[.EOJ/[,WQ02WGN-);2=3UOQ3\,-9U )(\5IXD\)>(-
M0U/4-'M+EQ%;"^\&:II$>EH6O6T#6W0V4_\ &WXS_87_ &E? /[6.E_L6>)O
M -Q9_'37O&6B>#_#NE)*\VA>(D\1W@M]$\7Z+KJ0>1>>!KVT\S5Y/$0A2+3=
M,M-2;5X-/O=*U2RL_*S?AG-<FJ4HXBE&M3KU%2H5\,Y5:52K+X:5G"%2%67V
M83A'GL_9N?+)K[/@?Q>X+X]PV+JY7CJF Q678:IC,PRW-XTL'C,-@Z2O5QMX
M5JV&KX.E_P O:]#$5%03@\3&@ZE-2^:_!G@CQI\1_$NE^#/A[X1\3>.O%^N3
M_9=&\+>#]"U3Q+XBU:YP6\C3M%T:UO-1O90H+%+>VD94#,0%!(_5#P9_P0E_
MX*C>--)AUJ#]FN3PY9W,7FVT/C/XD_"OPQJT@VA@DV@ZCXT37-/E.=OEZKIU
MBX;(8* 2/[;?^">?_!./X'?\$^?A/IGA7P-HVFZ_\5=8TNT/Q4^,M]IT!\5>
M-=::.":_L[&\E1[O0O UE>Q[?#OA*TG6SM;>&&^U-M3\07&HZQ>_H77W&6>'
M5"5"%3-L7B%7G%2>'P;I0C1;7P3JU*=;VLE]IPC"*E=1<XKFE_/'%_TJ,QAF
M5?#<%9-ELLMH5)TJ>99Y#&5ZV.4)-?6*.#PN*P*PE&=KTHUZE>M*FXSJ0H5)
M2I0_S!OC[_P2]_;Z_9ETF]\1?%_]F3XA:1X6TV.2XU+Q=X831_B/X4TNSCY-
M]K7B'X<:KXKTO0;,C&)]<N=-5698GV3$1U\$5_KX$ @@C(/!!Z$>AK^:G_@L
M-_P1)^'7QL\#>,?VDOV3/!.F^!OC[X7L;_Q/XL^'7A'3X=.\,?&G3+.-KS63
MI_A^R2*RT?XFI;QW&H:;>:/;0Q>-+X3Z7K5G<ZWJEIKEGPYWX?SPM"IBLIQ%
M7%*E%SGA*\8/$2A%7DZ-2E&$*LTKOV3I0E)*T)2FU!_1>'WTG,/G.8X7)^-L
MLP>3U,95A0P^=9;.M'+85ZLE"G#'87%U*];!T9R:B\9'%XBG3E).O2HT(U*\
M/X9:*4@@D$$$$@@C!!'!!!Y!!X(/2DK\U/ZT"BBB@ HHHH *Y?QG_P BUJ7_
M &Y_^E]K745R_C/_ )%K4O\ MS_]+[6M:'\>C_U]I_\ I<3BS+_D78__ + L
M5_Z8J'Z6?\&\O_*83]D+_NOW_K+WQKK_ $[*_P Q/_@WE_Y3"?LA?]U^_P#6
M7OC77^G97[GP3_R*L1_V,*O_ *C80_SF\?\ _DLLL_[)G!_^K7.0HHHK[ _#
M0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#^3[_@NQ_P G<?#K_LW+
MPC_ZLSXO5^+%?M/_ ,%V/^3N/AU_V;EX1_\ 5F?%ZOQ8K&?Q/Y?DCMI_!'T/
MT:_X)*_\I!?@!_W57_U2?Q(K^TZOXL?^"2O_ "D%^ '_ '57_P!4G\2*_M.J
MX;/U_1&%?XU_A7YL****LQ"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MCLJ(B*6=B%4$D"HZ_=?_ ((O_L=6'Q)\::K^TY\0-)2]\*?#'5H](^&VGWT
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MQW\1Z<Z2:?X@^,OQ0UNQDC(,;V>J^-]<O[5XR"04:"X1E()!4@@D5G4Z?/\
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M6Z1V]K:6MO''!;V\$<<,$*)'&BHJJ+C&^KVZ>9C5J<ONQ^+J^W;3JW^!\J_
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MJVJ:AJ;1Y!\MK^[FNF3( !V&4KD  XX K.IT^?Z'30O:7:Z^_6_Z&77]2?\
MP0:UFYN/@)\:= =V-II?Q=M=6MT))5)]<\':):714=MZ:!;%L<$@'KFOY;*_
MJK_X(2^&YK#]FGXH^)YHS&OB/XSWMA:E@09K7P]X-\*?OT/1H_MFKWEN"/\
MEI;2@]!E0W^7^15;X'ZJWW_Y7/V]HHHK4Y HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /\ .7HHHKG/
M0/ZP?^"$_P#R:/\ $7_LXWQ=_P"JS^$-?M/7XL?\$)_^31_B+_V<;XN_]5G\
M(:_:>MX[+T7Y'%4^.7J%%%%,@**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI#8Z?90+D[8;6T@A@B7)PD:C/%:,DB0QR2RNJ1Q(TDCL<*B(I9W8]E5023V
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MF,%D-LOA2UT_64@=5%O?:]J04'>SNHJ[7EJ75ERP=MWHOGO^!^G%%%%;'&?
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M11VJX1:;;TTM^O\ 7_ ,:TU))1=]6W;RV_/\"[1116A@%%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!_)]_P78_Y.X^'7_9N7A'_U9GQ>K\6*_:?_ (+L
M?\G<?#K_ +-R\(_^K,^+U?BQ6,_B?R_)';3^"/H?HU_P25_Y2"_ #_NJO_JD
M_B17]IU?Q8_\$E?^4@OP _[JK_ZI/XD5_:=5PV?K^B,*_P :_P *_-A1115F
M(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !7\3W_!R'_P GQ?"O_LU+P/\ ^K>^.=?VPU_$]_P<A_\
M)\7PK_[-2\#_ /JWOCG7T?"O_(VA_P!>*_\ Z2CQL^_Y%\O^OM+\V?E+^P?_
M ,GQ?L9_]G6_L[_^K>\'U_I=U_FB?L'_ /)\7[&?_9UO[.__ *M[P?7^EW7=
MQC_O.#_Z\5/_ $XCEX<_@8G_ *^P_P#2 HHHKXX^C"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "OP"_X+K?'K^Q? WPQ_9ST>]V7_ (TU
M%_B/XTABDVR+X9\.RSZ9X6LKE,_O+36?$<FIZBOR@I=^$(&#8)4_OX2 "20
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M=1)Y:ZEJ5M;+)K>LNF!MGUS6I=0UBY&U0;B^E(50<#UFBBM]C@;NVWN]6(2
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MUKE+_6I6MDN+W3M'TJY;]*Y)$B1Y972..-&DDDD8(D:("SN[L0JHJ@LS,0%
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MB_\ 9QOB[_U6?PAK]IZWCLO1?D<53XY>H4444R HHHH **** "BBB@ HHHH
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M+%?^F*A^EG_!O+_RF$_9"_[K]_ZR]\:Z_P!.RO\ ,3_X-Y?^4PG[(7_=?O\
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M%%?''T84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\(_\
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M!7AY(]!\**L+8%O)<Z+I]IJ%[$@"G4KV]F.Z25W;^T?]JSPC\5?B!^SW\4_
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M%>%!_8>@7%LI)$*:S!:2>(;B)2RK?ZQ=L&.[)^2*_83_ (<A?ME_]!3X*_\
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MA?ME_P#04^"O_A<:_P#_ #%5CRR[/^O^'_/LSLYX?S1^]>7^?]69Z7_P0W^
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MQ5/CEZA1113("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MP9-0E5YFC6)(_"***\JI5J5IRJUJDZM2;O.I4G*<YOO*<FY2?FVV?9X3"83
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5_$]_P<A_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7^?]>I56:MR1MV=NEMDNGKVV[D]%%%:'.%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '^<O1117.>@?U@_P#!
M"?\ Y-'^(O\ V<;XN_\ 59_"&OVGK\6/^"$__)H_Q%_[.-\7?^JS^$-?M/6\
M=EZ+\CBJ?'+U"BBBF0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !7\6__!WS_P X]/\ N[/_ -]GK^TBOXM_^#OG_G'I
M_P!W9_\ OL]?/\4_\B''_P#<K_ZF8<_3/!W_ ).-P[_W5_\ U19F?R#_  V_
MYC7_ '#O_;^O4*\O^&W_ #&O^X=_[?UZA7X#C?\ >:O_ &Y_Z;@?Z9</?\B?
M!_\ <Q_ZE5PHHHKE/:"BBB@ HHHH *4 D@ $DD  #))/   Y))Z"DK]Q_P#@
M@)^R%H'[3_[;MIXN\=Z5!K/P\_9O\/)\5]1TN^A2XTW6O' U6UTKX;Z/J$#@
MK+;V^L27WC$PRJ]K>-X-&G7L4UI>S0R=F78&KF6.PN!HV53$UHTE)JZ@GK.I
M)+5QIP4IR2U:BTM3P.*>(<'PGP]F_$>8*4L+E&"JXN=.#4:E><;0H8:G)IQC
M4Q6(G2P].4ERJ=6+E[J9]T_\$U_^#=JZ^)_A;P[\;?VY]0\3^"_#^OVMKK/A
M;X ^&YCH7C*_TFZ1+BROOB=K\T,M[X22_MV$H\':+!!XH@MYX7U;7O#>IP76
MB+_13X<_X)'?\$U_"VC1Z%IO['/P:N[**)85N/$>BWOC#6650HW2>(?%FHZU
MK\LIV@M/)J33$EB7RS9_1>N/\9?$+P!\.=/BU;XA>./!_@32IY6@@U/QEXFT
M7POI\TR@,T,5[K=[8VTDJJRLT:2,X!!(P17[YE_#>295AU3C@\-5E&*]KBL7
M3I5:M1[2E*=6+5.+?V*?)36GNWU?^:G$WBOX@\99K4Q-7/<UPE.K5E]3R?),
M7B\%@L-"[=.E2P^$J0EB:D(K7$8CVV)F[MU%&T8_@_\ M=_\&ZG[&WQG\/:K
MJ?[.EOJ/[,WQ02WGN-);2=3UOQ3\,-9U )(\5IXD\)>(-0U/4-'M+EQ%;"^\
M&:II$>EH6O6T#6W0V4_\;?C/]A?]I7P#^UCI?[%GB;P#<6?QTU[QEHG@_P .
MZ4DKS:%XB3Q'>"WT3Q?HNNI!Y%YX&O;3S-7D\1"%(M-TRTU)M7@T^]TK5+*S
M_P!1;PUXJ\+^,](M_$'@_P 2:#XLT&[+BTUOPUK&GZ[I%T8R XM]2TNXNK.<
MH2 XBF;:2 <&O)_%W[-WPB\;_'CX2?M)^(/#%O<_%WX)Z!XZ\->!/$\:Q17%
MII'Q!L(=-UFVOV$)FOUM+/\ M*/1%FF":0?$'B%[15;6+PR>/G7!66YFZ%?
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MX;/U_1&%?XU_A7YL****LQ"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MCA/"?AVK2A&%3,*^=8W%2BDG5K?VSCL'"<VE>4EA<)AJ5W=J-.,;V21^H_\
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M@_\ U:YR%%%%?8'X:%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8^CF>74\QCBJ='+,5B*47B<WS#&4N6M3BX3O0Q%*3Y7[LFXO5,_D\_X)T_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_)]_P7
M8_Y.X^'7_9N7A'_U9GQ>K\6*_:?_ (+L?\G<?#K_ +-R\(_^K,^+U?BQ6,_B
M?R_)';3^"/H?HU_P25_Y2"_ #_NJO_JD_B17]IU?Q8_\$E?^4@OP _[JK_ZI
M/XD5_:=5PV?K^B,*_P :_P *_-A1115F(4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7\3W_!R'_P G
MQ?"O_LU+P/\ ^K>^.=?VPU^4O_!7+_@G_P#\-U?L[C_A!]-^V?M#_!S^U?$7
MP1^T^*/^$<TC6?[<NO#W_"?^ ]8^W076@3_\)EH'AZT_X1N\U3^P_P"S?'.B
M^%?MOC/PSX.O/&?]I>SD.,I8+,Z%6L^6E-2HRG=)4_:KEC.5[+DC*W.[KE@Y
M2UY>5^;FN'J8G!5:=)7G%QJ1C:[GR.[BK?::ORJSO)*.E[K^$?X#_$[_ (4E
M\<?@S\9O[#_X2;_A4?Q7^'?Q._X1O^TO[%_X2#_A ?%^C^*O[#_MC^S]6_LG
M^UO[)^P?VE_9>I?8/M'VK^S[SROL\G]YW[(?_!7G]C+]K.S\!^'K;XCZ3\*O
MC?XMTFQ.H?!CXB37^BWECXMNM<L/"Z>#_"OCW5M)T;P)\1M6UO7-2L7\$Z3X
M8U9_&GBC0[ZVU"X\%:%J=IXAT'0/X,?C-\#/C#^SOXYO_AO\;_ASXK^&7C2P
M^U2_V-XJTJ>P_M/3K75]4T'^W_#>HXDTGQ9X4O=6T35K31_%_AB^U?POKOV"
MYGT75[^V3SCY37WV991@\XA2J2J2C.$7[&O1G&<7"6MG%WA.#?O7BXR=E:=K
MI_)X+,,1ETYP4(N,I+VE*I%QE=6U4M)0E;37FCK=P;LU_JT45_F7?L__ +9/
M[4O[+-Y;7'P"^.?Q!^'-A;ZMJFO/X3T[66U3X=ZEKFLZ&GAO4-9U[X8^(8]8
M^'?B/5I='@LK:'4=?\,:E>64NEZ-?64UO?Z)I-U9?I?\-_\ @X0_X*"^!M#N
M])\3S?!/XR7]QJT^HP^)_B1\-;G2]<L+.:SL;:/0;2W^$'B?X5>&GTFUFM+C
M4()K[P]>:XUYJE\ESK-Q81Z98Z=\I7X1QT&_J]?#UX:6YN>C4;N[^XU4@DE9
MW]K=ZZ::^_2XAPLE^]I5J4NME&I#I]I.,FV[_P#+M+3?6Q_=%17\QGPW_P"#
MF'X5:IKEW;_%_P#96^(/@;PTFDSS6.K?#?XC^'/BKKEQKBWEBEMIUWX>\3^'
M/@W86>DS6$FIW,^LP^)[^\M[RTL;&/0;J'4;C4-+^P_AC_P7_P#^"=WC[^W/
M^$J\2?%?X)?V3_9OV#_A9WPOU/5O^$F^W_VA]J_L/_A3-]\7/L_]B_8[;^TO
M^$D_X1_S?[6T_P#L?^UO+U3^S?(JY'FU&_/@:[M9OV2C7W=E;V,JG-OJE=I7
M;LDST*>:9?4MRXJDKW7[SFI;*^OM8PMY-V3>BNS]L**^$?AO_P %//\ @GU\
M5=#N_$/AC]KKX)Z786>K3Z--;_$CQ=;?!O7'O+>SL;Z2:T\,?%]/ WB6_P!)
M:'4;=(->L=)N-#NKR.^T^VU&:_TO4[:T^@OAO^TM^SE\9-<N_#'P@^/_ ,$_
MBKXEL-)GUZ^\/?#?XJ^!/'.N6>AVMY8Z?<ZS=Z3X8U[5+^WTFWO]4TRQGU&:
MW2SAO-1L;:299KNW23AJ87$TN;VN'KT^3XO:4:D.7_%S15OG8ZHUZ$[<E:E/
MF^'EJ0ES>EF[_(]LHHHK U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** /\Y>BBBN<] _K!_P""$_\
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M (?/?\%/O^CO/'W_ ((_A_\ _,?7Z1_Q$?*/^@+,O_ ,+_\ -/K_ $]/Y/\
M^)4N./\ H?\ "G_@_-__ )T'^EE17^:;_P /GO\ @I]_T=YX^_\ !'\/_P#Y
MCZ/^'SW_  4^_P"CO/'W_@C^'_\ \Q]'_$1\H_Z LR_\ PO_ ,T^O]/0_P")
M4N./^A_PI_X/S?\ ^=!_I945_FF_\/GO^"GW_1WGC[_P1_#_ /\ F/H_X?/?
M\%/O^CO/'W_@C^'_ /\ ,?1_Q$?*/^@+,O\ P#"__-/K_3T/^)4N./\ H?\
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M=*$KW]T****\P^N"BBB@ KE_&?\ R+6I?]N?_I?:UU%<OXS_ .1:U+_MS_\
M2^UK6A_'H_\ 7VG_ .EQ.+,O^1=C_P#L"Q7_ *8J'Z6?\&\O_*83]D+_ +K]
M_P"LO?&NO].RO\Q/_@WE_P"4PG[(7_=?O_67OC77^G97[GP3_P BK$?]C"K_
M .HV$/\ .;Q__P"2RRS_ +)G!_\ JUSD****^P/PT**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MFA7T%X(_9+_:J^)OA?2_''PW_9F_:"^(/@O6_MO]C>+_  1\&?B-XL\+ZO\
MV;J-WI&H_P!EZ_H/AN_TF_\ L&K6%]I=[]DNY?LNHV5W93^7<VTT2<U;"Y?R
MKZQA\'R<RM[:C0Y>:SM;GC;FMS6MK:_2YO3KXOF?L:V)YK._LZE7FY;J]^5W
MM>U^E[>1]L?\/N_^"H'_ $<Y_P"87_9[_P#G3T?\/N_^"H'_ $<Y_P"87_9[
M_P#G3U\I?\,'_MQ?]&:?M6_^([_%[_YCZ/\ A@_]N+_HS3]JW_Q'?XO?_,?7
M-]5R3_H'RK_P3A/_ )$V]OFG_/['_P#@S$?YGU;_ ,/N_P#@J!_T<Y_YA?\
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M$/\ %[_Y^=?*7_#D3_@J!_T;'_YFC]GO_P">Q1_PY$_X*@?]&Q_^9H_9[_\
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ML!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MDJ\YU6U_@I^RY>UN>7>_0]REPY22_?XFI)]J48P2?^*?M+^O+'T1_&_\-_\
M@VJ_:-U37+NW^+_[0_P3\#>&DTF>:QU;X;Z7X[^*NN7&N+>6*6VG7?A[Q/HW
MP;L+/29K"34[F?68?$]_>6]Y:6-C'H-U#J-QJ&E_5OPW_P"#9[X5:7KEW<?%
M_P#:I^(/CGPT^DSPV.D_#?X<>'/A5KEOKC7EB]MJ-WXA\3^(_C)87FDPV$>I
MVT^C0^&+"\N+R[L;Z/7K6'3KC3]4_ISHKR:G$F<5+KZTJ<6K<M.C1C;S4G3E
M43?6T_2R.^&2Y="W[AS:=[SJ5'\G%34&O6+\[GXG_#'_ (( ?\$[O /]N?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MI.7?;T"BBBF2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MT445L<84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9_\ OL]?VD5_%O\ \'?/_./3_N[/_P!]GKY_BG_D0X__ +E?_4S#GZ9X._\
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M *.0^ O_ (>#X>__ #14?\-4_LP?]'(? 7_P\'P]_P#FBK#ZAP__ - >3?\
MA/@O_D/)?<=_^L?B7_T/N.O_  Z9_P#_ "_R7W'R#_PYH_X)B_\ 1H/P[_\
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M_P"QA5_]1L(?YS>/_P#R666?]DS@_P#U:YR%%%%?8'X:%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 ?R??\%V/^3N/AU_V;EX1_P#5F?%ZOQ8K]I_^
M"['_ "=Q\.O^S<O"/_JS/B]7XL5C/XG\OR1VT_@CZ'Z-?\$E?^4@OP _[JK_
M .J3^)%?VG5_%C_P25_Y2"_ #_NJO_JD_B17]IU7#9^OZ(PK_&O\*_-A1115
MF(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MY<C0[1F7<&:?PE?#.TJJA65_QEHHYI=W]X.$']F/R5ORL?VN_LA_\%*?V?\
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M]7O(-/TG1]/O-5U2_N7$=M8Z=I]M)=WMY<2'A(+:VAEFE<\+&C-VK^:?6?\
M@O3\14UC5DT#X#^!I]"34KY-%GU/Q'X@CU*;25NI1ITNH1V\?D1WTEF(7NT@
M_<I.9%C^0+7Z/_\ !7GX]?\ "FOV1?$7AC2[W[-XK^-M_'\--+2*3;<1^';N
M&2_\=7NS(+VC^';:7PY<LIS%/XFLVP037\<%$Y-.R?K^@Z4(R3<E?6R^7]?U
MU_>[_A_9\7/^B!_#G_PIO$W_ ,:K[J_8 _X*1?&#]M'XO:SX'U#X0>#/"7@[
MPKX2O?$_B?Q-I6L:]?75M*]U:Z9H6DVT=XBVOVO5+ZZDN )B<Z=I>IO&/,B4
MU_)/7]=W_!&+X"_\*L_99?XE:K9?9_$_QVUU_%!>2/R[F/P5X?-UHG@VUD!&
M6BN9#K_B2TD#%9;+Q';':"O*BVWOZ_A_P/Q[CJ0A&#:CJ[):O?[^R_J[/UZH
MHKY%_;L^/(_9Q_99^+'Q)M+P6GB8:#)X7\#,K[;@^-/%I_L/0[FV7(\V319+
MJ;Q'/&&4M9:-=D'(%:['.E=I+=M+[S\D_CA_P6_\4^ OB]\1O _P]^$?@GQ9
MX.\'^+=8\,:+XFU/Q!K<%UKT6A73Z9=:L([&,VHL[Z_MKJXTTQ??TY[5Y/WC
M/7E?_#^SXN?]$#^'/_A3>)O_ (U7X)$EB68DL2222222<DDGDDGDD\DTE8\T
MN_\ 7]+^KLZU2A_*OQ\O/R_/NS^NK_@GO_P44^+W[:WQ-\6>&-6^$G@[P?X+
M\$>$QKVO^)=(U?7-0NDU74=0AT_P[H<,5XJVZ3:H$UB_\R7(%IH=ZJ_O&CKW
M_P#:G_X*3?LU?LK2WWA[7O$,WCWXEVJ.I^&_@)K75-6L+G'[N+Q3JLD\>B^%
M0&,;3VNHW;Z\MM(MU::%>Q%=W\K/PR_;(^(7P*^ GB#X-?!-YO >N_$;Q%=:
M[\3_ (H6,XC\8ZEIMO9II/AWP=X5O(0K^&](TNS%_J5UK-O)_P )!<ZGKU];
MV%UI-E;.VJ?($LLL\LD\\DDTTTCRS32NTDLLLC%Y)))')>221R6=V)9F)9B2
M2:?.TK;ON_T_X/7N1[%.3>T=+);NRW;N^OS]&?LW\6O^"W_[4/C"[NH?A;X>
M\!?!_12[&RD33!X\\5Q(<@"\U?Q-$/#=R0,,OD>"[/#;@S2K@#Y4G_X*>_MX
M7%T+N3]HGQ,LH9GV0>'_  ):VN79F(-E;>%8K(J"QVH;<HBX5%554#X+HJ>:
M7=_>:J$%HHKYJ_YW/V"^#W_!:O\ :T\#:I9CXG?\(C\:?#@EC74;75M TOP;
MXD-HI&Y=)U[P;8:7IEK=[1@7&K>&M<1^=\1D;S5_ID_9G_:7^&?[5GPNTWXI
M?#&_GDL)YWTS7M!U)8H=?\)>(K:*&6]T#7;6&6:*.ZBCG@N;:YMY9K/4+"XM
MKVTF>*;"_P #-?JW_P $G?VL/#'[,'Q3^*D_Q,\2-HGPM\1?"W4M6U:V&Z>:
M\\7>$+^RN_"\6DV =3?ZW?V6H^(=$T^RB\MKF?586GGAMK:26.HR:>KT??IY
MF=2FFFXJTET2W\K+]#^P#4=2T[1["]U75K^RTO2].MIKW4-2U&Z@L;"PL[:-
MI;B[O;RYDBM[6VMXE:6:>>2.**-6>1U4$C\>OVD/^"T7[//PGN;_ ,.?!_2[
M_P"//BJT:6WDU/2;U?#_ ,.;2Y0E&QXJN;2]O->\IR)$;P]HMYI%]$"L'B"(
ML'7\+?VU_P#@H=\8/VP->O=*EO+WP-\&+.]+>'?AAI5\ZVUW';R[K35_&UW!
MY7_"3:ZVU)DCG7^QM&<+'I%E%/\ :]1O_P ^Z;GV^\4**WGOV7ZO\[?)GZP_
M$7_@LY^VMXRNIV\+:]X'^%6GN[""S\'>"=)U:X2WSA$GU#QZOC"62XV8$MS:
M16 9RSP06P*HGB=K_P %/?V\+2[^V1?M$^)7FW;MEUX>\"7MIG(./L%[X4N+
M';D?=^S[<9&,$@_!5%1=]W][->2"^S'[D?O%^SA_P7"^*V@:WINB?M+>&=%\
M?>$;F>&"^\9^#]+M_#?C?1TD<++J4VCVDL/A;Q#;P+\S:99V/AJY*F22/4)V
M2.TD_I>\$^-?"OQ'\)>'O'?@?7+'Q)X2\5Z5::UH&N:=(9+34-.O(Q)#,@=4
MEAE7YH;FTN8X;NRNHYK2\@@NH)H4_P [^OZ@/^"$/Q7UGQ#\*?C-\(-4NYKK
M3OAKXH\->)O#*3R-)]AT_P"(=OKR:IIEF"2(;&#6/"DVK>2H"B^UZ^G&6N'(
MN,FW9Z]C&K3BES15K;I;:Z?+Y'[T4445H<YY7\</BKHGP.^$'Q'^+GB'8^E_
M#_PEK'B-[5I1"=3O;*U?^R=%AE((2ZUS5GL='LR1C[5?0@D DC^=G_A_9\7/
M^B!_#G_PIO$W_P :KZ6_X+G_ !Z_X1KX6?#S]GK1[W9J?Q*UEO&GB^"*3$B>
M#O!\ZIHME=QY&;?6_%DL>H6S@']_X.F4E00'_E[K.4FG9:6_X?\ KYG12IQ<
M;R5[O3?;_A_P/WN_X?V?%S_H@?PY_P#"F\3?_&J_4'_@G3^V_P#%3]MB+XE:
M]XJ^&/A;P)X-\"R:'I%AJFB:GK.H7&M^)M66ZO;JPC_M!5@2'1M*M[:XO]H\
MX/K&E[/D:6OXT*_N(_X)T_ 7_AGG]DCX6>$+ZR^Q^*O$FF?\+%\<(\?E7(\3
M^-8K?4VLKU,#%YH&B#1?#$W+ G1 0S Y)!MO=V2_K^O7NPJQA&.BLWHM7TM=
M_A;Y^;/N"BBBM#G$)"@LQ 4 DDD   9))/  '))X K^;OXD_\%UO%^@_$'QM
MH7@/X.>!O$?@O1?%.NZ3X6\1:CXBUZ&]U_0M-U*XL]-UN>&TB^SP'5K6&/4$
M@B++#'<)$7D9"[?JI_P4G^/7_#/O[(?Q.\16%[]B\5^,[)?ACX)=)/*N!KWC
M2"ZLKN]M) =T=WHGAF'Q!X@M9%5L7.E0J0 ^X?Q$5G.3323]?T-Z4%)-R5U>
MR^6K_3\3][O^']GQ<_Z('\.?_"F\3?\ QJOK?]B/_@J3\:/VO?C[H/PC7X+^
M!O#^@'1]=\3>,?$FGZWXAO;O0?#NBV@1;J&VN$2"26_UZ]T/1(?.<1QRZJDS
M!Q$4;^5JOZE/^"&OP%_X13X.>._C]K%ELU;XJZ[_ ,(QX5GEC^=/!/@F>>"_
MN[20@%8M9\73:E9WD?S*S>%+&0$<BE%R;2N^[]-/^!^/F54A",&U%7V6KW?S
MZ)7^_NS]U***YCQMXOT+X?>#?%?CSQ/=BQ\.>#/#FM>*M>O#M_T;2- TZYU3
M4)E#,H9TM;64QIN!D?:@.6%:G,?S$_\ !<?X]?\ "8?&SP1\!='O?,T?X1Z!
M_;_B>&*3Y'\<>.+>UO+>VNHU)5WT?PC!HUQ9R,0\3>)=2AVC)9OPTKT;XO\
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M#OVG=8TOX?\ BG3[CX-_%?57CM=)T#7M3@U/PMXJOY,JECX7\6K;Z<K:K<.
M+?1-;TW2;NZEF@LM'FUNZ+JO\=-20S2V\L4\$LD$\$B30S0NT<L,L;!XY8I$
M*O')&ZAT=&#(P#*00#34VO/U_P R94H2Z6?=:?AL?Z,E%?FW_P $MOVIM9_:
M?_9ILKCQK?OJ7Q)^%^K?\(#XPU*X<O>>((+:QMKWPUXINR<E[O5M(G%EJ=Q(
M[2WVN:-J^H.L:W<:#])*U3NK]SD:<6T]T[%#5=4T_0]+U+6M7O(-/TK2+"\U
M34[^Y?R[:QT_3[>2[O;RX?G9!;6T,LTKX^6-&/:OYI]:_P""]/Q%CUG5H_#_
M ,"/ ]QH*:G?IHD^I^(O$,6I3:0MU*NFRZA'!%Y$=])9B%[M(?W23M(L?R!:
M_2+_ (*[?'G_ (4U^R'XF\.:9>_9O%?QKOHOAEI*1R;;B/0+Z&2^\<WOE@JS
M6C^&K6X\/SNI_=7'B2Q8A@<5_&Y43DTTD_7]#:E34DY25];+Y;_?^G9GW7^V
MU^WE\0/VVM0\!2^*_#&B>"M'^']GK<>F:#X?O]1OK2ZU/Q!/8MJ.KWDM_M=[
M@VNEZ=96T80K;1Q7#1L#>3 _"E%%9MWW.A)1225DN@5^W7PY_P""V'CWX7>
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MN P( KZ(^'7_  6M_;'\)7-O_P )F_PZ^*NGAE%W'XB\(6_AS5)8@<N;._\
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MC);7?%#V^W[#9S2(D_\ PCOAN*232] @=85:+[7JTMM!J&L:@'<>9O=V6_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7\6__  =\_P#.
M/3_N[/\ ]]GK^TBOXM_^#OG_ )QZ?]W9_P#OL]?/\4_\B''_ /<K_P"IF'/T
MSP=_Y.-P[_W5_P#U19F?R#_#;_F-?]P[_P!OZ]0KR_X;?\QK_N'?^W]>H5^
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M>69[BYD9F/4DGO43>B7??Y6-Z"O)OLM/G?\ 1/[S K[=_8%_9"N?VR?CG!X
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MX2MI PV[[:S7Q)X@MI V^"_T*Q<*=P9?ZY*T@M&^_P"7]?D85Y7:CV5WZO\
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M2KFVU_QG:2 63*HFT_PI*$\[?XBU"SM?W6IJ(D:+'&JHB*J(B*%1$4!5554
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M69B0%4 DD@ 9-?Z%?PM\/W7A/X9?#KPM? K>^&O GA'P_>*W+"ZT;P_I^G7
M)R<D2VS@\GGN>M?Q1_\ !/;X+/\ 'C]KWX,^#9[0W6@:5XE@\=^+@R;[9?#7
M@7'B2\MKW@E;;6KNQL/#FX#/GZS"NY-V]?[EZT@MW\OZ_ YZ[UBNUV_G:WY,
M*_$;_@K?^WU<?!3PW+^SC\)-9-M\5?&^C^;XY\1:=<%;WX>^#-3B*Q6%G/"P
M>R\6>++9I#;S!UO-$\/LVJ0I!>:OH6HV_P"G/[47Q_\ #O[,?P,\>_&7Q$L-
MT/#&E%- T:2;R7\1^+-2<6/AK0(F7,H74-5F@^W30)+)8Z5%J&I&)HK*7'\(
M_P 0?'GBGXH^-_%7Q$\;ZI-K7BSQGKFH>(=>U*<G-QJ&HSO/*L,>2EM9VX9;
M:PLH=MO8V4-O9VR1V\$:*YRLK+=_E_7ZBI0YGS/:+^]_\#?[CCZ**_93_@DK
M^PG:?M">.)_CC\4M'6]^#WPSU>&#1]%OX0]A\0/'UJL%[%IUW!*C1WOAGPS#
M+;:AKL$G^C:I?W.EZ/*MY8MKEM'FDV[(Z9244V]E_5C7_85_X)$^*OCUH^C_
M !8^/NHZS\./A=JL5OJ/AKPOIL45OX]\<:;*$FM]4>2_M[BW\*>&[^)@]C>7
M-E>ZOK%J6N;*QT^PN-.UFY_>?P=_P3H_8E\$Z5%I.F?LY_#O5HXXA')>^,=-
ME\<:K<,8VCDGEU+Q;<:Q=)+)N:0BV>WABD(:WBA$<2Q_:JJJJJJH55 554 *
MJ@8"J!@     # ' I:U44NEWW..524GNTNR=E_P?F?BM^V-_P1Y^#'Q%\'ZS
MXI_9LT"V^%OQ5TNTN+^P\,V%]<KX#\;201M*=$N-.U"XN(/"VIW:H(-)U/1Y
M;#1X;EA'J^G20W#:E8?RFZGINH:+J6H:/J]E=:9JNDWUWINIZ=?026U[I^H6
M,\EK>V5Y;3*DMO=6ES%+!<02HLD4L;QNJLI _P!%NOXO_P#@K7\/]+\ _MQ_
M%%M&MXK.R\;6'A7Q^]K"BI&FJ>(=#MH]?N,+UEU/Q!I^J:O<.WS-<ZA,>A!J
M9Q2U7S_S\C:C-N\6V[*ZOTZ-?BK'YKT445F;GZ#_ /!,'X"_\+[_ &P/AQI^
MH67VOPG\.IG^*WB\/'YENUCX.N+2?0[*X1AY4T.J^+[GP[IUU;2'$VG3W[;)
M%B=#_;#7XD_\$0?@+_P@WP"\5_'#5[+RM<^,_B(V6ARRQ_O(_ G@:>]TNUDA
M+@20_P!J>*9_$CW"H!'=VNF:/<[I%6+9^VU;05EZZ_Y?UYG)6E>;72.GSZ_C
MI\@HHHJC(**** "BBB@ HHHH **** "BBB@ HHHH **** /\Y>BBBN<] _K!
M_P""$_\ R:/\1?\ LXWQ=_ZK/X0U^T]?BQ_P0G_Y-'^(O_9QOB[_ -5G\(:_
M:>MX[+T7Y'%4^.7J%%%%,@**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "OXM_^#OG_G'I_P!W9_\ OL]?VD5_%O\ \'?/
M_./3_N[/_P!]GKY_BG_D0X__ +E?_4S#GZ9X._\ )QN'?^ZO_P"J+,S^0?X;
M?\QK_N'?^W]>H5Y?\-O^8U_W#O\ V_KU"OP'&_[S5_[<_P#3<#_3+A[_ )$^
M#_[F/_4JN%%%%<I[04444 %%%% !1110 5Z;\*?C5\8/@3XBN_%WP4^*7Q!^
M$GBF_P!(N/#]]XC^&_C#7_!>MWNA75W8W]SHUWJ?AV_T^\N-+N+[3-.O9K":
M9[62ZL+.X>(RVT+IYE150G.G)3IRE"<7>,X2<91?=2333\TS*O0H8JC4P^)H
MTL10JQY:M"O3A5HU([\M2G4C*$XW2=I1:TV/M#_AX[_P4"_Z/;_:L_\ #^?$
M_P#^::OE7QGXT\7_ !%\4ZWXX\?>*-?\:>,O$M\^I^(O%7BG5K[7?$.NZC*J
M)+?ZOK&I3W-_J-Y(J()+F[GEF<*-SG%<S16E7$XFNE&MB*]:*=U&K5J5$G:U
MTIR:3LVKK6S./!Y1E.75)5<ORO+L#5G#V<ZF#P6&PU2<+J7)*="E"4H<T8RY
M6VKI.UT@HHK^['X1?\&[7_!/CQM\)_AAXSUJ;X\#6?%WP\\%>)]6%G\2M+@M
M!J>O^&],U6_^RP-X-E:&V^U7<OD1-+(T<6U#(Y7<?4R;(<?GLZ\,#["^&C3E
M4]M4=-6J.2CRVA.[O!WVMH?(<>>)7#?AS1RVOQ$LP<,UJ8FEA?J&%ABI<V$C
M1G5]JI5Z/(K5Z?*TY<SYM%;7^$ZBOZ1O^"VW_!*W]EW]@'X.?!GQU\!9/B4^
MN>._B9J?A/7!XW\6V7B*R&E6GA:^UB(V5O;:!I#6]U]KMX]TS32JT6Y/+!(8
M?S<URYIEF)RC&5,#B_9^WIQIRE[*;G"U2"G&TG&+;Y9*^FC/9X/XNRGC?(L/
MQ#DGUK^S\35Q-&G]<HQP]?GPM:="KS4HU*J2YX/E:F[QL[+8****\\^G"BBB
M@ HHHH *Y?QG_P BUJ7_ &Y_^E]K745R_C/_ )%K4O\ MS_]+[6M:'\>C_U]
MI_\ I<3BS+_D78__ + L5_Z8J'Z6?\&\O_*83]D+_NOW_K+WQKK_ $[*_P Q
M/_@WE_Y3"?LA?]U^_P#67OC77^G97[GP3_R*L1_V,*O_ *C80_SF\?\ _DLL
ML_[)G!_^K7.0HHHK[ _#0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M#^3[_@NQ_P G<?#K_LW+PC_ZLSXO5^+%?M/_ ,%V/^3N/AU_V;EX1_\ 5F?%
MZOQ8K&?Q/Y?DCMI_!'T/T:_X)*_\I!?@!_W57_U2?Q(K^TZOXL?^"2O_ "D%
M^ '_ '57_P!4G\2*_M.JX;/U_1&%?XU_A7YL****LQ"BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_B
M>_X.0_\ D^+X5_\ 9J7@?_U;WQSK^V&OXGO^#D/_ )/B^%?_ &:EX'_]6]\<
MZ^CX5_Y&T/\ KQ7_ /24>-GW_(OE_P!?:7YL_*7]@_\ Y/B_8S_[.M_9W_\
M5O>#Z_TNZ_S1/V#_ /D^+]C/_LZW]G?_ -6]X/K_ $NZ[N,?]YP?_7BI_P"G
M$<O#G\#$_P#7V'_I 4445\<?1A1110 4444 %%%% !1TZT5\F?MU?%>7X*?L
MC_'CX@V=R;35K+P+?:#H%RC%9K;Q%XUGMO!F@W< !#--8:IK]K?J!D!;5G<>
M6CD&PTKM);MI?>?R-_\ !0+]H>?]I;]J;XD^.K:^:[\(Z+J+^!/AXBR>9;1^
M"_"=Q<V-C>6G+;8O$6H-J?BMU+,4GUV6,$(B*OQ=117/N=R2226R5CZ"_98^
M!.J_M*?'[X:?!O3#<00>+?$$*^(-1MUW/HWA'2XY-6\5ZNK,K1+/9:#97SV*
MS[8KG4FLK,L'N4!_O+\->'-$\'^'=!\)^&=-MM'\.^&='TW0-!TFS3R[33-'
MTBSAL--L+9,DK#:V=O#!&"2VU!N).2?YX_\ @@[\$X9&^,O[0VIVBO+ ]C\)
M?"%R\>?)9H[+Q5XWDC+@@2-')X+MX9HL.L3ZA 7V3.A_HWK6"LK]7^1S5I7E
MR](_F]_\OO"BBBK,0HHHH **** /P8_X+H?'J;PU\,/AQ^SWHMZ8KSXE:O-X
MT\910R%7/A+P?/"FA:==QYPUIK/BJX74X2 2+GP;@LJG$G\OU?I/_P %:/B;
M+\2?VX/B?;I<&?2OAQ9^'/AGHX+%O(CT#2X]0UV#&2J>7XPUKQ(-JXX(+ .6
M%?FQ6,G>3^[[CMIJT(^:N_G_ ,"R"OZ_/^"/O[,$'P3_ &;K3XHZ]IRP_$'X
M])9>++B:>("[TSP!"LO_  @ND1LR[HXM2L[B?Q;<-&4^T#7K"WN59]+@*?RT
M?L[_  ME^-OQU^$OPGC\U8?'OC[PUX>U*:$D2VFAW>I0'Q!?H0"0VGZ''J%]
MP,_Z/QCK7]^^G:?8Z3I]CI6F6L%CINF6=MI^GV5M&L5M9V-E"EM:6MO$H"QP
M6\$<<,4:@*D:*H& *J"W?R_K^NIG7E9*/?5^BV_'\BY1116AS!7SO^UO\1(?
MA1^S'\>/'\LZ6\_A_P"%WB]M*DD;:K>(=2TBXT?PU;ENQN_$.H:9:@C+;IAM
M#-@'Z(K\)_\ @N5\?K?PO\(/!'[/.DWH&O?%#6X/%_BJUC<%X/ W@^Z\S3(;
MN/(9$USQBMC=6$@#JS>$=2C8*0A*;LFRH1YI)>>OHM_P/Y;Z***P.X_HY_X(
M&>#9E@_:1^(4\1%O-+\._!NF3;?E>:V3Q1K>NQ;B,9BCNO#K[5)XFRP'R9_9
MS]K[XXV_[.7[-WQ9^+C30Q:KX;\+75OX4CFVL+KQIKKQZ%X1@\ELF>)=?U&P
MN;V-%9DTZWO)V CAD9?F?_@DQ\'9OA%^Q9\/[C4;4VFN?%6_U7XM:K&Z%7^S
M>)Q:67A9]S89H[GP7HWAR_52%6-[V55!):1_SR_X+M_'K=)\)_V;='O>(Q+\
M6/'$$4G&]_M_ASP/8SF,\%$'BO4KFSF)R)=$O/+'[B0Z_#"_E^?^5SE:YZK[
M7UZZ16OWVT]3\!Y?B=\29I))IOB%XWEEE=Y99'\5Z\SR22,7=W8WY+,[$LS$
MDDDD\FF?\+*^(O\ T/WC7_PJM=_^3ZXJBLCJ.U_X65\1?^A^\:_^%5KO_P G
MT?\ "ROB+_T/WC7_ ,*K7?\ Y/KBJ* />OA%_P +B^,?Q1\ ?"OPUX\\;-K?
MC_Q;H?A:QD_X2;7I8[,ZO?PVL^I7"KJ"D6>EVKSZE?.658K.UGE9E5"1_>=X
M3\-:;X,\+>&O"&C"?^R/"N@:/X<TO[5,]S='3]$T^WTVS-U<R$R7%RUO;1F>
MXD)DFE+RN2S$U_,!_P $.?@+_P )A\;?&OQYUBR\S1_A%H']@^&9I8_D?QQX
MX@NK*:XMI&!61]'\)0:U!=QJ \+>(],FWKE0_P#4_6L%I?O^7_#_ )'+7E>2
MC_*OQ>OY6"OX-OVR/@%K?[-?[1GQ,^%^JV$UKI=GX@O]:\$W;QNEOK/@+7;R
MXOO"NI6DI'ESA-/==-U#R'DCM-:T[5-.:0S64H']Y-?'_P"U_P#L4_"']LGP
M=:Z#X_M[K1?%6@+<OX+^(>A1VX\1>&IKD S6KK.I@UGP_>2I$^HZ%>LL4Q03
MV-UIFHK%J$3E&ZTW7]6)ISY&[[/>W3L_/^O1_P *]%?I)^TK_P $L?VJ/V>)
MM0U6R\*R?%_X?VIEEB\:?#6TN]6N;:R3+";Q#X.19?$FB/%"#-?3PVVK:#9@
M,#K\H4M7YNNK(S(ZLCHQ5T<%65E)#*RD JRD$$$ @@@C-9--;JQUII[-/T8V
MOI7X,?MA?M,_L_26J_"GXR>,_#NE6C*8_"]SJ/\ ;_@UE!&Y6\(>(H]5\.*9
M$S&T\.FQ72H1Y5Q&ZHR_-5%(;2>Z3]=3^C/]G;_@NH[36&@?M._#:&.%S%;R
M?$/X7)*/)Z1BZUGP-J]Y,TJ<B>^O-"UY70+(+#PW*S1VX_>WX5?%_P"&7QP\
M'V/CWX3^--#\<>%-0)2/5-%N3(;:Y5$DDT_5;"=(=1T758$DC:YTK5[2RU&V
M$B&>UC#H6_SWZ^KOV/?VM/B#^R%\6M)\?>$[R\O/#%Y<V=C\1/!'VEDTOQGX
M8$^;JUE@<FW@UNPBDGNO#FL[/M&EZ@2K&;3;S4["]N,WL]N_7_@_F8SHIJ\=
M'VZ/_)_A^9_=U17-^#O%N@^/?"7ACQQX6ODU/PUXP\/Z/XGT#48P0E[HVNV%
MOJ>FW(4_,AFM+F)VC;#QL3&X#*0.DK4Y0K\8_P#@ME\>O^%=_LW:)\'M)O?)
M\0_''Q$EKJ$<4FR>/P)X,FL=;UY]R'S(OM^NR^%M,VMLCO=/GU>W+.B31G]G
M*_BX_P""J_QZ_P"%Y?M@^.X=-O?M7A/X3+'\)_#7ER;K>2;PS<W3>++Y A,,
MC77C&[UR"*\B+?:M,LM+/F-'%$%F;LO73_,UI1O-=HZ_Y?CK\C\WJ**^C/V2
M?@A=?M&?M&?"?X01Q3/IWBGQ5:/XGE@WJ]GX-T5)-<\7W2RK@0S1^'M.U%+-
MW9%>_DM( PDF0''<ZV[)M[+5G]6O_!*/X"_\*._8^\$7>I67V7Q9\7))/BOX
MC,D>VXCM?$=M;1^$;%F8"5([?P?::+=O:2!1:ZEJ6J 1J\DK/^D]5[2UMK&U
MMK&RMX;2SL[>&UM+6WC2&WMK:WC6&"W@BC"I%##$B1Q1HH1$554  "K%;I62
M78X&[MONVPK\&_\ @NA\>O\ A&_A9\._V>]'O=FI_$G66\:^+X(I/WB>#_!\
MZIHEG=QDC-OK7BR:/4+9P&/G^#IE)4'#_O)7\-__  4-^/7_  T3^UI\5/&M
MC>_;?"NAZJ?A_P"!G23S;4^%/!;S:5;WUDV2?LGB#55U;Q1&#@JVN."J8V+,
MW96[_P!?\#YFE&-YWZ1U^?3_ #^1\3T45]F?\$__ ("_\-%_M7_"GP%>V7VW
MPMI^LKXW\=(\?F6Q\'^#6CUC4;*]&"5MM?NXM/\ "^\ E9]<A.5&77):M+N=
M3:2;>R5S^KW_ ()U? 7_ (9X_9(^%GA"^LOL7BKQ'IG_  L7QRCQ^5<CQ1XT
MBM]2>RO4P,7F@:*-%\,3=03H@(9@<G[?HHKH6B2['"VVVWNW<_*O_@L%\>O^
M%/\ [)&M>$-+O?LWBKXXZG'\.M/2*39<Q^%S%_:?CJ]"9'F6<NB01^&+S[Q4
M^*K<[3RR_P ==?K1_P %D?CU_P +9_:ON_ .EWOVGPM\"M&C\$VR12;[63QA
MJ)AUCQQ>H,DI<P7;Z9X7O4(7$_A7@$'<WY+UC-WD_+3^OG<ZZ4>6"[O5_/;\
M+?.X5_6U_P $7_V<H?A;^SE<_&36].6+QG\=;_\ M2TGGB"W=C\.]!GN-/\
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M&9+?Q9XT"LP(65X_^$)2-X]KK$UU&QV3X/\ 1U6L%97[_D<U:5Y<O2/YO?\
MR^\****LQ"OYHO\ @O9\1(;SQI^S_P#"FVN$,WA_PUXN\?:O;JV6QXJU/3M
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MNMSZGJ:R&SDTZWL_T(K:,;+S?X>7]?H<M6?,[+X5MYOO_E_P0HHHJC(****
M"BBB@ KY[^.?[5?[/G[-U@MY\9?BAX<\(74\!N+'P^TT^K>+=3B^8)+IWA/1
M(-1\0W5L\B^2;]=.&G0RLHN;R!3N'YG?\%-?^"G,W[/]Q?\ P&^ E[97/QBE
MM(_^$R\9M';W]G\,K:^@2>VTW3K2=)K._P#&UY:31W;?;(YK#P]9RV\D]K>Z
ME=K%IG\L_B/Q+XB\8:YJ?B?Q9KNK^)O$>M74E]J^O:]J-WJVL:G>2X\RYO\
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M@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5*A6E"C7Q*IU8N&(I5J7+--0;E"Z;2339YS_ ,0LOP2_Z.Q^*?\ X;_PE_\
M+:C_ (A9?@E_T=C\4_\ PW_A+_Y;5_5+17ZW_J=PW_T*Z7_@[%?_ "_R_/NS
M^(?^(Z^+'_18XS_P@R?_ .=WE^?=G\K7_$++\$O^CL?BG_X;_P )?_+:C_B%
ME^"7_1V/Q3_\-_X2_P#EM7]4M%'^IW#?_0KI?^#L5_\ +_+\^[#_ (CKXL?]
M%CC/_"#)_P#YW>7Y]V?RM?\ $++\$O\ H['XI_\ AO\ PE_\MJ_IX\ ^$X/
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M\3W_  <A_P#)\7PK_P"S4O __JWOCG7T?"O_ "-H?]>*_P#Z2CQL^_Y%\O\
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M?LI=2U[Q-K.E^']$T^$9FO\ 5]9OH-.TVSB'>2ZO+F&! >-SBL6OUJ_X(V_
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M8%O+-H>G6=[>Q(JJVI7=[,VZ29W;YFHHK#<[TK))=%;[C]%?^"6GP%_X7O\
MM@_#Z/4;+[7X3^%[2?%CQ5YD>^W>/PG<VC>&K&4./)F6_P#&-WX?BN+.0G[3
MID>IGRY(X90/[4Z_%?\ X(C_  %_X0#]G?Q%\:-7LO)U_P"-OB)AI,LL>V:/
MP)X)GOM'TK9Y@$D/]I>(YO$]Y)L"Q7MC%HUS^\1(7'[45M!67KJ<E65YOM'3
M_/\ '3Y'R3^W'^T2/V7?V9_B-\5+.2 >*H;"+PUX!MYUCD6X\<>)7.G:),8)
M08KJ'10]UXEOK1]HNM.T2\@#!G6OX6]3U/4=:U+4-8U>^NM3U;5KZ[U/4]2O
MIY+J]U#4;^>2ZO;Z\N9F>6XNKNYEEGN)Y7:26:1Y'9F8D_TB?\%\/'5U;>&/
MV=?AG;S.++6==\=>.=5@#$(;GPWI^A:!H,K)]UV$7BGQ&JL>8QN SYIQ_-;4
M3>MNQM15H7ZR;_!V7Z_>%?O1_P $[O\ @DQHWQE\&:!\=_VD9M8M_!'B2--3
M\"_#32+J;1[[Q1H;,1;>(O%6LVY34]-T+5D#3:-INBRV.IZC8M;:P=8M+*>W
MM[S\%Z_T.?AZ_AF3P#X'?P5):R^#7\(>&F\)2V10V<GADZ-9'0GM/+)C^S-I
M?V4P;"4\HKM.,402;=^G]?H*M)Q22TO?7T\^ESD_A=\!/@K\%-/CTWX3_"WP
M/X!A2(0R7'ASP]IUEJMX@&W=JFMB%M9U:8K\K7.J7]W<.H"O*P  ];HKYT_:
M7_:D^$?[*?P^O/'OQ3U^"T=H;E/#/A.SF@E\5>--5A12FE>'=+>1);@^9)"M
M]J4HBTO2(9DN=3N[:)D+ZZ+R1S:R?5M_-L_,#_@MY^T?#X*^#GAG]G70=05?
M$WQ<O[?Q#XM@AE GLOAWX7OTN;6*X52LD(\2^+;6R2TD!:.XM/#.NVDJ%)1G
M^6&O<?VCOC[XT_::^,7C#XQ>.I$35?$UZHL-(MY9)=.\->'K%/LVA^&]+\P*
M?L>E6*1Q-,8XY-0O6O-4NE-[?7+OX=6$G=M_<=D(\D4NN[]7O_E\@K^YO_@G
M]\!!^SE^RC\*_ 5Y9?8_%.I:0OCCQVKQ^7<_\)AXQ2+5M0L[P  -<:!9R:=X
M6W@?-!H4!RQR[?R;?\$]O@@OQ_\ VN?A!X)OK07GAK3->7QUXQCD026K>&?!
M"?\ "075E>K@G[+KM]::=X:<@9WZU'\R#,B?W+5<%N_E_7X&5>6T5ZO]/U_
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M_!77]LZS^!?P?NO@=X*U9!\6OC)I%UI]]]CN,7G@[X;WGFV6N:U.8R9+6_\
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M&;364\,V0FC\RUU'_A)Y(9'M]10U\=53=TET27WV_0B$>5R;WE)OY7T_X/\
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MRO'Y=P-=\9V]K=V5C=(1OCNM#\,0^']!NHF9@MWIEPZ[?,*C[TI  H"J JJ
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MO[07B1%07^J^/_"6B7+@#>UGH'AV^O[)6.,[%F\2WY09P&=\#DY_?6OY=?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQQ^&/$M]-IU]<M!!H/B6_P!1U"#0;;^ASKTK_(/K]\O^";'_  7>^.?['_\
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MQ&#P]:JU',JZBG4J4Y3:BDDDWHDDM$=Y\0_BI\3_ (O:U:^)?BQ\1_'GQ/\
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M+NN[C'_><'_UXJ?^G$<O#G\#$_\ 7V'_ *0%%%%?''T84444 %%%% !1110
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MB"WMV\3:YM*2R6-@L>^'PYX<%PBRP:#ICE7\JVEU>]UF_MDOS]FUI&-M7O\
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MRL#D,I&""" 00<@\BOJS]IG]B[X__LHZ]<Z=\3_!EXWAHW;6^B_$;0(+K5/
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M*X>YU#P/>6SN#B6PN/AEX+:Q:-CD.D=N$@RI(1X7B.&C91^>M?TQ_P#!9_\
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M?$\OE:!X"\*Z[XLU4AU226TT/3KB_>TM]V0]Y>M MG91 ,\]W/##&CO(JG^
M+XA^.=>^)WCWQG\1?%%Q]I\1>.?%&N>+-:F!8QG4M?U*YU.Z2 .6,=M#+<M#
M:P@[(+>.*% J(JA3>B7?]"J$;R<NVB]7_P #\SCJ[?X:> ->^*OQ#\$?#3PO
M#Y_B'QYXJT+PGI"E6:..]UW4;?3HKFXV<I:6AG-U>3$JD%K#--(R1QLPXBOV
MO_X(B? 7_A//V@_$_P ;-7LO-T+X*^'6@T666/,4GCOQQ!>Z38-'O!CG_LSP
MQ#XFGF50TEG>7FC768G:%FS2NTNYO*7+%R[+\=E^)_4-\.? F@_"_P  >"OA
MQX7@^S^'? GA;0O">C1%5$AT_0=-M]-MY9RH DNKA+<7%W,<O/<RRS2,TDC,
M>SHHK<X3^<;_ (+Y^$M1,W[-OCN**2325B^(WA*^G /E6FHR/X5UG2HG;[OF
M:A;1ZR\0 !VZ9*3D8Q_.A7]X7[97[,FA_M:_ 3Q7\(]3N8-+UF=K?Q!X%\0W
M$;RQ^'/&^CQW!T;49DC5Y&L+J*YO=$UD11R3G1=6U'[*HNQ;NG\0GQ9^$GQ#
M^!_CO7/AM\4/#&H^%/%WA^X:&\TZ_B(CN8"[BVU32[M0;;5=&U!$,^FZK8R3
MV5[ 1)!*PW!<IIWOT?\ D==&2<>6^L>GET?Z?GOKYQ7Z1_LP_P#!4O\ ::_9
M@\(67PZT67PG\0_ .E+)'H/A[XAZ=JE]/X:MY9&F>ST#6]%UC1=4@T\3.S1:
M=J,VJZ?9(SQ:=:V2.<?FY14)M;&C2DK-)KS/V*\?_P#!;K]KSQ7ITVG>%-(^
M%7PS,T;(-9\/>&-2UO7H&;(+PR^,-=U_0AM7&S?X>D=6+-YA^4)^5GQ"^)7Q
M ^+/B>]\9_$OQEXB\<^*=0VK<ZWXFU6ZU6^\E&9H;2![J1UL["VWLMII]FD%
MC:1GRK6WBC 0;?PD^"?Q7^._BFW\&?"+P'XA\=^()VB$MMHEDTEIIL,SF-+W
M7-6F,.DZ!IH<%7U+6KZQL$8;6N Q /[OZ-_P2G\-_LU_LB_M#?%[XQW&E^/_
M (W6GP-^(MUH6E62-=>"_AM-+X5U%)+O3#<PQR>(?%=K;O*R:_<V\%CH\^6T
M.S-W:6^OS4E*7^;V(;IT]$DF[:+?7]/7Y:G\YU%%%2:']$W_  03^&=M+J7Q
M_P#C%=0*;NQLO"OPVT*XV@LD&I37?B?Q3%N/W0[Z7X090OWMK[L +G^D*OP]
M_P""#YM_^&:OBT%V_:A\<KXS<C=]G/@'P/\ 9LCJ%\P7>TG@G=CH:_<*MHJR
M7W_><=5WJ2^2^Y(*_FV_X+Y^)=1;6_V;?!RR21Z3!I7Q&\2RQ D176HW5WX5
MTNWDD'W6DL+:TN5A(Y1=1GSQ(*_I)K\>/^"Q?[)_BSX_?!KPI\2?ASI%UX@\
M;?!*[UZ]O/#NFP/<:KKO@;Q'!IQ\0G2[6%7FU'5-"N]#TK5+;3HU:>?36UP6
M2S7QM[2Z)*\7;^M0I-*<6_3T;5C^1ZBE(*DJP(8$@@@@@@X((/((/!!Y!I*Q
M.P^X?V7_ /@H7^TE^R5H-_X1^&>M^'M4\%W^IRZT?"'C;0FUW1[/5KF*&&\O
M=-FL[[2-:TXWL=M!]JM;75X["66,W7V07<LT\GZ3_LN?\%/OVVOVI?VBOA9\
M';"'X5>'M+\4>(X9?%5YX=\"Z@]QI_@S1()-:\6W<,^O>)==AMKH:%IU]#IT
MLR&,ZK=6<.US+%$?Y]Z_H\_X(2? 3R[?XK_M)ZS9?-</%\*/ TTT>"(8C8>(
MO'%_ )!RLLI\*Z;;7D&,-;:W9&0YGC%1<FTKNWZ?TOZN95%!1E)Q3?ZO1?YG
M]%E>7_&OX7:/\;/A'\1OA+KS"+3/B#X/USPQ+=^6)7TVXU*QEBT_5X8R0KW.
MCZC]DU2U#<?:;.(G(R*]0HK8Y$[.ZW6J/\\OXC?#_P 4_"GQWXM^&_C?3)=(
M\5^"M=U#P]KEA*&Q'>Z=.T+2V\C*@N;&[C$=YIUY&#!?6%Q;7ENSP3QNW%U_
M8?\ \%%O^";&A?M<V0^)/P[N=,\)?'K0]-6R2\O@UOH'Q$TJRC(LM#\3S01R
M2V.K6*#R-!\2I#.T5N5T?5X;C34TZZT+^3WXK_!GXI_ SQ7=>"?BUX&\0>!?
M$EJTF++7+)X8+^"-_+-]HVI1&72]=TQWXAU31KR^T^8Y$5RY! PE%I^71_UU
M.V%2,UV?5=?EW7],\W@GGM9X;FVFEM[FWECGM[B"1X9X)X7$D4T,L962*6*1
M5>.1&5T=0RD, :_2WX6_\%<?VU_AAHMIX??QWH?Q&TZPACM[%_B;X=B\1:M!
M!&H54G\16%WHGB+57XR;C6]5U.Z.<>?M"JOYFT4DVMBG%2T:3]3],_B5_P %
M=/VWOB-ID^D0?$+1OAW8W<1ANC\-?#%CH.IR1LFT^1X@U&36_$6ERY_>"XT;
M5M.N5?A)E3Y*_-O5=5U37=2OM9UO4K_6-7U.YFO=2U75;RXU#4M0O+AS)/=W
MU]=R375W<SR,7FGGEDED<EG=F)-4*NZ=INHZQ?VFEZ187NJ:G?SQVMCIVG6L
M]]?WMS*P6*WM+.VCEN+F>5B%CAAC>1V("J3Q0VWNV_4$DMDEZ(I5]!_LU_LR
M_%7]JKXD:?\ #CX6Z*]Y<.T-SXB\1WB31>&O!FB-+Y<^N>(]12.1;6VC =;2
MTC$FHZM=*+'3+6ZNG$8_0/\ 91_X(Z_'KXS76F^)?C;%>_ KX<.T-Q+::O:Q
MO\3M=M20[6^F>%9\CPR955X9+_Q>+2\LG:*Y@\-ZQ 2M?T]_ K]G[X3?LW>!
M;+X>?"'PG9>&-!MRL]_.N;G6O$.I^6L<VM>)-9F!O=8U6<* 9[E_*M8!'8Z=
M!9:=!;6<-Q@WJ]%^9G.JHZ1M*7X+U?Z+YV.._92_98^''[(_PITWX:> +<W5
MT[1ZEXR\7WEO%%K?C7Q,\*176L:CL:3[-:QA?LVC:/%-+;:/IRQVZ27-T][?
MWGTQ116NQRMMN[U;/PA_X+G?'K_A&/A+\/\ ]GW1[W9JGQ.UL^,/%L$4GSIX
M,\&3QG2;.[BR#Y&M>+9K6_M),,#+X/N4.WC=_+K7V_\ \%%/CU_PT/\ M;?%
M/QA8WOVSPKX=U/\ X5WX&=)/,MCX7\%2SZ8E[9/DYM-?UHZUXGAS@@:V5*IC
M:/B"L).[;Z=#LIQY8)=7J_5_U8*_M_\ ^"<'P%_X9Z_9%^%_A>_LOL7BOQ98
M'XE>-T>/RKE?$?C6&VOXK&\3&4N]!\/1Z#X;N5)8>=H[L&PU?RB?L$? 8_M&
M_M5_"CX>7EF;SPO;ZVOC#QTK1[[;_A#?!^W6M6M+O@[(->EM[/PPDFT[;K7+
M;. 2P_ND  & , < #H!Z5<%N_E_7X&5>6T?F_P!/U"BBBM#G"BBB@ KPG]J0
M;OV9/VBU_O? GXNC\_A_XA%>[5X;^T\N[]FK]H9?[WP-^+*_GX!U\4#CNO5?
MF?P$T445SG>%>N? KX*>.?VAOBIX1^$?P[T\WWB3Q9J*6JSRK(-/T73(09]6
M\0ZS-&CM;:/HE@D]_?2A7E>.(6UI%<7MQ;6TWE$,,US-%;V\,MQ<7$L<,$$,
M;RS332N(XH8HHPSR2R.RI'&BL[NP5020*_L9_P""7O[#4/[*OPK_ .$V\=Z7
M$OQU^)^G6EUXG\^-'N?!'AIS'>:9X"MI2"8KM'$.I>+7A*I<ZVMOI[-=6WA_
M3[N6HQYGY=2*DU!7W;V7]=%_P#[6_9P_9^\#?LQ_"#PI\(/ %MC2_#]KYNJZ
MO-#'%J7BGQ)=K&^M^*-8:,MOU#5;E RQF22/3["*QTFS*6&GVD4?NE%%;'&V
MV[O5L****!!1110 4444 %?SV_\ !?3PEJ%UX3_9L\=PQ.=*T+Q#\2/"6HS@
M$QQZAXKTWPCK&CQ,W1'EM_!NN,HQF00MS^[Y_H2KYQ_:P_9T\.?M4? KQI\'
M/$,Z:=-K=M%?^&-?,)G?PUXPTES=>'];6)2KRP0W0:SU2WB>.6]T6]U*QCEA
M:Z$J*2NFBH2Y9*79Z^CT?YG\$M%>J_&CX*?$G]G[X@ZW\,OBIX;O/#?BC1)W
M4QS([Z?J]@9)$M-<T#4-BP:OH>HK&TMCJ-J6C<!X)E@NX+FVA\JK [M]C]$_
MV6O^"G?[2W[*OA:#X?\ AJY\+^._AY92W$ND>$_B#IVI:A%X<-W-)<W<?AO5
MM'U;1=6T^UN+J1[EM-NKK4=)AGEN9[33K:XN[F:7W_QU_P %P/VN/$VG3:?X
M4T#X2_#F26-E&M:+X9U;7=<MW;($ENWBWQ!K6@#:N-JW'AZY^<%BQ4A!^-M>
MC_"[X0?$_P"-?BFU\%_"CP-XB\=^);MH\:=X?T^6[%I#(XC%[JMZ0FGZ+ID;
M']_JFKW=EIULN6N+J)02'>6R;(<(7NXKNV_UZ?YD'Q*^*OQ(^,?B>Z\9_%+Q
MMXC\>>)[M1')J_B34[C49X;=69X[*QCE;[-IFG0,[?9M-TZ&UL+8,5M[:-3B
MO/Z_H\^&_P#P2:T/]G_]F?X]_&7X[2Z5XY^,VD_ /XNZQX1\)V&+[P9\/-8M
M_AYXAN=/U%IIHE'BGQ?I\Z126E^T,>BZ'?!I]*@U.^M=.U^'^<.AIJS?7[_F
M.,HRNH[1TVLOEY+_ (8*_?\ _P"""_PTMM2^(7QV^+MW K3>$_"GAGP'HTDB
MA@)?&FIWNMZU+!D$1SVUOX-TN!I1MD$&IR1*3'+,I_ "OZ@/^""IM_\ A3GQ
MX"[?M8^)F@&?!&[[.?"R?9<CJ%\P7>TG@G?CD&G#XE_7]=R:O\.7R_%H_>BJ
M6I:C8Z1IU_JVJ7<%AIFEV5UJ.HWURXBMK.QLH)+F[N[B5OEC@M[>*2:5VX2-
M&8\"KM?F%_P5O^/7_"EOV0O%6A:9>_9O%?QHNX_A=HRQR;;B/1=5MYKOQO>^
M6"KM:GPM:WVA2RJP\B\\0Z>QW;@K:MV3?8Y(KF:2ZNQ_*?\ M0_&F^_:&_:
M^*OQBO6G\GQIXMO[O0[>XW>=8>%+ 1Z1X1TR0$D"73O#.GZ59S;0JO/#+($3
M>5'@E%%8'>E966RT1^G'_!)3X"_\+K_:_P#".LZG9?:?"?P9M9?BGK;21[K>
M35M'N(+7P39>8P,8N3XLN].UE('5C<6.A:DH ",Z?V85^/7_  1;^ O_  K'
M]F"[^*6JV7V?Q-\=M??7HWDC\NXC\#^&'O-#\)6TBL-VRZO7\2>(+>0,$N+#
M7+!P@VAF_86MH*R]=3CJRYIOLM/NW_$***\F^._Q8T?X%_!OXE?%[7?+:P\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% '\GW_!=C_D[CX=?]FY>$?\
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M\2^ /$.ID*H*HTVI2L,[G,A&#WG@#_@C;^Q'X)NH+S5?#'CCXE36Y#QIX_\
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MCQ;\0-1MH'(.0)%\%6W@YV7.,KY@5@,,"I8'[T^%7[.GP)^!T'D_"7X2^!/
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M_P"SK 731!6G%G;B0L(D ]8HH$FUJG9]T?)__#"7[&G_ $;'\%?_  @= _\
MD2C_ (82_8T_Z-C^"O\ X0.@?_(E?6%%*R[+^O\ AE]Q7-+^:7WO^NB^XR=
MT'1?"VAZ/X9\-Z58:%X>\/:78:+H>BZ5:Q66F:3I&EVL5EIVFZ?9P*D-K9V5
MI#%;VUO$BQQ0QHB*%4"M:BBF2%<?X\^'W@CXH>&;[P7\1/"NB>-/"6IR6<NH
M^'/$=A!JFCWTFGW<-_8O=V-RKP3FTOK>WN[?S$817,$,R@21HP["B@-MCY/_
M .&$OV-/^C8_@K_X0.@?_(E'_#"7[&G_ $;'\%?_  @= _\ D2OK"BE9=E_7
M_#+[BN:7\TOO?]=%]QP/PX^%?PW^$&@2^%OA;X'\,?#_ ,.3ZE<:Q/HGA/1[
M/1=-FU6[@M;:YU&:UL8HHI+R>VLK."2X=6E:&UMXBVR&-5[ZBBF2%%%% !7Q
M%\</^"=/[(7Q_P!1O=?\;?"33-,\6:A))/>>+O UW>^"M<O+J8YFO=370YK;
M2-<OI3@O>Z]I.J71V@>:!D'[=HH&FT[IM/R/Q=N/^"%?[(DUP\T?CW]H:UB=
MF86L'B_X=M#%DKM2)[GX57%QY:@,#YTTTAR#YHVX/LGP]_X(_P#[#W@2ZM[Z
M^\!^)/B+>6K))!)\0O&6JW]J)4.=]QI'AW_A&=#OU?H]OJ.F7=HP)S;YP1^G
MU%+ECV7]?U_5V5[2?\S^\YKPCX,\(> -"L_"_@7PKX=\&>&]/!%CH'A;1=.T
M#1K3=C>;?3=*MK6SB:3:#(Z0AY"-SLQYKSSXE_LY_ ?XRZK8:[\5_A)X"^(>
ML:5IXTG3=1\7>'-.UN[L=-%S/>?8K26^AE:"W-U<SSM''M#22,S9.,>T44R;
MM.Z;3[WU/D__ (82_8T_Z-C^"O\ X0.@?_(E:6C?L5?LD>'=8TKQ!H?[.7P>
MTK6M#U*QUC1]3LO NA0WFFZIIEU%>Z??VDRVFZ&YL[N"&XMY5^:.6-'7D"OI
MZBE9=E_7_#+[@YI?S/[W_71?<%%%%,04444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110!_G+T445SGH']8/_!"?_DT?XB_]G&^+O\ U6?PAK]I
MZ_%C_@A/_P FC_$7_LXWQ=_ZK/X0U^T];QV7HOR.*I\<O4****9 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?Q;_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %?Q;_P#!WS_SCT_[NS_]]GK^TBOXM_\ @[Y_YQZ?
M]W9_^^SU\_Q3_P B''_]RO\ ZF8<_3/!W_DXW#O_ '5__5%F9_(/\-O^8U_W
M#O\ V_KU"O+_ (;?\QK_ +AW_M_7J%?@.-_WFK_VY_Z;@?Z9</?\B?!_]S'_
M *E5PHHHKE/:"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ KE_&?_ "+6I?\ ;G_Z7VM=17+^,_\ D6M2_P"W/_TOM:UH?QZ/_7VG
M_P"EQ.+,O^1=C_\ L"Q7_IBH?I9_P;R_\IA/V0O^Z_?^LO?&NO\ 3LK_ #$_
M^#>7_E,)^R%_W7[_ -9>^-=?Z=E?N?!/_(JQ'_8PJ_\ J-A#_.;Q_P#^2RRS
M_LF<'_ZM<Y"BBBOL#\-"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /
MY/O^"['_ "=Q\.O^S<O"/_JS/B]7XL5^T_\ P78_Y.X^'7_9N7A'_P!69\7J
M_%BL9_$_E^2.VG\$?0_1K_@DK_RD%^ '_=5?_5)_$BO[3J_BQ_X)*_\ *07X
M ?\ =5?_ %2?Q(K^TZKAL_7]$85_C7^%?FPHHHJS$**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K^)[
M_@Y#_P"3XOA7_P!FI>!__5O?'.O[8:_B>_X.0_\ D^+X5_\ 9J7@?_U;WQSK
MZ/A7_D;0_P"O%?\ ])1XV??\B^7_ %]I?FS\I?V#_P#D^+]C/_LZW]G?_P!6
M]X/K_2[K_-$_8/\ ^3XOV,_^SK?V=_\ U;W@^O\ 2[KNXQ_WG!_]>*G_ *<1
MR\.?P,3_ -?8?^D!1117QQ]&%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MFN^HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\6__  =\_P#./3_N[/\ ]]GKY_BG_D0X_P#[E?\ U,PY^F>#O_)QN'?^ZO\
M^J+,S^0?X;?\QK_N'?\ M_7J%>7_  V_YC7_ '#O_;^O4*_ <;_O-7_MS_TW
M _TRX>_Y$^#_ .YC_P!2JX4445RGM!1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5R_C/_D6M2_[<_P#TOM:ZBN7\9_\ (M:E_P!N
M?_I?:UK0_CT?^OM/_P!+B<69?\B['_\ 8%BO_3%0_2S_ (-Y?^4PG[(7_=?O
M_67OC77^G97^8G_P;R_\IA/V0O\ NOW_ *R]\:Z_T[*_<^"?^15B/^QA5_\
M4;"'^<WC_P#\EEEG_9,X/_U:YR%%%%?8'X:%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@#_ #EZ***YST#^L'_@A/\ \FC_ !%_[.-\7?\ JL_A#7[3U^+'_!"?
M_DT?XB_]G&^+O_59_"&OVGK>.R]%^1Q5/CEZA1113("BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K^+?_@[Y_P"<>G_=
MV?\ [[/7]I%?Q;_\'?/_ #CT_P"[L_\ WV>OG^*?^1#C_P#N5_\ 4S#GZ9X.
M_P#)QN'?^ZO_ .J+,S^0?X;?\QK_ +AW_M_7J%>7_#;_ )C7_<._]OZ]0K\!
MQO\ O-7_ +<_]-P/],N'O^1/@_\ N8_]2JX4445RGM!1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5R_C/_D6M2_[<_\ TOM:ZBN7
M\9_\BUJ7_;G_ .E]K6M#^/1_Z^T__2XG%F7_ "+L?_V!8K_TQ4/TL_X-Y?\
ME,)^R%_W7[_UE[XUU_IV5_F)_P#!O+_RF$_9"_[K]_ZR]\:Z_P!.ROW/@G_D
M58C_ +&%7_U&PA_G-X__ /)999_V3.#_ /5KG(4445]@?AH4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ML%%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MXKUN<:S\1=C:EK^I7.IW:PJWP[8QV\<URT5M"#MAMTCA0!$4#C_^'$7[4/\
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M^#L#X!_\)K^R+^S_ /M#Z;IOC75=:^ _QIU'P7JO]AV?V[P=X>^'7QR\-?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MNLYQ#I45ZS*&DCWQ@O7\*%'3I2YWV7X_YENA&VCE?N[/\++]#_1HH) !)(
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MN(+2":ZNIX;:VMXGFN+BXD2&""&)2\DLTLC+'%%&@+/([*J*"S$ $U\D^/\
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MKX:\2:%>PZCHVO:'?W.F:MI=];MNANK&_LY(KFVF0Y >*125+(V59@?[/_\
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M',RERK^OF73ASNU[)*[=OP/['/\ A</PC_Z*E\.?_"W\,_\ RSH_X7#\(_\
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MQ;2?$WQ):PG;F_G^&GCUK1=V,Y2UT&YOODR2VVR.=K;-QV[OL?X.?M._L_\
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M/[;/_0^_LL_^%3\6O_G5T?ZH\0_]"VM]\?\ Y+^K/RN?\1R\+_\ HJL%_P"
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M76B_ .R\6+JNF:UIG]IZ+J<WBSXAZSX(M=6USPUX.LM/T*74OA_XA^)_P_\
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M)JVK_$'X>V/@HS!#-!XDAU>35+R>SW LL_\ PA^G>*K=WCPWV6XN$)V.P/\
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MNPB7QS\2[FT4WMQ+($EGT#POYZ&?1/"=K.JK':Q>5=ZS)#%J.M-+,EG;:?\
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MFL/"&C:_I4+E#ND@N->@NH&(BGMXY1*D?[(_\$S_ /@GPG[)'A?6O&GQ0L-
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MVU/_ +\VO_R;1_PL#1O^?;4_^_-K_P#)M>044<\O+[OZ_IORL>QAY_>>O_\
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M_P"L*H@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MXT#X5"R^$N@QARR0/X4\]_%(*@[!-_PF^H>)8V=1O:"&VC=CY2A=)NR]=/\
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M6DZ#IL1 EU#6M1L]+L8R<D"2[OIH+="0"0&D&<'TKYV\1_MK_LA^%'EBUO\
M:5^"D-Q!N$]I8_$7PSK5]"RY)CEL=%U#4+N.7 R(GA$I!!"'<N?X7?%?C;QG
MX\U236_''B[Q/XSUF4LTNK^*]>U7Q%J<A<@N9+_5[N\NG+$ L6E.X@$YKF*G
MVCZ+^OP-E0763^2/[6_$/_!5?]@OPZ)%F^/-EJMP@)6V\/>"_B)K9E(_A2[L
M/"4NF@^AEOHE/9J^<_&/_!<7]DO0DFC\+>%_C!XYNUW>0]IX;T+0-)D(Z>=>
M:[XFMM3@5OX2FA7#8SN12 #_ "844N>7D-48+>[^>GX)/\3]&_V_O^"A.O\
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M'7?$L,4GR-XW\=0VM[%;74:DK(^D^$;;0[FTD8AXCXCU&$*N6+_AO7HWQ?\
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M4TCR2/\ *I)8EF)+$DDDDDDG)))Y))Y)/)-0ZG9?>;*AWE]R_5_Y']RFO?\
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M!_G+T445SGH']8/_  0G_P"31_B+_P!G&^+O_59_"&OVGK\6/^"$_P#R:/\
M$7_LXWQ=_P"JS^$-?M/6\=EZ+\CBJ?'+U"BBBF0%%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% '\GW_!=C_D[CX=?]FY>$?\
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MODV[(W99C\2_KT_$NK_#E;R_-7_ _IJHHHK8XPK\I_\ @KM^TW!\"_V9-4\
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MU;V-C9VT;37-W>7<R6]M;6\2 O+///(D44:@L\CJJ@D@55K],_\ @DQ\!?\
MA=G[8'@[5=2LOM/A/X.6\GQ4UUI(]UO)J>AW%O;^"[(NP,?VA_%MWI>JBW<,
M;FPT74E"[4=TS2NTNYTR?*FWT5S^K/\ 95^"=G^SM^SU\*/@];1P+=^$/"=C
M%XAGM]IBOO%VJ&36?%^H(ZY+Q7GB74-4FMBS.T=HT$(=EB4U]!445OL<#=VV
M]WJS^(+_ (*7^/Y/B+^W!^T!JAG,UKX?\7)X L8]VZ.UB^'VEV'A"\@B&3M#
MZOI&I7<JY_X^;F=L#=@?"E>K?'?4YM;^.'QEUFY9GN-6^*WQ$U.=F)+--?\
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MU\,LZRVQ\;^)71[/4/'5Y:2".2*T-N9-.\*6MW&+NSTF6]OYTL[O7KW3K/\
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M-GI=C9Z9IUK!9:?IUI;V-C9VT:Q6UI9VD*6]K:V\2 )%!!!&D44:@*D:*J@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO_ZM[P?7^EW7=QC_ +S@_P#KQ4_].(Y>'/X&)_Z^P_\ 2 HHHKXX^C"BBB@
MHHHH **** "BBB@#^=+_ (+T?"2]F@^!GQSL+5Y+&S.N_"WQ-=*A(MI+IO\
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MJ,^E:[H.KVSVNH:=?6[8>*:)LAT=2DUM<PM);7EK+#=VDTUM-%*^,U9WZ/\
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MYO9?-_U_6YTT(Z.7?1?F_P!/N"OT(_X)@? 7_A??[8'PYL-0LOM?A/X<3/\
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M2OZ\?#7AO0/!WA_1?"GA72+#0/#?AS3++1M"T32[>.TT[2]+TZ!+:RL;.WB
M2*"W@C2-% S@98LQ+&XQZOY?Y_U^6^=6I9."W>_DNWJ_R-NBBBM#F"BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /\ .7HHHKG/0/ZP?^"$
M_P#R:/\ $7_LXWQ=_P"JS^$-?M/7XL?\$)_^31_B+_V<;XN_]5G\(:_:>MX[
M+T7Y'%4^.7J%%%%,@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M '57_P!4G\2*_M.JX;/U_1&%?XU_A7YL****LQ"BBB@ HHHH **** "BBB@
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MY:]LM/U*Z2[;PS-JMIIWD6V]+^YMI_-C6%B?YJO^'(7[9?\ T%/@K_X7&O\
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MQW?QT_X(17LNIWNK?LY?%S3(-,N)))K;P9\6(+^*3303O^SVWC7PUI^I27\
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M;2MH*R]=?\OZ\SEJRYI63TCHO7K_ )?(*_)+_@J'^R-^TK^V%#\+O!WPCO/
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MA_PY"_;+_P"@I\%?_"XU_P#^8JOZY**'%-W8HU)05E:U[ZKT\_+\7Y'\C?\
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M%DR3PZ[\28K.[T&PNT((GT;P/;1#0(=CJDUO+KJ^)-1LKA?.L]1@; 7\H?\
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M['Q%HL<K%AI>M6US]E22Y.D76DW-U+='[/HH&FT[IM/R/Y*/C/\ \$3/VIO
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M7@^:WMKP:'86=QJ<-M+) =6N+^999FE::3YO_P"'(7[9?_04^"O_ (7&O_\
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M?2M-TK6]8M7TVWUJXOK:SOYH6T5+J35K94M)O/NK."W9565G7U6BJ,C^1O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'X?_ !9_Y*I\
M2_\ LH'C+_U(]2KXZUK_ )#.K?\ 83O_ /TJEK[%^+/_ "53XE_]E \9?^I'
MJ5?'6M?\AG5O^PG?_P#I5+6=3I\_T-Z&\O1?F9E%%%9G2%%%% !1110 5O\
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MO:T<>O\ B>2-]'T&'$DJ2R76K-;RV&CZ@T47[)O[#/QT_:\\16]KX$T";1?
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@#_ #EZ***YST#^L'_@A/\ \FC_ !%_[.-\7?\ JL_A#7[3U^+'_!"?
M_DT?XB_]G&^+O_59_"&OVGK>.R]%^1Q5/CEZA1113("BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _#_ .+/_)5/
MB7_V4#QE_P"I'J5?'6M?\AG5O^PG?_\ I5+7V+\6?^2J?$O_ +*!XR_]2/4J
M^.M:_P"0SJW_ &$[_P#]*I:SJ=/G^AO0WEZ+\S,HHHK,Z0HHHH **** "OM;
M]@3_ ). M_\ L3_$O\K&OBFOM;]@3_DX"W_[$_Q+_*QIQW7JOS(J?!+T/W"K
MFO%_A'P[X\\-ZKX3\5:;!JV@ZU:M:WUG,#AE)#Q3P2KB2WN[698[FSNX62>V
MN8HIX761%8=+7Y@?!?\ :P7P7\6?'_PK^)6HD>$9_B/XRM_"OB2\D)7PO/-X
MGU(+I.IS.3M\/3RM_HMTYVZ),Y28C2I/,TS9M*R?7[OF<D8R=W&]XV>F_JO-
M'QM^T1^SAXI^!'B%O,2XUCP-J=RX\.>*4A_=L&WR)I.L^6OE66M6\2ME2$M]
M1BC:\L>%N;:S^;Z_I]U_P_H'B_1+[0?$6EV&NZ#JUOY-[I]]#'=6=U ^'1MI
MR Z,$FM[B)EF@F2.>WDCE1'7\H_CC^P+X@T66\\0_!F9_$>C$O/)X.U"YC3Q
M!IRDEVCTF^G:*VUJUB7<(H+F2VU946.%#J]R[2'.4+:K7RZK_,WIU4U:3L^_
M1^O9]^A^;U%:.JZ1JNA:A<Z3K>F7^CZI92&*[T[5+.XL+ZUE'6.XM+J.*>%\
M<[9(U.""."*SJ@W"OZ"OV3? T'@/X#> [-85BOO$.F1^,=7DVA99[WQ,D>HV
MYG&!B6TTE],T[!&Y4LD5OF!)_ [P[H.I>*=?T7PWH\#W.JZ]JECI&GP(K,TE
MWJ%S':P A02%$DH9VQA$#.V%4D?TWZ3IL&CZ5IFD6HQ:Z5I]EIML,8Q!8VT=
MM", D#$<2\ G'3-:06K?R_K^NIA7>D5W;;^6WY_@5_$'B#1?"NBZEXB\1:E:
MZ/HFD6KWFI:E>R>7;6MO'@%W(!9F=V6*&&-7FGF>."&.2:1$;@OAM\;OA;\7
M&U"/X?>+;/7KG2E62^L3::EI>HP0,XC2[&GZS9:?>RV32,D?VR&"2V262.&2
M5)G6,_-?_!0?7)M,^!VGZ7!*4_X2/QUHFGW488CSK&RT_6=:8,/XE2_TW3GP
M<@.$;J!7YI_LO_$S0OA+\8="\8>)[K4;7P_#8:UIVJ-IMJU[-)%J.FSP6RRV
MRRQO);17_P!DNI?+$LBFW1HX9'4 -RM)+[_G_5S.-/F@Y:WULNCM_GLMC^@#
M7=$TSQ)HNK>'M9M4O=)UO3KS2M2M)!E+BRO[>2VN8CW4O%(P5Q\R-AU(901_
M-)XW\,7/@KQCXJ\(7C%[GPQXAUC0I967;YYTN_GLUN%7ILN4A6>,C*LDBLI(
M(-?T(^"_C[\&OB#Y*>%?B)X:OKN?;Y6EW=Z-&UEV;^%-'UI-/U.0J2%8Q6KJ
M&(^;#*3^+G[85A'IO[2/Q/MXE"K)J&B7Y"C ,FJ^%="U29OJTMX[,?[Q-*>J
M3OUM]ZO_ %ZE4;J4HM-:7L]-G;]3YIHHHK,Z0HHHH ]?^'__ "!KG_L)S?\
MI+95^O/[%/\ R2O7_P#LH&J_^HYX4K\AOA__ ,@:Y_["<W_I+95^O/[%/_)*
M]?\ ^R@:K_ZCGA2MX[+T7Y'%4^.7J?8%%%%,@**** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH _D^_P""['_)W'PZ_P"S<O"/_JS/B]7XL5^T_P#P78_Y
M.X^'7_9N7A'_ -69\7J_%BL9_$_E^2.VG\$?0_1K_@DK_P I!?@!_P!U5_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!_G+T445SGH']8/_!"?_DT?XB_]G&^
M+O\ U6?PAK]IZ_%C_@A/_P FC_$7_LXWQ=_ZK/X0U^T];QV7HOR.*I\<O4**
M**9 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%C_P25_Y2"_ #_NJO_JD_B17]IU7#9^OZ(PK_&O\*_-A1115F(4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !7\3W_!R'_R?%\*_^S4O _\ ZM[XYU_;#7\3W_!R'_R?%\*_^S4O _\
MZM[XYU]'PK_R-H?]>*__ *2CQL^_Y%\O^OM+\V?E+^P?_P GQ?L9_P#9UO[.
M_P#ZM[P?7^EW7^:)^P?_ ,GQ?L9_]G6_L[_^K>\'U_I=UW<8_P"\X/\ Z\5/
M_3B.7AS^!B?^OL/_ $@****^./HPHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _#_P"+/_)5/B7_ -E
M\9?^I'J5?'6M?\AG5O\ L)W_ /Z52U]B_%G_ )*I\2_^R@>,O_4CU*OCK6O^
M0SJW_83O_P#TJEK.IT^?Z&]#>7HOS,RBBBLSI"BBB@ HHHH **** "BO5/A/
M\&O'GQHU\Z#X)TK[3]G$4FJZQ>N]KH>AV\K,J3ZG?".7RS)LD^SVEO%<W]WY
M<IM;680RF/\ 23PK_P $XO UO91'QKX]\5:KJ116F7PQ#I.A6$4A&6BC.J6/
MB"YN8T.56<FT:4 .8(=WEJU%O8B52,=&]>RU?_ ^9^0]%?JWX\_X)QZ3]@GN
M/AGX[U1-2B1G@TKQK%9W5K>N%RL)UG1;+3GL"3PLC:/?*20KB,9D'YE>,/!O
MB;P#XBU'PKXNTBZT37=+E\N[L;I5SM8;HKBWFC9X+NSN8R);6\MI);:YB99(
M974@T.+6XXSC/9Z]MF<S5RRAU":8#38KR6X X%E',\P!XX$ +@']:_3/]E7]
MC#2==T72_B5\7K*6[M-4BBO_  SX*=Y;:";3Y!OM=7\1-&8[B6.]0I<Z?I44
ML4+6ABGU%KA+IK&']0]%T#0O#=C%IGA[1M*T+3H55(K#1]/M--LXU1=JA+:S
MBAA7:HP,)TJE!M7O:_S,Y5HQ=DN:V^ME]^MS^8>\2]CG9=02Z2Y &Y;Q9EG"
M\[=PG DQUQGCKBJM?T^:]X9\.>*K)]-\3:!HWB'3Y%97LM:TRSU.V(<8;]S>
MPS1@D?Q*H8$ @@@&OSD_:&_82TJ>PO\ Q=\$K>2QU*V22ZO? 4D\EQ9:E&H,
MDI\-7-R\EQ9WX^9DTJYFEL[H$0V,E@\<5M<C@UL[A&LF[27+YWNO^!^G<_)Z
MBI)H9;>66">*2">"1X9H9D:.6&6-BDD4L;A7CDC=2CHZAD8%6 ((J.H-@HHH
MH **** "BBB@#U_X?_\ (&N?^PG-_P"DME7Z\_L4_P#)*]?_ .R@:K_ZCGA2
MOR&^'_\ R!KG_L)S?^DME7Z\_L4_\DKU_P#[*!JO_J.>%*WCLO1?D<53XY>I
M]@4444R HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_G+T44
M5SGH']8/_!"?_DT?XB_]G&^+O_59_"&OVGK\6/\ @A/_ ,FC_$7_ +.-\7?^
MJS^$-?M/6\=EZ+\CBJ?'+U"BBBF0%%%% !1110 4444 %%%% !1110 4444
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MBO[3JN&S]?T1A7^-?X5^;"BBBK,0HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OXGO^#D/_ )/B^%?_
M &:EX'_]6]\<Z_MAK^)[_@Y#_P"3XOA7_P!FI>!__5O?'.OH^%?^1M#_ *\5
M_P#TE'C9]_R+Y?\ 7VE^;/RE_8/_ .3XOV,_^SK?V=__ %;W@^O]+NO\T3]@
M_P#Y/B_8S_[.M_9W_P#5O>#Z_P!+NN[C'_><'_UXJ?\ IQ'+PY_ Q/\ U]A_
MZ0%%%%?''T84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MUO[._P#ZM[P?7^EW7^:)^P?_ ,GQ?L9_]G6_L[_^K>\'U_I=UW<8_P"\X/\
MZ\5/_3B.7AS^!B?^OL/_ $@****^./HPHHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#_.7HHHKG/0/ZP?\ @A/_ ,FC_$7_ +.-\7?^JS^$-?M/7XL?\$)_^31_
MB+_V<;XN_P#59_"&OVGK>.R]%^1Q5/CEZA1113("BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _#_P"+/_)5/B7_
M -E \9?^I'J5?'6M?\AG5O\ L)W_ /Z52U]B_%G_ )*I\2_^R@>,O_4CU*OC
MK6O^0SJW_83O_P#TJEK.IT^?Z&]#>7HOS,RBBBLSI"BBB@ HHHH **** /;_
M (+?M ?$'X&:K-=^%+V*[T;4)8WUGPOJHEGT74R@5//$<<D<MAJ*Q )%J-E)
M%-M6.*Y6ZM4^S-^G?@7_ (*!?![Q!;PQ^,K/7O 6IE5^T>?9S>(=%\PCD6VH
M:/#)J+KNSEKK1+-4!4EV&YE_%6BJ4FO3S(E3C/5JS[K1_P"3^:-CQ#J\WB#7
M]<U^YS]HUO6-3U>?<<MYVI7L][+N/<[YFR<\FL>BI8H9IVV012S/_=BC:1O^
M^4!/Z5)>Q%15R;3M0MUWSV-Y F,[YK::-<>NYT48]\XJG0!^W_P(_:&^$GA3
M]GWX:MXS^(7AK2=2TSPW_9EUH[:@E]K\"Z->WNEP"30=-%YK*B2VLHI+?-B!
M+$\;Q[D=2?FOX^?MZ77B*POO"?P:M=0T2QNTDM;[QMJ*K:ZU/;N"DL?A^QC>
M1M)69,A=5NI3J2QR'[/9Z9=1QW(_-2BJYW:RTTMY[&2I13N[O5NSM;[K:_UH
M*S,S%F)9F)9F8DLS$Y))/))/))Y)Y-)114FH4444 %%%% !1110!Z_\ #_\
MY US_P!A.;_TELJ_7G]BG_DE>O\ _90-5_\ 4<\*5^0WP_\ ^0-<_P#83F_]
M);*OUY_8I_Y)7K__ &4#5?\ U'/"E;QV7HOR.*I\<O4^P****9 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]>A:%XN\)^*$,GAGQ/X>\11JN]GT+6M-U=%0G <MI]S<*%)(&XG&>]&C[/\
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M/[%/_)*]?_[*!JO_ *CGA2MX[+T7Y'%4^.7J?8%%%%,@**** "BBB@ HHHH
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MX(3_ /)H_P 1?^SC?%W_ *K/X0U^T];QV7HOR.*I\<O4****9 4444 %%%%
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MUW8M,EW]M^R026Y_7ROY:59D971F1U8,K*2K*RG*LK#!# @$$$$$9'-?TU>
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MFI>!_P#U;WQSK^V&OXGO^#D/_D^+X5_]FI>!_P#U;WQSKZ/A7_D;0_Z\5_\
MTE'C9]_R+Y?]?:7YL_*7]@__ )/B_8S_ .SK?V=__5O>#Z_TNZ_S1/V#_P#D
M^+]C/_LZW]G?_P!6]X/K_2[KNXQ_WG!_]>*G_IQ'+PY_ Q/_ %]A_P"D!111
M7QQ]&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M5_\ 9J7@?_U;WQSK^V&OXGO^#D/_ )/B^%?_ &:EX'_]6]\<Z^CX5_Y&T/\
MKQ7_ /24>-GW_(OE_P!?:7YL_*7]@_\ Y/B_8S_[.M_9W_\ 5O>#Z_TNZ_S1
M/V#_ /D^+]C/_LZW]G?_ -6]X/K_ $NZ[N,?]YP?_7BI_P"G$<O#G\#$_P#7
MV'_I 4445\<?1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '^<O1117.>@?U@_
M\$)_^31_B+_V<;XN_P#59_"&OVGK\6/^"$__ ":/\1?^SC?%W_JL_A#7[3UO
M'9>B_(XJGQR]0HHHID!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M -1SPI6\=EZ+\CBJ?'+U/L"BBBF0%%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7\3W_!R'_R?%\*_^S4O _\ ZM[XYU_;#7\3W_!R'_R?%\*_^S4O _\ ZM[X
MYU]'PK_R-H?]>*__ *2CQL^_Y%\O^OM+\V?E+^P?_P GQ?L9_P#9UO[._P#Z
MM[P?7^EW7^:)^P?_ ,GQ?L9_]G6_L[_^K>\'U_I=UW<8_P"\X/\ Z\5/_3B.
M7AS^!B?^OL/_ $@****^./HPHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_.7H
MKUCX]>!-(^%OQS^-'PR\/W.I7F@_#KXL?$7P)HEWK,UK<:O=:1X1\8:QX?TV
MYU6XLK/3[*?4I[+3X9;Z:TL+&UENFE>WL[:)DA3R>N<]!:I/N?U@_P#!"?\
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MB("TVG7L5M>QJ#*L4ELT=Q(W%K?[R85(ST3L^SW^7<\9HHHI%A1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH _@V_;8T;5]"_;"_:ALM;TK4M'O9_CW\5M9AM-5L;K3[J;2/$7C76?$'A
M_58K>[BAEDTW7=!U/3=;T>^1#:ZGI&H6.I64L]E=V\TGS!7Z6?\ !7?1M7TS
M]OOXSWNI:5J6GV7B+3?A?K/A^[OK&ZM+77=(@^%7@SP_-JNC7%Q%'%J>FPZ]
MH6MZ)+?63SVL>KZ/JNFO*+W3[N&'\TZP>C:[-G='6,7_ '5^1_1I_P $ /\
MF[3_ +H/_P"]FK^C2OY+/^"&NLZ1IG[87BRRU+5=-T^]\1? 3QGHWA^TOKZU
MM+K7=7@\:_#;Q!-I6C6]Q+'+J>I0Z#H6MZW+8V23W4>D:/JNI/$++3[N:'^M
M.M(/W?1V_7]3FK+]X_-)_A;] HHHJS(**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "OXGO^#D/_ )/B^%?_ &:EX'_]6]\<Z_MAK^)[_@Y#_P"3XOA7
M_P!FI>!__5O?'.OH^%?^1M#_ *\5_P#TE'C9]_R+Y?\ 7VE^;/RE_8/_ .3X
MOV,_^SK?V=__ %;W@^O]+NO\T3]@_P#Y/B_8S_[.M_9W_P#5O>#Z_P!+NN[C
M'_><'_UXJ?\ IQ'+PY_ Q/\ U]A_Z0%%%%?''T84444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MR!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MK_P__P"0-<_]A.;_ -);*OUY_8I_Y)7K_P#V4#5?_4<\*5^0WP__ .0-<_\
M83F_]);*OUY_8I_Y)7K_ /V4#5?_ %'/"E;QV7HOR.*I\<O4^P****9 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&4FEW:BG9$RG"%N><87VYI*-_2[5SZ7HKY2_X;P_8=_Z/+_92_\ $B/A#_\
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M55M<WVN6+<=+1;NN"KQ'5=U1PT(;I2J3E4ZZ-QBJ=G;IS-)]6E9_U:?M(_\
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MFM+R:5U%291117AGJ!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MLK8 4%F.U%5% 55 S:*EMO=FL81C\*MW?5_/]-@HHHI%!1110 4444 %%%%
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M^S-X3^P7WQO^-/Q7^,>K:=XKM=7_ +.\*V.@_"+P-K?A>T_LN;_A$/$FC?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\,N@:)8V/B'3O%OA?1DU2P\++K-_][ULG=7[G"TXMI[H****8@HHHH ****
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M_E;2]FN[_K^G_2U/;O\ E7WL^.O[%UG_ *!.I_\ @!=?_&J/[%UG_H$ZG_X
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]NUW6O[&T[5M2M/#GAO34O/$'B;5+;3;W^Q_#VF:GJLT#P64N,3LV\C]/O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;F-);7^U_$>K_9;RV\)>$K:\M;[Q#?6MW--=Z1X<TCQ+XET'^V#X&?!?P/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[6M$TWR_%.J:;I7BOQ'\.[/\6***R;;=V=<8J*LO^'?=^85]8?L??L??$_\
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M_#.WCR7SO^)=\0-9M+CX?7WE_P!OWG_$I^*GV72-&M?LNC:18SW_ /PG>E^
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[/8VES=S;(()9$]JJC.S6ZL%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P"=O7YRT4[ON_O$XQ>\8OU2/T:_X>T_\%!?^B__ /F*O@G_ /.WH_X>T_\
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M.2'\L?\ P%?Y'Z-?\/:?^"@O_1?_ /S%7P3_ /G;T?\ #VG_ (*"_P#1?_\
MS%7P3_\ G;U^<M%%WW?WL.2'\L?_  %?Y'Z-?\/:?^"@O_1?_P#S%7P3_P#G
M;T?\/:?^"@O_ $7_ /\ ,5?!/_YV]?G+11=]W][#DA_+'_P%?Y'Z-?\ #VG_
M (*"_P#1?_\ S%7P3_\ G;T?\/:?^"@O_1?_ /S%7P3_ /G;U^<M%%WW?WL.
M2'\L?_ 5_D?HU_P]I_X*"_\ 1?\ _P Q5\$__G;T?\/:?^"@O_1?_P#S%7P3
M_P#G;U^<M%%WW?WL.2'\L?\ P%?Y'Z-?\/:?^"@O_1?_ /S%7P3_ /G;T?\
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M^"@O_1?_ /S%7P3_ /G;U^<M%%WW?WL.2'\L?_ 5_D?HU_P]I_X*"_\ 1?\
M_P Q5\$__G;T?\/:?^"@O_1?_P#S%7P3_P#G;U^<M%%WW?WL.2'\L?\ P%?Y
M'Z-?\/:?^"@O_1?_ /S%7P3_ /G;T?\ #VG_ (*"_P#1?_\ S%7P3_\ G;U^
M<M%%WW?WL.2'\L?_  %?Y'Z-?\/:?^"@O_1?_P#S%7P3_P#G;T?\/:?^"@O_
M $7_ /\ ,5?!/_YV]?G+11=]W][#DA_+'_P%?Y'Z-?\ #VG_ (*"_P#1?_\
MS%7P3_\ G;T?\/:?^"@O_1?_ /S%7P3_ /G;U^<M%%WW?WL.2'\L?_ 5_D?H
MU_P]I_X*"_\ 1?\ _P Q5\$__G;T?\/:?^"@O_1?_P#S%7P3_P#G;U^<M%%W
MW?WL.2'\L?\ P%?Y'Z-?\/:?^"@O_1?_ /S%7P3_ /G;T?\ #VG_ (*"_P#1
M?_\ S%7P3_\ G;U^<M%%WW?WL.2'\L?_  %?Y'Z-?\/:?^"@O_1?_P#S%7P3
M_P#G;T?\/:?^"@O_ $7_ /\ ,5?!/_YV]?G+11=]W][#DA_+'_P%?Y'Z-?\
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M\/:?^"@O_1?_ /S%7P3_ /G;U^<M%%WW?WL.2'\L?_ 5_D?HU_P]I_X*"_\
M1?\ _P Q5\$__G;T?\/:?^"@O_1?_P#S%7P3_P#G;U^<M%%WW?WL.2'\L?\
MP%?Y'Z-?\/:?^"@O_1?_ /S%7P3_ /G;T?\ #VG_ (*"_P#1?_\ S%7P3_\
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ML.2'\L?_  %?Y'Z-?\/:?^"@O_1?_P#S%7P3_P#G;T?\/:?^"@O_ $7_ /\
M,5?!/_YV]?G+11=]W][#DA_+'_P%?Y'Z-?\ #VG_ (*"_P#1?_\ S%7P3_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M .=#1_PXG_:X_P"BB_LY?^%=\3/_ )T-%%"2TT[?^V?YL.>7?\%_D'_#B?\
M:X_Z*+^SE_X5WQ,_^=#1_P .)_VN/^BB_LY?^%=\3/\ YT-%%"2TT[?^V?YL
M.>7?\%_D'_#B?]KC_HHO[.7_ (5WQ,_^=#1_PXG_ &N/^BB_LY?^%=\3/_G0
MT44)+33M_P"V?YL.>7?\%_D'_#B?]KC_ **+^SE_X5WQ,_\ G0T?\.)_VN/^
MBB_LY?\ A7?$S_YT-%%"2TT[?^V?YL.>7?\ !?Y!_P .)_VN/^BB_LY?^%=\
M3/\ YT-'_#B?]KC_ **+^SE_X5WQ,_\ G0T44)+33M_[9_FPYY=_P7^0?\.)
M_P!KC_HHO[.7_A7?$S_YT-'_  XG_:X_Z*+^SE_X5WQ,_P#G0T44)+33M_[9
M_FPYY=_P7^0?\.)_VN/^BB_LY?\ A7?$S_YT-'_#B?\ :X_Z*+^SE_X5WQ,_
M^=#110DM-.W_ +9_FPYY=_P7^0?\.)_VN/\ HHO[.7_A7?$S_P"=#1_PXG_:
MX_Z*+^SE_P"%=\3/_G0T44)+33M_[9_FPYY=_P %_D'_  XG_:X_Z*+^SE_X
M5WQ,_P#G0T?\.)_VN/\ HHO[.7_A7?$S_P"=#110DM-.W_MG^;#GEW_!?Y!_
MPXG_ &N/^BB_LY?^%=\3/_G0T?\ #B?]KC_HHO[.7_A7?$S_ .=#110DM-.W
M_MG^;#GEW_!?Y!_PXG_:X_Z*+^SE_P"%=\3/_G0T?\.)_P!KC_HHO[.7_A7?
M$S_YT-%%"2TT[?\ MG^;#GEW_!?Y!_PXG_:X_P"BB_LY?^%=\3/_ )T-'_#B
M?]KC_HHO[.7_ (5WQ,_^=#110DM-.W_MG^;#GEW_  7^0?\ #B?]KC_HHO[.
M7_A7?$S_ .=#1_PXG_:X_P"BB_LY?^%=\3/_ )T-%%"2TT[?^V?YL.>7?\%_
MD'_#B?\ :X_Z*+^SE_X5WQ,_^=#1_P .)_VN/^BB_LY?^%=\3/\ YT-%%"2T
MT[?^V?YL.>7?\%_D'_#B?]KC_HHO[.7_ (5WQ,_^=#1_PXG_ &N/^BB_LY?^
M%=\3/_G0T44)+33M_P"V?YL.>7?\%_D'_#B?]KC_ **+^SE_X5WQ,_\ G0T?
M\.)_VN/^BB_LY?\ A7?$S_YT-%%"2TT[?^V?YL.>7?\ !?Y!_P .)_VN/^BB
M_LY?^%=\3/\ YT-'_#B?]KC_ **+^SE_X5WQ,_\ G0T44)+33M_[9_FPYY=_
MP7^0?\.)_P!KC_HHO[.7_A7?$S_YT-'_  XG_:X_Z*+^SE_X5WQ,_P#G0T44
M)+33M_[9_FPYY=_P7^0?\.)_VN/^BB_LY?\ A7?$S_YT-'_#B?\ :X_Z*+^S
ME_X5WQ,_^=#110DM-.W_ +9_FPYY=_P7^0?\.)_VN/\ HHO[.7_A7?$S_P"=
M#1_PXG_:X_Z*+^SE_P"%=\3/_G0T44)+33M_[9_FPYY=_P %_D'_  XG_:X_
MZ*+^SE_X5WQ,_P#G0T?\.)_VN/\ HHO[.7_A7?$S_P"=#110DM-.W_MG^;#G
MEW_!?Y!_PXG_ &N/^BB_LY?^%=\3/_G0T?\ #B?]KC_HHO[.7_A7?$S_ .=#
M110DM-.W_MG^;#GEW_!?Y!_PXG_:X_Z*+^SE_P"%=\3/_G0T?\.)_P!KC_HH
MO[.7_A7?$S_YT-%%"2TT[?\ MG^;#GEW_!?Y!_PXG_:X_P"BB_LY?^%=\3/_
M )T-'_#B?]KC_HHO[.7_ (5WQ,_^=#110DM-.W_MG^;#GEW_  7^0?\ #B?]
MKC_HHO[.7_A7?$S_ .=#1_PXG_:X_P"BB_LY?^%=\3/_ )T-%%"2TT[?^V?Y
ML.>7?\%_D'_#B?\ :X_Z*+^SE_X5WQ,_^=#1_P .)_VN/^BB_LY?^%=\3/\
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M_P#G0T44)+33M_[9_FPYY=_P7^0?\.)_VN/^BB_LY?\ A7?$S_YT-'_#B?\
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M^SE_X5WQ,_\ G0T?\.)_VN/^BB_LY?\ A7?$S_YT-%%"2TT[?^V?YL.>7?\
M!?Y!_P .)_VN/^BB_LY?^%=\3/\ YT-'_#B?]KC_ **+^SE_X5WQ,_\ G0T4
M4)+33M_[9_FPYY=_P7^0?\.)_P!KC_HHO[.7_A7?$S_YT-'_  XG_:X_Z*+^
MSE_X5WQ,_P#G0T44)+33M_[9_FPYY=_P7^0?\.)_VN/^BB_LY?\ A7?$S_YT
M-'_#B?\ :X_Z*+^SE_X5WQ,_^=#110DM-.W_ +9_FPYY=_P7^0?\.)_VN/\
MHHO[.7_A7?$S_P"=#1_PXG_:X_Z*+^SE_P"%=\3/_G0T44)+33M_[9_FPYY=
M_P %_D'_  XG_:X_Z*+^SE_X5WQ,_P#G0T?\.)_VN/\ HHO[.7_A7?$S_P"=
M#110DM-.W_MG^;#GEW_!?Y!_PXG_ &N/^BB_LY?^%=\3/_G0T?\ #B?]KC_H
MHO[.7_A7?$S_ .=#110DM-.W_MG^;#GEW_!?Y!_PXG_:X_Z*+^SE_P"%=\3/
M_G0T?\.)_P!KC_HHO[.7_A7?$S_YT-%%"2TT[?\ MG^;#GEW_!?Y!_PXG_:X
M_P"BB_LY?^%=\3/_ )T-'_#B?]KC_HHO[.7_ (5WQ,_^=#110DM-.W_MG^;#
MGEW_  7^0?\ #B?]KC_HHO[.7_A7?$S_ .=#1_PXG_:X_P"BB_LY?^%=\3/_
M )T-%%"2TT[?^V?YL.>7?\%_D'_#B?\ :X_Z*+^SE_X5WQ,_^=#1_P .)_VN
M/^BB_LY?^%=\3/\ YT-%%"2TT[?^V?YL.>7?\%_D'_#B?]KC_HHO[.7_ (5W
MQ,_^=#7H_P /_P#@@G\7-2_M?_A:GQ\^''@WR?L']A?\*_\ #7B;XE_VEYGV
MW^U/[7_X2.3X3?V+]C\O3OL'V/\ M_\ M+[5>_:/[*^P0?VD44XQ3W73S[1_
MS8I3DDVG^"[^AZ-_PX _ZNS_ /,#_P#XYJ^C?^'$_P"R/_T47]HW_P *[X9_
M_.AHHJN6/;\S)U9O[3^Y+\D?6'A+_@E_^P;X*\0Z?XFT;]G;PY>ZEIGVO[-;
M>+?$GC[Q_P"'I/MMC<Z?-_:'A+QWXL\2>%-6V07<LEI_:NBWOV"^2VU.Q^SZ
ME96=W!]8_#_X._"/X3?VO_PJOX6?#CX:?V_]@_MW_A7_ ((\,^#?[:_LK[;_
M &7_ &O_ ,(YI>F_VE_9O]I:C]@^V>=]C^WWOV?R_M4_F%%.R6R2(<I/=M^K
M;/1J***8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
.BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>13
<FILENAME>caba-20241231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-03-31T06:40:27.7550+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.cabalettabio.com/20241231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:caba="http://www.cabalettabio.com/20241231" xmlns:srt="http://fasb.org/srt/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" namespace="http://fasb.org/srt/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd" namespace="http://xbrl.sec.gov/cyd/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" namespace="http://xbrl.sec.gov/ecd/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" namespace="https://xbrl.org/2023/calculation-1.1"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails2" id="DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails2">
        <link:definition>100020 - Disclosure - Leases - Schedule of Company's operating and finance leases (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails2" id="DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails2">
        <link:definition>100030 - Disclosure - Leases - Schedule of Future Minimum Payments for Operating Leases and Finance Leases (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100040 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails3" id="DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails3">
        <link:definition>100050 - Disclosure - Leases - Schedule of Future Minimum Payments for Operating Leases and Finance Leases (Details) 3</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100060 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails4" id="DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails4">
        <link:definition>100070 - Disclosure - Leases - Schedule of Future Minimum Payments for Operating Leases and Finance Leases (Details) 4</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" id="StatementConsolidatedStatementsOfStockholdersEquity">
        <link:definition>100080 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" id="StatementConsolidatedStatementsOfStockholdersEquityParenthetical">
        <link:definition>100090 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100100 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" id="DisclosureCybersecurityRiskManagementStrategyAndGovernance">
        <link:definition>995453 - Disclosure - Cybersecurity Risk Management, Strategy, and Governance</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentation" id="Role_DisclosureBasisOfPresentation">
        <link:definition>995463 - Disclosure - Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>995473 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>995483 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipment" id="Role_DisclosurePropertyPlantAndEquipment">
        <link:definition>995493 - Disclosure - Property, Plant and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilities" id="Role_DisclosureAccruedAndOtherCurrentLiabilities">
        <link:definition>995503 - Disclosure - Accrued and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreements" id="Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreements">
        <link:definition>995513 - Disclosure - Collaborations, Licensing Agreements and other Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSegmentInformation" id="DisclosureSegmentInformation">
        <link:definition>995523 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>995533 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeases" id="DisclosureLeases">
        <link:definition>995543 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStock" id="Role_DisclosureCommonStock">
        <link:definition>995553 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>995563 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShare" id="Role_DisclosureNetLossPerShare">
        <link:definition>995573 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_Disclosure401KSavingsPlan" id="Role_Disclosure401KSavingsPlan">
        <link:definition>995583 - Disclosure - 401(k) Savings Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSubsequentEvent" id="DisclosureSubsequentEvent">
        <link:definition>995593 - Disclosure - Subsequent Event</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>995603 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>995613 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>995623 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentTables" id="Role_DisclosurePropertyPlantAndEquipmentTables">
        <link:definition>995633 - Disclosure - Property, Plant and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesTables" id="Role_DisclosureAccruedAndOtherCurrentLiabilitiesTables">
        <link:definition>995643 - Disclosure - Accrued and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" id="Role_DisclosureCommitmentsAndContingenciesTables">
        <link:definition>995653 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSegmentInformationTables" id="DisclosureSegmentInformationTables">
        <link:definition>995663 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesTables" id="DisclosureLeasesTables">
        <link:definition>995673 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockTables" id="Role_DisclosureCommonStockTables">
        <link:definition>995683 - Disclosure - Common Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>995693 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareTables" id="Role_DisclosureNetLossPerShareTables">
        <link:definition>995703 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAdditionalInformationDetails" id="Role_DisclosureBasisOfPresentationAdditionalInformationDetails">
        <link:definition>995713 - Disclosure - Basis of Presentation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>995723 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails">
        <link:definition>995733 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives for Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" id="Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>995743 - Disclosure - Fair Value Measurements - Financial Assets Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" id="Role_DisclosureFairValueMeasurementsAdditionalInformationDetails">
        <link:definition>995753 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails" id="Role_DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails">
        <link:definition>995763 - Disclosure - Fair Value Measurements - Schedule of Debt Securities Classified as Available-for-Sale Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails" id="Role_DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails">
        <link:definition>995773 - Disclosure - Property, Plant and Equipment - Schedule of Property Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails" id="Role_DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails">
        <link:definition>995783 - Disclosure - Property, Plant and Equipment - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails" id="Role_DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails">
        <link:definition>995793 - Disclosure - Accrued and Other Current Liabilities - Schedule of Accrued and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails" id="Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails">
        <link:definition>995803 - Disclosure - Collaborations, Licensing Agreements and other Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>995813 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsForOperatingLeasesDetails" id="Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsForOperatingLeasesDetails">
        <link:definition>995823 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Payments for Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails" id="DisclosureSegmentInformationAdditionalInformationDetails">
        <link:definition>995833 - Disclosure - Segment Information (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfProfitAndLossFromSegmentsDetails" id="DisclosureSegmentInformationScheduleOfProfitAndLossFromSegmentsDetails">
        <link:definition>995843 - Disclosure - Segment Information - Schedule of Profit and Loss from Segments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" id="DisclosureLeasesAdditionalInformationDetails">
        <link:definition>995853 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails" id="DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails">
        <link:definition>995863 - Disclosure - Leases - Schedule of Future Minimum Payments for Operating Leases and Finance Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails" id="DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails">
        <link:definition>995873 - Disclosure - Leases - Schedule of Company's operating and finance leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails" id="Role_DisclosureCommonStockAdditionalInformationDetails">
        <link:definition>995883 - Disclosure - Common Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails" id="Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails">
        <link:definition>995893 - Disclosure - Common Stock - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsDetails" id="Role_DisclosureCommonStockScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsDetails">
        <link:definition>995903 - Disclosure - Common Stock - Schedule of Assumptions Used to Estimate Fair Value of Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockBasedCompensationDetails" id="Role_DisclosureCommonStockSummaryOfStockBasedCompensationDetails">
        <link:definition>995913 - Disclosure - Common Stock - Summary of Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails" id="Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails">
        <link:definition>995923 - Disclosure - Income Taxes - Reconciliation of Federal Statutory Income Tax Rate to Company's Effective Income Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails" id="Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails">
        <link:definition>995933 - Disclosure - Income Taxes - Summary of Principal Components of Company's Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>995943 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails" id="Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails">
        <link:definition>995953 - Disclosure - Net Loss Per Share - Schedule of Basic and Diluted Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails" id="Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails">
        <link:definition>995963 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Shares Excluded from Calculation of Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails" id="DisclosureNetLossPerShareAdditionalInformationDetails">
        <link:definition>995973 - Disclosure - Net Loss Per Share - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_Disclosure401KSavingsPlanAdditionalInformationDetails" id="Role_Disclosure401KSavingsPlanAdditionalInformationDetails">
        <link:definition>995983 - Disclosure - 401 (k) Savings Plan - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSubsequenteventsAdditionalInformationDetails" id="DisclosureSubsequenteventsAdditionalInformationDetails">
        <link:definition>995993 - Disclosure - SubsequentEvents - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:href="caba-20241231.xsd#StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:href="caba-20241231.xsd#StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:href="caba-20241231.xsd#StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:href="caba-20241231.xsd#DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails" xlink:href="caba-20241231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="caba-20241231.xsd#Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails" xlink:href="caba-20241231.xsd#Role_DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails" xlink:href="caba-20241231.xsd#Role_DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails" xlink:href="caba-20241231.xsd#Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="caba-20241231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" xlink:href="caba-20241231.xsd#DisclosureLeasesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails" xlink:href="caba-20241231.xsd#Role_DisclosureCommonStockAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails" xlink:href="caba-20241231.xsd#Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsDetails" xlink:href="caba-20241231.xsd#Role_DisclosureCommonStockScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockBasedCompensationDetails" xlink:href="caba-20241231.xsd#Role_DisclosureCommonStockSummaryOfStockBasedCompensationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="caba-20241231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails" xlink:href="caba-20241231.xsd#Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:href="caba-20241231.xsd#Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails" xlink:href="caba-20241231.xsd#DisclosureNetLossPerShareAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSubsequenteventsAdditionalInformationDetails" xlink:href="caba-20241231.xsd#DisclosureSubsequenteventsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="caba-20241231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="caba-20241231.xsd#StatementConsolidatedBalanceSheets" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="caba-20241231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="caba-20241231.xsd#StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentation" xlink:href="caba-20241231.xsd#Role_DisclosureBasisOfPresentation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="caba-20241231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:href="caba-20241231.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipment" xlink:href="caba-20241231.xsd#Role_DisclosurePropertyPlantAndEquipment" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilities" xlink:href="caba-20241231.xsd#Role_DisclosureAccruedAndOtherCurrentLiabilities" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreements" xlink:href="caba-20241231.xsd#Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSegmentInformation" xlink:href="caba-20241231.xsd#DisclosureSegmentInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:href="caba-20241231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeases" xlink:href="caba-20241231.xsd#DisclosureLeases" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStock" xlink:href="caba-20241231.xsd#Role_DisclosureCommonStock" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="caba-20241231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShare" xlink:href="caba-20241231.xsd#Role_DisclosureNetLossPerShare" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_Disclosure401KSavingsPlan" xlink:href="caba-20241231.xsd#Role_Disclosure401KSavingsPlan" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSubsequentEvent" xlink:href="caba-20241231.xsd#DisclosureSubsequentEvent" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="caba-20241231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="caba-20241231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:href="caba-20241231.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentTables" xlink:href="caba-20241231.xsd#Role_DisclosurePropertyPlantAndEquipmentTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesTables" xlink:href="caba-20241231.xsd#Role_DisclosureAccruedAndOtherCurrentLiabilitiesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" xlink:href="caba-20241231.xsd#Role_DisclosureCommitmentsAndContingenciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSegmentInformationTables" xlink:href="caba-20241231.xsd#DisclosureSegmentInformationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesTables" xlink:href="caba-20241231.xsd#DisclosureLeasesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockTables" xlink:href="caba-20241231.xsd#Role_DisclosureCommonStockTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:href="caba-20241231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareTables" xlink:href="caba-20241231.xsd#Role_DisclosureNetLossPerShareTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAdditionalInformationDetails" xlink:href="caba-20241231.xsd#Role_DisclosureBasisOfPresentationAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="caba-20241231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:href="caba-20241231.xsd#Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails" xlink:href="caba-20241231.xsd#Role_DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails" xlink:href="caba-20241231.xsd#Role_DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsForOperatingLeasesDetails" xlink:href="caba-20241231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsForOperatingLeasesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails" xlink:href="caba-20241231.xsd#DisclosureSegmentInformationAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfProfitAndLossFromSegmentsDetails" xlink:href="caba-20241231.xsd#DisclosureSegmentInformationScheduleOfProfitAndLossFromSegmentsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails" xlink:href="caba-20241231.xsd#DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails" xlink:href="caba-20241231.xsd#DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails" xlink:href="caba-20241231.xsd#Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails" xlink:href="caba-20241231.xsd#Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/Role_Disclosure401KSavingsPlanAdditionalInformationDetails" xlink:href="caba-20241231.xsd#Role_Disclosure401KSavingsPlanAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails2" xlink:href="caba-20241231.xsd#DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails2" xlink:href="caba-20241231.xsd#DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails3" xlink:href="caba-20241231.xsd#DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails3" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails4" xlink:href="caba-20241231.xsd#DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails4" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_December2022FinancingMember" xlink:label="caba_December2022FinancingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForCommissions" xlink:label="us-gaap_PaymentsForCommissions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_PreFundedWarrantsExercised" xlink:label="caba_PreFundedWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_ChangeInStateAndLocalTaxRate" xlink:label="caba_ChangeInStateAndLocalTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_OperatingLeasesAbtract" xlink:label="caba_OperatingLeasesAbtract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_CollaborationsLicensingAgreementsAndOtherAgreementsAbstract" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_CashPaidInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:label="caba_CashPaidInTheMeasurementOfLeaseLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_FundingTermEndingDate" xlink:label="caba_FundingTermEndingDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentDueInNextTwelveMonths" xlink:label="us-gaap_OtherCommitmentDueInNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_IssuanceOfCommonStockAndPreFundedWarrantsForThePurchaseOfCommonStockNetOfIssuanceCosts" xlink:label="caba_IssuanceOfCommonStockAndPreFundedWarrantsForThePurchaseOfCommonStockNetOfIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantExercisePriceDecrease" xlink:label="us-gaap_WarrantExercisePriceDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenses" xlink:label="us-gaap_OtherExpenses"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_StockIssuedDuringPeriodShareStockOptionsExercised" xlink:label="caba_StockIssuedDuringPeriodShareStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_MayTwoThousandTwentyThreeFinancingMember" xlink:label="caba_MayTwoThousandTwentyThreeFinancingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_AnnualIncreasePercentageOfBaseRent" xlink:label="caba_AnnualIncreasePercentageOfBaseRent"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_OperatingLossCarryforwardsLocalCommencementOfExpirationDate" xlink:label="caba_OperatingLossCarryforwardsLocalCommencementOfExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:label="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:label="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_ArunDasOneMember" xlink:label="caba_ArunDasOneMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_OperatingLossCarryforwardsFederalCommencementOfExpirationDate" xlink:label="caba_OperatingLossCarryforwardsFederalCommencementOfExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_ObligationToBePaidCommencementDate" xlink:label="caba_ObligationToBePaidCommencementDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_IncreaseInShareReservedPercentage" xlink:label="caba_IncreaseInShareReservedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" xlink:label="us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_WorkOrdersTerm" xlink:label="caba_WorkOrdersTerm"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_TerminationFees" xlink:label="caba_TerminationFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateNoteSecuritiesMember" xlink:label="us-gaap_CorporateNoteSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearThree" xlink:label="caba_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_WuXiAdvancedTherapiesMember" xlink:label="caba_WuXiAdvancedTherapiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForUnderwritingExpense" xlink:label="us-gaap_PaymentsForUnderwritingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_FinancingCashFlowsUsedForFinanceLeases" xlink:label="caba_FinancingCashFlowsUsedForFinanceLeases"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossRelatedToLitigationSettlement" xlink:label="us-gaap_GainLossRelatedToLitigationSettlement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_GwendolynBinderOneMember" xlink:label="caba_GwendolynBinderOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate" xlink:label="caba_DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_MilestonePayments" xlink:label="caba_MilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_DevelopmentAndManufacturingServicesAgreementMember" xlink:label="caba_DevelopmentAndManufacturingServicesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_ArunDasMember" xlink:label="caba_ArunDasMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_OxfordBiomedicaMember" xlink:label="caba_OxfordBiomedicaMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_ManufacturingOfPreclinicalAndClinicalSupplies" xlink:label="caba_ManufacturingOfPreclinicalAndClinicalSupplies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestmentsAbstract" xlink:label="us-gaap_ShortTermInvestmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_ContractualCostIncurred" xlink:label="caba_ContractualCostIncurred"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_AutolusHoldingsMember" xlink:label="caba_AutolusHoldingsMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_AnupMardaOneMember" xlink:label="caba_AnupMardaOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_AmortizationExpense" xlink:label="caba_AmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_IssuanceOfCommonStockUponExerciseOfPreFundedWarrants" xlink:label="caba_IssuanceOfCommonStockUponExerciseOfPreFundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_GwendolynBinderMember" xlink:label="caba_GwendolynBinderMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_VariableLeaseCosts" xlink:label="caba_VariableLeaseCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionExpense" xlink:label="us-gaap_AccretionExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:label="caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:label="caba_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_FixedLeaseCost" xlink:label="caba_FixedLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_EarningsPerShareBasicAndDilutedTable" xlink:label="caba_EarningsPerShareBasicAndDilutedTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonvotingCommonStockMember" xlink:label="us-gaap_NonvotingCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_PreFundedWarrantsMember" xlink:label="caba_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_SubscriptionAndTechnologyTransferAgreementMember" xlink:label="caba_SubscriptionAndTechnologyTransferAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_NumberOfFaculty" xlink:label="caba_NumberOfFaculty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_LeaseAmendmentPeriod" xlink:label="caba_LeaseAmendmentPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_OperatingLeaseAgreementMember" xlink:label="caba_OperatingLeaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_VotingCommonStockMember" xlink:label="caba_VotingCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_Rese-CelAndMuSK-CAARTMember" xlink:label="caba_Rese-CelAndMuSK-CAARTMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_NonCashLeaseExpense" xlink:label="caba_NonCashLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_FinanceLeasesAbstract" xlink:label="caba_FinanceLeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_TwoThousandNineteenStockOptionAndIncentivePlanMember" xlink:label="caba_TwoThousandNineteenStockOptionAndIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_Rule10B51ArrModifiedFlag" xlink:label="caba_Rule10B51ArrModifiedFlag"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_AdvancePayments" xlink:label="caba_AdvancePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_ChildrenSHospitalOfPhiladelphiaMember" xlink:label="caba_ChildrenSHospitalOfPhiladelphiaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_DeferredTaxAssetsOperatingLossCarryforwardsFederal" xlink:label="caba_DeferredTaxAssetsOperatingLossCarryforwardsFederal"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_LeaseExpirationMonth" xlink:label="caba_LeaseExpirationMonth"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic" xlink:label="us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:label="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_StevenNichtbergerMember" xlink:label="caba_StevenNichtbergerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_OperatingCashFlowsUsedForFinanceLeases" xlink:label="caba_OperatingCashFlowsUsedForFinanceLeases"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_AtTheMarketOfferingSalesAgreementMember" xlink:label="caba_AtTheMarketOfferingSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_IncreaseInTheRouAsset" xlink:label="caba_IncreaseInTheRouAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_LeaseExpirationMonthAndYear" xlink:label="caba_LeaseExpirationMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_WuxiAgreementMember" xlink:label="caba_WuxiAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_StevenNichtbergerOneMember" xlink:label="caba_StevenNichtbergerOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityAbstract" xlink:label="us-gaap_FinanceLeaseLiabilityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock" xlink:label="caba_EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_NanjingIasoBiotherapeuticsCoLtdMember" xlink:label="caba_NanjingIasoBiotherapeuticsCoLtdMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_OperatingLossCarryforwardsStateCommencementOfExpirationDate" xlink:label="caba_OperatingLossCarryforwardsStateCommencementOfExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_ExpectedCostIncurredForPurchaseOfPlasmids" xlink:label="caba_ExpectedCostIncurredForPurchaseOfPlasmids"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockConversionFeatures" xlink:label="us-gaap_CommonStockConversionFeatures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_InitialTermsOfAgreementDescription" xlink:label="caba_InitialTermsOfAgreementDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_PaymentOfObligationTerm" xlink:label="caba_PaymentOfObligationTerm"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_ClinicalTrials" xlink:label="caba_ClinicalTrials"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_ContractualExpenses" xlink:label="caba_ContractualExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_CapitalizedRDCosts" xlink:label="caba_CapitalizedRDCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_MilestonePayment" xlink:label="caba_MilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_NonVestedCommonStockMember" xlink:label="caba_NonVestedCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_OperatingLeaseAssets" xlink:label="caba_OperatingLeaseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_PercentageOfEligibleTaxPositionsForRecognition" xlink:label="caba_PercentageOfEligibleTaxPositionsForRecognition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_PersonnelExpenses" xlink:label="caba_PersonnelExpenses"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_PropertyPlantAndEquipmentEstimatedUsefulLives1" xlink:label="caba_PropertyPlantAndEquipmentEstimatedUsefulLives1"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_ResearchServiceAgreementMember" xlink:label="caba_ResearchServiceAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_OtherInformationAbstract" xlink:label="caba_OtherInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_UpfrontPayment" xlink:label="caba_UpfrontPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_AgreementWithContractManufacturingOrganizationMember" xlink:label="caba_AgreementWithContractManufacturingOrganizationMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_DevelopmentServices" xlink:label="caba_DevelopmentServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees" xlink:label="us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_FinanceLesseeUndiscountedLeasePayments" xlink:label="caba_FinanceLesseeUndiscountedLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplyCommitmentAxis" xlink:label="us-gaap_SupplyCommitmentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockDividendsShares" xlink:label="us-gaap_CommonStockDividendsShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplyCommitmentArrangementMember" xlink:label="us-gaap_SupplyCommitmentArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_LesseeUndiscountedLeasePayments" xlink:label="caba_LesseeUndiscountedLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_IncomeTaxDisclosureTable" xlink:label="caba_IncomeTaxDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="us-gaap_EarningsPerShareDilutedAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_Caba201AndMuskCaartMember" xlink:label="caba_Caba201AndMuskCaartMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:label="caba_EmergingGrowthCompanyStatusPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_LeaseCommencementMonthAndYear" xlink:label="caba_LeaseCommencementMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_FederalMember" xlink:label="caba_FederalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_LonzaAgreementMember" xlink:label="caba_LonzaAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="caba_DeferredTaxAssetsOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" xlink:label="caba_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_IncomeTaxDisclosureLineItems" xlink:label="caba_IncomeTaxDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_LicenseMaintenanceFee" xlink:label="caba_LicenseMaintenanceFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_LaboratoryEquipmentMember" xlink:label="caba_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_EarningPerShareBasicAndDilutedLineItems" xlink:label="caba_EarningPerShareBasicAndDilutedLineItems"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_DeferredTaxAssetsOperatingLossCarryforwardsLocal" xlink:label="caba_DeferredTaxAssetsOperatingLossCarryforwardsLocal"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_CommitmentsAndContingenciesDisclosureTable" xlink:label="caba_CommitmentsAndContingenciesDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_EffectiveIncomeTaxRateReconciliationNondeductibleItemsAndOther" xlink:label="caba_EffectiveIncomeTaxRateReconciliationNondeductibleItemsAndOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_AdditionalOptionsToBePurchasedByUnderwriters" xlink:label="caba_AdditionalOptionsToBePurchasedByUnderwriters"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportingUnits" xlink:label="us-gaap_NumberOfReportingUnits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_AccruedResearchAndDevelopmentServicesCurrent" xlink:label="caba_AccruedResearchAndDevelopmentServicesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:label="us-gaap_OperatingLeasesRentExpenseMinimumRentals"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock" xlink:label="caba_PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_TotalFixedFinanceLeaseCost" xlink:label="caba_TotalFixedFinanceLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_OperatingCashFlowsUsedForOperatingLeases" xlink:label="caba_OperatingCashFlowsUsedForOperatingLeases"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_DeferredTaxAssetsLicenseFeesDeductions" xlink:label="caba_DeferredTaxAssetsLicenseFeesDeductions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_TotalFinanceLeaseCost" xlink:label="caba_TotalFinanceLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_CollaborativeAgreementPaymentsDue" xlink:label="caba_CollaborativeAgreementPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_NonRule10B51ArrModifiedFlag" xlink:label="caba_NonRule10B51ArrModifiedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_SharesRemainingAvailableForIssuance" xlink:label="caba_SharesRemainingAvailableForIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_TwoThousandEighteenStockOptionAndGrantPlanMember" xlink:label="caba_TwoThousandEighteenStockOptionAndGrantPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_MasterTranslationalResearchServicesAgreementMember" xlink:label="caba_MasterTranslationalResearchServicesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:label="us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_DeferredTaxAssetsOperatingLossCarryforwardsState" xlink:label="caba_DeferredTaxAssetsOperatingLossCarryforwardsState"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="caba_CommitmentsAndContingenciesDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:label="caba_TwoThousandNineteenEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_PercentageOfPayrollDeductionOnEligibleCompensation" xlink:label="caba_PercentageOfPayrollDeductionOnEligibleCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_LicenseAgreementMember" xlink:label="caba_LicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_StateMember" xlink:label="caba_StateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_RentExpense" xlink:label="caba_RentExpense"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_AccruedGeneralAndAdministrativeServicesCurrent" xlink:label="caba_AccruedGeneralAndAdministrativeServicesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_AccruedAndOtherCurrentLiabilitiesMember" xlink:label="caba_AccruedAndOtherCurrentLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_SponsoredResearchAgreementsMember" xlink:label="caba_SponsoredResearchAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_LicenseOfIntellectualProperty" xlink:label="caba_LicenseOfIntellectualProperty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_IncreaseInTheLeaseLiability" xlink:label="caba_IncreaseInTheLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_RemainingResearchAndDevelopmentExpenseToBeIncurred" xlink:label="caba_RemainingResearchAndDevelopmentExpenseToBeIncurred"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_RegentsOfUniversityOfCaliforniaMember" xlink:label="caba_RegentsOfUniversityOfCaliforniaMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_AnupMardaMember" xlink:label="caba_AnupMardaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_December2022FinancingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">December 2022 Financing [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_December2022FinancingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">December Two Thousand Twenty Two Financing [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_December2022FinancingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">December 2022 Financing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment for commissions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Commissions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_PreFundedWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre-funded warrants exercised.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_PreFundedWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-Funded Warrants Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_PreFundedWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ChangeInStateAndLocalTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in state and local tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ChangeInStateAndLocalTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change In State And Local Tax Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ChangeInStateAndLocalTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Change In State And Local Tax Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OperatingLeasesAbtract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases [Abtract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OperatingLeasesAbtract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating Leases [Abtract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OperatingLeasesAbtract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Leases:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted, Adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Add: Conversion of non-voting to voting common shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Adjustment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborations licensing agreements and other agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborations Licensing Agreements And Other Agreements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_CashPaidInTheMeasurementOfLeaseLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Paid In The Measurement Of Lease Liabilities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_CashPaidInTheMeasurementOfLeaseLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash Paid In The Measurement Of Lease Liabilities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_CashPaidInTheMeasurementOfLeaseLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid in the measurement of lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_FundingTermEndingDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Funding term ending date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_FundingTermEndingDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Funding Term Ending Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_FundingTermEndingDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Funding term end date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Options Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Other Observable Inputs (Level 2)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Leases [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentDueInNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Committed payment obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentDueInNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Commitment, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock, Class of Stock [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_IssuanceOfCommonStockAndPreFundedWarrantsForThePurchaseOfCommonStockNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock and pre-funded warrants for the purchase of common stock, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_IssuanceOfCommonStockAndPreFundedWarrantsForThePurchaseOfCommonStockNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of common stock and pre-funded warrants for the purchase of common stock, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_IssuanceOfCommonStockAndPreFundedWarrantsForThePurchaseOfCommonStockNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of pre-funded warrants, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, to be Paid, Next Rolling 12 Months</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantExercisePriceDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant, Exercise Price, Decrease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantExercisePriceDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Decrease in exercise price of Warrents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Available For Sale Securities [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of shares, Forfeited/Cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorOpinionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Opinion [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorOpinionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Opinion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, issued shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining lease term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Description and Basis of Presentation [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under employee stock purchase plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_StockIssuedDuringPeriodShareStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period share stock options exercised.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_StockIssuedDuringPeriodShareStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Share Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_StockIssuedDuringPeriodShareStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in connection with exercise of stock options, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_MayTwoThousandTwentyThreeFinancingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">May 2023 Financing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_MayTwoThousandTwentyThreeFinancingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">May Two Thousand Twenty Three Financing [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_MayTwoThousandTwentyThreeFinancingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">May Two Thousand Twenty Three Financing [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Options Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share of voting and non-voting common stock, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AnnualIncreasePercentageOfBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual increase percentage of base rent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AnnualIncreasePercentageOfBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Annual Increase Percentage Of Base Rent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AnnualIncreasePercentageOfBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of annual increase of base rent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OperatingLossCarryforwardsLocalCommencementOfExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards local commencement of expiration date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OperatingLossCarryforwardsLocalCommencementOfExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Local Commencement Of Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OperatingLossCarryforwardsLocalCommencementOfExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards local commencement of expiration date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Unrealized Gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options outstanding aggregate intrinsic value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Aggregate Intrinsic Value [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Principal Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Principal payments on finance leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ArunDasOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Arun Das One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ArunDasOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Arun Das One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OperatingLossCarryforwardsFederalCommencementOfExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards federal commencement of expiration date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OperatingLossCarryforwardsFederalCommencementOfExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Federal Commencement Of Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OperatingLossCarryforwardsFederalCommencementOfExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards federal commencement of expiration date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ObligationToBePaidCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Obligation to be paid, commencement date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ObligationToBePaidCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Obligation To Be Paid Commencement Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ObligationToBePaidCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment commencement date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average discount rate - finance leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_IncreaseInShareReservedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase in share reserved percentage.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_IncreaseInShareReservedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase In Share Reserved Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_IncreaseInShareReservedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in share reserved percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Off-Balance-Sheet Credit Exposure, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Off-Balance Sheet Risk and Concentrations of Credit Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Shares, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Shares, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares reserved for issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_WorkOrdersTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Work orders terms</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_WorkOrdersTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Work Orders Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_WorkOrdersTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Work Orders Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_TerminationFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Termination fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_TerminationFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Termination Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_TerminationFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Termination Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, plant and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Measurements, Recurring</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateNoteSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">U.S. Treasury securities - original maturity less than three months</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateNoteSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Note Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateNoteSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Note Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease liability payments due after rolling year three.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due After Rolling Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock Options to Purchase Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive loss:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other comprehensive income:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Basic and Diluted Earnings Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_WuXiAdvancedTherapiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">WuXi Advanced Therapies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_WuXiAdvancedTherapiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Wu Xi Advanced Therapies [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_WuXiAdvancedTherapiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">WuXi Advanced Therapies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForUnderwritingExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting discounts and commissions and offering expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForUnderwritingExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Underwriting Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Antidilutive Shares Excluded from Calculation of Diluted Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_FinancingCashFlowsUsedForFinanceLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financing Cash Flows Used For Finance Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_FinancingCashFlowsUsedForFinanceLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Financing Cash Flows Used For Finance Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_FinancingCashFlowsUsedForFinanceLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing cash flows for finance leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossRelatedToLitigationSettlement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) from Litigation Settlement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossRelatedToLitigationSettlement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss related to litigation settlement accrued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity of Counterparty, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal Entity of Counterparty, Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development credit, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Research and development credit, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, net of current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Profit and Loss From Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares, Options Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan, contribution amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_GwendolynBinderOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gwendolyn Binder One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_GwendolynBinderOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gwendolyn Binder One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets tax credit carryforwards commencement of expiration date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credit Carryforwards Commencement Of Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets tax credit carryforwards commencement of expiration date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">General and administration expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total milestone payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_DevelopmentAndManufacturingServicesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development and manufacturing services agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_DevelopmentAndManufacturingServicesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development And Manufacturing Services Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_DevelopmentAndManufacturingServicesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Wuxi Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborations licensing agreements and other agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborations Licensing Agreements And Other Agreements Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborations, Licensing Agreements and other Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ArunDasMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Arun Das [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ArunDasMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Arun Das [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, issued shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock in connection with the exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payables and Accruals [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under employee stock purchase plan, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Short-Term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Monthly fee included in minimum lease payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OxfordBiomedicaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Oxford Biomedica.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OxfordBiomedicaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Oxford Biomedica [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OxfordBiomedicaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Oxford Biomedica</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ManufacturingOfPreclinicalAndClinicalSupplies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Manufacturing of Preclinical and Clinical Supplies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ManufacturingOfPreclinicalAndClinicalSupplies_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Manufacturing of Preclinical and Clinical Supplies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ManufacturingOfPreclinicalAndClinicalSupplies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Manufacturing of preclinical and clinical supplies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Forfeited/Cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, outstanding shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestmentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Investments [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestmentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ContractualCostIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contractual cost incurred.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ContractualCostIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Cost Incurred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ContractualCostIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost incurred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AutolusHoldingsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Autolus Holdings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AutolusHoldingsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Autolus Holdings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AutolusHoldingsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Autolus Holdings Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AnupMardaOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Anup Marda One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AnupMardaOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Anup Marda One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from maturities of investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amortization Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Sale Products</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_IssuanceOfCommonStockUponExerciseOfPreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock upon exercise of pre-funded warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_IssuanceOfCommonStockUponExerciseOfPreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of common stock upon exercise of pre-funded warrants, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity Type of Counterparty [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal Entity Type of Counterparty</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position Location, Balance [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less imputed interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total fixed operating lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total fixed operating lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_GwendolynBinderMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gwendolyn Binder [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_GwendolynBinderMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gwendolyn Binder [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Assets, Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_VariableLeaseCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_VariableLeaseCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Variable Lease Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_VariableLeaseCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Future Minimum Payments for Operating Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation, number of shares available for grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation cost, weighted average period for recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect of exchange rate changes on cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accretion of lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accretion of operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued liabilities and other liabilities current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities And Other Liabilities Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accrued and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Recently Issued Accounting Pronouncements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Adopted Accounting Pronouncements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued expenses and other current liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Expenses And Other Current Liabilities Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued and Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt issuance commissions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Stock Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_FixedLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fixed Lease Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_FixedLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fixed Lease Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_FixedLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shareholders' Equity and Share-Based Payments [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Depreciation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Offering Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Charges, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_EarningsPerShareBasicAndDilutedTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Earnings per share basic and diluted.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_EarningsPerShareBasicAndDilutedTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_EarningsPerShareBasicAndDilutedTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Earnings Per Share Basic And Diluted [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonvotingCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Non-voting Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonvotingCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonvoting Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonvotingCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-voting Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-funded Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-funded Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre-Funded Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_SubscriptionAndTechnologyTransferAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Subscription and technology transfer agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_SubscriptionAndTechnologyTransferAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subscription And Technology Transfer Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_SubscriptionAndTechnologyTransferAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subscription and Technology Transfer Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average discount rate - operating leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest or penalties related to uncertain income tax benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_NumberOfFaculty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of faculty.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_NumberOfFaculty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Faculty</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_NumberOfFaculty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of faculty member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in connection with exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Included in Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Rolling Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Agencies Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Government securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">U.S. Treasury securities - due in one year or less</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LeaseAmendmentPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease amendment period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LeaseAmendmentPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Amendment Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LeaseAmendmentPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Amendment Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position Location, Balance [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OperatingLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating Lease Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OperatingLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OperatingLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Company's Operating and Finance Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_VotingCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Voting Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_VotingCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Voting common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_VotingCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Voting Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_VotingCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Voting Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of Shares, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total property, plant and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principles of Consolidation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_Rese-CelAndMuSK-CAARTMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Rese-Cel and MuSK-CAART [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_Rese-CelAndMuSK-CAARTMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Rese-Cel and MuSK-CAART [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_Rese-CelAndMuSK-CAARTMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rese-Cel and MuSK-CAART [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_NonCashLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non cash lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_NonCashLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non cash lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_NonCashLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_NonCashLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Non-cash operating lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Finance Lease, Right-of-Use Asset, after Accumulated Amortization, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance lease right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, to be Paid, Rolling Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Assumptions Used to Estimate Fair Value of Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Rolling Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_FinanceLeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance leases [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_FinanceLeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Finance leases [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_FinanceLeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance Leases:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_TwoThousandNineteenStockOptionAndIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen stock option and incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_TwoThousandNineteenStockOptionAndIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Stock Option And Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_TwoThousandNineteenStockOptionAndIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_Rule10B51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Rule 10b51 Arr Modified Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_Rule10B51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Rule 10b5-1 Arrangement Modified [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_Rule10B51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rule 10b5-1 Arrangement Modified</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AdvancePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Advance payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AdvancePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Advance Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AdvancePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Advance payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets, operating loss carryforwards, not subject to expiration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ChildrenSHospitalOfPhiladelphiaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Children S Hospital Of Philadelphia [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ChildrenSHospitalOfPhiladelphiaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Children's Hospital of Philadelphia</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ChildrenSHospitalOfPhiladelphiaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Children&#8217;s Hospital of Philadelphia.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of Federal Statutory Income Tax Rate to Company's Effective Income Tax Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Securities Available For Sale [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_DeferredTaxAssetsOperatingLossCarryforwardsFederal_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets operating loss carryforwards federal.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_DeferredTaxAssetsOperatingLossCarryforwardsFederal_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards Federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_DeferredTaxAssetsOperatingLossCarryforwardsFederal_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets operating loss carryforwards federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Net [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LeaseExpirationMonth_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration month</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LeaseExpirationMonth_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Month</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LeaseExpirationMonth_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease Expiration Month</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Allocation of undistributed losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Undistributed Earnings (Loss) Available to Common Shareholders, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allocation of undistributed losses attributable to common stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Undistributed Earnings (Loss) Available to Common Shareholders, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and stockholders&#8217; equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options outstanding weighted average remaining contractual term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term (years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal, state and local net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive shares have been excluded from calculation of diluted net loss per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other research and development costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_StevenNichtbergerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Steven Nichtberger [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_StevenNichtbergerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Steven Nichtberger [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OperatingCashFlowsUsedForFinanceLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Cash Flows Used For Finance Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OperatingCashFlowsUsedForFinanceLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating Cash Flows Used For Finance Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OperatingCashFlowsUsedForFinanceLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating cash flows used for finance leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gross deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AtTheMarketOfferingSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At-the-market offering sales agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AtTheMarketOfferingSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At The Market Offering Sales Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AtTheMarketOfferingSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At-The-Market Offering Sales Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_IncreaseInTheRouAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase in the ROU asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_IncreaseInTheRouAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase in the ROU asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_IncreaseInTheRouAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in the ROU asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LeaseExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease expiration month and year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LeaseExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Month And Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LeaseExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation cost related to unvested stock-based awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gross Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_WuxiAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">WuXi Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_WuxiAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">WuXi Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_StevenNichtbergerOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Steven Nichtberger One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_StevenNichtbergerOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Steven Nichtberger One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: accumulated depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant-date fair value of stock options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&#8217; equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee stock purchase plan maximum annual rights to purchase common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Purchase Plan Maximum Annual Rights To Purchase Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee stock purchase plan maximum annual rights to purchase common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Right-of-use asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_NanjingIasoBiotherapeuticsCoLtdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Nanjing IASO Biotherapeutics Co., Ltd. member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_NanjingIasoBiotherapeuticsCoLtdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nanjing IASO Biotherapeutics Co., Ltd. [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_NanjingIasoBiotherapeuticsCoLtdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IASO Biotherapeutics</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share of voting and non-voting common stock, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OperatingLossCarryforwardsStateCommencementOfExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards state commencement of expiration date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OperatingLossCarryforwardsStateCommencementOfExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards State Commencement Of Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OperatingLossCarryforwardsStateCommencementOfExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards state commencement of expiration date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ExpectedCostIncurredForPurchaseOfPlasmids_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Expected cost incurred for purchase of plasmids.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ExpectedCostIncurredForPurchaseOfPlasmids_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Expected Cost Incurred For Purchase Of Plasmids</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ExpectedCostIncurredForPurchaseOfPlasmids_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockConversionFeatures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-voting common stock, terms of conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockConversionFeatures_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Terms of Conversion, Common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockConversionFeatures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Terms of Conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock, net of issuance costs, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issuance, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation, vesting period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_InitialTermsOfAgreementDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Terms agreement description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_InitialTermsOfAgreementDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Initial Terms of Agreement, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_InitialTermsOfAgreementDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial Terms of Agreement, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_PaymentOfObligationTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of obligation, term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_PaymentOfObligationTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Of Obligation Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_PaymentOfObligationTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_PaymentOfObligationTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Payment term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ClinicalTrials_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Clinical Trials</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ClinicalTrials_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical Trials</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ClinicalTrials_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical trials</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized income tax benefits that would affect effective tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense) [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional in fixed undiscounted lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less imputed interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ContractualExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contractual expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ContractualExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ContractualExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expense related to agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Aggregate Intrinsic Value, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Aggregate Intrinsic Value, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_CapitalizedRDCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Capitalized R&amp;D costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_CapitalizedRDCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized R&amp;D costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_CapitalizedRDCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized research and development costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_MilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_MilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_MilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_NonVestedCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-vested common stock member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_NonVestedCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Vested Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_NonVestedCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-vested Founder Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Weighted Average Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining lease term - finance leases (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Compensation and Employee Benefit Plans [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">401(k) Savings Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Reportable Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of reportable segment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Allocation of undistributed losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average number of shares used in basic per share computation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average common stock outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OperatingLeaseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OperatingLeaseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OperatingLeaseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating lease assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance lease liabilities, net of current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_PercentageOfEligibleTaxPositionsForRecognition_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of eligible tax positions for recognition.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_PercentageOfEligibleTaxPositionsForRecognition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Eligible Tax Positions For Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_PercentageOfEligibleTaxPositionsForRecognition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of eligible tax positions for recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, authorized shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, authorized shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated useful life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Interest Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Quoted Prices in Active Markets for Identical Assets (Level 1)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the issuance of common stock under employee stock purchase plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term (years), Options Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_PersonnelExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Personnel Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_PersonnelExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Personnel Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_PersonnelExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Personnel</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_PropertyPlantAndEquipmentEstimatedUsefulLives1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lesser of estimated useful life or remaining lease term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_PropertyPlantAndEquipmentEstimatedUsefulLives1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Estimated Useful Lives 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_PropertyPlantAndEquipmentEstimatedUsefulLives1_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Property Plant And Equipment Estimated Useful Lives 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ResearchServiceAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Service Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ResearchServiceAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research Service Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ResearchServiceAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research service agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OtherInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Information [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OtherInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other Information [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OtherInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other inforamation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss on foreign currency exchange rates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transaction Loss, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_UpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront license fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_UpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_UpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AgreementWithContractManufacturingOrganizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreement with contract manufacturing organization.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AgreementWithContractManufacturingOrganizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreement With Contract Manufacturing Organization [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AgreementWithContractManufacturingOrganizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreement with Contract Manufacturing Organization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_DevelopmentServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development Services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_DevelopmentServices_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development Services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_DevelopmentServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Termination fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Subject to Compromise, Early Contract Termination Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Early termination fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_FinanceLesseeUndiscountedLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lessee Undiscounted Lease Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_FinanceLesseeUndiscountedLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Finance Lessee Undiscounted Lease Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_FinanceLesseeUndiscountedLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total undiscounted lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_FinanceLesseeUndiscountedLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total undiscounted lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Role of Management [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available-for-sale securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplyCommitmentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supply Commitment [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplyCommitmentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supply Commitment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Undistributed Earnings (Loss) Allocated to Participating Securities, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allocation of undistributed losses for basic computation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Undistributed Earnings (Loss) Allocated to Participating Securities, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockDividendsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock dividends, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockDividendsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Dividends, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplyCommitmentArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supply Commitment Arrangement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplyCommitmentArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supply Commitment Arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LesseeUndiscountedLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee Undiscounted Lease Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LesseeUndiscountedLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Undiscounted Lease Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LesseeUndiscountedLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total undiscounted lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LesseeUndiscountedLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total undiscounted lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property Plant and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_IncomeTaxDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_IncomeTaxDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_IncomeTaxDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Disclosure [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDilutedAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDilutedAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Diluted net loss per share:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, authorized shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_Caba201AndMuskCaartMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CABA-201 and MuSK-CAART [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_Caba201AndMuskCaartMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">CABA-201 and MuSK-CAART [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Emerging growth company status.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Emerging Growth Company Status Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Emerging Growth Company Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net (decrease) increase in cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LeaseCommencementMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease commencement month and year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LeaseCommencementMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Commencement Month And Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LeaseCommencementMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease commencement period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_FederalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Federal.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_FederalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Federal [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_FederalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation deductions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State and local taxes, net of federal benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseAndServiceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License and Service [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseAndServiceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License and Service [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense, Operating and Nonoperating</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Operating and Nonoperating, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LonzaAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lonza Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LonzaAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lonza Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LonzaAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lonza Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LonzaAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Lonza Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Tax Assets, Operating Lease Liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of estimated useful lives of property and equipment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Estimated Useful Lives Of Property And Equipment Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Estimated Useful Lives for Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term (years), Options Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_IncomeTaxDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_IncomeTaxDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_IncomeTaxDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Disclosure [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, and Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents and investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, and Short-Term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LicenseMaintenanceFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License maintenance fee.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LicenseMaintenanceFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Maintenance Fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LicenseMaintenanceFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License maintenance fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.00001 par value: 10,000,000 shares authorized as of December 31, 2024 and December 31, 2023; no shares issued or outstanding at December 31, 2024 and December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred but Not yet Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment purchases included in accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents&#8212;end of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents&#8212;beginning of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory equipment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_EarningPerShareBasicAndDilutedLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Earning per share basic and diluted.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_EarningPerShareBasicAndDilutedLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earning Per Share Basic And Diluted [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_EarningPerShareBasicAndDilutedLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Earning Per Share Basic And Diluted [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_DeferredTaxAssetsOperatingLossCarryforwardsLocal_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets operating loss carryforwards local.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_DeferredTaxAssetsOperatingLossCarryforwardsLocal_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards Local</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_DeferredTaxAssetsOperatingLossCarryforwardsLocal_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets operating loss carryforwards local</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected income tax benefit at the federal statutory rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies Disclosure [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, outstanding shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Jurisdiction [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Warrant Exercises</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from exercise of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_EffectiveIncomeTaxRateReconciliationNondeductibleItemsAndOther_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation nondeductible items and other.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_EffectiveIncomeTaxRateReconciliationNondeductibleItemsAndOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Nondeductible Items And Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_EffectiveIncomeTaxRateReconciliationNondeductibleItemsAndOther_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Non-deductible items and other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_EffectiveIncomeTaxRateReconciliationNondeductibleItemsAndOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-deductible items and other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock and pre-funded warrants for the purchase of common stock, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value By Balance Sheet Grouping [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, by Balance Sheet Grouping [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Principal Components of Company's Deferred Tax Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets obtained in exchange for operating lease obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Jurisdiction [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic net loss per share:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses and Other Current Assets [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid Expenses and Other Current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AdditionalOptionsToBePurchasedByUnderwriters_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional options to be purchased by underwriters</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AdditionalOptionsToBePurchasedByUnderwriters_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Options to be purchased by underwriters</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AdditionalOptionsToBePurchasedByUnderwriters_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional Options to be purchased by underwriters</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborations licensing agreements and other agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborations Licensing Agreements And Other Agreements [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborations Licensing Agreements And Other Agreements [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Operating Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Other Operating Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportingUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Reporting Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportingUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of reportable segment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AccruedResearchAndDevelopmentServicesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development services current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AccruedResearchAndDevelopmentServicesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Services Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AccruedResearchAndDevelopmentServicesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesRentExpenseMinimumRentals_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases, Rent Expense, Minimum Rentals</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesRentExpenseMinimumRentals_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial annual base rent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of shares purchased at fair market value of common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Shares Purchased At Fair Market Value Of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of shares to be purchased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_TotalFixedFinanceLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Total Fixed Finance Lease Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_TotalFixedFinanceLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Total Fixed Finance Lease Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_TotalFixedFinanceLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total Fixed Finance Lease Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_TotalFixedFinanceLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total Fixed Finance Lease Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OperatingCashFlowsUsedForOperatingLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Cash Flows Used For Operating Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OperatingCashFlowsUsedForOperatingLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating Cash Flows Used For Operating Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OperatingCashFlowsUsedForOperatingLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating cash flows used for operating leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_DeferredTaxAssetsLicenseFeesDeductions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets license fees deductions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_DeferredTaxAssetsLicenseFeesDeductions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets License Fees Deductions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_DeferredTaxAssetsLicenseFeesDeductions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License fee deductions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_TotalFinanceLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Total Finance Lease Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_TotalFinanceLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of lease cost recognized by lessee for lease contract.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_TotalFinanceLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total finance lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_TotalFinanceLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total finance lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_CollaborativeAgreementPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative agreement payments due.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_CollaborativeAgreementPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Agreement Payments Due</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_CollaborativeAgreementPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amounts due to agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_NonRule10B51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non Rule 10b51 Arr Modified Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_NonRule10B51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-Rule 10b5-1 Arrangement Modified [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_NonRule10B51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-Rule 10b5-1 Arrangement Modified</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Gain (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net unrealized gains (losses) on available-for-sale securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Unrealized Gain (Loss), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_SharesRemainingAvailableForIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares available for issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_SharesRemainingAvailableForIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">shares remaining available for issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_SharesRemainingAvailableForIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">shares remaining available for issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lesser of estimated useful life or remaining lease term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets, operating loss carryforwards, subject to expiration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_TwoThousandEighteenStockOptionAndGrantPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand eighteen stock option and grant plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_TwoThousandEighteenStockOptionAndGrantPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Eighteen Stock Option And Grant Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_TwoThousandEighteenStockOptionAndGrantPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2018 Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance lease liabilities, current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Voting and non-voting common stock, $0.00001 par value: 150,000,000 (143,590,481 voting and 6,409,519 non-voting) shares authorized as of December 31, 2024 and December 31, 2023; 50,743,101 voting shares issued and outstanding as of December 31, 2024 and 47,823,232 (46,378,937 voting and 1,444,295 non-voting) shares issued and outstanding as of December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_MasterTranslationalResearchServicesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Master translational research services agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_MasterTranslationalResearchServicesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Master Translational Research Services Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_MasterTranslationalResearchServicesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Master Translational Research Services Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Interest income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of finance lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Right-of-Use Asset, Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reallocation of undistributed losses as a result of conversion of non-voting to voting common shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_DeferredTaxAssetsOperatingLossCarryforwardsState_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets operating loss carryforwards state.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_DeferredTaxAssetsOperatingLossCarryforwardsState_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_DeferredTaxAssetsOperatingLossCarryforwardsState_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets operating loss carryforwards state</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money market funds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Next Rolling 12 Months</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Financial Assets Measured at Fair Value on Recurring Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Lease, Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Debt Securities Classified as Available-for-Sale Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (see Notes 6 and 7)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_TwoThousandNineteenEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen employee stock purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_TwoThousandNineteenEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_TwoThousandNineteenEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 ESPP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted average number of shares used in diluted per share computation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_PercentageOfPayrollDeductionOnEligibleCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of payroll deduction on eligible compensation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_PercentageOfPayrollDeductionOnEligibleCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Payroll Deduction On Eligible Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_PercentageOfPayrollDeductionOnEligibleCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payroll deduction percentage of eligible compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation unvested number of shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Lessee, Operating Lease, Liability, to be Paid, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Third Party Engaged [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_StateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_StateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_StateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">State [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_RentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Rent expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_RentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Rent Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_RentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AccruedGeneralAndAdministrativeServicesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued general and administrative services current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AccruedGeneralAndAdministrativeServicesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued General And Administrative Services Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AccruedGeneralAndAdministrativeServicesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AccruedAndOtherCurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued and other current liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AccruedAndOtherCurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued And Other Current Liabilities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AccruedAndOtherCurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued and Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_SponsoredResearchAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sponsored Research Agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_SponsoredResearchAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sponsored Research Agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_SponsoredResearchAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sponsored Research Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LicenseOfIntellectualProperty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License of Intellectual Property</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LicenseOfIntellectualProperty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License of Intellectual Property</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LicenseOfIntellectualProperty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License of intellectual property</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractualObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractualObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Obligation to be paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractualObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Contractual Obligation, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractualObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">liability related to agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Amortization of discount on investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Amortization of (discount) premium on investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_IncreaseInTheLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase in the lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_IncreaseInTheLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase in the lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_IncreaseInTheLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in the lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued and Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of use assets obtained in exchange for lease obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_RemainingResearchAndDevelopmentExpenseToBeIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Remaining research and development expense to be incurred.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_RemainingResearchAndDevelopmentExpenseToBeIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Remaining Research And Development Expense To Be Incurred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_RemainingResearchAndDevelopmentExpenseToBeIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining research and development expense to be incurred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Unobservable Inputs (Level 3)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining lease term - operating leases (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net unrealized (loss) gain on available-for-sale investments, net of tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborations licensing agreements and other agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborations Licensing Agreements And Other Agreements [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborations, Licensing Agreements And Other Agreements [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_RegentsOfUniversityOfCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Regents of the university of California.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_RegentsOfUniversityOfCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Regents Of University Of California [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_RegentsOfUniversityOfCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Penn</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AnupMardaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Anup Marda [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AnupMardaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Anup Marda [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term lease cost</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_December2022FinancingMember" xlink:to="caba_December2022FinancingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForCommissions" xlink:to="us-gaap_PaymentsForCommissions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_PreFundedWarrantsExercised" xlink:to="caba_PreFundedWarrantsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_ChangeInStateAndLocalTaxRate" xlink:to="caba_ChangeInStateAndLocalTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_OperatingLeasesAbtract" xlink:to="caba_OperatingLeasesAbtract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsAbstract" xlink:to="caba_CollaborationsLicensingAgreementsAndOtherAgreementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_CashPaidInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="caba_CashPaidInTheMeasurementOfLeaseLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_FundingTermEndingDate" xlink:to="caba_FundingTermEndingDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentDueInNextTwelveMonths" xlink:to="us-gaap_OtherCommitmentDueInNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_IssuanceOfCommonStockAndPreFundedWarrantsForThePurchaseOfCommonStockNetOfIssuanceCosts" xlink:to="caba_IssuanceOfCommonStockAndPreFundedWarrantsForThePurchaseOfCommonStockNetOfIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceDecrease" xlink:to="us-gaap_WarrantExercisePriceDecrease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorOpinionTextBlock" xlink:to="dei_AuditorOpinionTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_StockIssuedDuringPeriodShareStockOptionsExercised" xlink:to="caba_StockIssuedDuringPeriodShareStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_MayTwoThousandTwentyThreeFinancingMember" xlink:to="caba_MayTwoThousandTwentyThreeFinancingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_AnnualIncreasePercentageOfBaseRent" xlink:to="caba_AnnualIncreasePercentageOfBaseRent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_OperatingLossCarryforwardsLocalCommencementOfExpirationDate" xlink:to="caba_OperatingLossCarryforwardsLocalCommencementOfExpirationDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:to="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_ArunDasOneMember" xlink:to="caba_ArunDasOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_OperatingLossCarryforwardsFederalCommencementOfExpirationDate" xlink:to="caba_OperatingLossCarryforwardsFederalCommencementOfExpirationDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_ObligationToBePaidCommencementDate" xlink:to="caba_ObligationToBePaidCommencementDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_IncreaseInShareReservedPercentage" xlink:to="caba_IncreaseInShareReservedPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" xlink:to="us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_WorkOrdersTerm" xlink:to="caba_WorkOrdersTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_TerminationFees" xlink:to="caba_TerminationFees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateNoteSecuritiesMember" xlink:to="us-gaap_CorporateNoteSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearThree" xlink:to="caba_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_WuXiAdvancedTherapiesMember" xlink:to="caba_WuXiAdvancedTherapiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForUnderwritingExpense" xlink:to="us-gaap_PaymentsForUnderwritingExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_FinancingCashFlowsUsedForFinanceLeases" xlink:to="caba_FinancingCashFlowsUsedForFinanceLeases_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossRelatedToLitigationSettlement" xlink:to="us-gaap_GainLossRelatedToLitigationSettlement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_GwendolynBinderOneMember" xlink:to="caba_GwendolynBinderOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate" xlink:to="caba_DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_MilestonePayments" xlink:to="caba_MilestonePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_DevelopmentAndManufacturingServicesAgreementMember" xlink:to="caba_DevelopmentAndManufacturingServicesAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock" xlink:to="caba_CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_ArunDasMember" xlink:to="caba_ArunDasMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_OxfordBiomedicaMember" xlink:to="caba_OxfordBiomedicaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_ManufacturingOfPreclinicalAndClinicalSupplies" xlink:to="caba_ManufacturingOfPreclinicalAndClinicalSupplies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestmentsAbstract" xlink:to="us-gaap_ShortTermInvestmentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_ContractualCostIncurred" xlink:to="caba_ContractualCostIncurred_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_AutolusHoldingsMember" xlink:to="caba_AutolusHoldingsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_AnupMardaOneMember" xlink:to="caba_AnupMardaOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_AmortizationExpense" xlink:to="caba_AmortizationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_IssuanceOfCommonStockUponExerciseOfPreFundedWarrants" xlink:to="caba_IssuanceOfCommonStockUponExerciseOfPreFundedWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_GwendolynBinderMember" xlink:to="caba_GwendolynBinderMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_VariableLeaseCosts" xlink:to="caba_VariableLeaseCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionExpense" xlink:to="us-gaap_AccretionExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:to="caba_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_FixedLeaseCost" xlink:to="caba_FixedLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_EarningsPerShareBasicAndDilutedTable" xlink:to="caba_EarningsPerShareBasicAndDilutedTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonvotingCommonStockMember" xlink:to="us-gaap_NonvotingCommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_PreFundedWarrantsMember" xlink:to="caba_PreFundedWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_SubscriptionAndTechnologyTransferAgreementMember" xlink:to="caba_SubscriptionAndTechnologyTransferAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_NumberOfFaculty" xlink:to="caba_NumberOfFaculty_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsMember" xlink:to="us-gaap_CashAndCashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_LeaseAmendmentPeriod" xlink:to="caba_LeaseAmendmentPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_OperatingLeaseAgreementMember" xlink:to="caba_OperatingLeaseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_VotingCommonStockMember" xlink:to="caba_VotingCommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_Rese-CelAndMuSK-CAARTMember" xlink:to="caba_Rese-CelAndMuSK-CAARTMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_NonCashLeaseExpense" xlink:to="caba_NonCashLeaseExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_FinanceLeasesAbstract" xlink:to="caba_FinanceLeasesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_TwoThousandNineteenStockOptionAndIncentivePlanMember" xlink:to="caba_TwoThousandNineteenStockOptionAndIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_Rule10B51ArrModifiedFlag" xlink:to="caba_Rule10B51ArrModifiedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_AdvancePayments" xlink:to="caba_AdvancePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_ChildrenSHospitalOfPhiladelphiaMember" xlink:to="caba_ChildrenSHospitalOfPhiladelphiaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_DeferredTaxAssetsOperatingLossCarryforwardsFederal" xlink:to="caba_DeferredTaxAssetsOperatingLossCarryforwardsFederal_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_LeaseExpirationMonth" xlink:to="caba_LeaseExpirationMonth_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic" xlink:to="us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:to="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_StevenNichtbergerMember" xlink:to="caba_StevenNichtbergerMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_OperatingCashFlowsUsedForFinanceLeases" xlink:to="caba_OperatingCashFlowsUsedForFinanceLeases_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_AtTheMarketOfferingSalesAgreementMember" xlink:to="caba_AtTheMarketOfferingSalesAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_IncreaseInTheRouAsset" xlink:to="caba_IncreaseInTheRouAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_LeaseExpirationMonthAndYear" xlink:to="caba_LeaseExpirationMonthAndYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_WuxiAgreementMember" xlink:to="caba_WuxiAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_StevenNichtbergerOneMember" xlink:to="caba_StevenNichtbergerOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock" xlink:to="caba_EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_NanjingIasoBiotherapeuticsCoLtdMember" xlink:to="caba_NanjingIasoBiotherapeuticsCoLtdMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_OperatingLossCarryforwardsStateCommencementOfExpirationDate" xlink:to="caba_OperatingLossCarryforwardsStateCommencementOfExpirationDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_ExpectedCostIncurredForPurchaseOfPlasmids" xlink:to="caba_ExpectedCostIncurredForPurchaseOfPlasmids_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockConversionFeatures" xlink:to="us-gaap_CommonStockConversionFeatures_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashMember" xlink:to="us-gaap_CashMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_InitialTermsOfAgreementDescription" xlink:to="caba_InitialTermsOfAgreementDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_PaymentOfObligationTerm" xlink:to="caba_PaymentOfObligationTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_ClinicalTrials" xlink:to="caba_ClinicalTrials_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_ContractualExpenses" xlink:to="caba_ContractualExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_CapitalizedRDCosts" xlink:to="caba_CapitalizedRDCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_MilestonePayment" xlink:to="caba_MilestonePayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_NonVestedCommonStockMember" xlink:to="caba_NonVestedCommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:to="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_OperatingLeaseAssets" xlink:to="caba_OperatingLeaseAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_PercentageOfEligibleTaxPositionsForRecognition" xlink:to="caba_PercentageOfEligibleTaxPositionsForRecognition_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_PersonnelExpenses" xlink:to="caba_PersonnelExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_PropertyPlantAndEquipmentEstimatedUsefulLives1" xlink:to="caba_PropertyPlantAndEquipmentEstimatedUsefulLives1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_ResearchServiceAgreementMember" xlink:to="caba_ResearchServiceAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_OtherInformationAbstract" xlink:to="caba_OtherInformationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_UpfrontPayment" xlink:to="caba_UpfrontPayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_AgreementWithContractManufacturingOrganizationMember" xlink:to="caba_AgreementWithContractManufacturingOrganizationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_DevelopmentServices" xlink:to="caba_DevelopmentServices_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees" xlink:to="us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_FinanceLesseeUndiscountedLeasePayments" xlink:to="caba_FinanceLesseeUndiscountedLeasePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplyCommitmentAxis" xlink:to="us-gaap_SupplyCommitmentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:to="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockDividendsShares" xlink:to="us-gaap_CommonStockDividendsShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="us-gaap_SupplyCommitmentArrangementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_LesseeUndiscountedLeasePayments" xlink:to="caba_LesseeUndiscountedLeasePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_IncomeTaxDisclosureTable" xlink:to="caba_IncomeTaxDisclosureTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_EarningsPerShareDilutedAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_Caba201AndMuskCaartMember" xlink:to="caba_Caba201AndMuskCaartMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:to="caba_EmergingGrowthCompanyStatusPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_LeaseCommencementMonthAndYear" xlink:to="caba_LeaseCommencementMonthAndYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_FederalMember" xlink:to="caba_FederalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAndServiceMember" xlink:to="us-gaap_LicenseAndServiceMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_LonzaAgreementMember" xlink:to="caba_LonzaAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:to="caba_DeferredTaxAssetsOperatingLeaseLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" xlink:to="caba_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="caba_IncomeTaxDisclosureLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_LicenseMaintenanceFee" xlink:to="caba_LicenseMaintenanceFee_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_LaboratoryEquipmentMember" xlink:to="caba_LaboratoryEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_EarningPerShareBasicAndDilutedLineItems" xlink:to="caba_EarningPerShareBasicAndDilutedLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_DeferredTaxAssetsOperatingLossCarryforwardsLocal" xlink:to="caba_DeferredTaxAssetsOperatingLossCarryforwardsLocal_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_CommitmentsAndContingenciesDisclosureTable" xlink:to="caba_CommitmentsAndContingenciesDisclosureTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_EffectiveIncomeTaxRateReconciliationNondeductibleItemsAndOther" xlink:to="caba_EffectiveIncomeTaxRateReconciliationNondeductibleItemsAndOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasicAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_AdditionalOptionsToBePurchasedByUnderwriters" xlink:to="caba_AdditionalOptionsToBePurchasedByUnderwriters_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable" xlink:to="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportingUnits" xlink:to="us-gaap_NumberOfReportingUnits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_AccruedResearchAndDevelopmentServicesCurrent" xlink:to="caba_AccruedResearchAndDevelopmentServicesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:to="us-gaap_OperatingLeasesRentExpenseMinimumRentals_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock" xlink:to="caba_PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_TotalFixedFinanceLeaseCost" xlink:to="caba_TotalFixedFinanceLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_OperatingCashFlowsUsedForOperatingLeases" xlink:to="caba_OperatingCashFlowsUsedForOperatingLeases_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_DeferredTaxAssetsLicenseFeesDeductions" xlink:to="caba_DeferredTaxAssetsLicenseFeesDeductions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_TotalFinanceLeaseCost" xlink:to="caba_TotalFinanceLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_CollaborativeAgreementPaymentsDue" xlink:to="caba_CollaborativeAgreementPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_NonRule10B51ArrModifiedFlag" xlink:to="caba_NonRule10B51ArrModifiedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_SharesRemainingAvailableForIssuance" xlink:to="caba_SharesRemainingAvailableForIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_TwoThousandEighteenStockOptionAndGrantPlanMember" xlink:to="caba_TwoThousandEighteenStockOptionAndGrantPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_MasterTranslationalResearchServicesAgreementMember" xlink:to="caba_MasterTranslationalResearchServicesAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:to="us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_DeferredTaxAssetsOperatingLossCarryforwardsState" xlink:to="caba_DeferredTaxAssetsOperatingLossCarryforwardsState_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="caba_CommitmentsAndContingenciesDisclosureLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:to="caba_TwoThousandNineteenEmployeeStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_PercentageOfPayrollDeductionOnEligibleCompensation" xlink:to="caba_PercentageOfPayrollDeductionOnEligibleCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_LicenseAgreementMember" xlink:to="caba_LicenseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_StateMember" xlink:to="caba_StateMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_RentExpense" xlink:to="caba_RentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_AccruedGeneralAndAdministrativeServicesCurrent" xlink:to="caba_AccruedGeneralAndAdministrativeServicesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_AccruedAndOtherCurrentLiabilitiesMember" xlink:to="caba_AccruedAndOtherCurrentLiabilitiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_SponsoredResearchAgreementsMember" xlink:to="caba_SponsoredResearchAgreementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_LicenseOfIntellectualProperty" xlink:to="caba_LicenseOfIntellectualProperty_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_IncreaseInTheLeaseLiability" xlink:to="caba_IncreaseInTheLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_RemainingResearchAndDevelopmentExpenseToBeIncurred" xlink:to="caba_RemainingResearchAndDevelopmentExpenseToBeIncurred_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_RegentsOfUniversityOfCaliforniaMember" xlink:to="caba_RegentsOfUniversityOfCaliforniaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_AnupMardaMember" xlink:to="caba_AnupMardaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="87.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="88.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorOpinionTextBlock" order="89.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:label="caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_VotingCommonStockMember" xlink:label="caba_VotingCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonvotingCommonStockMember" xlink:label="us-gaap_NonvotingCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="caba_VotingCommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_NonvotingCommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_IssuanceOfCommonStockUponExerciseOfPreFundedWarrants" xlink:label="caba_IssuanceOfCommonStockUponExerciseOfPreFundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_StockIssuedDuringPeriodShareStockOptionsExercised" xlink:label="caba_StockIssuedDuringPeriodShareStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_IssuanceOfCommonStockAndPreFundedWarrantsForThePurchaseOfCommonStockNetOfIssuanceCosts" xlink:label="caba_IssuanceOfCommonStockAndPreFundedWarrantsForThePurchaseOfCommonStockNetOfIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_14"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_15"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="caba_IssuanceOfCommonStockUponExerciseOfPreFundedWarrants" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="caba_StockIssuedDuringPeriodShareStockOptionsExercised" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="caba_IssuanceOfCommonStockAndPreFundedWarrantsForThePurchaseOfCommonStockNetOfIssuanceCosts" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_14" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding_15" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_NonCashLeaseExpense" xlink:label="caba_NonCashLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionExpense" xlink:label="us-gaap_AccretionExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_6"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionLossBeforeTax"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_InterestPaidNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="caba_NonCashLeaseExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionLossBeforeTax" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_StevenNichtbergerMember" xlink:label="caba_StevenNichtbergerMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_StevenNichtbergerOneMember" xlink:label="caba_StevenNichtbergerOneMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_AnupMardaMember" xlink:label="caba_AnupMardaMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_AnupMardaOneMember" xlink:label="caba_AnupMardaOneMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_ArunDasMember" xlink:label="caba_ArunDasMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_ArunDasOneMember" xlink:label="caba_ArunDasOneMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_GwendolynBinderMember" xlink:label="caba_GwendolynBinderMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_GwendolynBinderOneMember" xlink:label="caba_GwendolynBinderOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_Rule10B51ArrModifiedFlag" xlink:label="caba_Rule10B51ArrModifiedFlag"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_NonRule10B51ArrModifiedFlag" xlink:label="caba_NonRule10B51ArrModifiedFlag"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="caba_StevenNichtbergerMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="caba_StevenNichtbergerOneMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="caba_AnupMardaMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="caba_AnupMardaOneMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="caba_ArunDasMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="caba_ArunDasOneMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="caba_GwendolynBinderMember" order="8.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="caba_GwendolynBinderOneMember" order="9.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="caba_Rule10B51ArrModifiedFlag" order="14.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="caba_NonRule10B51ArrModifiedFlag" order="15.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipment" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilities" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_CollaborationsLicensingAgreementsAndOtherAgreementsAbstract" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsAbstract" xlink:to="caba_CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSegmentInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeases" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStock" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShare" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/Role_Disclosure401KSavingsPlan" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSubsequentEvent" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" xlink:label="us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:label="caba_EmergingGrowthCompanyStatusPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="caba_EmergingGrowthCompanyStatusPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" xlink:label="caba_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="caba_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:label="caba_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="caba_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSegmentInformationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportingUnits" xlink:label="us-gaap_NumberOfReportingUnits"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NumberOfReportingUnits" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_LaboratoryEquipmentMember" xlink:label="caba_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_PropertyPlantAndEquipmentEstimatedUsefulLives1" xlink:label="caba_PropertyPlantAndEquipmentEstimatedUsefulLives1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="caba_LaboratoryEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="caba_PropertyPlantAndEquipmentEstimatedUsefulLives1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:label="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestmentsAbstract" xlink:label="us-gaap_ShortTermInvestmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermInvestmentsAbstract" xlink:to="us-gaap_ShortTermInvestments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="us-gaap_ShortTermInvestmentsAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_InvestmentTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended"/>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateNoteSecuritiesMember" xlink:label="us-gaap_CorporateNoteSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CashMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateNoteSecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_AccruedResearchAndDevelopmentServicesCurrent" xlink:label="caba_AccruedResearchAndDevelopmentServicesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_AccruedGeneralAndAdministrativeServicesCurrent" xlink:label="caba_AccruedGeneralAndAdministrativeServicesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:label="caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="caba_AccruedResearchAndDevelopmentServicesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="caba_AccruedGeneralAndAdministrativeServicesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_CollaborationsLicensingAgreementsAndOtherAgreementsAbstract" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_RegentsOfUniversityOfCaliforniaMember" xlink:label="caba_RegentsOfUniversityOfCaliforniaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplyCommitmentAxis" xlink:label="us-gaap_SupplyCommitmentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplyCommitmentArrangementMember" xlink:label="us-gaap_SupplyCommitmentArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_LicenseAgreementMember" xlink:label="caba_LicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_AccruedAndOtherCurrentLiabilitiesMember" xlink:label="caba_AccruedAndOtherCurrentLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_SponsoredResearchAgreementsMember" xlink:label="caba_SponsoredResearchAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_PaymentOfObligationTerm" xlink:label="caba_PaymentOfObligationTerm"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_MasterTranslationalResearchServicesAgreementMember" xlink:label="caba_MasterTranslationalResearchServicesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_ObligationToBePaidCommencementDate" xlink:label="caba_ObligationToBePaidCommencementDate"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_SubscriptionAndTechnologyTransferAgreementMember" xlink:label="caba_SubscriptionAndTechnologyTransferAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_LicenseMaintenanceFee" xlink:label="caba_LicenseMaintenanceFee"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_OxfordBiomedicaMember" xlink:label="caba_OxfordBiomedicaMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_MilestonePayments" xlink:label="caba_MilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_NanjingIasoBiotherapeuticsCoLtdMember" xlink:label="caba_NanjingIasoBiotherapeuticsCoLtdMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_CollaborativeAgreementPaymentsDue" xlink:label="caba_CollaborativeAgreementPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_AutolusHoldingsMember" xlink:label="caba_AutolusHoldingsMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_NumberOfFaculty" xlink:label="caba_NumberOfFaculty"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_FundingTermEndingDate" xlink:label="caba_FundingTermEndingDate"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_ContractualCostIncurred" xlink:label="caba_ContractualCostIncurred"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_AdvancePayments" xlink:label="caba_AdvancePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenses" xlink:label="us-gaap_OtherExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentDueInNextTwelveMonths" xlink:label="us-gaap_OtherCommitmentDueInNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_RemainingResearchAndDevelopmentExpenseToBeIncurred" xlink:label="caba_RemainingResearchAndDevelopmentExpenseToBeIncurred"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_UpfrontPayment" xlink:label="caba_UpfrontPayment"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_MilestonePayment" xlink:label="caba_MilestonePayment"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsAbstract" xlink:to="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseAndServiceMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="caba_RegentsOfUniversityOfCaliforniaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplyCommitmentAxis" xlink:to="us-gaap_SupplyCommitmentArrangementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_LicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="us-gaap_ContractualObligation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="caba_AccruedAndOtherCurrentLiabilitiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_SponsoredResearchAgreementsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable" xlink:to="us-gaap_SupplyCommitmentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_PaymentOfObligationTerm" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_MasterTranslationalResearchServicesAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_ObligationToBePaidCommencementDate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_SubscriptionAndTechnologyTransferAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable" xlink:to="srt_ProductOrServiceAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_LicenseMaintenanceFee" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_OxfordBiomedicaMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_MilestonePayments" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_NanjingIasoBiotherapeuticsCoLtdMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_CollaborativeAgreementPaymentsDue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_AutolusHoldingsMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable" xlink:to="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_NumberOfFaculty" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_FundingTermEndingDate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_ContractualCostIncurred" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_AdvancePayments" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="us-gaap_OtherExpenses" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="us-gaap_OtherCommitmentDueInNextTwelveMonths" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_RemainingResearchAndDevelopmentExpenseToBeIncurred" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_UpfrontPayment" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_MilestonePayment" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_AccruedAndOtherCurrentLiabilitiesMember" xlink:label="caba_AccruedAndOtherCurrentLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_WuXiAdvancedTherapiesMember" xlink:label="caba_WuXiAdvancedTherapiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplyCommitmentAxis" xlink:label="us-gaap_SupplyCommitmentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplyCommitmentArrangementMember" xlink:label="us-gaap_SupplyCommitmentArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_OperatingLeaseAgreementMember" xlink:label="caba_OperatingLeaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_CommitmentsAndContingenciesDisclosureTable" xlink:label="caba_CommitmentsAndContingenciesDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="caba_CommitmentsAndContingenciesDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_Caba201AndMuskCaartMember" xlink:label="caba_Caba201AndMuskCaartMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_DevelopmentAndManufacturingServicesAgreementMember" xlink:label="caba_DevelopmentAndManufacturingServicesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_LeaseCommencementMonthAndYear" xlink:label="caba_LeaseCommencementMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_Rese-CelAndMuSK-CAARTMember" xlink:label="caba_Rese-CelAndMuSK-CAARTMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_LonzaAgreementMember" xlink:label="caba_LonzaAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_LeaseExpirationMonthAndYear" xlink:label="caba_LeaseExpirationMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_ChildrenSHospitalOfPhiladelphiaMember" xlink:label="caba_ChildrenSHospitalOfPhiladelphiaMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_ResearchServiceAgreementMember" xlink:label="caba_ResearchServiceAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_LeaseExpirationMonth" xlink:label="caba_LeaseExpirationMonth"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_AgreementWithContractManufacturingOrganizationMember" xlink:label="caba_AgreementWithContractManufacturingOrganizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:label="us-gaap_OperatingLeasesRentExpenseMinimumRentals"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_AnnualIncreasePercentageOfBaseRent" xlink:label="caba_AnnualIncreasePercentageOfBaseRent"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_RentExpense" xlink:label="caba_RentExpense"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_LeaseAmendmentPeriod" xlink:label="caba_LeaseAmendmentPeriod"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_InitialTermsOfAgreementDescription" xlink:label="caba_InitialTermsOfAgreementDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees" xlink:label="us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_PaymentOfObligationTerm" xlink:label="caba_PaymentOfObligationTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_ExpectedCostIncurredForPurchaseOfPlasmids" xlink:label="caba_ExpectedCostIncurredForPurchaseOfPlasmids"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_ContractualExpenses" xlink:label="caba_ContractualExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossRelatedToLitigationSettlement" xlink:label="us-gaap_GainLossRelatedToLitigationSettlement"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="caba_AccruedAndOtherCurrentLiabilitiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="caba_WuXiAdvancedTherapiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplyCommitmentAxis" xlink:to="us-gaap_SupplyCommitmentArrangementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_OperatingLeaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_SupplyCommitmentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="caba_CommitmentsAndContingenciesDisclosureTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="caba_Caba201AndMuskCaartMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_DevelopmentAndManufacturingServicesAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="caba_LeaseCommencementMonthAndYear" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="caba_Rese-CelAndMuSK-CAARTMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_LonzaAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_CounterpartyNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="caba_LeaseExpirationMonthAndYear" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="caba_ChildrenSHospitalOfPhiladelphiaMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_ResearchServiceAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="caba_LeaseExpirationMonth" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_AgreementWithContractManufacturingOrganizationMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CommitmentsAndContingenciesDisclosureTable" xlink:to="caba_CommitmentsAndContingenciesDisclosureLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseMinimumRentals" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="caba_AnnualIncreasePercentageOfBaseRent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="caba_RentExpense" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="caba_LeaseAmendmentPeriod" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="caba_InitialTermsOfAgreementDescription" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="caba_PaymentOfObligationTerm" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_ContractualObligation" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="caba_ExpectedCostIncurredForPurchaseOfPlasmids" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="caba_ContractualExpenses" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_GainLossRelatedToLitigationSettlement" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsForOperatingLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearThree" xlink:label="caba_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearThree"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="caba_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearThree" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfReportableSegments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfProfitAndLossFromSegmentsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_PersonnelExpenses" xlink:label="caba_PersonnelExpenses"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_ClinicalTrials" xlink:label="caba_ClinicalTrials"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_DevelopmentServices" xlink:label="caba_DevelopmentServices"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_ManufacturingOfPreclinicalAndClinicalSupplies" xlink:label="caba_ManufacturingOfPreclinicalAndClinicalSupplies"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_LicenseOfIntellectualProperty" xlink:label="caba_LicenseOfIntellectualProperty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="caba_PersonnelExpenses" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="caba_ClinicalTrials" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="caba_DevelopmentServices" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="caba_ManufacturingOfPreclinicalAndClinicalSupplies" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="caba_LicenseOfIntellectualProperty" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_NetIncomeLoss" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_WuxiAgreementMember" xlink:label="caba_WuxiAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_LonzaAgreementMember" xlink:label="caba_LonzaAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_TerminationFees" xlink:label="caba_TerminationFees"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_WorkOrdersTerm" xlink:label="caba_WorkOrdersTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_IncreaseInTheRouAsset" xlink:label="caba_IncreaseInTheRouAsset"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_IncreaseInTheLeaseLiability" xlink:label="caba_IncreaseInTheLeaseLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="caba_WuxiAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="caba_LonzaAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="caba_TerminationFees" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="caba_WorkOrdersTerm" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseCost" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_VariableLeaseCost" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ShortTermLeaseCost" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseCost" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="caba_IncreaseInTheRouAsset" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="caba_IncreaseInTheLeaseLiability" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityAbstract" xlink:label="us-gaap_FinanceLeaseLiabilityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_LesseeUndiscountedLeasePayments" xlink:label="caba_LesseeUndiscountedLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_FinanceLesseeUndiscountedLeasePayments" xlink:label="caba_FinanceLesseeUndiscountedLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="caba_LesseeUndiscountedLeasePayments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="caba_FinanceLesseeUndiscountedLeasePayments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_OperatingLeasesAbtract" xlink:label="caba_OperatingLeasesAbtract"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_FixedLeaseCost" xlink:label="caba_FixedLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_CashPaidInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:label="caba_CashPaidInTheMeasurementOfLeaseLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_OperatingCashFlowsUsedForOperatingLeases" xlink:label="caba_OperatingCashFlowsUsedForOperatingLeases"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_FinanceLeasesAbstract" xlink:label="caba_FinanceLeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_OtherInformationAbstract" xlink:label="caba_OtherInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_OperatingCashFlowsUsedForFinanceLeases" xlink:label="caba_OperatingCashFlowsUsedForFinanceLeases"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_AmortizationExpense" xlink:label="caba_AmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_FinancingCashFlowsUsedForFinanceLeases" xlink:label="caba_FinancingCashFlowsUsedForFinanceLeases"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_TotalFixedFinanceLeaseCost" xlink:label="caba_TotalFixedFinanceLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_VariableLeaseCosts" xlink:label="caba_VariableLeaseCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_TotalFinanceLeaseCost" xlink:label="caba_TotalFinanceLeaseCost"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_OperatingLeasesAbtract" xlink:to="caba_FixedLeaseCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CashPaidInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="caba_OperatingCashFlowsUsedForOperatingLeases" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_FinanceLeasesAbstract" xlink:to="us-gaap_FinanceLeaseInterestExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="caba_FinanceLeasesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_OtherInformationAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_OperatingLeasesAbtract" xlink:to="us-gaap_OperatingLeaseCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CashPaidInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="caba_OperatingCashFlowsUsedForFinanceLeases" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_FinanceLeasesAbstract" xlink:to="caba_AmortizationExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="caba_OperatingLeasesAbtract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_OtherInformationAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_OperatingLeasesAbtract" xlink:to="us-gaap_VariableLeaseCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CashPaidInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="caba_FinancingCashFlowsUsedForFinanceLeases" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_FinanceLeasesAbstract" xlink:to="caba_TotalFixedFinanceLeaseCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="caba_CashPaidInTheMeasurementOfLeaseLiabilitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_OtherInformationAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_OperatingLeasesAbtract" xlink:to="us-gaap_ShortTermLeaseCost" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_FinanceLeasesAbstract" xlink:to="caba_VariableLeaseCosts" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="caba_OtherInformationAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_OtherInformationAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_OperatingLeasesAbtract" xlink:to="us-gaap_LeaseCost" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_FinanceLeasesAbstract" xlink:to="caba_TotalFinanceLeaseCost" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_AtTheMarketOfferingSalesAgreementMember" xlink:label="caba_AtTheMarketOfferingSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_VotingCommonStockMember" xlink:label="caba_VotingCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_TwoThousandEighteenStockOptionAndGrantPlanMember" xlink:label="caba_TwoThousandEighteenStockOptionAndGrantPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonvotingCommonStockMember" xlink:label="us-gaap_NonvotingCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_TwoThousandNineteenStockOptionAndIncentivePlanMember" xlink:label="caba_TwoThousandNineteenStockOptionAndIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_2"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_PreFundedWarrantsMember" xlink:label="caba_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_AdditionalOptionsToBePurchasedByUnderwriters" xlink:label="caba_AdditionalOptionsToBePurchasedByUnderwriters"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:label="caba_TwoThousandNineteenEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockConversionFeatures" xlink:label="us-gaap_CommonStockConversionFeatures"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_MayTwoThousandTwentyThreeFinancingMember" xlink:label="caba_MayTwoThousandTwentyThreeFinancingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_December2022FinancingMember" xlink:label="caba_December2022FinancingMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_PreFundedWarrantsExercised" xlink:label="caba_PreFundedWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForUnderwritingExpense" xlink:label="us-gaap_PaymentsForUnderwritingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockDividendsShares" xlink:label="us-gaap_CommonStockDividendsShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantExercisePriceDecrease" xlink:label="us-gaap_WarrantExercisePriceDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForCommissions" xlink:label="us-gaap_PaymentsForCommissions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_SharesRemainingAvailableForIssuance" xlink:label="caba_SharesRemainingAvailableForIssuance"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_IncreaseInShareReservedPercentage" xlink:label="caba_IncreaseInShareReservedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_PercentageOfPayrollDeductionOnEligibleCompensation" xlink:label="caba_PercentageOfPayrollDeductionOnEligibleCompensation"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock" xlink:label="caba_EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock" xlink:label="caba_PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="caba_AtTheMarketOfferingSalesAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="caba_VotingCommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="caba_TwoThousandEighteenStockOptionAndGrantPlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_NonvotingCommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="caba_TwoThousandNineteenStockOptionAndIncentivePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember_2" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="caba_PreFundedWarrantsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="caba_AdditionalOptionsToBePurchasedByUnderwriters" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="caba_TwoThousandNineteenEmployeeStockPurchasePlanMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockConversionFeatures" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="caba_MayTwoThousandTwentyThreeFinancingMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="caba_December2022FinancingMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="caba_PreFundedWarrantsExercised" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsForUnderwritingExpense" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockDividendsShares" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantExercisePriceDecrease" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsForCommissions" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="caba_SharesRemainingAvailableForIssuance" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="caba_IncreaseInShareReservedPercentage" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="caba_PercentageOfPayrollDeductionOnEligibleCompensation" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="caba_EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="caba_PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_TwoThousandNineteenStockOptionAndIncentivePlanMember" xlink:label="caba_TwoThousandNineteenStockOptionAndIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:label="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:label="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="caba_TwoThousandNineteenStockOptionAndIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockBasedCompensationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_EffectiveIncomeTaxRateReconciliationNondeductibleItemsAndOther" xlink:label="caba_EffectiveIncomeTaxRateReconciliationNondeductibleItemsAndOther"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_ChangeInStateAndLocalTaxRate" xlink:label="caba_ChangeInStateAndLocalTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="caba_EffectiveIncomeTaxRateReconciliationNondeductibleItemsAndOther" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="caba_ChangeInStateAndLocalTaxRate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_OperatingLeaseAssets" xlink:label="caba_OperatingLeaseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_CapitalizedRDCosts" xlink:label="caba_CapitalizedRDCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_DeferredTaxAssetsLicenseFeesDeductions" xlink:label="caba_DeferredTaxAssetsLicenseFeesDeductions"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="caba_DeferredTaxAssetsOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="caba_OperatingLeaseAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="caba_CapitalizedRDCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="caba_DeferredTaxAssetsLicenseFeesDeductions" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="caba_DeferredTaxAssetsOperatingLeaseLiabilities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_IncomeTaxDisclosureTable" xlink:label="caba_IncomeTaxDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_IncomeTaxDisclosureLineItems" xlink:label="caba_IncomeTaxDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_FederalMember" xlink:label="caba_FederalMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_DeferredTaxAssetsOperatingLossCarryforwardsFederal" xlink:label="caba_DeferredTaxAssetsOperatingLossCarryforwardsFederal"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_StateMember" xlink:label="caba_StateMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_DeferredTaxAssetsOperatingLossCarryforwardsState" xlink:label="caba_DeferredTaxAssetsOperatingLossCarryforwardsState"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_DeferredTaxAssetsOperatingLossCarryforwardsLocal" xlink:label="caba_DeferredTaxAssetsOperatingLossCarryforwardsLocal"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_OperatingLossCarryforwardsFederalCommencementOfExpirationDate" xlink:label="caba_OperatingLossCarryforwardsFederalCommencementOfExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_OperatingLossCarryforwardsStateCommencementOfExpirationDate" xlink:label="caba_OperatingLossCarryforwardsStateCommencementOfExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_OperatingLossCarryforwardsLocalCommencementOfExpirationDate" xlink:label="caba_OperatingLossCarryforwardsLocalCommencementOfExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate" xlink:label="caba_DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_PercentageOfEligibleTaxPositionsForRecognition" xlink:label="caba_PercentageOfEligibleTaxPositionsForRecognition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="caba_IncomeTaxDisclosureTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_IncomeTaxDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="caba_FederalMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_IncomeTaxDisclosureTable" xlink:to="caba_IncomeTaxDisclosureLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="caba_DeferredTaxAssetsOperatingLossCarryforwardsFederal" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="caba_StateMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="caba_DeferredTaxAssetsOperatingLossCarryforwardsState" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="caba_DeferredTaxAssetsOperatingLossCarryforwardsLocal" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="caba_OperatingLossCarryforwardsFederalCommencementOfExpirationDate" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="caba_OperatingLossCarryforwardsStateCommencementOfExpirationDate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="caba_OperatingLossCarryforwardsLocalCommencementOfExpirationDate" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="caba_DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="caba_PercentageOfEligibleTaxPositionsForRecognition" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_VotingCommonStockMember" xlink:label="caba_VotingCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_EarningsPerShareBasicAndDilutedTable" xlink:label="caba_EarningsPerShareBasicAndDilutedTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="us-gaap_EarningsPerShareDilutedAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_EarningPerShareBasicAndDilutedLineItems" xlink:label="caba_EarningPerShareBasicAndDilutedLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic" xlink:label="us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonvotingCommonStockMember" xlink:label="us-gaap_NonvotingCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:label="us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="caba_VotingCommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_EarningsPerShareBasicAndDilutedTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="caba_EarningsPerShareBasicAndDilutedTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_EarningPerShareBasicAndDilutedLineItems" xlink:to="us-gaap_EarningsPerShareBasicAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_NonvotingCommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_EarningsPerShareBasicAndDilutedTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_EarningPerShareBasicAndDilutedLineItems" xlink:to="us-gaap_EarningsPerShareDilutedAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_EarningsPerShareBasicAndDilutedTable" xlink:to="caba_EarningPerShareBasicAndDilutedLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_NonVestedCommonStockMember" xlink:label="caba_NonVestedCommonStockMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="caba_NonVestedCommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonvotingCommonStockMember" xlink:label="us-gaap_NonvotingCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_EarningsPerShareBasicAndDilutedTable" xlink:label="caba_EarningsPerShareBasicAndDilutedTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_PreFundedWarrantsMember" xlink:label="caba_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_EarningPerShareBasicAndDilutedLineItems" xlink:label="caba_EarningPerShareBasicAndDilutedLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_NonvotingCommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_EarningsPerShareBasicAndDilutedTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="caba_EarningsPerShareBasicAndDilutedTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="caba_PreFundedWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_EarningPerShareBasicAndDilutedLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_EarningsPerShareBasicAndDilutedTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_EarningPerShareBasicAndDilutedLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_EarningsPerShareBasicAndDilutedTable" xlink:to="caba_EarningPerShareBasicAndDilutedLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_EarningPerShareBasicAndDilutedLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/Role_Disclosure401KSavingsPlanAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSubsequenteventsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_UpfrontPayment" xlink:label="caba_UpfrontPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_MilestonePayments" xlink:label="caba_MilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplyCommitmentAxis" xlink:label="us-gaap_SupplyCommitmentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplyCommitmentArrangementMember" xlink:label="us-gaap_SupplyCommitmentArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_AutolusHoldingsMember" xlink:label="caba_AutolusHoldingsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="caba_UpfrontPayment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseAndServiceMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_UpfrontPayment" xlink:to="caba_MilestonePayments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplyCommitmentAxis" xlink:to="us-gaap_SupplyCommitmentArrangementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_AutolusHoldingsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SupplyCommitmentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_ProductOrServiceAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_VotingCommonStockMember" xlink:label="caba_VotingCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonvotingCommonStockMember" xlink:label="us-gaap_NonvotingCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="caba_VotingCommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_NonvotingCommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_IssuanceOfCommonStockUponExerciseOfPreFundedWarrants" xlink:label="caba_IssuanceOfCommonStockUponExerciseOfPreFundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_StockIssuedDuringPeriodShareStockOptionsExercised" xlink:label="caba_StockIssuedDuringPeriodShareStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_IssuanceOfCommonStockAndPreFundedWarrantsForThePurchaseOfCommonStockNetOfIssuanceCosts" xlink:label="caba_IssuanceOfCommonStockAndPreFundedWarrantsForThePurchaseOfCommonStockNetOfIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="caba_IssuanceOfCommonStockUponExerciseOfPreFundedWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="caba_StockIssuedDuringPeriodShareStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="caba_IssuanceOfCommonStockAndPreFundedWarrantsForThePurchaseOfCommonStockNetOfIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_StevenNichtbergerMember" xlink:label="caba_StevenNichtbergerMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_StevenNichtbergerOneMember" xlink:label="caba_StevenNichtbergerOneMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_AnupMardaMember" xlink:label="caba_AnupMardaMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_AnupMardaOneMember" xlink:label="caba_AnupMardaOneMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_ArunDasMember" xlink:label="caba_ArunDasMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_ArunDasOneMember" xlink:label="caba_ArunDasOneMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_GwendolynBinderMember" xlink:label="caba_GwendolynBinderMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_GwendolynBinderOneMember" xlink:label="caba_GwendolynBinderOneMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="caba_StevenNichtbergerMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="caba_StevenNichtbergerOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="caba_AnupMardaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="caba_AnupMardaOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="caba_ArunDasMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="caba_ArunDasOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="caba_GwendolynBinderMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="caba_GwendolynBinderOneMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_LaboratoryEquipmentMember" xlink:label="caba_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_PropertyPlantAndEquipmentEstimatedUsefulLives1" xlink:label="caba_PropertyPlantAndEquipmentEstimatedUsefulLives1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="caba_LaboratoryEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="caba_PropertyPlantAndEquipmentEstimatedUsefulLives1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:label="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestmentsAbstract" xlink:label="us-gaap_ShortTermInvestmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermInvestmentsAbstract" xlink:to="us-gaap_ShortTermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="us-gaap_ShortTermInvestmentsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateNoteSecuritiesMember" xlink:label="us-gaap_CorporateNoteSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CashMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateNoteSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_RegentsOfUniversityOfCaliforniaMember" xlink:label="caba_RegentsOfUniversityOfCaliforniaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplyCommitmentAxis" xlink:label="us-gaap_SupplyCommitmentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplyCommitmentArrangementMember" xlink:label="us-gaap_SupplyCommitmentArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplyCommitmentArrangementMember" xlink:label="us-gaap_SupplyCommitmentArrangementMember_default"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_LicenseAgreementMember" xlink:label="caba_LicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_AccruedAndOtherCurrentLiabilitiesMember" xlink:label="caba_AccruedAndOtherCurrentLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_SponsoredResearchAgreementsMember" xlink:label="caba_SponsoredResearchAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_PaymentOfObligationTerm" xlink:label="caba_PaymentOfObligationTerm"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_MasterTranslationalResearchServicesAgreementMember" xlink:label="caba_MasterTranslationalResearchServicesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_ObligationToBePaidCommencementDate" xlink:label="caba_ObligationToBePaidCommencementDate"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_SubscriptionAndTechnologyTransferAgreementMember" xlink:label="caba_SubscriptionAndTechnologyTransferAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_LicenseMaintenanceFee" xlink:label="caba_LicenseMaintenanceFee"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_OxfordBiomedicaMember" xlink:label="caba_OxfordBiomedicaMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_MilestonePayments" xlink:label="caba_MilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_NanjingIasoBiotherapeuticsCoLtdMember" xlink:label="caba_NanjingIasoBiotherapeuticsCoLtdMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_CollaborativeAgreementPaymentsDue" xlink:label="caba_CollaborativeAgreementPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_AutolusHoldingsMember" xlink:label="caba_AutolusHoldingsMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_NumberOfFaculty" xlink:label="caba_NumberOfFaculty"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_FundingTermEndingDate" xlink:label="caba_FundingTermEndingDate"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_ContractualCostIncurred" xlink:label="caba_ContractualCostIncurred"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_AdvancePayments" xlink:label="caba_AdvancePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenses" xlink:label="us-gaap_OtherExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentDueInNextTwelveMonths" xlink:label="us-gaap_OtherCommitmentDueInNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_RemainingResearchAndDevelopmentExpenseToBeIncurred" xlink:label="caba_RemainingResearchAndDevelopmentExpenseToBeIncurred"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_UpfrontPayment" xlink:label="caba_UpfrontPayment"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_MilestonePayment" xlink:label="caba_MilestonePayment"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseAndServiceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="caba_RegentsOfUniversityOfCaliforniaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SupplyCommitmentAxis" xlink:to="us-gaap_SupplyCommitmentArrangementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SupplyCommitmentAxis" xlink:to="us-gaap_SupplyCommitmentArrangementMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_LicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="us-gaap_ContractualObligation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="caba_AccruedAndOtherCurrentLiabilitiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_SponsoredResearchAgreementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable" xlink:to="us-gaap_SupplyCommitmentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_PaymentOfObligationTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_MasterTranslationalResearchServicesAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_ObligationToBePaidCommencementDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_SubscriptionAndTechnologyTransferAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_LicenseMaintenanceFee" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_OxfordBiomedicaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_MilestonePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_NanjingIasoBiotherapeuticsCoLtdMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_CollaborativeAgreementPaymentsDue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_AutolusHoldingsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_NumberOfFaculty" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_FundingTermEndingDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_ContractualCostIncurred" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_AdvancePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="us-gaap_OtherExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="us-gaap_OtherCommitmentDueInNextTwelveMonths" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_RemainingResearchAndDevelopmentExpenseToBeIncurred" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_UpfrontPayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_MilestonePayment" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="caba_CommitmentsAndContingenciesDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_CommitmentsAndContingenciesDisclosureTable" xlink:label="caba_CommitmentsAndContingenciesDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_AccruedAndOtherCurrentLiabilitiesMember" xlink:label="caba_AccruedAndOtherCurrentLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_WuXiAdvancedTherapiesMember" xlink:label="caba_WuXiAdvancedTherapiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplyCommitmentAxis" xlink:label="us-gaap_SupplyCommitmentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplyCommitmentArrangementMember" xlink:label="us-gaap_SupplyCommitmentArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_OperatingLeaseAgreementMember" xlink:label="caba_OperatingLeaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_Caba201AndMuskCaartMember" xlink:label="caba_Caba201AndMuskCaartMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_DevelopmentAndManufacturingServicesAgreementMember" xlink:label="caba_DevelopmentAndManufacturingServicesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_LeaseCommencementMonthAndYear" xlink:label="caba_LeaseCommencementMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_Rese-CelAndMuSK-CAARTMember" xlink:label="caba_Rese-CelAndMuSK-CAARTMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_LonzaAgreementMember" xlink:label="caba_LonzaAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_LeaseExpirationMonthAndYear" xlink:label="caba_LeaseExpirationMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_ChildrenSHospitalOfPhiladelphiaMember" xlink:label="caba_ChildrenSHospitalOfPhiladelphiaMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_ResearchServiceAgreementMember" xlink:label="caba_ResearchServiceAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_LeaseExpirationMonth" xlink:label="caba_LeaseExpirationMonth"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_AgreementWithContractManufacturingOrganizationMember" xlink:label="caba_AgreementWithContractManufacturingOrganizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:label="us-gaap_OperatingLeasesRentExpenseMinimumRentals"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_AnnualIncreasePercentageOfBaseRent" xlink:label="caba_AnnualIncreasePercentageOfBaseRent"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_RentExpense" xlink:label="caba_RentExpense"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_LeaseAmendmentPeriod" xlink:label="caba_LeaseAmendmentPeriod"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_InitialTermsOfAgreementDescription" xlink:label="caba_InitialTermsOfAgreementDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees" xlink:label="us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_PaymentOfObligationTerm" xlink:label="caba_PaymentOfObligationTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_ExpectedCostIncurredForPurchaseOfPlasmids" xlink:label="caba_ExpectedCostIncurredForPurchaseOfPlasmids"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_ContractualExpenses" xlink:label="caba_ContractualExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossRelatedToLitigationSettlement" xlink:label="us-gaap_GainLossRelatedToLitigationSettlement"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="caba_CommitmentsAndContingenciesDisclosureTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="caba_AccruedAndOtherCurrentLiabilitiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="caba_WuXiAdvancedTherapiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SupplyCommitmentAxis" xlink:to="us-gaap_SupplyCommitmentArrangementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_OperatingLeaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="caba_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_SupplyCommitmentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="caba_Caba201AndMuskCaartMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_DevelopmentAndManufacturingServicesAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="caba_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="caba_LeaseCommencementMonthAndYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="caba_Rese-CelAndMuSK-CAARTMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_LonzaAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="caba_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="caba_LeaseExpirationMonthAndYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="caba_ChildrenSHospitalOfPhiladelphiaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_ResearchServiceAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="caba_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="caba_LeaseExpirationMonth" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_AgreementWithContractManufacturingOrganizationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseMinimumRentals" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="caba_AnnualIncreasePercentageOfBaseRent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="caba_RentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="caba_LeaseAmendmentPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="caba_InitialTermsOfAgreementDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_OperatingLeaseExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="caba_PaymentOfObligationTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_ContractualObligation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="caba_ExpectedCostIncurredForPurchaseOfPlasmids" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="caba_ContractualExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_GainLossRelatedToLitigationSettlement" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_WuxiAgreementMember" xlink:label="caba_WuxiAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_LonzaAgreementMember" xlink:label="caba_LonzaAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_TerminationFees" xlink:label="caba_TerminationFees"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_WorkOrdersTerm" xlink:label="caba_WorkOrdersTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_IncreaseInTheRouAsset" xlink:label="caba_IncreaseInTheRouAsset"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_IncreaseInTheLeaseLiability" xlink:label="caba_IncreaseInTheLeaseLiability"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="caba_WuxiAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="caba_LonzaAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="caba_TerminationFees" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="caba_WorkOrdersTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_VariableLeaseCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ShortTermLeaseCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="caba_IncreaseInTheRouAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="caba_IncreaseInTheLeaseLiability" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_AtTheMarketOfferingSalesAgreementMember" xlink:label="caba_AtTheMarketOfferingSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_VotingCommonStockMember" xlink:label="caba_VotingCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_TwoThousandEighteenStockOptionAndGrantPlanMember" xlink:label="caba_TwoThousandEighteenStockOptionAndGrantPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonvotingCommonStockMember" xlink:label="us-gaap_NonvotingCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_TwoThousandNineteenStockOptionAndIncentivePlanMember" xlink:label="caba_TwoThousandNineteenStockOptionAndIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_PreFundedWarrantsMember" xlink:label="caba_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_AdditionalOptionsToBePurchasedByUnderwriters" xlink:label="caba_AdditionalOptionsToBePurchasedByUnderwriters"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:label="caba_TwoThousandNineteenEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockConversionFeatures" xlink:label="us-gaap_CommonStockConversionFeatures"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_MayTwoThousandTwentyThreeFinancingMember" xlink:label="caba_MayTwoThousandTwentyThreeFinancingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_December2022FinancingMember" xlink:label="caba_December2022FinancingMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_PreFundedWarrantsExercised" xlink:label="caba_PreFundedWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForUnderwritingExpense" xlink:label="us-gaap_PaymentsForUnderwritingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockDividendsShares" xlink:label="us-gaap_CommonStockDividendsShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantExercisePriceDecrease" xlink:label="us-gaap_WarrantExercisePriceDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForCommissions" xlink:label="us-gaap_PaymentsForCommissions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_SharesRemainingAvailableForIssuance" xlink:label="caba_SharesRemainingAvailableForIssuance"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_IncreaseInShareReservedPercentage" xlink:label="caba_IncreaseInShareReservedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_PercentageOfPayrollDeductionOnEligibleCompensation" xlink:label="caba_PercentageOfPayrollDeductionOnEligibleCompensation"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock" xlink:label="caba_EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock" xlink:label="caba_PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="caba_AtTheMarketOfferingSalesAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="caba_VotingCommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="caba_TwoThousandEighteenStockOptionAndGrantPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_NonvotingCommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="caba_TwoThousandNineteenStockOptionAndIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="caba_PreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="caba_AdditionalOptionsToBePurchasedByUnderwriters" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="caba_TwoThousandNineteenEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockConversionFeatures" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="caba_MayTwoThousandTwentyThreeFinancingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="caba_December2022FinancingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="caba_PreFundedWarrantsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsForUnderwritingExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockDividendsShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantExercisePriceDecrease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsForCommissions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="caba_SharesRemainingAvailableForIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="caba_IncreaseInShareReservedPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="caba_PercentageOfPayrollDeductionOnEligibleCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="caba_EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="caba_PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_TwoThousandNineteenStockOptionAndIncentivePlanMember" xlink:label="caba_TwoThousandNineteenStockOptionAndIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:label="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:label="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="caba_TwoThousandNineteenStockOptionAndIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockBasedCompensationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_IncomeTaxDisclosureLineItems" xlink:label="caba_IncomeTaxDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_IncomeTaxDisclosureTable" xlink:label="caba_IncomeTaxDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_FederalMember" xlink:label="caba_FederalMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_DeferredTaxAssetsOperatingLossCarryforwardsFederal" xlink:label="caba_DeferredTaxAssetsOperatingLossCarryforwardsFederal"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_StateMember" xlink:label="caba_StateMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_DeferredTaxAssetsOperatingLossCarryforwardsState" xlink:label="caba_DeferredTaxAssetsOperatingLossCarryforwardsState"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_DeferredTaxAssetsOperatingLossCarryforwardsLocal" xlink:label="caba_DeferredTaxAssetsOperatingLossCarryforwardsLocal"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_OperatingLossCarryforwardsFederalCommencementOfExpirationDate" xlink:label="caba_OperatingLossCarryforwardsFederalCommencementOfExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_OperatingLossCarryforwardsStateCommencementOfExpirationDate" xlink:label="caba_OperatingLossCarryforwardsStateCommencementOfExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_OperatingLossCarryforwardsLocalCommencementOfExpirationDate" xlink:label="caba_OperatingLossCarryforwardsLocalCommencementOfExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate" xlink:label="caba_DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_PercentageOfEligibleTaxPositionsForRecognition" xlink:label="caba_PercentageOfEligibleTaxPositionsForRecognition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="caba_IncomeTaxDisclosureTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="caba_IncomeTaxDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="caba_FederalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="caba_DeferredTaxAssetsOperatingLossCarryforwardsFederal" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="caba_StateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="caba_DeferredTaxAssetsOperatingLossCarryforwardsState" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="caba_DeferredTaxAssetsOperatingLossCarryforwardsLocal" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="caba_OperatingLossCarryforwardsFederalCommencementOfExpirationDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="caba_OperatingLossCarryforwardsStateCommencementOfExpirationDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="caba_OperatingLossCarryforwardsLocalCommencementOfExpirationDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="caba_DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="caba_PercentageOfEligibleTaxPositionsForRecognition" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails">
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_EarningPerShareBasicAndDilutedLineItems" xlink:label="caba_EarningPerShareBasicAndDilutedLineItems"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_EarningsPerShareBasicAndDilutedTable" xlink:label="caba_EarningsPerShareBasicAndDilutedTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_VotingCommonStockMember" xlink:label="caba_VotingCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="us-gaap_EarningsPerShareDilutedAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic" xlink:label="us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonvotingCommonStockMember" xlink:label="us-gaap_NonvotingCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:label="us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="caba_EarningPerShareBasicAndDilutedLineItems" xlink:to="caba_EarningsPerShareBasicAndDilutedTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="caba_VotingCommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="caba_EarningsPerShareBasicAndDilutedTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_EarningPerShareBasicAndDilutedLineItems" xlink:to="us-gaap_EarningsPerShareBasicAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_NonvotingCommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="caba_EarningsPerShareBasicAndDilutedTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_EarningPerShareBasicAndDilutedLineItems" xlink:to="us-gaap_EarningsPerShareDilutedAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_NonVestedCommonStockMember" xlink:label="caba_NonVestedCommonStockMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="caba_NonVestedCommonStockMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_EarningPerShareBasicAndDilutedLineItems" xlink:label="caba_EarningPerShareBasicAndDilutedLineItems"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_EarningsPerShareBasicAndDilutedTable" xlink:label="caba_EarningsPerShareBasicAndDilutedTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonvotingCommonStockMember" xlink:label="us-gaap_NonvotingCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_PreFundedWarrantsMember" xlink:label="caba_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="caba_EarningPerShareBasicAndDilutedLineItems" xlink:to="caba_EarningsPerShareBasicAndDilutedTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_NonvotingCommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="caba_EarningsPerShareBasicAndDilutedTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="caba_PreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_EarningPerShareBasicAndDilutedLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="caba_EarningsPerShareBasicAndDilutedTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_EarningPerShareBasicAndDilutedLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_EarningPerShareBasicAndDilutedLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSubsequenteventsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_UpfrontPayment" xlink:label="caba_UpfrontPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_MilestonePayments" xlink:label="caba_MilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplyCommitmentAxis" xlink:label="us-gaap_SupplyCommitmentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplyCommitmentArrangementMember" xlink:label="us-gaap_SupplyCommitmentArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_AutolusHoldingsMember" xlink:label="caba_AutolusHoldingsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="caba_UpfrontPayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseAndServiceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_UpfrontPayment" xlink:to="caba_MilestonePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SupplyCommitmentAxis" xlink:to="us-gaap_SupplyCommitmentArrangementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_AutolusHoldingsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SupplyCommitmentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UsefulLifeDescriptionOfTermDomain" xlink:label="us-gaap_UsefulLifeDescriptionOfTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_PropertyPlantAndEquipmentEstimatedUsefulLives1" xlink:label="caba_PropertyPlantAndEquipmentEstimatedUsefulLives1"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UsefulLifeDescriptionOfTermDomain" xlink:to="caba_PropertyPlantAndEquipmentEstimatedUsefulLives1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ShortTermInvestments" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:label="caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="caba_FixedLeaseCost" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_ShortTermLeaseCost" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_FixedLeaseCost" xlink:label="caba_FixedLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="caba_FinanceLesseeUndiscountedLeasePayments" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="caba_FinanceLesseeUndiscountedLeasePayments" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_FinanceLesseeUndiscountedLeasePayments" xlink:label="caba_FinanceLesseeUndiscountedLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails3">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="caba_LesseeUndiscountedLeasePayments" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="caba_LesseeUndiscountedLeasePayments" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_LesseeUndiscountedLeasePayments" xlink:label="caba_LesseeUndiscountedLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InvestmentIncomeInterest" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestExpense" order="2" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails4">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="caba_LesseeUndiscountedLeasePayments" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="caba_LesseeUndiscountedLeasePayments" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_LesseeUndiscountedLeasePayments" xlink:label="caba_LesseeUndiscountedLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="caba_NonCashLeaseExpense" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionExpense" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="6" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ForeignCurrencyTransactionLossBeforeTax" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="8" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="9" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="11" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="12" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_NonCashLeaseExpense" xlink:label="caba_NonCashLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionExpense" xlink:label="us-gaap_AccretionExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="0" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="2" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="caba_AccruedResearchAndDevelopmentServicesCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="caba_AccruedGeneralAndAdministrativeServicesCurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="3" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:label="caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_AccruedResearchAndDevelopmentServicesCurrent" xlink:label="caba_AccruedResearchAndDevelopmentServicesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_AccruedGeneralAndAdministrativeServicesCurrent" xlink:label="caba_AccruedGeneralAndAdministrativeServicesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfProfitAndLossFromSegmentsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestExpense" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InvestmentIncomeInterest" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="caba_LicenseOfIntellectualProperty" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="5" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="caba_ManufacturingOfPreclinicalAndClinicalSupplies" order="6" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="caba_DevelopmentServices" order="7" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="caba_ClinicalTrials" order="8" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="caba_PersonnelExpenses" order="9" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_LicenseOfIntellectualProperty" xlink:label="caba_LicenseOfIntellectualProperty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_ManufacturingOfPreclinicalAndClinicalSupplies" xlink:label="caba_ManufacturingOfPreclinicalAndClinicalSupplies"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_DevelopmentServices" xlink:label="caba_DevelopmentServices"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_ClinicalTrials" xlink:label="caba_ClinicalTrials"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_PersonnelExpenses" xlink:label="caba_PersonnelExpenses"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="caba_FinanceLesseeUndiscountedLeasePayments" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="caba_FinanceLesseeUndiscountedLeasePayments" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_FinanceLesseeUndiscountedLeasePayments" xlink:label="caba_FinanceLesseeUndiscountedLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="caba_TotalFixedFinanceLeaseCost" xlink:to="us-gaap_FinanceLeaseInterestExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="caba_TotalFinanceLeaseCost" xlink:to="caba_TotalFixedFinanceLeaseCost" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="caba_TotalFixedFinanceLeaseCost" xlink:to="caba_AmortizationExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="caba_TotalFinanceLeaseCost" xlink:to="caba_VariableLeaseCosts" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_TotalFixedFinanceLeaseCost" xlink:label="caba_TotalFixedFinanceLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_TotalFinanceLeaseCost" xlink:label="caba_TotalFinanceLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_AmortizationExpense" xlink:label="caba_AmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_VariableLeaseCosts" xlink:label="caba_VariableLeaseCosts"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="caba_ChangeInStateAndLocalTaxRate" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="caba_EffectiveIncomeTaxRateReconciliationNondeductibleItemsAndOther" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_ChangeInStateAndLocalTaxRate" xlink:label="caba_ChangeInStateAndLocalTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_EffectiveIncomeTaxRateReconciliationNondeductibleItemsAndOther" xlink:label="caba_EffectiveIncomeTaxRateReconciliationNondeductibleItemsAndOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="caba_DeferredTaxAssetsOperatingLeaseLiabilities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="caba_DeferredTaxAssetsLicenseFeesDeductions" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="caba_CapitalizedRDCosts" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="7" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="caba_DeferredTaxAssetsOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_DeferredTaxAssetsLicenseFeesDeductions" xlink:label="caba_DeferredTaxAssetsLicenseFeesDeductions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="caba-20241231.xsd#caba_CapitalizedRDCosts" xlink:label="caba_CapitalizedRDCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" order="1" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="caba_December2022FinancingMember" name="December2022FinancingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_PropertyPlantAndEquipmentEstimatedUsefulLives1" name="PropertyPlantAndEquipmentEstimatedUsefulLives1" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_LicenseAgreementMember" name="LicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_VotingCommonStockMember" name="VotingCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_EmergingGrowthCompanyStatusPolicyTextBlock" name="EmergingGrowthCompanyStatusPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_WuXiAdvancedTherapiesMember" name="WuXiAdvancedTherapiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_LeaseExpirationMonth" name="LeaseExpirationMonth" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_LicenseMaintenanceFee" name="LicenseMaintenanceFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="caba_Rese-CelAndMuSK-CAARTMember" name="Rese-CelAndMuSK-CAARTMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_MayTwoThousandTwentyThreeFinancingMember" name="MayTwoThousandTwentyThreeFinancingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_ChangeInStateAndLocalTaxRate" name="ChangeInStateAndLocalTaxRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_DeferredTaxAssetsOperatingLossCarryforwardsFederal" name="DeferredTaxAssetsOperatingLossCarryforwardsFederal" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_OperatingLossCarryforwardsStateCommencementOfExpirationDate" name="OperatingLossCarryforwardsStateCommencementOfExpirationDate" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_OperatingCashFlowsUsedForFinanceLeases" name="OperatingCashFlowsUsedForFinanceLeases" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_DeferredTaxAssetsOperatingLossCarryforwardsLocal" name="DeferredTaxAssetsOperatingLossCarryforwardsLocal" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_RemainingResearchAndDevelopmentExpenseToBeIncurred" name="RemainingResearchAndDevelopmentExpenseToBeIncurred" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_FixedLeaseCost" name="FixedLeaseCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_ExpectedCostIncurredForPurchaseOfPlasmids" name="ExpectedCostIncurredForPurchaseOfPlasmids" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_LeaseAmendmentPeriod" name="LeaseAmendmentPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_OperatingLeaseAssets" name="OperatingLeaseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_IssuanceOfCommonStockUponExerciseOfPreFundedWarrants" name="IssuanceOfCommonStockUponExerciseOfPreFundedWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_IncomeTaxDisclosureLineItems" name="IncomeTaxDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_InitialTermsOfAgreementDescription" name="InitialTermsOfAgreementDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_NonVestedCommonStockMember" name="NonVestedCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_AccruedResearchAndDevelopmentServicesCurrent" name="AccruedResearchAndDevelopmentServicesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="caba_DeferredTaxAssetsLicenseFeesDeductions" name="DeferredTaxAssetsLicenseFeesDeductions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_OperatingLossCarryforwardsLocalCommencementOfExpirationDate" name="OperatingLossCarryforwardsLocalCommencementOfExpirationDate" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_SharesRemainingAvailableForIssuance" name="SharesRemainingAvailableForIssuance" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="caba_CollaborativeAgreementPaymentsDue" name="CollaborativeAgreementPaymentsDue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="caba_PreFundedWarrantsExercised" name="PreFundedWarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_AutolusHoldingsMember" name="AutolusHoldingsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_ArunDasOneMember" name="ArunDasOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_AnupMardaOneMember" name="AnupMardaOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_NonCashLeaseExpense" name="NonCashLeaseExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_LonzaAgreementMember" name="LonzaAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_Rule10B51ArrModifiedFlag" name="Rule10B51ArrModifiedFlag" type="xbrli:booleanItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_TerminationFees" name="TerminationFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock" name="PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_GwendolynBinderOneMember" name="GwendolynBinderOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_PreFundedWarrantsMember" name="PreFundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_WuxiAgreementMember" name="WuxiAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_StateMember" name="StateMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_LicenseOfIntellectualProperty" name="LicenseOfIntellectualProperty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_AccruedAndOtherCurrentLiabilitiesMember" name="AccruedAndOtherCurrentLiabilitiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_TotalFixedFinanceLeaseCost" name="TotalFixedFinanceLeaseCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_EffectiveIncomeTaxRateReconciliationNondeductibleItemsAndOther" name="EffectiveIncomeTaxRateReconciliationNondeductibleItemsAndOther" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_MasterTranslationalResearchServicesAgreementMember" name="MasterTranslationalResearchServicesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock" name="CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_PercentageOfPayrollDeductionOnEligibleCompensation" name="PercentageOfPayrollDeductionOnEligibleCompensation" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_AmortizationExpense" name="AmortizationExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_TotalFinanceLeaseCost" name="TotalFinanceLeaseCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_ContractualExpenses" name="ContractualExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_IssuanceOfCommonStockAndPreFundedWarrantsForThePurchaseOfCommonStockNetOfIssuanceCosts" name="IssuanceOfCommonStockAndPreFundedWarrantsForThePurchaseOfCommonStockNetOfIssuanceCosts" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_EarningsPerShareBasicAndDilutedTable" name="EarningsPerShareBasicAndDilutedTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_NonRule10B51ArrModifiedFlag" name="NonRule10B51ArrModifiedFlag" type="xbrli:booleanItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_FinancingCashFlowsUsedForFinanceLeases" name="FinancingCashFlowsUsedForFinanceLeases" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_IncreaseInTheRouAsset" name="IncreaseInTheRouAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_IncomeTaxDisclosureTable" name="IncomeTaxDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_FundingTermEndingDate" name="FundingTermEndingDate" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_ObligationToBePaidCommencementDate" name="ObligationToBePaidCommencementDate" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_OperatingCashFlowsUsedForOperatingLeases" name="OperatingCashFlowsUsedForOperatingLeases" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate" name="DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_StockIssuedDuringPeriodShareStockOptionsExercised" name="StockIssuedDuringPeriodShareStockOptionsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_EarningPerShareBasicAndDilutedLineItems" name="EarningPerShareBasicAndDilutedLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_StevenNichtbergerOneMember" name="StevenNichtbergerOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock" name="EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_TwoThousandEighteenStockOptionAndGrantPlanMember" name="TwoThousandEighteenStockOptionAndGrantPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_ContractualCostIncurred" name="ContractualCostIncurred" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_FinanceLesseeUndiscountedLeasePayments" name="FinanceLesseeUndiscountedLeasePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="caba_ClinicalTrials" name="ClinicalTrials" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_NanjingIasoBiotherapeuticsCoLtdMember" name="NanjingIasoBiotherapeuticsCoLtdMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" name="ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_AnnualIncreasePercentageOfBaseRent" name="AnnualIncreasePercentageOfBaseRent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_TwoThousandNineteenEmployeeStockPurchasePlanMember" name="TwoThousandNineteenEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_OtherInformationAbstract" name="OtherInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_IncreaseInTheLeaseLiability" name="IncreaseInTheLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_AnupMardaMember" name="AnupMardaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_LeaseCommencementMonthAndYear" name="LeaseCommencementMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_OperatingLeaseAgreementMember" name="OperatingLeaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" name="CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_RentExpense" name="RentExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_SponsoredResearchAgreementsMember" name="SponsoredResearchAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_UpfrontPayment" name="UpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="caba_AtTheMarketOfferingSalesAgreementMember" name="AtTheMarketOfferingSalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_CashPaidInTheMeasurementOfLeaseLiabilitiesAbstract" name="CashPaidInTheMeasurementOfLeaseLiabilitiesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent" name="AccruedLiabilitiesAndOtherLiabilitiesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="caba_DeferredTaxAssetsOperatingLeaseLiabilities" name="DeferredTaxAssetsOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_DeferredTaxAssetsOperatingLossCarryforwardsState" name="DeferredTaxAssetsOperatingLossCarryforwardsState" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_DevelopmentServices" name="DevelopmentServices" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_RegentsOfUniversityOfCaliforniaMember" name="RegentsOfUniversityOfCaliforniaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_IncreaseInShareReservedPercentage" name="IncreaseInShareReservedPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_FederalMember" name="FederalMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_WorkOrdersTerm" name="WorkOrdersTerm" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_DevelopmentAndManufacturingServicesAgreementMember" name="DevelopmentAndManufacturingServicesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_CommitmentsAndContingenciesDisclosureTable" name="CommitmentsAndContingenciesDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_ChildrenSHospitalOfPhiladelphiaMember" name="ChildrenSHospitalOfPhiladelphiaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_AccruedGeneralAndAdministrativeServicesCurrent" name="AccruedGeneralAndAdministrativeServicesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="caba_AdditionalOptionsToBePurchasedByUnderwriters" name="AdditionalOptionsToBePurchasedByUnderwriters" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_PersonnelExpenses" name="PersonnelExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_ManufacturingOfPreclinicalAndClinicalSupplies" name="ManufacturingOfPreclinicalAndClinicalSupplies" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_ArunDasMember" name="ArunDasMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_SubscriptionAndTechnologyTransferAgreementMember" name="SubscriptionAndTechnologyTransferAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable" name="CollaborationsLicensingAgreementsAndOtherAgreementsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearThree" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearThree" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="caba_LeaseExpirationMonthAndYear" name="LeaseExpirationMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_FinanceLeasesAbstract" name="FinanceLeasesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_StevenNichtbergerMember" name="StevenNichtbergerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_AdvancePayments" name="AdvancePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_CapitalizedRDCosts" name="CapitalizedRDCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_PercentageOfEligibleTaxPositionsForRecognition" name="PercentageOfEligibleTaxPositionsForRecognition" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_MilestonePayments" name="MilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="caba_PaymentOfObligationTerm" name="PaymentOfObligationTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" name="AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_CommitmentsAndContingenciesDisclosureLineItems" name="CommitmentsAndContingenciesDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_NumberOfFaculty" name="NumberOfFaculty" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="caba_OperatingLossCarryforwardsFederalCommencementOfExpirationDate" name="OperatingLossCarryforwardsFederalCommencementOfExpirationDate" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_LesseeUndiscountedLeasePayments" name="LesseeUndiscountedLeasePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="caba_OperatingLeasesAbtract" name="OperatingLeasesAbtract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_VariableLeaseCosts" name="VariableLeaseCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_CollaborationsLicensingAgreementsAndOtherAgreementsAbstract" name="CollaborationsLicensingAgreementsAndOtherAgreementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_OxfordBiomedicaMember" name="OxfordBiomedicaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_Caba201AndMuskCaartMember" name="Caba201AndMuskCaartMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_TwoThousandNineteenStockOptionAndIncentivePlanMember" name="TwoThousandNineteenStockOptionAndIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_AgreementWithContractManufacturingOrganizationMember" name="AgreementWithContractManufacturingOrganizationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_MilestonePayment" name="MilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_ResearchServiceAgreementMember" name="ResearchServiceAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_GwendolynBinderMember" name="GwendolynBinderMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 27, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CABA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CABALETTA BIO, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001759138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,743,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-1685768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2929 Arch Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Philadelphia<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">759-3100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.00001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Philadelphia, Pennsylvania<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorOpinionTextBlock', window );">Auditor Opinion</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Opinion on the Financial Statements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Cabaletta Bio, Inc. (the Company) as of December 31, 2024 and 2023, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity and cash flows for each of the two years in the period ended December 31, 2024, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorOpinionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X<br> -Number 210<br> -Section 2<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorOpinionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 163,962<span></span>
</td>
<td class="nump">$ 193,238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">48,011<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,713<span></span>
</td>
<td class="nump">3,241<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">166,675<span></span>
</td>
<td class="nump">244,490<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,743<span></span>
</td>
<td class="nump">2,541<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right-of-use assets</a></td>
<td class="nump">7,020<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">6,315<span></span>
</td>
<td class="nump">4,910<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">2,293<span></span>
</td>
<td class="nump">1,709<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">185,046<span></span>
</td>
<td class="nump">253,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">4,923<span></span>
</td>
<td class="nump">4,547<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">12,188<span></span>
</td>
<td class="nump">7,887<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities, current portion</a></td>
<td class="nump">5,989<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current portion</a></td>
<td class="nump">3,986<span></span>
</td>
<td class="nump">3,560<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">27,086<span></span>
</td>
<td class="nump">15,994<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities, net of current portion</a></td>
<td class="nump">3,241<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">2,384<span></span>
</td>
<td class="nump">1,458<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">32,711<span></span>
</td>
<td class="nump">17,452<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (see Notes 6 and 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.00001 par value: 10,000,000 shares authorized as of December 31, 2024 and December 31, 2023; no shares issued or outstanding at December 31, 2024 and December 31, 2023</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Voting and non-voting common stock, $0.00001 par value: 150,000,000 (143,590,481 voting and 6,409,519 non-voting) shares authorized as of December 31, 2024 and December 31, 2023; 50,743,101 voting shares issued and outstanding as of December 31, 2024 and 47,823,232 (46,378,937 voting and 1,444,295 non-voting) shares issued and outstanding as of December 31, 2023</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">501,435<span></span>
</td>
<td class="nump">469,396<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(349,101)<span></span>
</td>
<td class="num">(233,237)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">152,335<span></span>
</td>
<td class="nump">236,198<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 185,046<span></span>
</td>
<td class="nump">$ 253,650<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued liabilities and other liabilities current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized shares</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized shares</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,823,232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,823,232<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=caba_VotingCommonStockMember', window );">Voting Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized shares</a></td>
<td class="nump">143,590,481<span></span>
</td>
<td class="nump">143,590,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued shares</a></td>
<td class="nump">50,743,101<span></span>
</td>
<td class="nump">46,378,937<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding shares</a></td>
<td class="nump">50,743,101<span></span>
</td>
<td class="nump">46,378,937<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember', window );">Non-voting Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized shares</a></td>
<td class="nump">6,409,519<span></span>
</td>
<td class="nump">6,409,519<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,444,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,444,295<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=caba_VotingCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=caba_VotingCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 97,203<span></span>
</td>
<td class="nump">$ 55,424<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">27,938<span></span>
</td>
<td class="nump">19,236<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">125,141<span></span>
</td>
<td class="nump">74,660<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(125,141)<span></span>
</td>
<td class="num">(74,660)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">10,025<span></span>
</td>
<td class="nump">6,985<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(748)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(115,864)<span></span>
</td>
<td class="num">(67,675)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net unrealized (loss) gain on available-for-sale investments, net of tax</a></td>
<td class="num">(39)<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net comprehensive loss</a></td>
<td class="num">$ (115,903)<span></span>
</td>
<td class="num">$ (67,589)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share of voting and non-voting common stock, basic</a></td>
<td class="num">$ (2.34)<span></span>
</td>
<td class="num">$ (1.65)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share of voting and non-voting common stock, diluted</a></td>
<td class="num">$ (2.34)<span></span>
</td>
<td class="num">$ (1.65)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 104,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 270,129<span></span>
</td>
<td class="num">$ (47)<span></span>
</td>
<td class="num">$ (165,562)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, Shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,445,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="nump">185,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,098,399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock in connection with exercise of stock options</a></td>
<td class="nump">2,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_StockIssuedDuringPeriodShareStockOptionsExercised', window );">Issuance of common stock in connection with exercise of stock options, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">489,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_IssuanceOfCommonStockAndPreFundedWarrantsForThePurchaseOfCommonStockNetOfIssuanceCosts', window );">Issuance of common stock upon exercise of pre-funded warrants, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,773,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss', window );">Net unrealized gains (losses) on available-for-sale securities</a></td>
<td class="nump">86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">11,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(67,675)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(67,675)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="nump">$ 236,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">469,396<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="num">(233,237)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, Shares at Dec. 31, 2023</a></td>
<td class="nump">47,823,232<span></span>
</td>
<td class="nump">47,823,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="nump">$ 10,876<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">10,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,483,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock in connection with exercise of stock options</a></td>
<td class="nump">1,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_StockIssuedDuringPeriodShareStockOptionsExercised', window );">Issuance of common stock in connection with exercise of stock options, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_IssuanceOfCommonStockAndPreFundedWarrantsForThePurchaseOfCommonStockNetOfIssuanceCosts', window );">Issuance of common stock upon exercise of pre-funded warrants, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,168,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss', window );">Net unrealized gains (losses) on available-for-sale securities</a></td>
<td class="num">(39)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (39)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">19,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(115,864)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(115,864)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2024</a></td>
<td class="nump">$ 152,335<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 501,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (349,101)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, Shares at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,743,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_IssuanceOfCommonStockAndPreFundedWarrantsForThePurchaseOfCommonStockNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock and pre-funded warrants for the purchase of common stock, net of issuance costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_IssuanceOfCommonStockAndPreFundedWarrantsForThePurchaseOfCommonStockNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_StockIssuedDuringPeriodShareStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period share stock options exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_StockIssuedDuringPeriodShareStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of Stock Issuance Costs</a></td>
<td class="nump">$ 252<span></span>
</td>
<td class="nump">$ 8,647<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (115,864)<span></span>
</td>
<td class="num">$ (67,675)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">19,465<span></span>
</td>
<td class="nump">11,343<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">1,711<span></span>
</td>
<td class="nump">1,426<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of finance lease</a></td>
<td class="nump">3,102<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_NonCashLeaseExpense', window );">Non-cash operating lease expense</a></td>
<td class="nump">2,838<span></span>
</td>
<td class="nump">2,070<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionExpense', window );">Accretion of operating lease liabilities</a></td>
<td class="nump">405<span></span>
</td>
<td class="nump">408<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of discount on investments</a></td>
<td class="num">(1,528)<span></span>
</td>
<td class="num">(1,222)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionLossBeforeTax', window );">Loss on foreign currency exchange rates</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">528<span></span>
</td>
<td class="num">(954)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(584)<span></span>
</td>
<td class="num">(1,144)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,011<span></span>
</td>
<td class="nump">1,675<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued and other current liabilities</a></td>
<td class="nump">3,947<span></span>
</td>
<td class="nump">2,980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="num">(3,291)<span></span>
</td>
<td class="num">(2,456)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(88,222)<span></span>
</td>
<td class="num">(53,549)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(2,211)<span></span>
</td>
<td class="num">(687)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(84,264)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Proceeds from maturities of investments</a></td>
<td class="nump">49,500<span></span>
</td>
<td class="nump">62,500<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">47,289<span></span>
</td>
<td class="num">(22,451)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="nump">10,875<span></span>
</td>
<td class="nump">185,202<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of common stock in connection with the exercise of stock options</a></td>
<td class="nump">1,430<span></span>
</td>
<td class="nump">2,321<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans', window );">Proceeds from the issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">269<span></span>
</td>
<td class="nump">108<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Principal payments on finance leases</a></td>
<td class="num">(897)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">11,677<span></span>
</td>
<td class="nump">187,631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(20)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash and cash equivalents</a></td>
<td class="num">(29,276)<span></span>
</td>
<td class="nump">111,631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents&#8212;beginning of year</a></td>
<td class="nump">193,238<span></span>
</td>
<td class="nump">81,607<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents&#8212;end of year</a></td>
<td class="nump">163,962<span></span>
</td>
<td class="nump">193,238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">748<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment purchases included in accounts payable</a></td>
<td class="nump">404<span></span>
</td>
<td class="nump">702<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of use assets obtained in exchange for lease obligations</a></td>
<td class="nump">10,963<span></span>
</td>
<td class="nump">2,048<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Right-of-use assets obtained in exchange for operating lease obligations</a></td>
<td class="nump">$ 4,242<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_NonCashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non cash lease expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_NonCashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481639/420-10-35-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized loss recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (115,864)<span></span>
</td>
<td class="num">$ (67,675)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Award Timing Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgDiscLineItems', window );"><strong>Award Timing Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgMnpiCnsdrdFlag', window );">Award Timing MNPI Considered</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MnpiDiscTimedForCompValFlag', window );">MNPI Disclosure Timed for Compensation Value</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgDiscLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgDiscLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgMnpiCnsdrdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgMnpiCnsdrdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MnpiDiscTimedForCompValFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MnpiDiscTimedForCompValFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rule 10b5-1 Trading Plans</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the fiscal quarter ended on December 31, 2024, none of our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">modified</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">terminated</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> a &#8220;Rule 10b5-1 trading arrangement&#8221; or &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as those terms are defined in Item 408(a) of Regulation S-K, except as described in the table below:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
     <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
      <tr style="visibility:collapse;">
       <td style="width:21.5%;box-sizing:content-box;"></td>
       <td style="width:12.42%;box-sizing:content-box;"></td>
       <td style="width:15.34%;box-sizing:content-box;"></td>
       <td style="width:16.64%;box-sizing:content-box;"></td>
       <td style="width:14.7%;box-sizing:content-box;"></td>
       <td style="width:19.4%;box-sizing:content-box;"></td>
      </tr>
      <tr style="height:54.4pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
       <td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name and Title</span></p></td>
       <td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Action</span></p></td>
       <td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Action Date</span></p></td>
       <td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Duration of Trading Arrangements</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
       <td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Rule 10b5-1 Trading Arrangement?</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Y/N)*</span></p></td>
       <td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate Number of Securities Subject to Trading Arrangement</span></p></td>
      </tr>
      <tr style="height:35.95pt;word-break:break-word;white-space:pre-wrap;">
       <td style="padding-top:0in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Steven Nichtberger</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Terminate</span></span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">October 18, 2024</span></span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_12ddf4b5-a62c-4ffa-84f2-711a71acbce0;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">July 8, 2024 - July</span></span></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31, 2025</span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Y</span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Up to </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">350,000</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares to be sold</span></p></td>
      </tr>
      <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
       <td style="padding-top:0in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Steven Nichtberger</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adopt</span></span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">October 18, 2024</span></span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_f0564499-a995-4065-9bd0-26aa3bce6fbe;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 16, 2025 &#8211; July 27, 2026</span></span></span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Y</span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Up to </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">350,000</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares to be sold</span></p></td>
      </tr>
      <tr style="height:46.3pt;word-break:break-word;white-space:pre-wrap;">
       <td style="padding-top:0in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gwendolyn Binder</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">President of Science and Technology</span></span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Terminate</span></span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 21, 2024</span></span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_823872a2-58d2-4796-aa66-411b0b1f08f7;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 20, 2024 &#8211; February 21, 2025</span></span></span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Y</span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Up to </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100,756</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares to be sold</span></p></td>
      </tr>
      <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
       <td style="padding-top:0in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gwendolyn Binder</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">President of Science and Technology</span></span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adopt</span></span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 18, 2024</span></span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_e881d3fc-fad6-4460-a675-9db9c9ce22a6;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 27, 2025 to December 12, 2025</span></span></span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Y</span></p></td>
       <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Up to </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100,756</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares to be sold</span></p></td>
      </tr>
     </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* Denotes whether the trading plan is intended, when adopted, to satisfy the affirmative defense of Rule 10b5-1(c).</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) Except as indicated by footnote, each trading arrangement permitted or permits transactions through and including the earlier to occur of (a) the completion of all purchases or sales or (b) the date listed in the table.</span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2) Represents the modification, as described in Rule 10b5-1(c)(1)(iv) under the Exchange Act, of a written trading arrangement adopted on November 9, 2023 that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_Rule10B51ArrModifiedFlag', window );">Rule 10b5-1 Arrangement Modified</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_NonRule10B51ArrModifiedFlag', window );">Non-Rule 10b5-1 Arrangement Modified</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=caba_StevenNichtbergerMember', window );">Steven Nichtberger [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Steven Nichtberger<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Executive Officer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrTerminationDate', window );">Termination Date</a></td>
<td class="text">October 18, 2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">388 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">350,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=caba_StevenNichtbergerOneMember', window );">Steven Nichtberger One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Steven Nichtberger<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Executive Officer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">October 18, 2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">527 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">350,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=caba_GwendolynBinderMember', window );">Gwendolyn Binder [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Gwendolyn Binder<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">President of Science and Technology<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrTerminationDate', window );">Termination Date</a></td>
<td class="text">November 21, 2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">368 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">100,756<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=caba_GwendolynBinderOneMember', window );">Gwendolyn Binder One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Gwendolyn Binder<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">President of Science and Technology<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">December 18, 2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">180 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">100,756<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_NonRule10B51ArrModifiedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non Rule 10b51 Arr Modified Flag</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_NonRule10B51ArrModifiedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_Rule10B51ArrModifiedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rule 10b51 Arr Modified Flag</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_Rule10B51ArrModifiedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrSecuritiesAggAvailAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrSecuritiesAggAvailAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrTerminationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrTerminationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=caba_StevenNichtbergerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=caba_StevenNichtbergerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=caba_StevenNichtbergerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=caba_StevenNichtbergerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=caba_GwendolynBinderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=caba_GwendolynBinderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=caba_GwendolynBinderOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=caba_GwendolynBinderOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management, Strategy, and Governance<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><p id="item_1c_cybersecurity" style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1C. Cybersecurity.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cyber Risk Management and Strategy</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We, under the oversight of the audit committee of our board of directors, have </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">implemented</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and maintain a cybersecurity risk management program that is designed to identify, assess, and mitigate risks from cybersecurity threats. Our risk management is supported by various tools and technologies, including third-party security solutions, monitoring, and alerting tools, designed to monitor, identify, and address risks from cybersecurity threats.</span></p></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">engage </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">with other third-party providers and consultants to support our cyber risk management efforts, including through periodic security testing and assessments. We have a process to assess certain major </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">third-party vendors and service providers</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, including through a review of responses to compliance questionnaires and contractual requirements, as appropriate.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We, like other companies in our industry, face a number of risks from cybersecurity threats in connection with our business. Although such risks have not </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">materially affected</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and we do not believe they are reasonably likely to materially affect, us, including our business strategy, results of operations or financial condition, to date, we have, from time to time, experienced threats to and security incidents related to our data and systems. For more information about the risks from cybersecurity threats we face, please see Item 1A- Risk Factors.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governance Related to Cybersecurity Risks</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors, as a whole and through its committees, has responsibility for the periodic review and oversight of information technology risks, including risks from cybersecurity threats.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The audit committee is responsible for oversight of our cyber risk management program</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The day-to-day management of the cyber program is directed by the Director of IT under the direction of the </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Financial Officer</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Currently,</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the Director of IT reports to the Chief Financial Officer and provides periodic updates to the Chief Financial Officer on cyber matters.</span></span></span></p><div><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Director of IT meets with the Chief Financial Officer periodically to discuss and review our cybersecurity risk management processes and to address matters related to potential cybersecurity and information technology risks, with input from the Company&#8217;s third-party technology providers, as appropriate. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Chief Financial Officer provides periodic reports on cybersecurity and information technology matters to the audit committee, which is responsible for reviewing and overseeing the Company&#8217;s risk management process, including risks from cybersecurity threats, as set forth in the audit committee charter.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The audit committee periodically reports</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> on cybersecurity risk management to the full board of directors.</span></p></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We, under the oversight of the audit committee of our board of directors, have </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">implemented</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and maintain a cybersecurity risk management program that is designed to identify, assess, and mitigate risks from cybersecurity threats. Our risk management is supported by various tools and technologies, including third-party security solutions, monitoring, and alerting tools, designed to monitor, identify, and address risks from cybersecurity threats.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors, as a whole and through its committees, has responsibility for the periodic review and oversight of information technology risks, including risks from cybersecurity threats.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The audit committee is responsible for oversight of our cyber risk management program</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The day-to-day management of the cyber program is directed by the Director of IT under the direction of the </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Financial Officer</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Currently,</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the Director of IT reports to the Chief Financial Officer and provides periodic updates to the Chief Financial Officer on cyber matters.</span></span></span></p><div><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Director of IT meets with the Chief Financial Officer periodically to discuss and review our cybersecurity risk management processes and to address matters related to potential cybersecurity and information technology risks, with input from the Company&#8217;s third-party technology providers, as appropriate. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Chief Financial Officer provides periodic reports on cybersecurity and information technology matters to the audit committee, which is responsible for reviewing and overseeing the Company&#8217;s risk management process, including risks from cybersecurity threats, as set forth in the audit committee charter.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The audit committee periodically reports</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> on cybersecurity risk management to the full board of directors.</span></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The audit committee is responsible for oversight of our cyber risk management program</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the Director of IT reports to the Chief Financial Officer and provides periodic updates to the Chief Financial Officer on cyber matters.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Director of IT meets with the Chief Financial Officer periodically to discuss and review our cybersecurity risk management processes and to address matters related to potential cybersecurity and information technology risks, with input from the Company&#8217;s third-party technology providers, as appropriate. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Chief Financial Officer provides periodic reports on cybersecurity and information technology matters to the audit committee, which is responsible for reviewing and overseeing the Company&#8217;s risk management process, including risks from cybersecurity threats, as set forth in the audit committee charter.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The audit committee periodically reports</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> on cybersecurity risk management to the full board of directors.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The day-to-day management of the cyber program is directed by the Director of IT under the direction of the </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Financial Officer</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Currently,</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the Director of IT reports to the Chief Financial Officer and provides periodic updates to the Chief Financial Officer on cyber matters.</span></span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Chief Financial Officer provides periodic reports on cybersecurity and information technology matters to the audit committee, which is responsible for reviewing and overseeing the Company&#8217;s risk management process, including risks from cybersecurity threats, as set forth in the audit committee charter.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. Basis of Presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cabaletta Bio, Inc. (the Company or Cabaletta) was incorporated in April 2017 in the State of Delaware as Tycho Therapeutics, Inc. and, in August 2018, changed its name to Cabaletta Bio, Inc. The consolidated financial statements include the accounts of Cabaletta Bio and its wholly owned subsidiaries: Cabaletta Bio GmbH and Cabaletta Bio (Germany) GmbH. All intercompany balances and transactions have been eliminated in consolidation.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is headquartered in Philadelphia, Pennsylvania. Cabaletta is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Principal operations commenced in April 2018.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risks and Uncertainties</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company does not expect to generate revenue from sales of engineered T cell therapies for autoimmune diseases or any other revenue unless and until the Company completes preclinical and clinical development and obtains regulatory approval for one or more product candidates. If the Company seeks to obtain regulatory approval for any of its product candidates, the Company expects to incur significant commercialization expenses.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing. As a result, the Company is unable to predict the timing or amount of increased expenses or when or if the Company will be able to achieve or maintain profitability. Further, the Company is dependent on third parties for certain research and development activities, including manufacturing services (Note 6 and Note 7). Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization. Even if the Company is able to generate revenues from the sale of its product candidates, if approved, it may not become profitable. If the Company fails to become profitable or is unable to sustain profitability on a continuing basis, then it may be unable to continue its operations at planned levels and be forced to reduce its operations.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Liquidity and Going Concern</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 205-40, Going Concern, ("ASC 205-40") the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern. The Company has sustained annual operating losses since inception and expects to continue to generate operating losses for the foreseeable future. As of December 31, 2024, the Company has incurred an accumulated deficit of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">349,101</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and has a cash and cash equivalents balance of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">163,962</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company&#8217;s ultimate success depends on the outcome of its research and development activities. Management expects to incur additional losses in the future as it continues its research and development and will need to raise additional capital to fully implement its business plan and to fund its operations. The Company intends to raise such additional capital through a combination of equity offerings, debt financings, government funding arrangements, strategic alliances or other sources. However, if such financing is not available at adequate levels and on a timely basis, or such agreements are not available on favorable terms, or at all, as and when needed, the Company will need to reevaluate its operating plan and may be required to delay or discontinue the development of one or more of its product candidates or operational initiatives. The Company expects that its current cash and cash equivalents may not be sufficient to fund operations for at least the next twelve months from the date of issuance of these consolidated financial statements. The Company's cash forecast contains estimates and assumptions based on success of ongoing clinical trials, and management cannot predict the amount or timing of all expenditures with certainty. Accordingly, the Company has concluded that substantial doubt exists about the Company&#8217;s ability to continue as a going concern. The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. Summary of Significant Accounting Policies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Principles of Consolidation</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying consolidated financial statements included herein have been prepared in conformity with accounting principles generally accepted in the United States ("GAAP") and under the rules and regulations of the U.S. Securities and Exchange Commission ("SEC"). All intercompany balances and transactions have been eliminated in consolidation.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying consolidated financial statements include but are not limited to advance payments and accruals related to the Company&#8217;s research and development expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Off-Balance Sheet Risk and Concentrations of Credit Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist of cash and cash equivalents, which are invested in U.S. treasury-based money market funds. As of December 31, 2023, the Company held available-for-sale securities, which were invested in U.S. treasury securities. These investments matured in 2024. A portion of the Company&#8217;s cash is maintained at two federally insured financial institutions, and account balances may at times exceed federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk. The Company has no off&#8209;balance sheet risk, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investments</span></p><p style="text-indent:27.8pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investments are available-for-sale and carried at estimated fair value. The Company&#8217;s valuations of available-for-sale debt securities are generally derived from independent pricing services based upon quoted prices in active markets for similar securities, with prices adjusted for yield and number of days to maturity, or based on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets. Management determines the appropriate classification of its investments in debt securities at the time of purchase and at the end of each reporting period. Investments with original maturities beyond three months at the date of purchase and which mature at, or less than, twelve months from the balance sheet date are classified as current.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unrealized gains and losses are excluded from earnings and are reported as a component of comprehensive income. The Company periodically evaluates whether declines in fair values of its available-for-sale securities below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors including the severity and duration of the unrealized loss as well as the Company&#8217;s ability and intent to hold the available-for-sale security until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the security or if more likely than not it will be required to sell any available-for-sale securities before recovery of its amortized cost basis. Realized gains and losses and declines in fair value judged to be other-than-temporary, if any, on available-for-sale securities are included in interest and other income, net. The cost of investments sold is based on the specific-identification method. Interest income on investments as well as amortization of discount or premium is included in interest income.</span></p></div><div><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Property, Plant and Equipment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property, plant and equipment are recorded at cost less accumulated depreciation. Cost includes the acquisition costs and all costs necessary to bring the asset to the location and working condition necessary for its intended use. Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the accompanying statements of operations. Expenditures for normal, recurring or periodic repairs and maintenance related to property and equipment are charged to expense as incurred. The cost for planned major maintenance activities, including the related acquisition or construction of assets, is capitalized if it will result in future economic benefits.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Estimated useful lives for property and equipment are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
         <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
          <tr style="visibility:collapse;">
           <td style="width:24.825%;box-sizing:content-box;"></td>
           <td style="width:16.023%;box-sizing:content-box;"></td>
           <td style="width:59.152%;box-sizing:content-box;"></td>
          </tr>
          <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Property and equipment</span></p></td>
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated useful life</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Laboratory equipment</span></p></td>
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> Three years</span></span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> Three years</span></span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment</span></p></td>
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> Three years</span></span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_11fb0b7e-26ca-48c1-8f03-76b57f37f299;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> Lesser of estimated useful life or remaining lease term</span></span></span></p></td>
          </tr>
         </table></div></div><div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value Measurement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1&#8212;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2&#8212;Inputs (other than quoted prices included in Level 1) that are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has leases related to its facilities used for offices and laboratory space, which are classified as operating leases as well as leases related to its manufacturing arrangements, which are classified as finance leases.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease and its classification based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets and current and non-current lease liabilities, as applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate to discount lease payments. Subsequent to the initial measurement, the Company will continue to account for:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the lease liability at the net present value using the incremental borrowing rate that was in effect as of the lease commencement, lease modification, or transition date, and;</span></div></div></div><div style="font-size:10pt;font-family:Times New Roman;"><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the finance lease and operating lease expense on a straight line basis.</span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leases with terms of 12 months or less are considered short-term leases and right-of-use assets and lease obligations are not recognized. Payments associated with short-term leases are expensed on a straight-line basis over the lease term.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In accordance with ASC 842, components of a lease should be split into three categories: lease components, non-lease components and non-components. The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components. Entities may elect not to separate lease and non-lease components. Rather, entities would account for each lease component and related non-lease component together as a single lease component. The Company has elected to aggregate all lease and non-lease components for each class of underlying assets into a single lease component for real-estate leases and embedded manufacturing arrangements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASC 842 allows for the use of judgment in determining whether the assumed lease term is for a major part of the remaining economic life of the underlying asset and whether the present value of lease payments represents substantially all of the fair value of the underlying asset. The Company applies the guidance in ASC 842-10-55-2 to assist in determining lease classification across its leases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development costs include costs incurred for internal and external research and development activities and are expensed as incurred in the accompanying statements of operations. Research and development costs consist of salaries and benefits, including associated stock-based compensation, and laboratory supplies and facility costs, as well as fees paid to entities that conduct certain research and development and clinical trial activities on the Company&#8217;s behalf.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records accrued liabilities for estimated costs of research and development activities conducted by service providers, which include preclinical studies, contract manufacturing activities and clinical trial activities. The Company records the estimated costs of research and development activities based upon the estimated amount of services provided and in accordance with agreements established with service providers and includes these costs in accrued and other current liabilities in the accompanying balance sheets and within research and development expense in the accompanying statements of operations. Non-refundable advance payments made for goods or services that will be used or rendered for future research and development activities are deferred and capitalized and recognized as expense as the goods are received or the related services are rendered. The Company makes significant judgments and estimates in determining the accrued liabilities and prepaid expenses in each reporting period. As actual costs become known, the Company adjusts its accrued liabilities and prepaid expenses. The Company has not experienced any material differences between accrued costs and actual costs incurred since its inception.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company measures its stock-based awards granted to employees and non-employees based on the estimated fair values of the awards on the respective grant dates. The Company uses the Black-Scholes option-pricing model (Black-Scholes) to estimate the fair value of its stock-based awards. The Company recognizes compensation expense for time-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award. The Company accounts for forfeitures of stock option awards as they occur.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to temporary differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax base, as well as for net operating loss carryforwards and research and development credits, and are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Valuation allowances are established when necessary to reduce deferred tax assets where, based upon the available evidence, the Company concludes that it is more-likely-than-not that the deferred tax assets will not be realized. In evaluating its ability to recover deferred tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. Because of the uncertainty of the realization of deferred tax assets, the Company has recorded a full valuation allowance against its deferred tax assets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reserves are provided for tax benefits for which realization is uncertain. Such benefits are only recognized when the underlying tax position is considered more-likely-than-not to be sustained on examination by a taxing authority, assuming they possess full knowledge of the position and facts. Interest and penalties related to uncertain tax positions are recognized in the provision of income taxes; however, the Company currently has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> interest or penalties related to uncertain income tax benefits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Loss Per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company calculates basic and diluted net loss per share in conformity with the two-class method required for participating securities because the Company had both voting and non-voting common stock outstanding in 2023 and for a portion of 2024. The rights, including the liquidation and dividend rights, of the holders of the voting and non-voting common stock are identical, except with respect to voting. Each share of non-voting common stock may be converted at any time into one share of voting common stock at the option of its holder by providing written notice to the Company, subject to the limitations provided for in the amended and restated certificate of incorporation. As of December 31, 2024, no shares of non-voting common stock remain outstanding.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted average number of shares of common stock, including any pre-funded warrants to purchase shares of common stock that may be outstanding. The undistributed loss for each year is allocated to common stockholders based on the contractual participation rights of the voting and non-voting common stock as if the losses for the year had been distributed. As the liquidation and dividend rights are identical, the undistributed losses are allocated on a proportionate basis. Diluted net loss per share attributable to common stockholders is computed under the if-converted method and assumes that all non-voting common stock has been converted to common stock. Since the Company was in a loss position for all periods presented, the effects of the other potentially dilutive securities are antidilutive.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segments</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (CODM) in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#8217;s CODM is its Chief Executive Officer (CEO). The Company has determined it operates in a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_d4311f9a-8cf2-4c85-b6fa-4408d3790ae7;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">single </span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">operating segment and has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reportable segment. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Refer to Note 8 &#8211; Segment Reporting for further information related to our segment.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Deferred Offering Costs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After consummation of the equity financing, these costs are recorded as a reduction to the carrying value of stockholders&#8217; equity as a reduction of additional paid-in capital or equity generated as a result of such offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the statements of operations and comprehensive loss.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Emerging Growth Company Status</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to December 31, 2024, the Company was an &#8220;emerging growth company&#8221; (EGC) as defined in the Jumpstart Our Business Startups Act, (JOBS Act), and elected to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies until the Company no longer qualifies as an EGC, including using the extended transition period for complying with new or revised accounting standards. As of December 31, 2024, the Company ceased to qualify as an EGC.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the FASB issued Accounting Standards Update, or ASU, 2023-07, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Reporting (Topic 280) &#8211; Improvements to Reportable Segment Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This ASU requires that a public entity provide additional segment disclosures on an interim and annual basis. The amendments in this ASU should be applied retrospectively to all prior periods presented in the consolidated financial statements, unless impracticable. Upon transition, the segment expense categories and amounts disclosed in the prior periods should be based on the significant segment expense categories identified and disclosed in the period of adoption. The Company adopted this ASU for the annual period ended December 31, 2024 and the amendments have been applied retrospectively to all prior periods presented in the financial statements. Refer to Note 8 &#8211; Segment Reporting for further information related to our segment.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Improvements to Income Tax Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. ASU 2023-09 enhances the transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The guidance is effective for public business entities for annual periods beginning after December 15, 2024. Early adoption is permitted. This update is effective beginning with the Company&#8217;s 2025 fiscal year annual reporting period. The Company is currently planning to adopt this guidance when effective and is assessing the impact of the adoption on the Company&#8217;s consolidated financial statements and accompanying footnotes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03, Income Statement (Subtopic 220-40): Reporting Comprehensive Income-Expense Disaggregation Disclosures. ASU 2024-03 requires enhanced disclosures about components of expense captions on the face of the income statement. This standard will be effective for fiscal years beginning after December 15, 2026. Early adoption is permitted. ASU 2024-03 applies on a prospective basis for periods beginning after the effective date. However, retrospective application to any or all prior periods presented is permitted. The Company is currently planning to adopt this guidance when effective and is assessing the impact of the adoption on the Company&#8217;s consolidated financial statements and accompanying footnotes.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There have been no other new accounting pronouncements or changes to accounting pronouncements that, if adopted, would have or may have a material impact on the Company&#8217;s consolidated statements or disclosures.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3. Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024 and 2023, the Company&#8217;s financial instruments included cash and cash equivalents, available-for-sale debt securities, accounts payable and accrued expenses. The carrying amounts for cash and cash equivalents, accounts payable and accrued expenses reported in the Company&#8217;s consolidated financial statements for these instruments approximate their respective fair values because of the short-term nature of these instruments.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables present information about the Company&#8217;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values:</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.38%;box-sizing:content-box;"></td>
         <td style="width:1.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Quoted<br/>Prices in<br/>Active Markets<br/>for Identical Assets <br/>(Level 1)</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial assets</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">162,634</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">162,634</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term investments:</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">162,634</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">162,634</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="text-indent:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.38%;box-sizing:content-box;"></td>
         <td style="width:1.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Quoted<br/>Prices in<br/>Active Markets<br/>for Identical Assets<br/>(Level 1)</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial assets</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">180,124</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">180,124</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities - original maturity less than three months</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,371</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_aacb9393-82a1-4484-8aab-edf9ca81d63c;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,371</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_b8a328b1-c384-428d-aa72-eece52e52e47;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term investments:</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,011</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,011</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">240,506</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">180,124</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60,382</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Money market funds are measured at fair value on a recurring basis using quoted prices and are classified as Level 1. Investments are measured at fair value based on inputs other than quoted prices that are derived from observable market data and are classified as Level 2 inputs.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For debt securities classified as available-for-sale investments,</span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the Company records unrealized gains or losses resulting from changes in fair value between measurement dates as a component of other comprehensive income. The Company did not hold any available-for-sale securities as of December 31, 2024:</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:46.218%;box-sizing:content-box;"></td>
         <td style="width:1.321%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.124%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.321%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.124%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.321%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.124%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.321%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.124%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized Cost</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross Unrealized Gains</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross Unrealized Losses</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair value</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial assets</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">743</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">743</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">180,124</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">180,124</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities - original maturity less than three months</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,367</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,371</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Included in cash and cash equivalents</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">193,234</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">193,238</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities - due in one year or less</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Included in short-term investments</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47,976</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,011</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">241,210</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">241,249</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4. Property, Plant and Equipment</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property, plant and equipment consists of the following:</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Laboratory equipment</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,663</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,893</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">277</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">277</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">196</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">113</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">113</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property, plant and equipment</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,249</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,336</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: accumulated depreciation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,506</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,795</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property, plant and equipment, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,743</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,541</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation expense was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,711</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,426</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the years ended December 31, 2024 and 2023, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued and Other Current Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5. Accrued and Other Current Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued and other current liabilities consist of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development services</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,491</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,459</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative services</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">342</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">188</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Compensation expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,315</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,200</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,188</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,887</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations, Licensing Agreements and other Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_CollaborationsLicensingAgreementsAndOtherAgreementsAbstract', window );"><strong>Collaborations Licensing Agreements And Other Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock', window );">Collaborations, Licensing Agreements and other Agreements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6. Collaborations, Licensing Agreements and other Agreements</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Amended and Restated License Agreement with the Trustees of the University of Pennsylvania and Children&#8217;s Hospital of Philadelphia</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2018, the Company entered into a license agreement with Penn, as amended and restated in July 2019 to include the Children&#8217;s Hospital of Philadelphia (CHOP) as a party, and as amended in May 2020 and October 2021 (the License Agreement) pursuant to which the Company obtained (a) a non-exclusive, non-sublicensable worldwide license to certain of Penn&#8217;s intellectual property to conduct research, product development, clinical trials, cell manufacturing and other activities, and (b) an exclusive, worldwide, royalty-bearing right and license, with a right to sublicense, on a target-by-target basis, under certain of Penn&#8217;s intellectual property to make, use, sell, offer for sale, import, and otherwise commercialize products for the treatment of autoimmune and alloimmune diseases. Unless earlier terminated, the License Agreement expires on the expiration or abandonment or other termination of the last valid claim in Penn&#8217;s intellectual property licensed by the Company. The Company may terminate the License Agreement at any time for convenience upon 60 days' written notice. In the event of an uncured, material breach, Penn may terminate the License Agreement upon 60 days' written notice. Under the terms of the License Agreement, the Company was obligated to pay $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> annually for </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> beginning August 2018 for funding to the laboratories of each of Drs. Milone and Payne. This was satisfied through completed sponsored research agreements with a total cost of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,560</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. During the term of the License Agreement until the first commercial sale of the first product, the Company is obligated to pay Penn a non-refundable, non-creditable annual license maintenance fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In May 2020, the Company paid Penn an additional, non-refundable, non-creditable license fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> under the amended License Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is required to pay certain milestone payments upon the achievement of specified clinical and commercial milestones. Milestone payments are reduced by a certain percentage for the second product that achieves a milestone, by an additional percentage for the third product that achieves a milestone, and so on, for each subsequent product that achieves a milestone. In the event that the Company is able to successfully develop and launch multiple products under the License Agreement, total milestone payments could be approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Penn is also eligible to receive tiered royalties at percentage rates in the low single-digits, subject to an annual minimum royalty, on annual worldwide net sales of any products that are commercialized by the Company or its sublicensees that contain or incorporate, or are covered by, the intellectual property licensed by the Company. To the extent the Company sublicenses its license rights under the License Agreement, Penn would be eligible to receive tiered sublicense income at percentage rates in the mid-single to low double-digits. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> amounts due under the License Agreement as of December 31, 2024.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Master Translational Research Services Agreement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2018 and February 2023, the Company entered into services agreements (the CAART and CARTA Services Agreements) with Penn for research, development and manufacturing services from various laboratories within Penn. The activities are detailed in separately executed Penn organization-specific addenda. In May 2020, the Company amended its Addendum with the Center for Advanced Retinal and Ocular Therapeutics (CAROT) to expand access to vector manufacturing.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expense related to executed addenda under the master translational research service agreements with Penn recognized in the accompanying statements of operations was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,250</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,786</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for the years ended December 31, 2024 and 2023, respectively. The Company is </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">committed to pay up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> under the CARTA Services Agreement for cell processing manufacturing through December 31, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company may incur additional expenses up to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">643</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> t</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">hrough the remaining term of the CAROT Amended Addendum.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Exclusive License Agreement with IASO Biotherapeutics</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 7, 2022, the Company entered into an Exclusive License Agreement (the IASO Agreement) with Nanjing IASO Biotherapeutics Co., Ltd. (IASO). Pursuant to the IASO Agreement, the Company received an exclusive, worldwide license under certain IASO intellectual property to use a novel clinical-stage anti-CD19 binder to develop, manufacture, commercialize and otherwise exploit T cell products directed to CD19 for the purpose of diagnosis, prevention or treatment of any autoimmune or alloimmune indications in humans. As partial consideration for the exclusive license, IASO received an upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,500</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. IASO is also eligible to receive up to mid double digit millions in milestone payments based upon the achievement of specified pre-clinical, development and regulatory milestones, and up to an additional low triple digit millions in milestone payments based upon achievement of specified sales milestones, for a total consideration, inclusive of the upfront payment, of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">162,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, along with tiered mid-single digit royalties on future net sales for licensed products that may result from the IASO Agreement. Upon the U.S. Food and Drug Association&#8217;s clearance of the rese-cel Investigational New Drug application for the treatment of systemic lupus erythematosus in March 2023, a milestone payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was recognized in the accompanying statements of operations. A milestone payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,500</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was paid to IASO in the first quarter of 2024 after the first patient in a rese-cel trial was dosed.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IASO has the right of first negotiation if the Company desires to grant a third party an exclusive license to develop, manufacture, commercialize or otherwise exploit the licensed products in the Greater China region. Pursuant to the IASO Agreement, each of IASO and the Company have agreed, subject to certain exceptions, to refrain from engaging in certain competitive activities with respect to certain programs. The Company also may sublicense through multiple tiers the rights granted to it by IASO under the IASO Agreement at any time, however, it must pay IASO a low double-digit percentage of any revenue obtained from sublicenses or options to third parties, subject to certain customary exclusions. The IASO Agreement will continue on a country-by-country, licensed product-by-licensed product basis until the expiration of the royalty term as identified in the IASO Agreement, unless earlier terminated. Each of the Company and IASO may terminate the Agreement for a material, uncured breach or insolvency of the other party. The Company may also terminate the Agreement at will upon advance written notice and in the event IASO rejects the Agreement due to bankruptcy-related matters. IASO may also terminate the Agreement if the Company fails to achieve certain specified diligence milestones in a timely manner and/or if the Company commences any patent challenges with respect to the patents and patent applications relating to the licensed sequence, in each case upon advance written notice.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Licence and Supply Agreement with Oxford Biomedica</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2021, the Company entered into a Licence and Supply agreement (LSA) with Oxford Biomedica (UK) Limited (Oxford), wherein the LSA grants the Company a non-exclusive license to Oxford&#8217;s LentiVector&#174; platform for its application in the Company&#8217;s DSG3-CAART program and put in place a multi-year vector supply agreement. Under the terms of the agreement, the Company was required to pay Oxford an upfront fee, as well as costs associated with initial vector manufacturing activities for a total cost incurred of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Oxford is eligible to receive regulatory and sales milestones in the low tens of millions and royalties in the low single digits on net sales of products that incorporate the Oxford technology. In May 2023, the Company amended the LSA with Oxford to expand the license to include the Company's rese-cel program for an upfront fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">500</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and in August 2023, the Company and Oxford entered into a vector supply agreement for rese-cel, and a related second amendment to the LSA, with a total cost under the vector supply agreement of up to approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, of which </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,500</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,500</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> were recognized as research and development expense for the years ended December 31, 2024 and 2023, respectively. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2024, the Company and Oxford entered into a third amendment to the LSA to update the patent schedule. In June 2024, the Company and Oxford entered into a fourth amendment to the LSA elimin</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ating royalties on net sales of products that incorporate the Oxford technology if Oxford manufactures the vector. In December 2024, the Company and Oxford entered into a work order with a cost of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for certain process characterization activities as part of commercial readiness activities. The Company can terminate the LSA or any work order under the LSA at will upon advance written notice and subject to certain cancellation fees.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Option and License Agreement with Autolus</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2023, the Company entered into an Option and License Agreement (Autolus Agreement) with Autolus Holdings (UK) Limited (Autolus), wherein the Autolus Agreement granted the Company a non-exclusive license to access Autolus' RQR8 technology in its CD19-CAR T cell therapy program, and subject to additional nominal option exercise fees, up to four additional t</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">argets. In January 2025, the Company and Autolus agreed to novate the Autolus Agreement with both Autolus and Autolus Limited jointly assuming the rights, obligations and liabilities of Autolus, under the Autolus Agreement. Under the terms of the Autolus Agreement, the Company was required to pay Autolus an upfront license fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,200</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that was recognized as expense in the first quarter of 2023 in the accompanying statements of operations, of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was paid in 2023 and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was paid in January 2024. Autolus is also eligible to receive regulatory milestones of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for each licensed target, sales milestones of up to a total of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and royalties in the low single digits on net sales of all products that incorporate the RQR8 technology. The Autolus Agreement will continue on a country-by-country, licensed product-by-licensed product basis until the expiration of the royalty term as identified in the Autolus Agreement, unless earlier terminated. The Company can terminate the Autolus Agreement at will upon advance written notice. Each of the Company and Autolus may terminate the Agreement for a material, uncured breach or insolvency of the other party.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_CollaborationsLicensingAgreementsAndOtherAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborations licensing agreements and other agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_CollaborationsLicensingAgreementsAndOtherAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborations licensing agreements and other agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8. Segment Information</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the CODM in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#8217;s CODM is the CEO. The Company has determined that it has one operating and reportable segment. The segment consists of the development of clinical and preclinical product candidates for the discovery and development of innovative engineered T cell therapies and related administrative activities. The</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CODM assesses performance and allocates resources based on the Company&#8217;s consolidated statement of operations, which is reported on the income statement as consolidated net loss and considers forecast-to-actuals variances on a quarterly basis for expenses that are deemed significant. Further, the CODM reviews the segment&#8217;s assets based on the consolidated balance sheet to assess liquidity and funding capacity. The majority of the Company's assets are located in the United States.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s CODM views specific categories within expenses as significant given the direct correlation between cash burn and profitability as a pre-revenue company. Significant segment expenses, as provided to the CODM, are presented below. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For additional information on the year over year change of segment expenses refer to Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:57.12%;box-sizing:content-box;"></td>
         <td style="width:2.1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:17.34%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2.1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:17.34%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
         <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development expenses:</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,239</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,375</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Clinical trials</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,286</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,302</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Development services</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,417</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,486</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Manufacturing of preclinical and clinical supplies</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,523</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,498</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License of intellectual property</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,523</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,383</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other research and development costs </span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,215</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,380</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administration expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,938</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,236</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,025</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,985</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">748</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">115,864</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67,675</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other research and development costs includes costs associated with information technology, travel, medical and scientific symposiums and conferences.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7. Commitments and Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Manufacturing Agreements</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2021, the Company entered into a Development and Manufacturing Services Agreement (WuXi Agreement) with WuXi Advanced Therapies, Inc. (WuXi) to serve as an additional cell processing manufacturing partner for the MuSK-CAART Phase 1 clinical trial, or MusCAARTes</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial. The WuXi Agreement is scheduled to expire upon completion of WuXi's services related to MuSK-CAART and rese-cel. In August 2023, and as extended in August 2024, the Company entered into an agreement with WuXi to serve as one of the Company's manufacturing partners for the global clinical development of rese-cel in multiple indications, including potential late-stage clinical trials and commercial readiness activities for rese-cel. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the August 2023 work orders, WuXi converted the Company&#8217;s non-dedicated suite to a dedicated suite for GMP manufacturing for the Company&#8217;s rese-cel and MuSK-CAART programs, or the Dedicated Suite, for an initial term of 18 months with two 18-month extensions at the Company&#8217;s sole option on six months' notice prior to the end of the term. In August 2024, the Company sent a notice to WuXi to extend the initial term of the WuXi Agreement by 18 months through August 2026.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In addition, the Company agreed to certain monthly minimum runs. In August 2024, the 2023 work order related to GMP manufacturing was amended to reduce the minimum monthly runs through the end of 2024. In lieu of the original $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,500</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> termination fee under the terms of the WuXi Agreement, the Company would incur up to a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,080</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> termination </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fee if it terminates both the rese-cel and MuSK-CAART work orders for any reason. The Company may terminate for</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">convenience </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the WuXi Agreement or any work order with six months' prior written notice. However, the Company may not terminate the Dedicated Suite without terminating both the MuSK-CAART </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and rese-cel GMP run work orders. WuXi may terminate for convenience the WuXi Agreement or any work order on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18 </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">months' prior written notice, but such notice may not be effective prior to February 2028.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, the Company entered into a Development and Manufacturing Services Agreement (the Lonza Agreement) with Lonza Houston Inc. (Lonza) to serve as one of the Company's manufacturing partners for the global clinical development of rese-cel in multiple indications, including potential late-stage clinical trials and preparations for commercial readiness. Under the initial work order, Lonza will perform cell therapy manufacturing activities for Cabaletta&#8217;s CAR-T cell therapy product rese-cel for a term of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12 </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">months and total cost of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> with the ability to extend the manufacturing period subject to the terms of the Lonza Agreement.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Purchase Commitments</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the normal course of business, the Company enters into various purchase commitments with third-party contract manufacturers for the manufacture and processing of its product candidates and related raw materials, contracts with contract research organizations for clinical trials and agreements with vendors for other services and products for operating purposes. These agreements generally provide for termination or cancellation, other than for costs already incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Indemnification</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company enters into certain types of contracts that contingently require the Company to indemnify various parties against claims from third parties. These contracts primarily relate to (i) the Company&#8217;s Amended and Restated Bylaws, as amended, (bylaws) under which the Company must indemnify directors and executive officers, and may indemnify other officers and employees, for liabilities arising out of their relationship, (ii) contracts under which the Company must indemnify directors and certain officers and consultants for liabilities arising out of their relationship, (iii) contracts under which the Company may be required to indemnify partners against certain claims, including claims from third parties asserting, among other things, infringement of their intellectual property rights, and (iv) procurement, consulting, or license agreements under which the Company may be required to indemnify vendors, consultants or licensors for certain claims, including claims that may be brought against them arising from the Company&#8217;s acts or omissions with respect to the supplied products, technology or services. From time to time, the Company may receive indemnification claims under these contracts in the normal course of business. In addition, under these contracts, the Company may have to modify the accused infringing intellectual property and/or refund amounts received.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event that one or more of these matters were to result in a claim against the Company, an adverse outcome, including a judgment or settlement, may have a material adverse effect on the Company&#8217;s future business, operating results or financial condition. It is not possible to determine the maximum potential amount under these contracts due to the limited history of prior indemnification claims and the unique facts and circumstances involved in each particular agreement.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Litigation</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, the Company may become involved in litigation or legal proceedings. While the outcome of any such proceedings cannot be predicted with certainty, as of December 31, 2024, the Company is not involved in any material litigation or legal proceedings that it would expect to have a material adverse impact on its financial position, results of operations, or cash flows.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Leases</span><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company leases office and laboratory space in addition to a manufacturing agreement which has been determined to contain an embedded lease.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating lease commitments</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company leases office and laboratory space which include rent escalations and are subject to additional variable charges, including common area maintenance, property taxes and property insurance. Given the variable nature of such costs, they are recognized as expense as incurred. Additionally, some of the Company&#8217;s leases are subject to certain fixed fees which the Company has determined to be non-lease components. The Company has elected the practical expedient to account for lease and non-lease components as a single-lease component and has included fixed payments related to non-lease components in calculating the operating lease liability. In 2024, the Company extended the terms of its lab and office operating leases and leased additional lab space </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">resulting in an increase in the right-of-use asset and lease liability of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,242</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Finance lease commitments - Embedded leases</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As described further in Note 7, in August 2023, the Company entered into new work orders under the WuXi Agreement for WuXi to serve as one of the Company&#8217;s cell processing manufacturing partners for the global clinical development of rese-cel. WuXi converted the Company&#8217;s non-dedicated suite to a Dedicated Suite for GMP manufacturing for the Company&#8217;s rese-cel and MuSK-CAART programs, for an initial term of 18 months. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">terms of the August 2023 work orders included both fixed costs and contingent variable costs. The lease commenced October 1, 2023. In 2024, the Company remeasured the lease due to resolution of the contingency related to variable costs and an amendment to the 2023 work order to extend the term of the agreement for an additional 18 months through August </span></span><span style=""></span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2026 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">resulting in an increase in the right-of-use asset and lease liability of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,963</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company may terminate the Dedicated Suite lease for convenience with six months&#8217; prior written notice and up to a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,080</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> termination fee if both the rese-cel and MuSK-CAART work orders are terminated</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As described further in Note 7, in December 2024, the Company entered into the Lonza Agreement with Lonza to serve as one of our manufacturing partners. Under the initial work order, Lonza will perform cell therapy manufacturing activities for our CAR-T cell therapy product rese-cel for a term of 12 months and total cost of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> with the ability to extend the manufacturing period subject to the terms of the Lonza Agreement. The Lonza Agreement is currently being evaluated for lease accounting under ASC 842. No right-of-use asset or liability was recognized as of December 31, 2024, as lease commencement begins in fiscal year 2025.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Summary of lease costs recognized under ASC 842</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company&#8217;s operating and finance leases for the years ended December 31, 2024 and 2023.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:59.224%;box-sizing:content-box;"></td>
         <td style="width:2.001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:16.387%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2.001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:16.387%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the year ended December 31,</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Finance leases</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">748</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,102</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total fixed finance lease cost</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,850</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Variable lease cost</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">930</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total finance lease cost</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,780</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Operating leases</span></p></td>
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fixed lease cost</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,247</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,477</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total fixed operating lease cost</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,247</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,477</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Variable lease cost</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">296</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term lease cost</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">750</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">717</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease cost</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,293</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,259</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash paid in the measurement of lease liabilities</span></p></td>
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating cash flows used for operating leases</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,291</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,456</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating cash flows used for finance leases</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">748</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financing cash flows for finance leases</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">897</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Other information</span></p></td>
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average remaining lease term - finance leases (in years)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.7</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average discount rate - finance leases</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.5</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average remaining lease term - operating leases (in years)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.7</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.5</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average discount rate - operating leases</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.5</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For finance leases embedded in CDMO arrangements, interest expense is recognized using the effective interest method, applying the Company's incremental borrowing rate as required by ASC 842, and amortization expense is recognized on a straight-line basis over the shorter of the life of the asset or the term of the lease.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future lease payments under the non-cancelable operating and finance leases as of December 31, 2024 are as follows</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:
<br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Finance Leases</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Operating Leases</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,328</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,227</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,792</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,769</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Total undiscounted lease payments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,120</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,996</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less imputed interest</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">890</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">626</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Total lease liability</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,230</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,370</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">Common Stock</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10. Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the Company&#8217;s Third Amended and Restated Certificate of Incorporation filed in October 2019, the Company is authorized to issue </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">143,590,481</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of voting common stock and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,409,519</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of non-voting common stock. Holders of voting common stock shall have the exclusive right to vote for the election of directors of the Company and on all other matters requiring stockholder action. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each share of the Company&#8217;s non-voting common stock may be converted at any time into one share of common stock at the option of its holder by providing 61 days written notice to the Company</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, subject to certain limitations, as described in the amended and restated certificate of incorporation. In May 2024, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,444,295</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of non-voting common stock was converted to voting common stock and no shares of non-voting common stock remain outstanding.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">May 2023 Financing</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2023, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,337,500</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock in an underwritten public offering, including the exercise in full by the underwriters of their option to purchase an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,087,500</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, at a public offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. Aggregate net proceeds were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93,755</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> after deducting underwriting discounts and commissions and offering expenses of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,295</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">December 2022 Financing</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2022, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">126,815</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.52</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and to certain investors in lieu of common stock, pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,213,776</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.51999</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per pre-funded warrant. The purchase price per share of each pre-funded warrant represents the per share offering price for the common stock, minus the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share exercise price of such pre-funded warrant. Aggregate net proceeds were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,562</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> after deducting underwriting discounts and commissions and offering expens</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">es. As of December 31, 2024, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,213,775</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> pre-funded warrants had been exercised and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> warrants remain outstanding.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The pre-funded warrants were classified as a component of permanent stockholders&#8217; equity within additional paid-in capital and were recorded at the issuance date using a relative fair value allocation method. The pre-funded warrants are equity classified because they (i) are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, (ii) are immediately exercisable, (iii) do not embody an obligation for the Company to repurchase its shares, (iv) permit the holders to receive a fixed number of shares of common stock upon exercise, (v) are indexed to the Company&#8217;s common stock and (vi) meet the equity classification criteria. In addition, such pre-funded warrants do not provide any guarantee of value or return.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">At-the-Market Offering</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 21, 2024, the Company filed an automatic shelf registration statement (S-3ASR) in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof for the purposes of selling, from time to time, the Company&#8217;s common stock, debt securities or other equity securities in one or more offerings. This S-3ASR became effective immediately. We intend to convert the S-3ASR to S-3 by post-effective amendments in connection with the filing of this Annual Report.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has a Sales Agreement with Cowen and Company, LLC (Cowen) to provide for the offering, issuance and sale of up to an aggregate amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">200.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of common stock from time to time in &#8220;at-the-market&#8221; offerings (2024 ATM Program) pursuant to its S-3ASR, and subject to the limitations thereof. In December 2024, the Company sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,225,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares pursuant to the 2024 ATM Program for net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,129</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, after deducting commissions of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company previously had a Sales Agreement with Cowen to provide for the offering, issuance and sale of up to an aggregate amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of common stock from time to time in &#8220;at-the-market&#8221; offerings (2023 ATM Program) pursuant to its shelf registration statement on Form S-3 (File No. 333-270599), which was declared effective April 26, 2023. During the year ended December 31, 2023, the Company sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,760,899</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares pursuant to the 2023 ATM Program for net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">91,740</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, after deducting commissions of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,352</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In the first quarter of 2024, the Company sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">258,070</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> additional shares, completing the 2023 ATM Program for net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,746</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, after deducting commissions of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">147</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2018 Stock Option and Grant Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2018, the Company adopted the 2018 stock option and grant plan (the 2018 Plan), which provided for the Company to sell or issue common stock, or other stock-based awards, to employees, members of the board of directors and consultants of the Company. The Company generally granted stock-based awards with service conditions only (service-based awards), although there was one grant with performance conditions. As of December 31, 2020, there are </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> unvested options with performance conditions. Stock options granted under the 2018 Plan generally vest over </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_12ab2f03-70f4-4da9-bb26-c88cd3cb34ae;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,959,411</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> options granted under the 2018 Plan prior to the Company&#8217;s IPO in October 2019. No further grants may be made under the 2018 Plan subsequent to the IPO.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2019 Stock Option and Incentive Plan</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 2019 Stock Option and Incentive Plan (2019 Plan) was approved by the Company&#8217;s board of directors on October 14, 2019, and became effective on October 23, 2019. The 2019 Plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock units, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights to the Company&#8217;s officers, employees, directors and consultants. The number of shares initially reserved for issuance under the 2019 Plan was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,342,288</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which will be increased each January 1 thereafter by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the number of shares of the Company&#8217;s common stock outstanding on the immediately preceding December 31 or such lesser number of shares determined by the Company&#8217;s board of directors or compensation committee of the board of directors. On June 1, 2023, at the 2023 Annual Meeting of Stockholders of the Company, the stockholders of the Company approved Amendment No. 1 to the 2019 Plan, increasing the number of shares of common stock reserved for issuance under the 2019 Plan by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares. On January 1, 2025, the total number of shares under the 2019 Plan was increased by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,029,724</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares pursuant to the 2019 Plan Evergreen Provision. As of December 31, 2024, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,379,305</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares remaining available for issuance under the 2019 Plan.</span></p><div><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A summary of the stock option activity is presented below:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;">
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:33.84%;box-sizing:content-box;"></td>
         <td style="width:1.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.6%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.66%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.120000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.64%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.66%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.120000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Shares</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Exercise Price</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (years)</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of January 1, 2024</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,141,035</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.28</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.6</span></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">117,384</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,476,700</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.13</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">210,695</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.79</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,889</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited/Cancelled</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">175,892</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.04</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2024</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,231,148</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.63</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.4</span></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">989</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options Exercisable at December 31, 2024</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,642,705</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.92</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.1</span></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">966</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate intrinsic value of options granted is calculated as the difference between the exercise price of the options and the estimated fair value of the Company&#8217;s common stock. The weighted average grant-date fair value of stock options granted during the year ended December 31, 2024 and 2023 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.44</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.51</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of each award is estimated using Black-Scholes based on the following assumptions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:53.049%;box-sizing:content-box;"></td>
         <td style="width:1.8%;box-sizing:content-box;"></td>
         <td style="width:21.676%;box-sizing:content-box;"></td>
         <td style="width:1.8%;box-sizing:content-box;"></td>
         <td style="width:21.676%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.43</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.60</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.38</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.68</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years&#8212;</span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.2</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years&#8212;</span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.1</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">106</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">111</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Black-Scholes requires the use of subjective assumptions which determine the fair value of stock-based awards. These assumptions include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected term</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The expected term represents the period that stock-based awards are expected to be outstanding. The expected term for option grants is determined using the simplified method, which is the midpoint between the vesting period and the contractual term of the option.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected volatility</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;As a privately held company prior to the Company&#8217;s IPO in October 2019, the Company has limited trading history for its common stock and, as such, the expected volatility is estimated based on a weighted average volatility for the Company's stock price and comparable publicly traded biotechnology companies over a period equal to the expected term of the stock-based awards. The comparable companies were chosen based on their similar size, stage in the life cycle or area of specialty. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of a stock-based award.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected dividend</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has recorded stock-based compensation in the accompanying statements of operations as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,163</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,520</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,302</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,823</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,465</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,343</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, there was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">51,239</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of unrecognized compensation cost related to unvested option awards, which is expected to be recognized over a weighted-average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.8</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2019 Employee Stock Purchase Plan</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 2019 Employee Stock Purchase Plan (2019 ESPP) was approved by the Company&#8217;s board of directors on October 14, 2019, and became effective on October 23, 2019. A total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">234,229</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock were initially reserved for issuance under the 2019 ESPP, and such number of shares will be increased each January 1 thereafter through January 1, 2029 by the least of (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">234,229</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock, (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the number of shares of the Company&#8217;s common stock outstanding on the immediately preceding December 31 or (iii) such lesser number of shares determined by the 2019 ESPP&#8217;s administrator. There was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> increase to the total number of shares </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">available under the 2019 ESPP on January 1, 2024, 2023 or 2022, respectively. As of December 31, 2024, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">314,259</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares remaining available for issuance under the 2019 ESPP.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employee contributions are made through payroll deductions of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of eligible compensation over the offering period. A participant may not accrue rights to purchase more than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> worth of the Company&#8217;s common stock for each calendar year in which such right is outstanding. At the end of each offering period, shares of the Company&#8217;s common stock may be purchased at </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the lesser of the Company&#8217;s common stock on (i) the first trading day of the relevant offering period and (ii) the last trading day of the relevant offering period. Each offering period will be six months in duration and will commence on each December 1 and June 1.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11. Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The reconciliation of federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:54.151%;box-sizing:content-box;"></td>
         <td style="width:1.78%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:19.144000000000002%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.78%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:19.144000000000002%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected income tax benefit at the federal statutory rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State and local taxes, net of federal benefit</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.7</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.6</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development credit, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.3</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.4</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-deductible items and other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in state and local tax rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.7</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.9</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33.8</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. </span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The principal components of the Company&#8217;s deferred tax assets and liabilities consisted of the following: </span></span><span style=""></span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal, state and local net operating loss carryforwards</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,369</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34,534</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized research and development costs</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,646</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,830</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development tax credits</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,296</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,192</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation deductions</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,919</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,066</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License fee deductions</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">221</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">240</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,607</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,482</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,603</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,665</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gross deferred tax assets</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">114,661</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74,009</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: valuation allowance</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">110,723</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72,560</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,938</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,449</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,938</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,449</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred tax assets</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company increased its valuation allowance by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,163</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the year ended December 31, 2024 in order to maintain a full valuation allowance against its deferred tax assets. Based on the Company&#8217;s history of losses, the Company recorded a full valuation allowance against its deferred tax assets as of December 31, 2024. The Company intends to maintain a valuation allowance until sufficient positive evidence exists to support a reversal of the allowance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the Company had federal, state and local net operating loss carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">157,448</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">181,362</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88,701</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively; $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">157,198</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the federal net operating losses do not expire, and the remaining $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">250</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2037</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The state net operating losses begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2037</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The local net operating losses begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2042</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As of December 31, 2024, the Company had federal and state research and development tax credit carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,684</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">612</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively, which begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2038 </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2036</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively. Under the provisions of Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the IRC), these net operating losses, credit carryforwards and other tax attributes may be subject to limitation based on previous significant changes in ownership and upon future significant changes in ownership of the Company, as defined by the IRC.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company files income tax returns in the U.S. federal jurisdiction as well as in Pennsylvania and Philadelphia. The tax years 2023, 2022 and 2021 remain open to examination by the jurisdictions where the Company is subject to tax.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company evaluates tax positions for recognition using a more-likely-than-not recognition threshold, and those tax positions eligible for recognition are measured as the largest amount of tax benefit that is greater than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% likely of being realized upon the effective settlement with a taxing authority that has full knowledge of all relevant information. As of December 31, 2024, the Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> unrecognized income tax benefits that would affect the Company&#8217;s effective tax rate if recognized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12. Net Loss Per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company calculates basic and diluted net loss per share in conformity with the two-class method required for participating securities. For the year ended December 31, 2023, the Company had voting and non-voting common stock outstanding. In May 2024, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,444,295</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of non-voting common stock was converted to voting common stock and as of December 31, 2024, no shares of non-voting common stock remain outstanding. Since the rights of the voting and non-voting common stock are identical, except with respect to voting, the undistributed losses of the Company have been</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> allocated on a proportionate basis to the two classes. Basic net loss per share of common stock is computed by dividing the net loss per share of common stock by the weighted average number of shares of common stock outstanding for the period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted average shares of common stock outstanding as of December 31, 2023 included outstanding pre-funded warrants to purchase up to an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,168,054</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> pre-funded warrants remain outstanding as of December 31, 2024.</span></p><div><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Diluted net loss per share is calculated using the if-converted method, which assumes conversion of all non-voting common stock to voting common stock.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.4%;box-sizing:content-box;"></td>
         <td style="width:1.92%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.88%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.92%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.88%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Voting common stock</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Non-voting common stock</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Basic net loss per share:</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;text-indent:5pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Allocation of undistributed losses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">114,728</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,136</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;text-indent:5pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average number of shares used in basic per share computation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,038,726</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">485,378</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share, basic</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.34</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.34</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Diluted net loss per share:</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;text-indent:5pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Allocation of undistributed losses for basic computation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">114,728</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,136</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reallocation of undistributed losses as a result of conversion of<br/>&#160;&#160;&#160;&#160;&#160;non-voting to voting common shares</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,136</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Allocation of undistributed losses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">115,864</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,136</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;text-indent:5pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average number of shares used in basic per share computation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,038,726</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">485,378</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Add: conversion of non-voting to voting common shares outstanding</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">485,378</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average number of shares used in diluted per share computation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,524,104</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">485,378</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share, diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.34</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.34</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.4%;box-sizing:content-box;"></td>
         <td style="width:1.92%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.88%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.92%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.88%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31, 2023</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Voting common stock</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Non-voting common stock</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Basic net loss per share:</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;text-indent:5pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Allocation of undistributed losses</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64,776</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,899</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;text-indent:5pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average number of shares used in basic per share computation</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,192,445</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,753,505</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share, basic</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.65</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.65</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Diluted net loss per share:</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;text-indent:5pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Allocation of undistributed losses for basic computation</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64,776</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,899</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reallocation of undistributed losses as a result of conversion of<br/>&#160;&#160;&#160;&#160;&#160;non-voting to voting common shares</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,899</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Allocation of undistributed losses</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67,675</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,899</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;text-indent:5pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average number of shares used in basic per share computation</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,192,445</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,753,505</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Add: conversion of non-voting to voting common shares outstanding</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,753,505</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average number of shares used in diluted per share computation</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,945,950</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,753,505</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share, diluted</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.65</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.65</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share, as their effect is anti-dilutive:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.967%;box-sizing:content-box;"></td>
         <td style="width:1.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.357%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.357%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options to purchase common stock</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,231,148</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,141,035</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,231,148</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,141,035</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Savings Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">401(k) Savings Plan</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13. 401(k) Savings Plan</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company maintains a defined-contribution savings plan under Section 401(k) of the IRC, or the 401(k) Plan. The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pretax basis. Effective January 1, 2020, the Plan provided for matching contributions on a portion of participant contributions pursuant to the 401(k) Savings Plan&#8217;s matching formula, up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of eligible compensation. All matching contributions and participant contributions vest immediately. Contributions totaled $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">894</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">521</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the years ended December 31, 2024 and 2023, respectively, and have been recorded in the statements of operations.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/710/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 712<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/712/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Principles of Consolidation</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying consolidated financial statements included herein have been prepared in conformity with accounting principles generally accepted in the United States ("GAAP") and under the rules and regulations of the U.S. Securities and Exchange Commission ("SEC"). All intercompany balances and transactions have been eliminated in consolidation.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying consolidated financial statements include but are not limited to advance payments and accruals related to the Company&#8217;s research and development expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock', window );">Off-Balance Sheet Risk and Concentrations of Credit Risk</a></td>
<td class="text"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Off-Balance Sheet Risk and Concentrations of Credit Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist of cash and cash equivalents, which are invested in U.S. treasury-based money market funds. As of December 31, 2023, the Company held available-for-sale securities, which were invested in U.S. treasury securities. These investments matured in 2024. A portion of the Company&#8217;s cash is maintained at two federally insured financial institutions, and account balances may at times exceed federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk. The Company has no off&#8209;balance sheet risk, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investments</span></p><p style="text-indent:27.8pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investments are available-for-sale and carried at estimated fair value. The Company&#8217;s valuations of available-for-sale debt securities are generally derived from independent pricing services based upon quoted prices in active markets for similar securities, with prices adjusted for yield and number of days to maturity, or based on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets. Management determines the appropriate classification of its investments in debt securities at the time of purchase and at the end of each reporting period. Investments with original maturities beyond three months at the date of purchase and which mature at, or less than, twelve months from the balance sheet date are classified as current.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unrealized gains and losses are excluded from earnings and are reported as a component of comprehensive income. The Company periodically evaluates whether declines in fair values of its available-for-sale securities below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors including the severity and duration of the unrealized loss as well as the Company&#8217;s ability and intent to hold the available-for-sale security until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the security or if more likely than not it will be required to sell any available-for-sale securities before recovery of its amortized cost basis. Realized gains and losses and declines in fair value judged to be other-than-temporary, if any, on available-for-sale securities are included in interest and other income, net. The cost of investments sold is based on the specific-identification method. Interest income on investments as well as amortization of discount or premium is included in interest income.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Property, Plant and Equipment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property, plant and equipment are recorded at cost less accumulated depreciation. Cost includes the acquisition costs and all costs necessary to bring the asset to the location and working condition necessary for its intended use. Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the accompanying statements of operations. Expenditures for normal, recurring or periodic repairs and maintenance related to property and equipment are charged to expense as incurred. The cost for planned major maintenance activities, including the related acquisition or construction of assets, is capitalized if it will result in future economic benefits.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Estimated useful lives for property and equipment are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
         <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
          <tr style="visibility:collapse;">
           <td style="width:24.825%;box-sizing:content-box;"></td>
           <td style="width:16.023%;box-sizing:content-box;"></td>
           <td style="width:59.152%;box-sizing:content-box;"></td>
          </tr>
          <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Property and equipment</span></p></td>
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated useful life</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Laboratory equipment</span></p></td>
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> Three years</span></span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> Three years</span></span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment</span></p></td>
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> Three years</span></span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_11fb0b7e-26ca-48c1-8f03-76b57f37f299;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> Lesser of estimated useful life or remaining lease term</span></span></span></p></td>
          </tr>
         </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement</a></td>
<td class="text"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value Measurement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1&#8212;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2&#8212;Inputs (other than quoted prices included in Level 1) that are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has leases related to its facilities used for offices and laboratory space, which are classified as operating leases as well as leases related to its manufacturing arrangements, which are classified as finance leases.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease and its classification based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets and current and non-current lease liabilities, as applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate to discount lease payments. Subsequent to the initial measurement, the Company will continue to account for:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the lease liability at the net present value using the incremental borrowing rate that was in effect as of the lease commencement, lease modification, or transition date, and;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the finance lease and operating lease expense on a straight line basis.</span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leases with terms of 12 months or less are considered short-term leases and right-of-use assets and lease obligations are not recognized. Payments associated with short-term leases are expensed on a straight-line basis over the lease term.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In accordance with ASC 842, components of a lease should be split into three categories: lease components, non-lease components and non-components. The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components. Entities may elect not to separate lease and non-lease components. Rather, entities would account for each lease component and related non-lease component together as a single lease component. The Company has elected to aggregate all lease and non-lease components for each class of underlying assets into a single lease component for real-estate leases and embedded manufacturing arrangements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASC 842 allows for the use of judgment in determining whether the assumed lease term is for a major part of the remaining economic life of the underlying asset and whether the present value of lease payments represents substantially all of the fair value of the underlying asset. The Company applies the guidance in ASC 842-10-55-2 to assist in determining lease classification across its leases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development costs include costs incurred for internal and external research and development activities and are expensed as incurred in the accompanying statements of operations. Research and development costs consist of salaries and benefits, including associated stock-based compensation, and laboratory supplies and facility costs, as well as fees paid to entities that conduct certain research and development and clinical trial activities on the Company&#8217;s behalf.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records accrued liabilities for estimated costs of research and development activities conducted by service providers, which include preclinical studies, contract manufacturing activities and clinical trial activities. The Company records the estimated costs of research and development activities based upon the estimated amount of services provided and in accordance with agreements established with service providers and includes these costs in accrued and other current liabilities in the accompanying balance sheets and within research and development expense in the accompanying statements of operations. Non-refundable advance payments made for goods or services that will be used or rendered for future research and development activities are deferred and capitalized and recognized as expense as the goods are received or the related services are rendered. The Company makes significant judgments and estimates in determining the accrued liabilities and prepaid expenses in each reporting period. As actual costs become known, the Company adjusts its accrued liabilities and prepaid expenses. The Company has not experienced any material differences between accrued costs and actual costs incurred since its inception.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based Compensation</a></td>
<td class="text"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company measures its stock-based awards granted to employees and non-employees based on the estimated fair values of the awards on the respective grant dates. The Company uses the Black-Scholes option-pricing model (Black-Scholes) to estimate the fair value of its stock-based awards. The Company recognizes compensation expense for time-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award. The Company accounts for forfeitures of stock option awards as they occur.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to temporary differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax base, as well as for net operating loss carryforwards and research and development credits, and are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Valuation allowances are established when necessary to reduce deferred tax assets where, based upon the available evidence, the Company concludes that it is more-likely-than-not that the deferred tax assets will not be realized. In evaluating its ability to recover deferred tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. Because of the uncertainty of the realization of deferred tax assets, the Company has recorded a full valuation allowance against its deferred tax assets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reserves are provided for tax benefits for which realization is uncertain. Such benefits are only recognized when the underlying tax position is considered more-likely-than-not to be sustained on examination by a taxing authority, assuming they possess full knowledge of the position and facts. Interest and penalties related to uncertain tax positions are recognized in the provision of income taxes; however, the Company currently has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> interest or penalties related to uncertain income tax benefits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Loss Per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company calculates basic and diluted net loss per share in conformity with the two-class method required for participating securities because the Company had both voting and non-voting common stock outstanding in 2023 and for a portion of 2024. The rights, including the liquidation and dividend rights, of the holders of the voting and non-voting common stock are identical, except with respect to voting. Each share of non-voting common stock may be converted at any time into one share of voting common stock at the option of its holder by providing written notice to the Company, subject to the limitations provided for in the amended and restated certificate of incorporation. As of December 31, 2024, no shares of non-voting common stock remain outstanding.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted average number of shares of common stock, including any pre-funded warrants to purchase shares of common stock that may be outstanding. The undistributed loss for each year is allocated to common stockholders based on the contractual participation rights of the voting and non-voting common stock as if the losses for the year had been distributed. As the liquidation and dividend rights are identical, the undistributed losses are allocated on a proportionate basis. Diluted net loss per share attributable to common stockholders is computed under the if-converted method and assumes that all non-voting common stock has been converted to common stock. Since the Company was in a loss position for all periods presented, the effects of the other potentially dilutive securities are antidilutive.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segments</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (CODM) in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#8217;s CODM is its Chief Executive Officer (CEO). The Company has determined it operates in a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_d4311f9a-8cf2-4c85-b6fa-4408d3790ae7;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">single </span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">operating segment and has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reportable segment. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Refer to Note 8 &#8211; Segment Reporting for further information related to our segment.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Offering Costs</a></td>
<td class="text"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Deferred Offering Costs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After consummation of the equity financing, these costs are recorded as a reduction to the carrying value of stockholders&#8217; equity as a reduction of additional paid-in capital or equity generated as a result of such offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the statements of operations and comprehensive loss.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_EmergingGrowthCompanyStatusPolicyTextBlock', window );">Emerging Growth Company Status</a></td>
<td class="text"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Emerging Growth Company Status</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to December 31, 2024, the Company was an &#8220;emerging growth company&#8221; (EGC) as defined in the Jumpstart Our Business Startups Act, (JOBS Act), and elected to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies until the Company no longer qualifies as an EGC, including using the extended transition period for complying with new or revised accounting standards. As of December 31, 2024, the Company ceased to qualify as an EGC.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the FASB issued Accounting Standards Update, or ASU, 2023-07, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Reporting (Topic 280) &#8211; Improvements to Reportable Segment Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This ASU requires that a public entity provide additional segment disclosures on an interim and annual basis. The amendments in this ASU should be applied retrospectively to all prior periods presented in the consolidated financial statements, unless impracticable. Upon transition, the segment expense categories and amounts disclosed in the prior periods should be based on the significant segment expense categories identified and disclosed in the period of adoption. The Company adopted this ASU for the annual period ended December 31, 2024 and the amendments have been applied retrospectively to all prior periods presented in the financial statements. Refer to Note 8 &#8211; Segment Reporting for further information related to our segment.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Improvements to Income Tax Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. ASU 2023-09 enhances the transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The guidance is effective for public business entities for annual periods beginning after December 15, 2024. Early adoption is permitted. This update is effective beginning with the Company&#8217;s 2025 fiscal year annual reporting period. The Company is currently planning to adopt this guidance when effective and is assessing the impact of the adoption on the Company&#8217;s consolidated financial statements and accompanying footnotes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03, Income Statement (Subtopic 220-40): Reporting Comprehensive Income-Expense Disaggregation Disclosures. ASU 2024-03 requires enhanced disclosures about components of expense captions on the face of the income statement. This standard will be effective for fiscal years beginning after December 15, 2026. Early adoption is permitted. ASU 2024-03 applies on a prospective basis for periods beginning after the effective date. However, retrospective application to any or all prior periods presented is permitted. The Company is currently planning to adopt this guidance when effective and is assessing the impact of the adoption on the Company&#8217;s consolidated financial statements and accompanying footnotes.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There have been no other new accounting pronouncements or changes to accounting pronouncements that, if adopted, would have or may have a material impact on the Company&#8217;s consolidated statements or disclosures.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_EmergingGrowthCompanyStatusPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Emerging growth company status.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_EmergingGrowthCompanyStatusPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 12<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policies and methodologies used to estimate the entity's liability for off-balance sheet credit exposures and related charges for those credit exposures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock', window );">Schedule of Estimated Useful Lives for Property and Equipment</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Estimated useful lives for property and equipment are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
         <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
          <tr style="visibility:collapse;">
           <td style="width:24.825%;box-sizing:content-box;"></td>
           <td style="width:16.023%;box-sizing:content-box;"></td>
           <td style="width:59.152%;box-sizing:content-box;"></td>
          </tr>
          <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Property and equipment</span></p></td>
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated useful life</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Laboratory equipment</span></p></td>
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> Three years</span></span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> Three years</span></span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment</span></p></td>
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> Three years</span></span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_11fb0b7e-26ca-48c1-8f03-76b57f37f299;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> Lesser of estimated useful life or remaining lease term</span></span></span></p></td>
          </tr>
         </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of estimated useful lives of property and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Financial Assets Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables present information about the Company&#8217;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values:</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.38%;box-sizing:content-box;"></td>
         <td style="width:1.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Quoted<br/>Prices in<br/>Active Markets<br/>for Identical Assets <br/>(Level 1)</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial assets</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">162,634</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">162,634</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term investments:</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">162,634</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">162,634</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="text-indent:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.38%;box-sizing:content-box;"></td>
         <td style="width:1.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Quoted<br/>Prices in<br/>Active Markets<br/>for Identical Assets<br/>(Level 1)</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial assets</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">180,124</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">180,124</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities - original maturity less than three months</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,371</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_aacb9393-82a1-4484-8aab-edf9ca81d63c;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,371</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_b8a328b1-c384-428d-aa72-eece52e52e47;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term investments:</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,011</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,011</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">240,506</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">180,124</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60,382</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Debt Securities Classified as Available-for-Sale Investments</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the Company records unrealized gains or losses resulting from changes in fair value between measurement dates as a component of other comprehensive income. The Company did not hold any available-for-sale securities as of December 31, 2024:</span><p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:46.218%;box-sizing:content-box;"></td>
         <td style="width:1.321%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.124%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.321%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.124%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.321%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.124%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.321%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.124%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized Cost</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross Unrealized Gains</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross Unrealized Losses</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair value</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial assets</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">743</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">743</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">180,124</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">180,124</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities - original maturity less than three months</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,367</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,371</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Included in cash and cash equivalents</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">193,234</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">193,238</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities - due in one year or less</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Included in short-term investments</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47,976</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,011</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">241,210</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">241,249</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property Plant and Equipment</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property, plant and equipment consists of the following:</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Laboratory equipment</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,663</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,893</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">277</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">277</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">196</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">113</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">113</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property, plant and equipment</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,249</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,336</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: accumulated depreciation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,506</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,795</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property, plant and equipment, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,743</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,541</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock', window );">Schedule of Accrued and Other Current Liabilities</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued and other current liabilities consist of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development services</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,491</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,459</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative services</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">342</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">188</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Compensation expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,315</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,200</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,188</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,887</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Payments for Operating Leases</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future lease payments under the non-cancelable operating and finance leases as of December 31, 2024 are as follows</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:
<br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Finance Leases</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Operating Leases</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,328</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,227</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,792</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,769</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Total undiscounted lease payments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,120</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,996</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less imputed interest</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">890</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">626</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Total lease liability</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,230</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,370</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Schedule of Profit and Loss From Segments</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For additional information on the year over year change of segment expenses refer to Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:57.12%;box-sizing:content-box;"></td>
         <td style="width:2.1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:17.34%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2.1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:17.34%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
         <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development expenses:</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,239</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,375</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Clinical trials</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,286</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,302</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Development services</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,417</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,486</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Manufacturing of preclinical and clinical supplies</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,523</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,498</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License of intellectual property</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,523</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,383</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other research and development costs </span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,215</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,380</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administration expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,938</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,236</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,025</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,985</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">748</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">115,864</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67,675</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other research and development costs includes costs associated with information technology, travel, medical and scientific symposiums and conferences.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Payments for Operating Leases</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future lease payments under the non-cancelable operating and finance leases as of December 31, 2024 are as follows</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:
<br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Finance Leases</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Operating Leases</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,328</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,227</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,792</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,769</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Total undiscounted lease payments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,120</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,996</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less imputed interest</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">890</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">626</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Total lease liability</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,230</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,370</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Company's Operating and Finance Leases</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company&#8217;s operating and finance leases for the years ended December 31, 2024 and 2023.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:59.224%;box-sizing:content-box;"></td>
         <td style="width:2.001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:16.387%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2.001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:16.387%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the year ended December 31,</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Finance leases</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">748</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,102</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total fixed finance lease cost</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,850</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Variable lease cost</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">930</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total finance lease cost</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,780</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Operating leases</span></p></td>
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fixed lease cost</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,247</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,477</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total fixed operating lease cost</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,247</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,477</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Variable lease cost</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">296</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term lease cost</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">750</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">717</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease cost</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,293</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,259</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash paid in the measurement of lease liabilities</span></p></td>
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating cash flows used for operating leases</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,291</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,456</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating cash flows used for finance leases</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">748</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financing cash flows for finance leases</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">897</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Other information</span></p></td>
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average remaining lease term - finance leases (in years)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.7</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average discount rate - finance leases</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.5</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average remaining lease term - operating leases (in years)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.7</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.5</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average discount rate - operating leases</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.5</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A summary of the stock option activity is presented below:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:33.84%;box-sizing:content-box;"></td>
         <td style="width:1.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.6%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.66%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.120000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.64%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.66%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.120000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Shares</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Exercise Price</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (years)</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of January 1, 2024</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,141,035</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.28</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.6</span></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">117,384</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,476,700</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.13</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">210,695</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.79</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,889</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited/Cancelled</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">175,892</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.04</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2024</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,231,148</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.63</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.4</span></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">989</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options Exercisable at December 31, 2024</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,642,705</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.92</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.1</span></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">966</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Assumptions Used to Estimate Fair Value of Stock Options</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of each award is estimated using Black-Scholes based on the following assumptions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:53.049%;box-sizing:content-box;"></td>
         <td style="width:1.8%;box-sizing:content-box;"></td>
         <td style="width:21.676%;box-sizing:content-box;"></td>
         <td style="width:1.8%;box-sizing:content-box;"></td>
         <td style="width:21.676%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.43</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.60</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.38</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.68</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years&#8212;</span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.2</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years&#8212;</span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.1</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">106</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">111</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock-Based Compensation</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has recorded stock-based compensation in the accompanying statements of operations as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,163</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,520</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,302</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,823</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,465</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,343</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Federal Statutory Income Tax Rate to Company's Effective Income Tax Rate</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The reconciliation of federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:54.151%;box-sizing:content-box;"></td>
         <td style="width:1.78%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:19.144000000000002%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.78%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:19.144000000000002%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected income tax benefit at the federal statutory rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State and local taxes, net of federal benefit</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.7</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.6</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development credit, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.3</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.4</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-deductible items and other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in state and local tax rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.7</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.9</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33.8</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Summary of Principal Components of Company's Deferred Tax Assets</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The principal components of the Company&#8217;s deferred tax assets and liabilities consisted of the following: </span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal, state and local net operating loss carryforwards</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,369</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34,534</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized research and development costs</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,646</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,830</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development tax credits</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,296</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,192</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation deductions</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,919</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,066</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License fee deductions</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">221</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">240</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,607</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,482</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,603</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,665</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gross deferred tax assets</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">114,661</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74,009</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: valuation allowance</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">110,723</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72,560</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,938</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,449</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,938</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,449</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred tax assets</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Earnings Per Share</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Diluted net loss per share is calculated using the if-converted method, which assumes conversion of all non-voting common stock to voting common stock.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.4%;box-sizing:content-box;"></td>
         <td style="width:1.92%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.88%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.92%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.88%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Voting common stock</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Non-voting common stock</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Basic net loss per share:</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;text-indent:5pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Allocation of undistributed losses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">114,728</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,136</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;text-indent:5pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average number of shares used in basic per share computation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,038,726</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">485,378</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share, basic</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.34</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.34</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Diluted net loss per share:</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;text-indent:5pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Allocation of undistributed losses for basic computation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">114,728</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,136</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reallocation of undistributed losses as a result of conversion of<br/>&#160;&#160;&#160;&#160;&#160;non-voting to voting common shares</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,136</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Allocation of undistributed losses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">115,864</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,136</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;text-indent:5pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average number of shares used in basic per share computation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,038,726</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">485,378</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Add: conversion of non-voting to voting common shares outstanding</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">485,378</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average number of shares used in diluted per share computation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,524,104</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">485,378</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share, diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.34</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.34</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.4%;box-sizing:content-box;"></td>
         <td style="width:1.92%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.88%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.92%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.88%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31, 2023</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Voting common stock</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Non-voting common stock</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Basic net loss per share:</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;text-indent:5pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Allocation of undistributed losses</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64,776</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,899</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;text-indent:5pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average number of shares used in basic per share computation</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,192,445</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,753,505</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share, basic</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.65</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.65</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Diluted net loss per share:</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;text-indent:5pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Allocation of undistributed losses for basic computation</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64,776</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,899</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reallocation of undistributed losses as a result of conversion of<br/>&#160;&#160;&#160;&#160;&#160;non-voting to voting common shares</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,899</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Allocation of undistributed losses</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67,675</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,899</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;text-indent:5pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average number of shares used in basic per share computation</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,192,445</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,753,505</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Add: conversion of non-voting to voting common shares outstanding</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,753,505</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average number of shares used in diluted per share computation</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,945,950</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,753,505</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share, diluted</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.65</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.65</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Shares Excluded from Calculation of Diluted Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share, as their effect is anti-dilutive:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.967%;box-sizing:content-box;"></td>
         <td style="width:1.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.357%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.357%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options to purchase common stock</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,231,148</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,141,035</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,231,148</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,141,035</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash and cash equivalents and investments</a></td>
<td class="nump">$ 163,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (349,101)<span></span>
</td>
<td class="num">$ (233,237)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Interest or penalties related to uncertain income tax benefits | $</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of Operating Segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reportable segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives for Property and Equipment (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=caba_LaboratoryEquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration', window );">Lesser of estimated useful life or remaining lease term</a></td>
<td class="text">Lesser of estimated useful life or remaining lease term<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482190/360-10-35-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=caba_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=caba_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Financial Assets Measured at Fair Value on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 48,011<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">162,634<span></span>
</td>
<td class="nump">240,506<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">48,011<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">162,634<span></span>
</td>
<td class="nump">180,124<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">162,634<span></span>
</td>
<td class="nump">180,124<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | U.S. Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">162,634<span></span>
</td>
<td class="nump">180,124<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">60,382<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | U.S. Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">48,011<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | U.S. Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Debt Securities Classified as Available-for-Sale Investments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 241,210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">241,249<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">180,124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">180,124<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember', window );">Included in Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">193,234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">193,238<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashMember', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">743<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">743<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateNoteSecuritiesMember', window );">U.S. Treasury securities - original maturity less than three months</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">12,367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">12,371<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. Treasury securities - due in one year or less</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">47,976<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">$ 48,011<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateNoteSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateNoteSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Plant and Equipment - Schedule of Property Plant and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
<td class="nump">$ 8,249<span></span>
</td>
<td class="nump">$ 6,336<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(5,506)<span></span>
</td>
<td class="num">(3,795)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">2,743<span></span>
</td>
<td class="nump">2,541<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
<td class="nump">7,663<span></span>
</td>
<td class="nump">5,893<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
<td class="nump">277<span></span>
</td>
<td class="nump">277<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
<td class="nump">196<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
<td class="nump">$ 113<span></span>
</td>
<td class="nump">$ 113<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 1,711<span></span>
</td>
<td class="nump">$ 1,426<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued and Other Current Liabilities - Schedule of Accrued and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_AccruedResearchAndDevelopmentServicesCurrent', window );">Research and development services</a></td>
<td class="nump">$ 3,491<span></span>
</td>
<td class="nump">$ 2,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_AccruedGeneralAndAdministrativeServicesCurrent', window );">General and administrative services</a></td>
<td class="nump">342<span></span>
</td>
<td class="nump">188<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation expense</a></td>
<td class="nump">8,315<span></span>
</td>
<td class="nump">5,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">$ 12,188<span></span>
</td>
<td class="nump">$ 7,887<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_AccruedGeneralAndAdministrativeServicesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued general and administrative services current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_AccruedGeneralAndAdministrativeServicesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued liabilities and other liabilities current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_AccruedResearchAndDevelopmentServicesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development services current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_AccruedResearchAndDevelopmentServicesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations, Licensing Agreements and other Agreements - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Aug. 31, 2023</div></th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Oct. 07, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems', window );"><strong>Collaborations, Licensing Agreements And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97,203<span></span>
</td>
<td class="nump">$ 55,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_UpfrontPayment', window );">Upfront license fee</a></td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=caba_LicenseAgreementMember', window );">License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems', window );"><strong>Collaborations, Licensing Agreements And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Obligation to be paid</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_PaymentOfObligationTerm', window );">Payment term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_LicenseMaintenanceFee', window );">License maintenance fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_MilestonePayments', window );">Total milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_CollaborativeAgreementPaymentsDue', window );">Amounts due to agreement</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=caba_SponsoredResearchAgreementsMember', window );">Sponsored Research Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems', window );"><strong>Collaborations, Licensing Agreements And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Obligation to be paid</a></td>
<td class="nump">12,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=caba_MasterTranslationalResearchServicesAgreementMember', window );">Master Translational Research Services Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems', window );"><strong>Collaborations, Licensing Agreements And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,250<span></span>
</td>
<td class="nump">3,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_RemainingResearchAndDevelopmentExpenseToBeIncurred', window );">Remaining research and development expense to be incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=caba_OxfordBiomedicaMember', window );">Oxford Biomedica</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems', window );"><strong>Collaborations, Licensing Agreements And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Obligation to be paid</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_UpfrontPayment', window );">Upfront license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=caba_NanjingIasoBiotherapeuticsCoLtdMember', window );">IASO Biotherapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems', window );"><strong>Collaborations, Licensing Agreements And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_UpfrontPayment', window );">Upfront license fee</a></td>
<td class="nump">$ 162,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=caba_AutolusHoldingsMember', window );">Autolus Holdings Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems', window );"><strong>Collaborations, Licensing Agreements And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_UpfrontPayment', window );">Upfront license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=caba_AutolusHoldingsMember', window );">Autolus Holdings Member | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems', window );"><strong>Collaborations, Licensing Agreements And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=caba_AutolusHoldingsMember', window );">Autolus Holdings Member | Maximum | License and Service [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems', window );"><strong>Collaborations, Licensing Agreements And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Master Translational Research Services Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems', window );"><strong>Collaborations, Licensing Agreements And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborations licensing agreements and other agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_CollaborativeAgreementPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative agreement payments due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_CollaborativeAgreementPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_LicenseMaintenanceFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License maintenance fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_LicenseMaintenanceFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_PaymentOfObligationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of obligation, term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_PaymentOfObligationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_RemainingResearchAndDevelopmentExpenseToBeIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining research and development expense to be incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_RemainingResearchAndDevelopmentExpenseToBeIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_UpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_UpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentAxis=caba_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentAxis=caba_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentAxis=caba_SponsoredResearchAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentAxis=caba_SponsoredResearchAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentAxis=caba_MasterTranslationalResearchServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentAxis=caba_MasterTranslationalResearchServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentAxis=caba_OxfordBiomedicaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentAxis=caba_OxfordBiomedicaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentAxis=caba_NanjingIasoBiotherapeuticsCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentAxis=caba_NanjingIasoBiotherapeuticsCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentAxis=caba_AutolusHoldingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentAxis=caba_AutolusHoldingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_InitialTermsOfAgreementDescription', window );">Terms agreement description</a></td>
<td class="text">Under the August 2023 work orders, WuXi converted the Company&#8217;s non-dedicated suite to a dedicated suite for GMP manufacturing for the Company&#8217;s rese-cel and MuSK-CAART programs, or the Dedicated Suite, for an initial term of 18 months with two 18-month extensions at the Company&#8217;s sole option on six months' notice prior to the end of the term. In August 2024, the Company sent a notice to WuXi to extend the initial term of the WuXi Agreement by 18 months through August 2026.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 97,203<span></span>
</td>
<td class="nump">$ 55,424<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=caba_Rese-CelAndMuSK-CAARTMember', window );">Rese-Cel and MuSK-CAART [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees', window );">Early termination fee</a></td>
<td class="nump">$ 1,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=caba_DevelopmentAndManufacturingServicesAgreementMember', window );">Wuxi Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_LeaseExpirationMonth', window );">Lease expiration month</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees', window );">Early termination fee</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=caba_LonzaAgreementMember', window );">Lonza Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_PaymentOfObligationTerm', window );">Payment term</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">liability related to agreement</a></td>
<td class="nump">$ 16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_CommitmentsAndContingenciesDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_CommitmentsAndContingenciesDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_InitialTermsOfAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial Terms of Agreement, Description</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_InitialTermsOfAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_LeaseExpirationMonth">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease Expiration Month</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_LeaseExpirationMonth</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_PaymentOfObligationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of obligation, term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_PaymentOfObligationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of early contract termination fees included in liabilities subject to compromise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=caba_Rese-CelAndMuSK-CAARTMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=caba_Rese-CelAndMuSK-CAARTMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentAxis=caba_DevelopmentAndManufacturingServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentAxis=caba_DevelopmentAndManufacturingServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentAxis=caba_LonzaAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentAxis=caba_LonzaAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Future Minimum Payments for Operating Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths', window );">2023</a></td>
<td class="nump">$ 4,227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo', window );">2024</a></td>
<td class="nump">$ 2,769<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Additional Information) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Schedule of Profit and Loss from Segments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and development expenses:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_PersonnelExpenses', window );">Personnel</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 39,239<span></span>
</td>
<td class="nump">$ 22,375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_ClinicalTrials', window );">Clinical trials</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">22,286<span></span>
</td>
<td class="nump">8,302<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_DevelopmentServices', window );">Development Services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,417<span></span>
</td>
<td class="nump">12,486<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_ManufacturingOfPreclinicalAndClinicalSupplies', window );">Manufacturing of preclinical and clinical supplies</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,523<span></span>
</td>
<td class="nump">8,498<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_LicenseOfIntellectualProperty', window );">License of intellectual property</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,523<span></span>
</td>
<td class="nump">2,383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Other research and development costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,215<span></span>
</td>
<td class="nump">1,380<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administration expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">27,938<span></span>
</td>
<td class="nump">19,236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(10,025)<span></span>
</td>
<td class="num">(6,985)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">748<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 115,864<span></span>
</td>
<td class="nump">$ 67,675<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other research and development costs includes costs associated with information technology, travel, medical and scientific symposiums and conferences.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_ClinicalTrials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clinical Trials</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_ClinicalTrials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_DevelopmentServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development Services</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_DevelopmentServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_LicenseOfIntellectualProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License of Intellectual Property</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_LicenseOfIntellectualProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_ManufacturingOfPreclinicalAndClinicalSupplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Manufacturing of Preclinical and Clinical Supplies</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_ManufacturingOfPreclinicalAndClinicalSupplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_PersonnelExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Personnel Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_PersonnelExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 24, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,315<span></span>
</td>
<td class="nump">$ 4,910<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate - operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">9.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Fixed lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,293<span></span>
</td>
<td class="nump">$ 3,259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Additional in fixed undiscounted lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">296<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750<span></span>
</td>
<td class="nump">717<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Total fixed operating lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,247<span></span>
</td>
<td class="nump">$ 2,477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_IncreaseInTheRouAsset', window );">Increase in the ROU asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=caba_WuxiAgreementMember', window );">WuXi Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_TerminationFees', window );">Termination fees</a></td>
<td class="nump">$ 1,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_WorkOrdersTerm', window );">Work orders terms</a></td>
<td class="text">The terms of the August 2023 work orders included both fixed costs and contingent variable costs. The lease commenced October 1, 2023. In 2024, the Company remeasured the lease due to resolution of the contingency related to variable costs and an amendment to the 2023 work order to extend the term of the agreement for an additional 18 months through August 2026 resulting in an increase in the right-of-use asset and lease liability of $10,963. The Company may terminate the Dedicated Suite lease for convenience with six months&#8217; prior written notice and up to a $1,080 termination fee if both the rese-cel and MuSK-CAART work orders are terminated<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_IncreaseInTheLeaseLiability', window );">Increase in the lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=caba_LonzaAgreementMember', window );">Lonza Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Fixed lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_IncreaseInTheLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in the lease liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_IncreaseInTheLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_IncreaseInTheRouAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in the ROU asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_IncreaseInTheRouAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_TerminationFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Termination Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_TerminationFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_WorkOrdersTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Work Orders Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_WorkOrdersTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=caba_WuxiAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=caba_WuxiAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=caba_LonzaAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=caba_LonzaAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Future Minimum Payments for Operating Leases and Finance Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityAbstract', window );"><strong>Finance Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths', window );">2025</a></td>
<td class="nump">$ 6,328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo', window );">2026</a></td>
<td class="nump">3,792<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_FinanceLesseeUndiscountedLeasePayments', window );">Total undiscounted lease payments</a></td>
<td class="nump">10,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(890)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total lease liability</a></td>
<td class="nump">9,230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths', window );">2025</a></td>
<td class="nump">4,227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo', window );">2026</a></td>
<td class="nump">2,769<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_LesseeUndiscountedLeasePayments', window );">Total undiscounted lease payments</a></td>
<td class="nump">6,996<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(626)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease liability</a></td>
<td class="nump">$ 6,370<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_FinanceLesseeUndiscountedLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance Lessee Undiscounted Lease Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_FinanceLesseeUndiscountedLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_LesseeUndiscountedLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee Undiscounted Lease Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_LesseeUndiscountedLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease due in next rolling 12 months following current statement of financial position date. For interim and annual periods when interim period is reported on rolling approach.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Company's operating and finance leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_FinanceLeasesAbstract', window );"><strong>Finance Leases:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest expense</a></td>
<td class="nump">$ 748<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_AmortizationExpense', window );">Amortization expense</a></td>
<td class="nump">3,102<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_TotalFixedFinanceLeaseCost', window );">Total Fixed Finance Lease Cost</a></td>
<td class="nump">3,850<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_VariableLeaseCosts', window );">Variable lease cost</a></td>
<td class="nump">930<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_TotalFinanceLeaseCost', window );">Total finance lease cost</a></td>
<td class="nump">4,780<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_OperatingLeasesAbtract', window );"><strong>Operating Leases:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_FixedLeaseCost', window );">Fixed lease cost</a></td>
<td class="nump">3,247<span></span>
</td>
<td class="nump">2,477<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Total fixed operating lease cost</a></td>
<td class="nump">3,247<span></span>
</td>
<td class="nump">2,477<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease costs</a></td>
<td class="nump">296<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">750<span></span>
</td>
<td class="nump">717<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total operating lease cost</a></td>
<td class="nump">4,293<span></span>
</td>
<td class="nump">3,259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_CashPaidInTheMeasurementOfLeaseLiabilitiesAbstract', window );"><strong>Cash paid in the measurement of lease liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_OperatingCashFlowsUsedForOperatingLeases', window );">Operating cash flows used for operating leases</a></td>
<td class="nump">3,291<span></span>
</td>
<td class="nump">2,456<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_OperatingCashFlowsUsedForFinanceLeases', window );">Operating cash flows used for finance leases</a></td>
<td class="nump">748<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_FinancingCashFlowsUsedForFinanceLeases', window );">Financing cash flows for finance leases</a></td>
<td class="nump">$ 897<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_OtherInformationAbstract', window );"><strong>Other inforamation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term - finance leases (in years)</a></td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate - finance leases</a></td>
<td class="nump">11.50%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term - operating leases (in years)</a></td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate - operating leases</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">9.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_AmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_AmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_CashPaidInTheMeasurementOfLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Paid In The Measurement Of Lease Liabilities [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_CashPaidInTheMeasurementOfLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_FinanceLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance leases [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_FinanceLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_FinancingCashFlowsUsedForFinanceLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financing Cash Flows Used For Finance Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_FinancingCashFlowsUsedForFinanceLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_FixedLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed Lease Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_FixedLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_OperatingCashFlowsUsedForFinanceLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Cash Flows Used For Finance Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_OperatingCashFlowsUsedForFinanceLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_OperatingCashFlowsUsedForOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Cash Flows Used For Operating Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_OperatingCashFlowsUsedForOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_OperatingLeasesAbtract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Leases [Abtract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_OperatingLeasesAbtract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_OtherInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_OtherInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_TotalFinanceLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_TotalFinanceLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_TotalFixedFinanceLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total Fixed Finance Lease Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_TotalFixedFinanceLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_VariableLeaseCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Variable Lease Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_VariableLeaseCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 23, 2019</div></th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>Oct. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jan. 01, 2025</div></th>
<th class="th"><div>May 31, 2024</div></th>
<th class="th"><div>Jan. 01, 2024</div></th>
<th class="th"><div>Jun. 01, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Oct. 30, 2019</div></th>
<th class="th"><div>Jan. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,876,000<span></span>
</td>
<td class="nump">$ 185,495,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockConversionFeatures', window );">Non-voting common stock, terms of conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Each share of the Company&#8217;s non-voting common stock may be converted at any time into one share of common stock at the option of its holder by providing 61 days written notice to the Company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,875,000<span></span>
</td>
<td class="nump">185,202,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Debt issuance commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 252,000<span></span>
</td>
<td class="nump">$ 8,647,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_SharesRemainingAvailableForIssuance', window );">Shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,379,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value of stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.44<span></span>
</td>
<td class="nump">$ 9.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost related to unvested stock-based awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost, weighted average period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=caba_AtTheMarketOfferingSalesAgreementMember', window );">At-The-Market Offering Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issuance, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">258,070<span></span>
</td>
<td class="nump">1,225,000<span></span>
</td>
<td class="nump">4,760,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,746<span></span>
</td>
<td class="nump">$ 5,129<span></span>
</td>
<td class="nump">$ 91,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Debt issuance commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForCommissions', window );">Payment for commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=caba_AtTheMarketOfferingSalesAgreementMember', window );">At-The-Market Offering Sales Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=caba_TwoThousandEighteenStockOptionAndGrantPlanMember', window );">2018 Plan | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Share-based compensation unvested number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,959,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=caba_TwoThousandEighteenStockOptionAndGrantPlanMember', window );">2018 Plan | Maximum | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based compensation, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=caba_TwoThousandEighteenStockOptionAndGrantPlanMember', window );">2018 Plan | Minimum | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based compensation, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=caba_TwoThousandNineteenStockOptionAndIncentivePlanMember', window );">2019 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance</a></td>
<td class="nump">2,342,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_IncreaseInShareReservedPercentage', window );">Increase in share reserved percentage</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=caba_TwoThousandNineteenStockOptionAndIncentivePlanMember', window );">2019 Plan | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,029,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=caba_TwoThousandNineteenStockOptionAndIncentivePlanMember', window );">2019 Plan | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,476,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=caba_TwoThousandNineteenEmployeeStockPurchasePlanMember', window );">2019 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issuance, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">314,259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance</a></td>
<td class="nump">234,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=caba_TwoThousandNineteenEmployeeStockPurchasePlanMember', window );">2019 ESPP | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">234,229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_IncreaseInShareReservedPercentage', window );">Increase in share reserved percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_PercentageOfPayrollDeductionOnEligibleCompensation', window );">Payroll deduction percentage of eligible compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock', window );">Employee stock purchase plan maximum annual rights to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock', window );">Percentage of shares to be purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=caba_MayTwoThousandTwentyThreeFinancingMember', window );">May 2023 Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issuance, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,337,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=caba_MayTwoThousandTwentyThreeFinancingMember', window );">May 2023 Financing | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_AdditionalOptionsToBePurchasedByUnderwriters', window );">Additional options to be purchased by underwriters</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,087,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=caba_December2022FinancingMember', window );">December 2022 Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issuance, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=caba_VotingCommonStockMember', window );">Voting Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,590,481<span></span>
</td>
<td class="nump">143,590,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,590,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=caba_VotingCommonStockMember', window );">Voting Common Stock | 2019 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember', window );">Non-voting Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,409,519<span></span>
</td>
<td class="nump">6,409,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,444,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,409,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=caba_PreFundedWarrantsMember', window );">Pre-funded Warrants | May 2023 Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForUnderwritingExpense', window );">Underwriting discounts and commissions and offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceDecrease', window );">Decrease in exercise price of Warrents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Net proceeds from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=caba_PreFundedWarrantsMember', window );">Pre-funded Warrants | December 2022 Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issuance, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,213,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_PreFundedWarrantsExercised', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,213,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.51999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceDecrease', window );">Decrease in exercise price of Warrents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Net proceeds from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_AdditionalOptionsToBePurchasedByUnderwriters">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Options to be purchased by underwriters</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_AdditionalOptionsToBePurchasedByUnderwriters</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee stock purchase plan maximum annual rights to purchase common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_IncreaseInShareReservedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in share reserved percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_IncreaseInShareReservedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_PercentageOfPayrollDeductionOnEligibleCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of payroll deduction on eligible compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_PercentageOfPayrollDeductionOnEligibleCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of shares purchased at fair market value of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_PreFundedWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pre-funded warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_PreFundedWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_SharesRemainingAvailableForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>shares remaining available for issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_SharesRemainingAvailableForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockConversionFeatures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of common stock conversion feature. Includes, but is not limited to, conversion price; conversion right; timing of right; terms, event or change in circumstance causing contingency to be met or adjustment to conversion price or number of shares; manner of settlement upon conversion; and method of settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockConversionFeatures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for commissions during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForUnderwritingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash paid for expenses incurred during underwriting activities (the process to review insurance applications, evaluate risks, accept or reject applications, and determine the premiums to be charged) for insurance companies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForUnderwritingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantExercisePriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantExercisePriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=caba_AtTheMarketOfferingSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=caba_AtTheMarketOfferingSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=caba_TwoThousandEighteenStockOptionAndGrantPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=caba_TwoThousandEighteenStockOptionAndGrantPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=caba_TwoThousandNineteenStockOptionAndIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=caba_TwoThousandNineteenStockOptionAndIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=caba_TwoThousandNineteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=caba_TwoThousandNineteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=caba_MayTwoThousandTwentyThreeFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=caba_MayTwoThousandTwentyThreeFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=caba_December2022FinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=caba_December2022FinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=caba_VotingCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=caba_VotingCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=caba_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=caba_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Summary of Stock Option Activity (Details) - Employee Stock Option - 2019 Plan - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares, Beginning Balance</a></td>
<td class="nump">8,141,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Shares, Granted</a></td>
<td class="nump">3,476,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Shares, Exercised</a></td>
<td class="num">(210,695)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of shares, Forfeited/Cancelled</a></td>
<td class="num">(175,892)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares, Ending Balance</a></td>
<td class="nump">11,231,148<span></span>
</td>
<td class="nump">8,141,035<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Shares, Options Exercisable</a></td>
<td class="nump">5,642,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Beginning Balance</a></td>
<td class="nump">$ 8.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">16.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="nump">6.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited/Cancelled</a></td>
<td class="nump">15.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Ending Balance</a></td>
<td class="nump">10.63<span></span>
</td>
<td class="nump">$ 8.28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options Exercisable</a></td>
<td class="nump">$ 7.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted Average Remaining Contractual Term (years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (years), Options Outstanding</a></td>
<td class="text">7 years 4 months 24 days<span></span>
</td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (years), Options Exercisable</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Beginning Balance</a></td>
<td class="nump">$ 117,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate Intrinsic Value, Exercised</a></td>
<td class="nump">2,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Ending Balance</a></td>
<td class="nump">989<span></span>
</td>
<td class="nump">$ 117,384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Options Exercisable</a></td>
<td class="nump">$ 966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options outstanding aggregate intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options outstanding weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=caba_TwoThousandNineteenStockOptionAndIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=caba_TwoThousandNineteenStockOptionAndIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Schedule of Assumptions Used to Estimate Fair Value of Stock Options (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">3.43%<span></span>
</td>
<td class="nump">3.38%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">4.60%<span></span>
</td>
<td class="nump">4.68%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">106.00%<span></span>
</td>
<td class="nump">105.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">111.00%<span></span>
</td>
<td class="nump">107.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Summary of Stock-Based Compensation (Details) - Employee Stock Option - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 19,465<span></span>
</td>
<td class="nump">$ 11,343<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">10,163<span></span>
</td>
<td class="nump">5,520<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 9,302<span></span>
</td>
<td class="nump">$ 5,823<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Federal Statutory Income Tax Rate to Company's Effective Income Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Expected income tax benefit at the federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State and local taxes, net of federal benefit</a></td>
<td class="nump">7.70%<span></span>
</td>
<td class="nump">7.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development credit, net</a></td>
<td class="nump">5.30%<span></span>
</td>
<td class="nump">6.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_EffectiveIncomeTaxRateReconciliationNondeductibleItemsAndOther', window );">Non-deductible items and other</a></td>
<td class="num">(1.10%)<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_ChangeInStateAndLocalTaxRate', window );">Change in state and local tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(0.70%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(32.90%)<span></span>
</td>
<td class="num">(33.80%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_ChangeInStateAndLocalTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In State And Local Tax Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_ChangeInStateAndLocalTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_EffectiveIncomeTaxRateReconciliationNondeductibleItemsAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation nondeductible items and other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_EffectiveIncomeTaxRateReconciliationNondeductibleItemsAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Summary of Principal Components of Company's Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Federal, state and local net operating loss carryforwards</a></td>
<td class="nump">$ 44,369<span></span>
</td>
<td class="nump">$ 34,534<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_CapitalizedRDCosts', window );">Capitalized research and development costs</a></td>
<td class="nump">36,646<span></span>
</td>
<td class="nump">19,830<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credits</a></td>
<td class="nump">16,296<span></span>
</td>
<td class="nump">10,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation deductions</a></td>
<td class="nump">9,919<span></span>
</td>
<td class="nump">6,066<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_DeferredTaxAssetsLicenseFeesDeductions', window );">License fee deductions</a></td>
<td class="nump">221<span></span>
</td>
<td class="nump">240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_DeferredTaxAssetsOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">4,607<span></span>
</td>
<td class="nump">1,482<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">2,603<span></span>
</td>
<td class="nump">1,665<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">114,661<span></span>
</td>
<td class="nump">74,009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(110,723)<span></span>
</td>
<td class="num">(72,560)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">3,938<span></span>
</td>
<td class="nump">1,449<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_OperatingLeaseAssets', window );">Operating lease right-of-use assets</a></td>
<td class="num">(3,938)<span></span>
</td>
<td class="num">(1,449)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_CapitalizedRDCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capitalized R&amp;D costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_CapitalizedRDCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_DeferredTaxAssetsLicenseFeesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets license fees deductions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_DeferredTaxAssetsLicenseFeesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_DeferredTaxAssetsOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Operating Lease Liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_DeferredTaxAssetsOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_OperatingLeaseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_OperatingLeaseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="nump">$ 38,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_DeferredTaxAssetsOperatingLossCarryforwardsFederal', window );">Deferred tax assets operating loss carryforwards federal</a></td>
<td class="nump">157,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_DeferredTaxAssetsOperatingLossCarryforwardsState', window );">Deferred tax assets operating loss carryforwards state</a></td>
<td class="nump">181,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_DeferredTaxAssetsOperatingLossCarryforwardsLocal', window );">Deferred tax assets operating loss carryforwards local</a></td>
<td class="nump">88,701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">Deferred tax assets, operating loss carryforwards, not subject to expiration</a></td>
<td class="nump">157,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Deferred tax assets, operating loss carryforwards, subject to expiration</a></td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_OperatingLossCarryforwardsFederalCommencementOfExpirationDate', window );">Operating loss carryforwards federal commencement of expiration date</a></td>
<td class="text">2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_OperatingLossCarryforwardsStateCommencementOfExpirationDate', window );">Operating loss carryforwards state commencement of expiration date</a></td>
<td class="text">2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_OperatingLossCarryforwardsLocalCommencementOfExpirationDate', window );">Operating loss carryforwards local commencement of expiration date</a></td>
<td class="text">2042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credits</a></td>
<td class="nump">$ 16,296<span></span>
</td>
<td class="nump">$ 10,192<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_PercentageOfEligibleTaxPositionsForRecognition', window );">Percentage of eligible tax positions for recognition</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized income tax benefits that would affect effective tax rate</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=caba_FederalMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credits</a></td>
<td class="nump">$ 15,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate', window );">Deferred tax assets tax credit carryforwards commencement of expiration date</a></td>
<td class="text">2038 <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=caba_StateMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credits</a></td>
<td class="nump">$ 612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate', window );">Deferred tax assets tax credit carryforwards commencement of expiration date</a></td>
<td class="text">2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_DeferredTaxAssetsOperatingLossCarryforwardsFederal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets operating loss carryforwards federal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_DeferredTaxAssetsOperatingLossCarryforwardsFederal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_DeferredTaxAssetsOperatingLossCarryforwardsLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets operating loss carryforwards local.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_DeferredTaxAssetsOperatingLossCarryforwardsLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_DeferredTaxAssetsOperatingLossCarryforwardsState">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets operating loss carryforwards state.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_DeferredTaxAssetsOperatingLossCarryforwardsState</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets tax credit carryforwards commencement of expiration date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_IncomeTaxDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_IncomeTaxDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_OperatingLossCarryforwardsFederalCommencementOfExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards federal commencement of expiration date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_OperatingLossCarryforwardsFederalCommencementOfExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_OperatingLossCarryforwardsLocalCommencementOfExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards local commencement of expiration date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_OperatingLossCarryforwardsLocalCommencementOfExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_OperatingLossCarryforwardsStateCommencementOfExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards state commencement of expiration date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_OperatingLossCarryforwardsStateCommencementOfExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_PercentageOfEligibleTaxPositionsForRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of eligible tax positions for recognition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_PercentageOfEligibleTaxPositionsForRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=caba_FederalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=caba_FederalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=caba_StateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=caba_StateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Basic and Diluted Earnings Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares used in basic per share computation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,168,054<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share of voting and non-voting common stock, basic</a></td>
<td class="num">$ (2.34)<span></span>
</td>
<td class="num">$ (1.65)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares used in basic per share computation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,168,054<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share of voting and non-voting common stock, diluted</a></td>
<td class="num">$ (2.34)<span></span>
</td>
<td class="num">$ (1.65)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=caba_VotingCommonStockMember', window );">Voting Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic', window );">Allocation of undistributed losses</a></td>
<td class="num">$ (114,728)<span></span>
</td>
<td class="num">$ (64,776)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares used in basic per share computation</a></td>
<td class="nump">49,038,726<span></span>
</td>
<td class="nump">39,192,445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share of voting and non-voting common stock, basic</a></td>
<td class="num">$ (2.34)<span></span>
</td>
<td class="num">$ (1.65)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic', window );">Allocation of undistributed losses for basic computation</a></td>
<td class="num">$ (114,728)<span></span>
</td>
<td class="num">$ (64,776)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther', window );">Reallocation of undistributed losses as a result of conversion of non-voting to voting common shares</a></td>
<td class="num">(1,136)<span></span>
</td>
<td class="num">(2,899)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted', window );">Allocation of undistributed losses</a></td>
<td class="num">$ (115,864)<span></span>
</td>
<td class="num">$ (67,675)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares used in basic per share computation</a></td>
<td class="nump">49,038,726<span></span>
</td>
<td class="nump">39,192,445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Add: Conversion of non-voting to voting common shares outstanding</a></td>
<td class="nump">485,378<span></span>
</td>
<td class="nump">1,753,505<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares used in diluted per share computation</a></td>
<td class="nump">49,524,104<span></span>
</td>
<td class="nump">40,945,950<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share of voting and non-voting common stock, diluted</a></td>
<td class="num">$ (2.34)<span></span>
</td>
<td class="num">$ (1.65)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember', window );">Non-voting Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic', window );">Allocation of undistributed losses</a></td>
<td class="num">$ (1,136)<span></span>
</td>
<td class="num">$ (2,899)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares used in basic per share computation</a></td>
<td class="nump">485,378<span></span>
</td>
<td class="nump">1,753,505<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share of voting and non-voting common stock, basic</a></td>
<td class="num">$ (2.34)<span></span>
</td>
<td class="num">$ (1.65)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic', window );">Allocation of undistributed losses for basic computation</a></td>
<td class="num">$ (1,136)<span></span>
</td>
<td class="num">$ (2,899)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther', window );">Reallocation of undistributed losses as a result of conversion of non-voting to voting common shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted', window );">Allocation of undistributed losses</a></td>
<td class="num">$ (1,136)<span></span>
</td>
<td class="num">$ (2,899)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares used in basic per share computation</a></td>
<td class="nump">485,378<span></span>
</td>
<td class="nump">1,753,505<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Add: Conversion of non-voting to voting common shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares used in diluted per share computation</a></td>
<td class="nump">485,378<span></span>
</td>
<td class="nump">1,753,505<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share of voting and non-voting common stock, diluted</a></td>
<td class="num">$ (2.34)<span></span>
</td>
<td class="num">$ (1.65)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise of dilutive convertible securities excluding adjustments related to ESOP convertible preferred stock, stock options, and restrictive stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 65<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-65<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 66<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-66<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) allocated to participating securities for the diluted earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 65<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-65<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 66<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-66<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) allocated to common stock as if earnings had been distributed. Excludes distributed earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 66<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-66<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=caba_VotingCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=caba_VotingCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Antidilutive Shares Excluded from Calculation of Diluted Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares have been excluded from calculation of diluted net loss per share</a></td>
<td class="nump">11,231,148<span></span>
</td>
<td class="nump">8,141,035<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options to Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares have been excluded from calculation of diluted net loss per share</a></td>
<td class="nump">11,231,148<span></span>
</td>
<td class="nump">8,141,035<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Additional Information (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>May 31, 2024</div></th>
<th class="th"><div>Oct. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_EarningPerShareBasicAndDilutedLineItems', window );"><strong>Earning Per Share Basic And Diluted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,168,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized shares</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=caba_PreFundedWarrantsMember', window );">Pre-funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_EarningPerShareBasicAndDilutedLineItems', window );"><strong>Earning Per Share Basic And Diluted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember', window );">Non-voting Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_EarningPerShareBasicAndDilutedLineItems', window );"><strong>Earning Per Share Basic And Diluted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common stock outstanding</a></td>
<td class="nump">485,378<span></span>
</td>
<td class="nump">1,753,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized shares</a></td>
<td class="nump">6,409,519<span></span>
</td>
<td class="nump">6,409,519<span></span>
</td>
<td class="nump">1,444,295<span></span>
</td>
<td class="nump">6,409,519<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_EarningPerShareBasicAndDilutedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earning per share basic and diluted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_EarningPerShareBasicAndDilutedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=caba_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=caba_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401 (k) Savings Plan - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Defined contribution plan, contribution amount</a></td>
<td class="nump">$ 894<span></span>
</td>
<td class="nump">$ 521<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SubsequentEvents - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_UpfrontPayment', window );">Upfront Payment</a></td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=caba_AutolusHoldingsMember', window );">Autolus Holdings Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_UpfrontPayment', window );">Upfront Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_UpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_UpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentAxis=caba_AutolusHoldingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentAxis=caba_AutolusHoldingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>79
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( /TY?UI&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( /TY?UHLADPM\@   "L"   1
M9&]C4')O<',O8V]R92YX;6S-DL%JPS ,AE]E^)XH3D@9)LVEHZ<.!BML[&9L
MM36+8V-K)'W[.5F;;FP/L*.EWY\^@1KEA7(!GX+S&,A@O!MMUT>A_)J=B+P
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MNIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_#
M"J5,7K5::0##.'W)$Q+#W(*+"$MX%,O67.!;&B\CUNJTV]U6A&ELH1A'9&!]
M7BQH0-!445IO7R"TY1\S^!7+5(UEHP$35T$FN8BT\OELQ?S:WCYES^DZ'3*!
M;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'T=)(@(+)?90%NDGVH],5"#(-.SJ=
M6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+<!P$X%&[GL*=]&R_I$$)M*-IT&38
M]MJND::JC5-/T_=]W^N;:)P*C5M/TVMWW=..B<:MT'@-OO%/A\.NB<:KT'3K
M:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8<';6S-(#EEXI^G64&MD=N]U!7/!8
M[CF)$?[&Q036:=(9EC1&<IV0!0X -\313%!\KT&VBN#"DM)<D-;/*;50&@B:
MR('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_::L!I^V[F\^3_'/HY)^GD]=-0LYP
MO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR
M([O=]EA]]D]';B/7J<"S(M>41B1%G\@MNN01.+5)#3(3/PB=AIAJ4!P"I DQ
MEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7H5A)VH3X$$8:XIQSYG/1;/L'I4;1
M]E6\W*.76!4!EQC?-*HU+,76>)7 \:V</!T3$LV4"P9!AI<D)A*I.7Y-2!/^
M*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S&L%&KQMUAVC2/'K^!?F<-0H<D1L=
M F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV&G*U%H&V<:F$8%H2QM%X3M*T$?Q9
MK#63/F#([,V1=<[6D0X1DEXW0CYBSHN0$;\>ACA*FNVB<5@$_9Y>PTG!Z(++
M9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'HYI9";V$5FJ?JH<T/J@>,@H%\;D>
M/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y?RY]SZ7ON?0]H=*W-R-]9\'3BUO>
M1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@YG\#L_6@^GO'M^MDDA*^:62TC%I!+
M@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2GD(;;NE3]4J5U^6ON2BX/%ODZ:^A
M=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*]+',<$X>RPP[9SR2';9WH!TU^_9=
M=N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*TU*0;\/YZ<5X&N(YV02Y?9A7;>?8
MT='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#AWE[7YAGE<90-!1M;*PD+$:W8+C7
M\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B?$R,1>APYY=<7^/1DN/;IF6U;J\I
M=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*POFH]M!5.S_Y9K<B?#!%.%@L22&.4
M%Z9*HO,94[[G*TG$53B_13.V$I<8O./FQW%.4[@2=K8/ C*YNSFI>F4Q9Z;R
MWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=WP6#R_7#)1P_E.^=?]%U#KG[VW>/Z
M;I,[2$R<><41 71% B.5' 86%S+D4.Z2D 83 <V4R43P H)DIAR F/H+O?(,
MN2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7<N/O[Y-J=XS7^BR!;814,F35%\I#
MB<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@2\-Z;ITM)__;7M0]M!<]1O.CF> >
MLX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[
MM'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ
M#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'50.4_V]0-:/8--!R1!5XQF;8VH^1.
M"CS<_N\-L,+$CN'MB[\!4$L#!!0    ( /TY?UJ9@_&X/0D  )4W   8
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M%W]@*D"^7U(J7BOJ:EG^E3#^!U!+ P04    " #].7]:^-J?9QL$  "=#@
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M._BM@W_N,+G@$+0.@1':,#.R[HDBBYG@.R2T-:#I&Q,;XPUJ"J;3^*0$_%N
MGUHL.9.\+#*B:(:>%%P@1THBOD)_;J@@.M82$9:A):^@4'*=P9JB+UQ*-$+?
MG^[1^W<?T#M4,/0MYUL)IG+F*J"F/^"F+8V[AH9_@0;VT5?.5"[1KRRCV2F
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M#((-I_TKS *4-0!%"Z'0FC])UVX&N=3-N,A<)%W7@3BM==A<WZ7!/U:?01F
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M_^K]_D3R3?FJ^#V7DJ?EX9I1M8PO&JCO5YS+IY/B[?/#/T#,_@-02P,$%
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MFJ,T6(-N6F+3 V4=<#^7TIP,>\#01I._4$L#!!0    ( /TY?UJQG[\M6@<
M )HB   9    >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;+5:;7/;-A+^WE^!
M46<Z=D>V2%"2E<36C9VD=[F.'8^=]J9S<Q\@$A)Q)0D5 *7XW]\"?(%J4TM9
MU_B#)9#8!P]VL<\"%"^W4OVN4\X-^9IGA;X:I,:LWXY&.DYYSO2Y7/,"[BRE
MRIF!IEJ-]%IQECBC/!O1()B.<B:*P?S27;M7\TM9FDP4_%X17>8Y4T\W/)/;
MJT$X:"X\B%5J[(71_'+-5OR1FU_6]PI:HQ8E$3DOM) %47QY-;@.W]Z,J35P
M/7X5?*MWOA,[E864O]O&I^1J$%A&/..QL1 ,/C;\/<\RBP0\_JA!!^V8UG#W
M>X/^DYL\3&;!-'\OLW^)Q*17@]F )'S)RLP\R.T_>#VAB<6+9:;=?[*M^D9O
M!B0NM9%Y;0P,<E%4G^QK[8@=@UFPQX#6!LX1HVH@Q_(#,VQ^J>26*-L;T.P7
M-U5G#>1$8:/R:!3<%6!GYI_ OPE7Y(MBB2A6Y%HI5JPX^-WHRY&!$6R_45RC
MW51H= ]:1&YE85)-/A8)3_YL/P)F+3W:T+NA*. ''I^3*!P2&M QT2E37".P
M43OKR,%&>V"[9CLDBR?RJ4C$1B0ER[HF7X&.NT%M_KS5:Q;SJP$DB.9JPP?S
M'[X/I\$[A/*XI3S&T.>WS' E6$:^<)5K(I==(>LBC<,^E!DG8;"8G(4MX'W&
M"DT^E,HV3,K)4N@81OZC9 I($&Z#2R"E(#H\7\"5)D)#4LB"6W*R5"01"G)/
M*DU8 ?V72Q%S:)PP;?,&B"1$%*1B,&5GX<GRE)2%78UVT(]?X]3.BUS'YI2P
M1*X-& Q)+A.Q%)8 ] -?B(+9&XS\\/V,TN#=[HQ,/2/F7>1ZA>^L=6T E,]Z
MC(:-%5 WJ=3<C0SS4GQW*I\,S\DXF)VP4^N#![XJ,^;$Y_'LYR'A7V.^-L1-
M7\=*+"HK.UG#%D!@847R[7=W+.?.95^$R=S\+43] 5G.;6PJW.YE #X.3TE7
M:'<Z_8V<_#:Z._V17*]6BJ\L[%WIH@F@CSR&\!O!-7DL%_^%,!(CNU"^>S1\
MPPMR)^+4@/$*[-^G@B\A?H!A)9=\KB+O5JZ+%CFAI^0S+ T[6CBKL_N?9?9$
MFL99U:P7UH3\1GY96PK1)!@&05!+@;VRX$3++'D-D6N[F+I)_,07"I;Y$ZS(
M>F0;^A!"[_C0"W=U>@"?OV\A3V3V5) ;X1;U/70 K2V,<W L>!'78>9Q6LA,
MKIYV7'0G-U5NT? Y-1K45QIJ_LYS=X5!,+R83/\J>I7CVK1OO7;+5)PVSIG8
M87P?>B@E\B-8%=+ Q6W*(2LJ'6C2<0VJ1(2&C#%.@(:V5]$(P] ":4@*O7QR
M9@QB;:NVC3ND*.PCG"[M),5)?'KN$N5CFY?@"1$[.8%:L)326#J0N QFUR$+
M9&W#94PE1E5#VXZ%9BY;K5HH6:Y2YTA1Q%F9-*+*F<J$G:,D,H9LL^RL<-A[
ML<S7&6\RG&4969?@8=A]:#N29EGUY611]4_LBLF$-L\4Y=PM\@?NZI'5!7NG
M$M#8"<CPA1K]V4'@GA.QV2?+0\>.;)7U0='IH4:W82;MBG[C5D0$<,R0+?,A
M/22&L8085;Y]$<X]-,^1\CMIR^_DX#JY(W]51CS?ZE2%%P=<LDQSA-BT)39%
M<>Z>5:\#R>&@?>0N6G(71WFME;E.;CAF'[=9RVUVM.-P?CAN'[\W+;\W1_GN
MMM[_=#'#$?N8A8$_- 1'^P[CUP/;2W#G5!.B2!V;@7_?.O7Y3R<O%.W(G7U(
M/5OZ+8XC->I?S-J?H4+TO#.WV]1.6KC9R]!@;/SQ*,0/,FZOW$D'M]NS1\0X
M^9H1'E<T<'GI 36J1'/$%XX0%_F&17.JZ.2"0SS?/F.\?,T(<8'?]51ST.GD
MAL-$LQGLBYZPQP6AKQ4A+NK^C'2]82*S>ZM.2A7*Q*'8!V*;.1P0X.]RM.D:
MW]>"$)?N#CW[# =M5--0Q"/5@?H208-OH6D4K1#'LO9U@^)U8Y^F]9B]2M.H
MKPL45?#]FM9C]WI-HU[U*2[?1^PU>Q![!(WZ$D!Q*7<4,#7KL7^%FE%? R@N
MUX>J60_,A%[TJ1GURD]QV3Y0S6J40]6,>H6GN#2_>/: Z1B.=:PB>.6GLV^B
M8V@].9:UKQ<4KQ=[=0PW>QX8[%&[KP01OJO?JV(]=@<\D,+X><V/</$^;I?6
M ]HC:I&O 5%/#3A@E]8#\>)1(D9LYR<47+8/%;8>F&C:NTV+? 6(>BK 8<)6
MH^P*6Q@$%Y-IM[!%7NPC7*5?"%O?)@W'.U(F(E\(HNDW^1T,+2_'LO;E(\++
MQSYQZS%[C;CY\A#A!X/]XH;;_9_BY@M!=-Q3)&2[UH/8HVQC7Q?&N+[W;M=Z
M[%_\#(&Q\M5@C OWH;+6 Q/.@CY9&_L:,,8%_$!9JU%Z96VT\[I ;D\K]J4(
M36)9%J9Z<Z"]VKYX<5V];N"[5V]MW#*U$H4F&5^":7!^ 8.KZD6(JF'DVKU\
ML)#&R-Q]33F#[+,=X+[]D:5IV ':UU'F_P-02P,$%     @ _3E_6CRE,S@1
M @  W00  !D   !X;"]W;W)K<VAE971S+W-H965T,3$N>&ULI53;CM,P$/T5
MRT@\H3I)+Z"21&IW0:S$2M4NEP?$@QM/$VM]";:S6?X>VTE#0=T*B9?88\\Y
M<X[C<=YK\V ; (>>I%"VP(US[9H06S4@J9WI%I3?.6@CJ?.AJ8EM#5 605*0
M+$E61%*N<)G'M9TI<]TYP17L#+*=E-3\W(+0?8%3?%RXXW7CP@(I\Y;6< _N
M<[LS/B(3"^,2E.5:(0.' F_2]781\F/"%PZ]/9FCX&2O]4,(;EB!DR (!%0N
M,% _/,(5"!&(O(P?(R>>2@;@Z?S(_CYZ]U[VU,*5%E\Y<TV!WV#$X$ [X>YT
M_P%&/\O 5VEAXQ?U0^YRCE'56:?E"/8*)%?#2)_&<S@!I*MG -D(R*+NH5!4
M>4T=+7.C>V1"MF<+DV@UHKTXKL)/N7?&[W*/<^6-/UX&!GTRE'%5HYT6O.)@
M$54,[8RN@'4&;$Z<+Q8@I!J)MP-Q]@QQFJ%;K5QCT3O%@/U)0+S*26IVE+K-
M+C)>0S5#\_05RI)L<8%O/EF?1[[Y_UE'WSYZ(+IQ(.WW<^<P5%F<KQ*::FU;
M6D&!?==8,(^ RY<OTE7R]H*'Q>1A<8G]GSULF&[=WW]AD'^Y@#,=G--)3JZ<
M!%/'QK*HTIURP^V;5J?>W0Q7]G?ZT/BWU-1<623@X*')[/42(S,TTQ XW<8+
MO-?.MT.<-O[] 1,2_/Y!:W<,0H'I12M_ 5!+ P04    " #].7]:/K2L@X@'
M  #W)@  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6SM6MMNVT@2_96&
M!I@G11*5BS,9VX#M3'8-3!##\6X>@GUHD46QUR2;Z6[:T=_OJ6Y>)%NF[#@#
M[&+U8$NDNJM.W4X5+X>WVES;C,B)[T5>VJ-1YESU;CJU<4:%M!-=48E?4FT*
MZ7!HEE-;&9*)WU3DT_EL]F9:2%6.C@_]N0MS?*AKEZN2+HRP=5%(LSJE7-\>
MC:)1>^)2+3/')Z;'AY5<TF=R_Z@N#(ZFG91$%51:I4MA*#T:G43O3J,#WN!7
M_%/1K5W[+MB4A=;7?'">'(UFC(ARBAV+D/BXH3/*<Y8$'-\:H:-.)V]<_]Y*
M_^"-AS$+:>E,YU]4XK*CT=N12"B5=>XN]>W?J3'H-<N+=6[]?W';K)V-1%Q;
MIXMF,Q 4J@R?\GOCB,=LF#<;YAYW4.11OI=.'A\:?2L,KX8T_N)-];L!3I4<
ME<_.X%>%?>[X;+4@8RFNC7(K<:GLM?@H2\0#GG=C@:72T7(U%K),Q-_T#9E2
MEC$=3AV4LXAIW"@Z#8KF#RB*YN*C+EUFQ1]E0LFF@"E0=]#G+?33^:#$]Q1/
MQ,MH+.:S^:L!>2\[5[ST\E[^7%>(KW]"D#AW5-A_;?-+T/IJNU:NNG>VDC$=
MC5!6ELP-C8Y__25Z,_M]P*97G4VOAJ0/VR0NC([)6K("Y2U.^)M5Y7(LSA/\
MK-*5/V!S_28<B:L,M>^L^'I%WYTXS75\O=7H85CL+!&=3<0&ON;P'DP&T'I?
M?*&QJ)%!1KB,!$?!<N$)G?H3LDZ4$[$N"N4<$9_6-0I72Y/P0:(,^$ ;.Q:9
MO"&ABBKW6BCQ>IC('/Z$%/&&[PR#*GI0E=%+(PLHE4XH"R8 CA)2G!:J<1]\
MYWT:? A$:@DCO"BXW.CBC@X7G#L1GP#YKD+HL'55:<-0%RMQ(XW2M84^4(!7
MX"C.2IWKI2*H5&6<PQF(F<N425Y4TD!%I\OJO&9>Q,I"EPHNZ8(M<S+.;V31
MXPW3FK7C=1MY2Y(@>>TC3/M"@LHEC +1N4QH!,UL((1C;R#<!)MB( 3!RM*Q
MI:T'?$R]@GMNHA2Y[.[8;W2]S$1%\%BBXMX)CJPWU)O@0\4R DJ?'I+A<(VP
M\K!"Q/ .9T@A_ZTWH=]0F>@&.%>R COTYFR#)-'9;KAW(37AP K6DM>%#*YR
MY?GE6\TH=5E*Y&[G%=1#[&J98]NW&C]XX)QP0E;061F%5)OX<LG5-36.9K&R
M1'X BW>B*A,T&8,PIN @X"GK@MW*>';$DD4 2-GTUQ!.KK4:) )'3<1)[C)O
MIJWCK)'GW5IJ!_<YQ$/F^4K(-(40)%A(IEL2B?9K%I0KPGI@QRJ#TB%I=2D7
MV,16X8-S\JXD,,1& JRC$K;C<7@3J64]1R WI"\'@9BFBID=$MD^\ G.CUE1
M@HUCAL=&C(-K'&84_HT_QX*^<Y(1PI9T;N+,\0G1N ^X?/&@6BB7+M050X1X
M&9:N+'>3B<#@@8J#W:H, Y@?9!:8KCS9[8P0H')8QP(DA]$%&$*C$M')BT"S
M'Z1GP\EZ0[OL8=WO']:3TS8^Y=03MYG.*;!1D^(*.#H^]K1KVU17"Y6SW%0'
M-N\*M"D*%K/!\.MNZ-@N</-&P'?3T-667J'6@,$(1K6A_6'2:9M!D)O(U0NG
M7^!C?4W3H(* =@,W#N_!P.F\X'WC4=YP?K76Z\)"-KT1=98I2L6'+ED_I2D8
MQP#%66T,=.9(\BTB#3&'^L0<$L/>;]C+]J&I*ZZ"G9N!,EB*:*$Z&X_? 5)@
M:K6!.(9DM;I]A7,9*HO).#!A2Y]M:(;Z=3/K^.347<MJ *X78Z4=-S>N_PV9
MO',X!;TMJJQ0H($=V"S/N:M??WD[CPY^MQL=8TU"URCND_C5D'/N1:@-;QN"
MQ\!OG=!$]4YEP*Y,@<&W%$CP?]M#?;D0A0YWW_('8O*4RO7.L;A:Y2[/KMXZ
M]<49O$MF>YEOI-.#SKJ+M?%,6N?Y%O:;#,SJK[M9_?5/F=7/,:PNC<_5KQ]R
MN=PZ?P^K<J:F <1O.L1O?CKB'=<-PPKWP___]/ _D'('7<H=/"/EKMA8<>&-
M_<-?90S5R+"F'37RM@/\]JF UU%^ZG*8/=E<=X.;/$'W%?2P$</:=QCQ6V?$
M;T_W>C=TG[3C._K!93^@_]D-Z/?68ME2\2".F#ULVC"F5.9VR+9HUM\"FSW5
MNM.6,MJ)Q:Y%:A>'[5"WGY_W\_-^?M[/S_OY^7'S<[3V+"/Z,2(_ZT="(S[7
MB]Z8RSOQ> ++#V/Y2PARR$OSWDOSIWJI&30\HG.?X9Q+?Z'O!A%N?R;R7\/$
M0T'HGS5%@X]]M@7ADCL_[%J;9W?Z<5C)OF7L6\;_9\OHGX]&SWI JJWJG@IT
M1&@WF._AZY<=JG=<FT7]?:/H63>.'F/#+IX9!K ?VG^@5?0WV:(GWV7;WJ_7
M@OZ,4 ^#V?/B#_+B4"KT-[^BY]S]>DRE7_J(L'/#=#? 7C]V>VRZ]BY206;I
MW[CB.QAUZ<)K2=W9[JVND_ N4[\\O!+V49JE@C4YI=@ZFQR A4QXRRH<.%WY
M-YL6VCE=^*\925 '+\#OJ<94T1RP@NY=M^/_ %!+ P04    " #].7]:EX2:
M-",)  "@%@  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6RM6-N.W+@1
M_16B-]C80&_W=,_XLO;, #/V^@+$R<#V)@]!'BB)DAA3I$Q2W=/[]3E5E#32
MW&($>>G6A56LRZE319WNG?\6:J6BN&Z,#6>+.L;VU7H=\EHU,JQ<JRS>E,XW
M,N+65^O0>B4+%FK,>GMT]'S=2&T7YZ?\[,J?G[HN&FW5E1>A:QKI#Y?*N/W9
M8K,8'GS651WIP?K\M)65^J+B[^V5Q]UZU%+H1MF@G15>E6>+B\VKRQ-:SPO^
MKM4^3*X%>9(Y]XUN/A9GBR,R2!F51](@\;=3;Y0QI AF?.]U+L8M27!Z/6A_
MQ[[#ETP&]<:9?^@BUF>+EPM1J%)V)GYV^P^J]^<9Z<N="?PK]OW:HX7(NQ!=
MTPO#@D;;]"^O^SC\B,"V%]BRW6DCMO*MC/+\U+N]\+0:VNB"765I&*<M)>5+
M]'BK(1?/+V700;A27'D5E(V28G6ZCE!-"]9YK^8RJ=D^H&:S%9^<C740O]E"
M%7,%:]@T&K8=#+O</JKQK<I7XGBS%-NC[<DC^HY'1X]9W_$#^O[F*VGU'^S?
M4KQQ-CBC"YF@88N9_Q2/=]I*FVMIQ!<\5,!A#.*?%UF('DCZUWTA2@:<W&\
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MU.M-OT-82RIZ6C] <=)ERA0_@_DJ]G/=-2[VRJ#K-^D3RMAUB_YXK$/H!CK
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MP,&,OX>FF^A:_@:9N1A=PY?T,4)Y6H#WI<,(WM_0!N-'Z?/_ %!+ P04
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M,N-H 9@>W\/CD<V!-S<4P9.+5B?>=X'  EM5)YMN@@WSMDZL?J1*47&FZ($
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M"H'U!UI9@Y)N[!QH$W64>'Y:&0]O+;L6R* 9V &!E3+?.D$AO-=;5C0A B2
M5 R'+ZG;TE0^]&"+<_RT&4@OO38SJ(- LRZ$%J6!C0MV0RI1 @ 5/6WS@G.!
MDI8KVJYK%VWG =Z8SY/L?;38TF 58$&>%ONYV70MEB&=*RJ$,K90[\1LT*&
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M)1@1#C$7H1^'*'P2.0D1>UK1OU.15^"Y3$5V)HG#NJT$<Q\6R#:C! ;S<M2
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MGSR(;^L%HG53("@R&;(DKK+U@//MX$)UI.T2?TP^))V'ZE_8AXZ01"P/@P+
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MWJ+)I?;UKF$]Z 1@\?P7UY?9\Z?GLUBYE,*^CL/RBG(=;(0LA#60,A,/Z W
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M^-))NY$9UZ'8?X0ZEP@1PGO(KBHCDLWI$3/5 F^X*\!G+5ZAJ/CKF7$]=H!
M=0A#.PYFK#H'A3#-YKC*_9=8VJFAQ5FD:4 .[?0L73GU(78/!.3PXGNE%0]
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M2$IO_@,\ ;_W<-'V?5OSGVN3(^ND!_ [;8'_0 N$%V&^_F]02P,$%     @
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MV"(TF%Q-/:(Z9^DV1C9NFG-IT!O<LD(S!F4#\'XKI3EL;(+!WK._4$L#!!0
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M98UBY"<UM8VTG&G/]C0+KB675"0&X==75[?O0XN"'U=;]G6'?5O!R: 'P@D
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M$<D*E /N$Z.85)R.$#<HSV@=/#6CP2*_JF4@ YA>1 ??/B!R*Q2]$J6^:&H
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M"+JTIHJT:'>TF/1:468K2&%MI8P3Y NZV!P8Q:[2_$#@?U0H+42%ZVTI-^!
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M?$R\62&LH4V/G\@6BT!+5,?*JT%)6K+O8+O)2NXW%? &0K)OI_(QG%#=D2$
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M4V]R?MPJB9C1 GQ?&XR8U0_:H+G6OOX/4$L#!!0    ( /TY?UIP&N4/V!
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M+^B%7J3@!@5 Y'JE*_:1,A"R1'HL4ZOOG;/0;MGQ-=OX6MKW-=WUM1"N)SY
M;,H'@8B#X7 8)+/1TQXA'L# 3E/.P$?=K##/H&85E3B!N@:N"U)4V/ U$#_J
M0A8I[=EQ.]@/"/A_)J;!8# )1E'4.9(,T3L+Y\A"U-"4;8RPKN]SG6+U7)%?
M!:2EO&9[.7=6-M4E.8&8U_!'6)2>MS14Z[W:-CX E:QKFRY1U.@\F66:GLL<
M:HZF72X#=K1])N SY!@@^YV(DQ"KU_ EWA&*Z\7"J@69M "T@'>E2F5P*@77
M_$[,!L%D-!)R#L;@)5F=LL9;=NE'ILO4U 640T8B!4&'Y%HN[AHFU%< E-)I
M\CND#'*.4*".J)5+34G2MT_OU5$CQ<DXF,:CQTSD]+&3?Q2.DIWXS&$G+C2\
ML.0,PD&BZOWH#$!+7<YK#HX'::TDN;L&@F QE#89=[AZBJ-X-ILQ4X?$0R1_
MM:/N]NWX!P5%6>IP(P*!JR#SM^SOZ;E%DTG[8@+"U&[C=R*"RT11W"'1NG$K
M1UD?Y>(I_QHDP6B<_!?]2Z@29[+66_]I8$K0&F=TU(Q+F2%K(X@;\;(F[;1+
MCF47-M 1<BQBFDLP.]=$"PP3^VOD?M@''$*A*\D_.N6G]-5%* >)'G2UU+VH
M7TN=7>)1*M?(XCDSR8>A_!F;N7)#IJ,P03PIU GH'V44:I)8E4N"V&(ND6,V
M,D>]1VDTJ0,-*P4XD)T6B^WO6.L(=Z]269=<L[?B0K_@97.K5*,G@!&.;?"K
M"V"\>N5=D^(!:W,X29YOX005'%K>YRXX2[66J# *;[Q5^-7<FI5+J(Z3#LD
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M7:X$:D+3!JPOE+*;&U*P_1AU^2=02P,$%     @ _3E_6MFAM,5>!0  GA$
M !D   !X;"]W;W)K<VAE971S+W-H965T,C0N>&ULQ5AM;]LV$/[N7T&H0[$"
MBJU7OZ2)@:3IL )K$#1;BV'8!UHZ6T0E4B6I./[W.U*2[=22XV+=^L46)=YS
MS_&>.U*Z6 OY664 FCP6.5>73J9U>3X:J22#@JJA*('CDZ60!=4XE*N1*B70
MU!H5^2CPO/&HH(P[\PM[[T[.+T2E<\;A3A)5%065FVO(Q?K2\9WVQ@>VRK2Y
M,9I?E'0%]Z#_*.\DCD9;E)05P!43G$A87CI7_OEU9.;;"1\9K-7>-3&1+(3X
M; ;OTDO',X0@AT0;!(I_#_ &\MP (8TO#::S=6D,]Z];]%]L[!C+@BIX(_)/
M+-79I3-U2 I+6N7Z@UC_"DT\L<%+1*[L+UG7<T//(4FEM"@:8V10,%[_T\=F
M'?8,IGT&06,06-ZU(\ORAFHZOY!B3:29C6CFPH9JK9$<XR8I]UKB4X9V>GZ+
M>?]-*$7N0)+[C$JX&&G$-4]'28-Q76,$/1A^0-X+KC-%WO(4TJ< (R2T916T
MK*Z#HX@WD Q)Z+LD\(+H"%ZXC3*T>&$/WELJ.>.KO2C)7U<+I26*XN^N@&NX
MJ!O.%,JY*FD"EPY6@@+Y ,[\Y0M_[+T^0C;:DHV.H9^8DN,8?C DASCD]PS(
M&U&4E&](0O.DRJD&963-$D)Y2E*65QI2PM$V-[8EVBIKRSA)!#=M@.D-JE1G
M1".<7HNS)*<XM0"=B10K]4O%)&+@5%)2J5G"2JIQ^8F"I)),,U!#@C5E[3=
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M36B\B*%&:R(G#1?E/C@ZE607%M,L__WA#[@76VDV'FZ5,+,T$# ?IV4/LNQ
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MQ\^U7SJ8CQK=)KX"GJ)L3>A&Y5%Z?&BNN_GZI-Z]4I^%VW"_*%R3:39^<Y&
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M<VEDDV8P3G^XCOK1Q0G)T%-\8$$>G+UR/8;@ 3M<51,^"M-E;+J]+48=Y>%
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M$_!%"*[)%S:J QV@PB Z=,DV"K4C5:>2$VO/]VB+I690EB1IJW>0G'?&IH$
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M[K$OBY8#D279YW LA6.\3R(?Y_U6IJ:/ 7V9<HGMJ8VV9$P%I)0<VYR)S72
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M \ZL</""L@YXOY'2[#<VP##*\[]02P,$%     @ _3E_6B/%VXO3 @  *P8
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M3<,(CM4]/'C $LVV;%,62FG56VYVFTYX436 W^%5&[UA9LN5)1D;@D;GPWX
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MCD>S20BZ?U7Z@U6MW^0K9>E=\&)%#S%JIT#?UTK9YX-S,#SMR_\ 4$L#!!0
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M->C'>(1*M[VY!RU*NS$MA<;]R]YN<>%ETAC@][40NGDP =H5>OX?4$L#!!0
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M['!%%T.4QH#6<R'T=F("=%?-^0]02P,$%     @ _3E_6CYZ^O9:!   10X
M !D   !X;"]W;W)K<VAE971S+W-H965T,S8N>&ULQ5=;;]LV%'[7KR#4H6@
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M#N\\(O0!V,\XN*2=: 7=RW'Q#U!+ P04    " #].7]:6Q1+IH$"   P!@
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MHV,F\P'F_$0(_7J0/VU</5T^_!]02P,$%     @ _3E_6L^]NYF5!    A<
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MYX*R 7B^DM+L%O:"H8L7OP%02P,$%     @ _3E_6F&D:9'/ @  Y <  !D
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MXCA[OE(,\!@GW[8/9_)?4$L#!!0    ( /TY?UH"W0B.H 0  -T2   9
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MM(L3(XN[E.)%BX6]CI@(K45F'Q.@>%0S'?#[3 C]\F(&J&ZTAO\!4$L#!!0
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ME(#I!J@+G&YBTZZT\R,0E[7_YZ )"?Y\K;5[#,(<#'^QXA=02P,$%     @
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M&^BS5,_[@Q)PEX&?FGZD()I$EV@614S/!(G1;9H_3WI>W@94$1;+=V#RY2%
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M,!1^%8M54R>M!9P$0I<@K:VJ36JUJ&FW:P=.$JO&9K9)VK>?#832!K*JVF[
M-OY^CNUSS&0KY(-: VCTF#&NILY:Z_S,=56RAHRH4Y$#-U^60F9$FZY<N2J7
M0-(2E#$7>U[@9H1R)YZ48S,93T2A&>4PDT@564;DTSDPL9TZOK,;N*6KM;8#
M;CS)R0KFH._SF30]MV%):09<4<&1A.74^>J?G?L#"RAG_*2P5:TVLJ$LA'BP
MG>_IU/&L(V"0:$M!S&L#%\"893(^?M>D3J-I@>WVCOVJ#-X$LR *+@3[15.]
MGCIC!Z6P) 73MV+[#>J 1I8O$4R53[2MYWH.2@JE15:#C8.,\NI-'NN%: $P
M[@'@&H!+WY50Z?*2:!)/I-@B:6<;-MLH0RW1QASE=E?F6IJOU.!T? TF)(5.
MT-SL=UHP0&*)K@I=2$ WE-.LR-",/)E]T J90X!^Y"")IGR%:BCA*;JBG/ $
M=D/'EZ )9>H3.D*4H[NU*)29IB:N-I:ML)O4]LXK>[C'WB4DIVC@?T;8PT-T
M/[]$QT>?7M*X)N(F;-R$C4O>00_O2\-=OBK\L!MO<^5,Y22!J6.208'<@!-_
M_. 'WI<#[@:-N\$A]M@$.^KR5*&"$F73;1,' SR>N)L.K6&C-?R;5M"E5:%&
M+:U!&.%NK5&C-3JH=2<T8:C@*56)*+B&%#&[ 2BO3UB7D=&>$=_SL=?M)&B<
M! >=7(-2B&9Y83U0X\1LHNY2#_;43\91CWC8B(=O6(8J<D;)@C*JG[K$PSWQ
M" ]ZQ,>-^/C@R7^=OUVZX_]P]J/&7_2NLQ_MK<40X[![+7SON?IY[SK]-:PM
MA\,@ZI%K%5O_WR= S=GV$D11T./EN0+Z!TO8VU.@YGF1 P'NTW^N<?[A(O?F
M+/"[RE[X.@W<UAUH_R=NB%Q1KHS TL"\T]#XE]45776TR,MK<2&TN63+YMK\
MUH"T$\SWI1!ZU[$W;?.C%/\!4$L#!!0    ( /TY?UJP+6Z!N00  %$4   9
M    >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;*U8;6_B.!#^*U9N=;>5MDWL
M0" <(+5TJUOI5EMM]^6SFQBP-HDYVY3V?OU-7II G!AZXDN;A)G'S\S8\]B>
M[H3\I=:,:?2<)IF:.6NM-Q/75=&:I51=B0W+X)>ED"G5\"I7KMI(1N/"*4U<
MXGF!FU*>.?-I\>U>SJ=BJQ.>L7N)U#9-J7RY88G8S1SLO'[XRE=KG7]PY],-
M7;$'IK]O[B6\N35*S%.6*2XR)-ERYESCR8+XN4-A\8.SG=I[1GDHCT+\RE\^
MQ3/'RQFQA$4ZAZ#P[XDM6)+D2,#CGPK4J<?,'?>?7]'OBN AF$>JV$(D/WFL
MUS-G[*"8+>DVT5_%[B]6!33,\2*1J.(OVE6VGH.BK=(BK9R!0<JS\C]]KA*Q
MYT &/0ZD<B M!QST./B50Y$YMV16A'5+-9U/I=@AF5L#6OY0Y*;PAFAXEI?Q
M04OXE8.?GO_-( <*7:('F"#Q-F%(+-%"I!N:O?RA$$P7237/5HAF,5KRC&81
M0TGI]/Z6:<H3=0'NWQ]NT?MW%^@=XAGZMA9;!0YJZFK@F(_D1A6?FY(/Z>&#
M"?HL,KU6Z&,6L_@0P(7@Z@C):X0WQ(IXRZ(KY.,/B'ADT$%H<;J[;Z'CUPGW
M"SR_!^^NRF&9^$E7ADJ 03= OJXG:D,C-G-@X2HFGY@S__TW''A_=D5W)K"#
M6 =UK ,;^OQ3IAF@:L2>H>THUA5LB1 4"'G/>9J/!N.I^[0?@VGCU18'Q(8U
ML:&5V'4JI.;_TJ*36,B5*,.]@7WLD18[TZB'75"S"ZSLO@E-$W3'GUF,#J8+
M+$RENW@&)L_QT&OQ-(UZ>(YJGB,KSQ]4<OJ85/T 13WD1L:XH=_F9MKT<!O7
MW,8GY/"@8?42'!N##T;C-D/3J(=A6#,,K8W@2]U:+:T@/&<K.!/80;38:X3&
MLU:DG,_V2E00!Q.9#$:M4G18@=&HNQQX3PGQ25,FI]GHWA'"^"3"II6%,&D(
MD[>NOV[%)>;P8=#F:!H%PQZ&C=9AJ[S,'];09R]!!-)C>?2-T4=& ^LRPGU9
M;#0*VT6J+/O)!1^8S8*$?INI:>638=A#M5$M/+2VC 55:[2A/,XW67K-4 I<
MMY+!MEKG^[:2>@*3@B=<<]8]&ZS2^-:><BZTPXPT2HGM4MDTT2C/S1).)0IM
M%:Q@..&TB]J=C@[M)"%N%]2T(H-AT%/01D"Q74'M] ^WVYWD3=TT=T\=1CW2
MA1MUQ79Y+;<E+>(G<AX;N[EQ:'1,TZB/<Z.W^(C@PHJ1L'* )DV+K5\GO;-*
M[KG0#D\^C>82N^;^+$ZQ,)WH$TRT%8.#=WZT;]I<T9HOC8,=M)<71J6ZZ,K0
MD3%QX8K&*"W/<7"BB^E+UU18V)'^;W8:P2=VP3>R$W,5B2WT4EB4S$A+9RZJ
MT[6W/U&O,!ZVYG-E%QZ?SZ21?V*7_U.+V^Z"Q\IK'_4MY3T)*:B0;"5M-AS$
MON$X6M)3)*$:(VS5M%U2OZOT7MC>-+E[ES,IDZOBSDJA@E5YBU%_+>_%;O!D
M45P?M;Y?X\EU<4OD-C#E9=MG*E<\4Q#2$B"]JQ'T>EG>7Y4O6FR**Z!'H;5(
MB\<UHS&3N0'\OA1"O[[D ]2WB//_ %!+ P04    " #].7]:V6?6#:(8   R
MO $ &0   'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6RMW5MSV]:AAN&_@E'W
M=-H9VR+ <VIKQC'.9]0[[<6>?0&3D,0)2:@ ),>=_/@")"5PD= 2D;ZY2"@)
MZUD\2%]P^H"/W_/BU_(^RRKEM\UZ6WZZNJ^JAY^NK\O%?;9)RP_Y0[:M?W*;
M%YNTJK\L[J[+AR)+E[M!F_6U-AA,KC?I:GMU\W'WO;BX^9@_5NO5-HL+I7S<
M;-+BQ\_9.O_^Z4J]>O[&WU=W]U7SC>N;CP_I7?8UJWYYB(OZJ^L79;G:9-MR
ME6^5(KO]=/59_2F939H!NR7^L<J^ET>/E>:E?,OS7YLOG.6GJT'SC+)UMJ@:
M(JW_\Y1]R=;K1JJ?Q[\.Z-7+G,W X\?/NKE[\?6+^9:6V9=\_<_5LKK_=#6[
M4I;9;?JXKOZ>?[>SPPL:-]XB7Y>[?RO?]\M.)U?*XK&L\LUA</T,-JOM_K_I
M;X<WXFB .GIE@'88H)T.&+\R8'@8,#P9,!N\,F!T&#"Z=(;Q8<#X9(#VVH#)
M8<#DTA<]/0R87CI@=A@PNW3 _#!@?CI@^-H'-WC^Y :7SJ&^?-@7?]KJ\\>M
MGGW>KPYY_L#5TT_\]2'/'[EZ]IF_.N3Y0U=//_77ASQ_[.K%G[OZ_,&KNT_^
M>O]WM?NCU-,JO?E8Y-^5HEF^]IH'N[_LW?CZ;W&U;4+H:U74/UW5XZJ;+_EF
M4V?!URI?_*J\5SXOEZLF'-*UXFSW$==$Q5_TK$I7Z_*O]2*_?-65O_S/7S]>
M5_7T#7*].$SU93^5]LI4JA+DV^J^5(SM,EMVC#?DXX=OC3??F%^3 -?U^_;R
MYFG/;][/FE2,%M4'11N^4[2!.N]Z0^3#@_2',E2;T=JP8[1^P>3[X9V3&V]-
M7CP/UT9=;Z9\N)XMI,.MRX=WO7;[\N%:QW!'/MQ-MQ^4P7[XN&.X>_'GUO72
MO<LG[QKNOS'\L1W>]<X%E\_>-3R\?'C7&Q]=_KD-.H;'E_S*#U[]E4\N>/+=
M?S'"G__P)3N'.V_X6G:NT[)4HMM#>OZ?7_]<<:IL4_Y_QY/[>8^-NK%F9?.G
M\B%=9)^NZK7),BN>LJN;/_])G0S^UI4L)*:3F$%B)HE9)&:3F$-B+HEY).:3
M6$!B(8E%)!:36 )A0EJ.7M)R)-.?US3+)BO?*>EC=9\7JW]G2Z6\3^O9NA)3
M"O9-3!+32<P@,7./C7=8LP?BZ48=#_;_?+Q^.H[#BY>TR2?HD)A+8AZ)^206
MD%A(8A&)Q2260)B0=>.7K!M?G'7*JBP?T^TBZTHX*=,WX4A,)S&#Q,P]-CG.
MK<%L.CD/N(X%9^/1?'P><.3S<TC,)3&/Q'P2"T@L)+&(Q&(22R!,"+C)2\!-
MI $7YMOW3WFUVMXI"V&]KLJ*3:GDM_6WMT]9T1RKZ,H]J=XW]TA,E[]N(UW<
M[U=8F]=8W6=*'?4/Z?;'G_\TT]3IWTIEV_W.*)OTA_(M.[PM5;W:FU9*/4ZI
M5IM,66VK7,FW64L+8^M%FZGRA]W.V/JGJZI4[O/U,BN4;S^4AR)_6BV;&2>J
MLDQ_E,KW8E55V;9^,M5JD2DU?O14NP*:? M-$K-(S"8QA\1<$O-(S">Q@,1"
M$HM(+":Q!,*$G)^^Y/Q4FG=QD2^R;%DJMT6^>5F3/0VH=\HVJW:Y]+S (B^K
MSDUZZ71]@Y_$=!(S2,R<GF^HURN\YZNQ5L>"LW&SJ_ULA9=\?@Z)N23FD9A/
M8@&)A206D5A,8@F$"4$X>PG"F30(]>Q;=1QOFTW]1;TVUAER4JIOR)&83F(&
MB9FSLXUU;7P>7-;Y8K/):'H><.1S<TC,)3&/Q'P2"T@L)+&(Q&(22R!,"+CY
M2\#-I0'W=7<41DF?TM4Z_;;.E-N\D.ZZE')]0X[$=!(S2,R<GZ^@#:?SX6!\
MDG+DI#:).23FDIA'8CZ)!206DEA$8C&))1 F1*$Z>,G"YEQ521C^<W?N<K.3
M[BDKTKM,N2O2;?5^F59U+J:K0GE*UX^[S>#]#KK]GKEROUCGN8D_RV?LFY>H
MIJ.:@6KF09L)F?EA-#I)S([%YA_&ZLE:(?K4'%1S4<U#-1_5 E0+42U"M1C5
M$DH30_'H3'%5&HJ_;(MLD=]M=R?MU%O #]FVW)\>WNSM4XILG3:16>7*X_8I
M*YO'NW1\WY1$ZBC]GA;+SLUE^;R]HY'4=%0S4,T\:,<;PV-5&\Y/HY&<U$8U
M!]5<5/-0S4>U -5"5(M0+4:UA-+$"-7:"-7^BPA]IWP_7>]\R(I5OMQMBQ]&
M5J\<49?/W#M$24U'-0/5S#<^,4WYD:5%J<R5S;X[I,YVA]B[#E6C3\Q&-0?5
M7%3S4,U'M0#50E2+4"U&M832Q*!MFSFJ]%3VF\_5^_^]S]X':?%K5BG1[6V=
MH]L[Y6NZSDKE\UV199ML6W7F*%K3034=U0Q4,U'-0C4;U1Q4<U'-0S4?U0)4
M"U$M0K48U1)*$Z.TK>TT7?,2:SD>-"H_24U'-0/53%2S4,U&-0?57%3S4,U'
MM0#50E2+4"U&M832Q/QLJT#J'^@"O9.T'N5>[P1%6T&H9ARTX^/AVG@VF)Z<
MS&-V+*=J6L<)D!T+CJ:3P6P^/ST0A#9^4,U%-0_5?%0+4"U$M0C58E1+*$U,
MM+;[H\I+,/A)X?+Y>B<>V@="->.@"8=LIJ/):=YU+*5J9\=USI>:J]/1Z9F0
MZ MP4,U%-0_5?%0+4"U$M0C58E1+*$V,NK;^HLK[+[U.^Y9;O6,,;;>@FG'0
MA&KU:'J:8N24EGI>;M&&8^TT[-!B"ZJYJ.:AFH]J :J%J!:A6HQJ":6)8==6
M7%1YQR5.?S1'179'F]^*.K3B@FHZJAFH9AXTL<MW>O8W.J6-:@ZJN:CFH9J/
M:@&JA:@6H5J,:@FEB9'8EF)4>2OFLN/(RN]*D/ZVVCQN.K,2;<J@FHYJ!JJ9
MJ&:AFHUJ#JJYJ.:AFH]J :J%J!:A6HQJ":6)%\UNVS7:@#RBK*'-&5334<U
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MA-+$%-7:%)47:F)A+7-_9F.3D]^REZCL+!W*V=[QB'9M4,U -?.@B:N9L[.
M1#LTJ.:@FHMJ'JKYJ!:@6HAJ$:K%J)90FAB0;8=F+#W'_"9(?RC:0!LJYFJ;
M;A>K[5UG'*+5&5334<U -1/5+%2S4<U!-1?5/%3S42U M1#5(E2+42VA-#$V
MV^I,_1 \F>B@4?E):CJJ&:AFHIJ%:C:J.:CFHIJ':CZJ!:@6HEJ$:C&J)90F
MYF=;KQG+ZS6]JX=RKW>"GC<09L/A='QZ;1P=G=9 -1/5+%2S4<U!-1?5/%3S
M42U M1#5(E2+42VA-#$<VX;/6-[P.=\F[W.U7CG>.RG1X@^J&:AFHIJ%:C:J
M.:CFHIJ':CZJ!:@6HEJ$:C&J)90FQFE;_!FCQ9\Q6OQ!-1W5#%0S4<U"-1O5
M'%1S4<U#-1_5 E0+42U"M1C5$DH3\[,M_HSEQ9_/R^6J6=E,UR^7ZSTY@JY\
M^Z$\;I=9\;U855G1O0&/UH'&YZ?RJX-9UP8\VO1!-1/5+%2S4<U!-1?5/%3S
M42U M1#5(E2+42VA-#$QVS[06-X'TK-%MKO">;T5K[UQ9!V]MPZJZ:AFH)J)
M:A:JV:CFH)J+:AZJ^:@6H%J(:A&JQ:B64)J0G9.V*31![ZTS0?M J*:CFH%J
M)JI9J&:CFH-J+JIYJ.:C6H!J(:I%J!:C6D)I8GZVO:&)O#?4^\BZW.N=H&@3
M"-4,5#-1S4(U>W)^[Q]5F\Q.^YX..JN+:AZJ^:@6H%J(:A&JQ:B64)J8C5J;
MC?(VD)"-#\5JD34U]'TV=D8CV@)"-1W5#%0S4<U"-?N@S8ZB<?QAK)T&(]H"
M0C4/U7Q4"U M1+4(U6)42RA-#,:V!321MX#^D5?-64:'?/SZ6FE<KO3.0[0&
MA&H&JIFH9J&:C6H.JKFHYJ&:CVH!JH6H%J%:C&H)I8FYV=: ZH?DSLH1FI^D
MIJ.:@6HFJEFH9J.:@VHNJGFHYJ-:@&HAJD6H%J-:0FEB?K8UH,GE-:!W2OI8
MW>?%ZM_94K:[$BT"H9J.:@:JF9/SRI,Z&H[G@]'LY'JCUN6+VNAS=%#-134/
MU7Q4"U M1+4(U>++?S43:F(QVMH2ST1>XA&C[2$ME*=T_=B]FQ%M[*":CFH&
MJID';7K\RY"]'YQ>;>BRQ6STN3FHYJ*:AVH^J@6H%J):A&HQJB64)J9=V[&9
M2,]![]J!J/RN[&Y5%J_3SIZB7.R=>FC/!M4,5#-1S4(U&]4<5'-1S4,U']4"
M5 M1+4*U&-422A,SM.W93&;HSD2T4(-J.JH9J&:BFH5J-JHYJ.:BFH=J/JH%
MJ!:B6H1J,:HEE";F9]NZF<A;-WUO4";G>@<H6KU!-0/53%2S4,U&-0?57%3S
M4,T_:,?[U8:#W3_B7I( G39$M0C58E1+*$W(QFG;JIG*[[\3YMOW3Y>=Y".7
M^L8BJNFH9J":B6H6JMFHYJ":BVH>JOFH%J!:B&H1JL6HEE":F)UMHV:JDMOE
M4[1/@VHZJAFH9J*:A6HVJCFHYJ*:AVH^J@6H%J):A&HQJB64)N:GUN;GY:V;
M"T_RD8N],Q0MWJ":@6KF03O>C)N,!O.Q.C\Y)G[I@C;Z_!Q4<SM>A#H:C;3Y
MR:%]#YW61[4 U4)4BU MOO1W+J&F%?.J+<-,Y668'F?NR*7>.8468E#-0#7S
MH+UUYLYEB]GH<W-0S44U#]5\5 M0+42U"-5B5$LH34R[ML)2/Y2E75QD[V^;
MBS<NE7^F19%NJU+Y7;GLMF!RNG?\D9J.:@:JF:AFH9J-:@ZJN:CFH9J/:@&J
MA:@6H5J,:@FEB6':]EFF8W17(=IE034=U0Q4,U'-0C4;U1Q4<U'-0S4?U0)4
M"U$M0K48U1)*$_.S+<U,Y:697YXO(MX<J%ZNRD7^V*R/IMNELJBWRE=EN;O\
M>/-U?GN;%<UBV6\/V;9\93\BVJPY:)/C'1AG.YMT=$X#U4Q4LU#-1C4'U5Q4
M\U#-1[4 U4)4BU M1K6$TL3@;/LW4WG_1L\619:6F;+:UH&8%8M5_7A_A;/\
M=K=AG]5!VAF1: WGH!U'I*J=!B1:KD$U$]4L5+-1S4$U%]4\5/-1+4"U$-4B
M5(M1+:$T,2#;<LU4?A.;,*OJ/,P76;8LE=LBW[0Q60?D]\.>S\Z 1'LV!^TX
M(.?#Z?AL)1(MT*":B6H6JMFHYJ":BVH>JOFH%J!:B&H1JL6HEE":F)%M@68J
M+]!T'PKJ<3,;N=\[*M%&#:H9J&:BFH5J-JHYJ.:BFH=J/JH%J!:B6H1J,:HE
ME"8DZJRMW<S0F]G,T.H-JNFH9J":B6H6JMFHYJ":BVH>JOFH%J!:B&H1JL6H
MEE":F)]M]68&W\Q&[O5.4+1\@VH&JIFH9J&:/3N_F<U$4X?3Z>3DI@WHM"ZJ
M>:CFHUJ :B&J1:@6HUI":6(X:FTXRGLU+]OHSWLREYV)B%9I4$U'-0/5S%E'
M6V&7.J<GJ:/3VJCFH)J+:AZJ^:@6H%J(:A&JQ:B64)J8B&US9R9O[KPD8OY8
ME56Z7;ZRGU+.],Y$M+:#:@:JF:AFH9I]T([S>G"Z?H@V>U#-0S4?U0)4"U$M
M0K48U1)*$].P;?;4#R_>>+[@;H=RKG<JDIJ.:@:JF:AFH9I]T(X;E.,/8W4^
MGY]F(SFMBVH>JOFH%J!:B&H1JL6HEE":F(UM46<FO_','S]?4@[W3DFTLX-J
M!JJ9J&:AFGW0WNB9.^BD+JIYJ.:C6H!J(:I%J!:C6D)I8D:V99R9O(SSQT^9
ME,.],Q*]H0VJ&:AFHIJ%:O;LO/PTU,:3TQMGHY.ZJ.:AFH]J :J%J!:A6HQJ
M":7M,_*ZO,^R2D^K].;C)BONLB_9>ETJNQIB<Y;/T7>5(KNMPTG]25>OKL^^
M;ZH_V5W?_ZS^]%EKOG_=\C<?']*[+$B+N]6V5-;9;3W5X$/3Q"Q6=_<O7U3Y
MPZ<K]4KYEE=5OMD]O,_2958T"]0_O\WSZOF+9H+O>?'K[N7<_ =02P,$%
M  @ _3E_6@4MV/_%!   -Q@  !D   !X;"]W;W)K<VAE971S+W-H965T-30N
M>&ULM9EK<]HX%(;_BL:[LY/.--B2;Y %9H"TN_W0;2;9MI\56X GML5*(B3_
M?F5;^!YQ*<F'8!OK/>?1D:S78KRC[(FO"1'@)8E3/C'60FQN3),':Y)@/J ;
MDLIOEI0E6,A3MC+YAA$<YHV2V$26Y9D)CE)C.LZOW;'IF&Y%'*7DC@&^31+,
M7N<DIKN) 8W]A?MHM1;9!7,ZWN 5>2#B^^:.R3.S5 FCA*0\HBE@9#DQ9O!F
M@9RL07['CXCL>.T89"B/E#YE)U_"B6%E&9&8!"*3P/+CF2Q('&=*,H__E*A1
MQLP:UH_WZI]S> GSB#E9T/AG%(KUQ!@:("1+O(W%/=W]3120F^D%-.;Y?[!3
M]UH&"+9<T$0UEADD45I\XA?5$;4&R'VC 5(-4+N!\T8#6S6P<] BLQSK%@L\
M'3.Z RR[6ZIE!WG?Y*TE391F97P03'X;R79BNJ!)(GOS0=#@"5R#AZ*:@"[5
MI6^;O+=G66]'XA5<W1*!HYA_D#=_2C8Q?26D>>LU0!8<@;L89\??'V[!U>\?
MQJ:0R68AS4 E-B\20V\D!A'X2E.QYN!3&I*P*6!*RA(5[5'G2*MX2X(!L.%'
MF1]R>A):'-_<UJ1CESUOYWKV&WK_;)-'PO*>7F-&>%\7%0I.OT(VPV_X!@=D
M8L@IS E[)L;TC]^@9_W9AW<AL0:L4\(Z.O4.[$<P)ZLH3:-T!>98#I6 ]/$7
MHFXNFCV0GJ=#Z$#+=L?F<QU-&_Q,-+=$<T]$^XOA5+2'; 'D=H!LQ_=\RVH!
M:4.>">250-Z)0)]>" LBWH_D=9"N$;2\4;M&VJ!G(ODEDG\D$E=(<@U8DDA6
MR5QD@R^.^^'\+ASTW>$(M>"TX<^$&Y9PPU/KE88')M:PPP4ALB%TABVP[HWM
M&=C(>53F/#HQYV+UX/NQAA_CWL1'G7Q<ST&^U1YMVO!G%@1:U:)J:9_M/W/W
M0$(P>R9,NJ%R!H$[%O571"E>Z%E_*;4F?\U40&UY#_ ?^?1708;UP3= _JC^
MURJ[/J]SN5'%C7Z-6[,T*&D(ZY/2&T"[C:A-X5S$RK5 K4\XC*A=+)1X ](;
M^)TROH=7@959@7JW<I#QR-5#A6F6U!U83AOW/?P+K P,U#N8PR4]N)ZH"$U2
M:^!U!J][PI1NXE3V!>K]RT&<(Y<:%::>JS_HK/SZ9,ZM765LH'_:2G-/LI?W
MK%P+^?K$Y&OR%L?@7\(2</5*,./][V(7,C"J3][##L'*#T&](3JC3ZI!\6TK
MN,#Y@._M*'UH'^1ZP %)\?**'!#BU[Z7N\614OY>RNM1:O90Y;Z@WG[]4@\=
MFC;ZT)["@@56+Y7JG_?P<*CR<$COX6:K%2,K+ CX(GLD2GD4@!\XWO9"HXNZ
MMTNI-<DK]X;T[NU-\B-]FY+W&F\7OCUL+WOZ-,[%K,P:TILU#:;6PRC9^CL(
M&@[;%D8?_%RXRJ8AO4W3P1U<S95VG7#4!;0/5;F9>N6^D-Y]:5(_\A&D M13
M&WE>._^+FBZSM@6;$+;*=Z8Y".@V%<4697FUV/V>PYM%ODG<NCZ#-[-\+]BL
M9(HM]:^8R<G'04R64M(:^+(^K-BE+DX$W>0;O8]4")KDAVN"0\*R&^3W2TK%
M_B0+4/Y6,/T?4$L#!!0    ( /TY?UH7HB'SF0,  )@.   9    >&PO=V]R
M:W-H965T<R]S:&5E=#4U+GAM;,57VV[;.!#]%4(%%BW06C??DK4%V$Z*+;#!
M!C':?5CL R.-;2*BJ)*T'?_]#BE%MEQ)3;L&^F*+U)S#,\,A-3/9"_FD-@":
M//,T4U-GHW5^[;HJW@"GJB=RR/#-2DA.-0[EVE6Y!)I8$$_=P/.&+J<L<Z*)
MG;N7T41L=<HRN)=$;3FG\C"'5.RGCN^\3#RP]4:;"3>:Y'0-2]"?\WN)([=B
M21B'3#&1$0FKJ3/SKQ=^WP"LQ1<&>W7R3(PKCT(\F<&G9.IX1A&D$&M#0?%O
M!PM(4\.$.KZ6I$ZUI@&>/K^P?[3.HS./5,%"I'^S1&^FSM@A":SH-M4/8O\'
ME X-#%\L4F5_R;ZT]1P2;Y46O 2C LZRXI\^EX$X 02#%D!0 H)S0-@""$M
M:!TME%FW;JBFT42*/9'&&MG,@XV-1:,W+#/;N-02WS+$Z6@A.,=H+K6(G\@'
MLL0T2;8I$+$B,X5[FYM@*_)904*T(+=*,XP=D(^42?*%IEMK6L#_*HW?WH"F
M+%7O)JY&B68A-R[ES LY08L</R!W(M,;16ZS!)(Z@8N^50X&+P[.@T[&&XA[
M)/3?D\ +^@V"%J^'AQURPBK>H>4+6_B6&RJ!S*F))\8>3Z.B-I]G4M)L#7A"
M-)D?R*G=/3W8Z=F>RH3\\R=2DD\:N/JW*<#%^OWF]<VM<*UR&L/4P6.O0.[
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M90WP>RZE.4SL!EV?F?P'4$L#!!0    ( /TY?UH?7;>/^0,  +,-   9
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MWLD@[Z\B140@:X#_0)ST5@]#VB%TR,1G]L"T!9P. OYQ/&> 426YX/<B%T:
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M<OXTYGIL>L<KY4]"*;C'.7A<A3D&Y^"1%TM4)!B0!;@.:3P'81:!FS@I&([
MUS#/XFRYK?+Y!K,P3N@7KOST> ,^?_H"/@$+4/&4@C@#3UG,Z!F_R3__M2(%
MY1;II<4X!.&(-9?N7E?NHA9W(0*W)&,K"KYF$8Z:!BR.O0X >@O -3):O,'S
M"^# ,X!LY&H<FAVN[AC<<>I\.*4]I\5>%>Z,9R4165GS$)=!'.MB59ER]:;$
M !C3=3C'DP'O<(KS#1Y,?_T%^O9O.IP]&6N@=FO4KLGZ]$?9;;RVP@W.^?0
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M@*:NJ.!^% 0#OZ!,>/'0Q>8J'LK*<"9@KHBNBH*JEPEPN1EYH;<-/+!5;FS
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MPF ND*S+$HO'<Z!\.W-\YZGAAJP+91K<)*[P&A:@;JNYT#6W<\E)"4P2SI"
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M!3*2V1Z0L ,2#@(YJQ6GM427G.:$K26ZAG()H@_,H-%K_Z@QS=*1S/8 3CN
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MW&,EC'%BM/XU@LD/['X 4$L#!!0    ( /TY?UKL"1 Q,04  (\J   /
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MLN]P"P_[4YFG,R?JG_:#C#BIUTB759Y/8=^MN;8RVWU/N?L6]/Q?4$L#!!0
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M&?7.WZEW'3\/I5Y[OM;X_.^D>CS?6ZZ/ORR_3D[>W@O.Z;:B/O\%4$L#!!0
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M460M4&0M4&0M4&0M4&0M_E/69VN7?QP_///6U-TAGPU_NYJ] 5!+ 0(4 Q0
M   ( /TY?UI&QTU(E0   ,T    0              "  0    !D;V-0<F]P
M<R]A<' N>&UL4$L! A0#%     @ _3E_6BR&3"WR    *P(  !$
M     ( !PP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ _3E_6IE<
MG",0!@  G"<  !,              ( !Y $  'AL+W1H96UE+W1H96UE,2YX
M;6Q02P$"% ,4    " #].7]:F8/QN#T)  "5-P  &               @($E
M"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ _3E_6LE;
MTL4+!@  D!D  !@              ("!F!$  'AL+W=O<FMS:&5E=',O<VAE
M970R+GAM;%!+ 0(4 Q0    ( /TY?UJ'.7K3< ,  %80   8
M  " @=D7  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " #]
M.7]:^-J?9QL$  "=#@  &               @(%_&P  >&PO=V]R:W-H965T
M<R]S:&5E=#0N>&UL4$L! A0#%     @ _3E_6B6)BQ?,!@  ##$  !@
M         ("!T!\  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0
M   ( /TY?UKA(]J/-0(  -8$   8              " @=(F  !X;"]W;W)K
M<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " #].7]:A@[QEEH'  "Y(
M&               @($]*0  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L!
M A0#%     @ _3E_6F:4S ]/ @  I04  !@              ("!S3   'AL
M+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( /TY?UIK\"UR+0(
M %(%   8              " @5(S  !X;"]W;W)K<VAE971S+W-H965T.2YX
M;6Q02P$"% ,4    " #].7]:L9^_+5H'  ":(@  &0              @(&U
M-0  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( /TY?UH\
MI3,X$0(  -T$   9              " @48]  !X;"]W;W)K<VAE971S+W-H
M965T,3$N>&UL4$L! A0#%     @ _3E_6CZTK(.(!P  ]R8  !D
M     ("!CC\  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( /TY?UKES@M7G@(  .H%   9              "
M@:UT  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ _3E_
M6LF&?:")#P  WB\  !D              ("!@G<  'AL+W=O<FMS:&5E=',O
M<VAE970Q."YX;6Q02P$"% ,4    " #].7]:\D$+%>8%    #0  &0
M        @(%"AP  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0
M   ( /TY?UJCI/!]<PD  )(:   9              " @5^-  !X;"]W;W)K
M<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ _3E_6D_'!GNA"   XA8
M !D              ("!"9<  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q0
M2P$"% ,4    " #].7]:<!KE#]@0   ?,0  &0              @('AGP
M>&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( /TY?UHY!"7]
M?P<  )@2   9              " @?"P  !X;"]W;W)K<VAE971S+W-H965T
M,C,N>&UL4$L! A0#%     @ _3E_6MFAM,5>!0  GA$  !D
M ("!IK@  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " #]
M.7]:QR9QQF4#  "*!P  &0              @($[O@  >&PO=V]R:W-H965T
M<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( /TY?UIKR(X'71P  ,I;   9
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M970S,"YX;6Q02P$"% ,4    " #].7]:(\7;B],"   K!@  &0
M    @('ZZP  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    (
M /TY?UH!NI)PV@,  .8'   9              " @03O  !X;"]W;W)K<VAE
M971S+W-H965T,S(N>&UL4$L! A0#%     @ _3E_6K]9&4A;!   3@L  !D
M             ("!%?,  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"
M% ,4    " #].7]:2K2D'UP$  #A"0  &0              @(&G]P  >&PO
M=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( /TY?UJB>@5&= 0
M '8*   9              " @3K\  !X;"]W;W)K<VAE971S+W-H965T,S4N
M>&UL4$L! A0#%     @ _3E_6CYZ^O9:!   10X  !D              ("!
MY0 ! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " #].7]:
M6Q1+IH$"   P!@  &0              @(%V!0$ >&PO=V]R:W-H965T<R]S
M:&5E=#,W+GAM;%!+ 0(4 Q0    ( /TY?UK8/1&?D@(  /X%   9
M      " @2X( 0!X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%
M  @ _3E_6@*7I37H @  2@L  !D              ("!]PH! 'AL+W=O<FMS
M:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " #].7]:G$2D9NX%  !I+@
M&0              @($6#@$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+
M 0(4 Q0    ( /TY?UK/O;N9E00   (7   9              " @3L4 0!X
M;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ _3E_6FP?/)V;
M P  8A$  !D              ("!!QD! 'AL+W=O<FMS:&5E=',O<VAE970T
M,BYX;6Q02P$"% ,4    " #].7]:,SR@^6@"  #1!0  &0
M@('9' $ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( /TY
M?UIAI&F1SP(  .0'   9              " @7@? 0!X;"]W;W)K<VAE971S
M+W-H965T-#0N>&UL4$L! A0#%     @ _3E_6NZ<="#1"@  2)8  !D
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M=#0Y+GAM;%!+ 0(4 Q0    ( /TY?UHF._)#TP4  "0:   9
M  " @94[ 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @
M_3E_6AS-R/[G @  - D  !D              ("!GT$! 'AL+W=O<FMS:&5E
M=',O<VAE970U,2YX;6Q02P$"% ,4    " #].7]:L"UN@;D$  !1%   &0
M            @(&]1 $ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4
M Q0    ( /TY?UK99]8-HA@  #*\ 0 9              " @:U) 0!X;"]W
M;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ _3E_6@4MV/_%!
M-Q@  !D              ("!AF(! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX
M;6Q02P$"% ,4    " #].7]:%Z(A\YD#  "8#@  &0              @(&"
M9P$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( /TY?UJ)
M:)H,NP(   X(   9              " @5)K 0!X;"]W;W)K<VAE971S+W-H
M965T-38N>&UL4$L! A0#%     @ _3E_6GT-9S9L P  <PH  !D
M     ("!1&X! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( /TY?UI:3"84PP,  )$3   9              "
M@?.# 0!X;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @ _3E_
M6FM7(T:P @  U@8  !D              ("![8<! 'AL+W=O<FMS:&5E=',O
M<VAE970V,RYX;6Q02P$"% ,4    " #].7]:EV*VMY<"  "Q"0  &0
M        @('4B@$ >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0
M   ( /TY?UK%=YKQ+P,  /(2   -              "  :*- 0!X;"]S='EL
M97,N>&UL4$L! A0#%     @ _3E_6I>*NQS     $P(   L
M ( !_) ! %]R96QS+RYR96QS4$L! A0#%     @ _3E_6NP)$#$Q!0  CRH
M  \              ( !Y9$! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (
M /TY?UK22;QM$0(  !<F   :              "  4.7 0!X;"]?<F5L<R]W
M;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( /TY?UK B&UTZ0$  'XE   3
M              "  8R9 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !(
- $@ KQ,  *:; 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>164</ContextCount>
  <ElementCount>347</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>53</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100080 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100090 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100100 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995443 - Disclosure - Award Timing Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure</Role>
      <ShortName>Award Timing Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995453 - Disclosure - Cybersecurity Risk Management, Strategy, and Governance</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance</Role>
      <ShortName>Cybersecurity Risk Management, Strategy, and Governance</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995463 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995473 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995483 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995493 - Disclosure - Property, Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipment</Role>
      <ShortName>Property, Plant and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995503 - Disclosure - Accrued and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995513 - Disclosure - Collaborations, Licensing Agreements and other Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreements</Role>
      <ShortName>Collaborations, Licensing Agreements and other Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995523 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995533 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995543 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995553 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995563 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995573 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995583 - Disclosure - 401(k) Savings Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20241231/taxonomy/role/Role_Disclosure401KSavingsPlan</Role>
      <ShortName>401(k) Savings Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995603 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995613 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995623 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurements</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995633 - Disclosure - Property, Plant and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentTables</Role>
      <ShortName>Property, Plant and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipment</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995643 - Disclosure - Accrued and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilities</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995653 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995663 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSegmentInformation</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995673 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeases</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995683 - Disclosure - Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockTables</Role>
      <ShortName>Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStock</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995693 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995703 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShare</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995713 - Disclosure - Basis of Presentation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAdditionalInformationDetails</Role>
      <ShortName>Basis of Presentation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995723 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995733 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives for Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives for Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995743 - Disclosure - Fair Value Measurements - Financial Assets Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Financial Assets Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995763 - Disclosure - Fair Value Measurements - Schedule of Debt Securities Classified as Available-for-Sale Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Debt Securities Classified as Available-for-Sale Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995773 - Disclosure - Property, Plant and Equipment - Schedule of Property Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails</Role>
      <ShortName>Property, Plant and Equipment - Schedule of Property Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995783 - Disclosure - Property, Plant and Equipment - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails</Role>
      <ShortName>Property, Plant and Equipment - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995793 - Disclosure - Accrued and Other Current Liabilities - Schedule of Accrued and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued and Other Current Liabilities - Schedule of Accrued and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995803 - Disclosure - Collaborations, Licensing Agreements and other Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails</Role>
      <ShortName>Collaborations, Licensing Agreements and other Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995813 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995823 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Payments for Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsForOperatingLeasesDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Future Minimum Payments for Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995833 - Disclosure - Segment Information (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails</Role>
      <ShortName>Segment Information (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSegmentInformationTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995843 - Disclosure - Segment Information - Schedule of Profit and Loss from Segments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfProfitAndLossFromSegmentsDetails</Role>
      <ShortName>Segment Information - Schedule of Profit and Loss from Segments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995853 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995863 - Disclosure - Leases - Schedule of Future Minimum Payments for Operating Leases and Finance Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails</Role>
      <ShortName>Leases - Schedule of Future Minimum Payments for Operating Leases and Finance Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>995873 - Disclosure - Leases - Schedule of Company's operating and finance leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails</Role>
      <ShortName>Leases - Schedule of Company's operating and finance leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>995883 - Disclosure - Common Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails</Role>
      <ShortName>Common Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>995893 - Disclosure - Common Stock - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails</Role>
      <ShortName>Common Stock - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>995903 - Disclosure - Common Stock - Schedule of Assumptions Used to Estimate Fair Value of Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsDetails</Role>
      <ShortName>Common Stock - Schedule of Assumptions Used to Estimate Fair Value of Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>995913 - Disclosure - Common Stock - Summary of Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockBasedCompensationDetails</Role>
      <ShortName>Common Stock - Summary of Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>995923 - Disclosure - Income Taxes - Reconciliation of Federal Statutory Income Tax Rate to Company's Effective Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Federal Statutory Income Tax Rate to Company's Effective Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>995933 - Disclosure - Income Taxes - Summary of Principal Components of Company's Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Summary of Principal Components of Company's Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>995943 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>995953 - Disclosure - Net Loss Per Share - Schedule of Basic and Diluted Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Basic and Diluted Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>995963 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Shares Excluded from Calculation of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Antidilutive Shares Excluded from Calculation of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>995973 - Disclosure - Net Loss Per Share - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails</Role>
      <ShortName>Net Loss Per Share - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>995983 - Disclosure - 401 (k) Savings Plan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20241231/taxonomy/role/Role_Disclosure401KSavingsPlanAdditionalInformationDetails</Role>
      <ShortName>401 (k) Savings Plan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cabalettabio.com/20241231/taxonomy/role/Role_Disclosure401KSavingsPlan</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="caba-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>995993 - Disclosure - SubsequentEvents - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSubsequenteventsAdditionalInformationDetails</Role>
      <ShortName>SubsequentEvents - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="caba-20241231.htm">caba-20241231.htm</File>
    <File>caba-20241231.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img63895535_0.jpg</File>
    <File>img63895535_1.jpg</File>
    <File>img63895535_2.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="536">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="14">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="32">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>86
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "caba-20241231.htm": {
   "nsprefix": "caba",
   "nsuri": "http://www.cabalettabio.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "caba-20241231.htm"
     ]
    },
    "schema": {
     "local": [
      "caba-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    }
   },
   "keyStandard": 286,
   "keyCustom": 61,
   "axisStandard": 19,
   "axisCustom": 0,
   "memberStandard": 25,
   "memberCustom": 25,
   "hidden": {
    "total": 15,
    "http://xbrl.sec.gov/dei/2024": 4,
    "http://fasb.org/us-gaap/2024": 7,
    "http://xbrl.sec.gov/ecd/2024": 4
   },
   "contextCount": 164,
   "entityCount": 1,
   "segmentCount": 53,
   "elementCount": 663,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 536,
    "http://xbrl.sec.gov/dei/2024": 39,
    "http://xbrl.sec.gov/ecd/2024": 32,
    "http://xbrl.sec.gov/cyd/2024": 14
   },
   "report": {
    "R1": {
     "role": "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets",
     "longName": "100010 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_fbb2803e-11f2-411e-bc43-c725c0d90cee",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fbb2803e-11f2-411e-bc43-c725c0d90cee",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
     "longName": "100040 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_fbb2803e-11f2-411e-bc43-c725c0d90cee",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fbb2803e-11f2-411e-bc43-c725c0d90cee",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "longName": "100060 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "us-gaap:OperatingExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
     "longName": "100080 - Statement - Consolidated Statements of Stockholders' Equity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_2c83b4bd-a25b-4fdd-8a75-b19f7b147a93",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2c83b4bd-a25b-4fdd-8a75-b19f7b147a93",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical",
     "longName": "100090 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "shortName": "Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R7": {
     "role": "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
     "longName": "100100 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
     "longName": "995443 - Disclosure - Award Timing Disclosure",
     "shortName": "Award Timing Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "ecd:AwardTmgMnpiCnsdrdFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "ecd:AwardTmgMnpiCnsdrdFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_438de52d-5f54-466c-a0d0-ff8e3b765da2",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_438de52d-5f54-466c-a0d0-ff8e3b765da2",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance",
     "longName": "995453 - Disclosure - Cybersecurity Risk Management, Strategy, and Governance",
     "shortName": "Cybersecurity Risk Management, Strategy, and Governance",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentation",
     "longName": "995463 - Disclosure - Basis of Presentation",
     "shortName": "Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies",
     "longName": "995473 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurements",
     "longName": "995483 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipment",
     "longName": "995493 - Disclosure - Property, Plant and Equipment",
     "shortName": "Property, Plant and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilities",
     "longName": "995503 - Disclosure - Accrued and Other Current Liabilities",
     "shortName": "Accrued and Other Current Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreements",
     "longName": "995513 - Disclosure - Collaborations, Licensing Agreements and other Agreements",
     "shortName": "Collaborations, Licensing Agreements and other Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "caba:CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "caba:CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSegmentInformation",
     "longName": "995523 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies",
     "longName": "995533 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeases",
     "longName": "995543 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStock",
     "longName": "995553 - Disclosure - Common Stock",
     "shortName": "Common Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes",
     "longName": "995563 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShare",
     "longName": "995573 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.cabalettabio.com/20241231/taxonomy/role/Role_Disclosure401KSavingsPlan",
     "longName": "995583 - Disclosure - 401(k) Savings Plan",
     "shortName": "401(k) Savings Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "995603 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "longName": "995613 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "caba:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "caba:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables",
     "longName": "995623 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentTables",
     "longName": "995633 - Disclosure - Property, Plant and Equipment (Tables)",
     "shortName": "Property, Plant and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesTables",
     "longName": "995643 - Disclosure - Accrued and Other Current Liabilities (Tables)",
     "shortName": "Accrued and Other Current Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "caba:AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "caba:AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables",
     "longName": "995653 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R32": {
     "role": "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSegmentInformationTables",
     "longName": "995663 - Disclosure - Segment Information (Tables)",
     "shortName": "Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesTables",
     "longName": "995673 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockTables",
     "longName": "995683 - Disclosure - Common Stock (Tables)",
     "shortName": "Common Stock (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables",
     "longName": "995693 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareTables",
     "longName": "995703 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAdditionalInformationDetails",
     "longName": "995713 - Disclosure - Basis of Presentation - Additional Information (Details)",
     "shortName": "Basis of Presentation - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_fbb2803e-11f2-411e-bc43-c725c0d90cee",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fbb2803e-11f2-411e-bc43-c725c0d90cee",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "longName": "995723 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_fbb2803e-11f2-411e-bc43-c725c0d90cee",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fbb2803e-11f2-411e-bc43-c725c0d90cee",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails",
     "longName": "995733 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives for Property and Equipment (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives for Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_540f0e6d-d008-4d25-b45d-014688c83725",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "caba:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_540f0e6d-d008-4d25-b45d-014688c83725",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "caba:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails",
     "longName": "995743 - Disclosure - Fair Value Measurements - Financial Assets Measured at Fair Value on Recurring Basis (Details)",
     "shortName": "Fair Value Measurements - Financial Assets Measured at Fair Value on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_fbb2803e-11f2-411e-bc43-c725c0d90cee",
      "name": "us-gaap:ShortTermInvestments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3cf6ca28-81b1-4647-b307-30db6e6d90f1",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails",
     "longName": "995763 - Disclosure - Fair Value Measurements - Schedule of Debt Securities Classified as Available-for-Sale Investments (Details)",
     "shortName": "Fair Value Measurements - Schedule of Debt Securities Classified as Available-for-Sale Investments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_f1261fee-7643-4642-aa6e-b30416d960fc",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f1261fee-7643-4642-aa6e-b30416d960fc",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails",
     "longName": "995773 - Disclosure - Property, Plant and Equipment - Schedule of Property Plant and Equipment (Details)",
     "shortName": "Property, Plant and Equipment - Schedule of Property Plant and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_fbb2803e-11f2-411e-bc43-c725c0d90cee",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fbb2803e-11f2-411e-bc43-c725c0d90cee",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails",
     "longName": "995783 - Disclosure - Property, Plant and Equipment - Additional Information (Details)",
     "shortName": "Property, Plant and Equipment - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "us-gaap:Depreciation",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R44": {
     "role": "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails",
     "longName": "995793 - Disclosure - Accrued and Other Current Liabilities - Schedule of Accrued and Other Current Liabilities (Details)",
     "shortName": "Accrued and Other Current Liabilities - Schedule of Accrued and Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_fbb2803e-11f2-411e-bc43-c725c0d90cee",
      "name": "caba:AccruedResearchAndDevelopmentServicesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "caba:AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fbb2803e-11f2-411e-bc43-c725c0d90cee",
      "name": "caba:AccruedResearchAndDevelopmentServicesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "caba:AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails",
     "longName": "995803 - Disclosure - Collaborations, Licensing Agreements and other Agreements - Additional Information (Details)",
     "shortName": "Collaborations, Licensing Agreements and other Agreements - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9cdb36a0-6755-4f07-b415-12eeed80884e",
      "name": "caba:PaymentOfObligationTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "caba:CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "longName": "995813 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "caba:InitialTermsOfAgreementDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "caba:InitialTermsOfAgreementDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsForOperatingLeasesDetails",
     "longName": "995823 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Payments for Operating Leases (Details)",
     "shortName": "Commitments and Contingencies - Schedule of Future Minimum Payments for Operating Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_fbb2803e-11f2-411e-bc43-c725c0d90cee",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R48": {
     "role": "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails",
     "longName": "995833 - Disclosure - Segment Information (Additional Information) (Details)",
     "shortName": "Segment Information (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R49": {
     "role": "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfProfitAndLossFromSegmentsDetails",
     "longName": "995843 - Disclosure - Segment Information - Schedule of Profit and Loss from Segments (Details)",
     "shortName": "Segment Information - Schedule of Profit and Loss from Segments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "caba:PersonnelExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "caba:PersonnelExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
     "longName": "995853 - Disclosure - Leases - Additional Information (Details)",
     "shortName": "Leases - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_fbb2803e-11f2-411e-bc43-c725c0d90cee",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "caba:IncreaseInTheRouAsset",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails",
     "longName": "995863 - Disclosure - Leases - Schedule of Future Minimum Payments for Operating Leases and Finance Leases (Details)",
     "shortName": "Leases - Schedule of Future Minimum Payments for Operating Leases and Finance Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_fbb2803e-11f2-411e-bc43-c725c0d90cee",
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fbb2803e-11f2-411e-bc43-c725c0d90cee",
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails",
     "longName": "995873 - Disclosure - Leases - Schedule of Company's operating and finance leases (Details)",
     "shortName": "Leases - Schedule of Company's operating and finance leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "us-gaap:FinanceLeaseInterestExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "us-gaap:FinanceLeaseInterestExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
     "longName": "995883 - Disclosure - Common Stock - Additional Information (Details)",
     "shortName": "Common Stock - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_fbb2803e-11f2-411e-bc43-c725c0d90cee",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_42bda966-2bcc-4366-9ccc-53d8a69b796d",
      "name": "us-gaap:CommonStockConversionFeatures",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails",
     "longName": "995893 - Disclosure - Common Stock - Summary of Stock Option Activity (Details)",
     "shortName": "Common Stock - Summary of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_fdc8bd52-362d-49f3-9e45-6677140ad037",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7bbcce38-fe4c-402a-abef-f39d1a8317bc",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsDetails",
     "longName": "995903 - Disclosure - Common Stock - Schedule of Assumptions Used to Estimate Fair Value of Stock Options (Details)",
     "shortName": "Common Stock - Schedule of Assumptions Used to Estimate Fair Value of Stock Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockBasedCompensationDetails",
     "longName": "995913 - Disclosure - Common Stock - Summary of Stock-Based Compensation (Details)",
     "shortName": "Common Stock - Summary of Stock-Based Compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "C_50ec53a6-211e-4704-8e25-521e6deb405e",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_50ec53a6-211e-4704-8e25-521e6deb405e",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails",
     "longName": "995923 - Disclosure - Income Taxes - Reconciliation of Federal Statutory Income Tax Rate to Company's Effective Income Tax Rate (Details)",
     "shortName": "Income Taxes - Reconciliation of Federal Statutory Income Tax Rate to Company's Effective Income Tax Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails",
     "longName": "995933 - Disclosure - Income Taxes - Summary of Principal Components of Company's Deferred Tax Assets (Details)",
     "shortName": "Income Taxes - Summary of Principal Components of Company's Deferred Tax Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "C_fbb2803e-11f2-411e-bc43-c725c0d90cee",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fbb2803e-11f2-411e-bc43-c725c0d90cee",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
     "longName": "995943 - Disclosure - Income Taxes - Additional Information (Details)",
     "shortName": "Income Taxes - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails",
     "longName": "995953 - Disclosure - Net Loss Per Share - Schedule of Basic and Diluted Earnings Per Share (Details)",
     "shortName": "Net Loss Per Share - Schedule of Basic and Diluted Earnings Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "C_a1e38241-900a-43de-9175-5ee71906e75a",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b76590bb-7198-4431-94bb-7578a594bad1",
      "name": "us-gaap:UndistributedEarningsLossAvailableToCommonShareholdersBasic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails",
     "longName": "995963 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Shares Excluded from Calculation of Diluted Net Loss Per Share (Details)",
     "shortName": "Net Loss Per Share - Schedule of Antidilutive Shares Excluded from Calculation of Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails",
     "longName": "995973 - Disclosure - Net Loss Per Share - Additional Information (Details)",
     "shortName": "Net Loss Per Share - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "C_a1e38241-900a-43de-9175-5ee71906e75a",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_50b61005-316a-440c-b7d7-051b2270374c",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.cabalettabio.com/20241231/taxonomy/role/Role_Disclosure401KSavingsPlanAdditionalInformationDetails",
     "longName": "995983 - Disclosure - 401 (k) Savings Plan - Additional Information (Details)",
     "shortName": "401 (k) Savings Plan - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_526c68e0-6d1b-4b6d-885c-8856f7637c5c",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSubsequenteventsAdditionalInformationDetails",
     "longName": "995993 - Disclosure - SubsequentEvents - Additional Information (Details)",
     "shortName": "SubsequentEvents - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "C_fbb2803e-11f2-411e-bc43-c725c0d90cee",
      "name": "caba:UpfrontPayment",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity of Counterparty, Type [Axis]",
        "terseLabel": "Legal Entity of Counterparty, Type",
        "documentation": "Information by legal entity of counterparty. A counterparty is the other party that participates in a financial transaction."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r65"
     ]
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "Accrued and Other Current Liabilities",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r695"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Amortization of discount on investments",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Amortization of (discount) premium on investments",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_AccretionExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccretionExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accretion Expense",
        "terseLabel": "Accretion of lease liabilities",
        "verboseLabel": "Accretion of operating lease liabilities",
        "documentation": "Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations."
       }
      }
     },
     "auth_ref": [
      "r670",
      "r883"
     ]
    },
    "caba_AccruedAndOtherCurrentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "AccruedAndOtherCurrentLiabilitiesMember",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued and other current liabilities.",
        "label": "Accrued And Other Current Liabilities [Member]",
        "terseLabel": "Accrued and Other Current Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "caba_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued expenses and other current liabilities.",
        "label": "Accrued Expenses And Other Current Liabilities Table [Text Block]",
        "terseLabel": "Schedule of Accrued and Other Current Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "caba_AccruedGeneralAndAdministrativeServicesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "AccruedGeneralAndAdministrativeServicesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued general and administrative services current.",
        "label": "Accrued General And Administrative Services Current",
        "terseLabel": "General and administrative services"
       }
      }
     },
     "auth_ref": []
    },
    "caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued liabilities and other liabilities current.",
        "label": "Accrued Liabilities And Other Liabilities Current",
        "terseLabel": "Accrued and other current liabilities",
        "totalLabel": "Accrued and other current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "caba_AccruedResearchAndDevelopmentServicesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "AccruedResearchAndDevelopmentServicesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development services current.",
        "label": "Accrued Research And Development Services Current",
        "terseLabel": "Research and development services"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r121",
      "r511"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total",
        "terseLabel": "Accumulated other comprehensive income",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r14",
      "r66",
      "r127",
      "r507",
      "r536",
      "r537"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "caba_AdditionalOptionsToBePurchasedByUnderwriters": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "AdditionalOptionsToBePurchasedByUnderwriters",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional options to be purchased by underwriters",
        "label": "Additional Options to be purchased by underwriters",
        "documentation": "Additional Options to be purchased by underwriters"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r551",
      "r850",
      "r851",
      "r852",
      "r853",
      "r926",
      "r986"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation",
        "totalLabel": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42",
      "r307"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "caba_AdvancePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "AdvancePayments",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advance payments.",
        "label": "Advance Payments",
        "terseLabel": "Advance payments"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r734",
      "r745",
      "r755",
      "r788"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r737",
      "r748",
      "r758",
      "r791"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "caba_AgreementWithContractManufacturingOrganizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "AgreementWithContractManufacturingOrganizationMember",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement with contract manufacturing organization.",
        "label": "Agreement With Contract Manufacturing Organization [Member]",
        "terseLabel": "Agreement with Contract Manufacturing Organization"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r738",
      "r749",
      "r759",
      "r783",
      "r792",
      "r796",
      "r804"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense",
        "verboseLabel": "Stock-based compensation",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r344"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "caba_AmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "AmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails": {
       "parentTag": "caba_TotalFixedFinanceLeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization Expense",
        "documentation": "Amortization Expense",
        "terseLabel": "Amortization expense"
       }
      }
     },
     "auth_ref": []
    },
    "caba_AnnualIncreasePercentageOfBaseRent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "AnnualIncreasePercentageOfBaseRent",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual increase percentage of base rent.",
        "label": "Annual Increase Percentage Of Base Rent",
        "terseLabel": "Percentage of annual increase of base rent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive shares have been excluded from calculation of diluted net loss per share",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r182"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "caba_AnupMardaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "AnupMardaMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Anup Marda [Member]",
        "label": "Anup Marda [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "caba_AnupMardaOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "AnupMardaOneMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Anup Marda One [Member]",
        "label": "Anup Marda One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)",
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r7",
      "r14",
      "r840",
      "r841",
      "r842"
     ]
    },
    "caba_ArunDasMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "ArunDasMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arun Das [Member]",
        "label": "Arun Das [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "caba_ArunDasOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "ArunDasOneMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arun Das One [Member]",
        "label": "Arun Das One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r99",
      "r123",
      "r152",
      "r187",
      "r195",
      "r209",
      "r212",
      "r252",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r387",
      "r391",
      "r423",
      "r503",
      "r590",
      "r662",
      "r663",
      "r695",
      "r712",
      "r888",
      "r889",
      "r943"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r128",
      "r152",
      "r252",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r387",
      "r391",
      "r423",
      "r695",
      "r888",
      "r889",
      "r943"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Assets, Fair Value Disclosure, Total",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Total",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r405",
      "r684"
     ]
    },
    "caba_AtTheMarketOfferingSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "AtTheMarketOfferingSalesAgreementMember",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At-the-market offering sales agreement.",
        "label": "At The Market Offering Sales Agreement [Member]",
        "terseLabel": "At-The-Market Offering Sales Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r717",
      "r718",
      "r741"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r717",
      "r718",
      "r741"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r717",
      "r718",
      "r741"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]",
        "terseLabel": "Auditor Opinion"
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "caba_AutolusHoldingsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "AutolusHoldingsMember",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSubsequenteventsAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Autolus Holdings [Member]",
        "label": "Autolus Holdings [Member]",
        "terseLabel": "Autolus Holdings Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r227"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r261",
      "r502"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Available-for-sale securities",
        "verboseLabel": "Fair value",
        "totalLabel": "Debt Securities, Available-for-Sale, Total",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r261",
      "r404",
      "r496",
      "r684",
      "r687",
      "r862",
      "r930",
      "r931",
      "r932"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockBasedCompensationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r309",
      "r310",
      "r311",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position Location, Balance [Axis]",
        "terseLabel": "Balance Sheet Location",
        "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported."
       }
      }
     },
     "auth_ref": [
      "r267",
      "r954",
      "r955"
     ]
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position Location, Balance [Domain]",
        "terseLabel": "Balance Sheet Location",
        "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r45",
      "r267",
      "r954",
      "r955"
     ]
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Basis of Presentation",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r74",
      "r75"
     ]
    },
    "caba_Caba201AndMuskCaartMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "Caba201AndMuskCaartMember",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CABA-201 and MuSK-CAART [Member]",
        "documentation": "CABA-201 and MuSK-CAART [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Property and equipment purchases included in accounts payable",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r22"
     ]
    },
    "caba_CapitalizedRDCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "CapitalizedRDCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capitalized R&amp;D costs",
        "label": "Capitalized R&amp;D costs",
        "terseLabel": "Capitalized research and development costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAbstract",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]",
        "terseLabel": "Cash and cash equivalents:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r119",
      "r648"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Money market funds",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r928",
      "r929"
     ]
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsMember",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Member]",
        "terseLabel": "Included in Cash and Cash Equivalents",
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "terseLabel": "Cash and cash equivalents and investments",
        "totalLabel": "Cash, Cash Equivalents, and Short-Term Investments, Total",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Cash and cash equivalents\u2014end of year",
        "periodStartLabel": "Cash and cash equivalents\u2014beginning of year",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r71",
      "r150"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net (decrease) increase in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r71"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosures"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashMember",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash [Member]",
        "terseLabel": "Cash",
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "caba_CashPaidInTheMeasurementOfLeaseLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "CashPaidInTheMeasurementOfLeaseLiabilitiesAbstract",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Paid In The Measurement Of Lease Liabilities [Abstract]",
        "documentation": "Cash Paid In The Measurement Of Lease Liabilities [Abstract]",
        "terseLabel": "Cash paid in the measurement of lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "caba_ChangeInStateAndLocalTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "ChangeInStateAndLocalTaxRate",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in state and local tax rate",
        "label": "Change In State And Local Tax Rate",
        "documentation": "Change In State And Local Tax Rate"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r774"
     ]
    },
    "caba_ChildrenSHospitalOfPhiladelphiaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "ChildrenSHospitalOfPhiladelphiaMember",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Children S Hospital Of Philadelphia [Member]",
        "terseLabel": "Children's Hospital of Philadelphia",
        "documentation": "Children\u2019s Hospital of Philadelphia."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r124",
      "r125",
      "r126",
      "r152",
      "r173",
      "r174",
      "r177",
      "r181",
      "r189",
      "r190",
      "r252",
      "r275",
      "r277",
      "r278",
      "r279",
      "r282",
      "r283",
      "r287",
      "r288",
      "r290",
      "r291",
      "r293",
      "r423",
      "r544",
      "r545",
      "r546",
      "r547",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r578",
      "r599",
      "r617",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r829",
      "r846",
      "r854"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r125",
      "r126",
      "r189",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r544",
      "r545",
      "r546",
      "r547",
      "r673",
      "r829",
      "r846"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants outstanding",
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "caba_ClinicalTrials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "ClinicalTrials",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfProfitAndLossFromSegmentsDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfProfitAndLossFromSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical Trials",
        "documentation": "Clinical Trials",
        "terseLabel": "Clinical trials"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "caba_CollaborationsLicensingAgreementsAndOtherAgreementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "CollaborationsLicensingAgreementsAndOtherAgreementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborations licensing agreements and other agreements.",
        "label": "Collaborations Licensing Agreements And Other Agreements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "caba_CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborations licensing agreements and other agreement.",
        "label": "Collaborations Licensing Agreements And Other Agreements Disclosure [Text Block]",
        "terseLabel": "Collaborations, Licensing Agreements and other Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "CollaborationsLicensingAgreementsAndOtherAgreementsLineItems",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborations licensing agreements and other agreements.",
        "label": "Collaborations Licensing Agreements And Other Agreements [Line Items]",
        "terseLabel": "Collaborations, Licensing Agreements And Other Agreements [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "CollaborationsLicensingAgreementsAndOtherAgreementsTable",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborations licensing agreements and other agreements.",
        "label": "Collaborations Licensing Agreements And Other Agreements [Table]",
        "terseLabel": "Collaborations Licensing Agreements And Other Agreements [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "caba_CollaborativeAgreementPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "CollaborativeAgreementPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative agreement payments due.",
        "label": "Collaborative Agreement Payments Due",
        "terseLabel": "Amounts due to agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (see Notes 6 and 7)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r93",
      "r504",
      "r577"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "caba_CommitmentsAndContingenciesDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "CommitmentsAndContingenciesDisclosureLineItems",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies disclosure.",
        "label": "Commitments And Contingencies Disclosure [Line Items]",
        "terseLabel": "Commitments and Contingencies [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "caba_CommitmentsAndContingenciesDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "CommitmentsAndContingenciesDisclosureTable",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies disclosure.",
        "label": "Commitments And Contingencies Disclosure [Table]",
        "terseLabel": "Commitments And Contingencies Disclosure [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r269",
      "r270",
      "r643",
      "r881",
      "r884"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares reserved for issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_CommonStockConversionFeatures": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockConversionFeatures",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-voting common stock, terms of conversion",
        "verboseLabel": "Terms of Conversion, Common stock",
        "label": "Common Stock, Terms of Conversion",
        "documentation": "Description of common stock conversion feature. Includes, but is not limited to, conversion price; conversion right; timing of right; terms, event or change in circumstance causing contingency to be met or adjustment to conversion price or number of shares; manner of settlement upon conversion; and method of settlement."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r111",
      "r112",
      "r294"
     ]
    },
    "us-gaap_CommonStockDividendsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockDividendsShares",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock dividends, shares",
        "label": "Common Stock Dividends, Shares",
        "documentation": "Number of shares of common stock issued as dividends during the period. Excludes stock splits."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r702",
      "r703",
      "r704",
      "r706",
      "r707",
      "r708",
      "r709",
      "r850",
      "r851",
      "r853",
      "r926",
      "r985",
      "r986"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, authorized shares",
        "verboseLabel": "Common stock, authorized shares",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r578"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, issued shares",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance, Shares",
        "periodStartLabel": "Beginning balance, Shares",
        "terseLabel": "Common stock, outstanding shares",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r58",
      "r578",
      "r596",
      "r986",
      "r987"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Voting and non-voting common stock, $0.00001 par value: 150,000,000 (143,590,481 voting and 6,409,519 non-voting) shares authorized as of December 31, 2024 and December 31, 2023; 50,743,101 voting shares issued and outstanding as of December 31, 2024 and 47,823,232 (46,378,937 voting and 1,444,295 non-voting) shares issued and outstanding as of December 31, 2023",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r506",
      "r695"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_Disclosure401KSavingsPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "terseLabel": "401(k) Savings Plan",
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r86",
      "r87",
      "r88"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Net comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r133",
      "r135",
      "r140",
      "r497",
      "r517",
      "r518"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive loss:",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "verboseLabel": "Other comprehensive income:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer Equipment",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principles of Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r652"
     ]
    },
    "caba_ContractualCostIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "ContractualCostIncurred",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual cost incurred.",
        "label": "Contractual Cost Incurred",
        "terseLabel": "Cost incurred"
       }
      }
     },
     "auth_ref": []
    },
    "caba_ContractualExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "ContractualExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual expenses.",
        "label": "Contractual Expenses",
        "terseLabel": "Expense related to agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractualObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractualObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contractual Obligation",
        "terseLabel": "Obligation to be paid",
        "totalLabel": "Contractual Obligation, Total",
        "verboseLabel": "liability related to agreement",
        "documentation": "Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments."
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "us-gaap_CorporateNoteSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CorporateNoteSecuritiesMember",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "U.S. Treasury securities - original maturity less than three months",
        "label": "Corporate Note Securities [Member]",
        "terseLabel": "Corporate Note Securities",
        "documentation": "This category includes information about short-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest)."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "auth_ref": [
      "r154",
      "r155",
      "r284",
      "r289",
      "r457",
      "r477",
      "r501",
      "r649",
      "r651"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r726",
      "r815"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r726",
      "r815"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r728",
      "r817"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r728",
      "r817"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r730",
      "r819"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r728",
      "r817"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r721",
      "r810"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r722",
      "r811"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r722",
      "r811"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r720",
      "r809"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r720",
      "r809"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r720",
      "r809"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r723",
      "r812"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r725",
      "r814"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r725",
      "r814"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r726",
      "r815"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r729",
      "r818"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r727",
      "r816"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r724",
      "r813"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Table]",
        "terseLabel": "Debt Securities Available For Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "terseLabel": "Schedule of Debt Securities Classified as Available-for-Sale Investments",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Unrealized Gain (Loss)",
        "terseLabel": "Net unrealized gains (losses) on available-for-sale securities",
        "totalLabel": "Debt Securities, Available-for-Sale, Unrealized Gain (Loss), Total",
        "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r867",
      "r868"
     ]
    },
    "caba_December2022FinancingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "December2022FinancingMember",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "December 2022 Financing [Member]",
        "documentation": "December Two Thousand Twenty Two Financing [Member]",
        "terseLabel": "December 2022 Financing"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredChargesPolicyTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Offering Costs",
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r366"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net",
        "terseLabel": "Net deferred tax assets",
        "totalLabel": "Deferred Tax Assets, Net, Total",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "caba_DeferredTaxAssetsLicenseFeesDeductions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "DeferredTaxAssetsLicenseFeesDeductions",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets license fees deductions.",
        "label": "Deferred Tax Assets License Fees Deductions",
        "terseLabel": "License fee deductions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNetAbstract",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "auth_ref": []
    },
    "caba_DeferredTaxAssetsOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "DeferredTaxAssetsOperatingLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Deferred Tax Assets, Operating Lease Liabilities",
        "documentation": "Deferred Tax Assets, Operating Lease Liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "caba_DeferredTaxAssetsOperatingLossCarryforwardsFederal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsFederal",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets operating loss carryforwards federal.",
        "label": "Deferred Tax Assets Operating Loss Carryforwards Federal",
        "terseLabel": "Deferred tax assets operating loss carryforwards federal"
       }
      }
     },
     "auth_ref": []
    },
    "caba_DeferredTaxAssetsOperatingLossCarryforwardsLocal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsLocal",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets operating loss carryforwards local.",
        "label": "Deferred Tax Assets Operating Loss Carryforwards Local",
        "terseLabel": "Deferred tax assets operating loss carryforwards local"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration",
        "terseLabel": "Deferred tax assets, operating loss carryforwards, not subject to expiration",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates."
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "caba_DeferredTaxAssetsOperatingLossCarryforwardsState": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsState",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets operating loss carryforwards state.",
        "label": "Deferred Tax Assets Operating Loss Carryforwards State",
        "terseLabel": "Deferred tax assets operating loss carryforwards state"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local",
        "terseLabel": "Federal, state and local net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration",
        "terseLabel": "Deferred tax assets, operating loss carryforwards, subject to expiration",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates."
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "caba_DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets tax credit carryforwards commencement of expiration date.",
        "label": "Deferred Tax Assets Tax Credit Carryforwards Commencement Of Expiration Date",
        "terseLabel": "Deferred tax assets tax credit carryforwards commencement of expiration date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development tax credits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock-based compensation deductions",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "terseLabel": "Accrued expenses",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities."
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less: valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanCostRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_Disclosure401KSavingsPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Defined contribution plan, contribution amount",
        "documentation": "Amount of cost for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r303"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_Disclosure401KSavingsPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_Disclosure401KSavingsPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "documentation": "Percentage employer matches of the employee's percentage contribution matched."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "terseLabel": "Depreciation",
        "verboseLabel": "Depreciation expense",
        "totalLabel": "Depreciation, Total",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r30"
     ]
    },
    "caba_DevelopmentAndManufacturingServicesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "DevelopmentAndManufacturingServicesAgreementMember",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development and manufacturing services agreement.",
        "label": "Development And Manufacturing Services Agreement [Member]",
        "terseLabel": "Wuxi Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "caba_DevelopmentServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "DevelopmentServices",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfProfitAndLossFromSegmentsDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfProfitAndLossFromSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Development Services",
        "documentation": "Development Services",
        "terseLabel": "Development services"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DilutiveSecuritiesEffectOnBasicEarningsPerShareOther",
     "crdr": "credit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities",
        "terseLabel": "Reallocation of undistributed losses as a result of conversion of non-voting to voting common shares",
        "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise of dilutive convertible securities excluding adjustments related to ESOP convertible preferred stock, stock options, and restrictive stock units."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r717",
      "r718",
      "r741"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r717",
      "r718",
      "r741",
      "r784"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "verboseLabel": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r715"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "caba_EarningPerShareBasicAndDilutedLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "EarningPerShareBasicAndDilutedLineItems",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earning per share basic and diluted.",
        "label": "Earning Per Share Basic And Diluted [Line Items]",
        "terseLabel": "Earning Per Share Basic And Diluted [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share of voting and non-voting common stock, basic",
        "label": "Earnings Per Share, Basic",
        "totalLabel": "Earnings Per Share, Basic, Total",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r171",
      "r173",
      "r177",
      "r180",
      "r181",
      "r186",
      "r382",
      "r385",
      "r401",
      "r402",
      "r498",
      "r519",
      "r654"
     ]
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasicAbstract",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Basic net loss per share:"
       }
      }
     },
     "auth_ref": []
    },
    "caba_EarningsPerShareBasicAndDilutedTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "EarningsPerShareBasicAndDilutedTable",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnings per share basic and diluted.",
        "label": "Earnings Per Share Basic And Diluted [Table]",
        "terseLabel": "Earnings Per Share Basic And Diluted [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share of voting and non-voting common stock, diluted",
        "label": "Earnings Per Share, Diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r173",
      "r177",
      "r180",
      "r181",
      "r186",
      "r382",
      "r385",
      "r401",
      "r402",
      "r498",
      "r519",
      "r654"
     ]
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDilutedAbstract",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted [Abstract]",
        "terseLabel": "Diluted net loss per share:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r183"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r182",
      "r184",
      "r185"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r424"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Total",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r681"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Expected income tax benefit at the federal statutory rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r352",
      "r374",
      "r681"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "negatedLabel": "Change in valuation allowance",
        "terseLabel": "Change in valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r356",
      "r681",
      "r848",
      "r921"
     ]
    },
    "caba_EffectiveIncomeTaxRateReconciliationNondeductibleItemsAndOther": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleItemsAndOther",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation nondeductible items and other.",
        "label": "Effective Income Tax Rate Reconciliation Nondeductible Items And Other",
        "negatedLabel": "Non-deductible items and other",
        "terseLabel": "Non-deductible items and other"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State and local taxes, net of federal benefit",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r355",
      "r681",
      "r848",
      "r921"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "terseLabel": "Research and development credit, net",
        "negatedLabel": "Research and development credit, net",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r681",
      "r848",
      "r921",
      "r922"
     ]
    },
    "caba_EmergingGrowthCompanyStatusPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "EmergingGrowthCompanyStatusPolicyTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Emerging growth company status.",
        "label": "Emerging Growth Company Status Policy [Text Block]",
        "terseLabel": "Emerging Growth Company Status"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Compensation expense",
        "totalLabel": "Employee-related Liabilities, Current, Total",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost related to unvested stock-based awards",
        "totalLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation cost, weighted average period for recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockBasedCompensationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "verboseLabel": "Stock Options to Purchase Common Stock",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "caba_EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee stock purchase plan maximum annual rights to purchase common stock.",
        "label": "Employee Stock Purchase Plan Maximum Annual Rights To Purchase Common Stock",
        "terseLabel": "Employee stock purchase plan maximum annual rights to purchase common stock"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquipmentMember",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equipment [Member]",
        "terseLabel": "Laboratory Equipment",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r115",
      "r137",
      "r138",
      "r139",
      "r156",
      "r157",
      "r158",
      "r160",
      "r165",
      "r167",
      "r169",
      "r188",
      "r253",
      "r254",
      "r265",
      "r295",
      "r372",
      "r373",
      "r379",
      "r380",
      "r381",
      "r383",
      "r384",
      "r385",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r400",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r433",
      "r435",
      "r456",
      "r515",
      "r532",
      "r533",
      "r534",
      "r551",
      "r617"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r734",
      "r745",
      "r755",
      "r788"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r731",
      "r742",
      "r752",
      "r785"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "caba_ExpectedCostIncurredForPurchaseOfPlasmids": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "ExpectedCostIncurredForPurchaseOfPlasmids",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected cost incurred for purchase of plasmids.",
        "label": "Expected Cost Incurred For Purchase Of Plasmids",
        "terseLabel": "Total cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Financial Assets Measured at Fair Value on Recurring Basis",
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r928",
      "r929"
     ]
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByBalanceSheetGroupingTable",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value By Balance Sheet Grouping [Table]",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r47"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r403",
      "r405",
      "r406",
      "r407",
      "r408",
      "r414",
      "r415",
      "r417",
      "r464",
      "r465",
      "r466",
      "r671",
      "r672",
      "r675",
      "r676",
      "r677",
      "r684",
      "r687"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r405",
      "r406",
      "r408",
      "r684",
      "r931",
      "r934"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r412",
      "r413",
      "r414",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r495",
      "r684",
      "r688"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r297",
      "r302",
      "r405",
      "r415",
      "r464",
      "r675",
      "r676",
      "r677",
      "r684"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant Other Observable Inputs (Level 2)",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r297",
      "r302",
      "r405",
      "r406",
      "r415",
      "r465",
      "r671",
      "r672",
      "r675",
      "r676",
      "r677",
      "r684"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Significant Unobservable Inputs (Level 3)",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r405",
      "r406",
      "r407",
      "r408",
      "r415",
      "r466",
      "r671",
      "r672",
      "r675",
      "r676",
      "r677",
      "r684",
      "r687"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r405",
      "r406",
      "r408",
      "r684",
      "r931",
      "r934"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r403",
      "r405",
      "r406",
      "r407",
      "r408",
      "r414",
      "r415",
      "r417",
      "r464",
      "r465",
      "r466",
      "r671",
      "r672",
      "r675",
      "r676",
      "r677",
      "r684",
      "r687"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r684",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r934"
     ]
    },
    "caba_FederalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "FederalMember",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal.",
        "label": "Federal [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails": {
       "parentTag": "caba_TotalFixedFinanceLeaseCost",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Interest expense",
        "documentation": "Amount of interest expense on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r438",
      "r445",
      "r694"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityAbstract",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability [Abstract]",
        "terseLabel": "Finance Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Finance lease liabilities, current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Finance lease liabilities, net of current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails2": {
       "parentTag": "caba_FinanceLesseeUndiscountedLeasePayments",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid",
        "totalLabel": "Total lease liability",
        "terseLabel": "Total lease liability",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails": {
       "parentTag": "caba_FinanceLesseeUndiscountedLeasePayments",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Next Rolling 12 Months",
        "terseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease due in next rolling 12 months following current statement of financial position date. For interim and annual periods when interim period is reported on rolling approach."
       }
      }
     },
     "auth_ref": [
      "r941"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueInRollingYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails": {
       "parentTag": "caba_FinanceLesseeUndiscountedLeasePayments",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Rolling Year Two",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date."
       }
      }
     },
     "auth_ref": [
      "r941"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails2": {
       "parentTag": "caba_FinanceLesseeUndiscountedLeasePayments",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Principal Payments",
        "negatedLabel": "Principal payments on finance leases",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r439",
      "r449"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "totalLabel": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization, Total",
        "terseLabel": "Finance lease right-of-use assets",
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of finance lease",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r438",
      "r445",
      "r694"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate - finance leases",
        "documentation": "Weighted average discount rate for finance lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r452",
      "r694"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term - finance leases (in years)",
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r451",
      "r694"
     ]
    },
    "caba_FinanceLeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "FinanceLeasesAbstract",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance leases [Abstract]",
        "documentation": "Finance leases [Abstract]",
        "terseLabel": "Finance Leases:"
       }
      }
     },
     "auth_ref": []
    },
    "caba_FinanceLesseeUndiscountedLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "FinanceLesseeUndiscountedLeasePayments",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lessee Undiscounted Lease Payments",
        "documentation": "Finance Lessee Undiscounted Lease Payments",
        "terseLabel": "Total undiscounted lease payments",
        "totalLabel": "Total undiscounted lease payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r255",
      "r256",
      "r257",
      "r258",
      "r260",
      "r262",
      "r263",
      "r264",
      "r286",
      "r292",
      "r399",
      "r422",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r516",
      "r669",
      "r684",
      "r685",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r696",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r875",
      "r876",
      "r877",
      "r878",
      "r927",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934"
     ]
    },
    "us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]",
        "terseLabel": "Financial assets"
       }
      }
     },
     "auth_ref": []
    },
    "caba_FinancingCashFlowsUsedForFinanceLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "FinancingCashFlowsUsedForFinanceLeases",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing Cash Flows Used For Finance Leases",
        "documentation": "Financing Cash Flows Used For Finance Leases",
        "terseLabel": "Financing cash flows for finance leases"
       }
      }
     },
     "auth_ref": []
    },
    "caba_FixedLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "FixedLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails2": {
       "parentTag": "us-gaap_OperatingLeaseCost",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fixed Lease Cost",
        "documentation": "Fixed Lease Cost",
        "terseLabel": "Fixed lease cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on foreign currency exchange rates",
        "label": "Foreign Currency Transaction Loss, before Tax",
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized loss recognized in the income statement."
       }
      }
     },
     "auth_ref": [
      "r936",
      "r937"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r738",
      "r749",
      "r759",
      "r792"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r738",
      "r749",
      "r759",
      "r792"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r738",
      "r749",
      "r759",
      "r792"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r738",
      "r749",
      "r759",
      "r792"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r738",
      "r749",
      "r759",
      "r792"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    },
    "caba_FundingTermEndingDate": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "FundingTermEndingDate",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding term ending date.",
        "label": "Funding Term Ending Date",
        "terseLabel": "Funding term end date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossRelatedToLitigationSettlement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossRelatedToLitigationSettlement",
     "crdr": "credit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) from Litigation Settlement",
        "terseLabel": "Loss related to litigation settlement accrued",
        "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process."
       }
      }
     },
     "auth_ref": [
      "r662",
      "r885"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfProfitAndLossFromSegmentsDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfProfitAndLossFromSegmentsDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "totalLabel": "General and Administrative Expense, Total",
        "verboseLabel": "General and administration expenses",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r601"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "caba_GwendolynBinderMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "GwendolynBinderMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gwendolyn Binder [Member]",
        "label": "Gwendolyn Binder [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "caba_GwendolynBinderOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "GwendolynBinderOneMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gwendolyn Binder One [Member]",
        "label": "Gwendolyn Binder One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r717",
      "r718",
      "r741"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "terseLabel": "Income Statement Location",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r267",
      "r268",
      "r409",
      "r411",
      "r416",
      "r529",
      "r531",
      "r602",
      "r646",
      "r686",
      "r956"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "terseLabel": "Income Statement Location",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r267",
      "r268",
      "r409",
      "r411",
      "r416",
      "r529",
      "r531",
      "r602",
      "r646",
      "r686",
      "r956"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "terseLabel": "Income Tax Authority",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r352",
      "r353",
      "r361",
      "r370",
      "r681",
      "r924"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Domain]",
        "terseLabel": "Income Tax Authority",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r352",
      "r353",
      "r361",
      "r370",
      "r681",
      "r924"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "caba_IncomeTaxDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "IncomeTaxDisclosureLineItems",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax disclosure.",
        "label": "Income Tax Disclosure [Line Items]",
        "terseLabel": "Income Tax Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "caba_IncomeTaxDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "IncomeTaxDisclosureTable",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax disclosure.",
        "label": "Income Tax Disclosure [Table]",
        "terseLabel": "Income Tax Disclosure [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r349",
      "r352",
      "r357",
      "r358",
      "r359",
      "r363",
      "r369",
      "r375",
      "r376",
      "r377",
      "r378",
      "r549",
      "r681"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r350",
      "r351",
      "r363",
      "r364",
      "r368",
      "r371",
      "r543"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued and other current liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r845"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Lease liabilities",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r830",
      "r845"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets",
        "totalLabel": "Increase (Decrease) in Other Operating Assets, Total",
        "negatedTerseLabel": "Other assets",
        "documentation": "Amount of increase (decrease) in operating assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "caba_IncreaseInShareReservedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "IncreaseInShareReservedPercentage",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in share reserved percentage.",
        "label": "Increase In Share Reserved Percentage",
        "terseLabel": "Increase in share reserved percentage"
       }
      }
     },
     "auth_ref": []
    },
    "caba_IncreaseInTheLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "IncreaseInTheLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase in the lease liability",
        "documentation": "Increase in the lease liability",
        "terseLabel": "Increase in the lease liability"
       }
      }
     },
     "auth_ref": []
    },
    "caba_IncreaseInTheRouAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "IncreaseInTheRouAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase in the ROU asset",
        "documentation": "Increase in the ROU asset",
        "terseLabel": "Increase in the ROU asset"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r738",
      "r749",
      "r759",
      "r783",
      "r792",
      "r796",
      "r804"
     ]
    },
    "caba_InitialTermsOfAgreementDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "InitialTermsOfAgreementDescription",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Terms agreement description",
        "label": "Initial Terms of Agreement, Description",
        "documentation": "Initial Terms of Agreement, Description"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r719",
      "r808"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r719",
      "r808"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r719",
      "r808"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfProfitAndLossFromSegmentsDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      },
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfProfitAndLossFromSegmentsDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense, Operating and Nonoperating",
        "totalLabel": "Interest Expense, Operating and Nonoperating, Total",
        "verboseLabel": "Interest expense",
        "terseLabel": "Interest expense",
        "negatedLabel": "Interest expense",
        "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r195",
      "r197",
      "r198",
      "r212",
      "r432",
      "r662",
      "r663"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r147",
      "r148"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfProfitAndLossFromSegmentsDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfProfitAndLossFromSegmentsDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income",
        "verboseLabel": "Interest income",
        "negatedLabel": "Interest income",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r196",
      "r212",
      "r662",
      "r843"
     ]
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentPolicyTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Investments",
        "documentation": "Disclosure of accounting policy for investment in financial asset."
       }
      }
     },
     "auth_ref": [
      "r520",
      "r539",
      "r540",
      "r541",
      "r542",
      "r623",
      "r624"
     ]
    },
    "us-gaap_InvestmentTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentTypeAxis",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type",
        "documentation": "Information by type of investments."
       }
      }
     },
     "auth_ref": [
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r620",
      "r622",
      "r626",
      "r629",
      "r630",
      "r631",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r704"
     ]
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentTypeCategorizationMember",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments [Domain]",
        "terseLabel": "Investments",
        "documentation": "Asset obtained to generate income or appreciate in value."
       }
      }
     },
     "auth_ref": [
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r620",
      "r622",
      "r626",
      "r629",
      "r630",
      "r631",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r704"
     ]
    },
    "caba_IssuanceOfCommonStockAndPreFundedWarrantsForThePurchaseOfCommonStockNetOfIssuanceCosts": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "IssuanceOfCommonStockAndPreFundedWarrantsForThePurchaseOfCommonStockNetOfIssuanceCosts",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock and pre-funded warrants for the purchase of common stock, net of issuance costs",
        "label": "Issuance of common stock and pre-funded warrants for the purchase of common stock, net of issuance costs",
        "terseLabel": "Issuance of common stock upon exercise of pre-funded warrants, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "caba_IssuanceOfCommonStockUponExerciseOfPreFundedWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "IssuanceOfCommonStockUponExerciseOfPreFundedWarrants",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock upon exercise of pre-funded warrants",
        "label": "Issuance of common stock upon exercise of pre-funded warrants, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "caba_LaboratoryEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "LaboratoryEquipmentMember",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory equipment.",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "caba_LeaseAmendmentPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "LeaseAmendmentPeriod",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease amendment period.",
        "label": "Lease Amendment Period",
        "terseLabel": "Lease Amendment Period"
       }
      }
     },
     "auth_ref": []
    },
    "caba_LeaseCommencementMonthAndYear": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "LeaseCommencementMonthAndYear",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease commencement month and year.",
        "label": "Lease Commencement Month And Year",
        "terseLabel": "Lease commencement period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost",
        "terseLabel": "Fixed lease cost",
        "totalLabel": "Total operating lease cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r444",
      "r694"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Company's Operating and Finance Leases",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "caba_LeaseExpirationMonth": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "LeaseExpirationMonth",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease expiration month",
        "label": "Lease Expiration Month",
        "documentation": "Lease Expiration Month"
       }
      }
     },
     "auth_ref": []
    },
    "caba_LeaseExpirationMonthAndYear": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "LeaseExpirationMonthAndYear",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease expiration month and year.",
        "label": "Lease Expiration Month And Year",
        "terseLabel": "Lease expiration period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r454"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LegalEntityTypeOfCounterpartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LegalEntityTypeOfCounterpartyDomain",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity Type of Counterparty [Domain]",
        "terseLabel": "Legal Entity Type of Counterparty",
        "documentation": "Nature of the other party participating in a financial transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r442",
      "r455"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r442",
      "r455"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r441"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseDescription",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Description",
        "terseLabel": "Operating lease, description",
        "documentation": "Description of lessee's operating lease."
       }
      }
     },
     "auth_ref": [
      "r443"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesTables",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Payments for Operating Leases",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r941"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails3": {
       "parentTag": "caba_LesseeUndiscountedLeasePayments",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Lessee, Operating Lease, Liability, to be Paid, Total",
        "terseLabel": "Total lease liability",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "caba_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearThree",
     "crdr": "credit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsForOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease liability payments due after rolling year three.",
        "label": "Lessee Operating Lease Liability Payments Due After Rolling Year Three",
        "terseLabel": "Thereafter"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree",
     "crdr": "credit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsForOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Rolling Year Three",
        "terseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date."
       }
      }
     },
     "auth_ref": [
      "r941"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails4": {
       "parentTag": "caba_LesseeUndiscountedLeasePayments",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsForOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Rolling Year Two",
        "terseLabel": "2024",
        "verboseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date."
       }
      }
     },
     "auth_ref": [
      "r941"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails4": {
       "parentTag": "caba_LesseeUndiscountedLeasePayments",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsForOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Next Rolling 12 Months",
        "terseLabel": "2023",
        "verboseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date."
       }
      }
     },
     "auth_ref": [
      "r941"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails3": {
       "parentTag": "caba_LesseeUndiscountedLeasePayments",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional in fixed undiscounted lease payments",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term",
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r455",
      "r939"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r434"
     ]
    },
    "caba_LesseeUndiscountedLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "LesseeUndiscountedLeasePayments",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails3": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails4": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee Undiscounted Lease Payments",
        "label": "Lessee Undiscounted Lease Payments",
        "totalLabel": "Total undiscounted lease payments",
        "terseLabel": "Total undiscounted lease payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r50",
      "r51",
      "r52",
      "r53",
      "r54",
      "r55",
      "r56",
      "r152",
      "r252",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r388",
      "r391",
      "r392",
      "r423",
      "r576",
      "r655",
      "r712",
      "r888",
      "r943",
      "r944"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r94",
      "r509",
      "r695",
      "r847",
      "r879",
      "r935"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders\u2019 equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r118",
      "r152",
      "r252",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r388",
      "r391",
      "r392",
      "r423",
      "r695",
      "r888",
      "r943",
      "r944"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesSubjectToCompromiseEarlyContractTerminationFees",
     "crdr": "credit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Termination fees",
        "label": "Liabilities Subject to Compromise, Early Contract Termination Fees",
        "terseLabel": "Early termination fee",
        "documentation": "The amount of early contract termination fees included in liabilities subject to compromise."
       }
      }
     },
     "auth_ref": [
      "r942"
     ]
    },
    "caba_LicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "LicenseAgreementMember",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement.",
        "label": "License Agreement [Member]",
        "terseLabel": "License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicenseAndServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LicenseAndServiceMember",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSubsequenteventsAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License and Service [Member]",
        "label": "License and Service [Member]",
        "documentation": "Right to use intangible asset and performance of related service. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "caba_LicenseMaintenanceFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "LicenseMaintenanceFee",
     "crdr": "credit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License maintenance fee.",
        "label": "License Maintenance Fee",
        "terseLabel": "License maintenance fee"
       }
      }
     },
     "auth_ref": []
    },
    "caba_LicenseOfIntellectualProperty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "LicenseOfIntellectualProperty",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfProfitAndLossFromSegmentsDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfProfitAndLossFromSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License of Intellectual Property",
        "documentation": "License of Intellectual Property",
        "terseLabel": "License of intellectual property"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "caba_LonzaAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "LonzaAgreementMember",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lonza Agreement [Member]",
        "documentation": "Lonza Agreement [Member]",
        "terseLabel": "Lonza Agreement [Member]",
        "verboseLabel": "Lonza Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "caba_ManufacturingOfPreclinicalAndClinicalSupplies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "ManufacturingOfPreclinicalAndClinicalSupplies",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfProfitAndLossFromSegmentsDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfProfitAndLossFromSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Manufacturing of Preclinical and Clinical Supplies",
        "documentation": "Manufacturing of Preclinical and Clinical Supplies",
        "terseLabel": "Manufacturing of preclinical and clinical supplies"
       }
      }
     },
     "auth_ref": []
    },
    "caba_MasterTranslationalResearchServicesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "MasterTranslationalResearchServicesAgreementMember",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Master translational research services agreement.",
        "label": "Master Translational Research Services Agreement [Member]",
        "terseLabel": "Master Translational Research Services Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSubsequenteventsAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r271",
      "r272",
      "r273",
      "r274",
      "r304",
      "r345",
      "r408",
      "r493",
      "r528",
      "r530",
      "r538",
      "r568",
      "r569",
      "r621",
      "r625",
      "r627",
      "r628",
      "r632",
      "r644",
      "r645",
      "r668",
      "r673",
      "r678",
      "r687",
      "r688",
      "r692",
      "r693",
      "r698",
      "r890",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950"
     ]
    },
    "caba_MayTwoThousandTwentyThreeFinancingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "MayTwoThousandTwentyThreeFinancingMember",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "May 2023 Financing",
        "label": "May Two Thousand Twenty Three Financing [Member]",
        "documentation": "May Two Thousand Twenty Three Financing [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "caba_MilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "MilestonePayment",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment",
        "label": "Milestone payment",
        "documentation": "Milestone payment"
       }
      }
     },
     "auth_ref": []
    },
    "caba_MilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "MilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSubsequenteventsAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments.",
        "label": "Milestone Payments",
        "terseLabel": "Total milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]",
        "verboseLabel": "Minimum"
       }
      }
     },
     "auth_ref": [
      "r271",
      "r272",
      "r273",
      "r274",
      "r304",
      "r345",
      "r408",
      "r493",
      "r528",
      "r530",
      "r538",
      "r568",
      "r569",
      "r621",
      "r625",
      "r627",
      "r628",
      "r632",
      "r644",
      "r645",
      "r668",
      "r673",
      "r678",
      "r687",
      "r688",
      "r692",
      "r698",
      "r890",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "caba_NanjingIasoBiotherapeuticsCoLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "NanjingIasoBiotherapeuticsCoLtdMember",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nanjing IASO Biotherapeutics Co., Ltd. member",
        "label": "Nanjing IASO Biotherapeutics Co., Ltd. [Member]",
        "terseLabel": "IASO Biotherapeutics"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r72",
      "r73"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfProfitAndLossFromSegmentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfProfitAndLossFromSegmentsDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "totalLabel": "Net loss",
        "negatedTotalLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r73",
      "r97",
      "r116",
      "r132",
      "r134",
      "r139",
      "r152",
      "r159",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r168",
      "r169",
      "r175",
      "r252",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r382",
      "r385",
      "r402",
      "r423",
      "r514",
      "r598",
      "r615",
      "r616",
      "r710",
      "r888"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Recently Issued Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "caba_NonCashLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "NonCashLeaseExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non cash lease expense",
        "label": "Non cash lease expense",
        "terseLabel": "Non-cash lease expense",
        "verboseLabel": "Non-cash operating lease expense"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r738",
      "r749",
      "r759",
      "r783",
      "r792"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "caba_NonRule10B51ArrModifiedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "NonRule10B51ArrModifiedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Rule 10b51 Arr Modified Flag",
        "label": "Non-Rule 10b5-1 Arrangement Modified [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Modified"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "caba_NonVestedCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "NonVestedCommonStockMember",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-vested common stock member.",
        "label": "Non Vested Common Stock [Member]",
        "terseLabel": "Non-vested Founder Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonvotingCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonvotingCommonStockMember",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non-voting Common Stock",
        "label": "Nonvoting Common Stock [Member]",
        "terseLabel": "Non-voting Common Stock [Member]",
        "documentation": "Common stock securities that do not empower a holder to vote on corporate resolutions or the election of directors."
       }
      }
     },
     "auth_ref": []
    },
    "caba_NumberOfFaculty": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "NumberOfFaculty",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of faculty.",
        "label": "Number Of Faculty",
        "terseLabel": "Number of faculty member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segment",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r663",
      "r857"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segment",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r657",
      "r667",
      "r857"
     ]
    },
    "us-gaap_NumberOfReportingUnits": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportingUnits",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Reporting Units",
        "terseLabel": "Number of reportable segment",
        "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment."
       }
      }
     },
     "auth_ref": []
    },
    "caba_ObligationToBePaidCommencementDate": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "ObligationToBePaidCommencementDate",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Obligation to be paid, commencement date.",
        "label": "Obligation To Be Paid Commencement Date",
        "terseLabel": "Payment commencement date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OffBalanceSheetCreditExposurePolicyPolicyTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Off-Balance-Sheet Credit Exposure, Policy [Policy Text Block]",
        "terseLabel": "Off-Balance Sheet Risk and Concentrations of Credit Risk",
        "documentation": "Description of accounting policies and methodologies used to estimate the entity's liability for off-balance sheet credit exposures and related charges for those credit exposures."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r259"
     ]
    },
    "caba_OperatingCashFlowsUsedForFinanceLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "OperatingCashFlowsUsedForFinanceLeases",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Cash Flows Used For Finance Leases",
        "documentation": "Operating Cash Flows Used For Finance Leases",
        "terseLabel": "Operating cash flows used for finance leases"
       }
      }
     },
     "auth_ref": []
    },
    "caba_OperatingCashFlowsUsedForOperatingLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "OperatingCashFlowsUsedForOperatingLeases",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Cash Flows Used For Operating Leases",
        "documentation": "Operating Cash Flows Used For Operating Leases",
        "terseLabel": "Operating cash flows used for operating leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "terseLabel": "Loss from operations",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r656",
      "r856",
      "r858",
      "r859",
      "r860",
      "r861"
     ]
    },
    "caba_OperatingLeaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "OperatingLeaseAgreementMember",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease Agreement.",
        "label": "Operating Lease Agreement [Member]",
        "terseLabel": "Operating Lease Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "caba_OperatingLeaseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "OperatingLeaseAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "documentation": "Operating lease assets",
        "label": "Operating lease assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails2": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Cost",
        "terseLabel": "Total fixed operating lease cost",
        "totalLabel": "Total fixed operating lease cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r694"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Expense",
        "verboseLabel": "Monthly fee included in minimum lease payment",
        "terseLabel": "Rent expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability",
        "totalLabel": "Operating Lease, Liability, Total",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityAbstract",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities, current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating lease liabilities",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, net of current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease payments",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r449"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets",
        "verboseLabel": "Right-of-use asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate - operating leases",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r452",
      "r694"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term - operating leases (in years)",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r451",
      "r694"
     ]
    },
    "caba_OperatingLeasesAbtract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "OperatingLeasesAbtract",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases [Abtract]",
        "documentation": "Operating Leases [Abtract]",
        "terseLabel": "Operating Leases:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeasesRentExpenseMinimumRentals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasesRentExpenseMinimumRentals",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases, Rent Expense, Minimum Rentals",
        "terseLabel": "Initial annual base rent",
        "documentation": "This element represents the payments that the lessee is obligated to make or can be required to make in connection with a property under the terms of an agreement classified as an operating lease, excluding contingent rentals and a guarantee by the lessee of the lessor's debt and the lessee's obligation to pay (apart from the rental payments) executory costs such as insurance, maintenance, and taxes."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r102",
      "r103"
     ]
    },
    "caba_OperatingLossCarryforwardsFederalCommencementOfExpirationDate": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "OperatingLossCarryforwardsFederalCommencementOfExpirationDate",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards federal commencement of expiration date.",
        "label": "Operating Loss Carryforwards Federal Commencement Of Expiration Date",
        "terseLabel": "Operating loss carryforwards federal commencement of expiration date"
       }
      }
     },
     "auth_ref": []
    },
    "caba_OperatingLossCarryforwardsLocalCommencementOfExpirationDate": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "OperatingLossCarryforwardsLocalCommencementOfExpirationDate",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards local commencement of expiration date.",
        "label": "Operating Loss Carryforwards Local Commencement Of Expiration Date",
        "terseLabel": "Operating loss carryforwards local commencement of expiration date"
       }
      }
     },
     "auth_ref": []
    },
    "caba_OperatingLossCarryforwardsStateCommencementOfExpirationDate": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "OperatingLossCarryforwardsStateCommencementOfExpirationDate",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards state commencement of expiration date.",
        "label": "Operating Loss Carryforwards State Commencement Of Expiration Date",
        "terseLabel": "Operating loss carryforwards state commencement of expiration date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "us-gaap_OtherCommitmentDueInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentDueInNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Committed payment obligation",
        "label": "Other Commitment, to be Paid, Year One",
        "documentation": "Amount of commitment classified as other to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "totalLabel": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total",
        "terseLabel": "Net unrealized (loss) gain on available-for-sale investments, net of tax",
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r130",
      "r131",
      "r515"
     ]
    },
    "us-gaap_OtherExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Expenses",
        "terseLabel": "Expenses",
        "documentation": "Amount of expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r69"
     ]
    },
    "caba_OtherInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "OtherInformationAbstract",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Information [Abstract]",
        "documentation": "Other Information [Abstract]",
        "terseLabel": "Other inforamation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r695"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfProfitAndLossFromSegmentsDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfProfitAndLossFromSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Research and Development Expense",
        "terseLabel": "Other research and development costs",
        "documentation": "Amount of other research and development expense."
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r736",
      "r747",
      "r757",
      "r790"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r739",
      "r750",
      "r760",
      "r793"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r739",
      "r750",
      "r760",
      "r793"
     ]
    },
    "caba_OxfordBiomedicaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "OxfordBiomedicaMember",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oxford Biomedica.",
        "label": "Oxford Biomedica [Member]",
        "terseLabel": "Oxford Biomedica"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "caba_PaymentOfObligationTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "PaymentOfObligationTerm",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of obligation, term.",
        "label": "Payment Of Obligation Term",
        "terseLabel": "Payment term",
        "verboseLabel": "Payment term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForCommissions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForCommissions",
     "crdr": "credit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment for commissions",
        "label": "Payments for Commissions",
        "documentation": "The amount of cash paid for commissions during the current period."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_PaymentsForUnderwritingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForUnderwritingExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underwriting discounts and commissions and offering expenses",
        "label": "Payments for Underwriting Expense",
        "documentation": "Cash paid for expenses incurred during underwriting activities (the process to review insurance applications, evaluate risks, accept or reject applications, and determine the premiums to be charged) for insurance companies."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt issuance commissions",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "negatedLabel": "Purchases of investments",
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r142",
      "r221"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r774"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r774"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "caba_PercentageOfEligibleTaxPositionsForRecognition": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "PercentageOfEligibleTaxPositionsForRecognition",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of eligible tax positions for recognition.",
        "label": "Percentage Of Eligible Tax Positions For Recognition",
        "terseLabel": "Percentage of eligible tax positions for recognition"
       }
      }
     },
     "auth_ref": []
    },
    "caba_PercentageOfPayrollDeductionOnEligibleCompensation": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "PercentageOfPayrollDeductionOnEligibleCompensation",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of payroll deduction on eligible compensation.",
        "label": "Percentage Of Payroll Deduction On Eligible Compensation",
        "terseLabel": "Payroll deduction percentage of eligible compensation"
       }
      }
     },
     "auth_ref": []
    },
    "caba_PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of shares purchased at fair market value of common stock.",
        "label": "Percentage Of Shares Purchased At Fair Market Value Of Common Stock",
        "terseLabel": "Percentage of shares to be purchased"
       }
      }
     },
     "auth_ref": []
    },
    "caba_PersonnelExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "PersonnelExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfProfitAndLossFromSegmentsDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfProfitAndLossFromSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Personnel Expenses",
        "documentation": "Personnel Expenses",
        "terseLabel": "Personnel"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "caba_PreFundedWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "PreFundedWarrantsExercised",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-funded warrants exercised.",
        "label": "Pre-Funded Warrants Exercised",
        "terseLabel": "Warrants exercised"
       }
      }
     },
     "auth_ref": []
    },
    "caba_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-funded Warrants [Member]",
        "terseLabel": "Pre-funded Warrants",
        "documentation": "Pre-Funded Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r287"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, authorized shares",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r578"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, issued shares",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r287"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, outstanding shares",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r578",
      "r596",
      "r986",
      "r987"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.00001 par value: 10,000,000 shares authorized as of December 31, 2024 and December 31, 2023; no shares issued or outstanding at December 31, 2024 and December 31, 2023",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r505",
      "r695"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expenses and Other Current Assets [Member]",
        "terseLabel": "Prepaid Expenses and Other Current Assets",
        "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock, net of issuance costs",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised",
        "terseLabel": "Proceeds from the issuance of common stock under employee stock purchase plan",
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r11"
     ]
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale",
        "terseLabel": "Proceeds from maturities of investments",
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r143",
      "r863"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from issuance of common stock in connection with the exercise of stock options",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r11"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Net proceeds from exercise of warrants",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r844"
     ]
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductMember",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSubsequenteventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product [Member]",
        "terseLabel": "Net Sale Products",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSubsequenteventsAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r216",
      "r494",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r647",
      "r674",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r886",
      "r887",
      "r891",
      "r953",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSubsequenteventsAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r216",
      "r494",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r647",
      "r674",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r886",
      "r887",
      "r891",
      "r953",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r132",
      "r134",
      "r145",
      "r152",
      "r159",
      "r165",
      "r168",
      "r169",
      "r252",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r382",
      "r385",
      "r386",
      "r389",
      "r390",
      "r402",
      "r423",
      "r499",
      "r513",
      "r550",
      "r598",
      "r615",
      "r616",
      "r682",
      "r683",
      "r711",
      "r842",
      "r888"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r454"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property, Plant and Equipment",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r106",
      "r109",
      "r113"
     ]
    },
    "caba_PropertyPlantAndEquipmentEstimatedUsefulLives1": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives1",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lesser of estimated useful life or remaining lease term",
        "label": "Property Plant And Equipment Estimated Useful Lives 1",
        "documentation": "Property Plant And Equipment Estimated Useful Lives 1"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property, plant and equipment",
        "totalLabel": "Property, Plant and Equipment, Gross, Total",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r120",
      "r512"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r454"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Property, plant and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r454",
      "r500",
      "r512",
      "r695"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property, Plant and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r106",
      "r109",
      "r510"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property Plant and Equipment",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r454"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lesser of estimated useful life or remaining lease term",
        "label": "Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]",
        "documentation": "Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value."
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSubsequenteventsAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r271",
      "r272",
      "r273",
      "r274",
      "r296",
      "r304",
      "r334",
      "r335",
      "r336",
      "r345",
      "r408",
      "r467",
      "r476",
      "r493",
      "r528",
      "r530",
      "r538",
      "r568",
      "r569",
      "r621",
      "r625",
      "r627",
      "r628",
      "r632",
      "r644",
      "r645",
      "r668",
      "r673",
      "r678",
      "r687",
      "r688",
      "r692",
      "r693",
      "r698",
      "r704",
      "r882",
      "r890",
      "r931",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSubsequenteventsAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r271",
      "r272",
      "r273",
      "r274",
      "r296",
      "r304",
      "r334",
      "r335",
      "r336",
      "r345",
      "r408",
      "r467",
      "r476",
      "r493",
      "r528",
      "r530",
      "r538",
      "r568",
      "r569",
      "r621",
      "r625",
      "r627",
      "r628",
      "r632",
      "r644",
      "r645",
      "r668",
      "r673",
      "r678",
      "r687",
      "r688",
      "r692",
      "r693",
      "r698",
      "r704",
      "r882",
      "r890",
      "r931",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950"
     ]
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Profit and Loss From Segments",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r731",
      "r742",
      "r752",
      "r785"
     ]
    },
    "caba_RegentsOfUniversityOfCaliforniaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "RegentsOfUniversityOfCaliforniaMember",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regents of the university of California.",
        "label": "Regents Of University Of California [Member]",
        "terseLabel": "Penn"
       }
      }
     },
     "auth_ref": []
    },
    "caba_RemainingResearchAndDevelopmentExpenseToBeIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "RemainingResearchAndDevelopmentExpenseToBeIncurred",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining research and development expense to be incurred.",
        "label": "Remaining Research And Development Expense To Be Incurred",
        "terseLabel": "Remaining research and development expense to be incurred"
       }
      }
     },
     "auth_ref": []
    },
    "caba_RentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "RentExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rent expense.",
        "label": "Rent Expense",
        "terseLabel": "Rent expense"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "auth_ref": [
      "r154",
      "r155",
      "r284",
      "r289",
      "r457",
      "r477",
      "r501",
      "r650",
      "r651"
     ]
    },
    "caba_Rese-CelAndMuSK-CAARTMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "Rese-CelAndMuSK-CAARTMember",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rese-Cel and MuSK-CAART [Member]",
        "documentation": "Rese-Cel and MuSK-CAART [Member]",
        "terseLabel": "Rese-Cel and MuSK-CAART [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development expense",
        "totalLabel": "Research and Development Expense, Total",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r646",
      "r662",
      "r951"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseAbstract",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfProfitAndLossFromSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Abstract]",
        "terseLabel": "Research and development expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "verboseLabel": "Research and Development",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "caba_ResearchServiceAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "ResearchServiceAgreementMember",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research Service Agreement [Member]",
        "terseLabel": "Research Service Agreement",
        "documentation": "Research service agreement."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r732",
      "r743",
      "r753",
      "r786"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r733",
      "r744",
      "r754",
      "r787"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r740",
      "r751",
      "r761",
      "r794"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureBasisOfPresentationAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r84",
      "r508",
      "r535",
      "r537",
      "r548",
      "r579",
      "r695"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r156",
      "r157",
      "r158",
      "r160",
      "r165",
      "r167",
      "r169",
      "r253",
      "r254",
      "r265",
      "r372",
      "r373",
      "r379",
      "r380",
      "r381",
      "r383",
      "r384",
      "r385",
      "r393",
      "r395",
      "r396",
      "r398",
      "r400",
      "r433",
      "r435",
      "r532",
      "r534",
      "r551",
      "r986"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets obtained in exchange for operating lease obligations",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r450",
      "r694"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of use assets obtained in exchange for lease obligations",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r450",
      "r694"
     ]
    },
    "caba_Rule10B51ArrModifiedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "Rule10B51ArrModifiedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rule 10b51 Arr Modified Flag",
        "label": "Rule 10b5-1 Arrangement Modified [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Modified"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Shares Excluded from Calculation of Diluted Net Loss Per Share",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Schedule Of Available For Sale Securities [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Summary of Principal Components of Company's Deferred Tax Assets",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Basic and Diluted Earnings Per Share",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r855"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of Federal Statutory Income Tax Rate to Company's Effective Income Tax Rate",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r354",
      "r681",
      "r921"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Stock-Based Compensation",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "caba_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of estimated useful lives of property and equipment.",
        "label": "Schedule Of Estimated Useful Lives Of Property And Equipment Table [Text Block]",
        "terseLabel": "Schedule of Estimated Useful Lives for Property and Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r454"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r308",
      "r309",
      "r310",
      "r311",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r10",
      "r89"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of Assumptions Used to Estimate Fair Value of Stock Options",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r34",
      "r35",
      "r36",
      "r37",
      "r80",
      "r82",
      "r83",
      "r84",
      "r124",
      "r125",
      "r126",
      "r189",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r544",
      "r545",
      "r546",
      "r547",
      "r673",
      "r829",
      "r846"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r187",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r199",
      "r200",
      "r201",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r216",
      "r217",
      "r219",
      "r657",
      "r660",
      "r661",
      "r662",
      "r664",
      "r666",
      "r667"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segments",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r215",
      "r218",
      "r658",
      "r659",
      "r665"
     ]
    },
    "us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedArrangementsToObtainGoodsAndServicesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation",
        "totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Share-based compensation, vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r335"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility, maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r308",
      "r309",
      "r310",
      "r311",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Share-based compensation, number of shares available for grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of Shares, Options Exercisable",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Options Exercisable",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercised",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of shares, Forfeited/Cancelled",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r319"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of Shares, Granted",
        "terseLabel": "Number of options granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r317"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant-date fair value of stock options granted",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options outstanding aggregate intrinsic value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Aggregate Intrinsic Value, Ending Balance",
        "periodStartLabel": "Aggregate Intrinsic Value, Beginning Balance",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of Shares, Ending Balance",
        "periodStartLabel": "Number of Shares, Beginning Balance",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r314"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price, Ending Balance",
        "periodStartLabel": "Weighted Average Exercise Price, Beginning Balance",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r314"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options outstanding weighted average remaining contractual term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Term (years)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Share-based compensation unvested number of shares",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockBasedCompensationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r309",
      "r310",
      "r311",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Forfeited/Cancelled",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r319"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r317"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r312",
      "r331",
      "r332",
      "r333",
      "r334",
      "r337",
      "r340",
      "r341",
      "r342",
      "r343"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Options Exercisable",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term (years), Options Exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term (years), Options Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity and Share-Based Payments [Text Block]",
        "terseLabel": "Common Stock",
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP)."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r88"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Common stock price per share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "caba_SharesRemainingAvailableForIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "SharesRemainingAvailableForIssuance",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares available for issuance",
        "label": "shares remaining available for issuance",
        "documentation": "shares remaining available for issuance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Investments",
        "terseLabel": "Short-term investments",
        "totalLabel": "Short-Term Investments, Total",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r96",
      "r838"
     ]
    },
    "us-gaap_ShortTermInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermInvestmentsAbstract",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Investments [Abstract]",
        "terseLabel": "Short-term investments:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails2": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Lease, Cost",
        "terseLabel": "Short-term lease cost",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r447",
      "r694"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r151"
     ]
    },
    "caba_SponsoredResearchAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "SponsoredResearchAgreementsMember",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sponsored Research Agreements.",
        "label": "Sponsored Research Agreements [Member]",
        "terseLabel": "Sponsored Research Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "caba_StateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "StateMember",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "State [Member]",
        "documentation": "State [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r124",
      "r125",
      "r126",
      "r152",
      "r173",
      "r174",
      "r177",
      "r181",
      "r189",
      "r190",
      "r252",
      "r275",
      "r277",
      "r278",
      "r279",
      "r282",
      "r283",
      "r287",
      "r288",
      "r290",
      "r291",
      "r293",
      "r423",
      "r544",
      "r545",
      "r546",
      "r547",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r578",
      "r599",
      "r617",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r829",
      "r846",
      "r854"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "terseLabel": "Accumulated Other Comprehensive Income",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r58",
      "r62",
      "r63",
      "r115",
      "r137",
      "r138",
      "r139",
      "r156",
      "r157",
      "r158",
      "r160",
      "r165",
      "r167",
      "r169",
      "r188",
      "r253",
      "r254",
      "r265",
      "r295",
      "r372",
      "r373",
      "r379",
      "r380",
      "r381",
      "r383",
      "r384",
      "r385",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r400",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r433",
      "r435",
      "r456",
      "r515",
      "r532",
      "r533",
      "r534",
      "r551",
      "r617"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockBasedCompensationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r157",
      "r158",
      "r188",
      "r435",
      "r494",
      "r539",
      "r562",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r578",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r597",
      "r600",
      "r601",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r617",
      "r705"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockBasedCompensationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r157",
      "r158",
      "r188",
      "r220",
      "r435",
      "r494",
      "r539",
      "r562",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r578",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r597",
      "r600",
      "r601",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r617",
      "r705"
     ]
    },
    "caba_StevenNichtbergerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "StevenNichtbergerMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Steven Nichtberger [Member]",
        "label": "Steven Nichtberger [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "caba_StevenNichtbergerOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "StevenNichtbergerOneMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Steven Nichtberger One [Member]",
        "label": "Steven Nichtberger One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r735",
      "r746",
      "r756",
      "r789"
     ]
    },
    "us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock and pre-funded warrants for the purchase of common stock, net of issuance costs",
        "label": "Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants",
        "documentation": "Value of preferred stock and warrants for common stock issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "caba_StockIssuedDuringPeriodShareStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "StockIssuedDuringPeriodShareStockOptionsExercised",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period share stock options exercised.",
        "label": "Stock Issued During Period Share Stock Options Exercised",
        "terseLabel": "Issuance of common stock in connection with exercise of stock options, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock under employee stock purchase plan, Shares",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r57",
      "r58",
      "r84"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock, net of issuance costs, shares",
        "terseLabel": "Common stock issuance, shares",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r57",
      "r58",
      "r84",
      "r544",
      "r617",
      "r639"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Number of Shares, Exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r57",
      "r58",
      "r84",
      "r318"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock under employee stock purchase plan",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r57",
      "r58",
      "r84"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock, net of issuance costs",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Common stock issuance",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r57",
      "r58",
      "r84",
      "r551",
      "r617",
      "r639",
      "r711"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock in connection with exercise of stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r58",
      "r62",
      "r63",
      "r84"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r62",
      "r63",
      "r76",
      "r580",
      "r596",
      "r618",
      "r619",
      "r695",
      "r712",
      "r847",
      "r879",
      "r935",
      "r986"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "auth_ref": []
    },
    "caba_SubscriptionAndTechnologyTransferAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "SubscriptionAndTechnologyTransferAgreementMember",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subscription and technology transfer agreement.",
        "label": "Subscription And Technology Transfer Agreement [Member]",
        "terseLabel": "Subscription and Technology Transfer Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSubsequenteventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r431",
      "r459"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSubsequenteventsAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r431",
      "r459"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSubsequenteventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r431",
      "r459"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSubsequenteventsAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r431",
      "r459"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSubsequenteventsAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r431",
      "r459"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSubsequentEvent"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r458",
      "r460"
     ]
    },
    "us-gaap_SupplyCommitmentArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplyCommitmentArrangementMember",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSubsequenteventsAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supply Commitment Arrangement [Domain]",
        "terseLabel": "Supply Commitment Arrangement",
        "documentation": "This item is intended to be populated, by the entity, with Members identifying each supply commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r93"
     ]
    },
    "us-gaap_SupplyCommitmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplyCommitmentAxis",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSubsequenteventsAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supply Commitment [Axis]",
        "terseLabel": "Supply Commitment",
        "documentation": "Information by arrangements in which the entity has committed resources to supply goods or services to a customer."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r93"
     ]
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "caba_TerminationFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "TerminationFees",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination fees",
        "label": "Termination Fees",
        "documentation": "Termination Fees"
       }
      }
     },
     "auth_ref": []
    },
    "caba_TotalFinanceLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "TotalFinanceLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Finance Lease Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "terseLabel": "Total finance lease cost",
        "totalLabel": "Total finance lease cost"
       }
      }
     },
     "auth_ref": []
    },
    "caba_TotalFixedFinanceLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "TotalFixedFinanceLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails": {
       "parentTag": "caba_TotalFinanceLeaseCost",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Fixed Finance Lease Cost",
        "documentation": "Total Fixed Finance Lease Cost",
        "terseLabel": "Total Fixed Finance Lease Cost",
        "totalLabel": "Total Fixed Finance Lease Cost"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r774"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r286",
      "r292",
      "r399",
      "r422",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r516",
      "r684",
      "r685",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r696",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r875",
      "r876",
      "r877",
      "r878",
      "r927",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "caba_TwoThousandEighteenStockOptionAndGrantPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "TwoThousandEighteenStockOptionAndGrantPlanMember",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand eighteen stock option and grant plan.",
        "label": "Two Thousand Eighteen Stock Option And Grant Plan [Member]",
        "terseLabel": "2018 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "caba_TwoThousandNineteenEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "TwoThousandNineteenEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand nineteen employee stock purchase plan.",
        "label": "Two Thousand Nineteen Employee Stock Purchase Plan [Member]",
        "terseLabel": "2019 ESPP"
       }
      }
     },
     "auth_ref": []
    },
    "caba_TwoThousandNineteenStockOptionAndIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "TwoThousandNineteenStockOptionAndIncentivePlanMember",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand nineteen stock option and incentive plan.",
        "label": "Two Thousand Nineteen Stock Option And Incentive Plan [Member]",
        "terseLabel": "2019 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. Government securities",
        "verboseLabel": "U.S. Treasury securities - due in one year or less",
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)."
       }
      }
     },
     "auth_ref": [
      "r653",
      "r675",
      "r952"
     ]
    },
    "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Undistributed Earnings (Loss) Allocated to Participating Securities, Basic",
        "terseLabel": "Allocation of undistributed losses for basic computation",
        "totalLabel": "Undistributed Earnings (Loss) Allocated to Participating Securities, Basic, Total",
        "documentation": "Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r178",
      "r179"
     ]
    },
    "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted",
        "totalLabel": "Allocation of undistributed losses",
        "documentation": "Amount of undistributed earnings (loss) allocated to participating securities for the diluted earnings (loss) per share or per unit calculation under the two-class method."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r178",
      "r179",
      "r828"
     ]
    },
    "us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UndistributedEarningsLossAvailableToCommonShareholdersBasic",
     "crdr": "credit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Allocation of undistributed losses",
        "label": "Undistributed Earnings (Loss) Available to Common Shareholders, Basic",
        "terseLabel": "Allocation of undistributed losses attributable to common stockholders",
        "totalLabel": "Undistributed Earnings (Loss) Available to Common Shareholders, Basic, Total",
        "documentation": "Amount of undistributed earnings (loss) allocated to common stock as if earnings had been distributed. Excludes distributed earnings."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r179"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Interest or penalties related to uncertain income tax benefits",
        "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total",
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r680"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "crdr": "credit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized income tax benefits that would affect effective tax rate",
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate."
       }
      }
     },
     "auth_ref": [
      "r362",
      "r680"
     ]
    },
    "caba_UpfrontPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "UpfrontPayment",
     "crdr": "credit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureSubsequenteventsAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront license fee",
        "documentation": "Upfront payment",
        "label": "Upfront Payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r27",
      "r104",
      "r105",
      "r107",
      "r108"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase in valuation allowance",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r365"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails2": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable lease costs",
        "label": "Variable Lease, Cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r448",
      "r694"
     ]
    },
    "caba_VariableLeaseCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "VariableLeaseCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails": {
       "parentTag": "caba_TotalFinanceLeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Lease Costs",
        "documentation": "Variable Lease Costs",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "auth_ref": []
    },
    "caba_VotingCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "VotingCommonStockMember",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Voting Common Stock",
        "documentation": "Voting common stock.",
        "label": "Voting Common Stock [Member]",
        "terseLabel": "Voting Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r770"
     ]
    },
    "us-gaap_WarrantExercisePriceDecrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantExercisePriceDecrease",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant, Exercise Price, Decrease",
        "terseLabel": "Decrease in exercise price of Warrents",
        "documentation": "Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision."
       }
      }
     },
     "auth_ref": [
      "r294"
     ]
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
        "terseLabel": "Add: Conversion of non-voting to voting common shares outstanding",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment, Total",
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation."
       }
      }
     },
     "auth_ref": [
      "r855"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Weighted average number of shares used in diluted per share computation",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r181"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails",
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average number of shares used in basic per share computation",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "verboseLabel": "Weighted average common stock outstanding",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r181"
     ]
    },
    "caba_WorkOrdersTerm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "WorkOrdersTerm",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Work orders terms",
        "label": "Work Orders Term",
        "documentation": "Work Orders Term"
       }
      }
     },
     "auth_ref": []
    },
    "caba_WuXiAdvancedTherapiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "WuXiAdvancedTherapiesMember",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "WuXi Advanced Therapies.",
        "label": "Wu Xi Advanced Therapies [Member]",
        "terseLabel": "WuXi Advanced Therapies"
       }
      }
     },
     "auth_ref": []
    },
    "caba_WuxiAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20241231",
     "localname": "WuxiAgreementMember",
     "presentation": [
      "http://www.cabalettabio.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "WuXi Agreement [Member]",
        "documentation": "WuXi Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-12"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/710/tableOfContent"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "712",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/712/tableOfContent"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715/tableOfContent"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-9"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481155/840-10-25-5"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Subparagraph": "(Note 3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481418/840-10-55-40"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481501/840-20-50-1"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "65",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-65"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "66",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-66"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-21"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "12",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5D"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481639/420-10-35-4"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482190/360-10-35-3"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-2"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>87
<FILENAME>0000950170-25-047201-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-25-047201-xbrl.zip
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M+%E,LE1P*03Q8=] Q0\DJ/B^)#25TIA02ZE[B[N;. ?R7]HYT"9A@&%ZFPG
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M8/0_!-:3_*KE<Q^)_J3+%2JF!.-:$*DDB,\(5>782*(536(NPT@$O=6NMLK
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M5( LTCHD <(A\)X@?AQR#*(P*NAME]M>E4SIB0;^4I1>RWC$+$!*' 4^":*
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MYQ@]2 >B-)5QE#( 7<QF$#P%JR[BQ#"5<.Z' /.]M>IZS6Q7RT7=B]FX2'E
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M! T2PA,3^<HW0C*U&34"<T:J,?8@RK (%Y#903DIFFIZ4&ISW4U2XQ7CJKS
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M?I.86"DATH-=>IC#R\#0F"GMDRB5(0DT]XE(=$R2R(2!2*@2]-XE8]JPHW\
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MAPM%;P"^ ?@&X+L%^%Z&@9J*TZ[18MU&P>MM!Y<>=,-QR/5I/J0!KS:&5VS
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MY[A^YV1IT0SQB&?5FI'R1HG[,$:G*!G&+2LUL4UPZ/-X5( G$?]% >&P\VQ
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M#[*VPA) Q2$+T0$G_;T;_<^[]#^5B,8&=!,-Z%I%(3'=!T<)"(S3@F[V@!V
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MOT,M4IZ]PV+A*=^7RP*+]0^::IE&5LE![6L>(HM.-,[J6"&#R%%8W;:+=^3
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MY7)/D+H9I@&]L](8_OAG5NUTJ9[]6.7T&5D/V+AE)=V]'/=-NZD$!=*72?O
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M.CT:G>6^Y8Y+MJKM91PAED"0)5.C1W,L N'A9LL_6II2H;/NW613<=:F 0:
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MX-%Z?OGB7L1#F54-G83W%@.?:AXC/'^$YW\,Z1XW;ASA^2,\_U/ \_^VP?)
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M;O/9;)+\HUJ5C<H"_;/]PL^&KM$\>2K7L@?P.2-SNFAQQP1L9!'R3;@&*=K
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MB=YA4#'EKN-NT/SC;;?9L6!_<6[,EW0!SV$AN=(JIS9@&C5;Q;)J5$BE&%.
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M[!IP.]&$;,TCQRKLP#/'A-TQB-SCUR9MP*DU24PNH38.^B:0M^ (TXI*B8[
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M.F\O?YHJQV34G'I0-;V+3204F+=37BIT&?6%FEGQ=$+M(@1:X@]U-!P&'SP
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M4SEGKL(.DVBJ==1"F]ZX84(5+F9R8PWZKF!\\SF95#H>A!5+;J[U)PKYTYV
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MVOYLJQ$!M(RC,SX)S<*%F&5N+5_32^#ALBNA/YOO2KHA602*A\DDK1@1B J
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M0\]G?EAP\8UCL$W42(H 4@.(5KDT7RN]W5A9<3_2^M90+F-Z!%%D[[*X;&,
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M>P)$BEZ_;'C5UU&L7@5[K,RDQ&/)#R:-U^3%L6SU6,DX4]XQ!? "VO(B1V:
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M$'@T.*1YX.&,<N[*QBF5<R74MDX1KLH9YYSZNB5+B/(%@BC8C 6ZN_;Y1[4
MNCZFX0XK(\*\%2UVPEAO)JD<6_G3Q?-(Y1BD&IX-+:TGFA8:"+?7'.?-YW8C
M?F@^ &B/KPNK6LL=]E*)QW^>+MYPN!@MKM6?4YUAM6:!G18<9:KP.+JY&*]
MMA A+J,;C37)1IT*D1W2($]:A88=#6"DQ0&B*0$7L,G*=_+ @1LI*MS+QZJ1
MV34G7&8(H-!%3R=ES6$O-%/I\D'H+&*O%/Z43@%X+?3E!(+@\=$&<J</.-[>
M>[*9Z>+FCZU&U]+(9Z2JP!>8\</=Q)KOG.XY+;YG".,[DWZ6:V,<H/'ORTI1
MLC>M>T !JO)=H2S04-Q%HW XVX621L5JV1"[A(8(\Y:]J,_]4#+UE52!LGB/
M*A]JD'Q,[I#%6@X'!>C(N@Q]<=WDML831H(W?6R#^BR+$10$_LSIW/7Q*W6/
M?HCO^R^YDJF=1XGGUR[_\F_1#?*[/4G=B];SA0'\T119"O( S28 <=9W1$)S
MRP<:V:/"=CPS!V^9\"JR@GIC9DHOP6*P(54BK\)LMY/(B<;:<RX[+VXJ:A$:
MGLB^)ZZ>$#1[DF65+#<@5\Q[HYOA<G**C($0Y\X1M)\6'.5$(;O)+ F")5NV
M3;ZN]IYT\?U:/I&PSPVILNWI6:H#M?9*X,<Z.7'>6N?Q)C,A5]+K7):[+C!F
MA9<C;R5C[7#5/H^:U0:YOOW[/(I85?$B _3_26!I.DEG=&R=_+E<O5OFJW?X
MU= 7*@255_33\RHOMYVRN[&HU8M79V?3Y\'O=N]S,6!R(NE%O4.?^8(V.60X
M E\FK7TTD+O>E61;(U1+J #NA78+T>\0GDH&-RT+IFAE,3!I[I">'7Y;;%PV
M _2,$"'W$-4HR)?,R'!L!)_.W2D\)CJ'AKH(??U(2PNHD1L[Y%]"&IIWE_+G
MQ;NR7BMY69D*TY0U(E'T]E[GK5(:MM#82#5_=P-S271%-K)UF?J@HGN;6CSO
M ?-496Z?T/,$6#D\^G6AN9L\K/O4%G$E)79;!46XH Y7DF__-Y&]#\)O90<Y
M EQA8)XT&!\*XLLMF?&NT9I0$$"!YDDVEH86?6;R=8M]E$'!J],.8F;@$#0N
M/V^Y4PV%^H8G&2N-Y+K:( H"]H<(/[:^# G_::71%7D)48P0TP9*\8\(PC @
M>-62@\/$T'G%^EM-6S2 @2MCHUEZ1ZOHFMD0(%#<T?;6-+5B<^/6!PKF#N#<
MC367<[V_([N]T;:))2]%LH#6 XP<FW$^(X8*L&B, 0')T/)9TXVO+&]M;""E
M*CA]UQ L>CD'!M.#^Y;_PQ\>1N XBCR\.>BL#5%X_^JU]PR6XGSHOC(M\-#L
MI<&(NP8?AA@^#G1.!-7#=BG\(U%,0[B50Z['-;XPJ(U&T2X!;5:B4&8%D8"8
M&;\394BLZ*@(-)\G*2E0Q2R-%SCQKY'6XZTJY!ZR.KMHG@V@S^J$XS.C,RC\
M9<&B/Z5TTP0J]YN7L[4$BOQ$I]]*M)JB%1?71KY"/^OZJEA**IRV$<4XBS[?
MJNH4K\:+G!'Q.%?(.@S,HFS&B=?'O7CIY'' 6I/H'K(AKKF.'\\]W@-2-1<>
MV7P 08T$M_JA;#Y[?K.;_K[A$(#@@IX"]VWVV3@<F"8_(XHN""1=$W8FN_%B
M>.6!:8*S"OQE%9!W/XS0T:&._6 'EV,J$#M=I,%K_+J=';763WJMA1*42O^G
MG _K?)LS?4Y'NT9Z'91MQF,A0/!.+V\M!F*T>*27EALX8F<NQH,GT\RCJ3&J
MZLNO/@Z%BC6W3>57_L$D@&U(!MN9,VR->X<D23?,H>2^.J%MXZ[8@G.5S,D:
MMYVY!B:A(P?(Z'Q<%\5VM*GMO%;B$E[AQ3IP8J4<^@R-.7;&,3%=HJECW"8X
M>>M\M1KP:I;D1<+=Y.2>?ACUQY!X[,BJXD!!%H_5-M6EU0ZES>9$5'5.;;K4
MN.A2^_CG_)%=Y_?.^'B?/M"/KA5ISH+Z1+?(0_-<-&KFIJ/56E]68AS#.^-
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M."&8U=#6&U9$7"A,&\6U"B!'S'-7_H^BOBK;9HJFN2TXRL_(B67TE" _:-U
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M\4+3J(W\OZA N![5+KGI5QGZ=<' '3*H+D=MM!+R2)X" 9GN*W%.5IHEEH;
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MG"S:\N]$ :<476JU'%;\D8<!-#FNS[OO%_QN#XNW9M]T85GQ!@8AF&P#>\$
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M4M8=$I29@6H[\TK,LQL-V(3B 30+S>DR&11>HLTX],])1G7/+7QLT^CMM>0
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M%\^.]Z4H8J=@DHAXW[T.,X2B"%E%Q\YX?R5)H2=<R(RB8A?N[KM8X.JE3)H
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MC1(+57!=N@G_^F>O?<E+50'=%$5UMY43YUCL;J J*VMGYKZLO=:OWU@:MVO
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M<2=Y+*VAR.V]^%D4GM+32O8)Y%OHK/=T#-W0MJC7"-]'[,B#/:NA%[N@FQ2
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M#JR]8:XC:Z3QR 8>-5Q ?;J: M.F?5>R/-N*[B'MJ/$;+_AJ4J([^2W67@O
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M3R5[PT% ?EWMN?X0R.!,T.#?>@Y#4TO@K8:NHP9Y>E"XR-&DV7D'-U/7ED^
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M^:$"$;UTSEDB>\0).\"1T>E$[C_@8302-H2&$X'%'LE+;IL![KUG #M2R#<
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M,BH]YNW]P6[O+Q*HU=Q2C1*?\<Z#I491$DP*7%]I5E>^8_XJG??#H1,NYF!
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MHZ3SO) S:XU7QE@37?H)1W6:;-W9NA^*/Z<R,Y&M(T&$+O)R-2B/Q+8MZ&>
MX5+V1$.>=8J,M4M\N-LVL]282S\OE+Q0[M/;VFSN2*%/BP2]V4*\$%/GS^GG
MANZK$17I*7E7"%>A>5%K^5-'2A$ORYB?>G3MF!4%L#\%@&KS:";V/T'0T1C
M6815]S'*'X!E[&,T9#GXI;55WQX+_7!S*UI*AT(] O_FY._^G?OF8F,M%'[Q
M%'UL5)G2U1^+1VLS G?1F3@D^^BM-""A"TZ(O4,G-G2%%BU8@!@[O*,ANIK9
M]T-+?L*.+OX,FW"$2.E=YT^.,2+EI(>_]"6)D>S1W$?EE, 'YU#H&H!T<R 7
M6Z<AP!F?=>AYEG\?PPOX@/2"E]EN:N:!,DXF2/2R(%/'O) LFM9T?>!VB&@/
M/,@6X-NCZV.X_D0W(G$Q V7PS'F[/#/LI*?0I8F=;@TX>62812M6(JWY0?*&
MQ[.A(36>[<FA-YN[00V\-.<A1,\>VB19"]D_7'B<\6[',Q[Z<"+:9:_E%S]:
MTF8 ,N5"!\+?TKMDE/K#W8._IRTOXOM..+9EQQTOJ$#+S1;B=U+=/4TIN$WW
M5E=S,C#:3=-VKL6WVL>CY!7U0$;5T+[:<B<@+!RL"TR2(\NZZQHR.JQA[OJ]
MO8%H.=5"$"6#'IW'(-XKM>6_Q_9RQ8LSJ+/X;F_?^<+[F*N5,GTY1_U_XF%?
M#5$#C37."4J=<>D3-J*,3\\!P^\]8.@#GUM]%!Z 3FBXO.<TIR2B&=38[4\U
MP'.&-%OZP[)T/:<TNO L;;>I-);2\*1<9I']&ZR]#*PHS+/&3"/H)11BLJ)>
M*B.\409]@X_DM9#7PD/9]3D\NI#PR&)JL?K3J"6X:4[*:1S&;!T 3^B[[J31
M>_9K%];73&9>[G,*YX08RN/SVE.J"N_#4PSDF'?T[EY\%#M%\=(H#26<DZVP
M))W)V)QIS(_H#.[:F&\,!W'<SG6W4SF>D$(XGR_R^0&F>D6S ;T8;<JM_20O
M^5P!U:U$C.RBF;['TGRW,.:A?E<W-S6P(:PTPB$DBVAZ9JA"^10FK-<=:SAM
M8\V;J+7YI,8G+*95MD3]F@IBZK6\P<S(BXZ#7HGH#FW)Q*"=?<LS[^D-]$^<
MC9(FZ<WTI1O3MSZZ)Y*0'! S!NR:"B3#2F;)U(J]< 0;XYC273R"S$OFZKD+
M5T^Q0,JS#VR1](YWY'/1.HY(!H62K>S#ZF-29EKC@S#U.)^^5B/W)&O&HL$(
M%18UY$^%-07:$;;_1'.1%FR:YXD.Y8CP74HGG,P^([=&HRDK66LQ+"93_3QJ
M%^$G"#$Q:^FZ:0^-I-UI)W[ZV9.O52N@5$X&!6!M%MPLQ49I*"POX%JP-*9^
M@)E3H'F%"SX;KE LHNO^2:D=?M'E_E'4/S.[^K,WKYB%G0ZHXL >2K=XWEPN
M%W_O-Y<</.$C?*J\HF.+N60_>_KT<O&L.B<QRIG17CP0JV?XG$62I8AR&5SG
MB#E_/K"4X=$R\'<GH@ZA"E6189%9K)DOZ%!>-_U4M6-Y!EB05@?\%T?@:ZF!
MQ!.[O+=*R$P%Y-6)P]Y>IDGJ2561K+U;AH(6C1-O1\E(^'1G70Z^[Q[3KX1G
MP>$,+@JH?*]!5:0.2C3.L;-GA<\/0?[%1X5D[WEHM]9\/K#,DV7'<O/PK] \
M_#0W#^?FX4]@6+?*COUN734<?&?BC"!?(V",BL4<-/5#@RHWT*F^;JIK#D&5
M[Y[^0(=NZ2"S<GN,$C.L^.!$NA,ETQ.%))%HAQS:9M6@B(1FJ V=05EU]$C&
MZH^Q=.P32<!CU:'H)CY@:D,(%*N;QL%/R'4=^4SEDSTD2D)2+,Z.D-=) ;QC
M]D-X#6WI:A5!,/_I@MV_2'8!L)/Q?/,4=Y<+D1)7-X1VAY;#.R[BRP!BQW"9
M1H$\8#01.7(*WH@,&3X4LZL5^@Y.*'^%21;NNVZ:X0C<CW=E>S0*]V)Q7=#\
M]%R[VYIB^3ZA%(=_'>F,,PMW4S%C7>#CXU0*^/LUE0)[ 1,YYJR%_0P'RQ'I
M4VC-4$=8'879LQZDEQ ,?6)DM&\@T84ZC4\LA3F)33:'B:,P4=<]D%=BO<J-
M>+%C,1EZ$]P&UXW:W)PFAJ=%WE-><(AW\(GGSUXOW@JO^#/^)^]<QHW3>0P:
M8&=8Y4"A*G?QM+O'4*&I[A"'J-80U]\TBY<B+O<VZ05Z;<G=-_+EQ3/3#Y'X
MB+4(:(AO[0-=^(2.__7;9S-_3,D;EQJ.<<E#?X-+3[^GSPY-(UX4].3\),PN
MJYOT1-H+J> +FL))'&67F)F:LO/G#J]R#!;R+IM(J@;$J$O><>6/ZR1)) _%
M^$R_-2=BV.Q",<&J:P$>E'P8:"%M.%R00#V _ML,L!BRNKFWSQ(MHP9-_TQT
M@9?#F_^YD!<EP%:9$.S:7C!.MPF&#(=.R>_BNL?+B7&]53#HW!M6^Q -&_OU
M'=\!?^G3O /5'?_%L_]B.ZW_A!:+$-7+T4^SN2L/7NHJ)!#PO[5K/3=AR#2B
M[) ^1 3HUGD/9YV=!J);(<5S,@5Z*LE@B<J85@_6O14\K(3@#UJ5WM23]AEG
M1\^-B2-^=B)$9<BOT/&C&D O4*K.^1]I4>ZT X**2/"7U/. 6@[;];P',I90
M/777C>O6;;ER2'JTKJSS>9C2!R=)Q*NVV'<>;IY4Z$+R\%1Q,))Q37X[5PN,
M]ZB?:>?IX'2+$0>@^&COXU;T9>A"M\0_62,4;=FNK74I3@,V[149E22MEDF9
M,U*X&G.TA^R>,9&J$!H9O<_4P5.S+!TO2?,".$M(NZ+U],J\RCS/SJ\!Z8_I
M[-+WZV3N$WQ^-,NT@\521"=RPMSEL'(I?WMXTCG\#YZ9IN44#BA,"F*N4?(N
MX-ES@?#?I$ (=]G,?S.U_S-%MUM*VS/K)Y8FB-C,)87=C0C]K6ZM832WQ=0#
MDX9C/P Z(Q?X'O5)=9<V+NOL]I(:OMNNJHH5BH+8\+ +AJ:;D\U=ON*@WL_T
M>(ANQ&(>099#QK60^579R[6V#ETU#<RWJ38S.A=W*>MI0<]Q@BRT)HU+-P;U
MN>4X5]3F'4YOB+&J4Q:(6>;/TZ5*NDF%T(?1)YEGDD/]KN<P1*;O?A;?LO_8
MMM*D.X?/_GAO$YY&SQMAB&-RWT1&T/[N$;3TS0 !2 K$=V(^CZO&J[%>3U<U
M-ZZ5 C'MHGN1)*:'OHGS>9%<F,>\:<4[5>7P:=>)('? _1;K@E4XQZB"2&\Q
M-W#D)7>?2V[D4WOTS8M_?'?!Z6J.FZ,EEX!U5%:#M30$>4&&+X)!0=X\VWBV
M\?MM4E+BO[LT*]V2K. E(C"N&5+/J)%)KF8+1ZM\TK)D-!XC"AW)J' 7?G):
MW(J5LI E2WSD]?<@U]_HC(E%*%%G8?JHONRVHHUM,(T/6):F?@B]RJ5$U&O\
M0[3"!6#K92U%.A.9@-HAP%9]R[R^\OIZI.M+H=G7185RV'*Q&83B28EM0*XC
M.)20:^K MBO].O%Q)8JO9=>!'2.NL$G-\^3R.+DT&#Q,BR<OD;Q$[GN)6/)T
M"H4ANT5,8S";&1M?.?SQBB:0\5^:-@C)@FS?V;[OV[XU>]:ZM2L/;.D!=#)+
M8LMBSA_F:64[SW9^WW:.G"Q]L-;FT,/NV-$N7##P@\%0Z,L&DR%'Y8K))H>(
M04CD^ ]]R:4YN/6;YM"?9]@YZ]YP_()# 6ND*??[H78 8J"1OT.[/GWK6T9I
MBI8\9A38WH9Q==I/V"L7@$G=X$>]1EYN>;D]E,A=P43^9ZMU&)A/8H2;'1TJ
MJ*AHB0,K)&&8M/+VR8Y+8+14]>,7QN-+*^W3_T.E' 7NFG%=/,03J;T(BK9<
MT %9^BYS6YC1,.F<18]%Y4;>I'J2,;>@,$J@$,UWI\/6(WT-F?PW##(%T?Z
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M"0R348:6PL&Z,\!%T<O2TGT$)*%[S"%KBG/PO0=_FAQR:"H&O0/]UP*_7V.
M2^641.RD;QNN1"MJ1+R9"#(0SB-]&U/.>]_EX@W.(=D'F8@0G%AA2[*KA W)
M]C0CO(AW'_$\:C+H,!S9C( ]T2V4^5<H]G:US1DB\[)R5_1CYVIP"RH#AFUJ
M,UMR#FT>[N[TPQW//_PM<E/)X5-0ZK_$P[N"VV4GL/$YZ"4Y;>:$@1/M1(T_
M^VK8;L&9E93@(6K8(H/J=D5[XK3'+M5>JYZ&.08+ID+DBSS][,F?%V_XHZ\.
M7DSYA7^\'SAV:Z(/RV_0A$(+"KMF=?2)0/;L_V]!D14Y=$+ \V5@S)S_SL(5
MM&K]EV+Y$9\)X\W(-N[T^G]>8B_XXC_-N^@;'!,GY\:8+N1%#+V73*.!1]Q!
MWE=!OEZ."U#?;(IV<:1=7Y*_G'2ACT]NYG=*WJ>8_K0IV@U#Y.P-(]'(29OY
M/R]<Q9K5<-J%(#FP#4_N%[(ZVZ#B*!;'DZM#'OM73 D;^-MG7+:E%B_NXH61
MT?A+,%OK,_I[M?B:W]+GRU//R=*4Q@-52,2)+Q@AM<'%I]ZA4D0LF7B55MUF
MKTQ$(U-5X\4/BV?VN>5D5B,RI<G\AJ5\;AGQ'>B%?[ZD/0K_7[^_Q%'ULY+D
MA/!1(V@ P^I.O PLW;)'>!:94!\1YDJGO8U:'M66^(,]17+'9^[X_,B.SR]S
MQV?N^/P-.S[O\,3_3E[NH6FJZ#1+C\J0LZ4#]V>A[C+Z\ALZS]F1#214$C3M
M2C[XPC?T.)]\T0=?W@U6$BB$S.0?&2$5QK4OKNJR1R*6?A$=WNHVH"6 _JP^
M3 C;3-%W6X:2V>:ZE'-_KX6IJGR'2OJV9)HL*SMRJC8\FWPY/H0W<L;;(:R3
M*$Y,<)8[<5!"1]O8&;$L:4JI" >GW+A)T"$SWK/P,&H%0L,E5&&]5H;];'*!
M!$FWLF'7J[]IV"$<UT<$JPZ??Z,4^].!_@KLQQ]S*#VP5?,L""F)<A(K'5F:
M("U-DY'L$R$$:0M#WHO^&6H/'I@P)DL:I?T#S9MXX7.Q'Y>A&,GQV[^W!Y16
M_V6\_?#-7\1=3#]H%]-]99L_(GN3ZR>W)* 91+5SQ759L3:2(<0"E\W&&M7N
MUI6IT*I:0@5-^0[M'5D6"Q8^27CVF2_U&"[4K&BV=3\(9XX_3$?\J?-#U4?3
MXFC282<U0SD8@3\T<(A5C@QV4NY1)H[R8U[G)1=E'K-#^"H%8'RP<@5X0G4Y
M":LF&WR\H*3\*&M*K>JVI<49+=F=AV[2%'H)! >M@ +$PDLI6#"?9[2N,=J_
MJRD_,RX-,?\?7"UG[O/_?O6#Y;UNR'/C0)AK39PQ@E_WIZ7WY_24[OG8H+_^
MWX'N!-=/_#$#+MK'Z1,O"WS@Z6?\]U?KOD&NB7[Q9)D46SUJ6 KG]-T_%'\D
M1XY>VX5[OZYHG5W38^+'CNM'2"))Q;UIJPW@J*%$9<N7GV!N:I5FMQ(/-9D+
M?&E?O*,+,^AN7VR$2W8(3';"JGT#V,AJ6[I*.,CI \O%'U9_C#S+@O\0'IIG
M$A)4_GG\X,FO;8Y%U1\O5O0,V-/T(9:V7>EN)'"5E?^K[(:V@R.)-S#/^-QC
M^T?CL:)ZM10P)7O-7F1:=KGT:5FZ$16PV<?&M_ZPOO71QV_SSD]O_+.ADG]V
M"O!"57FJ6T"VZV+7W)B1V\\*QT!USKZZ;DNNF2FLP'1"63UP/V NP3^,A23H
MQ_7.;0;8X-1FSLSQTB88=^$OR,\X=.\ZY1*HH> 76'RQVK^WR3VU[E\\>_/J
MW'*/5NC3VU9H$;] _UK]ZDM?RTF+U,UV&?=,+D?;KM\J&5KIWE.P5_:+MW3Q
MJ@J3)KE*>3?/OZ-PU+HSZ3$.C3!O;TH*JINNE%HF AB&:K3"G&^."L+QH6_*
M_7Z0VC&]>?N)SD>5B<-\[8:]%,3D3IC>,.4>*\>S+',<E1ULHB*:HZ3"+QGS
MF4_Y'7PI6Q;7L'!G&%(7:,ICH('IN\U=C2;1OGE-RZ\9,)=T3@L\GLY69!;H
MT0_%4>)W7:VH71MP/9QFL:\&=&TW%E&ZW;D3XE [.J68(C^E#-6SDQ  T_&>
M*?6%PE/P3R>"Q??$RD7#%S $_OI(;U0;V$]QW;_5.RD&2/6'F_E7:9!),T.'
MK2Y\.?J6W_UF:OWX&#VRHAEK=]6(N A24WP'Y(KXS$Z=X#&,&C"U7)Y_N'[J
M3ZGTP!33ZE^O C-C%A'>?*Y])X;WEG1[N_DPE0#=8GBA;1I6&9P#RNB(Q_II
M/I44+7/N#U@@S=B8O$[7*_P_^JVV(P%VJ>U(+[2WB5=M+*D6MRH(/#;!6WF=
M )H*>LRUS%'$[>K#0'>HZ.5*P=7X+([S[1\;.JR;>9GJZ,KI\<8I-7:=@@^0
MB@A'9>E):BU-O4FSAL&&):'*.%YK,>HLJTNV<0';.&I<XN&_'%;K/64#I,=0
M%?N-)Z.)L=+S2MZI^!+#O",U'U=*J(!C].>AEAV0/KLK5V4H@4MK8M.J(XB^
M7*TL1W]&"XD_0\P58MU>#KJ.>EXI1.V_8FXUH1Y,JM)<9XXCK;PA/M@-4>5N
M .U;"N@-)))%-U*]G[H#&@$:ZH5>M3;Y:=^$@-N4R$S[T30C=HAU@@7QYL6L
M^7*RFN##7G.?6K1G>!QZR S,;-6CV'X,2DZ=S*7\K _42?P7@3*]$YPD'[Q3
M(=D%<;ODJ\%[':/![I9+X!\_Q7"X:W++KYI6\XZQ4BP-([M<61\&'JK$.&E4
M+W+*G8N&$C<*C-MDE;E>]T4K5YE! (5CKUR3(GY[C%&D0+0AA+2)PG.OR)<6
M,1VG?#.I7O2+;=J%TJ:>.PI\?'[$/*DP&R#+1\=L+++.AWB/K9-;M_7!FG;.
MJD=O8SEJA^/78E?@=3)S"7\"H[%G$WNV.F'^FN<3;I'W?(J3'><O!\N*.K(<
MR-AO]AV,8\5NM\E;_,/=XK]3%CV)>UKI[.QOH.4^!.5S6R^2A1PM& #=VC-$
M?3%>;1JDQ?$F[3KL#UK=+,LA95Z1S"L2]7KJ7FNUBP"RF?H.S=B3&55$V@.@
M'CA.+FS! 8J:*::RP=^OP=_L'!NIU[)L 3M7Z/)=[=PN @>'W16YBK:)A^-H
MS2$TPYFRW6>[?PAV;P!#>ETNK@W!#XM"70VAT?;.?7C">"QE\3DO3+%EYK:)
M<U]*3TBT),)G.$ZW1975ES(6_Y-@\;_*6/R,Q?\-L?CY/,_G^6]C@4D*+@!J
MIM#/D/M+*XJ*\ BYR.N4XDJ6=U.#\B)';=G:[]W:/:HEP9R,*XOP,(?.I0XI
MPKO@VS)W:>7KA6.L\[QX^VW5=$YFATJ)X-..FG.<'7JF%<[KZK[7%;-_Q<1&
MZ$2K0^N.QUN&ZK]G#?NY*4%R!NB=XI]TW<U'B,HN$!+[ LSU10"K@V5:X#M4
MRS<?5%>9JT.&LLJ,#<P*(LD6*:CK@8D"UKM$6'D$VJ']"]IW!MA@]"<S^&RM
M/'P25AJ5 )M6,4+:LA;:&N7Z4I^TZRH:=N:J92<E?1D_ [FU_V12,Y(S)1G#
MB4<$;CA&<"FTD@F+QL!+P1N0J>V6<X^X_67/A/S*79^+J5CJ4Q"K".4ZATJ+
MIN?7Q:(I5$G!'F,JZW I)JQ.@601K74NN\9[Q8MMV"%@'*=6FBY>3H2;I[2,
MP7,)I-FCKEDZ?7\HRG;,?AHP"]'V<X*Q>9:H? YZI_2;VX%)M4ZB#6X!XCT"
MF$#N?;S%J+EO4-CMM.>\=\JL"J-N2]>#;:DN3+M)VM]G>Q]#^^P8@A U(\XU
M/+:.=ZIB0[LG_2;!JD5 <U%1BWK5F4=*R;> 0<]MAX]ZCT5[AQ$#2Q\/=X!4
M] A.\*N*98VV1X^@#KID)\Q335L;56#&/];<1?6F]US%DM]9@U&X+=TT%#[5
MXR#(9\4+FQE7_IZ,]Q)$G%)5G.X=7II88$R!:"O T;VY :<6KBK1")>/<YL9
MG CF5HV8\F_#2_,"#3-:K'=,TTWCHM<3-!K"YJ"SX#<'RU\O_<FW+2O%M<WT
M4(<>Z?F74*S:IMAH0D%:.'0[.HEW.]V(#)3D#")/;F32*UJ6@_?'N'AIQ^.^
M'/?>Y,#<A:AE&.FW$OL'_W]FQ\(\)-A9Q]S4M</M,'50*/#4_G/ P5-- (RK
MQ*C(R@1>F1VV9#.)WKO9)XZO5=F,:[)8$32>@:D)E8<5BU]4/YBLL%OLR&CI
M7Y['^W+QCR8&M!X:>F?'40R(-,@&75U;K^H,;UY@L;>.Q#"E._0EDE=VI=SR
M6/BSBT?,@C'?)I/^\T"1++C284PCDCX1:NS3]JQTC8[W/QIS+%TZ'K!U'@H/
M"9_.UPWD&_Q:JFA^Y+O<VDC__N< NG@&C\LVA<?E?"(*G\I5LT(8/@*U[B7<
MZS7YQS(\A695Y.&,J6\I>"QT\U4LCK.TW=BVO=3UQ>>&0-6?=JG3;C.UA1]4
M^'AN!0=(]:1G)"T?'$#H4Z[->"+C8.,1JQ$0>'S]08@D16T'XC6%5U5F>)BD
MER;?PWS);B;I"JEL1,(U#$V7*_EIHH??.YI=]>V,BW1;MET?]KNY_;:,UQ/R
M87TEYAS [Q%E_:%5[MR7' 8_^0HTDD\^7\[:_6@,DF^S;M[9^_S Q1WKR=R*
M2 R:$UQH-68:)K01P<9 OB/^+UV ')(K>IV[4G$?:LC1198G<>"W>![)<A4D
M]_&@C*G<P32P2IFS5_WD3Z9V(92IICDO.T$'!0+N_A"_1/O#HKZ!TXC_FYD#
M[L8IM-S/-6=K)"+P2<[(6*/V#\;6GUXE2Z\F<.-\LNW<G=G2@H7&WEUH^K<Q
M/8) ]7=[3K\D0VQXT:]<H+7R)*OH& [[F2;G:NNM+SAH+=F;Q,MN..,ZV>\C
M_]O+H-W=-L."N*EE9?E>)77/USM:6*Z^"E9/OG:;-)0T8'9SMWJ]4QH3O44"
M@@SG!D(,YR>+/K2G'^PHYTU4V_[XII=O:.\+U>RW+84JB)P7KWATO A_?//#
MVU>26'4L8:)G.#\:>5+]A5 +M^ZZI-?-KO-F8+J_C6-A,FU<7#NF3N8^1SR0
M.AF\U'^C]?A+PW*&6_/\NNY!;1TZZ?.G(/;K@_FZ:3R[1T,?AQCAO2Q$KWOJ
M)BZ]/5O;:>H"S7:LP5G"S>!7U-92-'(OM=.9-V>_9#H5QK3>_:H162 CT-#E
M"^.3&ZHGO7(875VT+1QJE@W :N<,%'U^YRH<DG[55T[Y#!I1/RNE32R-C55&
M*<TP=#UZE/G9Q)4:.E6_B9.E+"! 7Z^*EB^/C5Q$)28(4.W^];)-[(</K7?!
MH\E-3[5Y0.DT&1$[^5>T38JUF%#25AJ]?:5B1K.==D<7F,0BL5*U/[I&+6M_
M4GNP+=5&CFGA]QVB=NFAID";;D^O<<M*P>VBVU$(STUHO56S1CG")#F=F]0>
M\*'^?%?PT@Y][9%15\6-QJIQ4\O(\OE#=\[380LQ%53^BH_@XF,^[3-&%HUW
MCT72L1/M=V'US43.\A1;OX6F@U&Z 9\NBR%CRF.D<''9B_QOM546CDUTD\DL
MC/R$[_\_]KZUNVTCV_*O\,M=T[T6I+:==_N3HCAIWQNWLVSG9N8C2!9)M$&
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M=5EX BCF+ XU_ (.>\CN-UU?%9$#9(#EX[S5O4TTS,;\.2X1']JU!7FW?I>
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MQ*:)#IGJ4!RG!KU1<9SF;%0C#WV0H1#^/B^:H*\36=4BN%-TS$5CP('IG4_
M#YH;NB*AVU-;-E.\:J%I4U#P2,^&< -20.)&3J;:6A%H&C_@ZTVT:)\86)(K
MF_)\7%0G$ [EQ&T H=@66KX4PAGB[-C_S[D7_/Z>[3/Z=4:_?B3Z];L9_3JC
M7^\"_?IY.'O<&0U19^;#<\"8<?HS\$0J+R)1#-"!:<A -43(*W(J'&6A('R6
M=!U(3T.M'O+ET(/5LR;"*<TL4PP8E-G+?,5PP2M7PA?KI7=+^I;JM/+I=5.
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M!$Q<%IJS_!-CI$5(3^K+GEI7*H:0YG+++*C%'[5%BQ+; \H_Z]YL^QR*3B[
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M%P5^UC(!F!SH4![\GRR][,9QSV-3'_-2A!W17+AX^ .(J_;OOL:<E7X3/18
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M;>JRJ)^&'10"GGDGS3OI#PL*,H'^CA=K  -CT;@L\R5PF"$"GJAI%-2S=$[
M\"S-B+NQLZJ4[7"S1!A7.A>GX/M:)9%J0 6D"8'O&R&T4CD5VA%#C37OLWF?
M_3GW&4F@)G7<F)MM%7.U$'U=T9B-.>^.>7?<$W\NR?5LD4AYV?E+YF-B:JC8
M]K3^7<0U;;\DN#+3>AS:7J9X<3CLFW?)O$ON<I<4V"ISJ-L6>4BU"6CJ0)G0
M]U35L-+E:^V(T5:C>97/J_Q.5WG<U:OHJ!I832C]AM$%AOZ(I3'-8Z;+A1I
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M5C%Q@@E\3*\LE?LZ<E:QAM_JW1*)*KZ9I2M5/S3<?>JV?HY$/!>^%+_*$68
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MZP?GS30$V$^^R!9/'CWY,L//%A>'PQNWRL#L.GJ< QME^JE(AJU9D,+[$9
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MHK55[G_WD(6BQ+M)]<J?,\T#<_X?;S_8S3<?1AQX&OEP*X]8)8JI@]3S53$
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MX\/Q*Y/7V4!Z',H;])+]Q*RUWPYO5\!,![""1@R#ORNO;*03!P_O9^5K>OS
M,SP<Q#D[6&#S3\R^=//$3ITNP@^8&7P[C[^-7P]D6/T&Y]=TOO@1<$WX,EE1
M2[T;%ZC M'=S[<W@.A>NT\D[XRJ7/<4[C_VNQ)-3W9POC5]4.4Y:2R0R0?2<
MU[&X0[YV_\:V$T7(DJ-KZ%07I'O,#\GL7WG;]GOMHBR6EK/8OL51_W],3^6H
M+H(=,#4R59%";\GMS+CSN$ND-:+1B":#B<FBG+:E\E+74%OY<B5]UE(8W5_X
M3M^/F&+QS!^*AIX@24X0GF+P"%E$DH4$F93(AZH!M&K#T'4^8-ZK6#?[6H(=
M*(5A$"MSXKV'1CIKS/UI%<P.[OWU&-Z@37CUYN(CG(0?W;+!MF1R$K[^=$["
M]+@^M9,P<:>1D_ !I_/40TR>SD/[_VGL_L0P9KL_V_W9[G^6=G^00INP]OVA
MK@;FG-/RNCX,GNA%__I_SLC)Y.4<&NT_E)( B,JNZ^;M DN,UFX/GF##)8,I
MMH);,5H8#8\R]U9J_0!8#'[5&3%S;.<LXQ0L!Z# M<'YSNK,OX*"9*S;'HCF
MD%!F^$>X'TBY#8H8G+36*8"AFR7@YWK;Y/M6R6%^T,N^ALL2XTD.6-Z"J.V
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MNOT K\Z?7JO[+G& (?P>]@T,P\[QS?Q^ECU,<XM%-.]QED":X\]F+7]YQY;
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M]*K%#8_ET/']T]7C,I<-!5)L$9^"ZP$N.N4<2*(9O(F9$B)A#F> ]0RP_DB
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M=]CAG:2X"86##R.[0?$:C1^#O"=BA5&4#%"#-U/;",01<OPEPI@_);M-(.;
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M?*:)ID-+;'D6$UL>0W,&D5LJI27P;T<<E^#\^8@ .F6GZ2ZYW7;9*H\ZNW^
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MQ'XW[UD2=YCR4)V'?;X&AQ))KYC6@#@944CY^<0[2%LHU*% G9@%H1*!FKQ
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M[+PE%[+GDLE5RS(<<>Y<ID*=9#]<B*+9%6ZWSFWAD8X-9;D;SI[XSU/ZQ+_
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MTCJQ-1_U/W\>NZJG0_V [6[VD>R>3EX( 8RW(4I#%I!37_Y*.$N"WUM2XS)
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M;GW9<(1.<>L;<8"B=^[\9+?4AF5:UU9NN":JHFWQLY:KN;1#E^#/NZ!32;.
MK/ -SM!%W:[B=]?31C^I1,;X5CX??7T)$%F(V?A2-P4DTI5X>$]K/YB#=&A_
M@WCD(>PC'W+9"!<IJ;R/@?T+DM+D+V2]G\2W#XWO-& _5/WK/ON!3F#>-UXV
MK /^0PQB7JYJD9CME[G^L/,>!@YP@WSM+>USJI%GLMNM6(VY6!NM)LEB)8#P
M@"95\6"C$VQRAE:WE\KC=%C1-:\#+-<"?IS_&+;\5$:6X 3U7L6SS2-8Y=_.
M0AC&AKJ622U(X 0K?_H),NI7D+I?T-_WO:4\/Z8@K4 +730WR D+L08+?_=C
M=^7\+[CWM57(%3L'D"C/&5"WWK.'-G8F&WX(T: N;X6E,P>[P@H/.K'U$8J,
M]OCL:^:7UT[S[ZH@&_X*- X7 L_]^KM7>9*5#A);QS8$DW5W%(Q.0';<X<$L
M![C?Q5B13[.[W/=^;1$.MR6I>OTS0YS :Q?7?*V8O*A%X$>/RI(Q/>9W#J+4
M0:L'$'<K+M]NW7#IW=$Y1)Z5KZ=!HH395NB"_+W:>LK=;U079%SZ&R%A47)+
M ,B4_Z<_*E=?+I16^*=][#RZ9E?\T!0^X&/D^A<73CXQ5#U?IVNWK3PE0@V2
ML6"X)3>'^1DE1CDE"+S)?-,-U2]7<M^OQ,,^W.KM?*,"WKO4!A1F:LHUP*1B
M!5AP!^$38_][U1"T(AHMCP'W8]O$IG]J0+E[<\A@MV?P+/;K]5^_^Y[G^Z_G
MW_<!;)6JE\:%3GXOC4R"F(2B'9D;CL'"9ORI(F3TU;K9@92G PPU5+:J!K@_
M!=(49!_][.,+?PCJQ+R=T,JI!@6SEL@!TUM!?Y&'=)X]GTMJS-D:XC_FJ@B/
M0W[ BJ T&ORFX+7T;3F';'ZC$""!D&.Q=<$LRNF!'&T,D"4!X/O@N!"(MC\;
MTY(G4WL-J?79* @8.:[>%P*6),IQ20.D#QQ6)Q,]$(366QX>D@9^JCHA0TF/
M%F1/J/M&23KH!UXC=F$\7],:]+\'PL?$J^)27%^V6_A7;?>:-8!MY0]^3XG2
M*('G&\<+QP=NM,9IXFD)4,S/J.(P4M&4[.@D[Y[K:ZAM3$;K2(>EANM\T##7
MARZ<HA&D\S"6>R,?9'9U6?Y<;X>==G;)3PTN\G.\(!8L>DP(I+S<-G[/I" &
M<T9Z*1"<?OP8)]J+KU[^X"W*DH4$JC<N^-.58L4? Z_]L7WUAL9ZN SV[%^K
MXL6GHT 73 /XN.:8 R4MRRL$E?ULIFEBBS<LB&5+W!PZP.H2ZRW]&;FN1"\R
M"#92NH)8?L!=4_5Q*XR5)(M>\*N_?>WL)4*KF2EKKY2/Y!<13OD]^8H!,6 B
MHF.[FP"6^7R6;3P<W5DWUM&1DJ/2&X2WNPO9'_()IIUK0'Y(Z7GZ<4MH%^L+
MJ"NDX$.YM^F!4H[@GGLW9E3;Y2RD39L0QZ7KU]XW87C6K-'HHL)5/Q*"QCX#
M%^VC+]K-Y@1.#_T=OSO[XN.<);.*\*#>D/PL=_L36:[$VHFN(XB%8;_S-]6T
MG<GNL7LP<3O#D*>?K9JKMK[2]<.90('.@9^IAK=:G&;?LK 6K24_N'OF&0I$
MYTI">9>X,#23L&[%R;@++8_Q:Q,E=6W&2*25K4^(O2R-40$7$MGA#21!?&2!
M;3#<9;BLNO*$-> A_5K1 032M2.^*FBDPLYTAS ZGT3R-&:]00I'6PF4U<P:
M!Q26' OF)&"/M@]];<9-##S=;7?0@V/<*7-=<O3YI=*+)C%#NH 4\YS\5C&C
M%#%%@/]+\6.U1XK6)T^#ZV?7-LU'<Q'E2Q["UI9D!1;J[X7Z^[<B2$E/+0Z@
MU94ZV*%N2E(F+I;UD@)H1K8/?U6J,#4#@?+X%B5O:/H-?]+ZB>@7#8ME<=QK
MA9R*T=ZR"WPVJ]TPR+E]V=9EGZA9<"YCL=C%8N]W.]^,?4)>:=/)*@*:4'NV
MW%IIL[WJ*<Y3@([RG7['  .N4E^UD2]!=%]C+G]9%LNRN,]EH7Y%[ZK_4$C5
MLG1SPX$.[)?7#4J9G0^/.4Q%3E\*E/C7,??G"T2RBY$O1GY_1EXU/\?FURX8
M<(RVU]55!6*I=5=MH3L:RO:+&,_=Q'@":LYH>@O#O&;831>3+6$H TX#06R+
MB)1.9\G+\=Y4%[-%\9OHFOX9R,&TQR"5L,BSIAAD\T/E!]O9[-/RTZ&%#QA/
M!'#2I%53&;".=!6FX>%*KNW6(WY@5ALTKW&K^O1/BMD\R)W:(3>)<==<%-QT
M04_=L]XY<]#SABJ%-IMVQ"A(E[@?;V8]FC: K]QAQS<I WP323RHC9'2MPTJ
M4$B=%3NN,,8BA'OCAV):A-+%6)3M3I<BY<:FGS&RZIVA#P%=HMR3E'BF?8BV
MU"38G!HM\\U^CM9<BZVA^43)C7*+[F&.1B8+86</M_77\.M#9N3A@A"7WI.E
M]^0]>T^>+;TG2^_)??2>+%C:6S26CJ!+77-5=2T\&0+Q"W,;ZHM<@ZJ+:RU9
M!J^,*57AA:W<FO@P#7)HHZQ9$=R*NNT:^*-^Z _:6F[$^#.E'7>L3TAHEBK_
MM+V8>=/"5#14;B?8U#O.\I15A+U>Y'2+%6'_I?B@6"3M)?&>7<F(048]*@@P
M:@6!C,0?R!!\\M-Z6?RGZ$IZ5#4%OMHU,:YY+_WEV-V%R43JY0P5(5EA?VF%
MRPCCXK$[<6S@S-]Q;T.5^D^7,><C,:(&)!U6$0K5K$3C^B"-9%^0/?GYEXLA
MB*L18:J&%^$\*0"EPVM;1;(["EF)"T0*1/;"*<AU78QP:1DY(!PD@;7/,$OQ
MI1F@Q9U%\T,MGV <TF'769Y:6E866R;4,8U*M ?0 -:N: A<0)?RCOA*H7=2
MK(ZPM3G;-*8H4VW,3,WOP,KF)H$@A,QM.YWO>7YMP2[+NC'&[R,TINA:[0_
M"RD D>QCYADC)5#RD-;FXKZ=DD?ZC44A+YS"[N>'S7)A7XP%V$G#2Q&SC^B
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M&W$G*8;$+%UQQZDER^RODAE7UQG-H9T&C $+8[ZA#;+,5<6K4D0ZV'D09X%
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MY*I B!/3ZXLYD"%3@QX_\XH6!8<OE.X=MYQ&1$:=!0UZ<3?B(1+I(>*N+L+
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M5OLLA8=SAJ,QVEA4$(JD#&PV-[$S+L1^=R^MZ<8^@1@]R#S^!S*F6+YM']C
MC[%GQU5[V$5".Y=4E4KF<I;4\7_HV%]SYW6;T&B$N!>]HTQ6:]T8<S?-<">I
M@1@9QI+?5/!I)M$<*=QN%XD"U5K<,)@9 7V3Z<X@!S:U88=V&Z>)H*G^@-GQ
M/C!#60I4!_20$O^DQ_BX UI#COJ.3@L(1!8(IQR?2L'%&"ZI)A.",RMO,45U
MKZ4 .JWCRG?S@U3KD678[_N@ ,@MRD2TKEPU4EVG7$2[K8@5T?]_L"/"N>FZ
M<:=)$1S0(=%[4'?2^[3,TGW^W<L^28$R5!O-)DSQ;D&=[!6Z7@M.TMQP_L-+
MPS5]L$>9[O3#38J95VB(R-OQ4T&^B@XBWN[(@%,'B.%("C47KMV'+>U!GD(+
MZG-!??X"J,\G"^IS07TNJ,]?DPYYUM$E?34E%#*<+Z$ <A *L7=:,5$$UY1'
MZM:QAWZ"O- ,\W[ZD:Y003+U=$R4$%V>O9S)HJ%C-;O-,1WYR^2D-EY24OWQ
MBT%S(6G^%5M#*6(Q&J++FZI/0AFF>7GFAE*#E#&N>O]:$(^D[WG?B%@XKJ&C
M[&K*NFS'1@M,2*Y34K8#_$0R4/**?;N[I,SD&FE^;L8JAH'%CU.B+_]_FR%7
MC61\>5SU[M\C&K;@7<$G5)V>=>?$I2#?KO-O0Q5UU=4!-Q;X 4P=@(" .@'^
MN_ZK)^WF1)V@\%R$B&NWUR@2Z^_"T%/S=&T\/Q9,8O/9TFY,?MF6H@;N]FE+
M^LA5U3%#49@@\\S4/PRY$4B5)#XKCR&R)8ZJ9X[;=C\RQ'U^?"^1ON9'_5C
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MR)E>BX"H=)L-2R)*$BJQ3)3.]NW(LG&.JKQHB*'?>3_5VQ'[[_0/XD5NTK-
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M[,5!NYE? W*!C&KPZ[Y",E[WF\);D]\LO,WYK6A7X5_<)SH@4(Q&139/D]C
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M]DNX:V^)1+JJ3P*2G-.H1"O=!<RU\(:M+\FX_76HA=Q_K/\#2FR]3X'P@;D
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M[,&@A88Q75^@WHVC@1L@HYX?K? BPMT)B+[W414)8I 76X9>=I930%BDV-^
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MM97=;];483:-@U$H_Q4P&W:C1L @ <@XHF034*.3>*,1MH=:"8IJAFF^U4#
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ME7HP4'_.3%?_7NU=5@7+LM<L/>W--SV]*^ ,$<?&<1<4XC2^.&ZQM,@$-WG
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MB-,<16UNZ+AB<W"_/EFAEY&%((PJ5R4G:H5R$051P9Z=R5%_6!'8AU)GM6R
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M)&6U64H"-<I")BF\1OCA'UAT#]\$,L,EO  V 52:;31IP9.LOS:.<0'W1DI
M1!L ]/%(;\LVO3DR4OK3W[H0_++Y&2)AA%I; ?HG4_4ZRDQR!8&:;G[#ZC.H
M<1$J88R=2FFH;\^'U0 G<D^*+([P(N!!4![@GOK>\38AJ#2@>OB./ $ &^8/
M_)I%E,$M*8,%GV(%$D,,UO=KV#RN&B%8 /& P&6,= GT@BN'J.Y42F85 '&J
M@5,-'DLU^/ -.&C(*H$RLD[+]1HT=(M+=DD]^)=AL4C=N>85HF("P%4O0)0
M"?Y91AGS:.2PZJB6<K"0F):5P\^!K<'_LB\0Z##%'"QXD@03"&E21LZ!:P)G
MK9NWEG<211&:/&].?QGW3HZ//WU&7@>"8@7:AG8UH+,3-JCM?MSZKZ?'_"*U
M0=@N\$*\"?S6B*14FSCT$L-?U"NT@\(ZFLH7J]@;+@G,J;+ >2\4)B:>BHJ%
M/F;.6" LWF^VZ*O<-(HTHJX 1A]^@(>BWRHS#D[&:H/9+2U2*1%Y42D&P.6R
M]%N$MB:\]\6!E:E:B=4=FR, _RSG68E"C ,:^/.3=+5&D8G;5=!MG):%8]O.
M\<]RC28H?0+<';_/@Z4,RUB2ZA  P(V,J:,A2GR2EJQEA>=D!5]D40'+H+$;
M*6IK$<=U#,OC%,=ZHOLK5GJPM ,-3HXX.?+X<N2X+%+0'+T/:Y.[VG$S$SC&
M/X#0%,-H8X7)I:>AP"'2O#ZZ]0VQ.?WY?Z4Q)G'DWLM__?-'6&<5(<]\J;[^
M$7Z]A)<J57-K,;8T0%'.,1DX37I;UB\QSP"]K_KI_^M]^G^?9L":@F4"X#W;
MZ%3ADS?#(Q!-G[S/[+6%-P* -UJ(^$V.9-F828IL+E:&11410V;D*Q:^P'=8
MSQ28.8W.NCJL#[:9LSXV\4\2@4EZKIGJ-DP(OL!+*B#;BV@0_Y'"/:*8R/-R
MI>.0;+_Y-?=E(UD:99)>JQ(]6[OH>SMTD3:$V*&35-LWDEO?JI;@P[YE+\,'
M0"+!$C\>;MLM<,V(RSJ3L/T7UDU,^F8'E[E"6MT1MDE?!5Y1VDL!&S3V'B.!
MO^50L"2_T@?HM'5UI3+^%7V@?6R[!\@K4+D#T$3F:(3E" "]*<W6::;QJ4$<
M;.FV(5FWC-T6M+K$WFU53[8/>0TUI>^]Q0NUB(+\4#DY31KKFW796:0#![C3
MH$2\1Z&)BV5PJCR-SZE<1X$@179$CHI-JWKCLE%=-NJ=9:,>NFQ4EXWZ2-FH
MSDYS=MHCV6FHZGR42=)BG774S==B>*$#K:%,K\17V1;J(KTF+\D\6I0QE7;&
MI@I3>URL^)MO:[MD#FWIK:@)6LJ>UO'PQV<2#:GU$L-ZK/2Q=FDB#EL)*ZU'
MI..QZGF&_Z13J-@71G_@8'"F)>6VH,FU*XAWV;DH#RJCO KK<)0')5DGG+>
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M6O;%T3*9]?O>8#!RPOZ((^.:.+X;3>&$1]YD D<8;#.[:Y^P<;0\0!X1>#P
M43=T0F\P=H8CSW-\/O4!.48#YH9]?SH>?R\&72$C_[8]+32]\;+\P COCP>3
MZ130/$)<'WJ Z_[,G3FC:9]SSW5]/F WPS()UXR+Y7#1YT(72]0?C8?#V<QA
M@!I@9XQ'SLP/^XXW9FS@!WP<^?Q6K:Q7W,\KK-GHCH4'@M*R7?<9>5LL;T+?
MCG>[70P2&"_%#WP*]^JEF S $@O<D1,-IF":32:!,_4#SP%[+1Q-W-DLFFZ;
M9HQ/?'<X<"8!7BP;1D-GYH(,ZP^B41A-8'U=4LAX*79X*8;CWL#X*?9!)?,F
MOA?T)\SINVR,%ST'H%F!,0 ZUG T'/5Y,-JZ%>P-9X'G>I$S&<"3PV@2.HS!
M$(P/@WY_/.23R?WX*5Z?\S3,DG5J/<<[]\9+\>JS.PEF$9MXCC<#0W,8#B>.
M'PY<!Y3M,8\B-_2&6\SNVN=[ZUZ*$^ ],96IPZ2U0'1;I_L3/%BD,--\;33P
MV_1J!MR;3@$?1OUPX@RG7N"P"?P5\6@21&.0IVPK?>RJV'1XJ2$&I[X'IV9!
MY/IN$#E]G_G.<#:=X97LR!D/ S<(W9D73;82UJ['H>XP]>)]=B9JFWBN<0S<
MG6-@Z@VF$X]YSF@:>J#:S\: %V/0:T#<]7TWZD^CR=TX!KR^3,!0CH'FE\VD
M!>,<V!>SU#@']N$4[M4YX$V]67\X#)W^># "?3D<.,S#9*Y@XD^&(%Z\X59,
M)ARRR7 X +DUG+C.D TC9S88N<X8Q%1_XH:S$>-WXQQP^WU[,AH?MG/ I##L
MAV(63 8!H*OO#-@4$QG]J>/W/5"R)CZ@-P-<\[<4,S:9#:<<"T4%@PA(8=IW
M_& Z=-QH/!O[KCN9^4/C&M@/UP"<X- ?!WW''<^&SG PFCE3SK@3NFXTF4Z8
MR_O\QL[7N 8>.+<8!;-9%$Q&3G_* #,B^-_4![P:C"+F,Q"*?+ E.*^*30>6
MS& 0ZKO$#XN&WF0T<B8^J&-#/O)!_ RGH([-AD,P_H<S;RM9X'KLZ:Z2!>J"
MIR9;X"Z= GPZ=<-!%, LX=@9#L=]AXV!4<U"?Q;, NYY;'RK!LT[E@<+E10P
M0O6XP03/. /VU PUSH!].(5[=08,QU/0:2(PYV=AWQF.T1DP#KDS&@7<#_O]
M8!)M6T C/YH&XX'CNE@Y=^H.'& SKC.=^@-_P";!)(R,,Z#;&0!_8C7$>ZD@
M>9_-8_:50F]ZY_\7!%^:E?#V^8)C!PI11E26&5DEL,)8=$W$&O$V/I5:LCBW
MC9A4L#(N(M'HDD78C8QR>;&<*4]%5U6M+L_CX,E5>X,\"#!CA^R7==G6. VQ
M2Z;H$!IE68DG8%N<@4[24356]J#&Y[-<?BC:+:S+19Y5\P59UZ*39BQ+_7.6
M)S$>:R8ZR>"!8%U9:EJ*'6QYW4$[2;#I>K!@V,<19BI8(OYX[(OGL:>RE6 O
MNG;!V7;GN$W-^;)MF&[.<)&M-)@F-R[=3F,OL,5[@JV8@%=3*W'JITX%P^O6
MJANE?]L4!LCV.#[;U7K!IK.VSG/$J+03WR1]8T>(.FHZ(ZUX('H*G;.&)UR&
M"33-E+?YP8YE]G1+3#_0_2H7??^-CH+/85P$2594.?]<=V3_#'H(AU?VM6>+
M:'MTW&XCA)LB8?2YS#[7;:4^-SW#'WW7X=]^VZ$7]4E@T6YQ$M8K<1+6+Z!.
M%L#X%<<&.CJ1+=+?IL5*]D"_^[;#^]VUYGT&_&BU2H#W;4D:TZ/4]"B]&2QS
M7<_T*+TJTIH>I7?7H_2[Z8R$ZPKP]7,<Q]?6='>(T)OKWG!R]/'3+<CX&VPO
M\?;MV_U>X+VKI&[_<]TI[C-7]]<_BVYQGX,LOVGTNV&UU.WW0).3&[#;-_#W
M6O\4[?C0!W"<Y:L,FY)8K[%'*VK2_(!:=MY#R^%]\A9]PA:-69)DY^3%$=UK
M>%F@<[E<6%I76XOY655V-&>LR:YIT\C(^&Y'OG1]^K^L/6B5<\E&.=MM<J:]
MV?3;?6"VV\=<XYW+-,?9GJ@WN40WGNW7W-ZU7KOF;./+-!NZJ=D&/7?\S=>:
M6,1V6N(4*,YGP9=YGE5IZ$ARC>B_ZZ0K[@HC]DASW@@*"C9R0W%!=V=<<+H'
MWO#K=]+I#C#=/IP%#O0'^P+I&PG?W1<P+T+:CGW?(FCOHSC_B;1<A5P519@*
MZPU/0NL\!FE\S'R6\+)D!M<-KA\XKLL28S\KZ^<??O[SOTYC,!X,<AOD/G#D
M/D;G*C'QOSC+,6SZYR(&6PCOH%I_QDD"EOX*$-^@ND'U T?UHWDW%E]D3)'_
M8@^MJ2M0PUZD#EWOQ+;*?!8W0#G+. P3OL] W1<><T5(78Z#W'*L]$!A9[#,
M8)G!LOV!E,$R@V4&R[X3=M=0K .P]:+@UA7K'7>7]@6=;[DI@FV]Z[WHW:H1
MNB^0W!?&<$5([05CN(N^#;95UT.PK>,%PR1YNG>!F>_/,Y:'^.%%*XI?^V$-
M AL$OC,$]OKNQ&"<P;@[9)GDFG_[]BV5YO.>[>X@:##08.!M8.!X<& .\Q])
MKV\JA?W:D\7"0)M:&,W>,(D[91*: O^-<F8&'0TZWH6>/C,89S#N[C!.JN<&
MZ0S2W1W2C?K&Y;ZWJOE16JWP3E'(;.O=\R/#&0QGN&M/^RM5*&2K0[)!0H.$
M1@LW&/? ,,YHX0;I[ASIAMTA0>,@WP<M_ 4[BT/KEQ[F%:1SD?2"_S_IO3$N
M<L,F[EPE?\>QP*E1R T*&H7<8-R#QSBCD!NDN_N,%<^XQ?=6(7\7!PO&$^LU
MSUD>VJ":FUP5PQ[NDCV\YBG@7F(= Z47@(F8J'+*@YR7+#=Y*@85[U0A]UR#
M<0;CC$)ND.X!(]VP^\J"\9#O@T)^E%>I]8(5YD*H80SWXQ-_7A5QRHO".,4-
M#MZ+#M[M+S(89S#.Z. &Z1X&T@T.30???]R^Y2+Q6>J\7*Z2;,UY4_S"5'(R
ME9PN9!H'"CN#90;+#);M#Z0,EADL,UAV][4/C8/[YC-.6/[%.HV7V![^W?,C
M"YO >T\>#YX8 ]P8X'=G@)N*A0;K[B7E>VHPSF#<'<;T3,5"@X$/I&*AR?^^
M\<,Y#6!6ZWE>I2+AA-1QHXL;#F%T<8-U#QOK3+:WP;A[T<4;37QL\,_@W]WA
MW\B41MEC37S!SE/K$ZRCX$F22>>X9U1QPR*,*FZP[D%C':A"W4XB@W$&XXPJ
M;O#OP>'?N!O?C%-\'U3Q8U8N>!ZGV.XP2:@NRKOGQXOGRD5N_..&61BEW&#=
MP\8Z4Y[08-S]Y*HT6KEI[VH0T#C(C5:.(W_$4H5Y:+WA:1[_7?%"SQ\W?,+P
M":.0&ZQ[R%AG%'*#<48A-PCX R'@N)OAU0HY_,'\A%]JGV/X> ^Z+:UE^HVY
M+P\14'>M=WSI\]S*(JM<<.NH"N/2.LZ6R[@L.6_5#/QQP.)M@@4 LN)IP<HX
M2W]XZ PVH?,^@V<!-NF<"FX?9_DJRUG)K=<9\"#L4\FO#S37NQ+4Z'$-</^N
MBC*.UM>%W59]GV:--P/-EU]Y4)7Q&5<5$HM.^-".XC2$EYX.>^/1]*?-Y5P;
MS\9[ S":ZFE<PD*"JR2[E?R,I]9[,.E+P,HYS]OU3J]-,S=XS-:+O*>OT%JP
MPBIX?L9#"_[*JMP2!3.W\,&V3G)>Q'CR@KH6+,YA<B0^?,W/T(\!'T)51\HJ
M8J0X_#%"-Q+299Q:H/%/>M8;;L6%Q9(BLQB,G$6\*#*B9/D!.!Q+X ,+0'G@
M^"*2^!]LSI.LL'X[?6>M\FR>LR6MAH7_KM*@Q._D2*RT/L$+?RY87@*S/ T6
M698H3O%["CO+B[A<TXP\38MU<L;2F.%$J(80ARTSR^?$3JQEB]-T;%;^\CS.
MCL(S8C6O<\[31585W'H%V^\A ,]B^)RL[:US:,Y@I<!L6P$=!:^/(E-'05N^
MU)H^\70>8UF"MVG0LZ(\6\(!](>X-3@(MP??XQ=3VUK >22<A0"71;RRSF$I
M,$XV3P$%0RLEF<.29&V=Q^5"\%OYG?4R3XO2^M]LN7IF_05'/;=>IF7.82<I
MK^H%_L59;AV=XRHC.""^Y$C^<RL H0:@YT7/>LGR)(8MP2'@<@(&(,PO A:.
MNX!%XQSS)/-A,<!5OG 2 CC+.YX'7PA>,.89RQ'^."-,3EV+LQ7/A<C(LP2(
M"M &QQ1K6@N N;/92 "L/R#,78ACDH>I+:?S3(I.1#E*DIC0!%?YD<^I8P2=
M,O5OPT#]8QJQIATQ]!.[C:^ <-9C(+2DHH?@E4!2YA.!)_! R8-%"AQGOH;C
M#H&QYFOK0SZ']_]#1]BS7DG$F$K$F $^<,*!G6B&,K6 XREH!_A30V-'>5E(
M?#@-8@[;K"&[F_1Z6^<,(.,Q@A:1@=(4Z#QHKA(%>WLP9(A_9?D7G.IY%44,
M,X[QU>>]4_EJ!TOXYKH(BF*8(VT%%VWDC<"@A)<<$0\LBA2)RK8D;0=K&C3"
MI.AS(C?)WU[P%2QNB4PVBQI,P(?IY_@L1LZ(/Q[#.<3B4.71O -,*:U3T('B
MN@G@,=DS.+R"3L_Z$TZ1 YT!KFU"'';Y=P5R+XIAX8 *A-HMS+XD[_=YP)#S
MP9<(N@*Q .1Y'-  2[FZ)L: <YP#./!?(OU:>=-X$O\*U$KHU*V]&>WD@I8T
MYSP-LV2=6K_V@"< D%"D+_91/Q&KL_Z= >J'A&"*'0,:O^)^7C%@8,BEE,[2
M:"M_H+)PTHA0R7X(ZSXU;! _$G=;K3*DS_ 2[\#DO[!4SNUY/7VMJ,NDUD=B
M>2\TB4VRLEAQE#4D1PF%R[BH-9HP+@)DI6)-(")!H 1)G!)]A$"C2;9:*J4K
M6Y7Q4C)M)"T4[BGP8!CXDQ4@^6"2%UN1,#T!89<C$2,@438<,Y"/O"R9K2_]
M7(I1H?=I^Y6*'_'SD.',RPIXT2>:@</^@L(Z20+!$=^Q/%C@F8QQQ@9.*$G.
MX0UN%3!'E< H0-2PQX0+E@9@Y_1NR4&7B[( *[7/+=A?A<LK2J:D'\BU-"Z6
M0H)6RPSE0['*TD*<%)X?/BT/KLQ96B1"M)?(4=K#P2)3(&=+R5V8#W3'L K*
M@EZOCZ HJW -!U$ V1>D+JT(KJ0NV!N;=W%<'4/'-NV;%^C2B>'/D$97FZ\7
M26I4#0IDB2 L-E11? &HJ8I ):YR9>42NP89A. KK$81(/&,7*86W%6<A%E%
MGP%7@0"%;MH>$OZ*<;RV+@;_Z+J8Q)Q&[U&Q(QS[PTH"M%$,/K6V^5%M\T0I
M\-^2P#H*-7^1_@_*/BQAB8@%XA86>P:PCN=JKA1X4)A7<ZNH_&5,5H585@KP
M25KTX[3I!_?]YNT?@NS2@$C"UN!+)/,"6-#QT4?K[?L7%@O^KF(<R5];[S-0
M-8'*K<=I=F[]NE[F,5N /H8O13%@H;6H4'XB]ED<CQA&A$%L*>D!U-:GXX\[
MZ7M-:"E7J59'[\*2-<HO%ZP4&-A2F?>*X[><H6%\AC[0?\"_0(*L*/[Y*(J_
M\E"\2J\Q@$C^2"U;2FGT2SUE59G53F3ZIM\;Q^DS,>VD-^CK_Z%S65,'Z&4_
M^XH;Q$7+%8+\_ZH>$W[IUBS*53T6/GU<MES8?T@1^?K4&3R+$O[5$:H1X!^,
MG%3+]!DP_E7"UD_QURUO>&^$JT,:E1D9\%'J' IV]*(#0OW9*BN(23S->4(F
MA+X//\N!5FD;EW.=7]'1=8/>\YM&+=<=;"%7@V*+? .'XA1X/JRL!-(5I]S^
M 4 MOA9S3>F,5FS.13*,PR+8^U.6G+-U\>S1SW>)QS>(M^T #FY1P^0-C+Q9
MQ+NC:-=-8UE'8(P0[<8=\3=K@MPT&'05X+2Q]H[ # >!AS+^C[<?OY[^=5K[
MY5&M ?'UFL4HU J_RN>H2:T34LYK,5]4H*/GI=28=(U8*C9"H-8*6X)3G\78
M?O-,K*@JR H7,A=U-JF6@/(/-M0WE>DUO4""]6VCD;4T(<V+F@FU_KDRB5_H
MCI^W*9Q9(GPV[UD1LK^?6I_>_H:>FGH#R(#FH*[%V6K!P,H.2-6&W=0^*=21
MQ4P2&L)%N8I7'!D53B34&UV9J1U$9%!;)R^<W]RO?[Q\_0IF(@-%V.9E[&>A
MV'&1)7$H-&T FG#F_E(E9/WTI0]RVS^DGWUX%A<9*,("&#CFVR6H_V XH$87
M@PJ(=I.UJD W#F!@4(=#V)C:J+:[[;,A:R333RA W3_?6FG+3A-J4V@)_!!C
MU+K3#FU<JJ>_9 O0'=]DJR\Q_*LIJX!9SQD:-EG.[2X,AF'0D&7"W,;GCV$'
M5<*$-^4=6!(!?:K]/>0F[X.)>;H0WD9@WHL,=X]JO37H2YA)/5N:DE',D["E
MHV8KZ7U2F_HW6,OP+V!KA3LK+,R"\/K/I,E+G]QGXG#E3^\9F :-5U(^(I9&
MQZ=YB86O1JW';WD>"T&,BOC:P&Z97$PXT!6-"US>M&]IH!6\#T\5TL[FPKT+
MFA5G!9C QDET12?145JM$(-#1GFH^^4:>@=D3&O;X1G2G0[M8-:K&(._Z.Z7
M/@WI\#X"4SY!2G.WG1;-; N@*DNI.B3)GN=Q46:)\VZ-[N]3L/M\7Z,[VUIF
M()'0>YV6&.R!Q6SZI=[(H,5K$;1H8M7-6D^ C9#?1CC2CX!.UD5<".+4P@\P
MNAI-O Q<2'FB-&.<K,-=SYV A(V WV>PYQ3$3^UQDNM3[F090')5 &G:,C9Q
M<1MP(Q</,#B<M?'2*:%H6[^C:_ZD)>B*>A9/SC*DI1P5PL%36I] WRZ *<'[
MQ\ ,2EP@17WJ5^M !O#09D7M>,+SH\:9_RMP(U#'2RV&4;<,1&=$E8=5RT/1
MQ 308T8\?<&7!*.74E:1.T5-\#8-8Z A4@#*JN0B-E<SQ^?9TF=KP["NRK!>
ML#/047[I84@""0^#1/C_D]Z;_6)>J(/0&G<Q+W2M;G,N17=MOJ4>IJCD.[9N
M1^Q.>8H4V>8X-?EC)#A*&.EAJ,4>@5E(>A!BM> T[WF59X70"&P+M;8C^N']
MJ=WB!T@>U@O=15T"D8)@_Q^>\H!MD?5O)\J1!RLE_R0[;RGTJSS[-T</+! '
M8.@"-0@@#W0TX_*+)0,-8"G4)>'[8A33Y<)E"#12JT2ZEQ6T#"ZUZD[/>J:%
M0H66JO8KX?T!>!6JN,!7)B0I%/QM[5RE_J^%F5LRXW7"OF:G2]!3?B4E?94$
MNJKVQXE^0J27.NV#.E9+UR#>L_Y<Q,!<-P O&'=K/L(.@"^02ZVGJ<!CF(.]
M)%V:.T,/.9_'.(6REO#A+$6E_3S37.<KG(,+9;]8%R7R1"NI5@ .GJ_A)=A.
M5E2USOK[*;DP4:L=]ZTUJ,H%A4]WA'[K$*_&BAN6K;#2EF\A%Q#OO5RB'=+)
MOU5H^"^6Z!R^IQUM$\O%5YIX;AUW$"'=.%7:=B(BG!2Z%=9#O? W64$22Z8?
M@^!/4:_5EK81NMT.%.<+7B$8A>$BQE?#$N!/1<#).JTPJ+N^[%1&_%Q5_+S#
MZUM@G+P&+0LK*OR"B+I/<@=U'[&X'7+GE*]*8;]CZ5 E?%Y35 S5TBHMN##/
M3GF0\Q(4Y(LCB]J,3<P!5+<,,!)3,3=&1F_1"KNGZ&%%D:U$HH=^E&&VUEK[
M./]1-0><H:5KJY+O;*]$X\T)GZ.-KW)^3F&'V7_4O Q,R";10J26RH#.:Q&:
M\X$;"N5<9+0-["8M2E/^A>HK<LBZM-^=<+$;]?/%!B/^#>1Z6I"9<8K\F$OO
M1:W"[TRCVG4T4JO>.G00*CG#=*K&UY/$%%P3^75"MIZC TY$9=]E.5A& #6A
M1[S*,."*,__VFQ!OO](/OUFO8=F%^+J5F:*ML!8 3.3=P',G&4Z/_$I%Z'<D
MXR!9PC)1NTE3V(2?Y3)E[I=:DBAN^!ML0$@0P_ZN["[(J]1ZP8H]S7.%E>W4
MMA/E)\"@#9&#S)YC\%Q:5 F1A(RZJS>%9Q$36(41WK"5 H@T5PQEP_[OH'R5
MK78B]*;&U*>$O0[*MV7609.16B>N=#>XW\Y6:67<_L8QX-^XZD#O3(!]'3/T
M]#4> "T=3=+[5?-IOYV&@J<D$@UK6V6U6!>@/3$1'Y!LZ01T%5;F9 R4*F,E
M"7.>DGXS>58T2A N GX$)3=9+6(F*%YI[5-=A9^UTW)5TF,J,PEHZSY+OXC#
M00],J6"V()@A<Q4)&Z3E _5A8/^4!8O&C]%OG!%;$03</H4/5CA5G<A FK!"
M12EG?'7&VVE!K90+A8P4R72J5;'#(8MTV*L7L4/CWNGVWE:[)8\E=DV(C+IU
M6)$Q,<>4ALOD3IIK&5?KT&P$U=7[\]V1I+KF8O=+D*)*1I#316E'PB^PF,9-
M@GYA*6^4DMK$ VLQ*G1XY >O,LK.$\G%+S^050"J1=N!I'+7,?CS6QGVM!BB
MT$3!V"U0>'1&3>-4^&#5Y0FY!9]D>-Z>T9)7.,(F5^U8#B,F)N>4",$UUQ>T
M*827JP%=7.A16Q8$/%'7#F#I,8KA%"P,&1('Z4#9%,6&T&XK)J= @Z"EOX\!
M-5BETNW5.A^__^OTY5/K]-43$5O+G$C"&!W/H*?S-;-.0#Z <"5-_!C-'GF%
MHD/VH8Y?JTFM+1/L82E6H3+]8W7' -//U#KK]#@RF+R!IABHQ>'0<FFV!CQY
M"P&U$GQ"H9QPX<B QN8"MF5W:1VC[4*"6@4)9'RA/VK<DI2+"ZN4D.A$)MPX
M67M,G"J>*6&?$XAHA/(E8GX7SQM?%\A#VWI9Y2"O:?6_,!A- T2]0GW[^NV2
M=PH(M2()^_J(1%>BV75:\M6"BX P6+36JQQ#2460T6RU"ZK>K+CC0SFTL9^(
MJR@$ .4-;"L,'6 505U0($3V**H.P#@P7BROAZB1Y+;DI#!2EDC5.6<Q9?P.
M1S]1:BK89.UI0ZI76="#XA4%S/IZSLS!(%Z'KHE/=BR[ ?)>\5J3"FE2(6\K
M%7)H4B%-*J1)A;P+,.AJ2R&"L6V)UJ2628]"IQ2WZUM**5N2(_1/%(Z@3W->
MXOU1Y[3$&[5R#)%8A6:V\!U0=#3/SDF)]/F<Z<Y@G/'7.$1]\(0S2OFCY>Y:
M9^VGAE'=V50D9*!O" S_%2L;L?SVA+3WUSS]SWK97%P4]YHBD=N2SLE;W"A3
M*AGM:#GG:4_3?8(*M$'RH9$65*CLRAWW:I7C0R: 82)9%C!YV7*%#J$4()2M
M0&LGA;.=/M?<\CA^?_ISJ@7!Y9W%$@"%&C_#]!,"Z_8E8'V!6^M#%SU&H>65
M7'$GNTX$/?GXZ?43JTHQ0U1E)GE#'1S=^2MO6'Z&L]4N0'6Q=>O:ZC&*6S]F
M^$?"Y[QU%924]9;)TG$3%",BE[KP"<2)40IXI;FTJ6X-6X-1@Z,7F ^X@39"
MDM-5!#?+]:9R3AF%C!0+D_IW]>H5&TU3]THQI@Q>##9\TP<A_;H8#ZQ?0JY7
M,Q(M(T:X:\&H*K#4D/*T*F,8';4R?YF,7TRP)1-:FK#N#,E"IE18A*0J>S66
M+*.H71_S*@[I:B*I!X*BMC.\-;D0ZDY>N\GM7M6)>LO:36]K!0VTRZ%X]ZW4
M+VNVEX3O5&F=,*,M3"4%(BV=@5:#CH@:F)(1D[3X R9'6T_Z$2ABZ ,(SV&1
MBSKHQU1&DLHV4'X@F.HW5J6P7SWXJUEQB^;D5&2E7L<"#'],/0F![X2<V*O&
M:5J1WCK7I0[W'OG^'S%7X=XF"\=5C$E&& "M87Q14$0ZDFQ\&4GE-Y &.89"
M"3Z?Z'+FO^&3\&EKHA:]^S[GJ>X"PD61?4JW-EO9S[LRD^"Q "022>D\@]UK
MF4_:,0OII"?\JP0OV"\)-<JHLF7N"B5? [^?6Y1++\0:ZASM$%:3G[J15K;C
MMH>6:RI@K7"EH*L.]6AG$H.B2F32M%P1FN&>T1T03%)3SA<X83%R'?U1:+L-
M#*VV@"9,P.0$4I*A:TK<0?>ABMF,526,[;HM#1V06V8G;'0H;+@R-[/F!(S4
MW ,Y][C+L:*A;[T8E4Q7>_!:*6WDJZJ!B]=[5?[\!@3Q&'.=QR!1D>9&Z70=
M:73(]UN9836C0G)!=MF"OJC-(J]XB%_E63;*E\)1O&U;W\^P!:HBK4;D.VC2
M_*6:G"VU0*#0UYK/(E2WC1D='J,MV(K '.DM.GOHX ):=N-&SC@A6( SXA0Z
M1])/92V2\:IYBP=( "$[4AB>M6JWZ'+ND@5HCKYB>ABJH5M9-Z+J01X7BRIA
MG5DYPOF=QV> #_9EKRT1>'YA ,R\8]!&"?[E].3CDRU#I./J4XD.5_*@+U%^
MX^40)>'X4G[$Z ( '7X%K1]66=\,H0=?X:TR!(+2/#?7\NKYQ_\?UP)(OK'+
MCO4T;+:Y?_(MSE%+1DTBBJOZ'8%>JH\ >WD#N/8?F+!5AV&5!,VZW_S/^Y,G
MBIEX,OB,'O=Z"2U#@L*T>(DIS@+,82?=>T>H]FT"@,ABHH#?<Q]4$.=X 4C)
M0.E5!2S2SH(]5X@C;]3/P;%:29: 86"L),M6 B1H<:#\+^ XRK*P7JZ%!O82
M#.2W*>IO+(<S4*:2TD1DXL]F11Q%3=\HA7.=ZC=ZQ1M$5H ;?H\QG;;ZTMR&
M$I)1*(8\ K9=&O/FZN9-1R?:/0\#[U<B*>JX"GJZ&=9QT;5)L$*F(^\)-A;8
MC@*#%*++J!):DX<IQ8QBN+IM@#5)--L 3K2UQ':-.#'G<5/W32MN\RO 4.IG
M>J$1I5-1]$IH59UFUE^\ $4?LYF4^C92EZ-:Y4* Z.<+*\8D>0R%"M4 BX6\
MCNE&+NIC_^VZO1G(/N"RXG*T%E*?"%">MVO/[=P80%/JG&M@)4&A;RT1&IAZ
M1:_(Q90&7]M^\MZNGU=@U[+__;_<R1 OB(IKU\!N''+J"T%+@@J?%WG^9&F
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M'?F^L&[^QC6U6 PCR^2G\[KS3WU'?2CNGC4;;?>'V"JE6/L28I .X@[B.\P
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MNW-%R"WX*5[&Q5[5[^F"Z4;RB+@E>YT4$FN)E=%]+K4E82^P\(R,;3G@YAT
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MC]>9:Y\'B8B&VQT2[ X4R1X@MQM/;6_6-VAX2&AH>-TAP>Y D>SA\3H3[SQ
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M%3 JG&':15'XQXK%ZI>1^F5H6WB"0+AP!,G:ME957E2(^_) C[,E['M=DU7
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M%\ 9<3Q.*\%OX1"9Y'[2R".^]Y&% /(0V9UU].&]]8;#$DO%VFSDVH@&0+U
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MP(N;-IZ\>A0BT\;IM2W@XS#D%HI>'M]V'RTB&IWM%8!XT8C/Q(@Q0C.J$KQ
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MX@;4DS^><0JGM-P 2IY\GR_,"(3K>0 D]*M:+3+&_U6,?X6\/X#=[VS8_32
MS$<TY'>QT2_1Y"';^Q?HGY<U]4TVE\GFNLEL+L]D<YELKOO.YC)NRYNXFVUT
MBFOGX!-D]]!O>8MNRW8V3Z\-!N.UW!.,KD_%I 7>25K@ _!9WG^:WHVYV^[#
M82EXX/[[*R\YZOWY+*4P,2[+^W!9"N";=*7K>2PEZAJ'I2&^"QR6 DL>LK]R
MM^9IW)7&77D?[LJ!<5<:=Z5Q5^ZSN_*:]8N,LK&IZ6M7B$@YA1D+4@+CE&I2
MD3S/^1Q@2_?_0!O,--@+HTZ:;90$V;+RE*EVF7H[:"FC2L #OL1*/P/7II/4
M1?U!-[SR)KV9>[V65]?I7C7KS0;3.YO-=7N#.YQNVAM,[G!S_9[K/MC-7>[D
M#K!+V15*A+KNO6@5<OS_<PPO^WG\?^R"I853\#R.OD^7N.G>3 :4&VW()J8-
MV6VV(?NP$MX%4BSVL^O8CXS] X/]MXG]IYI6?>5N!GLJC$W+4-,R=%]:'Q@.
M]=UH7)&-#O;Z*=CQ>5S&L%K*C$K6Z!?X/95U(L#4_R"= 8__UQ/K95,]PE"!
MH8(?E KJ[PT=&#IX '0@K37)W+EUDF.]J,?_O:?]H@UN&]R^.FZO8IG/]H*5
MAFD;Q#YTQ-:4EP7+.:5]_9[&HA6.\$!0\LX;=L:M]UEI_<$+3.0&!<9@O\'^
M \?^=RS_P@&G65+Q:]# #M7FAKN,WIQ?[@?J,GJ93C+W&1][D,U$34/,C23"
MZ=@>CMQ_^/G/__*\F3V>3.COV<R>N$/Z<]#OVS"3^-OU[/%H+!X?N[8W$M^[
M4WAF,J*_*476^U%/QV#VGF"V0D,-)1^[3UH?O?;'@?CH]>WI</AX(CZY[M2>
MC/J/I_+'@6N/O-'CF?@X& V0-AZ[_=O5-??WS R^[PF^N[ Q@;'U'_"79,_#
MWFRHOAL*#C_H><UC,XG<O=GD!ST+@\?[@L?]G[WISU[?FPKLW/XXP(\28\6/
M@W[KD\3KG]T)?O):GP:M)X<_Z(D9;-\3;._04F[L[Q_S> QJ_Z"H?76?UAWE
MFOU /JW+%94W7BW#>FY9A^R#T2[<5..Q/1X+D\>;V;.^U"/=B>U.U=^-@VLR
MJ?\T8M3@\A[@LO).#9]8$BT1LNK;4>>W7NO;B3UUO<>3UG<C0OG'T]:7LQE]
M.6M]Z0[ZQL5E2&$?2 $]6RU\[8V&+51%A]?&%\.)_@4ZO3;?F.E?&!>8P?/[
MQ_.VSPO^=!N7UPX/F/%Y&?0^$/0V?BZ#S@:=;]FW9?*U;OJ<+UMYW'BW#,.Y
MY9RMD3V1(?OAU)X.A*-K,+6]@8J2CNUA7WP]\\#\%QK@>&2//9.D95!Y;U!9
M.:S&3S0;?"L]2_O24EE:RK75G]6I6N*KH6>[T\F&9VLZM >3.FO+.+8,&>P5
M&8Q[@TV_U88C"Q.XC&?+(/JA(WK+=V62N0QV/R3L-HXM@\X&G:_GV((_L,C(
MC9?2OH7*QK,;*VS\V'TB6WVH0L38.T8T#HJP!C$V(2ILT?? &_U4MY;)4NM#
M4&9X+]JE\L/N3'3,P:8%.5^R&">W"G%95+T5I]9@+%L\J<Y!<5J4+$E$0XVF
M;T&K/1E3O:4XD _/S[!HAJB)#DM>Q"O5EZ&[1\:/<([>]Y^C-Z0RTOW+G:/K
MR7.$_^4EUO$Q)WDC)SFX_DF^8WFPL$0U<-<<X[T>X_#F&*LYR/L\R-'U#_*H
MFL->+,\SC'4/#G)\_8/\I4JYY4[,,>[!,4YN1CYZYACO]1BGWT&-+*VPEZH[
MI9,<F).\UY.<W=A)#LU)WJ\SH'\SO'6T?^=H.A_6A<UBT_GP^SL?#K>0RW0^
M_ ;>MAW>IO/A=0()IO/AY<%W%(KVP"!@WK,\)S2R7L1%D&1%E?\X'0ZO";YA
MWWW\Y8EURL[@T<(Z25C:LQ30]H$)_XF-N#%@%J]8R45#[9R7( VI*7(A%PZB
M,+6Q7*7<D/A,Q2IC;-X(H\E.[:B+P)%0*^6(G66Y:$+.OEHEL.&21MWH$@Y#
MLB?M/N&H^:C.T*BKL&*!LX<\XCEVI8Y@*$"_SA4L.2^EVO1W)3=2R*KY]81?
MGK0[J?_>.^W);M <0'F^ !4)QH?1$\[0_>0*O0W? IE"/\YYBAWC0>.J6\G#
M]!O@Q"E:0-.4L(#GN$,KR.&X\YCUK!/U,BX9N\,OV1?JDDE-S0DJ\IVFU?GC
MCUFY>()=W-$*$" "<D7PY;%?"1U4]G'')5A1GBWQ4YPW"X>]I732U4H]"Y*V
M!*&4 X)1GTY8I0\09FF*ZF82+V-UD@T86^M70!SUV["#@\0&\CEML%XFKUN1
MP^ALF54XA,^PF4&6MA:T%I,7A&,!*X.% ZMN[;>UD@U0X)*H4RB>3HZ^158H
M7*'VH0D[[UE':8T.=;=PQ+(<E7EX<Q%3^59L5GXQY.$YM]\7:CZ,?[[@J;;I
ML&<!"2ZPX"MND8GVGH3&>/*@A09(C@"4?+TQ< -[.E5JMYXDVI$VV!S#]Z#?
M<F3>#+A1Q*TW+ <5 &8!\*$IH8\MD6#X$YY8/=Z*":K&&:GG+4V+)]MM[!DQ
M4'/9-YPE8$[A$?W)DP@Q\#DP#WBHV"=A %B/#7=%X]RH2A*GA+$:1+(!\8.D
M"LE:A4>ZNNK"UB[@AHI[+7F(.1HV(KC">80.B Y\#E0+EH)%Z@L@ ?O)YCE;
M(@<!&A-4"K:I]:? 2J(!8/1QM11, <ATN3D6#9^AZHP_:O/B"ZS9]Q5V2PM@
M29'A L_BD L"[!I@^V7I 6 6&HH$KF+%19MC%@3(_AJZ7K$81!N>!;RMH%(T
MP]O6&0O(=@?Y$F,9:7P6WUQ@]6VP>&BI86:E&0CU%; /W'2ZEN(Z1B:;PX^I
MTWP!_ QLH+ Y!%B- "^^N DM?+_>Y)7=/X>K5U^*L(ZS)9QM(1HZ?(R++]91
M4?"B0-7DA^&=E]5'?> ?_$SJ=L@WLVJ.=++*<H*?U-L"'::2_DC_V\69@!HR
M](9I. NR><5SZCP.+,(A;</>&&!S'F1$0$GP-M(23X%4<]1J^-< 3I2FS$$V
MIQP_HM3.\;Q+]@7VWK,^P-A=(PK.&?("SD1LHQGY"AN"]X2S$.@TJ*3N! >_
ML(H%@$_POC8G+$KL/SZ/ VN> 2]#IB6Y=@5J#3'M#'=#JR66A>L!MNL W!P-
M?!O[6L1@(F:KQ1JD2D%615$E)7"]F@^U#CJ[$#!@.A2@ _D)ZGY?>$(:$FE-
M#%485)Y!:0S/ "YP$B D0,%&/<8PHC9YG8 X"-8(FD\Y$Y+C).'AG*0.H,4;
M^3?0&/(L9/34E\ PJ18[EUH,4 Y@:R#U_)1PN&A:LSTNJF"!QL6JRH,%\!9!
MLV N<+*%5I4/IX&X#&<!I+JJ2F'BD38B@@?"%";B%2\^ 6N1HS;%+.'JX\@O
MD'*2F*B0V T:1ED%-HY\F&R+U0IT=7H&)E^" H2P)8/<Y^4Y![L$P  ,A[ZB
M:?'H%V2K@0+Q-JTM-%O?IK*ED!+Q#&OU!1:Q0N1"H[' ;KX)4BIF+8+.YG/L
M#!(21\DJLM$*G#<6W#T[3S%>PN*DJ&WZ>@(!('(',. IA3(0DTQX):I"[!LQ
MF1P!Q(%)G! 0:0%9 #NPZ#O2EL@P8ZGBKS0^!07@#Y 3V!Y7 $ZR&YO4)7&&
ML'WB@D(^Y8(MGV-OLEB("6"38+&6@K/3<2/$%(DUP!0" I36F&P[0:,@^8AJ
M^5<TPPLRQ[-%[*,*J&$&'1F\%I\)+UT+.Z6Z1B>*VG.W3+'K+<.?C531_0Y"
M1+&2D"Y%EDZVOG+8Y$R^W:B^^A+5,JZ]8;M&&$+I\$SH]BM4 %BMPS.8&5%J
M24#GMD:!6:X3( Z(V%38];'I(-2P7-,Z2/T56G#WLX1JRB3 MSB )EL"GJ"7
M =:)B(Y+123':)N14A>HRP \D.MK2\JNQ\<).\=*"?*+)T8VM1K(I=8I7Y6<
MNFVYGDKN.$=B 9F"O-BZ"+Y$".30:X/9%II@+69($^SRLN)W+[(P=%X!_P%#
M)P"=#PQ)(,[3E\=67BE.!30+XY)W^#TK0O8W:'8BJET 2PFQ&;GU& =#]YO7
M?R;&"-2J:"#ZR7WV!/:WB$'6TDX*H4M6>:[D&/)FWLWO&C:EN0!2M@0X==G[
MOS?^S@[P$*F?X:S$ <ZYU%VE:Q'=(3E?D5\9U>$2N.A2L0+4J7-^%F<5\KNX
M*# RCWM. ]1MZX<+*ZRX,G-JU1=08O-LD#TU[\.\:#[!/K7SDBY$C7/!I@J[
M:^&YP!+4:;;<U^2-)8 %7*8\A+6[6()E US"JU$+Q<:5V77*3V@O*@: BRHQ
MR0&CV7 ZPFIKVP[2UTE^(GI7(@/&)';@@G"HBR,D^P%_"U%W4G&"CAW(S96+
MG'/IXU[E,1*0<*'3^YW0I/,4?K:N,V[B&M*N5*L0CG&)7Z3AD17DH_;6[%KW
MFLNYNI')")[=@N=8J0^@^6)B#6A.@G.]E=I*'6+ QXT4T@'YD@$W!I3]"%P9
M.#G8E6D>_UVA3_0=R[]8I_$R^W_LO7ESVTB2/OQ5*KS3N_8;  ?W(4]/A*RV
M>[S3;6M;GIEW_W(4@(*(:1!@ X2._?2_S"H !"^=D B0Y>BV)1*H(ROKR:.R
M,H5K\V)*K\$:A?9+EJ:YPJ.1EMR[LJU;A0XPL$ LBY,2M#>^\_B1Q(1\05NA
MJ31Y1P.@#")4%V+GK*K]C>*[/"'D.A\VGK'6\;GID.$CY_*3[\EZ(O50N7V"
M)XF=,2MH%]&U 0<Y$@Q^Z:CBVR>QU%F'=(A 9,28C!A[J8@Q6T:,R8BQ?4>,
M'8<(%W)H*3%K3S\_S%QZ,>(J6WJ8N&-$G$B :HYA#*BFHJCE@A/LE1R/A[=+
M3FZ#U4\*$=L*0"[GLLTC@G9P4HW=X>5'A0+:J5WZI]?<JH:?OM9V&FI@7_F*
MB4_47Y+?4=\M%T7%#02IUJXX5W9R(.?R94#894&SQ3)8JK99*:?_BF^4^V.%
MKU^\5#:V_2XG1.MIB),"U,DZ[)]'ZJ#2O:)>EG,6)C%&6F"0&L7+ ?R*P9HS
M/P-23!.\6- $"6T;%Q4^USH,H0X@@]?XN>;'C:BC]?")W?-!;_P5Z% @0GFP
M&=@*>9HV!RH?&VU<%,@^KSVY/):2\V\;V)0U T9'2_-8?6."^_DQFHJ;SU7)
MO<STEG<4L:BJ08R&836K4FXO=Q1W8=27R8U(N-#$;K2=H)U?BA.%HKZ7\2L5
M+H(O^157[R?D)]&>N**S36-_!,O"?DAND%>_P#8M\  B^O'-I^^>ZP:Q83+5
MMJ-0M:C.5,\/(]77?-^U[#"D=OR&^^EAB_W&XA_?G'VW#2=T/*:I3J0'JA4X
MD>IY=HA_.;'KF&YHAV_XZOWXAH71"0>1;[/+7[-Y<I:541%]2NGE&R(.0'Y\
MD]R )LM5HYBF)1O(SMTM.X K(GY&L\" NR3#RS'U 1;*LZZ+;<MA#S\UBAB>
MI(L;.O46:0Y4\0N.N.MNJP8,6H!=6<^_#LJBPXF\#,.Z9NQ9FN\!FP:>:NF&
MI0:!8ZC,M&W7"B+J:?9S&189%2/6<4C1I[Q <_Z?-!T#UUYWN!-AE_L4V^#[
M[FGD#O9LXC4!J4"WYV]0X=VL6174N(I_O#W@93(&]EP!U@[)N-Q:$67W"M<&
M]''G@\*;Y!C^!NH)W]K\]EZ L@,=LAA5!U_&J-+B!JEC]U!_[3[3\2O'2<J?
MP-A*F%<YK=4R2H K9T37U/]1\.^_XR,>_,/5YWJ]67G/6A]/$.[#=&",VT<G
M'*BS"X;4Y9L!H)K'%!3L$N!7!#[#UL 0*'*))QSH(V==W:5Q(M:F<6.<['+)
MK<62_\8N*W&KDES BEJ:^Y:]P[PFR#+XH_U.&B^K"=J;H(NN,U[R=I=$WQ!,
M0'/-KSF#\C-4C)1H+OP"RBWX/80.BR+S<P,!8*WDBDO>>*BY$QJ#65K']](C
MS2%OPR/=U;NCS7YXW%-SJ[BC1G?=]>*ZSD_0!N_*%)>>K4EMC@+T93BPDBVP
M25"VF[,V/EL1ZM*<,7*W L:K8U@14&5%"LQI?0;8&:4B;E?@QRNF61,$O?KA
M(N>>]J8AX>%8F33JC"(F&H>XA93E';2$B8F9_PL/ZY)94&$0X_WO(:7;N$@>
M[G/%4HR9@6%A8,U/8'-\2<+I MJYQ.O?V,[9-&$Q^=@*OJ_-Z2<0]!Q8*,'=
MI+3$6]I6MYO+C%=@FE7N'F1@6V=3FF!8Z$/FO3;0]KK-)E]U.EM>SQ%7S9:L
M58K;*3@*C'W@0;YB<XCCZ#J>8$F#+M#460YY"Q?5;(8!O"NG@M^0V),Z\* #
M2SS[H6#.71[@VH&*"(%;7'O/'U=3>IM7BZXG6M>TB?9#\SP/G)N7[*3$V $0
M5%O<P&\VRHI<)64B+CB<- ULJPTB.C3MB6.X/^QR.PO?][87C8EF/>$U_2GO
M.!/#,U^KL]=ZQYAXSFM-ZC472YN8AG%X\_(GKO<RT[JK-I WWV/=Z]T)=-L#
MH>:(<[[ F%X0'8U*](B:-]X+GAT]6;=]D#;V!6S)%TU4? >=!0]HYE H_<)9
MGV$A\:L?WQAO]LC 6VCP@F1^WA'\TUCZ$T9]?Z1%QN\%\O3/YW@%\7-&SC ,
M[^V?7K;8RI,Y?@A+,]+,YQ(L)%@\"2S$R7%SN/Q6?X<EGR0Z2'20Z"#1X:^8
M44*X]';Y<R4^2'R0^#!<CGQ9?/C&CRJD0;$72.BY(/7#_$M;IW.\!:G/*$K'
M)&/D _KIBT@AOWXXFWX0I:F?LBL>0F!9I_HAU,OR4=+NM<G4$Y,=7NTUA]<F
MEEPX)BZ44#<FVHV4R0X/ZG1/5SQ=8MVHV%!BW9AH-U(F.SRL>T9E9\F&$NLD
MUATLDQT>UAF6U.M>W<MZ9VB?]+(^@8TO0NB5?"BJ3/I5I5"20FG<0LFQI5]U
M;%PHH6Y,M!LIDQT>U$F_Z@C94&+=F&@W4B8[/*R3?M41LJ'$NC'1;J1,=GA8
M9UB.U.MD].K8_:K;$KQ_.!T(:DC1-";:2=$T$-'D:(HMO:OCXD()=6.BW4B9
M[/"@3GI71\B&$NO&1+N1,MGA89WTKHZ0#276C8EV(V6RP\,ZPS(44^IUK^M=
ME5&K?;/QKVVM3.E6E3))RJ11RR3'E&[5L7&AA+HQT6ZD3'9X4"?=JB-D0XEU
M8Z+=2)GL\+!.NE5'R(82Z\9$NY$RV>%AG6'9TJTJ@U;'[E:]F-+KC'R#<90L
M37/I6Y6"20JF40LFVY0) <;&A1+JQD2[D3+9X4&=]*V.D TEUHV)=B-ELL/#
M.NE;'2$;2JP;$^U&RF2'AW6&:4F]KB??*OQ @Y1MG86N[06)EGW?U=USR-#S
M7!UXM3/;?U?E(HEOG[H%6@;J9_9O]7?D=)97V8*4T_PZ(P6+4Q8N2K*8,G)9
M4/@BH@M&8IH4Y(JF%2-Y3&#<N:A62[%:K7B0122J"NB2&)IA3<BWG2U<TY*$
M^6Q>X3L)-!*&>1'1+(2ODL64?$HR^"6A*3F%;V!PV.C%@F81+XW[(<<^MWYU
MED=)#/N5C^U;/D]"XNJ>LE(SLU:&+A9Y^/O*%PK)"_+I].(#.;TXZ[X=)67!
M+J$#[ P)P^(8B(248+":,XKSB/,B9LFB*F I"I;RSQ8Y*5EQE81,#6@)'USA
M\]GEA%PP1K[D0!9=PZ>PT;B==;F MV>P0B52)Z\*3E%RFF45?/L;F^<%=)Z1
M3WDQ@P;4OY/E\&A95C.^-B6Y9F1&(X:-1 RP';B@F<'J>G87LYP<[68P8#.4
M2(^?6,AF 2N(J2N<]@HG&KV\1$+#JF45_QH>+:<45[RL@G\C2\!:KA"33%D:
MD>"6KR+TKK+9/,UO8?6CI( 7\@*7J6 GY*=BTE2N.R$Z"#'+\-Z+3XLJ@X]T
M7@3K/?D5/FK3A'0>Q<]YC'O[&>S3B/Q:3I9'-,1QL)')X^=99<B[P,+UA/-J
M4>*V0X9ZVAP-0\QG.<7FD[49=C^N)R@^VC(_RU4<Q]W.PISQDBR"U3ZQ)H[M
M_; N4CI<K1OW\-4J8_/'^^/LC1J@CQ![O*N39 $#"1_!_:< .!&L+]+T-\8A
M* *(RM2/S6K^5*_F"FB2\QSZN7T^P9U'T?L%@*1'I>(?,.>";X=F!W!YU])L
MSFFF($#/Z9W[AI*0EE/ ]P5-,F@3I$PC4E "X&X-N#B$+=IY*XO6GV0TG.(@
M9LEBP?@G0 [X"%MH!YE@AS,."4)^AU.0$S,4]_%Z"_ *2P 3X(TI,"N,;760
M%3Q=]\_;*D'H,'R\X)-&O9++_J)@M.""+D8ZL#]0QL%?!0BL]!8^!U9,4R$-
MZQFGM$2EXK8=5?VX0AHV?&$F>.(6FQ?Y50)[[)5&^: Q#9QDBRE=#(I<7#X*
MC1FE/W(Y<#.R)^X>6.&BT09A%]X25-5PQS?/UIQ*<%X;>R_+%V++@$S-A>*W
MN;DG@R*'Q/V5(MS3&N3F-.':_PY4[PW%XUWOWHOOO&5N5B @4QP3Z$_7Y<F*
M1R!*KM 1\!?XEX0 NR48 LD-B\3L^<PYY+>UW>O50IO^A%:+O/6+\$^TB8-N
M%DXY=V)JW3_H+^FP!7\YR&]PC9#N-9&!#VZ:QX2K9:67QOOB".<+#KL>V/]Q
MAKPY4<WW8.'>J((FL#6AY;2:9>_!R)NG]/8$O]UP\$QL'!WT64>8X6!KWFN6
MG[^H@@[U?IZ7"6^9FX$@([OS:"NHW^SP#CU3$>VQ$'W?NT,WG WF6K+8M%CC
MH21+@;5 < !BBE5>_0)(+3X6?7E\C>;TDHGH/I7&,/<3FE[3V_+]FS^_)A_W
MR+>K;DJ<8H>3USBR7\8[&(=>PV+D+]R;N7.):PKA(+$7F!,^K@(H@+';934=
M+&CMA^;Y$ W:><E.2C:G*/VWK/.;C5#5JZ1,@B1-%K<G30/;@E!%A[8S,;T?
M=K&5X.UM[QD3PWG":_I3WK$G[BMU]9JS\B?6BW1U5_BR]_BL$%NWU\-BFA]\
MPM$"2",2YZ"M@B$;D4:4/.(,Q#O$8\P^2"F663./A)C W/C5CV^,-WODT2TT
M>$$R/T\KVW -/BP#BE#ZQ1'"7X+BSW_]K?'6O/W3NV$R^Q!69?A8(G%"XD1_
M.'&&#M\Y*\H\DV Q'+"0M]WV?]OM0^-E:\[!RH'$<,E P3'13@8*#B10T-+D
M7;>Q<:&$NC'1;J1,=GA0)^]_R#2^!Z"!GU91LL#H,W'\/1"XD#)I3+23,FD@
M,LF567S'QH02Z<9$NY$RV>$AG6Y+1X-T?X]=^5ZY]"%U<"F9I&0:O62RI0X^
M-B:42#<FVHV4R0X/Z71=ZN#2 3YV'?Q+#M]0GO,"+X>=Y<6<WS<D/^= E(QG
MT)"JN1184F"-7F!)G]'HF% BW9AH-U(F.SRDTV4<GG2/CUXUOP@3ANHWZN7?
M6#C-H/'+6ZF-2QFU;W20,DH&JQPA$TJD&Q/M1LIDAX=T,ECE!;-GOV0&TF%G
M1ON<D4\L*"I:W&+6,9OGOJ1URM'[$F5.>+)GGM\XO14I:D>69<V^*\O:$>5B
MDEF8'OZ:S,(DLS!M2DJ9A6G_N28.CI@RN\IC]2.9A>DU5V7X6")Q0N)$?S@A
MLS -$BSD.=O^S]ED%J;]2T7IZ9/^9IF%Z7BY4$+=F&@W4B8[/*B369CD)90#
MT,!E%B8IDP8!!E(FR>#K8^1""75CHMU(F>SPH,Z04"?]WZ/7OF4:)BF9AH0)
M4C(]?T\[BF%+P30J)I1(-R;:C93)#@_I=$->I),>\+'KX#(-DQ18(X **;!D
M&J8C9$*)=&.BW4B9[/"03IX$2O?X^%5SF89)RJAAHH.443(-TQ$RH42Z,=%N
MI$QV>$@GTS#)-$PK([IK! ^GU[] ,T[+G!0LF05543*>>^F._$E@CI1YQA/V
MY-5"S6-UGH>_LP5A-QB& L-(LK J"A;!#P0ZRN!E#$VY3A930D'ESI"C>#<;
M"92XEK[,LS1C#'WJY61K<J1'+9IS0&OV.2.X+9&JBDA-E4$K6]>,L!3^93PI
MUE:*E[ N:4H"1BX+FN&3,+\D@\9IJA 8A;J <1)Z7;]'8?*PWB2?\T6%9N=5
M$4XI,(YE(4*1<DH+5BIU'BSX#9J_8N4"V8']4=&4P%\%0')Z"Q^5"_A^!O,J
M"1Z50/N+:<&8>LMH0>:L2/*(Q$4^$PFU\$@%!H'-(0\AIZ!QA^\KI*R"?\.<
M<$Q(JR2K8#9-$B^**;A:JD ?>74Y%<0K*_BK:1*[F) 5"M>9PIK.^3N4W\%O
M&!0_YF29YFG$, U8S*F-F<MH=MLLTM8%XN2'GUERA49JT_(*E5OJ&\:])(XK
M^*6:UX,&*J8)D!67/X1MV:0NBY,"'H>^H->BQ!QL]1?-+#DW$$ZJY8?X<P;;
M8GWZS?9\X<W!6SY)@&.2\!';95[D5TG$HE<:Y8/&I R<9M/\F@%G#(MDBRD%
MUJMY'?E.<'[($'V2>#7G'FP0@.YR"1[;LO7!?H"OBNL$&N#-E+A3$#/6$$,A
M59:RLMS54L0 T&#DV ".$A\+DR*L9@!P@%  L[3@6ZJ&)A&NN<0R*>)6%OO;
M-"D);%R H1FF3TSPBTC(L7H_HZC(@:_7\D/2\'=ZR<0J,*ZGE*3BRPJZ1T'#
M!=<Q"IXX!251FL0)EWH1UV *[BU$W25*H!?X?I4E5M-$8JM(OI6$E26_UNF^
MYX,&-ER40O=93/.2-:*A*RY6UO[/T"]JJ7^!?TF8TK($]3>Y89&@$Z<1S_G2
M)MS92)C8*.W\$VWBH W :>Q.3*W[!Y7Y#@/5V1:W)LC;S)VX;AHXPC+ 8=<#
M^S_.NC<GJOD^3MF-*@@$JX2I%:M9]CY*RGE*;T_PVPWK8V+CZ*#/VF&.@ZVY
MM&$4_J(*C/%^GI=<6I\4+ 5&N&+=>;3):VYVF"[/U/![S [4]S[2#7>#N98L
M-BW6>"C)4F M$!J@H(E57OT"2-U-N.GQ-9K#?A.'%2J-8>XG-+VFMV6=4_&U
M^+A'OEVUH7&*'4Y>X\A^&>]0LKK6C-;_5N./;Q-;)(E^? /SG7W7C>\E U4W
M6=Q^SZ^!P<II,O\>L@+9[7O LN]Z7ZF[>C?L8/Q$-R;DHIX ^=I, .7&F9@#
M^< R%B<A6&CX_7-TM!>?$:L%Y:\T Y1 .XW_^AMN%I"R%TLI"(^ S=\1AH.<
M#]FJIKT\>P^4'!__J)!+5ZX@G:<PT,]9G!<S_H%4;%<56U:G_$8#1B2^KA5:
MU');JJ&NB3G-6"@RA)JZ@FG#+=!<+RE/?%Y[ ? I](/D6>TSX)KOC-ZB3R<I
M2W2"5!EN,%0[F5BP5949%JQ4T# ID[)Q9Z !8VBZQY=3:7[UQ>IRU;?YY&/C
MTN";F9PW[B#Q8NU!^'AQ?CXA_V)D2D&/SO+= Q'COP;%&1X#M)@C=6 .P2UI
M8)ULT9M'G4?<,B=/RIS]JFG$M9?)N+UM6NZK=?6DEX:]5(8V>9E9R=SH^P]Y
M>EKV6 [:9P!=EWEQ.\P\L3(SLLR,_"3>_E)Q_0A/8(1ZD+"2YT9>Y%T-: Z*
M*'[*;E@1)HT?;H'>6:0:_TZ<MI3HZTT6PF[AQ"S)V_^0Z95E+G:).!)Q>,@$
MOL4B%4R9@EZR55R9%[QF5"P098DPI$$7_L4FPL@$[A)A),)(A+E3IRG8C";X
M/J%7-$FYNR/."_Y=7"VJ0B@\_+XQ=_KP;\2R[O*X\$?>LILPK81;:;W+F!7-
MF6@=-R*.[R1@[0&P!GNE:/ QI+U&XW[<Z;Z\RV'Y5G_2GCD(\@]"-,E(\X?$
M#.B*8>J*;GEOC:'PZR"H/(A[)!( CO#^P^K^?CC1_C00;AO$]NWY<OS$,8^4
M&R7D#0/RI,[3WW96'-]4;,=Z:[Y[:TFM9Z"VK,Q<]WJ&['W1-P/9(P>'ZB^C
M.O0:"7'<RL7SW=8'(C3W5+ZLYQB3XV;F@1!*8NIQLZ'$5(FI!\/, R&4Q-3C
M9D.)J1)3]Y)?:6BA"4?DSOF&&1&DQ!N3Q!L([88OSXY$6BW#+R0GCHD3)=R-
MB78RHF)PN"<C*B3D2<B33';X2-<$FTA&?)%LSLM9'&Q^K0?,=>]9<_S>YO]6
M?T?.1'J:-K<NSSTC4LY\K;/D9A'YG"%&8"I=D7Z&I[#9>.IGGHE3/(&_WYO'
M9D(^M3E[L/,Z03*95T&:A#"DF!7PG4*NVPPW(M$5S^Z+OXA\NC2[%<E\RTY.
MGOO'&%0B[VGW.NE*,VVVGCN:$6-I,B,3<3W^DM>G% $^T$A2$'93)P'"A*;E
MA&#"HAV9AGC?Z2T?S7)B31[I1XPL?]ARU@E@"W[G+6; ?)%"0KSLEN)/!:/A
M'U52B-E4F#\TR7GJXSK'JD(PP*GD^3XQ(R>0DX^OO3+7I'%65C/#BM2N/&'9
M6_XI#B3#3II;O^_:E$AW)67"D6._4Y:*C 2DFXU@+;,VC*!DBT4JDJ;AR#!-
MM<@$S3-<7]747;]Y#)_2&]%/GG)6:3)\ _J+#*IW#'3E7N':9<)ESJ=[%FI[
M,MOC@"KC'1(CK3"?U]*5LXO<G,!([67&[NT)*MKKX_BYR/N-C=N*97N<L3K9
MSQ\"*OQ77_%]&Y01;4<+<J'O6&CS'3G=GJ.-ITO#O8Y_Z8KI^HJIV0T+K.XP
M(1<>M[WX1Z9N*8;MW]%JN=[LG1+NB%?2>L>EW(-(W^;J:]-\9\O+VF(IX'_,
M%BUR2M^+I_-6-&,F.4S^!YH\+XT0%CRQ.:\=\-\TJS!+/W!8P("P_ XXC+#S
M.7">IJ!0LGYH$OAU\6-CF,L:!4LXJC$HF<U8E(# @W',L38!;Z'#YY,EP>YB
MJKZHU1]YFL(/JU_X2JW_D!3:Y-+6,&%[&?X=Q%*(_O*$YIH(E_R8?1X^VFB=
M=I+/<\6G*3S1AG.W]50>N\<//'GI8Y+L;N:QE6E-[TMK"NHK+QFTF'83FRJ-
M @IS0<WV]RR_SFJ%'0L E76F9H$"6+RA-K+B)(6VL>H))M,'UI_7R@HOR;!<
MK;R[FAL;3Z15_94"2A&7;WX;.C_IKF8G83DFE%93,(A4)A1Q3L+YCJ3EVL0T
M?=LSEW\P=_A*DONUY=^:SYYG7W_/EUG% 90G 0 =YE_?PA++!8'>+<UPEW^\
M5>?9WCG&FGB>9VF>ZSJ&:^B>_D,W\N-WQN8PTK2E5YURGI/M#CJ)\![#:=TC
MG43N;3K7']9:'<JVX<*K9M.V?,32T;/,UB^94C+E/I@RHZ"@H$T:5EP'SF-
M629Y5/+H?GF4>T/7<+.NX;/.JJ*0$P8>SM_C(Y)S)>?N&UV!G<I<9,?GC,G]
MOS%JN-S+++[F!?YRK'[5U9&YW[Y1=L%LQ&\N@9Q@ JKHEE;MB?;#-M5WLHWQ
MI>6"EHO(9T?0S[-(@?Z<O;3W%\+"_M E-]J"$?]>?X]+@_LT0G.^J48&E+<U
MQ;5,1=?T.UT W<.<3:M$%H1;6:8/VPR\9,7W 48[#4. E]IGQ$NN,5)46 ).
M%'V[K%)NA):-X^;BXQG_*FE<]E>YJ("!9WQX;,1/7^;Y-2LV[,Z-#48N=J]V
MU[D^KX=0-$4!R^7Y$"^=FRW2]FQ)5-HM5G[%D<!L'8U$]':+0<L;PO/2B.%I
MV JGP637\:,]_JN!AS0'1]RUM66T<5W58UX5\[JF74C3D!.W?@U:0K\IEN);
M,<CY1.MN\%@3ST:?T1R>.XHC.='FA'R\"=E\P7=4>X 'G> !X7*&M:Z ^SWA
M=5?@.V FX;?@![AE#C_5S" 8I"DZN9T9:H5D]61M@PMV4GZV5KYV-L,,P>@4
MS&'$BS9I_Q"VXDH-)%FNL+W>D\ARA<\O5^AM,)<L5W@/WZX&B<ERA4^)*GMH
MN<)#4JE2>LU-##RE!@LW34(4?]LE*);##;EMDHB3*R$J Y;FUPH&EA1X/,6%
MGG 9;3CDN5("+X?X+YZST("F;+&@Y$.2*WC,.@'MQ3=\<HJJS,6B8&RAD(L*
MR &:CJ:0\VF2THBE\VE"X3>69>5M>D6SA!+=US7K8,J!.>;$T=RGE'YZQ2)=
MUL2PGS+&)Y6TFMBV_[2J9;9Y_R!'6-CJ$9&\NKX7T*[;_Z\S>#DHDO]22IJ5
M:LF*)'Z5@'U)RJ=FD[1E<8>7+.Y0.PDV3<%'7ZH?*#;)HGNBB ?H02*H26A'
MJ/2L:T5/+ @@R_')TC4#13=1NF:83#T$ZLM25L/  XD!+UANMG76OT;:YX&9
M6T-(%;09.HOOGR0+:#I\S":Z7+PG]@\BM+M.^WS2PYZ:)5&4L@$3>HC*R".)
M]C"8Z8N(PQ9VDG1RJPZ,4(?-8S(5X/Y3 7Y(@<B_\8M*>+@RG%IN1X01,EF'
MS!K3UWXV%=-W%</1)"..B1&/%.WZW\9[4Y-ZW<7.Q/U!%L,:J,KTL0D(/5W&
MXO- S],((T_/Z!Q=*.2<%@L,:5'(+Y/SR5M3*E92L3H:>7:(BI5C6HKEVI(1
MQ\2(1XIV4K':3EUW8O2E6$E?5-^+\VT"@[AFY)RGJ/N\O%FUS*=2>ZD&4WOW
M2.%%RC"I3#U3F7)-Q35D;N-1,>*1HIU4IEY<F9)>JA?S4M$U+]5Y46%B (PN
M_I1D-,,XXUJMLJ5:)=6JHY%FAZ=6&8KK>XHG"^2,BQ&/%.VD6K6=NO;$ECZJ
MH:I5'S#K;W/$]TL2,W(1)BP+88!?Y_.\6&!&%E2[/G_^K)!?SM\Z4J>2.M71
MB+*#U*D<3?$\66=U5(QXI&@G=:I=.I4E755#U:DPN>8_:7998=6JGS'3Z5M7
M:DU2:SH:876(6I-MFXJKRS#T43'BD:*=U)IV:4W:JVA-\G+^BUW._\+S+'YL
MZQU\;>L=9!'YJ2F*(*_KR^OZ^[\/+*]2#Y-T![=5)8^]SG5]Z2KI6R.[6+ K
MEI$O23A=!*RX9(5"?IW\-'GK28>)=)@<C9UZ> X34]$-5S%MZ3 9%2,>*=I)
MA\DNAXDO8W<&JSS]?,VR*$]O,_+W"?F Q4\*K!>!ZI,OU2>I/AV-U#H\]<G1
M3,4S=<F&8V+#(\4ZJ3SM*.LVT3T9I#-4Y>DG>I5$Y&Q*LTOA<L*_SR=_F[S5
M-:D\2>7I:*36 2I/NJ%XEB/9<$QL>*18)Y6GG<J3+SU/0U6>SBC62$TR1CY@
M7<\B N7IP]GT0WUXIS^MP)=$%:E!C1Q\#T2#TG53L0QY16Q4;'BD6"<UJ.W4
MU2:&3&<T6 WJ(H1>R8>BRAJ=258JD3K3\0BKP].9/$^!5B07CHD+CQ3JI,JT
M2V72>ZM3(IU.?:_.;TDXQ1OU?V-9D?Q1L1*=3J=O=5F)1"I.QR.R#D]QTG5#
M.IO&QH9'BG52<Y+.IO%I3K_2XG=RD<SRK%:99+T1J3(=CZPZ/)7)L&W%=@W)
MAF-BPR/%.JDR[5*9[-ZR$4EG4^_G<U-ZG9%O,(Z2I6E>ZTVRH(C4FXY'8!VB
MWJ0XCBNY<$Q<>*10)]6F76J3UEM* NEIZGMU3M.4L#8Y8]Y-SA@UR1D)A?\(
MKL2<O-5U,H<G\JQ\)]6K?6..%&Q2O7K6Q3M%L^%_QY>,."9&/%*TDQK6CO-X
M;>([]ZA8\ ,-4K9UJKJV.E<'?GWX;/'ISGS_796+)+Y]ZH1;VM\U@(>3YO\C
MOS'HH(3?2A*PC(%^@X5G\^L,E)AI,@>5AZ2L+,EB"H.%IE"[P36;=.EY7$1[
MJ[\C_\@X57*\-GB=E(PD601;;L$B!4C%"&RL A^(\X(P&DXWB$N2DH1_SLD9
M#6C*%@M*/B2Y*/.K$,,W?'):P&L7BX*QA4(N*I@<<30-$V(E*8U8.I\F%'YC
M65;>IE<T2RC1?5VSCGEEC'<$B]4D&=!]1A=)GI&"8=4_%B'! UK"#_!A]X$D
M ^W](IRRJ$H9T<V?_WRJH$H?)RD\'-R2#RD86K_EX>]B>4259ESDBX]GV-@G
M%A05+6Z)#2NG&?8$'L/]LL F$DS'L=Z"&%-)RAQZO,H7\!"9Y]? %;QMX)PY
MF!9DD1-3,0U?T7R7E%,*G^-^#//9+$=20X/<$N'-1$DYS\N$VRD[V_)=Q7"T
MNBV%OYPF)8PD@?\;GH6YVQKY6Q6!%4/^EQ81/(FK\;]Y\?OR)Z+#TNK'S&SF
M)K-U>6R=J6J&6N>>+_D5FP6P7+K!V<>:D#.P'OFJP&*;BF8ZBF/9=S& #>OJ
MF=JN1Y*RK%"ZD6J>9[QO,&F+$&$+'D4BQ546X=AH45 4!5.6<M8_C>@E:\MI
MGM-B@7)!(;],S@&F -M.S\XG.YXB/Y_C@[],SMI'\9.DY".X!#PLX.FY>!H'
MLJ6M7VD&O\Z X"M]_MHVDV17K%S@ V3&G]W5TFETE92Y&'MG2*>\)?XJ;L*9
M6 K1Q,_G+7<_F=UTO3=^(\\>3'^\OV/%?_GEC-/UB2/E6SUB85[PW72"3%FD
M>"L?$"Z)7F8F9^<PZ@&1]NX= IR_#NOX['+CU])D9?\+3U5ZN]S6N#]^RX'5
M%^1T$4Z3#*$>D025BQ34OI^+'"5!P=;W1BG&<<J?YIN$_X1/K@VX;'?B1U2
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M4Q6S&TR<S"VR&M8#X6?(@*93FL8B*^<V1L(ZJ'4K#043Q-*V+J@@[7(=5A=
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MSDO-@NU]E1>=>R.B\#!_DWO:@,W32+@T>)%='EY?%VD5!2L;(;&8)@#X/%A
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MG>VV[ !^T PT4-I 3\IE\%1$.O-X90J@Q#,\K$8G;CGA$QMV&]WK._VB$_%
MYRT:XI95ZA?2V^X9-68;P%>1'%6ZX,&;-+I*RKRX[82KM_P.'V,LJ;BIM,D=
M[4A@X4#;!@0!(B>T2$2H-V_L&E<6 R>R99A%JZ!LY;D[6EU#M$2TR96E*Y;B
M#2HT;I.L49A6=F3MGUQNGVDNMA#&H/+8#+K!]MMWOG+_/F[ M3:T-UO> OD\
MQJ3A5(Q!Y2'V^$T-R"'/! %;BUW5D1W="3?>@0Y"3#F;K>[%7 37-L06(0_
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M(#8"7PVI'JN61SV5FJ8-4M9SS1B$LZEO.D6?8'BU"/."II>CF+H,+QSYSI,
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M,RS#M3?OESTENJ#&E7,!*_WFL;<4W]A_4/I0]IZ,(I 0+R%>0GP#\9'!H@B
M7+4-TP>XAK\\S0E59MF&YF@1U6.]E]/_EX5XVW(EQ(\_)%P::,\VT(J*13P
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MC!W5"BV [,!E:N@['G-CY@$:]J$KON3,='M(1TL;7M>W>V+:D!ENR% &\X
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M"TIB7,0;*9N=H9( HWB,C AX-R[BC93- .^ $0?!B(!WXR+>2-GL#/'N<!#
M9+G"HLB1S%.#B$M8$S&EB&N>945A\C1FNT& #%-)F8X158E 1%"%&,ND^P\U
M.4USF>TE(4 0X,E*[VDZS$"VPL/@XFW3+%U+FJ@R+EOANG*WJ>2?DVBF%^[+
M<G6 K)I%X[[YRXER=&.BF4NE0AQKC8CD"1)<Y"[I-DV8$1;%>L&P]_S& ]@[
MXU,Y5A1ZY9Z_KY2J[/0M1,X*?,!T.)K8<6LV,)<+3WGA)D7G.2ITG+AF<8S$
M!18YI;MB)[2D-,\(,KI0KJLI1CPV%.4XHSHVF6;97H?2M;!I]<NRMHL-%D!H
MXF,IY']J'MC")YD0ED[B/ ;Q&[?X@8,X+N*-E,V>#,JG6F>86X@6.HN1M;3L
M7RJS_Q&,ID9B5J3I$5'>.W>'0?X!7AZ _+BE#T!^7,0;*9L]&9#/*6,L3@J4
MT,*"?$9RA^\225>#)(6D6O22"O2H(!]/&'2-'KL( M*/BW@C9;,S1'K8WQXC
M(P+>C8MX(V4SP#M@Q$$P(N#=N(@W4C8[0[P[[,GK0F4XL4Z\IL8@0A1#/,XY
MHI1RF<NTT/WD\SRZ)W_ZAKUG)8+00N2<DG*B<N9D>J8#%'PI%U>1_JIK63;^
MV'!0-7>_-B WH+J&J+JPH$075" C=8;LGQEB/*:(98IGJ4QR+8N'[#1*+O@W
MDTG\;^^"D+QNI4<],*\$6^5%"PA#CUP(P4T9%_%&RF9GB/40EADC(P+>C8MX
M(V6S,\2[6[+H:)XZ8Q0)HPDBB9:(:UP@JI2,8YR1A.Q-3>H[P>+[YNT#0C03
MDD+J],BE$4!_7,0;*9N=(>B#D3M&1@2\&Q?Q1LIF@'? B(-@1,"[<1%OI&QV
MAGAW2P-5IAAU&1:I8A@120DJ..76J;?>/A&*:K,WP;+O7 MPZD<EC= +Y:S2
M+NQKTG6DK^?3ZD;K]LOYLI97O-'1?,IAN OHKD'JKCR31,E"(9XRC8C58XCE
M2B&<Z[@0:99G+#YZ\X[7K>#X@]ZW8O/>2LU#NWED;!)GD#$X<F$$?V5<Q!LI
MFYTAYD-\9HR,"'@W+N*-E,W.$.\.V[B")$SFB4'*"(P(20WB.4F1LB8O29*,
MIZD^=M+%K29N7PTC:0%F[KCE$6!_7,0;*9N=(>R#F3M&1@2\&Q?Q1LIF@'?
MB(-@1,"[<1%OI&QVAGAWR\B:),=<88F4,#DB&4L1TT8B'A>I+*@P1N\UJ^P[
M[0+<^I')(_2[.*_$B[G]L]OAPEW<N'0,%7WA=<UG"^AS ?IKF/HKQ:D1*D,%
MEL3J(D(05YE!E"<%,2PUB=IKT?3#?2Y6DO/.O/)RXQ75Y4R]K_4;+R;_KY62
M-U7]\4JO5-C6X;_IQ3MS^Y2C^PQ922B;Q(2!;ANWK()+,R[BC93-SE E0 AG
MC(P(>#<NXHV4S0#O@!$'P8B =^,BWDC9#/ .&'$0C AX-R[BC93- .^ $0?!
MB(!WXR+>2-D,\ X8L9^]>&B"</*]^-_T(EK.+-6G=MTJFE9-8]=6S2+^F9=3
M+J8:F:I&#9_JJ-%R69>+4L,F/" V(#8PXA@H!1;JTV,SP#M@Q$$P(N#=N(@W
M4C8#O -&' 0C MZ-BW@C9;,SQ+N?5J0]VAT.IZTSE::))C'21.6(8(D1S],"
MD;S 14P)3?3>"!N<L=0PAE&2*XI(DF6(,QXC+AAF>9K'IN"[95>_:+'XL(X?
M7:Z"2V^J^@.?ZC_6$:A_\'+V:]7\P)#AQKX@^]=WDM13J+PZS%5W9Z"?!R+]
MH&3&13Q0,D-1,F!4CY$1 >_&1;R1LMD9XMVIC.I4%H+%.$=:QPH1PPD25&DD
MDP*37*8Y*_9J0>_3RP",ZL$(?;]&-?0U&&LNA4N@>*HR (IO*(H/#/TQ,B(8
M^N,BWDC9#/ .&'$0C AX-R[BC93- .^ $0?!B(!WXR+>2-D,\ X8<1","'@W
M+N*-E,W.$.].M7$E"B:95"[]BR2()(E$19HIE,6"4Y6D4KO,KNV-JU1FHL@D
M1=00AHCD$C&)#5(%+@A-&,]4L;MQ]9M>O)W)ZEH?8U<J2;()HP2VIB#?"]0(
MJ!%0(X^N1K*8&,DQ1UKF%)$"4\05RQ&5*F,Z%I0(U4?^ ZB1T:J1TW2+.&9"
MPQ@S%E[RJ>L"W[K7OVBIKX6NHS291#C&Y+%97=@WJ>OU-Q?9?!$UU;14T>IY
MA_(6AJ_C[DG+,]2"AW64CJUVR1A#,DM31)@2J)"Y0)G))8DI9W[VPLX888IS
M+C!!+&?./;(^$DL50VF<./VDK'NT-T:X,WGA@Q^M\&ZY:!9\YDC_P,$+63S)
M23I)XN3D2NH;W!82T^(49'=T*G^4;M!XE,A]+:J_@#89FC81(B589PG*59XA
M0HG5$4+;_Q##"$\),UKVH4V\'KFJIO9E-*__O2P7-SV-I@,5 BH$5 BH$% A
MIU(AA2&:2:P0(6X JL(&L3C-D<X(2U,N8YPGNRJ$YR))"HFMGL&N>C^5J,AP
MAG*LK1:)4V4=F4=3(5F<3$B:@2(!10**!!0)*))S38L"@ 6 !8 %@#U_@#U9
M P&2*4FX1%3C%!%.)1(&<T0QD4FJ=*S%7CA):BP2Z3;0$RX0B8E G-,899BE
M5$H1FSSNTQ>X8XL 4L &!21L@?("Y07*:PAA)BZD*$RA4")BX<),&1(T2Y!,
MN-43E"@9XUW58H3 +$XU2A*#75JP1D*2%,D<9S)612RU?KR=B@Q/4@@S/;X7
MM$[9LG^X-D/'?8R-%-X-YS=W_]8-'T*(QW_:N\)!W\_^\4I'7,KJVJ[EQAX=
MS:J%O12O[=<61^QAGVH^C>:\7D25B197NM$.,CS[\X56D2EG?"9+>U"SL%]<
MV^LV%P\QIOM^Q&B+Q57YV7'VW^V_D9SRQN*0*;]J%4[UI_%RINMGJV5WNQ?Q
MY:):2WKH9^2@Q=^47F3EK,LA_F!1?74/Y!;9KL@RQ=?580$LMJX:OFK!PRVR
M7<9_?,.DK\]1^L),]5>DREI[-+37G2ZO9R]4V<RG_.:Y^W4/Q,+:[!U7>9?V
MX[^6S:(T-RM*^1.1GJD7\ZHI_95K/>6+\K/N/L4:"[_>$=T2_)TW.1I9>8.&
MQ-9TCZTWS'U5[W!O.9M:ID960NN6W[9_L*\]?!WNQ#R_S/DG'=)O$3?V/3SG
MTR_\IGGQ[&_'E*#>)&;;"'"7[LC0CBSTR_*/Y.\<7P\&MAJN-OP2WJ"PMN=Q
M2/+J\N7EKZ\_?KR,7KY]-XG>_O;J0:KMZ.N-'MN*\:[&1O'_4_+FZI]F6GUI
M!OM*N\;+A_7*K74S[#?[RE(V>N,H.^QUCL../CH=?BIGUEJNE@V?J>9G>&7W
M56_?LQX?H-Z\@^O]VULME5;UN^6YZ]NG\7-2K9U=+1==BRF)K<O_U]7Q]M5.
M^;S1SQMM/2<+,0?,EV=[-5&?RZ84Y;1<W#Q?7>!0L5-K+&47&<[_>INY%&RT
M0R<F%_<ZZS[GI!=9^F@W.X?'^E:I'/OQ7L '96M?'N\2/CO&-@$[4?SHR/L$
M0*H=4EE6=3_]US/ZK ^R];J7<ES"WEO%WXGN_ZMY';VV'JV*NO6<1^79GD/A
M8^5K .HQO"4@U3V!&@-0]PG4]RVP!U0&>0=Y'Z6\IR#OI[7"[M-9YN!*[V5V
MG4EGF?NQOX]4^SV R-35=53-=<T7+KG Y>]\]A.LG@\%P,><J]@S?@\X6VZD
M-@,0#^05Y'4\+'?NQ#O-L$%HQ7><X8%0PP'=.8==H3%@D#V/XD&:")S) F4%
M4XCPV&(T36-4)(2+."G2 O<R??A]7=GE0.O=X0HW% 2",@%E LKD(<I$X1B[
MKE1Q%C-$5,Z12$2!E%!82R,U3M.]KE2)3ADF"2KBF".2*FUU3YZA3.L\*6*J
M\VRO*]7QE G-)S0_?;G@V&7[<=JX/R#8OC>]'@;5W_8N+Y4K\PH9[HLJJK7]
M2993'<U:)]1]Z_YVB?O1LM$J*F<0L8<(X'"#6! !'"KQ0%Z!Y4!>SR!BW[5[
ML+O+,4/X7:L+GX?5Y3NB(,&=.>5Z*^A9PYTK,A"G^?QP^KP=N<>F$\1F?BQR
MHIB)><XPRK31B'!LD,!IB@R3G%$1TX32/L+P?JK02X<JKSJ@TE>SI6)"* 1/
M1BYS .WC(MY(V>S)0#O72F>\,,BHQ(U=T 8QF5"D<DIYG&MM1"]!\>-">S))
M20K0WJ?,G6:J*3AF#Q/R7[0]29;@C('&!HU]GAI;%8K1A*4H2W2!B,ZL,V:T
MU=C6H<))@B4N]H8KW<<9ZT))7WIZDB>G[Y\.@C8V2@&>/STV>S)XGC%1X(Q(
ME*;4>E,F2Y'(N4;8Q"+53"2&QWUX8$?!<X(IX/F)W2[8#SNYVW5Y75G2_,?+
MEFLC'GJ&ZVBJ>:,' JB@M\=%/-#; ]?;A76]#-.(Q=89([*P.C@G.4J94FEB
M-"_R7FI3W@0L^=5!R>_N6=^9/QI]V31ZT86=GE1Z.DEB#"I]W#((4#\NXHV4
MS9X,U'/&<J55CK J8D1B;A#C0B)J,3[&A4DY5WVX:$>%^C##XC^ZKCK3=@'G
M8<?L:;MNOU4SY&M#-C4AWFN+]%>W30W>&ZAT4.GGI])5EG&>4H%B6ABKTB5%
MK. QPJF2IM %3KEXB/<FN>#/+;:X7G%>G[\.<-*3FX8G+&6@OL<M;(#IXR+>
M2-GLR6 Z*0H64Z%0F@CKIA'C(G(%0P46.6.%,2++'^*F'1W3XSP&3(?=M*?N
MDEU*6>O55MJN6S8MN9\A56KH+P=J'-3X^:EQI521:R*1T+A A!%NE;/BB&6$
M9JJ(B[0@?6RLK6&F7S5.8B@R&[FH :*/BW@C9;,G@^@,:RX+I5"6,6P1W>1(
M2%,@G%F'R^29*431Q_[9T1 =0FVG=LM@I^ST;ME.DJ,J&VE?T2)R<C[[K-LV
M; ,!5]#AXR(>Z/"AZ/!3]6?5L4@3)JW[EAB%2&$=N<+8C]SZ?%+:CYSI7OV^
M+J"],[^T<-9<SM3[6E^7R^OF[0;6>BN9R#!8$X>YZNX,!-W 0<F D@$E<X^L
M?:QUG%*),AH31'"*$3=8(<UCQDV:9#B6O;JBIU$R&$,2_W&4#&PICM%W==WX
MG9]JQ<:^JEDDEW6M9_(FTE_E%9]]TE'-%["C"&8%F!6C-BMNF?S!5)(1F:-8
M)*Y^PTW^D"9!Q!"3D"PM9+I7OW&O4KV +J]:</E8\UD3%N+PYZ5VZ/.1?^VK
M5 _\R)$+(.#\N(@W4C9[,C@OB!$X8Q0IZ\HADF.)1*(S1$U&"TR$PL5>!/%>
M=7K'Q'FHTQO9[F-/@Y[PD08]G8D']\J[:<W.]"97&MM$?*:Z>:$PR0DFPPQB
MN E,AADJ\4!>@>5 7L]LDE/ZF('Q]#S,JO>UGO-2K;H=!%NJ6ESINHV1+UHC
M:R"^[/D!-WAL$#(Y7<A$:\,RC2E*8FK<_(\<,9-1) EGN&"8Y?NIV?<)C;^=
MR=K5[_VBP[]O9RWR_**-MCBCVI3MRYEZY]#'-SWJ?8 VY%Z-7C)! 8R+>"-E
MLS-4 *=*N6*%M?Q%KE&<4:LN<L81QXPA37E>V!]QDO12_7-L%?--S5)D!#3+
M4!*N>BX6 K_RQZ' 2QBXCF Y@.4 EL.]G=.4)$21#,DT9LC^G2).*4<)UDE:
MI)J19&\X93_.J8>O=ZM]QEXMA8R!I0#U/Z!20*6 2CE!_4\<FX0R@K!ARJH'
MGB%68(J*M% B3921^T6F_3BC1U0IR20AH%0&XW["MN;)W<]+&<KLHCF_X6(*
M7=S!7@![8<SVPBV%/8I(P=(8Q:;($9%<()&F#!6"%:;0.)?QD1S$%<"\#_C2
MFR*/84#RV*4/0'Y<Q!LIFST9D#<%YI3FTH*\3U%)"&+4Q*C@S V^=UN(>_U@
M^W'9C@7R-(<6L8,NZ0$G[9&<M'JIU8&44VCR#DI] + "2OUH2AV3F!'C&@&G
MV"IHG6%44)(B86+,,BX+QHZ4=]JBSJ\;B%DE!*V#LYW?>ANK7) <=/ZXA1-T
MP+B(-U(V>S(Z0.2\4";3R"B96"<M+A!/8X.,YG&<YG%:\",EAIY$!^!)P6"^
MUZG]/MB<.[G?]RL,\AJU?A=65'2]_N8BFR^BIIJ6*EHQR%#(.WP+X)ZT/$,;
MX50907&2",D3BEA:9(@4"B,AL$)I*HA,N3)FOSREIR33M:WA/J\,CIN^BQ[3
M"2Y.OZGX#48/*CE.!P,;D)8*B@P4&2BR<2DRCDW.4I8@+ 5#)!,&B=Q(E,0D
MYERG0O'D2*FMCZ/(\(1D%!39F%)A>]YE)8_I;9/S\+9_TXM(\N8J6C9:[;1/
MM!+T&3QP,%S < '#Y72&2Y$S2205SE)Q99[8.M(J-TAJ8W(M*98T[L,#MTCX
MR@+A^[KZ7"JM7M[\81&Q8[U<KN&P;\N%L4%,Y'FZI@NH,E!EH,I E1T]F"QI
MDN!<((J%54LQC9$H!$>Y,(KA%#.:\CY\\-.ILBR=9*0 538F+_R;>]X/&%_0
MD],],*_Z2Z"EJ*;J1^83.!?;3*LO363JZKJ=B+[M9<-@ FAT/HA>W=#H?*C$
M WD%E@-Y/?5@@IZW+9+'W+9(SF/;XOVREE?<322H3#2OW:;%XL:7BNE_+\NY
M&Y<-D9Y117J&0KSAQW$&#--G$:51:4*5PAJ96+F(2Q$C'IL"$8J)IHE*)=[+
ME+C/AL-[?N-PJOE874H+6K5^W^+8^RF?+2YGZO4*RGHK,<#0/P2V$$"Q@&(!
MQ7**G>R449QD.6(^!8_E">))CE%2Y''&LH)SSOH(_S^Z8J$,JI?'$<X'[_31
MO=,0ZO<".1!(!\MA7,0#RV$HEL,M#F-!1<XR@A*>)(@0JZB%R@3*L-1%+)CA
M>$^O]^(P7G[FY=3U'GM3U1^LWOZ@Y;+V>XF_:'%/Y6[*KUJA_^BZ<NS$<()?
M@&X?MR "WH^+>"-ELS/$^U-YBC@G).%ICH2(K7;0A*+"Q!(91J6B.,=9W$OO
MDT?1*/OYSF2"*4PD&(S'"/N9I_<8ZTIJK=KL,"LZK=2! SEF@P*RUR%[_;%,
MACPM2);F%!DWYX"DTE@G-,^1_93GK)!2Y[(7)[1%JC<6J/Y[C5-^EFZP)2YG
MZA6?3IMWYG9CHB=#@A23+#Y]T[0Q99L/7]"'0BG0.$^<$4'C?&<[4PI&1)&A
MV*36X<QR@1AE.:+"I'FNN.']=!09DL:A&#3.TVSE"<U%'M!<9-Y6(D;B)OJI
M[33R\\$B*+ WP-X8+@R!O7%">X-(PZE6%LV5\W +%5M[PSJO7 N*E938NKI'
M; 3R=H56]ZF>_K8;FT\P@Z+I\Y+FH5 *U,H39T10*Z?>S4VD2G*-"Q1+UT,Z
M3E,DM'2:2&%N_60ADCW%U6/;CP<IKCOVWG3--T]?6C(F#3;L75]H^W&4MA^F
MG/&9+*'M![01&%XE/+01&"KQ0%Z!Y4!>3]WV PJK3KZAL)TFM[C24=DT2VM2
M:9<H)ZOKZ\K=N))_3J*97OCLN=4!LFH@@6YD<:"A$&_X49X!@_@C1%A,HA(2
MNPFA@DA$8I&@0A..<FR(T)CEBO6R-=!-17C; LL[\\KCS@<'.SWM""3QA.79
MR>,I('YCHQ2@_--CLR>#\E05,J,R106/F4-YB42B,&)*9U04/,$ZZSOA[*@H
MS[()CD\_^.&LY _JG\;OV-WFU+GY5/:<F0ZH\*5<7#DG\.^B_MO_T5]U+<O&
MGQ,.KN;N*'#YP!@ 8^#\C &99()DJD BBQ4BU"1(8,60$5G*.#7"&-RWR^>5
M_[L *Z];O%%]&0,3DIX^L1RD;VR4 I!_>FSV9$">$IU@EJ=(%SA&).,9XGF2
M(\XTBYG"@N!^^F \$LCC28I/GR9U5M('&WEG[._9EZ;K2%_/I]6-UN%+[^W-
MVPZ+T7S*9P-!95#^XR(>*/]A*_\XU8SG)D6)Q*[[OL16[Q<489*23#.5I'$O
M@W\/AWL_7/%:-W\X 'H[<X0N/^O+F?)?O[3(HUY5UW,]:[A;L6NLW%<U$*:G
M+P4"$1T;I4 3/#TV>S*:0"8$Q[E6*&',NH&R((A1D:%<Q(IIS0O!Z/$V_DZF
M"9*8@2: O4'P%<N9+.=\&JT:OD06&4(IC8ZFVC7:'P@B@^*'^M['9D2H[SUU
M?2^6"<5%8A4$8=(ZJGF.N"ARE,<FHSRWOJ?J)?OT38"\7QWBK4%QU<*YK][,
MQ>E'^3S=,E[06*"Q0&,]'8UU2Z.C6'!L5(PX-P01SG+$E'5=25'@F!DJ."=]
MN+M'T"=#G!XS)G5R)ENBT"RQIV:)AQI&@.4 EL-PP0<LAU/F2]%$2XICE"O7
MDMGD,6)$I4@(ZTX:;1*>[N5+]=@B\<T*K7IOD9@D$^M6@REQ5M(\%$J!6GGB
MC AJY=MJ)=-QHI7&*$_=@%-JU4J1Q1(EG&O-1&)_[67_]?'5"LLG-#U]1NZ3
MTRNGV8D]ID<Z1I?SM3%:^BXY^JN\XK-/.JKY0D?A;[_-ZCU2/E/A#_WO9?G9
MRAF,HAN;N3 4X@W?&'@JJOY4NZ5IK!2/=8Y2XPHW8V*-"9-B:U:D:2%<R%ON
M&1/W\5$#N+TSKUMH^]TBV[N9LR_<_U]OD.QWW2SJ4BZT<C]<SM3V%YTC>V^;
M# 6?L(\*>@CTT%/60[<,ETL9U8E)D9%.2Z2,(8Z%1EF6$\YH3C.Y5_QQ'Y?S
MI%IBZ#NG9R6LI]D5!9=S?Y?S)RL%M4LZ<"/@PE^^LP^XFJ#BAX8:H.)'[&KJ
M.%$YQ@7*5&*-B)QIQ+DU#0J#39%;S9_&O6R'/LA<>*_KLE)O6R#\I85&^WFZ
M=,S1-4R"L=*[%UI,<$[!V !/%-04J*DGK*8.*Q%!9980;E!>Q :1)(T1*ZBP
M3Z RS-.,:KK7:.X^GNA0E<AW\G*206R@GI4PP^;H$#S55[>YHVUT1FB[-'<9
MMW\Z]_(W$&@&"P!2J""%:EA6!"%*&)-;8T!:VX$DG""19P*E"N=<%G%*Z5[O
M>I-@FABM44Y)B@@EV+JO5".1QB2AJJ 6\GNU(M;VPB]E,Z\:/OV'53)S>X;]
M[)96SI9:O;-8YUM=]):$5:03G)Z^U<632\("S02:Z?P9$333=_S;7,6:656D
MB,H1$=97989C^]&ZJM:+%33GNYH)2Y8*>RCBV)Y(C%*(<>O?BJ0PN4A(SHOT
M##03L\YM#%4G8W" 8:OVT1U@;7\"U_<<# Q\@1VFJ&HIIGIP)L9]-V3^<FI;
MXP?(^F2LC2RA4NH\05Q1URM)6G=6$88HT]+^(H01R9X?+ 1F<:I1DAAL?>?$
MGB.M1RQSG,E8%;'4^@RLC82FDX*>?AS<-YGX/ T.4%2@J$!1@:+J*BH2$YS$
M&DGF$I"9DHA9EQ?E'.>::E/DL8* +2BJP7O&W]P:/B@Z=W.7S],S_A)H*:JI
M^@$(^;"<SZ?:]4WCTTA9V9M6S;*^7ZLFL"NV*67?G/OIOY[A9T>CVC"TVLD,
M-"#>R8@'\@HL!_+:*_%@]V PNP=S7BKG2T2EXS/KQ4#T9531EZ$0;T21E0%#
M[F/,[&.$F)QSI(UK0)DD HE4**0*P7(J$BY5WD?%U=L63]Y;@/E-]Y7-GI/3
M!S6&(G(05P=D!V0'9%^W%BYR7<24H%@HADA!$L02G*&4,2&D+ IE=!]E4+T@
M.S33&%D<&GRL>TY1G]NGO_%96BY!:^Y"T-%J.'KCVFM,EVZ40#F+N)3V=2P:
M-T6/NRT2=Y+]LE[:W_57-\$29@N %@<M?LY:O$B3E*DT0R;-"C=)5R&>Q=K]
M9=(T8PK'II^.&/-RP:>O':RH<N'VPM[.Y+*NM7JY7/Q6+?Y7>PW?D^-&8@+Z
M'1PW@'R ?(#\W>FD N-,NO0E&EO'+=8&"4X3I*SSE8A,%P>FD]ZO?\6C0GX>
MGSY3=BBR"-MFPT'"!\KP[^YA4&70LK$>6M-H-^U<+'@Y"U[<NE&_VU7;FH%N
M#[-+#(E^ \%8T.GC(A[H])'H]((I&7.<(NM_.3?._L73A",C<BYYEE"*>W'C
M/!J],W\T^M)!T;L6B-[.5@VEWE1UFUX\^^3GR/Y:<E%.R\5-7[G&\:2@*6AZ
M<.Y $8 B $6P/YE-))GUT3*39(@PS*QSIP7*",4D$]*D9*^MT'V<N],K CR)
M(3OCY!X?;.*=UN.K5C(&/A^H>E#U3TK5XS25*2'(:ND4$2UC5 B9HR36BC&>
MZSR6C^7SA8FL^BB*GDPP@= N.'R@!4 +@!;8B_QQ6A2Q88BF0B)B%0*RT"^0
MR=+,Q"K-N-A+L#^6P]>C%H"$S<?R]>P?+OMO2/@<[HWMO;]UNX>0X9C/NL&;
M^T#!9BW]//O'*^TS/:_M6FZ<GSBK%O92O';YGKX,[U/-I]&<UW[N]^)*6R_2
MGN[[2?*%=3G#IF)I#VH6]@N74=I</&2 4]^/&)WVS3[>@QX09U5^=E+\=_MO
M)*>\L5 :H-.?[\]U.%VO2Z_;QW,"^9PO%]4:U?PW'B+]G>E%5LZZ5/,'B^JK
M>RJWTG99EE!?5X<%8-RZ:OBJ!4JWR'89_T'E3.FOSU'ZPDSU5Z3*6GM4M]>=
M+J]G+U39S*?\YKG[=0^,P]KL'5?!*?OQ7\MF49J;%;G\B4C/U(MYU93^RK6>
M\D7Y67>?8MTRYNL=D?R[L#0:9'B#AB3$^1Y;;YC[JM[AWG(VM4R-+![5+;]M
M_V!?>_@ZW(EY?IGS3SK$*!$W]CT\Y],O_*9Y\>QOQY2@WB1FVYAQE^[(T(XL
M],ORCZKUCXZ68Q#R_E7C?=:RU_JH[S?TZO+EY:^O/WZ\C%Z^?3>)WO[VZD%V
MQ='7^Z.&!GTX%WDOSYML_UQ4_^S:9?_<6&-]M;;JFUZ_>5-S43FK,GK5M2G?
MK&W*#^NG.*M7?R+OX>AT^*F<V;=9+1L^4\W$[45IUWS^*O@3RC7_7GVZ]M5E
M/X_GM7:4[0_<;!V8^6UYK>M2KK*LXR0E6*5(IZX\-BU2)&A2(,UDFNE8\2+I
M)3K_<ME8ZZ1I?M&-K,NYT_J7,_62-V7SSKROK3=G[1?W[4=[GY?32O[Y++*'
M\KF]QJ)>ZJ-8O?[P#E.WMOE@N3JYB#S%G ?<I=EX>'?]#CW5G5UH72!,W&B(
MW;O?6T'17E]J[\8$%WRJ%PL>O2PK:TS,Y$7T4U \/O81576T/N;GZ OWU;!5
M/:]JKY(LL%W.ZW(:6<G-(P]S.F@GQQ6_6$/ZBX>U)OIX(Z^JZ..5ML^BEXM2
M-NWM+ !._'66GRQMW(78) K147O]1>-%U^G#0VMU@9KOQEU6!;Q^<>L"7KN^
MK2MZ)';W^W)53:?VR;^XU(%F*9I2E;PN=?-\YX1_7(O_Z\_:_OJG?^C:OH6;
MG_T!%]'E=!HZ-[7QI,@>["*^C3]W4?-9$V*S373%/^M(:#V+]+2T[VQ%X\TC
MVL,N@(5W8W4K;K5@=*6Y^O?2NKBZ#K1[?U5.N=+3^57))]%[/9LU-]//?%;R
MB\Z+LV=RZ\F6,Q_4MKSSR;Z(TIIB\FIF'^S33;1Z>Z:2R\9>N@K,[OJ45I]U
M'<K'E?ZLIU4H(+<,IF>6C-JOY&,DM66$A1< RTP^$<7YL.7U]7+FK^-V )H+
MBZ667\NY9>%JW7/8W=U>5.Z('!M!2+'K^7^7,<>K,OVMGKO:K5+^4-Y2\V<
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M39O;.+)%P>_S*RKT;D_;$4QV5>XE]^T(6;*[?9_=\K7D>3.?.G(5JQL$T"B
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M2<+D&! R"9/KA8FA.5,FYTB%X<@@#'*DF9*(*<<((QR7;B=5"O-2&64X(L2
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MW-&QC,1SQPS 1+L)]1+M'B< $^TFU$NT>YP 3+2;4"_1[MC\%&G2\"C\&K_
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MX5<PQA:BD"FXZ_+YU2VXG^./HWCURW+2J5T9?6'Q2N?VHLA44WI#=D^_\]I
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M!)5@8\@;^:1"FF)P'"DWGC/)#-M+,>@!ZOV%J0JEARYF[:/74QU5256[;/6
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MR[R?_I*CB.\OZV7NQ#JHC3ZS3^X- B;5JS^-)_UFF16?W+90Z,6&,8MYO4/
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M1G=/&KV=(5@O]%<[_1<LW?N%R;FQ!WCW!M_\\S^:)F]F[9895'9FN.XNY0X
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MT]U/F\5XH__8WTY^!?8$CFWG@ ^_Q>D$>'-^GCU3,#5CMC*;F!*(59X$F,\
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M88X$YEWD2&L5$1?!Y6U %#FPNY5V!ANKKR;#%MFM&'8GOW(>?]S&AXS=)GA
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MSW&*<).B,8GV\F6%4\$EJU'0GJ(,9<AYG. ]#+:":!GTUA971:/1T3@4E!%
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MH?X^_=R1Z]LEM=Z/OX/5'P*#KH?+]V;07U]7VP<>*Q9]7+S_9H*F9%7*H$=
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M/-H>D*YP_%"&/"*FY8>$FRHBO@+4ZH<!][E#?64N-";;S D=3YG$D30@/'"
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MB(4DB)1/+&[20*C(='V_"0\<[1W:N^?\\X/N1]%RG[S#A17]I!;6]'2 ]9"
M*+LHN]UDO6,@(,[P;E.J8O4FC#C%&[5OZY0':M\V$Q!E%UD/9;=MR D[1%N
MLW"*-VKFUBH6U,QM)B#*+K(>RF[;4!7VA[8"5ST_Q5MGR.OF4&P);8-*.N;)
MB3A-M9<511'UF!L$E' I!.$>5R00U"=21;[KA,SU7;7;V=Z5&E3R:_99:*:(
M1T+O5'NAPDD>CV.% [[;KAJP6!9-$IHD-$E-%;E2&CJ<<N)[OD^X8T?$"Y1/
MF..'CO+]P/*LW0[X/I!)PBG?AZMFW4NW*;K,V^F++TH\[S0+^)^1JV*2C/4Q
M<#80M*C.^"G(7]<&=]5/> !RG6EQ-\:94?\6EG/^Z[E-+;(ZB'9P6@9.RSA:
MH"1HX"@;@)(;A.#  T;R@L GMD?-T',"B_N-^.YEI5U\K>[QS[LH4N'X4UKB
MH,?-0I_&ERKO+SCJTI0.].C1QJ&-0QNW*POD.J[PJ.,2V_(9X9:@Q).!2U@H
MA,/@*VEZ3;CJN[5 \X8GBF^5)'^J/-.<YS'*3M'J=&PV%":X6^&MXS;5/449
M;2$@Y@U:"14.Y0X'RN16&#HDM!33PZ!\XH>,DL#WE+1=SGUO86/0/:>RZYZU
MYI/9]L!SVC$OH^O* 5U?-$IHE- H-624+&8&/' $B5S?(=RT&?$B.R+4L43D
M*0Y>;",><@N-4FLBMEU7#:T?SK3@*??**>YP%T0_ 00VX'2 ]9" *+LHN]UD
MO6,@((XDZ&YF 3>M1MW<8M6"NKG-!$391=9#V6T;KL*:C58@*]RTN@O*OM]A
M\FZ4AK98P>\AK>5X*K1].R T"GS"6> 1G[L1\849,<OUH\A>2&OAAM,HCJC]
M4?OWEMV.1OM'OO"9R2D!*@C=>.80W[(9J-( O@FH*YU&BAJ.=2/HWLDBMMUW
MV2D\D_+D81^]\7R7O)'=RV>+=#1" NPFQ&["=L(*%DD%7F% N&5:!+"" %C!
M Z(LY5 )WJ'EF3MS*NLJR 5L<2;_,2G&5_#</0(81]E-B,8&C<WQ,"0:FZ>-
MC4TC)7RJB&4J\$=M&1$1,9,(X4>V8-168J%;K#$?MFEC@UWK+1)KS(!VV=E=
M/P,JZPT(,0>***3#Z@I1R %1B*^8;_G<(7XD.;B\3DB\@#J$6J%I!?"?L*(=
MYE%7X9#M,ZDVXP-JMJ,E_2A1"-H9M#/'PY!H9YZV,]3T)%,F& EFFX1[GB1>
M)$WB^10<7M/BCLUVF+'=E9W!D&HG7=V&\KJ[]&R[Z+I^5.-RL-J]1SJ8.JD(
M$WH $]B0::TBLTF0J-8!A8X-OMF8M#W$#(<:CB-=Y5') A(Q"IYL:)HD</V0
M!(%KTD!& $L6=GK9Q/M]/!]VZ<0;^!40REB, :%$9U<J!S9ZFR6)R(ORI-D\
M'',>HK!UQ^&PH=5&;_@1X[<.JN 8-[1X:/'0XO7$XBE+6&;$(^)['OCAMNF2
MP.**V,*T)>61YT5^$WXX6CRT>,N]=/A#P(NWR23=W_NIVVUEO2HN_#@IF1S^
MEO'URD_U3Z#63_"O$2:B )ZOZBO*>Y7W$7&J-QA8D@47DW$V8Z4J+ZZYMWQ*
M9VC'Z3Q]RX.#[%930+]5_0I TMOI814W/KAJ]5'-G?HAZ\?XLTR\WYX0ZS1*
MU"V1<:Y*H8/K)I.K]%3&Q2@1=R?ZVP4YJ9X-[C@-W<"?NA@ECNZFI"U/)"J5
MIZ.LB,LKYRH1>F.&^;>8B=OMFN)#V3-+_P2GW1ND331YTYSWGFQC5YI^&N8^
MD(&'W'V9/V+?.$V JTDQ%GG-< ^_@'6O/JYNY94,,Q+?5!7"(R*"A3@1R8VX
M*TY?O=ZE"#4F,@\-C;[TG! ]$H9F>;X_JK5DJ_('J%-]9)Q.Q'Q5-_5,X7&?
M>*[-"&>.27PS\@AU;5W1S3QE1K_3A^LR]^STT;-_?PYT"/+X^T$ATH(4H+JC
M&FXMN;EG22I-0%F.)>'FD3")9_H.493;,K0!BS&WO/DNEZQ6HRU:M1D8*+'
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MC'27@TIU\Z/>?Z;:H&8^N[,>_.!/IFBF'Y79H8MI1\$,BEP0.H=$+,LBS.)
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MS46<UHXE/0Q'=3F4M UT^IA=5^4XM"(I@B=404B1]E,$P=,>P1-%INR=F#:
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M80B'E8/GHSB_0O</I00ITEV*H-T_M-VW>A?1;90\1N=)\P@ 6"T([9YK$D5
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MDQ'GY#Q+R6^OR!0WV>;&V<%GF1 U5VXWZS#T](PEWW&FONUWIM@L$)\&$O-
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M-.@Y#;GQ/DFR#5WCY#.9WGTD@JSR<!MUOSOM(MH&:#])/]29;(LG2?4)Y'.
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M:QM(-_2>2*R0*@.8PL!UI6+MU[V'/7M.MLD03 LF9"Y/W$>79,E9N-,=3M,
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MJ<!ND!C.@^@E 6'A/(H+'L+6"._VGO-YS=IBH!H:ZW;8I?=/^,J)?X,J6&1
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M.=&V :,+U-4$['*Y;B'QD;IR44P,93H*B@?# DKH*7/K5<,1]^DYL;521M1
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M@H@>%M?\9$B#.>QF@7M+H#SPZ!%))98A/B,=F(Q:'J]DT7.IA9&R0%#D9K+
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M=5OYV*!4-*2*- R-Q-A?YE)(1XXZ.*Q%_I7S55&-)V(28&)0IS&!S?@:ISE
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M?7O&RK#P@.F0SCL#\+T$D+S ;K3W?5&)HI=4B:A'U'V?TS4=)Z^%&2G>Y4P
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M"1\D8P5'+@WKWDH>MY)'+,8X,.:4M[G/UEEZG_4RR0)-[E(G3O=B]1@_^B&
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MJR7D48T0;#%5%E+Y%RI 0SZ?"4(FIUW"HNR]V3CQCA8'4Y;D<\( P,Z2U-]
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M+OT0?QI71(Y36H@?$- T&>>CE9>:RG+6&<H1H7.SVE44IJ/ 3BY%9#PGB#9
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ME.=<QYFRA>V>/N%8*X ]_ZXH85GQ8JHR"OK9*T"\4Q[CIO(#+ME2H[K2?>R
M4>9NMWF(AHIIG 9B1&8[VP*NM)4I,]-92O8SO/;=I_0!QX\XUI+0P*@BA:R=
M;!1-W C[J7TN\D* 90?'4'V3=EZ (EWPF=Z0J]N\(#F>C3)J-<>C?K"#1ZUK
M_BK8> XC?C!,5#3YJ5QC4G\%>]XYY.^"&>\\B@L8-*/KM5!K(27/(+L@BMU2
M851S7#;64?XBN:TO5./F>=\9L IRZ;H FF3=)#.FND:M!<I*30T];*CW"B5
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MCN3Z%_PZHNA\V*,AU0DU$*M_AWO_.DK_@5/N_?T/]LQ(-0")Q^<B$G6HUQF
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M)UFZ,H#<V$>_BAYG]7W7QDX9SI!";$F>+( K;7#\2#CY*8Y>TB<X0TXX,M=
MD$2,)N)$#X27.JPHNPR),W85A7AWY<2_X?2<O!'CD DI,<2H(4K.6HRH'CX*
MEJH*,\81D2$"34&Q&HJ84@YJ.Y!Y!\J453 O:S@U)2U:2.TL5UYQX9 7SG<'
M<E<Q'>12/!NGZ FD0QTTWZV&A% RS_ 6$$=_00\PE(*X"V$966HE*L/L:B@"
M^I"C8 FTUN@:%)-P*F>B8-V-\K$LX7N"[8HELA\HOKXV?IHQ:RE+!\)%4+\A
M=L##:BO\00S6J!>RJ70A"^^R\U9JYJRN>B';J$ 5!#@6D4" V[)<(+.9APQ\
MA-Q,J_59X-."U/?.ZTW$4%V3\RB^99DA&K+"\\$HE"\?CN:/;,6 %#(RSH<T
MG/EJE'U^H!6V ==9L W91'(@"AZI#'7 7!<BXP?L^&RCG20P++FJ_W_VWKVY
M<=S:%_TJJGU.W3NI<B?CGIDDL_<]?\BOCF]LR]=VSYR<_4>*EB";&8I42,IM
MS:>_6'B0( F X!.0Z%1ENEO$:RV\%M;CMW8;ZOK$X3=_B0+<#)P2$(K%TA?9
M<[P3\&:%P9[,,N32?+PDHNUD-G"".O>97W8#)6QZRUH^X2FA1L3XHP+I?)>^
M1C$X*?6"\,>$[[S5 R)(A6QW,O.R-D?"MNN1JN*+P3)=RGBIKPE:[X(;?]W6
M7E$3(D;;GT$'!TACX?1(4G]#S'0[2E,P#DU+A%;)51QM.-KE8MT]E2!O=[;&
M#<]$',TQL@0.1ETI?$\@T6\&%3H&5"->HO '+-,W+P![5,>(9P(V"?N/_$5H
M=\1HYWX)*^-2$NI(+!#*&Q\L[EGV;.0P#2RDI)_'< 9.,5(T6H\$%7+#<3+0
M2&1PX?$ZW.[2Y ;<NT\[V8)R 1LF!1H]F9%F9Z>C&85ZI$J<G/]O%\'==1_[
M2T32R\\IS .U%='GVO4*[R>"'\.03;]CQ _N#">_":@(]A7\,J]#>''B 4,.
M9NEK@[B.=;P.3PI7(<<;K@U0O'SG:#0T= ;_@%_(?C*\%&Z+;^J+-GU%RLMV
M1EULD29%[Y"V\ NFMTH AB/>1H!NLCK;/P 8+&2CZNIYD;4_$SN -WW6Q2BN
M&(/2*LZ\ <'6-0]*=R,6Y?8%PE$PERAN:\F&Q/<Q.34'U/OHG;B$B$LZ6CB^
M.2AZQ2#'QTR/^@GS7VK$E7.),7;X\YI*7KX77(=8(B:;9_[NM[VVLM9F>7-8
MUL<-#N_P!W/Z7*_Q>ZX/+E7% 0A!X! -\+G7^<^#'\3@=NAG]AWU_\]VG6C1
M_F#KX''D#:9J;%_&?D"59.E][2$I]4RC':]-;O]*HC!$7=$NLG;&P;KH/.RJ
M.?:@AE\R+-+&AAVR2E&<J7BYQO@-)9V"T AV$W&.0C+M\8R82*MA:0=,?<DJ
MP(P"\P*<=ZY)SZP#N*O9Z0&37=Z#SI'_P( 0'E'\A@7>#+B_D[J,-SICK>;Y
M ,8)"NZ7*''CJBD[(()*BS*C*6$T91A( ^=E!]_HZW =Q1LJS7:S<E!7:Z&]
ML=(#]$5'V47QT.F1X='B1KW-*)[/5U&,'PPA];;'@BND+H?<FU$(HN<9PB,!
M+ZA.MSC(L'A>UK0KYLF'Q73TOJ29GD#O-;Q?YC"4<ET"(XXW/Q/:)U+\R>R9
M= $>;D.3^@6%^.T7X'MSOMI@Z0@6)BBQF8S9Z=)B;1-38K%U+C"/9NH9A$QQ
MY:II'?1D^;I=Q_BIW@/R#FL)2\M+,C-KY/+(2R<['_P8$#;=!AX4N7T_[(#Y
M\K_PDV40);N8.GUD*J0'"M-(@, JVJZN3A(UQKRQ+M],M/O5AX!,JM>Z]<+=
M&O1;D/9T$;]XH?\[X4@O\E\NG'_#?<Z6K-/91NP5/TGS;H>5"\=@ 9OTG'3H
M*],CS@J]S<3NQGG C,&" LAW<0D8\&%0\B]R0#[VXFFKLQ-:XD^V8=5>/0R]
MM#T/D82",5@8?S+P^#-L]#S.YG'W_"^T3)\BDNPFVO@)NO3B8,_7.-@+_)#P
M^@KUD3*>-08BR1'1R?:3T.&,]0CH-'F?)S/2:WZ$B"RY.BJ6%)R "=%I<?H'
MW:69KQYD 1#A_HGW'A>*.OLA0NO%) <4%(YW<( TEL[7HZ:UD%L7@JUMY.X8
MDCXA!-T>??O5/\_WS\!J GFU?_"3WQXB0#W" I1''Q"=,?O$#F;0PPRZ !M2
MWLFHB#[S-\\/  KI*HH?/8"!RP"_T'.:_ZNUZ/:<%H#.LOX^K:/X$_1XJ!06
M1.\"58E'8.]XPX=*8%$J(M[3;V. _P\V8<(Q8[ N1P*VF"_).4?R2 ;^$@^F
MHPXD;W#&6QPQ1*0.*XY$_C#?(.*DC@]" L76]6BM]>.FG9[,>*\, FY,=YSQ
MF5- T-MM-EZ\)\[OQ#>;^;/SG@:G?K?=@MR^V?AI1]](VM0L;VLLQ\@>2"A.
M28D.AP% NV!,]8*1.@KRU-@,*D@1M?BH))"'(E&-B#\U.D^$B[J_E3/2?4ZS
MP#YY[[D!I..%SM+; O9(WN:849]YR.X%OBA6*%Q1RTVW1"YBZ-"*MWLR/A1
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M+4S=2.E\E/$O7:=+"P!F08/:/Z'2'"/1>E:*\BD0/NA1+E$@M#I"2N($TR(
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M('6&S_Q((,L6ZZ\)(JME\9QZH)R\#GF:,'RD4<\(5.1#%P:03C]%ZT\[2!G
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M_Z6+:5!H:Y8W=A 4%-R0LU9X[LX1# 3]4"%8 ^23,9+6OQ=JBH$\F6)_%J/
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M%%]2':V\J!-DD+T")^+U9AM';S3AJ_H>TQ2WO\-JG(CA@$/ADL&IYM;7<I1
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M\%=DH7@!P'D^OB(DH&F/#J>T]I)GPCL&2D4=TE&0)OR7W#,]@T$CT*3LZ:(
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MHN$):"AH95I(/W-06YWF0@3@64*9%]1=R+H:UK9W*;6C.F&0\),0:4\GL>X
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M(^Y9>#T<9"381P11C;. E$37(HB$Y JE]9FOXIN:<*%F;=CSA"H-KKA5YQN
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MQ"!@"UQZW0OH[P ]B9=) ,C'!01**?%=6W6>'=<A&S98!)^^11WY4&GNP!B
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MJ_+VH!FOG/E-<<+B1JLD06E"[HQS 1,$T7<GY+[@I_LKP. B]6_],//#W?J
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MLH-,S?OJ!!DJXX>YWERESJ;34V>M.\"Y3N&^V=:]4.$U-<_0]B;FC^"$7[!
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M8N2YRM5"(RF Z<$'#8+2+I$[^.LHC#L%+4%+M(_F@VLQ.VT*SU\=9'4?O>5
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MVO9#S;*T-(1:&Q0J7E-+XZA'*5>5<\;2X&G-FJ6""]?2H.H10#$<OI:&3H\
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MV[_..JW6TZB=B35_GQ\Q1I)W\[<%[Y*\4)^Q75)\?EYVS#_*9\?&[_8E3;'
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MH>P<>7(3XRFZTCG<_<4:LNHQ%F62X,;Y>(H2JL62E".2AKL+_8(C.LF&*KV
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MKDS4),  H%[NUW<7)&72EI.X?F-\TF1B4R06NXL'^RR I0]"&T>'/["#$'B
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M(B3Q@X<!1.=C6KV!KLV^SKI[[\8DX9?@337P*X_/, ;U>+3@*_.G>%NCU@G
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MC8PV2LEQ7%V5!CP?U3UI'#5/])_3(HE:=I$_37(=%W#[(AKX4=+RJS2J)MC
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MC(6#?#CHUU)YE+PS6HRR58-A5E4&TLH'D%(PGD)[IVI=Z2X:*31?(85UJZX
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M0F!'>M8*S1HVH;ZF*1N:?#X=!YA(B307AH$(X8Z?R\9 *!.W;V1JYF;VI\$
M& +.V@;YWN &+#M.0KQ7L98)W]JKU_8E'6Z?)S>>SQVR#3V7MF#CY3X7;3C<
M$K$;)[%L^F9PMZE +WP5=T0@A2P%&[.M&>2?+X6:5-2.=J,H$1+;X8@HLD/D
ME O&!X2QZ1,)JF(7F4<.PM?9 \$1>^$3;UV:$WR&\*RHL5>E8-XJP6F_2LDJ
MG:YSPQKZ-(,?B!E[J W!@:D)M:J;I>EFR]SSOO'&P&_;TT'3("RFWB/8XUF3
M#YE0=@Q=?5$\2A*T1)SHQAF6GN!F2V[S5.NE'[/W_*^9:3_=GVKRQ>A/.!4E
M-I-Y5]%RY_=3EY+4JNAB1<B ^H1@QA!S:4PE.;)=C^AA.2$E[Y@HC!DE#K,I
MQ_VYW*3YKL"K O)WKV/OJTOO7GL^;PWW[=]1#T[E:N<;SIC5%KX3)*&M=I@,
M4;#BGDO]7?8:R(EEJ]I:)RE,0>6K+37IW^S1^)S0&G1N,UDB$MQ]$=TP0=NK
MWJQ8C5KCL#J5N"HS[V7FO<R\EYGW[96V.2= J]I<4A>S.@? [-P*(7$[1O5(
M1[I '?C+HPO6YIR:M4:SWF^L'AS-=]CZ_L(>=4/7_KX2B=#MK["D]]:#=6-=
M6/\#_[VSVM:U=0__?P'_NH*?7\//+JV_6[_#_\.5!39\U[<B"PR,!1&GFB%K
MNS/A98;^@:R3S>G16E'H^)9N+QK?<37_Z5Z^F+<&PO3"[MJ>B&/;^N0&6/CG
M5+^/K'M,0H+A/B,RBY$X'1G?X_8]S</SZ2OIQ_OP2 K/=G7'PQEO-)ZCXS1X
M,U6>3YC/-D[I;'-U;CGHK1U1C, A(Y.(H\]6U0DK^W[;YGFTJO4EXK_N)7C)
M6;*DKY*EGK:977)W^???+^\?+N^LJ^LO-W>_M1^N;JY?O[)-P^=[VZ5=^PI)
M-0#ZXMH>B;._+$ %+!K<\L_<J(MZ?^$D7KYC_K*R<JB]T_<KSM:XNGZXO'ZP
M'FZLV]_O+GYIWU^NN(@[M FNDU&7@4%</'<&)UK, 0\^K; [U,HGT$XLS6_"
MEOQ<!#9%\T"N4<&7XWTUDK6J2EJ'B[CK:U2D'=5&)J65C+IOC99=7]7?>[^3
M:NV:I(T*A(-+NF9+)80MR;LCJ[O&GB#Z%()13O;/%F$5BRO?I7A_)/&^36M#
M6;85\X=J3!N,A2_I/$K!^$""<4/(@(^JTW;G.WX&'^#CSCZ-$]P3:"L)MV<Q
MBN-T7US>/5Q]N;J8'X=:Y"'4=T665#096]*Y1&]KQR_5AYO1<WL;&,W+%ZQ>
MJ+79W\2G>HTTV2/B IEJY8>9A"6DMX@\=?@M9@*"T(.J<66V?S5J0-VRVJ"V
MD,"JP)^"7"&XZK-NAUVH3UFQBB7HC4*MSK["P'419,QY+ U+K:BZ:D2URCCA
M7K1O>4SRQZ2/FLB;<>]"\;U+DJQLV?,TO^=]FB#+4'W"K^NGS4,3XTI5BLQ$
M?7AH$,D8CTCO;&;O1 '=:^ZO?)X?[XQQHU2(I+!1T.;Y"<J 7#F8').'^?!-
M'^%91F%#JBYF\(A95_R)B.62CC\JJKF2X68F\U;*#$.N!$\VU!9U6<M64RAB
MT2G9PO2M!'<:K  1<@4)RW$?70\EX =XI!-BRP3;L\!5M3V<=R6%AA9J:RXL
M7WU[ 3+6M0>:WAV319GCFC)*6E)^]Y5!WKOC4GQLQ[A G[",Z:R,9D,REC+0
M5PK%7*$H,QL?7*[+5&Z9[GYENKL,F!HHI?O+7W\M$4K]%Z)OZKL3/)Z!S+(T
M2BD2GO<*C%*YXWYJ__[PR\W=U?^[_&RU;V_O;O[17G7;';UUB<(ZI__<(H6Z
M$?TJA &P(9M6)?MP<Q4J I0OGR]4/ @9 509_^IQU9WQB%Z4,G_;NHUWKN?Z
M0*5KM6I^ &]<D;/Q0V%I'>CN,70448T5QY:ZN+G^<B6KCJR;+];#7?OZOGWQ
M O!'HWJX*X="BOX(_+X;CC1KG=D5#S.ILK19)U.Q?<_>$]R[C]U^G(1^$\EF
MVH6O1RA"3&IW+ N-MGVQ1[Q#B_&?KXT.O,M:%"2$_0ZC?H784__&,=,XA^+L
M+VAA,S\:=AG_YHX(9(),9R ,JB'/61FOGV&M-1:;:KNC'NY5YXCMT0VEGMSX
M 9K3)!]W)1:J4.RZ\H'7YKFH?U.OUJJ'"S7K\7O14FR:.^'CBLE+XGP?RMI\
MWU+G8J1/RLGNZF1-[7]4/=KRO!@]>O56'_]Y??-P>6;]EGBQ.P:#VPOB2'<S
MD$4!U&1[;(=H82"6FQBS"3SH6]@]3O9)*)E32^;4#0;OWYPY]<<?ND%O\M._
M_?C#,!YY/_U_4$L#!!0    ( /TY?UHF?BP=>@,  (,7   /    8V%B82UE
M>#(Q7S$N:'1M[5A=<],X%'WG5X@P,+LS*'$*=#IVR$QI2PD/S4X:9G;W3;:O
MXPNRY)&4.NZO7TFV.VU) X44=B!Y2&SI?AP?'5W%=Y2;@H\?D5$.++6_9&30
M<!B?_$WWAOWA:-#<6H-!:S&*95H3;6H.KWLE2U,4B_"@7$4%4PL4(5L:^1B+
M4BK#A(EZ/FB*%R3A3.O7O0Q7D-(*4Y/31 K#4(#J=0&;()1#9GRDJ,W0C Q1
M1-XSW.^_LM>Q7%&-EPZ!"P7"4#O4(J$*%_FM*,V0"],;>U!MVDN*(H552%]$
MA?7,X<JNE!H-2A$JX,S@!3C/@74=C\K..[.Y'0X(AT%INO1&EF$0^;F,%<CK
M<(X%:'(&%9G)@HG.,);&R,+:&E@9RC@N;#8'P*5R_EV>1'*IPB>!_T15C@:H
M+ED"8:F 5HJ53;JJ@1]+GD:WL&V"X^<^@1*.3R$%>"X:OC,TM*78HCI9Y1BC
M(8U$G)_EI/PJ1H9[7T"Q@93$9@?UOV7EB,6,@S&,O$'YG$Q$TO^!Y+@-\JW4
M;)N)>0XDDYS+RIH2U(01CMH0F1&]C#6FR!3:V/9^#6F$^9EC2*"(09$7P^=D
M+]A[>5\V[[/Y#JSK%\C\<?0]>S+<#Z)K3VM+J"W,+.9P9YV,I4I!>7@NOI6&
M,Z><U7+9FC2IAD'0#YYV]E8AG)4:0@TE4\S FN+I2[@#H+KL%ZCM_N=HZK +
MT%E9L_2*,9_PE<^VME"[4FK2[W2T5^HSA%T%=XM2V4>EL0+V*?3?U VLWPUK
M'J([.KRB^H$[$RY &4P8;\5B9ZX.F&YGNI/CQIG3NO8>]MCXGB+P67W\*JV>
M?WAS/CF>',[^N;X[UZ[JCLG-3,X/YR=D.B/3^;N3&7G_838Y/YX<S2?3,S)]
M2R9G1]/97]/983-@S6:GAV>3?_W]6N[7;HS??#/<O6C?5IE_4:4_'$V[:KV=
M&K.-?Z2_IG:WRN"Q?>NKF(*=EG_V2MS0,CDMXG<[*=^+P/,*S24HSD2Z4_//
M7HR;:O[C%)1%5/^YT_7]J6RYVZQI>^'>AW^SOD'3J'S !NPUUMHNQ/8;LAF'
M%4U10>+[L%8[RT)$*>J2LSITL[=[MA^7VF!6=\QX&PHBW=3,O6(J5[>H0,$M
M0U0;IEKP-R=LX.O]E0-/3,D6T-1*RC(#*F2\8K7VA7$T<"WT\:/1P#??_P-0
M2P,$%     @ _3E_6J8QTVN;!   SRH   \   !C86)A+65X,C-?,2YH=&WM
M6NV/VC88_]Z_PJ/JRTD$ B%<2"C2[7J5IG4=ND[:]M%)'.*=8T>V.:!__1X[
MX8YC=]PJE0H:\@&"\[S^\GOL1]CC7!=L\@*-<X)3^$9C334CDZN_G+[7Z8V[
MU4\0Z-82XUBD*Z3TBI%WK1*G*>6S,"B748'EC/(0S[7XB1:ED!IS';6LT93>
MHH1AI=ZU,KHDJ;.@J<Z=1'"-*2>RM398&7$8R;2U%-4>JI$>Y9'5#(<='^YC
ML704_6(B,*8(UPX,U9$XDL[R+2O5D#'3FMB@:K=?',I3L@P=+RI ,R=W<J50
M5%/!0TD8UO26&,TNJ$[&Y5H[ ]\F#A+VW%*OW6M1AFYDGV6XH&P5_D$+HM G
MLD#7HL!\+1@+K44!LIHLM8,9G8$W$X!Q9?37?A+!A Q?>O:*%CG5Q%$E3DA8
M2N(L)"XK=XLJ_%BP--J,K>-#=)L!74B*635R0R0W.'+!B<6@PCFCVJFAA6BN
MECF-J485-8P>8%'N%XD$7!.Y#<73R5?>^UN9;CO\_SF_?MD;NM%A9_O?-_OF
M$NS%DKYI*\R5HXBDV9$E7;/=M=<.MN\)@DO!%=PAD:%?8&XH"7S SVLRHPJB
M)2F:SF-&$W21)&+.-1A$'Z@L&@T:^E[9_S-7FF:K TO_3X*2FC9:()T31'DB
M)*R%V*PA*%XA23(@#T_,(RN1"<;$PK"GHE8M^EEC30JPI,)F8_J 4AM]!(11
M. P <PBS0-E0RB=Z";?C>2,_\.XOTS^D5)4,K\*,D>4FA$-(H49C'8F5<93&
M4D<6+L<$H,(8*\*HB7\+V/M\P/? [9_?7P&XWC_N->P[H?8[?M_S?;<_](.1
MZXY&_JMH(63JQ)+@F_"&D!*"9'= 46YR=2Q>.P!J3=[VSM;O;:/-JISV7/?5
MEL4#X]SCE8C>?A"R0)^= 'T2'00<@AYYX W/SQ#0SC2RIHKKPK_$,69$:XQ^
MIJ(-2TC207VW%X YD=R@WTMK&_/4/ +CT%FB*<.\O4M[]+RV&=MIX:HHF5@1
M4IN:SF62 X=K];MBLQUN]7DJNF,INGY#BNY\$ R^HNB>+9M3U32Y:KQF5(T_
M\ ;] ZJ:4]$<<]$,FE$T0V_H?4U_]WR'=J+],=/>;P;MSUU_Y)]H?Z)]3?MA
M0VCO!4/O6](^.M'^F&E__@/3WMN@?=#K#\_,3L<C/+=_*9UH?,PT#GY@&@</
M:?Q-_Q9Z=/;>YPZ,*8\#@_^[[>@=8.XP(8JY1)*8PRPH!>JEZ#<LDQQYO38P
MJ.^WT8+J'"1429*[33^S!R@8K10RRC%/*&:0U'I+[XFIUNP6LGD*2G9OD"IT
MP?D<-*^K""K.]USGUZ<F:Y0):4-8$2R1V;).T7N2D"(F<AWTH-/@5]ID.G=5
M%UU)KC1ZC8LR0G^+.<R1'S].&XQ)D_DPS2G#*6%E3G$;30GG:L5N,:>XP: \
MG-\W@;#+_QX/,VX :H7W<;C1]H4IE;!8F3.-@/6\V&Z]'YY_?+2SA(5EU\'(
M.Z1RN05%W;/:SK0*_N$#,%P-5\ $%I@2STC5!#LXTT2&F"WP2MFCI>.N.8XZ
M>3'NVH.L_P)02P,$%     @ _3E_6M6)'$-X"0  "3T   \   !C86)A+65X
M,S%?,2YH=&WM6VU3V[@6_MS^"ETZW0LS<4@"M-V$92:%=)>YN] !.M/]J-C'
MB1;9\DIR7O;7WW,D.W%>2@-]6=J&#X#M(^GHT7/>9/EX:!-Y\I0=#X%'^)<=
M6V$EG/3>!P?->O-XWU^BP'XA<=Q7T909.Y7PRT[&HTBD@_:K;-))N!Z(M,US
MJ_XCDDQIRU/;V7&=1F+$0LF-^64G%A.(@K&([# (56JY2$'OE!WZ3@()L74]
M=8H1_)VF2#NN9?M%O?42+_IJ$ACQ#ZE ?4%J [Q5J!)H,1@N=>-O43\[)TZK
M8MQ_ I%&,&D'!YT$6PYA)I<I(ZQ0:5N#Y%:,@%KN8].3XZQL'>/8I >TFXW,
MEL-;E;4;'?<LYHF0T_:-2,"P"QBS*Y7PM!3L*VM5@K(6)C;@4@QP-%* AJ+V
MY3BADDJWGS7<3V<\%!8"D_$0VIF&8*QYYH<;>_7[2D:=)=WN4L<]NP6=$IZI
M2L%AX0&/A0T*B%&KWF0H^L(RSQ%JAYAD&R'2;'U$BSM "7%TT(\6E=/>U<WY
MF_/3[LWYY05[^^[J^EWWXH;=7-X3H@>3YI'C<_7N]]XU:Q[PH'FXR_=8]^*,
M-8^BXNK=Q5GOBMW\UF/7O=-W5^<WYRC<>W_Z6_?BUQ[KGMZPRS>L^?/!86T+
MIX.S>\VZ9Y=O;WIG5:X1>HY_!XT6(>8 [5Z][E[TKH/+][_W_BRQ;#4:K:]H
MO.3!'XKEYX;NO,:N+8P@91<B'-H^Z 'H&@M!6Q%/F1URVZY"4XE?J&(22&%L
M !(2BCBD9E:)89$PF>33=BQAL@+>7[FA(4I=G%!@+->VXV *J'_3[G,#4M ,
ME@"=SZA1/SALM%[.?UYAM'HT>!_5#ULOGW?&2D=!7P._;=\"9*B:[)3XB)1F
M&#B8[H!EYZ19+]>B$K'],,U&X_E2AX^&8VS(1\ TC 2,(4)2"<.Z:9ISR:Z
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MF8+<%;POI+!32D/6#4MVXTCE^.(IOR!:J1:<ZY\4$\IRG2%?C4N;PA #JE/
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M#U'%N9WYJ+3UVMR3DF.OVM[<J9(-W2/Q64F/42F.R;%5VLRR#'<#.TL282W
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M<3-BB5034Y%R'J$8IYM>;]2R4>.6J919TG9+KXVCU^%W2:_K!2S^VY34*6L
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M]UI2*'U;O_3QY[0P7R#5<-F!#HAX>QODMML@2P*EZ@I#F.!('*?05%4Q7>]
M:%<?-1_:F.1T N7)S:$)9H^ \AE=%/;LUFV:>TG'+[I->Z/I;U!+ P04
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M&*_GLW8+ _UA524."YP+(=W;;:ZZ7OWS_L4SJ0GK%"-^/-$SE]\MYZRZ]]-
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MRA/]O&Y(Y"6OG)3%KI"#Y)E4$?^%WH#H9&_$)0'F=VE;<&Z@+F#./?44,/
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M %.@*RN%'.%H>H5=(0^3,2D/>G.(2MAG0?*7%ET:Q-8NF7\6%(W=]=Q1DM:
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MGC-'/\FWX'TJ("]Z 8##,H"X89HDTR'=C93:O\-/7@<UT]V<'\KIDQML/C6
M6!!C(4PD_"V54U/E!][GYFX+56&*&"_];V/:"M)A8>E@R_+Q/X9Z>X/MHA&0
M]PS#Q9N7?MR_2YC8:3VG&IUQBRVTD+"7?92O8D"'QPE@@.8],]W3VO:])[+N
M+4P]@W0)3>%^%#"!RDA"RKT2^,]4?7'WR+-P[%;1A[YOO#^XQJTB."W_#V0+
MH!:_0DX @N)DXS T<-_^J>"6]C!.O!8V^A_#G "2*!-5I:>(7*58KT=9\L/
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M[D1)[=OD;UA,L_]-S +W%GA*]L2Z68F6<>[G+IK^-;1W\GPN?FDM]<\%H[<
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M2-V _YD/6QESW>,KKCX^H+6 C.D9*F/)PHP:1Q<U!\QJ: BYN@E3N6DH2)M
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MWDC3!,^NU=T\2_N7*BX@*,X20(S=%WFII74FB>4M$+]Y>G7?0S.Z+NES9P%
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M^^2C*9>X(2FFT\6_]\RSK'<@@_F*HUI"+N 5#U20XMKMU!J&L&/>F@57O_P
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M=W-BX>>92P[>WWX5E"VV4$:W>T4(P$^(;])K;8,@%E(;-B)%WYGL1<)A,E[
M9#W28)._E_IU;;>/'WGPX>]S7S4M=]LZMBSJC:66;EB\__ZA?&O9]?O;(CFZ
M?4!I2J"'UHMD%(BK5P!J@P?2Z71"A(< 86('A]E+7!SXN+TB.B,YU6WF5>=B
MJEE4"[:N_O5U]<;&XI(_?T0(;P?9KN2-9<U*!7??]X:9RN2A$-UB]PN7<RUW
M2E^4Q@UZY?*KH!YH;V)\Y]"ZZ4_VA?Z\X/&9M4'9%%^I3BTW3P-K\6-;/8?Q
M) ]@CC[TC_9ZXX<&#?^O_;HD\S?I?+QN*B\=BB^P^.>7ZUC5X*SR_33D[&A5
M3R:X?5S2,P-J!S]\@WNOH'F^>IA%!.;N2"_^*@F]E%3@-:0=,/#Q2[6JT;MG
M[WV)'UL.!G=47!-?'OVQ2@D<!I^Q7[S3IBR;_27M,$L",C%:RG343*WJ9L0@
MXXJO4+-!7O S)"8L.!EV%I*'V4LWE" E8"*B#]),[0F@%*AM+-EV9)S 2"R!
M&HDA*K;"S<)X"X5RBWP>=K1DX6YSN9BN'X%C01@XQ8Q0N1-"%J+-1  O/N%(
M*%8@5 ZQ@SV^MOBGZ5TC.%260#@U1.TP37Z+&W%LAY&/\MT''O.T1=?4'G!Z
M\_;E.NF3I##O,.QL#\\5AURX4IGPR4HGWO,@DN0'!M/Z^T?$RI-1GKY>#VQ[
M5>U&?NZJU-J5"CI4O$NI\OWS]P[A>B^0[T_G&U%STC>J!?-NE>/[CXC%@TU,
MI9! \H'*AQRY"Q57W%KLS<;D_(OCM,?9:0=06>I[;\(\2GF1%6O8@#&>5.P]
M3S$FE:XU-S;/2/5DNT_!1/H81X7:"B*X7BMI/#/C@DQIK[=Q=JM)9!]E"!US
M[!R0C2#>].*\S_H<Y5%S'%3Q':0G[$:0;_6*ZU)+=[Y);96OFJGB]_YEUN[.
M^],,9Z]HO*RVX.(/&EO]1D8=1[Q >@&70E&14O5*M5Z8B61$"U^>YWLW-X7#
M4!??2,66GO*1E<"<>BD5(Z:"R%ZW[.72CJR'G!ZF>+YL:=0NF'B3&MO-34@Q
M)TPDTOBW5OA(U-H5"#^F/+[C RG6AF"8\F'Y,R;*M[9;9.YX>3RZ<F6;X#1F
M4-2<.^F7IV)8&B+:_=B/=^$$<!$G,Z;Z9@Z<VVTI'8?M?!K(SVL59_XZ8V<+
MJI,VNF5;_KPVN7(L<4 ?J"X[6S\F:'9C2>.!81 I4:?8-6XDE T^NVW2=L$"
MF(2Z4\MHC/,NQGSDV9H9G"ZU^: .^]BQU9^5<GOC1ZJK__%9:AG(;S4>T02/
M;>Z!@]L[")I=V.W#22CK&I+%=1D2.P!3G\,Q6B%*?/,-*JJ>Z0</XXVCGO&6
MS76&?K\AN7T]ZSX&-@ILKD_MU5\F(:P)ASN'!.4UJ0;,-_4T4^M&PL_:$2,L
M*[NS4N;O1RTR?T<4=2H;<QG3MX8M%$>E(,7&:0]2@>CZA3U,ZSN\-S:/P@U'
M(3D#=IO]WQ@R4?QF%( #>0'/ C@&K+FV-3TDO@;4M6AU==S4&)BN?,HUB%*_
M',3W!8/8=8G*^.6X$T38)KXA9.R*DF] F:EE2C"1+7XP\]\@)G]#WAD:\->\
M"]0QMU=F1O\&JP9U-#]MY_'-W,Y'P2U-@X&3;GWZB?,L(XI/C_;^>? &Q+$.
M7VA >6O77+CPM%5:KS9CP-._1@02TVK*^^KG$UZHE%2:K&W9/C-6E:O*7+M3
MK6(M.^7W9\B\RECH*')[NCK',\2I_<$W:$4N5_J5C#G)5Y.CTZ,ALY46W-?+
MG>Y4'<A,EN"TKM=(E6'+8(A)8U[29_)Y&V,>P/_=<5E;<"CJ@UN6G\&#,+'Y
M?3(JQ$=:)#_QYF##<Y,SVN.PAP"Q%UZ"^L4+FX4&!3Z;69'A0 3H2V)'J/:7
M<1?UMWMAY0>1,)?("XM+<-/CK3@V#L!DN[<@<&.UW+B[WOYV>.J9EV8BPT]%
M& 4NA69^SW[>Z[D<\T+LS0;R&K.]K77%#J[09BSJG7K.=%?\H<O6@;OZ_I&0
M?^_RW D@O'IZ)C?YFM&X'I<NY["V0>3^]Q +2[TR<G6B3$GRW?^O]:=ZZP55
M=/T:_#VZ7F?HS"6V\Q+A$V"_M-?GM!7WHC]].HZQ=@,P,TU?RHM1 6RG%T;^
M8_0C/31VJ8[=XD]03Z&+@\/Z;%GQL?KN>M8]2\U=#:E.1>Q.<<_4GZ,>@.%-
M@6TK-@ZKJ"@D^@10;Z,6*<, 1.^OL44H#AD0K!QT^D3-A)]O.=9;WT!K_Q"Y
M_]B"HJO=1G1->>SH<4!5+OG5O.V;FIT:$!$4;FL3_AA\;%TTVWTH49(LE\+R
M/UWU]"'<[BVR\7?]56&X-(4&K]P<,\$)!JH./>W[NQ>].00KQ#L)I%)B+Z4^
MZ.W.8K;5#3ZOOS\>(KN\*?,9;%\[MZ2^^X.R:N1>GY([MN#A$#X]8K78V_EH
M5_NNU9GUV'&3\_J9P[MTTF)HX)M:*B@@XEW/0!349TD"KE]*O<CSXS<K[2O[
M\YK59<#?SW=5DX-R+4RE)S=_M41*%%&.CWF.0/EC.\5[TT&?Z'%TTB]7*S]J
M.*AI==%MP4W@!T2*;/!#D;T?%<+L7/M#KB_+Z8V'UK]A=X?EUQ )2+R5=6PQ
M,RD%@TQ:G$^&*5!N$Z1CK-ZNG ,GKUX\ (EL%E^,LA[G?[S)IYM6<\U"N9!U
M1*V[:Q<3I.4_+D%E,%6<\1)DSXSM,N@0%SB<N!57)3\WTO1]5:8T%?6@(U[\
MK(5J^4Y()FK,+FSSCWGAVXU 2-7UQR\Z)/EEM 0]M$PS7]]W=O!W94X<#;X3
M$A:L1GSM[)"A6Z[7;VZN;#+SMESL_M&#/7D]#3SH.6BMF,X,80*0#0L"*)KR
M@ !'K?!.=AM+)ZLC7[@$#;@[+&$TTBNUBD)4$OI*M-J>R6J8N=[)&L)N/?.M
MK\A]:B?+-3NF13Q#LBPA[:$]E">[;0@69I/09T^QM:YW2-X5I'7B!":NM0NG
M]Z!UOJ5+^1SZ_/10J3;7]QL:F"Z+9REOQ!:%0]D+7*D+QI%TRBY7I9LCY]U^
M--XJINV2_0HSIJN":([)OFUE[Z7W^9[$RF4MZ=T@6:T-TUCMAYPO/%]Y>@F%
M_4R,,7=(,QN\#NT]F-4QEI23FRG*P92TH?,/=XSQ=H/@ILHXT$,0IY._;@9J
M@M&TP@R3$EL]$H -X+:?K+O?,]6RK.?2;.'=-OLHL++XSNNEYM#N%^XWU+FL
M@Y3@<4C/U?A.( J8C&#MOH%=309S/:E/.8X@@I-;X(DK.K-0ZSI3?S8MO).H
MV-9O:VF+_$'E?ZL4:\X_Z(Q6 E\(SVC^57-Y$&K*HA%,& _YD/8(3BPWA\VJ
M$TX 3O&*6"](FU59@SK&!38VI%;%*UNE$>H;7,GQI5;WSXC*>*T^D CU'JGN
M(S/%WY&>*O-*R*97$-+G#9V:,R:6@VC,.#QJ@ ZT4,QN!!HL$,8A )7IG//&
M:PW6DYPB7X"XU?6B($M2Y>5+I'>*MZ9]@WS]1>-JRW=K)[X]6KP9\,-,M(ZY
M'MZG SM/2ND#<U THFJA-B> %P68UM+W6\6"I \(SK!I@B%K4?C.,B19&,%[
M<\HBPK-67J-V-C5WQ$>1::'V;8OI0^#;.X[FN$#YC(;;$ZHS<T!>5T&CZR&I
MOHX#SZP#-\M938K  ?;CR=018O8A[[AWGYNJM/V$+,IR[ITIN_V8CNZK]\\T
M+/(M.W3Z;"MR+/87-1]'>']9907=A\<#S\.X2-MKJW'(MJ7^U8LM0/ZMXDO9
M=^;W#D0=L/M#K2%.VZ%UE9!Y;FH)5MLK;_RUV^>-:/5:_9_KV?NQ.,2.8PV)
MPX'$N;;*3I$A91-0Q$B2*T8Y\=@J&[.7L*+7C$</U,H/PI0*S)$)MV<IU\+@
MYSRL,?N"\^HMK4VS[,V3*U7=C4\?%-N1D\-_;.A0HO3NO?^^[.H*F-=264J2
MD&5U,\\\]X"-?'MTN_V5B??-82F->Q!!46<M,8*8\QNLZAZGHTJQ4@_42JY8
MJ4Y6KKW&1 ABAI.9[;<O343=PR74VN;HDB)?;; \#K;.,Q[)QRO=>'-79LT7
M@XE.Y\L1,1!Z#<'\P"64)U4FI8MUJ]ZN,ND5G*^DETWSJ9OC(2DA 7HT#XH0
M-3&P5QHV? )@[16$S7D/7*7\BX?5UT&R^WNO3.O[5DT0.# UV=N1,[U\S4V$
M484\-?]\IOBZY@+6S3L:37Y"SS[_[+89R/D[L;-,%H,:4 O"5H5)7=<(3 ,<
M0A TED%7(Q>)K4^D*741 IN/O1-HWXX]"OQ#0H)\17MJM(1RJ"C&YU_VW88]
M(AS.(VQ14=[J:6Q:*A9RZG'O]C&^CA>^K';:WC=6* <\$/2<D%B?R2Z1-Y-'
MLPQUA#_E=5"=6+UW_2WZ<4CZB_W44"MU+'2\V#>F^K4#:DVM,  :+B[W]OM5
MD@5O2OS5.^]M?+\4,3N^\.L,SI.O$GOJ\3@[]RCH7##-7;^)WX+)@O/U VUS
M;7.=.%/F>_GO;FP1BOR2A@JWAE[\9-3,O@W-]%.-27OY:>,]VFTZ>N)*(W9F
MQ_OE#?:#FL:/$M?S5/7+9'4\N1H>E_KJ?;H4_=)\WT7UI=&0MH3(XPO,@DRK
MO'\T>-[N2N D6F*M+5N@GPW"7,H[#PSKN.W%A3+]LQPM[*7#_+?YIO==0/(L
M;F=3@=,47ZW4)SI__U*B##;3-$7S/"^'4U#2$@< 1HG=X7&UU/WDU"_BJ^+R
MNS:YWVHVUO4!/($PB-X9EF#7LQ(L'MN/8Y/-G%<H$\:MVPZU]1['_)"NVO(
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MJZ_ZN)A(_+.#[PB.-$@5)K@C%\CWP1S>52NRJ%90J=-K;[?5\O%UGD _L[E
ML<,[7AYL<M68I3FE(2MK^F@/3F'*M?ALMC),U;;+I#--(VJD=XON:T3$.Y'B
M'O+]9R&K1_<0X"[?R>6(*"C-NV)GI> )G?=&_^<PL>-5[9?U7U2>?F>)4?MT
MH[#)*Y<&[ 0PZ32 $<@6>'+++BLQAIJVH]X3=&>ZN=8+RY3(D:B^)+Q=K6?P
M<,2Z<3I7+\HRH$[3HX_M.-6N_-5<N8>]<^], THQYP3PIN"A>F.-\-"\8ZE5
M+]^K5;4,Y;F0.\&3V3]?+#5_J'P@ZF+S^(5;I4 ACO&IGK_8<:7VX ["+-R0
MHO1M.W;"DP2[@U(Z?_2-[</:!RZ+8&;QCCYMD8A/;H[K>0G(M1)52!<V*%:?
MN80B3(B@B",O0CVK(2"4H4[GS*.A[/>B7$YKLQH^C,T1?HIWS7+_-3-2E!O.
M&FXPV>= P.\KI_5>Q:^B)_A\5@P)'DW5$#"Z,V)0-,)<:*@<KJ[+/H'R_]'1
M'<\W)_WF$;9C>N\6P;4I,>"%C%1#<_%FIF%XO>@/I-O(K]LYYG\)D"_M<NWI
MYJ\CM<TSG1R9;.[)]-N+>T!J=,NU/1"*QLH^I??W<Y40ZCI>I=FV4W-M2FGJ
M!<BK])AVB&AE5=YC>P2[>V:I[8*11)"X]E+.7<T8JSGM_OP&<!JH86\P2!1J
M1&WJCJK:ADG/!>DKXX+^@<0.T?/FSYEZB4GU:AY"$$7\V&Q:(5"#]37?(A%M
M%N6@H^B9:'5HJ6!C$<0V4DK[_(Z,TD&U00E]!P9JZ:J_SXQ%%NH@)K$*HK<"
MQ5YMVL;+<R;$%'15"7$EI]D_X'GGP)6*$S:0['+I++>Q3\EW</LM/_Y9;ZF"
MFO>.OU@??4O3#O#3O.XFPT52GVB28)_V]J!VPT8AV^$NB5@_1H^@%&<DGFEW
MH<9].W*EFA^%/ ]#&^H1:,A2J9(&7\Z)MY 1JW;=^6\_Y>^%*>_4@FP^)ONG
MK!K<3?YCTOJQ+=XLD*+5!\;;3(A @WM)"?BOL/%>59)'&[ I(K7W*@0^Y#*?
MO$.9Q1<L^44Z)AS$M32T-'9->W=T6!NXL&YT-4. .]G+$]Z1 0:\;SRQNW9O
M[,/\)N/4RR6ES<WU)W(53=\T'_@NF<*<-8CJ[6HZ Y-.A1IRD%2)8.U;@?*<
MN[\\W\57)E?J)LLZU KEE)^_[D8;5ZPR-LW=CT'L/,],N2L&./" C%^/D\!1
M,</2#!?NW\J>CYY'N-#\81P08:QIG_6"Q5KE+J&$$D6:Q((Y?0YAHAVD#/P>
M%I0:QOZLST,>_[L)YT/AQ899JMUVE?D[9HZR0A;83M:5Y]3.8<>%V_FNZ8]D
M_)I'"<VV):DK<@]HIEK6M90O^+6^"3:+IRWJO3JR7[[ 9:R7\X-)+^>CD3)3
MVO$4=.:!B6V<[F1J^2BUR,I50R(W;45):;'2O[H)D=@>=C^TA:U?L$),8-3!
MU973Z@7^2S'HC#V*T\RD-+!,1\?/I,8U=6:W+"<]/EFF;G^]_W\W[DR ELX.
M>4C@V]"(;T,CQH1SE66^](P_L/MX=6".3[>0Z) _5.!?UJ>=X! OM1 6(.#[
M,TGJ3L(86,D,D.,L&$J&^B+P#<W*#"0XQC2E99E[ "8]"U4K(7WW6#0J6=5*
MJ/'JG@\J>1#S8X2Q1LKLDD_9F\"2U.'[28?_-H,"HEC=9GK5:>C\WJ(2O\[<
M3$Q&8K'XK+Y9E*^7XOB;<M_&3<W@J$JG#J>Z*TW-DNZ23^\I!"Q&/%=/-(9*
MXLTWK%KI-0X*Q$-:'QG,1T<'TB1)9!2<XV#BO)]0!$5NQ)J3]!NTX]KUZU*W
M<D2=B\=*+X*!/SQ"R7BR*_^R2O<KX$*C?H;D*,E;><CKX^VA":;LAW+JGDD0
M;SM>1Y6Q94'S.WZ319$SLRQ7TX2RNS]^\9.MLZ#9%'H+%C.!!N_BVSLP7LEC
M'^7L#9(''M_=Q*APU;,$5YO7R/2WM;R*JKDRW]KT2E*^_.!<FF<-;/(E:0_G
MG7)Z%O$BY1(^"IU\< )@HLA//IFX".\W\"XI^L?(R_.#1]-6_GV7GMW=&;5E
MB_)A,3/*<.G5=_$K3G S&I^3=1F)M>_8?3[5%<LX6!'KS4J:_-GVION69]H-
M?[& YJS!2XC1-!ZTPMLK[WS=DQY2(*2",D@*QANEG )L-*G&@P=[#83&.["U
MUFOP 5%NE*K_HD$C:?!M@/:VX^'-/"&/CHH1P_* IQ^<Z50E'C 84#+BN(7<
M6< $>/>!_C'D@C@.7#3SKOTEQO"UN<AVW/MU3\M@;2/'Y=),KR4%EENV0-GS
M<MR2?/J00M_X%X]KE)0YDLL^AHY2XVWRIM*9^W7^#5;_F3#87PXD-O\4?"9R
M?4#).W&]R'KEV=1?D@6G\[K&QQ:563&I8O?=T%M/YJ2+GV8/?1%(U9\UP>\J
M^AE-0ILWR2_-V67(Y3PVX'Q@">/_:IH10:<T+ULXX7_WE/LL=G>>:WCO<QQ7
MEUV[]*%E*.>]M;]$>.0+HT0[HD6L2$WJM9?_O'AN5K\^@LW8528_I$C,&TI2
MF&9[%2%M=J0J?(HM AT)3W[K&L(Q8/U/%,(J?]^B[6.4D&N&TM=5S2JFK#99
M!4W^7&7)GMJF$>#?%1*3_C^ZQ4S75,R(8KT'?Y0']Q80J%Y]$@8/Q]4XS!$@
M",Q*)?Q!3?=<:Z-1+<34#H],5J]Z%,AZ[8]%"./OZ@"YHYU[FE^/;FFQ/D:$
M]@G2'+.Q(0WC5T?Y0*Q@9@>(=Q+*IM8A%W3AU7L3[B*=+SP-#I"G@X86LW%F
M4ABO']I-LNCU5\%37PCMA7SB'(F50EMQOI-QMR0A?^:K;$QNIRY+CF@OF_V:
M<7GL>#2"!N-OUU_8!'W\'4TV\>6K#L&N\MPH@UB-]%M_\,WT^PC!_"Z;UD@L
M3\M?O]OJR">40QQHZ6KGRSR7M6P^:K?&$0L7/@$\ J:!>6 B4!Y\'EI9 ,&S
M]#D !T_UN%P\;ZGKF-#LOUTDY],M+V3LKS^O6/G-3RE>?K-Y4[HK?FLB--'6
M'RQ&\L7T,'G,&[)#K.VF!R<2D)CZ7KE/<ZZC*@J:2'SF=U<7H)KJ(ZYO;RY9
M3K]AX/INQB(A94Z],TT3-24#(/*XA%W^2HB\*^D=UCH)=A5)R$A_8JF)7Z!S
M77E,CSHIAK;\]R4QCYVHI\>8O'T[WB$9V.;6TX\.X'D\!J[P>DP#8EP$1KM8
M<SQ#1;9U!NY59MT0->6PY=AV2GB!\G0CV.3H/@E6UZDVL9<TN^?M\.H^L:W/
M4W4!S3F'\@H13'O$Y_JJ/T=_#A+9<J<$_]%>#@MLR"K\@*WV>(43^(RA%J3:
MA:<B[=Z!E;2_#O_>%)*_N: H-7LV%-CIW.B<_ECXTOU0NT#]PXFS3*D9&S-B
M_OL@#)C"D]*'N&@H"^''T*K71B98-\'<%%!0'8ECB#]_.6<HK[J@.C$@V_R)
MSRX2ZQ\D/\*[VU*6!_:^S_B-;W'E,]D5]@UVD9KS]P3 9ESE&^&A1,A(K=^M
MZ=98*Y(CKBS=F?',);*ZIAFEU&3U^?J+)QI/Y 8L>O^YG^E4L3>T%9QW\?;H
MQP7[1XUMQ'A-KNJXTET9B\5^Q0]9=I5V"_WJA9+CY1K#+>&6H;!RZ\0_YNT*
M)I[6*N4*?'Q/, Y-E1YRW/EQ)3.E$TIA$J4/Y,T/9]5[1XZ:YA'A0(\W54Q&
M?ZEP%@J%Q$P._$R^!GU T.K?8X->G?'\2N$_R\$%O2XTV+,>[5^5PBI?6G9-
M,6#=K'YJ_>]"LQ3.1S."2[]!;S 0?LV+T<9(XJ6*V;AUQX2.@?_$V-5"E.1@
M-Y^WD6>#>9%N74J.CI7*^WHF#:MR*T?)O<>?*[*MYORHSN$/8L9\%#S ]HXH
M<[L7?D,:7H+:VK4&)8XKQXJ:X;YEQS(EW;BO5W*^ !:T!8<!(C^>Z_X=BC+U
MH-AI]:XQ]UU:NV"TZ"@9/X=F^,/,),+Y4CZ:U+)6U7L%JD]PC%5LJ75$M442
M,R-\O6I_180Z^2T&ON4>_]C9W!US\T<B.HS'Y,D%I$_;?L#G@7CD:Z=>.=KI
MI;\M!;,$Z0%K?C>H,S4_C*I[ K#!2S5\(!4?FI$RU]@M'/.?AA5=']^X8W$4
MG^?[X;O!X/?6*9<1_Z>E#=R&Q6U<47FLP4]('W)U,*'ZFL+\,4\0,Q^FJG1;
MJF:M5*H%3<SE"NJJ;K_?5?;>];+U^/W_L/9646T_X;MO6MH"A4)QE^+NKBT4
M37'W8L4:7();<2O>HBWNM$!(<8?BKL&#0X"@ 0+L_M99_[WW6N?RG(NY_EZ\
M\YUYGIGG_4S2]I_PF,(>R*_V-0P+@JB^55FC4C$.SPJ=--/]/T," 0]=0U7!
MV9GIQHC:@XVM&Q5F8M8UKLXGH1GBS]U"\'P!EO77X!O>J][[/(NK+)1\\/HK
MT5ZR=CPD<^Y]1L?&.(F)O/?:QQDA.%/*6QMHUN+5JDE4HX"2J\PXUZ^AB%61
M=Z=T")4['POPW3JTRR)J#3/O4 Z5<*<&]NAI[CG,@*IQR3R9L)TMK4/B%;IY
ME%@P;[?Z@792 Z"I19\;LSX3?<?X=38_+&OY#FD"?P0,K%B-:Z-"D2_NUFL[
M<; O8&9Z$(2CF P#JA\X?G1X>'.RG6(B>4@ZRP7AO#,1ZX[V_'NQ5S22YRO3
M;]!EU*^5J;O9?). FU>C8=X&GJA^M^FHFTA9T</IC\ZLC=?IZ<\I@(N5LA33
M>=T8'G,,GW.!9*@+OU0F%G^?ZIG.]?,2)V$W"*MEF;JNQI5,,+<7.[3U7)G_
MF_^R73Q "X6_B6"]BFEN0&:4RH8%*&!VN23)$#?-",OR:L[:\3/7-.$:.$B)
M3!U0ND0<VP0CJ)S>2!^)G(<SU2^KKZD%=VG(VC\"J-"*2)F8T_J->!FA*33)
M.B]6%Y)H$X%(@FU.7^)(FW$)O\+7F%%,>]W6 /H$4ETS'7@^VK?Q@N2,;/3.
M[@J%DMZ0?18TGM^0E'C!^3[) %5:A=(P0S(W5%+KLY?9&WLN?2";2^YS8<19
MK/ZZ#&0,F5Y-&>=Z^6!CNMO=@0\FZ@TF#G8,)-L4*2RQ?WC9BG*[$U>I7EM;
M65I8''!R7-J>+6Z[1(QNS?6/W1X,'Z6^8RP8IE)R<;_^NK88$W3^JE=<W5:*
ME[HU,;O7YA%@V#/5HW"GH-?<1((UOOBGV<O1DO6[51YASOYPU@R<F6H@$^YD
M*Y[X9&Y# V'\^^?W"N%2<S>W=%J];S-IOH4R8/G7OV8*S:L<E12/YEMS\D^!
M^(MKO4&$J."* %=4UK4!K3 J52RUI]F[S$NQ[33_"[?^SNK8B/1-2'#OG&2X
MYU"&/>6"<4/JV/[K\,M?3U^0O100S$G<#?&WEOD&I[9C'&T(CGT$X%QR S^<
MKL;]FULO5@]NB^M,]R6XHZ(]*RL/#^T2=A*.0#_SQYICUA7S& F=[1E3WI8(
M^= DUM?LK=)..4-J7SO>!D45&O6GFCMFM2U3VB:D:0OT)GAX^3#QP3A5#\D%
MFNGXPP+AL6B#Z'K<<:DQI%&B*(YV(B-?-<5$CVKVE_()-;D$#C[7L!336.Q^
M6G1:L1V[Y$-M\D=7"G,=><S(6M4:.FQ\6P,B1$WZ^Z:#(0_W3*ZL%E3;0J7"
M6;6,T7VC$&]"<VD7R$(3A0%?T>B2D3F%C)9&OW:HR(8@1,2_B!I_J$%^Z,)U
MXIX@Z#U38>)T7FO^WH6.1['_6X=>H+YO:-"A15%0I-. 7T=<.R[Z8^1A%]DJ
M;N3FDE-M)*W$M'J^+==MSE-R4D[.[ 4(C=R0 QW"@-)KMC<%)D^;1?QPM(2V
M1XE7F"XZ9 03HE^5F1UJ-7B3:H(K%9NR[K'_)'FU:IFUJ(]N ZF8'(^QP+E/
M5C'7DQ"/@#O6_%!9_&#[<:K]5=/55ZA\9.6&: R:TX%2-3-+L=B#+L86R1T6
M$?U^GWME^CX>IEZ1<0ARY@:M4C WW6.$T.I%%QI$H.)82Y#DMZ>))C&581%<
M($-K1R4<XP2N#^457\NCRMFLV&;<_;0K50FC)./;>>/@63J50.E!094JF9<Y
MI?$]/43BEC].D0GV,[G/950J?JFG*Y<U ;-R=BGZ1:/F.Z ="$DD+7YL'@"%
M>4HV<&V./0NZ ";%R!(%>!6M+$A)R(:_<0"II6)SUQ*4)HH5SY0*##M<67$3
M6FDC2,TT4*QT2;+V%DN8IO]A *,M"-"Z0:2+AX1[=/BM.%7&W8SSW#+C/CN'
M*<MQG R-IT5SO*\33K:RD.2#$O*XKV2'\O!15('(W4T71/YZ-26G9&"PT60[
M@3V?HZ@6I&>_^?G]V"]A7X;O'_+ *9PF_JE7]HQU#MKD=F<[1L:'UYD;M2$7
M&I%YV*?04"E9S.0BL,:[*2E9^VUK%><?DPTP,Q[.EN27BBFFIO)V1"KTFB:.
M(0!-E=YO.7%O-N)E\2SYR"5N1HT-]6(&9GHFP4.>;F(!,M;&T(8<5J;#81)<
M%I+R?MWRB=12YE$O(SPJL3'!VZ9C1@IS"AO'3>G$%\(VO] 7CD!,RH"8/AG#
M*2\.5CJ_JA.F$LC)O-C@R71>3]+YH7H)SQ,I9.@@O$:9KA8J77Y#6U@2C&]1
M'/2^L>VXYFC-::]-&W)2:UZZ'Y3IB&!!-QP0:RF0F<W_LTUX[:<OV0J^_=_R
M___SH-M%/WAJNZ4>^)W?<]C67Q?3\!X7P50J]S\A=AJG;I\ ->OK9SX[']5:
M1AY,'2_M3&U2:(MKF_B7T:YNDJI@,')-J"(E^#CVMBF,#,M1\QL=1W2GLAM)
M"0TGE'N%?;?%.Z&!'F4H:V4D6:Q7H)W<:=OL\(KL]T('J"C+W()B)@ZU$Y/[
M^ONZ%#L"%>(U EF01J0%C@S#03!.J\M/U+@2\N4^96+3#PHIJ?/]=A'([PRP
M#?2T;[3X:-RW?/0^WV-K8?A5X:\LP(LKP]U+C7]"^"KL%!_!N!Z!G.]I:2F_
M6'!)_%ZVY"A2Z5"V[Q>V9&(&M//_S/PGP89_N2+HV!?.;%20];;*:7L[=N/S
MKF#AE]S/+519VY>.NC_E*DMUB**J%55FTACN]X:RPU(G(4,E[53?5"9SCI8\
M(LM92:?5>:[GS;,DS7C^7MN/CP"5\002_EQXB?\=)AA380S[HRD $)9QQYO"
MI@X2&Y.6? 3DI9]F]I[ 3M8-NM=BS.E1;E46CL:)M1MT^!HUX&SMB2,RS<D+
M<FTV9M+,:Z= (IX?4ZN&?301;<5](]/+)DMRKT:WBP3OL4^)X'91[;(!TO6H
MI T076^61M0E%>P0Q-^J5O0(L#%UY#,:FPBV-Y*_BDN2U<A-N\_:$Z@ZP'BF
MN$+I8^F!SJ=*+,_\>,XEPTBCM"3QS5A=V%9C03>"H_K,?#)"I1\/8:P3KP<S
M:/9B'SSK*F6N3)CV,S*#M7@[@.;U_97'7OA=%Q=6DQS[P;8+;GCB?O_XGUR(
MP>XUPG9#ELBI@[K#9NVU@PSMG# (IVM5$,E3NZFF/M;MGTLEWV@F,:F]:]$>
MR_FMX8\1[N&S:Q%D%>Q3(V5$O+:IDN\MAAX/]T93K#W/&R.K+/$"+\LY<;A]
MD6:GK4_O<?P[3%PEZMWA,8&_.ZB7WRA&NP4K(ZO!#=D99$1*).H\"%8*W4(2
ML99RQ?V2FAQUO()M_7U_6%$A<T>.%GHOZ.^9,=A_T^X_*F" ^NEU7.GI3@=2
MOG_)H/O5)ZK#]Z=RX/S>K,8?J8UQ)9"Z@Y)5N,9T-6(=^)UVD352ED'29(_1
MX (_6K8^O_]?*1<W+C5>H21[[3;UOR.G^_U "75@OT,$]_I)C(BV/67C3[QL
M"86M_:NY:=@X:4F%92,!;Y:^'MVG>]Y3LB/F.UFT&-([9O,>4Q'Y;#Z(=,9N
M+H#;M@*<J=,^%2!;8;:JY.OE:UWZ?3-JU+>0T$HW1>23;ZG*L=RHA34\.>PM
M#3$/IMC@X.Z\M&!RXKOQG2:#*$AIN@9&MH&GJ?F;";"*8FM;"4,&QI)!M;&G
MY<C>)I]6'N%+J0NV=B/]'16EC#Q"TT1!D/>V#U#9#&I;'UNW!_7+3[>HM^BB
M(T'SWE<VR$EQUBZA>%7NT]$D&_9H#>FBK_N"3ADI?3R%A<,>S\)F'/7G!80.
M[<B.$859[[BX!M0R8)>&^-FL4J0/(5[CCP +:NMB5@X5#)SIU$2/&7=W_L3%
M ;BJV;N!H+9F.XK#'/_Y/2,\)7F&'KV>#3OQJ>KHRAA5D"@^B-+MRG%TG[Q;
M\@#F[M?H.1U62&6QF=I8Z9VR;>9]4E.%3KZO#I"M=:!K$.T+CH'>JBW3 B#W
MH4$"J$_POJ65ADDPQW@OV5)_O@=MG%?@CAJ(>WLVO:F)M!SD4F[:Z9Q"57EH
M^*FQ 7WV" @+;H=N5(Y3@UDWU\*".!S6J&18'@8DJO,[]] NP1NYSFM:*)<"
M(Z"4#.T_F;2Q0J3QI\X04DNXOT]YZ)=^-XB_6'7L4C+#E +7?$A&^Z[7O@I0
M/4V*"<#?O.?AMNZA99N\Y,8Q^.UK$X<@I:Q.Z$N?&N!NX3J5-!D[?#7:$@-/
MA@Y TOAO@%?>]Z'M3QY&VCE;D0,AU5(69> 2EU<PE,RX/C(I3AB?$%@(UE_3
MALZ^B"LT69$P7MBO];+]M(_K2A;Q\7V4@X.Q@@5[-9<W%8%B%0G;3*5$HDFM
M(UPB65-U.GVVD,=>#&C@V7!OS0'/:4YZ^>F[C$0DXZ'7WO8,W^^"+.V'T3A=
M9BZY:C)%PE2=/BU=3BXS$@ZW*_=_.GH;&I(/=^EU692\<KV/ONA8/(3[1)7,
M>FE@P] ?D2<Q:)(JL*3R*5VDE"@21P$95"I<?-5BTVB<.U=>T+D/<H'4?&T;
MK32&(" [WX)_<F,H02>$<GG?0[CFEA1SG4I@@AE<'^LCQ1@&[3Q2DDMQ1Q2Q
M!L6%?XCDA%2&"2Q_S'MB&A^P(ID3'H_WYWO0*:.T^-\]5_#N_@#$9_T7)S:.
M:D/EH$ZIHD":KJ^EXG*R5D**2N,QS!L"LT<]O-E4L9LM'LR<&BZ3^L0KF$LI
MS&EPA5H>JJ@T;U.93\T!D6!UY^B^42< *:RL&K,5M"1E_T]JBK(WM OC,.GP
MPQA@92(IS2[G$7#;YI&(J1/KL16ZG^?$:]1.&90=Z >JX=4?&CLX,C8J&/1P
MNP+Z.DN5$6R%J BU6V024FA*Q<?]>6JHK:[.%Z:ND]*^,F.5O0?S3@INU<EQ
MF$[;RBE(34O3VRJHKDTQAF[[.PX>;\0>XV2K3*BXN#T)LY6F8=9FBC\+,HBN
MDX!J=5$9MTN>VAVQG_)VKKUN> 1$9]'4QF@'TNF#/.1.(2?1+L=HNI^'7*D1
M'5.>*KF%#6";S'%H M/K=VZ4:H2<12"ZJ%(TB<E58))&>_N,)W[,DI5]'JL%
M-K@?)PFKOQ[,\PCP[ZY#I:<:6I8:#?N0(-+(Q)(I_:EJ^12H+;./$29PNIYJ
MC VOZSY8$K&#!PI#;>)8>&?^Z)@AI3]08DG<+&M,@S_%U];>!@J-5PZ I9_I
MQ0A?C&/T4XNKZZ;C3O.6YD#"K[02#.5I1GZ2*$ZHJ;I'*/S-;!,3=S<39]P-
M:NFAF%72]A) @SY7MP++#N3<N\LD/<[[]57Q1'<RFZM*&MQ<9I3ALCQK.OU*
MU%M7LN9HM]C788K$_J\US#T&--1W:QW1NZ?Y:.+2]:3XDE.2C(B" *7F^2 V
M<+2].=8$5??I*Q.C!EX/XJR[)9Y:MH9)?> _#S"U8W/?US"2K'PZ3/D0#5.>
MJM)N=2$"$CN_<279X*:L9_KARJQM1,[.2 __6<LH,%C_.<]S(VL=24XQIYTN
MIM]*H]RM2I1F]<!6ODKHI,0V)%F2!.09.:7(X= =1GHBB<LU4IS3X-I\J5II
MUIRR7D/<PEX5LY^'T[04? <*_N^H(3EFV:@2_3W,&H#HE,G+G0]].+M7,D[Y
MSKK\V6N _! ]<$ZG-9<T@"1NI[!PDOW[8!:$%R$CAA+3;?@8M-!!F4M<Y[)0
MOJG 7_\BI%EE9X#K6TP],Z2E\NVS$I?]:>.I*J]11IU)+S%MN-KLQ>&HR /V
M"VTGR07FQJ:$7^^>;*3WZU;B8=&'*)V3G'IF(CNZ[(::A^^LT)9G.T^7O_L8
MH<H1R>9OH0Q8U2-%PSC<37;A.^G,*D2W48>ATU!9;:<K7E(F>-(@AZ*:L#R5
MMJ!)R6^'?@-C#Q:H^K'J\;0[\!S_%7L_6&J.Q-+/N4U,5= @(5<BV7%J4;)%
M8:_6WORE0/"007_^HF"?Q8M6:21<8[8$29I?@"9$1?T$7Z^7U)8%9IF G!1F
MB/0;?/51BEQ#PV[%^[]73)J5/#XN!7BH$.M/=ST/Q+Y3!"OU!9-VV,O&K1%:
MMK1U(.VZ>!>'-R[: 9-51P7-HNW,R+5(GL*P8*:,8'[>8^=>NX]_FIJ;H9%B
M.V?PA ZEX/6RY-[\.J5$NX_B&2LLUG\$N[;6,N-;P<F%3QV(Z=U^FWVQ]!$)
M@%^!$ECO&V7XWG$!I>S6\SO+*>B&;(W(NC-WW4+C4L_*$IS5^Z+5A*CB-*CP
M@Y_W+:"=%6B9JLF!?,._OL^R>?0C4WZ@C-/M5:3GV)O3.<\6>V!WM7K,&]9@
MEU>18\5?)U.+OPQ8"0REA*EQN%=S[12+FWP7Y=#:3I <]#@S@G*67O@<L=X)
M]]P)!#P]O0[G??,5#-7-.K1 IO?NB&;?.=X@KPR-65Q8QL86&1.QH/4A)XS?
M5I:8[A3YOVCM\1\^!/-V%VH^#7LR+CXF<\*T2PUGRE,6YTY<2 _:0P=_K^T^
MYQH@R88C?3-$3%&MS@R-# U'4^[EHIR*9ZF:L6[Q)!?QH(G[J"=A/S,_GBY0
M2_G:;]AW1W :3Y5BR4E-3?H? _53S/P2"V(YHX\8TH@@D>HXMJXO<\JWZ_/(
MJ*W+Z7UJ1\9AK%=VOV8#C.!T2^YCVPA>*?$[P0#+4\4.*X)7[<6T/W\L#Q>L
MD:[69;=\<HHFT9;J_CY2@-,"R;Q8WOUUY#O&IZ$NN;79BG]5^/EA=(TF]/ 1
M\#)_P)K^JVN 9)G-MO^3L'?=7['<RYNB?O<LC)CCB'4-XVCU'(K%BG&,\8P9
M?M93]:R8]MYGVO9?K*:<&CGSJ.*FUC>)20![<+S.X\FN<Q1VO=@6<\Y2@Q0X
M'"W)YKHLCK]M0AKTK2VT]#0*2D/&.NZX C2GN:BNW>-\CR$NT8T9F=Z3JGVM
M?2D[*WED?VQC@1X,+RQDCEWVH%=>*.&2 "S4NPV7R%OG&PO5L*MK[18WLNS@
M:B>RZ4.)MBX"A@K%VXCM;KE8P6T.0=+DE:1UC2.KHJ"ICE.-(V?X%1@9;YW&
MOQV@!A?DS="VJF-LECQ.WG&?E/IE,O#:B/XAZVMN!1_&\V?Q]8"W&("OV.0G
MH3F[@%2+G^#:A#XEBM#A_;$%XS^."\U?@QTA4H>2Q:J@XQMK5M)&;1!LPZX'
MY151S"7"2<+&6Z55K9@@SGPZG:>7IEKD?+63\6MNB&=L[ K%^?!2)Q]E$QS=
M8<(_+MOCU>\VG]A$<Z\&7NL*!NQU$ >Q/<ROX:'EZD22-]?"UYY=2,[R];UI
M-).70WJR^SJF,O2G=G$4M5".+6.#"D"5DX&I#R]U@^$$[8PB>)@+"^A2;Y$5
M3TT<HA0^3-9?XC4Z5ZI+__%"^3B/,39..C5)F)0B^(M0V=QD:7JO/[RT%KFJ
M9.BE?);\/HPG(*M:50KCV_Q/T9<S_.05#17RFZ7:%%'88T0F3A1]P(KF>9"$
MAZ/G ;+Q18)]OV>EI;U.KGB 8/POWUY64LB*N,)BUV*;5T/'*TN4-+)CX_DC
M(.9B?N(XJD]V =8K8="+CZOFA"NG01X@/G\I[M4R>&D4?TTP6.K@9I]IX"WR
MB\&TN[FQA,&()7&]=&ZM<0UA@L2YBD.!3N773R(:R$%"+G'_YJ85:A(I<**1
M8NU?ZD!+-L-; ^&T9Z(-(%WB*(VZQ(%FZ#;[%]LCIMA5O]5TV ;;:T314LO@
MHVJ12D-Y^*0F:"(D-)+ICTHGI&4J^#<D+@[, V)B(<W"=CXF85&K:QY*%O]N
M%<.)3+JR.0W*1E+!?8YZUD%>.VID?6N_7.(ON-\;W6B:<K?_W)16'#L&^L3D
MIKR'\J6O@+ ,/B7O? -F!T.'4)68O6EL2!%)SIY6 YP*5*R@"NR0;E$/"?[.
MQK*\06W[//XG)F=WT58U^=D?=*-D%%*<6\7&\,-8J[W;L[+I:M+,)N"=7"(5
M7E-1U@[8KR)!$7Y:R6/GI0/]I[%U'H:6,B";+?E+J0-^PF@_[I+853J4N(,_
M25MU;E\:2"8SL(K[:R15C+5]-<71=A;+E_%@/UAN07Q2A>SZ[]:'@?>Y96NG
MD';:L)'7;#Q+-7K# T)6+/2^?1,_M/L_L"W+?@AXOCZ*L[$;+L6];O'*!)(9
MA7[S8S^/9O)HL3=R36,*I#VV3(%MYV-?J'9T)N.*CVL(W4E"DXJWUBY<%JT2
MN?3E1\73.7YML=#O HV__#*^YB'TAHB'-3I).(@,HW<ACQ,IR#3*V2WTL3X
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M\BAQI!2;X&N[UL>JMU/TQ\,]MR5<LU.2I/\X36GF0Q*.MY\U.Z?X67C7M 1
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M:ES"2&" H?,\<0#X/#+M)]CJU[?X0KKP2M;G%):'DSEF>D>P^_93?#1Q]_Q
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M,& 1TY[J]W6BC'9UI$6@]5"2MJP<YW"[$$I6"Q5^FK1I$.KIP%TP&V"YGD2
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M/MA,?U)3.C=R^(RHO]9]R!25G4S6'!H"4RPI'_80N@T@08S2]7^%+\T9-I%
M,GE,A&,/OK[8D9HIEZ.P>K%C@$*N8DXI^9*@JTZ:U=%:&TN[=)!_V*\_OI9(
M\EIK;"MV(+YBQIOB<:QACF%>K,;EPM$62$9R7 >7KZX@   + 5!@BM%V\!7D
MJ=J<^CT"\BX,=AR)L]2FTU>R9WV#_8>1@>,3)*H.3(A@A>W[X!X!5;:"LJ\%
ML7)=[Y@N**X? :P_KG\\+VA:T3&'3.M^3U2?VI"/)Z'I=_NJKH3!2!TB7L,2
M'$L90/C,?B9TGJAF4WPK8*$+3AV?APW@Q[Q<N3#Q@Y35G#A;J.EW\ Y?[!\2
M&WQ;1*M.'>=J>G&1Q1@P96@J:R]^%,4-G78/<^^13JB-YG*>(5]Y)]XIP"KI
MEE(,? J@S_\0.DA/]$!G1K=R+F\ 66IL/)FD:M#5:FYB5@>/B3Y]$=@2?'M@
M+$W3F^4O&4&L]?;_-,+%*AK.KGP[;1.UIK:./\6^E+[UZH)?:I O[(><O%F@
MMA[!N.L-P^;"FTR_6Y2B%15H$2VPB#5V6)M7?P2X2DMX/P*B[B#GDL:<?Y7Z
M0'Q#0WH!K;A\N>[8_:)/W]'U:FAU]OL[+X+O@*T<&*#EXE BI?!E/(MP:)Z&
M&)Q^B]1QOK%QL=P)E-M\@V.^EE1ZT]$R<D')R0/3@38]*4BVX,";@KMBDC/A
MWL+7&I6$R_YY@#!I)8:OO,(?_[D$\O^#(])J;HV=(//Y2_/NX[^";*W?8TJY
M8C][D?X(T!!=$#I ')@7M!YJHR)*# 6?OK,5H__[ R/EQ5LKN2T\UW>X;8*Q
M8W&;&>DL.#4SN]P[#!';+RCBCFZ )?"<5STS-O5'Z 90X*%&QW0@AIGGI(E)
M=6Z[GP5T)TF_X ^,CGS?)^*]2R03)V]6/L^F;N <EZLX.>VW+H;F;\YOTCZ)
M_)4B-.7#S,,?6]A3HK:CG8$\M!'=OZ^=-;EM&Q;29NL.S5WVVLT/4GD 7W1N
M9H1&_.]DIJYIRAH_P&97RNLV5JW8Z1+F)NKDX'^DO.;U>Q[SQF#;#L%W'.R(
M,&?H[96UZ:"6>'^DSW!NA-H1IR*/\1#H(];F.X^K<J#"EN.N>,@^D)AMS'G[
MM=Y&D+H.T?T;,Z5'JC*@D$LU[X4X.OF^)$#-VNM. Q5Y\W;Q/THKDG;F>4OB
MWZ$=7O(>FN95Q>=]E:KU<J^&AZE=CT2)%#_&/(?VNNVVI7^<&[ZSP!B!Q1OT
ML16M*)$S;8NM92L$?:KZ'LER\'K'M'7VC8ND=""AG]EMOFM0+V'5(Z#.IS-F
MML@KL]/;G?-#6;W L(\7R_[[=U:$?!RF[POX[L(LWV(<-*. 5TS(U53K.^X
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M0!WR3TZ?_JI:D849'J**AED*9S@*$SG'0Y('MZ<8YH=^F^F^G4-]OZ[_ -=
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MFE456$9*UVDVD[VNDW]UUY]+75CZ#HJ.*:.9=\;!E]1^/X=NQZ5)6!H%%%%
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M"O;EBFWK9M_-]NWJ>6'P3&GF26NO:K'(^\CS/)F16=LY5LJRXPNXIM9B@Y7
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M*4 >9:HTAPSKYC1.RD(R@LJB1&,&E:+!9VSP1!HH9)6FD9BSR32L0&DGD)R
M,*554+94*-P9<>MALNDWS5G;E::@FDIV:E;5[--:=.KZ'#7QM*"DJ<KRL[-Z
M<LK*RZ:IM[JZM=I:(YNYT*XU9A+K6K7,UWL ;["R6T"*1M8*FV4!B&(;)RI>
M3();Y<\^"8(P9;'6-3@F  02&*X0E54JQ+HN06Y(&0Q4;B&^>O5(;1 ,>7*
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M8N!G2Y3MLL8=U:0^24;YRP9MQ#HRD?HWH5XMYI5M=A@WF1'CIDQELXX&?P4
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M@:G+*UUHU^MG=.6\M9!%(T!G7RP8&+R(KS%&">8!M!:/)_1+3+HW-A;3A/\
M61MQA@<KN_A905+%?NMAAGA2*^=JP5.HZ>NG5N][6O9];75V[7NG9;'O1<9P
M52#O&5OQ5[JUU;1_\'<TJ***S 0L%QG/-5+R[CLXWDE+!=ORE1DYR0< ?-D
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MO;@9&9YW=(B"!T^1F<@Y 1?O!C&WSY86KAB+@F2YES)<2GF1YB0%#$G(6$*
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M!@<2M(6.X!F0L,KD2.B-G$=WX:C:(J#$6())8 ;&)D D4*7*E&8)@C;N&-^
MBCZYY/DS@J7U2BHVMS*/OI]U/D4DU_-S7M;4]Q8'#J*C&G"-EI:$--4[_#>^
MB5V^:RU;UO\ K]\*/VB_AA\8WCT[0]3.E^*?LKW4WA?6HVM=3,<1*3R68/FQ
M7MNF2WF6\\P6-T+,P8NWM,UK&67>%_>#<'R^%W;G&<9*[N 2"02&("A3G^?=
M;?5_#6IV>KZ!?7.F:M8GS[*^L;F6*ZCG+2!I+>:.5759XFDA>%@\;P-+'-&$
MDD+?L/\ LX?'/3/C3X2^QWDKKXZ\-6.G+XLM)X1%%-]H>XM+76+*6)5@:+4)
M(/WD"1PO;3RF-0T<8<_%Y[D"R[_;L)SSPNG/&[DZ;E9)MI6=/5*\F[/1WW/'
MQN7>SA*<&K.UE9:6M=IW>CM=JZT;T<=(Z/CGP+=M=)KWA8I9ZS%Y\MW:Q +#
MK5JI$D<CJ(W)OT<,%E41&8.%F=E ([SX7_%6YEG@L;R9X;J&2**XAE3;*A53
M&8V4ME761'C=,;E*Y"^7R.IO;=F) /SJ66(A=Q5"<&,$E5_@SGD*5PREE9*\
M*\>Z9+I=W9>,-+:*WCTMS_;=O;+Y<MY"UTJ12LBCRV\IIY&E<&.6101)*ZKL
MKX_&8.%6GSQTK**;L]&M&DTM$TMO+1W5FN3!XKDY:,VW=V3>R;=MVKZ^;OH]
M+[_H[H6JIJEJLX?<7)('!P S+C@M_=R><9^M;E?._P %/$XUFS2 ,[[ Z[F;
M<&EBWR,N<[AG>K*[??W%F4/EI/H93G=R?O$<XXP ".">,C/.#ST[GY]JSMV_
MI_\  /8:M]R:]&NOGWW]6.HHHI"///B->R6/A759(V*LUE.(V !V,5VJS#:V
M5!))X.!R1P"/E_28-L%K&,*1'YSD?.7+[G'S ,&\QOFR'&,(H!! KZ'^+H;_
M (16\8,0%5#UQQ]JM,\DC (W#()'S$.K(7!\+L5 N V0JA2A( 4(FT$%L\$Q
M_,RC*@*6P">3[N6.V'J6M?GM>Z32Y4K7Z+7:]M--6>1F+=Z*O=<C:6RYHI:^
MJ=M='=+6[1\*?MT>.IHM,\*?#'3A)$=5F/B+6S!-E+JTM(ECLK6=!ND9!=R-
M= !]I\E?E;:I7XO\/Z J+$Z)&7E6-G=4 (&W!174#> HVHVX*B%MF,S$^Q_M
M(W$VM?M!>+9G>(PZ/8:#H,+1J#O6UTVSN")CAD+O-<M*64D@ +@31LR5?#>E
M!8H)& +$+RH!!!)8L"5 94WD@C<QD&-P2)%'Z]E=*.!RG!TXJ,95*4:\_.5=
M1FW+1;1:2U=U:Y]'@:2I86DE9<T(R>VKFE*]]KMMVMIJM-+":=X;0!?-12<
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MH_DO-_F_4^G@[\K].M_Q./\ '%]_9_A?5[D9!AM)RAY(5MI",1D E6(*[F4
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M"OEE4/.'4[E&X1ARKJ2S_<!/S&O /$>GF)Y9$ !RO95SN;9D$*,9/[D [0
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M41@2-\>](S IB23 ]=\5W]A<64*Q&)F1,-@%MK",(BLT8DA56GCP_P Y611
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MMD9OT@\=7=E(LTD(3!BN"WWR,.NT;EV[L3,5)<QON4 *5"-O^ ?B&\;F4Y'
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M$%&,++=VLDDM-'?33KJM]$]66*8_0?7^AI](PW#&<<YK)NVI,DVFE_6IY/\
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M'/S+G(8G/O:XQ\O(YYSGJ3GG)SSGO6'H&G)I]DB*FP[5 !4*R@* 5P,  =,
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M^/\ ]?\ I_6EHKFE:SN6>-?&'1SJ&BI-#%NGL5>Z@8*2WFV\<KQJ"%<D-N=
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MNGL>9"JXQ3C-\G\R=]5RWB^W9NVEK/3:&_\  W@35@W]I>#M O/,?S"WV*(
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MQLAW/EHD $J;W+L9(U$P8)"26+LF]@S]);760%E8@A0K,& R0&4$' S@MRI
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M[K8!$FS='+-;VGE28\N:(M#(\C'9@I*C!S7NGP5^&::3868$*KY>2Q\A0!E
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MC&4J$E=3DFF[6V3LTW:VG9:O=[+@QM'VE-5%I*E)Z6UE=K9[K67W.7E?3MI
MZY'<,V3R!\I)!/(! #$9[Y.5QFMBWE=,*Q+H79B&/F?,0T9#%OO!E)7"YPI
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M(90 K7*KT8'G V@' WL"68  Y4#'A&N_ PV5XM_I]G/'<H47SDNP'8D#(\P
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M-&?F02P+H"5AJC!0CZNI7@^)5.39A5PPD:GN,E%:)$%),B?%&\/#7MZBZG<
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MM=OHKNMLYUVN Y@"B'4,0WU\++VXVIG[D=]G2$C&NC<.;+R;E]Y+$42<#&,
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M#OQ8 *H)QR<#::VA@(RK5]*O8T)<!,<YT,S_B@EN@ZA!C&48@Q=.WYXF0V2
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M] *]R,F$J[T&O<3^$.RV;_B"\8K^D=,69F*.<07 #@GA1,PA\;H8+1AKTSU
MM>U\ KG'Z)O#Q=AI$BZ8>BL]/@EOK8<[D^\!0N_Y.B_T@G'G@;3[*TSIL>FU
MOCQB'07$DIZ^^!V&;7IO97=.7VXM#UK"0-NMJ&D:^VF</PYV@\\V@;ZQL=",
MIY_;^?H5VNS1L.L6O&>;DXZ$*71[<1[I]FXGII,R85QN]8+X5 ?DU#U-\1P^
MY>+*L>E1<=,\(8?'+XXWQK"E79;NH HZP98XFN9*K7?@.3_N>D&()C#7)/Y=
M3(4G\\J83]>1LRF7_/AX9:Y\N6AYMI1AKSJ?G?/&YH+!Q7,'W9GG>G#?3G[*
MZA,CM[4.9ELU@4H?>,N_?\HM:I%_2=[8\^Z0:? JG]) M$>%OA0N09#9.]Y@
M'#':\BG?2'+,;-&H0T_O+?)S_\72MZ6@>S;^H [QW0G^I1*Y.'Y6;;42[?FX
M.K]0":%-#J#'3;L'$1>4#RQGWZ".JILPI4BM3,G?+U.4LHFQX,MZ&"3>$/>,
M-%:H4/ Q8I3]7!PPU)CH#M?:TS/6N,=6KXM%G(@\>NM-Z&;LL:2F3Y!>;M[
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M0+* 8O 8!>3B/)1%&FG\3WR>0'SS0'Q1H2I]D_<9XVJO#Y$OJ"W_FHSI Z!
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MM3=6!<C)M_/ UWB&*>9AQ%](,D!0K9D!XT0%O0#&,B&R0<#7T23[9E*X/W/
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M/<[ZJZ@\,,U<_<$:A*9.Y2@ST6EF84.""F)3J@(SK'JD"OO$DX4*1"#>'L\
MPV+#1?Y?F%SRZ-J8V6;FN[U9H!Q%")S\*M66([+[O26[W\%NM_L1G?\81_UV
MQU%:?2=D9ULO)U;^ 5&_(;X]>F_2PVR?D3\ZB:/ )16Z8&%KV<6A,NJOS^FQ
MRE=._ZU,_K1)N]- )5+D$4)EV4":O8.^%KG-NV*(6I5MP)1207?@;N02=[==
M$^L-J-=I++.^3^&]2OC(R,:3:Z&=-B8#?%6E5YSW'"<AS%?^J PG[6+<VX8E
M!^$A_P9>!N^JQY#S^T[_#TWWGLG]8=RHH!=7"4:4YZ28CP._FP5^!JD-/M%
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M&JE"!$<!+%56D!^ZIX!GVC70%3,$O\\[ _N'">Z<V+A4*4@=1ZA]6_QDK6A
MRX[?&+*ZHMKX0#=%P!L3<7XU;8>\LT+\E@S'N44 #B(:&R!@-S2&E;0.&YR8
MV+^M\$G@SBPZ'XW^0NH +R,&R6'7R:AU+O.VKK;=0M;_:+R*S$@ /X3/K)I.
MQ]12 ,@\@.CMP"&:/\*6SE!+'G:@EON",V#%"V6+*0U!'VWL9H895.M=:R7
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MC+?1\9(L,GBX4G!YL:BP=:&->(D0)[4VJ@SQV.I=8Z(=EGV(]53=>:8\5?^
M4YR K%>+X#,MS[.0<V-_>W:$Q_L( "B?L//4*GR,7Q*3J7FHKZ;U^P.;P,?/
M?:+J59N.3N)?G/\B&4LW1];/UM=/MQ2S5Y7.7M;42!I:(@(WZ!-GGR<P'A'C
M*<%MO)^1-L_*,+P[['KM07EYK']I3M5J/GPR+?"\_]EF4/.NEU=*&5F(."A4
MD=AWFP((B\(S_/@L@ 7.=W0^P!("5JW\5V#74,_!Q1QD/R!Q=7'_!N_-U:S+
MU,:9JIN_W74E.ABCR:KQ0-.W,_@KO$VFBKHGC.QE0XM925RL,KL^>X&OJ&5
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MSBON3@]:E\1XNX^#Y*-.4\84@)+N%,1K[='DF&C"M)WP?!KMVF6W%W;\$<)
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MNW-;_,#GKC9@T>(/P#UEC$'JC[8L;:>PW]4=&+NF'D;>!HTZ<G1>4-<-D79
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MA<!-B((XC"[R+F#?.5+@I3PA$#8.?C7[>@__@+D!ZQM+ER.W88JQ+W3",[9
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M/D;'(,\N-'#.6!0YGX\Z'Y$9W"R,<1_S'5^@3=)&^ZFA 0XS'O !*4=T:N]
M0S-<#B+VW[ [V@N.E:*S"J1-1:-0BF\5#%%'(>-Z JX6= 6-7\$RF?1@+.OW
M:^T"^3AT>]$2-.KE%.B2,OJ+21;*A_47T4HKRD1P7^:$ +:>)W$M9')I<I'G
M,9PNQ^___A(@X[=YZI*V$HA(>* 9XZOP%0S*6T2DGCIWS>#[\.TE6%U]J0$W
M"T*_ 0O[@K#2&UQ'4AG1$2&=XO;%D8ZRUTJX5')XL85C=1JN/[WS>NHZ=NUU
M>5&0OX]:]_KWSLQ^$X^-S9V']=ZLNS5SG:D\APM'5@H*C ZRTW RDU6C+>TW
MVX</*=B5) \L3*5^K*BHT/4FJ]?TZ*\B9)?=\SMEX7^Q*F[JUB8CU74C\S+?
M@?NMDK9.8N><]%"GY=O15![X5[1_J<@;HC^A4R^0XC@XWA G+P)9!HD,IS1J
M!_'N<61@]=X:\Q 6=1WR"MG_%E97CPN06C_DXOT,PK<4^U@/UN#[JW)>M>?Y
M&(*#?K]4_+9XZJC*!^UVE2PR>G%19!M)MY<L2>Y2PK1@I8D7&".FQ5S*"[(1
M)R6Z1OL)R3JHS]K"TIF!75>F(\O(\TH=\=ZWMRU%6:7K87FM>>[*H=ZM'GZ=
M(>U_)1Q&B;Q;T(%,DJ+@(2)-E&"-WJK9FD6R@JHY62UNRSIG @OQLH=93$D8
M2^]X4F:!D_;IZ[NR=&>@O"!@LCI6*]CB(-_"OBKTC:M)UHTGV?-H9\-62#'
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M'O4[[U\7Y^)Z\WR2N^D[0^8-3'E='(>"*!3-Q-:M\*3+P>;\GWP&/J ]$K8
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M0>+P"$&62&TD8SE41OLR2-V,SLV)SV&]-K0$[;ARGUXM!)4[2"8/_-PLYW+
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MUK*(>F_.++@M6IR7\CR@??FMR4Q9MYDB:T&9$(E_Y1<._2_\P3ULO L:>\;
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M-+C>4.DOW1^+]:P.ED'U=$E_G-(=3V$:!U+>X(#Z=)_G%W.+M,O8(W!QW9:
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M^G#2@ *%?0)T8!0#CD]8/OV;;74M9X%="/M8!Z8]W/)CY#N+ZV<M3[WA,N9
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M_F.T0NHNA/_ 0,X_?H-Q(\@%2_=&G0C,O69QAMF -=N%G)O^;T-RU__WC%R
M>[@:3)Y5YWY(H_D7.2UAJX3:,T9\L .&I;N0%6L$!@YJTQ-R,$>GP%V(,X!,
M^T35@<F@A-S 2M:!K^:-1J]HO=R][TC*^K;C:*NDXS4WKJC?4G;R&;UZM/GQ
MCC\A(3Y9V..ZIP@Y&+_>0E'>!*T\8KM./*+%_[GX201?6+9OFLQ38//E9+$X
MHCA;$NP):$"^#V5QQZ"MBY^3=M0<=&<_-;:H4RSA PKD-476RM<SU^9%M,0.
MH$^_BR#9ZNV=-O,;#/L\^CH].8W*[,-*HXV!G7Y_ 5!BYRAXKI_<ZLF6<D*
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M2O$P?C<4IJ-VP_B+MGZF[\:,1V?3EU/YHP@[:NAZQU.6@7O78D+SQY(H*[5
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MMFBC&/9N2HA43),E7KGXLC?BYG+:VH:YR;)_.SK?'1@E8I2L^>07)KWHN\S
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M#:\TE1*$B*>J-UT44&"B#Y0=8AAAC=)*E5U,6S?%E:/OA8KX$XT\.8JCML&
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M:6H97$_5>#_,//=PND-*<WC3[7;GVE-OF&J'/__9Y&B0>?;X=.<T36GK/=8
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M<HI" !C"9(R6Y-)4)8L\7HTV0,D<DXI'']J8#CZ:VK!V;JYTI ]O?I$+D/$
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MN8>LN_8035CU(_=H;W0(7>J& OGSJ63C%X/T7XC9MF#4:ZX4"2WJ!K(*@(A
M\OH4T2Y,)I^B35RLG=&R0B/5$FKM91RL5_S[?UD])XP_M'V@-"XL;Z_%GYZ#
M079G)]O0QRKOI!B@.&>22E<;(OS-];3='4ML(I73YE8^VKI))76?\Y*[2Y/5
M#?N]E5?FU/E\<,^+-^,'GKZ<C=");W7+U^]0N=/1Q^Q__'C&K>@X7!L7J$_K
M]L'R:*QFW^D8K=V\4M8-WQ6.3LYTAQT 3ZXU''''VR=[IWKEVFNIQR03/_5.
MQ'JG2#(L!U6BZ05DJ8-69WC8E'K3T#7.70OK2N.\ZT^UY#M/)Y^BI[=^]U%H
MV]];B5(<K:RJ;9%=^E:7MO%%D+T*2U'C=,:)GC5UZ+O -+Z()X;%8U5,N",N
M=FL9PMU@[-(0U+?Z&['T5.T@>4_ 3_9/63U$,@1Q":(-PG5IO-N^,GVHC/;E
MK#$X9%XUV6#.3/%W \:HD1A&45!#ND.Q^\<W! %=2Q(P](7NH/]L)YC<AM44
M*0E5H<!Q.(>Y1%M[1M]+6C<X)_308W7V)&%0T'TT 2AJX>#C35!;/Q*=<?)!
MHLT G,F5M1<D@#I5&273GH\;2YB_+5_U\NH:1A?)%Y=U(&P=GKK$EJ--#PV4
M>!)]/9]"V09!>9IVY<ZF?M+VZ4'I.:6'44IR'=>+I]!6(1IM%ONRC..(XY,3
M?SY]?SE$"IX3X[WGU=67_2R<4EJG3BS37MIB8&J59 *&%Z#/;G46VB;_;#V@
MO\!5).PC8<"%%?-8X\_/P/QJJ5LD)[-[XR.0QH4E;>/!76Q?)E-M:/Z;M\=,
MO:K:/FRGT<F/;@SR7]P74BS:R)'VL4, @BF';VTPIHV'QN?TL)++T]0^<CVF
M."W/!B-"X9,8&7:547#(7Z!_BM"&%IB/ )K,;57RNDNO_M$5MN."W H>Z%\J
M!4(R5LUL*331,$<U-RI<DJXNW8:*",60C2]$!>:7: !JS@'L]HEQ 4M;;T3Q
M+/,?\!&_,VKAK[F:T-/OCK9-H>!1Z[(""'5V\'%_)![.#:CCV N55BV%H?T4
M?^Z'XX*OM>.T'8$KJ+D=@K04"9XT)]QLL@P:QH[D1$DPY!9'Q #+O4'74^O[
M3*3INP(H<!,]N>B0JJISZ7K5A ASZ:36W_8.M=I5[1[A39^;.;]_6YS=OC*$
M_]&!N.UO\SP3SU2Z#A14CJ7CFR(#>N?S;["(PLV1]INR*AH/%CSX_,/7XTYE
M?/LP$S=S_?Z^/Q]&>KH_U-W1*7>K-=S/\(AA#%#SK*]5 (HVP%_/JW0"F^$<
M1?MRC6#X:6B:6CT1-_XJ.-(#'<9'J%N-UX)5S\.+W8]?U*ELI_)F8O(,K0:1
M5BV#C'K37!FOF!W;_IIIG<:L T4I?&F23@6TH2,'FQP\AZW1 [(JQQE*4_D&
ML8[?''J6[HYIT-F/AOC]HG>584M?GGL=#:G<G_O6F;FR-W>)OI9(T@>S>6>X
MTB0",&2):,/*,BXC.*CC ^A % LE2SH,2:]>) \M^\J8C4F!RW?H"(X7\<OK
M9<PZ("&>A!N_H<1'W2IZQ0"0\W=,@@GV \AQ?"WGDR1-TY3$"@T/DB^(C:.C
M25N@T*?D+NR+S<\!U&M$S>-D_CP'WX'9"G#;42,:?'JZ+J!,16#,@ZC;Z,;$
M(AN);=PF(06=H;+"7Q.82]IJ@&LEO]GWBU5_MEV_ACOYU05([VO_NX#NTW8'
MSES<FEI4<BQ?3^'0J\';BDLA]7J,[5:]=R_-NUXMX3L+/HID.'PB'F$=O_-M
MB;X@\/R^<IG%BG:Z6Q;O:7NJDL*=7.*?OZGXJZN$*7FDV-64?3NWUZ5=I$DR
M6\O#Z)"LP>PTM+3NO3*B$HLJCU&6!)SYQ 6:%I'0IHZI#2V -*P3SOAHH^0P
MDI@OK03%M@UG<QQO\@P//GX:Y$E_7EIP+_CS@30S7 )5 8]O!/Z PD$ID>(:
MAF 8;-^ZX;5(/U0U,-OS?J_7U%!#6GRVK<5H2G=1>&1P<"DSTD\Y>UG-#/ T
M8O<H8F<1+-3(028#3H8+C]5!_JLV7*'-6@D907Z#W4+Q2X.38JH'FMQ%!Z'<
M<$%HJJ\AU 9VM"'DF_!\K^TDGZAQ?!Q=N9]T&$AHS3<#-W6G\;U&'*SF(TY6
MSAK/IM1%=> XR]9])*G57T=(.]:*4*:HI#'+/NPYR@?$2:B@D)C;9B]H]ALO
M?3U_>UE;#VH!CXN48MKJP .!])U0QXUSO$324:20O*N1O1!3?O*36<B%D.@_
M->G;&MKK]UI'&AR*V9I2*NL2M^4)7]/'_6SKJKZC7#_%O<3)[DJ9 PHGQ_KH
MY*5@?#G..B6Z9M^?[H/N*PJWB^Z\\<,?*->_V%V)5KFL>A6\_\3-J>WHYY<?
M]TPYT^)8?PF7V92+B*3\75 ,:,[')YC,V9R1V$X+)4ZD!&6 KAK4C22KWEJX
M]!AQN V$<,> ]3:5D'.W5CBK2Q8@UBV[LB<R6I;R%<VCJPE?<VZ\33,?$BE
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MDJBL,OZMW06?38.*0D\W]:SO3Z\D38(*X%B3<@*SE%/#/LS( /=\8@PPSPS
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MRYU]Q_6 .,\)?L5EYFE_EP^KY]8L'7O/O:K)'>SF;UT(,' \>0C8"NZN8R&
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M\@TO5?")Q2:%X+NAPUZ11;MIQZ[H'O64\BH\D[RO5N:9MRW<C MIEH.I8BR
M!1Z*,3DYH"+[(B.Y:)*7G34I#QB@=&+9KJ5MA49%?LLSE -L[_R/C>_"'))S
M+CX?L1B8+\UGG<X^U!8@?F-9[ %I-TP#'),Y4<VIQ 7@?\%<Y&F.B+G!P1OH
MTKLG"R@_OG_;V@RO^H)O/WUDI3F!RCG)G*8&GU9K'DT:?L#)*NK1>G9;+V=P
M!,'+<WS,I$^*+>$_A3!YJ=[]]V G90<HC8$  8PZ<#=#APR/L;P34( 71.M,
M8HFTN*">JVT2&7$U4?5#9:5!=RQ*VE\/!PM7/IP9GA'&>4=;TH24@@AT7NE*
MMR/P\+H:M1#(L&"Z ?DLP8^  #,;Z.1"^!RJB4FY0D )C2#J&X"B<N"_5E:E
MH 1F;DL$)Q^J3EM4"5BL.25AZNSUVK;_\-J-D]0&4BR:*+&B*M%*U7#V4KK\
M<*:;3P)]SD*_9:30 A0&;IUJGO S:"HXU[*_NZ30*LUO?Y'Q\OD5]838BHV=
M?)[PJE=X@82NR?OYV8,E>^UG+Q6;'B6:%*  2YIROEC2\XH/D86VH4GBBJD%
M+D&SXQ=.RS+Q/ZY?X>CG"=$4\28I[$>HI($EC4<Z^A95M*8 <^.#)GXOL!,!
M]#UCVP-Q$VK\M8V3I&W^'@+#DR]Q@(F!7>"MY[ZW:T>-V]->;(3HE"B9,,E4
MTBB!F<"IQNYA^W%>-&UEGP1&&$@DG=E()?*QY0"=R4;L2$O8=",]H0/)U_0+
MH,%, 5(9 A<&)^AI4;GY1>A>*IZM+/)H_*/9I='A')]:Q]ME!]HI'T;>-JI-
MJN!;!+;/X*JQ^?2Q5K@X+X@^8H>^8!_O7TO2H#9./ZFO6<V\A?:R8!S2:RO+
MUH,SW>Q,L0:]"[NN/XO=Y:(<UNWJJGOE#EH\)T%?TZ;BMD_2&XT#SZH.[HY,
M3;ET5&/Y0,WR*9GC+5,.#$UU76W7[('"I!X_NVQJ!%,C758LX]*-6Y%YZ78.
MQSR5)I0&"ZTT7]@08]XI>0Y#^6,>?A_<;$#MI57IG0H#,)/JG;.#S5-!LV<.
MM+&<% ^ZD042(ZD&7<2JLH3\Y+S=[QW\A\DC;VU:#4R.UB<YA:+>PO?[C2L#
M(G37-CW._&CR&QHRDK(/8UCF)Z8D\1DY.]H;L1I@:MOXRLDK6CYS=GG:=\HI
M+_[$8K.L<0O>^9F#O<-9WN^>XB>*Q2]:BE^\W0/Y\7,QT (IXA%8XE)SSM N
MR;Q&0<)ON%"\I]/0V=AE]XL2$\7NL[6PKD1Y\R3%FUE%BD%%+0[22[87XA.R
MWJ0V9-X,20T)JWME8RSRX,4?%]D9W;QP=N''$]4POW(J2-=(DFP7.J*==!^V
MJU]%,QS^=D1"#4_$!*#*VXJ!JZX,S;J!2A\9P>%Y6,>)H8NN5\2>W^Q[)Q]]
M:#^)J87L(OS82K=GK1PD(VOPB=@],R2( 9RA_:5Z#"G)*Z9,BS&_#AFHWY1G
MP&IH!Y&68$\5O9THF/R[[YZ^+Y*-*Y+1_,*7M+[0 K?=U)U:".1W>5C)A028
MK=@F'[5E@NM5CBWM#M<F>T.N6XJL56PBHK30RQDB*\"M:#+M%9ZE)M&8KA@:
M=!QW5>\1JJRSH;],2NWDBY?L$L+H[,:1$2W2$2%PUVE&8[OI@A%+\06O!G0
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M '@$?&-JCG,:AOCY E ZE93$8S@(5TD ^;%*N)5J8C&<)H\7XT+ZLGX\-%1
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M;2?&+*EA\I\Z^:_S*P>V/1V?3=]\\'CX2UDZ=3)N43?=73&P3(J\55%+L=1
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M.M):+S$SSO\RP;%R4/-[6<TY56) N<JH;@[A"Y$+N8:/;((.8 T\V/R<M(N
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MGA".&T=.*_&1<<M;*WDU%HL+L5CT@S)DP3V$38>3&<UJ#-/EQW7&P@X_VM=
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MV"I 99 'Q25=<U1M73;R4GDM@)B(Z_W&_[/M!.\2&W$?ZB*",GW\:H$X ._
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MOE'^ZG9@=9.4M>G)S\.8<7Q8TYV2INX<7Z*$/D^?@2,HX?'+EB",":<K ^/
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M6<=@ZP:X<D%[>)#OW>E^R"W:)@&^=M9GG =!T9>_&7TJ:5<&E9^-[0!]RP+
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MR2J/?W3M^:?)<?< SA" U;J4\Y^3YV('-K',>6[6  :PHT#YE]KW#,(;D8)
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M(<;3;2H33D/N.@B7G5J;<Z#+*SD8%(<5'Y!MYV<?,V0LTZP+(G?AJIU!@"^
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MQ;,19EQ^D&']FD+MX1Z"Q>/8$SM55$%>=_<6]N-1H)8'23"C@.[_5#;[*SK
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M$+-[E ?Q\34,?SR);J:&UI[7U&CXEJP??S^[>JG[],-/76%E$V7]'7=/<_F
M<3J\"_>S#GSW^'+[83HBO0&1)+=K,$:>?1J(I=>[M#$D[W /HY'VPSJ:^Y:,
MY%Z.:*=#EW]W=T9GFHP:GJE8F)B+?>(_<:L:;_7+Z&7=NRZA'>@ RK1^M8!8
M3K!UN_RN^)ZA4I3T7F2FN$"]O6*?1;!SBW#QZ<LJJKH'IV]D.YM6%1>=)..$
MGVM7CI5K%)7M,](5O5/NF,!7) .X7(PEB"V="Q)T#2OOC \7PR-N!N-U+4YR
MR\$H\&?-I/\9=X3Y*"J4+=I'P]\>ZYX(S+W'A6(N@/T: +GF?HPZ0W+V6V>Z
MK#OPBDJ,A<=H^N>A$MF[PBK1P6R#I\X# 94 SFW04"MZSX.J)5="PD:U1?<,
M.>]Z5JZ6Q2>/$YSX=DW =5A6L!O[BY%Z@#ZJB_@+>R]PAX*- ^%:PCA53\=1
MQ\@!K&KICG91!J>[N'0A!G9>)PV+'#$$J1@_,EZ'* :8]G@,?@OM6[TY'7I6
M'D\A)N@XG+;KN?Q%JEH%L:J=VR8@KMIK[7REV+I*2\_O8J5=3B&VZJ*]MZY'
MWB.$2*OEDR53M*&"M[FN'DAM\?!;87[OM6QJ/L];H/V7VO3][8I7U%MJGS[K
M)VT;_1V4/01C'I3IR A?F:O%B;!_!71HCU9;?0AL/89U)GVR6[^FE(J%H%DD
MQ^6P"G1(=Q&4$91@>(C:9J3<O(8R9SCB2OV+^,>D)N8TY<FYF:;R,<JS/:^)
MDI@@(B.(J50]^VT/8$892T"FMBNQ+P*9-7T47")J?ZN.4G%@J=_FM,*H9B@'
M99>WZ3$&O[8.%T)'D;:/-5.1PDMCZ@%E?KI'I<L/+R;&>\C9=W!BQ$,D8QLY
M]3TONIIUK+5L<L2MWH?)>%KCX&=<WHO@#^D_L)W#)7L<MNOBF(9^_Y*"!!#C
MC)OFQA,6UC9D/95S!9>6K-Z>RY(_;6US,3-]P^K''C\+2UK'SA;BUL^W:V I
M#P"0P_>7Q1AP>V%TJYE]RS,-NV= -N&'D$3;D6?VP[%7I^1IRO&&EG0[JM!H
M:>G2YL[JZY%%(C\X-/N:&3*NM[*#=Q.36\UBIH]825!'#4I+4@(";TYW;A%"
M)X,D %&6K"_(I%?2&"S:?)>L.EFR2/?*H.$NEA9@>6%TDK18@3D[;*0"!%%,
M>M)T6*%.^<[TC9[[K;\:BE/:-'-7]&O**3,RETZ^H#/0[/(;L 2;0E_3B"XG
MTR:[1%M\:FR\_WB7:];SAH7>T.(!-9LR-:!,4=Q,B#7Y_JOZ2+HLD$,QO7G?
MQLJA+,\IN/Q.P\+'7E6;\J1RU^/E1N='LITO=DX^&B5[9%RL>\"B_1V-*2^A
M0-BMD&;3DSRT.47(E7F6,_?C+LJ>,@3IVP0?LQZ 50+YX'?C1*G9U4]^!^XO
M4P8ZJ@5?;^?>V4#\C$:0;S5O6^/P; N&!XZ*E%W<-BVOZ*@ HJ]?R^G[GCTB
M86ZK>H&A,*1PLD%I"A^O&)H<WGS"(G#:M_,-<\[EPOYN>8U7NLW%N6BWUX]R
M#4KC!_S.:2\XXO6!)1&'9Y>]5#]4'K1S\/_(S)JMB-KG;7CLF'"!HA-TMPX6
M :,FRGQY+U*=_&;)VD']8X'O;VI]GT9)%L+5%B'/G@U64&Q:8B;Y[$3C"R@V
M=F0K$G)%_8=Q3^5?T2_#!0*2>WA@-W:@=8P'$02ODULQT>/S6/)E&G)K*QMT
M>V!:-_0-OM0[\\GG[Y"5B(]F[+-%(%O&11"XD@2NSW?V3FW2>UW=N+4UD!F3
M=B:X\-.HD6SB\X&_'+^!M9)T(-80Y-%&:R@V',4>^+*U4Z94)"4-,3_G!#Y_
MXPL/@FPE5JIC/7%TSLX2'N< / 4&7(F1P*Z!B>R?N^#$F#>!,?:@U;G1<T3
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MS?TGC-/LC"2 ZFJ7#+E53D7N6]ZV;GMLX/>5@:I8EG*8FB[H[CW_Q_T5P8S
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M"IK</7^0;2W/KS9(<JJ\5U#Q(>>H5GR$77YX2O7!;AVI\ QS@P3)Q!,R0@+
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M"T$+^E( ]0+\";T8AJEQ@Y6#$["\CVX=H6X?@?-CV$6M=@J8+") O6N@F,Z
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M(4K,E"X"FR#^$T )\K5Y7O<L35-)J+4BY/*P1M=LUB%;'&U/SZ,7HDA^@P/
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MUT4.A='M>B;:1MWEHQW)J1YICTA'7Q^,BN19\#-@%3P&1">9[OI*E((WX,^
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M2\.*3/@6HPYI2RK\\>S-X*7=9#<SL9LGDVK8<@%&>2:'3[U;'/*2:AE_EG;
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MLLX=3B#D#]X?"$"#]QHWU(TFB'O3>9BGIVP*(=,;[L%A(A:P0?ZAW!M%Z1^
M0WSGMQI=+ .3?)S")P_'?(GRW4\.K8]M=")E6$HK9!:Y?=#;<@WK2-9N_T1_
M[S=N%'6&WKNW=Z^!MY&N.=LBS*Y.[."%RM83S3TQ^T(O+X*X]ZXZA<<'I[I2
M-3*J2D6%E>RRQ!O['F:S]O.BUEB=*^EN[<H[V+XX:(WL/76\*/9R@JGF)YXH
M\NLL_!&CV* .DE@3S9CHZ_%I/"6V'O-U>7(15,#LJ]U]I[A-A%PIDC=;FMY\
M,1BF[0J)S%<ZNG$@XKQ;6T$4'0TZ 2D"5)5]7 T%#1'@36QV13-CRTXD:9UK
M&\9 B3[LM6^NN]X$NYN'C=*'6Y&DIRXAG:79/IT:WG1]EI/W8,HCC1BLDQL1
M":SU$!>=0-.RH[6 \T11GAF_3!OP'W*#-Q-'[)48\"=,C5U)@3]RL]KX5ELA
M9E;!B.><_(=0D5 JLTR\IITFSJ I%W&&K)3-PLZ*_N9JM?/8)WA>@&H\$>:)
M34:#%L2$@0FJMAAK=W4A](I);!1Q:[JN0V&67<<F9AN;,+::;OO<3Q"'+@[8
MLS;R+)6)<B_H0=^T1;[(JH=K=SUY:SU]%YP0\UE9WC)"%VV-N.1_;V3^LSG>
MC':Y9LI2 73@+%8R!C._-^NE6B]MGSS1Y&#OD5%\Q-Q2BY(0PKMFUGRRC6@M
MG^:9-1JR[;#"OK=7)&.>76FQ=2BY!;>1'&.-7IP@&7@\WUU"J7?<WT <HE2A
M9T78P9QD,#X1;\L.Y+@@44F=X6\\ED]\@ MA62;P]%B'!"C9R>7KML\?F5@]
ML6>FGZFM3+L1WSTP/*/]-E\6OVZ[6#8B2TB#>!,(  8*.+'\+$^F;X*I?"#Q
M)Q)[WAVJ:U96ZS*P562)5%"#MQ'60<43%L]KGE7GV@89E(>6G1L?'F=-V=Q0
MLEKWODP\?(F03!3&7"+(0?$C477< W /5HR\$:_]D:<T IFJXDW90*.()FMW
M_:@P-\AB>,$UUXY]H.!&8!BSM@'L&]I\"/<@Q!]7]C1Z/*^$]SL>"=MME%@R
M"A*@N/9X<0@856$;ZT+J=;,TKDED;(,JR_LI%J_+?]H@%#@R+2;I<23P27G!
MC0(_+[6:[J5(W>:-Z7Z<5<JG;SM>GNBR-KFDS&R(QKBWF<R_UU%1LA>SW$-E
M7KE7G&:>5N3:H&XFKT7-.AB;DJ6\%SOK'FM\I4*]OBO#OWGI171"]>?$,5&I
MA6VV6Y2LEZH#/J4HNZO[XN2.QA33A+8)9SPUV79%XJD U0\::%BG^!>'>1O]
MSJ^#Y)'0U02ILX.9<[.WV2'-V$T-D> "LV(&>(*[<:K'H-[@L%J+0D5SF4JK
MZ0XZ_M (ER \Z7K9GW(FM[G.XT+6:L"41V+5_!+7Z)*!7)#V-UW-0<H%!J2N
MEARUE^<%6C:A4["5AK,[N'L_\SP_AA'%><KLNK2+-8 L;FWK<P^9>\KU$3Y%
MN-Q&6IC/R-"%(!E<<&DH_\JMT_JW!X0?OWQ1G38]G\P,?@-LY:UGM_&D!YEN
ML10?&]K G:8H>0C#W0HITT:B*OG53"7=4;68&K'8ONOV:;,\)18NU 9: B2_
MBIL]Q27;QA^5" B9YCQK# PA3>]W-[@J0#V['_TSOYKBVR$$;^H4XDEAJ(RU
M.DL8<<SL%01L%W]LL \"T<R*6W>H RDYH5[RO28^F^W%4DKQEAK^+T7(N0:S
MO9^?OV,,&,HL*Z13:M.87M(E<;3IL7OX(D=2-K,2VN*ELK?,Y(!HII=,>XB?
M4XFK7']?T[D2[RO2&<H^V><NNV=,;'NU'KO>*]:?VOJ&C9'J;C[O'*(5&M!;
M1&@>N0*=.O!3RCZYXIH7Q+WO2(Z9&G?W.+:<]3\SZ1#B'G4VKM4'C*F$WLD-
M&$RV8I%\7(823$E";S3=@X\ 95YSM<K@1%!MY%HU]Q<&5&<+33"?9#<3MZ1S
MVSS48GR?@9^'M]J4B(GC"K"@\L.SX8^\L%6X:WWS- ?B"8KE5GUT-84G-=<(
MU 2WSD5CUC?H@J^:7_K06L3Z.7.CNHDFEC=8(CHL&C,[I>95R_,^\N; OJWN
M9:T/1T5D=MMT'%T=" P\%C11NYMNB%+K)DICSF-B,7(F5NSH%E/->G:,,:EU
MKI_3S@E@_]99^TE+^R$4?K8<HC3OM7](W9T;&CHG"?CA!MW%2MZJ?M:^]-PA
M,D;Q6@2.$H-])C:S!!YB/2;*F2K[PWNZ>.Z8U*B]N'F6T=*G\M ;J<&CEVZ#
M I0%&^_X28#RM53C^#Q&B^K?((I^L@S;=MV64\A2S*.KN6@*-;5)-U:W!UJ4
M>WIE^3W3.7C][O6[C#-L2C\[J<C+@+UT!SNP__[HS*A"P/WMA59-CLG<B+.X
M)OE,><?W?B[MIB])"22O?!&WU6SZYSQCG;0-F3EO+/;BY\.V31@J-+!3L@>E
M',SQ[IP=YE(GUGP_L&]]>5+M\*;3;"JG@U_.\V8#3 8!EL)Y4Z<+/N'TOP[K
M-[ O*K1QXN,-*B1L(D+&)O-E^[3(+?NG?A.^P/7-/WXU\4S*.EV^/_V+4 N0
MC%E+5N:=9/=%L]&<!^!<$V5K!^MTH!M6&"*PLG]M4 4VW .*A\LR9\F9+,6S
M42_#.F\Q@W30[]. G2YI;ON>FY9$5]^?WM$Q?&C'DZE1F.01O[.IU/>;AO.C
M*<JY44WW)N'\X5D>+8?5D+N;=I7XU+=6VD2H[ZG;.*ZBV.OUGMY4U=GZ@H8
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MV=CV;U4]1X(IDX5X6T3C?3<%J/>OT> M!M!I#>4B&V(9(NU[UQ>,2 *4Z9@
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M4DM;4IL$?BNOA;_R,'?+;4X)4(Y1\2N;-]V@<$,$*&O?;L8&RI>\2>(2W56
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M&#_6F',: WZ<>IXN9YG6@8X&\:64Z@/.LJ:><8$A4,D-9B+:":K X=;)#=5
M!RM'N86ZO;Z!ZURHW#:V>)?B<:FCF;JS,G)TE]E*--[P2^X>81[5 G<2\&41
M[_(FX<06]";1.F!MY;BPJ,&(D\]&Q(4PI.DRQ2SB6.94S8(;%\Y<H:?&4G6Y
M9X?FKS6LXQ+L*$#P#N"Q5V%998"P./]K<O%$0=OKY05AH:6.38R\9/S-HL=]
M4>>X-SJ_]I'.#]"=,C2R2"DAI(3BS3UKWZ"*T5$DE<-D%3'D_ 'D"-^,9Q11
M#9>/=2!EG'_RY$!:AV.Q8V9EZP?%KT>G\AVWNSJ%3D(5H]KL#Z2[G,W\T4L=
M7Q?[\/BI-!W%\@2;RIRG3,5[SM[1SAODH(K4-:G]S$2$/#@+OR=VW?YQ'"U-
M?[D%YW5-WW#.[@]LY(JEFT?UI%(CWZ5_:<&+[#+I7SV<X7>U^+HOX0MF*K-U
M8OT9()';C^9T+]AQ3OUHHLDA_";09X%4OB56M_4GY[V"3H;)"(PX]79H&0#%
M,HG#2P,=)XE-M*KA)D:BRIX)@-:&V-RPGNF3VB8R?#6XZ&,;Z-1J_ 4?#H2R
MT3$BW6$+27Q7)D/. @KXTHF@"BXMCGV'JPN.-Q#IGI* WQ0CB5;5G8)#<9$M
M8:8+#3=S3)A<3F,-/37F )WY&V\X5]FV$[EU=(QNDG:=][I2?C\8-*)JVW.5
M% *&;Y#CTD_WN$@YPY7W]Q1G.A2?.J?KA2?;1+OTM[&\3;>GG\C0:-QROEN(
MHK<;$ICV3UY>\G%.WOPN1L-P@D#V.O#:I:51KYUB6D&VE5WXZOS\J]>-/A)*
M9FZ0?*+*#[_WK]_8.O>#'PU_VE#_XN.;N]"<0?R5\V_/3]]5&YJ)%I@48;M;
M<U4XF;%Z:0[##1XL=?F6L8T/%M#5<_A=@_HA@3K]^*$1[0'XSFA&0+C7XX2<
MYZAO*_.+7,9485&^P+>'*MWQS ^_#[!G;+78@N]2=AU>D.;\X)WB+F?.CS\G
MM#@4X=R!#B8L$2$GD&=+;^IG*;<M)H8IX8T <H%?D1?[K=FNDB]92M'AQLE/
M/6<S$4>!,%9-"RP.P3D?"&/'Y)G0T9L%1P&?HFZNKL=P"%'9('^*$9>K)R3B
M%1@!LD QDJO1. 7FV'M:<S6!1JY$R]B9KX%F4.9C,P>6AZOM!,S:=V!W5B"S
M]='L0)=?0Z;LB:.WW.+:VPO.G#1-]W>.487&MS!)D5'>GD^X!\IFVU$/-;0E
M$_)LSN=;.V,[8V^<C4$9/>DI^R'5(1V9;HJ]_7#6J<#LY#7C/;)2UZ9U%/?$
MYFP>"'J516?=H+QL3WIY1^N[>O>\-7>-P:O,Y&FC9;"WY]A=-7$7.0L3T;DT
MJ4F95^$X<PRK=KFS6]G\X5DW (WD" =N9^276E^2FS3"9DP&W%<X1(Y&>,/C
M+33[R#C+$H#!PP$7F.E (AL:K;&#BVA').7"@(AG.&ON\-W0S8:T[7XTZ<+&
M5PWU7(WL/+3'+ <-9'SM/LT9K,I*?FBB4F4B9RV%+D-L)5Q%1VEL!_Z:0H]Y
MH\%4ZBX%EH1005QF2... ]F$8%:$C-OBQEE:9693<6$CX(/7JM4G"<X!*^!D
M\F5^SJ*JODX"'O";1%M>QUUH)"8(WHK<A$\,"P8LE'%[.,,)9N'\W:)>V"M2
MXC>)% LS'$)88+$'@#.AK=VC=UBHN.5=/MR,%6:;@+JOS^*07UB-Z=[T0B#S
M#ZX$W0VS'1O&TENX:$3<8%R\H7IANFS/A\:'!:X*!XJAT>]FAYZ4#WKK.1^E
M'TP)5),J/A^C\H2=T-R7=X_N[=^7?+7H)LO7S%ZQ TPR4:\P =M[<W!G*K8_
M>1?BI6:G5/Y:T4E?]#;#V-"O6]Y1CGYI!JT:W]Q7I",W/4,_=<3=AI!!D\6K
M8>E,[52<!Z>#91)[A4-+:=A2Y@&$M9EN[!]S[R3Y9]S9T7>L<T?9-?C\MYT/
M)"<0#N6UM14#UPP"R=>^[:W)/:J:])TMAN2"' %'!E 17!OX^G&!/9 <R*&[
M#POL..^&.SQUJX @%EQQ"ZJU;N9N8&CG.$'"/^OKA[_.U!7,Q.;W?ZZW]HH\
MF9Y :=BPW2F*W$#_4'#&?,M@79&I(<EIQ2F/_]8ID?A-Q[[ 1F-9# DV3=>V
M>2?W9%I9F[/,M%><.Y'E^4'QY2GBHI=G3])8[.)LRQ-=5QU$8[3IC:+KV!99
M__VY[H0?78C%=#%DJ]EKD'UE$1BZ(H4UW0#JXM^*)8.2_ZU^T3<3)OB!Y$\3
M6E(-$*N?B2OOQ)!HBP0#/NUG$63SO]5,[ICN$$/,^D6K:$Y^9ZHHG"3\3F,B
MGR7^6V\W_JU2,R8\""1.(-NCH@3[_H.2G+X\6ZS_6\FGDD<F." I*O.?"+BO
M_IL8\K-@<N.OY/NF_>O[I@[#@+TP@<)B*Z,"$Y\'!')W!Z+:T)6P! KZV(5>
MKQ]P"B%ZK'$IH4;#A'.R_J!OY2U=>$+#?EG;B"L; BV1+J%OSI,)E-2M0#%=
MXQBG_1X;O3%@#94@@+$:=?K=.</Q(<=>+U8E8TY3DVP#"%ZALKJ:COMUN.76
M"R3KP+)+,9]W7$+^<.>@(P5N7%@;59VC?+?AV$N@IAVO/Q@8@I#&!EA2[DR@
M7 8QZ,M*U>7:@JT79M+SJZNJ4P**B_*J8RXX\6O!U-]/U"XR$"8@?&W1L19F
MP/V76'J[AN9@:E+#2>8(96\C!T:/<!2-.LZU4'^+'P[+K)<'B,[)??V>P[)D
MO=*=-<E7ZD4AW.Q=;PZ0H4]Z6YV:9QZ--5#*%9A=P@(;4Z3ZD1,,5/') I5'
M\09GG/QEEI]] GEAPX[N2H%-ZV5*^7+08PV9M'2U"&N0OUTY?^M&4_M-]()"
M\=YI)%2Y.]JZRS7JX9XU^9,*J"GM1>8_X5:_Y%MIORBBO$YBH%<R5Q-:. S!
MW7D: ^2H??RL6,%I4!$D4?J9 HZMP$%0&-A[4O%R]#_9+.^7+_5LX9 8TF.G
M\&_\U7#=(( 6G23*B"$CDF#O_1&-"MB_:U#\/D-6SWPF2%J4([QI*P._</VY
M=-M&HR(@X.\6RJVY_OO*M.^_)>PK_J?UI/_Y.!Z4Z]\=U[.AD2&L_7G<SNSB
M??1W^R7DVEPQ879RK?$4S3"-IT-D 8AM\KPF80U5L>SUA_PFFH3HR"P5"H0_
M XU3[Q?>8W8L:"KP2B"";SE/&+N=*SS%7G!MG!:R5FUO[$H60S@+<^2UT\H"
MA6(Q1 YM]?/$P/_,5=40S;"WL()SJ,]DP;';<Z('&\60C3H@=\OL!8GF*/A'
M9K).#'E^C]!L0^-J+1%$MT(W$O^EWX>L6SM_$N\/TLZ:,MKL3C3'D2RPCH")
M(3DYL%_(]_N_)LW_Z?W_N][1;R4$"C.B+;[<%=X[(5G@S0UCDI*H<E\T5#U4
MD9RP$1RF!%M(OR#JXWRCL*PQOM\-,5OF;A$N/?3_4])/^LOC!-O/Q[>=A_,#
M_OX&J2#,5IEL\N@/)I1.B-/0X=2T0@$=JX74J<!;XVZ#!ILR66+(N&V3I_+P
MWO(,T5=5.QL[Q 6.1\%H3:/QCU74B74;%A2>[<7H<Y<^:K<>)4I]?O7^^V.'
M%/C7]/)ALHU1WGSQN?S]9=:&M=DD58N$M6-$>-OH*>N<:9AC]YS.=FAI3QE)
MS_V&[9P"V]4P?^$YBY+TU<*6/T2SY#Y# "8=O):'JXG<8[P;TC6JV:V,;>L#
MWQP+@\9N8&L?"Q[P5=POAMR_@[AVPA(6#_+!()\/0R!GC+29*8,*=).2IGS5
M@[KP;>,"4^$CGH#!<2&,Q1SN1H[_8)Y(ZZ_@Y*WO+\1J+'N+%(?GZ6*(=:+P
M!8V+$,F+(3^TT 6$UDOLU-75S)]G>&Y%3(A6R$O+ IIH%R.:L72P< &S^F(?
M)G\.-;.R?(N0["V2_BHLIZ_FLPCS'U]%/K?)!<5X4.2X]= [FLR&A#=-APZ5
M7[ZXX_1.V25$6RJ@N2A0M&038TH;=G%]><\!638<VE;L@HU<^S#C.+B4393'
MIMKTPT[U"6S9C6@Z;5-(1  +'F\X81"0:(Y <[_EL^P\/^@65]<TI+C5QVL*
MI<%$(I1_ '2:E\00?[@ "9(A,43PU@$,^7,\+]#B;:(!-$ 40[: 0'M0HH.M
M;%=\V5/JFHMTK=Y1ZS5W_ETY18<YC?#MUE'4[C)US-0+SS%1-G#QJ-_CCY-@
M-JJ$ONC]H&V3LNO4D81S0);"[*4]DM]/-1Y!G2W)ZS(X[WC(X7-.9L,B,,#@
M8) +4>]DJ7M%74GWMY_BPEM_RU>3V@]<_[UI*JC#7U4D/2LL?[*1$$^K]'[Y
M/:_!EKON[LZ+VZ#TFYLDU&Z11]$ "ET)%>Z%\T#?"Y)- !S+^W08IXQV!;9V
M!KUP\F_+?G_NE/M89P+;T6&*_P'_>2:J J%>N#AGOP9F0ML66\20M>W]8+.1
M-!2^=D=X86686T2;FB2.;TFHQ-D)LW>D?5/Z*1I*V(=7?= H<2;DZ=^*@ZIW
M.#MQ37C7=#J"]W--6G\K&9700S#=II[<O1G^9A/-A\#TP+]'+#VBC26*(2!2
MF @QY- Y0DN=\!%A]B"!HBS2%D-:"*+++SP/<C\0&SK7".\WPL \Z\XP9['H
M_Q(-'%I,;*;07%3"GP/ ",K!H!9B=_Z&C&=4>M^]N1[(9JV'1/R.B?GD._GP
MIV"$ZCU2)J V1BEW=][%(;F0N\??'$'('/SS]YT\LP1AVK]F_WS1'IC:+/\]
MC21H<A MKM"82_]4N$&P?1D_<D%;I(29'WW0_!;L.INUR38EA< :_TY?+SW@
M?=^2T-R(J)9_5?\WU0Y_J\1F=DQG2NP)@,5\2M+ FH?_:V953L(%DQ8/?2/^
M6&?%ITTNBW)) DN:I!CRQ1M)$@P8FM%F%Y=]&>AV!A!;SVL'\ZH\O@EH"P>N
M!.AUVV!<:-@"&)1/6O(PH#'R65 QY%C"SX?D_XJ.\OXKM@S^'5OHV:^$UF,<
MFB@&3+JYN_)^;AY.*+98$QF# S)G5)L(%:&C8-ZR-34.(?BV3PR)NT.[AEG3
M@5421(JP;835CZCY3($N>316E*;,=R"P" (0*Y]M4G^I&<EVBZ/]*X_#D*MW
M\X6,Q=O@S9Q^.A\Q9.D@J5_DKZ*!7EI9&Z;2DFF_'"Z"I;$XKBI*B)UG@..V
M:H6)PA1_/KC_-1Q^X0%/<%-30H2?/?I%%\&QA/$G:?T#X)C"F 2A%,@T6):6
MG:)<,<0Y8ED0^(NQ@EK=MH(?82R=0USYN76KQ4ZPT]?D4?C_)!R \?2_JJ!R
MD<S&""PG^-Z$WK/";/#:%S]/8OW 2OTE./!O?S59_PDTSC9XLW,0X?\I!B!8
MZ@!:#+%4(0!_]OS<[YTVU/B_J@H>@O.25GUP)Z&E5YB]NI/PII<K01/V)PC_
M^B<#=LID@DBH);"#")1MJ[%[>*!T9Z!H-/#'?_-G=?_NS]9N$[DR/Q=2Y25;
M$'^<_7==C(*<XC+HLXP:9/F*@/-<A\5^XBGNS,(.ED/1K,IBBAXSRT.^N4[3
M),W5FHF.)8X9#PV7NZ%+)(UI+-U$6W.4ZQ4W6>G<3 B%N'R+IE:%C$57FO#P
M>\%NF_$#QBGPY=]WH\=GF&=VDGC1'9G&'9P,EJ]=Y0Z+^0)!6TNY8O&O04[N
M/GR&;=@=1*D\TU=ZQOFP7'^1H_W!I$LE>3;I^PI4#/VT.^T?RB4YCF?9T7I>
MO?RH]=?%%]./G;W2F.78D(%=:AU;]MO;?PA].9 >9DIYV3E9Y!CX#FDGEX2:
M:U-<A?X+$\M=F2C@1UCT??_^0U26:LF_HPFJL/V\&!*K!LL46HA*9PG#";K?
M8;^ZUNH7_B.Q6Q1!)?J%AX>+(:CCPL8'A!XVF%/24Z"=(B+8YHI>9B4(8O\U
M[_?L;]NQD,8\/3T)@ST$S&7BTI%W- X;A-4T8Y"8+H9X[B._(?P+2(8C5GEK
M$073TS-"#PD>SQJ<0DF@J62.(.!K$3/ [?_7I'P'DQ$H 1)L:8P=ISN*-E5*
MI# 2S*Q+/DJ:P^B3&L)ZBQUSII.EMQP^N=F9V/0+=@3=B0AYD_(6$["A\LBI
ML5C%>2*G&458PB,XCDB!=2FH])QDW>[58^!@1)AO/X[=&/FX]Y!<T?U6)C>$
M;6"-E/9,QYZZE52KI>/TQ%MKQRGW4M*[?DH69O&E[A0:N%A,6T/ @/W:(LU)
M,&Q_:$_]QZ:?S\2U16<::%W"2=^3 N+$K(AP?SYB^20.G/E2BF%BB!68YFP$
M@=.:W4=8'>G]=6L7XI,8\C8S<Y56_Q[^2;2(_"& >?\_D\*+H+URFT"<XL,B
M'-"_@>C:Z"&&] +@-+=&</<N$46W# F_: M&KB*^^_Q-39*KB/I^@1@B,<+_
MF@ HB[;K+(I2.T1;02#$FSP'P5V1_ZNV+ *8<*3!X3\(88_0;X63Q!G HH-Q
M#M5$^X]&:?R;46#_V*36+T(*'H<3LOD-+2+DMR4Q!-',LQ @J;1%^ _%:"9M
M==TH@18AAA2L&''E\,VH.YFBPYVBK:<MO-X("Y>>+,.6SP2H_BZ\7S;=.P]J
M,P9T?9%_GLQHT'!'5'W(J-CO-AZM=4YP^)*)=W!PIY+9;Y#8_?S3?.(E@E]8
M :$>[:9 K-6'M<GD#- ,&E-[5?Y'=4_^#^-^;/*=$$9:%4$K5@85.7#!@?,,
M(2Q5H #^4 X#JFK&V^I7;6"6 G[:ZXG^+%H\0$OC-R*Z.1&IU!?D>P1F9!D8
M002$J>=$(.TV.,F.J2!^T7:4)""N'@+]NLE*>/3_0>'_;!2N/:."_#]F:[T8
MDL\%8?6 P+*;10CFK_ZR\3/Q.^%39Z> ,?%9^7]'//RWQ=F_-$H!K-QC[ EH
M<"QHU],?UJO!Q@)LFIO,U'"')"3R=J@Y_++3I;2_V[?K)5ZZ*@"S&>L\,LGX
MF$V0_G)#-;L^U?0K^UV_OO>/;SZ;(]WB;ZVFG9:U?/.^&75D(VXRAS$!@@7,
M=6Y_Y;F&>$0@IH23E__AP)'_?G5,]/\RU3%X%WP_@^-(EA=L%A82>:Z #U\5
M%RQ\T1 >P$G[ WC[$M&BCFPY;4C>.N>Y9T!@\&IR=FUZHG3,RN^EB]MQHY&]
M$IE.50D'T/@C;DA SXK>#5PAC*6RB7%4".XRQZ05,<)O]93@=+?31AGM-$[J
M5:I%+T:T*\#5.9T9/[\<3:WK,9B'YPT44N6MM1J8(7./NEZDW)',IJ43_%-'
M]_)YKT'$-P+\9FNN$YO6%-N/F,K-51LV@W./39'C0\D;WIEY0-L:O<_T+Z7*
M^?.V:6IH<>;7GQ<-#>#4-8I('IZ=OKXWX?JX](>X+01F-X!"<&SAP/Z.^5HV
M(@J_GS.S0.3T=S"DX7@+H(XUUR$R'T#XV1G/L6B1\DT,%9PY"R&7@W(:"BF>
M4/^<O&1^Z-NW\=\/ESWWHJC,ES?S/2^T"+22FBX;3BH.O@_HO/_UBD-^7'L_
M6<HX-,NK?.2CL]9@1X2GRQ:')YS2:<#ETH%'[T_)G-?>ZOB0! QYMWX\']7A
M6^F2;F60IZ%/RAPHC6TYEZ]W"IF!:KU8_CK45F*!G9+L0E>@TN)R8<I1=/8N
M>T6=]H.QBZ@FV#B?=P]XRT4UYZ[C$@3R2%XIH,Z$*U#SA/G< )9Z1R3TOIEV
MH-\S]%=>S>T^O[J'=:EI1>X7FI^/Q>WRV_@M+_#SSJ33J-:IG\=Q8&%G!Z\+
MT'GX-PQ*;#S"1Q4&^R@X6B<L%2"F(A HX(Y&A3<+ ?R!H41SVF(*@MA*G%)R
M7(7?WI?7Y(#?G4_UR2UD- G<^.L$+L(8LV-\*YQ>-7"2;TEH=K38*W#ERF26
M81$MHG7"YP;X Q,XJ<9A(XRDYP[EUJ YZD9*SU*<WLF'C)&QTJ[Y/V=-+/[X
M2[\_KE>D",268=V:<G=R4RA\+1SHK"(3\.#TY3@>6X2A345O$%)5C.V"T\(L
M@0_;-E7NM7)I: 2S$=%L0H,*T-YFN;MK!R[Q+1*],4%FM_%1(6W*->;;KTN_
M/;BC^K"$V\XVYL7R"W?H=ZY^KHW8"I>-[^AO\ZYXR+V0<=@P[\3!@A,'NXJ8
MW%%[B0<!ZI'!I3:.';)MJX-2Q1*)^3G,H,/8DN#6ETB]#E3)"Z_OJR AL'E]
M;9.\7JFK8W'<DU=UZ9P+A8=SH1L3S^8['Q3=M3#[N1I:<)Y#YV5S&?-T3BI/
M$Q#RSP+YS)E(L_7L1=DY]&8*0D(8TV$)Q'H;328:#<;4A/G=N19C&[Z@=.%0
M99=4C-'6J.'CK&Y@'Z*#(8G;RM%N_TF _$6#MW,;6:ERV!5K+JHEP):\03M)
MI'+50BIA\@YL![;,.G07B> %O-IQ7;.7VJ&7N;D:M8F)6KD#4E%$ !_,KF^;
M"!08; L:WPL,D;PN0#,T=32;=R5&&L/3A6V[-CU$!745F]E^>U-]*:!+Q^_T
ML*1GF=,K9[>=<=:L\].46WULR:_A*V/94XP4,>0B3;:9 VU'5)FTHG\#K$X#
MM5-S!$51_ZU)'<0.H](KNNJ6G@.;*,&LKCVGABB)MF%<!6,5K2_]#]9[8V2(
MU_N,TK*XE;C8O>\.I:AWT'=F'-J>=52/._(RU30%*N\$RSS*VEVI<S3I!E+X
MTO]&032]ITC9SFGF4_)YI]%WP>_91EW! JD?+YA:L>0G3LU>LV+(9:1R;(SD
M@;-Y79GGFSJ5R-%)^3J/LI;S#7P=3GTO9*)X4G\K^ZOG3==5#^DCO%-3T)NH
M<@&>6VC<V/LB8V#&@9-;, 7=T>E-OO %,:(BW1X;KC\_]O"[;9&'E>:?6J]C
M3])0%UD[!<0%:3"LF7/1+;"QV';&JXZ6[I%L]N*".1L6*_J-@VI%R/N#9H9O
MIE!S\K 3UV-RM#YDEWBX,5HK/HY97_%9;6MK=U9H>KO*Y\EP)!;B67! $S%O
M]13_#J'8L(4CP?+,+@@PL= 9$!T0P*G<QM+AZ-A$T:[G=9H6:J_3[.O[EJU#
MCRYE XN?'42Q@8;'MT[HIN98S1/Y)P5@D(Q\)KC&^5#/OX#S!22X>UJ(%<CY
M5H8<]9"H:\V(?-\0D^AID&)G:\^5+JTRG4[)\R9=]2O:891\[(^*VH )8^NX
MC-\KRLZ;I4;3:H LE[AI%QQ9FY1]-B_#5KE5\>797(]LYJ$U%T%(^4KK0,S>
M] NO^UN\=42\H)MY]D\NLT@Y08??O X\&YZ#ZS0I>CA,?J1G8'4JW>7*#N<]
MZFX;[R=?>>&4JU%ZI BI&%6XNF??R_XGSXA?E.D(0'>X!99@0GMUH8^JA+/N
MJ4*,Q;)F6@FC<^<&S<Z-&2='<&S9P_0<TTD1(8:P+015FQ&0*(;(JM9C&Q 1
M^1[NED<>JK[0O^[]NNK^UT8DK[Z<,"[A*$S![>#\<..2DQJ,.+^QV1W)9N?]
MRJZ.H6,:]DCS:H*>8K6;79]2]6_C+-D!<[=RW[FP^1K$0OD7$QGQZJ@?]WD-
MH$(Q &I*6R OV>8)$3YYSB7'6VCAN]%RAC\?C] U#G'U^=A$%CQ9= @+\Z1P
MT4D"ZR+&F*M;PUI-G.!@8,GL7Q=F,X+V)ZB;]IP,-@L,,GD%.@FMI45Y@5LO
MX2IQ?(6%B%Y&;P'&>?W R[J.:($)2]7J_@5.;!,X:4TOXR& +[-EV.%DN()<
MEP]+WX]U8+PM!%Z*P=5*)>J&CP@JH[4>7E&S3'<L6E8SPM&U6YA!+ED5K:CW
MQ=[E0%*QLF-6Z4+^\<LC20%)NP>T4/L26CT+;C\1CN)]VPYVE>_8%.!('*XP
M/"1@R";0O6;-S*7J,K96PXQ:^HOF<_:C1"-Y4?:.]D$%637'7X;L>FL%DGV.
MLWH8DW&W@<!59?G._\4F2 %WF+0%Q>>B]]0]*L@V9"Q5GXJ,^^U] /YP'872
M-[272)_<RJG?2PLJNNX\V(/T\?[-_?=/0@+_ 'Y4M$U81-7"]VNLXQ"BEANU
M[84Y9I@\K"E<A>%OZL&[SS4==T7*6H*\WRI*&?G .K^G=!DC&>!Z#J6<9+>4
M4<@:>62_065E?@<'T3J&2! @RMRQPPZ]#0'\,W-B" 459[BZG*-?NFBQ$YO9
MG*FQ8;!*G39R%+W>+L_]O;*5%L6P 8/@!_T9?KZ1KX=O8TC0O!=,Q1!;P J1
MF-OIR%%N(<36.  DE_+!23OXE"B'98<X/NCI9@>S>8#>-A?(*D6?Y7H6'+;6
M*'[Q5K&-4I8;U_/V$YNKIHK2;1/:KH^G7UD<U=L3Q;W9W&93O7'PILL3S]W^
M(;..[>UF'VX0AQ:OODO>V^B^409>\-C+V40UMG7:>A!+.N*U)^FZ847" S2J
MI:>0Z5CJKEGP=KL][+S_]V3_>&'@2054._'BO]<U"Z @ID+Q/33.69B&ZIT_
M:J4Y_?3=LUGO=/,Q@:#J$ FJ"[_Y77PT6\J+JJX6]20__<LYV'=F%?7 TF2E
M&=UL(E ^OGQ.2*/N*GL<'!RH0)/$'58JWUEOW.L^:]5&W4VH]&PQT!=#JJZ!
M+W;?-QEB_(K[^+C'ZM%*^>;QNV((Z'A>.X$Y;Y%(^P>M+T*;&4TTH@V=(3%1
MA&^C.55U?6*(\M6)N0J.=A-M-)6EO;"+!5<#8%/O;Q/B<0>GX)+N.!27EK*,
MENK(JTYF8J3\_E0/+]5J2)E!93O5J% $KKYWYY?KP[BE[0_KDI3XI8$SKV9$
M:O@/D^9 /H?(8K3?V5[5)3\UT^2Q"]/@Q,YQ[IM\9X=TYJJ_I7!JHG&(*]+5
M^:R).Q>&8&>J&FIJZAHTMO8;':'H6_KD6P:$K<'$D U+0.\4(=)3F3L3=TU@
M/RG+F6E'CV7R3@/[@Z>@<H)3?;Z-B<ROI 3!<>Z=#I5Y?9EH'V%<G)[A/=:"
M);UGMDX]YM68PEH46?UC36[OU**"Z ->$M#GK/"<N+ 4P7X")W*<5P>8< AM
MIH4Y7,GCKVJ&0Z4-[C 2B%6^[?SZVD *2"JB'?&:;1PBL^RODKTY/L\ 8@M,
MDLE7JK\2:EOJ.-Z;[OK7PP<IF0FN'E4/9FY?G>Z_HS\XWRNX__ &1L;[^_M\
MY;CW^WM;+QTX*N ^G$[@N1SQSMU][HCOUL9GN8=B+IC8N\R?O]#BDO!GNMZQ
M#(WJO<E717*3N]W=&H>J>[_440K_8E(XHE18%*L_GZOTZ%*"YL#EW _2%H,V
MLY>D'2B=XV[\5"7#S^%P X.] 45ZL]/.+'TW^SM@CJ$*E?4_^W8JAF->712@
MF#ERIKM(W>*.6ZE*$.\M9EZ9#ALY5I5WL2YR^[/3>VJ$XYP%!GT"VI[53N9[
M8%>FR D-&/YYT:BQJ[ C>I@-O4?=#>@R8^F(2$\%[G"2A33V,*NLAJENV>:Z
M]SZ'V$:3;?#E\.D]5TU/T7SSKFILX\S;EH0[&P_7Z9=BUN,N J42B2&)Z%1B
M%;0)IHX?SS*Y1[@*__F@.)?R NB>$N4QNR,9BF:VSX%@>NX6SBT*-XU>72&
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M*]-3^4C3V;RDM<@B*UDU5Y*GH8[H.!;!C*EEI\J V6^;<8LN+):P.<2:LJ@
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MW=7X<R-;OG=$O?T5%LKO4UE/8K'D\;*%GM*2AJ,$D^B9U):B+5RS^!)[Y[%
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MK'10ZAX\V,[39#.K/5;;)@J/D()Z R_,.A<[0G>YI.UE3&'07J8:JQ<%#\$
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MT%4^LLD"%8M;6-;^#VX^1HFV+J^W^.<%0'^50'*0-Z7#DFCO%O.>K.]XQGH
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MN1\>$;^A5C:YQ!YF!Z_J;3\IQ-S84@:?_C8K*-5UB:$!DG[6 -._:H#WES2
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M)CGT7-_Y$B=@KXU]235=7MFWL5M$O07JL=S'U1Y=7?! 0]_G];4RQ4U%JEG
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M1OY.3-.B$H+Z;P]NW+=1I7XA7#35 -[[X[><#=HZO7K+V;]^E/\:LFWB#CE
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MN7Z@Q^7S&9>]S;W,Z[;..T4+\VNB:#:^/.9>\(?<#H\7ZLG94NLPZQGW=QK
M+G@. UG82/2(2H=8'G4]ZVL[1=[%,0U@$NXK7,?>Y54U[>\67Q) 0G0Z5N=@
M(VG3[,]YMC,0P\NAY<8"/5$50R$2]F3MEM#C0WHB%IH/G1@@'KFI;N%_Z.(O
M9BF-R6&-ZD)D2,8MI-'"O@7+%S%M['7,&GE$X:.I);<LXB-HO-4AIV"=G/?$
M*/]!0Z^5[4APA[D9;\'+W')O53#\:U--:"\CV=_+^N6#10QR1G:(CDC 6'R@
M]R_%:E';AF__MY'+NQSZ0MCR]>E8]X?[X&LJ+$'8M%'?K]8 D4CE]S -^0_;
MH=[E_"-#8[EH"5PFSP%^PUG8='/Z$N?= 2[XFJ ^\6C+V>.DT(?_[LGYCW(<
M,/Q[6/JS;?U5E]1,,D@H[2X;#4.NB1JQ'&-GQ@273R\1!]KYMT/[F38F1ZO*
MJD75"U8(,2J)A1-!3#W'WLX3S;VV:?OQSG9K?IJY05?HRRTZ;[BW"A.#7* \
ML2[>X_U1B#A&-R1) Q@](N;3@3E&QII)-/QY/XU1&3/\PN4YQ2/&RB6LZF(3
MIX:9/57T/]A[TZBFMG5M,'O;H"*@(* (Q!84!+;2*2#9BHB(& 4! 2%;V4@3
M,2(]!-86A- (J AL08B*@+0124 A)$)H-B(B/01I$FSH61$(2[*R4LOSW:I1
M=>^M456GOC'.N=\]/^: $9)%UIS/^[S/,^>[YK1):O-^^ 6_,"](32);_-C(
M.;2D)4JG!\=@.HT3-D_GZ@B,2H0VV^5F<9N@-/N:/L,RBQD33T9&MJ=P^+3P
MR]>9K,B<_&3VPT]<UV,_6\E[&3]UDV LPJ6==-^. K Q/R!]Q5F"69T.Z1$%
M:<)><$UST=KLL,?PSNX@0K)*7;KP2<EDOY.R^V:J;3=9V?S.RO&UM3UT(,%\
M%^@4O[=[:7NMVJ[E4UV&%X.D>G9=?NK+S@H2XX'Z]2S%'Z>[@-+\ZJ:2-MSF
M@2G"%O/=@]#-%M'9T9D1]5[F;K#CI 23X%C+HQJ?C8Z08/2;H@P%HY2E,CLU
MFW/=ZB*._Z3CAXN^+N:5PM>)M>XNXN9>M2>:_20V_B_QVZ>)VA[Q_^B9\?_*
M[:N9!T]/+A0=)',M4#,I4(*9)6T([>=D?;W-M,V/+%]!%1!G9$^W+CV2B!<%
M/PSP+'*.K+:M>UTE<J>&^42B"J@O\Y>S]]Y2OXX*--]DL1M&XUGFD"=?.L=H
MP1T*&B<HABJXUG9^J7G5I<L UDU7(]B>\L"2I*&CYL)(HXAA<Y]K5VM?5-1D
M]#Z-2#+U<>;A%_5IGTB(M ](0S;1N"M#_#4YU/CWV8),7DLL;!59,A7\'5S,
MU07O=X 2C,,'ICZ@E..SZL>TI#TG:G4OHTR7.&QO_X(E, M9UA_RJ>E+]EQM
MZTTE]8S$+&?-T18(X#9HF=!E#&_R&+<LS;)JGA\<02*-I(=L;?!0)\_T(EU\
M:6HEI_P),3\4R]^XS'T>1M^Z.+S!39_W(-PQ5S"YPNQWW]5W_4KDE;?K,X\C
MUXF+NY'U_J@^':N>+0$3>84]F<<@:I%Q/: PZ.,2=0\(*G:!+7.[;4&Z/*L4
M-*(63$HP\K^!QO&&.1:G:ZMZ^5T&Q D_>_M$_OB)7OVD2O<J47NQKK=U&&&N
M!QE A^DC_^_6XC\VW?EQ[,B/GZ*4C1+,PTQQJP0SU_D-MI9@?B$LZTLPK^2F
MNO_CRARP'_AW=HR#>C4U#V#.58(YOT^] #5GN]X9BYLEF)[$)Y9;G.+";_W#
M=T?Y5Y/ZJ@<K!O#[82W2 (7?,L \)K[%QR4  ^SU9&,4=[19PBP-.L-8+<'<
M'N)(,'7=0=HRQB(;GF.V8!6B42W!_";"IJ%O3#[=WWC3.]=+X$'HQL/*+2WA
M+"HX+0R"/&6JLKAR24SB.$UMRNDF)Y#+5&%SRJ0M0"3!S^-&9H*G4G:0I\"F
M47[JQ<>+EX;Q05YY1_,_WW%<?C&%?<?P,*8]Z;=T49X;$N-^I<V-"Y5^G+"P
MP4-X3$PUQ[9Y\8_JV[V$_/.@U$83JR0_I(FOIM T@B.FQJL?^L"07MM-+UH<
MG<$I0GG.77X&M=-[>A;;MFL391PCAD^/3 G'(2HD/6:[FY_9@HN68#8RCP44
M.4_@-D<=()N &M4A>>U$4@EW4EU7$)?*$Y_^>OI57>6_G:F@D=%,K)6>OEB>
MH?FJ\G6"N[($<VS#<YW1MA5X73FB."7!6*[$;CGOHLK[)QCG_[*-$,<&W:BQ
M '@/_AFR%_B^[V@,X68V2##QR[FJ+.1=M0A/H5/7P6<ZV7QB.93]MKLPE],F
M($0SU_/$RA>R[;H7&UF"/5D.[Y17,BKR(M.6M5A')9CH6Z$*IZ!DD6)4%X+M
MFPO2=M7!\7 )S)"--1?Z7K@9T<"JU5 V3^3C/O=^1:.;9#B_SJ<JZ]W^#6Z7
M?!1&70?=?99?#HT.[=<N2(RA\^'^CXO +?A 7T9JZ12BUKM(VQ0*./30=2*.
M]Y0&Y2BX=LZ7T]L)5KV+;<]I@<-.IWM*\Z.7\3UTT<#.V@H6/6M[B<WS*Z^J
M,XYX6&VC.TKY(_$L60'I;XN"TJ'S#2Z4?UL4E&MB;>N-:OW?%P4S:IJ3GD=2
M[*O^;5%PZ)(X[5SEWQ8%LVN]-:UWG4UAJ: WZQLZ[X3>K#3RWGQ'WRQ]R'48
M5^^4NSI.1VO[<QW74Y K/S*"ETF9\[2I;9MTM6-^(.\L&)[6W]-*]"_IB/3W
M]"H<M"%=]EO6N<ZP7CXUYMM>WDY['?OWEH3\JQ3DOTU#4+4^5LW2 9<3<-?J
M]*PZ@^2JIMPQD/88L#ZT:F@FLT^"&33?6=>/IH=:/]S[VJIH:534-^0:@N]+
MA'6'7(>V(-VBC9G[BYQ]E8*IJ4'+;%AQ51-+74";_2PZ,:V^K0='7QS";89(
M#3^J)%DOO\$68W(8"/\F5Z<;SCG.[0I!6@6$N*4R[5G_1B&:TJ[\T*41!1]=
MW/&@Y67-8/'9">WCVJ*2;S@\,);J+B^02\"1].),FI,*Q=6VH!3%?"]4W52-
M(U94(ZW@TOP?01+,SZZ^ZK;#[Q1&O^=J"VAQ@;27/O?<1S6%U*%G5;9&;>>8
M=.3M]'?4%D;+0C:-QE2Z4S-6;<@'\8HU,P8=\>N)+C3NC/V,^TX!+86\MS34
M"_^W>[P$^$RR, *_#N[L@:\5+Y'6;T'2V=;SBW_1@**IKNUD">:O+Z7SN!.9
M7R28<S^>?H[^A^\%\E^[R2W4"%)O,U'$H [Y!V(DF)=DIS$::I'E!4;IPMKM
M$LQ,QR:(9%_3N52&F^5ZMO_;69M?AF;#(S\/)[=D?G6YU+&J17LA?8DR.\33
MVP1I"]O$A0: @@\*[:STK\TT;&@5=V@VV)CEA1(ZS0WZP><YA1^'WU"Y(UL$
M&DG%XOO6=BN<6?;EGME2AG9$[6%S?'E G>DST3-D827W;RBJYO13*VG-V!_(
M\TJ$C07%>*5I%Z=!O;09=S08;C'WYD%>YT2!&:T%'P$?-,0$?M6#.GJ:+!1%
M"PQIXBF]Q582<+/D^W/T<FM"JSE]4;KB K/U <_#HK0%FA3SK:'5EEVL5A1C
M?N!R- .G,H%H])@/JU5.5OVXC\Q4>*^?T*;V+ST:P&#.FG/GI&7.NNI-NE<E
M,9V&EU73'8IM/B&+*""+]?_E//[5_I^;%&@MN@*T?HSJ&17ZL]% 6[H:FLNZ
M6=[/QZ<L 8F$S>1(@7&C$M<OMTZ@W,S2$HQ4^^1Q@DC/7*80W7X2?*S(U<=Q
MN3HK=D;EFG+-[<Z+G! @,DBQN#%3.?-0R3O8(2!G^D3=YA]+)!C<EUG<7(P$
M,W^5-M'%5L*-W99@OGE+,)N!F7&RFP13W,&3B>KNZW1,7&2/%K4ZC#RKLQ/=
M1\6-P[;8?W1YV'_QAFU*A15+$#MI@02#3#HA1;BXI>]M?RLV<4O];II*(0BO
MNV^68'H?"L+92MKKM:U71N=[YF*8NY$MK%DY+@#MQ,$Y+8T$D;&>,C#U#K(@
M],D JJ/@R0ZU*62SN,9,@2<V&K+-;>-G1K-VARHTRH]:!.GTYMXKA*Y,\Z\9
MF^@/C;A:DHJ,ZL"O)^@9Q($@:<<N789K8*7-X*S>#%"1U;4=1^A4[67A+K#_
M_JSZK_U#_ANUGY";B^<M W)OB7^38.K72S"?.I%=:)ILAFHE& =J@XJXD-:4
M^@.Y63@4N8='4>16HLBE+S&#W9.^'2XFWUQ"L][#?S0'_U=O4M\B)9@U Q),
MVBL(E>57/_.P8F>J<HG@"AM57V.UV&\A6%GVS$?F;@FF1)^_%'7 41^BMGVS
M\L-%FU,F^F%Y)Y29P%7(% TEI@1%<:&3P./'PH8$\R :QD@P-25H<L#S+0&?
MWAN#*TA\ [N9W< VVG+>TCG^[\'.OZI:_M-6.FSAW&5 U10Y.70'=M##<JV$
ML4MEU)S/UQ;(5'H;]N'G[_>^9QM?6U (-M;]U>!Y>0"B@%TGP7SHYG7 ZCY4
M.-T*UC!'L\B30@X5,NO&?=>Z-2@$^F$3T?N4Q*\XWD$P52QCKHH&ZY>'$DSK
M!:#!@X==42$?0?NV'566]Y]+FW>L2# 40EAGYZ6O__YBJ= 9,@HA"SP%!X85
M -\<?O)"^9H 3L^;F&@_DF!NMS3@%@V@  E&*LM+@ME[7H)9GWH;F/ !OR)R
M!AW(Z<<'1+AI1"WRJY5E !7\$[)"XJBRP-C"&90ZBF]"M0W7WR;P 3G3VC4G
MW(BV5Z]ZQ#J<OVFC+X_!R%N_V?;8,9)-FZ0Q)[S_"2S]W]LDF"/A^YZ^[O@5
M>0'\Y_JKG]\";Z(BMEB^GO@1*8F]Y SOI''#1TSU++^K.I@?"?\QX_3'_ZS"
MPO^F;=5W<]0!SJ#"FVPBP53>!%.1THZD7JCB_U:2;8/QG[_OKJ+68RT6B<AZ
M;=2AK8%^DF""G"28"]3&1*2[!*I KWE:@GE[+ H###N@']44[&+3IUY=$P,G
M+A/&"3Q"-AKII8U_#W#^]9CT?U[PKT8 +V)3"> K@)@<T&#B-L\UTP9-;5-Y
M[W/OM=9P\0K/"NT$O1-GJ+IS.C>#P*;1'8<@E^'HF/NCO4ZS6$'2&3$560.?
MAYJ*O^M@;YGM+O*MB2SC7$NR$VPLK@%B%X/]WCJ)O!HSLQP?;%4M8F[4O^,$
M[B^=5J'&!R6[$OIH&CU!.0%VK#Y#O^.?JS\2IL)S>JJKE]-8:R?+RPLSPEQ7
M!=2J;NP+B- 5H539U[RX._CSD.74,HS3-TK<5_K^[O\9F+1./+27]@8/$;!5
M4AR(L5V/ =GP(G!-@.+W>_/5H?#^ .^1[14/?OEVU<VBV=AEM9/2S31ACHZA
M_N=6U4.WOO<3^K#P9LTQ35A[?G"H$;MM*4)/LQ&[G7F\/=_Z0(17TINH#;DB
MJZZ?$Z2RY829\5<%1T4SZQ5GHR>J<74G;C59NM%THOA:-AERM9UD-$&X4>GT
M\Y;7_/_AH_SWNJZO>I9;G(Y,8/OD_C-*A2^B\:J WF<>;(F20+(@!"G!W384
MX5U;/"?8NQ,+6_10)[3_[O_44AFG=P0LSH\PJ"QT0;IBA!3Q,T2:O*N/WK'&
MG6R!YE#C9NHFV+" ;-EGIN8E?DD=4E> ?,1/-%-AHOA)"&^6=/H#2E'K0DF7
M>LVLRB<S7:0H,XRCOK@7V!9"$A8,E(,5I'G]\:5TO%2'Z!@<WJU+=_5S!+:2
M-2$;GSPHQ):5*[*C9W)"JMBJ, 'T:'I)= P6&M7DOUL)B9V'3?I,FK/5"MA!
M14TEDUPG6<U#;6#*P*.K*G?2JO=,<;C &/WC3 W+5;?*/$:;9Z[Q_FEA^N_.
M!49IE][6J:J12ESZ";.';M]8)EYLX0;8N%^8Z9C(34046'HH%0U1Z6<9Z'=?
MAO?A!K>/57/PE0 1:'"68*2!9N0(Q!,SO@)7@<M PU'T79=PE:/P;NP@R[%2
M7"9&J6Q]B+!_:+$#)=G?@-^' ;\HTH]3TV(2@+$2W%8]YO6:D)9VY;&6VTS2
MT[;'UF,$5$O*F$GS1%CIBR.AP5@YWS1H=PMK7R?32U#)">][/!W"7\>T)@KL
M\)M#(QI=[O2/R/62CY \GCK[N*M%_=(Z21AL4TCP>5:7+K5Z?OO(TF?+YX5S
M[)"LE>9#*8438<"M1P%W/H<6A[E?R+J9U7QU<]GAFSWG/I]O*QI_HG4_=JI>
M*S$[\7..2Q!V)Y+EL/"U*94[)+2'I/G:>E)P@+B [=41HZ[30W<ER?N,*$,5
M BJOA4/;3(""OXGLNF8-13H*S>I[.I=,RY2F[3N7(DV&'*+[;+;-T\M.=^WG
M\ING#K-;4:TPZR=R)(>#LYDQR!&DFT#'-@/K?6IZJQ,,YJ7ABU"'  4]Y9J9
MI9='D4]PEC@C85Q.GJCB6<X@%A!56#E^Q?5$M44ED_)\GRW3I,@@5=9E<(%7
MW4A(8AWL1-3)FJ!<<I0F),$TXKC8 ?6U4!C/+Z"9=; ?]S*P=CC  6D!.^)F
M#(\2[9%WG8'M-A=[S)L\<0.+=>;+YUY_F]71S,)IT;:_-MRHZ_)Y_^'G-8PA
MO^KK#J=SM*N&'_C9S8IS*8,\\]2[^>L=VZ%B@\GN9.O>% 6]<[=WKFF?]4QJ
MY/=X;&TZ[;#E19&EMNA$FM=*S-^"=A2HW\_:&)K8UH#\(J8C6XDJ.4B2'ZT^
M"*2>%?2WT&1;/((BBWPZCT6,R]W*E8>2>#K&+J[)6E,V5)DIDV%:?.F,9W>0
M39V6C/[%+MUYEA7$1D6K$8I1'7.5_P$_0B)B@'R@#A&XHUP"^-Q<CJBB!^_"
M#;('J:@WNDU!E+\\ 7&SN"$)AE2#M/XX'0:1!S1%RO;(,-*T$$B:)?&E>5]A
M^0AD T& :S;!W6(:BZ2CNKE7&>6 =V3B,A_;@%."=X&!V,$LM[F* '&%0([?
MG#-&PX1&O*-W?Z7@D5&!T4-Q6;&UYY-)PK4^QE%C?.W*. < KU-@Q2$W@=*M
MI[[42J.DL7;]BWWT,NWS DJ"N2F,J0'G8P\$24_HZ,+6-"Z$XWLEPJX!3R<<
M%ZR+?5^$$AJ0/8(M?4:5+4^]59H+^FJ"WI/B7V5NRE^Z5MQY\_P=WJUFAP?J
M*>^O7T^?Z?U85'+2Z65GCG8#&H$O6^V1WG'S\,YG4Q>>Q/,WIJX_RW1YI'CJ
M,N_X8<::?=5K\)LUM1Y\OU3P^K$$D]\!)4HPR'JTATYX";LD&$X(:"S!/#W$
MLD)5B]IGWA!A,U'(DA-'&Y:%-#AR^TJD8I?8\E%=&>9;!$H5O %28>J)7M30
M2D\"J\R\"D))+CT&38S:WD 9TV9U[8K.^0+J6;I HY;DIUZ$CCQ\_!9J@^71
M_] N4I)@>(W09]0;?76C<3H@@Q;A^Q[8(V^0?%'\#'<5NR;T9V!6;E:"42";
M4?FT1@EFZV2N>V:$4;HX=8PD3S:#+)].4Z_UY74'BBUFV9O@H^*'^<,CTTJC
MW/YPLHIZ@<VV9H:JQT:S2>,]-%4C1<U(98.2@(:#>">]()VA%T6_1V%X'HYE
MU[I2#FTN^-SJ9-">O^^YIL:D_9N(#;U:!J5%^8[VP7=V?.E%<B28>!8PK4[]
M7@4@MEN 1@)N*14/#^$D&(U$''\3:>4O N*+VJD'=5C!.F/Q[RB3&J)>[:T[
M#=%G3XNVMB!'?G@V]QADUW<)IC0<^(*:LN\&3D1P 9&=AH**H!:KEU"%2!;J
MKW?'4$46(J!Q5,[<9 )0@#T*PL+=9KA.0A2<UB"'IY14'EGIDFK;O217!5N
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M:N8_WA:Z5ZLF-=G,PF=/KNH+UIV#HU@*K.VO5.0KVW.?H'3JV\D.+^(N .\
M[XT:4=];)R#,9HO.^F;.?<,3!=26*)7D9T<N>XZU7_]:OW)SE?@ONGA#W^$6
ML#F1>>4IR29$C'OF9^GN%*G87](-=Z3M=W!^Z'#LZA7%"S_;'#R,^:EUSR/,
M$8W[#^37[;A[;/6F&\=4H]=]VA2V.K T)4]T67P;^(T=1WCIQ>F0\U5V5^]:
MZDAQ>9_J%39.P_HJO7"?"@_.C[R61@CU:,A4R*M*X,UJ6;OBKW8W,=ZS4$7'
M-:E\:YN?3YDPC%)%6@F@\VB,^@&0%L?<*3IM6P0;0Y3"2:&+8_[XO0(WHOHJ
M@4,OW?I:UKMO$P)W7T2E)TCCF'^1RXC/(>_@3'D;?R6&3$D2$3^(6T4^"0$"
M4\ND1D#6S(^'5YLX='NH!+(B=,$6OY5.O[+4>9\>%*2JC/EY3U5.7JZFD[6'
MU<GS-;YO1T/L$WU]JO?,C8C-\=6> S-N#KWW>MW43M<<WEA:NL[3<T><X^KH
M=3NBCVVE<;"0EC&L0.%EQB-*H1W">$B;=U2_'KN9N:K0/;2R.5PY[MJ3;O+1
M<=J&R8G^J#WLS!.5ITH-)!B%B2KM )J,/3Y:JN\QH\?/\*+>_-PUO6M H%:^
M.#:EQ",B?RK#,2OC89'+I0%?DR QW3C#6&A\MZYN.'TVO\&:%.031-IS]](0
M7O5NQ\;4+<__>O?,Q_#JOM:F@NQA0GMP9,="";VRMD?W<N4+QNLZYBM_5:6J
MNS8! :9W3YWZ+=;=^=(?IRZ</+QZ/''%HAY7D3E[6:#0"JQ#WDLPRD';79-9
M9PN#QI))%IV>HW_M+R?VU5Q-X:S6WQP9:U<ZX+A:@@DTWP(!8[B?72-3WR#K
MP=08/Z/;(KU8,^.\T."AWYH5_NHZ4,KG&I4K7U\KI;IANEC1?'[.*&CT%"V;
M_=GC>Q_*[VY1]5A&]<Q7D84+[ CEC;5KUIO+L$!<HIE.F7/'N)X,467VG<G+
M 5^5WWT*0[W.]_'6&29CSV0%UC"K[J^V;<?^&:>%)'H_+=N3?N_.LR]SLX#>
MY$.7+Z_S("_+7MB*KW:ZX^2'0)E#(N<^1N3QP*H778MEA_I<ARW.U;VZ&S_&
MJ*3'N28E7(I-V3>8\(;&1VW9!JPH"$H5<J!LP]R$H,A\LBQX]DD0"9SGR'I6
MF3 36'TD-2BE)WTA:/B*#FJP^[H+S([DG:GQK-'YW,R(*$*> O77 .+@XE%M
M:_%]IG2Q@3&RDUXA<&J6KMW_MIWT^*%E2RQ34;NY\4E?X>W05-=JDA9AIHT@
MUWRF3Z7]HRW<XQB0:=D-X"!2QX>1.P=>C\P)O[F)"9^GMIPGO"" UJ,#=MW"
M>P+Q:#,V4>5P':0'<ARJXT:MZRB1E$:L^HF[HZ[>R@=K_IR#C_)$87Y!!/DW
MGYJBEL/-DP\X.3JM%+N^M:W=[6-M:20D]"8# Z;(>AWTOKG;SW8B!\@WF;V(
M*KR#?9$$XYXZ6ZJQ4U@[!HS4M:?Q51P#<V6PB<^;#<INLZFSNE@E%J856EX.
M\2RG3MJ,+<\P1$?)J[K] N=OHP[&3)EW1,?CU/MJV532\]!RL!DC[^NNVVNY
MG!"T[:>V_<S>_XV]]XYJ:FOW1N-61$5$I I"%%! FH6B@&1;D"8B*B U&Q A
M($1%)$)@J4@OV8* @A % :F1+BV1OA41Z1)*FG20A!*6)%FYX3WWGCO.?=\S
MQG?.^;[OO'?<^\<,@T766),YG_)[?NN9SW/DQLL7YYZIC[JM'4#M4[%5,I/T
M*>\\X"NN?&&+K;BDT'6[+7;78:]AL-_PSFIY\V.,5Y-G)K+2*,QP;U6&SA90
MF7XD,9!&@6,0K29ZWP(8F++[@)1/R*VF LMDT3*Y_NLU]8^.RQX:W%HLY.7E
M=161C "/$A:,:*01!%TGRMB364.>ZJ&IMML6*QB=RZ#35S$:[4['JS.O,WE-
MB_W=0=KQ@!?@7^@#]_^0O8S0<"A_>#/B<FT:<D&)=!Q!+494(MIMR/%4G<?&
M^YGHEB&B&BLMFA5ORE+XXN T]9@&+A@?R][-&GI9Y'9F/49/2W_BQM?"=S/B
M9_)>I1LL-W3J/B"@T8&:1RWG_8@1>=J.6K>SDWYV#4_R83!(]QWANXX8T"P.
MW&ZZV1%D?9Y*>3KX_B8TQB*6!ZMX%HL299GI,;8_.LZ]>W[1>4N>Z>'.>C 8
MVJ',.C?MS3V,KX(_JG)97$'0%)A #-:V%A'JS4[+I8F"D,*$VT^.G[:C"6Z9
M^S7]JLBB3AHIM2<?H$9D'VL<(&X7 %KCY<::"4D0GS_//KKXP;F3 =\]ZM2S
MS7'RD(&B1"A.TWW;L,1?VW_=U.*4(W\+;R:]S\[DB/G ]]Z/MXDUP.]#FQSR
M-5$8T%D3P>UJI9VZC: =J!DL+:56E^.0+(F_!&&37X\*3HM]):?HR4Z]]7%_
M^;<$TMK&@6JYP ##@@!>ZOK*:?0!3.<Y\"&5)(U9;UL_U]6:O8LY44LO?;"P
M^$7N\N/\L;GT9:5*M8="I27$ZZ&/DZW+"5]:2(]LXO'[@B@)2$EC@&735N;L
MPN+#XO5Z)"F=4[KE9'T"H#<@%U1Y;)LCZD'/GBQ/12F/RNHGAP5"!EP%F$XD
M'))92KH5=I*FG1+Z Y/"*(BY9E6?=%K?Q8R*W-'E589)\[IIXB'2[60C,E.A
M+)2T9#-0;6Y5\?89:=G6L7L^8'2S0L74@+)/7? #MWA(;)-;/UO7/TO49V4G
M>BOBWV)JVS;LGAZY&-5I/5SM+'\JPU'.\=*#H=J[Y_<G.SQ4.?JH,>'KR"V5
M"3XL,I4E T4O;>;7VY7Q8<MA=Z]?$?83!!H:=!V>V(2>(" I=N7#?FP@:%Y8
M4S[L#:>#!-KYD;AX%SO)+63!GS^#\7S8^?5$@%DT#/PRP8&.2'%@)IQ%@*2<
ME@10;UC*%/: Q*P@*O%AWW@,)/=H-06R(<P'0SNW, EMX2*\5$WH$-A_;6C-
M1H+K-ZR-18KX922N\;IQ$?<I)R\P$]\"_MF MOP,==#8>MNS8RN+6%/_QEN'
M[: KT':L^E#X::P[Z,_$G5V1L04?TWGRK214$D)WMD8FW3PH\=:%Z2!B[%NS
ML.+Q.^8U%<\C/8X!)+0(B+[(1$<UGJ&)[1GI+,  +?6**;1N$9MXGET2+N>&
M\VR&UZLP$RL_C1N'D.PK=LU^0'K/!O>+QN=/9D1"KS\(79P$I.!,.PZR(IS"
MAU5MPWQ,GJ:U][&:.<@6.,RE7)%D7+(38NKQBH=9 E0H%%[-02PNL0)</!?)
M.JWR)1L+H!_-3U.PM-F(784+3<!%4[%$P7Y /MPN <A7?L>'7:#LSN\1!<,,
M;_?J/N_,'Q6YR],(J+QO-Y([J\[K/M$,+&7>B%XM/3ICS"1, Y"(!"<$\!Z=
M RIT6JS]>(;+LL.,Z)C5K@1YJ_V]MVI!%"I(Q'M1AJ4;'*Y[_$1,B=-PZ[U/
MZDTLT4C2C!A7,IY-ZP=NPI]VN]/B&XP(@KGL7=2YOQ1=?^V7@VHK^[$U,9>Q
MZ-3;6O!=][QJ:J[SN+)IR?R4"%IIVJ9\*&,8;!O4.V/F/%"MX'V#U#"H%^:V
ML71-<.D<W;F!9V9+RK8J'IT?K1N9KFMHJ$MSCL^,S9K,0"E:[,^*/?W55::'
M2RK+SE]U#_[*=GY(Y,-T>K[EFDJMPQ=D./LQZ>R_P%9_VD>=^_@H@670\J2G
MQ_OWH_I744> 2@Q@F7T!(Q;;>'EH9636G'[6RU_Z36DW.FA[ZN'2#A3RPGW]
MG,Q0Y04^#%2I71 6B'9MNSZ^"ME>*M,-FE$3G4UV?:O6P)*Y%UG9Z:>.3&$.
MN]82Q9EY8^Z$"/7*H>H91N^K<2?4Q,%RQ&!U8+@8,SH*NX6&%@-5F^OUTJ,;
M-6C^1[K.?].U-M0YVF/=MPKNFQ@B2QW.JNEXU*5+4%F7T$V7V==E7&$^?A@M
MY34]P'@U-AF>)8,&P]^82EX[^-]=Y^J?OQ869 =0:3J@)B4!\$(8L0_Q4M<(
M"V))V7I,NZ0Z%L"X&$F8O>='$C)6H!-J3?,Q\LUW9@T3.ZII.HDF6KW^#);"
M<&QUE[_$=3"4.=]F(L$R:P6#Q*0P2ZT3!B"J_84G\U> =+[./O)3S5S9XJ]Y
M%LCD5])C?:@Y<L+5>RFVU@0@"H,^06^DB*9XW4DHEUHR3/6U2HN2$;7N'/4H
M[K(OO'K5P?9JX=5[D4>O9%FTZ%0)H"9)$%BU(/>0;@JDS@E?L;00;\!5Y<.J
ML^-_8&Q<03Q;0<P)/,-4=FF AFM87H3,H+!@ 9+APSKPL+"4S>(K3[5MQ,:Y
MALS..#V"<F?]SVH"N+4#O[U:AV9$F]YDR:HIG:[PC^%;>[E^K%8&']8I)C<G
M<78;.;*#Q( +W!KR0],PUX*.EL"D(#=),E*\<2 #+^W+)KLEYHWZ9>NPPNO<
MWW[WK2]1*%@ .'!N$*^.: @ZL$-YV5Q!3+U3)A%K.N4K5U;\SN*N)W4I&MI3
M_J$J @E&L\203_HXD#A%"!.\.(0*#4D+)N<7%R%]($EF/HZN(P?&MX;+#R'Z
MK:"=/7S8MD9>!H*:*5 \71T1[C%F1SR=E'#21P!P) "4*- J9UK;CHBI)2^0
MI?BPF*KO>K:\-X7@25J$;[C\MYM,2DL8W+F.^3-Q3V2>;T9W3QSWH4$,-YB.
MZ)GY]N5#@]0B2P*#)3X=\_R,5Y%(OI=W5L_W1;1(J&6??6+.CV3V??PJ$7&"
M9K-M.2C=Z[X]JFTD47;@W9SET2942^;3XR^?YHR]?WG;3]U8?_OS7W.G[:X7
MJ&M>U$8(IBM OZ!!K0!L.O\M%;N#0BZ""V&QO!*N$>,ZR_MQM>@N3KL,19@H
M OS!A_F.8&[--X>8U'G2T* -UN\N^R]CSR"&38RB&)P9B<GI;/&DE472QH%F
M">QY%F$UPE1J0UID:V37C)G8TSRYZT.E>0\'4DNF[0$IBZ:ZM^/)MHDYN5+<
M3OS=/7?;1B(O=9WN&.SP\,8T6U2?%[5<[!1[^AI?V?HMWK_H/KTN?](^-PLU
M4*@4IU96V?Y?*6Z(^!,-'H5SY35HE)C:"55P6K!_\YFF3-4DO2R_-DB3%;W0
M2V]RZVPEB>BIW60NL2/+GG'.S$EGPYV!:*>A8OJX_I0(8@O(<,#1/+H9]^//
MLX!F_%90XC+S:S'7AVLL$)]A]@5P/A=<^1C2F1@NS 5 .,/UG*QJILV';\:>
M5$!V1D:F7CC6^"0=+3K/1K)EF/@DK"B]6VG::NA^0U9@BZ+.MZ753)Z#)9X7
M.\]"0[O:!9.\"0JD1T@>#**+[</8F#(=6G3(G$N4,HP.(R_[,3H?:'E8Y#@3
M8A_A1T7CTC.DLXY4,Y!"OG(ZT55:6R^R!(!M.B%< KB%JB<\H0UPS\#C30Z
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MVBJSD L+M- #+H>/WFV[;IG\JK^VG+#G1D>J797WVZ,HZ=RK7W-96UM").\
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MR8OEW>X);P%V/[SG_\&495H]PK)>==^1<=R;.F\==*@1YU,]J%W5^%>RU5Z
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M)NW,@[<2E3[P89%:O,Q"K#2TX">(#O^7+3%4M-E+&L%T70)=$<PHJ U?,YU
MHJ_R8:\QGE1X9X\$A0_[A.+#'+QSL=I@;LF$!1]VN(!G'?T$ZP]L-K);!?:
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MY!O2<IZ-WSMONL.UPB^#UY%7_$6_[$A3RJ1;Q'>?HH3KV+^RS(PT'+7"D&M
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M[+_9C\'_VNDA'G9\>Z>'!/:W-;XN^ !? >//>PG565#XE3V=. 5_)@"!^;N
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M$Y9"!B(N\HF^ I!FA0#4P0QQ$H .3(2VD%=M8)XTKCKT@ #T,XXXJQ#S'7_
M74JM.Z&@-/B)%<$\&+4XUY+A=9GHY86L6S4\U94=?/?.,BK&7Z6*,_.ZM+&Z
M:G,Q\2-S%U^LF_?"+\378*A*7"Z4PC_SCK+FI6O1R&IOF%J.'-X$1RTN$H_7
MU/3Y%R?NPRBQ9J+O4/RC[H7 +#):)H[W^7\J65(.47&@+ ]/;(KG";W.)_Q?
M$[I:,&XW>'L^]TH,SS&G9B9C.E7VR9?SGE1UX[731-Q;!KZX3BL!_NPYXNZY
MI<VMP6SM%5]+9+]'J*4 U/(2]M?\ZB/L!@[F8<X//H3]=TU2FU7ZAIPL-P'H
MQM$ OA0#MG$7;M&$[5/8S@(RAUW9]0/"O2S)WX,5@ PZ!*!7!,X+ 6CFO>$_
M:X076UOP\E]A^SKD!:!P="+?'OQONFKE[Q8Z"N_0CS3Q>D@><.,:;SM+T!A/
MY>86:E2=Z\/J;8%+8BP@8VMR#998IKD<]^9[MGN\)EE]FN-10JZNVA* %L<O
MJVG$ZR[6FH;'IY+L!*!]X*W] E _+K03#B1L+Q)L)!*+/4I<(5+*/\Z:'?]<
M/>9?I#46X$52K9XH;7#2L _:HUA@8:289#V99/);DD6YT:/$%#(]3(A9:)L7
MS;>710[2MN?PSZ]B6W;QA1KR$%^>SC]);@;S[R_,4T^'("4%H&M2 A#+WYQ_
M,[0YDKLA_%[/Z7S#3CBK20!ZM\P[DK\H;(I:WEX@^',3]L\Z7UOS.O1O>[H2
M+K[Q<WNIH86;8-6D\"M+NP4B.A>Z"T!-]N[%0%FNT1S:(FHW^F1+K>$++B07
MB_#4#FHD\-+?>&@]E36-'%M#;C$MUQ?37H846S34->"_"(.'W?QLSGNOSS5&
M).4QK^HQKW'A()"*4;;=$L(1$/X:?U;*,5*3,'EPR$+_^%^[F:6:N<; JTE8
M&'_O"/0$QH0-?447WPD\&1SWI$X4JRH>*#Z7((I$WS/R7EZ3&QU5\^-=:!;-
MO&%1EZ9JHHI84DK0X@NMS(,&J,,3UES,;_>1'YK_.@>58JU>,$'M2H0>=XCW
M;=/!G79SXEUL.>"B_.S-2>WN0X[U6:?2/+2,]*0E=<>NOTZB+:F?2^$X!@1C
M77'X 1LI($,8;!* MBTK/F4$+LT_C_$'\LO0=4V.)[^B)9L=C^(,(RJO[)UJ
MLX.[CW#U"PW=Z WB!K\[>\B:<Z0RR^ET#ZZ)GRM,9W<N?.R,9"TYE)$2Z&3Z
M=L2+K'C([H<=LU X[K; C2TU3\?TEMZ=<Y_9OE-2"8#FE5UF@TD=S5G[:L>>
MB<?6W]AGY[U9>;;I.ZLG$>6#>7[9:RUX6?P+APEA\#/_7O/H=[[014ECI%AC
M'VD'_1(CT[$'ZN$Y /QFOY[()%F\Y>Y=K:K":P](R9ZAQRO8X&A^V]MK9]-)
M%"/B[B3*!"/P>9'W;]^3JTLWI&0MDQJC48$(;#>7 R,ZJL*,WH=<-!GP&T41
M-8TT>-">=E,3BY</!S5E*JL3QI>)T];Z:2M,@K:,Y9D3]2LWFPX=V!EN\>=_
MZ BFZVEV"R<&@&Q= ER$+"ZY@ZH2YC?B0*YXM#2-S QVS9+:-QPJSV+&."-U
MQC\I[8C-'S65+_J XS@A'_^$8"=ATOI3-!&T53N':D9\0T636S;MHA_YA83*
M!7L%F ^LU9WREQ,-N4>A3*],=%DYZ4:)K<4%!,#NU2"\'!$*TO=<O$*"]_>,
M5)!"\8'#%OH8KZW@4 H)7)Z_V#\%C]%1_8IM1I[=A+_@@YT\;Y=VY_7&<J\]
ML=RC5.4>[YULV,^LPA_H\OPB/2VO<%/NQQ]]XU5WDKV4ZIY"/^>0$Q.!$'%F
M@]#2:)%@ %4"V[C0F,N+@TWFPDCBS,M;1MSS@+Y/*?H .MAAV,F:7364_ONC
MNUF]35 %4KH#^V1; .>5=.?T9G-_98@6DZ(?:SNXN"O]Y(7VOK<9)BXAL"_]
M_3C3.@?5!O@&UG:5O-JA?\CFU;_9$B6UD;<EY&E--E@W\BAEZC;K1U:=#QO+
MD(HUVC$A"?AH9O+Q;UW;C35)4?7WSY)9B7-/],\8B?S(PJO7E-F;9;E,QQZ\
M#(X1:A5YD@2N@L>KU(;1LUY.FH<%Z;X2>9TF^UOH)?:M4]^9,HZ]L7<_L'A=
M[1]V<R;$!OA>7SI']1.<DQ96#%[F7?8K7UH5@,( \'"I%%=U0>AW;HN/6;62
MQ'P+^ -@Z=)<]PM2?7H6OG23QQT%3N:BZO&>T7.RU]\366^*-B%,YI;[K+9J
MP/TM4\R]+!NW.[B1>$VXA)-$_C'-]*B\H;/C9M ''GO/T5.>ZT,\ZF +F]@!
M"N\%^56HROI=?:PR3(@IJLF5,\^(CYC0<PC70\ (_>-L^D#WVU&T7#MB]QUM
M^P6%(^5A+27L=OL_U\3WC)OX?7JV_.9AVD-^K #D1J/^G"0Q?2?G,%8L@NO+
M-;'S7@-MKGM'3D:TM$,/UM;LOQ-K/W#R0TV,DV[RT9P.AP%UXFKPU*&^IB!O
M)E'-"Y<4VOCP2?XISZ$1_R(A#/AI.+!JH6_Q-WTI0!BM1,X)+1>'<>&];M1%
MX'>%[H #MKM8,R_\F%8,D>&Z-TX+ Y"H>H/N@KF@WU0U6^_UV:-16Q"KERG>
M'W0V57]7^R.%:KQ8T-8]BOUH\H7'_J=:]^];\C.?8B,W<,%'!*" 90'H&<]A
M [ZUZY_>7+6Z#*CAF7D/V)J=F.-#PQ=,.@H ";XB?F8\VBR9X:5^]1?^8J#$
M]:=/C))G"%G0>YR+*\)P.;FMDFMT?:PV;"]LLD&G><*1BO$!I-XZV]_\!-$4
MAFG'\?'4H9R9F6#L'G1MB('JRK7.#I5X#6;X8U=3 4AE";[($WYP*5Y^O?($
M!-">,@%+4!W_O#>\&BAMJMO*/U*7Z4"H8,M$+N\(BGB]<GC:!$DX6ON0\-U<
M.1T;LL-+TS(I&)9NZ;;'T#\_9(3&=V_H_]\7$E!MY^M@0@&KK4MH811G0-IH
M4J/H^U<KQ\52U$/[2X PJQ7J30USL5DVN!JIT_#)TI(ZJE>'_BV=]'-T;GA=
M^P^L.NVH\#4K8%4!\=!C\[7Y37"),8P<X']0*U2!]8&5^#O&I<29>D,Q7#-1
MPI.OQNJ-@F]Y;MAK<!PUTH*@^+TM[OL"!IJ@I5AU(V_GTYW!'G4-#=)"(#&T
M"1[QD@+,A7$GG9>'?82B$CK@$O4F; *CGG\*L!.R_I9A66?'FRQPB_G^CB+T
M3"LI]"FNQ9K5&Z;A97G3ST7&:*@,XG6,'"_2GD^X\LDC\U[Z^CU<@-VA',:&
MD^E&(*])_Y"5XBEB#-D3.[;,\><EW0D6CU)027=F+U;GS)@#;I.#I&&]NQ=,
M#@<CXRUE:JH'ZB_>O>2'+N->P]Y9?QQ8/F=+S6A1O,&B,?!<&:>IX89 WUW-
MYA%P<:B"1]NX5QG&V!\N#V1T';'_H6WD3V_X9><?H6M,VM7&@UI?T^;=#)(0
M3TRP=84^^9<]4],#<H2^80562%4%AN' 66TF0SV\"7A%?QMUP#09H\$"C]KO
MT?[#Q4^IH0G^+9/DB6F\)L'G-#8#HMM3B>SQB-+[>:']9#$]& .\WU3CL3-0
M1W]MYR@3[??)H3%X 2\VOYE%(*"?)1_3K(H7*E[,;_NBO!]>V_?9#%*[=KH?
M9]>_H4*<0GWDOYHM$Z>GM])^P=QGP2+Y)[F:;&4\HW<G.JN766M0D:_[9Y[-
MTP@&=7I/DFJQF$'[].5':_):FZ+!3"CG2"E$C?XA>LIUI>33OYF9(/Z(Y,0)
M;?P3OW]3NP,6HP-N"K'[^ X#$7['V"J8.!IJ>J/9%M<]G/UV=G^M7FW_8%ZM
MD?JQ$6))V5KQN4]9^JF\AL;^'W:QV)99K-?RYG[N):$"A-P5@#ZG'EWHW=S
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MHU-"$O)0\"O/[F-S%I)?Y35Y"W8&GL[LO@SOVO*N2V_WP9?R0/?DGXKPK?>
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M]"G:7DE2K/BVF-PAK>J=8G%/4E1"*OB>I)V8)2@C/"(,TW3#Q!C3',5)XBK
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MT(,7BE*?6@[Y?6XO.8L^2VGT;G=7HF\^1QMZ*>=2123A&= 8'0T3K0T"N9V
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M!.)*A5'V%:M90SVG[;GE$99GQ"2L"MR1%$42")@DZW?X35Q@!&45^ 7K,4W
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MU47F*#D!.(0Q"=SW]PN1=!5>G&^9M[W&I5!AI]63T4$>O)-(=A@_OF=PKM4
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MTD)'.;F.Z&6W2A?F]RE'8=I#RW%&QQW8NNZYH[YUVNEQY14G@T"8S2I&*J<
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M0#&RAIP";=9A]2S:ZB!;8,K<Z[D6;%KN\$@95VF@W 7[+? =PI8R=OUNO8C
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MR,6,@I3O-5&GY2<J3^<EW!88(577M(&9%FQ_&(UEUK 6(+(3SAU@:;>SG'D
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MW3YI9<HQC^E(Z[E=W^?R7@U& 1X!CS)]B8'W]MU _J411_UQ[M>X^L&?4SR
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M#:KAK>ZX+ @>;O3JQQIH0!X:QAL.1G8!7Z<RV/J1# ?'>XHRH,,:@7AL9>0
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M![5W2V*],QX)+R2.3MR3J*M=*[S1W?W.V" K4FJ5H^,_S15_47 L4!ELY4R
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MF.X^Z=# RD;SBW\>MZATFA[5@=&OR8'=C6/S32>DQ&>O'ASY\#1WY<!I+)T
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MS,9WL:Y=9957'<,EC*ZJ*\;;57?+W+LWN:JBLU>!^&E.U,_U[< IB\S$:/G
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M?>' Q2X1.,)M ^\,*%QU]*TTK&Z(E7!4J*]QD+=ML)8U.2=-+)TN+1UJ%W_
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M-.)YX0J0<RHK0-TOF&MO'5))UOZ^IG Y\-[+?!$+E.@EF7:3F&FS-(\V(M1
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MM:+NFEY_<]HHB?C]N4BG ACT1&:?2MB+W1D=42,1", 1%8YW*G6#< 8/SOV
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MYPNFLM(>O>8QX?'+ZNQ^^OL9QO(0+C'*J.P((&RLR?/EVL(_YI>57^W&D8X
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M#*9V>XJ@JXAQ-Q(;)?<B G@B$-YG!NWC$A KO49#L\Z1[TV'8LT'N].#B]-
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MER3+ 63A!.+P'/H($+*:J7W8"6']5HB<]P0-KA.U&=P[K--[Y&(V\^&,/ +
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M8>KA&_ 4^&,T]ZU[Y_0J6L_)%75R&Q?EN!2]ROKIV.+<I&D+?EO.;]8:W[@
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M8D_,?1K&<N@MTF$&UAI=N1-!Z73M-B4-0;K9.N+9Z&X8#_;,<.M8KGTZ9M7
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M$DIE14KES8I3@-#6%%,S:O#"5ISAM9 WZA+'#'M*IK]I2<K09#M55?+(![K
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M?=@VXP[H]R]9M7%RF>V!5(!W0*N:\( D<."IV,B($S0@7?B0*VG.BRS)T84
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M):!F*6D=3=M7#G__VS? 2;CV(5>[V2*,^VZ/)WGC4D^[X4\-$[^T:3 ""U=
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M+UT9PE>N\;<OM]N7<\-3\&'$"7[R(K0&1:T+LOF>1CW[LQ!43J\B\62K.-\
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M\SUOU<KJ:F$%3[:T1C//GU=_X^<7H. SU:X(8DW'_#H8^/!:&,PJLWWBR(?
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M^.Q^[PV3AP;F+V=Z6#-P?^;/+-U(/($P!OYCNU<.B,( EEH$$>F+DBN(@09
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MW)H&1'+/X=$X,T 6$F.HAMLV:*!#6X]97#,OW3?'E&U/FB>7CZ%M@"0X12,
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M#9Z0_AI,TYU*FJ<S#_+@+',F(L80,HMH17!*:Y]>:%F*KA%Y&X=96E@2[YA
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M<1%X B!G?4XWDWA%(GN^X"/??$^./5&2F+ON(=CAQ9(5["/%*U[@/]..T]A
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M8&HZ\@&3<(NJ44@QA]KO@6(RZ&Z-'"ZAA4Z_)@]2UQ+ !8E[H,MA?PX0>47
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M^-K7$5KEK2D2DX6E-YAI7]0BVE_;7R3X7/^8=X+(.W+YH=6QU1!#G6K+9?8
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M*VNG,;TIP[BL31YAGH8D(ZFQ/P@[H= 09(L<XFJISQ[H ^P3X8.)J-E;1_A
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M&@]0CFT<$>I+VLGL=?BRY#&2B<R>&&?,[X'B#R.T]D"%B30TZP1.B(V*"K_
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MM(.AO^LU'INQ5K)E.-&,[G&.]2GF-]1'R5A?U2#FOE3;8 F[795[CI6>8/*
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M8O]U[EJY @3>=P *C #0[ZWQQTI/_F]EU0E QT,$(-?XK6].TEX!Z&4Z[X,
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MYT[%&G70,9K92$07%"SGN_AAQ5P$7U4I /FAKM2''IN7+]K KOZVB0SU\P;
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MM%6+ !0S);*@K8<3]Z/4=$9R=0O]0V;C%KC*OFAOZEP3@G;O89/M3):[?;0
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M2J)H:]8\<?,?H!N"1PTW">SP!/+1$O;!&\M0J2;VF[\#-_#_<@E_CW$K)5(
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M&]%9[%,^[AET8S3,<*L A[!OK2)D_((CE)B=#$_6KLMOFX:*AF^^ YYZ3PM
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MRM?.7#AE3]N$(]&[NDY_580I#0ID <5Y\P%X^$\(#T+4Y$6FPF+?U=!<SG7
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MDL3PBB.(8'\>\?(KOA-JV@H>:1A4"Q&,;%(=I(5(GK+!FE2&VS>E36Y+"CJ
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MQ;][M4'V>'^BT'>.(1XD5=5G6\P+=L/:,R9[/W&*QF4"<<,7-*+NWQL\E:8
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M2XN8BURC!;:J[,4<5SFH(5 7C(FS')P=*@BT$#X_<O#3)P?CZ%]B#6QO@J?
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M60[AO;*ET"3!@U7XY.(636G;,' O8FK*=$N+$$E@W6L2@(9] 3.+O,]S&^*
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MW[(K>55I>[4_4<@S9C3!+,W$7<;O*ANA7+2=M#'J_D?T:YR&+<B1J;SMQ8P
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M68E$,AYP0(DRY?I*L?VT@Y=7&D\%G8:O&$^DH$(7UI$+X\(L\58[P5X!B->
MUYBVMX6-6.3B17>_ +TAGAY0;TG:PV--6&;[:#T74*L-/2]^T+CEMJ3W]P"N
M\B[/H+X&O3<.>UD9T4F+#!MUY5O3RIT?R\3W1A9+2613/10ZV8CRU8#!7$Z;
M,_8]45D.3LW%S[<&^<IM$N\4:5_0.Y]KER#0O+ =7E-6]JY%_O!Q'M,3^)TT
M5CPER^2MGAHG+@I2Q?6I_/BI+LP^,+[)<X1YM5<A VC1N4K[M5PH)BY_QNX4
ME;#9&+? '?S\5E&),:]X"D:17$WO@4X.PWPM'?@4PC@.D$O -#:BIY:866](
M'8Y\4Q%IG_KMPMMZR:Y[;\QIEXCVIJ.]A4\26#V.J/N#]H[!OOU:0!^H'U5>
MDB:9Q"5$.U#19E[**-+H4XL/$T,^2''U5RUVPKK"_N$)?(/I?K4.*RD-S])1
M0Z$3!I<! M>BP%3/*(G^$,QG7&4:55"'<%/+T1-GXMNP9RNH6!R0ZW^79/+\
M8U];=F_EHI'9L.RBS"[%Z\_XADJ#9?^TC?EZWHRJQ^H2:S9[>V?$<._A]\63
MY1_V\)2'UF0MW@.M;KAXO>]*5:,F2Y>4E2Q@@;C20]JJPD_R 4>T0&2I48J5
M3:*KH6?MS.:=LEIU&.KQU[[^^UB%]V:E0+O\X^EIX#J5.&D4YLC@S*?QME*=
M_:R(B;>\MP]Y#%]P+_,E'@6+%X2>OGYA/<=&P#:GJ3^LILN*$'UM#Y2Q$0YL
MA/VLET9^L..1/V^_EC]_TTU;CL]<_OP;/3[/2ZG]]\.$CDB\+W6I<%;,-DP7
M4Y;/C)QQUD[46W>^GKW7A.#R1ZY>.E9BH%!LWQ6E\OI<,3Z_.E2.+'@<V':.
M[:8*0MBAB3.$?S15 %IPX6CB_VRJ$ >;KR,D!IW\WTT5&B-9. H7Q^S_ZJF@
MK]>XW5,!\J/O9G $:> L:.VO:9STCON)9!G%8+FK]0ESW(YM0E]<=Y7>IFFG
MPFSXLYK*5KI0*:'[0YP#JR';IC2^4[UA'#\]W$)"S$"'J!V/(($@C4]+[CY<
M^V<TA*A<CYA*CN<*2^VL9[;X<0[D90ZG^Q5HHX)Y*\('<_,J<V[] -_@(O3[
MH@W><=OW*Z@U#BJ&W(!KQD5@1:E!!]TVZ%4D-QK'^JO(9!.:"&BY[IKEE:3B
M,YSTZ8-V1DY/L$MU[\Q](=O<KKK1$/1;-<M6!3#_B9ST4FW"J>BR(?Z8C GA
MW5J2-]4T8EM2,_9ICNGQQ^HME;I*W'!<"S=(,GU_\<NY'3@I'^=\JQP+FB?O
MQOS@H(2"Y%.;*(M[>5D'1\]N8W3CO?6_?!O5SX,C?AX<\;<9?[^#([:'F6N7
MJKKVQV6C 1EW_(+L8GY%X^OZQU+%JEVJ!9D'TZSKG'O);ZK>A$T(3J:(2KST
M>_K;G=L<J6=W4O.G\,V%6*Z@WP;JSR0+*-6J#0W5]H2O'VRY*ROKH[HJ[2E<
M69'8Z^$FN^C+<3+@SN,F?&X_SB3"L**BH2H4X"-1;="?W\^3C=KW$5UPNV>M
M'' M7+&UF1DY_N\/2F4(M1MP33UP3FWXGB6M<>QU7V4DL4+C./B@I1RLG;;6
MC^.94XF+<X>.S]E)$/N$K:EMC<50(E");IK1..^_XWMSKZ(_OH7D,L044[L^
M^_U!Z155B>=&G%V^6#K)H3](\XG,DHC"P:/'!V0J8TUH92_Z8M-A"L%&=* >
M0T?!7NHPQ>AM3Y2*^KM/:NXOYNTX:&*Q[;C\6-?+]7^H<<^-NE<_\2DU[]*G
M :$*!3*^)$XT>E; :T;T;)_\N(&,P03N*-+A;;HE.N1-!$?J994_]:+G4I)$
ME!@+',Y-@_?T(?3UA!-/LH)%]%QX7'@SF!HG.@NG4QQL3KGPO615\6<SCC[1
MUCN _E*0*^FKJNVAJZPMOEG3BS; #I/*-V*(]J0XN_,@<DJ8N$A<,'HUU\A'
MBVV,+9I)M7A:+UPZ)O,]@N(N.6P6!S56RG);SPZ/3B2^!+M^HRF%ES OP]'W
MMF[!EZ N]/@;Z;O"%YIOO08E>UMO74B0N'UOD/PAVSS,23+A>T*"@ZA3IY)@
MNUQTO>/13GEBIM2GXO!2"RX[S@P7/G&]4F4K:J&AX<5HY\J%_B&9ME)3YSS8
M27Q2?IAV!6X3J;\1X>6>U&DZR$;$01I]E>^@4]"G6L<( K!?S4)%L<*7O/R8
MUWDH<"/L]E-H3$]@E#^?MF.+56]&B>49;DTMR_#+=@8.#5N\Z@VR?.$J9(N;
M0C-YY.@[V8CP<K!4M@UX(D4'8#V[L]Z('*MIT;?,5&45WZ+9MQM?\^WBBI Z
M4YU#\K_":.%7I"O"$,ZWX&%]?1 @"P\'J9-G?%SOT ;L)*G3&\+4+O+W&II.
M>Z!2R-JE<Y;+2[>"+:X_'O%X^<E'_DVXNJE=O>XY-[+BJ(_<WJL.]0171@>A
M;_&T*X-QU0'RH-4]/5[8>*C+!;XWL6[TDH#X_*,,-6T!V>CRF/1E(]XGGE[&
M,4Y]1/GB9E3A/2ZNSD['-P6$(_F'&CE[4AI=S%[+V%9F+_?EI%IX>!,2E5%%
MP.V>D$_^V:U*J".^E:OR^-USN@YDAO*)_J527]DC"M%&"MU]-FH;BC"!BQFS
M<ZY-#!%+YSJ'#\Y'6[IX=KZT';7!%@PKD[D.S(KNI3:&D47V(,7UJ%":>[Z5
MQ],AY26U!!:+M?QY<5$F=X @E91V?6 INRIB,36LNWNL_73*?#;^>\CZ[W_A
M%K*?6\E^;B7[VXZ_X5:R_S7X-D<8=X,.U!,3H?/^.@8U]2DR54S-ZO YZTB3
M'I@$5/8Q=1SSY0WGW6_=<J%C3[A:/^,KS6A,*^)0.!'1JE($1?;^BGR'6LQE
M\#,E6%70D6XJ@W((]7E"O+=QO( I!Z;DWVSQI1A%8$_7A1_]5DN(TBT%JH(N
ME+"2WH^U:W#6-!!>T<3"2M,_33C!GZF7I<1Q ;M1O!J"X,8D*2[(F-I" <+6
M47O\5YM2TU/_T8JG0VC\YKBTI\UE:=.Q+O6GN7DNYG*C<ZEGJG/'[69&Z;$/
M;I4Z56]L&; ROK(1\TB&,;:+2(UE(YR8>J!K/M"FQ!@C\?F;OY?=Y-_J]"R=
M2:+%;?)#:[5):3QL1)O2ZH1E/O,4UD=#F'F150'<DGV,K,(])-CN[;#B3WD1
MI!-WK:J*BFHO/76E/X^V'.)16:A@W2#TWGJ5KKK, _)A" V6Z\2(T:1"SMA"
MG2(2:3;>250Z3HMF%PV#0+C=&:-022/)[H9&\>-M9J%9[\;U4K2<NQEN6@<"
M:_]T*?+(D^+@"OYXH%%48\BLD((5C[YDHOS%7&[WPNS=&UEB4KE'IVX=9204
M&6D)O?(TSC:W\NKL+]KD4S:!$#/X+#;"67;$?@I8P$V-:[Y%"3+Y"F=X=0KG
MDD2/T=P4 V,F=H AKKDZ>5]Z2IDHFEE;;$9<I$_;ZZ$UZ^+/63=]<5RZ16/.
MHM)]\ES<'0'9HTP:^O.E:W8"(N'9,4VWSU)>O8ER*3VD+9KCTEML:&V8<55)
M4&8H3COUOG,V37+ ]=;<0)9=PLQ0KOB!A"*MYGO/Q_4NZN8/FQ4YEQZ%D>S3
MG7]G>1LH)N\R788FODB@S5^E(N,IP>)DBXBJ>=Q1Z+@_MKT9 _X6I"B#_]ZW
M5O=@W,ZIL@O@!>=-85%*%J)^ !R'91?J%RW:D=0H,.)7JM^3Q9=K)%"<Q.35
MH50OXJ9D3EG3]J10@ B@(O?IN&DKB<_#)[($($N_JAK$K*7%'6">KAETPUVC
MH2*7%=219GT*,EX3,J8M %=CRP. XK1,"-WN5*UFR7K)_(65@>7#]C1R]F,/
M!R% /]=)-H+#J,R69.7_X#>5]IIBUTPQVNX/QET!!2ZU#=]?4X CKLEATO)I
MJK'6)@/+Y+X%>0S7[#)_?,ZL57#^%/8TF/N87'2T)%F\Z+6-EGG,;&UEAC)Y
MQ='XDLJ;2#N]FZ!X3T33BM[YY[%N:!D%PW#Q)7^+4*GOA+-3M$\^7N\,Y:ZG
M)KA,U5@]#U.X,R2$YK!B=G8J'1!(5M"S56H&0B%.T')R>0_S.'AY<@S- >JW
MW*_*/$;U"ZE7=O:^=^.+386TL93"1&&I:^I0H9\Z5%B$[BEPG3@]3#@X;FW>
M,. ;J[VT-+6!H3N",FS$ >#M-,..2ZH=DF H;$0'->@LTJN(]L\9# %MPHJ)
MZFGH?7EC\N+*&*NB9W!I'2EE1NRC]-4_-:*[L%)+(+Z1)@H;(=#D#M!$MT9"
M/<.CYGJ:JOR,CZ09]N==H7YQ]>.NNUPR?UZN]9E:K4:<E'-W@8L0K*C-F(!Y
MJ=6ZBWFI2:[+8)%AJ17!43+19;!07"51\D::=X9N=XVAEX=)O%>\>Q5V;-^5
M]%.&Z?;[KEP(/;&OH)D[RO@_U.)7G/VKBXY^%A[]+#SZ>XR_;^'1_QY8=^PG
MW&O69/U@D"?UZ?N1$J'1*9-!YFZ/\MRO2I'2!JK^DD-'186C79_846CUE_JL
MNAQE2I(RCUFO$?M]1%37DF!?MX24@W: *(:>_X$I<G([+'N=,S6H-EN9::5Y
MR8!GX6RU%;8BY]VR??%,*CTD.-<_XM>!J7#7!@UK%I=9_U+9FKN^Q2>\&$Y[
M2$'_(/&;'[T*Q@ A9@"HQ:J>0H[TW& CPF!=11]FZ)NP$:$6G56]C1=!0"\$
MXC$P72!]QMZ>P?&@RBL-E#3[&\<FYTM1[7;G:>85=!17T&E"9?0'Y*PE+9_N
M"/,9+I1%#_/DA%(R0P,%ZKNYY]0SS$K#06Q7R0S1XW7YH-^(+MT?SQPSL.-Z
M/6L,.'7ESL)RR!3Z/<B0A<.*,\^N>M3K9+'J+L<Y,LWLD $$-!<'_ <T-B+W
M2W#FQ(9.]U+VG@P,J^%6+N"$/MT["WA$H90;^T-!QA-0)2?)(LKLO(*D9.)*
M_>U$-P[+1<D_\KL%R<5ZBJ:EX85ZOLH211-#\F2^R6DUY<3I9T8"6BV'C[[I
M;_ODDGGR\+BV247L37&_HV8Q4YS.*D'/$]+8"&D]*18'T0GY>8Q^FU4(5(B!
MR]0'+:(J VO :YU\_^3N0>:%*2E7#A3#N60-!1HP10K!!VVK_K>%X[CG!;8?
MM?24=I%K%*Q[%@-\J@<6%STFF19@-1NQ9]5?<7ZQFK0#Y13'.X.Z2VWKH?N%
M03*@M1[-D=X3DP7UI?8L-JI2?;8K=$(=6X2>+B*-:E8TCH$59KWU&?J6T8P'
MBXJU?/BUNSI3<?N_7XB1<_'_$'(X7XF0K]:RZTN:KFG;[[,J2T,V*_C'+<UJ
M[_N>FR0 YS^HH3[>*ZT_4G!7GE!].CN\[+G>T@W7;E.+NF\W:'QW%M8,<MB(
M9"$I^K(U;"6[L:.IYK'%,/4[S\I4TP_.FTW>H&./]:IAI@H4,K!S'X>LHX-Y
MK^):@8-K7%R:A7,5VDF*//.C],AL'5\UHR*7+?>HG@"NL!D<51L-GDTJ+ID5
M@GWX+4NNQ5PE*?_6K0"*.H9";)98<]\QM#(G]2 68Q'2DGEIF*FIF)*K>8J$
M;GLQHS)1(5;"DY><XV+1O3N=Y*L9]T;J\/Z!_#;E8_9&%+/50QI"&$.,5^89
MGR*S?BBX';M11W,*6C<\UE/X_D*2\9]*,AEJ"E:OK<8F$L]^/,]&5']Q(P0B
MDX]8+'-N/[MD8(=XYU5^$ST%$AAJSG:B:::OHNT&Y0V\*8;$DME:^63C,X5
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M6O/0!8D AR0+R6<=0E)JSU7_!WMO'I5D'_;[\F1E9F;.I:GEF#E53N7$T^"
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M=C;Y/[\N&\<8M!F5G8EY>J3XCXZU=5O_!\<:\!CVP5'U!4H2I!ZQ2J1'1*8
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MI3QB4H1B!D!/3+GJUL$0[C=<JPSI1XK#MYJK+.SPW'EC-5J45'>K%)WR$F\
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MZV75^MIVRK3/[9\=IFE4=:B(?R;N8LS]44V-K.! A<M<E0#F!E?P.6.%*X9
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M ].[\[6@8ECT#T!'![WF 25W]=OJP*KSVTSO!\[9;W_4B?W'*%6EC Q($?H
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MG_>.J& 7,1XQ&(,%J>J_JKO)'/KR\$WAQ;\'G-UX>4T>T'H0;LK)Y4JR?*C
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M>:&L3EQ"9ZQ\XH6\QSFI_OZGK/GOB+BYR9Q];BH/XE0;VQMG<>92%9KU6+_
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MW%+(9;$_R@9NM"]P:N:2S'L]:P8<^P?AZH/?\$/,,SE10"J+"\Q>:V+3].M
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M_<Y[QSCWNW>,\\_Y8X_!(&-G9Z\UUS.?9\VYYA2G"3UWR9LF'%F "QCP34/
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M8-0J%C3J<4ZW[/A+AG[PH2!9KC+"$Y<^AKZ/Q,N5H8B[V+:1F,2#N,&TWOZ
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MV#5-47H^4S;,,#EYS^C>W2W[I)8=XQRNN+_0IJ$LU>^)'8.326&OR+6YJ<%
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MM&Y\@7^'5MJJ-L&< 5/,P:+H 0@8[UGLVL:" '3J2#N!'RT$.$S;#0= A#D
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MC/7V$SH%T]R 7W\+'>5C+6VQRK8ZZM@@F^]LT!D(H)O*NL%#/XZ91+-!PR[
M"'QA%%Y+@3*B2\&TTX5LT*??QHQ9*F?U6:F6L[K>@UG%_J^SHU66!5HO19_\
ML/=_PR7PA\[BXV"NTD/*$JNGNP6R4VZD 2.WHP<X8Q\$^;-J)(,9K46:L4%V
M'NV+C%M%'E1(ZI^X,<S^,($^'""/8^1*$+F90W#F=8RP"MT&1^YD\:BP0<I<
MP!XV*!#&!MW$MD6S!CZ3RC>90N&86$PX^CX'.,L%_^L%Y$-9AXTY0$4&.-_N
MGD?$,!T)1Y?H=_X?/I@'8"S37QR0$V.#-MX@1[<8,1R A7NA[S/RF,_9H#\
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M#.N!GP2NB718W,;7I[?:I55HJIMO9P=?/=NVLO_5A,-\SR"9EDCO6P\4VPB
MEXZL/-3*O(DIFUL1P3_N"$:) 0E2.5_L]MK+4\;,)+[/__G^+>O(^>/FVLOH
M0QR:< \],74N\V0%![GH[7JJZO,*#=0,SC)%B7&5Z6AJ?0&P]@,:,Y>Y-60R
M,H8Z]\L?_EK,<5:3S&#CV?B_&HU@;E@N2@DPH8*GXV,WXB/AO REST!G>]U@
MED_%Y%F9+A]?&>$PJ&WCZTZW7$_:)9-0IN/UFLJ!Y>GC)>HBCR*8'8#T;C4
MJMOF4&8!_3+#H5]+YLP]"U^4'*5,LC+#>W'?,Y\YJM_+^ZH!Q5(S(<+2T,-
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MQ42O7%S@)!N4R-C\K2R9;/ON[:E/JC_:N&SW*;Q]#P+M3[0!_>D?B43W3\D
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M%<GS:QS^0;.KKO#1OW-\6E^\DB6=B_62?;X]W>-F5::;>=.44M )H.8*ZJ8
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M_(&_*R+.W(/CMF*X7I#3_2B 77X7 %[@H+@O!;#N KJ!I,WA^;]5/ [TX.J
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M$%E$)K$U1-+<^N8_3DUHH.83\!./V2: S763X>M+YJ.IP!VMO_Y#( +Z]=,
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MWN[O[(R_>J>KTH8@PT^NFPU>GUKO <BA?2+E X,$,'&@S_P_KE?:(9HRUY^
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MD#YA34N66I()1MVB#A0R<"%+U#UX;7X2U149KB_2"P[RHQD0%ZYOT&6TB<Q
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M[H%B=O,92$9!.N%+Q_H^X\5OF7_Y:I$^L1825?$ W0H!7L?.EPU_@[2GN*4
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M?L;J@M4&*ZLSVUZO9[QMOFKO5HF+3;UT44QQT,-A>-"['WFTV]S _/=_))O
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MV3<=ZC4ARY:ID\27)Y,-I1G>X_-?QDI;'ZNO09'0?I_EO#0!=06$S^\Z/&/
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M.J@MM.L35[YAR-I!![MK?/Z14TU>8:M;MJ/C)"IPF7:]:?!V#_6MZ"3I(N"
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ML4N/\G#.:=DK=M]I?]ZN>Q66>5*' JE(3;L?'-/LF)-?30LR!>R/U=:FJ8;
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M)M%S#-$](MP"@Y98[8"$]21;L?9W7' C@1,Z:@9;)RSUK@6&H^]B&BQY0*O
M2>-*81IQ0$CQ&SVM8,O>E=(EU><S D&3$+ZN/AMWTL5G;[<(-83/B]XY@$E#
M5.^6!MC]>%WGGD<UK&[F.\YG71'6);8< ]DJ+&LOO-0M;!=@9Y4@WM-4"!0T
M$V/D ^7"U]]1.^#N0PA\GHBI+/:Q!+/4K_AQP;B)'+V!43NE%,N%L,T9D2WD
M-X&O^G6A4T(6IHOA;W^H^-2>&_!8+Q4PB3!***V*%;L7/7JW[Y%+@.3(L&R
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ME$*7J1]5M)NW7^]GWIW#Y 0.\O_DP/]Z6R5/=_1"TBEL$GW7O>'_:A/AAGA
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MUS#F'$7"VI^GT1PPYE^KZV,ETM07@]K_'*(FI,Y@ /FVAF&2"+H%*[RB(?/
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MF5K/+!:?O:Q=H7W)VFB_K:V)8$GNWI+<HS=!H8?.:B29>9;XYF=V0@PU2<G
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M'OOD$#A8S+D^](='9#C89]GYM//>B4W'?DM_I.H.J$#C ?1K16^)BD^]YJ#
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MCR4V-*3\6/YAJ:DIYIRP4R0OB_.<0&Z _C>2T-J*8J79&'+#Z=97OR?FB18
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M?=B">0>'K(#L.WXR'?Y>=SSWAM2&I#/4I?34RJC)ASUM< HF-LT5S2+$;([
ML>W+G$$"&*G$\AE&:K+.5L9U7MSN?@_3#<E5RXJ4;B6ZU\A 8M827-3.CF=G
M'Q-L;=6?JQ7BZWS/;/AP)">!$WVJS,4Z,.7\PU"'$5?[P,U +BCN0 3O-6^2
MCN7!A*FS/"CN#J93,,FH-5>\^ Y Z 2S2BH6SJ-SS79*=XZMD=(JQJV[ER$9
M$.!A5Q=D2XTDP(.E[M,B'/L!+NC@X1TEF$D#!<(1:KS#!7VOY^2?RD\Q0J'6
MV;J_/7>.-#)BQQ*\WD#N@9_*:+2&K1OJ>C ,ZJ<:J%@91*)Y5'BXL%^[3,=@
MR][12O<\]U(95%RIEIJ,YL/WOR_ZN3UX8?6[\*?V-Q[,<AHS,"1#9/TXAX?\
MUS%B?Y"BC).5%)K\T@\U;?? ZP,5\* <G9EQR2]2&V-T5^(/_U_W1;]/V8CY
M:[/R@&Z.$'S['B*Q%]-6BQ)HW"4D=<CR'4)GVX&0<# DTYL1%V]@ZJG5/3EV
M/>ID,[MY3@TGBP2K"%RSE_4=P]?Q(-65K;D\0FS%$52+"<&?="RLS97] 2G_
M2W5S*E>DZ3,0\4ZN!,PZ_@05^\,R^=P1M^0/,W-+6$!QC)9:@=!E8AOHF$Y(
MO(?"6! X^8D5]CEES !&=;=SV>;':(W_TC XHM3#P86'*IY=Z DO!?S/MOT8
MT9Y4^YBB)Y_6:F=5X%U2>>-%2L!\3847*I-]W_$;5&ZG*#6<B9$.18DCQ?^(
M ^E+YXSTZ#-PBK5,PC^M;FY ]&6=4)GN*REWZQB"?E)GG!-J'F1MC:*K%8DC
M.MB@)90V1(Y ?CXE/W07/XKR%D%_1J2<:D\9!V2IS\_.7^R^EGD'[C5M)?;3
MAQ@S\U6T3:J TG?0N41]?EW;40DBA#\5<1I(I+MV/BEL6T$C14<-)*>%C[YO
M&@A^(ZETUNK+.,EI\M)?IX4L+V*)=GK)1W?W^;'X4F:=;7$*I#^7D-H'J*UT
M6(. %>8+NG5THU)@X4(]#T60]KK_\;@XJK41&UPW&NQ_W_W&>*NCM(V4F#OP
M^*?AY,2NR0<:VMO91PP:_FB\2[Q@HA1<F(%:7-,ML+7-4!EQ7AQQ)?S>",,F
MWK)QE9/KU\9(+FXIQ[ ,[SPJ7N0HCJQ-\E\9I#E&CN:7+&R\G-_R3ZJ_%Y"[
MO$J51;Q^*?3/NY<72GNCMWDX,,H-ZIN%69+<-G#SI2E,=KT#JCH53M]MLQSD
MR -=UP<D A0W87E$V/S^W@'!3HDS3_-7OJ]"GJ*$RI""$1(\3I\U:#8'C>/P
MT4FQ >74P\E<D-U04#<"EV1U;:2+F5O&G#2.'6ESP[X.JG K&TUXHA!U@X:K
M]J_(-GK(+L?KCG-ZL=5Q'16)/:KG%I"'Z6432.ED_Q=U'N='I]2$6G5HXO=Z
M!!@'"PJ[$?'EW7<DASLBOKS%D&MG9ZG,6>KJ:EAY^?)<^NS"+-4TBSI+#9-Q
MGLN%"9FK#EG0%*OT-1NJ-<7:LSBO4.1&L*S'T#7@PK;!?$8XU/$K'JB@+@:E
MWHMMN['M'1LA+?'LAA>N$9_=,7:^XZ2"]$7#YRT>9B-YG >+%YK\?R[DRU[C
M@GZLK+IHC+!:"7E<$' "W'Q[E>6\(YXQB'\.$6"):E7.A"6K&IA.)_Z\&KTK
M!0)<75OT^_(XI*?,.1.D>8W4&X,*(7TFM/KKDNN6,N@:S4PA 2SGD"&X0^;W
MC^.B852H[&4#UXH?]YO]XJG#N,RETMG464YO377\&5.Q:VC!E0$W%8N!NK_Z
M$>D5:U#-Q3.G\FHOB"1"R._!<BA*#N$>"8W7JVK:ED8'1QX'1'8,I4.O=. U
MS8,2]<=/*NX)?@?K*T84W)K1>B*1[\?NY,B4;!1RA/(9BQPQC032091WCMP&
M,IL^9PH_"K3NO_<#3N6"I"^?Z']0H?!M/#@/82O^R?6L4#;\B)Y2[VZDD(-=
M: B-C6K>/!;DZ0,MQ>UX\T#>.*XQ>"Q*%1!B/Z-/_X<&.@)5HOS4X-B_#*:Q
M,?==":(>1+-],D.NC*NU6T$+3FGU=+A@?@;'FZ7_SI>CPM@70X&+_+(L\IM2
M&@WJV7-UZ!VH#U6RJ/L91O1_?9Q\)*!"_4[463.^&4GV)FLW8/XA8C^@0>^C
M[$OX;9CQU.#$AS^:[I=S77R?U)P56*?!4H5J_0/=L3:CZOM&V.PU[)FUO9*3
MM#Q6AXL#&CUE38?2_1>+%G$S4+"1&@R\V^A A"5 *-NT]B*+[%_88CE40]+K
M<TL.[#O&;^+XG9;M-J8\5!,>^!6%BCRLVF1:/D9&L:2MI\>8_&VH6%(U'A->
M;0,\*]'%-'KNM;W[KQ[[61_\Y=Z%S>+U^'KUPMFSMB9CT4:KR>!K2]D7*/_:
M\E@(;>;X&)A2A:$=N2?&(NRH0K^"U<+;ZWN+J,)PF[?1VIR*4I+UIP7':M&6
M] 7F+&Q&(6I5IC,/W;P,>0(A\UC]+A1% 7C/D&;&CJK6S1,.:@73(=%SZ0:=
M' U&T#[W$.;@=;&ZB\HQ)RY&?D]Y-PY\/[_GD 7JIB3#D24^3M9@:=8M9=)+
M6J1KH7<9-RH_8.2 >3F(^A]$72=,JBS4Z\D7T"0"9>6OTMK;?&C@C\VQOHUQ
MF@OQS+?()6J1.JQNR.L/H80W.910Y"J4'(%BQ_GN: 0:7$'V4;')Q&&D4)W9
MS*] </1:Y;[JZ?!_.J]MA]$R+.@="X=^U3',F_?N@XX6<RX2R)]YX9KRD#,F
M,_<\J(%4@W DAV2#VW(,%5*#:W*5S6\43)?T9QJYS[C,+%(2\9>"Z;AJ/GZE
MA ;EN<)-SIX".5C)$@ZE1A!?K4*K_()X5SR_6-'5ET0Z8"3BPWGL!FQT$#T2
M0X-WQZ5>'S 8"J-:W3MQX(B6M8C+PI/&$ESUL=07<FG)<YXA5DWII9R=ZM/)
M_[JS-SG?LJ!)P98:U8B2Z=PR9<R*AQ/3W92B)UI3L?N7YFT!M9.#U :&R:O-
M>*CD=R'4;F3YJ$-,'LSC2/\:7/B/P\WY>N6XM3+]JP,UB\'C\#L%,)V7/V',
MFZ=W-D>GTUO$9B@*-JDNN'H'\Q ]Q<T/XPM<$ 4_(\DB<$$M04:&J%93QA7*
MV-+?_*F5(>11']HTYK"Q1&82"TK]L]=%,FTB3#\@R%KPJK:0]R[C.L;KI^G'
M]W(R#:RIACR$+<,026PT"9?+H7!!0CY/ZN+7>RY[QI<&18JU3ML-KR@9()>)
MWXEA6&Q]+.%I13)!<IV'DPYS%%GN8XT=PP8H*MNS_3+1]._![,))]_-_B%KP
M%!?2U8'\SX-JCW^8X%Y<JA;]\F,J?64+93;Z JZLS Q91\U@3I55" /AC@QX
M?!!8$$!^=[?T8.A4%P"HJT.4(UE<D.,H_-U0S;A>7)@Z;SH_VS4=B.ZH&*T
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M>(4R\CQG'/7HU_Y5$_4&@B-A,R**\)4 *&\T&V]?0'Z'"++XPKR8$(D%E\O
M=)<O8S,40G^#Z) ?P0GI-X.$'[US_E:(<$6 M60D^%4?TUC9J!9#_'Z-+BZ(
M.$?ACX*7\<W%UO2$101/'YXQ5BI!>+<(<$$"?"-I"V1LU6+=:%9H[-MG.5O#
MJ/,'_L%.X-RD5GZSD?OL?]<XEK AT.8SZ06??L[+!'/*BMVO>'Z<#W%T2<Z/
M?$S5#]>7/:7XM:'^RZLOR;+AB ]9C@:*/C\0DB$$;0*Y%"7K2AY;@DV/NQLM
M$0$,=:0GH]7]4#[5QH_J4[X<X7JR0][Z=*/T1T145Z]M"=_4>Z^O=1=-E>KN
MD3SWE]]/65A"*8-K-CK#>;V0GM[H@+YP[(&D34-W1-!J3=^,@N-B2D-@1J*#
M,WM?*@X9:-XI</I^ZTSC9_/C]E.W$(82#OQ/'!Q<U42WPGC#_B5PP$@+.<:1
M&-/6UZ@![,@=;PD2N/04@W%\]8<)8Q@Y4?,$G]0?1/%RFQM:RD&3Z",3]71W
M=073&9H(I5\A/2?"GW-!]ZTE(FZI'*C?Z"#(03N46G?-&E,J=@D$J8%OO'[I
M9"Y7%TPM8;8(TA>D\N__V="EJ?E+WFM<UUOX_C<R'3L'Q"!-42U^N,4D!>;I
M;.N8[UU4+)JSNS]@^*B &HTRUGCC4YO"<7?@,?%ZX%_YMX]>;4U#7Q/HS@2!
M240J\SCC9)&_N 5^'_",+"+EOM?V1WJUKZ/<P;"'YT.ZE!/OPF0/FVWHW[GU
MTI*"&JL@7S?2(VUFS!5247):-B9W0\%C?2S1&[V=8\Q3M;G]RD1M,!IOV#C,
MG'Z$3](R--(\>3"4U[^?,+(W?[<HXX7X%@G:H\P2%6$6T\=B-"+N;*LCQAQJ
M!Y48V'C^)(ZT._3'2^*"QTFL5=6@@25%.]=!2"Z_R&E>1J?@G8N79U-NGTO=
MBYQK"]^G_FZYEN4M9Q3@IY.+?1\3W!WS.64+$C90$&><"Z+?U(B!5I)BX*H?
M&H=8GHQ\N\_WZ1EM*OH=X6_NY4+6W,,[X0]FH2* KUCW^807%W.;*LNTG'*D
M-FR&8 V^_YA_^Z5"6-SZ^I? DAQC]E8#TG3D(CDT"G</+(4_#Y-VB=SXN7PN
MC+P2NY'KG_ZU[(;G24M7+DA<?A(!-^;O?MFZ-5L"UW*4,?F,W3Q6<0DH9%SI
M LOPT#$J@22Z/HX5!;HZZE]DI5<43;PL=BIN\_?R"G@3VV4YY"\?;3VXMNAE
MZ0ZQKJVKJ4N2CY$(8]]1#OW=O_3\@D) 0]T<QSV*\!$.G!A;ZGJT ](1?<Q\
MQK7<_BF >('%1^]WN^I@3''7O8E&22.BA,FQ<<X,OICT!*_S;V;C$7Z.T-SQ
MF]?@'?"?^4P+!ISVC%%H"J#R"V9SR#0U&JXB(5<#K=I"P0B8ZHG'WW\EMV]L
MO2H%AI2M"GY5B ]MRA(OF*_/Z:C;$"&O[ <"F^4DZ'-1!B<*7'V04O3TQ$)$
M>-N6259:W=!:SIE1%7T5GPVIT',M@@(GTW)A,R2M07/59-I-E\FRBT\R1W,R
MSDRNS!#('(]"<^@_&)94Z/082TV#F&DD,^](\*%W->?L@P@]3[8^3[26 9[Y
M!Q..N'<:MW;##_<;Z(8>N3G@ 3R>";@]@;(CR")/_R'L18I&7 -PU-U)!2P(
M/1E'-5>;,A8=#EA24_37,(WIV[WH,B+39U[];5=YQ1W;2Q? S1 TR[H,,=YA
MI,C(2-  V_ "<S -VEY/8V62PDO]ZF,ZBXHFORA2RC4"/KY^\1;>B2C.'IS<
MX!#*$M[+UJDGFO"8US?D?;XGIBTKL2XKG2@T5@0O <#,1QM1U![I-JG ,'_5
M$)5BCPZ^J:+':.-MJ5?W H(M9_>&A82D_F,F:!76A)Q'M0C_:Q^X,R.U"PK&
M)6IHF@,V[W@?:%*<=TQN9!%$ =I* $WQ>(EE/N+:L1N#J^=P+Q'%K9<FC7M4
M:AJR>]TJ'R\1CF5045:Y?/3[S^AS+1YB=/X8?ZFV-@]!^FPBQ5_PA_\/&8>8
MPO'YVM,*9SZEP*O'%:S/W1RZ[N'8W2 ^8F,2\/!?HH$(+FC;69A4U453QQ.J
M>0C(9I-UD7&XXIU*"\2WLH'IP?[@N,U+K&<Q?92Y^)@]R8LC2&^ZDHF$XX4I
ME!.A,J,++,3Y1J*;0_>P[C/N=IW[7 =DAK[W\3\5BQ('ZNR!DNE(W58\N.[X
M$0C5VQ!76E?==K2O\ _#5R:_G>YTG7]UDB%+%4%S5("5#JR806"Q92E0UYGU
MFPN*UYZ\YO9,>YW5HV("EYIU=94U8S487NR45UM25:.5EKTZ'J4%_8#R@1#/
M3W=!^7@Q!_-KL2TT1>,I4H!E5#NL[40-<8T,I(:^F&UB2,=K?#2NL< ?J1FU
M:].Y[,/J=C?EB(6=>$5;E]!FC-B%F@>91S+9^Y^'N65/V<)_1T+(7%"S(.<E
M#_LE<4&?"W^2*]D51F?^D.9#'UE+-[/WV-:UN3I_KW(A15A\J4T+G)WJ'()-
M'3S_2>C^&.<$^H+42ML& QG (^@ZD+OZ*\05ZI:OW*GJ^FAR1EMBR3%'JE2>
MP4_Q=EVO1K9*LXS_=__ T/+#+^J'1WM3YCWDDA?N//+[!/4AP3A]JJJJ025"
M:AJ6U;BAFDF=06+;C:&EV^C1[YV=O1)U-=75N&>VLGZNKHCIJ*G]-O*QBF;3
M]B8@/=.2311V?:R_MV;IJ]0*==4='QG19!ED8^(;R/<?5:TC^K;O1"!Q[$R(
M-R2!</BH:T\)CX%OBSQ_$/!P8$%.:ZPP\1J]J?$E-HLZ*NS %+YB%PO!;I_L
MY%RZ=:V7<-V1',>2+NP*=?%NQ3PE"5,RIVL9&(R!'77QYP!Z<Y&L)F0]2)M^
MHT%Z;C7]]VQ2;YO6.3.)QC/_?%C*/B.49>,N.S;@RP7MV7P[MD[S[K@X6TV%
MB_HZ/NDE4(_9<D&NH^OAFR[A-#N'$?4"_'"PT+?LV?39U>6P<N67JZMF72]&
MK7B9^=%VVH[@G(=%;6%<$-A N2 BA/U>?3U)DU);J9J*4&B^J-TV[]*55*I6
M&!ZF30MWM-?-THU5]T;[:'6[:RP11W%B.H4'"PI@A-O93IQDO"2R#[P'R>_4
M<8>>0;%^QMI?>?EX.$WH4E6<6^.EAL B(-EG;FP=9D%QB;2S;<Q\S0?;#[)?
M>29"B0,4Z&&-DDHUN2(\Q@PEGZ"$5I]F.O1+MQ)MYXU,TRWV2JF ! _>BBJ<
MW=?D4HLV5V=S0>5Q$G.G=4,&Y^70DV/(E35!EANO*R/( 3I+!]A5P#K0O[X+
MG,C1@[X;H42YN?V,N$ ?F<1Q*@P^:LZZ)J'<K!2NUCGO[O@T7T1UDGSK>CUM
MRW[[*G(0)8#R6HG;X((.<52!%))9)5H_?LWPH, );/N4QDA>O,$3<$Q-7-9I
MG-KE^S[/J^ZK".L<,9HL\7"",;J#P0RU;5O.P-1Y=C%>"U$XS?^BN3K#,44-
MTH8'QX9^J:1CG]<,G?%!'JU,&X5H^\NGNY9LXV(G?%UZE@N+9<-#\3XV-QP<
M%M;63 :C']O^P4YMN?9OSJ)5%OI^)I+CV>\)OO!HP@'U,JNI9Y^ 8I(K(^)!
M]GLX/\+V=(0EU36,Q'?'W?KZX.P ^54+M'9!IS(F-/C:-]_!Y>#_J^K;J"E+
MW)%\F(V%W+..?<+'SOC)<IWVTV1 .K_S\.P>=T9.4]ED6M*@*%Z_3*3M$( R
MKD_(C)J<SSC8$-&:OV)Q:??3XMW%3R4O@4#[0*"'H*,@O=WI]5()ZEU[0OWQ
MY7/=D-K"+B<NR!O\"T/MZS +L"5Y#+)TC3#D9HO-%,1X>V^62,R4'D97J' A
M@[ZP\;*PAYU=Z/&/LYA.,.>08HKYAQ38AQU_-G.O5[]F4DSO]BDFMU<W5*HN
MMU>?XWVMS1;:,<O$&T;6N0%VV[I_-AK*UES#D&<04_L_3,3=&G;8N$2W?TTQ
M6UU6#1IAJ.=K-V8GMI3-.^ZZN=>;$^9WNJ$AA$,@1R07GZO1&+W!!2GEL:$_
M5+;,=Y856'S;ZJG_<UFA4J?(X'\N*] >%?[2QL0;^(?OHT?\HZ&1W283)'W.
M7T GM828\=CK*N=AT+;0I .GFX='O'E33:7!3TA(Q8?HE]T]_BUE:G1T2I'O
M=RXU3 %]:E@J[)B]L:+C1M.V*DNRBIW#NT]],1#^,K%=@>05@9_CBT/CM'-0
M1)WM>3\YC6'/.]TFD53W*[>^UDWT?O-7/ ?W2K(ZY!A*VT37E,FB-%E2%6N&
M'/2ILAMV^DXC:R21>9GRIC(/XT*?K9/9D24+Q)CN![6?AX+&G>'P%74P_SVI
MVL_=!F71M5J>R2J )/N#T;D%: U_%QP-/8R[<I&0W.A>Y%L?C&L+R+:B+ZG7
MA\;4A-[^(3#0J.M5  M_UA:9^K#3;ZN$=Z<(+!Z:C]'?5EB<$A]<0?90*Y)E
M7J .:LTD6]6= WR=LFT8(W^N)S$?_]'AH<LD=]$4##71KF8FC7-A\723+8VP
MS@X(ZD]*S8B4SB,Q6%$$.Q3Y)6H7@?*(,^8!9C@4>3&Q@JQ#0P5 :I'!J^7:
MU/;TO^I8LJL\<$)#@<'7"J0,']K["G&7%KI['TJU9 O8$=W^J_*CW?894X:X
M?=4V!&VD[_<8@?=.AZC/0O;](?D,1(A[*X,-Q#NUL>+._QQ>J65<#2->VXUN
M\'#)<'#['#F5.$<@([\X]D)J15Z<I(LLE6U? 6H'[>"H#Q''@*=$MX4.EV,>
M&VU/8G,^7-\_=VXA-!WSU%C_H6#*_JV+>#G>3T@M:,=^[J/)U;:\B&[N;_#O
M1?9)Q]>8JW_KHB?>>E/G_VX./?(G>RFS6S+,)#0%FL RL#&1?#:!NH&B&Q\3
MZQ6)(=1()XC>A"[@(?3TA,=D89KW.T3(%N>;T[2^%%R,]/I(LW?$P1NH2+_-
M8-[ECG+Z\6"Z:7M%/&&7@=VG\?E":@<^L0(0"__F(!1>(8WP4+,0MFQCZ+\L
MM!FKL026ET2_)V#;'CNW]H6%^>TE#=O[2WUU3,="%NV2J]C3?ZNACZ%9=TPD
M-T>VPU MEY%'.5U38H2!H.X>C0[2,5R.8=?SQEV2S5^L),OSY,<[Y"Y(#0H$
ME>T;>SQ!A/4IX8NH,)L':P-\F</:.>K9M:7/WV:9NQ,6ER$0"+D.@LO!I2?F
M(;]Y"(](65D[9%]G9'3,U;P!5\*DRC.FA.F14ZW=<PL9W?R)P4(P@R):65#?
M@5Z#;G_GIQR_Q8^,PA>-U@R1CEQY1E^2=G;?(:"BXTG3<D/%HN.R8OVPMN'E
M^[FSH40IO=3 !U%3>]'$T4GYVEJT+"(OX4)62T-#SF?T<UN/LHU(%#F,#P7#
MTBU(3PGT/"[(<V673KX7$RH587\^PHD!R90;?PZ5&'<1$7+ZUBB0)X4\6-/O
MXG=!)]'==LZN':98E<ZQA7AR0<_JP#5PFA(]FW(XRCD(*XK(&UWL2#%ILJJ+
M6I-(=6<$33TFNW[?.I@3Z>>E4%7BJZOS\/1Y*YFZC6PXG*^@42K]<X>_G]\!
M!^8H_=HK8_C>4Y5M!\X=OX4^E6^?K#=@+RIQYBE(\J$KX55:F$\^R7$+Y7%U
MV,;$Y_^&'_]- \]I[.#+/^!1D?^=D)_E]-]XJ+MV>?TA** +NS1NYJ%/O_PW
M<]W_'YLDBT<46TB0OQCK[08(F_F$,Z@"U'%!T7C4G!QV(P2UO;3^=T=H+G\4
MQ?[.!2W</\K6;"%MZDWH<T'!*+;-?>]5D7\S1U_E@OY-[4_6(VUD$9ASG.QG
MG,R'&ZP$.FKC'!=49-^*/E5N1_Q/X283_I10H]&)^I5(U<$P/,FF[1J'(BXP
M1M'C=T9J]-,.^4JI*3Z>\)DZ/AB0,FW&D'OV9. JO$8MI.OF8/F/1P9,C*+-
M142/9-#"K0(]^X(+0T4W+!X6W;@A_CQOY<@U&U^;E"<?LV!+=Q):*95?GOR\
M?E\N644HH?"BW@N=DZ]5^BNNY3W*.3/L>^W6@MU;UQ?O];Y\T\GRX:Q#R-E@
M.M0Z&HP#,_E;K8E!?\"[\$;ND=G7AX+G XA=%)'V'@NK5Y>SU,N*)BPX_ PE
M5GL7.-; ,E(G)_)QO_$[()T+LAD^WN]/>-_;I,**7MSHY@A4[BA[@+EM,!=T
M.^(40-<F8%#5!86_:A95PKM_?P$*Z-W7,0_.8?;Z;7V8!\=KR0H]%!/9 ^0R
MU(['"KE"#BYRI*O1?N&$8;UPC,M,JW?RHIG=CQ/''$W6ZQ^Y,)G#^9%-!;IA
MMZ!=>&6VS"U\90X0]-IKQ:']8=.3VL1%Y=2[BY:3*-CM<\$7@E/:J'?3CBIP
MHE#D#RBZ)9883G5D;G2*_+1DUK/SD+( $UJS\*2K6<V4&0<4?F1I,^Q;)@U(
M](I@<Y;[[PC]477H#TN4".D"_>AJMS_<"_*L5,TK91H@ QG;9J@6$[PP@@0%
MX Q')II=:00&_K9N)'E6(!P[H#+XL_,RG5B]7=,PM?)&VUA7RT_.ZJ4:M!>C
M%Y->?_;XZ39!M#[0QTF%5F-I%^B:S"H _I'E .QAB%P!HLG;[)<3W1^_]R]P
MY(9_F&L11=!K0AW1SO3>_T'<>T8UU4;KHK&B(J!4 0&EB$J)2E-:5*2)B(#4
M"!$1*3%$I04(B:* @(" @* 0I8C42)>6T%$0D2Y!" F])PAA 2DW?/N>,^[9
M^]OCW/OGGA^+,4A&UECO^\XYG^=9:[WSJ7\8&Z>94CA,NE,GP#=5VNWJ@_#3
MBL&,R- L8,/O& R:!5.6 SJ.%I=$I=PHRR W8D5TU57*\9'Z^Y.M5@46$2%%
MQ:(;IIZCGVII;?6(?,";8;M]H^;>_%%',C3XTLRA9HU/?P\G2BGK>94P\M-U
MKXWQ"*?5)&G=-+_UIK#HK&=/XG5:])//:)X(S 7;\3_7*?@C*/]8MQ3*V1 K
MU/N;-A$11^_W?NJ7TKUQ7MC%^ER684Z7F2 E-E?RZSTE(^$O>.8$!T3A9B "
MO*5#)D5P0%S"WHIEPY58>IA=,+(7;C?FT'Q0^M)85IX7Y"#F.&Q>(HS5,I0R
MM#&4P=]3K+J"]%Z6-HLNJ"V(E,^@4@/ETP+3IY*&A]]R0!E@IK .^R#?]@UV
M@W;Z1J0&XA+[+'-WVL;W'GU- '*CFMU5$DMU$4F*:'':=[^^CL9?H:1[KFVC
M2FQ,O-_;/7S$D'XJ"^VM7(3]163X<$")P<!1#N@^G!+!_B@A%<@\:'RN:>+O
M*U77XX;:_7DNV("7;Z;@/VNLG[_)$;]J&EQQIDI<ONA4W*<MXPD =I$RMO?G
M1=M/-B\[Z6_K%E@%RCE7$Q+#990Q[4</^<X-Y#C'Z>5&M#2)?.ZXJ99[4#.N
M"0Q<4J-R)P/WG%PVM+A2@)8'/M*%*-X%!>@'@[Y+=M: SP12$)"[U;\&,(_F
M_6EW_>P,N%OWJ2(?]DX)4E2\[R?O2Q>UN2(;+M/^SQZDI1P.R#AX^Q9WPCD@
M ,\!=;EA'2 TWSCF.[O%;@[(K9.K=_IY;/!46X)[[/F+46C#J##M];Q6RZ:*
M8S;O[[UK[D/DB,L7KP=YK4.<MG2F')R5FA8S*Y54&N[!S63>Y]FTW*6MYU<<
M[ZB)\CMK_88492H_%BE?;AQ(%Z#FMG! T:0!?"1&&6U,WS%C.&H_]\C#WY$#
M:H$<0T6TU0QD1","@K&(+-(\0:'?3V<A1'5LV[H??[>/FJXB6]L/]G8->U";
M/CD^FTDX:_5F<NK2=2OO92MO*V2M]Q+1>FM_DH1]T*.LJTG:ZI[%CKYY5]7G
MFB"=!ZX8G7>V-.5BF<FOG3UK2BET'#/:,855S0'-A13YB70"W6S#(K,=>XLU
MPF#%1V809)V!8Z<(15_@@.+](>R&$MC6O8];#AS0?FZQ[W"!W =OX\E;G62)
M!9:.THXU^K]NV,#,-$)6S[9@?S?AV5DN G_?M7- F\JEW=NG'F&W*GY>C3J-
M_P+A^U]>YO__\8 DK@"J[<ST]F;\MA;X !?I?@#UL&B1;8O_9K-&":Z%#4O0
M\60>78,8$<<3B*NO84]E-FRPZZ9,$_R2-C%:YK\Z"A2$=P^M&8FP-=@BFU_^
MGSW@_[^;G$2N )<$V!;1%!@K+>49![2.1/O@E\+__?,L"FQ3TH!=9\<!]5I.
MN)-7P2FLD)S-LM44AL".R0#K%0>TN(!UQ[*@8P+XM5K\WVO_C9U [2OLV"/L
M.C67_=X8S(_=P^4Z,!<.*)L;3[#C(<?^ESTC;1#:+<C3#7(Y;/$='499CO 8
M(JA6]18Q7<<+//I"NH8BF5)^TM6>.:0SFY@A*J\.G /B:[#/+UB03'VM.K6M
M':4EX>]9U&>Q#/GIUC,1$'O-8S(F54KJ>HUV0F%LX1XEI=WB)GN/7 %%(;"&
M$)JU!:" B_03$ 3B&)&LU#H=U5K^^L=^Q6A3P#)S9#.MBU"FH]&60^W>X]G#
MMU5/*#J?\->1UII&*$#FFVDL1R*QGB$*X7',Y3\C=X;O_'$8@W9[!GBJ5P[9
M5ITWW==5T<+?T[6O13#?[/"O;T7'2TSRZ36EVN%[#TO ?2HO6-G!-(89>HH4
ML39<%&Y7'0PQT?U"7VNPCI?ZSL-QN()/UCY-<N&,E'SBS4'UVM_>Y>G(&PGV
MF6GF6O8EA)) 2KA_E9J!4"XY*(4I"F',$GOY4WEBZZ2RG=3UK>$D9#.1-_U.
MPD?'NS4QG[*RVL]/+D>;&-K><[UVTI_M:'D5\9 D^<JY^ QA22GC.5V)2FS!
MO\(HX%HY(&&F#Q4I#210;KC;T#6+_/*ZD-Y.V5 5_3.3FB3G=*&R8^JCFI)0
MWD?^C0@)NG.(8<C*MBJ7$EZ$>,:18A=N]I=;'+R#XJ6T=K8J=+=T2Y.<9K>.
M)UM4D)!\<[UM:>W14PDJU(%RJ%U/5T=TB#&T;\]FAT/5Z'.OLTO9*=^ %<I*
M<[<$TY:>_(RV32%':(!%4>TM&SUS)-6('(/I4:>;E Q3J>$$7C,E$T%HO8%E
M7?)8\\V2<.K6UO18[\%/%HOM[(.;V[PH=X8:@)"=%W"ARKS*4*\J_PI$4K=1
MG8T/2YYI5#U':RA_2VREU$L_<$^F)$CBCGBYK$-G/X:J*)KWUF*'>1CB@,KV
M<<#+#++'WI0J(#7/B(<"9=2 ERI+(RVDZ=Z$[ZYW2U8BFC..BQTH;?PP%VO#
M+/#T"QY]P!X&=P]79+LBG'<V9;,"5_L+NC)[(;A-Z-#0MYT$CILR8/-Z;FMY
MZ>\#IK(QOTB:.#F4UH0H+G?.^61=N!PC1(VJ%:[^;:T/^>16H.U$B[YHW]KH
MU69_>0*AM\Y49[^'TPA=@OC+=4*KL1N$1@-(*C(,)J1^>Y"I0"T ESE?/680
MXN(G5+B%*<L:>QA?SG(WK3/!EX_T&Q^]<ZU W7K$5*^.^(UG*9X#VCL +&R?
M\:JIK'7+]H(($@YG]UE\0IO0IG$JG7,2&*KK\_8:O0\9,\UBR=^L+E5<$K7@
M&ZMM>;AN6)/LI-UWIG6THHS)GV]M?KHJOR>P&*>?3,;[_$TCO&7A( ]E2(H,
M6$TU]CGVZ+H%_YQC6$/- %HI>%\RD<)G->'5MJ&E?WRP:,5W%IP==9&2:-.7
M63+PXWS[(7*A1[Z^>^:'X>R!-'/_H*SU7@Z(S>NR[>7LN>+F33[H6Y#\2G9^
M4'I/3>*MF*>@'_%>&;+]Y5ER1[]&JK='RR^]5!7&H)F>K&S]2^P>B7+M[C9L
M9,8I^FAK88)9[N]Y.TM'#XD;":&EA&A*S%E) 7Z/[K,NIT+4S"H"!V[?Z-UW
MC"YQIG)L*2'KV)(P+AB^$69V6.U.ETA]W84_=^Z8'3]WY3!2N<]<Z24U_'36
M_^AD65;[Q6;O:Z5YF>$9!IB51?1D71V3"8/P:\"[=INV:&7H#MU+N4SC?_N1
M8:'0'HFG0J'#" QSZT%X&J'2^JWO]]A=['3(/1B@D-($&;Z'4&L?4\L8HK:W
MU;K%!B,%R;\/U('':S,_OD7)&=3\=?([<.?M4*MC7J*=WRNS'!(0Z*VZ=,I+
M99.;A%-_K/..!1(B,?7$ D77J15 884I)#I!*=R269+9-O2X"I;)-\AC<A,C
M_[(X4V#Z1,)(*T&I_,T1PH733>9"ADEFJ!OG^L']*-PB#87<($0IW4ZP-9;/
MGEQF+T?O@/_]L/^A;+'\,-HMY##.DI5"],1) 48JVF:PW0#N5BV]O5FIY651
M3/MSYI5 O7Y'F_*G"#7 :K.8J18@])#+*A\THN]!$5=[IM@3\,GN$0'&9>#Q
MMBOZ7&)#AOIH%O#<)&'"BB80NXC(^CK E"KN$FR7+VE:O:RA(F1M\K%J:.V,
M]\GG5E51!S,S.F]_Z=-0$G_C73?8]F;FNXI_$.3OIDR3S=DR)24E$;>326]>
M=S1,7H@//7#BR)5ONE%;98Q45C0!PN[07O^93H<TIL10LOP'M\ MB-V\1=8-
MCLR'4PC2D).9K[DVXW$W0[5:-+7(.+2M]</Y;L4.F\C!-*^Y49EB<MD&4Q3*
M> ?H?)@C'*6WX2C=,6SI7@2E_$L]'4V*39EXJ[PTX!K::W',L_N"5^3QNWEU
M]/V1A?.K4N%.YCU[W1<\(>/$*J/?A;#2I!JGS;O*JVAD M1%=?^,9@$M0?S&
M_<F78=32T%VI+^4Y(&U?&Q]3/Q;V@M-%O4"[C@6:N=QZXL004U2+40PTYI!1
MR"8A5,!X7 22FC V;0$RQH)?%:L\L,+OS5 ?*/9679L^+EQ'JX\(7]_;#"8-
M2[UF6W2I#PF9/7ZLG/C'0C[10K=7O<Q<O=#9P2VI4S?!9+%;/K8U/?*!?(*7
M]@KA.%H)B*<_;_%G'P6<QK%"J+\M 3J'YIR/]8(U',;#WI^L)01[9/!I643&
M>FM(785">>_S*;2V6!:<,Z\BY"@<*Q(TVQKE@%(;AM:X7&(OFO7,S\3/7)'Q
M%2!FFKD@X$AYXEZT6CZT/,"NS/F*0AU1$+DX\^I8H6M9FKVNZ"FKC;([YE24
M:S@O3 !&#N)9A'!/XM7'%,-FHRU8A>'Q5 2FP\2/3VA\&J>KC0\KK_W,Z#S,
MUNV?X'.G!A<$!NH?[R5A^9!A-S_FH<)[J= #6$Q6[$57D\QK4:?C76,O#EA=
MG# \]/+EA[.RIP_E?SC[&03:=\=U@)FR^=8FOW!""IF%S<3BQO6C3A?Q^P#-
M'%!H#>J=)9UG:88>])-A*C'4%(1L[CX\2S<QW=9_3Q2HT\*;2^QI:M<LP7M5
M10F#,/W0A!9<ES9KA?O3(<SW,95>]JDKVS: M7'M0)T0=4G2X!=&?M2^4:$3
ML&MUW%>H+1I3X+4@F(CXN+#%1XC+<227OH,C8-<3>AE4\76$K"2N\5#3]:XM
M\HJ.9SE%TM<48D/<9)^$Y<KLPXX7$2MF&F5V>\CPE]<;-V T:3-AOIWF0LU8
MVA==<&#>?)!1=&Y+\I9_DG3!AP6"9%U]>=]2EAE4+O\[]O&^[,>.A1R0>^B!
M"69[9@+BH754<HSB//8VCG:# QI!,KZPRO3!0 OZ"G;W'/8000JP]./S%SB$
MNNJDO_/R "I\JE!7*2O=V&K +[@6E<8+.0*W4E<K+"8IV_:*ADXUL/+H6B_+
ML3R 3XNT"EUD,<C[&25$R(8N6OWYQV.^\+A,^^X\KX#2C![2,-1"AP,J#2=>
MQ(XGX'9A*=<QW_0%!RMTP&6HL@F-?IQP166"[AWC;"^: 7P\6F51I.L++:<8
M5YA]N( 1O!1L>4OR<0"5.%Y*E"92;F,Z?-!ZO?C_>#O[#X;_F5RBVP\,7Z]^
M=Q%J;/4\+N,@10(2#K:&>U?2S28\=Z7<7Y*L"@&SS;86?!),K^<J6UUG]'4&
M;-:RW5=KZ2-40@F]>T*Q!1]=L_*V)B*."2M$A2%RL.?F:OP&.D]%9\E-+C^_
MUI/YI5>%\$!V;*=I^!]T1I224,D_O0=9[MQ T&+NW!JOV+8;!C9NEVX;AQ'V
M>:RBJ%-3<2&%&>#^PS609XOOQ]]4A]/7P<(.FG9"J-N3K_TAC#VP) C-N/LI
MD9;+U='IDFT2.2G#=3;T3NM$JL)VI_3(6Z:J+/L'324>+7"AUTE"'&WAF=YJ
M$95K-2J"M2GP*%"8R6NWO=,7DAP]19QXA*<DL@_MH2^P)< ,/% T,:)$K@2@
M-P<M0G4/S2G^TP.^[U1<[MCP\81*$FO2,2Y*4RCIG=-;%Z.CV()NX#2^'0^X
MQPTK4G&OE)&85BK^J">.5LSDGU-,>J)K.6$RTR?(^+YZ/N"#1Y8C75?N\,&>
M V<;QCD@_@&U8#!N$_/IC5P=P6R=!3F"K^"*P(R=I<[$PB%AF(/UI=O(,%\G
M>Q0'M.,@D=S>A#F,\H.^4QIHA+@-K1OVHE4G#Q<LQ*=_V^4'9!(_@X&3V 88
M8,0695YC??2+5DG#M<2XH84H!Z?C!!6?,T_JF!8[#W]_]@Z!;$W4QSUY4;5E
M_/S>B=-3TV>70A8'LZOODIU2"MCX54C@Y\RHWU1=:T8LT/H)#0+$Z,83HODN
M'LR#%"D+V[ZE8LF'CBDO%0S[F."L,F\KXHB^7%UO^8>&T$^T<W.PAD]EA5Z8
MDX,:"*QCW3O+0;^NZ]OV Q6\R>3'V+SY *LQ\MA-0/)334V&P]1#OI^+C]1@
MO2E,,=C$$,/X.4:,_=-1;[F3+ ;[3@>W?3$\-2S67',X1<+B16'Q+:%I1R_V
MB1!72Y+-=2?4S9[F(R;X:>_2=X.C1-B<U&U7CVJ]2:[VY*IL=LT^#(O+R0\1
M=G- ". O%;DD5NB _$*[F8;C1XOKEBS'U%E033[VUUD&>P$=SAX$R;B;?;CI
M9D=4FTOY:W'L+I#\TUWR[T&7Y#.>\D\.;9AO[V/NERE+62R@95%&I]Z6T75)
M$JC:]NO?2V?80A"Q^*(%T13W/3_>786^@QUN/]53TW>M\J>)\FT1\B?B^<&D
MC]ZE?5-#3(+[[]N6A@^?R,23:0[8.!@M'^OFH"\U9T=TIQNW(Q"Z)P6-3W6^
M98IGA> <Z163:";M)NXW0;SN59X G!KXZ/93X]6CL#PLS0[/_7$U!(X_ L#,
MZK<MPO0/S-&9&KV]9[2@WZDZ#AG<J+&KW74WY3$03K7@^_/E8H+,88?*@4O=
M4SFNBO[L*590^INLSGVC\SOOG&_^4=H6XV8EY)^LU-F6F\6H#"@3NJC$6(DW
MN*/K8LEZ5>>!!R;AZ>-FLH"TV_L:83XJ_/(32Z;UDYR73?C5O&TMYO%^#LA#
M();(2^"?N^>6V.ZLVN=;9#0]&F#V"? 711BW:C>I#NZ='9,L'? SSW8A?"^?
MT&"M>Y",4BDLN>N_?*$7?9=DKO4]](U1M*AT2F9(/'@'%TD*2Z^YOQ0^.'CL
M0^03_[:H"X]M_L-<PDJIX[LQ =^#V"!^Z\V,4C)XRSZ-'<^O#&!@J]K;Z9^5
M(JK[=04"'R[S*WSY"KB-5Y9X_)[4-O86/)QW4EKL)27+32:C@G6>&R/<<G2/
M+(R:])2I@#1+"2XXU=/:([)HY-9T@>M5P>DFJ "SM.F5:_2NBO=G^\8,L@P#
M G* U$S!+O=LPRPO_>MS-<[X  3SIZV@+7*0 PH<,<\],))INI4MLGUE6PW;
MZ$%091X!0CXR+P*1M E38" '97VSLJ=.H]B,.D+<ARHE&Y>$(=98.HX#6(H,
M'1'[-<VO_+&CPVAEHMOG^G(3#=Z1[:?>%E26\*G!UNOG$\J3.*#B!6O&]H0
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M*H]J]N\L&*(KOE29/"Q(;;[SY=%SCP>LL*(/A?5^%^<[TY"E?<MD^J'3^%/
M"MW5&!"C(:EVK4L!G7 !$,K GGZ(U,&V[Z]0@C\P%S(R_C:B7UUDECO+:"F-
M*X==XSVM$":>$^!6VR/3L<(4M=[9BA='*L5&D)Q62+HJ-$7#N,8O\E;(RL0V
M[:KX0F!L5?]FYTM%A%RSV.>K2U]I97>/!&A-)B& E!;']FBF,1XH:]$J]7+D
M@"+7B^Q:M*<_GO\QM-56$:*?D^=\'3N3,[#THX^X?1,N^,5[B3"#ME.V6B1*
MXZ>[;0%Q6JX#,$6/H%0UZ?'\,#>F\D2O(?E9^1>9?9]^.SN='-1(%>+Q(T1F
MM8<4C-X]+SIH];K0J(^UC7)M#M)Z7J=!63D ^'?HZ32S17^MX?@]'-&ZAJY<
M2!#=>I#J+L-2VS'Z%=XQ^L6JR="N<D!/R;0$M#40N7T5+@I=ZPXGG064FH2Z
MI"WK7"8..*S7=E[:,8,#;HJK;V<K^" GCKWD^]D]SU\>VLO-&C#@DU:.5Y".
MAT4/K59112:)TNSC J]D]F)4F"K[U7%4GF;\,=3--L^71TGS08-A(6XYSN>1
M;T*BK9('%T4WK[P0W?N@WBNJ3'AQN<HQBSFGH:+) 1GU^_')V91_[5LW/\M8
M,.\O5,WR\"[$+[HG#*[V3HOMHGZM_!IE\B#FZ?UX<?O=?%;X623[4"TWCLAT
MW8RS=+$E8YI8<Y7SB3[T%7E2=^O*[MEDO%^AI^/@Z%9$G*^4)DD39]5;$5(4
M3.W4\9@B]OG9UM!!9D47."!+A,#FY-S@%\]<EE> T?7K"].U^JT%D@NC%QA]
M5GU(U7*6L45-**.)W4:%FHTH=3I8!4-KS3Y+7UHJ+LJ-.15*%1>T=[N6H&5W
MRW@!V10'J&@M^=!6+I?15J)4V#),:'C3@:6E=?)QCZT*8K3$L<LF"1OVM,&J
M3-*\M^PNM_K^\H)ZV_G+BG7]JHJ>]U-69:.$X ^TCG7ZIE=6;Q'I2#:OTK8K
MTZQWV1<F,*]_"#!P"1!JU!MJCMF_"CEJNO=IA U=(,H/*>@TU_=W%>9Q?K;J
MUY(U7PNB^MUJL^W NE.P-7&P8M3BUF!%NM4\?,G"=@#O[2=E85G_U4>A=8K%
MFBQS<G:RD%-/Y%($^=)JY>4?IG@H(+.MS71G9:&MQ5Y@^%&\4'ILIOQ++['*
M+[R(/5=";1OJZ&(O\1)\DM<J]BC'8 ,/5RD3#-_8:5D<%]@@+T5OBZ/U66$0
M=RY)=E8:?*A_DMU+E%C_XKVN<S])5XWVMV%,$&INUJ+)%BC_:K^BV+]N'O2W
MN>9&AO+ >$5UOV_8X$/?>BV3L'7[E1C'VF$_[-!Z/^Z)BJ'\N]FJE8!!DA_D
ME$=FH:.C$VQTQ/[W2%= </!COIR<HCJD1FO7P(]HOOJZHT;B4VF>3G)1ZE;+
MB_D?$O;)=L]VL@^8TL3N0T0AGBKW.J=3,P'+\<#I.)Z.5[^Y4"?VZR"/DCR.
M%N59.?3Z6?AS:-E??O=76,.!O[F+2;2K0PP?5KJ^$/-$U&GK6[2J,(1D2]^5
MBH2_;=J=WXM1A"6W.ZDNW#H0FUGY<'$Q^0P<Y'K\-$^/7YU- @R;UWS)QY20
MKB<:S6R*.OW)Y'_3!WD7^\F:I:%/QC/670YHI[O 9 ];E@,:;@.X\6Z#:Y)@
MY>);XX"3$&8:I 6V?9$LAITO PQ@Y>MU_L[1JQ?ST4_6N<0S]?]$W^E_/?ZE
MF_^2+#$:"^C,L!_/<4 ![AP0H1L&:86LGFSG@/[@V9]<NOMTI3B@Q)AFXH8=
M!S0@^@![@@/B(TYK<$"/5EA$_"T\&$!P0.?QVQ'8)590&&9/# <46, !>6/G
MOLK,I0A@O^%X." ?F:VD.UPJ/J7WX3_Y#NR9Q0\G,O# YK8,VJ04R-V&H*\.
M,'FI]NBW&E!H@!A&DNZ=*$R STJ?IXT.I68#<49O4V1';E4%%KJ[]:L7Q$!N
MAY*V!)8MV >Y0]K7"?!L>ZJ&T8A4,L.X 4FZO@C]#060UOTWL (8>:\;HMS+
MY]<US>N0&+(AX/;+[ *BQN'Y&T>&/;1QKR24:C]#NJ.2'.*3>J)*7W=T7"\M
M?1]N=>[*WMT'3H1>4)I]HJ_PX\G9R%NXRJ;K=P8>V=P?/0.C)FD5?+3!5^U[
ML#A_-?.ZXA1;%C!K(LBYY"BW1?2KY?MNG@MD'WHOJIEREC6J?!NFK'98WHDX
M3!?(..IC[PAX_K3&+A#SY[2=ZW/FM4]5?YK;^AE3,.SD65,9GS\\XJ7MG)?K
MW,08JI2("9OT<70>=AKY+B]F6W7>;%_+!5VKMMD?.23GU%R/M ?I61X,S33G
M^&Q[DF>:<ZH+4B0G/#W7'MKNZ>KJ!M^=K3F8G-QCB$0@#\G?:I8PEL@_O0?@
M@F0HG!O=#3@QB#MD4> %I*(6%3$1UZB$+?,,LHAMF; $&FG41G_# \$+FQ-<
MEA5#*1 ^INU<'2@06;YMA2VMNQ+H[N)"R<-F QS0>#6,=GU.SI1GR27K0[P(
MPY36/!%D4OM&<\B UGUZX?V%#)MG//&P$K<ZN_AI=9& 5\WC^=E9MN&:%<?U
M[$WG)\1OOW>U35^WSCUC[.UV<$P),(C6/487"O,1GRHXV:6V>#SG[-<;S1&T
MBXM]^UZ&>AW*N8YRU/"Z6R+JI?8Q.O=F3A_#"F]H5$C4PH[/R6QJXH=Q[,[D
M:@[H,W\!K*4(:\VELS <<%IK,7C['I,/$*& AZLF]'%TK1;]HT!)/A#=XHC
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M8D#RNY#0J/NG!O.&-XRY@Z0UP4IR69(RC3#F"5\!]K4L]C$SACH'E.4**'%
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M'\_7^3K>[YJ/$89WDB1E#HK=5IH1_#-BN2;L<Y>XY@-5Y$#P?*$=F+6[  ]
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M?45/['\=GQRXTF$LB_CXXODSS\:/4A9^;]@]NO _4KR55C;JO3QJ?S68O8B
M;E/6)56U5_$>]3G,UWK#38ED+'W-9N27.5H%^S.++> /<LT)/XR]1S.$!E@/
MHKWKU!;[J8Z=H>H##089H],M?6A#,"()PZLNR ?.VF",AE3D.)!GD<VR&F 9
M!;KWIPTQ_6F)-S'OB?MP40GV$7POZO65>@[DTA8;C9L:AW[S8$N:T<4&F\Z
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MXQO<P<.$>YFO!BY1:Y[J!&,=5;MCYPI&P3L_"?LK!#Z,U+U@E!\05%XID#W
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MUCCKL(!B#N1]T+_OXVHR9Q5Q('=[GP)E&T]%VH#]Z\9---EBL68J$C\A;*)
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MS@D6W]0_8%T,;1(.T8X';2WCOMX4YBY-_9U"]_4/AO%^%PK<^0@[?X;-.\I
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M@JZE16/X/>5U ;T9_C&ECP?=%*OKJ@,/I4L<+'IE\A.?)<6!Z,4_@PGX];X
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M@/[;G"<$.(FA$AFM&;1FU0JJM'F%%A\X'U#ZFTN&"%5Q@N RV<QH7/\4M:5
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M\I&1L1R!X%M#4LOS>J>[Q/3&WNWE9SS P:4DP$(, XC3GO8;EGA0.<K? 3\
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M\Q,.D)U*992O7RFXS4UBT02J 99HU2;F-E9"'>\B"7!4^$PR#;*,Y79#@>!
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M1I@ZQ78:*"(8- <ZL8(^17-.<,$QX!UI3NLQY8MI'_E\"I;3;',>TVMK($]
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M$:H&%;X/$ S6T_H<G3<!5/\T'2_(*'^2$XIHTLY=KBI\>!)_7UTQT7BWPL&
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M7&/[L:Q_II(=R3*&XXP1\F4EK!N,()?9G,L&&E*RD9 DZZ;,_B?*7#AHDRY
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M'!Y[A<'[+VO46+*6\.$[J7Q>N?TG$OT@S#?GCUR'YJ_18?-[TB*<*6DN3G2
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M+JUA0=>Y]EL6VA+#4&#*<@;W 7C3J\&2#$-*_QFO$G5H#T6NMF80*"=$JYE
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MW^;3YN;&=X8_0>J:0E0Y6_<BB-?+2>90._DTT#=N1KB)C$&K#C0=H%91C..
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M7?_ESB7,0O;?E7MQ#5?P:F-W]P$JJ<N<![ A&.MDZJS:A 8FFH2/JW![O1-
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M>9,G=V:K-_FVJ>ROG*!+9OZ]_J[KR=,-.7F*HY>&"W2JGGO5?TM6N'[[I&]
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M>2\:^-'I8*)!],A/HHATEYS'\40_]V:8PSA;R<$P[U3RG7-JGQ.@ 'CCR:2
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MOGCZ/Z-XZ:Q?<(N7.7]F^.#Y_&X_O_.Q@[\'SQ0M3H:3CKG?RJ%#FL!'T >
M3S3DJU'M1$NL!$I_FK6Y"=,Q837UV?2ORH*=<+>B5CHBU;-Z?W_3G,M_O8=D
M&0#73_)Q<M#4$3U%IB";)DQ$PJ/]/Q&#8<#C0(1O_4%&=B&=<!1UIV%S[]60
M@#87I3^UJND- 0\1CBVZ647Q.=?]PQ^;!P8*R'[Y++=+'Z(%#< V7D#KP&EX
M<B7+MT^=;O^PG/FHF'8=<KO!&:736*_$#'GW7"Y&:#$">4''UM=.)LK"+MD_
MROMG_4]"E3S)J!FWQY-P$+UK#!=A*//ZVA= K"GEP"O?5T/?VJT8W&1X%MGB
MM--+_1Y2 ?&0A6;B3\78WXN=P;JG"W_O8<3]-_,;K/ VR&-!;OU1+O.:DZ$Z
M\[&(^4K.2_UC^I99]B/M;Z_K$J.SR^K+WN[?#^5S5D#\&&%7$?_*,ZQW'/;_
M;(/*":U&DD.CG,JF>NE^ M49)=MKI3T$N#;:_(7E![MM7"HEKI46HM(.+ISP
MJQ6WT8Z+F./7J^ NS3'U8.U)_'XCFX19RG'\PC:(R]_(P^9C2RQCP)D:/ <N
M1N%;4P*!]W1?%#L_GF8DU8SX9NJ.^K /J0D6YD4/[PGS!Y/3OQM?>W%O\T@Y
M[GD[*X:3QSV"UJ\MW?((/TX4:Y/3A<1U5FR#7NDT2?L5NO0NO2R1];<(MCJ8
M^<G,L=";?'RW&7?F,NC^P5T->[[(O7_B2$A> XY!DGI<\*L<+ @?BT7BXHS^
MY?JMV-?:$,)#IO'@ZU$AAFK&_$X!2'N;=)FSRG*WTK7N+\T&2Y'#%W0</0-D
MSN]RG/?BNF+'JG%RA$K,<;8&)]4W>&03^\*W$HB@7SR9Z(N@X<2N*46$/R[*
MZ/X9D X\TALQ.2DI!*,?T?O 2%9VHXQP,*?NTKLTJ[TYDFO(CX 8L?"(75%8
MNE>]TN J]I"G_QTO!\IK+6>CZSVK<T^D:-L@VP%OZC]]\U]L+L.*BJ;"^5X<
MEXPW,;[OC^LEL _GC(%9X!<894Q/2FM2QS9(:M:<06_TZ9 ;EFR6DTD2LFK5
M&2QQ74\*ZHY4[/.=VGAA03CP.^ORB4_KR[5P%@JXDL7> YQ@-(^QXL?K",]K
M%;*F*P-NJ_]84WO2AM0W+WBEDN7HR!0:S,W_D75%U.6?!KQ[(>T_>J9VI%BN
MUJ=%WR\ 'T$EFC"0X;7&O+L5<3'-06&;JN4*:08!MY-?%_B&'&JBW^E?4AQ'
M)PW:E7;^C7LOY$T<1[(E7.E$M@I^V)8K"X,0/)BF[8AG1GPM\>83?]O'NHZ0
MYURT:N)P:8*OI,#A2 65:R0@[;&XZEL=-\K]_]SXQZ-]@/P"]E.@F:E FZR;
M5,]@[FG=['[=518WB7TTY.)\L6?5DY(ZN'DJ7C8V'I[0XFA_7?#\OKCWUL;W
M Y3<W4MZY LI#!,\3_F5\R+[#\P)KR0HC%'9D"IJ=?3W<GL]R>J8US;(LP<M
MXJ%\S.+U*81K"^O6,?^_@+W&=]D83@AD(H(M>H#'',Y0AJ6O,%URW5E(<?:3
M?C<@/E>_>*$JKOG.]>J %X^CQY"ER5<J>9,KJ?_P#7-:=-9?D]W<G/^S=;AD
M![9M:CR"+?&2JK348C6\&RH)L\/[?&/+,=O"Z/"LL(.)."%H<S#5 '42=*\9
M?JHF:TXG]MSQTE[EU!]19_BX5_(Y8F@+:A=O@<@2:Y5I"&W*/<94Y"K"JGF3
ME>B?M>!G('VOY)-5_[RZ^(WB\,7?-$]%TB^RHIZ]XUZL"+02/.]*1P[-T5JW
M01'(!?R:53CF9&T= 8#2DU^59U>F!Z9Y]JQ)?^B_<B"JC&\BML.AY('@;QO9
MA[V[LF>U8^YH$9>X!'S+X*OWGUW6JU><,;S%3XV+G%M;XO+[\)C?P5ZLNQK4
M ;!E^CM?J1= D6WC'%XZEE1\[R\RE$,5CX6VS4$0V@-*=?6,Q7)WA(=$%2*G
MV0_K\33'WDO*[WVSQ;=FOPU^XZL(O0R8L;DF"SO0O2H/A# 3J3JM(=H4.P#&
M5&[@ZOU3'>,>"Q4$/ID-*E[^=;35!^X>H#;ROC.0;) U?MC9\8?4)6JLL;LL
MY#4:0L7RW_N9"^!;4@Z$:PY99R;?9AXJSO&L.'\RU'Z\IK\(\>7Z;?Y',!!(
MU*P5FUHNCNGK8&Z#GC^8EUR!S6Q25HT**61!KL &0X]Z(*(<?Q"]AZA)>(.3
M4$<4/2X;N7,-6\G3)EG]Q65/9S=S7O=)&)Y.Z/GHC=#$"EE\<X#JFPB90GK?
MQNEM7!A80UBX#/@9!-C7\>)K#/QVW4"YL\E"9R5D,RG#1VUB;:$SXJ.Z>E%V
M4N#GY66SSJ#!$/%#EHMPOM.JZC65_:J;/&$>>H+[2^I-P.@)3J&^:[8YXOYC
M/_!>M$+LHH1)?=*D-9)N=)2$%&@BD4[+-^DB^A^9%656,^\>^C9HK<=VYI&1
MG0KM1R@Z*W/0%_>:(G;6#[J/VUVA8SUB\:U+IAI3Q03_>*OAR3UD;_THSOCC
MN\8\@( </F&EVW$]>,1:'7>#6XO6HM;M:1R5[T&?H3J?;+[,H$1H=JA)7^W1
MK$$M:"Z +?J^6,!5I?50S\V^5(9JQAPY..8>??ZL]_E9+G2*@W&<LLM*#!U9
M&J\)(OP@IT>I7OMP.CT*]/]T;8,N!9U.K^J^S/T'^S\N'R;2VMF'<5Q+>1J8
M\QD935BS9Y_ DX)&]<#&&S*VAI>"PHY8WWS^WYFU_J^[]C"V0;1N]GNK2"SK
MMK[[-BA7+@LJ"X<N'QL@S"MCMT%9-L0APG]7=CSGL UZ^[MP&_1 ;QO$44DJ
MW?%KE/XSZA*]HL$;J<X9@=/IS_]G+P,L=1O$?E&$G5?6X28,0^:ZY^_P1#L>
MNO.&.R6SEZ@WV.$ [V:.PW%;_%W;H,P*V\V5K2/;H)^JQ)VR9B_"9BS*IC*V
MHP=C*FX5ZY*STPCHPNZHTU_^5US"XUO_PZ)@3-\VJ-'?:'S14!8[7(4RW0;9
M>;3.LN\5>#"-DL=C2=B](<(]>$ 1S\Z4'#O &8!R;+"BJENW\+1V+K_J-NC,
M/F#7-L@/L@VZBVN)XO;E44O7.")AV!AL&.8Q;]1+#_]_G0AX6C#WT+5M4"(-
MX/WW1UEC6(XC169NZ\'_S1^F 0C7A,?=\.+;H-5WJ.%U=O3$-@@*PSQF9W%>
M;H/& 8*KT98N99C"^XSK+^<XZG/L'J/[VZ -0_!0-_=W)2M@&S10-\8# HOJ
M1;K\^F=Y#BIW&Y0CTM&,:VC9!A&'L#.[C(] VN5-_J^5V.(KZPLB6V"V!"<7
M+:<OS8QNTMY<J,M-<S[@4O8T!X5OJDP6B%9:"E^;MBXJD+MS1,W/7>7OC&[R
M\%B<;1_^:]A)^<L]E_M@(YX][#JT]TXQ$MO^C_>2EOQSK&CM>3I'V#>!! 2T
MNR!?LJ%[W>/>NTMDP9#? %?'5(B<.Z>_7C3RI]Y95W(XF\WT8(LA632&6V]S
M'N8W1J]?/_N^$N-#3^W3@WD7KK5P#PWX-?V:"[]MZW9,8#K!_<"ZB/&UT!63
MO++!V&XBMMFJ@<OOQHG=!L%?9YXWFJ_:NAZQ(G6B<BRG)1GB>_#>=28 2[ N
MEVV^_KL@RMG\2G4UX1"F81M4$1'E'B6KP7('FKV6"4D1+1BA?K;\8>^/24B)
M]O1K M@^\\Q8PRTF="3D2%W*(N\AS?!&&;(PP<YG&B6 7^UX_!)('6V5$J5H
M,P)#N;%.=MAR>L#OASZ,YOGPH2'<0+*Q#^J9;/-BY:@WVSF+OOAQC[OI0O?\
M3B%M)2<%^TBO3J_5,NLO&P)\RBG3D>!>9*[5I;;6QV#Y#ZJSE:AFUJLA^^^^
MMPFVV*H89%]YH)((PYN\^8$U/YUG;='='VG[N7K8WP';R+X:=3I/P_ )ITA?
MDNE*,YU?8)I2B8WFJZI&K^7T&:MI(L7]^J9Y(YZ;+JD9\+[F'"![ O^XC'-C
M1IW<K.%5D1(0CZ@#+R)R5ESOW<--YG-EPK9X /;GSAB>*RFU<[#AO"WGF;5Y
MJP%O#.8VIYV\;@C\(M7,UNFS>8"F@&6,@\E@;BAN'Y;QG8<B&U%X$A@X)3^O
M0XL;HC001)2 CSKAR'HE]A6F4@3)NQ8<XI<W4^%RB+'PPEG0*G9SR[)/6=+'
MJQK_&NRW-VKX 8I\TR[0K6*?T>UOF>F)U3R&,A!KZZ[D 0\$ T;$D8=1JDP>
M+@AMW43?YJ1RQ=$GHJG";\J-=@,U;?(B?H+1,4ASB<( G0@VF$J.#\GZ*;Y0
M-U)0$>"0_%K3\=.KA)%F@S<"MP;]'HV\__'&*3.]&O>/5B/[)O!@3/@-1G"P
M7@YMR:AX3Y<_@ K=M3\GW>M/V=L?UI7D$5*W6&M CI?=G7W?^]8L#6E$Z[[%
M!+U/JM^4K[_%*HSRQ%MH.^;OZ%$1]5QZW $4ZV+%"_DWAO*H9R>GZT3MV;)(
MJG05ZBA,;NPWN[3SMP5D0&[G)2RV7>ER1%P]B&W /'I4K/(E^P[-:I_W3%6Z
MI1>EG:SWMFC9?]]6_TKK$H '?*Q<K1$>B(*%=9?V &8?E\\X6#TG.!_S&RJI
M^4.S(U(QA=R(DSA.B++4%"/,LT:U&(.X7',LZ&^/0VL(U4S]1.S%L-'<8(6?
MSPAR1FP11]:P1:EWA9%@YBO#'DR:H;5GQYN-%XH]]/KAM'.##V]N@SKT?:"]
M1O/.6Q 8KL*H21 ?K0L)+9??U0BC"T$;>Z=3DDKA13_6=4T^?IW5<&G$PMUS
M\DD=G+(*9N;@DYMR@Z9N_(I^:^4R\?YPKOP2CX<9P6W4?Q,=O @_=\QR5L09
M!"Z?#M/B=G7E=Z"=F=\H)]%WK2!QAB*LV05O<RA@/G$@+VQR\"]7.;K4JOU4
MM?+O#X^+"#5<E"_%E5JQQ:98#SE)#D1;AO +HC.S4R2OLB5.MN- )/IA7*GK
MSZS?K J257B*,4S4A-&6F-'Q5.P#4JGJ\GE6%P:%;;0P@AMHL)PXJ>CKU2[Y
M,O+B]<KWO# ' ?B#O;/5,5FM:_CA\NYC*JJ!_Y!0II8U.O[K&*=X^<-_/;4O
MX).#%=HV7&41E6LSSYRFM#-"1@K*H'J^:T8?\,!I8GL6YRL!'A=EJ-:W9+S^
MBJWQ#=P<M^>G3!JB%( W/G."36[^NIDZ&,2JW9R*1,0>V0CJ#<V[(LX8.6*G
M1K'SRW)+F"X(B=G:B^F.V[+ ]!,.ULN.#)=37LVO7:$;O3YFR9H9B^/_>2@K
MWV'D,'^L&F8<QA6/<BZ<&)D;[#3YTX+U5<GC?8G?W6=[>W?>B^=Y^W?J[?>
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MM_59ZKR9!L^@]$->(J%0P?E!T/Q4@'(+[F'=>2=G['KW7TC-:$6XK^Z.4M%
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M= 0_%$J_DVP=HZ,O,REH57=8:G_5QA-MT8-U\PS @=T=M*1)D5+*TR%K=P8
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M Y;$=85%6$,1/Q-OPG]$;P0<YM>_"!8=+AQ>^^Z\^U*;9REU[P35BX92T_:
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MJY<\(^A@YX+9Y&349MZDT]+]V7G$/%T]@*T<]! RBIP"+B<3K54Q_(8P N:
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M_1.!0D#PP6 .@[.C9VZ<6 XVUMW 9\]_<MXU>YMM%64U;Q60E/KP<I2FG9M
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MRE6Z^.(I_%Q<[^4ZCV %/H$CUQHJU%ZX$%D,_0 /+'_<BT+G>]W.3+YNH]_
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MC=Y$LBQD6F[8W,RXL][JV<E?R1O1NE_[PX@^YZC9E6*SA2&-K_B\P$/,:U_
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MU47BKW:92%BER'10TSI:4'O*LD>9/^XKI0$:R;4'80 .,5TFH9KBS0 X3A.
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M^'8S ,;J!HTJP^@?\@6([[=^=LTVR$&5!$HQQ?X=2O+/U%H[=#=NP90\7,$
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M63U^ 96-ML>$<J-/!U[Q-=<;>GANL!Z4Q8+FI(3TKARL+:L>*'<>'!VUM39
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MRXBJ1*8CHYEE/3WNAOF__A?8<OC_:.N!]+OF^W4@"["K%:?H&PGCD?!5 1U
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MP_]ON9&4LI-9%VG>42HZ)1V6FY>45Z.&='0GU".T*D#+4_US+_P:F7IXWV%
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M<21Y\7--2X) F(!YBTY+'"1Q1H'UA+/@@W."%*S8/V5(!.5FYFDKO"3RYLO
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M_3(YU/<AY+0+II!5XQ\D7O!Y6;/H2^KD>D95[(772>G%,L:323;7-@T6JH:
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M?GG<Z: 3(GZNXO<YLY6>U+H%.G?'*Y[CY.536<XY$S5SFG_YZSF8TE__"U3
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M.VV^]75O^$1]HH=J7#Z.O!B?!"^"T"'68)K2LU_#Z;YBBKKS\S#9&L3_;IS
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M &-A8F$M,C R-#$R,S$N>'-D4$L! A0#%     @ _3E_6B7TI H/"0  3$8
M !               ( !C9$& &-A8F$M97@Q,%\Q-RYH=&U02P$"% ,4
M" #].7]:D5ZM3-TX   2^0$ #P              @ '*F@8 8V%B82UE>#$Y
M7S$N:'1M4$L! A0#%     @ _3E_6B9^+!UZ P  @Q<   \
M ( !U-,& &-A8F$M97@R,5\Q+FAT;5!+ 0(4 Q0    ( /TY?UJF,=-KFP0
M ,\J   /              "  7O7!@!C86)A+65X,C-?,2YH=&U02P$"% ,4
M    " #].7]:U8D<0W@)   )/0  #P              @ %#W 8 8V%B82UE
M>#,Q7S$N:'1M4$L! A0#%     @ _3E_6AGH-N!K"0  <#T   \
M     ( !Z.4& &-A8F$M97@S,5\R+FAT;5!+ 0(4 Q0    ( /TY?UH@('7E
M? 4  -@D   /              "  8#O!@!C86)A+65X,S)?,2YH=&U02P$"
M% ,4    " #].7]:3$/4?'D%  #1)   #P              @ $I]08 8V%B
M82UE>#,R7S(N:'1M4$L! A0#%     @ _3E_6GY9Q(2H/@( 3&T" !$
M         ( !S_H& &EM9S8S.#DU-3,U7S N:G!G4$L! A0#%     @ _3E_
M6I)?+2./8@( X_L" !$              ( !ICD) &EM9S8S.#DU-3,U7S$N
M:G!G4$L! A0#%     @ _3E_6MHS >A-BP< $P\* !$              ( !
K9)P+ &EM9S8S.#DU-3,U7S(N:G!G4$L%!@     -  T ) ,  . G$P    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>caba-20241231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:caba="http://www.cabalettabio.com/20241231"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="caba-20241231.xsd" xlink:type="simple"/>
    <context id="C_84c42e55-4cc8-4f96-915e-34a23c05bcb6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:December2022FinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_85326982-4e9e-4cd8-af12-fd49791a671c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_881cd698-8215-4730-9508-1b847dfa7222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">caba:StateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_8820b6d6-f9b3-4f60-970e-aabd2aa79a08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">caba:VotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_8a7792c8-f29b-4a61-9156-afc843c668af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:DevelopmentAndManufacturingServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_8c0ea3f5-c232-4ba9-935c-c4f9363bfb3d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_8c193bbc-bddd-4caa-a616-ab7149fe99f2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="C_8ca5d37c-2521-42fc-9e13-1ef37fce3df9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_8cac32c4-7629-42a9-a8fa-069e7af9b310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8fc080aa-f389-40f6-aa75-a26757919ae1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_91bebac1-a194-4aa0-bdad-e2db91554491">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-23</instant>
        </period>
    </context>
    <context id="C_91f04779-501e-4bce-bfef-a9538a16e993">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:WuxiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_977637ab-94d3-4e63-b46a-770bc602ae50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-01</instant>
        </period>
    </context>
    <context id="C_9adfe3c2-df06-47b1-8164-ee5bca829cf8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9be04dd4-fea1-4302-8462-56ed42a391b0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_9cdb36a0-6755-4f07-b415-12eeed80884e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_9d30fac2-b87d-470d-bf79-785e498650f5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_9d8c2f96-4509-44a0-991d-9d569f5f45f2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:AtTheMarketOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a03b5214-7513-436c-a38c-ffda0bc04870">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">caba:StevenNichtbergerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a19e5ed8-055f-4020-a172-1708aa7cf1d2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:MasterTranslationalResearchServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a1e38241-900a-43de-9175-5ee71906e75a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a2e82d17-72fd-4199-85b4-3a85429d0d81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a5bf8c63-11a0-4813-b9c1-88b3b3a7c7df">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">caba:GwendolynBinderOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a7948e46-0c3f-4a80-bc84-1f696b1179b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">caba:GwendolynBinderOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_a7b119c2-8427-423c-9525-72e30103d06a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a801e2f0-ef59-43bc-a0d1-f52d9f8fad06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:OxfordBiomedicaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="C_a9395bbb-6b73-4262-b752-6b65e91be8cd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:AutolusHoldingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_a9916f0c-e5a6-49b3-aa27-2f2599dab549">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b03d1e52-2a57-4c8e-a119-05d8db2d7eab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:NanjingIasoBiotherapeuticsCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_b19a2baa-3b2d-484b-b93b-09bbee5dbbdd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b1d3cbe4-887e-45db-abd2-b02478b909a8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_b2126428-bc71-49ae-8c88-165cc7805710">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
        </entity>
        <period>
            <instant>2025-03-27</instant>
        </period>
    </context>
    <context id="C_b595787c-5321-4455-b3f0-010647595978">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b642840b-d1a1-4660-9f4a-5c26a6b65c07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">caba:VotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-01</instant>
        </period>
    </context>
    <context id="C_b6d231da-185f-42c9-9b3d-442d6ca59665">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-21</startDate>
            <endDate>2019-10-23</endDate>
        </period>
    </context>
    <context id="C_b76590bb-7198-4431-94bb-7578a594bad1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">caba:VotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_b8337e36-0fb0-43e5-b463-b4b3890b87c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_b9ae082c-13ae-4e63-bf00-b9ef8a7a8fe2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b9c36061-77bc-4b94-8132-5e42f9fe5210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_bb64bdf7-38f7-44f3-bf1c-98b0765c39e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-21</startDate>
            <endDate>2019-10-23</endDate>
        </period>
    </context>
    <context id="C_bb8841ed-9927-4eb0-bfb9-ea102a2a8da5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:AtTheMarketOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_bc2a9f34-de0e-42e5-b295-2f8e567060bb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:OxfordBiomedicaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_bec66754-fe9d-4822-a0f6-7256e0f5e854">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_bee1c669-b105-4c4e-b815-f0043dad20ee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="C_bf0b7bb5-9f31-48ec-a4d1-ec777a17246d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:December2022FinancingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">caba:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c1ca12da-bcbe-461c-97eb-dc0872b56a45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_c31b10fb-e739-4340-b8e2-ac8464faec66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_c46ec4f4-c805-417a-8a4d-faada740c019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_c4c22bdc-057a-44d3-8274-7b307be3dfea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c76069af-3284-4046-a825-2b5ff929db4a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_c8879ca3-eb41-45e9-90ca-a45d8a858386">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c9d68995-263a-4813-8297-7b0cb06226df">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:NanjingIasoBiotherapeuticsCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-07</instant>
        </period>
    </context>
    <context id="C_cabc4cba-12e7-440b-9da0-7f7f6b8bb8ea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_cb855622-a323-4d6a-9e19-5673661f83fe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ce2b1ce0-61ab-404b-aa60-52836ccb0f70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_d4a74439-9471-4a4f-9351-6249071d95ae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">caba:GwendolynBinderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_d6f1f45c-9b4a-4db4-bf99-cf7cd3f55c9a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d8712004-ce9c-421a-b7c6-3e8c260bf228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:OxfordBiomedicaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_d8920710-db59-443d-8539-f9ab7adae181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">caba:StevenNichtbergerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_da3cad1c-31be-4130-aaba-7a1f51466edd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:NanjingIasoBiotherapeuticsCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_e24a8a97-a5dc-4f15-92b4-2d95326ebc6a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">caba:VotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-30</instant>
        </period>
    </context>
    <context id="C_e4eaaa6c-1a38-4348-b779-9f2c88c6727b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_e4f2dc83-5acc-4bcc-b167-66ba947b5532">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e627ab24-8781-4141-83d8-30137c5dce9f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_e718fe30-2e2a-42ee-8ebb-122b140ad979">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_eb964699-a57c-4d32-86ed-e6d61d366c5f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_edbf75ee-d36b-422e-9a54-1ab65dcfc82b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-30</instant>
        </period>
    </context>
    <context id="C_f01ad0a8-3dd5-4e30-b96a-3752be3dec4c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f1261fee-7643-4642-aa6e-b30416d960fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f4635c63-e1a0-4066-bb40-7f550db23dd1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandEighteenStockOptionAndGrantPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_f4db9c45-8c5b-4699-a20a-4009f98cad84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f5851d98-3e59-44ab-89c0-e44329981682">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_f59134f7-4690-4aaa-a4ad-dc44779c4c7a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:MasterTranslationalResearchServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_f5bebf2f-73b3-440e-bc7e-082d8b539b8f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandEighteenStockOptionAndGrantPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_fa08dd21-0e3b-409f-9df9-7d9051548e56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_fbb2803e-11f2-411e-bc43-c725c0d90cee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_fbb28abe-5658-4753-b0b7-f0b655b95e73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:WuxiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-24</startDate>
            <endDate>2024-02-24</endDate>
        </period>
    </context>
    <context id="C_fdc47b6b-c242-47bb-af45-4daed72aa461">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_fdc8bd52-362d-49f3-9e45-6677140ad037">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_00142f0e-bf74-4dac-98f2-8c7944fde213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_009b7691-4723-4a29-a462-e1c82235024a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-23</instant>
        </period>
    </context>
    <context id="C_02a92407-52fe-4b71-9603-dc350a954b27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_0603accc-761b-4dd7-9cb1-3b0483ce98b5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:AutolusHoldingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="C_067790e2-b88b-48e5-8bbf-2c266ffc2b13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_071a7623-23cd-43a4-8077-7f5f839577fb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">caba:Rese-CelAndMuSK-CAARTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_0c06bf87-692f-4caf-b799-574ffd3da54b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:December2022FinancingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">caba:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_0c1b371f-ae73-4a6c-ba1b-1ded4756d505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:AutolusHoldingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_0ca36e70-a499-407f-8dc9-ca889acf6ed1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_0f0de8fd-770f-40d6-b430-5691463bc993">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_1078f332-4fd3-4a24-94d7-ea03957d7227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:LonzaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_11dd7a1d-2e01-497c-a7de-cb3940339fe0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_11f1e157-c9cb-4fce-b81f-40d77ea635c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_12b0a7be-84f3-45d4-9d6e-95533e750a7a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">caba:VotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_16370771-1761-414a-82f7-374ff37b95d5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:LonzaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_1947669b-c145-49f5-aea0-60ae45e15e4f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:DevelopmentAndManufacturingServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_19532afe-5faa-47b1-a0ce-01e2a372f9f0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_1a070b4c-533f-43fc-9a6b-b37ff298a84e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_1b69037c-33e3-4056-95e8-3197e2253d28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:OxfordBiomedicaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_1e1e3aab-a61d-436a-a436-d1b68af34f64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:December2022FinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_1e81d161-d2c9-4466-ad56-b46b0e4daea1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_1f0087e0-dac4-4dce-a0b5-2502f2165631">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-31</instant>
        </period>
    </context>
    <context id="C_2050f55b-9729-46ca-976a-a50c6da04429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:AtTheMarketOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_205ec67f-4f43-4431-93b3-98f31625b5c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_22da4d01-1dd8-4662-b3be-4451dc2b3435">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:AtTheMarketOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_239a468d-472b-4684-b508-dd3ca371e2de">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:OxfordBiomedicaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_249c212f-73ed-4f7d-aa7a-ae4c0064e772">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">caba:GwendolynBinderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_2583f882-17d6-4155-a8a0-ab8287370f9a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_25d4f8d5-93ce-418d-8f55-f27f42cf8bf6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:LonzaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_26624392-0d0a-48e8-85da-f2115c4b9abd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandEighteenStockOptionAndGrantPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_269acac6-33ca-4743-9c91-3860f13c66c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_29f8f331-c6aa-4374-ab1d-8e739c14e615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:MayTwoThousandTwentyThreeFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="C_2aa93a55-952b-4b3f-94d7-89fe525c7f44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_2b388bdd-20d2-49ab-a3f5-a0e370b1edf7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:MayTwoThousandTwentyThreeFinancingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">caba:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="C_2c83b4bd-a25b-4fdd-8a75-b19f7b147a93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2dcaa877-5c12-4f55-882d-3d8601e906a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_32ecdf32-80a6-4f58-8b71-96d449c2f6c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandEighteenStockOptionAndGrantPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_343f9e90-d9f0-4ab3-ab0c-3a31e1b64b95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">caba:VotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_355bad0a-3e83-4a29-ad76-5f43d0ef52d7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_3577cd65-82b8-42e6-844e-ca6167dba709">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-31</instant>
        </period>
    </context>
    <context id="C_35f03d89-1210-4983-af91-5949af3be4e2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:December2022FinancingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">caba:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_3819e40f-e461-41a7-97d5-7e402dc0c022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:SponsoredResearchAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_3c5b95c6-6f48-4cac-8c2f-d9294618a5d9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_3cf6ca28-81b1-4647-b307-30db6e6d90f1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_3e97ca82-cc21-4f56-9fdf-9c22c00b90af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_40d8b316-eb73-435b-b720-1f6b7d1ba479">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_41424f02-2797-4d2b-9ae9-195e1bbcc839">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:OxfordBiomedicaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-31</instant>
        </period>
    </context>
    <context id="C_41757f68-a8c3-48bc-848b-2cb739ce9b63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:NanjingIasoBiotherapeuticsCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_42bda966-2bcc-4366-9ccc-53d8a69b796d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="C_438de52d-5f54-466c-a0d0-ff8e3b765da2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_43efc37e-6f8b-48fc-b2ca-860b7ba5abf4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_48b6f6be-97cc-4ef9-bae5-f20850435f20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_4911bc2b-bbb5-4139-af54-75d9d982736e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_4a78e058-f9de-403c-bcb2-4c5d292bf4a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_50b61005-316a-440c-b7d7-051b2270374c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">caba:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_50ec53a6-211e-4704-8e25-521e6deb405e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_540f0e6d-d008-4d25-b45d-014688c83725">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">caba:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_58107011-70e5-45db-96bf-b13e678c007f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_58f7eda9-d4b7-4543-b9f9-e26b3d10127c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_591ef989-ecdb-491c-873b-f35ee5894e2b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:MasterTranslationalResearchServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_5ae7b143-7cde-44f4-9122-03f5df7ace32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">caba:StevenNichtbergerOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_5c158f7e-d30a-4d7e-913b-54efddfa9032">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">caba:StateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_5c849a35-78e8-4658-b224-1c019b513ae4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_5d39951d-322e-4fbb-8300-8a74cf365c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">caba:StevenNichtbergerOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_5eb72df5-0321-4487-8ba8-cc5d3052b6cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:AutolusHoldingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_60702d76-a78f-433d-8046-7a817c666483">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">caba:FederalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_636f9b5e-113f-4fa8-938c-4b0bf99f0a58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_649a608e-fb57-4b77-b3df-53aea52c4927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_6525b174-f1b8-46c9-95b2-6b44e02a8e4d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-01</instant>
        </period>
    </context>
    <context id="C_68171875-88e5-4c5d-a904-b84ad5d56a17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:AtTheMarketOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_711abcf7-e6c1-4c74-8ec8-d2b808baace6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_71d3a4fa-64fd-456b-b2cd-92dccaa7ba87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_72321c97-c716-4fc6-b08a-a26615a95579">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_72b96170-7a04-4855-aa98-34638538347d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_72e98e9b-d795-49b3-92aa-8c76efc07029">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="C_734d3853-d0a8-4ac2-a327-a99b436ab861">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_751af1f3-2ee2-42ff-9b2c-27e58ba3e3be">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_7552d055-8ba4-480a-a069-f83dd0658987">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_75b117c4-870a-43ee-97dd-4b546ab94807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:MayTwoThousandTwentyThreeFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="C_76f2bc1f-8bfe-42b0-8ef5-bd09ee4372d6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_7bbbdb4f-492f-4e45-b1af-564db3e6c265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_7bbcce38-fe4c-402a-abef-f39d1a8317bc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_7e18ccc8-731c-4531-8ac3-a3a38fdbfbb4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_7f97431a-51bc-48de-b369-469db20bdb17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">caba:FederalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <unit id="U_Segment">
        <measure>caba:Segment</measure>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_bda6a701-ab11-43cc-b428-f88207a26173">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_a4a91c46-2193-43b0-aa9d-8eb044cecb29">0001759138</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_25eafd07-1076-4a8b-8d80-5c8a6d059661">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_193d1736-d030-4379-9165-2e37496bd364">--12-31</dei:CurrentFiscalYearEndDate>
    <ecd:TrdArrDuration
      contextRef="C_d8920710-db59-443d-8539-f9ab7adae181"
      id="F_12ddf4b5-a62c-4ffa-84f2-711a71acbce0">P388D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration
      contextRef="C_5d39951d-322e-4fbb-8300-8a74cf365c32"
      id="F_f0564499-a995-4065-9bd0-26aa3bce6fbe">P527D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration
      contextRef="C_249c212f-73ed-4f7d-aa7a-ae4c0064e772"
      id="F_823872a2-58d2-4796-aa66-411b0b1f08f7">P368D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration
      contextRef="C_a7948e46-0c3f-4a80-bc84-1f696b1179b4"
      id="F_e881d3fc-fad6-4460-a675-9db9c9ce22a6">P180D</ecd:TrdArrDuration>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      id="F_4ab01a83-cec0-465d-abc1-ee74933546db"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc"
      id="F_9b348112-6fc9-49be-b4f8-a3dfc1834bd8"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration
      contextRef="C_b9ae082c-13ae-4e63-bf00-b9ef8a7a8fe2"
      id="F_11fb0b7e-26ca-48c1-8f03-76b57f37f299">http://www.cabalettabio.com/20241231#PropertyPlantAndEquipmentEstimatedUsefulLives1</us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="0"
      id="F_d4311f9a-8cf2-4c85-b6fa-4408d3790ae7"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_72b96170-7a04-4855-aa98-34638538347d"
      id="F_aacb9393-82a1-4484-8aab-edf9ca81d63c"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_7e18ccc8-731c-4531-8ac3-a3a38fdbfbb4"
      id="F_b8a328b1-c384-428d-aa72-eece52e52e47"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_26624392-0d0a-48e8-85da-f2115c4b9abd"
      id="F_12ab2f03-70f4-4da9-bb26-c88cd3cb34ae">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_2f2c6847-af50-4feb-949b-5013b2930df4">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_c0e6552f-d6ec-474b-9d72-52e82ed76a50">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_935e48a0-2a61-4408-9a03-7f9e7d54af3f">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_3a262f1a-3df1-41b4-b6f0-f28c5c127343">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_77140168-2e52-468b-8c3f-ab3d15ef1a79">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_583cbb4f-cbb3-4a0b-b18a-e2098dd521a5">001-39103</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_e2eeb86b-6b1f-4fdd-abc9-14ca558bdc1d">CABALETTA BIO, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_45107ea6-aa20-4963-a048-28e63c3eab1c">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_72d36a34-4d9d-4fc4-aa14-7491155e8faa">82-1685768</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_2f11e6f3-7613-4531-ae5c-20e92b13f857">2929 Arch Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_abda6de5-9721-4901-889c-d962c4d96e9f">Suite 600</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_e1835495-eff5-4aa4-915b-0122472572c7">Philadelphia</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_a96ac548-33fb-41f8-88f3-1ba12f528907">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_b7c41b80-51f1-4afe-b1a5-c25d11050235">19104</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_fa78ccb9-7e15-41a3-b958-4430b21e14ca">267</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_f64d440e-fd74-4faa-a270-6c3fe6b3c5f7">759-3100</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_f78687fa-8eed-49c4-a3b1-28590a55f596">Common Stock, par value $0.00001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_09d92e55-a361-471a-b7fb-8ebe4f4045d3">CABA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_0c391e0e-24d1-460a-a754-ed9bc442edb3">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_4e071cd3-69b5-4d23-a8d7-86e54a80ca09">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_c9f91611-0272-4fa1-bba8-dc015ad392fa">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_733903b5-93de-4081-9516-b9a89235919f">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_e599efad-ff4d-44ef-a8a4-a9e0c0f52982">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_422274f0-102e-49e0-889e-15d0d20d7997">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_3106d169-5cc5-4178-9a6d-be66408fef4f">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_282ebf46-ee93-4ed4-9ba4-a85e2b413f19">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_41d5aa01-831f-4f2f-ab90-55fbf008305e">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_4a661273-e600-4fe5-a30a-b5e13fb01a15">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_b6b55afd-f3c6-4437-a666-ae0a25e12f0b">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_355bad0a-3e83-4a29-ad76-5f43d0ef52d7"
      decimals="-6"
      id="F_19b938bd-21e2-4f4c-ac41-7085d28056c1"
      unitRef="U_USD">350000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_b2126428-bc71-49ae-8c88-165cc7805710"
      decimals="0"
      id="F_47934cca-5386-4464-966a-eb6be6e47c99"
      unitRef="U_shares">50743101</dei:EntityCommonStockSharesOutstanding>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_ea3d7222-eb9e-4fa9-9b3d-f6e3c1191cd9">&lt;p id="item_1c_cybersecurity" style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Item 1C. Cybersecurity.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cyber Risk Management and Strategy&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We, under the oversight of the audit committee of our board of directors, have &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;implemented&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and maintain a cybersecurity risk management program that is designed to identify, assess, and mitigate risks from cybersecurity threats. Our risk management is supported by various tools and technologies, including third-party security solutions, monitoring, and alerting tools, designed to monitor, identify, and address risks from cybersecurity threats.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;engage &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;with other third-party providers and consultants to support our cyber risk management efforts, including through periodic security testing and assessments. We have a process to assess certain major &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;third-party vendors and service providers&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, including through a review of responses to compliance questionnaires and contractual requirements, as appropriate.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We, like other companies in our industry, face a number of risks from cybersecurity threats in connection with our business. Although such risks have not &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;materially affected&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, and we do not believe they are reasonably likely to materially affect, us, including our business strategy, results of operations or financial condition, to date, we have, from time to time, experienced threats to and security incidents related to our data and systems. For more information about the risks from cybersecurity threats we face, please see Item 1A- Risk Factors.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Governance Related to Cybersecurity Risks&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our board of directors, as a whole and through its committees, has responsibility for the periodic review and oversight of information technology risks, including risks from cybersecurity threats.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The audit committee is responsible for oversight of our cyber risk management program&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The day-to-day management of the cyber program is directed by the Director of IT under the direction of the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Chief Financial Officer&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Currently,&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; the Director of IT reports to the Chief Financial Officer and provides periodic updates to the Chief Financial Officer on cyber matters.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Director of IT meets with the Chief Financial Officer periodically to discuss and review our cybersecurity risk management processes and to address matters related to potential cybersecurity and information technology risks, with input from the Company&#x2019;s third-party technology providers, as appropriate. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Chief Financial Officer provides periodic reports on cybersecurity and information technology matters to the audit committee, which is responsible for reviewing and overseeing the Company&#x2019;s risk management process, including risks from cybersecurity threats, as set forth in the audit committee charter.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The audit committee periodically reports&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; on cybersecurity risk management to the full board of directors.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_9fa0b9e6-e4e5-4954-93fa-bdd0e90ada18">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We, under the oversight of the audit committee of our board of directors, have &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;implemented&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and maintain a cybersecurity risk management program that is designed to identify, assess, and mitigate risks from cybersecurity threats. Our risk management is supported by various tools and technologies, including third-party security solutions, monitoring, and alerting tools, designed to monitor, identify, and address risks from cybersecurity threats.&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_2f27f3f6-108d-42a8-ab94-3bd416adc067">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_84f80487-f2de-4031-a33f-52df630b9384">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_2b926224-5f4a-43f7-b049-219ff820be72">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_bc35de04-ae39-4af9-aa34-ef71a2871863">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_62ad7bad-9773-4622-b2e8-b3d22e918237">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our board of directors, as a whole and through its committees, has responsibility for the periodic review and oversight of information technology risks, including risks from cybersecurity threats.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The audit committee is responsible for oversight of our cyber risk management program&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The day-to-day management of the cyber program is directed by the Director of IT under the direction of the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Chief Financial Officer&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Currently,&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; the Director of IT reports to the Chief Financial Officer and provides periodic updates to the Chief Financial Officer on cyber matters.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Director of IT meets with the Chief Financial Officer periodically to discuss and review our cybersecurity risk management processes and to address matters related to potential cybersecurity and information technology risks, with input from the Company&#x2019;s third-party technology providers, as appropriate. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Chief Financial Officer provides periodic reports on cybersecurity and information technology matters to the audit committee, which is responsible for reviewing and overseeing the Company&#x2019;s risk management process, including risks from cybersecurity threats, as set forth in the audit committee charter.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The audit committee periodically reports&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; on cybersecurity risk management to the full board of directors.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_b6f2d28b-a959-4a90-a2e0-33bc0ba157e2">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The audit committee is responsible for oversight of our cyber risk management program&lt;/span&gt;</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_165de482-4075-4927-b4c0-f6da1ba74e59">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The day-to-day management of the cyber program is directed by the Director of IT under the direction of the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Chief Financial Officer&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Currently,&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; the Director of IT reports to the Chief Financial Officer and provides periodic updates to the Chief Financial Officer on cyber matters.&lt;/span&gt;&lt;/span&gt;</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_a45339e0-f061-4ebd-ab49-c4679691ed11">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_61a8dc57-7332-465e-9594-bf106907117e">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; the Director of IT reports to the Chief Financial Officer and provides periodic updates to the Chief Financial Officer on cyber matters.&lt;/span&gt;</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_10e4d4bb-ed62-4df3-b5c6-a3f316384ca1">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Director of IT meets with the Chief Financial Officer periodically to discuss and review our cybersecurity risk management processes and to address matters related to potential cybersecurity and information technology risks, with input from the Company&#x2019;s third-party technology providers, as appropriate. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Chief Financial Officer provides periodic reports on cybersecurity and information technology matters to the audit committee, which is responsible for reviewing and overseeing the Company&#x2019;s risk management process, including risks from cybersecurity threats, as set forth in the audit committee charter.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The audit committee periodically reports&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; on cybersecurity risk management to the full board of directors.&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_82b01fed-d41a-4757-b148-7ea212fb1b91">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Chief Financial Officer provides periodic reports on cybersecurity and information technology matters to the audit committee, which is responsible for reviewing and overseeing the Company&#x2019;s risk management process, including risks from cybersecurity threats, as set forth in the audit committee charter.&lt;/span&gt;</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_1b0187d8-7149-4e97-91d3-712b2494fa3e">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <ecd:MtrlTermsOfTrdArrTextBlock
      contextRef="C_438de52d-5f54-466c-a0d0-ff8e3b765da2"
      id="F_ba49fc90-86d5-401f-8311-7dc12b279195">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Rule 10b5-1 Trading Plans&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the fiscal quarter ended on December 31, 2024, none of our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;modified&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; or &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;terminated&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; a &#x201c;Rule 10b5-1 trading arrangement&#x201d; or &#x201c;non-Rule 10b5-1 trading arrangement,&#x201d; as those terms are defined in Item 408(a) of Regulation S-K, except as described in the table below:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
     &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
      &lt;tr style="visibility:collapse;"&gt;
       &lt;td style="width:21.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;td style="width:12.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;td style="width:15.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;td style="width:16.64%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;td style="width:14.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;td style="width:19.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr style="height:54.4pt;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
       &lt;td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Name and Title&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Action&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Action Date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Duration of Trading Arrangements&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Rule 10b5-1 Trading Arrangement?&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(Y/N)*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate Number of Securities Subject to Trading Arrangement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr style="height:35.95pt;word-break:break-word;white-space:pre-wrap;"&gt;
       &lt;td style="padding-top:0in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Steven Nichtberger&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Chief Executive Officer&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Terminate&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;October 18, 2024&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_12ddf4b5-a62c-4ffa-84f2-711a71acbce0;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;July 8, 2024 - July&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Y&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Up to &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;350,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;shares to be sold&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr style="height:10pt;word-break:break-word;white-space:pre-wrap;"&gt;
       &lt;td style="padding-top:0in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Steven Nichtberger&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Chief Executive Officer&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Adopt&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;October 18, 2024&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_f0564499-a995-4065-9bd0-26aa3bce6fbe;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;February 16, 2025 &#x2013; July 27, 2026&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Y&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Up to &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;350,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;shares to be sold&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr style="height:46.3pt;word-break:break-word;white-space:pre-wrap;"&gt;
       &lt;td style="padding-top:0in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Gwendolyn Binder&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;President of Science and Technology&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Terminate&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;November 21, 2024&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_823872a2-58d2-4796-aa66-411b0b1f08f7;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;February 20, 2024 &#x2013; February 21, 2025&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Y&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Up to &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100,756&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;shares to be sold&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr style="height:10pt;word-break:break-word;white-space:pre-wrap;"&gt;
       &lt;td style="padding-top:0in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Gwendolyn Binder&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;President of Science and Technology&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Adopt&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;December 18, 2024&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_e881d3fc-fad6-4460-a675-9db9c9ce22a6;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;March 27, 2025 to December 12, 2025&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Y&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Up to &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100,756&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;shares to be sold&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;/tr&gt;
     &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;* Denotes whether the trading plan is intended, when adopted, to satisfy the affirmative defense of Rule 10b5-1(c).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(1) Except as indicated by footnote, each trading arrangement permitted or permits transactions through and including the earlier to occur of (a) the completion of all purchases or sales or (b) the date listed in the table.&lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(2) Represents the modification, as described in Rule 10b5-1(c)(1)(iv) under the Exchange Act, of a written trading arrangement adopted on November 9, 2023 that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.&lt;/span&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="C_438de52d-5f54-466c-a0d0-ff8e3b765da2"
      id="F_ed32101e-27c6-46a4-b898-01d6bf0df2d5">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_438de52d-5f54-466c-a0d0-ff8e3b765da2"
      id="F_78329bf4-af50-49d2-b228-d0088211f6c0">false</ecd:Rule10b51ArrAdoptedFlag>
    <caba:Rule10B51ArrModifiedFlag
      contextRef="C_438de52d-5f54-466c-a0d0-ff8e3b765da2"
      id="F_0e433583-eea0-43fe-a846-0e9090d827c5">false</caba:Rule10B51ArrModifiedFlag>
    <caba:NonRule10B51ArrModifiedFlag
      contextRef="C_438de52d-5f54-466c-a0d0-ff8e3b765da2"
      id="F_e521c342-f6f8-48c9-80de-4f93655cb3d5">false</caba:NonRule10B51ArrModifiedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="C_438de52d-5f54-466c-a0d0-ff8e3b765da2"
      id="F_6697ff6b-918e-48ba-83f9-4107e2dce2b9">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_438de52d-5f54-466c-a0d0-ff8e3b765da2"
      id="F_a101396f-8878-4ba6-9747-78ff6852ee71">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:TrdArrIndName
      contextRef="C_d8920710-db59-443d-8539-f9ab7adae181"
      id="F_8c1b5cd2-9f1e-4c04-b5f9-cd8ffc78e4fc">Steven Nichtberger</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle
      contextRef="C_d8920710-db59-443d-8539-f9ab7adae181"
      id="F_40788efa-89db-4fb2-8a80-fa57f060d7d7">Chief Executive Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_d8920710-db59-443d-8539-f9ab7adae181"
      id="F_537853c2-69ae-4eb0-a116-80e3343a1708">true</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:TrdArrTerminationDate
      contextRef="C_d8920710-db59-443d-8539-f9ab7adae181"
      id="F_d1ff8d6a-33d9-4f37-8ef5-c87250188d9b">October 18, 2024</ecd:TrdArrTerminationDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="C_a03b5214-7513-436c-a38c-ffda0bc04870"
      decimals="0"
      id="F_f29b8f47-e3be-40de-8059-4c45fa576a9d"
      unitRef="U_shares">350000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrIndName
      contextRef="C_5d39951d-322e-4fbb-8300-8a74cf365c32"
      id="F_ad0c6520-413a-46c8-92e7-cee48123c6db">Steven Nichtberger</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle
      contextRef="C_5d39951d-322e-4fbb-8300-8a74cf365c32"
      id="F_79002335-d05e-4367-b1f8-ce5277322c9d">Chief Executive Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_5d39951d-322e-4fbb-8300-8a74cf365c32"
      id="F_c2ec38c4-d236-4522-be8b-3253a1d0b866">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate
      contextRef="C_5d39951d-322e-4fbb-8300-8a74cf365c32"
      id="F_b6378822-f522-428b-b919-580ee211be3a">October 18, 2024</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="C_5ae7b143-7cde-44f4-9122-03f5df7ace32"
      decimals="0"
      id="F_7392ec15-f38a-477c-8bc2-c65d57199f8b"
      unitRef="U_shares">350000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrIndName
      contextRef="C_249c212f-73ed-4f7d-aa7a-ae4c0064e772"
      id="F_27b2c07a-01a6-43f3-8aed-83045450ec50">Gwendolyn Binder</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle
      contextRef="C_249c212f-73ed-4f7d-aa7a-ae4c0064e772"
      id="F_17c9fa72-29c4-4d47-bd31-11b6eff1d24b">President of Science and Technology</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_249c212f-73ed-4f7d-aa7a-ae4c0064e772"
      id="F_ace2887d-50d7-482c-a7d7-fef7cf638aac">true</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:TrdArrTerminationDate
      contextRef="C_249c212f-73ed-4f7d-aa7a-ae4c0064e772"
      id="F_9cf1b1cf-0bab-4989-918f-64c1cd192f77">November 21, 2024</ecd:TrdArrTerminationDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="C_d4a74439-9471-4a4f-9351-6249071d95ae"
      decimals="0"
      id="F_2829044d-0635-4dd3-a2b5-ac7b74e4c246"
      unitRef="U_shares">100756</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrIndName
      contextRef="C_a7948e46-0c3f-4a80-bc84-1f696b1179b4"
      id="F_c73cecdb-3a8c-4fb8-b02a-a7b935a100b7">Gwendolyn Binder</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle
      contextRef="C_a7948e46-0c3f-4a80-bc84-1f696b1179b4"
      id="F_a104b6c0-1694-4359-8eae-d11f787a1e0e">President of Science and Technology</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_a7948e46-0c3f-4a80-bc84-1f696b1179b4"
      id="F_5c99fc75-08af-4faf-8b94-35faba4a4e36">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate
      contextRef="C_a7948e46-0c3f-4a80-bc84-1f696b1179b4"
      id="F_caf42755-7b4d-4e5b-b048-a2944212492a">December 18, 2024</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="C_a5bf8c63-11a0-4813-b9c1-88b3b3a7c7df"
      decimals="0"
      id="F_4689fcff-99d0-46d3-a6de-55cebd00c7f7"
      unitRef="U_shares">100756</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_a63e2146-4b8f-4855-aa3f-311dd2cd2642">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <ecd:AwardTmgMnpiCnsdrdFlag
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_877bf23e-55dc-4a1e-89cd-9099745cca5f">false</ecd:AwardTmgMnpiCnsdrdFlag>
    <ecd:MnpiDiscTimedForCompValFlag
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_73f84098-89b8-4124-bb62-e35574bda805">false</ecd:MnpiDiscTimedForCompValFlag>
    <dei:AuditorFirmId
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_1a4349a2-6a23-4691-bc8c-c0c71c3a97bf">42</dei:AuditorFirmId>
    <dei:AuditorOpinionTextBlock
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_bb9d6b21-e8c3-4b04-bc40-2c73be4b6034">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Opinion on the Financial Statements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have audited the accompanying consolidated balance sheets of Cabaletta Bio, Inc. (the Company) as of December 31, 2024 and 2023, the related consolidated statements of operations and comprehensive loss, stockholders&#x2019; equity and cash flows for each of the two years in the period ended December 31, 2024, and the related notes (collectively referred to as the &#x201c;consolidated financial statements&#x201d;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles.&lt;/span&gt;&lt;/p&gt;</dei:AuditorOpinionTextBlock>
    <dei:AuditorName
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_208eb534-e79b-40b2-9936-2511afd95abf">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_fbe5128a-952a-4f88-ad26-ffa8e1c9e2b3">Philadelphia, Pennsylvania</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_1d18dcd8-7992-4cb3-8e21-8eeee0d7e80d"
      unitRef="U_USD">163962000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc"
      decimals="-3"
      id="F_4a60002a-fb91-4a1c-8e10-c42459d2f59f"
      unitRef="U_USD">193238000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_823ff595-570b-42a1-9bec-43e81d093a56"
      unitRef="U_USD">0</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc"
      decimals="-3"
      id="F_7646a108-d293-42d5-9d12-d992fd17d71b"
      unitRef="U_USD">48011000</us-gaap:ShortTermInvestments>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_233f7aa9-0102-4ba8-9ec3-5c66dba02850"
      unitRef="U_USD">2713000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc"
      decimals="-3"
      id="F_b1feafb3-b46b-4756-8d34-3fcf710ea647"
      unitRef="U_USD">3241000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_4bd3fbf9-9445-4755-aa15-2cc3e042ee75"
      unitRef="U_USD">166675000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc"
      decimals="-3"
      id="F_0455c4eb-fb23-4bd5-9723-a9eb218bfc07"
      unitRef="U_USD">244490000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_1edd3ebb-b378-4439-99df-0f8edd240d5d"
      unitRef="U_USD">2743000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc"
      decimals="-3"
      id="F_54b727fb-f68e-4b1e-bbdc-29a3e21f8f8c"
      unitRef="U_USD">2541000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_e8cce044-ee24-416e-bb06-fefdb71dccc8"
      unitRef="U_USD">7020000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc"
      decimals="-3"
      id="F_e6bc608b-7425-44b2-a266-51b2412a08ca"
      unitRef="U_USD">0</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_e8dbf2b9-ca1f-48a8-a335-b3873f24131c"
      unitRef="U_USD">6315000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc"
      decimals="-3"
      id="F_1fdf4af6-5aa2-4937-b6a8-f685ea84b4eb"
      unitRef="U_USD">4910000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_02d7487a-aa75-4bae-93e9-2b50816273e2"
      unitRef="U_USD">2293000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc"
      decimals="-3"
      id="F_a7743452-fa8b-4836-94b3-79179f0daef4"
      unitRef="U_USD">1709000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_eb928439-31ec-45a5-b85c-48ee6765e7ca"
      unitRef="U_USD">185046000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc"
      decimals="-3"
      id="F_837b5261-1c85-41e4-ae87-0ecd82d9db24"
      unitRef="U_USD">253650000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_867a5134-5a40-46cf-a5a9-ad44c024275b"
      unitRef="U_USD">4923000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc"
      decimals="-3"
      id="F_d2edd427-5239-4139-806c-e452060da1f1"
      unitRef="U_USD">4547000</us-gaap:AccountsPayableCurrent>
    <caba:AccruedLiabilitiesAndOtherLiabilitiesCurrent
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_e687d651-3df5-4ad3-9a5d-9fd068618c56"
      unitRef="U_USD">12188000</caba:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <caba:AccruedLiabilitiesAndOtherLiabilitiesCurrent
      contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc"
      decimals="-3"
      id="F_bb01d3ba-4c92-4f1b-95c6-07528f9754e3"
      unitRef="U_USD">7887000</caba:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_0e01e0c6-2e93-4538-b566-aa28a23e78c7"
      unitRef="U_USD">5989000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc"
      decimals="-3"
      id="F_614c7eee-4b21-4198-a7f1-4eca1eb688ce"
      unitRef="U_USD">0</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_cbbf2ff3-e9a3-4559-8058-f6b06c6915be"
      unitRef="U_USD">3986000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc"
      decimals="-3"
      id="F_662496ef-ae6f-4028-ab8f-aab5b6099e21"
      unitRef="U_USD">3560000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_6c6d2af0-0b54-4a2f-a980-402692d90be6"
      unitRef="U_USD">27086000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc"
      decimals="-3"
      id="F_4256d3cd-7c17-41d6-84ac-bdfebe4cedf1"
      unitRef="U_USD">15994000</us-gaap:LiabilitiesCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_f2121fb6-7e8d-43d9-bbdf-effaa8cb5a32"
      unitRef="U_USD">3241000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc"
      decimals="-3"
      id="F_c2b5de20-6322-4aa6-b074-dc881ac6b76b"
      unitRef="U_USD">0</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_0d9de347-7a5c-4798-a78c-df388f693632"
      unitRef="U_USD">2384000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc"
      decimals="-3"
      id="F_688fbcd7-1eb9-4cba-9f8f-1dccad74a307"
      unitRef="U_USD">1458000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_c438a3b9-3dcb-48f0-9fd3-109da98fd5a4"
      unitRef="U_USD">32711000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc"
      decimals="-3"
      id="F_0d706ca5-cf37-4465-a189-65931d683bcd"
      unitRef="U_USD">17452000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="INF"
      id="F_eaf1ab88-c146-481e-a0db-cb364a0180d8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc"
      decimals="INF"
      id="F_c7ede224-15e8-4168-b911-59c1205f8201"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="INF"
      id="F_8ec1225c-4716-4f3e-8242-a7bc73c9a489"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc"
      decimals="INF"
      id="F_33c6ed8f-aa62-4ae5-b66e-f11d554c0964"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="INF"
      id="F_834bea8d-1fbf-44b4-a503-540540e3d387"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc"
      decimals="INF"
      id="F_891774c2-6815-4d5a-9d25-bad03712d8b7"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="INF"
      id="F_e07c90a1-6043-44f1-b781-3c0684be9ba1"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc"
      decimals="INF"
      id="F_cc6ebf22-986e-43b9-9f15-9cbc1b05b05c"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_de783f55-0cbc-48b9-a179-0ba2d0d266b7"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc"
      decimals="-3"
      id="F_e0d51eea-1094-4443-b1ea-d34159fb8593"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_12b0a7be-84f3-45d4-9d6e-95533e750a7a"
      decimals="INF"
      id="F_ba656154-bffb-49f9-af74-3a4a8fa27293"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_343f9e90-d9f0-4ab3-ab0c-3a31e1b64b95"
      decimals="INF"
      id="F_fcd8f34a-d1dd-4bf1-8d26-c837c6af36c0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_8ca5d37c-2521-42fc-9e13-1ef37fce3df9"
      decimals="INF"
      id="F_1ba98680-e884-44b3-a2cc-70e9d3318e8e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_e718fe30-2e2a-42ee-8ebb-122b140ad979"
      decimals="INF"
      id="F_bb566eff-c175-4913-9d1d-928a43fcd663"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="INF"
      id="F_5f9940e3-d42e-4bf4-89f2-925e2397ab64"
      unitRef="U_shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc"
      decimals="INF"
      id="F_3012b919-41f6-4c4e-9b7e-c968e7fe8d8f"
      unitRef="U_shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_12b0a7be-84f3-45d4-9d6e-95533e750a7a"
      decimals="INF"
      id="F_ce27ce6e-9146-4e47-803e-b120bd94c458"
      unitRef="U_shares">143590481</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_343f9e90-d9f0-4ab3-ab0c-3a31e1b64b95"
      decimals="INF"
      id="F_93387c18-0325-4e99-95fe-9291ce54d5f2"
      unitRef="U_shares">143590481</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_8ca5d37c-2521-42fc-9e13-1ef37fce3df9"
      decimals="INF"
      id="F_9eb1ac3c-82dc-4ce5-a49a-2695299c01d8"
      unitRef="U_shares">6409519</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_e718fe30-2e2a-42ee-8ebb-122b140ad979"
      decimals="INF"
      id="F_828c177e-4ac6-41aa-b1ce-5a1198c584d8"
      unitRef="U_shares">6409519</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_12b0a7be-84f3-45d4-9d6e-95533e750a7a"
      decimals="INF"
      id="F_14abca75-1b79-4591-a0aa-e38eac27e018"
      unitRef="U_shares">50743101</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_12b0a7be-84f3-45d4-9d6e-95533e750a7a"
      decimals="INF"
      id="F_83f08ddd-3a30-49fc-b5f2-d66d2bb5683e"
      unitRef="U_shares">50743101</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc"
      decimals="INF"
      id="F_3f5dbffe-8d46-4cb0-b519-d1f1753eaf24"
      unitRef="U_shares">47823232</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc"
      decimals="INF"
      id="F_f195616c-fab6-4437-9076-3a07ab90fcaa"
      unitRef="U_shares">47823232</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_343f9e90-d9f0-4ab3-ab0c-3a31e1b64b95"
      decimals="INF"
      id="F_c71affeb-7e1c-4d83-9f41-f0bce049a963"
      unitRef="U_shares">46378937</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_343f9e90-d9f0-4ab3-ab0c-3a31e1b64b95"
      decimals="INF"
      id="F_ae2b10f3-8405-4fcb-b8cf-402bd69f1679"
      unitRef="U_shares">46378937</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_e718fe30-2e2a-42ee-8ebb-122b140ad979"
      decimals="INF"
      id="F_c3e4856c-e4fb-471e-961c-b770b8ff8f34"
      unitRef="U_shares">1444295</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_e718fe30-2e2a-42ee-8ebb-122b140ad979"
      decimals="INF"
      id="F_97ce7c3a-8b3e-4a71-a713-a434200e5639"
      unitRef="U_shares">1444295</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_dda8b8cf-6666-43af-acae-ae877c785de4"
      unitRef="U_USD">1000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc"
      decimals="-3"
      id="F_bed362f5-edf4-4485-9d6c-476f1cc1ebda"
      unitRef="U_USD">0</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_1e761569-95fb-4dcb-bc08-259242249e71"
      unitRef="U_USD">501435000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc"
      decimals="-3"
      id="F_817ef410-1391-4eaa-8169-302654c00eac"
      unitRef="U_USD">469396000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_bd017419-77fa-41ed-81fc-ec2501de9ac2"
      unitRef="U_USD">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc"
      decimals="-3"
      id="F_99f0066f-942f-4404-8c3d-921e9b900b17"
      unitRef="U_USD">39000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_9e46f479-7df3-434c-b9d6-a6be526a182c"
      unitRef="U_USD">-349101000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc"
      decimals="-3"
      id="F_635f785a-78a4-4f74-b92f-ee57c30ba1c2"
      unitRef="U_USD">-233237000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_0c00cfae-bda5-4e52-97cf-b24b1a279e24"
      unitRef="U_USD">152335000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc"
      decimals="-3"
      id="F_dd625fcf-2ae1-4dce-9b13-366c51b9a25e"
      unitRef="U_USD">236198000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_931b0b4b-31ff-40c4-a892-c21c04cd9d68"
      unitRef="U_USD">185046000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc"
      decimals="-3"
      id="F_ae2a3850-ca73-49b0-a573-0f1e527c1424"
      unitRef="U_USD">253650000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_2fc44488-5ead-424a-bde3-fd4349187e42"
      unitRef="U_USD">97203000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_1f3d2031-2716-46b3-8cd6-af41b3f14ba7"
      unitRef="U_USD">55424000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_27d030b2-c23f-4854-aeb4-4e3c15c4469c"
      unitRef="U_USD">27938000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_9b7537b2-e4c3-406a-b0e4-4e84a66e4508"
      unitRef="U_USD">19236000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_f01b08f7-bd73-4898-b270-42143c65ebbf"
      unitRef="U_USD">125141000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_b728b479-e25d-48b7-b8e5-7de578d090d9"
      unitRef="U_USD">74660000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_df27dc50-4018-4e89-8c06-a257cd887d18"
      unitRef="U_USD">-125141000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_5fa606ca-2a45-43b7-97cf-3a48548976dd"
      unitRef="U_USD">-74660000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_6cf9ab91-3467-4ee5-8230-efdbaa632bc1"
      unitRef="U_USD">10025000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_bf10ba34-7e8c-42d8-be30-f859486d3f67"
      unitRef="U_USD">6985000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_4ae90abe-ba1c-437a-8e72-16773144758c"
      unitRef="U_USD">748000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_7059d7de-f1d4-4d6c-a9c0-aa8982131015"
      unitRef="U_USD">0</us-gaap:InterestExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_60245f9e-0eb8-4e52-8fa0-7ac1ddc46523"
      unitRef="U_USD">-115864000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_be350781-4599-4f69-9ad0-b061bae12e5d"
      unitRef="U_USD">-67675000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_43ff0736-f4ea-4ea0-884a-cc141ef2e79c"
      unitRef="U_USD">-39000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_89e757bd-90ed-4189-987e-e6b438f3f912"
      unitRef="U_USD">86000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_2ef9874d-70da-4394-b7ec-ca3ecb7a6853"
      unitRef="U_USD">-115903000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_7d577544-a800-4fe3-be36-25a405d7a579"
      unitRef="U_USD">-67589000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="2"
      id="F_ec292cf2-8968-4efb-b9f1-e624e6b151ee"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.34</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="2"
      id="F_01224b6b-00fe-44b1-839f-21f812c79e50"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.34</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="2"
      id="F_08846307-4416-4596-8b37-311bf289f09c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.65</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="2"
      id="F_1751971f-1a53-42b3-8644-c356f8505343"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.65</us-gaap:EarningsPerShareBasic>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_4a78e058-f9de-403c-bcb2-4c5d292bf4a9"
      decimals="0"
      id="F_57b282fd-7581-490a-b1e5-b4d4ce96d7f1"
      unitRef="U_shares">29445134</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_2dcaa877-5c12-4f55-882d-3d8601e906a2"
      decimals="-3"
      id="F_1e0e9fc1-3c9e-40ed-ad39-54464d770a1e"
      unitRef="U_USD">270129000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_9adfe3c2-df06-47b1-8164-ee5bca829cf8"
      decimals="-3"
      id="F_70057957-4c4a-4eb4-ba46-972f8a178865"
      unitRef="U_USD">-47000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_fdc47b6b-c242-47bb-af45-4daed72aa461"
      decimals="-3"
      id="F_b3c3c87d-2fb8-4687-9121-362a4b58914a"
      unitRef="U_USD">-165562000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_2c83b4bd-a25b-4fdd-8a75-b19f7b147a93"
      decimals="-3"
      id="F_5fcb77f6-7c62-4647-8889-fe1df28bbc91"
      unitRef="U_USD">104520000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_c8879ca3-eb41-45e9-90ca-a45d8a858386"
      decimals="-3"
      id="F_0b1ff1be-0dd3-42a1-bdd3-c12feb0e1628"
      unitRef="U_USD">11343000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_29626de9-a0da-4eb5-8e51-61fa2eb4c09a"
      unitRef="U_USD">11343000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_8c11c5a1-2575-4d43-8f9d-2e9082679e36"
      unitRef="U_USD">8647000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_19532afe-5faa-47b1-a0ce-01e2a372f9f0"
      decimals="0"
      id="F_d202342d-a91b-4ea0-bb1c-2d71d98f0543"
      unitRef="U_shares">13098399</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_c8879ca3-eb41-45e9-90ca-a45d8a858386"
      decimals="-3"
      id="F_d9add11f-ddef-4d84-8247-428fa8d70c49"
      unitRef="U_USD">185495000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_07220731-061c-47e2-8bf0-4bfe6511ea42"
      unitRef="U_USD">185495000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <caba:StockIssuedDuringPeriodShareStockOptionsExercised
      contextRef="C_19532afe-5faa-47b1-a0ce-01e2a372f9f0"
      decimals="0"
      id="F_022a1743-56c9-47da-a79a-69cd80a48851"
      unitRef="U_shares">489672</caba:StockIssuedDuringPeriodShareStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_c8879ca3-eb41-45e9-90ca-a45d8a858386"
      decimals="-3"
      id="F_25c4928b-f0ff-4db6-8ac0-e22bc0de96a2"
      unitRef="U_USD">2321000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_fa2f6986-b177-4963-8c7c-23044cd54783"
      unitRef="U_USD">2321000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_19532afe-5faa-47b1-a0ce-01e2a372f9f0"
      decimals="0"
      id="F_63cdbc1a-56fa-4f73-8794-bf5fb63794dc"
      unitRef="U_shares">16053</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_c8879ca3-eb41-45e9-90ca-a45d8a858386"
      decimals="-3"
      id="F_a3f6e846-5688-434d-a651-e9b3bbd8eb67"
      unitRef="U_USD">108000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_4c528dd4-4d1b-4a1a-b840-f7dff6bf9836"
      unitRef="U_USD">108000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <caba:IssuanceOfCommonStockAndPreFundedWarrantsForThePurchaseOfCommonStockNetOfIssuanceCosts
      contextRef="C_19532afe-5faa-47b1-a0ce-01e2a372f9f0"
      decimals="0"
      id="F_e6dce028-11c6-4d1e-be19-6c116618c370"
      unitRef="U_shares">4773974</caba:IssuanceOfCommonStockAndPreFundedWarrantsForThePurchaseOfCommonStockNetOfIssuanceCosts>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="C_0ca36e70-a499-407f-8dc9-ca889acf6ed1"
      decimals="-3"
      id="F_b8821e9e-4861-409f-bf87-3a666026a064"
      unitRef="U_USD">86000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_c7a46567-9a46-4d2d-a00c-5cf04b4a98ed"
      unitRef="U_USD">86000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_43efc37e-6f8b-48fc-b2ca-860b7ba5abf4"
      decimals="-3"
      id="F_896d6620-22b1-4825-8b2f-56eacb2efba5"
      unitRef="U_USD">-67675000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_6be83173-c271-4fc0-8ae5-8072be771275"
      unitRef="U_USD">-67675000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_71d3a4fa-64fd-456b-b2cd-92dccaa7ba87"
      decimals="0"
      id="F_39b12353-f098-4148-bcc8-f64b3d776ded"
      unitRef="U_shares">47823232</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_40d8b316-eb73-435b-b720-1f6b7d1ba479"
      decimals="-3"
      id="F_7bbbf4fa-4606-4848-a2ce-c63eec566abf"
      unitRef="U_USD">469396000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_fa08dd21-0e3b-409f-9df9-7d9051548e56"
      decimals="-3"
      id="F_297f1954-6fb6-499f-bbd9-724c84900415"
      unitRef="U_USD">39000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_48b6f6be-97cc-4ef9-bae5-f20850435f20"
      decimals="-3"
      id="F_2e3fa353-f437-4d81-bb3e-991530d3c59a"
      unitRef="U_USD">-233237000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc"
      decimals="-3"
      id="F_5a42d57e-72e6-4d4f-a650-9a76ae5da692"
      unitRef="U_USD">236198000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_eb964699-a57c-4d32-86ed-e6d61d366c5f"
      decimals="-3"
      id="F_17072ef8-0299-4feb-aaf2-49d482981292"
      unitRef="U_USD">19465000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_f57d2b97-c73f-47cc-b066-aea5599f7308"
      unitRef="U_USD">19465000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_04e842d5-a2ee-4ca1-bab7-bae318fb9f78"
      unitRef="U_USD">252000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_bec66754-fe9d-4822-a0f6-7256e0f5e854"
      decimals="0"
      id="F_ab978b3e-6a91-4077-9e01-91784092b766"
      unitRef="U_shares">1483070</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_bec66754-fe9d-4822-a0f6-7256e0f5e854"
      decimals="-3"
      id="F_3ee52af6-be50-4e86-bd56-bb863fc28933"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_eb964699-a57c-4d32-86ed-e6d61d366c5f"
      decimals="-3"
      id="F_76888019-1690-4547-bb8c-ca692cbc6eb2"
      unitRef="U_USD">10875000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_e9d52190-e6ff-44d8-a07a-666ac7c39e08"
      unitRef="U_USD">10876000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <caba:StockIssuedDuringPeriodShareStockOptionsExercised
      contextRef="C_bec66754-fe9d-4822-a0f6-7256e0f5e854"
      decimals="0"
      id="F_2b64e96b-fce5-4e95-8a06-85da53c17ec9"
      unitRef="U_shares">210695</caba:StockIssuedDuringPeriodShareStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_eb964699-a57c-4d32-86ed-e6d61d366c5f"
      decimals="-3"
      id="F_36735e85-bfe4-41ec-ae29-6ddc0025414f"
      unitRef="U_USD">1430000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_18d864d8-3d82-4c64-9a6a-6d6734bd6ef5"
      unitRef="U_USD">1430000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_bec66754-fe9d-4822-a0f6-7256e0f5e854"
      decimals="0"
      id="F_75c4dc9d-a38e-4864-87dd-27e09b357580"
      unitRef="U_shares">58056</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_eb964699-a57c-4d32-86ed-e6d61d366c5f"
      decimals="-3"
      id="F_b418c71f-dfb2-443f-a743-d38e4115a33e"
      unitRef="U_USD">269000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_f172ad2c-dbf7-4583-8efc-a093c96bffe2"
      unitRef="U_USD">269000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <caba:IssuanceOfCommonStockAndPreFundedWarrantsForThePurchaseOfCommonStockNetOfIssuanceCosts
      contextRef="C_bec66754-fe9d-4822-a0f6-7256e0f5e854"
      decimals="0"
      id="F_f323fbd5-92c4-4b44-ad5f-6a194f83f1d8"
      unitRef="U_shares">1168048</caba:IssuanceOfCommonStockAndPreFundedWarrantsForThePurchaseOfCommonStockNetOfIssuanceCosts>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="C_2583f882-17d6-4155-a8a0-ab8287370f9a"
      decimals="-3"
      id="F_8d331e40-e4d7-42c2-a739-4792906461ef"
      unitRef="U_USD">-39000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_3c9b8027-ee0d-4fa4-b6de-c19247c37898"
      unitRef="U_USD">-39000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_3c5b95c6-6f48-4cac-8c2f-d9294618a5d9"
      decimals="-3"
      id="F_b98c8cd9-4741-411c-935d-50ba6d13ce9a"
      unitRef="U_USD">-115864000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_504fca2a-ec76-4926-ad87-6cd58e0b64bd"
      unitRef="U_USD">-115864000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_e627ab24-8781-4141-83d8-30137c5dce9f"
      decimals="0"
      id="F_e085c588-c533-48db-9c7b-5f7c406a8854"
      unitRef="U_shares">50743101</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_e627ab24-8781-4141-83d8-30137c5dce9f"
      decimals="-3"
      id="F_bb342e51-7d75-4644-8be4-84f84a348fec"
      unitRef="U_USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a7b119c2-8427-423c-9525-72e30103d06a"
      decimals="-3"
      id="F_9f4e8c2d-44f7-4d2f-8037-e54833ac0271"
      unitRef="U_USD">501435000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_ce2b1ce0-61ab-404b-aa60-52836ccb0f70"
      decimals="-3"
      id="F_345dc4ac-6e23-4a6c-bf2a-624c13de0ebc"
      unitRef="U_USD">-349101000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_abcb9f9d-1b0b-4d25-b651-c1a83664dc02"
      unitRef="U_USD">152335000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_361b25c9-598d-4a0d-b630-914ab0193928"
      unitRef="U_USD">-115864000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_3d202c2d-0508-4d7a-b1b9-dbd2ecfce233"
      unitRef="U_USD">-67675000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_d8f0a782-5efe-4a2f-b233-f8ca86b06166"
      unitRef="U_USD">19465000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_aede5a9f-fd17-42ef-8c16-d766a07eefb3"
      unitRef="U_USD">11343000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_d9d86183-51e9-4e5f-bfe6-dc5c2112c291"
      unitRef="U_USD">1711000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_58b9254c-336a-4f53-b7ae-2f0b3e8b1fa0"
      unitRef="U_USD">1426000</us-gaap:Depreciation>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_59e5ff8e-8083-4c9e-9747-38dd31fea978"
      unitRef="U_USD">3102000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_a887ded7-2d90-40af-8abc-6a97029f3aad"
      unitRef="U_USD">0</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <caba:NonCashLeaseExpense
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_d55aa36b-069f-40c6-89a0-23dcf9e923ab"
      unitRef="U_USD">2838000</caba:NonCashLeaseExpense>
    <caba:NonCashLeaseExpense
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_499806bd-31b0-44fe-9798-92b7889ffb57"
      unitRef="U_USD">2070000</caba:NonCashLeaseExpense>
    <us-gaap:AccretionExpense
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_ddd97e4c-be29-484a-90da-85465d909394"
      unitRef="U_USD">405000</us-gaap:AccretionExpense>
    <us-gaap:AccretionExpense
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_82eac9dd-5582-48f7-bcf9-2543df75f9b9"
      unitRef="U_USD">408000</us-gaap:AccretionExpense>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_e0b318cb-41fd-491b-9fcb-ad90cc91ba8e"
      unitRef="U_USD">1528000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_52ee036c-5604-4232-af2d-ea08af31520c"
      unitRef="U_USD">1222000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:ForeignCurrencyTransactionLossBeforeTax
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_38d154c7-0b10-407a-bcf1-4f4f14539c3d"
      unitRef="U_USD">38000</us-gaap:ForeignCurrencyTransactionLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionLossBeforeTax
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_b4fb2586-daf3-472c-b1e5-6f56924bd29e"
      unitRef="U_USD">0</us-gaap:ForeignCurrencyTransactionLossBeforeTax>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_eef85e26-106f-42e7-8f56-c4a8298287b9"
      unitRef="U_USD">-528000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_89bacb7e-056b-478a-a288-e6a7989b2119"
      unitRef="U_USD">954000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_e3414d45-c308-4143-a66a-12e1393e8413"
      unitRef="U_USD">584000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_500f1684-2f8d-4ba5-8926-939db31dfc8e"
      unitRef="U_USD">1144000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_3d4cb830-0f97-4cab-b338-9b89f9e27c03"
      unitRef="U_USD">1011000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_f92a667c-0f6f-4214-86f0-9a8bfe6989b4"
      unitRef="U_USD">1675000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_24084ff7-b32a-4e52-9643-bf0285ac9889"
      unitRef="U_USD">3947000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_b7a9df5e-fdc1-4309-a30f-fea0037039a9"
      unitRef="U_USD">2980000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_011bca16-8395-49d2-bb2d-33b4c3adff19"
      unitRef="U_USD">-3291000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_a2f78381-2cb8-45bf-b7fc-1040aae3bda1"
      unitRef="U_USD">-2456000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_978c4c6b-1048-412c-8d7f-ceff7ec62c60"
      unitRef="U_USD">-88222000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_0c61127b-62bb-4060-b9ba-7bfd8232863a"
      unitRef="U_USD">-53549000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_d316dd2e-f0da-4390-a0f9-4624e61d3c21"
      unitRef="U_USD">2211000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_93862157-8cb8-4871-a172-19705859aaa8"
      unitRef="U_USD">687000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_d96b7854-1a11-440a-bd5b-52ce90b8fa28"
      unitRef="U_USD">0</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_27441a37-bb0b-4e46-9f0c-f86cd6272509"
      unitRef="U_USD">84264000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_73945376-fcab-43cf-bd77-cab7789cce7c"
      unitRef="U_USD">49500000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_9cb84b95-0f3a-457b-8687-6bf377dafaa1"
      unitRef="U_USD">62500000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_4cfa6edd-bdab-49d0-86e0-aeb62dcc2cab"
      unitRef="U_USD">47289000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_1cd17e29-0c95-4033-becd-88d2adafbb1b"
      unitRef="U_USD">-22451000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_f1d14009-ab4c-40b1-9e4a-72f4be287d8b"
      unitRef="U_USD">10875000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_6d9c56c3-9a08-40bc-b1d2-8de56b9a12e5"
      unitRef="U_USD">185202000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_c15b45d9-b50d-46f1-b2d8-fb538a6fbff2"
      unitRef="U_USD">1430000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_64e12873-e920-45a5-a717-a8e808d2b429"
      unitRef="U_USD">2321000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_03e8a7f3-1c29-46c2-a896-24345e8d1300"
      unitRef="U_USD">269000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_c14207ed-1880-4c94-86b5-7b0d8eea9b86"
      unitRef="U_USD">108000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_2c16291d-b48c-4677-ab97-70f56a7885db"
      unitRef="U_USD">897000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_40ba2fd0-aaf4-4a87-8d75-499208f6baa4"
      unitRef="U_USD">0</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_661ec620-7d3a-4f70-84d3-bbc5cfef1a39"
      unitRef="U_USD">11677000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_5e01ede2-7311-4670-950c-1aaee8b101e6"
      unitRef="U_USD">187631000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_30dda0e7-3f0d-4040-9f32-46339baaf4c6"
      unitRef="U_USD">-20000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_9386e1f3-fc0d-4388-a2be-5574a86765c0"
      unitRef="U_USD">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_e01d7229-5d1d-478e-aa0a-9f2f97ffe309"
      unitRef="U_USD">-29276000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_b6c514af-790f-4130-896b-fad52a356e62"
      unitRef="U_USD">111631000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc"
      decimals="-3"
      id="F_44dbff7a-4c6b-41a4-b75b-3d27ac903665"
      unitRef="U_USD">193238000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_2c83b4bd-a25b-4fdd-8a75-b19f7b147a93"
      decimals="-3"
      id="F_b7d0e85b-d4d7-4bde-8fa2-d4719382b67a"
      unitRef="U_USD">81607000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_516cce71-ad6c-46ce-bd48-68ec6ccbbfb1"
      unitRef="U_USD">163962000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc"
      decimals="-3"
      id="F_5404210e-c80d-48dc-8b4b-7a27e6ef970d"
      unitRef="U_USD">193238000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_0844f7aa-ef3a-411b-b3bd-d9b876b1acd7"
      unitRef="U_USD">748000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_697e9064-0bd8-4941-8125-388bbcc99dfe"
      unitRef="U_USD">0</us-gaap:InterestPaidNet>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_93138d35-f359-4c9d-a50e-4c9f3358d20f"
      unitRef="U_USD">404000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_2b225cdc-8608-40ef-ba61-d75a1b5e95db"
      unitRef="U_USD">702000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_98dc0a23-f769-4c23-a31a-fb7aca51662f"
      unitRef="U_USD">10963000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_5e0b150a-5f15-4828-baeb-546245bcf345"
      unitRef="U_USD">2048000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_5233c344-e713-4ec0-9bc7-10ed88a7e70c"
      unitRef="U_USD">4242000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_9a6990f8-63bc-4c34-a7eb-f535f0d35ab7"
      unitRef="U_USD">0</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_201342d3-e3d8-4393-b619-e8c35e0da91c">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;1. Basis of Presentation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cabaletta Bio, Inc. (the Company or Cabaletta) was incorporated in April 2017 in the State of Delaware as Tycho Therapeutics, Inc. and, in August 2018, changed its name to Cabaletta Bio, Inc. The consolidated financial statements include the accounts of Cabaletta Bio and its wholly owned subsidiaries: Cabaletta Bio GmbH and Cabaletta Bio (Germany) GmbH. All intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is headquartered in Philadelphia, Pennsylvania. Cabaletta is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Principal operations commenced in April 2018.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Risks and Uncertainties&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company does not expect to generate revenue from sales of engineered T cell therapies for autoimmune diseases or any other revenue unless and until the Company completes preclinical and clinical development and obtains regulatory approval for one or more product candidates. If the Company seeks to obtain regulatory approval for any of its product candidates, the Company expects to incur significant commercialization expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing. As a result, the Company is unable to predict the timing or amount of increased expenses or when or if the Company will be able to achieve or maintain profitability. Further, the Company is dependent on third parties for certain research and development activities, including manufacturing services (Note 6 and Note 7). Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization. Even if the Company is able to generate revenues from the sale of its product candidates, if approved, it may not become profitable. If the Company fails to become profitable or is unable to sustain profitability on a continuing basis, then it may be unable to continue its operations at planned levels and be forced to reduce its operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Liquidity and Going Concern&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) 205-40, Going Concern, ("ASC 205-40") the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern. The Company has sustained annual operating losses since inception and expects to continue to generate operating losses for the foreseeable future. As of December 31, 2024, the Company has incurred an accumulated deficit of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;349,101&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and has a cash and cash equivalents balance of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;163,962&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The Company&#x2019;s ultimate success depends on the outcome of its research and development activities. Management expects to incur additional losses in the future as it continues its research and development and will need to raise additional capital to fully implement its business plan and to fund its operations. The Company intends to raise such additional capital through a combination of equity offerings, debt financings, government funding arrangements, strategic alliances or other sources. However, if such financing is not available at adequate levels and on a timely basis, or such agreements are not available on favorable terms, or at all, as and when needed, the Company will need to reevaluate its operating plan and may be required to delay or discontinue the development of one or more of its product candidates or operational initiatives. The Company expects that its current cash and cash equivalents may not be sufficient to fund operations for at least the next twelve months from the date of issuance of these consolidated financial statements. The Company's cash forecast contains estimates and assumptions based on success of ongoing clinical trials, and management cannot predict the amount or timing of all expenditures with certainty. Accordingly, the Company has concluded that substantial doubt exists about the Company&#x2019;s ability to continue as a going concern. The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business.&lt;/span&gt;&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_7d9ccda5-7895-479d-8360-bb8b1732f52d"
      unitRef="U_USD">-349101000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_755523f6-7faa-42ca-9bc9-d04237de976b"
      unitRef="U_USD">163962000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_23f0b9d9-b91b-4d67-b361-bafe56e64c99">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2. Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accompanying consolidated financial statements included herein have been prepared in conformity with accounting principles generally accepted in the United States ("GAAP") and under the rules and regulations of the U.S. Securities and Exchange Commission ("SEC"). All intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying consolidated financial statements include but are not limited to advance payments and accruals related to the Company&#x2019;s research and development expenses&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Off-Balance Sheet Risk and Concentrations of Credit Risk&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist of cash and cash equivalents, which are invested in U.S. treasury-based money market funds. As of December 31, 2023, the Company held available-for-sale securities, which were invested in U.S. treasury securities. These investments matured in 2024. A portion of the Company&#x2019;s cash is maintained at two federally insured financial institutions, and account balances may at times exceed federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk. The Company has no off&#x2011;balance sheet risk, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Investments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:27.8pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Investments are available-for-sale and carried at estimated fair value. The Company&#x2019;s valuations of available-for-sale debt securities are generally derived from independent pricing services based upon quoted prices in active markets for similar securities, with prices adjusted for yield and number of days to maturity, or based on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets. Management determines the appropriate classification of its investments in debt securities at the time of purchase and at the end of each reporting period. Investments with original maturities beyond three months at the date of purchase and which mature at, or less than, twelve months from the balance sheet date are classified as current.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Unrealized gains and losses are excluded from earnings and are reported as a component of comprehensive income. The Company periodically evaluates whether declines in fair values of its available-for-sale securities below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors including the severity and duration of the unrealized loss as well as the Company&#x2019;s ability and intent to hold the available-for-sale security until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the security or if more likely than not it will be required to sell any available-for-sale securities before recovery of its amortized cost basis. Realized gains and losses and declines in fair value judged to be other-than-temporary, if any, on available-for-sale securities are included in interest and other income, net. The cost of investments sold is based on the specific-identification method. Interest income on investments as well as amortization of discount or premium is included in interest income.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property, plant and equipment are recorded at cost less accumulated depreciation. Cost includes the acquisition costs and all costs necessary to bring the asset to the location and working condition necessary for its intended use. Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the accompanying statements of operations. Expenditures for normal, recurring or periodic repairs and maintenance related to property and equipment are charged to expense as incurred. The cost for planned major maintenance activities, including the related acquisition or construction of assets, is capitalized if it will result in future economic benefits.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Estimated useful lives for property and equipment are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
         &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
          &lt;tr style="visibility:collapse;"&gt;
           &lt;td style="width:24.825%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:16.023%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:59.152%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
           &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
           &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated useful life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
           &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; Three years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
           &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; Three years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
           &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; Three years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
           &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_11fb0b7e-26ca-48c1-8f03-76b57f37f299;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; Lesser of estimated useful life or remaining lease term&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
         &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 1&#x2014;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 2&#x2014;Inputs (other than quoted prices included in Level 1) that are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 3&#x2014;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has leases related to its facilities used for offices and laboratory space, which are classified as operating leases as well as leases related to its manufacturing arrangements, which are classified as finance leases.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease and its classification based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets and current and non-current lease liabilities, as applicable.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate to discount lease payments. Subsequent to the initial measurement, the Company will continue to account for:&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the lease liability at the net present value using the incremental borrowing rate that was in effect as of the lease commencement, lease modification, or transition date, and;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the finance lease and operating lease expense on a straight line basis.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Leases with terms of 12 months or less are considered short-term leases and right-of-use assets and lease obligations are not recognized. Payments associated with short-term leases are expensed on a straight-line basis over the lease term.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In accordance with ASC 842, components of a lease should be split into three categories: lease components, non-lease components and non-components. The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components. Entities may elect not to separate lease and non-lease components. Rather, entities would account for each lease component and related non-lease component together as a single lease component. The Company has elected to aggregate all lease and non-lease components for each class of underlying assets into a single lease component for real-estate leases and embedded manufacturing arrangements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ASC 842 allows for the use of judgment in determining whether the assumed lease term is for a major part of the remaining economic life of the underlying asset and whether the present value of lease payments represents substantially all of the fair value of the underlying asset. The Company applies the guidance in ASC 842-10-55-2 to assist in determining lease classification across its leases.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Research and Development Expenses&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and development costs include costs incurred for internal and external research and development activities and are expensed as incurred in the accompanying statements of operations. Research and development costs consist of salaries and benefits, including associated stock-based compensation, and laboratory supplies and facility costs, as well as fees paid to entities that conduct certain research and development and clinical trial activities on the Company&#x2019;s behalf.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company records accrued liabilities for estimated costs of research and development activities conducted by service providers, which include preclinical studies, contract manufacturing activities and clinical trial activities. The Company records the estimated costs of research and development activities based upon the estimated amount of services provided and in accordance with agreements established with service providers and includes these costs in accrued and other current liabilities in the accompanying balance sheets and within research and development expense in the accompanying statements of operations. Non-refundable advance payments made for goods or services that will be used or rendered for future research and development activities are deferred and capitalized and recognized as expense as the goods are received or the related services are rendered. The Company makes significant judgments and estimates in determining the accrued liabilities and prepaid expenses in each reporting period. As actual costs become known, the Company adjusts its accrued liabilities and prepaid expenses. The Company has not experienced any material differences between accrued costs and actual costs incurred since its inception.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock-based Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company measures its stock-based awards granted to employees and non-employees based on the estimated fair values of the awards on the respective grant dates. The Company uses the Black-Scholes option-pricing model (Black-Scholes) to estimate the fair value of its stock-based awards. The Company recognizes compensation expense for time-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award. The Company accounts for forfeitures of stock option awards as they occur.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to temporary differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax base, as well as for net operating loss carryforwards and research and development credits, and are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Valuation allowances are established when necessary to reduce deferred tax assets where, based upon the available evidence, the Company concludes that it is more-likely-than-not that the deferred tax assets will not be realized. In evaluating its ability to recover deferred tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. Because of the uncertainty of the realization of deferred tax assets, the Company has recorded a full valuation allowance against its deferred tax assets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Reserves are provided for tax benefits for which realization is uncertain. Such benefits are only recognized when the underlying tax position is considered more-likely-than-not to be sustained on examination by a taxing authority, assuming they possess full knowledge of the position and facts. Interest and penalties related to uncertain tax positions are recognized in the provision of income taxes; however, the Company currently has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; interest or penalties related to uncertain income tax benefits.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company calculates basic and diluted net loss per share in conformity with the two-class method required for participating securities because the Company had both voting and non-voting common stock outstanding in 2023 and for a portion of 2024. The rights, including the liquidation and dividend rights, of the holders of the voting and non-voting common stock are identical, except with respect to voting. Each share of non-voting common stock may be converted at any time into one share of voting common stock at the option of its holder by providing written notice to the Company, subject to the limitations provided for in the amended and restated certificate of incorporation. As of December 31, 2024, no shares of non-voting common stock remain outstanding.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted average number of shares of common stock, including any pre-funded warrants to purchase shares of common stock that may be outstanding. The undistributed loss for each year is allocated to common stockholders based on the contractual participation rights of the voting and non-voting common stock as if the losses for the year had been distributed. As the liquidation and dividend rights are identical, the undistributed losses are allocated on a proportionate basis. Diluted net loss per share attributable to common stockholders is computed under the if-converted method and assumes that all non-voting common stock has been converted to common stock. Since the Company was in a loss position for all periods presented, the effects of the other potentially dilutive securities are antidilutive.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Segments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (CODM) in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#x2019;s CODM is its Chief Executive Officer (CEO). The Company has determined it operates in a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_d4311f9a-8cf2-4c85-b6fa-4408d3790ae7;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;single &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;operating segment and has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; reportable segment. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Refer to Note 8 &#x2013; Segment Reporting for further information related to our segment.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Deferred Offering Costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;After consummation of the equity financing, these costs are recorded as a reduction to the carrying value of stockholders&#x2019; equity as a reduction of additional paid-in capital or equity generated as a result of such offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Emerging Growth Company Status&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Prior to December 31, 2024, the Company was an &#x201c;emerging growth company&#x201d; (EGC) as defined in the Jumpstart Our Business Startups Act, (JOBS Act), and elected to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies until the Company no longer qualifies as an EGC, including using the extended transition period for complying with new or revised accounting standards. As of December 31, 2024, the Company ceased to qualify as an EGC.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2023, the FASB issued Accounting Standards Update, or ASU, 2023-07, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Segment Reporting (Topic 280) &#x2013; Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. This ASU requires that a public entity provide additional segment disclosures on an interim and annual basis. The amendments in this ASU should be applied retrospectively to all prior periods presented in the consolidated financial statements, unless impracticable. Upon transition, the segment expense categories and amounts disclosed in the prior periods should be based on the significant segment expense categories identified and disclosed in the period of adoption. The Company adopted this ASU for the annual period ended December 31, 2024 and the amendments have been applied retrospectively to all prior periods presented in the financial statements. Refer to Note 8 &#x2013; Segment Reporting for further information related to our segment.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. ASU 2023-09 enhances the transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The guidance is effective for public business entities for annual periods beginning after December 15, 2024. Early adoption is permitted. This update is effective beginning with the Company&#x2019;s 2025 fiscal year annual reporting period. The Company is currently planning to adopt this guidance when effective and is assessing the impact of the adoption on the Company&#x2019;s consolidated financial statements and accompanying footnotes.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the FASB issued ASU 2024-03, Income Statement (Subtopic 220-40): Reporting Comprehensive Income-Expense Disaggregation Disclosures. ASU 2024-03 requires enhanced disclosures about components of expense captions on the face of the income statement. This standard will be effective for fiscal years beginning after December 15, 2026. Early adoption is permitted. ASU 2024-03 applies on a prospective basis for periods beginning after the effective date. However, retrospective application to any or all prior periods presented is permitted. The Company is currently planning to adopt this guidance when effective and is assessing the impact of the adoption on the Company&#x2019;s consolidated financial statements and accompanying footnotes.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;There have been no other new accounting pronouncements or changes to accounting pronouncements that, if adopted, would have or may have a material impact on the Company&#x2019;s consolidated statements or disclosures.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_5cb88f3a-b96c-4475-8b67-29835a00c97f">&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accompanying consolidated financial statements included herein have been prepared in conformity with accounting principles generally accepted in the United States ("GAAP") and under the rules and regulations of the U.S. Securities and Exchange Commission ("SEC"). All intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_8bd14386-07e5-41bc-9461-fbfd9446a5ea">&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying consolidated financial statements include but are not limited to advance payments and accruals related to the Company&#x2019;s research and development expenses&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:OffBalanceSheetCreditExposurePolicyPolicyTextBlock
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_c4f99606-1b4b-478b-a7e3-4606e32bc334">&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Off-Balance Sheet Risk and Concentrations of Credit Risk&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist of cash and cash equivalents, which are invested in U.S. treasury-based money market funds. As of December 31, 2023, the Company held available-for-sale securities, which were invested in U.S. treasury securities. These investments matured in 2024. A portion of the Company&#x2019;s cash is maintained at two federally insured financial institutions, and account balances may at times exceed federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk. The Company has no off&#x2011;balance sheet risk, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:OffBalanceSheetCreditExposurePolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_0af23376-06a7-42f4-be3d-0b8d50212bb9">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_73a397a5-9ddf-40aa-b061-f290ca49dcf7">&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Investments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:27.8pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Investments are available-for-sale and carried at estimated fair value. The Company&#x2019;s valuations of available-for-sale debt securities are generally derived from independent pricing services based upon quoted prices in active markets for similar securities, with prices adjusted for yield and number of days to maturity, or based on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets. Management determines the appropriate classification of its investments in debt securities at the time of purchase and at the end of each reporting period. Investments with original maturities beyond three months at the date of purchase and which mature at, or less than, twelve months from the balance sheet date are classified as current.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Unrealized gains and losses are excluded from earnings and are reported as a component of comprehensive income. The Company periodically evaluates whether declines in fair values of its available-for-sale securities below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors including the severity and duration of the unrealized loss as well as the Company&#x2019;s ability and intent to hold the available-for-sale security until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the security or if more likely than not it will be required to sell any available-for-sale securities before recovery of its amortized cost basis. Realized gains and losses and declines in fair value judged to be other-than-temporary, if any, on available-for-sale securities are included in interest and other income, net. The cost of investments sold is based on the specific-identification method. Interest income on investments as well as amortization of discount or premium is included in interest income.&lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_d2473bcb-9625-43ec-ac80-a731dd7dfdad">&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property, plant and equipment are recorded at cost less accumulated depreciation. Cost includes the acquisition costs and all costs necessary to bring the asset to the location and working condition necessary for its intended use. Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the accompanying statements of operations. Expenditures for normal, recurring or periodic repairs and maintenance related to property and equipment are charged to expense as incurred. The cost for planned major maintenance activities, including the related acquisition or construction of assets, is capitalized if it will result in future economic benefits.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Estimated useful lives for property and equipment are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
         &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
          &lt;tr style="visibility:collapse;"&gt;
           &lt;td style="width:24.825%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:16.023%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:59.152%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
           &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
           &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated useful life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
           &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; Three years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
           &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; Three years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
           &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; Three years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
           &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_11fb0b7e-26ca-48c1-8f03-76b57f37f299;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; Lesser of estimated useful life or remaining lease term&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
         &lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <caba:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_20f78872-f300-4cda-a6e6-ee169fcfb4b0">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Estimated useful lives for property and equipment are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
         &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
          &lt;tr style="visibility:collapse;"&gt;
           &lt;td style="width:24.825%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:16.023%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:59.152%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
           &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
           &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated useful life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
           &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; Three years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
           &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; Three years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
           &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; Three years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
           &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_11fb0b7e-26ca-48c1-8f03-76b57f37f299;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; Lesser of estimated useful life or remaining lease term&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
         &lt;/table&gt;</caba:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_540f0e6d-d008-4d25-b45d-014688c83725"
      id="F_e8eed517-72d0-46c0-aafc-a08273968853">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_c76069af-3284-4046-a825-2b5ff929db4a"
      id="F_20bbe65b-3c16-4494-8732-9956e07b7e1c">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_cb855622-a323-4d6a-9e19-5673661f83fe"
      id="F_fb64719f-8433-4cb5-a60b-77a7af364c6d">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_5a99330b-0cb6-4385-ac55-816b529cc484">&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 1&#x2014;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 2&#x2014;Inputs (other than quoted prices included in Level 1) that are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 3&#x2014;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_114b0ef4-c3e8-4e68-8596-699e4a21654b">&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has leases related to its facilities used for offices and laboratory space, which are classified as operating leases as well as leases related to its manufacturing arrangements, which are classified as finance leases.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease and its classification based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets and current and non-current lease liabilities, as applicable.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate to discount lease payments. Subsequent to the initial measurement, the Company will continue to account for:&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the lease liability at the net present value using the incremental borrowing rate that was in effect as of the lease commencement, lease modification, or transition date, and;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the finance lease and operating lease expense on a straight line basis.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Leases with terms of 12 months or less are considered short-term leases and right-of-use assets and lease obligations are not recognized. Payments associated with short-term leases are expensed on a straight-line basis over the lease term.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In accordance with ASC 842, components of a lease should be split into three categories: lease components, non-lease components and non-components. The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components. Entities may elect not to separate lease and non-lease components. Rather, entities would account for each lease component and related non-lease component together as a single lease component. The Company has elected to aggregate all lease and non-lease components for each class of underlying assets into a single lease component for real-estate leases and embedded manufacturing arrangements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ASC 842 allows for the use of judgment in determining whether the assumed lease term is for a major part of the remaining economic life of the underlying asset and whether the present value of lease payments represents substantially all of the fair value of the underlying asset. The Company applies the guidance in ASC 842-10-55-2 to assist in determining lease classification across its leases.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_d304c9a7-69f0-4f24-9b71-c66489b51235">&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Research and Development Expenses&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and development costs include costs incurred for internal and external research and development activities and are expensed as incurred in the accompanying statements of operations. Research and development costs consist of salaries and benefits, including associated stock-based compensation, and laboratory supplies and facility costs, as well as fees paid to entities that conduct certain research and development and clinical trial activities on the Company&#x2019;s behalf.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company records accrued liabilities for estimated costs of research and development activities conducted by service providers, which include preclinical studies, contract manufacturing activities and clinical trial activities. The Company records the estimated costs of research and development activities based upon the estimated amount of services provided and in accordance with agreements established with service providers and includes these costs in accrued and other current liabilities in the accompanying balance sheets and within research and development expense in the accompanying statements of operations. Non-refundable advance payments made for goods or services that will be used or rendered for future research and development activities are deferred and capitalized and recognized as expense as the goods are received or the related services are rendered. The Company makes significant judgments and estimates in determining the accrued liabilities and prepaid expenses in each reporting period. As actual costs become known, the Company adjusts its accrued liabilities and prepaid expenses. The Company has not experienced any material differences between accrued costs and actual costs incurred since its inception.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_671d062d-054a-4a32-84ff-01c8b28cb523">&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock-based Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company measures its stock-based awards granted to employees and non-employees based on the estimated fair values of the awards on the respective grant dates. The Company uses the Black-Scholes option-pricing model (Black-Scholes) to estimate the fair value of its stock-based awards. The Company recognizes compensation expense for time-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award. The Company accounts for forfeitures of stock option awards as they occur.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_9ea6341f-8a05-463b-bc73-93da10f375b6">&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to temporary differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax base, as well as for net operating loss carryforwards and research and development credits, and are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Valuation allowances are established when necessary to reduce deferred tax assets where, based upon the available evidence, the Company concludes that it is more-likely-than-not that the deferred tax assets will not be realized. In evaluating its ability to recover deferred tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. Because of the uncertainty of the realization of deferred tax assets, the Company has recorded a full valuation allowance against its deferred tax assets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Reserves are provided for tax benefits for which realization is uncertain. Such benefits are only recognized when the underlying tax position is considered more-likely-than-not to be sustained on examination by a taxing authority, assuming they possess full knowledge of the position and facts. Interest and penalties related to uncertain tax positions are recognized in the provision of income taxes; however, the Company currently has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; interest or penalties related to uncertain income tax benefits.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="0"
      id="F_e616721a-cde5-479d-a4bf-c28cbd448c8c"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_617babe2-3688-4283-ab3f-e24514d7a125">&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company calculates basic and diluted net loss per share in conformity with the two-class method required for participating securities because the Company had both voting and non-voting common stock outstanding in 2023 and for a portion of 2024. The rights, including the liquidation and dividend rights, of the holders of the voting and non-voting common stock are identical, except with respect to voting. Each share of non-voting common stock may be converted at any time into one share of voting common stock at the option of its holder by providing written notice to the Company, subject to the limitations provided for in the amended and restated certificate of incorporation. As of December 31, 2024, no shares of non-voting common stock remain outstanding.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted average number of shares of common stock, including any pre-funded warrants to purchase shares of common stock that may be outstanding. The undistributed loss for each year is allocated to common stockholders based on the contractual participation rights of the voting and non-voting common stock as if the losses for the year had been distributed. As the liquidation and dividend rights are identical, the undistributed losses are allocated on a proportionate basis. Diluted net loss per share attributable to common stockholders is computed under the if-converted method and assumes that all non-voting common stock has been converted to common stock. Since the Company was in a loss position for all periods presented, the effects of the other potentially dilutive securities are antidilutive.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_26535a93-4e4b-441a-9ddc-93d2ecebaeab">&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Segments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (CODM) in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#x2019;s CODM is its Chief Executive Officer (CEO). The Company has determined it operates in a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_d4311f9a-8cf2-4c85-b6fa-4408d3790ae7;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;single &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;operating segment and has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; reportable segment. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Refer to Note 8 &#x2013; Segment Reporting for further information related to our segment.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportingUnits
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="0"
      id="F_ef431787-d736-476a-a566-9e90177b37c7"
      unitRef="U_Segment">1</us-gaap:NumberOfReportingUnits>
    <us-gaap:DeferredChargesPolicyTextBlock
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_340945cb-61c1-4718-9f37-a93bbd65f4ca">&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Deferred Offering Costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;After consummation of the equity financing, these costs are recorded as a reduction to the carrying value of stockholders&#x2019; equity as a reduction of additional paid-in capital or equity generated as a result of such offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;</us-gaap:DeferredChargesPolicyTextBlock>
    <caba:EmergingGrowthCompanyStatusPolicyTextBlock
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_740e5341-ca3b-4f32-a881-884c37b94c8f">&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Emerging Growth Company Status&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Prior to December 31, 2024, the Company was an &#x201c;emerging growth company&#x201d; (EGC) as defined in the Jumpstart Our Business Startups Act, (JOBS Act), and elected to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies until the Company no longer qualifies as an EGC, including using the extended transition period for complying with new or revised accounting standards. As of December 31, 2024, the Company ceased to qualify as an EGC.&lt;/span&gt;&lt;/p&gt;</caba:EmergingGrowthCompanyStatusPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_fda64f71-7930-4401-8162-e392cec8407b">&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2023, the FASB issued Accounting Standards Update, or ASU, 2023-07, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Segment Reporting (Topic 280) &#x2013; Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. This ASU requires that a public entity provide additional segment disclosures on an interim and annual basis. The amendments in this ASU should be applied retrospectively to all prior periods presented in the consolidated financial statements, unless impracticable. Upon transition, the segment expense categories and amounts disclosed in the prior periods should be based on the significant segment expense categories identified and disclosed in the period of adoption. The Company adopted this ASU for the annual period ended December 31, 2024 and the amendments have been applied retrospectively to all prior periods presented in the financial statements. Refer to Note 8 &#x2013; Segment Reporting for further information related to our segment.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. ASU 2023-09 enhances the transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The guidance is effective for public business entities for annual periods beginning after December 15, 2024. Early adoption is permitted. This update is effective beginning with the Company&#x2019;s 2025 fiscal year annual reporting period. The Company is currently planning to adopt this guidance when effective and is assessing the impact of the adoption on the Company&#x2019;s consolidated financial statements and accompanying footnotes.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the FASB issued ASU 2024-03, Income Statement (Subtopic 220-40): Reporting Comprehensive Income-Expense Disaggregation Disclosures. ASU 2024-03 requires enhanced disclosures about components of expense captions on the face of the income statement. This standard will be effective for fiscal years beginning after December 15, 2026. Early adoption is permitted. ASU 2024-03 applies on a prospective basis for periods beginning after the effective date. However, retrospective application to any or all prior periods presented is permitted. The Company is currently planning to adopt this guidance when effective and is assessing the impact of the adoption on the Company&#x2019;s consolidated financial statements and accompanying footnotes.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;There have been no other new accounting pronouncements or changes to accounting pronouncements that, if adopted, would have or may have a material impact on the Company&#x2019;s consolidated statements or disclosures.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_22fbaa35-b142-49ab-bd90-b3e739507d9a">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;3. Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024 and 2023, the Company&#x2019;s financial instruments included cash and cash equivalents, available-for-sale debt securities, accounts payable and accrued expenses. The carrying amounts for cash and cash equivalents, accounts payable and accrued expenses reported in the Company&#x2019;s consolidated financial statements for these instruments approximate their respective fair values because of the short-term nature of these instruments.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following tables present information about the Company&#x2019;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:50.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Quoted&lt;br/&gt;Prices in&lt;br/&gt;Active Markets&lt;br/&gt;for Identical Assets &lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;162,634&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;162,634&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Short-term investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;162,634&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;162,634&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="text-indent:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:50.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Quoted&lt;br/&gt;Prices in&lt;br/&gt;Active Markets&lt;br/&gt;for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;180,124&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;180,124&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities - original maturity less than three months&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_aacb9393-82a1-4484-8aab-edf9ca81d63c;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_b8a328b1-c384-428d-aa72-eece52e52e47;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Short-term investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48,011&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48,011&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;240,506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;180,124&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;60,382&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Money market funds are measured at fair value on a recurring basis using quoted prices and are classified as Level 1. Investments are measured at fair value based on inputs other than quoted prices that are derived from observable market data and are classified as Level 2 inputs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For debt securities classified as available-for-sale investments,&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; the Company records unrealized gains or losses resulting from changes in fair value between measurement dates as a component of other comprehensive income. The Company did not hold any available-for-sale securities as of December 31, 2024:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:46.218%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.321%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.124%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.321%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.124%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.321%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.124%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.321%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.124%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;743&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;743&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;180,124&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;180,124&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities - original maturity less than three months&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,367&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Included in cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;193,234&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;193,238&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities - due in one year or less&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Included in short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;47,976&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48,011&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;241,210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;241,249&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_e6be56cf-f22e-45ff-b50a-b8519c75415f">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following tables present information about the Company&#x2019;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:50.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Quoted&lt;br/&gt;Prices in&lt;br/&gt;Active Markets&lt;br/&gt;for Identical Assets &lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;162,634&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;162,634&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Short-term investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;162,634&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;162,634&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="text-indent:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:50.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Quoted&lt;br/&gt;Prices in&lt;br/&gt;Active Markets&lt;br/&gt;for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;180,124&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;180,124&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities - original maturity less than three months&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_aacb9393-82a1-4484-8aab-edf9ca81d63c;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_b8a328b1-c384-428d-aa72-eece52e52e47;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Short-term investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48,011&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48,011&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;240,506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;180,124&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;60,382&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_1a070b4c-533f-43fc-9a6b-b37ff298a84e"
      decimals="-3"
      id="F_26e4d58d-2301-4bf0-ba40-4c1d84cd5fb8"
      unitRef="U_USD">162634000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_e4eaaa6c-1a38-4348-b779-9f2c88c6727b"
      decimals="-3"
      id="F_e6f7869e-3643-46eb-8dac-49225a3fc2f6"
      unitRef="U_USD">162634000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_11dd7a1d-2e01-497c-a7de-cb3940339fe0"
      decimals="-3"
      id="F_f47e5f25-783b-4b6e-bb36-d253a0dcdfd0"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_f01ad0a8-3dd5-4e30-b96a-3752be3dec4c"
      decimals="-3"
      id="F_6c2facb6-0896-4225-8f85-a5d91528f42a"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:ShortTermInvestments
      contextRef="C_b9c36061-77bc-4b94-8132-5e42f9fe5210"
      decimals="-3"
      id="F_2f51a24a-0022-4735-8b1a-4920ae4c81b1"
      unitRef="U_USD">0</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_269acac6-33ca-4743-9c91-3860f13c66c8"
      decimals="-3"
      id="F_c405ac06-a85c-42f0-b5a8-5ae5353629e0"
      unitRef="U_USD">0</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_f4db9c45-8c5b-4699-a20a-4009f98cad84"
      decimals="-3"
      id="F_369faa5a-bf39-4acc-84be-278b4cc8a43b"
      unitRef="U_USD">0</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_711abcf7-e6c1-4c74-8ec8-d2b808baace6"
      decimals="-3"
      id="F_4fd72c37-d457-49d6-aab4-5f86ae474048"
      unitRef="U_USD">0</us-gaap:ShortTermInvestments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_3cf6ca28-81b1-4647-b307-30db6e6d90f1"
      decimals="-3"
      id="F_d6651a79-a794-4c07-a4f6-904ffaab9f10"
      unitRef="U_USD">162634000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_734d3853-d0a8-4ac2-a327-a99b436ab861"
      decimals="-3"
      id="F_75f07abf-07b9-4df3-bcc8-2698b222093b"
      unitRef="U_USD">162634000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_9be04dd4-fea1-4302-8462-56ed42a391b0"
      decimals="-3"
      id="F_cc313c4d-e133-45ac-959d-70e66659f2a9"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_3e97ca82-cc21-4f56-9fdf-9c22c00b90af"
      decimals="-3"
      id="F_4d8ae87d-a47e-4615-b509-8a3d60a9b1ea"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_58107011-70e5-45db-96bf-b13e678c007f"
      decimals="-3"
      id="F_2bea2a0a-5117-4ac3-a237-7e4bc1ae6f15"
      unitRef="U_USD">180124000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_205ec67f-4f43-4431-93b3-98f31625b5c5"
      decimals="-3"
      id="F_cb6b50d2-8a22-4cd3-b5ce-e7be34a58592"
      unitRef="U_USD">180124000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_c4c22bdc-057a-44d3-8274-7b307be3dfea"
      decimals="-3"
      id="F_00d5c32d-6c87-4911-b2d6-75fd93521492"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_649a608e-fb57-4b77-b3df-53aea52c4927"
      decimals="-3"
      id="F_065c7648-14ae-4843-81fa-d67fcd6f0b9e"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_b595787c-5321-4455-b3f0-010647595978"
      decimals="-3"
      id="F_5ba8d7f0-9eb1-4001-827d-33ee1416e7d8"
      unitRef="U_USD">12371000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_76f2bc1f-8bfe-42b0-8ef5-bd09ee4372d6"
      decimals="-3"
      id="F_34350506-0a58-4ce6-ae26-b20985abf2f2"
      unitRef="U_USD">12371000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:ShortTermInvestments
      contextRef="C_b595787c-5321-4455-b3f0-010647595978"
      decimals="-3"
      id="F_29e88312-025a-49d1-b146-fdc738b5063e"
      unitRef="U_USD">48011000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_72b96170-7a04-4855-aa98-34638538347d"
      decimals="-3"
      id="F_b499a156-deb5-4392-b7e6-cbacae98b08c"
      unitRef="U_USD">0</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_76f2bc1f-8bfe-42b0-8ef5-bd09ee4372d6"
      decimals="-3"
      id="F_85c9c508-3743-4a4e-8bca-ccb6fe87482d"
      unitRef="U_USD">48011000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_7e18ccc8-731c-4531-8ac3-a3a38fdbfbb4"
      decimals="-3"
      id="F_30484aaf-ff53-4d07-a0ff-f9f1fbd5548e"
      unitRef="U_USD">0</us-gaap:ShortTermInvestments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_d6f1f45c-9b4a-4db4-bf99-cf7cd3f55c9a"
      decimals="-3"
      id="F_57022b79-369d-431c-abc9-d88b1d9540a6"
      unitRef="U_USD">240506000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_7552d055-8ba4-480a-a069-f83dd0658987"
      decimals="-3"
      id="F_81bbd2e8-fee4-45e9-8279-ff0e04975be8"
      unitRef="U_USD">180124000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_636f9b5e-113f-4fa8-938c-4b0bf99f0a58"
      decimals="-3"
      id="F_96bece77-0e97-47d0-bc4c-5c5428ba026a"
      unitRef="U_USD">60382000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_b19a2baa-3b2d-484b-b93b-09bbee5dbbdd"
      decimals="-3"
      id="F_a3d5ceb2-ebf7-43c2-a50c-cc446d49862a"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_303636ba-e989-457a-ac86-f925871a97c9">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; the Company records unrealized gains or losses resulting from changes in fair value between measurement dates as a component of other comprehensive income. The Company did not hold any available-for-sale securities as of December 31, 2024:&lt;/span&gt;&lt;p style="text-indent:36pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:46.218%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.321%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.124%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.321%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.124%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.321%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.124%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.321%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.124%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;743&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;743&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;180,124&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;180,124&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities - original maturity less than three months&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,367&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Included in cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;193,234&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;193,238&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities - due in one year or less&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Included in short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;47,976&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48,011&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;241,210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;241,249&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_11f1e157-c9cb-4fce-b81f-40d77ea635c9"
      decimals="-3"
      id="F_3caebc41-cb19-407f-9158-f57accfca6fd"
      unitRef="U_USD">743000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_11f1e157-c9cb-4fce-b81f-40d77ea635c9"
      decimals="-3"
      id="F_dfb66b9c-750e-42a6-bb0d-a0631f9fbc5b"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_11f1e157-c9cb-4fce-b81f-40d77ea635c9"
      decimals="-3"
      id="F_780acd15-1a3e-45e5-9591-c49d9d85edc5"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_11f1e157-c9cb-4fce-b81f-40d77ea635c9"
      decimals="-3"
      id="F_b7258617-7085-4893-b65e-e245bdc35adf"
      unitRef="U_USD">743000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_a9916f0c-e5a6-49b3-aa27-2f2599dab549"
      decimals="-3"
      id="F_c86a90bd-99fc-4962-a052-222aabd8e854"
      unitRef="U_USD">180124000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_a9916f0c-e5a6-49b3-aa27-2f2599dab549"
      decimals="-3"
      id="F_a050f1eb-0e3d-4ed4-a1e5-f14e7527f0a0"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_a9916f0c-e5a6-49b3-aa27-2f2599dab549"
      decimals="-3"
      id="F_cf729780-38e7-4ffb-a755-54122364dbad"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_a9916f0c-e5a6-49b3-aa27-2f2599dab549"
      decimals="-3"
      id="F_d100c2f5-d7d4-4918-a486-25b4561ce648"
      unitRef="U_USD">180124000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_067790e2-b88b-48e5-8bbf-2c266ffc2b13"
      decimals="-3"
      id="F_c1695f8e-eee4-4ef5-9535-092154469955"
      unitRef="U_USD">12367000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_067790e2-b88b-48e5-8bbf-2c266ffc2b13"
      decimals="-3"
      id="F_f6f4dfd6-5033-44fe-b230-0d29b74ff7ec"
      unitRef="U_USD">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_067790e2-b88b-48e5-8bbf-2c266ffc2b13"
      decimals="-3"
      id="F_535e8679-accd-483b-9f94-72aa42a22e1c"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_067790e2-b88b-48e5-8bbf-2c266ffc2b13"
      decimals="-3"
      id="F_4563610b-98d1-43e8-88df-39f68774f10b"
      unitRef="U_USD">12371000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_9d30fac2-b87d-470d-bf79-785e498650f5"
      decimals="-3"
      id="F_9f89587b-8a34-47ca-ad6e-4a58ae9daeea"
      unitRef="U_USD">193234000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_9d30fac2-b87d-470d-bf79-785e498650f5"
      decimals="-3"
      id="F_98a16fdf-70e7-4116-a60e-a04bead7fe4c"
      unitRef="U_USD">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_9d30fac2-b87d-470d-bf79-785e498650f5"
      decimals="-3"
      id="F_cb55978c-c02b-438d-bd0c-1fb9388c9957"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_9d30fac2-b87d-470d-bf79-785e498650f5"
      decimals="-3"
      id="F_096548f5-6c84-465e-a43f-256ecf89fd01"
      unitRef="U_USD">193238000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_751af1f3-2ee2-42ff-9b2c-27e58ba3e3be"
      decimals="-3"
      id="F_5793ed36-96f7-4d1c-9f2a-0c85fd47872e"
      unitRef="U_USD">47976000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_751af1f3-2ee2-42ff-9b2c-27e58ba3e3be"
      decimals="-3"
      id="F_1cd58094-b711-4654-8eab-f1cca89ddab6"
      unitRef="U_USD">39000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_751af1f3-2ee2-42ff-9b2c-27e58ba3e3be"
      decimals="-3"
      id="F_0dcfbd5e-98ff-4ce7-a14d-5e0e997a4b66"
      unitRef="U_USD">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_751af1f3-2ee2-42ff-9b2c-27e58ba3e3be"
      decimals="-3"
      id="F_ee1c4b49-3727-420d-a751-918ad836750e"
      unitRef="U_USD">48011000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc"
      decimals="-3"
      id="F_de10d5c3-2a22-4a39-a23a-68740075a850"
      unitRef="U_USD">241210000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc"
      decimals="-3"
      id="F_2055c061-357c-4f90-acc3-97bdb6b8a078"
      unitRef="U_USD">43000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc"
      decimals="-3"
      id="F_841fd5bc-97b3-43e5-9a1b-a2ac18473ea2"
      unitRef="U_USD">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc"
      decimals="-3"
      id="F_5e280718-7b41-4b4f-bfb0-7b7c0bbafbc2"
      unitRef="U_USD">241249000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_b495580f-4367-43a3-9fa5-5598a2489685">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;4. Property, Plant and Equipment&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property, plant and equipment consists of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,663&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,893&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;277&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;277&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;196&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;113&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;113&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total property, plant and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,249&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,336&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,795&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,743&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,541&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Depreciation expense was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,711&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,426&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for the years ended December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_8c731623-f8ec-4c07-8b92-2feb6d58c9f8">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property, plant and equipment consists of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,663&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,893&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;277&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;277&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;196&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;113&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;113&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total property, plant and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,249&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,336&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,795&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,743&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,541&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_c31b10fb-e739-4340-b8e2-ac8464faec66"
      decimals="-3"
      id="F_ef3ae047-e668-4eff-9824-95a3b93efd83"
      unitRef="U_USD">7663000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_2aa93a55-952b-4b3f-94d7-89fe525c7f44"
      decimals="-3"
      id="F_e9a12173-bda6-4f56-aaa2-d16f38d57d15"
      unitRef="U_USD">5893000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_c76069af-3284-4046-a825-2b5ff929db4a"
      decimals="-3"
      id="F_07cb8f32-635d-4b36-a757-3144ddfedc00"
      unitRef="U_USD">277000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_58f7eda9-d4b7-4543-b9f9-e26b3d10127c"
      decimals="-3"
      id="F_c71a2878-1ac8-4223-bd03-26fe36ae51ea"
      unitRef="U_USD">277000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_cb855622-a323-4d6a-9e19-5673661f83fe"
      decimals="-3"
      id="F_9b96f3ce-2eee-474b-b64b-c570bb886dad"
      unitRef="U_USD">196000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_e4f2dc83-5acc-4bcc-b167-66ba947b5532"
      decimals="-3"
      id="F_89846c29-f00a-41d7-835a-64860d86a60b"
      unitRef="U_USD">53000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_b9ae082c-13ae-4e63-bf00-b9ef8a7a8fe2"
      decimals="-3"
      id="F_3c4f4e07-a251-48d6-adfa-7534917f8267"
      unitRef="U_USD">113000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_8cac32c4-7629-42a9-a8fa-069e7af9b310"
      decimals="-3"
      id="F_04bda1e9-6e95-4f68-bf58-ff9fda432cdc"
      unitRef="U_USD">113000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_06003895-1861-4775-8cde-c57cfdfa2f05"
      unitRef="U_USD">8249000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc"
      decimals="-3"
      id="F_f4b846e4-5fdc-4170-89b3-8b552859994a"
      unitRef="U_USD">6336000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_501a0531-6b21-49d2-a343-3ba2e6e6b241"
      unitRef="U_USD">5506000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc"
      decimals="-3"
      id="F_e1e823c9-2d34-43af-bb28-58d6338df5fb"
      unitRef="U_USD">3795000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_dd462f8e-6029-47af-849b-b1bd133166ff"
      unitRef="U_USD">2743000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc"
      decimals="-3"
      id="F_a082d7ac-2a50-4d57-b437-61d1c3bc4776"
      unitRef="U_USD">2541000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_b82c43ba-c169-4fe4-920d-52cf64228218"
      unitRef="U_USD">1711000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_da9ec90c-bf7a-4cc9-952e-bc5bd49c752e"
      unitRef="U_USD">1426000</us-gaap:Depreciation>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_5963bd17-0f8a-41e5-8569-b65c435843a1">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;5. Accrued and Other Current Liabilities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued and other current liabilities consist of the following:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,491&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,459&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;342&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;188&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,315&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,188&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,887&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <caba:AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_e0b0153e-3a26-40a4-af6e-52e45228081b">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued and other current liabilities consist of the following:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,491&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,459&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;342&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;188&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,315&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,188&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,887&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</caba:AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock>
    <caba:AccruedResearchAndDevelopmentServicesCurrent
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_23dcf7e4-e6c6-46ca-bb85-c6637b08dd12"
      unitRef="U_USD">3491000</caba:AccruedResearchAndDevelopmentServicesCurrent>
    <caba:AccruedResearchAndDevelopmentServicesCurrent
      contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc"
      decimals="-3"
      id="F_2f3c5845-7602-4867-9b0f-5822bd46594e"
      unitRef="U_USD">2459000</caba:AccruedResearchAndDevelopmentServicesCurrent>
    <caba:AccruedGeneralAndAdministrativeServicesCurrent
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_87f0cc2a-6499-47a9-a2dd-ece849308ee5"
      unitRef="U_USD">342000</caba:AccruedGeneralAndAdministrativeServicesCurrent>
    <caba:AccruedGeneralAndAdministrativeServicesCurrent
      contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc"
      decimals="-3"
      id="F_42d8b524-a0cc-43d7-b61c-3b0666f25500"
      unitRef="U_USD">188000</caba:AccruedGeneralAndAdministrativeServicesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_f4b613d7-9083-461f-b56a-ca5043e1a106"
      unitRef="U_USD">8315000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc"
      decimals="-3"
      id="F_ba5dc9c4-38bd-468e-b0a2-133a18916687"
      unitRef="U_USD">5200000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_208cf7bd-826c-4c71-b2bc-01a705bdd92b"
      unitRef="U_USD">40000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc"
      decimals="-3"
      id="F_67724abb-f4c2-4232-984c-0f2804df2229"
      unitRef="U_USD">40000</us-gaap:OtherLiabilitiesCurrent>
    <caba:AccruedLiabilitiesAndOtherLiabilitiesCurrent
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_863bec2c-c291-42a3-bb8e-4c3b2fc6f076"
      unitRef="U_USD">12188000</caba:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <caba:AccruedLiabilitiesAndOtherLiabilitiesCurrent
      contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc"
      decimals="-3"
      id="F_1e6dd4cc-b793-47a9-a679-9535db465bf4"
      unitRef="U_USD">7887000</caba:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <caba:CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_4d609147-aff6-490d-936d-d0497788a940">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;6. Collaborations, Licensing Agreements and other Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Amended and Restated License Agreement with the Trustees of the University of Pennsylvania and Children&#x2019;s Hospital of Philadelphia&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In August 2018, the Company entered into a license agreement with Penn, as amended and restated in July 2019 to include the Children&#x2019;s Hospital of Philadelphia (CHOP) as a party, and as amended in May 2020 and October 2021 (the License Agreement) pursuant to which the Company obtained (a) a non-exclusive, non-sublicensable worldwide license to certain of Penn&#x2019;s intellectual property to conduct research, product development, clinical trials, cell manufacturing and other activities, and (b) an exclusive, worldwide, royalty-bearing right and license, with a right to sublicense, on a target-by-target basis, under certain of Penn&#x2019;s intellectual property to make, use, sell, offer for sale, import, and otherwise commercialize products for the treatment of autoimmune and alloimmune diseases. Unless earlier terminated, the License Agreement expires on the expiration or abandonment or other termination of the last valid claim in Penn&#x2019;s intellectual property licensed by the Company. The Company may terminate the License Agreement at any time for convenience upon 60 days' written notice. In the event of an uncured, material breach, Penn may terminate the License Agreement upon 60 days' written notice. Under the terms of the License Agreement, the Company was obligated to pay $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; annually for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; beginning August 2018 for funding to the laboratories of each of Drs. Milone and Payne. This was satisfied through completed sponsored research agreements with a total cost of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,560&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. During the term of the License Agreement until the first commercial sale of the first product, the Company is obligated to pay Penn a non-refundable, non-creditable annual license maintenance fee of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. In May 2020, the Company paid Penn an additional, non-refundable, non-creditable license fee of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; under the amended License Agreement.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is required to pay certain milestone payments upon the achievement of specified clinical and commercial milestones. Milestone payments are reduced by a certain percentage for the second product that achieves a milestone, by an additional percentage for the third product that achieves a milestone, and so on, for each subsequent product that achieves a milestone. In the event that the Company is able to successfully develop and launch multiple products under the License Agreement, total milestone payments could be approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Penn is also eligible to receive tiered royalties at percentage rates in the low single-digits, subject to an annual minimum royalty, on annual worldwide net sales of any products that are commercialized by the Company or its sublicensees that contain or incorporate, or are covered by, the intellectual property licensed by the Company. To the extent the Company sublicenses its license rights under the License Agreement, Penn would be eligible to receive tiered sublicense income at percentage rates in the mid-single to low double-digits. There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; amounts due under the License Agreement as of December 31, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Master Translational Research Services Agreement&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In October 2018 and February 2023, the Company entered into services agreements (the CAART and CARTA Services Agreements) with Penn for research, development and manufacturing services from various laboratories within Penn. The activities are detailed in separately executed Penn organization-specific addenda. In May 2020, the Company amended its Addendum with the Center for Advanced Retinal and Ocular Therapeutics (CAROT) to expand access to vector manufacturing.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and development expense related to executed addenda under the master translational research service agreements with Penn recognized in the accompanying statements of operations was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,250&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,786&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;for the years ended December 31, 2024 and 2023, respectively. The Company is &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;committed to pay up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; under the CARTA Services Agreement for cell processing manufacturing through December 31, 2025.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The Company may incur additional expenses up to &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;643&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; t&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;hrough the remaining term of the CAROT Amended Addendum.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Exclusive License Agreement with IASO Biotherapeutics&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On October 7, 2022, the Company entered into an Exclusive License Agreement (the IASO Agreement) with Nanjing IASO Biotherapeutics Co., Ltd. (IASO). Pursuant to the IASO Agreement, the Company received an exclusive, worldwide license under certain IASO intellectual property to use a novel clinical-stage anti-CD19 binder to develop, manufacture, commercialize and otherwise exploit T cell products directed to CD19 for the purpose of diagnosis, prevention or treatment of any autoimmune or alloimmune indications in humans. As partial consideration for the exclusive license, IASO received an upfront payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,500&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. IASO is also eligible to receive up to mid double digit millions in milestone payments based upon the achievement of specified pre-clinical, development and regulatory milestones, and up to an additional low triple digit millions in milestone payments based upon achievement of specified sales milestones, for a total consideration, inclusive of the upfront payment, of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;162,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, along with tiered mid-single digit royalties on future net sales for licensed products that may result from the IASO Agreement. Upon the U.S. Food and Drug Association&#x2019;s clearance of the rese-cel Investigational New Drug application for the treatment of systemic lupus erythematosus in March 2023, a milestone payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; was recognized in the accompanying statements of operations. A milestone payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,500&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; was paid to IASO in the first quarter of 2024 after the first patient in a rese-cel trial was dosed.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;IASO has the right of first negotiation if the Company desires to grant a third party an exclusive license to develop, manufacture, commercialize or otherwise exploit the licensed products in the Greater China region. Pursuant to the IASO Agreement, each of IASO and the Company have agreed, subject to certain exceptions, to refrain from engaging in certain competitive activities with respect to certain programs. The Company also may sublicense through multiple tiers the rights granted to it by IASO under the IASO Agreement at any time, however, it must pay IASO a low double-digit percentage of any revenue obtained from sublicenses or options to third parties, subject to certain customary exclusions. The IASO Agreement will continue on a country-by-country, licensed product-by-licensed product basis until the expiration of the royalty term as identified in the IASO Agreement, unless earlier terminated. Each of the Company and IASO may terminate the Agreement for a material, uncured breach or insolvency of the other party. The Company may also terminate the Agreement at will upon advance written notice and in the event IASO rejects the Agreement due to bankruptcy-related matters. IASO may also terminate the Agreement if the Company fails to achieve certain specified diligence milestones in a timely manner and/or if the Company commences any patent challenges with respect to the patents and patent applications relating to the licensed sequence, in each case upon advance written notice.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Licence and Supply Agreement with Oxford Biomedica&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2021, the Company entered into a Licence and Supply agreement (LSA) with Oxford Biomedica (UK) Limited (Oxford), wherein the LSA grants the Company a non-exclusive license to Oxford&#x2019;s LentiVector&#xae; platform for its application in the Company&#x2019;s DSG3-CAART program and put in place a multi-year vector supply agreement. Under the terms of the agreement, the Company was required to pay Oxford an upfront fee, as well as costs associated with initial vector manufacturing activities for a total cost incurred of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Oxford is eligible to receive regulatory and sales milestones in the low tens of millions and royalties in the low single digits on net sales of products that incorporate the Oxford technology. In May 2023, the Company amended the LSA with Oxford to expand the license to include the Company's rese-cel program for an upfront fee of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;500&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, and in August 2023, the Company and Oxford entered into a vector supply agreement for rese-cel, and a related second amendment to the LSA, with a total cost under the vector supply agreement of up to approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, of which &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,500&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,500&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; were recognized as research and development expense for the years ended December 31, 2024 and 2023, respectively. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In February 2024, the Company and Oxford entered into a third amendment to the LSA to update the patent schedule. In June 2024, the Company and Oxford entered into a fourth amendment to the LSA elimin&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ating royalties on net sales of products that incorporate the Oxford technology if Oxford manufactures the vector. In December 2024, the Company and Oxford entered into a work order with a cost of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for certain process characterization activities as part of commercial readiness activities. The Company can terminate the LSA or any work order under the LSA at will upon advance written notice and subject to certain cancellation fees.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Option and License Agreement with Autolus&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In January 2023, the Company entered into an Option and License Agreement (Autolus Agreement) with Autolus Holdings (UK) Limited (Autolus), wherein the Autolus Agreement granted the Company a non-exclusive license to access Autolus' RQR8 technology in its CD19-CAR T cell therapy program, and subject to additional nominal option exercise fees, up to four additional t&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;argets. In January 2025, the Company and Autolus agreed to novate the Autolus Agreement with both Autolus and Autolus Limited jointly assuming the rights, obligations and liabilities of Autolus, under the Autolus Agreement. Under the terms of the Autolus Agreement, the Company was required to pay Autolus an upfront license fee of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,200&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; that was recognized as expense in the first quarter of 2023 in the accompanying statements of operations, of which $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; was paid in 2023 and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; was paid in January 2024. Autolus is also eligible to receive regulatory milestones of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for each licensed target, sales milestones of up to a total of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and royalties in the low single digits on net sales of all products that incorporate the RQR8 technology. The Autolus Agreement will continue on a country-by-country, licensed product-by-licensed product basis until the expiration of the royalty term as identified in the Autolus Agreement, unless earlier terminated. The Company can terminate the Autolus Agreement at will upon advance written notice. Each of the Company and Autolus may terminate the Agreement for a material, uncured breach or insolvency of the other party.&lt;/span&gt;&lt;/p&gt;</caba:CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock>
    <us-gaap:ContractualObligation
      contextRef="C_c1ca12da-bcbe-461c-97eb-dc0872b56a45"
      decimals="-3"
      id="F_b1b8b91e-c890-4e36-8acf-e83bdc622d7b"
      unitRef="U_USD">2000000</us-gaap:ContractualObligation>
    <caba:PaymentOfObligationTerm
      contextRef="C_9cdb36a0-6755-4f07-b415-12eeed80884e"
      id="F_97997435-0ed3-46a7-bc49-87ed40ec04ce">P3Y</caba:PaymentOfObligationTerm>
    <us-gaap:ContractualObligation
      contextRef="C_3819e40f-e461-41a7-97d5-7e402dc0c022"
      decimals="-3"
      id="F_42d470dc-ed99-455e-b9a7-124ea93e422d"
      unitRef="U_USD">12560000</us-gaap:ContractualObligation>
    <caba:LicenseMaintenanceFee
      contextRef="C_9cdb36a0-6755-4f07-b415-12eeed80884e"
      decimals="-3"
      id="F_5ffdae03-55a0-46ae-88d0-69c57eff5b1e"
      unitRef="U_USD">10000</caba:LicenseMaintenanceFee>
    <caba:LicenseMaintenanceFee
      contextRef="C_bee1c669-b105-4c4e-b815-f0043dad20ee"
      decimals="-3"
      id="F_ed50ca85-1091-42fe-a76d-20df1a6da773"
      unitRef="U_USD">33000</caba:LicenseMaintenanceFee>
    <caba:MilestonePayments
      contextRef="C_9cdb36a0-6755-4f07-b415-12eeed80884e"
      decimals="-3"
      id="F_fafd6349-2061-46fa-8d85-4780fa9e609b"
      unitRef="U_USD">21000000</caba:MilestonePayments>
    <caba:CollaborativeAgreementPaymentsDue
      contextRef="C_c1ca12da-bcbe-461c-97eb-dc0872b56a45"
      decimals="-3"
      id="F_d9f5ec2d-beb8-4dfe-8c0b-0cfc3721c264"
      unitRef="U_USD">0</caba:CollaborativeAgreementPaymentsDue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_f59134f7-4690-4aaa-a4ad-dc44779c4c7a"
      decimals="-3"
      id="F_4bf9c0a8-ba34-4673-899c-508a78f06c91"
      unitRef="U_USD">3250000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_a19e5ed8-055f-4020-a172-1708aa7cf1d2"
      decimals="-3"
      id="F_1319bd26-add5-4712-beb6-67b34612de6c"
      unitRef="U_USD">3786000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_591ef989-ecdb-491c-873b-f35ee5894e2b"
      decimals="-3"
      id="F_e7e14b10-c512-4825-aa9c-d26f2cc4373b"
      unitRef="U_USD">3000000</us-gaap:ResearchAndDevelopmentExpense>
    <caba:RemainingResearchAndDevelopmentExpenseToBeIncurred
      contextRef="C_f59134f7-4690-4aaa-a4ad-dc44779c4c7a"
      decimals="-3"
      id="F_17c332ee-fbb5-4b93-826d-cbe06bd00f89"
      unitRef="U_USD">643000</caba:RemainingResearchAndDevelopmentExpenseToBeIncurred>
    <caba:UpfrontPayment
      contextRef="C_c9d68995-263a-4813-8297-7b0cb06226df"
      decimals="-3"
      id="F_03bb0f87-f7f5-44a6-b0fd-a5e9e8464333"
      unitRef="U_USD">2500000</caba:UpfrontPayment>
    <caba:UpfrontPayment
      contextRef="C_da3cad1c-31be-4130-aaba-7a1f51466edd"
      decimals="-3"
      id="F_2bfcf2b2-aefb-4324-b2a5-5bbb24e4c0e9"
      unitRef="U_USD">162000000</caba:UpfrontPayment>
    <caba:MilestonePayment
      contextRef="C_b03d1e52-2a57-4c8e-a119-05d8db2d7eab"
      decimals="-3"
      id="F_2a5103cb-a321-4d1d-acde-f1643a42f8e4"
      unitRef="U_USD">1000000</caba:MilestonePayment>
    <caba:MilestonePayment
      contextRef="C_41757f68-a8c3-48bc-848b-2cb739ce9b63"
      decimals="-3"
      id="F_7adb6826-76eb-49a3-a6f4-66064ce925c6"
      unitRef="U_USD">1500000</caba:MilestonePayment>
    <us-gaap:ContractualObligation
      contextRef="C_d8712004-ce9c-421a-b7c6-3e8c260bf228"
      decimals="-3"
      id="F_9653ed06-2091-456e-b062-efb182022d5b"
      unitRef="U_USD">1100000</us-gaap:ContractualObligation>
    <caba:UpfrontPayment
      contextRef="C_a801e2f0-ef59-43bc-a0d1-f52d9f8fad06"
      decimals="-3"
      id="F_a4d378e6-0c69-46c2-9d09-e78fcddc2d67"
      unitRef="U_USD">500000</caba:UpfrontPayment>
    <us-gaap:ContractualObligation
      contextRef="C_41424f02-2797-4d2b-9ae9-195e1bbcc839"
      decimals="-3"
      id="F_58fb0764-0510-4bd8-a267-2f0c068e37d9"
      unitRef="U_USD">5000000</us-gaap:ContractualObligation>
    <us-gaap:OtherExpenses
      contextRef="C_1b69037c-33e3-4056-95e8-3197e2253d28"
      decimals="-3"
      id="F_ba169f1a-f7fd-4cc2-9cb1-c26db139fd34"
      unitRef="U_USD">3500000</us-gaap:OtherExpenses>
    <us-gaap:OtherExpenses
      contextRef="C_239a468d-472b-4684-b508-dd3ca371e2de"
      decimals="-3"
      id="F_df4eea89-83b9-43b1-86fb-c0c16b2bc0cc"
      unitRef="U_USD">1500000</us-gaap:OtherExpenses>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_bc2a9f34-de0e-42e5-b295-2f8e567060bb"
      decimals="-3"
      id="F_3b83477a-bcc0-49b6-a901-c02e505bb06f"
      unitRef="U_USD">9000000</us-gaap:ResearchAndDevelopmentExpense>
    <caba:UpfrontPayment
      contextRef="C_5eb72df5-0321-4487-8ba8-cc5d3052b6cc"
      decimals="-3"
      id="F_092af3de-8fd7-4792-811a-789fbcdcd47f"
      unitRef="U_USD">1200000</caba:UpfrontPayment>
    <caba:UpfrontPayment
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_215611c4-63fd-4a21-aaa8-04934d22f42b"
      unitRef="U_USD">1100000</caba:UpfrontPayment>
    <caba:UpfrontPayment
      contextRef="C_0603accc-761b-4dd7-9cb1-3b0483ce98b5"
      decimals="-3"
      id="F_ab788524-0c99-4312-a5e4-959a0ce0e226"
      unitRef="U_USD">100000</caba:UpfrontPayment>
    <caba:MilestonePayment
      contextRef="C_0c1b371f-ae73-4a6c-ba1b-1ded4756d505"
      decimals="-3"
      id="F_776555e9-5e5b-443e-b8ec-c1a8322ca670"
      unitRef="U_USD">12000000</caba:MilestonePayment>
    <caba:MilestonePayment
      contextRef="C_a9395bbb-6b73-4262-b752-6b65e91be8cd"
      decimals="-3"
      id="F_a5d81c85-471b-4a64-aa97-21f774d43c3c"
      unitRef="U_USD">15000000</caba:MilestonePayment>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_8321823b-0f46-451e-ba31-4dcce04be62e">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;7. Commitments and Contingencies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Manufacturing Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In January 2021, the Company entered into a Development and Manufacturing Services Agreement (WuXi Agreement) with WuXi Advanced Therapies, Inc. (WuXi) to serve as an additional cell processing manufacturing partner for the MuSK-CAART Phase 1 clinical trial, or MusCAARTes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;TM&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; trial. The WuXi Agreement is scheduled to expire upon completion of WuXi's services related to MuSK-CAART and rese-cel. In August 2023, and as extended in August 2024, the Company entered into an agreement with WuXi to serve as one of the Company's manufacturing partners for the global clinical development of rese-cel in multiple indications, including potential late-stage clinical trials and commercial readiness activities for rese-cel. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the August 2023 work orders, WuXi converted the Company&#x2019;s non-dedicated suite to a dedicated suite for GMP manufacturing for the Company&#x2019;s rese-cel and MuSK-CAART programs, or the Dedicated Suite, for an initial term of 18 months with two 18-month extensions at the Company&#x2019;s sole option on six months' notice prior to the end of the term. In August 2024, the Company sent a notice to WuXi to extend the initial term of the WuXi Agreement by 18 months through August 2026.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; In addition, the Company agreed to certain monthly minimum runs. In August 2024, the 2023 work order related to GMP manufacturing was amended to reduce the minimum monthly runs through the end of 2024. In lieu of the original $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,500&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; termination fee under the terms of the WuXi Agreement, the Company would incur up to a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,080&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; termination &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;fee if it terminates both the rese-cel and MuSK-CAART work orders for any reason. The Company may terminate for&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;convenience &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the WuXi Agreement or any work order with six months' prior written notice. However, the Company may not terminate the Dedicated Suite without terminating both the MuSK-CAART &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;and rese-cel GMP run work orders. WuXi may terminate for convenience the WuXi Agreement or any work order on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;18 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;months' prior written notice, but such notice may not be effective prior to February 2028.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2024, the Company entered into a Development and Manufacturing Services Agreement (the Lonza Agreement) with Lonza Houston Inc. (Lonza) to serve as one of the Company's manufacturing partners for the global clinical development of rese-cel in multiple indications, including potential late-stage clinical trials and preparations for commercial readiness. Under the initial work order, Lonza will perform cell therapy manufacturing activities for Cabaletta&#x2019;s CAR-T cell therapy product rese-cel for a term of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;12 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;months and total cost of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; with the ability to extend the manufacturing period subject to the terms of the Lonza Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Other Purchase Commitments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In the normal course of business, the Company enters into various purchase commitments with third-party contract manufacturers for the manufacture and processing of its product candidates and related raw materials, contracts with contract research organizations for clinical trials and agreements with vendors for other services and products for operating purposes. These agreements generally provide for termination or cancellation, other than for costs already incurred.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Indemnification&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company enters into certain types of contracts that contingently require the Company to indemnify various parties against claims from third parties. These contracts primarily relate to (i) the Company&#x2019;s Amended and Restated Bylaws, as amended, (bylaws) under which the Company must indemnify directors and executive officers, and may indemnify other officers and employees, for liabilities arising out of their relationship, (ii) contracts under which the Company must indemnify directors and certain officers and consultants for liabilities arising out of their relationship, (iii) contracts under which the Company may be required to indemnify partners against certain claims, including claims from third parties asserting, among other things, infringement of their intellectual property rights, and (iv) procurement, consulting, or license agreements under which the Company may be required to indemnify vendors, consultants or licensors for certain claims, including claims that may be brought against them arising from the Company&#x2019;s acts or omissions with respect to the supplied products, technology or services. From time to time, the Company may receive indemnification claims under these contracts in the normal course of business. In addition, under these contracts, the Company may have to modify the accused infringing intellectual property and/or refund amounts received.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In the event that one or more of these matters were to result in a claim against the Company, an adverse outcome, including a judgment or settlement, may have a material adverse effect on the Company&#x2019;s future business, operating results or financial condition. It is not possible to determine the maximum potential amount under these contracts due to the limited history of prior indemnification claims and the unique facts and circumstances involved in each particular agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Litigation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;From time to time, the Company may become involved in litigation or legal proceedings. While the outcome of any such proceedings cannot be predicted with certainty, as of December 31, 2024, the Company is not involved in any material litigation or legal proceedings that it would expect to have a material adverse impact on its financial position, results of operations, or cash flows.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <caba:InitialTermsOfAgreementDescription
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_14593ec2-0454-41e4-bfd8-bff4f7637cd7">Under the August 2023 work orders, WuXi converted the Company&#x2019;s non-dedicated suite to a dedicated suite for GMP manufacturing for the Company&#x2019;s rese-cel and MuSK-CAART programs, or the Dedicated Suite, for an initial term of 18 months with two 18-month extensions at the Company&#x2019;s sole option on six months' notice prior to the end of the term. In August 2024, the Company sent a notice to WuXi to extend the initial term of the WuXi Agreement by 18 months through August 2026.</caba:InitialTermsOfAgreementDescription>
    <us-gaap:LiabilitiesSubjectToCompromiseEarlyContractTerminationFees
      contextRef="C_1947669b-c145-49f5-aea0-60ae45e15e4f"
      decimals="-3"
      id="F_32602e1e-aba4-43b0-b8e5-ecb3f2612132"
      unitRef="U_USD">1500000</us-gaap:LiabilitiesSubjectToCompromiseEarlyContractTerminationFees>
    <us-gaap:LiabilitiesSubjectToCompromiseEarlyContractTerminationFees
      contextRef="C_071a7623-23cd-43a4-8077-7f5f839577fb"
      decimals="-3"
      id="F_0411d494-a873-4756-965f-e7eaa614416a"
      unitRef="U_USD">1080000</us-gaap:LiabilitiesSubjectToCompromiseEarlyContractTerminationFees>
    <caba:LeaseExpirationMonth
      contextRef="C_8a7792c8-f29b-4a61-9156-afc843c668af"
      id="F_811dc02b-4bcf-45c6-bc13-059b4d8674b9">P18M</caba:LeaseExpirationMonth>
    <caba:PaymentOfObligationTerm
      contextRef="C_16370771-1761-414a-82f7-374ff37b95d5"
      id="F_74bc3ebb-d384-4e9f-a048-3e643865c3df">P12M</caba:PaymentOfObligationTerm>
    <us-gaap:ContractualObligation
      contextRef="C_25d4f8d5-93ce-418d-8f55-f27f42cf8bf6"
      decimals="-3"
      id="F_bd936d1a-269b-4ea8-b235-798f6dcd5a4e"
      unitRef="U_USD">16000000</us-gaap:ContractualObligation>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_786c2a45-f350-4bec-9f14-2f4cb26863b7">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;8. Segment Information&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the CODM in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#x2019;s CODM is the CEO. The Company has determined that it has one operating and reportable segment. The segment consists of the development of clinical and preclinical product candidates for the discovery and development of innovative engineered T cell therapies and related administrative activities. The&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;CODM assesses performance and allocates resources based on the Company&#x2019;s consolidated statement of operations, which is reported on the income statement as consolidated net loss and considers forecast-to-actuals variances on a quarterly basis for expenses that are deemed significant. Further, the CODM reviews the segment&#x2019;s assets based on the consolidated balance sheet to assess liquidity and funding capacity. The majority of the Company's assets are located in the United States.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s CODM views specific categories within expenses as significant given the direct correlation between cash burn and profitability as a pre-revenue company. Significant segment expenses, as provided to the CODM, are presented below. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For additional information on the year over year change of segment expenses refer to Item 7. Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:57.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development expenses:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Personnel&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,375&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Clinical trials&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,286&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,302&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Development services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,417&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,486&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Manufacturing of preclinical and clinical supplies&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,523&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,498&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;License of intellectual property&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,523&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,383&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other research and development costs &lt;/span&gt;&lt;span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,215&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,380&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administration expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,938&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,236&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,985&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;115,864&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67,675&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Other research and development costs includes costs associated with information technology, travel, medical and scientific symposiums and conferences.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_0886231f-b079-4af3-81ba-391a7a4f883f">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For additional information on the year over year change of segment expenses refer to Item 7. Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations.&lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:57.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development expenses:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Personnel&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,375&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Clinical trials&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,286&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,302&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Development services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,417&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,486&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Manufacturing of preclinical and clinical supplies&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,523&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,498&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;License of intellectual property&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,523&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,383&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other research and development costs &lt;/span&gt;&lt;span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,215&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,380&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administration expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,938&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,236&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,985&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;115,864&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67,675&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Other research and development costs includes costs associated with information technology, travel, medical and scientific symposiums and conferences.&lt;/span&gt;&lt;/p&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <caba:PersonnelExpenses
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_056b9d9a-26ab-4fb1-86b9-63e0e77f9beb"
      unitRef="U_USD">39239000</caba:PersonnelExpenses>
    <caba:PersonnelExpenses
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_4e240853-dcbf-4b0b-bd1a-f8c7e895a55b"
      unitRef="U_USD">22375000</caba:PersonnelExpenses>
    <caba:ClinicalTrials
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_3b545a44-ccb1-4146-9973-4224b06ada51"
      unitRef="U_USD">22286000</caba:ClinicalTrials>
    <caba:ClinicalTrials
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_ae080ada-2776-4bce-b8d4-a4120243e3ad"
      unitRef="U_USD">8302000</caba:ClinicalTrials>
    <caba:DevelopmentServices
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_2e4faf97-7c41-4982-9418-97c3d1cd82be"
      unitRef="U_USD">16417000</caba:DevelopmentServices>
    <caba:DevelopmentServices
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_9583df05-d822-482d-b456-12d17e147b2b"
      unitRef="U_USD">12486000</caba:DevelopmentServices>
    <caba:ManufacturingOfPreclinicalAndClinicalSupplies
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_229d9d11-5f3e-47ad-9db1-3df9c47d8bc2"
      unitRef="U_USD">15523000</caba:ManufacturingOfPreclinicalAndClinicalSupplies>
    <caba:ManufacturingOfPreclinicalAndClinicalSupplies
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_5f65b428-7829-4614-91b7-fee455972b3f"
      unitRef="U_USD">8498000</caba:ManufacturingOfPreclinicalAndClinicalSupplies>
    <caba:LicenseOfIntellectualProperty
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_9c1c408a-fe38-49ab-a848-efa80e517ea3"
      unitRef="U_USD">1523000</caba:LicenseOfIntellectualProperty>
    <caba:LicenseOfIntellectualProperty
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_98714bd3-4fcf-4047-aa93-0d910d8629e4"
      unitRef="U_USD">2383000</caba:LicenseOfIntellectualProperty>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_79796396-a7d9-4c3c-85e3-fa935c557d67"
      unitRef="U_USD">2215000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_c44390f8-728e-4a16-874c-98d61b07a67a"
      unitRef="U_USD">1380000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_23dd32c5-164f-4cd4-9f37-9bf962bb6329"
      unitRef="U_USD">27938000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_96e7f203-9740-41b8-b52b-621df9297414"
      unitRef="U_USD">19236000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_892cfdc1-5748-4c7b-a4ae-b6973abf9b03"
      unitRef="U_USD">10025000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_1a714770-b9ba-4d94-9bb9-ca3253a2f532"
      unitRef="U_USD">6985000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_dcdce305-8c92-4ee0-8e52-d780e0520eeb"
      unitRef="U_USD">748000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_d098e5d7-7ad2-4aee-8703-714c97c02d7a"
      unitRef="U_USD">0</us-gaap:InterestExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_75f2952d-1139-4baf-a71e-1724dd72e730"
      unitRef="U_USD">-115864000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_19143ab4-827d-4bf8-a6cd-53180f3d0b64"
      unitRef="U_USD">-67675000</us-gaap:NetIncomeLoss>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_46311c08-170a-4dd0-8783-ca76ffb2e850">&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Leases&lt;/span&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company leases office and laboratory space in addition to a manufacturing agreement which has been determined to contain an embedded lease.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Operating lease commitments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company leases office and laboratory space which include rent escalations and are subject to additional variable charges, including common area maintenance, property taxes and property insurance. Given the variable nature of such costs, they are recognized as expense as incurred. Additionally, some of the Company&#x2019;s leases are subject to certain fixed fees which the Company has determined to be non-lease components. The Company has elected the practical expedient to account for lease and non-lease components as a single-lease component and has included fixed payments related to non-lease components in calculating the operating lease liability. In 2024, the Company extended the terms of its lab and office operating leases and leased additional lab space &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;resulting in an increase in the right-of-use asset and lease liability of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,242&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Finance lease commitments - Embedded leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As described further in Note 7, in August 2023, the Company entered into new work orders under the WuXi Agreement for WuXi to serve as one of the Company&#x2019;s cell processing manufacturing partners for the global clinical development of rese-cel. WuXi converted the Company&#x2019;s non-dedicated suite to a Dedicated Suite for GMP manufacturing for the Company&#x2019;s rese-cel and MuSK-CAART programs, for an initial term of 18 months. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;terms of the August 2023 work orders included both fixed costs and contingent variable costs. The lease commenced October 1, 2023. In 2024, the Company remeasured the lease due to resolution of the contingency related to variable costs and an amendment to the 2023 work order to extend the term of the agreement for an additional 18 months through August &lt;/span&gt;&lt;/span&gt;&lt;span style=""&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2026 &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;resulting in an increase in the right-of-use asset and lease liability of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,963&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company may terminate the Dedicated Suite lease for convenience with six months&#x2019; prior written notice and up to a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,080&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; termination fee if both the rese-cel and MuSK-CAART work orders are terminated&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As described further in Note 7, in December 2024, the Company entered into the Lonza Agreement with Lonza to serve as one of our manufacturing partners. Under the initial work order, Lonza will perform cell therapy manufacturing activities for our CAR-T cell therapy product rese-cel for a term of 12 months and total cost of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; with the ability to extend the manufacturing period subject to the terms of the Lonza Agreement. The Lonza Agreement is currently being evaluated for lease accounting under ASC 842. No right-of-use asset or liability was recognized as of December 31, 2024, as lease commencement begins in fiscal year 2025.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Summary of lease costs recognized under ASC 842&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company&#x2019;s operating and finance leases for the years ended December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:59.224%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:16.387%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:16.387%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Finance leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Amortization expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total fixed finance lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,850&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Variable lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;930&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total finance lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,780&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Fixed lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,247&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,477&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total fixed operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,247&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,477&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Variable lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Short-term lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;750&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;717&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,293&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,259&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Cash paid in the measurement of lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating cash flows used for operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,291&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,456&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating cash flows used for finance leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Financing cash flows for finance leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;897&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Other information&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average remaining lease term - finance leases (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average discount rate - finance leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average remaining lease term - operating leases (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average discount rate - operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For finance leases embedded in CDMO arrangements, interest expense is recognized using the effective interest method, applying the Company's incremental borrowing rate as required by ASC 842, and amortization expense is recognized on a straight-line basis over the shorter of the life of the asset or the term of the lease.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Future lease payments under the non-cancelable operating and finance leases as of December 31, 2024 are as follows&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;:
&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Finance Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,227&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,792&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,769&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;Total undiscounted lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,120&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,996&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;890&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;626&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;Total lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,230&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,370&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <caba:IncreaseInTheRouAsset
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_0eccf7b4-3f80-4646-b539-b717c00a317e"
      unitRef="U_USD">4242000</caba:IncreaseInTheRouAsset>
    <caba:WorkOrdersTerm
      contextRef="C_fbb28abe-5658-4753-b0b7-f0b655b95e73"
      id="F_2de9201e-d712-4134-9e61-5e7a8aa950d5">The terms of the August 2023 work orders included both fixed costs and contingent variable costs. The lease commenced October 1, 2023. In 2024, the Company remeasured the lease due to resolution of the contingency related to variable costs and an amendment to the 2023 work order to extend the term of the agreement for an additional 18 months through August 2026 resulting in an increase in the right-of-use asset and lease liability of $10,963. The Company may terminate the Dedicated Suite lease for convenience with six months&#x2019; prior written notice and up to a $1,080 termination fee if both the rese-cel and MuSK-CAART work orders are terminated</caba:WorkOrdersTerm>
    <caba:IncreaseInTheLeaseLiability
      contextRef="C_91f04779-501e-4bce-bfef-a9538a16e993"
      decimals="-3"
      id="F_b27729ca-fce0-4f0f-ab93-423c885b988d"
      unitRef="U_USD">10963000</caba:IncreaseInTheLeaseLiability>
    <caba:TerminationFees
      contextRef="C_fbb28abe-5658-4753-b0b7-f0b655b95e73"
      decimals="-3"
      id="F_c0aa2f9c-66af-413b-a045-1981ab78511d"
      unitRef="U_USD">1080000</caba:TerminationFees>
    <us-gaap:LeaseCost
      contextRef="C_1078f332-4fd3-4a24-94d7-ea03957d7227"
      decimals="-3"
      id="F_1d973522-131c-4f49-bc07-29cd9cb2687f"
      unitRef="U_USD">16000000</us-gaap:LeaseCost>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_9f65a08c-fc73-4488-8acb-a6c1aa2d03c4">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company&#x2019;s operating and finance leases for the years ended December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:59.224%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:16.387%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:16.387%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Finance leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Amortization expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total fixed finance lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,850&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Variable lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;930&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total finance lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,780&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Fixed lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,247&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,477&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total fixed operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,247&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,477&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Variable lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Short-term lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;750&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;717&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,293&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,259&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Cash paid in the measurement of lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating cash flows used for operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,291&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,456&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating cash flows used for finance leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Financing cash flows for finance leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;897&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Other information&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average remaining lease term - finance leases (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average discount rate - finance leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average remaining lease term - operating leases (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average discount rate - operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_777ca4f4-bc6e-4b86-93bf-05745b1355f1"
      unitRef="U_USD">748000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_5bc8998c-450d-45af-87b3-6b132dbd640c"
      unitRef="U_USD">0</us-gaap:FinanceLeaseInterestExpense>
    <caba:AmortizationExpense
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_d273eb09-2f56-4898-9990-3a091f5cc331"
      unitRef="U_USD">3102000</caba:AmortizationExpense>
    <caba:AmortizationExpense
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_23aaa067-ddd2-4edc-8040-777068ad8756"
      unitRef="U_USD">0</caba:AmortizationExpense>
    <caba:TotalFixedFinanceLeaseCost
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_10c46884-7a30-46c0-9b53-91460e7f142b"
      unitRef="U_USD">3850000</caba:TotalFixedFinanceLeaseCost>
    <caba:TotalFixedFinanceLeaseCost
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_f7bdd30b-7ac8-4268-8176-4d1646dd6f36"
      unitRef="U_USD">0</caba:TotalFixedFinanceLeaseCost>
    <caba:VariableLeaseCosts
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_94d0d8e3-bb57-4bc1-bf31-59e81bb42215"
      unitRef="U_USD">930000</caba:VariableLeaseCosts>
    <caba:VariableLeaseCosts
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_20622c75-a216-411c-82fa-5574828c1c7b"
      unitRef="U_USD">0</caba:VariableLeaseCosts>
    <caba:TotalFinanceLeaseCost
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_47ce3d2d-5e82-472e-b18d-b49665366ec5"
      unitRef="U_USD">4780000</caba:TotalFinanceLeaseCost>
    <caba:TotalFinanceLeaseCost
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_3fdcd52a-fd14-42d5-bbf0-7cb8d8b5c75c"
      unitRef="U_USD">0</caba:TotalFinanceLeaseCost>
    <caba:FixedLeaseCost
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_56e80b63-6b2d-4ed6-b020-2ad72176c74a"
      unitRef="U_USD">3247000</caba:FixedLeaseCost>
    <caba:FixedLeaseCost
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_0acfd0bd-af28-4526-b12b-f4888e322ea2"
      unitRef="U_USD">2477000</caba:FixedLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_1d81eb27-2452-413b-9fff-614d4349cb69"
      unitRef="U_USD">3247000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_b9b000be-7b0d-4256-a075-070173556b11"
      unitRef="U_USD">2477000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_26b092df-41b9-4706-849d-33148099d425"
      unitRef="U_USD">296000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_46346d25-dda6-4588-9694-5ef1bb3ff2a3"
      unitRef="U_USD">65000</us-gaap:VariableLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_fe481d92-c2dd-414f-b6a5-e4deff5a6994"
      unitRef="U_USD">750000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_c6993b8d-124a-4c11-b03c-b8f47e5ced07"
      unitRef="U_USD">717000</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_94ef0e7d-3a87-4780-aaa2-3b1d8ed4330b"
      unitRef="U_USD">4293000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_e1cf6e6d-aed8-4567-820e-9249c4363931"
      unitRef="U_USD">3259000</us-gaap:LeaseCost>
    <caba:OperatingCashFlowsUsedForOperatingLeases
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_3706c602-955b-47a6-8eb9-419761e667b6"
      unitRef="U_USD">3291000</caba:OperatingCashFlowsUsedForOperatingLeases>
    <caba:OperatingCashFlowsUsedForOperatingLeases
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_5fffaa27-2c2e-49ee-874a-a3259a535152"
      unitRef="U_USD">2456000</caba:OperatingCashFlowsUsedForOperatingLeases>
    <caba:OperatingCashFlowsUsedForFinanceLeases
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_547ae942-e67a-4e22-a9ea-59704e8783d9"
      unitRef="U_USD">748000</caba:OperatingCashFlowsUsedForFinanceLeases>
    <caba:OperatingCashFlowsUsedForFinanceLeases
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_bf0fbb16-6ded-4a44-a247-03303fc1158d"
      unitRef="U_USD">0</caba:OperatingCashFlowsUsedForFinanceLeases>
    <caba:FinancingCashFlowsUsedForFinanceLeases
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_1c1fb176-6df9-4f57-b290-d16b7227f7f2"
      unitRef="U_USD">897000</caba:FinancingCashFlowsUsedForFinanceLeases>
    <caba:FinancingCashFlowsUsedForFinanceLeases
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_9c635981-8efe-4a4c-a847-8952ff430927"
      unitRef="U_USD">0</caba:FinancingCashFlowsUsedForFinanceLeases>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      id="F_b4f7d0cb-5510-416c-97ef-b5b948bbcb1e">P1Y8M12D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="3"
      id="F_14914ed7-3cd3-4197-b733-fccb463c6552"
      unitRef="U_pure">0.115</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc"
      decimals="2"
      id="F_2bb31d21-04b7-47a8-8c29-a9a5c2dea239"
      unitRef="U_pure">0</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      id="F_df212b8f-cac5-4d6c-88cc-3afebfcb8c3c">P1Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc"
      id="F_ad620c02-dddc-4e0f-a9f7-a97558f4b6ff">P1Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="3"
      id="F_0255cbb1-8943-4c90-821f-312b213ecbe7"
      unitRef="U_pure">0.11</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc"
      decimals="3"
      id="F_9c39ef73-2a5c-4321-8b2b-5286c97b2095"
      unitRef="U_pure">0.095</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_65693f69-6a16-4a48-81f1-b51e7b7c8c99">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Future lease payments under the non-cancelable operating and finance leases as of December 31, 2024 are as follows&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;:
&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Finance Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,227&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,792&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,769&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;Total undiscounted lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,120&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,996&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;890&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;626&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;Total lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,230&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,370&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_e6740247-f1c4-422b-886d-f54006c6f0b0"
      unitRef="U_USD">6328000</us-gaap:FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_3d4981f5-d99d-4cb8-baad-832438ea735c"
      unitRef="U_USD">4227000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueInRollingYearTwo
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_00a128c0-07c2-49a0-8093-fe6b5a2748df"
      unitRef="U_USD">3792000</us-gaap:FinanceLeaseLiabilityPaymentsDueInRollingYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_022b0013-7e1a-44d7-bba7-2f4bc4fd8e8d"
      unitRef="U_USD">2769000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo>
    <caba:FinanceLesseeUndiscountedLeasePayments
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_97157af5-454e-486b-94b1-9da314e192ac"
      unitRef="U_USD">10120000</caba:FinanceLesseeUndiscountedLeasePayments>
    <caba:LesseeUndiscountedLeasePayments
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_60042ad8-9cd4-4a99-97e2-786d24347c54"
      unitRef="U_USD">6996000</caba:LesseeUndiscountedLeasePayments>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_5fa7e614-469e-49b2-8402-a04a73390cff"
      unitRef="U_USD">890000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_98bda9f5-1566-4ed8-85f6-bc7008df34f8"
      unitRef="U_USD">626000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_ba4385fe-960e-4a93-a42d-7a29c7e5d7b5"
      unitRef="U_USD">9230000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_ce3700d7-54d6-40bc-9937-016b74718d16"
      unitRef="U_USD">6370000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_71682c1b-3512-4b3a-a601-72b5a798b0dc">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;10. Common Stock&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Common Stock&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Pursuant to the Company&#x2019;s Third Amended and Restated Certificate of Incorporation filed in October 2019, the Company is authorized to issue &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;143,590,481&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of voting common stock and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,409,519&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of non-voting common stock. Holders of voting common stock shall have the exclusive right to vote for the election of directors of the Company and on all other matters requiring stockholder action. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Each share of the Company&#x2019;s non-voting common stock may be converted at any time into one share of common stock at the option of its holder by providing 61 days written notice to the Company&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, subject to certain limitations, as described in the amended and restated certificate of incorporation. In May 2024, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,444,295&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of non-voting common stock was converted to voting common stock and no shares of non-voting common stock remain outstanding.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;May 2023 Financing&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In May 2023, the Company issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,337,500&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of its common stock in an underwritten public offering, including the exercise in full by the underwriters of their option to purchase an additional &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,087,500&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares, at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share. Aggregate net proceeds were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93,755&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; after deducting underwriting discounts and commissions and offering expenses of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,295&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;December 2022 Financing&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2022, the Company issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;126,815&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of its common stock at a price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.52&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share and to certain investors in lieu of common stock, pre-funded warrants to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,213,776&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock at a price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.51999&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per pre-funded warrant. The purchase price per share of each pre-funded warrant represents the per share offering price for the common stock, minus the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share exercise price of such pre-funded warrant. Aggregate net proceeds were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,562&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; after deducting underwriting discounts and commissions and offering expens&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;es. As of December 31, 2024, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,213,775&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; pre-funded warrants had been exercised and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; warrants remain outstanding.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The pre-funded warrants were classified as a component of permanent stockholders&#x2019; equity within additional paid-in capital and were recorded at the issuance date using a relative fair value allocation method. The pre-funded warrants are equity classified because they (i) are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, (ii) are immediately exercisable, (iii) do not embody an obligation for the Company to repurchase its shares, (iv) permit the holders to receive a fixed number of shares of common stock upon exercise, (v) are indexed to the Company&#x2019;s common stock and (vi) meet the equity classification criteria. In addition, such pre-funded warrants do not provide any guarantee of value or return.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;At-the-Market Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On March 21, 2024, the Company filed an automatic shelf registration statement (S-3ASR) in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof for the purposes of selling, from time to time, the Company&#x2019;s common stock, debt securities or other equity securities in one or more offerings. This S-3ASR became effective immediately. We intend to convert the S-3ASR to S-3 by post-effective amendments in connection with the filing of this Annual Report.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has a Sales Agreement with Cowen and Company, LLC (Cowen) to provide for the offering, issuance and sale of up to an aggregate amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;200.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of common stock from time to time in &#x201c;at-the-market&#x201d; offerings (2024 ATM Program) pursuant to its S-3ASR, and subject to the limitations thereof. In December 2024, the Company sold &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,225,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares pursuant to the 2024 ATM Program for net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,129&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, after deducting commissions of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;105&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company previously had a Sales Agreement with Cowen to provide for the offering, issuance and sale of up to an aggregate amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of common stock from time to time in &#x201c;at-the-market&#x201d; offerings (2023 ATM Program) pursuant to its shelf registration statement on Form S-3 (File No. 333-270599), which was declared effective April 26, 2023. During the year ended December 31, 2023, the Company sold &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,760,899&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares pursuant to the 2023 ATM Program for net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;91,740&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, after deducting commissions of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,352&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. In the first quarter of 2024, the Company sold &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;258,070&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; additional shares, completing the 2023 ATM Program for net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,746&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, after deducting commissions of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;147&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;2018 Stock Option and Grant Plan&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In September 2018, the Company adopted the 2018 stock option and grant plan (the 2018 Plan), which provided for the Company to sell or issue common stock, or other stock-based awards, to employees, members of the board of directors and consultants of the Company. The Company generally granted stock-based awards with service conditions only (service-based awards), although there was one grant with performance conditions. As of December 31, 2020, there are &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; unvested options with performance conditions. Stock options granted under the 2018 Plan generally vest over &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_12ab2f03-70f4-4da9-bb26-c88cd3cb34ae;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,959,411&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; options granted under the 2018 Plan prior to the Company&#x2019;s IPO in October 2019. No further grants may be made under the 2018 Plan subsequent to the IPO.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;2019 Stock Option and Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The 2019 Stock Option and Incentive Plan (2019 Plan) was approved by the Company&#x2019;s board of directors on October 14, 2019, and became effective on October 23, 2019. The 2019 Plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock units, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights to the Company&#x2019;s officers, employees, directors and consultants. The number of shares initially reserved for issuance under the 2019 Plan was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,342,288&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, which will be increased each January 1 thereafter by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the number of shares of the Company&#x2019;s common stock outstanding on the immediately preceding December 31 or such lesser number of shares determined by the Company&#x2019;s board of directors or compensation committee of the board of directors. On June 1, 2023, at the 2023 Annual Meeting of Stockholders of the Company, the stockholders of the Company approved Amendment No. 1 to the 2019 Plan, increasing the number of shares of common stock reserved for issuance under the 2019 Plan by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares. On January 1, 2025, the total number of shares under the 2019 Plan was increased by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,029,724&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares pursuant to the 2019 Plan Evergreen Provision. As of December 31, 2024, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,379,305&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares remaining available for issuance under the 2019 Plan.&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A summary of the stock option activity is presented below:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:33.84%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.120000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.64%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.120000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding as of January 1, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,141,035&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.28&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;117,384&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,476,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16.13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;210,695&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.79&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,889&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited/Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;175,892&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,231,148&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;989&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options Exercisable at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,642,705&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;966&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The aggregate intrinsic value of options granted is calculated as the difference between the exercise price of the options and the estimated fair value of the Company&#x2019;s common stock. The weighted average grant-date fair value of stock options granted during the year ended December 31, 2024 and 2023 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.44&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.51&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair value of each award is estimated using Black-Scholes based on the following assumptions:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:53.049%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:21.676%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:21.676%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.43&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.60&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.38&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.68&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&#x2014;&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.2&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&#x2014;&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;106&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;111&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;105&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;107&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Black-Scholes requires the use of subjective assumptions which determine the fair value of stock-based awards. These assumptions include:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Expected term&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;The expected term represents the period that stock-based awards are expected to be outstanding. The expected term for option grants is determined using the simplified method, which is the midpoint between the vesting period and the contractual term of the option.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;As a privately held company prior to the Company&#x2019;s IPO in October 2019, the Company has limited trading history for its common stock and, as such, the expected volatility is estimated based on a weighted average volatility for the Company's stock price and comparable publicly traded biotechnology companies over a period equal to the expected term of the stock-based awards. The comparable companies were chosen based on their similar size, stage in the life cycle or area of specialty. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of a stock-based award.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Expected dividend&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock-based Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has recorded stock-based compensation in the accompanying statements of operations as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,520&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,302&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,823&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,465&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,343&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, there was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;51,239&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of unrecognized compensation cost related to unvested option awards, which is expected to be recognized over a weighted-average period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;2019 Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The 2019 Employee Stock Purchase Plan (2019 ESPP) was approved by the Company&#x2019;s board of directors on October 14, 2019, and became effective on October 23, 2019. A total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;234,229&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock were initially reserved for issuance under the 2019 ESPP, and such number of shares will be increased each January 1 thereafter through January 1, 2029 by the least of (i) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;234,229&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock, (ii) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the number of shares of the Company&#x2019;s common stock outstanding on the immediately preceding December 31 or (iii) such lesser number of shares determined by the 2019 ESPP&#x2019;s administrator. There was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; increase to the total number of shares &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;available under the 2019 ESPP on January 1, 2024, 2023 or 2022, respectively. As of December 31, 2024, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;314,259&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares remaining available for issuance under the 2019 ESPP.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Employee contributions are made through payroll deductions of up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of eligible compensation over the offering period. A participant may not accrue rights to purchase more than $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; worth of the Company&#x2019;s common stock for each calendar year in which such right is outstanding. At the end of each offering period, shares of the Company&#x2019;s common stock may be purchased at &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the lesser of the Company&#x2019;s common stock on (i) the first trading day of the relevant offering period and (ii) the last trading day of the relevant offering period. Each offering period will be six months in duration and will commence on each December 1 and June 1.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_e24a8a97-a5dc-4f15-92b4-2d95326ebc6a"
      decimals="0"
      id="F_ca1db452-5c9f-4d3f-923c-a9d831824099"
      unitRef="U_shares">143590481</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_edbf75ee-d36b-422e-9a54-1ab65dcfc82b"
      decimals="0"
      id="F_f6f51ec2-6d7e-434d-91ad-8af01b2dae4b"
      unitRef="U_shares">6409519</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockConversionFeatures
      contextRef="C_42bda966-2bcc-4366-9ccc-53d8a69b796d"
      id="F_f3125982-d823-4747-a599-7a4968188480">Each share of the Company&#x2019;s non-voting common stock may be converted at any time into one share of common stock at the option of its holder by providing 61 days written notice to the Company</us-gaap:CommonStockConversionFeatures>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_3577cd65-82b8-42e6-844e-ca6167dba709"
      decimals="0"
      id="F_68070ef5-f909-40ce-9bb9-3979fcd5496a"
      unitRef="U_shares">1444295</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_75b117c4-870a-43ee-97dd-4b546ab94807"
      decimals="0"
      id="F_ae540539-6bbc-41f4-a87b-ea9c64907ffa"
      unitRef="U_shares">8337500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <caba:AdditionalOptionsToBePurchasedByUnderwriters
      contextRef="C_29f8f331-c6aa-4374-ab1d-8e739c14e615"
      decimals="0"
      id="F_9a932df7-bdd7-4e93-ae03-cdfd278d8cb3"
      unitRef="U_shares">1087500</caba:AdditionalOptionsToBePurchasedByUnderwriters>
    <us-gaap:WarrantExercisePriceDecrease
      contextRef="C_2b388bdd-20d2-49ab-a3f5-a0e370b1edf7"
      decimals="2"
      id="F_7cc6e6c5-2611-449a-bb85-4d815dce223f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12</us-gaap:WarrantExercisePriceDecrease>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_2b388bdd-20d2-49ab-a3f5-a0e370b1edf7"
      decimals="0"
      id="F_10100d70-5864-4be6-b0b8-5fc4987e911a"
      unitRef="U_USD">93755</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:PaymentsForUnderwritingExpense
      contextRef="C_2b388bdd-20d2-49ab-a3f5-a0e370b1edf7"
      decimals="0"
      id="F_a9e73322-2396-4598-b013-4d9355c68545"
      unitRef="U_USD">6295</us-gaap:PaymentsForUnderwritingExpense>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_1e1e3aab-a61d-436a-a436-d1b68af34f64"
      decimals="0"
      id="F_b1c68ad0-d50e-4d64-b46e-070fad1d9eca"
      unitRef="U_shares">126815</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_84c42e55-4cc8-4f96-915e-34a23c05bcb6"
      decimals="2"
      id="F_ce44d98d-f874-42d5-8f39-7b55d5430803"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.52</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_35f03d89-1210-4983-af91-5949af3be4e2"
      decimals="0"
      id="F_9ab3e876-b8f6-49de-8230-6651d623a006"
      unitRef="U_shares">6213776</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_bf0b7bb5-9f31-48ec-a4d1-ec777a17246d"
      decimals="5"
      id="F_0b20e281-5ced-4f55-ae69-b0640a14ee7d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.51999</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:WarrantExercisePriceDecrease
      contextRef="C_35f03d89-1210-4983-af91-5949af3be4e2"
      decimals="5"
      id="F_fbadf753-0c62-49c5-9af6-8a61cd172e1b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.00001</us-gaap:WarrantExercisePriceDecrease>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_35f03d89-1210-4983-af91-5949af3be4e2"
      decimals="0"
      id="F_e3aebb95-127d-45d7-bef3-0cfc989a5b2e"
      unitRef="U_USD">32562</us-gaap:ProceedsFromWarrantExercises>
    <caba:PreFundedWarrantsExercised
      contextRef="C_0c06bf87-692f-4caf-b799-574ffd3da54b"
      decimals="0"
      id="F_f6ce3c0d-bdf9-434f-9299-fe91ed7715a2"
      unitRef="U_shares">6213775</caba:PreFundedWarrantsExercised>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_bf0b7bb5-9f31-48ec-a4d1-ec777a17246d"
      decimals="0"
      id="F_669babe3-4dba-4a41-9f50-d550486b9360"
      unitRef="U_shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_22da4d01-1dd8-4662-b3be-4451dc2b3435"
      decimals="-5"
      id="F_121419b7-5b8c-4439-9ad6-261a40c8c6f4"
      unitRef="U_USD">200000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_2050f55b-9729-46ca-976a-a50c6da04429"
      decimals="0"
      id="F_b682352e-0451-4bc2-a38a-fd05ac907cda"
      unitRef="U_shares">1225000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_2050f55b-9729-46ca-976a-a50c6da04429"
      decimals="0"
      id="F_0faa1e83-8cf5-47f4-9c4d-1bd9ae53cde3"
      unitRef="U_USD">5129</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsForCommissions
      contextRef="C_2050f55b-9729-46ca-976a-a50c6da04429"
      decimals="0"
      id="F_52c0ff3e-762b-4da8-9b0e-1275fba69fb6"
      unitRef="U_USD">105</us-gaap:PaymentsForCommissions>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_bb8841ed-9927-4eb0-bfb9-ea102a2a8da5"
      decimals="-5"
      id="F_fd8a32e2-b1d9-4b3b-be8c-5637270ba6ef"
      unitRef="U_USD">100000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_9d8c2f96-4509-44a0-991d-9d569f5f45f2"
      decimals="0"
      id="F_af92227f-3399-4979-a807-2e7f13b93a67"
      unitRef="U_shares">4760899</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_9d8c2f96-4509-44a0-991d-9d569f5f45f2"
      decimals="0"
      id="F_9c58f63a-4faf-45b0-9f5e-69dc153754a6"
      unitRef="U_USD">91740</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_9d8c2f96-4509-44a0-991d-9d569f5f45f2"
      decimals="0"
      id="F_a9058cb5-8664-4e10-a430-89b52a8ab426"
      unitRef="U_USD">2352</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_68171875-88e5-4c5d-a904-b84ad5d56a17"
      decimals="0"
      id="F_59d177a2-0451-4fd6-b126-e262c8afe502"
      unitRef="U_shares">258070</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_68171875-88e5-4c5d-a904-b84ad5d56a17"
      decimals="0"
      id="F_420c4fac-84fe-494c-96a9-59ee53a5ddca"
      unitRef="U_USD">5746</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_68171875-88e5-4c5d-a904-b84ad5d56a17"
      decimals="0"
      id="F_c8c8ac71-aec4-429b-9473-8278933162fc"
      unitRef="U_USD">147</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_f5bebf2f-73b3-440e-bc7e-082d8b539b8f"
      decimals="0"
      id="F_496f86d5-1254-4a95-8e51-fa478bd6e765"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_f4635c63-e1a0-4066-bb40-7f550db23dd1"
      id="F_90059e2e-477d-46ac-a637-66d401eb9db4">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_32ecdf32-80a6-4f58-8b71-96d449c2f6c1"
      decimals="0"
      id="F_62f39829-1c88-44d8-9810-67e16f4ca88a"
      unitRef="U_shares">1959411</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_009b7691-4723-4a29-a462-e1c82235024a"
      decimals="0"
      id="F_a5b65cb6-b9bd-4159-a55b-27604542daaa"
      unitRef="U_shares">2342288</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <caba:IncreaseInShareReservedPercentage
      contextRef="C_bb64bdf7-38f7-44f3-bf1c-98b0765c39e3"
      decimals="2"
      id="F_eeb24f45-da90-4643-afd3-b2532f3e7c44"
      unitRef="U_pure">0.04</caba:IncreaseInShareReservedPercentage>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_b642840b-d1a1-4660-9f4a-5c26a6b65c07"
      decimals="0"
      id="F_9777cdb8-60ff-4202-bf8b-d76aefb15071"
      unitRef="U_shares">3000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_977637ab-94d3-4e63-b46a-770bc602ae50"
      decimals="0"
      id="F_49fe6bb4-6056-4674-ae78-8308ff2a0222"
      unitRef="U_shares">2029724</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <caba:SharesRemainingAvailableForIssuance
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="0"
      id="F_8f2885f6-478b-4999-b88b-f34f5ba6410f"
      unitRef="U_shares">1379305</caba:SharesRemainingAvailableForIssuance>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_c182b43f-2f7c-4bac-b874-47f139152e4c">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A summary of the stock option activity is presented below:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:33.84%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.120000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.64%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.120000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding as of January 1, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,141,035&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.28&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;117,384&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,476,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16.13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;210,695&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.79&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,889&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited/Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;175,892&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,231,148&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;989&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options Exercisable at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,642,705&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;966&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_fdc8bd52-362d-49f3-9e45-6677140ad037"
      decimals="0"
      id="F_f5ef59b2-0130-4caa-9a12-d6f5a1ec8d72"
      unitRef="U_shares">8141035</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_fdc8bd52-362d-49f3-9e45-6677140ad037"
      decimals="2"
      id="F_c70c5f10-844d-49de-9159-6a73620c886f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_8c0ea3f5-c232-4ba9-935c-c4f9363bfb3d"
      id="F_975d1126-59de-421e-bf97-53d1784843a8">P7Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_fdc8bd52-362d-49f3-9e45-6677140ad037"
      decimals="0"
      id="F_920d1915-8a6a-4650-9724-819f16800510"
      unitRef="U_USD">117384</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_7bbcce38-fe4c-402a-abef-f39d1a8317bc"
      decimals="0"
      id="F_b5afb2f6-60a6-4e15-9c98-aa3479d00733"
      unitRef="U_shares">3476700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_7bbcce38-fe4c-402a-abef-f39d1a8317bc"
      decimals="2"
      id="F_5a6d52bd-2ec4-4341-8d5d-8379e82180e2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">16.13</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_7bbcce38-fe4c-402a-abef-f39d1a8317bc"
      decimals="0"
      id="F_144b931e-9405-4786-8a78-d9efec7007c7"
      unitRef="U_shares">210695</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_7bbcce38-fe4c-402a-abef-f39d1a8317bc"
      decimals="2"
      id="F_dea74be3-79c3-476f-bc0a-ac7cccd45873"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.79</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_7bbcce38-fe4c-402a-abef-f39d1a8317bc"
      decimals="0"
      id="F_f67c9a4d-8844-430e-99e3-139f5b9362fd"
      unitRef="U_USD">2889</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_7bbcce38-fe4c-402a-abef-f39d1a8317bc"
      decimals="0"
      id="F_bc9e7881-01a1-4177-8ef4-884641dec96f"
      unitRef="U_shares">175892</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_7bbcce38-fe4c-402a-abef-f39d1a8317bc"
      decimals="2"
      id="F_4ac275a9-349d-4866-b100-366dd0e53ce3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.04</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_72321c97-c716-4fc6-b08a-a26615a95579"
      decimals="0"
      id="F_86c30a54-4baf-4c55-9e18-207ae04fe081"
      unitRef="U_shares">11231148</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_72321c97-c716-4fc6-b08a-a26615a95579"
      decimals="2"
      id="F_bd98626c-d337-409f-b879-fc51956daef0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_7bbcce38-fe4c-402a-abef-f39d1a8317bc"
      id="F_694a7b79-0988-4b10-9dea-acac734c3f9f">P7Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_72321c97-c716-4fc6-b08a-a26615a95579"
      decimals="0"
      id="F_af910429-4f55-4d17-b559-c8f67ac80068"
      unitRef="U_USD">989</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_72321c97-c716-4fc6-b08a-a26615a95579"
      decimals="0"
      id="F_649901e0-5dd3-4bb5-a268-dc5d5296f35f"
      unitRef="U_shares">5642705</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_72321c97-c716-4fc6-b08a-a26615a95579"
      decimals="2"
      id="F_735b10f9-65c3-4c8e-890e-6b82da79a8f1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_7bbcce38-fe4c-402a-abef-f39d1a8317bc"
      id="F_db1fb2b3-9533-4687-a951-5ea6998e0a97">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_72321c97-c716-4fc6-b08a-a26615a95579"
      decimals="0"
      id="F_f33da71f-fec8-4d63-b6aa-b088ce4a9499"
      unitRef="U_USD">966</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="2"
      id="F_f7fc639e-9894-42a4-b72a-8d743d66f026"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">13.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="2"
      id="F_84616073-4435-44c7-a60e-d0dddaa90d97"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_aa5d490e-4146-4a77-91b6-5de0d3cc2f45">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair value of each award is estimated using Black-Scholes based on the following assumptions:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:53.049%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:21.676%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:21.676%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.43&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.60&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.38&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.68&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&#x2014;&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.2&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&#x2014;&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;106&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;111&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;105&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;107&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="4"
      id="F_d72a84af-0998-457e-9f1b-3f5469d86076"
      unitRef="U_pure">0.0343</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="4"
      id="F_04322ca6-8740-418b-a415-7d8b5fe29e6c"
      unitRef="U_pure">0.046</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="4"
      id="F_95ed7dd0-a1b4-451c-9857-5c0bc0f1b947"
      unitRef="U_pure">0.0338</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="4"
      id="F_304f8f79-9409-43e4-99b5-f7a4331916ba"
      unitRef="U_pure">0.0468</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_02a92407-52fe-4b71-9603-dc350a954b27"
      id="F_44c994da-4072-44ea-a28e-d3d34696fe74">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_cabc4cba-12e7-440b-9da0-7f7f6b8bb8ea"
      id="F_1b50e091-b286-4823-8ea5-17869cde7795">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0f0de8fd-770f-40d6-b430-5691463bc993"
      id="F_81919793-6469-4f1b-9b9c-ee28ff262d85">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_7bbbdb4f-492f-4e45-b1af-564db3e6c265"
      id="F_655199ab-b79b-4e41-9683-810ec0a81820">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="2"
      id="F_e728c349-02f1-4ee4-9581-86ff95ec9a41"
      unitRef="U_pure">1.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="2"
      id="F_84afd0ff-30fa-4482-b328-b656789c50e9"
      unitRef="U_pure">1.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="2"
      id="F_d8268ae2-aaf0-4c7b-94f7-f5e1f76861bc"
      unitRef="U_pure">1.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="2"
      id="F_ed0def39-a080-4b87-ba83-1987d88df2af"
      unitRef="U_pure">1.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="2"
      id="F_35b620e9-0e0f-4503-abd9-ead582d959ba"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="2"
      id="F_c5b817d1-dd47-40a8-8182-d5b4fc90e92b"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_1cc64067-2cef-4d5d-b614-b0cdb98b2108">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has recorded stock-based compensation in the accompanying statements of operations as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,520&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,302&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,823&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,465&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,343&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_b1d3cbe4-887e-45db-abd2-b02478b909a8"
      decimals="0"
      id="F_385e647d-2f82-4186-91ef-60a88296da02"
      unitRef="U_USD">10163</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_a2e82d17-72fd-4199-85b4-3a85429d0d81"
      decimals="0"
      id="F_87342fa5-f2bc-49e5-8e80-b4174bbc04bd"
      unitRef="U_USD">5520</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_5c849a35-78e8-4658-b224-1c019b513ae4"
      decimals="0"
      id="F_f69c34eb-273f-47f4-954e-d9568fc0df24"
      unitRef="U_USD">9302</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_8fc080aa-f389-40f6-aa75-a26757919ae1"
      decimals="0"
      id="F_fdb2761c-8576-4b14-9a82-79e9926cfebc"
      unitRef="U_USD">5823</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_50ec53a6-211e-4704-8e25-521e6deb405e"
      decimals="0"
      id="F_d944c956-0047-4516-9976-604a39aadd7f"
      unitRef="U_USD">19465</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_85326982-4e9e-4cd8-af12-fd49791a671c"
      decimals="0"
      id="F_b8e0a92f-1ac7-4e42-b4fc-554c57f654eb"
      unitRef="U_USD">11343</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="0"
      id="F_2c528e55-56cc-475b-868e-0fa2ac636da0"
      unitRef="U_USD">51239</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_c566b247-9e2e-4c70-86a3-baad3d14a6fe">P2Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_91bebac1-a194-4aa0-bdad-e2db91554491"
      decimals="0"
      id="F_e7f5c376-3f39-4f99-9308-0de8bccf5ce9"
      unitRef="U_shares">234229</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_1f0087e0-dac4-4dce-a0b5-2502f2165631"
      decimals="0"
      id="F_a3beba35-e8e0-410b-865e-52e5f04a48c0"
      unitRef="U_shares">234229</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <caba:IncreaseInShareReservedPercentage
      contextRef="C_b6d231da-185f-42c9-9b3d-442d6ca59665"
      decimals="2"
      id="F_44cb433b-828a-42e0-aa47-326eeed245fe"
      unitRef="U_pure">0.01</caba:IncreaseInShareReservedPercentage>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_6525b174-f1b8-46c9-95b2-6b44e02a8e4d"
      decimals="0"
      id="F_c1ae1ea3-a906-4569-a17d-4def52ce1010"
      unitRef="U_shares">0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_8c193bbc-bddd-4caa-a616-ab7149fe99f2"
      decimals="0"
      id="F_05067584-bf5a-4980-ae16-a8f2a11e9c5b"
      unitRef="U_shares">0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_72e98e9b-d795-49b3-92aa-8c76efc07029"
      decimals="0"
      id="F_5b7dbfa8-d8c2-4cb4-bc0f-bd90a5186d8d"
      unitRef="U_shares">0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_4911bc2b-bbb5-4139-af54-75d9d982736e"
      decimals="0"
      id="F_af795dfe-8976-4a48-b69f-1acffeee6259"
      unitRef="U_shares">314259</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <caba:PercentageOfPayrollDeductionOnEligibleCompensation
      contextRef="C_b8337e36-0fb0-43e5-b463-b4b3890b87c5"
      decimals="2"
      id="F_cca3a8f8-7582-47d9-a60f-c4ee32b61005"
      unitRef="U_pure">0.15</caba:PercentageOfPayrollDeductionOnEligibleCompensation>
    <caba:EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock
      contextRef="C_b8337e36-0fb0-43e5-b463-b4b3890b87c5"
      decimals="0"
      id="F_b2e5d884-68f1-4d7e-ac37-fae41f3a3dcd"
      unitRef="U_USD">25</caba:EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock>
    <caba:PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock
      contextRef="C_b8337e36-0fb0-43e5-b463-b4b3890b87c5"
      decimals="2"
      id="F_8f2331e8-ce21-43f1-86da-1f4aa78493cc"
      unitRef="U_pure">0.85</caba:PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_23ff72bd-2af0-441d-8914-3f43b9246254">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;11. Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The reconciliation of federal statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:54.151%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:19.144000000000002%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:19.144000000000002%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected income tax benefit at the federal statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State and local taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development credit, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Non-deductible items and other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in state and local tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The principal components of the Company&#x2019;s deferred tax assets and liabilities consisted of the following: &lt;/span&gt;&lt;/span&gt;&lt;span style=""&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Federal, state and local net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44,369&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34,534&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Capitalized research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,646&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,830&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,192&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation deductions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,919&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,066&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;License fee deductions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;221&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;240&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,607&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,482&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,603&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,665&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;114,661&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;74,009&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;110,723&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;72,560&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,938&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,449&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,938&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,449&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company increased its valuation allowance by $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38,163&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for the year ended December 31, 2024 in order to maintain a full valuation allowance against its deferred tax assets. Based on the Company&#x2019;s history of losses, the Company recorded a full valuation allowance against its deferred tax assets as of December 31, 2024. The Company intends to maintain a valuation allowance until sufficient positive evidence exists to support a reversal of the allowance.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, the Company had federal, state and local net operating loss carryforwards of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;157,448&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;181,362&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;88,701&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively; $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;157,198&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of the federal net operating losses do not expire, and the remaining $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;250&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2037&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The state net operating losses begin to expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2037&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The local net operating losses begin to expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2042&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. As of December 31, 2024, the Company had federal and state research and development tax credit carryforwards of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,684&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;612&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively, which begin to expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2038 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2036&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively. Under the provisions of Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the IRC), these net operating losses, credit carryforwards and other tax attributes may be subject to limitation based on previous significant changes in ownership and upon future significant changes in ownership of the Company, as defined by the IRC.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company files income tax returns in the U.S. federal jurisdiction as well as in Pennsylvania and Philadelphia. The tax years 2023, 2022 and 2021 remain open to examination by the jurisdictions where the Company is subject to tax.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company evaluates tax positions for recognition using a more-likely-than-not recognition threshold, and those tax positions eligible for recognition are measured as the largest amount of tax benefit that is greater than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% likely of being realized upon the effective settlement with a taxing authority that has full knowledge of all relevant information. As of December 31, 2024, the Company had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; unrecognized income tax benefits that would affect the Company&#x2019;s effective tax rate if recognized.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_f2952dda-33af-454d-8809-09b2b0fabcc0">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The reconciliation of federal statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:54.151%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:19.144000000000002%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:19.144000000000002%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected income tax benefit at the federal statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State and local taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development credit, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Non-deductible items and other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in state and local tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="3"
      id="F_c819d946-210b-4d0c-aec4-24d98e7191fa"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="3"
      id="F_36caf0b5-7afb-4e34-9967-46cc4259806f"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="3"
      id="F_75e4b7e6-dacc-4fbf-8a3b-eca6c0c21062"
      unitRef="U_pure">0.077</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="3"
      id="F_4c656df4-2641-47b5-8ba8-60b139c9c223"
      unitRef="U_pure">0.076</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="3"
      id="F_261722aa-ac8c-409e-aed9-930cc438fb83"
      unitRef="U_pure">-0.053</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="3"
      id="F_70620bd8-101d-4e17-b355-dfed7fe017a5"
      unitRef="U_pure">-0.064</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <caba:EffectiveIncomeTaxRateReconciliationNondeductibleItemsAndOther
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="3"
      id="F_9ff21ac6-3456-4f34-b30d-f1e6817aeb7e"
      unitRef="U_pure">0.011</caba:EffectiveIncomeTaxRateReconciliationNondeductibleItemsAndOther>
    <caba:EffectiveIncomeTaxRateReconciliationNondeductibleItemsAndOther
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="3"
      id="F_4efa23ab-0435-4232-9cce-e2e08f6d5728"
      unitRef="U_pure">0.005</caba:EffectiveIncomeTaxRateReconciliationNondeductibleItemsAndOther>
    <caba:ChangeInStateAndLocalTaxRate
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="2"
      id="F_6c7a8c72-4845-4138-903d-a7a41810aa89"
      unitRef="U_pure">0</caba:ChangeInStateAndLocalTaxRate>
    <caba:ChangeInStateAndLocalTaxRate
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="3"
      id="F_dc3d095e-4b24-458e-8101-7d962e7492d5"
      unitRef="U_pure">-0.007</caba:ChangeInStateAndLocalTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="3"
      id="F_34ffba2d-388a-4795-aed7-9cb13cfaf116"
      unitRef="U_pure">-0.329</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="3"
      id="F_8a948cbe-e2d8-487a-8a4e-11d66d1ce558"
      unitRef="U_pure">-0.338</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="3"
      id="F_3bfbdd3f-8dd0-40d5-9c46-712ce080b811"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="3"
      id="F_221d714b-d545-4393-912d-eb97c7ba7c88"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_4d401ac0-419c-4555-943b-ca341f461808">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The principal components of the Company&#x2019;s deferred tax assets and liabilities consisted of the following: &lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Federal, state and local net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44,369&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34,534&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Capitalized research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,646&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,830&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,192&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation deductions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,919&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,066&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;License fee deductions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;221&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;240&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,607&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,482&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,603&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,665&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;114,661&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;74,009&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;110,723&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;72,560&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,938&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,449&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,938&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,449&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_94a35c4e-7919-4a54-998a-e6cc7d824b84"
      unitRef="U_USD">44369000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc"
      decimals="-3"
      id="F_c6d870e5-e496-48e1-865c-a5d6bd9fbbac"
      unitRef="U_USD">34534000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <caba:CapitalizedRDCosts
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_90bcd3de-70c2-480c-9b85-71cefddc540a"
      unitRef="U_USD">36646000</caba:CapitalizedRDCosts>
    <caba:CapitalizedRDCosts
      contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc"
      decimals="-3"
      id="F_9ddd7476-3067-4530-a21b-38255cf3a5a9"
      unitRef="U_USD">19830000</caba:CapitalizedRDCosts>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_db0b98a4-6d4a-44d9-a71b-d49620386214"
      unitRef="U_USD">16296000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc"
      decimals="-3"
      id="F_2376181f-3309-4cca-912d-807a34c9bf52"
      unitRef="U_USD">10192000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_90dffe96-30d7-4b5b-b33f-164b45c53771"
      unitRef="U_USD">9919000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc"
      decimals="-3"
      id="F_ac1a16ec-ffb1-4668-99d7-b27a2915e6ee"
      unitRef="U_USD">6066000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <caba:DeferredTaxAssetsLicenseFeesDeductions
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_e2e3d650-edee-4f4c-88a6-0122e1ded240"
      unitRef="U_USD">221000</caba:DeferredTaxAssetsLicenseFeesDeductions>
    <caba:DeferredTaxAssetsLicenseFeesDeductions
      contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc"
      decimals="-3"
      id="F_ba31fcaf-f02c-4c75-b150-a73843c437f6"
      unitRef="U_USD">240000</caba:DeferredTaxAssetsLicenseFeesDeductions>
    <caba:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_8f50ac34-0a91-4058-aca1-597e40b4e5e6"
      unitRef="U_USD">4607000</caba:DeferredTaxAssetsOperatingLeaseLiabilities>
    <caba:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc"
      decimals="-3"
      id="F_5797f378-bf45-4f06-ac46-4b1efb90eb7e"
      unitRef="U_USD">1482000</caba:DeferredTaxAssetsOperatingLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_4c11a143-571e-475c-9079-d6b859eb0e93"
      unitRef="U_USD">2603000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc"
      decimals="-3"
      id="F_78e04ee0-46ca-449e-ae20-097eef0a4dcf"
      unitRef="U_USD">1665000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_1c0c0f1b-5952-4a3c-8a58-716e5461cfec"
      unitRef="U_USD">114661000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc"
      decimals="-3"
      id="F_9fa993fb-d92a-4e1c-b10b-4c6a8f05e363"
      unitRef="U_USD">74009000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_dc11702c-dde3-4434-82d4-b8b34a6e2e8d"
      unitRef="U_USD">110723000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc"
      decimals="-3"
      id="F_bf6b7e00-7e08-4cdd-9152-c9f4db34ead5"
      unitRef="U_USD">72560000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_296ccbb3-b463-44d3-a921-9a787463f812"
      unitRef="U_USD">3938000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc"
      decimals="-3"
      id="F_4a200aeb-c334-4255-a34a-98ca4f7444b0"
      unitRef="U_USD">1449000</us-gaap:DeferredTaxAssetsNet>
    <caba:OperatingLeaseAssets
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_b89d67df-d02d-4490-87eb-8d573a3862c0"
      unitRef="U_USD">-3938000</caba:OperatingLeaseAssets>
    <caba:OperatingLeaseAssets
      contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc"
      decimals="-3"
      id="F_2bdb42b0-e599-43d4-8792-de63a72f27cf"
      unitRef="U_USD">-1449000</caba:OperatingLeaseAssets>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_fdf8085d-3b7f-4d40-9cda-38e7e503e48d"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_f1261fee-7643-4642-aa6e-b30416d960fc"
      decimals="-3"
      id="F_03a8ef39-fdee-483a-b28d-5c1b61394bda"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_a69cdc4f-039c-40ef-9e6e-9cb494619e05"
      unitRef="U_USD">38163000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <caba:DeferredTaxAssetsOperatingLossCarryforwardsFederal
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_817bc51f-4291-4765-9b03-e4ff14ce8219"
      unitRef="U_USD">157448000</caba:DeferredTaxAssetsOperatingLossCarryforwardsFederal>
    <caba:DeferredTaxAssetsOperatingLossCarryforwardsState
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_2133a288-d5b8-4310-bb37-06f327ac7cea"
      unitRef="U_USD">181362000</caba:DeferredTaxAssetsOperatingLossCarryforwardsState>
    <caba:DeferredTaxAssetsOperatingLossCarryforwardsLocal
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_8704671b-7fc9-4089-938d-4222240f8963"
      unitRef="U_USD">88701000</caba:DeferredTaxAssetsOperatingLossCarryforwardsLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_677e038e-24a2-4a36-8403-33f7abee461a"
      unitRef="U_USD">157198000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_43db2cd1-d7ac-4030-9d52-1abb18a4a4eb"
      unitRef="U_USD">250000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <caba:OperatingLossCarryforwardsFederalCommencementOfExpirationDate
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_2ff0b412-07fa-4b75-be19-1439621d5833">2037</caba:OperatingLossCarryforwardsFederalCommencementOfExpirationDate>
    <caba:OperatingLossCarryforwardsStateCommencementOfExpirationDate
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_ca68e829-8a35-4d27-880f-859354d26cbb">2037</caba:OperatingLossCarryforwardsStateCommencementOfExpirationDate>
    <caba:OperatingLossCarryforwardsLocalCommencementOfExpirationDate
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_1a002b45-de79-46f5-b648-c61a3bcbcbfe">2042</caba:OperatingLossCarryforwardsLocalCommencementOfExpirationDate>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_60702d76-a78f-433d-8046-7a817c666483"
      decimals="-3"
      id="F_8e6eeed2-e70f-4ebd-b5a6-e66354ea29a6"
      unitRef="U_USD">15684000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_5c158f7e-d30a-4d7e-913b-54efddfa9032"
      decimals="-3"
      id="F_0b6789ab-299b-484b-b734-3c5360af3624"
      unitRef="U_USD">612000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <caba:DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate
      contextRef="C_7f97431a-51bc-48de-b369-469db20bdb17"
      id="F_28374468-1b5e-4e80-869c-358001b1f6be">2038</caba:DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate>
    <caba:DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate
      contextRef="C_881cd698-8215-4730-9508-1b847dfa7222"
      id="F_c3168ba7-3b14-4e82-8b82-9e03747b4dfa">2036</caba:DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate>
    <caba:PercentageOfEligibleTaxPositionsForRecognition
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="2"
      id="F_4e35e36f-aa3f-45b4-a28c-3049ea9b29ff"
      unitRef="U_pure">0.50</caba:PercentageOfEligibleTaxPositionsForRecognition>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="C_fbb2803e-11f2-411e-bc43-c725c0d90cee"
      decimals="-3"
      id="F_d0003b7f-abf0-4bb4-b665-c2a0df71c653"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_2180a849-8752-4260-90f8-175d13828e0f">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;12. Net Loss Per Share&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company calculates basic and diluted net loss per share in conformity with the two-class method required for participating securities. For the year ended December 31, 2023, the Company had voting and non-voting common stock outstanding. In May 2024, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,444,295&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of non-voting common stock was converted to voting common stock and as of December 31, 2024, no shares of non-voting common stock remain outstanding. Since the rights of the voting and non-voting common stock are identical, except with respect to voting, the undistributed losses of the Company have been&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; allocated on a proportionate basis to the two classes. Basic net loss per share of common stock is computed by dividing the net loss per share of common stock by the weighted average number of shares of common stock outstanding for the period.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The weighted average shares of common stock outstanding as of December 31, 2023 included outstanding pre-funded warrants to purchase up to an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,168,054&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; pre-funded warrants remain outstanding as of December 31, 2024.&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Diluted net loss per share is calculated using the if-converted method, which assumes conversion of all non-voting common stock to voting common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year ended December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Voting common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Non-voting common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Basic net loss per share:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Numerator&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Allocation of undistributed losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;114,728&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,136&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Denominator&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average number of shares used in basic per share computation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49,038,726&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;485,378&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss per share, basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Diluted net loss per share:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Numerator&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Allocation of undistributed losses for basic computation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;114,728&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,136&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Reallocation of undistributed losses as a result of conversion of&lt;br/&gt;&#160;&#160;&#160;&#160;&#160;non-voting to voting common shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,136&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Allocation of undistributed losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;115,864&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,136&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Denominator&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average number of shares used in basic per share computation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49,038,726&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;485,378&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Add: conversion of non-voting to voting common shares outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;485,378&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average number of shares used in diluted per share computation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49,524,104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;485,378&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss per share, diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year ended December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Voting common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Non-voting common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Basic net loss per share:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Numerator&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Allocation of undistributed losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;64,776&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Denominator&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average number of shares used in basic per share computation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,192,445&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,753,505&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss per share, basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Diluted net loss per share:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Numerator&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Allocation of undistributed losses for basic computation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;64,776&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Reallocation of undistributed losses as a result of conversion of&lt;br/&gt;&#160;&#160;&#160;&#160;&#160;non-voting to voting common shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Allocation of undistributed losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67,675&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Denominator&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average number of shares used in basic per share computation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,192,445&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,753,505&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Add: conversion of non-voting to voting common shares outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,753,505&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average number of shares used in diluted per share computation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,945,950&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,753,505&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss per share, diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share, as their effect is anti-dilutive:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,231,148&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,141,035&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,231,148&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,141,035&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_3577cd65-82b8-42e6-844e-ca6167dba709"
      decimals="0"
      id="F_6aa0f6f3-d5f6-4dd6-ad8d-6f55777c9f57"
      unitRef="U_shares">1444295</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="0"
      id="F_63654c15-34f4-4ae6-95eb-96ca0af9e383"
      unitRef="U_shares">1168054</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_50b61005-316a-440c-b7d7-051b2270374c"
      decimals="0"
      id="F_4fe8ae2a-91c0-4558-b1e8-5993a169ffb0"
      unitRef="U_shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_83d1d007-63d2-4fa0-8096-e145dc530f27">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Diluted net loss per share is calculated using the if-converted method, which assumes conversion of all non-voting common stock to voting common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year ended December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Voting common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Non-voting common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Basic net loss per share:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Numerator&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Allocation of undistributed losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;114,728&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,136&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Denominator&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average number of shares used in basic per share computation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49,038,726&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;485,378&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss per share, basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Diluted net loss per share:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Numerator&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Allocation of undistributed losses for basic computation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;114,728&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,136&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Reallocation of undistributed losses as a result of conversion of&lt;br/&gt;&#160;&#160;&#160;&#160;&#160;non-voting to voting common shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,136&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Allocation of undistributed losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;115,864&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,136&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Denominator&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average number of shares used in basic per share computation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49,038,726&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;485,378&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Add: conversion of non-voting to voting common shares outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;485,378&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average number of shares used in diluted per share computation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49,524,104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;485,378&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss per share, diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year ended December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Voting common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Non-voting common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Basic net loss per share:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Numerator&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Allocation of undistributed losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;64,776&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Denominator&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average number of shares used in basic per share computation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,192,445&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,753,505&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss per share, basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Diluted net loss per share:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Numerator&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Allocation of undistributed losses for basic computation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;64,776&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Reallocation of undistributed losses as a result of conversion of&lt;br/&gt;&#160;&#160;&#160;&#160;&#160;non-voting to voting common shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Allocation of undistributed losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67,675&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Denominator&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average number of shares used in basic per share computation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,192,445&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,753,505&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Add: conversion of non-voting to voting common shares outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,753,505&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average number of shares used in diluted per share computation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,945,950&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,753,505&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss per share, diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:UndistributedEarningsLossAvailableToCommonShareholdersBasic
      contextRef="C_b76590bb-7198-4431-94bb-7578a594bad1"
      decimals="-3"
      id="F_c0d48a13-3ec4-4c2e-8824-0717ced9c58b"
      unitRef="U_USD">-114728000</us-gaap:UndistributedEarningsLossAvailableToCommonShareholdersBasic>
    <us-gaap:UndistributedEarningsLossAvailableToCommonShareholdersBasic
      contextRef="C_c46ec4f4-c805-417a-8a4d-faada740c019"
      decimals="-3"
      id="F_458ce38d-e2cb-48e3-b68e-0dd16ee855a6"
      unitRef="U_USD">-1136000</us-gaap:UndistributedEarningsLossAvailableToCommonShareholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_b76590bb-7198-4431-94bb-7578a594bad1"
      decimals="0"
      id="F_cd337ad4-40f7-4955-86ec-a3090c67b9c1"
      unitRef="U_shares">49038726</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_c46ec4f4-c805-417a-8a4d-faada740c019"
      decimals="0"
      id="F_46e3b592-24fb-4e40-a82b-af55ac9e97ed"
      unitRef="U_shares">485378</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_b76590bb-7198-4431-94bb-7578a594bad1"
      decimals="2"
      id="F_cc29f862-785b-4871-a875-68f7399b6a4b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.34</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_c46ec4f4-c805-417a-8a4d-faada740c019"
      decimals="2"
      id="F_aeb7629b-22e1-4f2c-bfe9-3401baef0799"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.34</us-gaap:EarningsPerShareBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="C_b76590bb-7198-4431-94bb-7578a594bad1"
      decimals="-3"
      id="F_f1827bb1-4daa-484e-ba19-def976c2797e"
      unitRef="U_USD">-114728000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="C_c46ec4f4-c805-417a-8a4d-faada740c019"
      decimals="-3"
      id="F_a11c6414-9899-465f-8be9-269c6e99b383"
      unitRef="U_USD">-1136000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
      contextRef="C_b76590bb-7198-4431-94bb-7578a594bad1"
      decimals="-3"
      id="F_aa1b6e54-97bc-4de9-8bb9-5810c86b349e"
      unitRef="U_USD">-1136000</us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther>
    <us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
      contextRef="C_c46ec4f4-c805-417a-8a4d-faada740c019"
      decimals="-3"
      id="F_767a8167-5392-43a1-8db7-2caa62a81d08"
      unitRef="U_USD">0</us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
      contextRef="C_b76590bb-7198-4431-94bb-7578a594bad1"
      decimals="-3"
      id="F_be043cc6-c3e2-4879-9c21-b98ed5744986"
      unitRef="U_USD">-115864000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
      contextRef="C_c46ec4f4-c805-417a-8a4d-faada740c019"
      decimals="-3"
      id="F_320b4b6a-f796-4052-8f5f-163af8e4fec8"
      unitRef="U_USD">-1136000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_b76590bb-7198-4431-94bb-7578a594bad1"
      decimals="0"
      id="F_68ec595b-1fb9-42b8-947f-9a0f2379ff58"
      unitRef="U_shares">49038726</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_c46ec4f4-c805-417a-8a4d-faada740c019"
      decimals="0"
      id="F_f9a92041-adda-4de6-9352-deb9a9b17d68"
      unitRef="U_shares">485378</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="C_b76590bb-7198-4431-94bb-7578a594bad1"
      decimals="0"
      id="F_2fde431b-4303-4f4a-934b-e3e61dad1380"
      unitRef="U_shares">485378</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="C_c46ec4f4-c805-417a-8a4d-faada740c019"
      decimals="0"
      id="F_51fea91e-30e5-45df-af20-aa9f5a215ea6"
      unitRef="U_shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_b76590bb-7198-4431-94bb-7578a594bad1"
      decimals="0"
      id="F_9e293946-9fd4-4f6c-8b16-13c03bbbba3f"
      unitRef="U_shares">49524104</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_c46ec4f4-c805-417a-8a4d-faada740c019"
      decimals="0"
      id="F_108d2e0b-7250-488d-8fd0-891aa9034652"
      unitRef="U_shares">485378</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_b76590bb-7198-4431-94bb-7578a594bad1"
      decimals="2"
      id="F_d7e81d2b-f218-4c00-b79c-bb701bdf3463"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.34</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_c46ec4f4-c805-417a-8a4d-faada740c019"
      decimals="2"
      id="F_e3a30f4f-9880-4507-b34e-5a05d14f88f9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.34</us-gaap:EarningsPerShareDiluted>
    <us-gaap:UndistributedEarningsLossAvailableToCommonShareholdersBasic
      contextRef="C_8820b6d6-f9b3-4f60-970e-aabd2aa79a08"
      decimals="-3"
      id="F_d519e693-bae9-4bee-924a-78629ad30a6f"
      unitRef="U_USD">-64776000</us-gaap:UndistributedEarningsLossAvailableToCommonShareholdersBasic>
    <us-gaap:UndistributedEarningsLossAvailableToCommonShareholdersBasic
      contextRef="C_00142f0e-bf74-4dac-98f2-8c7944fde213"
      decimals="-3"
      id="F_4d9742fc-b039-49e5-bd14-60347c1ed5e3"
      unitRef="U_USD">-2899000</us-gaap:UndistributedEarningsLossAvailableToCommonShareholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_8820b6d6-f9b3-4f60-970e-aabd2aa79a08"
      decimals="0"
      id="F_d3b4e14e-da67-498d-92f7-7366d3e401c5"
      unitRef="U_shares">39192445</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_00142f0e-bf74-4dac-98f2-8c7944fde213"
      decimals="0"
      id="F_5aa69b6d-de9e-496d-9b5e-e1ff9ed22bce"
      unitRef="U_shares">1753505</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_8820b6d6-f9b3-4f60-970e-aabd2aa79a08"
      decimals="2"
      id="F_67072577-1d0e-4061-bd90-fbf1f61f0010"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.65</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_00142f0e-bf74-4dac-98f2-8c7944fde213"
      decimals="2"
      id="F_aeeab4b7-76ae-4fdb-a425-d8b431853330"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.65</us-gaap:EarningsPerShareBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="C_8820b6d6-f9b3-4f60-970e-aabd2aa79a08"
      decimals="-3"
      id="F_4a87a869-686b-45ef-849e-95049b192210"
      unitRef="U_USD">-64776000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="C_00142f0e-bf74-4dac-98f2-8c7944fde213"
      decimals="-3"
      id="F_85c81fc7-e110-49e2-b095-e29c65abeef0"
      unitRef="U_USD">-2899000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
      contextRef="C_8820b6d6-f9b3-4f60-970e-aabd2aa79a08"
      decimals="-3"
      id="F_04c92786-2749-43ae-ab0f-a8ca0a4e6351"
      unitRef="U_USD">-2899000</us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther>
    <us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
      contextRef="C_00142f0e-bf74-4dac-98f2-8c7944fde213"
      decimals="-3"
      id="F_a9b6cfe8-2d20-481a-85f4-9631d57fc1ad"
      unitRef="U_USD">0</us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
      contextRef="C_8820b6d6-f9b3-4f60-970e-aabd2aa79a08"
      decimals="-3"
      id="F_be395a05-bdcb-4569-a9e2-e3e450ab8c67"
      unitRef="U_USD">-67675000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
      contextRef="C_00142f0e-bf74-4dac-98f2-8c7944fde213"
      decimals="-3"
      id="F_3954f645-89c1-4376-b6ee-d723fe934ba6"
      unitRef="U_USD">-2899000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_8820b6d6-f9b3-4f60-970e-aabd2aa79a08"
      decimals="0"
      id="F_f318593d-156f-41e5-a60a-a1a7f0ca8171"
      unitRef="U_shares">39192445</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_00142f0e-bf74-4dac-98f2-8c7944fde213"
      decimals="0"
      id="F_342e5967-b8ea-401d-b64e-d0a87f0377b3"
      unitRef="U_shares">1753505</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="C_8820b6d6-f9b3-4f60-970e-aabd2aa79a08"
      decimals="0"
      id="F_db344903-b1f1-4cc7-b228-f6044c0cf1d1"
      unitRef="U_shares">1753505</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="C_00142f0e-bf74-4dac-98f2-8c7944fde213"
      decimals="-3"
      id="F_7552d1ad-13f0-460a-bc2b-776ba198debe"
      unitRef="U_shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_8820b6d6-f9b3-4f60-970e-aabd2aa79a08"
      decimals="0"
      id="F_5033d2b3-c57e-41a2-9143-5d5e1ca7b93c"
      unitRef="U_shares">40945950</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_00142f0e-bf74-4dac-98f2-8c7944fde213"
      decimals="0"
      id="F_0da210eb-2a78-46bd-9f0e-9ae56a18858b"
      unitRef="U_shares">1753505</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_8820b6d6-f9b3-4f60-970e-aabd2aa79a08"
      decimals="2"
      id="F_24bc6bb0-0cb4-4b20-8228-46701cac20cf"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.65</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_00142f0e-bf74-4dac-98f2-8c7944fde213"
      decimals="2"
      id="F_77110cc9-da59-44fe-89a1-10b2a72ca333"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.65</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_143be6af-45a0-4bfc-aa8f-c2ea22753604">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share, as their effect is anti-dilutive:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,231,148&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,141,035&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,231,148&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,141,035&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_f5851d98-3e59-44ab-89c0-e44329981682"
      decimals="0"
      id="F_7591595d-4290-4527-a7ef-0e3cc1bb3e86"
      unitRef="U_shares">11231148</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_1e81d161-d2c9-4466-ad56-b46b0e4daea1"
      decimals="0"
      id="F_24e9ca10-1824-4cce-8f89-a7dca2baf9e3"
      unitRef="U_shares">8141035</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="0"
      id="F_9e72c530-3bc7-455b-9cd8-9f6b01ca1744"
      unitRef="U_shares">11231148</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="0"
      id="F_cbf4f042-c25b-40d3-adc1-b015f147f7b6"
      unitRef="U_shares">8141035</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      id="F_d4eefa90-5123-402d-9a3b-4ee5c5338bb7">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;13. 401(k) Savings Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company maintains a defined-contribution savings plan under Section 401(k) of the IRC, or the 401(k) Plan. The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pretax basis. Effective January 1, 2020, the Plan provided for matching contributions on a portion of participant contributions pursuant to the 401(k) Savings Plan&#x2019;s matching formula, up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of eligible compensation. All matching contributions and participant contributions vest immediately. Contributions totaled $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;894&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;521&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for the years ended December 31, 2024 and 2023, respectively, and have been recorded in the statements of operations.&lt;/span&gt;&lt;/p&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="2"
      id="F_403830d0-6cbe-4046-8f03-ddaaff265f5d"
      unitRef="U_pure">0.04</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="C_526c68e0-6d1b-4b6d-885c-8856f7637c5c"
      decimals="-3"
      id="F_0370faeb-d909-4fda-bbbf-44367199572d"
      unitRef="U_USD">894000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="C_a1e38241-900a-43de-9175-5ee71906e75a"
      decimals="-3"
      id="F_a1c1ef00-b676-4716-a999-502cc53a9e1c"
      unitRef="U_USD">521000</us-gaap:DefinedContributionPlanCostRecognized>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#F_79796396-a7d9-4c3c-85e3-fa935c557d67"
          xlink:label="F_79796396-a7d9-4c3c-85e3-fa935c557d67"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_c44390f8-728e-4a16-874c-98d61b07a67a"
          xlink:label="F_c44390f8-728e-4a16-874c-98d61b07a67a"
          xlink:type="locator"/>
        <link:footnote id="FNT_a817dc11-a357-48c9-937a-02cf05c1a9c1" xlink:label="FNT_a817dc11-a357-48c9-937a-02cf05c1a9c1" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other research and development costs includes costs associated with information technology, travel, medical and scientific symposiums and conferences.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_79796396-a7d9-4c3c-85e3-fa935c557d67"
          xlink:to="FNT_a817dc11-a357-48c9-937a-02cf05c1a9c1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_c44390f8-728e-4a16-874c-98d61b07a67a"
          xlink:to="FNT_a817dc11-a357-48c9-937a-02cf05c1a9c1"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
